PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	WANG, SY; BASSIN, RH; RACKER, E				WANG, SY; BASSIN, RH; RACKER, E			EFFECT OF HIGH K+ HYPERTONICITY AND OUABAIN ON MEAIB UPTAKE AND ON GROWTH OF CIS-MYC AND V-RAS TRANSFECTED RAT FIBROBLASTS	ONCOGENE			English	Article									CORNELL UNIV,DIV BIOL SCI,BIOCHEM SECT,ITHACA,NY 14853; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BASSIN RH, 1984, CANCER CELL, V2, P463; BENADE LE, 1986, BIOCHEM BIOPH RES CO, V136, P807, DOI 10.1016/0006-291X(86)90512-7; BOERNER P, 1982, J CELL PHYSIOL, V113, P240, DOI 10.1002/jcp.1041130209; BUSSOLATI O, 1986, BIOCHIM BIOPHYS ACTA, V854, P240, DOI 10.1016/0005-2736(86)90116-1; CHRISTENSEN HN, 1975, BIOL TRANSPORT; FOSTER DO, 1969, J BIOL CHEM, V244, P2675; GRAVES JS, 1982, AM J PHYSIOL, V243, pC124, DOI 10.1152/ajpcell.1982.243.3.C124; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; ISSELBACHER KJ, 1972, P NATL ACAD SCI USA, V69, P585, DOI 10.1073/pnas.69.3.585; KLIP A, 1986, J CELL PHYSIOL, V127, P244, DOI 10.1002/jcp.1041270209; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAI CN, 1985, J CELL PHYSIOL, V125, P259, DOI 10.1002/jcp.1041250213; MAGER DL, 1979, DEV BIOL, V70, P268, DOI 10.1016/0012-1606(79)90024-1; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; SCHENERMAN MA, 1987, FASEB J, V46, P1984; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; TRAMACERE M, 1984, EXP CELL RES, V151, P70, DOI 10.1016/0014-4827(84)90356-2; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P197; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	19	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					53	57						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400008
J	Wang, MF; Yan, Q; Song, YF; Zhang, ZB; Chen, XJ; Gao, K; Wan, XP				Wang, Mengfei; Yan, Qin; Song, Yunfeng; Zhang, Zhenbo; Chen, Xiaojun; Gao, Kun; Wan, Xiaoping			Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer	ONCOGENE			English	Article; Early Access							TEAD-YAP COMPLEX; TUMOR-SUPPRESSOR; DIFFERENTIATION; CABOZANTINIB; CHROMATIN; PROTEINS; ACTS	Aberrant hyperactivation of the Hippo pathway effector YAP/TEAD complex causes tissue overgrowth and tumorigenesis in various cancers, including endometrial cancer (EC). The transcription factor SOX17 (SRY [sex-determining region Y]-box 17) is frequently mutated in EC; however, SOX17 mutations are rare in other cancer types. The molecular mechanisms underlying SOX17 mutation-induced EC tumorigenesis remain poorly understood. Here, we demonstrate that SOX17 serves as a tumor suppressor to restrict the proliferation, migration, invasion, and anchorage-independent growth of EC cells, partly by suppressing the transcriptional outputs of the Hippo-YAP/TEAD pathway. SOX17 binds to TEAD transcription factors through its HMG domain and attenuates the DNA-binding ability of TEAD. SOX17 loss by inactivating mutations leads to the malignant transformation of EC cells, which can be reversed by small-molecule inhibitors of YAP/TEAD or cabozantinib, an FDA-approved drug targeting the YAP/TEAD transcriptional target AXL. Our findings reveal novel molecular mechanisms underlying Hippo-YAP/TEAD pathway-driven EC tumorigenesis, and suggest potential therapeutic strategies targeting the Hippo-YAP/TEAD pathway in SOX17-mutated EC.	[Wang, Mengfei; Yan, Qin; Song, Yunfeng; Wan, Xiaoping] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Gynecol, Shanghai 201204, Peoples R China; [Zhang, Zhenbo] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Obstet & Gynecol, Shanghai 200080, Peoples R China; [Chen, Xiaojun] Fudan Univ, Dept Gynecol, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China; [Gao, Kun] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Clin Lab, Shanghai 201204, Peoples R China; [Wan, Xiaoping] Shanghai First Matern & Infant Hosp, Shanghai Key Lab Maternal & Fetal Med, Shanghai, Peoples R China	Tongji University; Shanghai Jiao Tong University; Fudan University; Tongji University	Wan, XP (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Gynecol, Shanghai 201204, Peoples R China.; Gao, K (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Clin Lab, Shanghai 201204, Peoples R China.; Wan, XP (corresponding author), Shanghai First Matern & Infant Hosp, Shanghai Key Lab Maternal & Fetal Med, Shanghai, Peoples R China.	kungao@tongji.edu.cn; Wanxiaoping@tongji.edu.cn			National Natural Science Foundation of China [91954106, 81872109, 81972438, 82172975]; Natural Science Foundation of Shanghai [18ZR1430100]; Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center [SHDC12020107]; Shanghai Sailing Program [22YF1434700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center; Shanghai Sailing Program	This work was supported by the National Natural Science Foundation of China (No. 91954106 and 81872109 to K.G., No. 81972438 and 82172975 to X.W.), Natural Science Foundation of Shanghai ((No. 18ZR1430100 to K.G.), Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center (SHDC12020107 to X.W.), and Shanghai Sailing Program (No. 22YF1434700 to Y.S.).	Azad T, 2020, ONCOGENE, V39, P334, DOI 10.1038/s41388-019-0988-y; Dhani NC, 2020, CLIN CANCER RES, V26, P2477, DOI 10.1158/1078-0432.CCR-19-2576; Diepenbruck M, 2014, J CELL SCI, V127, P1523, DOI 10.1242/jcs.139865; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kim I, 2007, CELL, V130, P470, DOI 10.1016/j.cell.2007.06.011; Kinnear S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51751-3; Kobayashi T, 2017, NATURE, V546, P416, DOI 10.1038/nature22812; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Li L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0782-8; Lilly AJ, 2017, SEMIN CELL DEV BIOL, V63, P50, DOI 10.1016/j.semcdb.2016.07.021; Lin KC, 2017, TRENDS BIOCHEM SCI, V42, P862, DOI 10.1016/j.tibs.2017.09.003; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Markowitz JN, 2018, PHARMACOTHERAPY, V38, P357, DOI 10.1002/phar.2076; Merino-Azpitarte M, 2017, J HEPATOL, V67, P72, DOI 10.1016/j.jhep.2017.02.017; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0; Mukherjee S, 2020, ELIFE, V9, DOI 10.7554/eLife.58029; Qiao Y, 2016, ONCOGENE, V35, P2664, DOI 10.1038/onc.2015.338; Sakamoto Y, 2007, BIOCHEM BIOPH RES CO, V360, P539, DOI 10.1016/j.bbrc.2007.06.093; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stanger BZ, 2012, GENE DEV, V26, P1263, DOI 10.1101/gad.196501.112; Walker CJ, 2017, ONCOTARGET, V8, P68758, DOI 10.18632/oncotarget.20213; Wang XQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06652-w; Wen XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0170-6; Wissmuller S, 2006, NUCLEIC ACIDS RES, V34, P1735, DOI 10.1093/nar/gkl105; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Ying L, 2015, STEM CELL REP, V5, P490, DOI 10.1016/j.stemcr.2015.08.014; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhang YL, 2016, ONCOTARGET, V7, P76036, DOI 10.18632/oncotarget.12582; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhu CJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1090-3; Zhu N, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0566-x; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	36	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02550-0	http://dx.doi.org/10.1038/s41388-022-02550-0		NOV 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6O2TJ	36446891				2022-12-17	WOS:000890096600001
J	Guan, XW; Deng, HL; Choi, UL; Li, ZF; Yang, YQ; Zeng, JM; Liu, YZ; Zhang, XJ; Li, G				Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang			EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis (October, 10.1038/s41388-02001484-9, 2020)	ONCOGENE			English	Correction; Early Access												gangli@um.edu.mo						Guan XW, 2020, ONCOGENE, V39, P7127, DOI 10.1038/s41388-020-01484-9	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02554-w	http://dx.doi.org/10.1038/s41388-022-02554-w		NOV 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6N3CK	36443397	Bronze			2022-12-17	WOS:000889435000002
J	Thirusangu, P; Ray, U; Bhattacharya, SS; Oien, DB; Jin, L; Staub, J; Kannan, N; Molina, JR; Shridhar, V				Thirusangu, Prabhu; Ray, Upasana; Sarkar Bhattacharya, Sayantani; Oien, Derek B.; Jin, Ling; Staub, Julie; Kannan, Nagarajan; Molina, Julian R.; Shridhar, Viji			PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma (vol 41, pg 4003, 2022)	ONCOGENE			English	Correction; Early Access												shridhar.vijayalakshmi@mayo.edu						Thirusangu P, 2022, ONCOGENE, V41, P4003, DOI 10.1038/s41388-022-02391-x	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02470-z	http://dx.doi.org/10.1038/s41388-022-02470-z		NOV 2022	4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6N3CK	36443398	hybrid			2022-12-17	WOS:000889435000003
J	Xie, YT; Tornkvist, M; Aalto, Y; Nilsson, G; Girnita, L; Nagy, B; Knuutila, S; Larsson, O				Xie, Yuntao; Tornkvist, Maria; Aalto, Yan; Nilsson, Gunnar; Girnita, Leonard; Nagy, Balint; Knuutila, Sakari; Larsson, Olle			Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene (Expression of Concern of Vol 22, art no 7628, 2003)	ONCOGENE			English	Expression of Concern; Early Access												sakari.knuutila@helsinki.fi; olle.larsson@onkpat.ki.se						Xie YT, 2003, ONCOGENE, V22, P7628, DOI 10.1038/sj.onc.1207153	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene											s41388-022-02552-y	10.1038/s41388-022-02552-y	http://dx.doi.org/10.1038/s41388-022-02552-y		NOV 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6N3CK	36443396	Bronze			2022-12-17	WOS:000889435000001
J	Tippett, VL; Tattersall, L; Ab Latif, NB; Shah, KM; Lawson, MA; Gartland, A				Tippett, Victoria L.; Tattersall, Luke; Ab Latif, Norain B.; Shah, Karan M.; Lawson, Michelle A.; Gartland, Alison			The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review	ONCOGENE			English	Review; Early Access							P-GLYCOPROTEIN EXPRESSION; HIGH-GRADE OSTEOSARCOMA; DOXORUBICIN-RESISTANCE; CELL-LINES; NEOADJUVANT CHEMOTHERAPY; METHOTREXATE RESISTANCE; CISPLATIN RESISTANCE; PROGNOSTIC-FACTORS; DIHYDROFOLATE-REDUCTASE; DOWN-REGULATION	Over the last 40 years osteosarcoma (OS) survival has stagnated with patients commonly resistant to neoadjuvant MAP chemotherapy involving high dose methotrexate, adriamycin (doxorubicin) and platinum (cisplatin). Due to the rarity of OS, the generation of relevant cell models as tools for drug discovery is paramount to tackling this issue. Four literature databases were systematically searched using pre-determined search terms to identify MAP resistant OS cell lines and patients. Drug exposure strategies used to develop cell models of resistance and the impact of these on the differential expression of resistance associated genes, proteins and non-coding RNAs are reported. A comparison to clinical studies in relation to chemotherapy response, relapse and metastasis was then made. The search retrieved 1891 papers of which 52 were relevant. Commonly, cell lines were derived from Caucasian patients with epithelial or fibroblastic subtypes. The strategy for model development varied with most opting for continuous over pulsed chemotherapy exposure. A diverse resistance level was observed between models (2.2-338 fold) with 63% of models exceeding clinically reported resistance levels which may affect the expression of chemoresistance factors. In vitro p-glycoprotein overexpression is a key resistance mechanism; however, from the available literature to date this does not translate to innate resistance in patients. The selection of models with a lower fold resistance may better reflect the clinical situation. A comparison of standardised strategies in models and variants should be performed to determine their impact on resistance markers. Clinical studies are required to determine the impact of resistance markers identified in vitro in poor responders to MAP treatment, specifically with respect to innate and acquired resistance. A shift from seeking disputed and undruggable mechanisms to clinically relevant resistance mechanisms may identify key resistance markers that can be targeted for patient benefit after a 40-year wait.	[Tippett, Victoria L.; Tattersall, Luke; Ab Latif, Norain B.; Shah, Karan M.; Lawson, Michelle A.; Gartland, Alison] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England; [Ab Latif, Norain B.] Univ Kuala Lumpur, Royal Coll Med Perak, 3 Jalan Greentown, Ipoh 30450, Perak, Malaysia	University of Sheffield; University of Kuala Lumpur	Gartland, A (corresponding author), Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	a.gartland@sheffield.ac.uk	Shah, Karan/B-2940-2012	Shah, Karan/0000-0001-9909-6409; Gartland, Alison/0000-0002-3712-2437; Tattersall, Luke/0000-0001-8835-0627; Ab.Latif, Norain Binti/0000-0003-1499-9049; Tippett, Victoria/0000-0003-1601-3546; Lawson, Michelle/0000-0002-5446-923X	Hannah's Willberry Wonder Pony; University of Sheffield Faculty of Medicine, Dentistry & Health, University Post Graduate Research Committee (UPGRC) Scholarship	Hannah's Willberry Wonder Pony; University of Sheffield Faculty of Medicine, Dentistry & Health, University Post Graduate Research Committee (UPGRC) Scholarship	This research was funded by Hannah's Willberry Wonder Pony and by The University of Sheffield Faculty of Medicine, Dentistry & Health, University Post Graduate Research Committee (UPGRC) Scholarship.	Abou Ali B, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.17.00241; Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872; ARCAMONE F, 1969, BIOTECHNOL BIOENG, V11, P1101, DOI 10.1002/bit.260110607; Bacci G, 2006, CANCER-AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724; Bacci G, 1998, J CLIN ONCOL, V16, P658, DOI 10.1200/JCO.1998.16.2.658; Bacci G, 2005, EUR J CANCER, V41, P2079, DOI 10.1016/j.ejca.2005.03.036; Bacci G, 2005, ACTA ONCOL, V44, P748, DOI 10.1080/02841860500327503; Baldini N, 1999, J ORTHOPAED RES, V17, P629, DOI 10.1002/jor.1100170502; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; Bertino JR, 1996, STEM CELLS, V14, P5, DOI 10.1002/stem.140005; BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11; Cavalcanti AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184891; Cheng M, 2018, EUR J PHARMACOL, V840, P1, DOI 10.1016/j.ejphar.2018.09.032; Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dai XW, 2008, NANOMED-NANOTECHNOL, V4, P49, DOI 10.1016/j.nano.2007.12.002; Eljack ND, 2014, METALLOMICS, V6, P2126, DOI 10.1039/c4mt00238e; Eselgrim M, 2006, PEDIATR BLOOD CANCER, V47, P42, DOI 10.1002/pbc.20608; Fan GT, 2021, BIOCHEM BIOPH RES CO, V554, P214, DOI 10.1016/j.bbrc.2020.12.109; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; Francis MN., R1205 NCIN, P1; Gao Y, 2016, J ORTHOP RES, V34, P1606, DOI 10.1002/jor.23173; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Guan HP, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02016-5; Guo W, 1999, CLIN CANCER RES, V5, P621; Hall MD, 2014, CANCER RES, V74, P3913, DOI 10.1158/0008-5472.CAN-14-0247; Han T, 2014, ONCOL REP, V32, P1133, DOI 10.3892/or.2014.3314; Hattinger CM, 2009, GENE CHROMOSOME CANC, V48, P289, DOI 10.1002/gcc.20640; Hauben EI, 2002, EUR J CANCER, V38, P1218, DOI 10.1016/S0959-8049(02)00037-0; Hawkins DS, 2003, CANCER-AM CANCER SOC, V98, P2447, DOI 10.1002/cncr.11799; HEGEWISCHBECKER S, 1993, BRIT J CANCER, V67, P430, DOI 10.1038/bjc.1993.83; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Hu YH, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23045; Ifergan I, 2003, CANCER-AM CANCER SOC, V98, P1958, DOI 10.1002/cncr.11741; Iwata S, 2021, ONCOL REP, V46, DOI 10.3892/or.2021.8086; Jiang KB, 2017, AM J CANCER RES, V7, P1407; Joo MW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172155; Kang JW, 2017, INT J CLIN EXP PATHO, V10, P359; Kelly RJ, 2011, CLIN CANCER RES, V17, P569, DOI 10.1158/1078-0432.CCR-10-1725; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kubota Daisuke, 2016, Sarcoma, V2016, P1390571, DOI 10.1155/2016/1390571; Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-66; Kumta SM, 2001, INT ORTHOP, V25, P279; Li CY, 2018, INT J MOL MED, V42, P1799, DOI 10.3892/ijmm.2018.3753; Li R, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.632206; Liu L, 2020, ONCOTARGETS THER, V13, P3853, DOI 10.2147/OTT.S232918; Liu XG, 2018, EUR REV MED PHARMACO, V22, P1249, DOI 10.26355/eurrev_201803_14465; Liu YY, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20193045; Liu YC, 2021, BIOL PHARM BULL, V44, P861, DOI 10.1248/bpb.b21-00163; Losos, 2014, NEWCASTLE OTTAWA SCA; Lourda M, 2007, INT J CANCER, V120, P611, DOI 10.1002/ijc.22327; Ma WL, 2020, BIOCHEM BIOPH RES CO, V521, P204, DOI 10.1016/j.bbrc.2019.10.108; Ma XL, 2017, INT J CLIN EXP PATHO, V10, P6254; MARCOVE RC, 1970, J BONE JOINT SURG AM, VA 52, P411, DOI 10.2106/00004623-197052030-00001; McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040; Meschini S, 2003, INT J ONCOL, V23, P1505; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72; Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179203; NIH, 2021, STUD QUAL ASS TOOLS; Oda Y, 2000, ONCOL REP, V7, P859; OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641; Pakbaz S, 2009, IRAN RED CRESCENT ME, V11, P277; Pakos EE, 2003, CANCER-AM CANCER SOC, V98, P581, DOI 10.1002/cncr.11546; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Posl M, 1997, Gen Diagn Pathol, V142, P317; PRICE CHG, 1958, J BONE JOINT SURG BR, V40, P574, DOI 10.1302/0301-620X.40B3.574; Pusztai L, 2005, CANCER-AM CANCER SOC, V104, P682, DOI 10.1002/cncr.21227; Quaresma M, 2015, LANCET, V385, P1206, DOI 10.1016/S0140-6736(14)61396-9; Rajkumar T, 2008, ANTI-CANCER DRUG, V19, P257, DOI 10.1097/CAD.0b013e3282f435b6; Roncuzzi L, 2014, ONCOL REP, V32, P389, DOI 10.3892/or.2014.3181; Rooney AA, 2014, ENVIRON HEALTH PERSP, V122, P711, DOI 10.1289/ehp.1307972; Salah S, 2014, MOL CLIN ONCOL, V2, P811, DOI 10.3892/mco.2014.325; SAMUELS BL, 1991, CANCER RES, V51, P521; Schneider K, 2009, TOXICOL LETT, V189, P138, DOI 10.1016/j.toxlet.2009.05.013; Scionti I, 2008, ANN ONCOL, V19, P1500, DOI 10.1093/annonc/mdn148; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; SERRA M, 1993, ANTICANCER RES, V13, P323; Serra M, 1995, EUR J CANCER, V31A, P1998, DOI 10.1016/0959-8049(95)00335-5; Serra M, 2004, ANN ONCOL, V15, P151, DOI 10.1093/annonc/mdh004; Serra M, 2003, J CLIN ONCOL, V21, P536, DOI 10.1200/JCO.2003.03.144; Serra M, 2006, INT J ONCOL, V29, P1459; Sha HH, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171440; Shen P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2573-2; Shu H, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02204-z; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SLAPAK CA, 1990, CANCER RES, V50, P7895; Song L, 2019, J CELL BIOCHEM, V120, P9656, DOI 10.1002/jcb.28244; Song L, 2017, INT J ONCOL, V50, P535, DOI 10.3892/ijo.2016.3820; Struck RF, 2000, CANCER CHEMOTH PHARM, V45, P59, DOI 10.1007/PL00006744; Sugiu K, 2021, CANCER CHEMOTH PHARM, V88, P513, DOI 10.1007/s00280-021-04310-5; Swensen AR, 1999, CANC INCIDENCE SURVI, P99; TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614; Takemura Y, 1996, INT J CANCER, V66, P29, DOI 10.1002/(SICI)1097-0215(19960328)66:1<29::AID-IJC6>3.0.CO;2-0; Thomas Hilary, 2003, Cancer Control, V10, P159; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Wang JJ, 2015, ONCOL LETT, V9, P940, DOI 10.3892/ol.2014.2773; Wang YJ, 2019, EPIGENOMICS-UK, V11, P1693, DOI 10.2217/epi-2019-0262; Watson MB, 2007, ANTI-CANCER DRUG, V18, P749, DOI 10.1097/CAD.0b013e3280a02f43; Whelan JS, 2015, ANN ONCOL, V26, P407, DOI 10.1093/annonc/mdu526; WICK MR, 1981, AM J SURG PATHOL, V5, P47, DOI 10.1097/00000478-198101000-00008; Wouters OJ, 2020, JAMA-J AM MED ASSOC, V323, P844, DOI 10.1001/jama.2020.1166; Wu DP, 2017, ONCOTARGET, V8, P63857, DOI 10.18632/oncotarget.19148; Xu RD, 2016, ONCOL REP, V35, P1757, DOI 10.3892/or.2015.4497; Xu W, 2018, MED SCI MONITOR, V24, P8812, DOI 10.12659/MSM.911972; Yan XD, 2007, ONCOL REP, V17, P1163; Yang JZ, 2016, MOL MED REP, V14, P3269, DOI 10.3892/mmr.2016.5590; Yuan JJ, 2021, CANCER MANAG RES, V13, P4433, DOI 10.2147/CMAR.S295147; Zhang CL, 2017, CANCER LETT, V396, P66, DOI 10.1016/j.canlet.2017.03.018; Zhang CL, 2016, TUMOR BIOL, V37, P2737, DOI 10.1007/s13277-015-4130-7; Zhang ZH, 2021, HUM CELL, V34, P1558, DOI 10.1007/s13577-021-00564-6; Zhang Z, 2015, INT J CLIN EXP MED, V8, P18032; Zhao PQ, 2018, MOL IMMUNOL, V101, P471, DOI 10.1016/j.molimm.2018.08.010; Zhou Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-12; Zhu KP, 2019, J CELL PHYSIOL, V234, P6927, DOI 10.1002/jcp.27435; Zhu KP, 2018, EPIGENOMICS-UK, V10, P1327, DOI 10.2217/epi-2018-0023; Zhu KP, 2018, INT J BIOL SCI, V14, P321, DOI 10.7150/ijbs.24360; Zhu KP, 2017, ONCOTARGET, V8, P71881, DOI 10.18632/oncotarget.17985; Zou YG, 2018, ONCOL LETT, V15, P1097, DOI 10.3892/ol.2017.7432	120	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02529-x	http://dx.doi.org/10.1038/s41388-022-02529-x		NOV 2022	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M2DF	36434179	hybrid			2022-12-17	WOS:000888684000001
J	Zheng, MZ; Ai, ZW; Guo, YY; Chen, YJ; Xie, P; An, W				Zheng, Mingzhe; Ai, Ziwei; Guo, Yuanyuan; Chen, Yujiao; Xie, Ping; An, Wei			Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma	ONCOGENE			English	Article; Early Access							FATTY LIVER-DISEASE; MITOCHONDRIAL FISSION; REGENERATION ALR; AUGMENTOR; ASSOCIATION; EXPRESSION; PROTEIN; CANCER; DRP1; HCC	Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Accumulating evidence indicates that nonalcoholic steatohepatitis (NASH) is a key predisposing factor for HCC occurrence. However, the precise mechanisms driving NASH transition to HCC remain largely obscure. Augmenter of liver regeneration (ALR) is a sulfhydryl oxidase and cytochrome c reductase that functions as an important regulator of mitochondrial dynamics. In this study, we focused on ALR ubiquitination-mediated degradation and its potential contribution to NASH-driven HCC progression at the mitochondria) level. Hepatic ALR expression in HCC patients was determined using immunohistochemical analysis. Mice with liver-specific deletion of ALR (ALR(CKO)) and ALR(WT) mice were fed a western diet (WD) and high-sugar solution for induction of NASH. HCC in animals was induced via peritoneal administration of CCl4. ALR expression was markedly decreased in liver tissues of patients with NASH and HCC compared with nonNASH and non-tumor tissues. Similarly, in ALR(WT) mice, the ALR level in tumor tissue was reduced relative to that in para-tumor tissue. In the ALR(CKO) group, mice fed WD plus CCl4 developed HCC starting at week 12 while ALR(WT) mice fed WD plus ca, developed HCC at week 24. Analysis of protein posttranslational modifications revealed ubiquitylation (Ub) and deubiquitination (DUb) of ALR by murine double minute 2 (MDM2) and ubiquitin-specific protease 36 (USP36), respectively. Imbalance between Ub and DUb of ALR resulted in profound ALR degradation, which appeared to be reversibly associated with Edmondson-Steiner tumor grade. Rescue of ALR levels via gene transfection abolished tumor malignant features to a certain extent in vitro. Notably, ALR deletion substantially enhanced mitochondrial fission by activating Drp1 phosphorylation at Ser616, thus disrupting the balance of mitochondria) dynamics between fission and fusion and severely impairing oxidative phosphorylation (OXPHOS) and ATP synthesis, instead enhancing anaerobic metabolism, which might be attributed to steatotic hepatocyte transition into the malignant HCC phenotype. Hepatic ALR depletion via dysregulation of ubiquitination is a critical aggravator of NASH-HCC progression and represents a promising therapeutic target for related liver diseases.	[Zheng, Mingzhe; Ai, Ziwei; Guo, Yuanyuan; Chen, Yujiao; Xie, Ping; An, Wei] Capital Med Univ, Dept Cell Biol, Municipal Key Lab Liver Protect & Regulat Regener, Beijing, Peoples R China; [Guo, Yuanyuan] China Japan Friendship Hosp Dept Pathol, Beijing, Peoples R China	Capital Medical University	Xie, P; An, W (corresponding author), Capital Med Univ, Dept Cell Biol, Municipal Key Lab Liver Protect & Regulat Regener, Beijing, Peoples R China.	xiep@ccmu.edu.cn; anwei@ccmu.edu.cn			National Natural Science Foundation of China (NSFC) [32071128]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (NSFC) (No. 32071128).	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Begriche K, 2013, HEPATOLOGY, V58, P1497, DOI 10.1002/hep.26226; Cao Y, 2009, FREE RADICAL BIO MED, V47, P1057, DOI 10.1016/j.freeradbiomed.2009.07.017; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Dayoub R, 2011, MOL MED, V17, P221, DOI 10.2119/molmed.2010.00117; Du JH, 2017, THERANOSTICS, V7, P4192, DOI 10.7150/thno.21400; Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fujiwara N, 2018, GUT, V67, P1493, DOI 10.1136/gutjnl-2017-315193; Galloway CA, 2014, AM J PHYSIOL-GASTR L, V307, pG632, DOI 10.1152/ajpgi.00182.2014; Gandhi CR, 2015, GASTROENTEROLOGY, V148, P379, DOI 10.1053/j.gastro.2014.10.008; Hashimoto E, 2012, HEPATOL RES, V42, P1, DOI 10.1111/j.1872-034X.2011.00872.x; Ho DWY, 2002, GUT, V50, P869, DOI 10.1136/gut.50.6.869; Huang DIQ, 2021, NAT REV GASTRO HEPAT, V18, P223, DOI 10.1038/s41575-020-00381-6; Hernandez-Alvarez MI, 2019, CELL, V177, P881, DOI 10.1016/j.cell.2019.04.010; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia XW, 2018, LAB INVEST, V98, P871, DOI 10.1038/s41374-018-0039-2; Kim MS, 2011, J CELL BIOCHEM, V112, P498, DOI 10.1002/jcb.22940; LABRECQUE DR, 1975, J PHYSIOL-LONDON, V248, P273, DOI 10.1113/jphysiol.1975.sp010973; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Mansouri A, 2018, GASTROENTEROLOGY, V155, P629, DOI 10.1053/j.gastro.2018.06.083; MEI MH, 1993, HEPATOLOGY, V17, P638; Nakagawa H, 2015, WORLD J HEPATOL, V7, P2110, DOI 10.4254/wjh.v7.i17.2110; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Nalesnik MA, 2017, HEPATOLOGY, V66, P266, DOI 10.1002/hep.29047; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Shi HB, 2017, ONCOTARGET, V8, P12637, DOI 10.18632/oncotarget.14478; Sung H, 2019, CA-CANCER J CLIN, V69, P88, DOI 10.3322/caac.21499; Thasler WE, 2005, HISTOPATHOLOGY, V47, P57, DOI 10.1111/j.1365-2559.2005.02172.x; Tilg H, 2006, GASTROENTEROLOGY, V131, P934, DOI 10.1053/j.gastro.2006.05.054; Tsuchida T, 2018, J HEPATOL, V69, P385, DOI 10.1016/j.jhep.2018.03.011; Wang N, 2014, EXP THER MED, V7, P93, DOI 10.3892/etm.2013.1140; Wang X, 2022, NUCLEIC ACIDS RES, V50, pD719, DOI 10.1093/nar/gkab962; Wu Y, 2007, ARCH BIOCHEM BIOPHYS, V464, P48, DOI 10.1016/j.abb.2007.03.025; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Younossi ZM, 2015, HEPATOLOGY, V62, P1723, DOI 10.1002/hep.28123; Yu HY, 2014, ONCOTARGETS THER, V7, P887, DOI 10.2147/OTT.S61531; Zhang C, 2017, HEPATOLOGY, V66, P1989, DOI 10.1002/hep.29326	41	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02549-7	http://dx.doi.org/10.1038/s41388-022-02549-7		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M2DF	36434180	Green Submitted			2022-12-17	WOS:000888684000002
J	Fattore, L; Cafaro, G; Di Martile, M; Campani, V; Sacconi, A; Liguoro, D; Marra, E; Bruschini, S; Stoppoloni, D; Cirombella, R; De Nicola, F; Pallocca, M; Ruggiero, CF; Castaldo, V; Catizone, A; Del Bufalo, D; Viglietto, G; Vecchione, A; Blandino, G; Aurisicchio, L; Fanciulli, M; Ascierto, PA; De Rosa, G; Mancini, R; Ciliberto, G				Fattore, Luigi; Cafaro, Giordana; Di Martile, Marta; Campani, Virginia; Sacconi, Andrea; Liguoro, Domenico; Marra, Emanuele; Bruschini, Sara; Stoppoloni, Daniela; Cirombella, Roberto; De Nicola, Francesca; Pallocca, Matteo; Ruggiero, Ciro F.; Castaldo, Vittorio; Catizone, Angiolina; Del Bufalo, Donatella; Viglietto, Giuseppe; Vecchione, Andrea; Blandino, Giovanni; Aurisicchio, Luigi; Fanciulli, Maurizio; Ascierto, Paolo A.; De Rosa, Giuseppe; Mancini, Rita; Ciliberto, Gennaro			Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance	ONCOGENE			English	Article; Early Access							TUMOR-ASSOCIATED MACROPHAGES; ACQUIRED-RESISTANCE; METASTATIC MELANOMA; CANCER; EXPRESSION; COMBINATION; MECHANISMS; MIR-204-5P; EVOLUTION; ANTI-PD-1	BRAF-mutated melanoma relapsing after targeted therapies is an aggressive disease with unmet clinical need. Hence the need to identify novel combination therapies able to overcome drug resistance. miRNAs have emerged as orchestrators of non-genetic mechanisms adopted by melanoma cells to challenge therapies. In this context we previously identified a subset of oncosuppressor miRNAs downregulated in drug-resistant melanomas. Here we demonstrate that lipid nanoparticles co-encapsulating two of them, miR-199-5p and miR-204-5p, inhibit tumor growth both in vitro and in vivo in combination with target therapy and block the development of drug resistance. Mechanistically they act by directly reducing melanoma cell growth and also indirectly by hampering the recruitment and reprogramming of pro-tumoral macrophages. Molecularly, we demonstrate that the effects on macrophages are mediated by the dysregulation of a newly identified miR-204-5p-miR-199b-5p/CCL5 axis. Finally, we unveiled that M2 macrophages programs are molecular signatures of resistance and predict response to therapy in patients. Overall, these findings have strong translational implications to propose new combination therapies making use of RNA therapeutics for metastatic melanoma patients.	[Fattore, Luigi; De Nicola, Francesca; Fanciulli, Maurizio] IRCCS Regina Elena Natl Canc Inst, Dept Res, SAFU Lab, Adv Diagnost & Technol Innovat,Translat Res Area, I-00144 Rome, Italy; [Cafaro, Giordana; Di Martile, Marta; Del Bufalo, Donatella] IRCCS Regina Elena Natl Canc Inst, Preclin Models & New Therapeut Agents Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Campani, Virginia; De Rosa, Giuseppe] Univ Napoli Federico II, Dipartimento Farm, Via D Montesano 49, I-80131 Naples, Italy; [Sacconi, Andrea; Pallocca, Matteo] IRCCS Regina Elena Natl Canc Inst, Clin Trial Ctr, Biostat & Bioinformat Unit, I-00144 Rome, Italy; [Liguoro, Domenico; Mancini, Rita] Sapienza Univ Rome, Dept Clin & Mol Med, I-00161 Rome, Italy; [Liguoro, Domenico; Bruschini, Sara; Cirombella, Roberto; Vecchione, Andrea; Mancini, Rita] Sapienza Univ Rome, Fac Med & Psychol, Dept Clin & Mol Med, St Andrea Hosp, I-00118 Rome, Italy; [Marra, Emanuele; Stoppoloni, Daniela; Aurisicchio, Luigi] Takis Srl, I-00128 Rome, Italy; [Ruggiero, Ciro F.; Ascierto, Paolo A.] Ist Nazl Tumori IRCCS Fdn Pascale, Unit Melanoma Canc Immunotherapy & Dev Therapeut, I-80131 Naples, Italy; [Castaldo, Vittorio; Catizone, Angiolina] Sapienza Univ Rome, Dept Anat Histol Forens Med & Orthoped, I-00161 Rome, Italy; [Viglietto, Giuseppe] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy; [Blandino, Giovanni] IRCCS Regina Elena Natl Canc Inst, Oncogen & Epigenet Unit, I-00144 Rome, Italy; [Ciliberto, Gennaro] IRCSS Regina Elena Natl Canc Inst, Sci Directorate, I-00144 Rome, Italy	University of Naples Federico II; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Fondazione Pascale; Sapienza University Rome; Magna Graecia University of Catanzaro	Ciliberto, G (corresponding author), IRCSS Regina Elena Natl Canc Inst, Sci Directorate, I-00144 Rome, Italy.	gennaro.ciliberto@ifo.it	Fattore, Luigi/K-7791-2016	Fattore, Luigi/0000-0002-9245-0126	Italian Association for Cancer Research (AIRC) [IG19865, IG24451]; Lazio Innova [85-2017-13750, A0375-2020-36657]; Italian Minister of Health grant PRIN [2017HWTP2K]; Lega Italiana per la Lotta ai Tumori (LILT) [2021U0001637]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Lazio Innova; Italian Minister of Health grant PRIN(Ministry of Education, Universities and Research (MIUR)); Lega Italiana per la Lotta ai Tumori (LILT)	This study was supported by Italian Association for Cancer Research (AIRC) grants IG19865 to G. Ciliberto and IG24451 to R. Mancini and by the Lazio Innova grants 2018 n. 85-2017-13750 and 2020 n. A0375-2020-36657 to R. Mancini and by Italian Minister of Health grant PRIN 2017 (Prot. 2017HWTP2K) to G. Ciliberto and R. Mancini. The study was also supported by Lega Italiana per la Lotta ai Tumori (LILT) grant n. 2021U0001637 to L. Fattore.	Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Bragelmann J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25728-8; Bruschini S, 2020, J CELL PHYSIOL, V235, P1877, DOI 10.1002/jcp.29121; Cerezo-Wallis D, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1073-3; De Luca T, 2016, MOL CARCINOGEN, V55, P2304, DOI 10.1002/mc.22437; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Di Martile M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000489; Di Mitri D, 2019, CELL REP, V28, P2156, DOI 10.1016/j.celrep.2019.07.068; Diaz-Martinez M, 2018, CANCER RES, V78, P1017, DOI 10.1158/0008-5472.CAN-17-1318; Duan ZJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00506-6; Dummer R, 2022, J CLIN ONCOL, V40, P1428, DOI 10.1200/JCO.21.01601; Erkes DA, 2020, CANCER DISCOV, V10, P254, DOI 10.1158/2159-8290.CD-19-0672; Fattore L, 2020, CANCERS, V12, DOI 10.3390/cancers12113368; Fattore L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061930; Fattore L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2048-5; Fattore L, 2019, CELL DEATH DIFFER, V26, P1267, DOI 10.1038/s41418-018-0205-5; Fattore L, 2017, CYTOKINE GROWTH F R, V36, P39, DOI 10.1016/j.cytogfr.2017.05.003; Fattore L, 2017, ONCOTARGET, V8, P22262, DOI 10.18632/oncotarget.14763; Fattore L, 2016, P NATL ACAD SCI USA, V113, pE5005, DOI 10.1073/pnas.1607753113; Fattore L, 2015, ONCOTARGET, V6, P24823, DOI 10.18632/oncotarget.4485; Fekete JT, 2019, INT J CANCER, V145, P3140, DOI 10.1002/ijc.32369; Ferrucci PF, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001806; Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29; Galasso M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0819-8; Gilot D, 2017, NAT CELL BIOL, V19, P1348, DOI 10.1038/ncb3623; Gogas H, 2020, J CLIN ONCOL, V38; Gutzmer R, 2020, LANCET, V395, P1835, DOI 10.1016/S0140-6736(20)30934-X; Haas L, 2021, NAT CANCER, V2, P693, DOI 10.1038/s43018-021-00221-9; Hong BS, 2019, CANCER RES, V79, P1520, DOI 10.1158/0008-5472.CAN-18-0891; Hong DVS, 2020, BRIT J CANCER, V122, P1630, DOI 10.1038/s41416-020-0802-1; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Johnson DB, 2017, J IMMUNOTHER, V40, P31, DOI 10.1097/CJI.0000000000000148; Kakavand H, 2017, CLIN CANCER RES, V23, P6054, DOI 10.1158/1078-0432.CCR-16-1688; Kohli K, 2022, CANCER GENE THER, V29, P10, DOI 10.1038/s41417-021-00303-x; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lau PKH, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002995; Lee JS, 2021, CELL, V184, P2487, DOI 10.1016/j.cell.2021.03.030; Li H, 2019, BIOCHEM CELL BIOL, V97, P109, DOI 10.1139/bcb-2018-0141; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Liguoro D, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188440; Lin X, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01397; Liu GT, 2015, CANCER LETT, V357, P476, DOI 10.1016/j.canlet.2014.11.015; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Marin-Bejar O, 2021, CANCER CELL, V39, P1135, DOI 10.1016/j.ccell.2021.05.015; Mason R, 2020, PIGM CELL MELANOMA R, V33, P358, DOI 10.1111/pcmr.12831; Molgora M, 2021, MED-CAMBRIDGE, V2, P666, DOI 10.1016/j.medj.2021.05.001; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Morris JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090353; Ozga AJ, 2021, IMMUNITY, V54, P859, DOI 10.1016/j.immuni.2021.01.012; Pisanu ME, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0989-7; Propper DJ, 2022, NAT REV CLIN ONCOL, V19, P237, DOI 10.1038/s41571-021-00588-9; Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059; Ruggiero CF, 2019, CANCERS, V11, DOI 10.3390/cancers11101425; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tremble LF, 2020, BRIT J CANCER, V123, P1553, DOI 10.1038/s41416-020-01037-7; Tupone MG, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0203-6; van Zandwijk N, 2015, ANN ONCOL, V26, P16, DOI 10.1093/annonc/mdv090.2; Vitiello M, 2017, ONCOTARGET, V8, P25395, DOI 10.18632/oncotarget.15915; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wang T, 2015, CLIN CANCER RES, V21, P1652, DOI 10.1158/1078-0432.CCR-14-1554; Wang YJ, 2021, CANCER CELL, V39, P1375, DOI 10.1016/j.ccell.2021.07.023; Winkle M, 2021, NAT REV DRUG DISCOV, V20, P629, DOI 10.1038/s41573-021-00219-z; Yang ZC, 2020, INT ARCH ALLERGY IMM, V181, P239, DOI 10.1159/000505064	71	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02547-9	http://dx.doi.org/10.1038/s41388-022-02547-9		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6J4TZ	36418472	Green Published, hybrid			2022-12-17	WOS:000886818700001
J	Fu, ZM; Zhang, PS; Zhang, RC; Zhang, BM; Xiang, SJ; Zhang, Y; Luo, Z; Huang, C				Fu, Zhongmao; Zhang, Pengshan; Zhang, Renchao; Zhang, Bimeng; Xiang, Shijun; Zhang, Yuan; Luo, Zai; Huang, Chen			Novel hypoxia-induced HIF1 alpha-circTDRD3-positive feedback loop promotes the growth and metastasis of colorectal cancer	ONCOGENE			English	Article; Early Access							INDUCIBLE FACTORS; CIRCULAR RNAS; STATISTICS; EXPRESSION; BINDING; P53	Tumor hypoxia and circular RNAs (circRNAs) are considered to play key roles in tumor progression and malignancy, respectively. Nevertheless, the biological functions and underlying mechanisms of specific circRNAs exposed to hypoxic microenvironments in colorectal cancer (CRC) remain largely elusive. Herein, a novel circRNA, circTDRD3, which is upregulated under hypoxic conditions, was identified. The expression of circTDRD3 was highly expressed in CRC tissues and positively correlated with overall survival, tumor size, lymph node invasion and clinical stage. CircTDRD3 facilitated CRC cell proliferation, migration and metastasis in vitro and in vivo. Mechanistically, circTDRD3 promoted HIF1 alpha expression by sponging miR-1231, which facilitated CRC progression. Meanwhile, HIF1 alpha directly combined with TDRD3 promoter to increase the expression of TDRD3 pre-mRNA. Then HIF1a-induced PTBP1 accelerated the formation of circTDRD3. Our findings reveal that circTDRD3 facilitates the proliferation and metastasis of CRC through a positive feedback loop mediated by the HIF1 alpha/PTBP1/circTDRD3/miR-1231/HIF1 alpha axis. Therefore, circTDRD3 may serve as a prognostic biomarker and therapeutic target for patients with CRC.	[Fu, Zhongmao; Zhang, Pengshan; Zhang, Renchao; Xiang, Shijun; Zhang, Yuan; Luo, Zai; Huang, Chen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai 200080, Peoples R China; [Zhang, Bimeng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Acupuncture Moxibust, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Huang, C (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai 200080, Peoples R China.	richard-hc@sohu.com			National Natural Science Foundation of China [81772526, 82072662]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20191425]; Shanghai Jiaotong University Medical Cross Fund [YG2017MS28]; Three year Action Plan for Clinical Skills and Clinical Innovation in Shanghai level Hospitals [SHDC2020CR4022]; Shanghai Anticancer Association Eyas Program [SACA-CY21C08]; China Postdoctoral Science Foundation [2021M702182]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Jiaotong University Medical Cross Fund; Three year Action Plan for Clinical Skills and Clinical Innovation in Shanghai level Hospitals; Shanghai Anticancer Association Eyas Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Natural Science Foundation of China (Grant nos. 81772526 and 82072662), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (Grant no. 20191425), Shanghai Jiaotong University Medical Cross Fund (Grant no. YG2017MS28), Three year Action Plan for Clinical Skills and Clinical Innovation in Shanghai level Hospitals (Grant no. SHDC2020CR4022), Shanghai Anticancer Association Eyas Program (Grant no. SACA-CY21C08 to PZ) and China Postdoctoral Science Foundation (Grant no. 2021M702182 to PZ).	Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen LY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01272-9; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen T, 2021, ONCOGENE, V40, P2756, DOI 10.1038/s41388-021-01739-z; Chen Y, 2018, J CLIN INVEST, V128, P1937, DOI 10.1172/JCI95089; de Heer EC, 2020, J CLIN INVEST, V130, P5074, DOI 10.1172/JCI137552; Georgilis A, 2018, CANCER CELL, V34, P85, DOI 10.1016/j.ccell.2018.06.007; Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Harrandah AM, 2018, CANCER LETT, V438, P126, DOI 10.1016/j.canlet.2018.09.019; He RF, 2022, CANCERS, V14, DOI 10.3390/cancers14194950; Huan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1122-z; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim S, 2021, MODERN PATHOL, V34, P672, DOI 10.1038/s41379-020-00681-x; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Li BT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20527-z; Li J, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01525-z; Loh XY, 2020, CANCER RES, V80, P219, DOI 10.1158/0008-5472.CAN-18-2796; Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Oberstrass FC, 2005, SCIENCE, V309, P2054, DOI 10.1126/science.1114066; Quintero M, 2004, EJSO-EUR J SURG ONC, V30, P465, DOI 10.1016/j.ejso.2004.03.008; Ren SS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1398-2; Rong ZY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02126-y; Rong ZY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01400-z; Rong ZY, 2020, CANCER SCI, V111, P1203, DOI 10.1111/cas.14341; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tiwari A, 2020, GASTROENTEROLOGY, V159, P1882, DOI 10.1053/j.gastro.2020.07.046; Wei YP, 2020, HEPATOLOGY, V71, P130, DOI 10.1002/hep.30795; Xia X, 2020, ONCOGENE, V39, P6231, DOI 10.1038/s41388-020-01425-6; Xu S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02824-z; Yang HO, 2020, THERANOSTICS, V10, P8211, DOI 10.7150/thno.44419; Zeng Z, 2021, ONCOGENE, V40, P5505, DOI 10.1038/s41388-021-01960-w; Zhang JY, 2018, HEPATOLOGY, V67, P1872, DOI 10.1002/hep.29681; Zheng J, 2016, NAT GENET, V48, P747, DOI 10.1038/ng.3568; Zhu ZL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1054-7	45	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02548-8	http://dx.doi.org/10.1038/s41388-022-02548-8		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6J4UB	36418471				2022-12-17	WOS:000886818900001
J	Zeng, WF; Xiong, LX; Wu, W; Li, SR; Liu, J; Yang, LB; Lao, LY; Huang, PH; Zhang, MM; Chen, HP; Miao, NY; Lin, ZR; Liu, ZF; Yang, XY; Wang, JY; Wang, P; Song, EW; Yao, YD; Nie, Y; Chen, JN; Huang, D				Zeng, Wenfeng; Xiong, Lixiong; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Zhang, Mengmeng; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di			CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype	ONCOGENE			English	Article; Early Access							CANCER-ASSOCIATED FIBROBLASTS; MESENCHYMAL TRANSITION; GROWTH-FACTOR; TGF-BETA; KAPPA-B; CARCINOMA; CELLS; METASTASIS; ANGIOGENESIS; IMMUNOSUPPRESSION	The heterogeneity of cancer-associated fibroblasts (CAFs) might be ascribed to differences in origin. CD10 and GPR77 have been reported to identify a chemoresistance-inducing CAF subset in breast cancer. However, the precise mechanism for the formation of the CD10(+)GPR77(+) CAFs remains unknown. In this study, we found that CCL18 expression was positively correlated with the density of CD10(+)GPR77(+) CAFs in breast cancer and associated with a poor response to chemotherapy. Moreover, CCL18 secreted by tumor-associated macrophages (TAMs) activated a CD10(+)GPR77(+) CAF phenotype in normal breast-resident fibroblasts (NBFs), which could then enrich cancer stem cells (CSCs) and induce chemoresistance in breast cancer cells. Mechanistically, CCL18 activated NF-kappa B signaling via PITPNM3 and thus enhanced the production of IL-6 and IL-8. Furthermore, intratumoral CCL18 injection significantly induced the activation of NBFs and the chemoresistance of xenografts in vivo. In addition, targeting CCL18 by anti-CCL18 antibody could inhibit the formation of CD10(+)GPR77(+) CAFs and recover the chemosensitivity in vivo, leading to effective tumor control. Collectively, these findings reveal that inflammatory signaling crosstalk between TAMs and fibroblasts is responsible for the formation of the CD10(+)GPR77(+) CAFs, suggesting CCL18-PITPNM3 signaling is a potential therapeutic target to block the activation of this specific CAF subtype and tumor chemoresistance.	[Zeng, Wenfeng; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China; [Zeng, Wenfeng; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China; [Zeng, Wenfeng; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di] Bioland Lab, Guangzhou 510005, Peoples R China; [Xiong, Lixiong] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pharm, Guangzhou 510655, Peoples R China; [Zhang, Mengmeng] Peking Univ, Peking Univ Peoples Hosp, Dept Breast Surg, Beijing 100044, Peoples R China; [Yao, Yandan] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Shenshan Med Ctr, Shanwei 516621, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); Sun Yat Sen University; Peking University; Sun Yat Sen University	Yao, YD; Nie, Y; Chen, JN; Huang, D (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.; Yao, YD; Nie, Y; Chen, JN; Huang, D (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China.; Yao, YD; Nie, Y; Chen, JN; Huang, D (corresponding author), Bioland Lab, Guangzhou 510005, Peoples R China.; Yao, YD (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Shenshan Med Ctr, Shanwei 516621, Peoples R China.	yaoyand@mail.sysu.edu.cn; nieyan7@mail.sysu.edu.cn; chenjn335@mail.sysu.edu.cn; huangd63@mail.sysu.edu.cn			Natural Science Foundation of China [92159303, 81930081, 81621004, 81720108029, 91940305, 82173054, 81872158, 82222029, 82002786, 81902699, 81972465, 82071859, 82071860]; Guangdong Science and Technology Department [2020B1212060018, 2020B1212030004, 2020B1515120007]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011485, 2019A1515011467, 2020A1515011458, 2022B1515020101, 2022B1515020048, 2019A050510016, 2021B1515230001, 2021A005]; Department of Natural Resources of Guangdong Province [GDNRC [2021]51]; Bureau of Science and Technology of Guangzhou [20212200003]; Program for Guangdong Introducing Innovative and Enterpreneurial Teams [2019BT02Y198]; Guangzhou Science Technology and Innovation Commission [202102010148]; Fundamental Research Funds for the Central Universities [20ykjc03]; Fountain-Valley Life Sciences Fund of University of Chinese Academy of Sciences Education Foundation; Clinical Innovation Research Program of Bioland Laboratory [2018GZR0201004]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Department; Guangdong Basic and Applied Basic Research Foundation; Department of Natural Resources of Guangdong Province; Bureau of Science and Technology of Guangzhou; Program for Guangdong Introducing Innovative and Enterpreneurial Teams; Guangzhou Science Technology and Innovation Commission; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Fountain-Valley Life Sciences Fund of University of Chinese Academy of Sciences Education Foundation; Clinical Innovation Research Program of Bioland Laboratory	This work was supported by grants from the Natural Science Foundation of China (92159303 (ES), 81930081 (ES), 81621004 (ES), 81720108029 (ES), 81930081 (ES), 91940305 (ES), 82173054 (YN), 81872158 (YN), 82222029 (DH), 82002786 (LY), 81902699 (JL), 81972465 (WW) 82071859 (YY), 82071860 (YY)), Guangdong Science and Technology Department (2020B1212060018 (ES), 2020B1212030004 (ES), 2020B1515120007 (YY)), Guangdong Basic and Applied Basic Research Foundation (2019A1515011485 (JL), 2019A1515011467 (SL), 2020A1515011458 (DH), 2022B1515020101 (DH), 2022B1515020048 (YN), 2019A050510016 (YY), 2021B1515230001 (YY), 2021A005 (YY)), Clinical Innovation Research Program of Bioland Laboratory (2018GZR0201004 (ES)), Department of Natural Resources of Guangdong Province (GDNRC [2021]51), Bureau of Science and Technology of Guangzhou (20212200003 (ES)), the Program for Guangdong Introducing Innovative and Enterpreneurial Teams (2019BT02Y198 (ES, YY)), Guangzhou Science Technology and Innovation Commission (202102010148 (YN)) and the Fundamental Research Funds for the Central Universities (20ykjc03 (YY)). The research is partly supported by Fountain-Valley Life Sciences Fund of University of Chinese Academy of Sciences Education Foundation.	Affo S, 2021, CANCER CELL, V39, P866, DOI 10.1016/j.ccell.2021.03.012; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Aravind A, 2022, J CELL COMMUN SIGNAL, V16, P293, DOI 10.1007/s12079-021-00633-3; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Dulauroy S, 2012, NAT MED, V18, P1262, DOI 10.1038/nm.2848; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Froese AR, 2016, AM J RESP CRIT CARE, V194, P84, DOI 10.1164/rccm.201508-1638OC; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Huang D, 2017, CANCER RES, V77, P3591, DOI [10.1158/0008-5472.CAN-16-2706, 10.1158/0008-5472.can-16-2706]; Huo XF, 2014, GUT, V63, P1042, DOI 10.1136/gutjnl-2013-305533; Islam SA, 2013, J EXP MED, V210, P1889, DOI 10.1084/jem.20130240; Jotzu C, 2011, CELL ONCOL, V34, P55, DOI 10.1007/s13402-011-0012-1; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kieffer Y, 2020, CANCER DISCOV, V10, P1330, DOI 10.1158/2159-8290.CD-19-1384; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kuppe C, 2021, NATURE, V589, P281, DOI 10.1038/s41586-020-2941-1; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Leek RD, 1996, CANCER RES, V56, P4625; Lewis CE, 2011, CANCER CELL, V19, P431, DOI 10.1016/j.ccr.2011.03.016; Li HY, 2014, J CELL BIOCHEM, V115, P596, DOI 10.1002/jcb.24697; Li HY, 2018, J CELL PHYSIOL, V233, P3207, DOI 10.1002/jcp.26164; Lin L, 2015, ONCOTARGET, V6, P34758, DOI 10.18632/oncotarget.5325; Liu RP, 2019, HEPATOLOGY, V70, P1317, DOI 10.1002/hep.30662; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Marigo I, 2020, CANCER DISCOV, V10, P1758, DOI 10.1158/2159-8290.CD-20-0036; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Nie Y, 2017, CANCER RES, V77, P3605, DOI 10.1158/0008-5472.CAN-16-2709; Niu N, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00349-4; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palumbo-Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777; Primac I, 2019, J CLIN INVEST, V129, P4509, DOI 10.1172/JCI125890; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437; She L, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0620-1; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Su SC, 2017, CELL RES, V27, P461, DOI 10.1038/cr.2017.34; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Sun XT, 2022, GUT, V71, P129, DOI 10.1136/gutjnl-2020-322744; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Vickman RE, 2020, PROSTATE, V80, P173, DOI 10.1002/pros.23929; von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127	62	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02540-2	http://dx.doi.org/10.1038/s41388-022-02540-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6J4UB	36418470	hybrid			2022-12-17	WOS:000886818900002
J	Song, FF; Zhang, YH; Chen, Q; Bi, DX; Yang, MQ; Lu, L; Li, M; Zhu, HY; Liu, Y; Wei, Q; Qin, HL; Li, JY				Song, Feifei; Zhang, Youhua; Chen, Qi; Bi, Dexi; Yang, Muqing; Lu, Ling; Li, Man; Zhu, Huiyuan; Liu, Ying; Wei, Qing; Qin, Huanlong; Li, Jiyu			Mast cells inhibit colorectal cancer development by inducing ER stress through secreting Cystatin C	ONCOGENE			English	Article; Early Access							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; PROGNOSTIC-SIGNIFICANCE; TUMOR ANGIOGENESIS; BREAST-CANCER; DENSITY; SURVIVAL; PATHWAY; PROGRESSION; CONTRIBUTE	Mast cells (MCs) are abundantly distributed in the human intestinal mucosa and submucosa. However, their roles and mechanisms in the development of colorectal cancer (CRC) are still unclear. In the present research, we found that the infiltration density of MCs in CRC tissues was positively correlated with improved patients' prognoses. Moreover, MCs suppressed the growth and induced the apoptosis of CRC cells in vitro and in vivo but had no effect on normal colonic epithelial cells. The present study revealed that MCs specifically induced endoplasmic reticulum stress (ERS) and activated the unfolded protein response (UPR) in CRC cells but not in normal cells, which led to the suppression of CRC development in vivo. Furthermore, we found that the secreted Cystatin C protein was the key factor for the MC-induced ERS in CRC cells. This work is of significance for uncovering the antitumor function of MCs in CRC progression and identifying the potential of CRC to respond to MC-targeted immunotherapy.	[Song, Feifei; Zhang, Youhua; Bi, Dexi; Lu, Ling; Li, Man; Zhu, Huiyuan; Wei, Qing] Tongji Univ, Dept Pathol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Chen, Qi] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol & Hepatol, Shanghai 200031, Peoples R China; [Yang, Muqing] Tongji Univ, Ctr Difficult & Complicated Abdominal Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Liu, Ying; Li, Jiyu] Tongji Univ, Dept Gen Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Qin, Huanlong] Tongji Univ, Dept Gastrointestinal Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Li, Jiyu] Fudan Univ, Geriatr Canc Ctr, HuaDong Hosp, Shanghai 200040, Peoples R China	Tongji University; Fudan University; Tongji University; Tongji University; Tongji University; Fudan University	Wei, Q (corresponding author), Tongji Univ, Dept Pathol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.; Li, JY (corresponding author), Tongji Univ, Dept Gen Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.; Qin, HL (corresponding author), Tongji Univ, Dept Gastrointestinal Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.; Li, JY (corresponding author), Fudan Univ, Geriatr Canc Ctr, HuaDong Hosp, Shanghai 200040, Peoples R China.	weiqing1971@tongji.edu.cn; qinhuanlong@tongji.edu.cn; lijiyu@fudan.edu.cn			National Natural Science Foundation of China [82072647, 31741087, 81602262, 82173190]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was financially supported by the National Natural Science Foundation of China (Nos. 82072647, 31741087, 81602262 and 82173190).	Acikalin MF, 2005, DIGEST LIVER DIS, V37, P162, DOI 10.1016/j.dld.2004.09.028; Amicarella F, 2017, GUT, V66, P692, DOI 10.1136/gutjnl-2015-310016; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Blatner NR, 2010, P NATL ACAD SCI USA, V107, P6430, DOI 10.1073/pnas.0913683107; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Chan JK, 2005, GYNECOL ONCOL, V99, P20, DOI 10.1016/j.ygyno.2005.05.042; Chen WQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1824-6; Chen Y, 2017, ONCOGENE, V36, P2879, DOI 10.1038/onc.2016.442; Cheng SJ, 2021, CELL, V184, P792, DOI 10.1016/j.cell.2021.01.010; Dabiri S, 2004, MODERN PATHOL, V17, P690, DOI 10.1038/modpathol.3800094; Dantas RCM, 2017, APPL IMMUNOHISTO M M, V25, pE83, DOI 10.1097/PAI.0000000000000587; Della Rovere F, 2007, ANTICANCER RES, V27, P2465; Dowling P, 2011, PROTEOMICS, V11, P794, DOI 10.1002/pmic.201000530; Dudeck A, 2019, J ALLERGY CLIN IMMUN, V144, pS4, DOI 10.1016/j.jaci.2018.10.054; Ferrone C, 2010, J CLIN ONCOL, V28, P4045, DOI 10.1200/JCO.2010.27.9992; Fu HC, 2017, ANN SURG ONCOL, V24, P1435, DOI 10.1245/s10434-016-5702-5; Fu SN, 2011, NATURE, V473, P528, DOI 10.1038/nature09968; Glab JA, 2017, CELL DEATH DIFFER, V24, P944, DOI 10.1038/cdd.2017.53; Gulubova M, 2009, J GASTROEN HEPATOL, V24, P1265, DOI 10.1111/j.1440-1746.2007.05009.x; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79; Hempel HA, 2017, PROSTATE, V77, P412, DOI 10.1002/pros.23280; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009; Hughes MR, 2015, METHODS MOL BIOL, V1220, pVII; Tran H, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00056; Ji XL, 2015, FEBS LETT, V589, P3938, DOI 10.1016/j.febslet.2015.11.029; Kim JL, 2019, CANCERS, V11, DOI 10.3390/cancers11050642; Kyritsi K, 2021, HEPATOLOGY, V73, P2397, DOI 10.1002/hep.31497; Leto G, 2018, LIFE SCI, V202, P152, DOI 10.1016/j.lfs.2018.04.013; Lin C, 2017, BRIT J SURG, V104, P1037, DOI 10.1002/bjs.10546; Ma Y, 2013, CANCER RES, V73, P3927, DOI 10.1158/0008-5472.CAN-12-4479; Maciel Thiago T, 2015, F1000Prime Rep, V7, P09, DOI 10.12703/P7-09; Majorini MT, 2020, CANCER RES, V80, P2311, DOI 10.1158/0008-5472.CAN-19-3596; Malfettone A, 2013, J CELL MOL MED, V17, P1025, DOI 10.1111/jcmm.12073; Mao YH, 2018, INT J CANCER, V143, P2271, DOI 10.1002/ijc.31613; da Silva EZM, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI 10.1369/0022155414545334; Marichal T, 2013, CANCER IMMUNOL RES, V1, P269, DOI 10.1158/2326-6066.CIR-13-0119; Marone G, 2016, EUR J PHARMACOL, V778, P146, DOI 10.1016/j.ejphar.2015.03.088; Mehdawi L, 2016, ACTA ONCOL, V55, P1434, DOI 10.1080/0284186X.2016.1198493; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Mussap M, 2004, CRIT REV CL LAB SCI, V41, P467, DOI 10.1080/10408360490504934; Nielsen HJ, 1999, J PATHOL, V189, P487, DOI 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I; Pihan P, 2017, CELL DEATH DIFFER, V24, P1478, DOI 10.1038/cdd.2017.82; Poh AR, 2017, CANCER CELL, V31, P563, DOI 10.1016/j.ccell.2017.03.006; Rajput AB, 2008, BREAST CANCER RES TR, V107, P249, DOI 10.1007/s10549-007-9546-3; Reissfelder C, 2015, J CLIN INVEST, V125, P739, DOI 10.1172/JCI74894; Ribatti D, 2016, EUR J PHARMACOL, V778, P152, DOI 10.1016/j.ejphar.2015.02.056; Ribatti D, 2013, IMMUNOL LETT, V152, P83, DOI 10.1016/j.imlet.2013.05.003; Rigoni A, 2015, CANCER MICROENVIRON, V8, P167, DOI 10.1007/s12307-014-0152-8; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Segura-Villalobos D, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11030349; Shikotra A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38352; Sinnamon MJ, 2008, CARCINOGENESIS, V29, P880, DOI 10.1093/carcin/bgn040; Song FF, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.10; Song FF, 2019, EBIOMEDICINE, V41, P156, DOI 10.1016/j.ebiom.2019.02.051; Suzuki S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1863-z; Tan SY, 2005, WORLD J GASTROENTERO, V11, P1210, DOI 10.3748/wjg.v11.i8.1210; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vis MAM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00911; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wu JJ, 2019, J EXP MED, V216, P867, DOI 10.1084/jem.20182192; Wu MS, 2020, CANCERS, V12, DOI 10.3390/cancers12010097; Xu YK, 2015, IMMUNOL CELL BIOL, V93, P442, DOI 10.1038/icb.2014.121; Yodavudh Sirisanpang, 2008, Journal of the Medical Association of Thailand, V91, P723; Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327; Zhu PJ, 2018, REDOX BIOL, V16, P157, DOI 10.1016/j.redox.2018.02.019	70	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02543-z	http://dx.doi.org/10.1038/s41388-022-02543-z		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H4PP	36402931				2022-12-17	WOS:000885424000001
J	Chen, D; Ning, Z; Chen, H; Lu, C; Liu, XL; Xia, T; Qi, H; Wang, W; Ling, T; Guo, X; Tekcham, DS; Liu, XM; Liu, J; Wang, A; Yan, Q; Liu, JW; Tan, G; Piao, HL				Chen, Di; Ning, Zhen; Chen, Huan; Lu, Chang; Liu, Xiaolong; Xia, Tian; Qi, Huan; Wang, Wen; Ling, Ting; Guo, Xin; Tekcham, Dinesh Singh; Liu, Xiumei; Liu, Jing; Wang, Aman; Yan, Qiu; Liu, Ji-Wei; Tan, Guang; Piao, Hai-long			An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases (Nov, 10.1038/s41388-019-1002-4, 2022)	ONCOGENE			English	Correction; Early Access												jiweiliudl@126.com; tanguangdl@126.com; hpiao@dicp.ac.cn						Chen D, 2020, ONCOGENE, V39, P587, DOI 10.1038/s41388-019-1002-4	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02514-4	http://dx.doi.org/10.1038/s41388-022-02514-4		NOV 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H1YQ	36400973	Bronze			2022-12-17	WOS:000885244700001
J	Dumetier, B; Zadoroznyj, A; Berthelet, J; Causse, S; Allegre, J; Bourgeois, P; Cattin, F; Racoeur, C; Paul, C; Garrido, C; Dubrez, L				Dumetier, Baptiste; Zadoroznyj, Aymeric; Berthelet, Jean; Causse, Sebastien; Allegre, Jennifer; Bourgeois, Pauline; Cattin, Florine; Racoeur, Cindy; Paul, Catherine; Garrido, Carmen; Dubrez, Laurence			cIAP1/TRAF2 interplay promotes tumor growth through the activation of STAT3	ONCOGENE			English	Article; Early Access							NF-KAPPA-B; UBIQUITIN LIGASE; TRAF2; CIAP1; KINASE; C-IAP1; INHIBITOR; DEGRADATION; COMPLEX; CANCER	Cellular inhibitor of apoptosis-1 (cIAP1) is a signaling regulator with oncogenic properties. It is involved in the regulation of signaling pathways controlling inflammation, cell survival, proliferation, differentiation and motility. It is recruited into membrane-receptor-associated signaling complexes thanks to the molecular adaptor TRAF2. However, the cIAP1/TRAF2 complex exists, independently of receptor engagement, in several subcellular compartments. The present work strengthens the importance of TRAF2 in the oncogenic properties of cIAP1. cIAPs-deficient mouse embryonic fibroblasts (MEFs) were transformed using the HRas-V12 oncogene. Re-expression of cIAP1 enhanced tumor growth in a nude mice xenograft model, and promoted lung tumor nodes formation. Deletion or mutation of the TRAF2-binding site completely abolished the oncogenic properties of cIAP1. Further, cIAP1 mediated the clustering of TRAF2, which was sufficient to stimulate tumor growth. Our TRAF2 interactome analysis showed that cIAP1 was critical for TRAF2 to bind to its protein partners. Thus, cIAP1 and TRAF2 would be two essential subunits of a signaling complex promoting a pro-tumoral signal. cIAP1/TRAF2 promoted the activation of the canonical NF-kappa B and ERK1/2 signaling pathways. NF-kappa B-dependent production of IL-6 triggered the activation of the JAK/STAT3 axis in an autocrine manner. Inhibition or downregulation of STAT3 specifically compromised the growth of cIAP1-restored MEFs but not that of MEFs expressing a cIAP1-mutant and treating mice with the STAT3 inhibitor niclosamide completely abrogated cIAP1/TRAF2-mediated tumor growth. Altogether, we demonstrate that cIAP1/TRAF2 binding is essential to promote tumor growth via the activation of the JAK/STAT3 signaling pathway.	[Dumetier, Baptiste; Zadoroznyj, Aymeric; Berthelet, Jean; Causse, Sebastien; Allegre, Jennifer; Bourgeois, Pauline; Cattin, Florine; Garrido, Carmen; Dubrez, Laurence] Inst Natl Sante & Rech Med Inserm, LNC UMR1231, Team Label Excellence Ligue Natl Canc, LabEx LIpSTIC, F-21000 Dijon, France; [Dumetier, Baptiste; Zadoroznyj, Aymeric; Berthelet, Jean; Causse, Sebastien; Allegre, Jennifer; Bourgeois, Pauline; Cattin, Florine; Garrido, Carmen; Dubrez, Laurence] Univ Bourgogne Franche Comte, F-21000 Dijon, France; [Racoeur, Cindy; Paul, Catherine] Univ Bourgogne Franche Comte, EA7269, LIIC, F-21000 Paris, France; [Racoeur, Cindy; Paul, Catherine] PSL Res Univ, Lab Immunol & Immunotherapy Canc, EPHE, F-75000 Paris, France; [Garrido, Carmen] Anticanc Ctr Georges Francois Leclerc Unicanc, Dijon, France; [Berthelet, Jean] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); La Trobe University; Olivia Newton-John Cancer Research Institute	Dubrez, L (corresponding author), Inst Natl Sante & Rech Med Inserm, LNC UMR1231, Team Label Excellence Ligue Natl Canc, LabEx LIpSTIC, F-21000 Dijon, France.; Dubrez, L (corresponding author), Univ Bourgogne Franche Comte, F-21000 Dijon, France.	ldubrez@u-bourgogne.fr	; Garrido, Carmen/G-1633-2018	DUMETIER, Baptiste/0000-0001-9087-2344; Berthelet, Jean/0000-0003-2562-0575; Garrido, Carmen/0000-0003-1368-1493	'Comites de Cote d'Or et de l'Yonne' of the 'Ligue Contre le Cancer'; La Ligue Nationale contre le Cancer; European Union; 'Conseil Regional de Bourgogne', a French Government [ANR-11-LABX-0021]; 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Fondation ARC pour la Recherche sur le Cancer; FEDER	'Comites de Cote d'Or et de l'Yonne' of the 'Ligue Contre le Cancer'; La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); European Union(European Commission); 'Conseil Regional de Bourgogne', a French Government; 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); FEDER(European Commission)	We thank Pauline Maes from the CLIPP proteomic platform, University of Burgundy, Philippe Hammann from the Strasbourg proteomic platform, IBMC, Valerie Saint Gorgio from zootechny center, University of Burgundy, and Romain Aucagne from the Crigen platform, University of Burgundy. This work was supported by grants from the 'Comites de Cote d'Or et de l'Yonne' of the 'Ligue Contre le Cancer' (LD), La Ligue Nationale contre le Cancer (CG's team), the European Union and the `Conseil Regional de Bourgogne', a French Government grant managed by the French National Research Agency under the program 'Investissements d'Avenir' with reference ANR-11-LABX-0021, and fellowships from the 'Ministere de l'Enseignement Superieur et de la Recherche' of France (to BD, AZ, JB and JA), the 'Fondation ARC pour la Recherche sur le Cancer' (to BD). We thank the FEDER for their financial support.	Annibaldi A, 2018, TRENDS MOL MED, V24, P49, DOI 10.1016/j.molmed.2017.11.002; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bishop GA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00326; Borghi A, 2016, BIOCHEM PHARMACOL, V116, P1, DOI 10.1016/j.bcp.2016.03.009; Ceccarelli A, 2015, BIOCHEMISTRY-US, V54, P6153, DOI 10.1021/acs.biochem.5b00674; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Cheng L, 2010, ONCOGENE, V29, P5700, DOI 10.1038/onc.2010.300; Csomos RA, 2009, J BIOL CHEM, V284, P20531, DOI 10.1074/jbc.M109.029983; Dhillon B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00104; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Dubrez L, 2013, ONCOTARGETS THER, V6, P1285, DOI 10.2147/OTT.S33375; Dumetier B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051118; Dupoux A, 2009, BLOOD, V113, P175, DOI 10.1182/blood-2008-02-137919; Hrdinka M, 2019, GENES IMMUN, V20, P641, DOI 10.1038/s41435-019-0078-8; Jin J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6930; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Korchnak AC, 2009, CELL SIGNAL, V21, P1620, DOI 10.1016/j.cellsig.2009.06.008; Kreckel J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02024; Li HY, 2018, P NATL ACAD SCI USA, V115, pE9317, DOI 10.1073/pnas.1807711115; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Ma O, 2009, CANCER RES, V69, P2559, DOI 10.1158/0008-5472.CAN-08-2929; Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055; Marivin A, 2014, ONCOGENE, V33, P5534, DOI 10.1038/onc.2013.499; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park HH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01999; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515; Peng C, 2012, J BIOL CHEM, V287, P25881, DOI 10.1074/jbc.M112.359521; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Sondarva G, 2010, CELL RES, V20, P89, DOI 10.1038/cr.2009.125; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Vischioni B, 2004, EXP CELL RES, V298, P535, DOI 10.1016/j.yexcr.2004.04.040; Vu NT, 2016, CANCER RES, V76, P2977, DOI 10.1158/0008-5472.CAN-15-2512; Xu L, 2007, MOL CELL, V28, P914, DOI 10.1016/j.molcel.2007.10.027; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yin Q, 2009, BIOCHEMISTRY-US, V48, P10558, DOI 10.1021/bi901462e; Zadoroznyj A, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020322; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200; Zheng C, 2010, MOL CELL, V38, P101, DOI 10.1016/j.molcel.2010.03.009; Zhou AY, 2013, CELL REP, V3, P724, DOI 10.1016/j.celrep.2013.01.031; Zhu SN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02111	47	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02544-y	http://dx.doi.org/10.1038/s41388-022-02544-y		NOV 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H1YQ	36400972				2022-12-17	WOS:000885244700002
J	Zhang, Y; Song, YX; Ren, S; Zhang, MQ; Zhang, Z; Fan, SQ; Liu, X; Peng, XY; Qi, Q; Shen, XC; Chen, Y				Zhang, Yue; Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Zhang, Zhao; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Qi, Qi; Shen, Xiangchun; Chen, Yan			GPER-mediated stabilization of HIF-1 alpha contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells	ONCOGENE			English	Article; Early Access							COUPLED ESTROGEN-RECEPTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BREAST-CANCER CELLS; EXPRESSION; ALPHA; ACTIVATION; MEMBRANE; UCH-L1; AXIS	Tamoxifen is a first-line therapeutic drug for oestrogen-receptor positive breast cancer; however, like other therapeutics, its clinical use is limited by acquired resistance. Tamoxifen-resistant cells have demonstrated enhanced aerobic glycolysis; however, the mechanisms underlying this upregulation remain unclear. Here, we demonstrated that G-protein coupled oestrogen receptor (GPER) was involved in the upregulation of aerobic glycolysis via induction of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression and transcriptional activity in tamoxifen-resistant cells. Additionally, GPER stabilized HIF-1 alpha through inhibiting its hydroxylation and ubiquitin-mediated degradation, which were associated with upregulation of C-terminal hydrolase-L1 (UCH-L1), downregulation of prolyl hydroxylase 2 (PHD2) and von Hippel-Lindau tumour suppressor protein (pVHL), induction of HIF-1 alpha/UCH-L1 interaction, and suppression of HIF-1 alpha/PHD2-pVHL association. The GPER/HIF-1 alpha axis was functionally responsible for regulating tamoxifen sensitivity both in vitro and in vivo. Moreover, there was a positive correlation between GPER and HIF-1 alpha expression in clinical breast cancer tissues, and high levels of GPER combined with nuclear HIF-1 alpha indicated poor overall survival. High levels of the GPER/HIF-1 alpha axis were also correlated with shorter relapse-free survival in patients receiving tamoxifen. Hence, our findings support a critical role of GPER/HIF-1 alpha axis in the regulation of aerobic glycolysis in tamoxifen-resistant cells, offering a potential therapeutic target for tamoxifen-resistant breast cancer. [GRAPHICS] .	[Zhang, Yue; Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Shen, Xiangchun; Chen, Yan] Guizhou Med Univ, Sch Pharmaceut Sci, High Efficacy Applicat Nat Med Resources Engn Ctr, Guiyang 550025, Guizhou, Peoples R China; [Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Shen, Xiangchun; Chen, Yan] Guizhou Med Univ, Translat Med Res Ctr, Guiyang 550025, Guizhou, Peoples R China; [Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Shen, Xiangchun; Chen, Yan] Guizhou Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Pollut Monitoring & Dis Control, Guiyang 550025, Guizhou, Peoples R China; [Zhang, Zhao] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Med Examinat Ctr, Shanghai 200021, Peoples R China; [Qi, Qi] Jinan Univ, Sch Med, Dept Pharmacol, MOE Key Lab Tumor Mol Biol,Clin Translat Ctr Targ, Guangzhou 510632, Peoples R China	Guizhou Medical University; Guizhou Medical University; Guizhou Medical University; Shanghai University of Traditional Chinese Medicine; Jinan University	Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, Sch Pharmaceut Sci, High Efficacy Applicat Nat Med Resources Engn Ctr, Guiyang 550025, Guizhou, Peoples R China.; Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, Translat Med Res Ctr, Guiyang 550025, Guizhou, Peoples R China.; Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Pollut Monitoring & Dis Control, Guiyang 550025, Guizhou, Peoples R China.; Qi, Q (corresponding author), Jinan Univ, Sch Med, Dept Pharmacol, MOE Key Lab Tumor Mol Biol,Clin Translat Ctr Targ, Guangzhou 510632, Peoples R China.	qiqikc@jnu.edu.cn; sxc@gmc.edu.cn; chenyan@gmc.edu.cn			National Natural Science Foundation of China [81860648, 81973341]; Excellent Young Talents Plan of Guizhou Province [QKHPTRC(2021)-5632]; Guizhou Provincial Science and Technology Projects [QKHJC-ZK(2021)-YB527]; Excellent Young Talents Plan of Guizhou Medical University [2020-101]; Science and Technology Innovation Fund for Advanced Individuals of the Guizhou Department of Education [QJHKY[2018]048]; Science Foundation of Administration of Traditional Chinese Medicine of Guizhou Province [QZYY-2022-025]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Excellent Young Talents Plan of Guizhou Province; Guizhou Provincial Science and Technology Projects; Excellent Young Talents Plan of Guizhou Medical University; Science and Technology Innovation Fund for Advanced Individuals of the Guizhou Department of Education; Science Foundation of Administration of Traditional Chinese Medicine of Guizhou Province	This work was financially supported by the National Natural Science Foundation of China (81860648, 81973341), the Excellent Young Talents Plan of Guizhou Province (QKHPTRC(2021)-5632), the Guizhou Provincial Science and Technology Projects (QKHJC-ZK(2021)-YB527), the Excellent Young Talents Plan of Guizhou Medical University (2020-101), the Science and Technology Innovation Fund for Advanced Individuals of the Guizhou Department of Education (QJHKY[2018]048), and the Science Foundation of Administration of Traditional Chinese Medicine of Guizhou Province (QZYY-2022-025).	Abdel-Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511; Alam MW, 2016, ONCOTARGET, V7, P11238, DOI 10.18632/oncotarget.7167; Barua D, 2020, CANCER LETT, V486, P29, DOI 10.1016/j.canlet.2020.05.020; Catalano S, 2014, BREAST CANCER RES TR, V146, P273, DOI 10.1007/s10549-014-3017-4; Chang M, 2012, BIOMOL THER, V20, P256, DOI 10.4062/biomolther.2012.20.3.256; Chen XS, 2020, THERANOSTICS, V10, P1833, DOI 10.7150/thno.39814; Cowman SJ, 2022, TRENDS CANCER, V8, P28, DOI 10.1016/j.trecan.2021.10.004; Das CK, 2019, BBA-MOL CELL RES, V1866, P1004, DOI 10.1016/j.bbamcr.2019.03.004; Daurio NA, 2016, CANCER RES, V76, P3295, DOI 10.1158/0008-5472.CAN-15-2197; De Francesco EM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072011; De Francesco EM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0923-5; De Francesco EM, 2014, CANCER RES, V74, P4053, DOI 10.1158/0008-5472.CAN-13-3590; De Francesco EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3458; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083; Goto Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6994; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; He MJ, 2019, ONCOGENE, V38, P5551, DOI 10.1038/s41388-019-0817-3; Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3; Hsu LH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020306; Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1; Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6; Ignatov T, 2020, ARCH GYNECOL OBSTET, V301, P565, DOI 10.1007/s00404-019-05384-6; Ignatov T, 2019, BREAST CANCER RES TR, V174, P121, DOI 10.1007/s10549-018-5064-8; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacenik D, 2016, MOL CELL ENDOCRINOL, V429, P10, DOI 10.1016/j.mce.2016.04.011; Jogi A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226150; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Kazi AA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3609; Kierans SJ, 2021, J PHYSIOL-LONDON, V599, P23, DOI 10.1113/JP280572; Kim MR, 2009, MOL CANCER THER, V8, P2163, DOI 10.1158/1535-7163.MCT-08-1061; Lappano R, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01667-y; Liu SS, 2020, THERANOSTICS, V10, P10729, DOI 10.7150/thno.46297; Liu XC, 2019, MOL CELL PROTEOMICS, V18, P2273, DOI 10.1074/mcp.RA119.001576; Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mo ZQ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3581; Molina L, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.563165; Najim O, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.188315; Ning KA, 2017, J SURG ONCOL, V115, P932, DOI 10.1002/jso.24614; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Padro M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3140-9; Powles TJ, 2007, JNCI-J NATL CANCER I, V99, P283, DOI 10.1093/jnci/djk050; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Ranganathan P, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00708; Recchia AG, 2011, J BIOL CHEM, V286, P10773, DOI 10.1074/jbc.M110.172247; San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127; Schroder C, 2013, J CANCER RES CLIN, V139, P1745, DOI 10.1007/s00432-013-1496-z; Sjostrom M, 2014, BREAST CANCER RES TR, V145, P61, DOI 10.1007/s10549-014-2936-4; Vallee A, 2021, CANCERS, V13, DOI 10.3390/cancers13215557; Vaupel P, 2021, J PHYSIOL-LONDON, V599, P1745, DOI 10.1113/JP278810; Wang KK, 2017, EXPERT OPIN THER TAR, V21, P627, DOI 10.1080/14728222.2017.1321635; Wang LJ, 2013, ONCOL REP, V29, P1563, DOI 10.3892/or.2013.2245; Wang MZ, 2021, EUR J MED CHEM, V220, DOI 10.1016/j.ejmech.2021.113487; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wang WJ, 2016, MOL CARCINOGEN, V55, P1329, DOI 10.1002/mc.22376; Woo YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132285; Yang J, 2015, P NATL ACAD SCI USA, V112, P15172, DOI 10.1073/pnas.1422015112; Yao JW, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.592912; Yin H, 2017, INT J ONCOL, V51, P1191, DOI 10.3892/ijo.2017.4117; Yu T, 2017, ONCOGENE, V36, P2131, DOI 10.1038/onc.2016.370; Yu TH, 2020, MOL CELL ENDOCRINOL, V506, DOI 10.1016/j.mce.2020.110762; Yuan J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0579-y; Zhang L, 2017, FERTIL STERIL, V107, P439, DOI 10.1016/j.fertnstert.2016.11.008	67	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene											s41388-022-02506-4	10.1038/s41388-022-02506-4	http://dx.doi.org/10.1038/s41388-022-02506-4		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H1YQ	36400971				2022-12-17	WOS:000885244700003
J	Chen, J; Dong, HH; Liu, QM; Ning, D; Du, PC; Mo, J; Xu, L; Zhang, XW; Liang, HF; Chen, Y; Chen, XP; Zhang, BX				Chen Jin; Dong Han-hua; Liu Qiu-meng; Ning Deng; Du Peng-Chen; Mo Jie; Xu Lei; Zhang Xue-Wu; Liang Hui-fang; Chen Yan; Chen Xiao-ping; Zhang Bi-xiang			MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma	ONCOGENE			English	Article; Early Access							ASTROCYTE-ELEVATED GENE-1; CELL-GROWTH; CANCER; ACTIVATION; METASTASIS; METADHERIN; PROTEIN; PROLIFERATION; RESISTANCE; ONCOGENE	Metadherin (MTDH) is a well-established oncogene in various cancers including Hepatocellular Carcinoma (HCC). However, the precise mechanism through which MTDH promotes cancer-related signaling pathways in HCC remains unknown. In this study, we identified DDX17 as a novel binding partner of MTDH. Furthermore, MTDH increased the protein level of DDX17 by inhibiting its ubiquitination. We confirmed that DDX17 was a novel oncogene, with dramatically upregulated expression in HCC tissues. The increased expression of DDX17 was closely associated with vascular invasion, TNM stage, BCLC stage, and poor prognosis. In vitro and in vivo tests demonstrated that DDX17, a downstream target of MTDH, played a crucial role in tumor initiation and progression. Mechanistically, DDX17 acted as a transcriptional regulator that interacted with Y-box binding protein 1 (YB1) in the nucleus, which in turn drove the binding of YB1 to its target epidermal growth factor receptor (EGFR) gene promoter to increase its transcription. This in turn increased expression of EGFR and the activation of the downstream MEK/pERK signaling pathway. Our results identify DDX17, stabilized by MTDH, as a powerful oncogene in HCC and suggest that the DDX17/YB1/EGFR axis contributes to tumorigenesis and metastasis of HCC.	[Chen Jin; Dong Han-hua; Liu Qiu-meng; Ning Deng; Du Peng-Chen; Mo Jie; Xu Lei; Zhang Xue-Wu; Liang Hui-fang; Chen Xiao-ping; Zhang Bi-xiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll,Hubei Key Lab Hepatopancreatobili, Hepat Surg Ctr,Clin Med Res Ctr Hepat Surg Hubei, Wuhan, Peoples R China; [Chen Yan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Gen Surg, Wuhan, Peoples R China; [Chen Xiao-ping; Zhang Bi-xiang] Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Chen Xiao-ping; Zhang Bi-xiang] Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Chen Xiao-ping; Zhang Bi-xiang] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College	Chen, XP; Zhang, BX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll,Hubei Key Lab Hepatopancreatobili, Hepat Surg Ctr,Clin Med Res Ctr Hepat Surg Hubei, Wuhan, Peoples R China.; Chen, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Gen Surg, Wuhan, Peoples R China.; Chen, XP; Zhang, BX (corresponding author), Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Chen, XP; Zhang, BX (corresponding author), Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Chen, XP; Zhang, BX (corresponding author), Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China.	c_yan66@yahoo.com; chenxiaoping1953@163.com; bixiangzhang@163.com		Liang, Huifang/0000-0001-6874-3634	National Natural Science Foundation of China [81874189, 82003003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81874189 to Bi-xiang Zhang, No. 82003003 to Jin Chen).	Berasain C, 2014, J GASTROENTEROL, V49, P9, DOI 10.1007/s00535-013-0907-x; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106; Ezzoukhry Z, 2012, INT J CANCER, V131, P2961, DOI 10.1002/ijc.27604; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Giraud G, 2018, BMB REP, V51, P613, DOI 10.5483/BMBRep.2018.51.12.234; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1124-1; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Lambert MP, 2018, NUCLEIC ACIDS RES, V46, P7686, DOI 10.1093/nar/gky545; Li GH, 2014, CANCER RES, V74, P5541, DOI 10.1158/0008-5472.CAN-14-0968; Li J, 2009, ONCOGENE, V28, P3188, DOI 10.1038/onc.2009.171; Li WF, 2015, INT J MOL SCI, V16, P19419, DOI 10.3390/ijms160819419; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Lyabin DN, 2014, WIRES RNA, V5, P95, DOI 10.1002/wrna.1200; Manna D, 2021, CANCERS, V13, DOI 10.3390/cancers13081792; Niu LL, 2017, BBA-REV CANCER, V1868, P564, DOI 10.1016/j.bbcan.2017.10.002; Robertson CL, 2014, CANCER RES, V74, P6184, DOI 10.1158/0008-5472.CAN-14-1357; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Srivastava J, 2015, HEPATOLOGY, V61, P915, DOI 10.1002/hep.27339; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x; Uribe ML, 2021, CANCERS, V13, DOI 10.3390/cancers13112748; Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027; Wang Z, 2014, MOL CLIN ONCOL, V2, P1139, DOI 10.3892/mco.2014.392; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Xing Z, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1519; Xue Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2044-9; Yao Y, 2014, BRIT J CANCER, V111, P355, DOI 10.1038/bjc.2014.267; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Zhu HD, 2015, ONCOL REP, V34, P539, DOI 10.3892/or.2015.4024; Zhu HD, 2020, J CELL PHYSIOL, V235, P5084, DOI 10.1002/jcp.29377; Zhu K, 2020, CARCINOGENESIS, V41, P130, DOI 10.1093/carcin/bgz065; Zhu K, 2011, CLIN CANCER RES, V17, P7294, DOI 10.1158/1078-0432.CCR-11-1327	42	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02545-x	http://dx.doi.org/10.1038/s41388-022-02545-x		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6G3AQ	36385375				2022-12-17	WOS:000884628600002
J	Li, CY; Lee, H; Jung, JH; Zhang, YW; Wang, JQ; Liu, C; Sheffmaker, RL; Segall, AM; Zeng, SX; Lu, H				Li, Caiyue; Lee, Hyemin; Jung, Ji Hoon; Zhang, Yiwei; Wang, Jieqiong; Liu, Chang; Sheffmaker, Roger L.; Segall, Allyson M.; Zeng, Shelya X.; Lu, Hua			Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation	ONCOGENE			English	Article; Early Access							MDM2 PROMOTES; UBIQUITIN; LIGASE; ACTIVATION; PROTEINS; PATHWAY; E3	Coiled-coil domain containing 3 (CCDC3) was previously shown to regulate liver lipid metabolism as a secretory protein. Here, we report an unexpected intracellular role of CCDC3 as a tumor suppressor in breast cancer (BrC). Bioinformatics datasets analysis showed that CCDC3 is under-expressed in BrCs, while its higher levels are correlated with higher overall survival and lower relapse of cancer patients, and CCDC3 is positively correlated with p53 and its target genes. Ectopic CCDC3 markedly suppressed proliferation, colony formation, and xenograft tumor growth by augmenting p53 activity in BrC cells. Depletion of endogenous CCDC3 by CRISPR-Cas9 increased proliferation and drug resistance of BrC cells by alleviating 5-Fluorouracil (5-FU)-induced p53 level and activity. Mechanistically, CCDC3 bound to the C-termini of p53 and MDM2, consequently stabilizing p53 in the nucleus and impairing MDM2 recruitment of p53 to the 26S proteosome without inhibiting p53 ubiquitination. p53 induced CCDC3 expression by binding to its promoter in BrC cells. Our results unveil a unique mechanism underlying CCDC3 activation of p53 in a positive feedback fashion to suppress BrC growth.	[Li, Caiyue; Lee, Hyemin; Jung, Ji Hoon; Zhang, Yiwei; Wang, Jieqiong; Liu, Chang; Sheffmaker, Roger L.; Segall, Allyson M.; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA; [Li, Caiyue; Lee, Hyemin; Jung, Ji Hoon; Zhang, Yiwei; Wang, Jieqiong; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA; [Jung, Ji Hoon] Kyung Hee Univ, Coll Korean Med, Seoul 02447, South Korea; [Liu, Chang] Tulane Univ, Dept Neurosci, New Orleans, LA 70118 USA	Tulane University; Tulane University; Kyung Hee University; Tulane University	Zeng, SX; Lu, H (corresponding author), Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA.; Zeng, SX; Lu, H (corresponding author), Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA.	szeng@tulane.edu; hlu2@tulane.edu		Wang, Jieqiong/0000-0003-3096-0208	NIH-NCI [R01CA095441, R01CA234605, R01CA127724, R21CA272890, U01CA252965]; Reynolds and Ryan Families Endowed Chair fund	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Reynolds and Ryan Families Endowed Chair fund	We thank James Jackson, Wesley D. Frey, Joe Gray, and Jean-Paul Borg for offering some BrC cell lines (Cal 51, MDA-MB-175, MPE600, SKBR7) and the CRISPR-p53KOmCherry construct (James Jackson) and Heather Machado for sharing her animal protocol (Mammary fat pad injection). HL and SXZ were supported in part by NIH-NCI grants R01CA095441, R01CA234605, and R01CA127724 as well as R21CA272890. HL was also in part supported by the Reynolds and Ryan Families Endowed Chair fund and the NIH-NCI grant U01CA252965.	Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Azad AK, 2014, CELL SIGNAL, V26, P2793, DOI 10.1016/j.cellsig.2014.08.025; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Broz DK, 2010, CARCINOGENESIS, V31, P1311, DOI 10.1093/carcin/bgp331; Chao TF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13755; Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu Wenwei, 2012, Genes Cancer, V3, P199, DOI 10.1177/1947601912454734; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890; Kobayashi S, 2015, J BIOL CHEM, V290, P7443, DOI 10.1074/jbc.M114.592493; Kobayashi S, 2010, BIOCHEM BIOPH RES CO, V392, P29, DOI 10.1016/j.bbrc.2009.12.142; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kulikov R, 2010, P NATL ACAD SCI USA, V107, P10038, DOI 10.1073/pnas.0911716107; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liao JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep23542; Liao Jun-Ming, 2013, Methods Mol Biol, V962, P201, DOI 10.1007/978-1-62703-236-0_17; Liao WJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09228-8; Liu YY, 2019, INT J ONCOL, V54, P1907, DOI 10.3892/ijo.2019.4786; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sparks A, 2014, ONCOGENE, V33, P4685, DOI 10.1038/onc.2013.413; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang Qi, 2014, Subcell Biochem, V85, P281, DOI 10.1007/978-94-017-9211-0_16; Zhang Q, 2012, EMBO MOL MED, V4, P298, DOI 10.1002/emmm.201100211; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2013, NEOPLASIA, V15, P523, DOI 10.1593/neo.13142; Zhou X, 2016, ELIFE, V5, DOI 10.7554/eLife.15099; Zhou Xiang, 2012, Genes Cancer, V3, P298, DOI 10.1177/1947601912455200; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	43	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02541-1	http://dx.doi.org/10.1038/s41388-022-02541-1		NOV 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H9DW	36396725				2022-12-17	WOS:000885732000001
J	Ma, D; Liu, P; Hu, CJ; Zhou, Z; Wang, P; Wang, Y; Zhang, YM; Ran, YS; Li, PH; Zhao, JY; Wang, JS; Zhang, CL; Tang, L				Ma, Dan; Liu, Ping; Hu, Chujiao; Zhou, Zhen; Wang, Ping; Wang, Yan; Zhang, Yaming; Ran, Yunsheng; Li, Pinghao; Zhao, Jiangyuan; Wang, Jishi; Zhang, Chengliang; Tang, Lei			Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia	ONCOGENE			English	Article; Early Access							SRC FAMILY KINASES; BONE-MARROW; STEM-CELLS; DRUG-RESISTANCE; TYROSINE KINASE; STAT5; ANGIOGENESIS; EXPRESSION; IMATINIB; INHIBITORS	Drug resistance from BCR-ABL tyrosine kinase inhibitors (TKIs) and other chemotherapeutics results in treatment failure and disease progression in chronic myeloid leukemia (CML). However, the mechanism is still uncertain. In this study, we investigated the role of angiopoietin-1 (ANG-1) as a potential prognostic factor for drug resistance in CML. Both intracellular and secretory ANG-1 (iANG-1 and sANG-1) were overexpressed in multidrug-resistant CML samples. The IC50 value was higher in primary CD34(+) CD38(-) cells with more ANG-1. Silencing ANG-1significantly sensitized three TKI-resistant CML cell lines to imatinib (IM) while recombinant human ANG-1 failed to retain cell survival in vitro. This indicated the important role of iANG-1 as opposed to sANG-1 in CML drug resistance. Moreover, a similar effect was observed in xenograft mice models bearing ANG-1-silenced CML cells. Subsequently, pathway analysis and protein validation experiments showed activation of the JAK/STAT pathway and augmentation of STAT5a phosphorylation in ANG-1 restored CML cells. Upstream Src phosphorylation, which plays a crucial role in CML drug resistance, was also upregulated as a key event in iANG-1-related JAK/STAT pathway activation. In conclusion, our study elucidated a new BCR-ABL independent molecular mechanism induced by intracytoplasmic ANG-1 overexpression as a potential strategy for overcoming CML resistance.	[Ma, Dan; Liu, Ping; Wang, Ping; Wang, Yan; Zhang, Yaming; Zhao, Jiangyuan; Wang, Jishi] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Key Lab Hematol Dis Diagnost & Treat Ctr Guizhou, Guiyang 550004, Peoples R China; [Ma, Dan; Hu, Chujiao; Ran, Yunsheng; Tang, Lei] Guizhou Med Univ, Guizhou Prov Engn Technol Res Ctr Chem Drug R &, Guiyang 550004, Peoples R China; [Zhou, Zhen] Guizhou Med Univ, Dept Pharm, Affiliated Baiyun Hosp, Guiyang 550014, Peoples R China; [Li, Pinghao] Guizhou Med Univ, Dept Pathol, Affiliated Hosp, Guiyang 550004, Peoples R China; [Zhang, Chengliang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Hubei, Peoples R China	Guizhou Medical University; Guizhou Medical University; Guizhou Medical University; Guizhou Medical University; Huazhong University of Science & Technology	Wang, JS (corresponding author), Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Key Lab Hematol Dis Diagnost & Treat Ctr Guizhou, Guiyang 550004, Peoples R China.; Tang, L (corresponding author), Guizhou Med Univ, Guizhou Prov Engn Technol Res Ctr Chem Drug R &, Guiyang 550004, Peoples R China.; Zhang, CL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Hubei, Peoples R China.	wangjishi96461@163.com; clzhang@tjh.tjmu.edu.cn; tlei1974@163.com			National Natural Science Foundation of China [82003835, 82160704, 82160665]; Basic Research Program of Guizhou Province Technology Bureau [ZK[2021] General-399, ZK[2022]General-451, ZK[2021] General-568]; Science and Technology Program of Guizhou Province Health Committee [gzwkj2021-466, gzwkj2021-158, gzwkj2021-442]; National-Local Joint EngineeringResearch Center for Innovative & Generic Chemical Drug, Guizhou; High-level Innovative Talents Supporting Program [2016-4015]; Guiyang City Technology Bureau Planned Project [2019-9-14-8]; public experimental platform of Department of Pathology of Affiliated Hospital of Guizhou Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Program of Guizhou Province Technology Bureau; Science and Technology Program of Guizhou Province Health Committee; National-Local Joint EngineeringResearch Center for Innovative & Generic Chemical Drug, Guizhou; High-level Innovative Talents Supporting Program; Guiyang City Technology Bureau Planned Project; public experimental platform of Department of Pathology of Affiliated Hospital of Guizhou Medical University	This study was supported, in part, by the National Natural Science Foundation of China (Nos. 82003835, 82160704 and 82160665), Basic Research Program of Guizhou Province Technology Bureau(No. ZK[2021] General-399, No.ZK[2022]General-451 and No. ZK[2021] General-568), Science and Technology Program of Guizhou Province Health Committee(Nos. gzwkj2021-466, Nos. gzwkj2021-158 and Nos. gzwkj2021-442), National-Local Joint EngineeringResearch Center for Innovative & Generic Chemical Drug, Guizhou. High-level Innovative Talents Supporting Program (2016-4015)Guiyang City Technology Bureau Planned Project (No. 2019-9-14-8). And we gratefully appreciated the support from public experimental platform of Department of Pathology of Affiliated Hospital of Guizhou Medical University.	Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Aranda-Tavio H, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112330; Atesoglu EB, 2016, INDIAN J HEMATOL BLO, V32, P162, DOI 10.1007/s12288-015-0548-8; Bavaro L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246141; Bibi S, 2014, HAEMATOLOGICA, V99, P417, DOI 10.3324/haematol.2013.098442; Bower H, 2016, J CLIN ONCOL, V34, P2851, DOI 10.1200/JCO.2015.66.2866; Braun TP, 2020, CANCER CELL, V37, P530, DOI 10.1016/j.ccell.2020.03.006; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Cheng CL, 2011, BRIT J CANCER, V105, P975, DOI 10.1038/bjc.2011.340; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494; Cortes JE, 2011, BLOOD, V118, P4567, DOI 10.1182/blood-2011-05-355594; Dong BW, 2018, SCI CHINA LIFE SCI, V61, P999, DOI 10.1007/s11427-018-9324-y; Fagiani E, 2011, CANCER RES, V71, P5717, DOI 10.1158/0008-5472.CAN-10-4635; Gleixner KV, 2017, HAEMATOLOGICA, V102, P1519, DOI 10.3324/haematol.2016.163436; Grenga I, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0096-7; Hashiyama M, 1996, BLOOD, V87, P93; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894; Ichim CV, 2014, STEM CELL TRANSL MED, V3, P405, DOI 10.5966/sctm.2012-0159; Jiang XX, 2019, LEUKEMIA LYMPHOMA, V60, P1709, DOI 10.1080/10428194.2018.1543875; Juen L, 2017, J MED CHEM, V60, P6119, DOI 10.1021/acs.jmedchem.7b00369; Ku M, 2015, LEUKEMIA LYMPHOMA, V56, P577, DOI 10.3109/10428194.2014.907897; Lee CY, 2007, BRIT J CANCER, V97, P877, DOI 10.1038/sj.bjc.6603966; Liu XH, 2008, WORLD J GASTROENTERO, V14, P1575, DOI 10.3748/wjg.14.1575; Ma D, 2021, J CELL PHYSIOL, V236, P6312, DOI 10.1002/jcp.30301; Minciacchi VR, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010117; Mirmohammadsadegh A, 2006, J INVEST DERMATOL, V126, P2272, DOI 10.1038/sj.jid.5700385; Mitchell R, 2018, JNCI-J NATL CANCER I, V110, P467, DOI 10.1093/jnci/djx236; Muller J, 2008, CHEMBIOCHEM, V9, P723, DOI 10.1002/cbic.200700701; O'Hare T, 2005, CLIN CANCER RES, V11, P6987, DOI 10.1158/1078-0432.CCR-05-0622; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Orlova A, 2019, CANCERS, V11, DOI 10.3390/cancers11121930; Parikh SM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5537; Pinz S, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0063-y; Schliemann C, 2006, HAEMATOLOGICA, V91, P1203; Teufel M, 2019, GASTROENTEROLOGY, V156, P1731, DOI 10.1053/j.gastro.2019.01.261; Tolomeo M, 2019, ANTI-CANCER AGENT ME, V19, P2036, DOI 10.2174/1871520619666190906160848; Torimura T, 2004, J HEPATOL, V40, P799, DOI 10.1016/j.jhep.2004.01.027; Warsch W, 2013, CELL CYCLE, V12, P1813, DOI 10.4161/cc.25116	40	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02536-y	http://dx.doi.org/10.1038/s41388-022-02536-y		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6G3AQ	36385374				2022-12-17	WOS:000884628600001
J	Zhao, SL; Li, BY; Zhao, RR; Pan, ZW; Zhang, SJ; Qiu, W; Guo, QD; Qi, YH; Gao, ZJ; Fan, Y; Xu, H; Li, M; Zhang, J; Wang, HZ; Xu, JY; Wang, SB; Wang, QT; Qiu, JW; Deng, L; Guo, X; Zhang, P; Xue, H; Li, G				Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Xu, Hao; Li, Ming; Zhang, Jian; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang			Hypoxia-induced circADAMTS6 in a TDP43-dependent manner accelerates glioblastoma progression via ANXA2/ NF-kappa B pathway	ONCOGENE			English	Article; Early Access							CENTRAL-NERVOUS-SYSTEM; ANNEXIN A2; POSTTRANSLATIONAL MODIFICATION; CIRCULAR RNAS; RESISTANCE; TUMORS; IDENTIFICATION; ACTIVATION; CELL	Circular RNAs (circRNAs) play important roles in the malignant progression of tumours. Herein, we identified an unreported circRNA (hsa-circ-0072688, also named circADAMTS6) that is specifically upregulated in the hypoxic microenvironment of glioblastoma and closely correlated with poor prognosis of gliblastoma patients. We found that circADAMTS6 promotes the malignant progression of glioblastoma by promoting cell proliferation and inhibiting apoptosis. Mechanistically, the hypoxic tumour microenvironment upregulates circADAMTS6 expression through transcription factor activator protein 1 (AP-1) and RNA-binding protein TAR DNA-binding protein 43 (TDP43). Moreover, circADAMTS6 accelerates glioblastoma progression by recruiting and stabilising annexin A2 (ANXA2) in a proteasomes-dependent manner. Furthermore, we found T-5224 (AP-1 inhibitor) treatment induces downregulation of circADAMTS6 and then inhibits tumour growth. In conclusion, our findings highlight the important role of the circADAMTS6/ANXA2 axis based on hypoxic microenvironment in glioblastoma progression, as well as its regulation in NF-kappa B pathway. Targeting circADAMTS6 is thus expected to become a novel therapeutic strategy for glioblastoma.	[Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan, Shandong, Peoples R China; [Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China; [Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Xu, Hao; Li, Ming; Zhang, Jian; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang] Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China; [Xu, Hao] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Shandong, Peoples R China; [Li, Ming] Taian Cent Hosp, Dept Neurosurg, Tai An, Shandong, Peoples R China; [Zhang, Jian] Dezhou Peoples Hosp, Dept Neurosurg, Dezhou, Peoples R China	Shandong University; Shandong University; Qingdao University	Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China.	xuehao@sdu.edu.cn; dr.ligang@sdu.edu.cn			National Natural Science Foundation of China [82273195, 81874083, 82072776, 82273286, 82072775, 82203419]; Natural Science Foundation of Shandong Province of China [ZR2019BH057, ZR2020QH174, ZR2021LSW025]; Jinan Science and Technology Bureau of Shandong Province [2021GXRC029]; Key Clinical Research Project of Clinical Research Center of Shandong University [2020SDUCRCA011]; Taishan Pandeng Scholar Program of Shandong Province [tspd20210322]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province); Jinan Science and Technology Bureau of Shandong Province; Key Clinical Research Project of Clinical Research Center of Shandong University; Taishan Pandeng Scholar Program of Shandong Province	We are grateful to Dr. Frederick F Lang and Dr. Krishna P.L. Bhat for providing GSC cell lines used in our study; and CGGA, TCGA, GEO, Granvendeel and Rembrandt for public sequence data. This work was supported by grants from the National Natural Science Foundation of China (Nos. 82273195; 81874083; 82072776; 82273286; 82072775; 82203419;), Natural Science Foundation of Shandong Province of China (Nos. ZR2019BH057;ZR2020QH174; ZR2021LSW025), the Jinan Science and Technology Bureau of Shandong Province (2021GXRC029), Key Clinical Research Project of Clinical Research Center of Shandong University (2020SDUCRCA011) and Taishan Pandeng Scholar Program of Shandong Province (No. tspd20210322).	Chen D, 2020, CANCER LETT, V495, P100, DOI 10.1016/j.canlet.2020.07.040; Chen J, 2017, ACS NANO, V11, P12849, DOI 10.1021/acsnano.7b08225; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Deng Shishan, 2012, Genomics Proteomics & Bioinformatics, V10, P153, DOI 10.1016/j.gpb.2011.12.001; Dudekulay DB, 2016, RNA BIOL, V13, P34, DOI 10.1080/15476286.2015.1128065; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Gao XY, 2021, NAT CELL BIOL, V23, P278, DOI 10.1038/s41556-021-00639-4; Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611; Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568-020-00306-0; Hambardzumyan D, 2015, TRENDS CANCER, V1, P252, DOI 10.1016/j.trecan.2015.10.009; Hsieh CH, 2015, CLIN CANCER RES, V21, P460, DOI 10.1158/1078-0432.CCR-14-0618; Huang SL, 2019, CIRCULATION, V139, P2857, DOI 10.1161/CIRCULATIONAHA.118.038361; Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914; Khan IN, 2018, SEMIN CANCER BIOL, V52, P85, DOI 10.1016/j.semcancer.2017.07.004; Kpetemey M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0428-8; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Li LF, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0152-8; Li SL, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0629-7; Liu J, 2016, IMMUNITY, V45, P15, DOI 10.1016/j.immuni.2016.06.020; Liu RY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022779118; Liu Y, 2021, NEURO-ONCOLOGY, V23, P743, DOI 10.1093/neuonc/noaa279; Lou JC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01253-y; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; Ni J, 2020, IMMUNITY, V52, P1075, DOI 10.1016/j.immuni.2020.05.001; Niu Y, 2021, HEPATOLOGY, V74, P1461, DOI 10.1002/hep.31846; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Qing GY, 2017, ADV MATER, V29, DOI 10.1002/adma.201604670; Qiu W, 2021, MOL THER, V29, P3449, DOI 10.1016/j.ymthe.2021.06.023; Reardon DA, 2006, J CLIN ONCOL, V24, P1253, DOI 10.1200/JCO.2005.04.5302; Sablok G, 2016, MOL PLANT, V9, P192, DOI 10.1016/j.molp.2015.12.021; Sarkar S, 2011, GASTROENTEROLOGY, V140, P583, DOI 10.1053/j.gastro.2010.08.054; Shang QF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0934-6; Shen SY, 2021, ANN RHEUM DIS, V80, P1209, DOI 10.1136/annrheumdis-2021-219969; Sheu-Gruttadauria J, 2018, CELL, V173, P946, DOI 10.1016/j.cell.2018.02.051; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2014, LANCET ONCOL, V15, P1100, DOI 10.1016/S1470-2045(14)70379-1; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tu YM, 2019, J CELL MOL MED, V23, P6907, DOI 10.1111/jcmm.14574; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0581-6; Wang YS, 2018, PROTEIN CELL, V9, P568, DOI 10.1007/s13238-018-0513-z; Wei WS, 2018, CANCER LETT, V435, P10, DOI 10.1016/j.canlet.2018.07.036; Wei YT, 2021, NEURO-ONCOLOGY, V23, P611, DOI 10.1093/neuonc/noaa214; Wen GX, 2021, PROTEIN CELL, V12, P911, DOI 10.1007/s13238-020-00799-3; Wick W, 2017, NEW ENGL J MED, V377, P1954, DOI 10.1056/NEJMoa1707358; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Zhang P, 2020, NUCLEIC ACIDS RES, V48, P1779, DOI 10.1093/nar/gkaa005; Zhang S, 2019, NEURO-ONCOLOGY, V21, P1284, DOI 10.1093/neuonc/noz128; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7	50	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02542-0	http://dx.doi.org/10.1038/s41388-022-02542-0		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H9DW	36396726				2022-12-17	WOS:000885732000002
J	Zhang, HW; Liao, ZB; Wang, WJ; Liu, YC; Zhu, H; Liang, HF; Zhang, BX; Chen, XP				Zhang, Hongwei; Liao, Zhibin; Wang, Weijian; Liu, Yachong; Zhu, He; Liang, Huifang; Zhang, Bixiang; Chen, Xiaoping			A micropeptide JunBP regulated by TGF-beta promotes hepatocellular carcinoma metastasis	ONCOGENE			English	Article; Early Access							TRANSCRIPTION; LNCRNA; EXPRESSION; PATHWAY	Transforming growth factor beta (TGF-beta) signaling pathway plays important roles in hepatocellular carcinoma (HCC) progression. Long intergenic non-protein coding RNAs (lincRNAs) are important components of TGF-beta signaling pathway and perform their functions through different mechanisms. Here, we found that LINC02551 was activated by TGF-beta transcriptionally and identified a 174-amino-acid peptide, Jun binding micropeptide (JunBP), encoded by LINC02551 in HCC tissues and HCC cell lines. Functional study showed that JunBP promotes HCC metastasis through binding to c-Jun and subsequent promotion of its phosphorylated activation. Activated c-Jun has higher binding affinity to SMAD3, which in turn leads to more SMAD3 recruited to the promoter region of LINC02551. We find a positive feedback among them, and this mechanism provides a novel potential prognostic biomarker and therapeutic target in HCC.	[Zhang, Hongwei; Liao, Zhibin; Wang, Weijian; Liu, Yachong; Zhu, He; Liang, Huifang; Zhang, Bixiang; Chen, Xiaoping] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Hubei, Peoples R China; [Zhang, Hongwei; Liao, Zhibin; Wang, Weijian; Liu, Yachong; Zhu, He; Liang, Huifang; Zhang, Bixiang; Chen, Xiaoping] Hubei Key Lab HepatoPancreato Biliary Dis, Wuhan, Hubei, Peoples R China; [Zhang, Bixiang; Chen, Xiaoping] Minist Educ, Key Lab Organ Transplantat, Wuhan, Hubei, Peoples R China; [Zhang, Bixiang; Chen, Xiaoping] Minist Hlth, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Liang, HF; Zhang, BX; Chen, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Hubei, Peoples R China.; Liang, HF; Zhang, BX; Chen, XP (corresponding author), Hubei Key Lab HepatoPancreato Biliary Dis, Wuhan, Hubei, Peoples R China.; Zhang, BX; Chen, XP (corresponding author), Minist Educ, Key Lab Organ Transplantat, Wuhan, Hubei, Peoples R China.; Zhang, BX; Chen, XP (corresponding author), Minist Hlth, Wuhan, Hubei, Peoples R China.	lianghuifang1997@126.com; bixiangzhang@163.com; chenxpchenxp@163.com		Liao, Zhibin/0000-0003-0305-2079	National Natural Science Foundation of China [81572855, 81572427, 81874189, 82103597]; Graduates' Innovation Fund, Huazhong University of Science and Technology [5003540055]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduates' Innovation Fund, Huazhong University of Science and Technology	This work was supported by The National Natural Science Foundation of China (No. 81572855 to XC, No. 81572427 and No. 81874189 to BZ, and No. 82103597 to ZL) and Graduates' Innovation Fund, Huazhong University of Science and Technology (No. 5003540055 to ZL).	Arrese M, 2018, CURR PROTEIN PEPT SC, V19, P1172, DOI 10.2174/1389203718666171117112619; Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045; Carrat F, 2019, LANCET, V393, P1453, DOI 10.1016/S0140-6736(18)32111-1; Cheetham SW, 2018, NAT STRUCT MOL BIOL, V25, P809, DOI 10.1038/s41594-017-0006-4; Chen J, 2019, TRENDS MOL MED, V25, P1010, DOI 10.1016/j.molmed.2019.06.007; Choi SW, 2019, BRIEF BIOINFORM, V20, P1853, DOI 10.1093/bib/bby055; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Finnson KW, 2020, SEMIN CELL DEV BIOL, V101, P115, DOI 10.1016/j.semcdb.2019.11.013; Giannelli G, 2016, J HEPATOL, V65, P798, DOI 10.1016/j.jhep.2016.05.007; Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568-020-00306-0; Gough NR, 2021, GASTROENTEROLOGY, V161, P434, DOI 10.1053/j.gastro.2021.04.064; Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061; Iaccarino I, 2021, METHODS MOL BIOL, V2348, P27, DOI 10.1007/978-1-0716-1581-2_2; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; Kaplan DE, 2019, GASTROENTEROLOGY, V156, P1693, DOI 10.1053/j.gastro.2019.01.026; Kim MS, 2020, CANCERS, V12, DOI 10.3390/cancers12041048; Liao ZB, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01838-5; Liao ZB, 2020, HEPATOLOGY, V72, P997, DOI 10.1002/hep.31104; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Mancarella S, 2019, CANCERS, V11, DOI 10.3390/cancers11101510; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Nahkuri S, 2012, WIRES DEV BIOL, V1, P743, DOI 10.1002/wdev.41; Pang YN, 2020, J HEPATOL, V73, P1155, DOI 10.1016/j.jhep.2020.05.028; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Rapisarda V, 2016, WORLD J HEPATOL, V8, P573, DOI 10.4254/wjh.v8.i13.573; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rossi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09754-1; Senmatsu S, 2020, GENES GENET SYST, V95, P213, DOI 10.1266/ggs.20-00024; Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152; Song MJ, 2021, HEPATOLOGY, V73, P1717, DOI 10.1002/hep.31792; Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496; Tan YT, 2021, CANCER COMMUN, V41, P109, DOI 10.1002/cac2.12108; Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x; Wu P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1147-3; Wu SQ, 2022, ONCOGENE, V41, P2163, DOI 10.1038/s41388-022-02229-6; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhu H, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01861-6; Zi ZK, 2019, J MOL BIOL, V431, P2644, DOI 10.1016/j.jmb.2019.05.022	41	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02518-0	http://dx.doi.org/10.1038/s41388-022-02518-0		NOV 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6G6YZ	36380240	hybrid			2022-12-17	WOS:000884899800001
J	Xu, CJ; Gu, L; Kuerbanjiang, M; Jiang, CH; Hu, LP; Liu, Y; Xue, HB; Li, J; Zhang, ZG; Xu, Q				Xu, Chunjie; Gu, Lei; Kuerbanjiang, Manzila; Jiang, Chunhui; Hu, Lipeng; Liu, Ye; Xue, Hanbing; Li, Jun; Zhang, Zhigang; Xu, Qing			Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake	ONCOGENE			English	Article; Early Access							PROTEINS	The microenvironment of distant organ plays vital roles in regulating tumor metastases. However, little is known about the crosstalk between metastasized tumor cells and target organs. Herein, we found that EFNB2 expression was upregulated in liver metastases (LM) of colorectal cancer (CRC), but not in pulmonary metastases (PM) or primary CRC tumors. EFNB2 played a tumor-promoting role in CRC LM in vitro and in vivo. Through forward signaling, EFNB2-promoted CRC LM by interacting with the EPHB4 receptor. EFNB2/EPHB4 axis enhances LDLR-mediated cholesterol uptake in CRC LM. Subsequently, EFNB2/EPHB4 axis promotes LDLR transcription by regulating STAT3 phosphorylation. Blocking LDLR reversed the role of the EFNB2/EPHB4 axis in promoting CRC LM. Using clinical data, survival analysis revealed that the survival time of patients with CRC LM was decreased in patients with high EFNB2 expression, compared with low EFNB2 expression. Inhibition of the EFNB2/EPHB4 axis markedly prolonged the survival time of BALB/c nude mice with CRC LM with a high cholesterol diet. These findings revealed a key step in the regulation of cholesterol uptake by EFNB2/EPHB4 axis and its tumor-promoting role in CRC LM.	[Xu, Chunjie; Gu, Lei; Kuerbanjiang, Manzila; Jiang, Chunhui; Liu, Ye; Xu, Qing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gastrointestinal Surg, 160 Pujian Rd, Shanghai, Peoples R China; [Hu, Lipeng; Li, Jun; Zhang, Zhigang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, 145 Middle Shandong Rd, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, 145 Middle Shandong Rd, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xu, Q (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gastrointestinal Surg, 160 Pujian Rd, Shanghai, Peoples R China.; Li, J; Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, 145 Middle Shandong Rd, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, 145 Middle Shandong Rd, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai, Peoples R China.	junli@shsci.org; zzhang@shsci.org; renjixuqing@163.com		Hu, Lipeng/0000-0002-5941-3825; Zhang, Zhi-gang/0000-0001-8965-223X; Li, Jun/0000-0003-0423-3381	National Natural Science Foundation of China [82072671]; Research Fund for medical engineering cross project of Shanghai Jiao Tong University [ZH2018ZDA08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for medical engineering cross project of Shanghai Jiao Tong University	This study was supported by the National Natural Science Foundation of China (82072671) and Research Fund for medical engineering cross project of Shanghai Jiao Tong University (ZH2018ZDA08).	Baeriswyl T, 2021, ELIFE, V10, DOI 10.7554/eLife.64767; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bertocchi A, 2021, CANCER CELL, V39, P708, DOI 10.1016/j.ccell.2021.03.004; Bhatia S, 2020, MOL CARCINOGEN, V59, P1064, DOI 10.1002/mc.23237; Bhatia S, 2018, CLIN CANCER RES, V24, P4539, DOI 10.1158/1078-0432.CCR-18-0327; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Chandra R, 2021, CANCERS, V13, DOI 10.3390/cancers13246206; Chedotal A, 2019, NAT REV NEUROSCI, V20, P380, DOI 10.1038/s41583-019-0168-7; de Boer JF, 2018, TRENDS ENDOCRIN MET, V29, P123, DOI 10.1016/j.tem.2017.11.006; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Gallagher EJ, 2017, ONCOGENE, V36, P6462, DOI 10.1038/onc.2017.247; Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4; Jurcak NR, 2019, GASTROENTEROLOGY, V157, P838, DOI 10.1053/j.gastro.2019.05.065; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Koohini Z, 2019, PATHOL ONCOL RES, V25, P1285, DOI 10.1007/s12253-018-00568-y; Kopecka J, 2020, DRUG RESIST UPDATE, V49, DOI 10.1016/j.drup.2019.100670; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Li J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0702-0; Lin WH, 2021, ONCOGENE, V40, P791, DOI 10.1038/s41388-020-01566-8; Liu AM, 2019, PHARMACOL THERAPEUT, V195, P54, DOI 10.1016/j.pharmthera.2018.10.004; Liu W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25354-4; Luo J, 2020, NAT REV MOL CELL BIO, V21, P225, DOI 10.1038/s41580-019-0190-7; Magic Z, 2019, INT J ONCOL, V55, P1275, DOI 10.3892/ijo.2019.4892; Minniti ME, 2020, HEPATOLOGY, V72, P656, DOI 10.1002/hep.31052; Neufeld G, 2016, DRUG RESIST UPDATE, V29, P1, DOI 10.1016/j.drup.2016.08.001; Sato S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.132447; Schoop V, 2021, BBA-MOL CELL BIOL L, V1866, DOI 10.1016/j.bbalip.2021.158989; Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0; Sun XW, 2012, NEOPLASIA, V14, P1122, DOI 10.1593/neo.121252; Tsilimigras DI, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00261-6; Van Battum EY, 2015, LANCET NEUROL, V14, P532, DOI 10.1016/S1474-4422(14)70257-1; Vos DY, 2020, MOL METAB, V50, DOI 10.1016/j.molmet.2020.101146; Waku T, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103180; Wang J, 2021, PHYTOMEDICINE, V91, DOI 10.1016/j.phymed.2021.153688; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Xu CJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.557730; Yang HX, 2020, CLIN CHIM ACTA, V500, P81, DOI 10.1016/j.cca.2019.09.022; Zhang XL, 2021, ONCOGENE, V40, P3959, DOI 10.1038/s41388-021-01827-0; Zhu F, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109972	39	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02519-z	http://dx.doi.org/10.1038/s41388-022-02519-z		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6E3DK	36376513	hybrid			2022-12-17	WOS:000883260200001
J	Li, DB; Wang, YH; Dong, C; Chen, T; Dong, AQ; Ren, JY; Li, WK; Shu, GG; Yang, JY; Shen, WH; Qin, L; Hu, L; Zhou, J				Li, Dongbao; Wang, Yuhong; Dong, Chao; Chen, Tao; Dong, Anqi; Ren, Jiayu; Li, Weikang; Shu, Gege; Yang, Jiaoyang; Shen, Wenhao; Qin, Lei; Hu, Lin; Zhou, Jin			CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1	ONCOGENE			English	Article; Early Access							CYSTATIN SN; CELL-PROLIFERATION; DEUBIQUITINASE; MIGRATION; INVASION	Metastasis is an important factor contributing to poor prognosis in patients with gastric cancer; yet, the molecular mechanism leading to this cell behavior is still not well understood. In this study, we explored the role of cysteine protease inhibitor SN (Cystatin SN, CST1) in promoting gastric cancer metastasis. We hypothesized that CST1 could regulate gastric cancer progression by regulating GPX4 and ferroptosis. Whole transcriptome sequencing suggested that the expression of CST1 was significantly increased in metastatic cancer, and high CST1 expression was correlated with a worse prognosis. Our data further confirmed that the overexpression of CST1 may significantly promote the migration and invasion of gastric cancer cells in vitro and enhance liver, lung, and peritoneal metastasis of gastric cancer in nude mice. Meanwhile, high expression of CST1 promoted the epithelial-mesenchymal transition (EMT) of gastric cancer cells. Mechanistically, a co-immunoprecipitation experiment combined with mass spectrometry analysis confirmed that CST1 could interact with GPX4, a key protein regulating ferroptosis. CST1 relieves GPX4 ubiquitination modification by recruiting OTUB1, improving GPX4 protein stability and reducing intracellular reactive oxygen species (ROS), thereby inhibiting ferroptosis and, in turn, promoting gastric cancer metastasis. Moreover, clinical data suggested that CST1 is significantly increased in peripheral blood and ascites of gastric cancer patients with metastasis; multivariate Cox regression model analysis showed that CST1 was an independent risk factor for the prognosis of gastric cancer patients. Overall, our results elucidated a critical pathway through which high CST1 expression protects gastric cancer cells from undergoing ferroptosis, thus promoting its progression and metastasis. CST1 may be used as a new oncological marker and potential therapeutic target for gastric cancer metastasis.	[Li, Dongbao; Dong, Chao; Chen, Tao; Dong, Anqi; Ren, Jiayu; Li, Weikang; Shu, Gege; Yang, Jiaoyang; Qin, Lei; Zhou, Jin] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China; [Wang, Yuhong] Soochow Univ, Dept Pathol, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China; [Shen, Wenhao; Hu, Lin] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, State Key Lab Radiat Med & Protect, Sch Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China; [Shen, Wenhao; Hu, Lin] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Sch Radiol & Interdisciplinary Sci RADX, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Qin, L; Zhou, J (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.; Hu, L (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, State Key Lab Radiat Med & Protect, Sch Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.; Hu, L (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Sch Radiol & Interdisciplinary Sci RADX, Suzhou 215123, Jiangsu, Peoples R China.	qinlei@suda.edu.cn; hulin@suda.edu.cn; zhoujinsuda@suda.edu.cn		Dong, Anqi/0000-0001-8503-4071; Wang, Yuhong/0000-0001-7864-0428; Li, Dongbao/0000-0002-2905-9079	National Natural Science Foundation of China (NSFC) [81902969, 81902977, 81871952]; Jiangsu Provincial Key Research and Development Program, China [BE2020657]; Gusu Health Talents Cultivation Program, China [GSWS2019008]; Gusu Leading Talent Program for Innovation and Entrepreneurship [ZXL2021441]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX22_3218]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Key Research and Development Program, China; Gusu Health Talents Cultivation Program, China; Gusu Leading Talent Program for Innovation and Entrepreneurship; Postgraduate Research & Practice Innovation Program of Jiangsu Province	This study was supported by grants from the National Natural Science Foundation of China (NSFC, nos. 81902969, 81902977, 81871952). Jiangsu Provincial Key Research and Development Program, China (no. BE2020657). Gusu Health Talents Cultivation Program, China (no. GSWS2019008). Gusu Leading Talent Program for Innovation and Entrepreneurship (no. ZXL2021441). Postgraduate Research & Practice Innovation Program of Jiangsu Province (no. KYCX22_3218). We thank MedSci Corporation (Shanghai, China) for language editing of this article. In addition, We thank Prof. Changshun Shao and Prof. Yufang Shi, Soochow University Institutes for Translational Medicine, for their helpful discussion of our work and manuscript preparation.	Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chatterjee R, 2020, EUR J CELL BIOL, V99, DOI 10.1016/j.ejcb.2020.151073; Chen S, 2021, CANCER MANAG RES, V13, P1901, DOI 10.2147/CMAR.S277770; Chen X, 2021, NAT REV CLIN ONCOL, V18, P280, DOI 10.1038/s41571-020-00462-0; Chen X, 2021, CELL DEATH DIFFER, V28, P1135, DOI 10.1038/s41418-020-00728-1; Choi EH, 2009, CLIN CHIM ACTA, V406, P45, DOI 10.1016/j.cca.2009.05.008; Cui YF, 2019, J CELL PHYSIOL, V234, P22623, DOI 10.1002/jcp.28828; D'Arcy P, 2015, PHARMACOL THERAPEUT, V147, P32, DOI 10.1016/j.pharmthera.2014.11.002; Dai DN, 2017, J MOL MED, V95, P873, DOI 10.1007/s00109-017-1537-1; de Sousa-Pereira P, 2013, ARCH ORAL BIOL, V58, P451, DOI 10.1016/j.archoralbio.2012.12.011; Ding JJ, 2021, FEBS OPEN BIO, V11, P2186, DOI 10.1002/2211-5463.13221; Ding YH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01016-8; Ernst A, 2013, SCIENCE, V339, P590, DOI 10.1126/science.1230161; Forcina GC, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800311; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hiltke TR, 1999, J DENT RES, V78, P1401, DOI 10.1177/00220345990780080501; Jiang J, 2018, INT J ONCOL, V53, P781, DOI 10.3892/ijo.2018.4419; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Kim JT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.485; Kim J, 2019, ONCOL REP, V42, P202, DOI 10.3892/or.2019.7164; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Liu YF, 2019, ONCOTARGETS THER, V12, P11359, DOI 10.2147/OTT.S234328; Liu YF, 2019, ONCOTARGETS THER, V12, P3411, DOI 10.2147/OTT.S194332; Lu YQ, 2021, CANCER LETT, V522, P1, DOI 10.1016/j.canlet.2021.09.014; Nagpal A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1177-1; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Oh BM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.100; Park J, 2020, ARCH PHARM RES, V43, P1144, DOI 10.1007/s12272-020-01281-8; Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769; Pohl SOG, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.018; Saldana M, 2019, ENDOCR-RELAT CANCER, V26, pR1, DOI 10.1530/ERC-18-0264; Smyth EC, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919867522; Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422-020-00441-1; Tseng CC, 2000, ARCH BIOCHEM BIOPHYS, V380, P133, DOI 10.1006/abbi.2000.1909; Ubellacker JM, 2020, NATURE, V585, P113, DOI 10.1038/s41586-020-2623-z; Wang Y, 2020, BIOCHEM BIOPH RES CO, V531, P581, DOI 10.1016/j.bbrc.2020.07.032; Wu J, 2019, NATURE, V572, P402, DOI 10.1038/s41586-019-1426-6; Yang L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00949; Zhou HH, 2018, ONCOGENE, V37, P3356, DOI 10.1038/s41388-018-0224-1; Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258; Zhu D, 2021, CELL DEATH DIFFER, V28, P1773, DOI 10.1038/s41418-020-00700-z	43	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02537-x	http://dx.doi.org/10.1038/s41388-022-02537-x		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D4SV	36369321	hybrid			2022-12-17	WOS:000882683400001
J	Wang, L; Li, D; Su, XT; Zhao, YC; Huang, AX; Li, H; Li, J; Xia, W; Jia, TQ; Zhang, HW; Dong, J; Liu, XM; Shao, NS				Wang, Lin; Li, Da; Su, Xueting; Zhao, Yuechao; Huang, Aixue; Li, Hui; Li, Jie; Xia, Wei; Jia, Tianqi; Zhang, Hongwen; Dong, Jie; Liu, Xuemei; Shao, Ningsheng			AGO4 suppresses tumor growth by modulating autophagy and apoptosis via enhancing TRIM21-mediated ubiquitination of GRP78 in a p53-independent manner	ONCOGENE			English	Article; Early Access							ARGONAUTE PROTEINS; AUTOANTIGEN RO52; METASTASIS; GENERATION; HALLMARKS; TARGET; SENSOR; HSPA5	Argonaute proteins, which consist of AGO1, AGO2, AGO3 and AGO4, are key players in microRNA-mediated gene silencing. So far, few non-microRNA related biological roles of AGO4 have been reported. Here, we first found that AGO4 had low expression in non-small cell lung cancer (NSCLC) patient tumor tissues and could suppress NSCLC cell proliferation and metastasis. Subsequent studies on the mechanism showed that AGO4 could interact with the tripartite motif-containing protein 21 (TRIM21) and the glucose-regulated protein 78 (GRP78). AGO4 promoted ubiquitination of GRP78 by stabilizing TRIM21, a new specific ubiquitin E3 ligase for promoting K48-linked polyubiquitination of GRP78 confirmed in this paper, which resulted in induced cell apoptosis and inhibited autophagy by activating mTOR signal pathway. Further studies showed that p53 had dominant effects on TRIM21-GRP78 axis by directly increasing the expression of TRIM21 in p53 wild-type cells and AGO4 may alternatively regulate TRIM21-GRP78 axis in p53-deficient cells. We also found that overexpression of AGO4 results in suppression of multiple p53-deficient cell growth both in vivo and vitro. Together, we showed for the first time that the AGO4-TRIM21-GRP78 axis, as a new regulatory pathway, may be a novel potential therapeutic target for p53-deficient tumor treatment.	[Wang, Lin; Li, Da; Su, Xueting; Zhao, Yuechao; Huang, Aixue; Li, Hui; Li, Jie; Xia, Wei; Jia, Tianqi; Dong, Jie; Liu, Xuemei; Shao, Ningsheng] Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China; [Li, Da] Chinese Acad Sci, Inst Zool, Beijing 100101, Peoples R China; [Su, Xueting] Chinese PLA Ctr Dis Control & Prevent, Beijing 100071, Peoples R China; [Zhang, Hongwen] Dongfang Hosp, Intervent Ward, Fuzhou 350025, Peoples R China	Academy of Military Medical Sciences - China; Chinese Academy of Sciences; Institute of Zoology, CAS	Dong, J; Liu, XM; Shao, NS (corresponding author), Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China.	13661363367@163.com; luckjinjin@hotmail.com; shaoningsheng@bmi.ac.cn			National Natural Science Foundation of China [3120566, 31370794]; key R&D of the Ministry of Science and Technology of China [2016YFC1309604]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); key R&D of the Ministry of Science and Technology of China	This work was supported by the National Natural Science Foundation of China (3120566, 31370794) and the key R&D of the Ministry of Science and Technology of China (2016YFC1309604).	Adiliaghdam F, 2020, CELL REP, V30, P1690, DOI 10.1016/j.celrep.2020.01.021; Alomari M, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2021.105443; Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038; Casas C, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00177; Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Espinosa A, 2009, J EXP MED, V206, P1661, DOI 10.1084/jem.20090585; Farshbaf M, 2020, J CONTROL RELEASE, V328, P932, DOI 10.1016/j.jconrel.2020.10.055; Fletcher AJ, 2015, P NATL ACAD SCI USA, V112, P10014, DOI 10.1073/pnas.1507534112; Fu YS, 2021, MOL CELL, V81, P3187, DOI 10.1016/j.molcel.2021.05.031; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hauptmann J, 2014, RNA, V20, P1532, DOI 10.1261/rna.045203.114; Hauptmann J, 2013, NAT STRUCT MOL BIOL, V20, P814, DOI 10.1038/nsmb.2577; Higgs R, 2008, J IMMUNOL, V181, P1780, DOI 10.4049/jimmunol.181.3.1780; Higgs R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011776; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kato H, 2012, CELL DEATH DIFFER, V19, P310, DOI 10.1038/cdd.2011.98; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim SY, 2018, AUTOPHAGY, V14, P385, DOI 10.1080/15548627.2017.1414126; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kong HJ, 2007, J IMMUNOL, V179, P26, DOI 10.4049/jimmunol.179.1.26; Kunishita Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00098; Lazzari E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103609; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Madhavan S, 2020, BIOCHIMIE, V175, P69, DOI 10.1016/j.biochi.2020.05.005; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; McEwan WA, 2013, NAT IMMUNOL, V14, P327, DOI 10.1038/ni.2548; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Modzelewski AJ, 2012, DEV CELL, V23, P251, DOI 10.1016/j.devcel.2012.07.003; Pobre KFR, 2019, J BIOL CHEM, V294, P2098, DOI 10.1074/jbc.REV118.002804; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Shen JL, 2017, P NATL ACAD SCI USA, V114, pE4020, DOI 10.1073/pnas.1616060114; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Wada K, 2006, BIOCHEM BIOPH RES CO, V342, P253, DOI 10.1016/j.bbrc.2006.01.144; Wada K, 2006, BIOCHEM BIOPH RES CO, V339, P415, DOI 10.1016/j.bbrc.2005.11.029; Wang P, 2020, SEMIN CANCER BIOL, V67, P131, DOI 10.1016/j.semcancer.2020.05.002; Wen X, 2020, SEMIN CANCER BIOL, V66, P3, DOI 10.1016/j.semcancer.2019.11.005; Xia SK, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02786-6; Yamauchi K, 2008, FEBS J, V275, P1540, DOI 10.1111/j.1742-4658.2008.06313.x; Yang B, 2013, CELL MOL IMMUNOL, V10, P190, DOI 10.1038/cmi.2013.12; Yang LT, 2018, J INVEST DERMATOL, V138, P2568, DOI 10.1016/j.jid.2018.05.016; Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679; Zhang ZQ, 2013, NAT IMMUNOL, V14, P172, DOI 10.1038/ni.2492; Zuo YB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14948-z	51	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02526-0	http://dx.doi.org/10.1038/s41388-022-02526-0		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C9US	36371565				2022-12-17	WOS:000882350000001
J	He, YT; OuYang, ZB; Liu, WW; Chen, Y; Zhang, QS				He, Yutian; OuYang, Zhenbo; Liu, Wenwen; Chen, Yu; Zhang, Qiushi			TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing	ONCOGENE			English	Article; Early Access							VEGF; TDP-43	Disruptions in alternative splicing regulation play an essential role in ovarian cancer progression. However, the underlying mechanism remains unclear. TAR DNA-binding protein (TARDBP) plays a crucial role in alternative splicing regulation. Herein we found that TARDBP expression was significantly upregulated in OC tissue samples, particularly in cases of metastasis; further, TARDBP expression was markedly upregulated in OC patients with poor prognosis. These findings were validated by extensive tissue microarray data. TARDBP was also found to promote tumorigenesis and metastasis of OC cells in vitro and in vivo. Mechanistically, TARDBP increased the binding of the splicing factor serine/arginine-rich splicing factor 1 (SRSF1) to intron 7 of vascular endothelial growth factor (VEGF), increasing the formation of the proangiogenic VEGF(165) isoform and decreasing that of the antiangiogenic VEGF(165)b isoform. The abnormal alternative splicing event was responsible for the activation of angiogenesis and contributed to the progression of OC. To conclude, TARDBP was found to regulate the alternative splicing of VEGF via SRSF1, induce the formation of VEGF(165) but inhibit that of VEGF(165)b, and promote OC angiogenesis. Hence, TARDBP can serve as an independent prognostic factor and new target for OC cancer therapy.	[He, Yutian; OuYang, Zhenbo; Liu, Wenwen; Chen, Yu; Zhang, Qiushi] Guangdong Second Prov Gen Hosp, Dept Gynecol, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China; [Zhang, Qiushi] Guangdong Second Prov Gen Hosp, Inst Maternal & Child Hlth, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China		He, YT; Zhang, QS (corresponding author), Guangdong Second Prov Gen Hosp, Dept Gynecol, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China.; Zhang, QS (corresponding author), Guangdong Second Prov Gen Hosp, Inst Maternal & Child Hlth, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China.	heyutian@stu.gzhmu.edu.cn; qiushizhangzx@aliyun.com			Doctoral workstation foundation of Guangdong Second Provincial General Hospital [2020072]; GuangDong Basic and Applied Basic Research Foundation [2021A1515111033]	Doctoral workstation foundation of Guangdong Second Provincial General Hospital; GuangDong Basic and Applied Basic Research Foundation	This work was supported by the Doctoral workstation foundation of Guangdong Second Provincial General Hospital (2020072) and the GuangDong Basic and Applied Basic Research Foundation (2021A1515111033).	Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Bao M, 2022, ANGIOGENESIS, V25, P71, DOI 10.1007/s10456-021-09804-7; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Barbagallo D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041678; Bonnal SC, 2020, NAT REV CLIN ONCOL, V17, P457, DOI 10.1038/s41571-020-0350-x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen XW, 2018, PROTEIN CELL, V9, P848, DOI 10.1007/s13238-017-0480-9; Clery A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20481-w; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Das S, 2014, MOL CANCER RES, V12, P1195, DOI 10.1158/1541-7786.MCR-14-0131; de Boer EMJ, 2021, J NEUROL NEUROSUR PS, V92, P86, DOI 10.1136/jnnp-2020-322983; Di Matteo A, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01753-1; Du JX, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01978-8; Gao J, 2018, J NEUROCHEM, V146, P7, DOI 10.1111/jnc.14327; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Guo FX, 2020, AM J CANCER RES, V10, P3285; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Karaman S, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.151019; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Koutsioumpa M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0287-3; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Liu HD, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01877-y; Lv YS, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00495-6; Ma XY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.755096; Nonaka T, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a024463; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Peres LC, 2019, JNCI-J NATL CANCER I, V111, P60, DOI 10.1093/jnci/djy071; Puszko AK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010072; Suk TR, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00397-1; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Xiong XS, 2021, NAT GENET, V53, P1156, DOI 10.1038/s41588-021-00890-3; Zeng QH, 2017, CANCER BIOL THER, V18, P8, DOI 10.1080/15384047.2016.1250984; Zhou XX, 2019, J CLIN INVEST, V129, P676, DOI 10.1172/JCI120279	39	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02539-9	http://dx.doi.org/10.1038/s41388-022-02539-9		NOV 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D4SS	36369320				2022-12-17	WOS:000882683100001
J	Burke, A; Borot, F; Du, X; Churchill, M; Ding, J; Grass, AM; DeSouza, P; Ali, AM; Mukherjee, S				Burke, Alan; Borot, Florence; Du, Xing; Churchill, Michael; Ding, Jian; Grass, Albert Mridul; DeSouza, Philip; Ali, Abdullah Mahmood; Mukherjee, Siddhartha			A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia	ONCOGENE			English	Article; Early Access							ANTIBODY	Many therapeutic bispecific T-cell engagers (BiTEs) are in clinical trials. A modular and efficient process to create BiTEs would accelerate their development and clinical applicability. In this study, we present the design, production, and functional activity of a novel bispecific format utilizing synthetic orthogonal heterodimers to form a multichain modular design. Further addition of an immunoglobulin hinge region allowed a stable covalent linkage between the heterodimers. As proof-of-concept, we utilized CD33 and CD3 binding scFvs to engage leukemia cells and T-cells respectively. We provide evidence that this novel bispecific T-cell engager (termed IgGlue-BiTE) could bind both CD3+ and CD33+ cells and facilitates robust T-cell mediated cytotoxicity on AML cells in vitro. In a mouse model of minimal residual disease, we showed that the novel IgGlue-BiTE greatly extended survival, and mice of this treatment group were free of leukemia in the bone marrow. These findings suggest that the IgGlue-BiTE allows for robust simultaneous engagement with both antigens of interest in a manner conducive to T cell cytotoxicity against AML. These results suggest a compelling modular system for bispecific antibodies, as the CD3- and CD33-binding domains can be readily swapped with domains binding to other cancer- or immune cell-specific antigens.	[Burke, Alan; Borot, Florence; Du, Xing; Grass, Albert Mridul; Ali, Abdullah Mahmood; Mukherjee, Siddhartha] Columbia Univ, Dept Med, Irving Med Ctr, New York, NY 10032 USA; [Burke, Alan] Columbia Univ, Irving Med Ctr, Dept Mol Pharmacol & Therapeut, New York, NY 10032 USA; [Churchill, Michael; Ding, Jian; DeSouza, Philip] Brahma Therapeut Inc, Cambridge, MA 02139 USA; [Ali, Abdullah Mahmood; Mukherjee, Siddhartha] Columbia Univ, Edward P Evans Ctr Myelodysplast Syndromes, Irving Med Ctr, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Ali, AM; Mukherjee, S (corresponding author), Columbia Univ, Dept Med, Irving Med Ctr, New York, NY 10032 USA.; Ali, AM; Mukherjee, S (corresponding author), Columbia Univ, Edward P Evans Ctr Myelodysplast Syndromes, Irving Med Ctr, New York, NY 10032 USA.	ama2241@cumc.columbia.edu; sm3252@cumc.columbia.edu		Burke, Alan/0000-0003-2018-2342	Office of the Director, National Institutes of Health [S10RR027050, S10OD020056]; NIH [P30 CA013696]	Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Research reported in this publication was performed in the CCTI Flow Cytometry Core, supported in part by the Office of the Director, National Institutes of Health under awards S10RR027050 (LSRII) and S10OD020056 (Influx sorter). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Mice imaging were performed using instrumentation maintained by the Cancer Center Small Animal Imaging Shared Resource with NIH grant #P30 CA013696 (National Cancer Institute).	Borot F, 2019, P NATL ACAD SCI USA, V116, P11978, DOI 10.1073/pnas.1819992116; Brinkmann U, 2021, SCIENCE, V372, P916, DOI 10.1126/science.abg1209; Chen ZB, 2019, NATURE, V565, P106, DOI 10.1038/s41586-018-0802-y; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; Evans R, 2010, PROTEIN COMPLEX PRED, V2004; Golay J, 2016, J IMMUNOL, V196, P3199, DOI 10.4049/jimmunol.1501592; Ha JH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00394; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; Krah S, 2017, NEW BIOTECHNOL, V39, P167, DOI 10.1016/j.nbt.2016.12.010; Li HL, 2020, CELL MOL IMMUNOL, V17, P451, DOI 10.1038/s41423-020-0417-8; Metz S, 2012, PROTEIN ENG DES SEL, V25, P571, DOI 10.1093/protein/gzs064; Mirdita M., 2022, NAT METHODS, V19, P679, DOI 10.1038/s41592-022-01488-1; Molhoj M, 2007, MOL IMMUNOL, V44, P1935, DOI 10.1016/j.molimm.2006.09.032; Payne G, 2003, CANCER CELL, V3, P207, DOI 10.1016/S1535-6108(03)00057-6; Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Roux KH, 1997, J IMMUNOL, V159, P3372; Schneider D, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00539	18	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02532-2	http://dx.doi.org/10.1038/s41388-022-02532-2		NOV 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C0KZ	36357573	Green Submitted			2022-12-17	WOS:000881714300002
J	Coetzee, AS; Carter, EP; Rodriguez-Fernandez, L; Heward, J; Wang, QY; Karim, SA; Boughetane, L; Milton, C; Uyulur, F; Morton, JP; Kocher, HM; Grose, RP				Coetzee, Abigail S.; Carter, Edward P.; Rodriguez-Fernandez, Lucia; Heward, James; Wang, Qiaoying; Karim, Saadia A.; Boughetane, Lina; Milton, Christopher; Uyulur, Firat; Morton, Jennifer P.; Kocher, Hemant M.; Grose, Richard P.			Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1	ONCOGENE			English	Article; Early Access							CANCER; TRANSLOCATION; CHEMOTHERAPY	Pancreatic stellate cells (PSCs) are key to the treatment-refractory desmoplastic phenotype of pancreatic ductal adenocarcinoma (PDAC) and have received considerable attention as a stromal target for cancer therapy. This approach demands detailed understanding of their pro- and anti-tumourigenic effects. Interrogating PSC-cancer cell interactions in 3D models, we identified nuclear FGFR1 as critical for PSC-led invasion of cancer cells. ChIP-seq analysis of FGFR1 in PSCs revealed a number of FGFR1 interaction sites within the genome, notably NRG1, which encodes the ERBB ligand Neuregulin. We show that nuclear FGFR1 regulates transcription of NRG1, which in turn acts in autocrine fashion through an ERBB2/4 heterodimer to promote invasion. In support of this, recombinant NRG1 in 3D model systems rescued the loss of invasion incurred by FGFR inhibition. In vivo we demonstrate that, while FGFR inhibition does not affect the growth of pancreatic tumours in mice, local invasion into the pancreas is reduced. Thus, FGFR and NRG1 may present new stromal targets for PDAC therapy.	[Coetzee, Abigail S.; Carter, Edward P.; Rodriguez-Fernandez, Lucia; Wang, Qiaoying; Boughetane, Lina; Milton, Christopher; Kocher, Hemant M.; Grose, Richard P.] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, London EC1M 6BQ, England; [Heward, James; Uyulur, Firat] Queen Mary Univ London, Ctr Canc Genom & Computat Biol, Barts Canc Inst, London EC1M 6BQ, England; [Karim, Saadia A.; Morton, Jennifer P.] Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Morton, Jennifer P.] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	University of London; Queen Mary University London; University of London; Queen Mary University London; Beatson Institute; University of Glasgow	Kocher, HM; Grose, RP (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, London EC1M 6BQ, England.	h.kocher@qmul.ac.uk; r.p.grose@qmul.ac.uk		Carter, Edward/0000-0003-4499-1101	Cancer Research UK core service grant [C16420/A18066]; Pancreatic Cancer Research Fund project award, EC - CRUK; Barts Charity grants [A27781, G-002189]; Breast Cancer Now [2017NovPR988]; CRUK [A25233, A29996]; Cancer Research UK centre grants [A17196, A31287]; Barts Cancer Institute [A25137]	Cancer Research UK core service grant; Pancreatic Cancer Research Fund project award, EC - CRUK; Barts Charity grants; Breast Cancer Now; CRUK(Cancer Research UK); Cancer Research UK centre grants; Barts Cancer Institute	We thank the microscopy, bioinformatics and pathology core facilities at Barts Cancer Institute, funded by a Cancer Research UK core service grant (C16420/A18066). AC funded by a Pancreatic Cancer Research Fund project award, EC funded by CRUK and Barts Charity grants (A27781, G-002189), LF funded by a Breast Cancer Now project award (2017NovPR988), and SK and JM funded by CRUK grants (A25233, A29996). This work also supported by Cancer Research UK centre grants to the Beatson Institute (A17196, A31287) and Barts Cancer Institute (A25137). We thank Prof. Jude Fitzgibbon for feedback on the manuscript.	Adams SD, 2021, CURR BIOL, V31, P1403, DOI 10.1016/j.cub.2021.01.028; Berdiel-Acer M, 2021, ONCOGENE, V40, P2651, DOI 10.1038/s41388-021-01719-3; Bhattacharyya S, 2020, J EXP MED, V217, DOI 10.1084/jem.20191805; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Carapuca EF, 2016, J PATHOL, V239, P286, DOI 10.1002/path.4727; Carter EP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040847; Carter EP, 2015, TRENDS CELL BIOL, V25, P221, DOI 10.1016/j.tcb.2014.11.003; Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007; Chioni AM, 2012, J CELL BIOL, V197, P801, DOI 10.1083/jcb.201108077; Coetzee A, 2021, CURR TOP MICROBIOL, V430, P183, DOI 10.1007/82_2019_155; Coleman SJ, 2014, EMBO MOL MED, V6, P467, DOI 10.1002/emmm.201302698; Coombes RC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30666-0; Doherty GJ, 2018, FUTURE ONCOL, V14, P13, DOI 10.2217/fon-2017-0338; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Guan ZH, 2019, ONCOL LETT, V17, P2303, DOI 10.3892/ol.2018.9876; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ho WJ, 2020, NAT REV CLIN ONCOL, V17, P527, DOI 10.1038/s41571-020-0363-5; Jones MR, 2019, CLIN CANCER RES, V25, P4674, DOI 10.1158/1078-0432.CCR-19-0191; Kabacaoglu D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01878; Kadaba R, 2013, J PATHOL, V230, P107, DOI 10.1002/path.4172; Kocher HM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18636-w; Liang C, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.255; McCarroll JA, 2006, GUT, V55, P79, DOI 10.1136/gut.2005.064543; Menezes S, 2022, J PATHOL, V257, P526, DOI 10.1002/path.5926; Mota JM, 2017, ONCOTARGET, V8, P89284, DOI 10.18632/oncotarget.18467; Murray ER, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2021.110227; Neuzillet C, 2019, J PATHOL, V248, P51, DOI 10.1002/path.5224; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Servetto A, 2021, CLIN CANCER RES, V27, P4379, DOI 10.1158/1078-0432.CCR-20-3905; Stachowiak MK, 2016, J CELL PHYSIOL, V231, P1199, DOI 10.1002/jcp.25298; van Mackelenbergh MG, 2019, CANCERS, V11, DOI 10.3390/cancers11050588; Zhang ZD, 2020, CANCER CELL, V38, P279, DOI 10.1016/j.ccell.2020.06.005	34	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02513-5	http://dx.doi.org/10.1038/s41388-022-02513-5		NOV 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C0KZ	36357571	hybrid			2022-12-17	WOS:000881714300003
J	Mo, JL; Tan, KZ; Dong, Y; Lu, WJ; Liu, F; Mei, YQ; Huang, HT; Zhao, KW; Lv, ZB; Ye, YQ; Tang, YJ				Mo, Jialin; Tan, Kezhe; Dong, Yu; Lu, Wenjie; Liu, Fang; Mei, Yanqing; Huang, Hongting; Zhao, Kewen; Lv, Zhibao; Ye, Youqiong; Tang, Yujie			Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex	ONCOGENE			English	Article; Early Access							EXPRESSION; REVEALS; ELEMENTS; GROWTH; RNA; SUSCEPTIBILITY; SENSITIVITY; METASTASIS; RESISTANCE; PROTEIN	EWS/ETS fusion transcription factors, most commonly EWSR1::FLI1, drives initiation and progression of Ewing sarcoma (EwS). Even though direct targeting EWSR1::FLI1 is a formidable challenge, epigenetic/transcriptional modulators have been proved to be promising therapeutic targets for indirectly disrupting its expression and/or function. Here, we identified structure-specific recognition protein 1 (SSRP1), a subunit of the Facilitates Chromatin Transcription (FACT) complex, to be an essential tumor-dependent gene directly induced by EWSR1::FLI1 in EwS. The FACT-targeted drug CBL0137 exhibits potent therapeutic efficacy against multiple EwS preclinical models both in vitro and in vivo. Mechanistically, SSRP1 and EWSR1::FLI1 form oncogenic positive feedback loop via mutual transcriptional regulation and activation, and cooperatively promote cell cycle/DNA replication process and IGF1R-PI3K-AKT-mTOR pathway to drive EwS oncogenesis. The FACT inhibitor drug CBL0137 effectively targets the EWSR1::FLI1-FACT circuit, resulting in transcriptional disruption of EWSR1::FLI1, SSRP1 and their downstream effector oncogenic signatures. Our study illustrates a crucial role of the FACT complex in facilitating the expression and function of EWSR1::FLI1 and demonstrates FACT inhibition as a novel and effective epigenetic/transcriptional-targeted therapeutic strategy against EwS, providing preclinical support for adding EwS to CBL0137's future clinical trials.	[Mo, Jialin; Liu, Fang; Mei, Yanqing; Zhao, Kewen; Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med,Res Ctr Translat Med, Dept Pathophysiol,Shanghai Childrens Hosp, Natl Minist Educ,Key Lab Cell Differentiat & Apop, Shanghai 200025, Peoples R China; [Mo, Jialin; Lu, Wenjie; Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med, Dept Histoembryol Genet & Dev Biol, Shanghai Key Lab Reprod Med, Shanghai 200025, Peoples R China; [Tan, Kezhe; Lv, Zhibao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Hosp, Dept Gen Surg, Shanghai 200062, Peoples R China; [Dong, Yu; Ye, Youqiong] Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Thanghai Inst Immunol, Shanghai 200025, Peoples R China; [Huang, Hongting] Shanghai Jiao Tong Univ, Sch Med, Dept Hepat Surg, Renji Hosp, Shanghai 200127, Peoples R China; [Huang, Hongting] Shanghai Jiao Tong Univ, Liver Transplantat Ctr, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tang, YJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med,Res Ctr Translat Med, Dept Pathophysiol,Shanghai Childrens Hosp, Natl Minist Educ,Key Lab Cell Differentiat & Apop, Shanghai 200025, Peoples R China.; Tang, YJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Histoembryol Genet & Dev Biol, Shanghai Key Lab Reprod Med, Shanghai 200025, Peoples R China.; Lv, ZB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Hosp, Dept Gen Surg, Shanghai 200062, Peoples R China.; Ye, YQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Thanghai Inst Immunol, Shanghai 200025, Peoples R China.	zhibaolyu@163.com; youqiong.ye@shsmu.edu.cn; yujietang@shsmu.edu.cn		Ye, Youqiong/0000-0001-8332-4710	Chinese Universities Scientific Fund, Innovative Research Team of High-Level Local Universities in Shanghai [SHSMU-ZDCX20212700]; National Natural Science Foundation of China [81772655, 81972646, 82002978]; Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases; Innovation Program of Shanghai Municipal Education Commission (China) [2019-01-07-00-01-E00036]; Recruitment Program of Global Experts of China; Postdoctoral Science Foundation of China [2019M651527]; National Research Center for Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	Chinese Universities Scientific Fund, Innovative Research Team of High-Level Local Universities in Shanghai; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases; Innovation Program of Shanghai Municipal Education Commission (China)(Innovation Program of Shanghai Municipal Education Commission); Recruitment Program of Global Experts of China; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); National Research Center for Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	This work was supported by Chinese Universities Scientific Fund, Innovative Research Team of High-Level Local Universities in Shanghai (SHSMU-ZDCX20212700), National Natural Science Foundation of China (81772655, 81972646 to YT, 82002978 to JM), Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases, the Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-01-E00036, China), the Recruitment Program of Global Experts of China (YT), Postdoctoral Science Foundation of China (2019M651527 to JM), and National Research Center for Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (Open research program to YT). We thank Jing Xue (Shanghai Renji Hospital) and Bing Li (Shanghai Jiao Tong University School of Medicine) for reagents and/or helpful suggestions.	Adane B, 2021, CANCER CELL, V39, P827, DOI 10.1016/j.ccell.2021.05.007; Amin HM, 2020, CANCERS, V12, DOI 10.3390/cancers12071768; Barone TA, 2017, NEURO-ONCOLOGY, V19, P186, DOI 10.1093/neuonc/now141; Bilke S, 2013, GENOME RES, V23, P1797, DOI 10.1101/gr.151340.112; Boulay G, 2018, GENE DEV, V32, P1008, DOI 10.1101/gad.315192.118; Carter DR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1803; Chang HW, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aav2131; Chiou YY, 2018, J BIOL CHEM, V293, P2476, DOI 10.1074/jbc.RA117.000971; Feng JX, 2012, BIOINFORMATICS, V28, P2782, DOI 10.1093/bioinformatics/bts515; Flores G, 2021, J BONE ONCOL, V31, DOI 10.1016/j.jbo.2021.100404; Formosa T, 2020, NUCLEIC ACIDS RES, V48, P11929, DOI 10.1093/nar/gkaa912; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Gollavilli PN, 2018, CANCER RES, V78, P4760, DOI 10.1158/0008-5472.CAN-18-0484; Goss KL, 2016, ONCOTARGET, V7, P63003, DOI 10.18632/oncotarget.11416; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Grunewald TGP, 2015, NAT GENET, V47, P1073, DOI 10.1038/ng.3363; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heitzeneder S, 2019, JNCI-J NATL CANCER I, V111, P970, DOI 10.1093/jnci/djy209; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kim M, 2016, CANCER RES, V76, P6620, DOI 10.1158/0008-5472.CAN-15-2764; Kirschner A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273301; Lamhamedi-Cherradi SE, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw182; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin LH, 2019, NUCLEIC ACIDS RES, V47, P1255, DOI 10.1093/nar/gky1207; Liu DM, 2013, J GERONTOL A-BIOL, V68, P1035, DOI 10.1093/gerona/glt015; Liu F, 2019, P NATL ACAD SCI USA, V116, P12986, DOI 10.1073/pnas.1815780116; Loganathan SN, 2019, MOL CANCER THER, V18, P929, DOI 10.1158/1535-7163.MCT-18-1151; Martins AS, 2006, CLIN CANCER RES, V12, P3532, DOI 10.1158/1078-0432.CCR-05-1778; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Mo JL, 2018, GLIA, V66, P1346, DOI 10.1002/glia.23308; Mo JL, 2021, CANCER RES, V81, P3105, DOI 10.1158/0008-5472.CAN-20-3186; Musa J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12071-2; Ohmura S, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01393-9; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Pishas KI, 2018, MOL CANCER THER, V17, P1902, DOI 10.1158/1535-7163.MCT-18-0373; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2021, NEW ENGL J MED, V384, P154, DOI 10.1056/NEJMra2028910; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Sanchez-Molina S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3058; Savola Suvi, 2011, ISRN Oncol, V2011, P168712, DOI 10.5402/2011/168712; Schmidt O, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02125-z; Scotlandi K, 2009, J CLIN ONCOL, V27, P2209, DOI 10.1200/JCO.2008.19.2542; Sen N, 2018, MOL CARCINOGEN, V57, P1342, DOI 10.1002/mc.22849; Seong BKA, 2021, CANCER CELL, V39, P1262, DOI 10.1016/j.ccell.2021.07.003; Somers K, 2020, INT J CANCER, V146, P1902, DOI 10.1002/ijc.32582; Song HY, 2021, CANCER LETT, V520, P201, DOI 10.1016/j.canlet.2021.07.020; Surdez D, 2021, CANCER CELL, V39, P810, DOI 10.1016/j.ccell.2021.04.001; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; Toretsky JA, 1999, CANCER RES, V59, P5745; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; Wakahara K, 2008, MOL CANCER RES, V6, P1937, DOI 10.1158/1541-7786.MCR-08-0054; Wang JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03201-6; Wang S, 2019, CLIN CANCER RES, V25, P4552, DOI 10.1158/1078-0432.CCR-17-0375; Xiao L, 2021, CLIN CANCER RES, V27, P4338, DOI 10.1158/1078-0432.CCR-20-2357; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	66	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02533-1	http://dx.doi.org/10.1038/s41388-022-02533-1		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C0KZ	36357572				2022-12-17	WOS:000881714300001
J	Yang, H; Zhao, XP; Liu, JJ; Jin, MM; Liu, XY; Yan, J; Yao, XF; Mao, XY; Li, N; Liang, BB; Xie, W; Zhang, KC; Zhao, J; Liu, L; Huang, G				Yang, Hao; Zhao, Xiaoping; Liu, Jianjun; Jin, Mingming; Liu, Xiyu; Yan, Jun; Yao, Xufeng; Mao, Xinyi; Li, Nan; Liang, Beibei; Xie, Wei; Zhang, Kunchi; Zhao, Jian; Liu, Liu; Huang, Gang			TNF alpha-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity	ONCOGENE			English	Article; Early Access							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; CANCER-CELLS; ACETYLATION; INHIBITION; RESISTANCE; PHOSPHORYLATION; CHEMORESISTANCE; GROWTH; SIRT3	The heterogeneity and drug resistance of colorectal cancer (CRC) often lead to treatment failure. Isocitrate dehydrogenase 1 (IDH1), a rate-limiting enzyme in the tricarboxylic acid cycle, regulates the intracellular redox environment and mediates tumor cell resistance to chemotherapeutic drugs. The aim of this study was to elucidate the mechanism underlying the involvement of IDH1 acetylation in the development of CRC drug resistance under induction of TNF alpha. We found TNF alpha disrupted the interaction between SIRT1 and IDH1 and increased the level of acetylation at K115 of IDH1. Hyperacetylation of K115 was accompanied by protein ubiquitination, which increased its susceptibility to degradation compared to IDH1 K115R. TNF alpha-mediated hyperacetylation of K115 sensitized the CRC cells to 5FU and reduced the NADPH/NADP ratio to that of intracellular ROS. Furthermore, TNF alpha and 5FU inhibited CRC tumor growth in vivo, while the K115R-expressing tumor tissues developed 5FU resistance. In human CRC tissues, K115 acetylation was positively correlated with TNF alpha infiltration, and K115 hyperacetylation was associated with favorable prognosis compared to chemotherapy-induced deacetylation. Therefore, TNF alpha-induced hyperacetylation at the K115 site of IDH1 promotes antitumor redox homeostasis in CRC cells, and can be used as a marker to predict the response of CRC patients to chemotherapy.	[Yang, Hao; Jin, Mingming; Liu, Xiyu; Yao, Xufeng; Mao, Xinyi; Li, Nan; Liang, Beibei; Xie, Wei; Zhang, Kunchi; Zhao, Jian; Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Jiading Dist Cent Hosp, Shanghai 201318, Peoples R China; [Zhao, Xiaoping; Liu, Jianjun; Huang, Gang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Nucl Med, Shanghai 200127, Peoples R China; [Yan, Jun] Shanghai Univ Med & Hlth Sci, Dept Oncol, Jiading Dist Cent Hosp, Shanghai 201800, Peoples R China; [Liu, Liu] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China	Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University; Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University	Zhao, J; Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Jiading Dist Cent Hosp, Shanghai 201318, Peoples R China.; Huang, G (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Nucl Med, Shanghai 200127, Peoples R China.; Liu, L (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China.	j-zhao@vip.126.com; chestnuclear@126.com; huanggang@sumhs.edu.cn		Yang, Hao/0000-0002-3781-7271	National Natural Science Foundation of China [81903065, 81830052, 82127807, 82003142]; Construction project of Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]; "Chen Guang" project - Shanghai Municipal Education Commission [19CG75]; Shanghai Education Development Foundation; Natural Science Foundation of Shanghai [21ZR1458900]; Nurture projects for the Youth Medical Talents-Medical Imaging Practitioners Program [SHWRS(2020)_087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construction project of Shanghai Key Laboratory of Molecular Imaging; "Chen Guang" project - Shanghai Municipal Education Commission; Shanghai Education Development Foundation; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Nurture projects for the Youth Medical Talents-Medical Imaging Practitioners Program	This study was supported by grants from the National Natural Science Foundation of China (Grant No.81903065, 81830052, 82127807, 82003142), Construction project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400), "Chen Guang" project (No. 19CG75) supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation, the Natural Science Foundation of Shanghai (Grant No.21ZR1458900), and the Nurture projects for the Youth Medical Talents-Medical Imaging Practitioners Program (Grant No. SHWRS(2020)_087).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Biedermann J, 2019, CANCERS, V11, DOI 10.3390/cancers11122028; Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Carafa V, 2018, CLIN CANCER RES, V24, P2886, DOI 10.1158/1078-0432.CCR-17-3081; Chen L, 2019, NAT METAB, V1, P404, DOI 10.1038/s42255-019-0043-x; Cruceriu D, 2020, CELL ONCOL, V43, P1, DOI 10.1007/s13402-019-00489-1; De Rosa V, 2015, CLIN CANCER RES, V21, P5110, DOI 10.1158/1078-0432.CCR-15-0375; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; denDekker AD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132306; Fluckiger A, 2016, ONCOGENE, V35, P4611, DOI 10.1038/onc.2015.523; Han CJ, 2019, ACTA PHARMACOL SIN, V40, P1292, DOI 10.1038/s41401-019-0225-9; Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015; Hu HG, 2017, HEPATOLOGY, V65, P515, DOI 10.1002/hep.28887; Huang JL, 2021, AM J CLIN PATHOL, V156, P777, DOI 10.1093/ajcp/aqab023; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jung G, 2020, NAT REV GASTRO HEPAT, V17, P111, DOI 10.1038/s41575-019-0230-y; Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980; Kong MJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0537-6; Kryeziu K, 2019, BBA-REV CANCER, V1871, P240, DOI 10.1016/j.bbcan.2019.01.002; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Lee JH, 2011, CLIN CANCER RES, V17, P7551, DOI 10.1158/1078-0432.CCR-11-1026; Liu B, 2018, MOL MED REP, V18, P1987, DOI 10.3892/mmr.2018.9195; Lizardo DY, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188447; Lu L, 2015, J CONTROL RELEASE, V210, P134, DOI 10.1016/j.jconrel.2015.05.282; Meng FY, 2021, CANCER IMMUNOL IMMUN, V70, P2247, DOI 10.1007/s00262-021-02862-2; Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398; Miller JJ, 2021, NEURO-ONCOLOGY, V23, P53, DOI 10.1093/neuonc/noaa180; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Moon DO, 2009, CANCER LETT, V274, P132, DOI 10.1016/j.canlet.2008.09.013; Narayanan S, 2020, DRUG RESIST UPDATE, V48, DOI 10.1016/j.drup.2019.100663; Nie H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13601-8; Pramono AA, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030358; Rardin MJ, 2013, P NATL ACAD SCI USA, V110, P6601, DOI 10.1073/pnas.1302961110; Shanmugasundaram K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01106-1; Shen J, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12441; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sizemore ST, 2018, CELL RES, V28, P1090, DOI 10.1038/s41422-018-0086-7; Sociali G, 2015, EUR J MED CHEM, V102, P530, DOI 10.1016/j.ejmech.2015.08.024; Tian M, 2021, ACTA PHARMACOL SIN, V42, P1180, DOI 10.1038/s41401-020-00546-8; Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447; Walther W, 2015, INT J ONCOL, V47, P2276, DOI 10.3892/ijo.2015.3189; Wang B, 2020, EMBO REP, V21, DOI 10.15252/embr.201948183; Wang SW, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002243; Weeks J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050740; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Xu F, 2021, CANCER SCI, V112, P4501, DOI 10.1111/cas.15116; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yang H, 2021, J CANCER, V12, P4862, DOI 10.7150/jca.58846; Yu W, 2012, J BIOL CHEM, V287, P14078, DOI 10.1074/jbc.M112.355206; Zhang TP, 2019, J HEPATOL, V70, P87, DOI 10.1016/j.jhep.2018.08.026; Zhang YJ, 2018, MOL CELL, V71, P201, DOI 10.1016/j.molcel.2018.06.023; Zhang ZY, 2018, ONCOGENE, V37, P3456, DOI 10.1038/s41388-018-0221-4; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	55	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02528-y	http://dx.doi.org/10.1038/s41388-022-02528-y		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6A2MU	36352097				2022-12-17	WOS:000880493900001
J	Cui, KS; Gong, L; Zhang, H; Chen, Y; Liu, BX; Gong, ZC; Li, JM; Wang, YB; Sun, SB; Li, YJ; Zhang, Q; Cao, YL; Li, QL; Fei, BJ; Huang, ZH				Cui, Kaisa; Gong, Liang; Zhang, Han; Chen, Ying; Liu, Bingxin; Gong, Zhicheng; Li, Jiuming; Wang, Yuanben; Sun, Shengbai; Li, Yajun; Zhang, Qiang; Cao, Yulin; Li, Qilin; Fei, Bojian; Huang, Zhaohui			EXOSC8 promotes colorectal cancer tumorigenesis via regulating ribosome biogenesis-related processes	ONCOGENE			English	Article; Early Access							RNA EXOSOME; P53; DELIVERY; SUBUNIT; NUCLEAR	Extensive protein synthesis is necessary for uncontrolled cancer cell proliferation, requiring hyperactive ribosome biogenesis. Our previous Pan-cancer study has identified EXOSC8 as a potential copy number variation (CNV)-driven rRNA metabolism-related oncogene in colorectal cancer (CRC). Herein, we further investigated proliferation-prompting functions and mechanisms of EXOSC8 in CRC by performing in silico analyses and wet-lab experiments. We uncovered that increased EXOSC8 expression and CNV levels are strongly associated with ribosome biogenesis-related factor levels in CRC, including ribosome proteins (RPs), eukaryotic translation initiation factors and RNA polymerase I/III. EXOSC8 silence decreases nucleolar protein and proliferation marker levels, as well as rRNA/DNA and global protein syntheses. Clinically, EXOSC8 is upregulated across human cancers, particularly CNV-driven upregulation in CRC was markedly associated with poor clinical outcomes. Mechanistically, EXOSC8 knockdown increased p53 levels in CRC, and the oncogenic proliferation phenotypes of EXOSC8 depended on p53 in vitro and in vivo. We discovered that EXOSC8 knockdown in CRC cells triggers ribosomal stress, nucleolar RPL5/11 being released into the nucleoplasm and "hijacking" Mdm2 to block its E3 ubiquitin ligase function, thus releasing and activating p53. Furthermore, our therapeutic experiments provided initial evidence that EXOSC8 might serve as a potential therapeutic target in CRC. Our findings revealed, for the first time, that the RNA exosome gene (EXOSC8) promotes CRC tumorigenesis by regulating cancer-related ribosome biogenesis in CRC. This study further extends our previous Pan-cancer study of the rRNA metabolism-related genes. The inhibition of EXOSC8 is a novel therapeutic strategy for the RPs-Mdm2-p53 ribosome biogenesis surveillance pathway in CRC.	[Cui, Kaisa; Zhang, Han; Chen, Ying; Gong, Zhicheng; Wang, Yuanben; Sun, Shengbai; Cao, Yulin; Huang, Zhaohui] Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi 214062, Jiangsu, Peoples R China; [Gong, Liang] Jiangnan Univ, Sch Biotechnol, Minist Educ, Key Lab Carbohydrate Chem & Biotechnol, Wuxi 214122, Jiangsu, Peoples R China; [Liu, Bingxin] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Key Lab Modern Toxicol,Minist Educ, Nanjing 211166, Jiangsu, Peoples R China; [Li, Jiuming] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Minist Educ,Key Lab Environm Med & Engn, Nanjing 210009, Jiangsu, Peoples R China; [Li, Yajun] Henan Normal Univ, Outstanding Overseas Scientists Ctr Pulm Fibrosis, Coll Life Sci,Henan Int Joint Lab Pulm Fibrosis, Inst Biomed Sci,State Key Lab Cell Differentiat &, Xinxiang 453000, Henan, Peoples R China; [Zhang, Qiang] Sun Yat Sen Univ, Mol Canc Res Ctr, Sch Med, Dept Biochem, Shenzhen Campus, Shenzhen 518107, Guangdong, Peoples R China; [Li, Qilin] CALTECH, Dept Elect Engn, Comp Vis Lab, Pasadena, CA 91125 USA; [Fei, Bojian] Jiangnan Univ, Affiliated Hosp, Dept Surg Oncol, Wuxi 214122, Jiangsu, Peoples R China	Jiangnan University; Jiangnan University; Nanjing Medical University; Southeast University - China; Henan Normal University; Sun Yat Sen University; California Institute of Technology; Jiangnan University	Cui, KS; Huang, ZH (corresponding author), Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi 214062, Jiangsu, Peoples R China.	ksxg@foxmail.com; zhaohuihuang@jiangnan.edu.cn		Cui, Kaisa/0000-0001-7255-2689	National Natural Science Foundation of China [82002550, 82173063]; Wuxi Medical Key Discipline [ZDXK2021002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wuxi Medical Key Discipline	We acknowledge the TCGA, GEO, CCLE and CPTAC projects. We would like to thank developers of each dataset, method and package used in this study. We thank the Affiliated Hospital of Jiangnan University for providing the CRC samples. We also thank the platforms of Medical Research Center (Wuxi School of Medicine, Jiangnan University). This work was supported by grants from the National Natural Science Foundation of China (82002550 and 82173063) and Wuxi Medical Key Discipline (ZDXK2021002).	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Andreatta M, 2021, COMPUT STRUCT BIOTEC, V19, P3796, DOI 10.1016/j.csbj.2021.06.043; Bian ZH, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02162-8; Boczonadi V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5287; Boutelle AM, 2021, TRENDS CELL BIOL, V31, P298, DOI 10.1016/j.tcb.2020.12.011; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao PB, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf4304; Chen XL, 2022, J CANCER, V13, P1456, DOI 10.7150/jca.69166; Cui KS, 2021, ONCOGENE, V40, P2130, DOI 10.1038/s41388-021-01677-w; Cui KS, 2020, ONCOGENE, V39, P786, DOI 10.1038/s41388-019-1026-9; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Ferdows BE, 2022, NANOSCALE, V14, P4448, DOI 10.1039/d1nr06991h; Gao RL, 2021, NAT BIOTECHNOL, V39, P599, DOI 10.1038/s41587-020-00795-2; GARDEN GA, 1995, MOL CELL NEUROSCI, V6, P293, DOI 10.1006/mcne.1995.1023; Gong L, 2021, SMALL, V17, DOI 10.1002/smll.202103463; Gong ZC, 2021, ADV SCI, V8, DOI 10.1002/advs.202004504; Hacot S, 2010, CURR PROTOC CELL BIO; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Hong F, 2021, CANCER IMMUNOL RES, V9, P939, DOI 10.1158/2326-6066.CIR-20-1026; Jhan YY, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118802; Jiang TJ, 2002, P NATL ACAD SCI USA, V99, P5295, DOI 10.1073/pnas.072083699; Kang J, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00728-8; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Li D, 2020, CARBOHYD RES, V493, DOI 10.1016/j.carres.2020.108032; Li WJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0523-z; Li YJ, 2021, CELL DEATH DIFFER, V28, P2112, DOI 10.1038/s41418-021-00739-6; Liu QL, 2021, ELIFE, V10, DOI 10.7554/eLife.69454; Morral C, 2020, CELL STEM CELL, V26, P845, DOI 10.1016/j.stem.2020.04.012; Morton DJ, 2018, RNA, V24, P127, DOI 10.1261/rna.064626.117; Muller JS, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000678; Pan HD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00643; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Prakash V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10100-8; Shen AL, 2019, CANCER RES, V79, P2257, DOI 10.1158/0008-5472.CAN-18-3238; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniue K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010496; van Eijndhoven MAJ, 2020, NAT BIOMED ENG, V4, P6, DOI 10.1038/s41551-019-0514-0; Yang BW, 2019, ADV MATER, V31, DOI 10.1002/adma.201802896; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zanchin NIT, 1999, NUCLEIC ACIDS RES, V27, P1283, DOI 10.1093/nar/27.5.1283; Zhang J, 2022, J BIOMED SCI, V29, DOI 10.1186/s12929-022-00789-z; Zhang Y, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951-022-01472-z; Zheng R., 2022, J NATL CANC CTR, V2, P1, DOI [10.1016/j.jncc.2022.02.002, DOI 10.1016/J.JNCC.2022.02.002]; Zhu YH, 2022, HEPATOLOGY, DOI 10.1002/hep.32518; Zhu YH, 2020, MOL CELL, V77, P138, DOI 10.1016/j.molcel.2019.10.015	48	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02530-4	http://dx.doi.org/10.1038/s41388-022-02530-4		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D2TY	36348012				2022-12-17	WOS:000882550800002
J	Sun, SJ; Ai, YJ; Duan, KL; Zhang, JY; Zhang, C; Sun, YP; Xiong, Y; Guan, KL; Yuan, HX				Sun, Si-Jia; Ai, Ying-Jie; Duan, Kun-Long; Zhang, Jin-Ye; Zhang, Cheng; Sun, Yi-Ping; Xiong, Yue; Guan, Kun-Liang; Yuan, Hai-Xin			TET2 deficiency sensitizes tumor cells to statins by reducing HMGCS1 expression	ONCOGENE			English	Article; Early Access							COA REDUCTASE INHIBITORS; 5-HYDROXYMETHYLCYTOSINE; CANCER; MECHANISM; MUTATION; PATHWAY; SAFETY; GENES	TET2 (ten-eleven-translocation) protein is a Fe(II)- and alpha-ketoglutarate-dependent dioxygenase that catalyzes DNA demethylation to regulate gene expression. While TET2 gene is frequently mutated in hematological cancer, its enzymatic activity is also compromised in various solid tumors. Whether TET2 deficiency creates vulnerability for cancer cells has not been studied. Here we reported that TET2 deficiency is associated with the change of lipid metabolism processes in acute myeloid leukemia (AML) patient. We demonstrate that statins, the inhibitors of beta-Hydroxy beta-methylglutaryl-CoA (HMG-CoA) reductase and commonly used cholesterol-lowering medicines, significantly sensitize TET2 deficient tumor cells to apoptosis. TET2 directly regulates the expression of HMG-CoA synthase (HMGCS1) by catalyzing demethylation on its promoter region, and conversely TET2 deficiency leads to significant down-regulation of HMGCS1 expression and the mevalonate pathway. Consistently, overexpression of HMGCS1 in TET2-deficient cells rescues statin-induced apoptosis. We further reveal that decrease of geranylgeranyl diphosphate (GGPP), an intermediate metabolite in the mevalonate pathway, is responsible for statin-induced apoptosis. GGPP shortage abolishes normal membrane localization and function of multiple small GTPases, leading to cell dysfunction. Collectively, our study reveals a vulnerability in TET2 deficient tumor and a potential therapeutic strategy using an already approved safe medicine.	[Sun, Si-Jia; Duan, Kun-Long; Zhang, Jin-Ye; Zhang, Cheng; Sun, Yi-Ping; Yuan, Hai-Xin] Fudan Univ, Shanghai Coll Med, Peoples Hosp Shanghai 5, Inst Biomed Sci,Mol & Cell Biol Res Lab, Shanghai, Peoples R China; [Ai, Ying-Jie] Fudan Univ, Zhongshan Hosp, Shanghai Coll Med, Dept Gastroenterol & Hepatol, Shanghai, Peoples R China; [Xiong, Yue] Cullgen Inc, 12730 High Bluff Dr, San Diego, CA 92130 USA; [Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92093 USA; [Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA; [Yuan, Hai-Xin] Chongqing Med Univ, Inst Life Sci, Ctr Novel Target & Therapeut Intervent, Chongqing 400016, Peoples R China	Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; Chongqing Medical University	Yuan, HX (corresponding author), Fudan Univ, Shanghai Coll Med, Peoples Hosp Shanghai 5, Inst Biomed Sci,Mol & Cell Biol Res Lab, Shanghai, Peoples R China.; Yuan, HX (corresponding author), Chongqing Med Univ, Inst Life Sci, Ctr Novel Target & Therapeut Intervent, Chongqing 400016, Peoples R China.	yuanhaixin@fudan.edu.cn		Yuan, Hai-Xin/0000-0002-1624-3934	National Key Research and Development Project of China [2018YFA0800304]; NSFC [82172595]; Development Fund for Shanghai Talents [2019109]; Supporting Fund for Innovation and Entrepreneurship by Chongqing Returned Oversea Scholars	National Key Research and Development Project of China; NSFC(National Natural Science Foundation of China (NSFC)); Development Fund for Shanghai Talents; Supporting Fund for Innovation and Entrepreneurship by Chongqing Returned Oversea Scholars	This work was supported by the National Key Research and Development Project of China (No. 2018YFA0800304 to H.-X.Y.), the NSFC grants (No. 82172595 to H.-X.Y.), and the Development Fund for Shanghai Talents (No. 2019109 to H.-X.Y.). H.-X.Y. is also supported by the Supporting Fund for Innovation and Entrepreneurship by Chongqing Returned Oversea Scholars.	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bottorff M, 2000, ARCH INTERN MED, V160, P2273, DOI 10.1001/archinte.160.15.2273; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; Bullinger L, 2017, J CLIN ONCOL, V35, P934, DOI 10.1200/JCO.2016.71.2208; Chen L, 2019, J LIPID RES, V60, P1765, DOI 10.1194/jlr.RA119000201; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; Cheng ML, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00266; Davidson MH, 2001, DRUGS, V61, P197, DOI 10.2165/00003495-200161020-00005; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Farmer JA, 2000, DRUG SAFETY, V23, P197, DOI 10.2165/00002018-200023030-00003; Garcia-Bermudez J, 2019, NATURE, V567, P118, DOI 10.1038/s41586-019-0945-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Illingworth DR, 2001, ADV PROTEIN CHEM, V56, P77; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jawert F, 2013, ANTICANCER RES, V33, P4325; Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Laukka T, 2016, J BIOL CHEM, V291, P4256, DOI 10.1074/jbc.M115.688762; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Nguyen UTT, 2009, NAT CHEM BIOL, V5, P227, DOI 10.1038/nchembio.149; Nibourel O, 2010, BLOOD, V116, P1132, DOI 10.1182/blood-2009-07-234484; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tefferi A, 2009, LEUKEMIA, V23, P1343, DOI 10.1038/leu.2009.59; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964; Wang YP, 2015, MOL CELL, V57, P662, DOI 10.1016/j.molcel.2014.12.023; Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Wu D, 2018, NATURE, V559, P637, DOI 10.1038/s41586-018-0350-5; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xu YP, 2019, J CLIN INVEST, V129, P4316, DOI 10.1172/JCI129317; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Zhang XX, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01456-9	40	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02531-3	http://dx.doi.org/10.1038/s41388-022-02531-3		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D2TY	36348011				2022-12-17	WOS:000882550800001
J	Tsang, SV; Rainusso, N; Liu, M; Nomura, M; Patel, TD; Nakahata, K; Kim, H; Huang, SX; Rajapakshe, K; Coarfa, C; Man, TK; Rao, PH; Yustein, JT				Tsang, Susan, V; Rainusso, Nino; Liu, Meng; Nomura, Motonari; Patel, Tajhal D.; Nakahata, Kengo; Kim, Ha Ram; Huang, Shixia; Rajapakshe, Kimal; Coarfa, Cristian; Man, Tsz-Kwong; Rao, Pulivarthi H.; Yustein, Jason T.			LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination	ONCOGENE			English	Article; Early Access							LONG NONCODING RNA; CELLS; IDENTIFICATION; RESISTANCE; DISCOVERY; ONCOGENE	Osteosarcoma, the most common pediatric bone tumor, is an aggressive heterogeneous malignancy defined by complex chromosomal aberrations. Overall survival rates remain at similar to 70%, but patients with chemoresistant or metastatic disease have extremely poor outcomes of <30%. A subgroup of tumors harbor amplification of chromosome 8q24.2 and increased expression of the oncogenic long noncoding RNA (IncRNA) Plasmacytoma Variant Translocation-1 (PVT-1), which is associated with an extremely poor clinical prognosis. This study demonstrates that PVT-7 is critical for osteosarcoma tumor-initiation potential. Chromatin Hybridization by RNA Purification analysis identified Tripartite-Motif Containing Family 28 (TRIM28) as a novel PVT-1 binding partner. Mechanistically, co-immunoprecipitation studies showed the PVT-1/TRIM28 complex binds and increases SUMOylation of phosphatidylinositol 3-kinase catalytic subunit type 3 (Vps34), which leads to enhanced ubiquitination and degradation of tumor suppressor complex 2 (TSC2), thus contributing to increased self-renewal and stem cell phenotypes. Furthermore, we identified that osteosarcoma cells with increased PVT-1 have enhanced sensitivity to the SUMOylation inhibitor, TAK-981. Altogether, this study elucidated a role for PVT-1 in the enhancement of cancer stem-like behaviors, including migration and invasion, in osteosarcoma, and identified the novel PVT-1/TRIM28 axis signaling cascade as a potential therapeutic target for osteosarcoma treatment.	[Tsang, Susan, V; Rainusso, Nino; Liu, Meng; Patel, Tajhal D.; Nakahata, Kengo; Kim, Ha Ram; Man, Tsz-Kwong; Rao, Pulivarthi H.; Yustein, Jason T.] Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA; [Tsang, Susan, V; Rainusso, Nino; Liu, Meng; Patel, Tajhal D.; Nakahata, Kengo; Kim, Ha Ram; Man, Tsz-Kwong; Rao, Pulivarthi H.; Yustein, Jason T.] Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA; [Tsang, Susan, V; Yustein, Jason T.] Baylor Coll Med, Integrat Mol & Biomed Sci Program, Houston, TX 77030 USA; [Rainusso, Nino; Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Dan L Duncan Canc Comprehens Ctr, Houston, TX 77030 USA; [Nomura, Motonari; Nakahata, Kengo] Osaka Univ, Grad Sch Med, Dept Pediat Surg, Suita, Osaka, Japan; [Huang, Shixia; Coarfa, Cristian] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Rajapakshe, Kimal] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA; [Yustein, Jason T.] Emory Univ, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Osaka University; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Emory University	Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Integrat Mol & Biomed Sci Program, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Dan L Duncan Canc Comprehens Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Emory Univ, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA.	yustein@bcm.edu		Coarfa, Cristian/0000-0002-4183-4939	Cancer Prevention Institute of Texas (CPRIT) [RP160283, RP170005]; NIEHS P30 Center [1P30ES030285]; CPRIT Core Facility Support Award [CPRIT-RP180672]; NIH [CA125123, RR024574]; Core Facility Award [CPRIT-RP170005]; NIEHS P30 Center grant [1P30ES030285]	Cancer Prevention Institute of Texas (CPRIT); NIEHS P30 Center; CPRIT Core Facility Support Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Core Facility Award; NIEHS P30 Center grant	We would like to acknowledge the Advanced Technologies Core services at the Baylor College of Medicine. This work was funded by The Faris D. Virani Ewing Sarcoma Center (to JTY). SVT was partially supported by Cancer Prevention Institute of Texas (CPRIT) RP160283, KR and CC were partially supported by (CPRIT) RP170005, NIH P30 shared resource grant CA125123, and NIEHS P30 Center grant 1P30ES030285; CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (CA125123 and RR024574 to the Cytometry and Cell Sorting Core at Baylor College of Medicine); and Core Facility Award (CPRIT-RP170005 to Proteomics and Metabolomics Core at Baylor College of Medicine). We thank Dr. Suzanne Fuqua and Dr. Xiang Zhang for generously providing the breast cancer cell lines.	Adriaens C, 2016, NAT MED, V22, P861, DOI 10.1038/nm.4135; Al-Romaih K, 2003, CANCER GENET CYTOGEN, V144, P91, DOI 10.1016/S0165-4608(02)00929-9; Assouline S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128773; Brisbin AG, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-156; Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019; Carramusa L, 2007, J CELL PHYSIOL, V213, P511, DOI 10.1002/jcp.21133; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chen SS, 2017, ONCOTARGET, V8, P110685, DOI 10.18632/oncotarget.22161; Chu C, 2015, CELL, V161, P404, DOI 10.1016/j.cell.2015.03.025; Colombo T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/304208; Czerwinska P, 2017, ONCOTARGET, V8, P863, DOI 10.18632/oncotarget.13273; Dasgupta A, 2021, CANCER RES, V81, P199, DOI 10.1158/0008-5472.CAN-20-0854; Du PZ, 2019, J ONCOL, V2019, DOI 10.1155/2019/9325407; Fan H, 2018, MOL MED REP, V17, P8309, DOI 10.3892/mmr.2018.8907; Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455; Feng Y, 2014, METHODS MOL BIOL, V1165, P115, DOI 10.1007/978-1-4939-0856-1_10; Fong KW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07475-5; Fu C, 2018, NEUROTHERAPEUTICS, V15, P1139, DOI 10.1007/s13311-018-0649-9; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; Han D, 2015, CANCER LETT, V361, P13, DOI 10.1016/j.canlet.2015.03.002; Houthuijzen J, 2012, BRIT J CANCER, V106, P1901, DOI 10.1038/bjc.2012.201; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Lang B, 2019, NUCLEIC ACIDS RES, V47, pD601, DOI 10.1093/nar/gky967; Langston SP, 2021, J MED CHEM, V64, P2501, DOI 10.1021/acs.jmedchem.0c01491; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li J, 2017, ONCOGENE, V36, P2991, DOI 10.1038/onc.2016.453; Liu XK, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0164-y; Madsen RR, 2020, BIOCHEM SOC T, V48, P301, DOI 10.1042/BST20190778; Livi CM, 2016, BIOINFORMATICS, V32, P773, DOI 10.1093/bioinformatics/btv629; Mirabello L, 2010, CARCINOGENESIS, V31, P1400, DOI 10.1093/carcin/bgq117; Misaghi A, 2018, SICOT-J, V4, DOI 10.1051/sicotj/2017028; Mohan N, 2016, ONCOTARGET, V7, P52239, DOI 10.18632/oncotarget.10469; Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216; Muff R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125611; Nomura M, 2019, JNCI-J NATL CANCER I, V111, P1216, DOI 10.1093/jnci/djz026; Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Peitzsch C, 2017, SEMIN CANCER BIOL, V44, P10, DOI 10.1016/j.semcancer.2017.02.011; Ping GF, 2018, AM J TRANSL RES, V10, P138; Pradhan SA, 2014, NUCLEIC ACIDS RES, V42, P6243, DOI 10.1093/nar/gku278; Rainusso N, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27579; Schiavone K, 2019, ADV EXP MED BIOL, V1139, P187, DOI 10.1007/978-3-030-14366-4_11; Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388-018-0310-4; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang HT, 2020, CANCER MANAG RES, V12, P7993, DOI 10.2147/CMAR.S263383; Xia P, 2015, AM J CANCER RES, V5, P1602; Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110	47	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02538-w	http://dx.doi.org/10.1038/s41388-022-02538-w		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D2TY	36348010	Green Submitted			2022-12-17	WOS:000882550800003
J	Li, M; Tsavachidis, S; Wang, FCC; Bui, TY; Nguyen, TDT; Luo, LJ; Multani, AS; Bondy, ML; Hunt, KK; Keyomarsi, K				Li, Mi; Tsavachidis, Spiridon; Wang, Fuchenchu; Bui, Tuyen; Tuyen Duong Thanh Nguyen; Luo, Linjie; Multani, Asha S.; Bondy, Melissa L.; Hunt, Kelly K.; Keyomarsi, Khandan			Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer	ONCOGENE			English	Article; Early Access							HUMAN-CELLS; COMBINATION; SUBTYPES; ORIGINS; GROWTH	Low-molecular-weight cyclin E (LMW-E) is an N-terminus deleted (40 amino acid) form of cyclin E detected in breast cancer, but not in normal cells or tissues. LMW-E overexpression predicts poor survival in breast cancer patients independent of tumor proliferation rate, but the oncogenic mechanism of LMW-E and its unique function(s) independent of full-length cyclin E (FL-cycE) remain unclear. In the current study, we found LMW-E was associated with genomic instability in early-stage breast tumors (n = 725) and promoted genomic instability in human mammary epithelial cells (hMECs). Mechanistically, FL-cycE overexpression inhibited the proliferation of hMECs by replication stress and DNA damage accumulation, but LMW-E facilitated replication stress tolerance by upregulating DNA replication and damage repair. Specifically, LMW-E interacted with chromatin and upregulated the loading of minichromosome maintenance complex proteins (MCMs) in a CDC6 dependent manner and promoted DNA repair in a RAD51- and Cl 7orf53-dependent manner. Targeting the ATR-CHK1-RAD51 pathway with ATR inhibitor (ceralasertib), CHK1 inhibitor (rabusertib), or RAD51 inhibitor (B02) significantly decreased the viability of LMW-E-overexpressing hMECs and breast cancer cells. Collectively, our findings delineate a novel role for LMW-E in tumorigenesis mediated by replication stress tolerance and genomic instability, providing novel therapeutic strategies for LMW-E-overexpressing breast cancers.	[Li, Mi; Keyomarsi, Khandan] Univ Texas MD Anderson Canc Ctr UTHlth Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Li, Mi; Bui, Tuyen; Tuyen Duong Thanh Nguyen; Luo, Linjie; Keyomarsi, Khandan] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Tsavachidis, Spiridon] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Wang, Fuchenchu] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Multani, Asha S.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Bondy, Melissa L.] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA; [Hunt, Kelly K.] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Stanford University; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr UTHlth Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Li, Mi/0000-0002-6038-4144; Hunt, Kelly K./0000-0001-9156-8723	Cancer Prevention Research Institute of Texas - Multi-Investigator Research Award (CPRIT-MIRA) [RP180712]; National Cancer Institute (NCI) [R01CA223772, R01CA255960]; CPRIT Research Training Program [RP170067, RP210028]; NCI through MD Anderson's Cancer Center Support Grant [P30CA016672]	Cancer Prevention Research Institute of Texas - Multi-Investigator Research Award (CPRIT-MIRA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT Research Training Program; NCI through MD Anderson's Cancer Center Support Grant	Research reported in this manuscript was supported by Cancer Prevention Research Institute of Texas - Multi-Investigator Research Award (CPRIT-MIRA #RP180712) to KK and KKH, by the National Cancer Institute (NCI) R01CA223772 and R01CA255960 to KK, CPRIT Research Training Program grant RP170067 and RP210028 to ML and by the NCI through MD Anderson's Cancer Center Support Grant (P30CA016672).	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bianchini G, 2022, NAT REV CLIN ONCOL, V19, P91, DOI 10.1038/s41571-021-00565-2; Bonnet F, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-54; Carey JPW, 2018, CANCER RES, V78, P742, DOI 10.1158/0008-5472.CAN-17-1494; Caruso JA, 2018, CANCER RES, V78, P5481, DOI 10.1158/0008-5472.CAN-18-1235; Caruso JA, 2010, CANCER RES, V70, P7125, DOI 10.1158/0008-5472.CAN-10-1547; Chen X, 2018, CLIN CANCER RES, V24, P6594, DOI 10.1158/1078-0432.CCR-18-1446; Chu C, 2021, TRENDS CELL BIOL, V31, P732, DOI 10.1016/j.tcb.2021.05.001; Delk NA, 2009, CANCER RES, V69, P2817, DOI 10.1158/0008-5472.CAN-08-4182; Duong MT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002538; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fagundes R, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.774845; Fragkos M, 2015, NAT REV MOL CELL BIO, V16, P360, DOI 10.1038/nrm4002; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Gorecki L, 2021, CANCERS, V13, DOI 10.3390/cancers13040795; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Hunt KK, 2017, CLIN CANCER RES, V23, P2991, DOI 10.1158/1078-0432.CCR-16-2217; Jabbour-Leung NA, 2016, MOL CANCER THER, V15, P593, DOI 10.1158/1535-7163.MCT-15-0519; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim R, 2022, ANN ONCOL, V33, P193, DOI 10.1016/j.annonc.2021.10.009; Kim ST, 2021, CLIN CANCER RES, V27, P4700, DOI 10.1158/1078-0432.CCR-21-0251; Loibl S, 2021, LANCET, V397, P1750, DOI 10.1016/S0140-6736(20)32381-3; Lu XY, 2009, J BIOL CHEM, V284, P35325, DOI 10.1074/jbc.M109.035949; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Masoud V, 2017, WORLD J CLIN ONCOL, V8, P120, DOI 10.5306/wjco.v8.i2.120; Nanos-Webb A, 2012, BREAST CANCER RES TR, V132, P575, DOI 10.1007/s10549-011-1638-4; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Petropoulos M, 2019, TRENDS BIOCHEM SCI, V44, P752, DOI 10.1016/j.tibs.2019.03.011; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sims AH, 2007, NAT CLIN PRACT ONCOL, V4, P516, DOI 10.1038/ncponc0908; Teixeira LK, 2015, CURR BIOL, V25, P1327, DOI 10.1016/j.cub.2015.03.022; Thompson PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023543; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang C, 2020, DNA REPAIR, V95, DOI 10.1016/j.dnarep.2020.102946; Yap TA, 2021, CLIN CANCER RES, V27, P5213, DOI 10.1158/1078-0432.CCR-21-1032; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099	47	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02527-z	http://dx.doi.org/10.1038/s41388-022-02527-z		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Z0JJ	36344674	Green Accepted			2022-12-17	WOS:000879664600002
J	Spina, R; Mills, I; Ahmad, F; Chen, CX; Ames, HM; Winkles, JA; Woodworth, GF; Bar, EE				Spina, Raffaella; Mills, Ian; Ahmad, Fahim; Chen, Chixiang; Ames, Heather M.; Winkles, Jeffrey A.; Woodworth, Graeme F.; Bar, Eli E.			DHODH inhibition impedes glioma stem cell proliferation, induces DNA damage, and prolongs survival in orthotopic glioblastoma xenografts	ONCOGENE			English	Article; Early Access							CENTRAL-NERVOUS-SYSTEM; PROMOTES RADIORESISTANCE; HYPOXIC MICROENVIRONMENT; THERAPEUTIC RESISTANCE; URIDINE LEVELS; CDP-CHOLINE; TUMORS; GROWTH; CLASSIFICATION; ACTIVATION	Glioma stem cells (GSCs) promote tumor progression and therapeutic resistance and exhibit remarkable bioenergetic and metabolic plasticity, a phenomenon that has been linked to their ability to escape standard and targeted therapies. However, specific mechanisms that promote therapeutic resistance have been somewhat elusive. We hypothesized that because GSCs proliferate continuously, they may require the salvage and de novo nucleotide synthesis pathways to satisfy their bioenergetic needs. Here, we demonstrate that GSCs lacking EGFR (or EGFRvIII) amplification are exquisitely sensitive to de novo pyrimidine synthesis perturbations, while GSCs that amplify EGFR are utterly resistant. Furthermore, we show that EGFRvIII promotes BAY2402234 resistance in otherwise BAY2402234 responsive GSCs. Remarkably, a novel, orally bioavailable, blood-brain-barrier penetrating, dihydroorotate dehydrogenase (DHODH) inhibitor BAY2402234 was found to abrogate GSC proliferation, block cell-cycle progression, and induce DNA damage and apoptosis. When dosed daily by oral gavage, BAY2402234 significantly impaired the growth of two different intracranial human glioblastoma xenograft models in mice. Given this observed efficacy and the previously established safety profiles in preclinical animal models and human clinical trials, the clinical testing of BAY2402234 in patients with primary glioblastoma that lacks EGFR amplification is warranted.	[Spina, Raffaella; Mills, Ian; Ahmad, Fahim; Ames, Heather M.; Bar, Eli E.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Chen, Chixiang; Winkles, Jeffrey A.; Woodworth, Graeme F.; Bar, Eli E.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Chen, Chixiang] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Ames, Heather M.; Winkles, Jeffrey A.; Woodworth, Graeme F.; Bar, Eli E.] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Winkles, Jeffrey A.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Winkles, Jeffrey A.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Bar, EE (corresponding author), Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.; Bar, EE (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.; Bar, EE (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.	ebar@som.umaryland.edu		Ahmad, Fahim/0000-0002-7216-5539; Chen, Chixiang/0000-0001-5474-2833; Mills, Ian/0000-0003-1334-2686; Winkles, Jeffrey/0000-0002-3305-1424	National Institutes of Health [R21NS106553, R01CA187780]; National Cancer Institute Cancer Center Support Grant (CCSG) [P30CA134274]; Maryland Department of Health's Cigarette Restitution Fund Program	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute Cancer Center Support Grant (CCSG); Maryland Department of Health's Cigarette Restitution Fund Program	This study is funded by National Institutes of Health grant R01CA187780 (EEB), National Institutes of Health grant R21NS106553 (EEB), National Cancer Institute Cancer Center Support Grant (CCSG) - P30CA134274, and Maryland Department of Health's Cigarette Restitution Fund Program.	Ashour OM, 2000, CANCER CHEMOTH PHARM, V45, P351, DOI 10.1007/s002800051002; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Cansev M, 2005, BRAIN RES, V1058, P101, DOI 10.1016/j.brainres.2005.07.054; Carruthers RD, 2018, CANCER RES, V78, P5060, DOI 10.1158/0008-5472.CAN-18-0569; Christian S, 2019, LEUKEMIA, V33, P2403, DOI 10.1038/s41375-019-0461-5; Chu Q, 2013, CLIN CANCER RES, V19, P3224, DOI 10.1158/1078-0432.CCR-12-2119; Dahan P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.509; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fuller GN, 2008, ARCH PATHOL LAB MED, V132, P906, DOI 10.1043/1543-2165(2008)132[906:TWCOTO]2.0.CO;2; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Grant GD, 2018, CELL CYCLE, V17, P2496, DOI 10.1080/15384101.2018.1547001; Hardee ME, 2012, CANCER RES, V72, P4119, DOI 10.1158/0008-5472.CAN-12-0546; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Henricks LM, 2018, BRIT J CLIN PHARMACO, V84, P2761, DOI 10.1111/bcp.13719; Hess KR, 2004, CANCER, V101, P2293, DOI 10.1002/cncr.20621; Honoki K, 2010, ONCOL REP, V24, P501, DOI 10.3892/or_00000885; Jialiang W, 2009, NOTCH PROMOTES RADIO, V28, P17; Kahlert UD, 2015, BRAIN PATHOL, V25, P724, DOI 10.1111/bpa.12240; Kahlert UD, 2012, FOLIA NEUROPATHOL, V50, P357, DOI 10.5114/fn.2012.32365; Kim Y, 2012, LAB INVEST, V92, P466, DOI 10.1038/labinvest.2011.161; Lal B, 2009, MOL CANCER THER, V8, P1751, DOI 10.1158/1535-7163.MCT-09-0188; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lim KS, 2014, ONCOGENE, V33, P4433, DOI 10.1038/onc.2013.390; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Mashimo M, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.014479; Nakano RMAI, 2011, J CARCINOGENE MUTAGE, P1; Osuka S, 2017, J CLIN INVEST, V127, P415, DOI 10.1172/JCI89587; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Quemeneur L, 2003, J IMMUNOL, V170, P4986, DOI 10.4049/jimmunol.170.10.4986; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Robinson AD, 2020, CANCER LETT, V470, P134, DOI 10.1016/j.canlet.2019.11.013; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Singh SK, 2003, CANCER RES, V63, P5821; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Spina R., 2020, NEUROONCOL ADV, V2; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-401; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Szeto MD, 2009, CANCER RES, V69, P4502, DOI 10.1158/0008-5472.CAN-08-3884; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Uribe D, 2017, MOL ASPECTS MED, V55, P140, DOI 10.1016/j.mam.2017.01.009; van Wijk Nick, 2017, Alzheimers Dement (Amst), V8, P139, DOI 10.1016/j.dadm.2017.04.005; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wang MX, 2013, INT J ONCOL, V43, P131, DOI 10.3892/ijo.2013.1929; Wang SD, 2012, ONCOGENE, V31, P5132, DOI 10.1038/onc.2012.16; Wang XX, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau4972; Williams MG, 2003, BIOMED CHROMATOGR, V17, P215, DOI 10.1002/bmc.210; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Wu YJ, 2012, CANCER SCI, V103, P1028, DOI 10.1111/j.1349-7006.2012.02260.x; Wurtman RJ, 2000, BIOCHEM PHARMACOL, V60, P989, DOI 10.1016/S0006-2952(00)00436-6; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Ying MY, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.588988; Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561	65	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02517-1	http://dx.doi.org/10.1038/s41388-022-02517-1		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Z0JJ	36344676				2022-12-17	WOS:000879664600003
J	Stubbs, FE; Flynn, BP; Rivers, CA; Birnie, MT; Herman, A; Swinstead, EE; Baek, S; Fang, H; Temple, J; Carroll, JS; Hager, GL; Lightman, SL; Conway-Campbell, BL				Stubbs, Felicity E.; Flynn, Benjamin P.; Rivers, Caroline A.; Birnie, Matthew T.; Herman, Andrew; Swinstead, Erin E.; Baek, Songjoon; Fang, Hai; Temple, Jillian; Carroll, Jason S.; Hager, Gordon L.; Lightman, Stafford L.; Conway-Campbell, Becky L.			Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation	ONCOGENE			English	Article; Early Access							CHROMATIN-REMODELING COMPLEX; GLUCOCORTICOID-RECEPTOR; TUMOR-SUPPRESSOR; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; SOLID TUMORS; 53BP1; BINDING; ARREST	ARID1a (BAF250), a component of human SWI/SNF chromatin remodeling complexes, is frequently mutated across numerous cancers, and its loss of function has been putatively linked to glucocorticoid resistance. Here, we interrogate the impact of siRNA knockdown of ARID1a compared to a functional interference approach in the HeLa human cervical cancer cell line. We report that ARID1a knockdown resulted in a significant global decrease in chromatin accessibility in ATAC-Seq analysis, as well as affecting a subset of genome-wide GR binding sites determined by analyzing GR ChIP-Seq data. Interestingly, the specific effects on gene expression were limited to a relatively small subset of glucocorticoid-regulated genes, notably those involved in cell cycle regulation and DNA repair. The vast majority of glucocorticoid-regulated genes were largely unaffected by ARID1a knockdown or functional interference, consistent with a more specific role for ARID1a in glucocorticoid function than previously speculated. Using liquid chromatography-mass spectrometry, we have identified a chromatin-associated protein complex comprising GR, ARID1a, and several DNA damage repair proteins including P53 binding protein 1 (P53BP1), Poly(ADP-Ribose) Polymerase 1 (PARP1), DNA damage-binding protein 1 (DDB1), DNA mismatch repair protein MSH6 and splicing factor proline and glutamine-rich protein (SFPQ), as well as the histone acetyltransferase KAT7, an epigenetic regulator of steroid-dependent transcription, DNA damage repair and cell cycle regulation. Not only was this protein complex ablated with both ARID1a knockdown and functional interference, but spontaneously arising DNA damage was also found to accumulate in a manner consistent with impaired DNA damage repair mechanisms. Recovery from dexamethasone-dependent cell cycle arrest was also significantly impaired. Taken together, our data demonstrate that although glucocorticoids can still promote cell cycle arrest in the absence of ARID1a, the purpose of this arrest to allow time for DNA damage repair is hindered.	[Stubbs, Felicity E.; Flynn, Benjamin P.; Rivers, Caroline A.; Birnie, Matthew T.; Lightman, Stafford L.; Conway-Campbell, Becky L.] Univ Bristol, Fac Hlth Sci, Henry Wellcome Labs Integrat Neurosci & Endocrino, Translat Hlth Sci, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England; [Stubbs, Felicity E.; Swinstead, Erin E.; Baek, Songjoon; Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, US Natl Inst Hlth, 41 Medlars Dr, Bethesda, MD 20892 USA; [Herman, Andrew] Univ Bristol, Fac Life Sci, Sch Cellular & Mol Med, Flow Cytometry Facil, Biomed Sci Bldg, Bristol, Avon, England; [Fang, Hai] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai,Sch Med, Thanghai Inst Hematol,State Key Lab Med Genom, Shanghai 200025, Peoples R China; [Temple, Jillian; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bristol; Chinese Academy of Sciences; Shanghai Jiao Tong University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Conway-Campbell, BL (corresponding author), Univ Bristol, Fac Hlth Sci, Henry Wellcome Labs Integrat Neurosci & Endocrino, Translat Hlth Sci, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	b.conway-campbell@bristol.ac.uk		Rivers, Caroline/0000-0002-2993-3723; Flynn, Benjamin/0000-0002-1871-3039	Wellcome Trust [089647/Z/09/Z]; MRC [MR/R010919/1]; Needham Cooper Charitable Trust; Neuroendocrinology Charitable Trust; Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program [W81XWH-17-1-0067]	Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Needham Cooper Charitable Trust; Neuroendocrinology Charitable Trust; Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program	Majority of materials and consumables were provided by funding from Wellcome Trust Grant 089647/Z/09/Z and MRC Grant MR/R010919/1 to BLC-C and SLL FES was awarded an early career grant by The Society for Endocrinology for the costs of the proteomics and FACS studies. FES was supported by a Ph.D. scholarship provided by the Needham Cooper Charitable Trust and a research fellowship awarded by the Neuroendocrinology Charitable Trust. BLC-C was supported by Wellcome Trust Grant 089647/Z/09/Z and MRC Grant MR/R010919/1. EES was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Programunder Award No. W81XWH-17-1-0067. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. Finally, we would like to thank The University of Bristol Genomics Facility (Dr. Christy Waterfall and Ms. Jane Coghill), Proteomics Facility (Dr. Kate Heesom), and FACS facility (Helen Rice and Lorena Sueiro Ballesteros) for their excellent technical support and invaluable advice throughout the course of the project.	Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Baell JB, 2018, NATURE, V560, P253, DOI 10.1038/s41586-018-0387-5; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Conway-Campbell BL, 2011, MOL ENDOCRINOL, V25, P944, DOI 10.1210/me.2010-0073; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Cuella-Martin R, 2016, MOL CELL, V64, P51, DOI 10.1016/j.molcel.2016.08.002; de Silva HC, 2019, CELL MOL LIFE SCI, V76, P2015, DOI 10.1007/s00018-019-03033-4; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Drane P, 2017, NATURE, V543, P211, DOI 10.1038/nature21358; Du F, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0315-y; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Fang H, 2014, BIOCHEM BIOPH RES CO, V443, P285, DOI 10.1016/j.bbrc.2013.11.103; Flores-Alcantar A, 2011, CELL TISSUE RES, V345, P137, DOI 10.1007/s00441-011-1182-x; Fragkos M, 2009, MOL CELL BIOL, V29, P2828, DOI 10.1128/MCB.01830-08; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; George CL, 2017, MOL CELL ENDOCRINOL, V439, P46, DOI 10.1016/j.mce.2016.10.019; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Grontved L, 2013, EMBO J, V32, P1568, DOI 10.1038/emboj.2013.106; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Han N, 2019, ONCOTARGETS THER, V12, P7591, DOI 10.2147/OTT.S222223; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; He B, 2016, J CELL PHYSIOL, V231, P233, DOI 10.1002/jcp.25076; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Herr I, 2006, LANCET ONCOL, V7, P425, DOI 10.1016/S1470-2045(06)70694-5; Hoffmann JA, 2018, ELIFE, V7, DOI 10.7554/eLife.35073; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Hu ZL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134299; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Johnson TA, 2018, NUCLEIC ACIDS RES, V46, P203, DOI 10.1093/nar/gkx1044; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kang Y, 2011, BIOCHEM BIOPH RES CO, V404, P476, DOI 10.1016/j.bbrc.2010.12.005; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lovejoy CA, 2006, MOL CELL BIOL, V26, P7977, DOI 10.1128/MCB.00819-06; MacPherson L, 2020, NATURE, V577, P266, DOI 10.1038/s41586-019-1835-6; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; Mattern J, 2007, CANCER BIOL THER, V6, P1345, DOI 10.4161/cbt.6.9.4765; Mirza-Aghazadeh-Attari M, 2019, DNA REPAIR, V73, P110, DOI 10.1016/j.dnarep.2018.11.008; Mittica G, 2018, RECENT PAT ANTI-CANC, V13, P392, DOI 10.2174/1574892813666180305165256; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Niida H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16102; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.bi.60.070191.004143; Pardo M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08456-2; Petrucco S, 2003, NUCLEIC ACIDS RES, V31, P6689, DOI 10.1093/nar/gkg890; Planey SL, 2000, BIOCHEM BIOPH RES CO, V279, P307, DOI 10.1006/bbrc.2000.3922; Pommier Y, 2022, NAT REV MOL CELL BIO, V23, P407, DOI 10.1038/s41580-022-00452-3; Pooley JR, 2017, ENDOCRINOLOGY, V158, P1486, DOI 10.1210/en.2016-1929; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Prekovic S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24537-3; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Sharma A, 2012, HISTONE H2AX PHOSPHO, V920; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shen PL, 2021, BIOCHEM BIOPHYS REP, V28, DOI 10.1016/j.bbrep.2021.101151; Sossey-Alaoui K, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1774-z; Soussi T, 2017, TRENDS CELL BIOL, V27, P311, DOI 10.1016/j.tcb.2016.10.004; Stubbs FE, 2018, MOL CELL ENDOCRINOL, V461, P226, DOI 10.1016/j.mce.2017.09.018; Sun JB, 2014, CANCER LETT, V355, P25, DOI 10.1016/j.canlet.2014.09.022; Swinstead EE, 2016, CELL, V165, P593, DOI 10.1016/j.cell.2016.02.067; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trizzino M, 2018, CELL REP, V23, P3933, DOI 10.1016/j.celrep.2018.05.097; Trotter KW, 2008, MOL CELL BIOL, V28, P1413, DOI 10.1128/MCB.01301-07; Trotter KW, 2015, MOL CELL BIOL, V35, P2799, DOI 10.1128/MCB.00230-15; Visconti R, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0433-9; Vyas S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3240; Wacker DA, 2007, MOL CELL BIOL, V27, P7475, DOI 10.1128/MCB.01314-07; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Yoon CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042006; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang XM, 2019, J RADIAT RES, V60, P318, DOI 10.1093/jrr/rrz003; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	99	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02516-2	http://dx.doi.org/10.1038/s41388-022-02516-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Z0JJ	36344675	Green Published, hybrid			2022-12-17	WOS:000879664600001
J	An, JB; Nagaki, Y; Motoyama, S; Kuze, Y; Hoshizaki, M; Kemuriyama, K; Yamaguchi, T; Ebihara, T; Minamiya, Y; Suzuki, Y; Imai, Y; Kuba, K				An, Jianbo; Nagaki, Yushi; Motoyama, Satoru; Kuze, Yuta; Hoshizaki, Midori; Kemuriyama, Kohei; Yamaguchi, Tomokazu; Ebihara, Takashi; Minamiya, Yoshihiro; Suzuki, Yutaka; Imai, Yumiko; Kuba, Keiji			Identification of Galectin-7 as a crucial metastatic enhancer of squamous cell carcinoma associated with immunosuppression	ONCOGENE			English	Article; Early Access							TUMOR PROGRESSION; CANCER; PATTERNS; MARKER; CHEMORADIOTHERAPY; LYMPHANGIOGENESIS; EXPRESSION; ESOPHAGEAL; PROMOTES; SURVIVAL	Metastasis predicts poor prognosis in cancer patients. It has been recognized that specific tumor microenvironment defines cancer cell metastasis, whereas the underlying mechanisms remain elusive. Here we show that Galectin-7 is a crucial mediator of metastasis associated with immunosuppression. In a syngeneic mouse squamous cell carcinoma (SCC) model of NR-S1M cells, we isolated metastasized NR-S1M cells from lymph nodes in tumor-bearing mice and established metastatic NR-S1M cells in in vitro culture. RNA-seq analysis revealed that interferon gene signature was markedly downregulated in metastatic NR-S1M cells compared with parental cells, and in vivo NR-S1M tumors heterogeneously developed focal immunosuppressive areas featured by deficiency of anti-tumor immune cells. Spatial transcriptome analysis (Visium) for the NR-S1M tumors revealed that various pro-metastatic genes were significantly upregulated in immunosuppressive areas when compared to immunocompetent areas. Notably, Galectin-7 was identified as a novel metastasis-driving factor. Galectin-7 expression was induced during tumorigenesis particularly in the microenvironment of immunosuppression, and extracellularly released at later stage of tumor progression. Deletion of Galectin-7 in NR-S1M cells significantly suppressed lymph node and lung metastasis without affecting primary tumor growth. Therefore, Galectin-7 is a crucial mediator of tumor metastasis of SCC, which is educated in the immune-suppressed tumor areas, and may be a potential target of cancer immunotherapy.	[An, Jianbo; Nagaki, Yushi; Hoshizaki, Midori; Kemuriyama, Kohei; Yamaguchi, Tomokazu; Kuba, Keiji] Akita Univ, Dept Biochem & Metab Sci, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Nagaki, Yushi; Motoyama, Satoru; Kemuriyama, Kohei; Minamiya, Yoshihiro] Akita Univ, Dept Surg, Grad Sch Med, Akita, Japan; [Kuze, Yuta; Suzuki, Yutaka] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba 2778562, Japan; [Hoshizaki, Midori; Ebihara, Takashi] Akita Univ, Dept Med Biol, Grad Sch Med, Akita, Japan; [Imai, Yumiko] Natl Inst Biomed Innovat Hlth & Nutr, Lab Regulat Intractable Infect Dis, Osaka 5670085, Japan; [Kuba, Keiji] Kyushu Univ, Dept Pharmacol, Grad Sch Med Sci, Fukuoka 8128582, Japan	Akita University; Akita University; University of Tokyo; Akita University; Kyushu University	Kuba, K (corresponding author), Akita Univ, Dept Biochem & Metab Sci, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan.; Kuba, K (corresponding author), Kyushu Univ, Dept Pharmacol, Grad Sch Med Sci, Fukuoka 8128582, Japan.	kuba.keiji.815@m.kyushu-u.ac.jp			Kaken from Japanese Ministry of Science [20H03426, 20K21566, 22K19551, 20K07285, 20K09048, 17H06179]; Naito Foundation; AMED [JP 21lm0203079]	Kaken from Japanese Ministry of Science; Naito Foundation(Naito Memorial Foundation); AMED	KKuba is supported by the Kaken [20H03426, 20K21566, 22K19551] from Japanese Ministry of Science and the Naito Foundation. JA is supported by the Kaken [20K16153, 22K06907], SM is supported by the Kaken [20K09048], YI is supported by the Kaken [17H06179], and TY is supported by the Kaken [20K07285] from Japanese Ministry of Science. This research was also supported by AMED under Grant Number JP 21lm0203079.	Advedissian T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122760; Albini A, 2008, CANCER METAST REV, V27, P75, DOI 10.1007/s10555-007-9111-x; Alves PM, 2011, PATHOL RES PRACT, V207, P236, DOI 10.1016/j.prp.2011.02.004; Arnold M, 2020, GUT, V69, P1564, DOI 10.1136/gutjnl-2020-321600; Bogucka K, 2020, ELIFE, V9, DOI 10.7554/eLife.52511; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Chen YS, 2018, THERANOSTICS, V8, P3841, DOI 10.7150/thno.25784; Cramer JD, 2019, NAT REV CLIN ONCOL, V16, P669, DOI 10.1038/s41571-019-0227-z; Demers M, 2010, AM J PATHOL, V176, P3023, DOI 10.2353/ajpath.2010.090876; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Gozgit JM, 2021, CANCER CELL, V39, P1214, DOI 10.1016/j.ccell.2021.06.018; Guo JP, 2017, ONCOL LETT, V13, P1919, DOI 10.3892/ol.2017.5649; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Huang WC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1091-5; Janssen LME, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0283-9; Johannes L, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208884; Kaur Manpreet, 2016, Asian Pac J Cancer Prev, V17, P455; Labrie M, 2014, ONCOTARGET, V5, P7705, DOI 10.18632/oncotarget.2299; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lawson DA, 2018, NAT CELL BIOL, V20, P1349, DOI 10.1038/s41556-018-0236-7; Li HJ, 2021, CANCER RES, V81, P4094, DOI 10.1158/0008-5472.CAN-20-3543; Liu XL, 2018, ONCOL RES, V26, P1123, DOI 10.3727/096504018X15166223632406; Liu Y, 2016, J MOL MED, V94, P509, DOI 10.1007/s00109-015-1376-x; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; Matsumoto G, 2010, CLIN EXP METASTAS, V27, P539, DOI 10.1007/s10585-010-9343-y; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mesquita JA, 2016, EUR ARCH OTO-RHINO-L, V273, P237, DOI 10.1007/s00405-014-3439-y; Mody MD, 2021, LANCET, V398, P2289, DOI 10.1016/S0140-6736(21)01550-6; Nagasawa S, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01959-9; Nguyen B, 2022, CELL, V185, P563, DOI 10.1016/j.cell.2022.01.003; Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162; Pape M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.186; Pham NTH, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101308; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rahma OE, 2019, CLIN CANCER RES, V25, P5449, DOI 10.1158/1078-0432.CCR-18-1543; Richardson AM, 2018, CLIN CANCER RES, V24, P420, DOI 10.1158/1078-0432.CCR-17-1776; Saussez S, 2006, CELL MOL LIFE SCI, V63, P686, DOI 10.1007/s00018-005-5458-8; Saussez S, 2008, ORAL ONCOL, V44, P86, DOI 10.1016/j.oraloncology.2006.12.014; Saussez S, 2006, ANN SURG ONCOL, V13, P999, DOI 10.1245/ASO.2006.08.033; Saussez S, 2009, INT J ONCOL, V34, P433, DOI 10.3892/ijo_00000167; Sewgobind NV, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111720; Si YL, 2021, BBA-GEN SUBJECTS, V1865, DOI 10.1016/j.bbagen.2020.129755; St-Pierre Y, 2012, FRONT BIOSCI-LANDMRK, V17, P438, DOI 10.2741/3937; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Terry S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01625; Tsai CJ, 2013, GYNECOL ONCOL, V131, P645, DOI 10.1016/j.ygyno.2013.04.056; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Wang JW, 2018, CANCER LETT, V418, P176, DOI 10.1016/j.canlet.2018.01.040; Wenig BM, 2017, MODERN PATHOL, V30, pS112, DOI 10.1038/modpathol.2016.207; Yang Ri-Yao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000719; Zhu H, 2013, INT J CANCER, V132, P1051, DOI 10.1002/ijc.27764; Zhu H, 2009, J PROTEOME RES, V8, P3969, DOI 10.1021/pr900287a; Zhu X, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-290	57	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02525-1	http://dx.doi.org/10.1038/s41388-022-02525-1		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Y2QR	36335283	Bronze			2022-12-17	WOS:000879132500001
J	Hu, HT; Zhang, HQ; Xing, Y; Zhou, Y; Chen, JN; Li, C; Xu, JJ; Guo, YY; Wang, J; He, Q; Liu, XM; Sheng, JZ; Song, EW; Wu, YT; Huang, HF				Hu, Hongtao; Zhang, Hanqiu; Xing, Yue; Zhou, Yan; Chen, Jianing; Li, Cheng; Xu, Jingjing; Guo, Yanyan; Wang, Jie; He, Qi; Liu, Xinmei; Sheng, Jianzhong; Song, Erwei; Wu, Yanting; Huang, Hefeng			The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer	ONCOGENE			English	Article							NONCODING RNAS; MESSENGER-RNA; LINCRNAS	Emerging evidence shows that the lncRNA THOR is deeply involved in the development of various cancers. However, the effects and underlying molecular mechanisms of THOR in breast cancer (BRCA) initiation and progression have not been fully elucidated. Here we show that THOR is critical for BRCA tumorigenesis by interacting with hnRNPD to regulate downstream signaling pathways. THOR expression was significantly higher in BRCA tissues than in normal tissues, and THOR upregulation was associated with a poor prognosis in BRCA patients. Functionally, THOR knockdown impaired cell proliferation, migration and invasion in BRCA cells in vitro and inhibited tumorigenesis and metastasis in a tumor xenograft model and THOR-deficient MMTV-PyMT model in vivo. Mechanistically, THOR bound to the hnRNPD protein and increased hnRNPD protein levels by maintaining hnRNPD protein stability through inhibition of the proteasome-dependent degradation pathway. The increased hnRNPD protein levels led to stabilization of its target mRNAs, including pyruvate dehydrogenase kinase 1 (PDK1), further activating downstream PI3K-AKT and MAPK signaling pathways to regulate BRCA cell proliferation and metastasis. Together, our findings indicate that THOR is a promising prognostic predictor for BRCA patients and that the THOR-hnRNPD-PDK1-MAPK/PI3K-AKT axis might be a potential therapeutic target for BRCA treatment.	[Hu, Hongtao] Nanjing Med Univ, Dept Gynecol, Affiliated Hosp 1, Nanjing, Peoples R China; [Hu, Hongtao; Zhang, Hanqiu; Xu, Jingjing; Guo, Yanyan; Wang, Jie; He, Qi] Shanghai Jiao Tong Univ, Int Peace Matern & Child Hlth Hosp, Sch Med, Shanghai, Peoples R China; [Hu, Hongtao; Zhang, Hanqiu; Li, Cheng; Xu, Jingjing; Liu, Xinmei; Huang, Hefeng] Shanghai Key Lab Embryo Original Dis, Shanghai, Peoples R China; [Xing, Yue; Zhou, Yan; Chen, Jianing; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China; [Xing, Yue; Zhou, Yan; Chen, Jianing; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Peoples R China; [Li, Cheng; Liu, Xinmei; Wu, Yanting; Huang, Hefeng] Fudan Univ, Obstet & Gynecol Hosp, Inst Reprod & Dev, Shanghai, Peoples R China; [Liu, Xinmei; Huang, Hefeng] Chinese Acad Med Sci, Res Units Embryo Original Dis, Shanghai, Peoples R China; [Sheng, Jianzhong] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Hangzhou, Peoples R China	Nanjing Medical University; Shanghai Jiao Tong University; Sun Yat Sen University; Sun Yat Sen University; Fudan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University	Huang, HF (corresponding author), Shanghai Key Lab Embryo Original Dis, Shanghai, Peoples R China.; Wu, YT; Huang, HF (corresponding author), Fudan Univ, Obstet & Gynecol Hosp, Inst Reprod & Dev, Shanghai, Peoples R China.; Huang, HF (corresponding author), Chinese Acad Med Sci, Res Units Embryo Original Dis, Shanghai, Peoples R China.	yanting_wu@163.com; huanghefg@sjtu.edu.cn		Hu, Hongtao/0000-0003-3704-6646; Xu, Jing-Jing/0000-0002-4496-0228	National Natural Science Foundation of China [82088102, 82171686]; National Key Research and Development Program of China [2021YFC2700701]; Collaborative Innovation Program of Shanghai Municipal Health Commission [2020CXJQ01]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5064]; Clinical Research Plan of SHDC [SHDC2020CR1008A]; Shanghai Municipal Key Clinical Specialty [shslczdzk06302]; Program of Shanghai Academic Research Leader [20XD1424100]; Outstanding Youth Medical Talents of Shanghai Rising Stars of Medical Talent Youth Development Program; Interdisciplinary Program of Shanghai Jiao Tong University [ZH2018QNB15, YG2019GD04, YG2020YQ29]; Youth Talents development Program of Jiangsu Women And Children Health Hospital [FYRC202004]; Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University [PY2021009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Collaborative Innovation Program of Shanghai Municipal Health Commission; CAMS Innovation Fund for Medical Sciences; Clinical Research Plan of SHDC; Shanghai Municipal Key Clinical Specialty; Program of Shanghai Academic Research Leader; Outstanding Youth Medical Talents of Shanghai Rising Stars of Medical Talent Youth Development Program; Interdisciplinary Program of Shanghai Jiao Tong University; Youth Talents development Program of Jiangsu Women And Children Health Hospital; Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University	This work was supported by the National Natural Science Foundation of China (82088102, 82171686), National Key Research and Development Program of China (2021YFC2700701), Collaborative Innovation Program of Shanghai Municipal Health Commission (2020CXJQ01), CAMS Innovation Fund for Medical Sciences (2019-I2M-5064), Clinical Research Plan of SHDC (SHDC2020CR1008A), Shanghai Municipal Key Clinical Specialty (shslczdzk06302), Program of Shanghai Academic Research Leader (20XD1424100), Outstanding Youth Medical Talents of Shanghai Rising Stars of Medical Talent Youth Development Program, and Interdisciplinary Program of Shanghai Jiao Tong University (ZH2018QNB15, YG2019GD04, YG2020YQ29), Youth Talents development Program of Jiangsu Women And Children Health Hospital (FYRC202004), and Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University (PY2021009). The funding agencies had no role in the study design, data collection and analysis, or decision to submit the article for publication.	Abdolahi S, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03405-8; Al-Khalaf HH, 2014, J BIOL CHEM, V289, P31433, DOI 10.1074/jbc.M114.593004; Amelio I, 2021, SEMIN CANCER BIOL, V72, P36, DOI 10.1016/j.semcancer.2020.06.019; Anwar S, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188568; Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Ding J, 2020, HEPATOLOGY, V72, P1666, DOI 10.1002/hep.31195; Du X, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.681736; Fabbiano F, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12043; Feng XF, 2018, INT J BIOL SCI, V14, P1630, DOI 10.7150/ijbs.26932; Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014; Ge J, 2020, J OVARIAN RES, V13, DOI 10.1186/s13048-020-00672-1; Ginsburg O, 2017, LANCET, V389, P847, DOI [10.1016/S0140-6736(16)31392-7, 10.1]; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Hosono Y, 2017, CELL, V171, P1559, DOI 10.1016/j.cell.2017.11.040; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jin X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01210-9; Li J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1150-y; Liang YR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01206-5; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Liu SJ, 2021, NAT REV CANCER, V21, P446, DOI 10.1038/s41568-021-00353-1; Ma HL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1123-y; Ma WR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01150-4; Mattijssen S, 2021, RNA BIOL, V18, P259, DOI 10.1080/15476286.2020.1868753; Moore AE, 2014, WIRES RNA, V5, P549, DOI 10.1002/wrna.1230; Portz B, 2021, TRENDS BIOCHEM SCI, V46, P550, DOI 10.1016/j.tibs.2020.12.005; Qiu HB, 2021, CANCER COMMUN, V41, P1037, DOI 10.1002/cac2.12197; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shang YM, 2018, BIOMED PHARMACOTHER, V106, P1243, DOI 10.1016/j.biopha.2018.07.052; Song H, 2018, BIOMED PHARMACOTHER, V108, P338, DOI 10.1016/j.biopha.2018.09.057; St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Tsagakis I, 2020, J PATHOL, V250, P480, DOI 10.1002/path.5405; Tsitsipatis D, 2021, NUCLEIC ACIDS RES, V49, P1631, DOI 10.1093/nar/gkaa1246; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Wang BB, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923507; Wang SS, 2019, CANCER LETT, V443, P13, DOI 10.1016/j.canlet.2018.11.028; Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y; Wang YQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21993-9; Xue J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2093-0; Yang HJ, 2019, BIOCHIMIE, V165, P9, DOI 10.1016/j.biochi.2019.06.012; Yang MH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0955-9; Yi M, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-021-00310-y; Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369; Zheng F., 2021, NAT COMMUN, V12; Zhu YF, 2020, INT J SURG, V84, P3, DOI 10.1016/j.ijsu.2020.10.004	48	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5298	5314		10.1038/s41388-022-02495-4	http://dx.doi.org/10.1038/s41388-022-02495-4		NOV 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36329124				2022-12-17	WOS:000878459600002
J	Klouch, KZ; Stern, MH; Trabelsi-Grati, O; Kiavue, N; Cabel, L; Silveira, AB; Hego, C; Rampanou, A; Popova, T; Bataillon, G; Nasr, S; Proudhon, C; Michel, M; Renault, V; Planchon, JM; Vincent-Salomon, A; Pierga, JY; Bieche, I; Renault, S; Bidard, FC				Klouch, Khadidja Zeyneb; Stern, Marc-Henri; Trabelsi-Grati, Olfa; Kiavue, Nicolas; Cabel, Luc; Silveira, Amanda Bortolini; Hego, Caroline; Rampanou, Aurore; Popova, Tatiana; Bataillon, Guillaume; Nasr, Sarah; Proudhon, Charlotte; Michel, Marc; Renault, Victor; Planchon, Julien Masliah; Vincent-Salomon, Anne; Pierga, Jean-Yves; Bieche, Ivan; Renault, Shufang; Bidard, Francois-Clement			Microsatellite instability detection in breast cancer using drop-off droplet digital PCR	ONCOGENE			English	Article							COLORECTAL-CANCER; MARKERS; TUMORS	The use of conventional methods (immunohistochemistry, pentaplex PCR) for detecting microsatellite instability (MSI), a predictive biomarker of immunotherapy efficacy, is debated for cancers with low MSI prevalence, such as breast cancer (BC). We developed two multiplex drop-off droplet digital PCR (ddPCR) assays targeting four microsatellites, initially identified from public BC whole-genome sequencing dataset. Performances of the assays were investigated and 352 tumor DNA and 28 circulating cell-free DNA from BC patients, with unknown MSI status were blindly screened. Cross-validation of ddPCR MSI status with other MSI detection methods was performed. We then monitored circulating tumor DNA (ctDNA) dynamics before and during pembrolizumab immunotherapy in one patient with MSI-high (MSI-H) metastatic BC. The assays showed high analytical specificity and sensitivity (limit of detection = 0.16%). Among N = 380 samples, seven (1.8%) were found as MSI-H by ddPCR with six of them confirmed by next-generation sequencing (NGS). Specificity was 100% in N = 133 microsatellite stable BC submitted to NGS. In the patient with MSI-H metastatic BC, ctDNA monitoring revealed an early decrease of microsatellite mutant allelic frequencies during immunotherapy. These results demonstrated MSI detection by ddPCR, a non-invasive, fast and cost-effective approach, allowing for large pre-screening of BC patients who may benefit from immunotherapy.	[Klouch, Khadidja Zeyneb; Cabel, Luc; Silveira, Amanda Bortolini; Hego, Caroline; Rampanou, Aurore; Proudhon, Charlotte; Michel, Marc; Pierga, Jean-Yves; Renault, Shufang; Bidard, Francois-Clement] Inst Curie, Dept Translat Res, Circulating Tumor Biomarkers Lab, Inserm CIC BT 1428, Paris, France; [Stern, Marc-Henri; Popova, Tatiana] PSL Res Univ, Inst Curie, DNA Repair & Uveal Melanoma DRUM Team, Inserm U830, Paris, France; [Trabelsi-Grati, Olfa; Bataillon, Guillaume; Nasr, Sarah; Renault, Victor; Planchon, Julien Masliah; Vincent-Salomon, Anne; Bieche, Ivan] PSL Res Univ, Inst Curie, Dept Diagnost & Theranost Med, Paris, France; [Kiavue, Nicolas; Cabel, Luc; Pierga, Jean-Yves; Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, Paris, France; [Kiavue, Nicolas; Cabel, Luc; Pierga, Jean-Yves; Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, St Cloud, France; [Cabel, Luc; Pierga, Jean-Yves] Univ Paris, Paris, France; [Proudhon, Charlotte; Michel, Marc] CNRS, Inserm U934, UMR3215, Paris, France; [Bidard, Francois-Clement] Paris Saclay Univ, UVSQ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Renault, S; Bidard, FC (corresponding author), Inst Curie, Dept Translat Res, Circulating Tumor Biomarkers Lab, Inserm CIC BT 1428, Paris, France.; Bidard, FC (corresponding author), Inst Curie, Dept Med Oncol, Paris, France.; Bidard, FC (corresponding author), Inst Curie, Dept Med Oncol, St Cloud, France.; Bidard, FC (corresponding author), Paris Saclay Univ, UVSQ, Paris, France.	shufang.renault@curie.fr; francois-clement.bidard@curie.fr	Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272; Michel, Marc/0000-0001-6613-8027				Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Cicek MS, 2011, J MOL DIAGN, V13, P271, DOI 10.1016/j.jmoldx.2010.12.004; Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180; Davies H, 2017, CANCER RES, V77, P4755, DOI 10.1158/0008-5472.CAN-17-1083; Fusco N, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky056; Gallon R, 2020, HUM MUTAT, V41, P332, DOI 10.1002/humu.23906; Georgiadis A, 2019, CLIN CANCER RES, V25, P7024, DOI 10.1158/1078-0432.CCR-19-1372; Gilson P, 2021, CANCERS, V13, DOI 10.3390/cancers13071491; Guardant Health, 2020, GUARDANT360 CDX 1 FD; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Hechtman JF, 2020, MODERN PATHOL, V33, P871, DOI 10.1038/s41379-019-0414-6; Hempelmann JA, 2015, J MOL DIAGN, V17, P705, DOI 10.1016/j.jmoldx.2015.05.008; Horimoto Y, 2020, CANCER SCI, V111, P2647, DOI 10.1111/cas.14500; Huggett JF, 2020, CLIN CHEM, V66, P1012, DOI 10.1093/clinchem/hvaa125; Huggett JF, 2013, CLIN CHEM, V59, P892, DOI 10.1373/clinchem.2013.206375; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee SC, 2001, AM J CLIN PATHOL, V115, P823; Long DR, 2020, CLIN CHEM, V66, P1310, DOI 10.1093/clinchem/hvaa177; Lorenzi M, 2020, J ONCOL, V2020, DOI 10.1155/2020/1807929; McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541; Middha S, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00084; Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014; Schmitt FC, 1999, INT J CANCER, V82, P644, DOI 10.1002/(SICI)1097-0215(19990827)82:5<644::AID-IJC5>3.0.CO;2-S; Silveira AB, 2020, CLIN CHEM, V66, P606, DOI 10.1093/clinchem/hvaa013; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Willis J, 2019, CLIN CANCER RES, V25, P7035, DOI 10.1158/1078-0432.CCR-19-1324; Woodhouse R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237802; Yu FY, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1175; Zhu LZ, 2018, J MOL DIAGN, V20, P225, DOI 10.1016/j.jmoldx.2017.11.007	31	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5289	5297		10.1038/s41388-022-02504-6	http://dx.doi.org/10.1038/s41388-022-02504-6		NOV 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36329125				2022-12-17	WOS:000878459600001
J	Carton-Garcia, F; Brotons, B; Anguita, E; Dopeso, H; Tarragona, J; Nieto, R; Garcia-Vidal, E; Macaya, I; Zagyva, Z; Dalmau, M; Sanchez-Martin, M; van Ijzendoorn, SCD; Landolfi, S; Hernandez-Losa, J; Schwartz, S; Matias-Guiu, X; Cajal, SRY; Martinez-Barriocanal, A; Arango, D				Carton-Garcia, Fernando; Brotons, Bruno; Anguita, Estefania; Dopeso, Higinio; Tarragona, Jordi; Nieto, Rocio; Garcia-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Sanchez-Martin, Manuel; van Ijzendoorn, Sven C. D.; Landolfi, Stefania; Hernandez-Losa, Javier; Schwartz Jr, Simo; Matias-Guiu, Xavier; Ramon y Cajal, Santiago; Martinez-Barriocanal, Agueda; Arango, Diego			Myosin Vb as a tumor suppressor gene in intestinal cancer	ONCOGENE			English	Article							MICROVILLUS INCLUSION DISEASE; APICAL PROTEIN LOCALIZATION; CELL POLARITY; COLORECTAL-CANCER; EPITHELIAL-CELLS; HUMAN-COLON; EXPRESSION; TRAFFICKING; MYO5B; PHOSPHORYLATION	Colorectal cancer causes >900,000 deaths every year and a deeper understanding of the molecular mechanisms underlying this disease will contribute to improve its clinical management and survival. Myosin Vb (MYO5B) regulates intracellular vesicle trafficking, and inactivation of this myosin disrupts the polarization and differentiation of intestinal epithelial cells causing microvillous inclusion disease (MVID), a rare congenital disorder characterized by intractable life-threatening diarrhea. Here, we show that the loss Myosin Vb interfered with the differentiation/polarization of colorectal cancer cells. Although modulation of Myosin Vb expression did not affect the proliferation of colon cancer cells, MYO5B inactivation increased their migration, invasion, and metastatic potential. Moreover, Myo5b inactivation in an intestine-specific knockout mouse model caused a >15-fold increase in the number of azoxymethane-initiated small intestinal tumors. Consistently, reduced expression of Myosin Vb in a cohort of 155 primary colorectal tumors was associated with shorter patient survival. In conclusion, we show here that loss of Myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Moreover, reduced expression of Myosin Vb in primary tumors identifies a subset of poor prognosis colorectal cancer patients that could benefit from more aggressive therapeutic regimens.	[Carton-Garcia, Fernando; Brotons, Bruno; Anguita, Estefania; Dopeso, Higinio; Nieto, Rocio; Garcia-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Martinez-Barriocanal, Agueda; Arango, Diego] Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Biomed Res Digest Tract Tumors, Barcelona, Spain; [Brotons, Bruno; Anguita, Estefania; Dalmau, Mariona; Martinez-Barriocanal, Agueda; Arango, Diego] Biomed Res Inst Lleida IRBLleida, Grp Mol Oncol, Lleida, Spain; [Tarragona, Jordi; Matias-Guiu, Xavier] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Lleida, Spain; [Tarragona, Jordi; Matias-Guiu, Xavier] Inst Recerca Biomed Lleida IRBLleida, Grp Oncol Pathol, Lleida, Spain; [Sanchez-Martin, Manuel] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Sanchez-Martin, Manuel] Univ Salamanca, Serv Transgenesis, Nucleus, Salamanca, Spain; [Sanchez-Martin, Manuel] Univ Salamanca, Dept Med, Salamanca, Spain; [van Ijzendoorn, Sven C. D.] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Sci Cells & Syst, Sect Mol Cell Biol, Groningen, Netherlands; [Landolfi, Stefania; Hernandez-Losa, Javier; Ramon y Cajal, Santiago] Univ Autonoma Barcelona UAB, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Barcelona, Spain; [Landolfi, Stefania; Hernandez-Losa, Javier; Matias-Guiu, Xavier; Ramon y Cajal, Santiago] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Schwartz Jr, Simo] Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Drug Delivery & Targeting, Barcelona, Spain; [Schwartz Jr, Simo] Vall dHebron Hosp, Clin Biochem Dept, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universitat de Lleida; University Hospital Arnau de Vilanova; Institut de Recerca Biomedica - IRB Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Groningen; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron	Arango, D (corresponding author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Biomed Res Digest Tract Tumors, Barcelona, Spain.; Arango, D (corresponding author), Biomed Res Inst Lleida IRBLleida, Grp Mol Oncol, Lleida, Spain.	darango@irblleida.cat	; Sanchez-Martin, Manuel/N-5327-2016	Tarragona, Jordi/0000-0002-1459-4087; Dopeso, Higinio/0000-0003-0060-1861; Sanchez-Martin, Manuel/0000-0001-8370-1336	World Cancer Research [AICR13-0245]; Instituto de Salud Carlos III [PI16/00540, PI19/00993, PI22/00773]; European Regional Development Fund [AC15/00066, AC19/00095, AC20/00022]; Spanish Association Against Cancer [AECC GCA15152966ARAN]; "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida	World Cancer Research; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund(European Commission); Spanish Association Against Cancer; "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida	This study was partially funded by grants of World Cancer Research (AICR13-0245), Instituto de Salud Carlos III (PI16/00540, PI19/00993, PI22/00773), the European Regional Development Fund (AC15/00066, AC19/00095, AC20/00022) and the Spanish Association Against Cancer (AECC GCA15152966ARAN) to DA. BB is supported by "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida.	Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bazzocco S, 2015, CLIN CANCER RES, V21, P3695, DOI 10.1158/1078-0432.CCR-14-2457; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carton-Garcia F, 2015, SCI REP-UK, V5, DOI 10.1038/srep12312; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; D'Agostino L, 2019, CANCER RES, V79, P4099, DOI 10.1158/0008-5472.CAN-18-4075; Dhekne HS, 2014, J CELL SCI, V127, P1007, DOI 10.1242/jcs.137273; Dong WJ, 2012, DIGEST DIS SCI, V57, P1247, DOI 10.1007/s10620-011-1989-z; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Gandalovicova A, 2016, ONCOTARGET, V7, P25022, DOI 10.18632/oncotarget.7214; Goldenring JR, 2011, BRIT J CANCER, V104, P33, DOI 10.1038/sj.bjc.6605983; Goldenring JR, 2013, NAT REV CANCER, V13, P813, DOI 10.1038/nrc3601; Groisman GM, 2000, HUM PATHOL, V31, P1404, DOI 10.1053/hupa.2000.19831; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; Kranz A, 2010, GENESIS, V48, P512, DOI 10.1002/dvg.20641; Kravtsov D, 2014, AM J PHYSIOL-GASTR L, V307, pG992, DOI 10.1152/ajpgi.00180.2014; Kravtsov DV, 2016, AM J PHYSIOL-GASTR L, V311, pG142, DOI 10.1152/ajpgi.00041.2016; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Leng CS, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000531; Letellier E, 2017, BRIT J CANCER, V117, P1689, DOI 10.1038/bjc.2017.352; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mariadason JM, 2002, CANCER RES, V62, P4791; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109; Melendez J, 2013, GASTROENTEROLOGY, V145, P808, DOI 10.1053/j.gastro.2013.06.021; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller T, 2008, NAT GENET, V40, P1163, DOI 10.1038/ng.225; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nam KT, 2010, J CLIN INVEST, V120, P840, DOI 10.1172/JCI40728; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; PETERSON MD, 1992, J CELL SCI, V102, P581; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Roland JT, 2011, P NATL ACAD SCI USA, V108, P2789, DOI 10.1073/pnas.1010754108; ROWLATT C, 1970, J PATHOL, V100, pPR12; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Ruemmele FM, 2010, HUM MUTAT, V31, P544, DOI 10.1002/humu.21224; Sato T, 2007, NATURE, V448, P366, DOI 10.1038/nature05929; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schneeberger K, 2015, P NATL ACAD SCI USA, V112, P12408, DOI 10.1073/pnas.1516672112; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sobajima T, 2015, BIOL OPEN, V4, P86, DOI 10.1242/bio.20148532; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Thoeni Cornelia E, 2014, Traffic, V15, P22, DOI 10.1111/tra.12131; Weis VG, 2016, CELL MOL GASTROENTER, V2, P131, DOI 10.1016/j.jcmgh.2015.11.009; Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438	53	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5279	5288		10.1038/s41388-022-02508-2	http://dx.doi.org/10.1038/s41388-022-02508-2		NOV 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316444	Bronze			2022-12-17	WOS:000876857300001
J	Watanabe, K; Kimura, S; Seki, M; Isobe, T; Kubota, Y; Sekiguchi, M; Sato-Otsubo, A; Hiwatari, M; Kato, M; Oka, A; Koh, K; Sato, Y; Tanaka, H; Miyano, S; Kawai, T; Hata, K; Ueno, H; Nannya, Y; Suzuki, H; Yoshida, K; Fujii, Y; Nagae, G; Aburatani, H; Ogawa, S; Takita, J				Watanabe, Kentaro; Kimura, Shunsuke; Seki, Masafumi; Isobe, Tomoya; Kubota, Yasuo; Sekiguchi, Masahiro; Sato-Otsubo, Aiko; Hiwatari, Mitsuteru; Kato, Motohiro; Oka, Akira; Koh, Katsuyoshi; Sato, Yusuke; Tanaka, Hiroko; Miyano, Satoru; Kawai, Tomoko; Hata, Kenichiro; Ueno, Hiroo; Nannya, Yasuhito; Suzuki, Hiromichi; Yoshida, Kenichi; Fujii, Yoichi; Nagae, Genta; Aburatani, Hiroyuki; Ogawa, Seishi; Takita, Junko			Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism	ONCOGENE			English	Article							ARGININE DEPRIVATION; SERINE BIOSYNTHESIS; GENE-EXPRESSION; SULFASALAZINE; CLASSIFICATION; PROLIFERATION; INHIBITOR; LYMPHOMA; SUPPORTS; GLYCINE	Neuroblastomas require novel therapies that are based on the exploitation of their biological mechanism. To address this need, we analyzed the DNA methylation and expression datasets of neuroblastomas, extracted a candidate gene characterizing the aggressive features, and conducted functional studies. Based on the DNA methylation data, we identified a subgroup of neuroblastoma cases with 11q loss of heterozygosity with extremely poor prognosis. PHGDH, a serine metabolism-related gene, was extracted as a candidate with strong expression and characteristic methylation in this subgroup as well as in cases with MYCN amplification. PHGDH inhibition suppressed neuroblastoma cell proliferation in vitro and in vivo, indicating that the inhibition of serine metabolism by PHGDH inhibitors is a therapeutic alternative for neuroblastoma. Inhibiting the arginine metabolism, which is closely related to serine metabolism using arginine deiminase, had a combination effect both in vitro and in vivo, especially on extracellular arginine-dependent neuroblastoma cells with ASS1 deficiency. Expression and metabolome analyses of post-dose cells confirmed the synergistic effects of treatments targeting serine and arginine indicated that xCT inhibitors that inhibit cystine uptake could be candidates for further combinatorial treatment. Our results highlight the rational therapeutic strategy of targeting serine/arginine metabolism for intractable neuroblastoma.	[Watanabe, Kentaro; Kimura, Shunsuke; Seki, Masafumi; Isobe, Tomoya; Kubota, Yasuo; Sekiguchi, Masahiro; Sato-Otsubo, Aiko; Hiwatari, Mitsuteru; Kato, Motohiro; Oka, Akira; Takita, Junko] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Kimura, Shunsuke] Hiroshima Univ, Dept Pediat, Grad Sch Biomed Sci, Hiroshima, Japan; [Hiwatari, Mitsuteru] Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Koh, Katsuyoshi] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan; [Sato, Yusuke] Univ Tokyo, Dept Urol, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Dept Integrated Analyt, Tokyo, Japan; [Kawai, Tomoko; Hata, Kenichiro] Natl Res Inst Child Hlth & Dev, Dept Maternal Fetal Biol, Tokyo, Japan; [Hata, Kenichiro] Gunma Univ, Dept Mol & Med Genet, Grad Sch Med, Maebashi, Gumma, Japan; [Ueno, Hiroo; Takita, Junko] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Ueno, Hiroo; Nannya, Yasuhito; Suzuki, Hiromichi; Yoshida, Kenichi; Fujii, Yoichi; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Suzuki, Hiromichi] Natl Canc Ctr, Div Brain Tumor Translat Res, Tokyo, Japan; [Nagae, Genta; Aburatani, Hiroyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Genome Sci Div, Tokyo, Japan; [Ogawa, Seishi] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Dept Pathol & Tumor Biol, Kyoto, Japan	University of Tokyo; Hiroshima University; Teikyo University; Saitama Children's Medical Center; University of Tokyo; Tokyo Medical & Dental University (TMDU); National Center for Child Health & Development - Japan; Gunma University; Kyoto University; Kyoto University; National Cancer Center - Japan; University of Tokyo; Kyoto University	Takita, J (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan.; Takita, J (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan.	jtakita@kuhp.kyoto-u.ac.jp		Seki, Masafumi/0000-0003-4671-7026; Isobe, Tomoya/0000-0002-3487-3307; Kubota, Yasuo/0000-0002-7909-5422; Sekiguchi, Masahiro/0000-0002-7941-9319	JSPS KAKENHI [JP19J11112, JP21K20795, JP22K15521, JP17H04224, JP18K19467, JP20H00528, JP21K19405, 15H05909, 19H05656, JP19cm0106509h9904]; Japan Agency for Medical Research and Development (AMED) [JP19cm0106509h9904, JP22ama221505h0001, JP19ck0106468h0001]; Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics	This work was supported by JSPS KAKENHI Grant Numbers JP19J11112, JP21K20795, and JP22K15521 to KW; JP17H04224, JP18K19467, JP20H00528, and JP21K19405 to JT; 15H05909 and 19H05656 to SO and YN; Project for Cancer Research and Therapeutic Evolution (P-CREATE; grant no. JP19cm0106509h9904), Project for Promotion of Cancer Research and Therapeutic Evolution (P-PROMOTE; grant no. JP22ama221505h0001), Practical Research for Innovative Cancer Control (grant no. JP19ck0106468h0001) from Japan Agency for Medical Research and Development (AMED), and Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan, and Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics to KW.	Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Arlt B, 2021, INT J CANCER, V148, P1219, DOI 10.1002/ijc.33423; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dillon BJ, 2004, CANCER-AM CANCER SOC, V100, P826, DOI 10.1002/cncr.20057; Ensor CM, 2002, CANCER RES, V62, P5443; Feun L, 2008, CURR PHARM DESIGN, V14, P1049, DOI 10.2174/138161208784246199; Fultang L, 2019, CANCER RES, V79, P611, DOI 10.1158/0008-5472.CAN-18-2139; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Haryu S, 2018, J NEURO-ONCOL, V136, P23, DOI 10.1007/s11060-017-2621-7; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Hishiki T, 2018, INT J CLIN ONCOL, V23, P965, DOI 10.1007/s10147-018-1281-8; Irwin MS, 2021, J CLIN ONCOL, V39, P3229, DOI 10.1200/JCO.21.00278; Ji JX, 2020, CLIN CANCER RES, V26, P4402, DOI 10.1158/1078-0432.CCR-19-1905; Ji XM, 2018, ONCOGENE, V37, P5007, DOI 10.1038/s41388-018-0307-z; Kremer JC, 2017, CELL REP, V18, P991, DOI 10.1016/j.celrep.2016.12.077; Krueger F, 2012, NAT METHODS, V9, P145, DOI [10.1038/NMETH.1828, 10.1038/nmeth.1828]; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Maris John M, 2010, N Engl J Med, V362, P2202, DOI 10.1056/NEJMra0804577; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Mullarky E, 2016, P NATL ACAD SCI USA, V113, P1778, DOI 10.1073/pnas.1521548113; Nakagawara A, 2018, JPN J CLIN ONCOL, V48, P214, DOI 10.1093/jjco/hyx176; Newman AC, 2017, TRENDS CELL BIOL, V27, P645, DOI 10.1016/j.tcb.2017.05.001; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pizzo PA, 2015, PRINCIPLES PRACTICE; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sekiguchi M, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-0125-y; Shitara K, 2017, GASTRIC CANCER, V20, P1004, DOI 10.1007/s10120-017-0720-y; Toya Y, 2007, J CHROMATOGR A, V1159, P134, DOI 10.1016/j.chroma.2007.04.011; Vandekeere S, 2018, CELL METAB, V28, P573, DOI 10.1016/j.cmet.2018.06.009; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xia YF, 2019, CANCER RES, V79, P3837, DOI 10.1158/0008-5472.CAN-18-3541; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028	48	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					4994	5007		10.1038/s41388-022-02489-2	http://dx.doi.org/10.1038/s41388-022-02489-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36319669	Green Published, hybrid			2022-12-17	WOS:000877420400001
J	Chen, H; Chen, XH; Zhang, ZJ; Bao, WH; Gao, ZQ; Li, DF; Xie, XY; Zhou, P; Yang, CX; Zhou, ZQ; Pan, JY; Kuang, XQ; Tang, RM; Feng, ZF; Zhou, LH; Zhu, DC; Yang, JA; Wang, L; Huang, HB; Tang, DL; Liu, JB; Jiang, LL				Chen, Han; Chen, Xuhong; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Zhou, Zhongqiu; Pan, Jinyuan; Kuang, Xiangqin; Tang, Ruiming; Feng, Zhengfu; Zhou, Lihuan; Zhu, Dachun; Yang, Jianan; Wang, Lan; Huang, Hongbiao; Tang, Daolin; Liu, Jinbao; Jiang, Lili			Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-kappa B via ANXA1-dependent ubiquitination of NEMO	ONCOGENE			English	Article							GLIOBLASTOMA; COMPLEX; CANCER; EXOSOMES; RIP1; IKK	Glioma is the most common malignant primary brain tumor with aggressiveness and poor prognosis. Although extracellular vesicles (EVs)-based cell-to-cell communication mediates glioma progression, the key molecular mediators of this process are still not fully understood. Herein, we elucidated an EVs-mediated transfer of suprabasin (SBSN), leading to the aggressiveness and progression of glioma. High levels of SBSN were positively correlated with clinical grade, predicting poor clinical prognosis of patients. Upregulation of SBSN promoted, while silencing of SBSN suppressed tumorigenesis and aggressiveness of glioma cells in vivo. EVs-mediated transfer of SBSN resulted in an increase in SBSN levels, which promoted the aggressiveness of glioma cells by enhancing migration, invasion, and angiogenesis of recipient glioma cells. Mechanistically, SBSN activated NF-kappa B signaling by interacting with annexin A1, which further induced Lys63-linked and Met1-linear polyubiquitination of NF-kappa B essential modulator (NEMO). In conclusion, the communication of SBSN-containing EVs within glioma cells drives the formation and development of tumors by activating NF-kappa B pathway, which may provide potential therapeutic target for clinical intervention in glioma.	[Chen, Han; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Kuang, Xiangqin; Yang, Jianan; Huang, Hongbiao; Liu, Jinbao; Jiang, Lili] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China; [Chen, Han; Chen, Xuhong; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Kuang, Xiangqin; Huang, Hongbiao; Liu, Jinbao; Jiang, Lili] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou 511436, Peoples R China; [Chen, Xuhong] Southern Univ Sci & Technol Hosp, Med Res Ctr, Shenzhen 518055, Peoples R China; [Zhou, Zhongqiu] Sichuan Univ, Alliance Hosp West China Univ Hosp 2, Meishan Women & Childrens Hosp, Meishan 620000, Peoples R China; [Pan, Jinyuan] Yangtze Univ, Dept Oncol, Huanggang Cent Hosp, Huanggang 438000, Peoples R China; [Tang, Ruiming; Feng, Zhengfu; Zhou, Lihuan] Guangzhou Med Univ, Qingyuan Peoples Hosp, Affiliated Hosp 6, Guangzhou 511518, Peoples R China; [Zhu, Dachun] Shenzhen Baoan Womens & Childirens Hosp, Dept Operating Room, Shenzhen 518000, Peoples R China; [Yang, Jianan] Guangzhou Med Univ, Dept Urol Oncosurg, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China; [Wang, Lan] Guangdong Pharmaceut Univ, Sch Basic Courses, Dept Pathogen Biol & Immunol, Guangzhou 510006, Peoples R China; [Tang, Daolin] UT Southwestern Med Ctr, Dept Surg, Dallas, TX 75390 USA	Guangzhou Medical University; Guangzhou Medical University; Southern University of Science & Technology; Sichuan University; Yangtze University; Guangzhou Medical University; Guangzhou Medical University; Guangdong Pharmaceutical University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, JB; Jiang, LL (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China.; Liu, JB; Jiang, LL (corresponding author), Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou 511436, Peoples R China.	jliu@gzhmu.edu.cn; jianglili@gzhmu.edu.cn			Basic and Applied Research Projects of Guangzhou Science and Technology Bureau [202002030067]; Natural Science Foundation of China [82273464, 81972619, 81672874, 81972399]; Natural Science Foundation of Guangdong Province [2021A1515012477, 2022A1515012260]; Key Discipline of Guangzhou Education Bureau (Basic Medicine) [201851839]; Natural Science Foundation research team of Guangdong Province [2018B030312001]; Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital [202011-202]; Innovative Academic Team of Guangzhou Education System [1201610014]; Guangzhou key medical discipline construction project fun	Basic and Applied Research Projects of Guangzhou Science and Technology Bureau; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Discipline of Guangzhou Education Bureau (Basic Medicine); Natural Science Foundation research team of Guangdong Province; Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital; Innovative Academic Team of Guangzhou Education System; Guangzhou key medical discipline construction project fun	This work was supported by the Basic and Applied Research Projects of Guangzhou Science and Technology Bureau (202002030067), the Natural Science Foundation of China (82273464, 81972619, 81672874, and 81972399), the Natural Science Foundation of Guangdong Province (2021A1515012477 and 2022A1515012260), the Key Discipline of Guangzhou Education Bureau (Basic Medicine) (201851839), the Natural Science Foundation research team of Guangdong Province (2018B030312001), the open research funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital (202011-202), the Innovative Academic Team of Guangzhou Education System (1201610014), and the Guangzhou key medical discipline construction project fun.	Abels ER, 2019, TRENDS CANCER, V5, P393, DOI 10.1016/j.trecan.2019.05.006; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Aoshima M, 2019, J DERMATOL SCI, V95, P107, DOI 10.1016/j.jdermsci.2019.07.009; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Bist P, 2011, ONCOGENE, V30, P3174, DOI 10.1038/onc.2011.28; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Cahill KE, 2016, NEURO-ONCOLOGY, V18, P329, DOI 10.1093/neuonc/nov265; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; de Vrij J, 2015, INT J CANCER, V137, P1630, DOI 10.1002/ijc.29521; Delgado-Lopez PD, 2016, CLIN TRANSL ONCOL, V18, P1062, DOI 10.1007/s12094-016-1497-x; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Gao XF, 2020, CELL REP, V30, P2489, DOI 10.1016/j.celrep.2020.01.089; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Ji JX, 2021, CELL DEATH DIFFER, V28, P367, DOI 10.1038/s41418-020-00606-w; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lauko A, 2022, SEMIN CANCER BIOL, V82, P162, DOI 10.1016/j.semcancer.2021.02.014; Lee IY, 2019, MOL CELL, V73, P1138, DOI 10.1016/j.molcel.2019.01.022; Liu YF, 2020, AGING-US, V12, P21559, DOI 10.18632/aging.103945; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; Matsui T, 2004, GENOMICS, V84, P384, DOI 10.1016/j.ygeno.2004.03.010; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Niu JX, 2011, EMBO J, V30, P3741, DOI 10.1038/emboj.2011.264; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Park GT, 2002, J BIOL CHEM, V277, P45195, DOI 10.1074/jbc.M205380200; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Pribyl M, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010108; Pribyl M, 2020, MOL ONCOL, V14, P2403, DOI 10.1002/1878-0261.12768; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Sarkar S, 2009, J NEURO-ONCOL, V91, P157, DOI 10.1007/s11060-008-9695-1; Song K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI129374; Srivastava C, 2020, BMC CANCER, V20, DOI 10.1186/s12885-019-6435-1; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Wang SS, 2017, MOL THER-NUCL ACIDS, V8, P482, DOI 10.1016/j.omtn.2017.07.015; Wei S, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13090; Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Wu YB, 2018, AM J TRANSL RES, V10, P881; Yamamoto M, 2006, NAT IMMUNOL, V7, P962, DOI 10.1038/ni1367; Yang YB, 2014, CANCER DISCOV, V4, P480, DOI 10.1158/2159-8290.CD-13-0915; Yanovich-Arad G, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108787; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	52	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5253	5265		10.1038/s41388-022-02520-6	http://dx.doi.org/10.1038/s41388-022-02520-6		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316443				2022-12-17	WOS:000876857500001
J	Wang, YN; Ruan, DY; Wang, ZX; Yu, K; Rong, DL; Liu, ZX; Wang, F; Hu, JJ; Jin, Y; Wu, QN; Pu, HY; Wang, M; Xu, RH; Zeng, ZL				Wang, Ying-Nan; Ruan, Dan-Yun; Wang, Zi-Xian; Yu, Kai; Rong, Dai-Lin; Liu, Ze-Xian; Wang, Feng; Hu, Jia-Jia; Jin, Ying; Wu, Qi-Nian; Pu, Heng-Ying; Wang, Min; Xu, Rui-Hua; Zeng, Zhao-Lei			Targeting the cholesterol-ROR alpha/gamma axis inhibits colorectal cancer progression through degrading c-myc	ONCOGENE			English	Article							ORPHAN NUCLEAR RECEPTORS; DOUBLE-BLIND; CELL-PROLIFERATION; PHASE-III; ALPHA; METABOLISM; MULTICENTER; SIMVASTATIN; OXYSTEROLS; SURVIVAL	Dysregulated cholesterol metabolism is a hallmark of colorectal cancer (CRC). However, the usage of cholesterol-lowering agents seemed to have no benefit in CRC patients. In this study, we focused on the cholesterol-nuclear receptors (NRs) axis as a strategy. Cholesterol and its derivatives work as ligands for different nuclear receptors, thus promoting cancer progression. The key NR downstream of cholesterol in CRC is unknown. Here, we treated CRC cells with a cholesterol-lowering agent and lipoprotein-depleted conditioned medium, and then detected the change of the putative NRs. The results revealed that ROR alpha/gamma (Retinoic acid receptor-related Orphan Receptor alpha/gamma) levels exhibited the most obvious increases in CRC cells subjected them to cholesterol deprivation. ROR alpha/gamma agonists significantly inhibited CRC cells proliferation and migration in vitro and in vivo. Also, ROR alpha/gamma overexpression repressed CRC cells proliferation and migration in vitro and in vivo and ROR alpha/gamma knockdown promoted it. Mechanistically, ROR alpha/gamma agonists promoted c-myc degradation by activating the transcription of the ubiquitinase NEDD4. Intriguingly, the combination of ROR alpha/gamma agonists and atorvastatin had a synergistic effect on inhibiting CRC cells. These findings demonstrate that the cholesterol- ROR alpha/gamma axis is important for maintaining c-myc protein levels. Combination therapy with atorvastatin and ROR alpha/gamma agonist is a promising therapeutic strategy for CRC.	[Wang, Ying-Nan; Wang, Zi-Xian; Wang, Feng; Jin, Ying; Xu, Rui-Hua] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Wang, Ying-Nan; Ruan, Dan-Yun; Wang, Zi-Xian; Yu, Kai; Liu, Ze-Xian; Wang, Feng; Hu, Jia-Jia; Jin, Ying; Wu, Qi-Nian; Pu, Heng-Ying; Wang, Min; Xu, Rui-Hua; Zeng, Zhao-Lei] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China; [Ruan, Dan-Yun] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Clin Res, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Yu, Kai; Liu, Ze-Xian; Hu, Jia-Jia; Pu, Heng-Ying; Wang, Min; Zeng, Zhao-Lei] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Rong, Dai-Lin] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Radiol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Wu, Qi-Nian] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Wu, Qi-Nian] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Wu, Qi-Nian] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China	Xu, RH (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Xu, RH; Zeng, ZL (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China.; Zeng, ZL (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.	xurh@sysucc.org.cn; zengzhl@sysucc.org.cn			National Natural Science Foundation of China [81930065, 82173128, 81903163, 82072612]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]; Natural Science Foundation of Guangdong Province [2019A1515010233]; China Postdoctoral Science Foundation [2020M673000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81930065, 82173128, 81903163, 82072612), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036), the Natural Science Foundation of Guangdong Province (2019A1515010233), and the China Postdoctoral Science Foundation (2020M673000).	Adhyaru BB, 2018, NAT REV CARDIOL, V15, P757, DOI 10.1038/s41569-018-0098-5; Baek SH, 2014, ANNU REV PHYSIOL, V76, P177, DOI 10.1146/annurev-physiol-030212-183758; Bardou M, 2010, GUT, V59, P1572, DOI 10.1136/gut.2009.190900; Bovenga F, 2015, CELL METAB, V21, P517, DOI 10.1016/j.cmet.2015.03.002; Brautbar A, 2011, NAT REV CARDIOL, V8, P253, DOI 10.1038/nrcardio.2011.2; Brown AJ, 2021, BRIT J PHARMACOL, V178, P3089, DOI 10.1111/bph.15073; Buren S, 2016, CANCER CELL, V30, P290, DOI 10.1016/j.ccell.2016.06.023; Cai DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12529-3; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng CM, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0301-4; Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586-019-0920-1; Dejure FR, 2017, EMBO J, V36, P3409, DOI 10.15252/embj.201796438; Dejure FR, 2017, EMBO J, V36, P1854, DOI 10.15252/embj.201796662; Dobrzycka M, 2020, EXP CLIN ENDOCR DIAB, V128, P255, DOI 10.1055/a-0668-5692; Du J, 2012, INT J MOL SCI, V13, P15755, DOI 10.3390/ijms131215755; Duffy MJ, 2021, CANCER TREAT REV, V94, DOI 10.1016/j.ctrv.2021.102154; Fan JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01187; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Hadjiphilippou S, 2019, CIRC RES, V124, P354, DOI 10.1161/CIRCRESAHA.118.313245; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kim H, 2011, MOL CELL, V44, P797, DOI 10.1016/j.molcel.2011.09.023; Kim ST, 2014, EUR J CANCER, V50, P2822, DOI 10.1016/j.ejca.2014.08.005; Kloudova A, 2017, TRENDS ENDOCRIN MET, V28, P485, DOI 10.1016/j.tem.2017.03.002; Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Liu J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15112-3; Ma LQ, 2019, MOL CELL ENDOCRINOL, V484, P42, DOI 10.1016/j.mce.2019.01.016; Marciano DP, 2014, CELL METAB, V19, P193, DOI 10.1016/j.cmet.2013.12.009; Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Qiu RM, 2018, J MED CHEM, V61, P5794, DOI 10.1021/acs.jmedchem.7b01314; Raza S, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0422-x; Rene O, 2015, ACS MED CHEM LETT, V6, P276, DOI 10.1021/ml500420y; Riscal R, 2019, MOL CELL, V76, P220, DOI 10.1016/j.molcel.2019.09.008; Roshan-Moniri M, 2014, CANCER TREAT REV, V40, P1137, DOI 10.1016/j.ctrv.2014.10.005; Seckl MJ, 2017, J CLIN ONCOL, V35, P1506, DOI 10.1200/JCO.2016.69.7391; Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098; Silvente-Poirot S, 2018, CANCER RES, V78, P4803, DOI [10.1158/0008-5472.CAN-18-1487, 10.1158/0008-5472.can-18-1487]; Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Tian Y, 2015, PUBLIC HEALTH NUTR, V18, P3355, DOI 10.1017/S1368980015000646; Villa GR, 2016, CANCER CELL, V30, P683, DOI 10.1016/j.ccell.2016.09.008; Wang C, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00500-y; Wang JJ, 2016, NAT MED, V22, P488, DOI 10.1038/nm.4070; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Ward NC, 2019, CIRC RES, V124, P328, DOI 10.1161/CIRCRESAHA.118.312782; Xiao L, 2015, AM J PHYSIOL-CELL PH, V308, pC385, DOI 10.1152/ajpcell.00091.2014; Xiong GF, 2014, MOL CELL BIOL, V34, P3066, DOI 10.1128/MCB.00279-14; Xiong GF, 2012, CANCER RES, V72, P1728, DOI 10.1158/0008-5472.CAN-11-2762	57	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5266	5278		10.1038/s41388-022-02515-3	http://dx.doi.org/10.1038/s41388-022-02515-3		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316442	hybrid, Green Published			2022-12-17	WOS:000876857500002
J	Zhang, QQ; Gao, YR; Zhang, YX; Jing, MR; Wang, D; Wang, YZ; Khattak, S; Qi, HW; Cai, CB; Zhang, J; Ngowi, EE; Khan, NH; Li, T; Ji, AL; Jiang, QY; Ji, XY; Li, YZ; Wu, DD				Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Khattak, Saadullah; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Ngowi, Ebenezeri Erasto; Khan, Nazeer Hussain; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong			Cystathionine gamma-lyase mediates cell proliferation, migration, and invasion of nasopharyngeal carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ENDOGENOUS HYDROGEN-SULFIDE; HUMAN PROSTATE-CANCER; PROMOTES; H2S; PI3K/AKT/MTOR; SUPPRESSES; MODULATION; MECHANISMS; PATHWAY	Nasopharyngeal carcinoma (NPC) is an epithelia-derived malignancy with a distinctive geographic distribution. Cystathionine gamma-lyase (CSE) is involved in cancer development and progression. Nevertheless, the role of CSE in the growth of NPC is unknown. In this study, we found that CSE levels in human NPC cells were higher than those in normal nasopharyngeal cells. CSE overexpression enhanced the proliferative, migrative, and invasive abilities of NPC cells and CSE downregulation exerted reverse effects. Overexpression of CSE decreased the expressions of cytochrome C, cleaved caspase (cas)-3, cleaved cas-9, and cleaved poly-ADP-ribose polymerase, whereas CSE knockdown exhibited reverse effects. CSE overexpression decreased reactive oxygen species (ROS) levels and the expressions of phospho (p)-extracellular signal-regulated protein kinase 1/2, p-c-Jun N-terminal kinase, and p-p38, but promoted the expressions of p-phosphatidylinositol 3-kinase (PI3K), p-AKT, and p-mammalian target of rapamycin (mTOR), whereas CSE knockdown showed oppose effects. In addition, CSE overexpression promoted NPC xenograft tumor growth and CSE knockdown decreased tumor growth by modulating proliferation, angiogenesis, cell cycle, and apoptosis. Furthermore, DL-propargylglycine (an inhibitor of CSE) dose-dependently inhibited NPC cell growth via ROS-mediated mitogen-activated protein kinase (MAPK) and PI3K/AKT/mTOR pathways without significant toxicity. In conclusion, CSE could regulate the growth of NPC cells through ROS-mediated MAPK and PI3K/AKT/mTOR cascades. CSE might be a novel tumor marker for the diagnosis and prognosis of NPC. Novel donors/drugs that inhibit the expression/activity of CSE can be developed in the treatment of NPC.	[Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong] Henan Univ, Sch Basic Med Sci, Kaifeng 475004, Henan, Peoples R China; [Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Khattak, Saadullah; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Ngowi, Ebenezeri Erasto; Khan, Nazeer Hussain; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong] Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng 475004, Henan, Peoples R China; [Khattak, Saadullah; Khan, Nazeer Hussain] Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China; [Ngowi, Ebenezeri Erasto; Ji, Xinying] Henan Univ, Henan Prov Engn Ctr Tumor Mol Med, Kaifeng Municipal Key Lab Cell Signal Transduct, Kaifeng 475004, Henan, Peoples R China; [Ngowi, Ebenezeri Erasto] Dar Es Salaam Univ, Fac Sci, Dept Biol Sci, Coll Educ, Dar Es Salaam 2329, Tanzania; [Wu, Dongdong] Henan Univ, Sch Stomatol, Kaifeng 475004, Henan, Peoples R China	Henan University; Henan University; Henan University; Henan University; University of Dar es Salaam; Henan University	Ji, XY; Li, YZ; Wu, DD (corresponding author), Henan Univ, Sch Basic Med Sci, Kaifeng 475004, Henan, Peoples R China.; Ji, XY; Li, YZ; Wu, DD (corresponding author), Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng 475004, Henan, Peoples R China.; Wu, DD (corresponding author), Henan Univ, Sch Stomatol, Kaifeng 475004, Henan, Peoples R China.	10190096@vip.henu.edu.cn; yanzhang206@163.com; ddwubiomed2010@163.com	Wu, Dongdong/GQP-4472-2022	Wu, Dongdong/0000-0001-6739-8437	National Natural Science Foundation of China [81802718, U1504817]; Foundation of Science & Technology Department of Henan Province, China [202102310480, 192102310151]; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China [2020GGJS038]; Science Foundation for Young Talents of Henan University College of Medicine, China [2019013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Science & Technology Department of Henan Province, China; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China; Science Foundation for Young Talents of Henan University College of Medicine, China	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81802718, U1504817), the Foundation of Science & Technology Department of Henan Province, China (Nos. 202102310480, 192102310151), the Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China (No. 2020GGJS038), and the Science Foundation for Young Talents of Henan University College of Medicine, China (No. 2019013).	Ascencao K, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2020.105393; Augsburger F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030447; Beneke S, 2004, INT J CANCER, V111, P813, DOI 10.1002/ijc.20342; Breza J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4508-1; Bruce JP, 2015, J CLIN ONCOL, V33, P3346, DOI 10.1200/JCO.2015.60.7846; Chakraborty PK, 2018, FASEB J, V32, P4145, DOI 10.1096/fj.201701095R; Chan KCA, 2017, NEW ENGL J MED, V377, P513, DOI [10.1056/NEJMoa1701717, 10.1056/nejmoa1701717]; Chen MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35468; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Dong Q, 2019, CANCER LETT, V455, P60, DOI 10.1016/j.canlet.2019.04.031; Fan CD, 2017, CELL MOL NEUROBIOL, V37, P211, DOI 10.1007/s10571-016-0362-3; Fan K, 2014, CELL SIGNAL, V26, P2801, DOI 10.1016/j.cellsig.2014.08.023; Filipovic MR, 2018, CHEM REV, V118, P377, DOI 10.1021/acs.chemrev.7b00205; Fu DA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.582273; George BP, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6797921; Giovinazzo D, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017225118; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han JM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052473; Hartle MD, 2016, CHEM SOC REV, V45, P6108, DOI 10.1039/c6cs00212a; Hsu HY, 2018, CANCER LETT, V432, P112, DOI 10.1016/j.canlet.2018.05.006; Hu YQ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4764071; Jiang CM, 2017, ARCH ORAL BIOL, V74, P108, DOI 10.1016/j.archoralbio.2016.11.016; Julien O, 2017, CELL DEATH DIFFER, V24, P1380, DOI 10.1038/cdd.2017.44; Jurkowska H, 2011, AMINO ACIDS, V41, P151, DOI 10.1007/s00726-010-0606-3; Ke LR, 2017, P NATL ACAD SCI USA, V114, P9683, DOI 10.1073/pnas.1705236114; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Li WP, 2021, CANCER LETT, V499, P301, DOI 10.1016/j.canlet.2020.11.001; Li WW, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4690857; Luo M, 2019, CANCER LETT, V455, P26, DOI 10.1016/j.canlet.2019.04.019; Lv HH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5021983; Martinez-Cutillas M, 2015, PHARMACOL RES, V93, P52, DOI 10.1016/j.phrs.2015.01.002; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pan Y, 2014, MUTAT RES-FUND MOL M, V763, P10, DOI 10.1016/j.mrfmmm.2014.03.002; Panza E, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12312; Pei YX, 2011, TOXICOL APPL PHARM, V257, P420, DOI 10.1016/j.taap.2011.09.026; Phillips CM, 2017, CANCER RES, V77, P5741, DOI 10.1158/0008-5472.CAN-16-3480; Pitchakarn P, 2011, CANCER LETT, V306, P142, DOI 10.1016/j.canlet.2011.02.041; Pupo E, 2011, FREE RADICAL BIO MED, V51, P1765, DOI 10.1016/j.freeradbiomed.2011.08.007; Sekiguchi F, 2016, BIOL PHARM BULL, V39, P887, DOI 10.1248/bpb.b15-01015; Shan BE, 2016, ONCOL REP, V36, P1551, DOI 10.3892/or.2016.4938; Shen Q, 2018, HEPATOLOGY, V67, P1360, DOI 10.1002/hep.29606; Shibuya N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2371; Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507; Sur S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111455; Szabo C, 2017, PHARMACOL REV, V69, P497, DOI 10.1124/pr.117.014050; Szabo C, 2016, NAT REV DRUG DISCOV, V15, P185, DOI 10.1038/nrd.2015.1; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433; Wang J, 2020, INT J MED SCI, V17, P1499, DOI 10.7150/ijms.47024; Wang LP, 2019, INT J ONCOL, V55, P473, DOI 10.3892/ijo.2019.4823; Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011; Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18; Wang YH, 2019, EMBO REP, V20, DOI 10.15252/embr.201845986; Wu DD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3831713; Wu DD, 2019, J CELL MOL MED, V23, P1698, DOI 10.1111/jcmm.14065; Wu DD, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4391-9; Wu DD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.585860; Wu DD, 2019, MOL BIOL REP, V46, P2665, DOI 10.1007/s11033-019-04698-7; Wu DD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6927298; Wu DD, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0762-9; Wu DD, 2015, NITRIC OXIDE-BIOL CH, V50, P38, DOI 10.1016/j.niox.2015.08.004; Wu DD, 2014, CANCER LETT, V351, P13, DOI 10.1016/j.canlet.2014.05.002; Xiao Q, 2020, J DERMATOL SCI, V98, P26, DOI 10.1016/j.jdermsci.2020.02.004; Xiao Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01463-w; Xie YY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113429; Xu YJ, 2019, CANCER LETT, V447, P33, DOI 10.1016/j.canlet.2019.01.022; Ye F, 2020, LIFE SCI, V261, DOI 10.1016/j.lfs.2020.118348; Youness RA, 2021, J ADV RES, V27, P177, DOI 10.1016/j.jare.2020.07.006; Zeng Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1807-7; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zhao LF, 2015, BIOL CHEM, V396, P1247, DOI 10.1515/hsz-2015-0148; Zhao YW, 2018, BIOMED PHARMACOTHER, V98, P36, DOI 10.1016/j.biopha.2017.12.029; Zhu LS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5905-9	75	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5238	5252		10.1038/s41388-022-02512-6	http://dx.doi.org/10.1038/s41388-022-02512-6		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36310322	Green Submitted			2022-12-17	WOS:000876210600001
J	Song, YL; Yang, MH; Zhang, S; Wang, H; Kai, KL; Yao, CX; Dai, FF; Zhou, MJ; Li, JB; Wei, ZR; Yin, ZN; Zhu, WG; Xue, LX; Zang, MX				Song, Yang-Liu; Yang, Ming-Hui; Zhang, Si; Wang, Hao; Kai, Kun-Lun; Yao, Chun-Xia; Dai, Fei-Fei; Zhou, Meng-Jiao; Li, Jin-Biao; Wei, Zhi-Ru; Yin, Zhongnan; Zhu, Wei-Guo; Xue, Lixiang; Zang, Ming-Xi			A GRIP-1-EZH2 switch binding to GATA-4 is linked to the genesis of rhabdomyosarcoma through miR-29a	ONCOGENE			English	Article							CYCLIN D1; DIFFERENTIATION; EXPRESSION; POLYCOMB; PROLIFERATION; PATHOGENESIS; PAX3-FOXO1; REPRESSES; GROWTH; CELLS	Terminal differentiation failure is an important cause of rhabdomyosarcoma genesis, however, little is known about the epigenetic regulation of aberrant myogenic differentiation. Here, we show that GATA-4 recruits polycomb group proteins such as EZH2 to negatively regulate miR-29a in undifferentiated C2C12 myoblast cells, whereas recruitment of GRIP-1 to GATA-4 proteins displaces EZH2, resulting in the activation of miR-29a during myogenic differentiation of C2C12 cells. Moreover, in poorly differentiated rhabdomyosarcoma cells, EZH2 still binds to the miR-29a promoter with GATA-4 to mediate transcriptional repression of miR-29a. Interestingly, once re-differentiation of rhabdomyosarcoma cells toward skeletal muscle, EZH2 was dispelled from miR-29a promoter which is similar to that in myogenic differentiation of C2C12 cells. Eventually, this expression of miR-29a results in limited rhabdomyosarcoma cell proliferation and promotes myogenic differentiation. We thus establish that GATA-4 can function as a molecular switch in the up- and downregulation of miR-29a expression. We also demonstrate that GATA-4 acts as a tumor suppressor in rhabdomyosarcoma partly via miR-29a, which thus provides a potential therapeutic target for rhabdomyosarcoma.	[Song, Yang-Liu; Yang, Ming-Hui; Zhang, Si; Kai, Kun-Lun; Yao, Chun-Xia; Dai, Fei-Fei; Zhou, Meng-Jiao; Li, Jin-Biao; Zang, Ming-Xi] Zhengzhou Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Zhengzhou, Peoples R China; [Wang, Hao; Yin, Zhongnan; Xue, Lixiang] Peking Univ Third Hosp, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China; [Wei, Zhi-Ru] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Zhu, Wei-Guo] Shenzhen Univ, Dept Biochem & Mol Biol, Sch Med, Shenzhen 518055, Peoples R China; [Xue, Lixiang] Peking Univ Third Hosp, Canc Ctr Peking Univ Third Hosp, Beijing 100191, Peoples R China	Zhengzhou University; Zhengzhou University; Shenzhen University	Zang, MX (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Zhengzhou, Peoples R China.; Xue, LX (corresponding author), Peking Univ Third Hosp, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China.; Xue, LX (corresponding author), Peking Univ Third Hosp, Canc Ctr Peking Univ Third Hosp, Beijing 100191, Peoples R China.	lixiangxue@hsc.pku.edu.cn; mzang@zzu.edu.cn			National Natural Science Foundation of China [82072975, 81771631, 81672091, 91749107]; High-Level Talents of Henan Province; Central Plains Basic Research [ZYQR201810120]; 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines); key project of discipline construction of Zhengzhou University in 2020 [XKZDQY202002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); High-Level Talents of Henan Province; Central Plains Basic Research; 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines); key project of discipline construction of Zhengzhou University in 2020	This study was supported by the National Natural Science Foundation of China (No. 82072975, 81771631, 81672091, and 91749107), the High-Level Talents of Henan Province, particularly the support for the Central Plains Thousand Talents Program, which are the leading talents of Central Plains Basic Research (ZYQR201810120), 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines), and the key project of discipline construction of Zhengzhou University in 2020 (XKZDQY202002).	Achour C, 2018, FRONT BIOSCI-LANDMRK, V23, P2106, DOI 10.2741/4693; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Ballarino M, 2016, J CLIN INVEST, V126, P2021, DOI 10.1172/JCI84419; Bersani F, 2016, CANCER RES, V76, P6095, DOI 10.1158/0008-5472.CAN-16-0709; Bevilacqua A, 2014, CARDIOVASC PATHOL, V23, P85, DOI 10.1016/j.carpath.2013.09.003; Cai R, 2018, J BIOL CHEM, V293, P19177, DOI 10.1074/jbc.RA118.003198; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01458; Chen SL, 2000, GENE DEV, V14, P1209; Chikenji A, 2016, J ORAL SCI, V58, P219, DOI 10.2334/josnusd.15-0684; Chinenov Y, 2012, P NATL ACAD SCI USA, V109, P11776, DOI 10.1073/pnas.1206059109; Ciesla M, 2014, INT J BIOCHEM CELL B, V53, P482, DOI 10.1016/j.biocel.2014.05.003; Dai XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0485-1; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DiPiazza ARC, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100699118; Hanna JA, 2018, ONCOGENE, V37, P1991, DOI 10.1038/s41388-017-0081-3; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Healy E, 2019, MOL CELL, V76, P437, DOI 10.1016/j.molcel.2019.08.012; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kouznetsova VL, 2019, PROTEIN SCI, V28, P1387, DOI 10.1002/pro.3647; Ma CX, 2015, CELL MOL LIFE SCI, V72, P2005, DOI 10.1007/s00018-014-1795-9; Megiorni F, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102673; Mikhailov AT, 2016, HEART FAIL REV, V21, P783, DOI 10.1007/s10741-016-9569-0; Missiaglia E, 2017, CANCER LETT, V385, P251, DOI 10.1016/j.canlet.2016.10.011; Pandey PR, 2017, J PATHOL, V241, P626, DOI 10.1002/path.4867; Qiu H, 2016, CELL DEATH DIFFER, V23, P1658, DOI 10.1038/cdd.2016.56; Qu Y, 2016, NUCLEIC ACIDS RES, V44, P7659, DOI 10.1093/nar/gkw463; Schwartz YB, 2014, CELL REP, V8, P321, DOI 10.1016/j.celrep.2014.07.001; Sun M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.225; Vella S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0107-z; Vu LP, 2013, INT J HEMATOL, V97, P198, DOI 10.1007/s12185-012-1247-y; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wannenes F, 2008, MOL CELL ENDOCRINOL, V292, P11, DOI 10.1016/j.mce.2008.05.018; Wei W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.184; Whitcomb J, 2020, IUBMB LIFE, V72, P53, DOI 10.1002/iub.2163; Xiong CJ, 2013, J CELL BIOCHEM, V114, P2708, DOI 10.1002/jcb.24619; Yao CX, 2015, J CELL BIOCHEM, V116, P1755, DOI 10.1002/jcb.25134; Yao CX, 2013, RNA BIOL, V10, P465, DOI 10.4161/rna.24370; Yao CX, 2012, J MOL BIOL, V415, P143, DOI 10.1016/j.jmb.2011.11.011; Zhang S, 2019, J CELL PHYSIOL, V234, P13252, DOI 10.1002/jcp.27997	43	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5223	5237		10.1038/s41388-022-02521-5	http://dx.doi.org/10.1038/s41388-022-02521-5		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36309571				2022-12-17	WOS:000875805200001
J	Wang, H; Song, K; Krebs, TL; Yang, J; Danielpour, D				Wang, H.; Song, K.; Krebs, T. L.; Yang, J.; Danielpour, D.			Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55 (vol 27, pg 6791, 2008)	ONCOGENE			English	Correction; Early Access												david.danielpour@case.edu						Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02510-8	http://dx.doi.org/10.1038/s41388-022-02510-8		OCT 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M7HB	36280700	Bronze			2022-12-17	WOS:000871267400001
J	Ma, ML; Zhang, CH; Cao, R; Tang, DM; Sang, XB; Zou, SL; Wang, XX; Xu, HX; Liu, G; Dai, LZ; Tian, Y; Gao, X; Fu, XH				Ma, Meilin; Zhang, Changhui; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Wang, Xiuxuan; Xu, Haixia; Liu, Geng; Dai, Lunzhi; Tian, Yan; Gao, Xiang; Fu, Xianghui			UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; QUALITY-CONTROL; E2 ENZYMES; EXPRESSION	Cancer cells rely on heightened protein quality control mechanisms, including the ubiquitin-proteosome system that is predominantly driven by ubiquitination comprising E1, E2, and E3 trienzyme cascades. Although E3s have been extensively studied, the implication of E2s in tumorigenesis is poorly defined. Here we reveal a critical E2 in the pathogenesis of hepatocellular carcinoma (HCC). Among all of E2s, UBE2O shows the strongest association with HCC survival prognosis, and its expression is increased in HCC tumors. Accordingly, UBE2O deficiency inhibits HCC growth and metastasis both in vitro and in vivo, while its overexpression has opposite effects. Depending on both E2 and E3 enzymatic activities, UBE2O can interact with and mediate the ubiquitination and degradation of HADHA, a mitochondrial beta-oxidation enzyme, thereby modulating lipid metabolic reprogramming. HADHA is reduced in HCC tumors and inversely correlated with UBE2O levels. Importantly, HADHA acts as a tumor suppressor and primarily mediates UBE2O's function on HCC. Moreover, liver-specific deletion of Ube2o in mice are resistant to DEN-induced hepatocarcinogenesis, along with HADHA upregulation and reduced hepatic lipid accumulation. These data reveal UBE2O as a novel oncogenic driver for metabolic reprogramming and HCC development, highlighting the potential of targeting UBE2O/HADHA axis for HCC therapy.	[Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Sichuan Univ, West China Hosp, Div Endocrinol & Metab, State Key Lab Biotherapy, Changchun 610041, Peoples R China; [Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Sichuan Univ, West China Hosp, Canc Ctr, Changchun 610041, Peoples R China; [Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Collaborat Innovat, Changchun 610041, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi; Gao, Xiang] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi; Gao, Xiang] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Gao, Xiang] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China; [Gao, Xiang] Sichuan Univ, West China Hosp, Inst Neurosurg, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Fu, XH (corresponding author), Sichuan Univ, West China Hosp, Div Endocrinol & Metab, State Key Lab Biotherapy, Changchun 610041, Peoples R China.; Fu, XH (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Changchun 610041, Peoples R China.; Fu, XH (corresponding author), Collaborat Innovat, Changchun 610041, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Inst Neurosurg, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.	xianggao@scu.edu.cn; xfu@scu.edu.cn			National Natural Science Foundation of China [82103128, 92157205, 81970561, 81802836]; National Key Research and Development Program of China [2018YFC2000305]; Ministry of Science and Technology of China [2018ZX09201018-005]; China National Postdoctoral Program for Innovative Talents [BX2021201]; China Postdoctoral Science Foundation [2021M692302]; 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University [ZYJC18049]; Sichuan Science & Technology Program [2019JDTD0013]; Post-Doctor Research Project, West China Hospital, Sichuan University [2020HXBH121]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Ministry of Science and Technology of China(Ministry of Science and Technology, China); China National Postdoctoral Program for Innovative Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University; Sichuan Science & Technology Program; Post-Doctor Research Project, West China Hospital, Sichuan University	This work was supported by the National Natural Science Foundation of China (82103128, 92157205, 81970561, and 81802836), the National Key Research and Development Program of China (2018YFC2000305), the Ministry of Science and Technology of China (2018ZX09201018-005), China National Postdoctoral Program for Innovative Talents (BX2021201), China Postdoctoral Science Foundation (2021M692302), the 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University (ZYJC18049), Sichuan Science & Technology Program (2019JDTD0013), and the Post-Doctor Research Project, West China Hospital, Sichuan University (2020HXBH121).	Amoedo ND, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI133081; Chen SP, 2018, J BIOL CHEM, V293, P11296, DOI 10.1074/jbc.RA117.001432; Chi ZX, 2020, MOL CELL, V80, P43, DOI 10.1016/j.molcel.2020.08.015; Costa-Mattioli M, 2020, SCIENCE, V368, P384, DOI 10.1126/science.aat5314; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Faust TB, 2018, ELIFE, V7, DOI 10.7554/eLife.31879; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YH, 2013, CELL, V152, P1051, DOI 10.1016/j.cell.2013.01.051; Huang YM, 2021, CELL DEATH DIFFER, V28, P671, DOI 10.1038/s41418-020-00616-8; Khare T, 2020, INT J CANCER, V147, P1461, DOI 10.1002/ijc.32943; Kim Y, 2016, NAT PROTOC, V11, P937, DOI 10.1038/nprot.2016.050; Lectez B, 2014, J PROTEOME RES, V13, P3016, DOI 10.1021/pr5001913; Liang KW, 2017, CELL, V168, P59, DOI 10.1016/j.cell.2016.12.011; Lim HY, 2013, ANN SURG ONCOL, V20, P3747, DOI 10.1245/s10434-013-3070-y; Liu J, 2022, THERANOSTICS, V12, P1342, DOI 10.7150/thno.65778; Liu S, 2019, EXP CELL RES, V384, DOI 10.1016/j.yexcr.2019.111558; Liu XM, 2020, HEPATOLOGY, V72, P2029, DOI 10.1002/hep.31222; Liu X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2194-9; Liu YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14190-2; Liu Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0841-3; Ljubkovic M, 2019, DIABETES, V68, P1924, DOI 10.2337/db19-0423; Ma ML, 2019, HEPATOLOGY, V70, P215, DOI 10.1002/hep.30602; Mashtalir N, 2014, MOL CELL, V54, P392, DOI 10.1016/j.molcel.2014.03.002; McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288; Meng Z, 2017, ONCOGENE, V36, P2446, DOI 10.1038/onc.2016.400; Mi BB, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00624-3; Miklas JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12482-1; Minguez B, 2011, J HEPATOL, V55, P1325, DOI 10.1016/j.jhep.2011.02.034; Muto Y, 2019, J EXP MED, V216, P950, DOI 10.1084/jem.20180900; Nguyen AT, 2017, SCIENCE, V357, DOI 10.1126/science.aan0218; Osada T, 1997, J HEPATOL, V26, P1266, DOI 10.1016/S0168-8278(97)80461-8; Osborne HC, 2021, TRENDS CELL BIOL, V31, P628, DOI 10.1016/j.tcb.2021.01.009; Pan A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28044-x; Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769; Shi Z, 2021, INT J MED SCI, V18, P3749, DOI 10.7150/ijms.63220; Shirahashi H, 2002, LIVER, V22, P413, DOI 10.1034/j.1600-0676.2002.01541.x; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stewart MD, 2016, CELL RES, V26, P423, DOI 10.1038/cr.2016.35; Tanaka M, 2013, MOL MED REP, V7, P365, DOI 10.3892/mmr.2012.1201; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tian Y, 2022, MOL THER-NUCL ACIDS, V30, P1, DOI 10.1016/j.omtn.2022.08.036; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vila IK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128269; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Villa E, 2016, GUT, V65, P861, DOI 10.1136/gutjnl-2014-308483; Wang JX, 2019, J HEPATOL, V71, P742, DOI 10.1016/j.jhep.2019.05.027; Xia CW, 2019, P NATL ACAD SCI USA, V116, P6069, DOI 10.1073/pnas.1816317116; Xu HX, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000603; Xu H, 2019, EMBO J, V38, DOI 10.15252/embj.2019101996; Yamamoto K, 2020, LAB INVEST, V100, P353, DOI 10.1038/s41374-019-0318-6; Yanagitani K, 2017, SCIENCE, V357, P472, DOI 10.1126/science.aan0178; Yokota T, 2001, GENE, V267, P95, DOI 10.1016/S0378-1119(01)00407-3; Yokoyama Y, 2004, PROTEOMICS, V4, P2111, DOI 10.1002/pmic.200300712; Yu HS, 2020, HEPATOLOGY, V72, P518, DOI 10.1002/hep.31045; Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922	56	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5199	5213		10.1038/s41388-022-02509-1	http://dx.doi.org/10.1038/s41388-022-02509-1		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36273042				2022-12-17	WOS:000871165700001
J	Lakshmanan, I; Marimuthu, S; Chaudhary, S; Seshacharyulu, P; Rachagani, S; Muniyan, S; Chirravuri-Venkata, R; Atri, P; Rauth, S; Nimmakayala, RK; Siddiqui, JA; Gautam, SK; Shah, A; Natarajan, G; Parte, S; Bhyravbhatla, N; Mallya, K; Haridas, D; Talmon, GA; Smith, LM; Kumar, S; Ganti, AK; Jain, M; Ponnusamy, MP; Batra, SK				Lakshmanan, Imayavaramban; Marimuthu, Saravanakumar; Chaudhary, Sanjib; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Chirravuri-Venkata, Ramakanth; Atri, Pranita; Rauth, Sanchita; Nimmakayala, Rama Krishna; Siddiqui, Jawed Akhtar; Gautam, Shailendra K.; Shah, Ashu; Natarajan, Gopalakrishnan; Parte, Seema; Bhyravbhatla, Namita; Mallya, Kavita; Haridas, Dhanya; Talmon, Geoffrey A.; Smith, Lynette M.; Kumar, Sushil; Ganti, Apar Kishor; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.			Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER-CELLS; JAK2	MUC16, membrane-bound mucin, plays an oncogenic role in pancreatic ductal adenocarcinoma (PDAC). However, the pathological role of MUC16 in the PDAC progression, tumor microenvironment, and metastasis in cooperation with Kras(G12D) and Trp53(R172H) mutations remains unknown. Deletion of Muc16 with activating mutations Kras(G12D/+) and Trp53(R172H/+) in mice significantly decreased progression and prolonged overall survival in Kras(G12D/+); Trp53(R172H/+); Pdx-1-Cre; Muc16(-/-) (KPCM) and Kras(G12D/+); Pdx-1-Cre; Muc16(-/-) (KCM), as compared to Kras(G12D/+); Trp53(R172H/+); Pdx-1-Cre (KPC) and Kras(G12D/+); Pdx-1-Cre (KC) mice, respectively. Muc16 knockout pancreatic tumor (KPCM) displays decreased tumor microenvironment factors and significantly reduced incidence of liver and lung metastasis compared to KPC. Furthermore, in silico data analysis showed a positive correlation of MUC16 with activated stroma and metastasis-associated genes. KPCM mouse syngeneic cells had significantly lower metastatic and endothelial cell binding abilities than KPC cells. Similarly, KPCM organoids significantly decreased the growth rate compared to KPC organoids. Interestingly, RNA-seq data revealed that the cytoskeletal proteins Actg2, Myh11, and Pdlim3 were downregulated in KPCM tumors. Further knockdown of these genes showed reduced metastatic potential. Overall, our results demonstrate that Muc16 alters the tumor microenvironment factors during pancreatic cancer progression and metastasis by changing the expression of Actg2, Myh11, and Pdlim3 genes.	[Lakshmanan, Imayavaramban; Marimuthu, Saravanakumar; Chaudhary, Sanjib; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Chirravuri-Venkata, Ramakanth; Atri, Pranita; Rauth, Sanchita; Nimmakayala, Rama Krishna; Siddiqui, Jawed Akhtar; Gautam, Shailendra K.; Shah, Ashu; Natarajan, Gopalakrishnan; Parte, Seema; Bhyravbhatla, Namita; Mallya, Kavita; Haridas, Dhanya; Kumar, Sushil; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Talmon, Geoffrey A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Ganti, Apar Kishor; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Ganti, Apar Kishor] VA Nebraska Western Iowa Hlth Care Syst, Div Oncol Hematol, Dept Internal Med, Omaha, NE 68105 USA; [Ganti, Apar Kishor] Univ Nebraska Med Ctr, Omaha, NE 68105 USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	mpalanim@unmc.edu; sbatra@unmc.edu	Nimmakayala, Rama Krishna/CAG-5670-2022	Nimmakayala, Rama Krishna/0000-0003-4637-4828; Muniyan, Sakthivel/0000-0001-9405-7857; Chaudhary, Sanjib/0000-0001-9630-1235; Seshacharyulu, Parthasarathy/0000-0002-2348-3901	National Institutes of Health [P01 CA217798, R01 CA263575, R01 CA256973, R01 CA273349, R01 CA247471, R01 CA254036, R01 CA206444, R01 CA210637, R01 CA228524, F99 CA234962, U01 CA200466, U01 CA210240]; Nebraska Department of Health and Human Services [LB595]; US Department of Veterans Affairs [I01 BX004676]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services; US Department of Veterans Affairs(US Department of Veterans Affairs)	We thank Dr. Richard R. Behringer, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, for providing the Muc16 whole-body knockout (C57BL/6J) mice. We thank Corinn Grabow for all the technical support. We thank the University of Nebraska Medical Center core facilities such as Advanced Microscopy Core Facility, Genomics Core Facility, and Tissue Science Facility. This work was, in parts, supported by the support from the National Institutes of Health P01 CA217798, R01 CA263575, R01 CA256973, R01 CA273349, R01 CA247471, R01 CA254036, R01 CA206444, R01 CA210637, R01 CA228524, F99 CA234962, U01 CA200466, and U01 CA210240, and the Nebraska Department of Health and Human Services LB595, US Department of Veterans Affairs (I01 BX004676).	Akita K, 2013, EUR J CELL BIOL, V92, P257, DOI 10.1016/j.ejcb.2013.10.005; Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Belisle JA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-118; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Buscail L, 2020, NAT REV GASTRO HEPAT, V17, P153, DOI 10.1038/s41575-019-0245-4; Caffrey T, 2019, FEBS LETT, V593, P2751, DOI 10.1002/1873-3468.13532; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Chen SH, 2012, FASEB J, V26, P1349, DOI 10.1096/fj.11-195669; Cheon DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004675; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Connor AA, 2019, CANCER CELL, V35, P267, DOI 10.1016/j.ccell.2018.12.010; Das S, 2015, CANCER RES, V75, P4669, DOI 10.1158/0008-5472.CAN-15-1050; Das S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09759; Das S, 2015, ONCOTARGET, V6, P5772, DOI 10.18632/oncotarget.3308; Encarnacion-Rosado J, 2021, NAT REV GASTRO HEPAT, V18, P482, DOI 10.1038/s41575-021-00431-7; Felder M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-129; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hingorani SR, 2018, J CLIN ONCOL, V36, P359, DOI 10.1200/JCO.2017.74.9564; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kaushik G, 2021, ONCOGENE, V40, P848, DOI 10.1038/s41388-020-01564-w; Lakshmanan I, 2016, ONCOGENE, V35, P4112, DOI 10.1038/onc.2015.478; Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297; Lakshmanan I, 2017, CLIN CANCER RES, V23, P3906, DOI 10.1158/1078-0432.CCR-16-2530; Lakshmanan I, 2015, ONCOTARGET, V6, P21085, DOI 10.18632/oncotarget.3912; Lee Jae W, 2016, Curr Protoc Pharmacol, V73, DOI 10.1002/cpph.2; Lennon S, 2019, CLIN CANCER RES, V25, P3352, DOI 10.1158/1078-0432.CCR-18-2811; Li GL, 2003, J IMMUNOL, V171, P669, DOI 10.4049/jimmunol.171.2.669; Mallya K, 2020, BIOL OPEN, V9, DOI 10.1242/bio.052878; Marimuthu S, 2022, MOL CANCER RES, V20, P1208, DOI 10.1158/1541-7786.MCR-21-0888; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Muniyan Sakthivel, 2016, Genes Cancer, V7, P110, DOI 10.18632/genesandcancer.104; Nallasamy P, 2021, GASTROENTEROLOGY, V161, P1998, DOI 10.1053/j.gastro.2021.08.023; Nimmakayala RK, 2021, ONCOGENE, V40, P215, DOI 10.1038/s41388-020-01518-2; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Rauth S, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188527; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sperb N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155486; Tian CX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22490-9; Tian CX, 2019, P NATL ACAD SCI USA, V116, P19609, DOI 10.1073/pnas.1908626116; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169	45	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5147	5159		10.1038/s41388-022-02493-6	http://dx.doi.org/10.1038/s41388-022-02493-6		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271032				2022-12-17	WOS:000870984500004
J	Lee, LM; Christodoulou, EG; Shyamsunder, P; Chen, BJ; Lee, KL; Fung, TK; So, CWE; Wong, GC; Petretto, E; Rackham, OJL; Ong, ST				Lee, Lin Ming; Christodoulou, Eleni G.; Shyamsunder, Pavithra; Chen, Bei Jun; Lee, Kian Leong; Fung, Tsz Kan; So, Chi Wai Eric; Wong, Gee Chuan; Petretto, Enrico; Rackham, Owen J. L.; Tiong Ong, S.			A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify (R)	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PLURIPOTENT STEM-CELLS; GENOME-WIDE ANALYSIS; TRANS-RETINOIC ACID; SELF-RENEWAL; CHIP-SEQ; EXPRESSION; ALPHA; PML; TRANSCRIPTION	Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer that is characterised by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. Methods which identify master transcriptional regulators of AML subtype-specific leukaemia cell states and their combinations could be critical for discovering novel differentiation-inducing therapies. In this proof-of-concept study, we demonstrate a novel utility of the Mogrify (R) algorithm in identifying combinations of transcription factors (TFs) and drugs, which recapitulate granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line, using two different approaches. In the first approach, Connectivity Map (CMAP) analysis of these TFs and their target networks outperformed standard approaches, retrieving ATRA as the top hit. We identify dimaprit and mebendazole as a drug combination which induces myeloid differentiation. In the second approach, we show that genetic manipulation of specific Mogrify (R)-identified TFs (MYC and IRF1) leads to co-operative induction of APL differentiation, as does pharmacological targeting of these TFs using currently available compounds. We also show that loss of IRF1 blunts ATRA-mediated differentiation, and that MYC represses IRF1 expression through recruitment of PML-RARa, the driver fusion oncoprotein in APL, to the IRF1 promoter. Finally, we demonstrate that these drug combinations can also induce differentiation of primary patient-derived APL cells, and highlight the potential of targeting MYC and IRF1 in high-risk APL. Thus, these results suggest that Mogrify (R) could be used for drug discovery or repositioning in leukaemia differentiation therapy for other subtypes of leukaemia or cancers.	[Lee, Lin Ming; Shyamsunder, Pavithra; Lee, Kian Leong; Tiong Ong, S.] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore; [Christodoulou, Eleni G.; Chen, Bei Jun; Petretto, Enrico; Rackham, Owen J. L.] Duke NUS Med Sch, Ctr Computat Biol, Singapore, Singapore; [Christodoulou, Eleni G.; Chen, Bei Jun; Petretto, Enrico; Rackham, Owen J. L.] Duke NUS Med Sch, Programme Cardiovasc & Metab Disorders, Singapore, Singapore; [Fung, Tsz Kan; So, Chi Wai Eric] Kings Coll London, Comprehens Canc Ctr, London, England; [Fung, Tsz Kan; So, Chi Wai Eric] Kings Coll Hosp London, Dept Haematol Med, London, England; [Wong, Gee Chuan; Tiong Ong, S.] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore; [Petretto, Enrico] Imperial Coll London, MRC London Inst Med Sci LMC, Fac Med, London, England; [Petretto, Enrico] China Pharmaceut Univ CPU, Inst Big Data & Artificial Intelligence Med, Sch Sci, Nanjing, Peoples R China; [Rackham, Owen J. L.] Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, England; [Tiong Ong, S.] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore; [Tiong Ong, S.] Duke Univ, Dept Med, Med Ctr, Durham, NC USA	National University of Singapore; National University of Singapore; National University of Singapore; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Singapore General Hospital; Imperial College London; University of Southampton; National Cancer Centre Singapore (NCCS); Duke University	Ong, ST (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore.; Petretto, E; Rackham, OJL (corresponding author), Duke NUS Med Sch, Ctr Computat Biol, Singapore, Singapore.; Petretto, E; Rackham, OJL (corresponding author), Duke NUS Med Sch, Programme Cardiovasc & Metab Disorders, Singapore, Singapore.; Ong, ST (corresponding author), Singapore Gen Hosp, Dept Haematol, Singapore, Singapore.; Petretto, E (corresponding author), Imperial Coll London, MRC London Inst Med Sci LMC, Fac Med, London, England.; Petretto, E (corresponding author), China Pharmaceut Univ CPU, Inst Big Data & Artificial Intelligence Med, Sch Sci, Nanjing, Peoples R China.; Rackham, OJL (corresponding author), Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, England.; Ong, ST (corresponding author), Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore.; Ong, ST (corresponding author), Duke Univ, Dept Med, Med Ctr, Durham, NC USA.	enrico.petretto@duke-nus.edu.sg; owen.rackham@duke-nus.edu.sg; sintiong.ong@duke-nus.edu.sg		Lee, Lin Ming/0000-0001-6229-3679	National Medical Research Council (NMRC) of Singapore [MOH-000059/MOH-CSASI18may-0002, NMRC/CIRG/1429/2015]; NMRC YIRG [NMRC/OFYIRG/0022/2016]; Singapore National Research Foundation grant [NRF-CRP20-2017-0002]	National Medical Research Council (NMRC) of Singapore(National Medical Research Council, Singapore); NMRC YIRG; Singapore National Research Foundation grant(National Research Foundation, Singapore)	The authors would like to acknowledge Dr. Sonia P. Chothani for providing the RNA-Seq data analysis pipeline, the ssCMAP developer, Dr. Shu-Dong Zhang, for helpful discussion on the algorithm's internal calculations, the Duke-NUS Genome Biology Facility (DGBF) for RNA, ChIP-and ATAC-sequencing services, as well as Dr. Gee Chuan Wong/Bryan Y.W. Teo, SGH Department of Haematology for providing primary APL samples. This work was funded by the National Medical Research Council (NMRC) of Singapore (MOH-000059/MOH-CSASI18may-0002) and NMRC/CIRG/1429/2015 to STO). OJLR is supported by NMRC YIRG (NMRC/OFYIRG/0022/2016) and by a Singapore National Research Foundation grant [NRF-CRP20-2017-0002].	Assi SA, 2019, NAT GENET, V51, P151, DOI 10.1038/s41588-018-0270-1; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Brodsky A, 1998, EUR J PHARMACOL, V350, P121, DOI 10.1016/S0014-2999(98)00227-1; Cao ZD, 2021, MOL CELL, V81, P3604, DOI 10.1016/j.molcel.2021.07.018; Chao MP, 2017, CELL STEM CELL, V20, P329, DOI 10.1016/j.stem.2016.11.018; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; Coccia EM, 2001, BIOCHEM J, V360, P285, DOI 10.1042/0264-6021:3600285; Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; dos Santos GA, 2013, J EXP MED, V210, P2793, DOI 10.1084/jem.20131121; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Fiedler K, 2012, AM J BLOOD RES, V2, P57; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Gao TS, 2016, BIOINFORMATICS, V32, P3543, DOI 10.1093/bioinformatics/btw495; Gonda TJ, 2015, NAT REV CANCER, V15, P686, DOI 10.1038/nrc4018; Hu MH, 2018, J MED CHEM, V61, P2447, DOI 10.1021/acs.jmedchem.7b01697; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; KALINYAK KA, 1985, LIFE SCI, V36, P1909, DOI 10.1016/0024-3205(85)90439-4; Khwaja A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.10; Kotini AG, 2017, CELL STEM CELL, V20, P315, DOI 10.1016/j.stem.2017.01.009; Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501; Leon J, 2009, CELL CYCLE, V8, P1148, DOI 10.4161/cc.8.8.8126; Li YL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53290-3; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin XJ, 2021, CLIN CANCER RES, V27, P3683, DOI 10.1158/1078-0432.CCR-20-4375; Liu QY, 2015, MOL PHARMACOL, V88, P469, DOI 10.1124/mol.115.097915; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lourenco C, 2021, NAT REV CANCER, V21, P579, DOI 10.1038/s41568-021-00367-9; Lucena-Araujo AR, 2019, BLOOD, V132, P951, DOI 10.1182/blood.2019000239; McClellan JS, 2015, P NATL ACAD SCI USA, V112, P4074, DOI 10.1073/pnas.1413383112; McNamara S, 2008, MOL CELL BIOL, V28, P2066, DOI 10.1128/MCB.01576-07; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Michalska A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01135; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Ng KP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205254; Nichol JN, 2016, CELL REP, V14, P2938, DOI 10.1016/j.celrep.2016.02.074; Norsworthy KJ, 2016, CURR OPIN HEMATOL, V23, P127, DOI 10.1097/MOH.0000000000000215; Padmanabhan A, 2013, J BIOL CHEM, V288, P14158, DOI 10.1074/jbc.M112.432377; Pan XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105381; Pantziarka P, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.443; Park SM, 2019, CELL STEM CELL, V24, P153, DOI 10.1016/j.stem.2018.10.016; Paul F, 2016, CELL, V164, P325, DOI 10.1016/j.cell.2015.12.046; Prunier C, 2015, CELL REP, V10, P883, DOI 10.1016/j.celrep.2015.01.024; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487; Ravandi F, 2009, J CLIN ONCOL, V27, P504, DOI 10.1200/JCO.2008.18.6130; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sapio L, 2017, J CELL PHYSIOL, V232, P922, DOI 10.1002/jcp.25650; SAWUTZ DG, 1984, J PHARMACOL EXP THER, V231, P1; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shayo C, 1997, MOL PHARMACOL, V51, P983, DOI 10.1124/mol.51.6.983; Shi LH, 2011, GENE, V487, P21, DOI 10.1016/j.gene.2011.07.004; Shyamsunder P, 2019, BLOOD, V133, P2507, DOI 10.1182/blood.2018886077; Si JL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-92; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan Y, 2021, BLOOD, V137, P1503, DOI 10.1182/blood.2020005698; Testa U, 2004, LEUKEMIA, V18, P1864, DOI 10.1038/sj.leu.2403472; Testa U, 2016, ANN HEMATOL, V95, P673, DOI 10.1007/s00277-016-2622-1; Vicente C, 2012, CRIT REV ONCOL HEMAT, V82, P1, DOI 10.1016/j.critrevonc.2011.04.007; Walf-Vorderwulbecke V, 2018, LEUKEMIA, V32, P882, DOI 10.1038/leu.2017.317; Wang E, 2021, CELL STEM CELL, V28, P718, DOI 10.1016/j.stem.2020.12.005; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang P., 2020, GENOME BIOL, V21; Yang LJ, 2003, J MOL DIAGN, V5, P212, DOI 10.1016/S1525-1578(10)60476-X; Yun HY, 2021, NAT GENET, V53, P1443, DOI 10.1038/s41588-021-00925-9; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang L, 2020, BLOOD, V135, P1133, DOI 10.1182/blood.2019001863; Zhang SD, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-258; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102	79	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5160	5175		10.1038/s41388-022-02505-5	http://dx.doi.org/10.1038/s41388-022-02505-5		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271030	Bronze			2022-12-17	WOS:000870984500001
J	Unlu, B; Kocaturk, B; Rondon, AMR; Lewis, CS; Swier, N; van den Akker, RFP; Krijgsman, D; Noordhoek, I; Blok, EJ; Bogdanov, VY; Ruf, W; Kuppen, PJK; Versteeg, HH				Unlu, Betul; Kocaturk, Begum; Rondon, Araci M. R.; Lewis, Clayton S.; Swier, Nathalie; van den Akker, Rob F. P.; Krijgsman, Danielle; Noordhoek, Iris; Blok, Erik J.; Bogdanov, Vladimir Y.; Ruf, Wolfram; Kuppen, Peter J. K.; Versteeg, Henri H.			Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer	ONCOGENE			English	Article							FACTOR EXPRESSION; CELLS; PROGNOSIS; CARCINOMA; EMT; COAGULATION; MECHANISMS; TRANSITION; INSIGHTS; THERAPY	Tissue Factor (TF) is the initiator of blood coagulation but also functions as a signal transduction receptor. TF expression in breast cancer is associated with higher tumor grade, metastasis and poor survival. The role of TF signaling on the early phases of metastasis has never been addressed. Here, we show an association between TF expression and metastasis as well as cancer stemness in 574 breast cancer patients. In preclinical models, blockade of TF signaling inhibited metastasis tenfold independent of primary tumor growth. TF blockade caused a reduction in epithelial-to-mesenchymal-transition, cancer stemness and expression of the pro-metastatic markers Slug and SOX9 in several breast cancer cell lines and in ex vivo cultured tumor cells. Mechanistically, TF forms a complex with beta 1-integrin leading to inactivation of beta 1-integrin. Inhibition of TF signaling induces a shift in TF-binding from alpha 3 beta 1-integrin to alpha 6 beta 4 and dictates FAK recruitment, leading to reduced epithelial-to-mesenchymal-transition and tumor cell differentiation. In conclusion, TF signaling inhibition leads to reduced pro-metastatic transcriptional programs, and a subsequent integrin beta 1 and beta 4-dependent reduction in metastasic dissemination.	[Unlu, Betul; Kocaturk, Begum; Rondon, Araci M. R.; Swier, Nathalie; van den Akker, Rob F. P.; Versteeg, Henri H.] Leiden Univ, Dept Internal Med, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands; [Lewis, Clayton S.; Bogdanov, Vladimir Y.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH USA; [Krijgsman, Danielle; Noordhoek, Iris; Blok, Erik J.; Kuppen, Peter J. K.] Leiden Univ, Dept Surg, Med Ctr, Leiden, Netherlands; [Ruf, Wolfram] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA USA; [Ruf, Wolfram] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Med Ctr, Mainz, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University System of Ohio; University of Cincinnati; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Scripps Research Institute; Johannes Gutenberg University of Mainz	Versteeg, HH (corresponding author), Leiden Univ, Dept Internal Med, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands.	h.h.versteeg@lumc.nl	; Unlu, Betul/L-2048-2018	Rondon, Araci M R/0000-0002-2703-8805; Unlu, Betul/0000-0001-5587-4176	Dutch Cancer Society [UL 2015-7594]; Netherlands Organization for Scientific Research [VIDI 91710329]; Worldwide Cancer Research [15-1186]; NIH/NCI [R01CA190717]	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Worldwide Cancer Research; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Dutch Cancer Society (UL 2015-7594), The Netherlands Organization for Scientific Research (VIDI 91710329) and Worldwide Cancer Research (15-1186). VYB and CSL are partially supported by the NIH/NCI (grant R01CA190717).	Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Beaver CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089834; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Chen QK, 2013, DIFFERENTIATION, V86, P126, DOI 10.1016/j.diff.2013.03.003; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Garg M, 2017, WORLD J STEM CELLS, V9, P118, DOI 10.4252/wjsc.v9.i8.118; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Ishiwata T, 2016, PATHOL INT, V66, P601, DOI 10.1111/pin.12447; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Kim KJ, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030032; Kocaturk B, 2013, J THROMB HAEMOST, V11, P285, DOI 10.1111/jth.12222; Kocaturk B, 2015, JOVE-J VIS EXP, DOI 10.3791/51967; Kocaturk B, 2013, P NATL ACAD SCI USA, V110, P11517, DOI 10.1073/pnas.1307100110; Kotiyal S, 2014, BIOCHEM BIOPH RES CO, V453, P112, DOI 10.1016/j.bbrc.2014.09.069; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Levy S, 2005, PHYSIOLOGY, V20, P218, DOI 10.1152/physiol.00015.2005; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Nitori N, 2005, CLIN CANCER RES, V11, P2531, DOI 10.1158/1078-0432.CCR-04-0866; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Paula AD, 2017, ANTICANCER RES, V37, P2173, DOI 10.21873/anticanres.11552; Richards JO, 2016, CANCER IMMUNOL IMMUN, V65, P1325, DOI 10.1007/s00262-016-1885-7; Rothmeier AS, 2018, BLOOD, V131, P674, DOI 10.1182/blood-2017-02-768218; Ryden L, 2010, INT J CANCER, V126, P2330, DOI 10.1002/ijc.24921; Sawada M, 1999, BRIT J CANCER, V79, P472, DOI 10.1038/sj.bjc.6690073; Schaffner F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061071; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shaker H, 2017, ONCOTARGET, V8, P25915, DOI 10.18632/oncotarget.13928; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; STURM U, 1992, VIRCHOWS ARCH A, V421, P79, DOI 10.1007/BF01607039; Teplyakov A, 2017, CELL SIGNAL, V36, P139, DOI 10.1016/j.cellsig.2017.05.004; Ueno T, 2000, BRIT J CANCER, V83, P164; Unlu B, 2017, THROMB RES, V156, P1, DOI 10.1016/j.thromres.2017.05.028; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van den Berg YW, 2012, BLOOD, V119, P924, DOI 10.1182/blood-2011-06-317685; van Nes JGH, 2011, BREAST CANCER RES TR, V125, P671, DOI 10.1007/s10549-010-0854-7; Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood-2007-07-101048; Yamashita H, 2007, J SURG ONCOL, V95, P324, DOI 10.1002/jso.20680; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang XS, 2017, ONCOTARGET, V8, P59086, DOI 10.18632/oncotarget.19175	51	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5176	5185		10.1038/s41388-022-02511-7	http://dx.doi.org/10.1038/s41388-022-02511-7		OCT 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271029	Bronze			2022-12-17	WOS:000870984500003
J	Yan, C; Yang, HJ; Su, P; Li, X; Li, ZB; Wang, DH; Zang, YF; Wang, TS; Liu, ZP; Bao, ZC; Dong, SX; Zhuang, T; Zhu, J; Ding, YL				Yan, Cheng; Yang, Huijie; Su, Peng; Li, Xin; Li, Zhongbo; Wang, Dehai; Zang, Yifeng; Wang, Tianshi; Liu, Ziping; Bao, Zhuocong; Dong, Shuxiao; Zhuang, Ting; Zhu, Jian; Ding, Yinlu			OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer	ONCOGENE			English	Article							ORGAN SIZE CONTROL; CELL-PROLIFERATION; PATHWAY; INVASION	Gastric cancer is one of the most lethal human malignancies in the world. Although great efforts are put in developing novel therapeutic targets, the effective targeting drugs are still limited. Recent studies reveal the abnormality of Hippo/YAP axis play critical role in the oncogenic process of gastric cancer. It is of great importance to demonstrate the regulation of Hippo signaling activity and YAP protein turnover in gastric cancer. Besides, the phosphorylation cascade on YAP function, which has been thoroughly investigated, the ubiquitination of YAP is also important in Hippo signaling status. Here, We utilized the DUB (Deubiquitinase) siRNA library to identify critical DUB for Hippo signaling. We discovered OTUB1 as a critical factor to facilitate gastric cancer cell stemness and progression, which deubiquitinated and stabilized YAP protein. The clinical data analysis implicated OTUB1 was higher expressed in gastric cancer, which correlated with YAP activity and poor survival. OUTB1 interacted with YAP protein via its OTU domain (Ovarian tumor domain) and deubiquitinated YAP at several lysine sites (K90, K280, K343, K494 and K497), which subsequently inhibited YAP degradation. Our study revealed a novel deubiquitinase of Hippo/YAP axis and one possible therapeutic target for YAP-driven gastric cancer.	[Yan, Cheng] Xinxiang Univ, Sch Med, Key Lab Nanocarbon Modified Film Technol Henan Pr, Diagnost Lab Anim Dis, Xinxiang 453003, Henan, Peoples R China; [Yang, Huijie; Li, Xin; Li, Zhongbo; Zhuang, Ting] Xinxiang Med Univ, Sch Lab Med, Xinxiang Key Lab Tumor Migrat & Invas Precis Med, Xinxiang 453003, Henan, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan 250033, Peoples R China; [Wang, Dehai; Zang, Yifeng; Wang, Tianshi; Liu, Ziping; Bao, Zhuocong; Zhu, Jian; Ding, Yinlu] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gen Surg, Jinan, Shandong, Peoples R China; [Dong, Shuxiao] Shandong Prov Third Hosp, Dept Gastroenterol Surg, Jinan 250000, Peoples R China; [Zhu, Jian] Shandong First Med Univ, Cent Hosp, Jinan 250013, Peoples R China; [Zhu, Jian] Shandong Acad Med Sci, Jinan 250013, Peoples R China	Xinxiang University; Xinxiang Medical University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan	Zhuang, T (corresponding author), Xinxiang Med Univ, Sch Lab Med, Xinxiang Key Lab Tumor Migrat & Invas Precis Med, Xinxiang 453003, Henan, Peoples R China.; Zhu, J; Ding, YL (corresponding author), Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gen Surg, Jinan, Shandong, Peoples R China.; Dong, SX (corresponding author), Shandong Prov Third Hosp, Dept Gastroenterol Surg, Jinan 250000, Peoples R China.; Zhu, J (corresponding author), Shandong First Med Univ, Cent Hosp, Jinan 250013, Peoples R China.; Zhu, J (corresponding author), Shandong Acad Med Sci, Jinan 250013, Peoples R China.	dongsx01@163.com; 77090993@qq.com; jian.zhu@email.sdu.edu.cn; dingyinlu@126.com			National Science Foundation of China [82172999, 82273013]; Program for Science & Technology Innovation Talents in Universities of Henan Province [21HASTIT049]; Henan Provincial National Natural Science Foundation of Excellent Young Scientist [222300420065]; Taishan Scholar Program of Shandong Province [tsqn202103175]; Shandong Provincial National Natural Science Foundation [ZR2016HQ44, ZR2021MH017]; Key Research Program of Education Department of Henan Province [22A310005]; National Science Foundation for Young Scholars of China [32200632]; Program for Science & Technology Innovation in Shandong Society of Geriatrics [LKJGG2021z002]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Science & Technology Innovation Talents in Universities of Henan Province; Henan Provincial National Natural Science Foundation of Excellent Young Scientist; Taishan Scholar Program of Shandong Province; Shandong Provincial National Natural Science Foundation; Key Research Program of Education Department of Henan Province; National Science Foundation for Young Scholars of China(National Natural Science Foundation of China (NSFC)); Program for Science & Technology Innovation in Shandong Society of Geriatrics	The project was supported by the National Science Foundation of China (No. 82172999, TZ; 82273013, YD), the Program for Science & Technology Innovation Talents in Universities of Henan Province (Grant No. 21HASTIT049 to TZ), the Henan Provincial National Natural Science Foundation of Excellent Young Scientist (222300420065 to TZ), the Taishan Scholar Program of Shandong Province (tsqn202103175 to JZ), Shandong Provincial National Natural Science Foundation (ZR2016HQ44 to YD; ZR2021MH017 for JZ), the Key Research Program of Education Department of Henan Province (22A310005 to JZ), the National Science Foundation for Young Scholars of China (32200632 to Cheng Yan) and the Program for Science & Technology Innovation in Shandong Society of Geriatrics (LKJGG2021z002 to YD).	Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; Boopathy GTK, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00049; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cenitagoya GF, 1998, DIGEST SURG, V15, P317, DOI 10.1159/000018645; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Garattini SK, 2017, WORLD J GASTRO ONCOL, V9, P194, DOI 10.4251/wjgo.v9.i5.194; Gerson JN, 2017, EXPERT OPIN INV DRUG, V26, P531, DOI 10.1080/13543784.2017.1315406; He MJ, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0013-6; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Jin D, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01161-1; Juris SJ, 2006, FEBS LETT, V580, P179, DOI 10.1016/j.febslet.2005.11.071; Kim J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00314; Kulathu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2567; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Padmanabhan R, 2020, CANCERS, V12, DOI 10.3390/cancers12030636; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rodriquenz MG, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051427; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Weng WW, 2016, AM J TRANSL RES, V8, P2234; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00312-6; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhou XF, 2019, NAT IMMUNOL, V20, P879, DOI 10.1038/s41590-019-0405-2; Zhu D, 2021, CELL DEATH DIFFER, V28, P1773, DOI 10.1038/s41418-020-00700-z; Zhu H, 2020, CANCER RES, V80, P2204, DOI 10.1158/0008-5472.CAN-19-2388	34	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5186	5198		10.1038/s41388-022-02507-3	http://dx.doi.org/10.1038/s41388-022-02507-3		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271031	Green Published, hybrid			2022-12-17	WOS:000870984500002
J	Kikuno, N; Shiina, H; Urakami, S; Kawamoto, K; Hirata, H; Tanaka, Y; Place, RF; Pookot, D; Majid, S; Igawa, M; Dahiya, R				Kikuno, N.; Shiina, H.; Urakami, S.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Igawa, M.; Dahiya, R.			RETRACTION: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity (Retraction of Vol 26, Pg 7647, 2007)	ONCOGENE			English	Retraction																		Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4981	4981		10.1038/s41388-022-02501-9	http://dx.doi.org/10.1038/s41388-022-02501-9		OCT 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36261628	Bronze			2022-12-17	WOS:000870094500002
J	Lin, M; Ku, AT; Dong, J; Yue, F; Jiang, WY; Ibrahim, AA; Peng, FL; Creighton, CJ; Nagi, C; Gutierrez, C; Rosen, JM; Zhang, XHF; Hilsenbeck, SG; Chen, X; Du, YCN; Huang, SX; Shi, AP; Fan, ZM; Li, Y				Lin, Meng; Ku, Amy T.; Dong, Jie; Yue, Fei; Jiang, Weiyu; Ibrahim, Ahmed Atef; Peng, Fanglue; Creighton, Chad J.; Nagi, Chandandeep; Gutierrez, Carolina; Rosen, Jeffrey M.; Zhang, Xiang H-F; Hilsenbeck, Susan G.; Chen, Xi; Du, Yi-Chieh Nancy; Huang, Shixia; Shi, Aiping; Fan, Zhimin; Li, Yi			STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; SIGNAL TRANSDUCER; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; BONE METASTASIS; TRANSGENIC MICE; CANCER CELLS; IN-VIVO; ACTIVATION; EXPRESSION	Signal transducer and activator of transcription 5 (STAT5) promotes cell survival and instigates breast tumor formation, and in the normal breast it also drives alveolar differentiation and lactogenesis. However, whether STAT5 drives a differentiated phenotype in breast tumorigenesis and therefore impacts cancer spread and metastasis is unclear. We found in two genetically engineered mouse models of breast cancer that constitutively activated Stat5a (Stat5a(ca)) caused precancerous mammary epithelial cells to become lactogenic and evolve into tumors with diminished potential to metastasize. We also showed that STAT5a(ca) reduced the migratory and invasive ability of human breast cancer cell lines in vitro. Furthermore, we demonstrated that STAT5a(ca) overexpression in human breast cancer cells lowered their metastatic burden in xenografted mice. Moreover, RPPA, Western blotting, and studies of ChIPseq data identified several EMT drivers regulated by STAT5. In addition, bioinformatic studies detected a correlation between STAT5 activity and better prognosis of breast cancer patients. Together, we conclude that STAT5 activation during mammary tumorigenesis specifies a tumor phenotype of lactogenic differentiation, suppresses EMT, and diminishes potential for subsequent metastasis.	[Lin, Meng; Ku, Amy T.; Dong, Jie; Yue, Fei; Jiang, Weiyu; Ibrahim, Ahmed Atef; Gutierrez, Carolina; Zhang, Xiang H-F; Hilsenbeck, Susan G.; Li, Yi] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Lin, Meng; Shi, Aiping; Fan, Zhimin] First Hosp Jilin Univ, Gen Surg Ctr, Dept Breast Surg, Changchun, Jilin, Peoples R China; [Yue, Fei; Creighton, Chad J.; Rosen, Jeffrey M.; Hilsenbeck, Susan G.; Huang, Shixia] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Peng, Fanglue; Rosen, Jeffrey M.; Zhang, Xiang H-F; Chen, Xi; Huang, Shixia; Li, Yi] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Creighton, Chad J.; Rosen, Jeffrey M.; Zhang, Xiang H-F; Hilsenbeck, Susan G.; Chen, Xi; Huang, Shixia; Li, Yi] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Du, Yi-Chieh Nancy] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA; [Huang, Shixia] Dept Educ Innovat & Technol, Houston, TX USA	Baylor College of Medicine; Jilin University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cornell University	Li, Y (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.; Li, Y (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Li, Y (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.	liyi@bcm.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X; Lin, Meng/0000-0001-8154-5720	DOD CDMRP [BC191649, BC191646]; SPORE-funded [P50CA186784]; CPRIT Core Facility Support Award [CPRIT-RP180672, RP210227]; NIH [P30 CA125123, S10 RR024574, CA125123]; expert assistance of Joel M. Sederstrom; P30 Cancer Center Support Grant [NCI-CA125123]; NIH S10 instrument award [S10OD028648-01]; Chinese Scholarship Council (CSC);  [T32-CA203690];  [NIH016303]	DOD CDMRP(United States Department of Defense); SPORE-funded; CPRIT Core Facility Support Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); expert assistance of Joel M. Sederstrom; P30 Cancer Center Support Grant; NIH S10 instrument award; Chinese Scholarship Council (CSC)(China Scholarship Council); ; 	This work was supported by DOD CDMRP BC191649 & BC191646 (to YL). The authors thank the SPORE-funded (P50CA186784) Pathology Core Facility at the Breast Center for tissue processing and Dr. Gary Chamness for helpful comments on the manuscript; the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (P30 CA125123 and S10 RR024574) and the expert assistance of Joel M. Sederstrom; the Antibody-Based Proteomics Core (RPPA core) at Baylor College of Medicine funded by CPRIT Core Facility Award (RP210227) and P30 Cancer Center Support Grant (NCI-CA125123), NIH S10 instrument award (S10OD028648-01), and the expert help of Dr. Xuan Wang. The authors thank Le Ma for gifting reagents and Dr. Wen Bu for intellectual input. ML is supported by the Chinese Scholarship Council (CSC), AK was supported by T32-CA203690. JMR is supported by NIH016303. CJC is supported by NIH CA125123.	Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bu W, 2020, J MAMMARY GLAND BIOL, V25, P389, DOI 10.1007/s10911-020-09469-w; Bu W, 2009, J MAMMARY GLAND BIOL, V14, P401, DOI 10.1007/s10911-009-9154-4; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Creighton CJ, 2015, DRUG DES DEV THER, V9, P3519, DOI 10.2147/DDDT.S38375; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dong J, 2010, DEV BIOL, V346, P196, DOI 10.1016/j.ydbio.2010.07.027; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Eilon T, 2007, INT J CANCER, V121, P1892, DOI 10.1002/ijc.22954; Gu L, 2010, ENDOCR-RELAT CANCER, V17, P481, DOI 10.1677/ERC-09-0328; Haricharan S, 2014, MOL CELL ENDOCRINOL, V382, P560, DOI 10.1016/j.mce.2013.03.014; Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Iavnilovitch E, 2006, MOL REPROD DEV, V73, P841, DOI 10.1002/mrd.20479; Johnston AN, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0969-z; Kinslechner K, 2018, MOL CANCER RES, V16, P135, DOI 10.1158/1541-7786.MCR-17-0292; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koppikar P, 2008, CLIN CANCER RES, V14, P7682, DOI 10.1158/1078-0432.CCR-08-1328; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Li HZ, 2005, CLIN CANCER RES, V11, P5863, DOI 10.1158/1078-0432.CCR-05-0562; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Metser G, 2016, NUCLEIC ACIDS RES, V44, P1052, DOI 10.1093/nar/gkv999; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Minieri V, 2018, CANCER RES, V78, P5793, DOI 10.1158/0008-5472.CAN-18-0195; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; Salas A, 2020, NAT REV GASTRO HEPAT, V17, P323, DOI 10.1038/s41575-020-0273-0; Schorr K, 2000, CANCER RES, V60, P5950; Shi AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132214; Strauss BL, 2006, HUM PATHOL, V37, P586, DOI 10.1016/j.humpath.2006.01.009; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Talati PG, 2015, AM J PATHOL, V185, P2505, DOI 10.1016/j.ajpath.2015.04.026; Vasaikar SV, 2021, BRIT J CANCER, V124, P259, DOI 10.1038/s41416-020-01178-9; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wang J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad3210; Watson CJ, 2008, SEMIN CELL DEV BIOL, V19, P401, DOI 10.1016/j.semcdb.2008.07.021; Yamaji D, 2013, NUCLEIC ACIDS RES, V41, P1622, DOI 10.1093/nar/gks1310; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095; Young A, 2022, CANCER PREV RES, V15, P3, DOI 10.1158/1940-6207.CAPR-21-0031; Yue F, 2021, CANCER RES, V81, P4441, DOI 10.1158/0008-5472.CAN-21-1112; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	57	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5214	5222		10.1038/s41388-022-02500-w	http://dx.doi.org/10.1038/s41388-022-02500-w		OCT 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36261627				2022-12-17	WOS:000870094500001
J	Twafra, S; Sokolik, CG; Sneh, T; Srikanth, KD; Meirson, T; Genna, A; Chill, JH; Gil-Henn, H				Twafra, Shams; Sokolik, Chana G.; Sneh, Tal; Srikanth, Kolluru D.; Meirson, Tomer; Genna, Alessandro; Chill, Jordan H.; Gil-Henn, Hava			A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis	ONCOGENE			English	Article; Early Access							FOCAL ADHESION KINASE; SH3 DOMAIN; MATRIX-METALLOPROTEINASE; STRUCTURAL BASIS; CORTACTIN; PROLINE; BINDING; SRC; PROTEIN; MEMBRANE	Dissemination of cancer cells from the primary tumor into distant body tissues and organs is the leading cause of death in cancer patients. While most clinical strategies aim to reduce or impede the growth of the primary tumor, no treatment to eradicate metastatic cancer exists at present. Metastasis is mediated by feet-like cytoskeletal structures called invadopodia which allow cells to penetrate through the basement membrane and intravasate into blood vessels during their spread to distant tissues and organs. The non-receptor tyrosine kinase Pyk2 is highly expressed in breast cancer, where it mediates invadopodia formation and function via interaction with the actin-nucleation-promoting factor cortactin. Here, we designed a cell-permeable peptide inhibitor that contains the second proline-rich region (PRR2) sequence of Pyk2, which binds to the SH3 domain of cortactin and inhibits the interaction between Pyk2 and cortactin in invadopodia. The Pyk2-PRR2 peptide blocks spontaneous lung metastasis in immune-competent mice by inhibiting cortactin tyrosine phosphorylation and actin polymerization-mediated maturation and activation of invadopodia, leading to reduced MMP-dependent tumor cell invasiveness. The native structure of the Pyk2-PRR2:cortactin-SH3 complex was determined using nuclear magnetic resonance (NMR), revealing an extended class II interaction surface spanning the canonical binding groove and a second hydrophobic surface which significantly contributes to ligand affinity. Using structure-guided design, we created a mutant peptide lacking critical residues involved in binding that failed to inhibit invadopodia maturation and function and consequent metastatic dissemination in mice. Our findings shed light on the specific molecular interactions between Pyk2 and cortactin and may lead to the development of novel strategies for preventing dissemination of primary breast tumors predicted at the time of diagnosis to be highly metastatic, and of secondary tumors that have already spread to other parts of the body.	[Twafra, Shams; Sneh, Tal; Srikanth, Kolluru D.; Meirson, Tomer; Genna, Alessandro; Gil-Henn, Hava] Bar Ilan Univ, Azrieli Fac Med, Cell Migrat & Invas Lab, IL-1311502 Safed, Israel; [Sokolik, Chana G.; Chill, Jordan H.] Bar Ilan Univ, Dept Chem, BioNMR Lab, IL-52900 Ramat Gan, Israel	Bar Ilan University; Bar Ilan University	Gil-Henn, H (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Cell Migrat & Invas Lab, IL-1311502 Safed, Israel.; Chill, JH (corresponding author), Bar Ilan Univ, Dept Chem, BioNMR Lab, IL-52900 Ramat Gan, Israel.	Jordan.Chill@biu.ac.il; Hava.Henn@biu.ac.il			Israel Cancer Research Fund [20-101-PG]; Israel Cancer Association [20210071]; Israel Science Foundation [964/19]	Israel Cancer Research Fund; Israel Cancer Association; Israel Science Foundation(Israel Science Foundation)	This paper is dedicated to the memory of Mr. Abd Elhaleem Abu Salah, who sadly passed away before completion of this work. We wish to thank Dr. Avraham Samson, Dr. Moshe Dessau, and Ms. Trishna Saha for technical assistance and advice, Mr. Jonathan Solomon and Ms. Michal Gendler for critical reading of the manuscript, and Ms. Natalia Saleev and Ms. Michal Gendler for technical assistance during revisions. This work was funded by the Israel Cancer Research Fund (grant number 20-101-PG), the Israel Cancer Association (grant number 20210071) and the Israel Science Foundation (grant number 2142/21) (to HG-H), and the Israel Science Foundation (grant number 964/19) (to JC).	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Genna A, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1449584; Genna A, 2018, J CELL BIOL, V217, P375, DOI 10.1083/jcb.201702184; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hashimoto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023359; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Hou P, 2003, HUM MOL GENET, V12, P1981, DOI 10.1093/hmg/ddg209; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim JM, 2008, J MOL BIOL, V377, P889, DOI 10.1016/j.jmb.2008.01.063; Kurochkina Natalya, 2013, Biophys Rev, V5, P29, DOI 10.1007/s12551-012-0081-z; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lipinski CA, 2010, EXPERT OPIN THER TAR, V14, P95, DOI 10.1517/14728220903473194; Liu WZ, 2012, ACTA CRYSTALLOGR F, V68, P154, DOI 10.1107/S1744309111056132; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Mayer BJ, 2001, J CELL SCI, V114, P1253; Meirson T, 2020, BIOINFORMATICS, V36, P154, DOI 10.1093/bioinformatics/btz527; Meirson Tomer, 2018, Oncotarget, V9, P22158, DOI 10.18632/oncotarget.25243; MONSKY WL, 1994, CANCER RES, V54, P5702; Morken JP, 1998, J AM CHEM SOC, V120, P30, DOI 10.1021/ja972729m; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Saksela K, 2012, FEBS LETT, V586, P2609, DOI 10.1016/j.febslet.2012.04.042; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sinha S, 2016, J CELL BIOL, V214, P197, DOI 10.1083/jcb.201601025; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stylli SS, 2008, J CLIN NEUROSCI, V15, P725, DOI 10.1016/j.jocn.2008.03.003; Sutoh M, 2010, ONCOL RES, V19, P85, DOI 10.3727/096504010X12875107808008; Teyra J, 2017, STRUCTURE, V25, P1598, DOI 10.1016/j.str.2017.07.017; Tomar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044041; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Yamamoto H, 2011, J UROLOGY, V185, P1930, DOI 10.1016/j.juro.2010.12.027; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zondlo NJ, 2013, ACCOUNTS CHEM RES, V46, P1039, DOI 10.1021/ar300087y	56	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02481-w	http://dx.doi.org/10.1038/s41388-022-02481-w		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5K2WQ	36258022	Green Submitted			2022-12-17	WOS:000869591700001
J	Zhang, XD; Hu, FY; Zhu, BW; Jiao, XL; Li, Y; Wu, S; Ren, GL; Li, JZ; Xie, QP; Pan, YF; Li, HY; Zhao, LL				Zhang, Xiaodong; Hu, Fangyu; Zhu, Baiwang; Jiao, Xueli; Li, Yun; Wu, Shuang; Ren, Ganglin; Li, Jizhen; Xie, Qipeng; Pan, Yifei; Li, Hongyan; Zhao, Lingling			Downregulation of TEX11 promotes S-Phase progression and proliferation in colorectal cancer cells through the FOXO3a/COP1/c-Jun/p21 axis	ONCOGENE			English	Article							C-JUN; TRANSCRIPTIONAL REGULATION; CYCLE; GENE; AZOOSPERMIA	Colorectal cancer (CRC) is the most common digestive tract malignancy, attributing to approximately 9.4% of global cancer-related deaths. However, the pathogenesis of CRC is poorly understood. The testis-expressed 11 (TEX11) gene is located on the X chromosome and is required for spermatogenesis, and is reported might serve as a biomarker for early onset CRC according to database analysis. However, the role played by TEX11 in cancer progression remains to be investigated. In this study, we show that TEX11 expression is significantly downregulated in CRC cell lines and clinical CRC tissue samples, and TEX11 expression correlates with poor prognosis in CRC patients. We further demonstrate that TEX11 can significantly inhibit the proliferative capacity of CRC cells in vitro and in vivo. Mechanistically, we demonstrate that TEX11 promotes transcription of COP1 by upregulating FOXO3a expression. This enhanced COP1 expression subsequently accelerates the degradation of the negative transcriptional regulator c-Jun, which, in turn, enhances p21 transcription inhibiting CRC cell cycle progression and proliferation. Overall, our findings suggest that TEX11 may be a valuable therapeutic target for the treatment of CRC.	[Zhang, Xiaodong; Zhu, Baiwang; Pan, Yifei] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325035, Zhejiang, Peoples R China; [Hu, Fangyu; Jiao, Xueli; Li, Yun; Wu, Shuang; Ren, Ganglin; Li, Hongyan; Zhao, Lingling] Wenzhou Med Univ, Sch Lab Med & Life Sci, Zhejiang Prov Key Lab Med Genet, Key Lab Lab Med,Minist Educ, Wenzhou 325035, Zhejiang, Peoples R China; [Li, Jizhen; Xie, Qipeng] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325027, Zhejiang, Peoples R China; [Li, Jizhen; Xie, Qipeng] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Pan, YF (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325035, Zhejiang, Peoples R China.; Li, HY; Zhao, LL (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Zhejiang Prov Key Lab Med Genet, Key Lab Lab Med,Minist Educ, Wenzhou 325035, Zhejiang, Peoples R China.	13506641535@139.com; hylee666@163.com; zhaolingling@wmu.edu.cn			Key Project of Science and Technology Innovation Team of Zhejiang Province [2013TD10]; Key Discipline of Zhejiang Province in Medical Technology; Wenzhou Science & Technology Bureau [Y20180857]; Wenzhou Medical University [89219018]	Key Project of Science and Technology Innovation Team of Zhejiang Province; Key Discipline of Zhejiang Province in Medical Technology; Wenzhou Science & Technology Bureau; Wenzhou Medical University	Bioinformatics results described here are based on data from the TCGA research network (http://cancergenome.nih.gov/).We thank all participants, specimen donors, and research groups who participated in the creation of the TCGA CRC cancer dataset. This work was partially supported by the Key Project of Science and Technology Innovation Team of Zhejiang Province (2013TD10), Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A), Wenzhou Science & Technology Bureau (Y20180857), and Wenzhou Medical University (89219018).	Akgul O, 2014, WORLD J GASTROENTERO, V20, P6113, DOI 10.3748/wjg.v20.i20.6113; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; Boeding JRE, 2018, INT J COLORECTAL DIS, V33, P1393, DOI 10.1007/s00384-018-3132-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chacko L, 2015, DIGEST DIS SCI, V60, P698, DOI 10.1007/s10620-014-3452-4; Chen FJ, 2022, NEOPLASIA, V24, P22, DOI 10.1016/j.neo.2021.11.014; Cheng JM, 2015, J BIOL REG HOMEOS AG, V29, P85; Csizmok V, 2018, STRUCTURE, V26, P28, DOI 10.1016/j.str.2017.11.003; Dapper AL, 2019, EVOLUTION, V73, P2368, DOI 10.1111/evo.13850; de Moraes GN, 2016, CURR DRUG TARGETS, V17, P164, DOI 10.2174/1389450115666141122211549; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fasano C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091110; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Gao BX, 2006, J BIOL CHEM, V281, P29711, DOI 10.1074/jbc.M604596200; Garcia R, 2008, Z NATURFORSCH C, V63, P17; Gausman V, 2020, CLIN GASTROENTEROL H, V18, P2752, DOI 10.1016/j.cgh.2019.10.009; Guiraldelli MF, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007381; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; Hume S, 2020, NUCLEIC ACIDS RES, V48, P12483, DOI 10.1093/nar/gkaa1002; Jin HL, 2018, MOL THER-NUCL ACIDS, V11, P312, DOI 10.1016/j.omtn.2018.03.003; Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008; Koo JH, 2010, J GASTROEN HEPATOL, V25, P33, DOI 10.1111/j.1440-1746.2009.05992.x; Li HY, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.602; Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3; Lukashev AN, 2016, BIOCHEMISTRY-MOSCOW+, V81, P700, DOI 10.1134/S0006297916070063; Luo TC, 2013, MOL BIOL REP, V40, P6561, DOI 10.1007/s11033-013-2694-0; Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; Nho Richard Seonghun, 2014, World J Biol Chem, V5, P346, DOI 10.4331/wjbc.v5.i3.346; Ray AL, 2020, BRIT J CANCER, V123, P624, DOI 10.1038/s41416-020-0913-8; Shamloo B, 2019, CANCERS, V11, DOI 10.3390/cancers11081178; Song YZ, 2020, SEMIN CANCER BIOL, V67, P43, DOI 10.1016/j.semcancer.2020.02.001; Tuttelmann F, 2018, MED GENET-BERLIN, V30, P12, DOI 10.1007/s11825-018-0181-7; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wang Feng, 2015, Intrinsically Disord Proteins, V3, pe1056906, DOI 10.1080/21690707.2015.1056906; Wang Y, 2019, ADV EXP MED BIOL, V1206, P527, DOI 10.1007/978-981-15-0602-4_25; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Watanabe M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13122502; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yang F, 2015, EMBO MOL MED, V7, P1198, DOI 10.15252/emmm.201404967; Yatsenko AN, 2015, NEW ENGL J MED, V372, P2097, DOI 10.1056/NEJMoa1406192; Zhang YQ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30342-3; Zheng K, 2010, J ANDROL, V31, P79, DOI 10.2164/jandrol.109.008193	45	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5133	5145		10.1038/s41388-022-02490-9	http://dx.doi.org/10.1038/s41388-022-02490-9		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36258021				2022-12-17	WOS:000869591700002
J	Bernard, D; Martinez-Leal, JF; Rizzo, S; Martinez, D; Hudson, D; Visakorpi, T; Peters, G; Carnero, A; Beach, D; Gil, J				Bernard, David; Martinez-Leal, Juan F.; Rizzo, Sian; Martinez, Dolores; Hudson, David; Visakorpi, Tapio; Peters, Gordon; Carnero, Amancio; Beach, David; Gil, Jesus			RETRACTION: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus (Retraction of Vol 24, Pg 5543, 2005)	ONCOGENE			English	Retraction												jesus.gil@cancer.org.uk						Bernard D, 2003, J CLIN INVEST, V112, P1724	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4980	4980		10.1038/s41388-022-02502-8	http://dx.doi.org/10.1038/s41388-022-02502-8		OCT 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36253447	Bronze			2022-12-17	WOS:000868969900003
J	Hong, SB; Xie, YB; Cheng, Z; Li, J; He, WM; Guo, ZM; Zhang, Q; Peng, S; He, MH; Yu, S; Xu, LX; Liu, RY; Xu, TY; Zhang, YJ; Li, YB; Wang, JG; Lv, WM; Yu, J; Xiao, HP				Hong, Shubin; Xie, Yubin; Cheng, Zhen; Li, Jie; He, Weiman; Guo, Zhuming; Zhang, Quan; Peng, Sui; He, Minghui; Yu, Shuang; Xu, Lixia; Liu, Rengyun; Xu, Tianyi; Zhang, Yunjian; Li, Yanbing; Wang, Jiguang; Lv, Weiming; Yu, Jun; Xiao, Haipeng			Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability	ONCOGENE			English	Article							NODE-METASTASIS; BRAF MUTATION; CANCER; ASSOCIATION; EXPRESSION; IDENTIFICATION; MANAGEMENT; PATHWAY	Papillary thyroid carcinoma (PTC) is heterogeneous and its molecular characteristics remain elusive. We integrated transcriptomic sequencing, genomic analysis and clinicopathologic information from 582 tissue samples of 216 PTC and 75 benign thyroid nodule (BTN) patients. We discovered four subtypes of PTC including Immune-enriched Subtype, BRAF-enriched Subtype, Stromal Subtype and CNV-enriched Subtype. Molecular subtypes were validated in an external cohort of 497 PTC cases from the TCGA. Tumors in the Immune-enriched Subtype showed higher immune infiltration and overexpression of immune checkpoints, whilst BRAF-enriched Subtype showed a higher tendency for extrathyroidal extension and more advanced TNM stage. Key oncogenes including LRRK2, SLC34A2, MUC1, FOXQ1 and KRT19 were overexpressed and enriched in oncogenic MAPK and PI3K/AKT signaling pathways in BRAF-enriched subtype. Further analysis of BRAF-enriched Subtype identified three subclasses with different degrees of malignancies. We also uncovered the molecular link of the initiation and progression from BTN to subtypes of PTC using trajectory analysis. Moreover, a 20-gene expression signature was generated for differential diagnosis of PTC from BTN patients. Together, our work identified previously unreported molecular subtypes of PTC, offering opportunities to stratify patients into optimal treatment plans based on molecular subtyping.	[Hong, Shubin; Cheng, Zhen; He, Weiman; Yu, Shuang; Xu, Tianyi; Li, Yanbing; Xiao, Haipeng] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Xie, Yubin; Peng, Sui; Liu, Rengyun; Yu, Jun] Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou, Peoples R China; [Li, Jie; Zhang, Yunjian; Lv, Weiming] Sun Yat Sen Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 1, Guangzhou, Peoples R China; [Guo, Zhuming; Zhang, Quan] Sun Yat Sen Univ, Dept Head & Neck Surg, Canc Ctr, Guangzhou, Peoples R China; [Peng, Sui; He, Minghui] Sun Yat Sen Univ, Clin Trials Unit, Affiliated Hosp 1, Guangzhou, Peoples R China; [Xu, Lixia] Sun Yat Sen Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Div Life Sci, Dept Chem & Biol Engn, State Key Lab Mol Neurosci, Hong Kong, Peoples R China; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Xiao, HP (corresponding author), Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Yu, J (corresponding author), Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Lv, WM (corresponding author), Sun Yat Sen Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 1, Guangzhou, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.	lvwm@mail.sysu.edu.cn; junyu@cuhk.edu.hk; xiaohp@mail.sysu.edu.cn	Liu, Rengyun/O-4039-2018; zhang, yunjian/T-2564-2019	Liu, Rengyun/0000-0002-1408-2372; zhang, yunjian/0000-0001-8457-8421; Li, Jie/0000-0003-1232-3248	National Natural Science Foundation of China [81772850, 82072956]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Yingtong Hou and Xuejie Wang for help with the sample collection. We thank Huanjing Hu for assistance with bioinformatics analysis, and thank Yijia Sun and Jiawei Ge for help with the fluorescent multiplexed immunohistochemistry (mIHC) and functional studies. This work was supported by the grants from National Natural Science Foundation of China (grant number 81772850 to H.X. and 82072956 to S.H.).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Alexander EK, 2022, LANCET DIABETES ENDO, V10, P533, DOI 10.1016/S2213-8587(22)00101-2; Altmann A, 2010, BIOINFORMATICS, V26, P1340, DOI 10.1093/bioinformatics/btq134; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147; Brown RL, 2011, J CANCER, V2, P193, DOI 10.7150/jca.2.193; Caronia LM, 2011, CLIN CANCER RES, V17, P7511, DOI 10.1158/1078-0432.CCR-11-1155; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Chmielik E, 2018, PATHOBIOLOGY, V85, P117, DOI 10.1159/000486422; Durante C, 2015, JAMA-J AM MED ASSOC, V313, P926, DOI 10.1001/jama.2015.0956; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607; Fagin JA, 2016, NEW ENGL J MED, V375, P1054, DOI 10.1056/NEJMra1501993; Ferrari SM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184413; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Han YL, 2021, J CANCER, V12, P1779, DOI 10.7150/jca.51551; Harmanci AS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13779-x; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; He J, 2020, ONCOGENE, V39, P2658, DOI 10.1038/s41388-020-1181-z; Howlader N, 2019, SEER CANC STAT REV 1; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Kimura ET, 2003, CANCER RES, V63, P1454; Liang JL, 2018, J PATHOL, V244, P215, DOI 10.1002/path.5005; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Noureldine SI, 2015, CURR OPIN ONCOL, V27, P21, DOI 10.1097/CCO.0000000000000150; Oler G, 2008, CLIN CANCER RES, V14, P4735, DOI 10.1158/1078-0432.CCR-07-4372; Pei XB, 2014, IEEE T CYBERNETICS, V44, P1821, DOI 10.1109/TCYB.2013.2296117; Pu WL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26343-3; Renaud F, 2014, THYROID, V24, P1375, DOI 10.1089/thy.2013.0594; Salem A, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188499; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shin JH, 2016, IMMUNE NETW, V16, P134, DOI 10.4110/in.2016.16.2.134; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Song YS, 2019, ENDOCR-RELAT CANCER, V26, P629, DOI 10.1530/ERC-17-0562; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Tuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102; Wang XH, 2019, ONCOL LETT, V18, P927, DOI 10.3892/ol.2019.10360; Xing MZ, 2013, JAMA-J AM MED ASSOC, V309, P1493, DOI 10.1001/jama.2013.3190; Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987; Ye L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15533; Yoo SK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10680-5; Zeng QW, 2021, CANCER BIOMARK, V30, P105, DOI 10.3233/CBM-200006; Zhang JW, 2020, DNA CELL BIOL, V39, P1545, DOI 10.1089/dna.2020.5596; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900	46	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5121	5132		10.1038/s41388-022-02499-0	http://dx.doi.org/10.1038/s41388-022-02499-0		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36253446	Green Published, hybrid			2022-12-17	WOS:000868969900001
J	Wang, XY; Liu, Y; Han, AN; Tang, CX; Xu, R; Feng, LY; Yang, Y; Chen, LY; Lin, ZH				Wang, Xinyue; Liu, Ying; Han, Anna; Tang, Chunxiao; Xu, Ran; Feng, Linyuan; Yang, Yang; Chen, Liyan; Lin, Zhenhua			The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; LIPID-METABOLISM; NQO1; CELLS	Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide, and its abnormal metabolism affects the survival and prognosis of patients. Recent studies have found that NAD(P)H quinone oxidoreductase-1 (NQO1) played an important role in tumor metabolism and malignant progression. However, the molecular mechanisms by which NQO1 regulates lipid metabolism during HCC progression remain unclear. In this study, bioinformatics analysis and immunohistochemical results showed that NQO1 was highly expressed in HCC tissues and its high expression was closely related to the poor prognosis of HCC patients. Overexpression of NQO1 promoted the cell proliferation, epithelial-to-mesenchymal transition (EMT) process, and angiogenesis of HCC cells. Luciferase reporter assay further revealed that NQO1/p53 could induce the transcriptional activity of SREBP1, consequently regulating HCC progression through lipid anabolism. In addition, Snail protein was stabilized by NQO1/p53/SREBP1 axis and triggered the EMT process, and participated in the regulatory role of NQO1/p53/SREBP1 axis in HCC. Together, these data indicated that NQO1/SREBP1 axis promoted the progression and metastasis of HCC, and might be a potential therapeutic target for HCC.	[Wang, Xinyue; Liu, Ying; Han, Anna; Tang, Chunxiao; Xu, Ran; Feng, Linyuan; Yang, Yang; Chen, Liyan; Lin, Zhenhua] Yanbian Univ, Key Lab Pathobiol, State Ethn Affairs Commiss, Yanji 133000, Peoples R China; [Wang, Xinyue; Feng, Linyuan; Yang, Yang; Lin, Zhenhua] Yanbian Univ, Affiliated Hosp, Cent Lab, Yanji 133000, Peoples R China	Yanbian University; Yanbian University	Lin, ZH (corresponding author), Yanbian Univ, Key Lab Pathobiol, State Ethn Affairs Commiss, Yanji 133000, Peoples R China.; Lin, ZH (corresponding author), Yanbian Univ, Affiliated Hosp, Cent Lab, Yanji 133000, Peoples R China.	zhlin720@ybu.edu.cn		Wang, Xinyue/0000-0002-8634-9590	Projects of Science and Technology Department of Jilin Province [210101207, 202002021JC]; National Natural Science Foundation of China [31760313]; Fund of Tumen River Scholar Project	Projects of Science and Technology Department of Jilin Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fund of Tumen River Scholar Project	This research was supported by the Projects of Science and Technology Department of Jilin Province (No.210101207, No.202002021JC), the National Natural Science Foundation of China (No.31760313), the Fund of Tumen River Scholar Project.	Patino-Morales CC, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101320; Cheng CM, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0301-4; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Deng ZQ, 2020, AUTOPHAGY, V16, P917, DOI 10.1080/15548627.2019.1644076; Dimri M, 2020, HEPATOLOGY, V71, P549, DOI 10.1002/hep.30818; Duan FF, 2018, J HEPATOL, V68, P1191, DOI 10.1016/j.jhep.2018.02.003; Fagerholm R, 2008, NAT GENET, V40, P844, DOI 10.1038/ng.155; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Han JB, 2015, NATURE, V524, P243, DOI 10.1038/nature14557; Karlsson MC, 2017, MOL ONCOL, V11, P781, DOI 10.1002/1878-0261.12092; Katikireddy KR, 2018, FREE RADICAL BIO MED, V116, P19, DOI 10.1016/j.freeradbiomed.2017.12.036; Kim J, 2019, CANCER CELL, V35, P191, DOI 10.1016/j.ccell.2018.12.012; Kumar DP, 2019, HEPATOLOGY, V69, P1520, DOI 10.1002/hep.30346; Lajin B, 2013, BRIT J CANCER, V109, P1325, DOI 10.1038/bjc.2013.357; Lewis AM, 2017, MOL CARCINOGEN, V56, P1825, DOI 10.1002/mc.20199; Lin LJ, 2017, HUM PATHOL, V69, P31, DOI 10.1016/j.humpath.2017.09.002; Liu J, 2019, J MOL CELL BIOL, V11, P284, DOI 10.1093/jmcb/mjy070; Liu J, 2020, HEPATOLOGY, V71, P1262, DOI 10.1002/hep.30917; Llovet JM, 2021, NAT REV GASTRO HEPAT, V18, P293, DOI 10.1038/s41575-020-00395-0; Long MT, 2022, GASTROENTEROLOGY; Luo SL, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9146528; Lyu JF, 2018, INT J BIOL SCI, V14, P1175, DOI 10.7150/ijbs.26011; Ma Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-414; Maan M, 2018, BIOCHEM BIOPH RES CO, V504, P582, DOI 10.1016/j.bbrc.2018.02.097; Oh ET, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13593; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pasquier J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02244-9; Piscaglia F, 2016, HEPATOLOGY, V63, P827, DOI 10.1002/hep.28368; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Santos PM, 2019, CANCER IMMUNOL RES, V7, P1001, DOI 10.1158/2326-6066.CIR-18-0513; Satriano L, 2019, NAT REV GASTRO HEPAT, V16, P748, DOI 10.1038/s41575-019-0217-8; Shimokawa M, 2020, CANCER SCI, V111, P1228, DOI 10.1111/cas.14320; Singal AG, 2020, J HEPATOL, V72, P250, DOI 10.1016/j.jhep.2019.08.025; Wang CC, 2018, HEPATOLOGY, V68, P1833, DOI 10.1002/hep.30030; Wang RQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2252-3; Wang XY, 2020, CANCER SCI, V111, P4061, DOI 10.1111/cas.14562; Wu XS, 2018, J MED CHEM, V61, P11280, DOI 10.1021/acs.jmedchem.8b01424; Xing R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.783236; Xu DQ, 2020, NATURE, V580, P530, DOI 10.1038/s41586-020-2183-2; Yang Y, 2019, CANCER LETT, V453, P170, DOI 10.1016/j.canlet.2019.03.054; Yang Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-14; Yin F, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.49; Zhang KJ, 2018, J MED CHEM, V61, P6983, DOI [10.1021/acsjmedchem.8b00124, 10.1021/acs.jmedchem.8b00124]; Zhang N, 2019, CELL DEATH DIFFER, V26, P843, DOI 10.1038/s41418-018-0158-8; Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5; Zhao WX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.747282	47	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5107	5120		10.1038/s41388-022-02477-6	http://dx.doi.org/10.1038/s41388-022-02477-6		OCT 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36253445				2022-12-17	WOS:000868969900002
J	Peng, X; Na, RS; Zhou, WT; Meng, XL; Yang, YH; Amini, S; Song, LW				Peng, Xiao; Na, Risi; Zhou, Wenting; Meng, Xiaole; Yang, Yunhai; Amini, Shohreh; Song, Liwei			Nuclear translocation of Gasdermin D sensitizes colorectal cancer to chemotherapy in a pyroptosis-independent manner	ONCOGENE			English	Article							KI-67 LABELING INDEX; OLAPARIB MONOTHERAPY; TARGETED THERAPY; GASTRIC-CANCER; OVARIAN-CANCER; CELL-SURVIVAL; DNA; HETEROGENEITY; COMBINATION; EXPRESSION	Gasdermin D (GSDMD) has recently been identified as a cytoplasmic effector protein that plays a central role in pyroptosis of immune cells. However, GSDMD is a universally expressed protein, and its function beyond pyroptosis, especially in cancer cells, has not been well characterized. Here, we report that predominant localization of GSDMD in the nucleoplasm in vivo indicates favorable clinical outcomes in colorectal cancer, while a lack of nuclear localization of GSDMD is associated with poor outcomes. Nuclear GSDMD, rather than cytoplasmic GSDMD, inhibits cell growth and promotes apoptosis in colorectal cancer. Hypoxia in the tumor microenvironment accounts for mild or moderate nuclear translocation of GSDMD in vivo. Under the stimulation of chemotherapy drugs, nuclear GSDMD promotes apoptosis via regulation of its subcellular distribution rather than pyroptosis-related cleavage. After nuclear translocation, GSDMD interacts with PARP-1 to dramatically inhibit its DNA damage repair-related function by functioning like the PARP inhibitor olaparib, thus forming a "hypoxia/chemotherapy-GSDMD nuclear translocation-PARP-1 blockade-DNA damage and apoptosis" axis. This study redefines the pyroptosis-independent function of GSDMD and suggests that the subcellular localization of GSDMD may serve as a molecular indicator of clinical outcomes and a promising therapeutic target in colorectal cancer.	[Peng, Xiao; Amini, Shohreh] Temple Univ, Dept Biol, BioLife Bldg,1900 North 12th St, Philadelphia, PA 19122 USA; [Na, Risi; Zhou, Wenting; Meng, Xiaole] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Gen Surg, 2000 Xiangan East Rd, Xiamen 361102, Peoples R China; [Yang, Yunhai; Song, Liwei] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Oncol Surg, Sch Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Xiamen University; Shanghai Jiao Tong University	Amini, S (corresponding author), Temple Univ, Dept Biol, BioLife Bldg,1900 North 12th St, Philadelphia, PA 19122 USA.; Yang, YH; Song, LW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Oncol Surg, Sch Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.	yangyunhai_oncobio@shchest.org; shohreh.amini@temple.edu; songliwei_chest@shchest.org		XL, Meng/0000-0002-6388-9084	National Natural Science Foundation of China [NSFC82002427, NSFC 30801132]; Shanghai Chest Hospital Outstanding Talent Cultivation Project [2018YNZYB03]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Chest Hospital Outstanding Talent Cultivation Project	We thank Professor Feng Shao (National Institute of Biological Science) for the kind gift of the PCS2-Flag-tagged GSDMD plasmid. This project was supported by the National Natural Science Foundation of China (NSFC82002427, NSFC 30801132) and the Shanghai Chest Hospital Outstanding Talent Cultivation Project (2018YNZYB03).	Basourakos SP, 2017, CURR MED CHEM, V24, P1586, DOI 10.2174/0929867323666161214114948; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Cagatay T, 2018, CURR OPIN CELL BIOL, V52, P30, DOI 10.1016/j.ceb.2018.01.006; Cheng SB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2162-4; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Gao JW, 2018, ONCOL REP, V40, P1971, DOI 10.3892/or.2018.6634; Gutting T, 2019, SEMIN CANCER BIOL, V55, P78, DOI 10.1016/j.semcancer.2018.04.003; Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Jakobsen JN, 2013, LUNG CANCER, V79, P1, DOI 10.1016/j.lungcan.2012.10.008; Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001; Jia H, 2017, ONCOGENE, V36, P2655, DOI 10.1038/onc.2016.418; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Karmakar M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16043-9; Kather JN, 2018, SEMIN CANCER BIOL, V52, P189, DOI 10.1016/j.semcancer.2018.02.010; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Khanova E, 2018, HEPATOLOGY, V67, P1737, DOI 10.1002/hep.29645; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Kim HJ, 2017, NEURON, V96, P285, DOI 10.1016/j.neuron.2017.07.029; Komiyama H, 2010, GENES GENET SYST, V85, P75, DOI 10.1266/ggs.85.75; Kumareswaran R, 2012, J CELL SCI, V125, P189, DOI 10.1242/jcs.092262; Lane RJ, 2018, FUTURE ONCOL, V14, P647, DOI 10.2217/fon-2017-0546; Langelier MF, 2013, CURR OPIN STRUC BIOL, V23, P134, DOI 10.1016/j.sbi.2013.01.003; Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Martin JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a027094; Mathew C, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01171; Matulonis UA, 2016, ANN ONCOL, V27, P1013, DOI 10.1093/annonc/mdw133; McKenzie BA, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01902-5; Pascal JM, 2018, DNA REPAIR, V71, P177, DOI 10.1016/j.dnarep.2018.08.022; Peddareddigari VG, 2010, CANCER MICROENVIRON, V3, P149, DOI 10.1007/s12307-010-0038-3; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Pyo JS, 2016, INT J BIOL MARKER, V31, pE204, DOI 10.5301/jbm.5000183; Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128; Rothkamm K, 2015, ENVIRON MOL MUTAGEN, V56, P491, DOI 10.1002/em.21944; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Saeki N, 2007, ONCOGENE, V26, P6488, DOI 10.1038/sj.onc.1210475; Saeki N, 2009, GENE CHROMOSOME CANC, V48, P261, DOI 10.1002/gcc.20636; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; SMITH AE, 1985, PROC R SOC SER B-BIO, V226, P43, DOI 10.1098/rspb.1985.0078; Wang WJ, 2018, J DIGEST DIS, V19, P74, DOI 10.1111/1751-2980.12576; Wang YJ, 2019, DNA REPAIR, V81, DOI 10.1016/j.dnarep.2019.102651; Wang YB, 2018, BIOCHEM BIOPH RES CO, V495, P1418, DOI 10.1016/j.bbrc.2017.11.156; Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393; Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098; Xu B, 2018, J HEPATOL, V68, P773, DOI 10.1016/j.jhep.2017.11.040; Xu KW, 2015, ONCOTARGETS THER, V8, P3047, DOI 10.2147/OTT.S89154; Zhai ZH, 2017, SEMIN CELL DEV BIOL, V64, P107, DOI 10.1016/j.semcdb.2016.08.033; Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9; Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548	55	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5092	5106		10.1038/s41388-022-02503-7	http://dx.doi.org/10.1038/s41388-022-02503-7		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36245058	Bronze			2022-12-17	WOS:000868470400001
J	Yousefi, H; Khosla, M; Lauterboeck, L; Okpechi, SC; Worthylake, D; Garai, J; Zabaleta, J; Guidry, J; Zarandi, MA; Wyczechowska, D; Jayawickramarajah, J; Yang, QL; Kissil, J; Alahari, SK				Yousefi, Hassan; Khosla, Maninder; Lauterboeck, Lothar; Okpechi, Samuel C.; Worthylake, David; Garai, Jone; Zabaleta, Jovanny; Guidry, Jessie; Zarandi, Mohammad Amin; Wyczechowska, Dorota; Jayawickramarajah, Janarthanan; Yang, Qinglin; Kissil, Joseph; Alahari, Suresh K.			A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; CELL-PROLIFERATION; CARCINOMA INVASION; STEM-CELLS; MECHANISMS; EXPRESSION; METASTASIS; RESISTANCE; PROTEIN	Treatment of patients with triple-negative breast cancer (TNBC) has been challenging due to the absence of well-defined molecular targets and the highly invasive and proliferative nature of TNBC cells. Current treatments against TNBC have shown little promise due to high recurrence rate in patients. Consequently, there is a pressing need for novel and efficacious therapies against TNBC. Here, we report the discovery of a novel small molecule inhibitor (NSC33353) with potent anti-tumor activity against TNBC cells. The anti-proliferative effects of this small molecule inhibitor were determined using 2D and 3D cell proliferation assays. We found that NSC33353 significantly reduces the proliferation of TNBC cells in these assays. Using proteomics, next generation sequencing (NGS), and gene enrichment analysis, we investigated global regulatory pathways affected by this compound in TNBC cells. Proteomics data indicate a significant metabolic reprograming affecting both glycolytic enzymes and energy generation through oxidative phosphorylation. Subsequently, using metabolic (Seahorse) and enzymatic assays, we validated our proteomics and NGS analysis findings. Finally, we showed the inhibitory and anti-tumor effects of this small molecule in vitro and confirmed its inhibitory activity in vivo. Doxorubicin is one of the most effective agents in the treatment of TNBC and resistance to this drug has been a major problem. We show that the combination of NSC33353 and doxorubicin suppresses the growth of TNBC cells synergistically, suggesting that NSC33353 enhances TNBC sensitivity to doxorubicin. In summary, our data indicate that the small molecule inhibitor, NSC33353, exhibits anti-tumor activity in TNBC cells, and works in a synergistic fashion with a well-known chemotherapeutic agent.	[Yousefi, Hassan; Khosla, Maninder; Okpechi, Samuel C.; Worthylake, David; Alahari, Suresh K.] Louisiana State Univ, Hlth Sci Ctr LSUHSC, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Lauterboeck, Lothar; Yang, Qinglin] Louisiana State Univ, Hlth Sci Ctr LSUHSC, Sch Med, Dept Pharmacol & Expt Therapeut,Cardiovasc Ctr Ex, New Orleans, LA 70112 USA; [Garai, Jone; Zabaleta, Jovanny; Wyczechowska, Dorota] LSUHSC, Stanley S Scott Canc Ctr, New Orleans, LA USA; [Zabaleta, Jovanny] LSUHSC, Dept Interdisciplinary Oncol, New Orleans, LA USA; [Guidry, Jessie] Louisiana State Univ, Hlth Sci Ctr LSUHSC, Prote Core Facil, New Orleans, LA USA; [Zarandi, Mohammad Amin; Jayawickramarajah, Janarthanan] Tulane Univ, Dept Chem, New Orleans, LA 70118 USA; [Kissil, Joseph] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA	Louisiana State University System; Louisiana State University System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Tulane University; H Lee Moffitt Cancer Center & Research Institute	Alahari, SK (corresponding author), Louisiana State Univ, Hlth Sci Ctr LSUHSC, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu			LSUHSC School of Medicine, Fred G. Brazda foundation; NIH [P20CA202922, P20GM121288-01, P30GM114732]	LSUHSC School of Medicine, Fred G. Brazda foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work is supported by funds from LSUHSC School of Medicine, Fred G. Brazda foundation, and from NIH grants P20CA202922, P20GM121288-01, P30GM114732 to JZ.	Adams S, 2019, JAMA ONCOL, V5, P334, DOI 10.1001/jamaoncol.2018.5152; Alvarez-Fernandez M, 2020, CANCER CELL, V37, P514, DOI 10.1016/j.ccell.2020.03.010; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Androic I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-391; Andrzejewski S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00372; Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006; Arumugam A, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-018-0197-8; Avagliano A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050401; Avanzato D, 2018, CANCER RES, V78, P3432, DOI 10.1158/0008-5472.CAN-17-3018; Barrett-Lee PJ, 2009, ANN ONCOL, V20, P816, DOI 10.1093/annonc/mdn728; Bianchini G, 2022, NAT REV CLIN ONCOL, V19, P91, DOI 10.1038/s41571-021-00565-2; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Christowitz C, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5939-z; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Clark AS, 2016, JAMA ONCOL, V2, P253, DOI 10.1001/jamaoncol.2015.4701; Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035; Coradini D, 2015, BREAST, V24, P294, DOI 10.1016/j.breast.2015.01.007; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Ferrari-Amorotti G, 2014, NEOPLASIA, V16, P1047, DOI 10.1016/j.neo.2014.10.006; Flygare JA, 2012, J MED CHEM, V55, P4101, DOI 10.1021/jm300060k; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; GILLETT C, 1994, CANCER RES, V54, P1812; Goodwin CM, 2015, CELL DEATH DIFFER, V22, P2098, DOI 10.1038/cdd.2015.73; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guestini F, 2019, BREAST CANCER RES TR, V173, P275, DOI 10.1007/s10549-018-4985-6; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hajra KM, 2002, CANCER RES, V62, P1613; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; He JC, 2019, BREAST CANCER RES TR, V178, P263, DOI 10.1007/s10549-019-05380-z; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HENNIG G, 1995, ONCOGENE, V11, P475; Huang XJ, 2016, BREAST, V30, P39, DOI 10.1016/j.breast.2016.08.014; Hussein YR, 2011, TRANSL ONCOL, V4, P321, DOI 10.1593/tlo.11256; Ji MJ, 2011, DIAGN PATHOL, V6, DOI [10.1186/1746-1596-6-48, 10.1186/1746-1596-6-49]; Jin XJ, 2019, J CELL PHYSIOL, V234, P6624, DOI 10.1002/jcp.27403; Karihtala P, 2013, BREAST CANCER RES TR, V138, P81, DOI 10.1007/s10549-013-2442-0; Keung MY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040940; Kim JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep31804; Kim J, 2019, CELL METAB, V30, P434, DOI 10.1016/j.cmet.2019.08.013; Kim S, 2013, TUMOR BIOL, V34, P1699, DOI 10.1007/s13277-013-0707-1; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kota S, 2018, ONCOGENE, V37, P4372, DOI 10.1038/s41388-018-0257-5; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Lev S, 2020, BIOCHEM SOC T, V48, P657, DOI 10.1042/BST20191055; Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lopez J, 2015, BRIT J CANCER, V112, P957, DOI 10.1038/bjc.2015.85; Lunetti P, 2019, FEBS J, V286, P688, DOI 10.1111/febs.14756; Ma F, 2014, CANCER LETT, V353, P153, DOI 10.1016/j.canlet.2014.06.022; Marinello PC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42357-w; Marra A, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-00197-2; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Masson N, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-3; Momeny M, 2018, INT J BIOCHEM CELL B, V99, P1, DOI 10.1016/j.biocel.2018.03.015; Moriai R, 2009, BREAST CANCER RES TR, V117, P261, DOI 10.1007/s10549-008-0164-5; O'Neill S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39789-9; Oh S, 2017, BMB REP, V50, P132, DOI 10.5483/BMBRep.2017.50.3.189; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Paredes J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01498; Pascale CL, 2020, J CEREBR BLOOD F MET, V40, P1077, DOI 10.1177/0271678X19858888; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x; Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325; Reznik E, 2018, CELL SYST, V6, P301, DOI 10.1016/j.cels.2017.12.014; Ribatti D, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100773; Rugo HS, 2019, ANN ONCOL, V30, P858; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sher I, 2009, INT J CANCER, V124, P553, DOI 10.1002/ijc.23963; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; Span PN, 2004, CLIN CHEM, V50, P1986, DOI 10.1373/clinchem.2004.039149; Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058; Stover DG, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0060-z; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sun XY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00428; Syn NL, 2017, LANCET ONCOL, V18, pE731, DOI 10.1016/S1470-2045(17)30607-1; Tadesse S, 2019, J MED CHEM, V62, P4233, DOI 10.1021/acs.jmedchem.8b01469; Tajbakhsh A, 2019, CRIT REV ONCOL HEMAT, V140, P17, DOI 10.1016/j.critrevonc.2019.05.009; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tolaney SM, 2021, CLIN CANCER RES, V27, P3061, DOI 10.1158/1078-0432.CCR-20-4726; Urra FA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31367-9; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang Liang, 2016, Front Pharmacol, V7, P249, DOI 10.3389/fphar.2016.00249; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Won KA, 2020, INT J ONCOL, V57, P1245, DOI 10.3892/ijo.2020.5135; Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Yamada A, 2013, BREAST CANCER RES TR, V137, P773, DOI 10.1007/s10549-012-2398-5; Yin L, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01296-5; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zhao H, 2018, ONCOL REP, V40, P3223, DOI 10.3892/or.2018.6716; Zhou M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-33	125	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5076	5091		10.1038/s41388-022-02497-2	http://dx.doi.org/10.1038/s41388-022-02497-2		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36243802	Bronze			2022-12-17	WOS:000869205700001
J	Dunn, S; Eberlein, C; Yu, J; Gris-Oliver, A; Ong, SH; Yelland, U; Cureton, N; Staniszewska, A; McEwen, R; Fox, M; Pilling, J; Hopcroft, P; Coker, EA; Jaaks, P; Garnett, MJ; Isherwood, B; Serra, V; Davies, BR; Barry, ST; Lynch, JT; Yusa, K				Dunn, Shanade; Eberlein, Cath; Yu, Jason; Gris-Oliver, Albert; Ong, Swee Hoe; Yelland, Urs; Cureton, Natalie; Staniszewska, Anna; McEwen, Robert; Fox, Millie; Pilling, James; Hopcroft, Philip; Coker, Elizabeth A.; Jaaks, Patricia; Garnett, Mathew J.; Isherwood, Beverley; Serra, Violeta; Davies, Barry R.; Barry, Simon T.; Lynch, James T.; Yusa, Kosuke			AKT-mTORC1 reactivation is the dominant resistance driver for PI3K beta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors	ONCOGENE			English	Article							AKT INHIBITOR; TUMORS; PI3K-ALPHA; COMBINATION; DISCOVERY; PATHWAY; MTORC1; CAPIVASERTIB; MULTICENTER; FULVESTRANT	The PI3K pathway is commonly activated in breast cancer, with PI3K-AKT pathway inhibitors used clinically. However, mechanisms that limit or enhance the therapeutic effects of PI3K-AKT inhibitors are poorly understood at a genome-wide level. Parallel CRISPR screens in 3 PTEN-null breast cancer cell lines identified genes mediating resistance to capivasertib (AKT inhibitor) and AZD8186 (PI3K beta inhibitor). The dominant mechanism causing resistance is reactivated PI3K-AKT-mTOR signalling, but not other canonical signalling pathways. Deletion of TSC1/2 conferred resistance to PI3K beta i and AKTi through mTORC1. However, deletion of PIK3R2 and INPPL1 drove specific PI3K beta i resistance through AKT. Conversely deletion of PIK3CA, ERBB2, ERBB3 increased PI3K beta i sensitivity while modulation of RRAGC, LAMTOR1, LAMTOR4 increased AKTi sensitivity. Significantly, we found that Mcl-1 loss enhanced response through rapid apoptosis induction with AKTi and PI3K beta i in both sensitive and drug resistant TSC1/2 null cells. The combination effect was BAK but not BAX dependent. The Mcl-1i + PI3K beta/AKTi combination was effective across a panel of breast cancer cell lines with PIK3CA and PTEN mutations, and delivered increased anti-tumor benefit in vivo. This study demonstrates that different resistance drivers to PI3K beta i and AKTi converge to reactivate PI3K-AKT or mTOR signalling and combined inhibition of Mcl-1 and PI3K-AKT has potential as a treatment strategy for PI3K beta i/AKTi sensitive and resistant breast tumours.	[Dunn, Shanade; Yu, Jason; Ong, Swee Hoe; Coker, Elizabeth A.; Jaaks, Patricia; Garnett, Mathew J.; Yusa, Kosuke] Wellcome Sanger Inst, Cambridge, England; [Dunn, Shanade; Staniszewska, Anna; McEwen, Robert; Fox, Millie; Davies, Barry R.; Barry, Simon T.; Lynch, James T.] AstraZeneca, Early Oncol, Biosci, Cambridge, England; [Eberlein, Cath; Yelland, Urs; Cureton, Natalie] AstraZeneca, Early Oncol, Biosci, Alderley Pk, England; [Gris-Oliver, Albert; Serra, Violeta] Vall dHebron Inst Oncol, Barcelona, Spain; [Pilling, James; Hopcroft, Philip; Isherwood, Beverley] AstraZeneca, Discovery Sci, Cambridge, England; [Yusa, Kosuke] Kyoto Univ, Inst Frontier Life & Med Sci, Kyoto, Japan; [Yu, Jason] Francis Crick Inst, Mol Biol Metab Lab, London, England	Wellcome Trust Sanger Institute; AstraZeneca; AstraZeneca; Vall d'Hebron Institut d'Oncologia (VHIO); AstraZeneca; Kyoto University; Francis Crick Institute	Yusa, K (corresponding author), Wellcome Sanger Inst, Cambridge, England.; Barry, ST (corresponding author), AstraZeneca, Early Oncol, Biosci, Cambridge, England.; Yusa, K (corresponding author), Kyoto Univ, Inst Frontier Life & Med Sci, Kyoto, Japan.	Simon.T.Barry@astrazeneca.com; k.yusa@infront.kyoto-u.ac.jp	Gris Oliver, Albert/AAL-6783-2021	Gris Oliver, Albert/0000-0003-1802-9541; Yu, Jason/0000-0001-5203-3603	Wellcome Trust [WT206194]; AstraZeneca	Wellcome Trust(Wellcome Trust); AstraZeneca(AstraZeneca)	This work was funded by the Wellcome Trust (WT206194) to KY and MJG and by AstraZeneca to KY, BRD, STB and JTL.	Balachander SB, 2020, CLIN CANCER RES, V26, P6535, DOI 10.1158/1078-0432.CCR-20-0863; Banerji U, 2018, CLIN CANCER RES, V24, P2050, DOI 10.1158/1078-0432.CCR-17-2260; Barlaam B, 2015, BIOORG MED CHEM LETT, V25, P5155, DOI 10.1016/j.bmcl.2015.10.002; Barlaam B, 2013, ACS MED CHEM LETT, V4, P742, DOI 10.1021/ml400146c; Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z; Cai YY, 2021, CANCER RES, V81, P2470, DOI 10.1158/0008-5472.CAN-20-3232; Cardoso F, 2020, ANN ONCOL, V31, P1623, DOI 10.1016/j.annonc.2020.09.010; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cortes I, 2012, P NATL ACAD SCI USA, V109, P11318, DOI 10.1073/pnas.1118138109; Cosentino K, 2022, MOL CELL, V82, P933, DOI 10.1016/j.molcel.2022.01.008; Costa C, 2020, CANCER DISCOV, V10, P72, DOI 10.1158/2159-8290.CD-18-0830; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Crafter C, 2015, INT J ONCOL, V47, P446, DOI 10.3892/ijo.2015.3062; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies BR, 2015, MOL CANCER THER, V14, P2441, DOI 10.1158/1535-7163.MCT-15-0230; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Fizazi K, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.TPS178; Gris-Oliver A, 2020, CLIN CANCER RES, V26, P3720, DOI 10.1158/1078-0432.CCR-19-3324; Guichard SM, 2015, MOL CANCER THER, V14, P2508, DOI 10.1158/1535-7163.MCT-15-0365; Hancox U, 2015, MOL CANCER THER, V14, P48, DOI 10.1158/1535-7163.MCT-14-0406; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jones RH, 2020, LANCET ONCOL, V21, P345, DOI 10.1016/S1470-2045(19)30817-4; Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948; Kale J, 2018, EMBO REP, V19, DOI 10.15252/embr.201745235; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Kingston Belinda, 2019, JCO Precis Oncol, V3, DOI 10.1200/PO.19.00130; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800; Lebok P, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1770-3; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Li M, 2018, CELL REP, V24, P489, DOI 10.1016/j.celrep.2018.06.027; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072; Lynch JT, 2018, MOL CANCER THER, V17, P2309, DOI 10.1158/1535-7163.MCT-18-0183; Millis SZ, 2016, JAMA ONCOL, V2, P1565, DOI 10.1001/jamaoncol.2016.0891; Millis SZ, 2015, CLIN BREAST CANCER, V15, P473, DOI 10.1016/j.clbc.2015.04.008; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Milton CK, 2020, MOL CANCER THER, V19, P1423, DOI 10.1158/1535-7163.MCT-19-1131; Mukherjee R, 2021, MOL CELL, V81, P708, DOI 10.1016/j.molcel.2021.01.033; Oliveira M, 2019, ANN ONCOL, V30, P1289, DOI 10.1093/annonc/mdz177; Pascual J, 2019, ANN ONCOL, V30, P1051, DOI 10.1093/annonc/mdz133; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Rahmani M, 2018, CANCER RES, V78, P3075, DOI 10.1158/0008-5472.CAN-17-3024; Rao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16061-7; Ros S, 2020, CANCER CELL, V38, P516, DOI 10.1016/j.ccell.2020.08.016; Schmid P, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.00368; Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008; Smyth LM, 2020, CLIN CANCER RES, V26, P3947, DOI 10.1158/1078-0432.CCR-19-3953; Sun L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0943-9; Tron AE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07551-w; Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079; Verret B, 2019, ANN ONCOL, V30, P12, DOI 10.1093/annonc/mdz381; Vis DJ, 2016, PHARMACOGENOMICS, V17, P691, DOI 10.2217/pgs.16.15; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111	61	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5046	5060		10.1038/s41388-022-02482-9	http://dx.doi.org/10.1038/s41388-022-02482-9		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36241868	Green Published, hybrid			2022-12-17	WOS:000873991500002
J	Tapmeier, TT; Howell, JH; Zhao, L; Papiez, BW; Schnabel, JA; Muschel, RJ; Gal, A				Tapmeier, Thomas T.; Howell, Jake H.; Zhao, Lei; Papiez, Bartlomiej W.; Schnabel, Julia A.; Muschel, Ruth J.; Gal, Annamaria			Evolving polarisation of infiltrating and alveolar macrophages in the lung during metastatic progression of melanoma suggests CCR1 as a therapeutic target	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; BREAST-CANCER; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; INTERNATIONAL UNION; PANCREATIC-CANCER; SERUM-LEVELS; CHEMOKINE; PROMOTES; SURVIVAL	Metastatic tumour progression is facilitated by tumour associated macrophages (TAMs) that enforce pro-tumour mechanisms and suppress immunity. In pulmonary metastases, it is unclear whether TAMs comprise tissue resident or infiltrating, recruited macrophages; and the different expression patterns of these TAMs are not well established. Using the mouse melanoma B16F10 model of experimental pulmonary metastasis, we show that infiltrating macrophages (IM) change their gene expression from an early pro-inflammatory to a later tumour promoting profile as the lesions grow. In contrast, resident alveolar macrophages (AM) maintain expression of crucial pro-inflammatory/anti-tumour genes with time. During metastatic growth, the pool of macrophages, which initially contains mainly alveolar macrophages, increasingly consists of infiltrating macrophages potentially facilitating metastasis progression. Blocking chemokine receptor mediated macrophage infiltration in the lung revealed a prominent role for CCR2 in Ly6C(+) pro-inflammatory monocyte/macrophage recruitment during metastasis progression, while inhibition of CCR2 signalling led to increased metastatic colony burden. CCR1 blockade, in contrast, suppressed late phase pro-tumour MR(+)Ly6C(-) monocyte/macrophage infiltration accompanied by expansion of the alveolar macrophage compartment and accumulation of NK cells, leading to reduced metastatic burden. These data indicate that IM has greater plasticity and higher phenotypic responsiveness to tumour challenge than AM. A considerable difference is also confirmed between CCR1 and CCR2 with regard to the recruited IM subsets, with CCR1 presenting a potential therapeutic target in pulmonary metastasis from melanoma.	[Tapmeier, Thomas T.; Muschel, Ruth J.; Gal, Annamaria] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Dept Oncol, Oxford OX3 7DQ, England; [Tapmeier, Thomas T.] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; [Tapmeier, Thomas T.] Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic 3168, Australia; [Howell, Jake H.; Gal, Annamaria] Univ Brighton, Sch Appl Sci, Brighton BN2 4GJ, E Sussex, England; [Zhao, Lei] Shandong First Med Univ, Shandong Canc Hosp & Inst, Shandong Canc Hosp, Jinan 250117, Peoples R China; [Papiez, Bartlomiej W.] Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford OX3 7LF, England; [Schnabel, Julia A.] Kings Coll London, Sch Biomed Imaging & Imaging Sci, London SE1 7EU, England; [Schnabel, Julia A.] Helmholtz Ctr Munich, German Ctr Environm Hlth, D-85764 Neuherberg, Germany; [Schnabel, Julia A.] Tech Univ Munich, Fac Informat, D-85748 Garching, Germany; [Schnabel, Julia A.] Tech Univ Munich, Inst Adv Study, D-85748 Garching, Germany	University of Oxford; Monash University; Hudson Institute of Medical Research; University of Brighton; Shandong First Medical University & Shandong Academy of Medical Sciences; University of London; King's College London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich	Tapmeier, TT; Gal, A (corresponding author), Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Dept Oncol, Oxford OX3 7DQ, England.; Tapmeier, TT (corresponding author), Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia.; Tapmeier, TT (corresponding author), Hudson Inst Med Res, Ritchie Ctr, Clayton, Vic 3168, Australia.; Gal, A (corresponding author), Univ Brighton, Sch Appl Sci, Brighton BN2 4GJ, E Sussex, England.	Thomas.Tapmeier@monash.edu; A.Gal@brighton.ac.uk		Gal, Annamaria/0000-0001-8171-1389	Cancer Research UK [C5255/A15935]; Medical Research Council [MC_PC_12004]; National Natural Science Fund of China [81272375]; School of Applied Sciences, University of Brighton	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); School of Applied Sciences, University of Brighton	We thank David M. Higgins for helping with the characterisation of macrophage compartments in the mouse lung and Sally A. Hill for providing the necessary platforms for animal experiments. We also thank Sabira Yameen for her help with immunohistochemistry. This work was funded by grants to RJM from Cancer Research UK (C5255/A15935) and the Medical Research Council (MC_PC_12004); LZ received support from the National Natural Science Fund of China (No. 81272375), and AG from the Output Enhancement Fund by the School of Applied Sciences, University of Brighton. Publications costs were supported by the Open Access Fund from the School of Applied Sciences, University of Brighton.	Amat M, 2006, BRIT J PHARMACOL, V149, P666, DOI 10.1038/sj.bjp.0706912; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Argyle D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02629; Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Bercovici N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01563; Biswas SK, 2013, SEMIN IMMUNOPATHOL, V35, P585, DOI 10.1007/s00281-013-0367-7; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Cai YH, 2014, J IMMUNOL, V192, P2821, DOI 10.4049/jimmunol.1302269; Chen HJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02887; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Cornforth AN, 2009, J CLIN IMMUNOL, V29, P657, DOI 10.1007/s10875-009-9299-3; Dairaghi DJ, 2012, BLOOD, V120, P1449, DOI 10.1182/blood-2011-10-384784; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Grossman JG, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1470729; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Higgins DM, 2008, J IMMUNOL, V180, P4892, DOI 10.4049/jimmunol.180.7.4892; Huang YK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11788-4; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jones KI, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809342; Kitagawa K, 2004, AM J PATHOL, V165, P237, DOI 10.1016/S0002-9440(10)63292-0; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kitamura T, 2010, P NATL ACAD SCI USA, V107, P13063, DOI 10.1073/pnas.1002372107; Kratofil RM, 2017, ARTERIOSCL THROM VAS, V37, P35, DOI 10.1161/ATVBAHA.116.308198; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Liegeois M, 2018, CELL IMMUNOL, V330, P91, DOI 10.1016/j.cellimm.2018.02.001; Lim SY, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23187; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin SS, 2012, CANCER SCI, V103, P904, DOI 10.1111/j.1349-7006.2012.02259.x; Liu YY, 2018, PEERJ, V6, DOI 10.7717/peerj.4928; Lucotti S, 2019, J CLIN INVEST, V129, P1845, DOI 10.1172/JCI121985; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Miao M, 2020, EXPERT OPIN DRUG MET, V16, P11, DOI 10.1080/17425255.2020.1711884; Mitsi E, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0777-0; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nosaka T, 2018, J IMMUNOL, V200, P1839, DOI 10.4049/jimmunol.1700544; Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4; Peiser L, 2000, INFECT IMMUN, V68, P1953, DOI 10.1128/IAI.68.4.1953-1963.2000; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Poeta VM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00379; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rosi S, 2005, NEUROSCIENCE, V134, P671, DOI 10.1016/j.neuroscience.2005.04.029; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sadeghi M, 2015, BRIT J CANCER, V113, P756, DOI 10.1038/bjc.2015.227; Samaniego R, 2014, J LEUKOCYTE BIOL, V95, P797, DOI 10.1189/jlb.0613345; Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525; Sasaki S, 2016, CANCER LETT, V378, P23, DOI 10.1016/j.canlet.2016.05.005; Sceneay J, 2012, CANCER RES, V72, P3906, DOI 10.1158/0008-5472.CAN-11-3873; Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC; Schyns J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5160794; Sharma SK, 2015, J IMMUNOL, V194, P5529, DOI 10.4049/jimmunol.1403215; Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857; Strachan DC, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26968; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Vela M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00012; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; Weide B, 2015, CANCER IMMUNOL IMMUN, V64, P1075, DOI 10.1007/s00262-015-1714-4; Yang M, 2018, CANCER RES, V78, P5492, DOI 10.1158/0008-5472.CAN-18-1367; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Yuan X, 2017, GYNECOL ONCOL, V147, P181, DOI 10.1016/j.ygyno.2017.07.007; Zaynagetdinov R, 2013, AM J RESP CELL MOL, V49, P180, DOI 10.1165/rcmb.2012-0366MA; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhao XX, 2017, ONCOTARGET, V8, P30576, DOI 10.18632/oncotarget.15736	76	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5032	5045		10.1038/s41388-022-02488-3	http://dx.doi.org/10.1038/s41388-022-02488-3		OCT 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36241867	hybrid, Green Published			2022-12-17	WOS:000873991500001
J	Blazquez, R; Chuang, HN; Wenske, B; Trigueros, L; Wlochowitz, D; Liguori, R; Ferrazzi, F; Regen, T; Proescholdt, MA; Rohde, V; Riemenschneider, MJ; Stadelmann, C; Bleckmann, A; Beissbarth, T; van Rossum, D; Hanisch, UK; Pukrop, T				Blazquez, Raquel; Chuang, Han-Ning; Wenske, Britta; Trigueros, Laura; Wlochowitz, Darius; Liguori, Renato; Ferrazzi, Fulvia; Regen, Tommy; Proescholdt, Martin A.; Rohde, Veit; Riemenschneider, Markus J.; Stadelmann, Christine; Bleckmann, Annalen; Beissbarth, Tim; van Rossum, Denise; Hanisch, Uwe K.; Pukrop, Tobias			Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain	ONCOGENE			English	Article							BREAST-CANCER; NITRIC-OXIDE; PROMOTES; RECEPTOR; METASTASIS; MICROENVIRONMENT; INTERFACE; TISSUE; GENE	Brain metastasis in breast cancer remains difficult to treat and its incidence is increasing. Therefore, the development of new therapies is of utmost clinical relevance. Recently, toll-like receptor (TLR) 4 was correlated with IL6 expression and poor prognosis in 1 215 breast cancer primaries. In contrast, we demonstrated that TLR4 stimulation reduces microglia-assisted breast cancer cell invasion. However, the expression, prognostic value, or therapeutic potential of TLR signaling in breast cancer brain metastasis have not been investigated. We thus tested the prognostic value of various TLRs in two brain-metastasis gene sets. Furthermore, we investigated different TLR agonists, as well as MyD88 and TRIF-deficient microenvironments in organotypic brain-slice ex vivo co-cultures and in vivo colonization experiments. These experiments underline the ambiguous roles of TLR4, its adapter MyD88, and the target nitric oxide (NO) during brain colonization. Moreover, analysis of the gene expression datasets of breast cancer brain metastasis patients revealed associations of TLR1 and IL6 with poor overall survival. Finally, our finding that a single LPS application at the onset of colonization shapes the later microglia/macrophage reaction at the macro-metastasis brain-parenchyma interface (MMPI) and reduces metastatic infiltration into the brain parenchyma may prove useful in immunotherapeutic considerations.	[Blazquez, Raquel; Trigueros, Laura; Pukrop, Tobias] Univ Hosp Regensburg, Dept Internal Med 3, Hematol & Med Oncol, D-93053 Regensburg, Germany; [Blazquez, Raquel; Chuang, Han-Ning; Wenske, Britta; Bleckmann, Annalen; Pukrop, Tobias] Univ Med Ctr Gottingen, Dept Hematol & Med Oncol, D-37075 Gottingen, Germany; [Wlochowitz, Darius; Beissbarth, Tim] Georg August Univ, Univ Med Ctr Gottingen, Inst Med Bioinformat, D-37075 Gottingen, Germany; [Liguori, Renato; Ferrazzi, Fulvia] Friedrich Alexander Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany; [Liguori, Renato; Ferrazzi, Fulvia] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephropathol, Inst Pathol, D-91054 Erlangen, Germany; [Regen, Tommy; Stadelmann, Christine; van Rossum, Denise; Hanisch, Uwe K.] Univ Med Ctr Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; [Regen, Tommy] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55131 Mainz, Germany; [Proescholdt, Martin A.] Univ Hosp Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany; [Rohde, Veit] Univ Med Ctr Gottingen, Dept Neurosurg, D-37075 Gottingen, Germany; [Riemenschneider, Markus J.] Univ Hosp Regensburg, Dept Neuropathol, D-93053 Regensburg, Germany; [Bleckmann, Annalen] Univ Hosp Munster, Dept Med Hematol Oncol & Pneumol A, D-48149 Munster, Germany; [van Rossum, Denise] Sartorius Canada Inc, Oakville, ON L6M 2V9, Canada; [Pukrop, Tobias] Fraunhofer Inst Toxicol & Expt Med, Div Personalized Tumor Therapy, D-93053 Regensburg, Germany	University of Regensburg; University of Gottingen; University of Gottingen; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Gottingen; Johannes Gutenberg University of Mainz; University of Regensburg; University of Gottingen; University of Regensburg; University of Munster; Fraunhofer Gesellschaft	Pukrop, T (corresponding author), Univ Hosp Regensburg, Dept Internal Med 3, Hematol & Med Oncol, D-93053 Regensburg, Germany.; Pukrop, T (corresponding author), Univ Med Ctr Gottingen, Dept Hematol & Med Oncol, D-37075 Gottingen, Germany.; Pukrop, T (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Div Personalized Tumor Therapy, D-93053 Regensburg, Germany.	tobias.pukrop@ukr.de		Liguori, Renato/0000-0002-5704-9409	Deutsche Forschungsgemeinschaft [DFG PU 355/4-1, FOR2127 (PU 355/5-1), SFB/TRR 305/1]; German Federal Ministry of Education and Research (BMBF) [0316173C, 031L0024]; DFG [INST 89/506-1 FUGG]; Projekt DEAL	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG)); Projekt DEAL	This work was supported by the Deutsche Forschungsgemeinschaft projects DFG PU 355/4-1, FOR2127 (PU 355/5-1) and SFB/TRR 305/1 (B03 and Z01); and the German Federal Ministry of Education and Research (BMBF) projects e:Bio MetastaSys on the platform Medical Systems (0316173C) and e:Med MyPathSem (031L0024). The FV3000 confocal microscope was also funded by a grant (INST 89/506-1 FUGG, 91b GG) from the DFG. Open Access funding enabled and organized by Projekt DEAL.	Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Bhatia S, 2019, CLIN CANCER RES, V25, P1185, DOI 10.1158/1078-0432.CCR-18-0469; Blazquez R, 2020, SEMIN CANCER BIOL, V60, P324, DOI 10.1016/j.semcancer.2019.10.012; Blazquez R, 2018, GLIA, V66, P2438, DOI 10.1002/glia.23485; Blazquez R, 2017, METHODS MOL BIOL, V1612, P213, DOI 10.1007/978-1-4939-7021-6_16; Cheng HW, 2014, CANCER LETT, V353, P1, DOI 10.1016/j.canlet.2014.07.014; Chuang HN, 2013, JOVE-J VIS EXP, DOI 10.3791/50881; Chuang HN, 2013, GLIA, V61, P1331, DOI 10.1002/glia.22518; COLEY WB, 1991, CLIN ORTHOP RELAT R, P3; Cosgrove N, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-27987-5; Drexler SK, 2010, INT J BIOCHEM CELL B, V42, P506, DOI 10.1016/j.biocel.2009.10.009; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Nunez NG, 2012, CANCER RES, V72, P592, DOI 10.1158/0008-5472.CAN-11-0534; Hajal C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg8139; Heinecke JL, 2014, P NATL ACAD SCI USA, V111, P6323, DOI 10.1073/pnas.1401799111; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hu F, 2015, NEURO-ONCOLOGY, V17, P200, DOI 10.1093/neuonc/nou324; Jang GY, 2020, EXP MOL MED, V52, P1926, DOI 10.1038/s12276-020-00540-4; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Kudo Y, 2019, ANN ONCOL, V30, P1521, DOI 10.1093/annonc/mdz207; Lechner M, 2005, SEMIN CANCER BIOL, V15, P277, DOI 10.1016/j.semcancer.2005.04.004; Lee CH, 2010, J IMMUNOTHER, V33, P73, DOI 10.1097/CJI.0b013e3181b7a0a4; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Li YPD, 2019, CANCER IMMUNOL IMMUN, V68, P1501, DOI 10.1007/s00262-019-02384-y; Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Pukrop T, 2010, GLIA, V58, P1477, DOI 10.1002/glia.21022; Regen T, 2011, BRAIN BEHAV IMMUN, V25, P957, DOI 10.1016/j.bbi.2010.10.009; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Rostami R, 2016, J NEURO-ONCOL, V127, P407, DOI 10.1007/s11060-016-2075-3; Sanmarco LM, 2021, J EXP MED, V218, DOI 10.1084/jem.20202715; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schulz M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101178; Shi SX, 2020, MOL MED REP, V21, P786, DOI 10.3892/mmr.2019.10853; Siam L, 2015, ONCOTARGET, V6, P29254, DOI 10.18632/oncotarget.4201; Somaiah N, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11006; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tehranian C, 2022, NEURO-ONCOLOGY, V24, P213, DOI 10.1093/neuonc/noab159; Tumurkhuu G, 2010, CELL IMMUNOL, V261, P122, DOI 10.1016/j.cellimm.2009.11.009; Weiss JM, 2010, J EXP MED, V207, P2455, DOI 10.1084/jem.20100670; Werner-Klein M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18701-4; Yu LX, 2010, HEPATOLOGY, V52, P1322, DOI 10.1002/hep.23845	45	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5008	5019		10.1038/s41388-022-02496-3	http://dx.doi.org/10.1038/s41388-022-02496-3		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36224342	hybrid, Green Published			2022-12-17	WOS:000866316700002
J	Huang, TT; Burkett, SS; Tandon, M; Yamamoto, TM; Gupta, N; Bitler, BG; Lee, JM; Nair, JR				Huang, Tzu-Ting; Burkett, Sandra Sczerba; Tandon, Mayank; Yamamoto, Tomomi M.; Gupta, Nitasha; Bitler, Benjamin G.; Lee, Jung-Min; Nair, Jayakumar R.			Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION EMT; MUTATIONS; PROTEIN; CELLS; DEGRADATION; RESECTION; PATHWAYS; DAMAGE; CHK1	Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a major advance in ovarian cancer, now as a treatment and as a maintenance therapy in the upfront and recurrent settings. However, patients often develop resistance to PARPis, underlining the importance of dissecting resistance mechanisms. Here, we report different dosing/timing schemes of PARPi treatment in BRCA2-mutant PEO1 cells, resulting in the simultaneous development of distinct resistance mechanisms. PARPi-resistant variants PEO1/OlaJR, established by higher initial doses and short-term PARPi treatment, develops PARPi resistance by rapidly restoring functional BRCA2 and promoting drug efflux activity. In contrast, PEO1/OlaR, developed by lower initial doses with long-term PARPi exposure, shows no regained BRCA2 function but a mesenchymal-like phenotype with greater invasion ability, and exhibits activated ATR/CHK1 and suppressed EZH2/MUS81 signaling cascades to regain HR repair and fork stabilization, respectively. Our study suggests that PARPi resistance mechanisms can be governed by treatment strategies and have a molecular basis on BRCA2 functionality. Further, we define different mechanisms that may serve as useful biomarkers to assess subsequent treatment strategies in PARPi-resistant ovarian cancer.	[Huang, Tzu-Ting; Gupta, Nitasha; Lee, Jung-Min; Nair, Jayakumar R.] NCI, Womens Malignancies Branch WMB, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA; [Burkett, Sandra Sczerba] NCI, Mol Cytogenet Core Facil, MCGP, CCR,NIH, Frederick, MD 20892 USA; [Tandon, Mayank] NCI, Ctr Canc Res Collaborat Bioinformat Resource, CCR, NIH, Bethesda, MD 20892 USA; [Yamamoto, Tomomi M.; Bitler, Benjamin G.] Univ Colorado, Dept OB GYN, Div Reprod Sci, Aurora, CO USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Colorado System; University of Colorado Anschutz Medical Campus	Lee, JM (corresponding author), NCI, Womens Malignancies Branch WMB, Ctr Canc Res CCR, NIH, Bethesda, MD 20892 USA.	leej6@mail.nih.gov		Gupta, Nitasha/0000-0003-4337-2368; Bitler, Benjamin/0000-0002-5809-5271; Burkett, Sandra/0000-0002-5476-4028	intramural research program of the CCR, NCI, NIH [ZIA BC011525]; NIH/NCI grant [R37CA261987-01]	intramural research program of the CCR, NCI, NIH; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was funded by the intramural research program of the CCR, NCI, NIH (ZIA BC011525 awarded to JL). This study was partly supported by an NIH/NCI grant (R37CA261987-01 awarded to BB).	Baribeau S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086987; Bhat KP, 2018, NAT STRUCT MOL BIOL, V25, P446, DOI 10.1038/s41594-018-0075-z; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Clairmont CS, 2020, NAT CELL BIOL, V22, P87, DOI 10.1038/s41556-019-0442-y; Clements KE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19961-w; Cong K, 2021, MOL CELL, V81, P3227, DOI 10.1016/j.molcel.2021.07.015; D'Andrea AD, 2018, DNA REPAIR, V71, P172, DOI 10.1016/j.dnarep.2018.08.021; Dias MP, 2021, NAT REV CLIN ONCOL, V18, P773, DOI 10.1038/s41571-021-00532-x; Do KT, 2021, CLIN CANCER RES, V27, P4710, DOI 10.1158/1078-0432.CCR-21-1279; Drean A, 2017, MOL CANCER THER, V16, P2022, DOI 10.1158/1535-7163.MCT-17-0098; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Gomez MK, 2020, CANCERS, V12, DOI 10.3390/cancers12061503; Gupta N, 2022, PHARMACOL RES, V178, DOI 10.1016/j.phrs.2022.106162; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hall T.A., 1999, NUCLC ACIDS S, V41, P95, DOI citeulike-article-id:691774; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Haynes B, 2018, CANCER TREAT REV, V71, P1, DOI 10.1016/j.ctrv.2018.09.003; Howlader N., 2021, SEER CANC STAT REV 1; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Jaspers JE, 2015, CANCER RES, V75, P732, DOI 10.1158/0008-5472.CAN-14-0839; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Kim H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17127-2; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kolinjivadi AM, 2017, MOL CELL, V67, P867, DOI 10.1016/j.molcel.2017.07.001; Kondrashova O, 2017, CANCER DISCOV, V7, P984, DOI 10.1158/2159-8290.CD-17-0419; Lee JM, 2014, ANN ONCOL, V25, P32, DOI 10.1093/annonc/mdt384; Lee JM, 2017, ONCOTARGET, V8, P95036, DOI 10.18632/oncotarget.20852; Lee JM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0604-z; Li H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01227-0; Lin KK, 2019, CANCER DISCOV, V9, P210, DOI 10.1158/2159-8290.CD-18-0715; McMullen M, 2020, CANCERS, V12, DOI 10.3390/cancers12061607; Mijic S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01164-5; Nair J, 2020, ONCOGENE, V39, P5520, DOI 10.1038/s41388-020-1383-4; Noordermeer SM, 2019, TRENDS CELL BIOL, V29, P820, DOI 10.1016/j.tcb.2019.07.008; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; Ordonez Liliana D, 2019, Oncotarget, V10, P2586, DOI 10.18632/oncotarget.26830; Peng J, 2011, PROTEINS, V79, P161, DOI 10.1002/prot.23175; Pettitt SJ, 2020, CANCER DISCOV, V10, P1475, DOI 10.1158/2159-8290.CD-19-1485; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rondinelli B, 2017, NAT CELL BIOL, V19, P1371, DOI 10.1038/ncb3626; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stewart CA, 2017, ONCOTARGET, V8, P28575, DOI 10.18632/oncotarget.15338; Taglialatela A, 2017, MOL CELL, V68, P414, DOI 10.1016/j.molcel.2017.09.036; Tew WP, 2020, J CLIN ONCOL, V38, P3468, DOI 10.1200/JCO.20.01924; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Watson ZL, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0758-2; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Yamamoto TM, 2019, MOL CARCINOGEN, V58, P1770, DOI 10.1002/mc.23064; Yang QY, 2017, P NATL ACAD SCI USA, V114, pE6054, DOI 10.1073/pnas.1700694114; Yazinski SA, 2017, GENE DEV, V31, P318, DOI 10.1101/gad.290957.116; Yuan SSF, 1999, CANCER RES, V59, P3547	56	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					5020	5031		10.1038/s41388-022-02491-8	http://dx.doi.org/10.1038/s41388-022-02491-8		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36224341				2022-12-17	WOS:000866316700001
J	Zimmerman, SM; Nixon, SJ; Chen, PY; Raj, L; Smith, SR; Paolini, RL; Lin, PN; Souroullas, GP				Zimmerman, Sarah M.; Nixon, Samantha J.; Chen, Pei Yu; Raj, Leela; Smith, Sofia R.; Paolini, Rachel L.; Lin, Phyo Nay; Souroullas, George P.			EZh2(Y641F) mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma	ONCOGENE			English	Article							CHROMATIN IMMUNOPRECIPITATION; TARGET GENES; EZH2; TRANSCRIPTION; EXPRESSION; GENOME; PLURIPOTENCY; METHYLATION; PROSTATE; ESBAF	Enhancer of Zeste Homolog 2 (EZH2) is the catalytic component of the Polycomb Repressive Complex 2, a chromatin modifying complex, which mediates methylation of lysine 27 on histone 3 (H3K27me3), a repressive chromatin mark. Genetic alterations in EZH2 in melanoma include amplifications and activating point mutations at tyrosine 641 (Y641) whose underlying oncogenic mechanisms remain largely unknown. Here, we found that expression of Ezh2(Y641F) causes upregulation of a subset of interferon-regulated genes in melanoma cells. Upregulation of these genes was not a direct effect of changes in H3K27me3, but via a non-canonical interaction between Ezh2 and Signal Transducer and Activator of Transcription 3 (Stat3). Ezh2 and Stat3 together function as transcriptional activators to mediate gene activation of numerous genes, including MHC Class 1b antigen processing genes. Furthermore, expression of Stat3 is required to maintain an anti-tumor immune response in Ezh2(Y641F) melanomas and to prevent melanoma progression and recurrence.	[Zimmerman, Sarah M.; Nixon, Samantha J.; Chen, Pei Yu; Raj, Leela; Smith, Sofia R.; Paolini, Rachel L.; Lin, Phyo Nay; Souroullas, George P.] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA; [Zimmerman, Sarah M.; Nixon, Samantha J.; Chen, Pei Yu; Raj, Leela; Smith, Sofia R.; Paolini, Rachel L.; Lin, Phyo Nay; Souroullas, George P.] Washington Univ, Sch Med, Div Oncol, Mol Oncol Sect, St Louis, MO 63110 USA; [Souroullas, George P.] Washington Univ, Sch Med, Siteman Comprehens Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Souroullas, GP (corresponding author), Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.; Souroullas, GP (corresponding author), Washington Univ, Sch Med, Div Oncol, Mol Oncol Sect, St Louis, MO 63110 USA.; Souroullas, GP (corresponding author), Washington Univ, Sch Med, Siteman Comprehens Canc Ctr, St Louis, MO 63110 USA.	george.souroullas@wustl.edu		Smith, Sofia/0000-0003-3454-6207; Zimmerman, Sarah/0000-0003-3923-3963; Souroullas, George P./0000-0003-2196-8662	US National Cancer Institute [K22-CA229612-01, T32 CA113275-10]; Cancer Research Foundation, Chicago IL, (GPS); Harry J. Lloyd Charitable Trust	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Foundation, Chicago IL, (GPS); Harry J. Lloyd Charitable Trust	This work was supported by the US National Cancer Institute K22-CA229612-01(GPS) and T32 CA113275-10 (SZ), the Cancer Research Foundation, Chicago IL, (GPS), The Harry J. Lloyd Charitable Trust (GPS).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Ballotti R, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01290-7; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Dasgupta M, 2015, P NATL ACAD SCI USA, V112, P3985, DOI 10.1073/pnas.1503152112; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Furlan-Magaril M, 2009, METHODS MOL BIOL, V543, P253, DOI 10.1007/978-1-60327-015-1_17; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Ho L, 2011, NAT CELL BIOL, V13, P903, DOI 10.1038/ncb2285; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kumar SM, 2014, ONCOGENE, V33, P832, DOI 10.1038/onc.2012.642; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Marine JC, 2020, NAT REV CANCER, V20, P743, DOI 10.1038/s41568-020-00302-4; McHugh JB, 2007, J CUTAN PATHOL, V34, P597, DOI 10.1111/j.1600-0560.2006.00678.x; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Schell TD, 2002, INT IMMUNOL, V14, P775, DOI 10.1093/intimm/dxf041; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Snyder M, 2008, J BIOL CHEM, V283, P3791, DOI 10.1074/jbc.M706976200; Souroullas GP, 2016, NAT MED, V22, P632, DOI 10.1038/nm.4092; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun W, 2006, FEBS LETT, V580, P5880, DOI 10.1016/j.febslet.2006.09.054; Tiffen J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12280; Tripathi SK, 2017, CELL REP, V19, P1888, DOI 10.1016/j.celrep.2017.05.013; Wang J, 2022, NAT CELL BIOL, V24, P384, DOI 10.1038/s41556-022-00850-x; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Zhang HK, 2016, CANCER DISCOV, V6, P1006, DOI 10.1158/2159-8290.CD-16-0164; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	46	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					4983	4993		10.1038/s41388-022-02492-7	http://dx.doi.org/10.1038/s41388-022-02492-7		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36220978				2022-12-17	WOS:000865904600001
J	Pelaz, SG; Tabernero, A				Pelaz, Sara G.; Tabernero, Arantxa			Src: coordinating metabolism in cancer	ONCOGENE			English	Review							ROUS-SARCOMA-VIRUS; DEPENDENT TYROSINE PHOSPHORYLATION; C-SRC; FAMILY KINASES; GLUCOSE-TRANSPORTER; GROWTH-FACTOR; OXIDATIVE-PHOSPHORYLATION; ONCOGENIC PROPERTIES; PHOSPHATASE-ACTIVITY; MEDIATED ACTIVATION	Metabolism must be tightly regulated to fulfil the dynamic requirements of cancer cells during proliferation, migration, stemness and differentiation. Src is a node of several signals involved in many of these biological processes, and it is also an important regulator of cell metabolism. Glucose uptake, glycolysis, the pentose-phosphate pathway and oxidative phosphorylation are among the metabolic pathways that can be regulated by Src. Therefore, this oncoprotein is in an excellent position to coordinate and finely tune cell metabolism to fuel the different cancer cell activities. Here, we provide an up-to-date summary of recent progress made in determining the role of Src in glucose metabolism as well as the link of this role with cancer cell metabolic plasticity and tumour progression. We also discuss the opportunities and challenges facing this field.	[Pelaz, Sara G.; Tabernero, Arantxa] Univ Salamanca, Inst Neurociencias Castilla & Leon INCYL, Dept Bioquim & Biol Mol, Inst Invest Biomed Salamanca IBSAL, Calle Pintor Fernando Gallego 1, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Tabernero, A (corresponding author), Univ Salamanca, Inst Neurociencias Castilla & Leon INCYL, Dept Bioquim & Biol Mol, Inst Invest Biomed Salamanca IBSAL, Calle Pintor Fernando Gallego 1, Salamanca 37007, Spain.	ataber@usal.es	G. Pelaz, Sara/AAO-3028-2020; Tabernero, Arantxa/K-5950-2014	G. Pelaz, Sara/0000-0001-6908-3172; Tabernero, Arantxa/0000-0001-6302-6134	FEDER [PID2021-128549OB-I00, RTI2018099873-B-I00, SA125P20]; Junta de Castilla y Leon; European Social Fund	FEDER(European Commission); Junta de Castilla y Leon(Junta de Castilla y Leon); European Social Fund(European Social Fund (ESF))	This study was funded by Spanish Ministerio de Ciencia e Innovacion, FEDER RTI2018099873-B-I00, FEDER PID2021-128549OB-I00 and Junta de Castilla y Leon, FEDER SA125P20. SGP was a fellowship recipient from the Junta de Castilla y Leon and the European Social Fund.	Alcala S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207437; Alessandro M, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101639; Almaguel FA, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.614726; Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Arachiche A, 2008, J BIOL CHEM, V283, P24406, DOI 10.1074/jbc.M709217200; Augereau O, 2005, CELL MOL LIFE SCI, V62, P1478, DOI 10.1007/s00018-005-5005-7; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BOSCA L, 1986, BIOCHEM J, V236, P595, DOI 10.1042/bj2360595; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burkhardt AL, 2001, CURR PROTOC IMMUNOL; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cardone L, 2004, MOL CELL BIOL, V24, P4613, DOI 10.1128/MCB.24.11.4613-4626.2004; Valle-Casuso JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032448; Carruthers A, 2009, AM J PHYSIOL-ENDOC M, V297, pE836, DOI 10.1152/ajpendo.00496.2009; Chatelain EH, 2011, CELL MOL LIFE SCI, V68, P2603, DOI 10.1007/s00018-010-0573-6; Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Chueh AC, 2021, ONCOGENE, V40, P3015, DOI 10.1038/s41388-021-01755-z; Ci SS, 2020, FASEB J, V34, P10443, DOI 10.1096/fj.201902904RR; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Colell A, 2009, CELL DEATH DIFFER, V16, P1573, DOI 10.1038/cdd.2009.137; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Cori CF, 1925, J BIOL CHEM, V64, P11; Cori CF., 1928, J CANC RES, V12, P301; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; DeLalio LJ, 2019, J BIOL CHEM, V294, P6940, DOI 10.1074/jbc.RA118.006982; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Djeungoue-Petga MA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2134-8; EIGENBRODT E, 1983, EMBO J, V2, P1565, DOI 10.1002/j.1460-2075.1983.tb01625.x; Eigenbrodt E, 1998, CELL GROWTH ONCOGENE, P15; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gangoso E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.560; GLOSSMANN H, 1981, MOL CELL ENDOCRINOL, V23, P49, DOI 10.1016/0303-7207(81)90116-7; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gonzalez-Sanchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454; Guedouari H, 2021, MITOCHONDRION, V57, P257, DOI 10.1016/j.mito.2020.12.012; Guedouari Hala, 2020, Cell Physiol Biochem, V54, P517, DOI 10.33594/000000237; Gupte RS, 2007, J CARD FAIL, V13, P497, DOI 10.1016/j.cardfail.2007.04.003; Gupte RS, 2009, FREE RADICAL BIO MED, V47, P219, DOI 10.1016/j.freeradbiomed.2009.01.028; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Hebert-Chatelain E, 2012, BBA-BIOENERGETICS, V1817, P718, DOI 10.1016/j.bbabio.2012.01.014; Heppner DE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06790-1; Higuchi M, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108876; Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042; Hua TNM, 2019, EBIOMEDICINE, V41, P134, DOI 10.1016/j.ebiom.2019.02.015; Hunter CA, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109651; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jain S, 2015, CANCER RES, V75, P4863, DOI 10.1158/0008-5472.CAN-14-2345; Jaraiz-Rodriguez M, 2020, NEURO-ONCOLOGY, V22, P493, DOI 10.1093/neuonc/noz243; Jaraiz-Rodriguez M, 2017, STEM CELL REP, V9, P451, DOI 10.1016/j.stemcr.2017.06.007; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6; Jin Y, 2016, ONCOTARGET, V7, P25113, DOI 10.18632/oncotarget.7159; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Kemble DJ, 2009, P NATL ACAD SCI USA, V106, P5070, DOI 10.1073/pnas.0806117106; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lee JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29142-x; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Li J, 2017, CANCER RES, V77, pE51, DOI 10.1158/0008-5472.CAN-17-0369; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Lin YC, 2012, NEOPLASIA, V14, P463, DOI 10.1596/neo.12300; Liu CJ, 2016, J BIOL CHEM, V291, P15540, DOI 10.1074/jbc.M115.712976; Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422; Liu RL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08921-8; Liu ST, 2014, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00416; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Luttrell DK, 2004, ONCOGENE, V23, P7969, DOI 10.1038/sj.onc.1208162; Ma HH, 2021, ONCOGENE, V40, P2567, DOI 10.1038/s41388-021-01673-0; Ma HH, 2020, CELL REP, V30, P4235, DOI 10.1016/j.celrep.2020.03.005; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Magaway C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121584; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; Martellucci S, 2020, CANCERS, V12, DOI 10.3390/cancers12061448; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MARTIN GS, 1971, P NATL ACAD SCI USA, V68, P2739, DOI 10.1073/pnas.68.11.2739; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Mayoral-Varo V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235850; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Muir A, 2018, SCIENCE, V360, P962, DOI 10.1126/science.aar5986; Ogura M, 2012, BIOCHEM J, V447, P281, DOI 10.1042/BJ20120509; OKADA M, 1991, J BIOL CHEM, V266, P24249; Okada M, 2012, INT J BIOL SCI, V8, P1385, DOI 10.7150/ijbs.5141; Pal R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06844-4; Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556-018-0176-2; Pan S, 2009, ARTERIOSCL THROM VAS, V29, P895, DOI 10.1161/ATVBAHA.109.184812; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pelaz SG, 2021, CANCERS, V13, DOI 10.3390/cancers13174262; Pelaz SG, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103134; Place AT, 2011, MOL PHARMACOL, V80, P665, DOI 10.1124/mol.111.073957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; PRESEK P, 1988, FEBS LETT, V242, P194, DOI 10.1016/0014-5793(88)81014-7; R Core Team, 2019, R LANG ENV STAT COMP; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Reynolds AB, 2014, ONCOGENE, V33, P4537, DOI 10.1038/onc.2013.416; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; SALTER DW, 1982, P NATL ACAD SCI-BIOL, V79, P1540, DOI 10.1073/pnas.79.5.1540; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Sato H, 2016, J DIABETES INVEST, V7, P171, DOI 10.1111/jdi.12407; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Shupnik MA, 2004, ONCOGENE, V23, P7979, DOI 10.1038/sj.onc.1208076; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Simpson IA, 2008, AM J PHYSIOL-ENDOC M, V295, pE242, DOI 10.1152/ajpendo.90388.2008; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Smolinski MP, 2018, J MED CHEM, V61, P4704, DOI 10.1021/acs.jmedchem.8b00164; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Song LT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19694-w; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Temps C, 2021, CANCER RES, V81, P5438, DOI 10.1158/0008-5472.CAN-21-0613; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thorens B, 2010, AM J PHYSIOL-ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009; Tian Q, 2020, ONCOGENE, V39, P3980, DOI 10.1038/s41388-020-1262-z; Tisdale EJ, 2007, TRAFFIC, V8, P733, DOI 10.1111/j.1600-0854.2007.00569.x; Valle S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18954-z; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WARBURG OTTO, 1926, KLIN WOCHENSCHR, V5, P829, DOI 10.1007/BF01726240; Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zang QS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043424; Zhang F, 2006, AM J PHYSIOL-CELL PH, V291, pC466, DOI 10.1152/ajpcell.00418.2005; Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhou ZF, 2018, CANCER RES, V78, P2248, DOI 10.1158/0008-5472.CAN-17-2726; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	147	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4917	4928		10.1038/s41388-022-02487-4	http://dx.doi.org/10.1038/s41388-022-02487-4		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36217026	Green Published, hybrid			2022-12-17	WOS:000865701400001
J	Guo, J; Lv, YY; Wang, S; Peng, ZY; Xie, Y; Wang, YX; Jiang, HM; Li, X; Wang, MQ; Hu, ML; Mu, JP; Wang, JY; Xie, YY; Cheng, XK; Zhao, ZG; Liu, ZQ				Guo, Jing; Lv, Yangyang; Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Hu, Meilin; Mu, Jiangpeng; Wang, Jingya; Xie, Yangyang; Cheng, Xiankui; Zhao, Zhigang; Liu, Zhiqiang			Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma	ONCOGENE			English	Article							BORTEZOMIB-RESISTANCE; RECEPTOR; DRUG; INVASION; SUMO	The bone marrow microenvironment in multiple myeloma (MM) is hypoxic and provides multi-advantages for the initiation of chemoresistance, but the underlying mechanisms and key regulators are still indistinct. In the current study, we found that hypoxia stimulus easily induced chemoresistance to proteasome inhibitors (PIs), and the steroid receptor coactivator 3 (SRC-3) expression was remarkably augmented at posttranslational level. Protein interactome analysis identified SENP1 as a key modifier of SRC-3 stability, as SENP1-mediated deSUMOylation attenuated the K11-linked polyubiquitination of SRC-3. SENP1 depletion in the SENP1(fl/fl)CD19(Cre/+) B cells showed impaired SRC3 stability, and knockdown of SENP1 in MM cells by CRISPR/cas9 sgRNA accelerated the degradation of SRC-3 and remarkably overcame the resistance to PIs. In the Vk*Myc and 5TGM1 mouse models as well as patient-derived xenograft (PDX) of myeloma, SENP1 inhibitor Momordin Iota c (Mc) increased the sensitivity to PIs in MM cells. Importantly, SENP1 level was positively correlated with SRC-3 level in the tissues from refractory/relapsed MM, as well as in xenograft tissues from mice treated with bortezomib and Mc. Taken together, our findings suggest that hypoxia-induced SENP1 is a crucial regulator of chemoresistance to PIs, and shed light on developing therapeutic strategies to overcome chemoresistance by using small molecules targeting SENP1 or SRC-3.	[Guo, Jing; Lv, Yangyang; Zhao, Zhigang; Liu, Zhiqiang] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Hematol,Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China; [Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Wang, Jingya; Xie, Yangyang; Liu, Zhiqiang] Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Wang, Jingya; Xie, Yangyang; Liu, Zhiqiang] Tianjin Med Univ, Tianjin Key Lab Cellular Homeostasis & Human Dis, Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Wang, Sheng; Peng, Ziyi; Xie, Ying; Wang, Yixuan; Jiang, Hongmei; Li, Xin; Wang, Mengqi; Wang, Jingya; Xie, Yangyang; Liu, Zhiqiang] Tianjin Med Univ, Dept Physiol & Pathophysiol, Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Hu, Meilin] Tianjin Med Univ, Tianjin Med Univ Sch Stomatol, Tianjin 300070, Peoples R China; [Mu, Jiangpeng] Tianjin Med Univ, Undergarduate Sch Basic Med Sci, Tianjin 300070, Peoples R China; [Cheng, Xiankui] Shandong Univ, Dept Pathol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China; [Zhao, Zhigang] Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Med Oncol, Tianjin 300192, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Nankai University	Zhao, ZG; Liu, ZQ (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Hematol,Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Sch Basic Med Sci, Tianjin 300070, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Tianjin Key Lab Cellular Homeostasis & Human Dis, Sch Basic Med Sci, Tianjin 300070, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Dept Physiol & Pathophysiol, Sch Basic Med Sci, Tianjin 300070, Peoples R China.; Zhao, ZG (corresponding author), Nankai Univ, Tianjin Cent Hosp 1, Sch Med, Dept Med Oncol, Tianjin 300192, Peoples R China.	zzhao01@tmu.edu.cn; zhigiangliu@tmu.edu.cn			Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital; Beijing Natural Science Foundation of China [Z200020]; National Natural Science Foundation of China [81870161, 82070221, 81900215, 81870150]; Tianjin Research Innovation Project for Postgraduate Students [2020YJSB162]; Tianjin Key Medical Discipline (Specialty) Construction Project [TJYXZDXK-009A]	Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital; Beijing Natural Science Foundation of China(Beijing Natural Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Research Innovation Project for Postgraduate Students; Tianjin Key Medical Discipline (Specialty) Construction Project	This work was supported by Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital. We thank Dr. Leif Bergsagel at the Mayo Clinic for kindly providing the Vk*Myc mouse spleen cells. This work was supported by the Beijing Natural Science Foundation of China (Z200020, ZQL), the National Natural Science Foundation of China (81870161, 82070221, ZQL; 81900215, JYW; 81870150, ZGZ), the Tianjin Research Innovation Project for Postgraduate Students (2020YJSB162, YX), and Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A).	Chang HM, 2020, PHYSIOL REV, V100, P1599, DOI 10.1152/physrev.00025.2019; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Chesi M, 2012, BLOOD, V120, P376, DOI 10.1182/blood-2012-02-412783; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; de Heer EC, 2020, J CLIN INVEST, V130, P5074, DOI 10.1172/JCI137552; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Hu JS, 2010, BLOOD, V116, P1524, DOI 10.1182/blood-2010-02-269126; Ikeda S, 2021, CANCER SCI, V112, P3995, DOI 10.1111/cas.15087; Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233; Kumar R, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201900185; Kunz K, 2018, J CELL SCI, V131, DOI 10.1242/jcs.211904; Lanz RB, 2010, MOL ENDOCRINOL, V24, P859, DOI 10.1210/me.2009-0499; Li LC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094760; Liu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21386-y; Lothrop AP, 2013, FEBS LETT, V587, P1247, DOI 10.1016/j.febslet.2013.01.047; Ma CC, 2014, TUMOR BIOL, V35, P12729, DOI 10.1007/s13277-014-2598-1; Mani DR, 2022, NAT REV CANCER, V22, P298, DOI 10.1038/s41568-022-00446-5; Martin SK, 2011, LEUKEMIA, V25, P1533, DOI 10.1038/leu.2011.122; Moser-Katz T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.625199; Mougenot P, 2006, ANTICANCER RES, V26, P2197; Murray MY, 2015, CELL CYCLE, V14, P2367, DOI 10.1080/15384101.2014.998067; PENNATHURDAS R, 1987, BLOOD, V69, P899; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Raninga PV, 2016, CELL CYCLE, V15, P559, DOI 10.1080/15384101.2015.1136038; Ria R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020613; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Sacks D, 2018, INT J STROKE, V13, P612, DOI [10.1016/j.jvir.2017.11.026, 10.1177/1747493018778713]; Scanlon SE, 2015, DNA REPAIR, V32, P180, DOI 10.1016/j.dnarep.2015.04.030; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; van de Donk NWCJ, 2021, LANCET, V397, P410, DOI 10.1016/S0140-6736(21)00135-5; Wang JJ, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI149526; Wirth M, 2020, CANCERS, V12, DOI 10.3390/cancers12123764; Wu HJ, 2006, J BIOL CHEM, V281, P21848, DOI 10.1074/jbc.M603772200; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu YY, 2021, ONCOGENE, V40, P1231, DOI 10.1038/s41388-020-01590-8; Yan XM, 2016, BIOTECHNOL APPL BIOC, V63, P435, DOI 10.1002/bab.1375; Yen CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113503; Yuen VWH, 2020, J CLIN INVEST, V130, P5052, DOI 10.1172/JCI137553	38	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4971	4979		10.1038/s41388-022-02494-5	http://dx.doi.org/10.1038/s41388-022-02494-5		OCT 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36209257	Green Submitted			2022-12-17	WOS:000865164100001
J	Sullivan, DK; Deutzmann, A; Yarbrough, J; Krishnan, MS; Gouw, AM; Bellovin, DI; Adam, SJ; Liefwalker, DF; Dhanasekaran, R; Felsher, DW				Sullivan, Delaney K.; Deutzmann, Anja; Yarbrough, Josiah; Krishnan, Maya S.; Gouw, Arvin M.; Bellovin, David, I; Adam, Stacey J.; Liefwalker, Daniel F.; Dhanasekaran, Renumathy; Felsher, Dean W.			MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; C-MYC; SWI/SNF COMPLEX; WEB SERVER; CANCER; INACTIVATION; CELLS; MOUSE; DIFFERENTIATION; ANGIOGENESIS	MYC is a transcription factor frequently overexpressed in cancer. To determine how MYC drives the neoplastic phenotype, we performed transcriptomic analysis using a panel of MYC-driven autochthonous transgenic mouse models. We found that MYC elicited gene expression changes mostly in a tissue- and lineage-specific manner across B-cell lymphoma, T-cell acute lymphoblastic lymphoma, hepatocellular carcinoma, renal cell carcinoma, and lung adenocarcinoma. However, despite these gene expression changes being mostly tissue-specific, we uncovered a convergence on a common pattern of upregulation of embryonic stem cell gene programs and downregulation of tissue-of-origin gene programs across MYC-driven cancers. These changes are representative of lineage dedifferentiation, that may be facilitated by epigenetic alterations that occur during tumorigenesis. Moreover, while several cellular processes are represented among embryonic stem cell genes, ribosome biogenesis is most specifically associated with MYC expression in human primary cancers. Altogether, MYC's capability to drive tumorigenesis in diverse tissue types appears to be related to its ability to both drive a core signature of embryonic genes that includes ribosomal biogenesis genes as well as promote tissue and lineage specific dedifferentiation.	[Sullivan, Delaney K.; Deutzmann, Anja; Yarbrough, Josiah; Krishnan, Maya S.; Gouw, Arvin M.; Bellovin, David, I; Adam, Stacey J.; Dhanasekaran, Renumathy; Felsher, Dean W.] Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA; [Sullivan, Delaney K.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Caltech Med Scientist Training Program, Los Angeles, CA 90095 USA; [Liefwalker, Daniel F.] Oregon Hlth & Sci Univ, Sch Med, Dept Mol & Med Genet, Portland, OR 97239 USA; [Dhanasekaran, Renumathy] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA	Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Oregon Health & Science University; Stanford University	Felsher, DW (corresponding author), Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA.	dfelsher@stanford.edu		felsher, dean/0000-0003-2496-523X; Yarbrough, Josiah/0000-0002-4521-0656; Deutzmann, Anja/0000-0002-3271-1427; Gouw, Arvin/0000-0002-9552-635X	National Institutes of Health (NIH) [R35 CA253180, R01 CA089305, R01 CA170378, U01 CA188383]; UCLA-Caltech Medical Scientist Training Program (NIH NIGMS) [T32 GM008042]; Lymphoma Research Foundation; NIH from the National Cancer Institute (NCI), American College of Gastroenterology Junior Faculty Career Development Grant [CA222676]; Stanford Cancer Translational Nanotechnology Training T32 Training Grant (NCI) [CA196585]; Tumor Biology Training Grant [NIH 5T32CA009151-38]; Stanford University (NCI); Burroughs Wellcome Fund Postdoctoral Enrichment Award; NCI [3U01CA188383-03S1, (K01) CA234453]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UCLA-Caltech Medical Scientist Training Program (NIH NIGMS); Lymphoma Research Foundation; NIH from the National Cancer Institute (NCI), American College of Gastroenterology Junior Faculty Career Development Grant; Stanford Cancer Translational Nanotechnology Training T32 Training Grant (NCI); Tumor Biology Training Grant; Stanford University (NCI); Burroughs Wellcome Fund Postdoctoral Enrichment Award(Burroughs Wellcome Fund); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by National Institutes of Health (NIH) grants: R35 CA253180, R01 CA089305, R01 CA170378, and U01 CA188383, with additional support as follows. DKS -UCLA-Caltech Medical Scientist Training Program (NIH NIGMS training grant T32 GM008042). AD -Lymphoma Research Foundation. RD -NIH grant CA222676 from the National Cancer Institute (NCI), American College of Gastroenterology Junior Faculty Career Development Grant. AMG -Stanford Cancer Translational Nanotechnology Training T32 Training Grant CA196585 (NCI). DFL Tumor Biology Training Grant (NIH 5T32CA009151-38), Stanford University (NCI), Burroughs Wellcome Fund Postdoctoral Enrichment Award, Research Supplement Award (NCI), 3U01CA188383-03S1, and (K01) CA234453 (NCI).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Brombin A, 2015, CURR OPIN GENET DEV, V34, P61, DOI 10.1016/j.gde.2015.07.006; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Ciribilli Y, 2017, ONCOTARGET, V8, P101808, DOI 10.18632/oncotarget.21981; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dhanasekaran R, 2021, NAT REV CLIN ONCOL, DOI 10.1038/s41571-021-00549-2; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Farrell AS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01967-6; Felsher Dean W, 2010, Genes Cancer, V1, P597, DOI 10.1177/1947601910377798; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Hartl M, 2010, P NATL ACAD SCI USA, V107, P4051, DOI 10.1073/pnas.0911060107; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jung M, 2017, CANCER RES, V77, P971, DOI 10.1158/0008-5472.CAN-15-2906; Khan A, 2016, NUCLEIC ACIDS RES, V44, pD164, DOI 10.1093/nar/gkv1002; Kieffer-Kwon KR, 2017, MOL CELL, V67, P566, DOI 10.1016/j.molcel.2017.07.013; Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709; Korotkevich G., 2021, 060012 BIORXIV, DOI [10.1101/060012, DOI 10.1101/060012]; Kress TR, 2016, CANCER RES, V76, P3463, DOI 10.1158/0008-5472.CAN-16-0316; Krishnan MS, 2021, HEPATOLOGY, V73, P2342, DOI 10.1002/hep.31614; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li Y, 2014, J INTERN MED, V276, P52, DOI 10.1111/joim.12237; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Muhar M, 2018, SCIENCE, V360, P800, DOI 10.1126/science.aao2793; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Perez-Riverol Y, 2022, NUCLEIC ACIDS RES, V50, pD543, DOI 10.1093/nar/gkab1038; Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Poole CJ, 2017, ONCOTARGET, V8, P76898, DOI 10.18632/oncotarget.20176; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sabo A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014191; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soshnikova NV, 2021, ONCOGENE, V40, P6071, DOI 10.1038/s41388-021-01994-0; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swaminathan S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16447-7; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tesi A, 2019, EMBO REP, V20, DOI 10.15252/embr.201947987; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; Turi Z, 2019, AGING-US, V11, P2512, DOI 10.18632/aging.101922; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Varlakhanova NV, 2010, DIFFERENTIATION, V80, P9, DOI 10.1016/j.diff.2010.05.001; Vivian J, 2017, NAT BIOTECHNOL, V35, P314, DOI 10.1038/nbt.3772; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Watanabe-Susaki K, 2014, STEM CELLS, V32, P3099, DOI 10.1002/stem.1825; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu CH, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000090; Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130; Yeh Elizabeth S, 2014, Cold Spring Harb Protoc, V2014, DOI 10.1101/pdb.top069823; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	82	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4960	4970		10.1038/s41388-022-02458-9	http://dx.doi.org/10.1038/s41388-022-02458-9		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36207533				2022-12-17	WOS:000864993400001
J	Wang, CX; Long, QL; Fu, Q; Xu, QX; Fu, D; Li, Y; Gao, LB; Guo, JM; Zhang, XL; Lam, EWF; Campisi, J; Sun, Y				Wang, Changxu; Long, Qilai; Fu, Qiang; Xu, Qixia; Fu, Da; Li, Yan; Gao, Libin; Guo, Jianming; Zhang, Xiaoling; Lam, Eric W-F; Campisi, Judith; Sun, Yu			Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance	ONCOGENE			English	Article							SENESCENCE; CANCER; PATHWAY; EGFR; AMPHIREGULIN; PANITUMUMAB; TRIAL	The tumor microenvironment (TME) represents a milieu enabling cancer cells to develop malignant properties, while concerted interactions between cancer and stromal cells frequently shape an "activated/reprogramed" niche to accelerate pathological progression. Here we report that a soluble factor epiregulin (EREG) is produced by senescent stromal cells, which non-cell-autonomously develop the senescence-associated secretory phenotype (SASP) upon DNA damage. Genotoxicity triggers EREG expression by engaging NF-kappa B and C/EBP, a process supported by elevated chromatin accessibility and increased histone acetylation. Stromal EREG reprograms the expression profile of recipient neoplastic cells in a paracrine manner, causing upregulation of MARCHF4, a membrane-bound E3 ubiquitin ligase involved in malignant progression, specifically drug resistance. A combinational strategy that empowers EREG-specific targeting in treatment-damaged TME significantly promotes cancer therapeutic efficacy in preclinical trials, achieving response indices superior to those of solely targeting cancer cells. In clinical oncology, EREG is expressed in tumor stroma and handily measurable in circulating blood of cancer patients post-chemotherapy. This study establishes EREG as both a targetable SASP factor and a new noninvasive biomarker of treatment-damaged TME, thus disclosing its substantial value in translational medicine. [GRAPHICS] .	[Wang, Changxu; Xu, Qixia; Li, Yan; Gao, Libin; Sun, Yu] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China; [Long, Qilai; Guo, Jianming] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai 200032, Peoples R China; [Fu, Qiang; Sun, Yu] Binzhou Med Univ, Inst Aging Med, Dept Pharmacol, Yantai 264003, Shandong, Peoples R China; [Fu, Da] Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab Med Res, Sch Med, Shanghai 200072, Peoples R China; [Zhang, Xiaoling] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Orthoped Surg, Sch Med, Shanghai 200092, Peoples R China; [Lam, Eric W-F] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Campisi, Judith] Buck Inst Res Aging, Novato, CA 94945 USA; [Campisi, Judith] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Sun, Yu] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Sun, Yu] Univ Washington, VAPSHCS, Seattle, WA 98195 USA	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Binzhou Medical University; Tongji University; Shanghai Jiao Tong University; Imperial College London; Buck Institute for Research on Aging; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sun, Y (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China.; Sun, Y (corresponding author), Binzhou Med Univ, Inst Aging Med, Dept Pharmacol, Yantai 264003, Shandong, Peoples R China.; Sun, Y (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Sun, Y (corresponding author), Univ Washington, VAPSHCS, Seattle, WA 98195 USA.	sunyu@sibs.ac.cn	fu, qiang/O-7262-2014	fu, qiang/0000-0002-6932-7103; Lam, Eric/0000-0003-1274-3576	National Key Research and Development Program of China [2020YFC2002800, 2016YFC1302400]; National Natural Science Foundation of China (NSFC) [81472709, 31671425, 31871380, 82130045]; Strategic Priority Research Program of Chinese Academy of Sciences [XDB39010500]; Anti-Aging Collaborative Program of SINH and BY-HEALTH [C01201911260006, C01202112160005]; Joint Fund Program of Natural Science Foundation of Shandong Province [ZR202108130049, ZR2021LSW021]; University and Locality Collaborative Development Program of Yantai [2019XDRHXMRC08, 2020XDRHXMXK02, 2021XDHZ082]; U.S. DoD PCRP [PC111703]; National Natural Science Foundation of China [81370730, 81571512]; Yantai Double Hundred Program	National Key Research and Development Program of China; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of Chinese Academy of Sciences(Chinese Academy of Sciences); Anti-Aging Collaborative Program of SINH and BY-HEALTH; Joint Fund Program of Natural Science Foundation of Shandong Province; University and Locality Collaborative Development Program of Yantai; U.S. DoD PCRP; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yantai Double Hundred Program	We are grateful to members of Sun laboratory for reagents, comments and other contributions to this project. We appreciate Ge Zhang for technical assistance of bioinformatics profiling of epigenetic datasets. The work was supported by grants from National Key Research and Development Program of China (2020YFC2002800, 2016YFC1302400), National Natural Science Foundation of China (NSFC) (81472709, 31671425, 31871380, 82130045) to YS, the Strategic Priority Research Program of Chinese Academy of Sciences (XDB39010500) to YS, Anti-Aging Collaborative Program of SINH and BY-HEALTH (C01201911260006 and C01202112160005) to YS, Joint Fund Program of Natural Science Foundation of Shandong Province (ZR202108130049 and ZR2021LSW021), the University and Locality Collaborative Development Program of Yantai (2019XDRHXMRC08 and 2020XDRHXMXK02) to YS, and the U.S. DoD PCRP (Idea Development Award PC111703) to YS; National Natural Science Foundation of China (81370730, 81571512), the University and Locality Collaborative Development Program of Yantai (2021XDHZ082) and Yantai Double Hundred Program to QF.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Apweiler R, 2010, NUCLEIC ACIDS RES, V38, pD142, DOI 10.1093/nar/gkp846; Babon JJ, 2019, BIOCHEM J, V476, P2869, DOI 10.1042/BCJ20190577; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Birch J, 2020, GENE DEV, V34, P1565, DOI 10.1101/gad.343129.120; Bruyere C, 2014, J INORG BIOCHEM, V141, P144, DOI 10.1016/j.jinorgbio.2014.08.015; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06860-4; Cho MC, 2008, BIOCHEM BIOPH RES CO, V377, P832, DOI 10.1016/j.bbrc.2008.10.053; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Costa VM, 2020, ARCH TOXICOL, V94, P4067, DOI 10.1007/s00204-020-02874-4; D'Alterio C, 2020, SEMIN CANCER BIOL, V60, P351, DOI 10.1016/j.semcancer.2019.08.019; Das T, 2021, DRUG RESIST UPDATE, V55, DOI 10.1016/j.drup.2021.100754; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z; Dueck AC, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2019.3332; El-Hashim AZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09349-0; Fedchenko N, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0221-9; Fitsiou E, 2022, SEMIN CANCER BIOL, V81, P5, DOI 10.1016/j.semcancer.2021.03.021; Flanagan KC, 2018, ONCOTARGET, V9, P21, DOI 10.18632/oncotarget.22940; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Gao L, 2018, PATHOL RES PRACT, V214, P732, DOI 10.1016/j.prp.2018.03.002; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; He MJ, 2019, ONCOGENE, V38, P5551, DOI 10.1038/s41388-019-0817-3; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Hollis A, 2012, CHEMBIOCHEM, V13, P302, DOI 10.1002/cbic.201100652; Job S, 2019, CANCERS, V11, DOI 10.3390/cancers11060795; Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kohsaka S, 2014, NEURO-ONCOLOGY, V16, P960, DOI 10.1093/neuonc/not315; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Li SQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.634097; Lim JJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9141343; Liu PY, 2021, NAT CELL BIOL, V23, P355, DOI 10.1038/s41556-021-00656-3; Liu SL, 2020, THERANOSTICS, V10, P10589, DOI 10.7150/thno.47176; Ma SQ, 2021, ONCOGENE, V40, P2596, DOI 10.1038/s41388-021-01734-4; Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237; Mancini M, 2018, EMBO MOL MED, V10, P294, DOI 10.15252/emmm.201708076; Neufert C, 2013, J CLIN INVEST, V123, P1428, DOI 10.1172/JCI63748; Parry AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04283-9; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Qu X, 2016, ONCOGENE, V35, P6403, DOI 10.1038/onc.2016.170; Qu YD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0992-4; Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005; Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Seligmann JF, 2020, ANN ONCOL, V31, P1021, DOI 10.1016/j.annonc.2020.04.476; Sen P, 2019, MOL CELL, V73, P684, DOI 10.1016/j.molcel.2019.01.021; Song SL, 2020, TRENDS BIOCHEM SCI, V45, P578, DOI 10.1016/j.tibs.2020.03.008; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strimpakos A, 2013, CLIN COLORECTAL CANC, V12, P267, DOI 10.1016/j.clcc.2013.07.001; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Torring N, 2005, PROSTATE, V64, P1, DOI 10.1002/pros.20214; Wang YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1277-x; Watanabe T, 2010, EUR J CANCER, V46, P2119, DOI 10.1016/j.ejca.2010.04.019; Westendorp F, 2021, ONCOGENE, V40, P1628, DOI 10.1038/s41388-020-01633-0; Wiley CD, 2017, AGING CELL, V16, P1043, DOI 10.1111/acel.12632; Williams CJM, 2021, CLIN CANCER RES, V27, P3422, DOI 10.1158/1078-0432.CCR-21-0120; Wilson KJ, 2009, PHARMACOL THERAPEUT, V122, P1, DOI 10.1016/j.pharmthera.2008.11.008; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xia QY, 2019, PATHOL RES PRACT, V215, P873, DOI 10.1016/j.prp.2019.01.030; Yang JL, 2014, CANCER CHEMOTH PHARM, V74, P637, DOI 10.1007/s00280-014-2523-8; Zhang BY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04010-4	72	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4941	4959		10.1038/s41388-022-02476-7	http://dx.doi.org/10.1038/s41388-022-02476-7		OCT 2022	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36202915	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000864553300001
J	Harrod, A; Lai, CF; Goldsbrough, I; Simmons, GM; Oppermans, N; Santos, DB; Gyorffy, B; Allsopp, RC; Toghill, BJ; Balachandran, K; Lawson, M; Morrow, CJ; Surakala, M; Carnevalli, LS; Zhang, P; Guttery, DS; Shaw, JA; Coombes, RC; Buluwela, L; Ali, S				Harrod, Alison; Lai, Chun-Fui; Goldsbrough, Isabella; Simmons, Georgia M.; Oppermans, Natasha; Santos, Daniela B.; Gyorffy, Balazs; Allsopp, Rebecca C.; Toghill, Bradley J.; Balachandran, Kirsty; Lawson, Mandy; Morrow, Christopher J.; Surakala, Manasa; Carnevalli, Larissa S.; Zhang, Pei; Guttery, David S.; Shaw, Jacqueline A.; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak			Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer	ONCOGENE			English	Article							LIGAND-BINDING DOMAIN; ACQUIRED ENDOCRINE RESISTANCE; ACTIVATING ESR1 MUTATIONS; ALPHA MUTATIONS; THERAPEUTIC VULNERABILITIES; AROMATASE INHIBITORS; CELLS; ANTAGONISM; LANDSCAPE; STABILITY	Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to just three residues at, or near, the C-terminal helix 12 of the hormone binding domain, at leucine-536, tyrosine-537 and aspartate-538. To investigate these mutations, we have used CRISPR-Cas9 mediated genome engineering to generate a comprehensive set of isogenic mutant breast cancer cell lines. Our results confirm that L536R, Y537C, Y537N, Y537S and D538G mutations confer estrogen-independent growth in breast cancer cells. Growth assays show mutation-specific reductions in sensitivities to drugs representing three classes of clinical anti-estrogens. These differential mutation- and drug-selectivity profiles have implications for treatment choices following clinical emergence of ER mutations. Our results further suggest that mutant expression levels may be determinants of the degree of resistance to some anti-estrogens. Differential gene expression analysis demonstrates up-regulation of estrogen-responsive genes, as expected, but also reveals that enrichment for interferon-regulated gene expression is a common feature of all mutations. Finally, a new gene signature developed from the gene expression profiles in ER mutant cells predicts clinical response in breast cancer patients with ER mutations.	[Harrod, Alison; Lai, Chun-Fui; Goldsbrough, Isabella; Simmons, Georgia M.; Oppermans, Natasha; Santos, Daniela B.; Balachandran, Kirsty; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Gyorffy, Balazs] Semmelweis Univ, Dept Bioinformat, H-1094 Budapest, Hungary; [Gyorffy, Balazs] TTK Canc Biomarker Res Grp, H-1117 Budapest, Hungary; [Allsopp, Rebecca C.; Toghill, Bradley J.; Guttery, David S.; Shaw, Jacqueline A.] Univ Leicester, Leicester Canc Res Ctr, Dept Genet & Genome Biol, Leicester Royal Infirm, Robert Kilpatrick Clin Sci Bldg, Leicester LE2 7LX, Leics, England; [Lawson, Mandy; Morrow, Christopher J.; Surakala, Manasa; Carnevalli, Larissa S.; Zhang, Pei] AstraZeneca, Early Oncol R&D, Biomed Campus,1 Francis Crick Ave, Cambridge CB2 0AA, England; [Harrod, Alison] Inst Canc Res, Fulham Rd, London SW3 6JB, England	Imperial College London; Semmelweis University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Leicester; AstraZeneca; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Buluwela, L; Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, London W12 0NN, England.	l.buluwela@imperial.ac.uk; simak.ali@imperial.ac.uk	; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Carnevalli, Larissa/0000-0001-7432-0195; Ali, Simak/0000-0002-1320-0816; Harrod, Alison/0000-0002-3977-2791	Cancer Research UK Imperial Centre; Medical Research Council [MR/P016413/1, MR/P018521/1]; Breast Cancer Now [2014MayPR234]; Cancer Research UK [C37/A18784]; Ministry for Innovation and Technology in Hungary [2020-1.1.6-JoVO-2021-00013, 2020-4.1.1.-TKP2020]; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre	Cancer Research UK Imperial Centre; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now; Cancer Research UK(Cancer Research UK); Ministry for Innovation and Technology in Hungary; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	We thank Dr Jun Liang (Genentech) for GDC-0810. AH was supported by a Ph.D. studentship from the Cancer Research UK Imperial Centre. IG and KB were supported by a Medical Research Council Industrial CASE studentship (MR/P016413/1) and clinical research training fellowship (MR/P018521/1), respectively. CFL was supported by Breast Cancer Now (2014MayPR234) and Cancer Research UK (C37/A18784). BG was supported by the 2020-1.1.6-JoVO-2021-00013 and 2020-4.1.1.-TKP2020 grants of the Ministry for Innovation and Technology in Hungary. Additional support was provided by the Imperial Experimental Cancer Medicine Centre and the Imperial NIHR Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Abe O, 2005, LANCET, V366, P2087; Anders S, 2012, GENOME RES, V22, P2008, DOI 10.1101/gr.133744.111; Andreano KJ, 2020, MOL CANCER THER, V19, P1395, DOI 10.1158/1535-7163.MCT-19-1148; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Arnesen S, 2021, CANCER RES, V81, P539, DOI 10.1158/0008-5472.CAN-20-1171; Bahreini A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0851-4; Baird R, 2021, CANCER RES, V81; Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293; Barrangou R, 2016, NAT BIOTECHNOL, V34, P933, DOI 10.1038/nbt.3659; Bidard FC, 2022, J CLIN ONCOL, V40, P3246, DOI 10.1200/JCO.22.00338; Bottcher R, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku289; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; Chumsri S, 2011, J STEROID BIOCHEM, V125, P13, DOI 10.1016/j.jsbmb.2011.02.001; Coombes RC, 2019, CLIN CANCER RES, V25, P4255, DOI 10.1158/1078-0432.CCR-18-3663; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dahlgren M, 2021, JNCI CANCER SPECT, V5, DOI 10.1093/jncics/pkab028; Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Fanning Sean W, 2016, Elife, V5, DOI 10.7554/eLife.12792; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gates LA, 2018, ONCOGENE, V37, P4581, DOI 10.1038/s41388-018-0284-2; Gelsomino L, 2018, CANCER LETT, V428, P12, DOI 10.1016/j.canlet.2018.04.023; Gu GW, 2021, ONCOGENE, V40, P997, DOI 10.1038/s41388-020-01563-x; HACKENBERG R, 1992, J STEROID BIOCHEM, V43, P599, DOI 10.1016/0960-0760(92)90284-P; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Herzog SK, 2022, BRIT J CANCER, V126, P174, DOI 10.1038/s41416-021-01564-x; Hickey TE, 2021, NAT MED, V27, P310, DOI 10.1038/s41591-020-01168-7; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Jia SH, 2018, ONCOLOGY-BASEL, V94, P176, DOI 10.1159/000485510; Kalinsky K, 2021, J CLIN ONCOL, V39, P100, DOI 10.1200/JCO.20.03040; Katzenellenbogen JA, 2018, NAT REV CANCER, V18, P377, DOI 10.1038/s41568-018-0001-z; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Mao CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34753; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Oesterreich S, 2013, NAT GENET, V45, P1415, DOI 10.1038/ng.2831; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Pleasance E, 2020, NAT CANCER, V1, P452, DOI 10.1038/s43018-020-0050-6; Puyang XL, 2018, CANCER DISCOV, V8, P1176, DOI 10.1158/2159-8290.CD-17-1229; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; Rinaldi J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231999; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Sava GP, 2020, ONCOGENE, V39, P651, DOI 10.1038/s41388-019-1008-y; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schurch NJ, 2016, RNA, V22, P839, DOI 10.1261/rna.053959.115; Shaw JA, 2017, CLIN CANCER RES, V23, P88, DOI 10.1158/1078-0432.CCR-16-0825; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579; STOVER EP, 1987, ENDOCRINOLOGY, V120, P2597, DOI 10.1210/endo-120-6-2597; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Williams MM, 2021, CANCER RES, V81, P732, DOI 10.1158/0008-5472.CAN-20-1200; Yu LQ, 2019, CANCER LETT, V442, P373, DOI 10.1016/j.canlet.2018.10.041; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhao CQ, 2003, J BIOL CHEM, V278, P27278, DOI 10.1074/jbc.M303840200	73	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4905	4915		10.1038/s41388-022-02483-8	http://dx.doi.org/10.1038/s41388-022-02483-8		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36198774	Green Published, hybrid			2022-12-17	WOS:000864316200001
J	Doolittle, WKL; Park, S; Lee, SG; Jeong, S; Lee, G; Ryu, D; Schoonjans, K; Auwerx, J; Lee, J; Jo, YS				Doolittle, Woo Kyung Lee; Park, Sunmi; Lee, Seul Gi; Jeong, Seonhyang; Lee, Gibbeum; Ryu, Dongryeol; Schoonjans, Kristina; Auwerx, Johan; Lee, Jandee; Jo, Young Suk			Non-genomic activation of the AKT-mTOR pathway by the mitochondrial stress response in thyroid cancer	ONCOGENE			English	Article							GENE-EXPRESSION; METABOLISM; PHOSPHORYLATION; PERSPECTIVE; SURVIVAL; WARBURG; PROTEOSTASIS; SUPPRESSION; HOMEOSTASIS; RESISTANCE	Cancer progression is associated with metabolic reprogramming and causes significant intracellular stress; however, the mechanisms that link cellular stress and growth signalling are not fully understood. Here, we identified a mechanism that couples the mitochondrial stress response (MSR) with tumour progression. We demonstrated that the MSR is activated in a significant proportion of human thyroid cancers via the upregulation of heat shock protein D family members and the mitokine, growth differentiation factor 15. Our study also revealed that MSR triggered AKT/S6K signalling by activating mTORC2 via activating transcription factor 4/sestrin 2 activation whilst promoting leucine transporter and nutrient-induced mTORC1 activation. Importantly, we found that an increase in (mt)DNA played an essential role in MSR-induced mTOR activation and that crosstalk between MYC and MSR potentiated mTOR activation. Together, these findings suggest that the MSR could be a predictive marker for aggressive human thyroid cancer as well as a useful therapeutic target.	[Doolittle, Woo Kyung Lee] NCI, Lab Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Park, Sunmi; Jeong, Seonhyang; Jo, Young Suk] Yonsei Univ, Dept Internal Med, Open NBI Convergence Technol Res Lab, Coll Med, Seoul 03722, South Korea; [Lee, Seul Gi] Eulji Univ, Dept Surg, Sch Med, Daejeon 34824, South Korea; [Lee, Gibbeum; Lee, Jandee] Yonsei Univ, Severance Hosp, Yonsei Canc Ctr, Dept Surg,Coll Med,Open NBI Convergence Technol R, Seoul 03722, South Korea; [Ryu, Dongryeol] Sungkyunkwan Univ, Dept Mol Cell Biol, Lab Mol & Integrat Biol, Sch Med, Suwon 16419, South Korea; [Schoonjans, Kristina] Ecole Polytech Fed Lausanne, Lab Metab Signaling, CH-1015 Lausanne, Switzerland; [Auwerx, Johan] Ecole Polytech Fed Lausanne, Lab Integrat Syst Physiol, CH-1015 Lausanne, Switzerland; [Doolittle, Woo Kyung Lee] Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Dept Med, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yonsei University; Yonsei University Health System; Eulji University; Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Case Western Reserve University; University Hospitals of Cleveland	Jo, YS (corresponding author), Yonsei Univ, Dept Internal Med, Open NBI Convergence Technol Res Lab, Coll Med, Seoul 03722, South Korea.; Lee, J (corresponding author), Yonsei Univ, Severance Hosp, Yonsei Canc Ctr, Dept Surg,Coll Med,Open NBI Convergence Technol R, Seoul 03722, South Korea.	jandee@yuhs.ac; joys@yuhs.ac	Doolittle, Woo Kyung Lee/CAJ-0252-2022	Doolittle, Woo Kyung Lee/0000-0002-6737-3173; Schoonjans, Kristina/0000-0003-1247-4265; Jo, Young Suk/0000-0001-9926-8389; Ryu, Dongryeol/0000-0001-5905-6760; Lee, Jandee/0000-0003-4090-0049	National Research Foundation of Korea grant - Korean government [NRF-2018R1A2B6004179, NRF-2021R1H1A2012035, NRF-2020R1A2C1006047, NRF-2020R1I1A1A01069524]; National Research Foundation of Korea GRL grant [NRF-2017K1A1A2013124]; Ecole Polytechnique Federale de Lausanne; European Research Council [ERC-AdG-787702]; Swiss Cancer Research [KFS-4226-08-2017]; Swiss National Science Foundation, Sinergia [CRSII3_160798]	National Research Foundation of Korea grant - Korean government(National Research Foundation of Korea); National Research Foundation of Korea GRL grant; Ecole Polytechnique Federale de Lausanne; European Research Council(European Research Council (ERC)European Commission); Swiss Cancer Research; Swiss National Science Foundation, Sinergia(Swiss National Science Foundation (SNSF))	We received funding from the National Research Foundation of Korea grant, funded by the Korean government NRF-2018R1A2B6004179 and NRF-2021R1H1A2012035 (YSJ); NRF-2020R1A2C1006047 (JL); NRF-2020R1I1A1A01069524 (SP); National Research Foundation of Korea GRL grant NRF-2017K1A1A2013124 (JA); Ecole Polytechnique Federale de Lausanne (JA and KS); European Research Council ERC-AdG-787702 (JA); Swiss Cancer Research KFS-4226-08-2017 (KS); and Swiss National Science Foundation, Sinergia CRSII3_160798 (KS).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bao XT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03505-1; Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877; Byun JK, 2017, CELL REP, V20, P586, DOI 10.1016/j.celrep.2017.06.066; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chandel NS, 2015, CELL METAB, V22, P204, DOI 10.1016/j.cmet.2015.05.013; Chantranupong L, 2014, CELL REP, V9, P1, DOI 10.1016/j.celrep.2014.09.014; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; D'Amico D, 2017, TRENDS BIOCHEM SCI, V42, P712, DOI 10.1016/j.tibs.2017.05.002; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garaeva AA, 2016, CELL CYCLE, V15, P64, DOI 10.1080/15384101.2015.1120929; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Houtkooper RH, 2013, NATURE, V497, P451, DOI 10.1038/nature12188; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Ishida S, 2013, P NATL ACAD SCI USA, V110, P19507, DOI 10.1073/pnas.1318431110; Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Knippler CM, 2019, ENDOCR-RELAT CANCER, V26, P699, DOI 10.1530/ERC-19-0188; Kowalsky AH, 2020, J BIOL CHEM, V295, P1769, DOI 10.1074/jbc.RA119.010857; Lee MH, 2011, J CLIN ENDOCR METAB, V96, pE19, DOI 10.1210/jc.2010-1071; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martinez-Reyes I, 2012, BIOCHEM J, V444, P249, DOI 10.1042/BJ20111829; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Matilainen O, 2017, TRENDS CELL BIOL, V27, P453, DOI 10.1016/j.tcb.2017.02.004; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; Moullan N, 2015, CELL REP, V10, P1681, DOI 10.1016/j.celrep.2015.02.034; Nacarelli T, 2015, EXP GERONTOL, V68, P66, DOI 10.1016/j.exger.2014.11.004; Nargund AM, 2012, SCIENCE, V337, P587, DOI 10.1126/science.1223560; O'Malley J, 2020, TRENDS CANCER, V6, P688, DOI 10.1016/j.trecan.2020.04.009; Park HW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5233; Parmigiani A, 2014, CELL REP, V9, P1281, DOI 10.1016/j.celrep.2014.10.019; Peng M, 2015, HUM MOL GENET, V24, P4829, DOI 10.1093/hmg/ddv207; Peng M, 2014, CELL, V159, P122, DOI 10.1016/j.cell.2014.08.038; Peng XX, 2018, CELL REP, V23, P255, DOI 10.1016/j.celrep.2018.03.077; Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Quiros PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23; Ringel MD, 2001, CANCER RES, V61, P6105; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2016, SCIENCE, V351, P53, DOI 10.1126/science.aad2087; Steffen KK, 2016, CELL METAB, V23, P1004, DOI 10.1016/j.cmet.2016.05.013; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Ye JB, 2015, GENE DEV, V29, P2331, DOI 10.1101/gad.269324.115; Yi HS, 2018, J MOL ENDOCRINOL, V61, pR91, DOI 10.1530/JME-18-0005; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Yu M, 2007, TOXICOL LETT, V170, P83, DOI 10.1016/j.toxlet.2007.02.013; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211; Zhang J, 2008, J BIOL CHEM, V283, P35375, DOI 10.1074/jbc.M806480200; Zheng XD, 2016, ELIFE, V5, DOI 10.7554/eLife.13378; Zhou Q, 2015, TOXICOL SCI, V143, P81, DOI 10.1093/toxsci/kfu211	70	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4893	4904		10.1038/s41388-022-02484-7	http://dx.doi.org/10.1038/s41388-022-02484-7		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36195659				2022-12-17	WOS:000864233500001
J	Guo, YM; He, JF; Zhang, HL; Chen, R; Li, L; Liu, XJ; Huang, CH; Qiang, Z; Zhou, ZH; Wang, YL; Huang, J; Zhao, X; Zheng, JK; Chen, GQ; Yu, JX				Guo, Yanmin; He, Jianfeng; Zhang, Hailong; Chen, Ran; Li, Lian; Liu, Xiaojia; Huang, Caihu; Qiang, Zhe; Zhou, Zihan; Wang, Yanli; Huang, Jian; Zhao, Xian; Zheng, Junke; Chen, Guo-Qiang; Yu, Jianxiu			Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR; COWDEN DISEASE; NUCLEAR PTEN; LIGASE; BREAST; LUBAC; STABILITY; OTULIN; NEMO	PTEN is frequently mutated in human cancers, which leads to the excessive activation of PI3K/AKT signaling and thus promotes tumorigenesis and drug resistance. Met(1)-linked ubiquitination (M1-Ubi) is also involved in cancer progression, but the mechanism is poorly defined. Here we find that HOIP, one important component of linear ubiquitin chain assembly complex (LUBAC), promotes prostate cancer (PCa) progression by enhancing AKT signaling in a PTEN-dependent manner. Mechanistically, PTEN is modified by M1-Ubi at two sites K144 and K197, which significantly inhibits PTEN phosphatase activity and thus accelerates PCa progression. More importantly, we identify that the high-frequency mutants PTENR173H and PTENR173C in PCa patients showed the enhanced level of M1-Ubi, which impairs PTEN function in inhibition of AKT phosphorylation and cell growth. We also find that HOIP depletion sensitizes PCa cells to therapeutic agents BKM120 and Enzalutamide. Furthermore, the clinical data analyses confirm that HOIP is upregulated and positively correlated with AKT activation in PCa patient specimen, which may promote PCa progression and increase the risk of PCa biochemical relapse. Together, our study reveals a key role of PTEN M1-Ubi in regulation of AKT activation and PCa progression, which may propose a new strategy for PCa therapy.	[Guo, Yanmin; He, Jianfeng; Zhang, Hailong; Chen, Ran; Li, Lian; Liu, Xiaojia; Huang, Caihu; Qiang, Zhe; Zhou, Zihan; Wang, Yanli; Huang, Jian; Zhao, Xian; Yu, Jianxiu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China; [Zheng, Junke] Shanghai Jiao Tong Univ, Sch Med, Chinese Minist Educ, Dept Pathophysiol,Key Lab Cell Differentiat & Apo, Shanghai 200025, Peoples R China; [Chen, Guo-Qiang] Shanghai Jiao Tong Univ, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes, Sch Med, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China.	Jianxiu.Yu@gmail.com			China's National Key R&D Programmes (NKP) [2019YFE0110600]; National Natural Science Foundation of China [81630075, 82103082, 81721004, 81902866, 82002712, 81972585]; Shanghai Science and Technology Commission [20JC1410100]	China's National Key R&D Programmes (NKP); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by grants from China's National Key R&D Programmes (NKP) (No. 2019YFE0110600), the National Natural Science Foundation of China (81630075, 82103082, 81721004, 81902866, 82002712, 81972585) and Shanghai Science and Technology Commission (20JC1410100).	Armstrong AJ, 2017, EUR J CANCER, V81, P228, DOI 10.1016/j.ejca.2017.02.030; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Chen Chang-fu, 2015, China Journal of Highway and Transport, V28, P1; Damgaard RB, 2012, MOL CELL, V46, P746, DOI 10.1016/j.molcel.2012.04.014; de Almagro MC, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.158; Deng R, 2021, MOL ONCOL, V15, P279, DOI 10.1002/1878-0261.12844; Dittmar G, 2020, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00915; Dou JZ, 2020, MOL ONCOL, V14, P2288, DOI 10.1002/1878-0261.12694; Fiil BK, 2013, MOL CELL, V50, P818, DOI 10.1016/j.molcel.2013.06.004; Fu YS, 2021, MOL CELL, V81, P3187, DOI 10.1016/j.molcel.2021.05.031; Ge MK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15578-1; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Goto E, 2017, BIOCHEM BIOPH RES CO, V485, P152, DOI [10.1016/J.bbrc.2017.02.040, 10.1016/j.bbrc.2017.02.040]; Gu TT, 2011, CANCER RES, V71, P2821, DOI 10.1158/0008-5472.CAN-10-3399; Guo J, 2015, BIOCHEM BIOPH RES CO, V464, P1302, DOI 10.1016/j.bbrc.2015.07.127; He LZ, 2010, J CLIN INVEST, V120, P2094, DOI 10.1172/JCI40778; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Inn KS, 2011, MOL CELL, V41, P354, DOI 10.1016/j.molcel.2010.12.029; Iwai K, 2014, NAT REV MOL CELL BIO, V15, P503, DOI 10.1038/nrm3836; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kharman-Biz A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197183; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Kliza K, 2017, NAT METHODS, V14, P504, DOI [10.1038/nmeth.4228, 10.1038/NMETH.4228]; Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6; Noad J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.63; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Peltzer N, 2014, CELL REP, V9, P153, DOI 10.1016/j.celrep.2014.08.066; Qiu P, 2018, ONCOL LETT, V15, P789, DOI 10.3892/ol.2017.7431; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Rivkin E, 2013, NATURE, V498, P318, DOI 10.1038/nature12296; Sakamoto H, 2015, ACS CHEM BIOL, V10, P675, DOI 10.1021/cb500653y; Sasaki Y, 2013, EMBO J, V32, P2463, DOI 10.1038/emboj.2013.184; Schaeffer V, 2014, MOL CELL, V54, P349, DOI 10.1016/j.molcel.2014.03.016; Serebriiskii IG, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29227-2; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shi YJ, 2014, NAT STRUCT MOL BIOL, V21, P522, DOI 10.1038/nsmb.2828; Singh G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-490; Smith IN, 2016, PROTEINS, V84, P1625, DOI 10.1002/prot.25105; Takiuchi T, 2014, GENES CELLS, V19, P254, DOI 10.1111/gtc.12128; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thompson HGR, 2004, EXP CELL RES, V295, P448, DOI 10.1016/j.yexcr.2004.01.019; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; van Well EM, 2019, EMBO J, V38, DOI 10.15252/embj.2018100730; Vanhaesebroeck B, 2021, NAT REV DRUG DISCOV, V20, P741, DOI 10.1038/s41573-021-00209-1; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17770-9; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wong CW, 2018, AUTISM RES, V11, P1098, DOI 10.1002/aur.1950; Wu PJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641469; Xie P, 2021, CELL RES, V31, P291, DOI 10.1038/s41422-020-00443-z; Yang M, 2017, ONCOGENE, V36, P3673, DOI 10.1038/onc.2016.493; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Zhang HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25739-5; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573; Zuo YB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14948-z	65	0	0	10	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4877	4892		10.1038/s41388-022-02485-6	http://dx.doi.org/10.1038/s41388-022-02485-6		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36192478				2022-12-17	WOS:000865226400002
J	Sh, Y; Zhang, XL; Yang, ZM; Dong, JR; Wang, YZ; Zhou, Y; Li, XJ; Guo, CX; Hu, ZY				Sh, Yuan; Zhang, Xiuli; Yang, Zhimin; Dong, Jierong; Wang, Yuanzhuo; Zhou, Ying; Li, Xuejie; Guo, Caixia; Hu, Zhiyuan			CaSee: A lightning transfer-learning model directly used to discriminate cancer/normal cells from scRNA-seq	ONCOGENE			English	Article							MAP	Single-cell RNA sequencing (scRNA-seq) is one of the most efficient technologies for human tumor research. However, data analysis is still faced with technical challenges, especially the difficulty in efficiently and accurately discriminating cancer/normal cells in the scRNA-seq expression matrix. If we can address these challenges, we can have a deeper understanding of the intratumoral and intertumoral heterogeneity. In this study, we developed a cancer/normal cell discrimination pipeline called pan-Cancer Seeker (CaSee) devoted to scRNA-seq expression matrix, which is based on the traditional high-quality pan-cancer bulk sequencing data using transfer learning. CaSee is the first tool directly used to discriminate cancer/normal cells in the scRNA-seq expression matrix, with much wider application fields and higher efficiency than copy number variation (CNV) method which requires corresponding reference cells. CaSee is user-friendly and can adapt to a variety of data sources, including but not limited to scRNA tissue sequencing data, scRNA cell line sequencing data, scRNA xenograft cell sequencing data and scRNA circulating tumor cell sequencing data. It is compatible with mainstream sequencing technology platforms, 10x Genomics Chromium, Smart-seq2, and Microwell-seq. Here, CaSee pipeline exhibited excellent performance in the multicenter data evaluation of 11 retrospective cohorts and one independent dataset, with an average discrimination accuracy of 96.69%. In general, the development of a deep-learning based, pan-cancer cell discrimination model, CaSee, to distinguish cancer cells from normal cells will be compelling to researchers working in the genomics, cancer, and single-cell fields.	[Sh, Yuan; Yang, Zhimin; Zhou, Ying; Li, Xuejie; Hu, Zhiyuan] Fujian Med Univ, Sch Basic Med Sci, Fujian Prov Key Lab Brain Aging & Neurodegenerat, Fuzhou 350108, Fujian, Peoples R China; [Sh, Yuan; Zhang, Xiuli; Yang, Zhimin; Dong, Jierong; Wang, Yuanzhuo; Hu, Zhiyuan] Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Standardizat & Measurement Nanotechno, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China; [Guo, Caixia] China Natl Ctr Bioinformat, Beijing, Peoples R China; [Guo, Caixia] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China; [Hu, Zhiyuan] Univ Chinese Acad Sci, Sch Nanosci & Technol, Sino Danish Coll, Beijing 100049, Peoples R China; [Hu, Zhiyuan] Wuhan Inst Technol, Sch Chem Engn & Pharm, Wuhan 430205, Peoples R China	Fujian Medical University; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Wuhan Institute of Technology	Sh, Y; Zhang, XL; Hu, ZY (corresponding author), Fujian Med Univ, Sch Basic Med Sci, Fujian Prov Key Lab Brain Aging & Neurodegenerat, Fuzhou 350108, Fujian, Peoples R China.; Sh, Y; Zhang, XL; Hu, ZY (corresponding author), Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Standardizat & Measurement Nanotechno, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.; Hu, ZY (corresponding author), Univ Chinese Acad Sci, Sch Nanosci & Technol, Sino Danish Coll, Beijing 100049, Peoples R China.; Hu, ZY (corresponding author), Wuhan Inst Technol, Sch Chem Engn & Pharm, Wuhan 430205, Peoples R China.	yuansh3354@163.com; zhangxl2020@nanoctr.cn; huzy@nanoctr.cn		Sh, yuan/0000-0002-6028-0185; Zhang, Xiuli/0000-0002-5694-0101; zm, yang/0000-0002-7527-2313; Hu, Zhiyuan/0000-0003-2212-0268	China Postdoctoral Science Foundation [2021M690806]; Beijing Natural Science Foundation Haidian original innovation joint fund [L202023]; National Natural Science Foundation of China [32027801, 31870992, 21775031]; Strategic Priority Research Program of Chinese Academy of Sciences [XDB36000000, XDB38010400]; CAS-JSPS [GJHZ2094]; Research Foundation for Advanced Talents of Fujian Medical University [XRCZX2017020, XRCZX2019005]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Beijing Natural Science Foundation Haidian original innovation joint fund(Beijing Natural Science Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of Chinese Academy of Sciences(Chinese Academy of Sciences); CAS-JSPS; Research Foundation for Advanced Talents of Fujian Medical University	This work was supported by the China Postdoctoral Science Foundation (2021M690806), Beijing Natural Science Foundation Haidian original innovation joint fund (L202023), the National Natural Science Foundation of China (32027801, 31870992, 21775031), the Strategic Priority Research Program of Chinese Academy of Sciences (Grant No. XDB36000000, XDB38010400), CAS-JSPS (Grant No. GJHZ2094), Research Foundation for Advanced Talents of Fujian Medical University (XRCZX2017020, XRCZX2019005). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. We thank Dr.Jianming Zeng(University of Macau), and all the members of his bioinformatics team, biotrainee, for generously sharing their experience and codes. We also thank Prof. Xiaopei Shen (Fujian Medical University) and his teammate, Hao Fu, Haibo Zhu, Guanghao Liu, Mengyao Wang, et al. for generously help, discussion, and advice about CaSee pipeline.	Andreatta M, 2021, COMPUT STRUCT BIOTEC, V19, P3796, DOI 10.1016/j.csbj.2021.06.043; Bassez A, 2021, NAT MED, V27, P820, DOI 10.1038/s41591-021-01323-8; Bell CC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10652-9; Bischoff P, 2021, ONCOGENE, V40, P6748, DOI 10.1038/s41388-021-02054-3; Gao RL, 2021, NAT BIOTECHNOL, V39, P599, DOI 10.1038/s41587-020-00795-2; Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586-020-2157-4; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; He Y, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02083-3; Hu J, 2020, NAT MACH INTELL, V2, P607, DOI 10.1038/s42256-020-00233-7; Hu LS, 2017, P NATL ACAD SCI USA, V114, pE3964, DOI 10.1073/pnas.1617816114; Kharchenko PV, 2014, NAT METHODS, V11, P740, DOI [10.1038/NMETH.2967, 10.1038/nmeth.2967]; Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16164-1; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Krizhevsky A., 2012, COMMUN ACM, P1097, DOI DOI 10.1145/3065386; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017; Nguyen QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04334-1; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Oren Y, 2021, NATURE, V596, P576, DOI 10.1038/s41586-021-03796-6; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Qiao K, ACCURATE RECONSTRUCT, P14; Qiu YPL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20167-3; Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025; Roels J, 2020, NAT IMMUNOL, V21, P1280, DOI 10.1038/s41590-020-0747-9; Sabour S., 2017, ARXIV; Shao X, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkab775; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wagner J, 2019, CELL, V177, P1330, DOI 10.1016/j.cell.2019.03.005; Wang LF, 2020, NAT MACH INTELL, V2, P693, DOI 10.1038/s42256-020-00244-4; Xi E, 2017, ARXIV; Yamada H, 2019, ACS CENTRAL SCI, V5, P1717, DOI 10.1021/acscentsci.9b00804; Yuan HT, 2019, NUCLEIC ACIDS RES, V47, pD900, DOI 10.1093/nar/gky939; Zarrei M, 2015, NAT REV GENET, V16, P172, DOI 10.1038/nrg3871; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900; Zhou Y, 2020, CANCER CELL, V38, P818, DOI 10.1016/j.ccell.2020.09.015; Zhu RC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23087-y	39	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4866	4876		10.1038/s41388-022-02478-5	http://dx.doi.org/10.1038/s41388-022-02478-5		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36192479	Green Submitted			2022-12-17	WOS:000865226400001
J	Battaglin, F; Jayachandran, P; Strelez, C; Lenz, A; Algaze, S; Soni, S; Lo, JH; Yang, Y; Millstein, J; Zhang, W; Torres, ETR; Shih, JC; Mumenthaler, SM; Neman, J; Lenz, HJ				Battaglin, Francesca; Jayachandran, Priya; Strelez, Carly; Lenz, Annika; Algaze, Sandra; Soni, Shivani; Lo, Jae Ho; Yang, Yan; Millstein, Joshua; Zhang, Wu; Roussos Torres, Evanthia T.; Shih, Jean C.; Mumenthaler, Shannon M.; Neman, Josh; Lenz, Heinz-Josef			Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment	ONCOGENE			English	Review							ALPHA-7-NICOTINIC ACETYLCHOLINE-RECEPTOR; GAMMA-AMINOBUTYRIC-ACID; CELL-PROLIFERATION; GENE-EXPRESSION; NERVOUS-SYSTEM; TUMOR-GROWTH; MCRC DATA; COLON; PATHWAY; GABA	The brain-gut axis, a bidirectional network between the central and enteric nervous system, plays a critical role in modulating the gastrointestinal tract function and homeostasis. Recently, increasing evidence suggests that neuronal signaling molecules can promote gastrointestinal cancers, however, the mechanisms remain unclear. Aberrant expression of neurotransmitter signaling genes in colorectal cancer supports the role of neurotransmitters to stimulate tumor growth and metastatic spread by promoting cell proliferation, migration, invasion, and angiogenesis. In addition, neurotransmitters can interact with immune and endothelial cells in the tumor microenvironment to promote inflammation and tumor progression. As such, pharmacological targeting of neurotransmitter signaling represent a promising novel anticancer approach. Here, we present an overview of the current evidence supporting the role of neurotransmitters in colorectal cancer biology and treatment.	[Battaglin, Francesca; Jayachandran, Priya; Lenz, Annika; Algaze, Sandra; Soni, Shivani; Lo, Jae Ho; Zhang, Wu; Roussos Torres, Evanthia T.; Mumenthaler, Shannon M.; Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Strelez, Carly; Mumenthaler, Shannon M.] Lawrence J Ellison Inst Transformat Med, Los Angeles, CA USA; [Yang, Yan; Millstein, Joshua] Univ Southern Calif, Keck Sch Med, Dept Populat & Publ Hlth Sci, Los Angeles, CA 90007 USA; [Shih, Jean C.] Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90007 USA; [Mumenthaler, Shannon M.] Univ Southern Calif, Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA 90007 USA; [Neman, Josh] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, USC Brain Tumor Ctr,Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lenz, HJ (corresponding author), Univ Southern Calif, Keck Sch Med, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.	lenz@med.usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163	National Cancer Institute [P30CA014089, R01CA241137]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; V foundation for cancer research; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund; Boyd and Elsie Welin Professorship; USC Trustee Tsai family fund	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; V foundation for cancer research; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund; Boyd and Elsie Welin Professorship; USC Trustee Tsai family fund	This work was partly supported by National Cancer Institute (grant numbers P30CA014089 and R01CA241137), Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Gene Gregg Pancreas Research Fund, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund, V foundation for cancer research, Victoria and Philip Wilson Research Fund, Fong research project, Ming Hsieh research fund, Boyd and Elsie Welin Professorship to JCS and USC Trustee Tsai family fund to JCS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute of the National Institutes of Health.	Agirman G, 2021, SCIENCE, V374, P1087, DOI 10.1126/science.abi6087; Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008; Alizadeh M, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.857563; Aljanabi R, 2021, MOLECULES, V26, DOI 10.3390/molecules26196019; An J, 2021, J MICROBIOL, V59, P202, DOI 10.1007/s12275-021-0562-5; Ataee R, 2010, J CANCER RES CLIN, V136, P1461, DOI 10.1007/s00432-010-0801-3; Auteri M, 2015, PHARMACOL RES, V93, P11, DOI 10.1016/j.phrs.2014.12.001; Battaglin F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3048; Battaglin F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3595; Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Bortolato M, 2008, ADV DRUG DELIVER REV, V60, P1527, DOI 10.1016/j.addr.2008.06.002; Carvajal AE, 2017, BBA-MOL BASIS DIS, V1863, P2126, DOI 10.1016/j.bbadis.2017.05.026; Castellano E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11245; Catala-Lopez F, 2014, PSYCHOTHER PSYCHOSOM, V83, P89, DOI 10.1159/000356498; Chan YL, 2020, CANCERS, V12, DOI 10.3390/cancers12071844; Cheng KR, 2005, BIOCHEM PHARMACOL, V70, P1035, DOI 10.1016/j.bcp.2005.07.023; Cheng KR, 2008, AM J PHYSIOL-GASTR L, V295, pG591, DOI 10.1152/ajpgi.00055.2008; Cheng KR, 2017, ONCOTARGET, V8, P21106, DOI 10.18632/oncotarget.15500; Cheng KR, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-77; Ngo DH, 2019, MOLECULES, V24, DOI 10.3390/molecules24152678; de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9; Deng H, 2018, AGEING RES REV, V42, P72, DOI 10.1016/j.arr.2017.12.007; Di YZ, 2019, WORLD J CLIN CASES, V7, P1554, DOI 10.12998/wjcc.v7.i13.1554; Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478; Drilon A, 2019, ANN ONCOL, V30, pVIII23, DOI 10.1093/annonc/mdz282; Eglen R. M., 2006, Autonomic & Autacoid Pharmacology, V26, P219, DOI 10.1111/j.1474-8673.2006.00368.x; Ejma M, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100416; Fang CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038886; Fang HS, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02497-z; Farhana L, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0439-4; Fatemi SH, 2001, MOL PSYCHIATR, V6, P129, DOI 10.1038/sj.mp.4000129; Feng DD, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0043-z; Fujikawa H, 2012, J GASTROENTEROL, V47, P775, DOI 10.1007/s00535-012-0532-0; Furness JB, 2012, NAT REV GASTRO HEPAT, V9, P286, DOI 10.1038/nrgastro.2012.32; Gemignani F, 2005, CANCER EPIDEM BIOMAR, V14, P1633, DOI 10.1158/1055-9965.EPI-05-0057; Grant CE, 2022, CARCINOGENESIS, V43, P517, DOI 10.1093/carcin/bgac045; Hajiasgharzadeh K, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03611; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Hayashi S, 2014, AM J PHYSIOL-GASTR L, V307, pG968, DOI 10.1152/ajpgi.00346.2013; Hering NA, 2021, CANCERS, V13, DOI 10.3390/cancers13133220; Huang D, 2022, NAT CELL BIOL, V24, P230, DOI 10.1038/s41556-021-00820-9; Huang SM, 2015, ENDOCR-RELAT CANCER, V22, P455, DOI 10.1530/ERC-15-0007; Jiang SH, 2020, ONCOGENE, V39, P503, DOI 10.1038/s41388-019-1006-0; Joseph J, 2002, CANCER RES, V62, P6467; Kannen V, 2020, TRENDS ENDOCRIN MET, V31, P611, DOI 10.1016/j.tem.2020.04.008; Kannen V, 2015, CELL SIGNAL, V27, P1781, DOI 10.1016/j.cellsig.2015.05.008; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Killinger BA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar5280; Kojadinovic A, 2021, CRIT REV ONCOL HEMAT, V165, DOI 10.1016/j.critrevonc.2021.103451; Kontos CK, 2010, BRIT J CANCER, V102, P1384, DOI 10.1038/sj.bjc.6605654; Kwon YH, 2022, AM J PHYSIOL-CELL PH, V323, pC550, DOI 10.1152/ajpcell.00433.2021; Lee GH, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00122; Lee H, 2021, CANCER SCI, V112, P3732, DOI 10.1111/cas.15026; Lee JYS, 2022, AGING-US, V14, P2148, DOI 10.18632/aging.203932; Leng ZG, 2017, AUTOPHAGY, V13, P1404, DOI 10.1080/15548627.2017.1328347; Li T, 2021, CANCER IMMUNOL RES, V9, P1008, DOI 10.1158/2326-6066.CIR-20-1043; Li WH, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/657570; Liu SM, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13446; Liu T, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/5544182; Lutgendorf SK, 2011, PSYCHOSOM MED, V73, P724, DOI 10.1097/PSY.0b013e318235be76; Margolis KG, 2021, GASTROENTEROLOGY, V160, P1486, DOI 10.1053/j.gastro.2020.10.066; Mawe GM, 2013, NAT REV GASTRO HEPAT, V10, P473, DOI 10.1038/nrgastro.2013.105; Meldolesi J, 2018, REV PHYSIOL BIOCH P, V174, P67, DOI 10.1007/112_2017_6; Miao YF, 2010, BIOMED PHARMACOTHER, V64, P583, DOI 10.1016/j.biopha.2010.03.006; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Mittal R, 2017, J CELL PHYSIOL, V232, P2359, DOI 10.1002/jcp.25518; Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510; Nocito A, 2008, CANCER RES, V68, P5152, DOI 10.1158/0008-5472.CAN-08-0202; Parrish WR, 2008, MOL MED, V14, P567, DOI 10.2119/2008-00079.Parrish; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Pavlov VA, 2015, IMMUNOL RES, V63, P38, DOI 10.1007/s12026-015-8718-1; Penedo MA., 2021, BRAIN BEHAV IMMUN HL, V12, P100199, DOI [10.1016/j.bbih.2021.100199, DOI 10.1016/J.BBIH.2021.100199]; Peng ZS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-204; Qiu YP, 2014, CLIN CANCER RES, V20, P2136, DOI 10.1158/1078-0432.CCR-13-1939; Radin DP, 2017, ANTICANCER RES, V37, P3983, DOI 10.21873/anticanres.11783; Raufman JP, 2008, CANCER RES, V68, P3573, DOI 10.1158/0008-5472.CAN-07-6810; Raufman JP, 2015, CARCINOGENESIS, V36, P1193, DOI 10.1093/carcin/bgv107; Ren YG, 2018, LIFE SCI, V209, P267, DOI 10.1016/j.lfs.2018.08.027; Sadighparvar S, 2021, EUR J PHARMACOL, V913, DOI 10.1016/j.ejphar.2021.174626; Said AH, 2017, BIOCHEM J, V474, P647, DOI 10.1042/BCJ20160704; Sakita JY, 2019, J PATHOL, V249, P102, DOI 10.1002/path.5285; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sarrouilhe D, 2019, BIOCHIMIE, V161, P46, DOI 10.1016/j.biochi.2018.06.016; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; Schledwitz A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143776; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; Shu Q, 2016, CANCER MED-US, V5, P1259, DOI 10.1002/cam4.686; Song LH, 2016, TUMOR BIOL, V37, P14885, DOI 10.1007/s13277-016-5367-5; Stein T, 2008, BREAST CANCER RES, V10, pS15, DOI 10.1186/bcr1909; Sui H, 2015, ONCOTARGET, V6, P25975, DOI 10.18632/oncotarget.4543; Tait C, 2021, EUR J INTERN MED, V84, P1, DOI 10.1016/j.ejim.2020.12.023; TATSUTA M, 1992, INT J CANCER, V50, P298, DOI 10.1002/ijc.2910500221; Tolaymat M, 2019, CANCERS, V11, DOI 10.3390/cancers11030308; Vignot S, 2015, EUR J CANCER, V51, P791, DOI 10.1016/j.ejca.2015.02.012; Von Rosenvinge Erik C, 2011, Cancers (Basel), V3, P971, DOI 10.3390/cancers3010971; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HH, 2021, INT J BIOL SCI, V17, P1953, DOI 10.7150/ijbs.58135; Wang X, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abh2383; Wang YC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23164-2; Wei PL, 2011, ANN SURG ONCOL, V18, P1782, DOI 10.1245/s10434-010-1504-3; Wong HPS, 2007, TOXICOL SCI, V97, P279, DOI 10.1093/toxsci/kfm060; Wong HPS, 2007, TOXICOL APPL PHARM, V221, P261, DOI 10.1016/j.taap.2007.04.002; Xia Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01029; Xiang T, 2016, ONCOL REP, V35, P205, DOI 10.3892/or.2015.4363; Yan H, 2016, ONCOGENE, V35, P3995, DOI 10.1038/onc.2015.423; Yan L, 2020, ONCOL LETT, V20, P275, DOI 10.3892/ol.2020.11573; Yang XM, 2013, EXP THER MED, V6, P1475, DOI 10.3892/etm.2013.1330; Yang YC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082813; Ye YN, 2004, J PHARMACOL EXP THER, V311, P123, DOI 10.1124/jpet.104.068031; Zhang BH, 2021, NATURE, V599, P471, DOI 10.1038/s41586-021-04082-1; Zhang HY, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00191-1; Zhang NQ, 2021, AM J GASTROENTEROL, V116, P2310, DOI 10.14309/ajg.0000000000001520; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zhu PP, 2022, NEURON, V110, P2268, DOI 10.1016/j.neuron.2022.04.024	115	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4769	4778		10.1038/s41388-022-02479-4	http://dx.doi.org/10.1038/s41388-022-02479-4		OCT 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36182970				2022-12-17	WOS:000862526800001
J	Mohanty, S; Mohapatra, P; Shriwas, O; Ansari, SA; Priyadarshini, M; Priyadarsini, S; Rath, R; Sultania, M; Das Majumdar, SK; Swain, RK; Dash, R				Mohanty, Sibasish; Mohapatra, Pallavi; Shriwas, Omprakash; Ansari, Shamima Azma; Priyadarshini, Manashi; Priyadarsini, Swatismita; Rath, Rachna; Sultania, Mahesh; Das Majumdar, Saroj Kumar; Swain, Rajeeb K.; Dash, Rupesh			CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis	ONCOGENE			English	Article							LESTAURTINIB CEP701; P53; PHOSPHORYLATION; INHIBITOR; CANCER; MDM2	Cisplatin, 5FU and docetaxel (TPF) are the most common chemotherapy regimen used for advanced OSCC. However, many cancer patients experience relapse, continued tumor growth, and spread due to drug resistance, which leads to treatment failure and metastatic disease. Here, using a CRISPR/Cas9 based kinome knockout screening, Misshapen-like kinase 1 (MINK1) is identified as an important mediator of 5FU resistance in OSCC. Analysis of clinical samples demonstrated significantly higher MINK1 expression in the tumor tissues of chemotherapy non-responders as compared to chemotherapy responders. The nude mice and zebrafish xenograft experiments indicate that knocking out MINK1 restores 5FU mediated cell death in chemoresistant OSCC. An antibody based phosphorylation array screen revealed MINK1 as a negative regulator of p53. Mechanistically, MINK1 modulates AKT phosphorylation at Ser473, which enables p-MDM2 (Ser 166) mediated degradation of p53. We also identified lestaurtinib as a potent inhibitor of MINK1 kinase activity. The patient derived TPF resistant cell based xenograft data suggest that lestaurtinib restores 5FU sensitivity and facilitates a significant reduction of tumor burden. Overall, our study suggests that MINK1 is a major driver of 5FU resistance in OSCC. The novel combination of MINK1 inhibitor lestaurtinib and 5FU needs further clinical investigation in advanced OSCC.	[Mohanty, Sibasish; Mohapatra, Pallavi; Shriwas, Omprakash; Ansari, Shamima Azma; Priyadarshini, Manashi; Priyadarsini, Swatismita; Swain, Rajeeb K.; Dash, Rupesh] Inst Life Sci, Bhubaneswar 751023, Odisha, India; [Mohanty, Sibasish; Mohapatra, Pallavi; Ansari, Shamima Azma] Reg Ctr Biotechnol, Faridabad, India; [Priyadarshini, Manashi] KIIT Univ, KIIT Sch Biotechnol, Bhubaneswar, India; [Rath, Rachna] SCB Dent Coll Hosp, Dept Oral & Maxillofacial Pathol, Cuttack 753007, Odisha, India; [Sultania, Mahesh] All India Inst Med Sci, Dept Surg Oncol, Bhubaneswar 751019, Odisha, India; [Das Majumdar, Saroj Kumar] All India Inst Med Sci, Dept Radiotherapy, Bhubaneswar 751019, Odisha, India	Department of Biotechnology (DBT) India; Institute of Life Sciences India (ILS); Department of Biotechnology (DBT) India; Regional Centre for Biotechnology; Kalinga Institute of Industrial Technology (KIIT); Srirama Chandra Bhanja Medical College & Hospital; All India Institute of Medical Sciences (AIIMS) Bhubaneswar; All India Institute of Medical Sciences (AIIMS) Bhubaneswar	Dash, R (corresponding author), Inst Life Sci, Bhubaneswar 751023, Odisha, India.	rupeshdash@ils.res.in			ICMR [5/13/9/2019-NCD-III]; Institute of Life Sciences, Bhubaneswar intramural; DBT [BT/INF/22/SP28293/2018]	ICMR(Indian Council of Medical Research (ICMR)); Institute of Life Sciences, Bhubaneswar intramural; DBT(Department of Biotechnology (DBT) India)	This work is supported by ICMR (5/13/9/2019-NCD-III), Institute of Life Sciences, Bhubaneswar intramural support and DBT BT/INF/22/SP28293/2018 (for imaging facility).	[Anonymous], 2020, Nat Rev Dis Primers, V6, P93, DOI 10.1038/s41572-020-00233-2; Chaturvedi A, 2020, HEAD NECK PATHOL, V14, P616, DOI 10.1007/s12105-019-01082-6; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Daulat AM, 2016, DEV CELL, V37, P311, DOI 10.1016/j.devcel.2016.04.011; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gross S, 2015, J CLIN INVEST, V125, P1780, DOI 10.1172/JCI76094; Hexner EO, 2008, BLOOD, V111, P5663, DOI 10.1182/blood-2007-04-083402; Jin LT, 2018, CANCER CELL, V34, P315, DOI 10.1016/j.ccell.2018.06.012; John LSS, 2000, CANCER GENE THER, V7, P749, DOI 10.1038/sj.cgt.7700166; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Maclaine NJ, 2009, AGING-US, V1, P490, DOI 10.18632/aging.100047; Maji S, 2019, CARCINOGENESIS, V40, P173, DOI 10.1093/carcin/bgy135; Maji S, 2018, ADV CANCER RES, V137, P37, DOI 10.1016/bs.acr.2017.11.001; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Moll UM, 2003, MOL CANCER RES, V1, P1001; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Vishak S, 2015, INDIAN J MED PAEDIAT, V36, P148, DOI 10.4103/0971-5851.166716; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; Yogosawa S, 2018, CANCER SCI, V109, P3376, DOI 10.1111/cas.13792	25	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2022	41	45					4929	4940		10.1038/s41388-022-02475-8	http://dx.doi.org/10.1038/s41388-022-02475-8		OCT 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5W8QC	36182968	Green Published, hybrid			2022-12-17	WOS:000862526800002
J	Srivastava, S; Jiang, J; Misra, J; Seim, G; Staschke, KA; Zhong, MH; Zhou, L; Liu, Y; Chen, C; Dave, U; Kapur, R; Batra, S; Zhang, C; Zhou, JH; Fan, J; Wek, RC; Zhang, J				Srivastava, Sankalpip; Jiang, Jie; Misra, Jagannath; Seim, Gretchen; Staschke, Kirk A.; Zhong, Minghua; Zhou, Leonardo; Liu, Yu; Chen, Chong; Dave, Utpal; Kapur, Reuben; Batra, Sandeep; Zhang, Chi; Zhou, Jiehao; Fan, Jing; Wek, Ronald C.; Zhang, Ji			Asparagine bioavailability regulates the translation of MYC oncogene	ONCOGENE			English	Article							C-MYC; GLUTAMINE; METABOLISM; DEPRIVATION; SUPPRESSION; ADAPTATION	Amino acid restriction has recently emerged as a compelling strategy to inhibit tumor growth. Recent work suggests that amino acids can regulate cellular signaling in addition to their role as biosynthetic substrates. Using lymphoid cancer cells as a model, we found that asparagine depletion acutely reduces the expression of c-MYC protein without changing its mRNA expression. Furthermore, asparagine depletion inhibits the translation of MYC mRNA without altering the rate of MYC protein degradation. Of interest, the inhibitory effect on MYC mRNA translation during asparagine depletion is not due to the activation of the general controlled nonderepressible 2 (GCN2) pathway and is not a consequence of the inhibition of global protein synthesis. In addition, both the 5' and 3' untranslated regions (UTRs) of MYC mRNA are not required for this inhibitory effect. Finally, using a MYC-driven mouse B cell lymphoma model, we found that shRNA inhibition of asparagine synthetase (ASNS) or pharmacological inhibition of asparagine production can significantly reduce the MYC protein expression and tumor growth when environmental asparagine becomes limiting. Since MYC is a critical oncogene, our results uncover a molecular connection between MYC mRNA translation and asparagine bioavailability and shed light on a potential to target MYC oncogene post-transcriptionally through asparagine restriction.	[Srivastava, Sankalpip; Jiang, Jie; Zhong, Minghua; Zhou, Leonardo; Kapur, Reuben; Zhang, Ji] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Srivastava, Sankalpip; Misra, Jagannath; Staschke, Kirk A.; Wek, Ronald C.; Zhang, Ji] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Seim, Gretchen] Univ Wisconsin Madison, Morgridge Inst Res, Madison, WI 53715 USA; [Seim, Gretchen] Univ Wisconsin Madison, Dept Nutr Sci, Madison, WI 53715 USA; [Chen, Chong] Sichuan Univ, West China Hosp, Dept Hematol, State Key Lab Biotherapy, Chengdu 610000, Sichuan, Peoples R China; [Chen, Chong] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu 610000, Sichuan, Peoples R China; [Dave, Utpal] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Batra, Sandeep] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN 46202 USA; [Zhang, Chi] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Zhou, Jiehao] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Wisconsin System; University of Wisconsin Madison; The Morgridge Institute for Research, Inc.; University of Wisconsin System; University of Wisconsin Madison; Sichuan University; Sichuan University; Indiana University System; Indiana University Bloomington; Indiana University System; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Zhang, J (corresponding author), Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.; Zhang, J (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	jzh1@iu.edu	Staschke, Kirk/HGC-5664-2022; Misra, Jagannath/AAW-8774-2021	Staschke, Kirk/0000-0001-8722-9585; Dave, Utpal/0000-0002-9416-1686; Chen, Chong/0000-0002-6787-0495	NIH/NCI [CA244625]; American Society of Hematologyand the Riley Children Foundation; NIH/NIGMS [GM136331]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Society of Hematologyand the Riley Children Foundation; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH/NCI CA244625, the American Society of Hematologyand the Riley Children Foundation. RCW is supported by NIH/NIGMS GM136331 and isa member of the advisory board of HiberCell, Inc.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; Averous J, 2016, SCI REP-UK, V6, DOI 10.1038/srep27698; Avramis VI, 2012, ANTICANCER RES, V32, P2423; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; BROOME JD, 1961, NATURE, V191, P1114, DOI 10.1038/1911114a0; Clasquin Michelle F, 2012, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1411s37; Concordet JP, 2018, NUCLEIC ACIDS RES, V46, pW242, DOI 10.1093/nar/gky354; Csibi A, 2014, CURR BIOL, V24, P2274, DOI 10.1016/j.cub.2014.08.007; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang Chi V, 2010, Genes Cancer, V1, P526; Dejure FR, 2017, EMBO J, V36, P1854, DOI 10.15252/embj.201796662; Delgado M Dolores, 2010, Genes Cancer, V1, P605, DOI 10.1177/1947601910377495; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deng LF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15573-6; Farrell AS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014365; Fine BM, 2005, CANCER RES, V65, P291; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gonzalez A, 2017, EMBO J, V36, P397, DOI 10.15252/embj.201696010; Halbrook CJ, 2020, BIORXIV, DOI [10.1101/2020.05.15.098368v1.full, DOI 10.1101/2020.05.15.098368V1.FULL]; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Jiang J, 2021, METABOLITES, V11, DOI 10.3390/metabo11060402; Jiang J, 2019, J BIOL CHEM, V294, P18674, DOI 10.1074/jbc.RA119.010447; Krall AS, 2021, CELL METAB, V33, P1013, DOI 10.1016/j.cmet.2021.02.001; Krall AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11457; Layer JH, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00652-19; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Melamud E, 2010, ANAL CHEM, V82, P9818, DOI 10.1021/ac1021166; Meng DL, 2020, J BIOL CHEM, V295, P2890, DOI 10.1074/jbc.AC119.011578; Misra J, 2021, NUCLEIC ACIDS RES, V49, P5726, DOI 10.1093/nar/gkab362; Nakamura A, 2018, P NATL ACAD SCI USA, V115, pE7776, DOI 10.1073/pnas.1805523115; Pathria G, 2019, NAT CELL BIOL, V21, P1590, DOI 10.1038/s41556-019-0415-1; Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006; Pelossof R, 2017, NAT BIOTECHNOL, V35, P350, DOI 10.1038/nbt.3807; Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.05033; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; Stine ZE, 2022, NAT REV DRUG DISCOV, V21, P141, DOI 10.1038/s41573-021-00339-6; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Sullivan LB, 2018, NAT CELL BIOL, V20, P782, DOI 10.1038/s41556-018-0125-0; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wilson GJ, 2013, AM J PHYSIOL-ENDOC M, V305, pE1124, DOI 10.1152/ajpendo.00080.2013; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Wu J, 2021, NAT CELL BIOL, V23, DOI 10.1038/s41556-020-00615-4; Ye JB, 2015, GENE DEV, V29, P2331, DOI 10.1101/gad.269324.115; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099	54	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4855	4865		10.1038/s41388-022-02474-9	http://dx.doi.org/10.1038/s41388-022-02474-9		OCT 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36182969	Green Accepted			2022-12-17	WOS:000862526800003
J	Li, T; Xie, J; Shen, C; Cheng, D; Shi, Y; Wu, Z; Deng, X; Chen, H; Shen, B; Peng, C; Li, H; Zhan, Q; Zhu, Z				Li, T.; Xie, J.; Shen, C.; Cheng, D.; Shi, Y.; Wu, Z.; Deng, X.; Chen, H.; Shen, B.; Peng, C.; Li, H.; Zhan, Q.; Zhu, Z.			RETRACTION: Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma (Retraction of Vol 35, Pg 1575, 2016)	ONCOGENE			English	Retraction												zhuzhecheng@126.com						Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223	1	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4839	4839		10.1038/s41388-022-02480-x	http://dx.doi.org/10.1038/s41388-022-02480-x		SEP 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36180782	Bronze			2022-12-17	WOS:000862230300001
J	Maiques-Diaz, A; Nicosia, L; Basma, NJ; Romero-Camarero, I; Camera, F; Spencer, GJ; Amaral, FMR; Simeoni, F; Wingelhofer, B; Williamson, AJK; Pierce, A; Whetton, AD; Somervaille, TCP				Maiques-Diaz, Alba; Nicosia, Luciano; Basma, Naseer J.; Romero-Camarero, Isabel; Camera, Francesco; Spencer, Gary J.; Amaral, Fabio M. R.; Simeoni, Fabrizio; Wingelhofer, Bettina; Williamson, Andrew J. K.; Pierce, Andrew; Whetton, Anthony D.; Somervaille, Tim C. P.			HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block	ONCOGENE			English	Article							TRANS-RETINOIC ACID; SNAG DOMAIN; DEMETHYLASE; INHIBITION; COREST; DEACETYLASE; COMPLEX; MLL; PROLIFERATION; NEUTROPENIA	Pharmacologic inhibition of LSD1 induces molecular and morphologic differentiation of blast cells in acute myeloid leukemia (AML) patients harboring MLL gene translocations. In addition to its demethylase activity, LSD1 has a critical scaffolding function at genomic sites occupied by the SNAG domain transcription repressor GFI1. Importantly, inhibitors block both enzymatic and scaffolding activities, in the latter case by disrupting the protein:protein interaction of GFI1 with LSD1. To explore the wider consequences of LSD1 inhibition on the LSD1 protein complex we applied mass spectrometry technologies. We discovered that the interaction of the HMG-box protein HMG20B with LSD1 was also disrupted by LSD1 inhibition. Downstream investigations revealed that HMG20B is co-located on chromatin with GFI1 and LSD1 genome-wide; the strongest HMG20B binding co-locates with the strongest GFI1 and LSD1 binding. Functional assays demonstrated that HMG20B depletion induces leukemia cell differentiation and further revealed that HMG20B is required for the transcription repressor activity of GFI1 through stabilizing LSD1 on chromatin at GFI1 binding sites. Interaction of HMG20B with LSD1 is through its coiled-coil domain. Thus, HMG20B is a critical component of the GFI1:LSD1 transcription repressor complex which contributes to leukemia cell differentiation block.	[Maiques-Diaz, Alba; Nicosia, Luciano; Basma, Naseer J.; Romero-Camarero, Isabel; Camera, Francesco; Spencer, Gary J.; Amaral, Fabio M. R.; Simeoni, Fabrizio; Wingelhofer, Bettina; Somervaille, Tim C. P.] Univ Manchester, Canc Res UK Manchester Inst, Leukaemia Biol Lab, Manchester Canc Res Ctr Bldg,555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England; [Williamson, Andrew J. K.; Pierce, Andrew; Whetton, Anthony D.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Wolfson Mol Imaging Ctr, Stem Cell & Leukaemia Prote Lab, 27 Palatine Rd, Manchester M20 3LJ, Lancs, England; [Pierce, Andrew] Fron Heulog Bangor Univ, Coll Human Sci, Sch Med & Hlth Sci, Bangor LL57 2TH, Gwynedd, Wales; [Whetton, Anthony D.] Univ Surrey, Sch Vet Med, VSM Bldg, Guildford GU2 7AL, Surrey, England; [Whetton, Anthony D.] Univ Surrey, Sch Biosci & Med, VSM Bldg, Guildford GU2 7AL, Surrey, England	Cancer Research UK; University of Manchester; University of Manchester; University of Surrey; University of Surrey	Somervaille, TCP (corresponding author), Univ Manchester, Canc Res UK Manchester Inst, Leukaemia Biol Lab, Manchester Canc Res Ctr Bldg,555 Wilmslow Rd, Manchester M20 4GJ, Lancs, England.	tim.somervaille@cruk.manchester.ac.uk		Nicosia, Luciano/0000-0003-3016-931X; Romero-Camarero, Isabel/0000-0002-2859-7641; Simeoni, Fabrizio/0000-0002-5543-6413; Maiques-Diaz, Alba/0000-0002-3365-3775	Cancer Research UK [C5759/A20971, C5759/A27412]; Kay Kendall Leukaemia Fund Junior Research Fellowship [KKL1185]; Blood Cancer UK [13005, 19007]; Imago Biosciences; Leukaemia UK [2020/JGF/005]	Cancer Research UK(Cancer Research UK); Kay Kendall Leukaemia Fund Junior Research Fellowship; Blood Cancer UK; Imago Biosciences; Leukaemia UK	This work was supported by Cancer Research UK grant numbers C5759/A20971 and C5759/A27412 (AM-D, LN, FC, IR-C, GJS, BW, FMRA, FS, TCPS); a Kay Kendall Leukaemia Fund Junior Research Fellowship (KKL1185) (to IR-C); Blood Cancer UK grant numbers 13005 and 19007 (to AP, AJKW, ADW); an educational grant from Imago Biosciences (to NJB); and Leukaemia UK grant number 2020/JGF/005 (to BW). We are grateful to Jeff Barry, Wolfgang Breitwieser, Gillian Newton, Duncan Smith, John Weightman for technical support; and to Andrew Porter for pre-submission review of the manuscript. Cancer Research UK grant numbers C5759/A20971 and C5759/A27412; Kay Kendall Leukaemia Fund Junior Research Fellowship KKL1185; Blood Cancer UK grant numbers 13005 and 19007; Leukaemia UK grant number 2020/JGF/005.	Barth J, 2019, LEUKEMIA, V33, P1411, DOI 10.1038/s41375-018-0375-7; Carmichael CL, 2020, BLOOD, V136, P957, DOI 10.1182/blood.2019002548; Deb G, 2020, LEUKEMIA, V34, P1266, DOI 10.1038/s41375-019-0659-6; Esteghamat F, 2011, HAEMATOL-HEMATOL J, V96, P1252, DOI 10.3324/haematol.2011.045211; Fiskus W, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00487-3; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Ishikawa Y, 2017, MOL CANCER THER, V16, P273, DOI 10.1158/1535-7163.MCT-16-0471; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Lee C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08269-5; Leiendecker L, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012525; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Maiques-Diaz A, 2018, CELL REP, V22, P3641, DOI 10.1016/j.celrep.2018.03.012; Maiques-Diaz A, 2016, EPIGENOMICS-UK, V8, P1103, DOI 10.2217/epi-2016-0009; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Marneth AE, 2018, HAEMATOLOGICA, V103, pE395, DOI 10.3324/haematol.2017.180844; McClellan D, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00020-19; McGrath JP, 2016, CANCER RES, V76, P1975, DOI 10.1158/0008-5472.CAN-15-2333; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Moroy T, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00824; Nicosia L, 2022, ONCOGENE, V41, P878, DOI 10.1038/s41388-021-02123-7; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Pettit K, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123244; Ravasio R, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2746; Rivero S, 2015, ONCOGENE, V34, P5264, DOI 10.1038/onc.2014.446; Salamero O, 2020, J CLIN ONCOL, V38, P4260, DOI 10.1200/JCO.19.03250; Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Song Y, 2020, CELL REP, V30, P2699, DOI 10.1016/j.celrep.2020.01.091; Sumoy L, 2000, CYTOGENET CELL GENET, V88, P62, DOI 10.1159/000015486; Takagi S, 2017, CANCER RES, V77, P4652, DOI 10.1158/0008-5472.CAN-16-3502; Tayari MM, 2021, CLIN CANCER RES, V27, P1893, DOI 10.1158/1078-0432.CCR-20-4054; van Bergen MGJM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01027; Wass M, 2021, LEUKEMIA, V35, P701, DOI 10.1038/s41375-020-0892-z; Welcker JE, 2013, DEVELOPMENT, V140, P4947, DOI 10.1242/dev.097642; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Wynder C, 2005, NAT CELL BIOL, V7, P1113, DOI 10.1038/ncb1312; Yamamoto Ryusuke, 2018, Oncotarget, V9, P21007, DOI 10.18632/oncotarget.24774; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	47	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2022	41	44					4841	4854		10.1038/s41388-022-02471-y	http://dx.doi.org/10.1038/s41388-022-02471-y		SEP 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5U1RX	36171271	hybrid, Green Published			2022-12-17	WOS:000861196200001
J	Ogden, S; Carys, K; Ahmed, I; Bruce, J; Sharrocks, AD				Ogden, Samuel; Carys, Kashmala; Ahmed, Ibrahim; Bruce, Jason; Sharrocks, Andrew D.			Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition	ONCOGENE			English	Article							CANCER-CELLS; ESOPHAGEAL; TRASTUZUMAB; DRIVES; COMBINATION; PLASTICITY; LAPATINIB; GENES; ALPHA; WOMEN	Oesophageal adenocarcinoma (OAC) patients show poor survival rates and there are few targeted molecular therapies available. However, components of the receptor tyrosine kinase (RTK) driven pathways are commonly mutated in OAC, typified by high frequency amplifications of the RTK ERBB2. ERBB2 can be therapeutically targeted, but this has limited clinical benefit due to the acquisition of drug resistance. Here we examined how OAC cells adapt to ERBB2 inhibition as they transition to a drug resistant state. ERBB2 inhibition triggers widespread remodelling of the accessible chromatin landscape and the underlying gene regulatory networks. The transcriptional regulators HNF4A and PPARGC1A play a key role in this network rewiring. Initially, inhibition of cell cycle associated gene expression programmes is observed, with compensatory increases in the programmes driving changes in metabolic activity. Both PPARGC1A and HNF4A are required for the acquisition of resistance to ERBB2 inhibition and PPARGC1A is instrumental in promoting a switch to dependency on oxidative phosphorylation. Our work therefore reveals the molecular pathways that support the acquisition of a resistant state and points to potential new therapeutic strategies to combat cellular adaptation and ensuing drug resistance.	[Ogden, Samuel; Carys, Kashmala; Ahmed, Ibrahim; Bruce, Jason; Sharrocks, Andrew D.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England	University of Manchester	Sharrocks, AD (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	andrew.d.sharrocks@manchester.ac.uk		Bruce, Jason/0000-0002-4503-1981	Wellcome Trust [103857/Z/14/Z, 102171/Z/13/Z]	Wellcome Trust(Wellcome Trust)	We thank Guanhua Yan for excellent technical assistance, Connor Rogerson for advice and help with RNA-seq data processing and staff in the Bioinformatics, Genomic Technologies and Flow cytometry core facilities. Rebecca Fitzgerald for providing the OAC organoid. We also thank Nicoletta Bobola, Tim Somervaille and Shen-Hsi Yang for critical appraisal of the manuscript. This work was funded by grants from the Wellcome Trust (103857/Z/14/Z and 102171/Z/13/Z).	Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Bang YJ, 2010, LANCET, V376, P1302; Bell CC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10652-9; Bi MJ, 2020, NAT CELL BIOL, V22, P701, DOI 10.1038/s41556-020-0514-z; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Britton E, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006879; Brunton H, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107625; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Charos AE, 2012, GENOME RES, V22, P1668, DOI 10.1101/gr.127761.111; Chen L, 2020, GUT, V69, P630, DOI 10.1136/gutjnl-2019-318325; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coleman HG, 2018, GASTROENTEROLOGY, V154, P390, DOI 10.1053/j.gastro.2017.07.046; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; De Vitto H, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0081-6; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Flavahan WA, 2019, NATURE, V575, P229, DOI 10.1038/s41586-019-1668-3; Frankell AM, 2019, NAT GENET, V51, P506, DOI 10.1038/s41588-018-0331-5; Hammerlindl H, 2018, J CELL COMMUN SIGNAL, V12, P133, DOI 10.1007/s12079-017-0435-1; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hecht JR, 2016, J CLIN ONCOL, V34, P443, DOI 10.1200/JCO.2015.62.6598; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Janjigian YY, 2018, CANCER DISCOV, V8, P49, DOI 10.1158/2159-8290.CD-17-0787; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Keld R, 2011, BRIT J CANCER, V105, P124, DOI 10.1038/bjc.2011.187; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kim J, 2014, J CLIN INVEST, V124, P5145, DOI 10.1172/JCI75200; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li XD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05190-9; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003; Ma S, 2021, CANCER RES, V81, P1216, DOI 10.1158/0008-5472.CAN-20-0652; Maag JLV, 2017, MOL CANCER RES, V15, P1558, DOI 10.1158/1541-7786.MCR-17-0332; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Pan J, 2020, CANCER RES, V80, P2722, DOI 10.1158/0008-5472.CAN-20-0390; Peters Y, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0086-z; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rogerson C, 2020, ELIFE, V9, DOI 10.7554/eLife.57189; Rogerson C, 2019, GENOME RES, V29, P723, DOI 10.1101/gr.243345.118; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shen SS, 2020, CELL, V183, P860, DOI 10.1016/j.cell.2020.10.027; Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051; Stachler MD, 2018, GASTROENTEROLOGY, V155, P156, DOI 10.1053/j.gastro.2018.03.047; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang DS, 2019, GUT, V68, P1152, DOI 10.1136/gutjnl-2018-316522; Weaver JMJ, 2014, NAT GENET, V46, P837, DOI 10.1038/ng.3013; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zeng Y, 2018, PHARM BIOL, V56, P393, DOI 10.1080/13880209.2018.1493610; Zhang YR, 2020, CANCER RES, V80, P30, DOI 10.1158/0008-5472.CAN-19-1389; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou Y, 2019, NAT COMMUN, V10, DOI [DOI 10.1038/S41467-019-09234-6, 10.1038/s41467-019-09234-6]	72	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4808	4822		10.1038/s41388-022-02465-w	http://dx.doi.org/10.1038/s41388-022-02465-w		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36153371	hybrid, Green Published			2022-12-17	WOS:000857812100001
J	Tang, WM; Pei, MM; Li, JY; Xu, NZ; Xiao, WS; Yu, Z; Zhang, JM; Hong, LJ; Guo, Z; Lin, JJ; Dai, WY; Xiao, YZ; Wu, XS; Liu, GN; Zhi, FC; Li, GX; Xiong, J; Chen, Y; Zhang, H; Xiang, L; Li, AM; Liu, SD; Wang, JD				Tang, Weimei; Pei, Miaomiao; Li, Jiaying; Xu, Nanzhu; Xiao, Wushuang; Yu, Zhen; Zhang, Jieming; Hong, Linjie; Guo, Zheng; Lin, Jianjiao; Dai, Weiyu; Xiao, Yizhi; Wu, Xiaosheng; Liu, Guangnan; Zhi, Fachao; Li, Guoxin; Xiong, Jing; Chen, Ye; Zhang, Hui; Xiang, Li; Li, Aimin; Liu, Side; Wang, Jide			The miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop modulates the metastasis and invasion of gastric cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; WNT SIGNALING PATHWAY; MOLECULAR-CLONING; TUMOR-METASTASIS; IN-VITRO; C-MYC; PROLIFERATION; FRAT1; EXPRESSION; REGULATOR	Although the abnormal expression of miRNAs in cancer cells is a widely accepted phenomenon, the molecular mechanisms underlying miR-3648 progression and metastasis in gastric cancer (GC) remain unclear. miR-3648 expression is downregulated and its ectopic expression in GC cells significantly suppressed cell proliferation and metastasis. Mechanistic analyses indicated that miR-3648 directly targets FRAT1 or FRAT2 and inhibits FRAT1- or FRAT2-mediated invasion and motility in vitro and in vivo. Moreover, FRAT1 physically interacted with FRAT2. Furthermore, FRAT1 overexpression promoted GC cell invasion, whereas siRNA-mediated repression of FRAT2 in FRAT1-overexpressing GC cells reversed its invasive potential. Besides, miR-3648 inactivated the Wnt/beta-catenin signalling pathway by downregulating FRAT1 and FRAT2 in GC. Interestingly, c-Myc, a downstream effector of Wnt/beta-catenin signalling, was also downregulated by miR-3648 overexpression. In turn, c-Myc negatively regulated miR-3648 expression by binding to the miR-3648 promoter. In addition, miR-3648 expression levels were negatively correlated with c-Myc, FRAT1, and FRAT2 expression in fresh gastric samples. Our studies suggest that miR-3648 acts as a tumour-suppressive miRNA and that the miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop could be a critical regulator of GC progression.	[Tang, Weimei; Pei, Miaomiao; Li, Jiaying; Xu, Nanzhu; Xiao, Wushuang; Yu, Zhen; Zhang, Jieming; Hong, Linjie; Dai, Weiyu; Xiao, Yizhi; Wu, Xiaosheng; Liu, Guangnan; Zhi, Fachao; Xiong, Jing; Li, Aimin; Liu, Side; Wang, Jide] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China; [Guo, Zheng] Shenzhen Univ, Gen Hosp, Int Canc Ctr, Dept Hematol & Oncol, Xueyuan AVE 1098, Shenzhen 518000, Guangdong, Peoples R China; [Lin, Jianjiao; Zhi, Fachao; Xiang, Li; Liu, Side; Wang, Jide] Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen 518172, Peoples R China; [Li, Guoxin] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou 510515, Peoples R China; [Chen, Ye] Southern Med Univ, Shenzhen Hosp, Clin Microecol Ctr, Shenzhen 518000, Peoples R China; [Zhang, Hui] Southern Med Univ, Hexian Mem Affiliated Hosp, Dept Gastroenterol, Guangzhou 511400, Peoples R China	Southern Medical University - China; Shenzhen University; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Li, AM; Liu, SD; Wang, JD (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Peoples R China.; Xiang, L; Liu, SD; Wang, JD (corresponding author), Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen 518172, Peoples R China.	shellyxiangli@163.com; lam0725@163.com; liuside2011@163.com; jidewang55@163.com			Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University; National Natural Science Foundation of China [81974448, 81772964, 82073066, 82103152]; GuangDong Basic and Applied Basic Research Foundation [2020A1515110059]; Guangdong Gastrointestinal Disease Research Center [2017B020209003]; Guangdong Medical Research Foundation [B2019126]; Shenzhen Science and Technology Innovation Commission [JCYJ20180306170328854]; Shenzhen Science and Technology Innovation Commission Fund [JCYJ20210324135005013]; Shenzhen Longgang District Science and Technology Innovation commission fund [LGKCYLWS 2021000012]	Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); GuangDong Basic and Applied Basic Research Foundation; Guangdong Gastrointestinal Disease Research Center; Guangdong Medical Research Foundation; Shenzhen Science and Technology Innovation Commission; Shenzhen Science and Technology Innovation Commission Fund; Shenzhen Longgang District Science and Technology Innovation commission fund	We acknowledge the generous support of the Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University. This study was supported by grants from the National Natural Science Foundation of China (Nos. 81974448, 81772964, 82073066 and 82103152), GuangDong Basic and Applied Basic Research Foundation (No. 2020A1515110059), Guangdong Gastrointestinal Disease Research Center (No. 2017B020209003), Guangdong Medical Research Foundation (No. B2019126), Shenzhen Science and Technology Innovation Commission (No. JCYJ20180306170328854), Shenzhen Science and Technology Innovation Commission Fund (No. JCYJ20210324135005013) and Shenzhen Longgang District Science and Technology Innovation commission fund (No. LGKCYLWS 2021000012).	Ahadi A, 2020, IUBMB LIFE, V72, P884, DOI 10.1002/iub.2259; Codolo G, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02923; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Doumpas N, 2019, EMBO J, V38, DOI 10.15252/embj.201798873; Fan HY, 2018, BIOCHEM BIOPH RES CO, V503, P3100, DOI 10.1016/j.bbrc.2018.08.099; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Freemantle SJ, 2002, GENE, V291, P17, DOI 10.1016/S0378-1119(02)00594-2; Gu XF, 2014, NEURO-ONCOLOGY, V16, P217, DOI 10.1093/neuonc/not194; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ibrahim HM, 2019, J GASTROINTEST CANC, V50, P370, DOI 10.1007/s12029-018-0079-2; Jiang JX, 2015, ONCOTARGET, V6, P2767, DOI 10.18632/oncotarget.3089; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Katoh M, 2009, INT J ONCOL, V34, P1411, DOI 10.3892/ijo_00000269; Kirikoshi H, 2001, INT J ONCOL, V19, P111; Li QW, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5683-4; Lin J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2474-4; Liu JJ, 2014, CANCER LETT, V347, P98, DOI 10.1016/j.canlet.2014.01.024; Liu LY, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109865; Liu Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1370-1; Lu J, 2020, J CELL PHYSIOL, V235, P6287, DOI 10.1002/jcp.29556; Lv YF, 2016, CANCER LETT, V373, P164, DOI 10.1016/j.canlet.2016.01.046; Lv ZB, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1357-7; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Paclikova P, 2021, CELL SIGNAL, V85, DOI 10.1016/j.cellsig.2021.110058; Pang YM, 2018, J CELL MOL MED, V22, P6262, DOI 10.1111/jcmm.13916; Peng Y, 2017, CANCER LETT, V385, P117, DOI 10.1016/j.canlet.2016.10.035; Peng YP, 2019, ONCOL RES, V27, P65, DOI 10.3727/096504018X15191223015016; Ren LL, 2019, THERANOSTICS, V9, P449, DOI 10.7150/thno.29055; Ruan ZY, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106003; Saitoh T, 2002, INT J ONCOL, V20, P785; Saitoh T, 2001, INT J ONCOL, V19, P311; Saitoh T, 2001, BIOCHEM BIOPH RES CO, V281, P815, DOI 10.1006/bbrc.2001.4421; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sun WR, 2019, MOL THER-NUCL ACIDS, V16, P519, DOI 10.1016/j.omtn.2019.04.006; Takahata M, 2009, J BIOL CHEM, V284, P3334, DOI 10.1074/jbc.M808989200; Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3; Tian WJ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1139-9; van Amerongen R, 2010, ONCOGENE, V29, P93, DOI 10.1038/onc.2009.310; van der Wal T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227435; Wang B, 2014, HEPATOLOGY, V59, P555, DOI 10.1002/hep.26712; Werner TV, 2017, AGING-US, V9, P932, DOI 10.18632/aging.101201; Xing RW, 2019, J NANOSCI NANOTECHNO, V19, P7526, DOI 10.1166/jnn.2019.16413; Xu K, 2019, MOL THER, V27, P1810, DOI 10.1016/j.ymthe.2019.05.017; Yan GQ, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118726; Yang C, 2016, SCI REP-UK, V6, DOI 10.1038/srep33078; Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1; Yang ZC, 2018, EXP CELL RES, V368, P194, DOI 10.1016/j.yexcr.2018.04.030; Ye GT, 2017, THERANOSTICS, V7, P3338, DOI 10.7150/thno.20512; Zhang M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1815-7; Zhang P, 2017, BRIT J CANCER, V117, P525, DOI 10.1038/bjc.2017.181; Zhang WJ, 2010, CARCINOGENESIS, V31, P1220, DOI 10.1093/carcin/bgq094; Zhang Y, 2019, J GASTRIC CANCER, V19, P315, DOI 10.5230/jgc.2019.19.e28; Zhao CC, 2017, ONCOL REP, V38, P352, DOI 10.3892/or.2017.5673; Zhao MY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0103-7; Zheng KH, 2016, CANCER LETT, V376, P178, DOI 10.1016/j.canlet.2016.03.024; Zhou DH, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10230; Zhou Y, 2020, J THORAC DIS, V12, P3478, DOI 10.21037/jtd-20-1557A	58	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4823	4838		10.1038/s41388-022-02451-2	http://dx.doi.org/10.1038/s41388-022-02451-2		SEP 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36153370	hybrid, Green Published			2022-12-17	WOS:000857812100002
J	Komatsu, M; Ichikawa, H; Chiwaki, F; Sakamoto, H; Komatsuzaki, R; Asaumi, M; Tsunoyama, K; Fukagawa, T; Matsushita, H; Boku, N; Matsusaki, K; Takeshita, F; Yoshida, T; Sasaki, H				Komatsu, Masayuki; Ichikawa, Hitoshi; Chiwaki, Fumiko; Sakamoto, Hiromi; Komatsuzaki, Rie; Asaumi, Makoto; Tsunoyama, Kazuhisa; Fukagawa, Takeo; Matsushita, Hiromichi; Boku, Narikazu; Matsusaki, Keisuke; Takeshita, Fumitaka; Yoshida, Teruhiko; Sasaki, Hiroki			ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer	ONCOGENE			English	Article							LIQUID-CHROMATOGRAPHY; STEM-CELLS; PROTEOMICS; MUTATIONS; CARCINOMA; SURVIVAL; ENTOSIS; ROLES; GAIN	Genetic alteration of Rho GTPase-activating proteins (ARHGAP) and GTPase RhoA is a hallmark of diffuse-type gastric cancer and elucidating its biological significance is critical to comprehensively understanding this malignancy. Here, we report that gene fusions of ARHGAP6/ARHGAP26 are frequent genetic events in peritoneally-metastasized gastric and pancreatic cancer. From the malignant ascites of patients, we established gastric cancer cell lines that spontaneously gain hotspot RHOA mutations or four different ARHGAP6/ARHGAP26 fusions. These alterations critically downregulate RhoA-ROCK-MLC2 signaling, which elicits cell death. Omics and functional analyses revealed that the downstream signaling initiates actin stress fibers and reinforces intercellular junctions via several types of catenin. E-cadherin-centered homotypic adhesion followed by lysosomal membrane permeabilization is a pivotal mechanism in cell death. These findings support the tumor-suppressive nature of ARHGAP-RhoA signaling and might indicate a new avenue of drug discovery against this refractory cancer.	[Komatsu, Masayuki; Chiwaki, Fumiko; Takeshita, Fumitaka; Sasaki, Hiroki] Natl Canc Ctr, Dept Translat Oncol, Res Inst, Tokyo, Japan; [Ichikawa, Hitoshi; Sakamoto, Hiromi] Natl Canc Ctr, Dept Clin Genom, Tokyo, Japan; [Komatsuzaki, Rie] Natl Canc Ctr, Div Canc Therapeut, Tokyo, Japan; [Asaumi, Makoto; Tsunoyama, Kazuhisa] Astellas Pharma Inc, Adv Informat & Analyt, Ibaraki, Japan; [Fukagawa, Takeo] Teikyo Univ, Dept Surg, Sch Med, Tokyo, Japan; [Matsushita, Hiromichi] Natl Canc Ctr, Dept Lab Med, Tokyo, Japan; [Boku, Narikazu] Natl Canc Ctr, Div Gastrointestinal Med Oncol, Tokyo, Japan; [Matsusaki, Keisuke] Kanamecho Hosp, Ascites Treatment Ctr, Tokyo, Japan; [Yoshida, Teruhiko] Natl Canc Ctr, Genet Med & Serv, Tokyo, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Astellas Pharmaceuticals; Teikyo University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Komatsu, M; Sasaki, H (corresponding author), Natl Canc Ctr, Dept Translat Oncol, Res Inst, Tokyo, Japan.	makomats@ncc.go.jp; hksasaki@ncc.go.jp		Komatsu, Masayuki/0000-0003-1180-1746; Chiwaki, Fumiko/0000-0002-0914-9157; Ichikawa, Hitoshi/0000-0003-0142-2240; Boku, Narikazu/0000-0002-1438-707X	National Institute of Biomedical Innovation [ID10-41]; National Cancer Center Research and Development Fund [28-A-11, 29-A-2, 2020-J-2]; AMED (Japan Agency for Medical Research and Development) [JP20ck0106519]; Astellas Pharma, Inc [CH27066]	National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); National Cancer Center Research and Development Fund(National Cancer Center - Japan); AMED (Japan Agency for Medical Research and Development)(Japan Agency for Medical Research and Development (AMED)); Astellas Pharma, Inc(Astellas Pharmaceuticals)	This research was supported by the National Institute of Biomedical Innovation (Program ID10-41), by the National Cancer Center Research and Development Fund (28-A-11, 29-A-2, and 2020-J-2), by AMED (Japan Agency for Medical Research and Development, JP20ck0106519), and by Astellas Pharma, Inc (CH27066). We thank H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.	Abe Y, 2020, THERANOSTICS, V10, P2115, DOI 10.7150/thno.37623; Alduaij W, 2011, BLOOD, V117, P4519, DOI 10.1182/blood-2010-07-296913; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bros M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070733; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; DUARTE I, 1981, HUM PATHOL, V12, P237, DOI 10.1016/S0046-8177(81)80124-4; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Fukagawa T, 2010, WORLD J SURG, V34, P563, DOI 10.1007/s00268-009-0355-1; Hamann JC, 2017, CELL REP, V20, P201, DOI 10.1016/j.celrep.2017.06.037; Han MKL, 2017, NAT CELL BIOL, V19, P14, DOI 10.1038/ncb3457; Hodge RG, 2020, CRIT REV BIOCHEM MOL, V55, P386, DOI 10.1080/10409238.2020.1810622; Ivanov A, 2009, J CLIN INVEST, V119, P2143, DOI 10.1172/JCI37884; Japanese Gastric Cancer Association Registration Committee, 2006, Gastric Cancer, V9, P51; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kumeta M, 2018, GENES CELLS, V23, P715, DOI 10.1111/gtc.12603; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Loh CY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101118; Lu M, 2014, MOL CELL, V54, P987, DOI 10.1016/j.molcel.2014.04.029; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; MacDonald Justin A., 2018, Cardiovascular & Hematological Disorders - Drug Targets, V18, P4, DOI 10.2174/1871529X18666180326120638; Maeda M, 2016, GASTRIC CANCER, V19, P326, DOI 10.1007/s10120-015-0525-9; Mendonsa AM, 2018, ONCOGENE, V37, P4769, DOI 10.1038/s41388-018-0304-2; Mimori K, 2008, CLIN CANCER RES, V14, P2609, DOI 10.1158/1078-0432.CCR-07-4354; Nakayama I, 2019, CANCER SCI, V110, P1352, DOI 10.1111/cas.13967; Negishi A, 2009, CANCER SCI, V100, P514, DOI 10.1111/j.1349-7006.2008.01055.x; Ono M, 2006, MOL CELL PROTEOMICS, V5, P1338, DOI 10.1074/mcp.T500039-MCP200; Petrova YI, 2016, MOL BIOL CELL, V27, P3233, DOI 10.1091/mbc.E16-01-0058; Polkowski W, 1999, ANN SURG ONCOL, V6, P290, DOI 10.1007/s10434-999-0290-2; Qiu MZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-58; Ratheesh A, 2012, NAT REV MOL CELL BIO, V13, P673, DOI 10.1038/nrm3431; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Shim HJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66637-y; Shu Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04907-0; Song HN, 2016, J THORAC ONCOL, V11, pE45, DOI 10.1016/j.jtho.2015.12.093; Sun Q, 2014, CELL RES, V24, P1288, DOI 10.1038/cr.2014.137; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Tanaka Atsushi, 2018, Oncotarget, V9, P29336, DOI 10.18632/oncotarget.25464; Tanaka Y, 2021, NAT CANCER, V2, P962, DOI 10.1038/s43018-021-00240-6; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Ushiku T, 2016, GASTRIC CANCER, V19, P403, DOI 10.1007/s10120-015-0493-0; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Xu XF, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0847-5; Yang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06747-4; Yang HHN, 2018, CELL STEM CELL, V23, P882, DOI 10.1016/j.stem.2018.09.016; Yao F, 2015, CELL REP, V12, P272, DOI 10.1016/j.celrep.2015.06.020; Zhang HS, 2020, CANCER DISCOV, V10, P288, DOI 10.1158/2159-8290.CD-19-0811; Zhang WH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01214; Zheng HC, 2008, VIRCHOWS ARCH, V452, P525, DOI 10.1007/s00428-007-0572-7	58	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4779	4794		10.1038/s41388-022-02469-6	http://dx.doi.org/10.1038/s41388-022-02469-6		SEP 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36127398				2022-12-17	WOS:000855639800002
J	Wang, Q; Wu, LH; Cao, RX; Gao, J; Chai, DM; Qin, YZ; Ma, L; Wu, SW; Tao, YS; Ma, J; Wang, ZW				Wang, Qi; Wu, Linhui; Cao, Ruoxue; Gao, Jing; Chai, Damin; Qin, Yanzi; Ma, Li; Wu, Shiwu; Tao, Yisheng; Ma, Jia; Wang, Zhi-wei			Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation	ONCOGENE			English	Article							F-BOX PROTEINS; TUMOR-SUPPRESSOR; LIGASE COMPLEX; MESENCHYMAL TRANSITION; PROLIFERATION; EXPRESSION; INVASION; SYSTEM; GROWTH; ROLES	Esophageal squamous cell carcinoma (ESCC) is one of the most common and deadly cancers. Fbxo45, a substrate recognition subunit of E3 ligase, is critically involved in tumorigenesis and tumor progression. However, the function of Fbxo45 and the underlying mechanisms have not been elucidated in ESCC. We used cellular and molecular methods to explore the molecular basis of Fbxo45-mediated ESCC development. We found that ectopic overexpression of Fbxo45 promoted the growth of Kyse-150, Kyse30 and ECA-109 cells and inhibited the apoptosis. Moreover, overexpression of Fbxo45 promoted the migration and invasion of ESCC cells. Consistently, knockdown of Fbxo45 exhibited the opposite effects on ESCC cells. Mechanistically, we observed that Fbxo45 binds to GGNBP2 via its SPRY domain and targets GGNBP2 for ubiquitination and degradation. GGNBP2 overexpression exhibited anticancer activity in ESCC cells. Furthermore, Fbxo45 exerted its functions by regulating GGNBP2 stability in ESCC cells. Notably, overexpression of Fbxo45 facilitated tumor growth in mice. Strikingly, Fbxo45 was highly expressed in ESCC tissues, and GGNBP2 had a lower expression in ESCC specimens. High expression of Fbxo45 and low expression of GGNBP2 were associated with poor prognosis in ESCC patients. Fbxo45 was negatively correlated with GGNBP2 expression in ESCC tissues. Therefore, Fbxo45 serves as an oncoprotein to promote ESCC tumorigenesis by targeting the stability of the tumor suppressor GGNBP2 in ESCC.	[Wang, Qi; Gao, Jing; Chai, Damin; Qin, Yanzi; Ma, Li; Wu, Shiwu; Tao, Yisheng] Bengbu Med Coll, Dept Pathol, Affiliated Hosp 1, Bengbu 233030, Anhui, Peoples R China; [Wang, Qi; Gao, Jing; Chai, Damin; Qin, Yanzi; Ma, Li; Wu, Shiwu; Tao, Yisheng] Bengbu Med Coll, Dept Pathol, Bengbu 233030, Anhui, Peoples R China; [Wu, Linhui; Cao, Ruoxue; Ma, Jia; Wang, Zhi-wei] Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Key Lab Canc Res & Clin Lab Diag, Bengbu 233030, Anhui, Peoples R China; [Wang, Zhi-wei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Wenzhou 325027, Zhejiang, Peoples R China	Bengbu Medical College; Bengbu Medical College; Bengbu Medical College; Wenzhou Medical University	Tao, YS (corresponding author), Bengbu Med Coll, Dept Pathol, Affiliated Hosp 1, Bengbu 233030, Anhui, Peoples R China.; Tao, YS (corresponding author), Bengbu Med Coll, Dept Pathol, Bengbu 233030, Anhui, Peoples R China.; Ma, J; Wang, ZW (corresponding author), Bengbu Med Coll, Sch Lab Med, Dept Biochem & Mol Biol, Key Lab Canc Res & Clin Lab Diag, Bengbu 233030, Anhui, Peoples R China.; Wang, ZW (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Wenzhou 325027, Zhejiang, Peoples R China.	taoyishengbbyxy@163.com; majiamj10@126.com; zhiweichina@126.com						Abshire CF, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.55; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen X, 2014, CELL DEATH DIFFER, V21, P1535, DOI 10.1038/cdd.2014.92; Cheng LL, 2020, DIAGN PATHOL, V15, DOI 10.1186/s13000-020-00929-9; Ciechanover A, 2017, BEST PRACT RES CL HA, V30, P341, DOI 10.1016/j.beha.2017.09.001; Cino EA, 2016, J PHYS CHEM B, V120, P1060, DOI 10.1021/acs.jpcb.5b11565; Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017; Glynn RW, 2010, CANCER TREAT REV, V36, P224, DOI 10.1016/j.ctrv.2009.12.007; Gong J, 2016, INT J ONCOL, V48, P886, DOI 10.3892/ijo.2016.3325; Gong J, 2015, INT J ONCOL, V47, P43, DOI 10.3892/ijo.2015.2983; Gong J, 2014, INT J ONCOL, V45, P2199, DOI 10.3892/ijo.2014.2684; Guan R, 2012, MOL CELL BIOCHEM, V365, P211, DOI 10.1007/s11010-012-1262-6; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Kim HY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03757-x; Kogure N, 2017, ANTICANCER RES, V37, P191, DOI 10.21873/anticanres.11305; Lan ZJ, 2016, BREAST CANCER RES TR, V158, P263, DOI 10.1007/s10549-016-3880-2; Levin AM, 2008, CANCER RES, V68, P6492, DOI 10.1158/0008-5472.CAN-08-0348; Li SQ, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.136358; Lin M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0291-2; Lin M, 2019, CANCER LETT, V466, P61, DOI 10.1016/j.canlet.2019.09.008; Liu JJ, 2019, BREAST CANCER RES TR, V174, P65, DOI 10.1007/s10549-018-5052-z; MacGurn JA, 2012, ANNU REV BIOCHEM, V81, P231, DOI 10.1146/annurev-biochem-060210-093619; Malhotra GK, 2017, J SURG ONCOL, V115, P564, DOI 10.1002/jso.24592; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Pickens A, 2003, ANN THORAC SURG, V76, pS1367, DOI 10.1016/S0003-4975(03)01202-5; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Richter KT, 2020, CELL DEATH DIFFER, V27, P758, DOI 10.1038/s41418-019-0385-7; Saiga T, 2009, MOL CELL BIOL, V29, P3529, DOI 10.1128/MCB.00364-09; Salat D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130288; Tada H, 2010, J BIOL CHEM, V285, P3840, DOI 10.1074/jbc.M109.046284; Tang XF, 2019, GENET TEST MOL BIOMA, V23, P791, DOI 10.1089/gtmb.2019.0129; Wang K, 2018, J CANCER RES CLIN, V144, P1509, DOI 10.1007/s00432-018-2653-1; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Wu LH, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04675-2; Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2; Xia J, 2014, CURR PHARM DESIGN, V20, P5348, DOI 10.2174/1381612820666140128215756; Xia J, 2012, CURR DRUG TARGETS, V13, P1750, DOI 10.2174/138945012804545597; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825; Xu YC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00689-5; Yang Q, 2014, BRIT J CANCER, V110, P1958, DOI 10.1038/bjc.2014.136; Yin FQ, 2014, ONCOL REP, V32, P362, DOI 10.3892/or.2014.3175; Yoshida K, 2005, ONCOL REP, V14, P531; Zhan A, 2017, ONCOL RES, V25, P831, DOI 10.3727/096504016X14816726393937; Zheng NN, 2016, BBA-REV CANCER, V1866, P12, DOI 10.1016/j.bbcan.2016.05.001; Zhu ZH, 2017, GYNECOL ONCOL, V147, P418, DOI 10.1016/j.ygyno.2017.08.025	49	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2022	41	43					4795	4807		10.1038/s41388-022-02468-7	http://dx.doi.org/10.1038/s41388-022-02468-7		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5M4RI	36127399				2022-12-17	WOS:000855639800001
J	Tan, QL; Liu, ZQ; Gao, XB; Wang, YB; Qiu, XF; Chen, JH; Liang, LC; Guo, HQ; Huang, SS; Wu, DL; Zhou, B; Hu, RG; Li, ZF				Tan, Qilong; Liu, Ziqun; Gao, Xiaobo; Wang, Yibo; Qiu, Xuefeng; Chen, Jiahui; Liang, Liuchun; Guo, Hongqian; Huang, Shengsong; Wu, Denglong; Zhou, Bing; Hu, Ronggui; Li, Zhenfei			Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors	ONCOGENE			English	Article							UBIQUITIN-PROTEIN LIGASE; PROSTATE-CANCER; ANDROGEN-RECEPTOR; E6-ASSOCIATED PROTEIN; E6-AP; ENZALUTAMIDE; RESISTANCE; COACTIVATOR; EXPRESSION; MUTATIONS	Strategies to degrade steroid receptors and their alternative splicing isoforms are critical for disease management. Here we report that celastrol recruited the ubiquitin ligase UBE3A and degraded androgen receptor (AR), AR-v7, and glucocorticoid receptor (GR) to suppress prostate cancer development. UBE3A was not an optimal endogenous AR ubiquitin ligase in mice and patients, but celastrol promoted the interaction between UBE3A and AR. Multiple domains of AR, including the DNA binding domain (DBD), were implicated into the UBE3A-AR interaction. Sharing a conserved DBD, GR, AR-v7, and other steroid receptors were recognized and degraded by UBE3A after celastrol treatment. Thus, celastrol suppressed prostate cancer cell proliferation more potently than enzalutamide. Modifying the carboxyl group of celastrol improved its anti-tumor activity. Together, our findings revealed that celastrol might be a potential molecular glue to enhance the interaction between UBE3A and steroid receptors to degrade multiple steroid receptors and splicing isoforms in prostate cancer, paving a way for further drug optimization and disease treatment.	[Tan, Qilong; Liu, Ziqun; Chen, Jiahui; Li, Zhenfei] Univ Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,Chinese Acad Sc, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Gao, Xiaobo] Fudan Univ, State Key Lab Med Neurobiol, Inst Translat Brain Res, Shanghai 200032, Peoples R China; [Gao, Xiaobo] Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai 200032, Peoples R China; [Hu, Ronggui] Univ Chinese Acad Sci, Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,State Key Lab M, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Wang, Yibo; Liang, Liuchun; Zhou, Bing] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Wang, Yibo; Zhou, Bing] Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou 310024, Peoples R China; [Qiu, Xuefeng; Guo, Hongqian] Nanjing Univ, Med Sch, Affiliated Drum Tower Hosp, Dept Urol, Nanjing 210008, Peoples R China; [Huang, Shengsong; Wu, Denglong] Tongji Univ, Tongji Hosp, Sch Med, Dept Urol, Shanghai 200065, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Fudan University; Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Nanjing University; Tongji University	Li, ZF (corresponding author), Univ Chinese Acad Sci, State Key Lab Cell Biol, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,Chinese Acad Sc, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Hu, RG (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, CAS Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol,State Key Lab M, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Zhou, B (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.; Zhou, B (corresponding author), Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou 310024, Peoples R China.	zhoubing@simm.ac.cn; coryhu@sibcb.ac.cn; zhenfei.li@sibcb.ac.cn	Li, Zhenfei/AAU-1097-2020	Li, Zhenfei/0000-0001-6520-431X; wang, yibo/0000-0002-6952-2582	National Key R&D Program of China [2018YFA0508200, 2019YFA0802103]; National Natural Science Foundation of China [92157101, 81973166, 91753207, 91853128, 81525019]; Department of Science and Technology of Zhejiang Province [2021C03104]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Zhejiang Province	We thank the staff members (Zhuo Yang, et al) of the chemical biology core facility, the high-performance computing service platform, and the bioinformatics core in Shanghai Institute of Biochemistry and Cell Biology (SIBCB), mass spectrometry staff members of the National Facility for Protein in Shanghai (NFPS), and the Zhangjiang Lab and staff members (Pengyu Wang, et al.) of Bio-Med Big Data Center /Shanghai Institute of Nutrition and Health (SINH) for providing technical support and assistance in data collection and analysis. This work was supported by funding from the National Key R&D Program of China (2018YFA0508200 to ZL; 2019YFA0802103 and 2018YFA0508200 to RH), National Natural Science Foundation of China (92157101 to ZL; 81973166, 91753207 to BZ; 91853128, 81525019 to RH). RH was also supported by funding from Department of Science and Technology of Zhejiang Province (Proj. No. 2021C03104).	Alyamani M, 2017, CELL CHEM BIOL, V24, P825, DOI 10.1016/j.chembiol.2017.05.020; [Anonymous], 2020, Cancer Discov, V10, P1084, DOI 10.1158/2159-8290.CD-NB2020-054; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Birch SE, 2014, ANN ONCOL, V25, P2392, DOI 10.1093/annonc/mdu454; Chadli A, 2010, J BIOL CHEM, V285, P4224, DOI 10.1074/jbc.M109.081018; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Efstathiou E, 2015, EUR UROL, V67, P53, DOI 10.1016/j.eururo.2014.05.005; Fang MM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.681295; Furr BJA, 1996, EUR UROL, V29, P83; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Groner AC, 2017, J CLIN INVEST, V127, P1126, DOI 10.1172/JCI88885; Han X, 2019, J MED CHEM, V62, P941, DOI 10.1021/acs.jmedchem.8b01631; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hou ZM, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100561; Hou ZM, 2021, CANCER LETT, V516, P1, DOI 10.1016/j.canlet.2021.04.010; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jones JO, 2009, ACS CHEM BIOL, V4, P199, DOI 10.1021/cb900024z; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014; Li HF, 2014, J MED CHEM, V57, P6458, DOI 10.1021/jm500802j; Li JN, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe8226; Lim HY, 2021, CANCER LETT, V521, P252, DOI 10.1016/j.canlet.2021.08.030; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mei ZJ, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100608; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Ponnusamy S, 2019, CLIN CANCER RES, V25, P6764, DOI 10.1158/1078-0432.CCR-19-1458; Ramamoorthy Sivapriya, 2008, Nucl Recept Signal, V6, pe006, DOI 10.1621/nrs.06006; Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schneekloth AR, 2008, BIOORG MED CHEM LETT, V18, P5904, DOI 10.1016/j.bmcl.2008.07.114; Seo HR, 2011, CHEM-BIOL INTERACT, V193, P34, DOI 10.1016/j.cbi.2011.04.009; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shi JF, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.558741; Smith CL, 2002, MOL CELL BIOL, V22, P525, DOI 10.1128/MCB.22.2.525-535.2002; Takwale AD, 2020, EUR J MED CHEM, V208, DOI 10.1016/j.ejmech.2020.112769; Tata JR, 2002, NAT REV MOL CELL BIO, V3, P702, DOI 10.1038/nrm914; Toure M, 2016, ANGEW CHEM INT EDIT, V55, P1966, DOI 10.1002/anie.201507978; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Xu XX, 2018, CELL RES, V28, P48, DOI 10.1038/cr.2017.132; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Zhao LJ, 2020, NEOPLASIA, V22, P522, DOI 10.1016/j.neo.2020.07.002; Zhou YQ, 2017, MOL BIOSYST, V13, P83, DOI 10.1039/c6mb00691d	51	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4754	4767		10.1038/s41388-022-02467-8	http://dx.doi.org/10.1038/s41388-022-02467-8		SEP 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36109631				2022-12-17	WOS:000854052300001
J	Gao, YF; Jiang, M; Guo, FQ; Liu, XJ; Zhang, Q; Yang, S; Yeung, YT; Yang, R; Wang, KK; Wu, Q; Zhang, DD; Zhang, CJ; Laster, KV; Ge, MM; Nie, WN; Liu, KD; Dong, ZG				Gao, Yunfeng; Jiang, Ming; Guo, Fangqin; Liu, Xuejiao; Zhang, Qi; Yang, Sen; Yeung, Yiu To; Yang, Ran; Wang, Keke; Wu, Qiong; Zhang, Dandan; Zhang, Chengjuan; Laster, Kyle Vaughn; Ge, Mengmeng; Nie, Wenna; Liu, Kangdong; Dong, Zigang			A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC	ONCOGENE			English	Article							MESSENGER-RNA STABILITY; LIQUID PHASE-SEPARATION; LONG NONCODING RNA; ONCOGENE; CONTRIBUTES; GROWTH	Abnormal translation of the MYC proto-oncogene is a hallmark of the initiation and maintenance of tumorigenesis. However, the molecular mechanism underlying increased MYC protein levels in certain cancer types without a corresponding increase in MYC mRNA levels is unclear. Here, we identified a novel lncRNA, MTAR1, which is critical for post-transcriptional regulation of MYC-induced tumorigenesis. MTAR1 is essential for recruiting IGF2BPs into PABP1-mediated liquid-liquid phase separation (LLPS) complexes and facilitates IGF2BPs-mediated MYC mRNA translation. MTAR1 enhanced binding between IGF2BPs and PABP1, thereby promoting MYC mRNA stability and increased MYC mRNA translation. In summary, MTAR1 is a novel MYC-related lncRNA that contributes to tumor progression by enhancing MYC translation through mediating PABP1/IGF2BPs liquid-liquid phase separation.	[Gao, Yunfeng; Jiang, Ming; Guo, Fangqin; Liu, Xuejiao; Zhang, Qi; Yang, Sen; Yang, Ran; Wang, Keke; Wu, Qiong; Zhang, Dandan; Laster, Kyle Vaughn; Ge, Mengmeng; Nie, Wenna; Liu, Kangdong; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China; [Liu, Xuejiao; Wu, Qiong; Liu, Kangdong; Dong, Zigang] Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, AMS, Zhengzhou 450000, Peoples R China; [Yeung, Yiu To] Univ Edinburgh, Ctr Reprod Hlth, Queens Med Res Inst, Med Res Council MRC, Edinburgh EH16 4TJ, Midlothian, Scotland; [Zhang, Chengjuan] Henan Canc Hosp, Dept Mol Pathol Cent Biorepository, Zhengzhou 450000, Peoples R China; [Liu, Kangdong; Dong, Zigang] Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Peoples R China; [Liu, Kangdong; Dong, Zigang] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Peoples R China	Zhengzhou University; University of Edinburgh; Zhengzhou University	Liu, KD; Dong, ZG (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou 450000, Peoples R China.; Liu, KD; Dong, ZG (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Pathophysiol Dept, AMS, Zhengzhou 450000, Peoples R China.; Liu, KD; Dong, ZG (corresponding author), Canc Chemoprevent Int Collaborat Lab, Zhengzhou 450000, Peoples R China.; Liu, KD; Dong, ZG (corresponding author), State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450000, Peoples R China.	kdliu@hci-cn.org; zgdong@hci-cn.org	Jiang, Ming/GSE-4312-2022	Jiang, Ming/0000-0001-6794-3116	National Natural Science Foundations of China [81872335, 81802875, 81972639]; Project of Science and Technology of the Henan Province for Tackling Key Problems [182102310128]	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC)); Project of Science and Technology of the Henan Province for Tackling Key Problems	This research is supported by the National Natural Science Foundations of China (No. 81802876), the Project of Science and Technology of the Henan Province for Tackling Key Problems (182102310128) and the National Natural Science Foundations of China (Nos. 81872335, 81802875, 81972639).	Aguzzi A, 2016, TRENDS CELL BIOL, V26, P547, DOI 10.1016/j.tcb.2016.03.004; Bachireddy P, 2012, CLIN EXP IMMUNOL, V167, P188, DOI 10.1111/j.1365-2249.2011.04514.x; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bolha L, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7243968; Borzi C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2003-5; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045; Cai DF, 2019, NAT CELL BIOL, V21, P1578, DOI 10.1038/s41556-019-0433-z; Cao JG, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4217259; Casey SC, 2018, BLOOD, V131, P2007, DOI 10.1182/blood-2017-11-742577; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Emst C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00168; Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556-021-00641-w; Fox AH, 2018, TRENDS BIOCHEM SCI, V43, P124, DOI 10.1016/j.tibs.2017.12.001; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Guo CJ, 2020, CELL, V181, P621, DOI 10.1016/j.cell.2020.03.006; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hunecke D, 2012, J PATHOL, V228, P520, DOI 10.1002/path.4059; Hyman AA, 2014, ANNU REV CELL DEV BI, V30, P39, DOI 10.1146/annurev-cellbio-100913-013325; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Lian Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317715804; Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102621; Lu Y, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0485-0; Marderosian M, 2006, ONCOGENE, V25, P6277, DOI 10.1038/sj.onc.1209645; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Patel GP, 2005, NUCLEIC ACIDS RES, V33, P7074, DOI 10.1093/nar/gki1014; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sauvageau M, 2019, ADV EXP MED BIOL, V1203, P285, DOI 10.1007/978-3-030-31434-7_10; Tsang B, 2020, CELL, V183, P1742, DOI 10.1016/j.cell.2020.11.050; Wang JY, 2018, CANCER LETT, V419, P64, DOI 10.1016/j.canlet.2018.01.051; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Yu YF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2149; Zaslavsky BY, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090473; Zhang H, 2020, SCI CHINA LIFE SCI, V63, P953, DOI 10.1007/s11427-020-1702-x; Zhang K, 2020, MOL CANCER RES, V18, P612, DOI 10.1158/1541-7786.MCR-19-0805; Zhou HX, 2018, TRENDS BIOCHEM SCI, V43, P499, DOI 10.1016/j.tibs.2018.03.007; Zhou W, 2021, MOL CELL, V81, P739, DOI 10.1016/j.molcel.2021.01.024; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	46	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4736	4753		10.1038/s41388-022-02464-x	http://dx.doi.org/10.1038/s41388-022-02464-x		SEP 2022	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36109629				2022-12-17	WOS:000854052400001
J	Shen, XJ; Kong, S; Ma, S; Shen, L; Zheng, M; Qin, SY; Qi, J; Wang, QH; Cui, XP; Ju, SQ				Shen, Xianjuan; Kong, Shan; Ma, Shuo; Shen, Lei; Zheng, Ming; Qin, Shiyi; Qi, Jing; Wang, Qiuhong; Cui, Xiaopeng; Ju, Shaoqing			Hsa_circ_0000437 promotes pathogenesis of gastric cancer and lymph node metastasis	ONCOGENE			English	Article							SRSF3 REPRESSES; CIRCULAR RNA; BIOMARKER; PROTEIN; CELLS	Cellular communication between gastric cancer (GC) cells with different metastatic potentials and microenvironments and resultant cancer progression is not fully understood. Circular RNAs (circRNAs) and exosomal circRNAs are known to play extremely important regulatory roles in GC occurrence and progression. Here, we revealed significant differences in coronin-like actin-binding protein 1C (CORO1C) derived circRNA hsa_circ_0000437 between GC and para-cancer tissues. Hsa_circ_0000437 regulated GC cell proliferation, invasion, migration and apoptosis by targeting Ser/Arg-rich splicing factor 3 (SRSF3) and inhibiting programmed cell death 4 (PDCD4). The ectopic expression of hsa_circ_0000437 dramatically promoted tumor growth in nude mice in vivo. Furthermore, both gain-of-function and loss-of-function experiments demonstrated that hsa_circ_0000437 promoted human lymphatic endothelial cells (HLECs) invasion, migration, and tube formation in vitro and also promoted lymphangiogenesis and lymph node metastasis (LNM) in popliteal LNM model in vivo, when it was enriched in GC-secreted exosomes and transferred into HLECs. Mechanistically, exosomal hsa_circ_0000437 induced LNM via HSPA2-ERK signaling pathway independent of VEGF-C. Clinical data showed that exosomal hsa_circ_0000437 was enriched in the serum of GC patients, which was associated with LNM. In summary, these findings highlight the potential role of hsa_circ_0000437 as an outcome biomarker in GC patients with LNM, which may provide a novel target for GC therapy.	[Shen, Xianjuan; Kong, Shan; Ma, Shuo; Shen, Lei; Zheng, Ming; Qin, Shiyi; Ju, Shaoqing] Nantong Univ, Lab Med Ctr, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Shen, Xianjuan; Qi, Jing] Nantong Univ, Res Ctr Clin Med, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Wang, Qiuhong] Nantong Univ, Dept Clin Lab, Nantong Maternal & Child Hlth Care Hosp, Nantong 226018, Jiangsu, Peoples R China; [Cui, Xiaopeng] Nantong Univ, Dept Gen Surg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China	Nantong University; Nantong University; Nantong University; Nantong University	Ju, SQ (corresponding author), Nantong Univ, Lab Med Ctr, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.; Cui, XP (corresponding author), Nantong Univ, Dept Gen Surg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.	cuixiaopeng2000@163.com; jsq814@hotmail.com			National Natural Science Foundation of China [81871720, 82072363]; Nantong Science and Technology Project [MS12021002]; Nantong Commission of Health [MB2021061]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nantong Science and Technology Project; Nantong Commission of Health	This work was supported by the National Natural Science Foundation of China (Nos. 81871720, 82072363), Nantong Science and Technology Project (MS12021002). The project of Nantong Commission of Health (MB2021061).	Cao LX, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.16; Cao YZ, 2021, GENE, V767, DOI 10.1016/j.gene.2020.145182; Chai PW, 2018, NUCLEIC ACIDS RES, V46, P6041, DOI 10.1093/nar/gky366; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Cheng X, 2019, FEBS OPEN BIO, V9, P1097, DOI 10.1002/2211-5463.12639; Deng Y, 2015, ARTERIOSCL THROM VAS, V35, P421, DOI 10.1161/ATVBAHA.114.304881; Feng W, 2019, CLIN CHIM ACTA, V496, P125, DOI 10.1016/j.cca.2019.07.003; Guo X, 2021, CLIN TRANSL ONCOL, V23, P1020, DOI 10.1007/s12094-020-02485-6; Huang AQ, 2020, THERANOSTICS, V10, P3503, DOI 10.7150/thno.42174; Huang XX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0969-3; Ishii M, 2019, MOL CELL BIOCHEM, V455, P185, DOI 10.1007/s11010-018-3481-y; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Kim J, 2014, CELL DEATH DIFFER, V21, P481, DOI 10.1038/cdd.2013.171; Kok VC, 2020, INT J NANOMED, V15, P8019, DOI 10.2147/IJN.S272378; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Kuranaga Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103012; Lei B, 2019, INT J MED SCI, V16, P292, DOI 10.7150/ijms.28047; Lei M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1135-7; Liang YK, 2021, MOL THER-NUCL ACIDS, V23, P355, DOI 10.1016/j.omtn.2020.11.012; Lim JP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3187-7; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01358-w; Ma S, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04158-w; Ma S, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01701-1; Maeng YS, 2016, ONCOGENE, V35, P196, DOI 10.1038/onc.2015.73; Mu GC, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1098-6; Park SK, 2016, BIOCHEM BIOPH RES CO, V470, P431, DOI 10.1016/j.bbrc.2016.01.019; Rong DW, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0958-6; Schwager S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00308; Shi XF, 2020, MOL THER-NUCL ACIDS, V19, P384, DOI 10.1016/j.omtn.2019.11.023; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Song X, 2019, CANCER RES, V79, P5288, DOI 10.1158/0008-5472.CAN-19-1504; Wang G, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01964-2; Wang M, 2020, MOL THER-NUCL ACIDS, V21, P367, DOI 10.1016/j.omtn.2020.06.008; Wang ZX, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.682594; Wu P, 2021, HISTOL HISTOPATHOL, V36, P447, DOI 10.14670/HH-18-305; Wu YY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01215-4; Xu LF, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9612425; Zang JK, 2020, J NEUROSCI RES, V98, P87, DOI 10.1002/jnr.24356; Zhang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1015-1; Zhang QG, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1125-9; Zhu YJ, 2019, THERANOSTICS, V9, P3526, DOI 10.7150/thno.32796; Zhu YX, 2020, ONCOGENE, V39, P6071, DOI 10.1038/s41388-020-01421-w	44	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4724	4735		10.1038/s41388-022-02449-w	http://dx.doi.org/10.1038/s41388-022-02449-w		SEP 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36109630				2022-12-17	WOS:000854052400002
J	Green, YS; dos Santos, MCF; Fuja, D; Reichert, E; Campos, AR; Cowman, SJ; Pilarte, KA; Kohan, J; Tripp, SR; Leibold, EA; Sirohi, D; Agarwal, N; Liu, XH; Koh, MY				Green, Yangsook Song; dos Santos, Maria C. Ferreira; Fuja, Daniel; Reichert, Ethan; Campos, Alexandre R.; Cowman, Sophie J.; Pilarte, Karen Acuna; Kohan, Jessica; Tripp, Sheryl R.; Leibold, Elizabeth A.; Sirohi, Deepika; Agarwal, Neeraj; Liu, Xiaohui; Koh, Mei Yee			ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma	ONCOGENE			English	Article							OXIDATIVE-PHOSPHORYLATION; TUMOR ANGIOGENESIS; HYPOXIA; HIF-2-ALPHA; PROTEIN; HIF2-ALPHA; LIGASE; DEGRADATION; HIF-1-ALPHA; BIOGENESIS	Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is typically initiated by inactivation of the von Hippel Lindau (VHL) gene, which results in the constitutive activation of the hypoxia inducible factors, HIF-1 alpha and HIF-2 alpha. Using a high throughput screen, we identify novel compounds that decrease HIF-1/2 alpha levels and induce ferroptosis by targeting Iron Sulfur Cluster Assembly 2 (ISCA2), a component of the late mitochondrial Iron Sulfur Cluster (L-ISC) assembly complex. ISCA2 inhibition either pharmacologically or using siRNA decreases HIF-2 alpha protein levels by blocking iron-responsive element (IRE)-dependent translation, and at higher concentrations, also decreases HIF-1 alpha translation through unknown mechanisms. Additionally, ISCA2 inhibition triggers the iron starvation response, resulting in iron/metals overload and death via ferroptosis. ISCA2 levels are decreased in ccRCC compared to normal kidney, and decreased ISCA2 levels are associated with pVHL loss and with sensitivity to ferroptosis induced by ISCA2 inhibition. Strikingly, pharmacological inhibition of ISCA2 using an orally available ISCA2 inhibitor significantly reduced ccRCC xenograft growth in vivo, decreased HIF-alpha levels and increased lipid peroxidation, suggesting increased ferroptosis in vivo. Thus, the targeting of ISCA2 may be a promising therapeutic strategy to inhibit HIF-1/2 alpha and to induce ferroptosis in pVHL deficient cells.	[Green, Yangsook Song; Fuja, Daniel; Reichert, Ethan; Cowman, Sophie J.; Pilarte, Karen Acuna; Leibold, Elizabeth A.; Koh, Mei Yee] Univ Utah, Salt Lake City, UT 84112 USA; [dos Santos, Maria C. Ferreira; Liu, Xiaohui; Koh, Mei Yee] Kuda Therapeut Inc, Salt Lake City, UT 84103 USA; [Campos, Alexandre R.] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA 92037 USA; [Kohan, Jessica; Tripp, Sheryl R.; Sirohi, Deepika] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84108 USA; [Sirohi, Deepika; Agarwal, Neeraj; Koh, Mei Yee] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Sanford Burnham Prebys Medical Discovery Institute; Utah System of Higher Education; University of Utah; ARUP Laboratories; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Koh, MY (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.; Koh, MY (corresponding author), Kuda Therapeut Inc, Salt Lake City, UT 84103 USA.; Koh, MY (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	mei.koh@utah.edu		Green, Yangsook/0000-0003-3620-0971	NIH [R03DA033980, CA181106, CA217905, R43 CA217385-A1]; Dod KCRP grant [KC190022]; NIH Hematology Training Program Grant [T32DK007115]; Huntsman Cancer Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dod KCRP grant; NIH Hematology Training Program Grant; Huntsman Cancer Foundation	This work was supported by NIH grants R03DA033980, CA181106 and CA217905 and Dod KCRP grant KC190022 to MYK, NIH grant R43 CA217385-A1 to XL, and NIH Hematology Training Program Grant T32DK007115 to DF. We acknowledge financial support by the Huntsman Cancer Foundation. Research reported in this publication utilized the Preclinical Research Shared Resource at Huntsman Cancer Institute at the University of Utah. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; [Anonymous], ONCOGENE; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Beilschmidt LK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15124; Bertout JA, 2009, P NATL ACAD SCI USA, V106, P14391, DOI 10.1073/pnas.0907357106; Biederbick A, 2006, MOL CELL BIOL, V26, P5675, DOI 10.1128/MCB.00112-06; Brancaccio D, 2014, J AM CHEM SOC, V136, P16240, DOI 10.1021/ja507822j; Briston T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00388; Bussolati B, 2013, CANCER LETT, V338, P141, DOI 10.1016/j.canlet.2012.05.007; Chen X, 2021, NAT REV CLIN ONCOL, V18, P280, DOI 10.1038/s41571-020-00462-0; Choi H, 2010, CANCER RES, V70, P10101, DOI 10.1158/0008-5472.CAN-10-0505; Choueiri TK, 2021, NAT MED, V27, P802, DOI 10.1038/s41591-021-01324-7; Conrad M, 2016, NAT REV DRUG DISCOV, V15, P348, DOI 10.1038/nrd.2015.6; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Cowman SJ, 2022, TRENDS CANCER, V8, P28, DOI 10.1016/j.trecan.2021.10.004; Cowman SJ, 2020, CLIN CANCER RES, V26, P4970, DOI 10.1158/1078-0432.CCR-19-3890; De Leon JAD, 2020, JOVE-J VIS EXP, DOI 10.3791/61122; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dowd AA, 2014, AFR J UROL, V20, P25, DOI 10.1016/j.afju.2013.11.001; Du WN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01965-8; Gelling C, 2008, MOL CELL BIOL, V28, P1851, DOI 10.1128/MCB.01963-07; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gourdoupis S, 2018, J AM CHEM SOC, V140, P14401, DOI 10.1021/jacs.8b09061; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Gudas LJ, 2014, J MOL MED, V92, P825, DOI 10.1007/s00109-014-1180-z; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001; Hervouet E, 2008, CARCINOGENESIS, V29, P1528, DOI 10.1093/carcin/bgn125; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3; Hu CL, 2019, J NEUROCHEM, V148, P426, DOI 10.1111/jnc.14604; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Kapitsinou PP, 2010, BLOOD, V116, P3039, DOI 10.1182/blood-2010-02-270322; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2015, CANCER RES, V75, P316, DOI 10.1158/0008-5472.CAN-13-2190; Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kumar T, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00227; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lill R, 2020, ANNU REV BIOCHEM, V89, P471, DOI 10.1146/annurev-biochem-013118-111540; Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163; Mastrogiannaki M, 2013, BLOOD, V122, P885, DOI 10.1182/blood-2012-11-427765; Micucci C, 2015, BRIT J CANCER, V113, P1178, DOI 10.1038/bjc.2015.338; Miess H, 2018, ONCOGENE, V37, P5435, DOI 10.1038/s41388-018-0315-z; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y; Muhlenhoff U, 2011, J BIOL CHEM, V286, P41205, DOI 10.1074/jbc.M111.296152; Nasta V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55313-5; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PaineMurrieta GD, 1997, CANCER CHEMOTH PHARM, V40, P209, DOI 10.1007/s002800050648; Pap EHW, 1999, FEBS LETT, V453, P278, DOI 10.1016/S0014-5793(99)00696-1; Paul VD, 2015, BBA-MOL CELL RES, V1853, P1528, DOI 10.1016/j.bbamcr.2014.12.018; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Sanchez M, 2007, NAT STRUCT MOL BIOL, V14, P420, DOI 10.1038/nsmb1222; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schneider M, 2010, NEOPLASIA, V12, P254, DOI 10.1593/neo.91782; Schonauer MS, 2009, J BIOL CHEM, V284, P23234, DOI 10.1074/jbc.M109.015594; Sheftel AD, 2012, MOL BIOL CELL, V23, P1157, DOI 10.1091/mbc.E11-09-0772; Society AC, SURV RAT KIDN CANC; Terzi EM, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4302; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Wada K, 2005, FEBS LETT, V579, P6543, DOI 10.1016/j.febslet.2005.10.046; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang J, 2005, BBA-MOL CELL RES, V1743, P79, DOI 10.1016/j.bbamcr.2004.08.011; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yang D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030275; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zanello P, 2019, J STRUCT BIOL, V205, P103, DOI 10.1016/j.jsb.2019.01.003; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhang Y, 2019, CELL CHEM BIOL, V26, P623, DOI 10.1016/j.chembiol.2019.01.008; Zilka O, 2017, ACS CENTRAL SCI, V3, P232, DOI 10.1021/acscentsci.7b00028; Zimmer M, 2008, MOL CELL, V32, P838, DOI 10.1016/j.molcel.2008.12.004; Zou Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09277-9	80	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4709	4723		10.1038/s41388-022-02460-1	http://dx.doi.org/10.1038/s41388-022-02460-1		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36097192	Green Submitted, hybrid, Green Published			2022-12-17	WOS:000852927100002
J	Kang, S; Wang, LX; Xu, L; Wang, RQ; Kang, QZ; Gao, XF; Yu, L				Kang, Synat; Wang, Lixin; Xu, Lu; Wang, Ruiqi; Kang, Qingzheng; Gao, Xuefeng; Yu, Li			Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype	ONCOGENE			English	Article							CANCER-TESTIS ANTIGEN; ACUTE MYELOID-LEUKEMIA; DNA METHYLTRANSFERASE; EPIGENETIC MODULATION; EXPRESSION; METHYLATION; LYMPHOCYTES; INDUCTION; IMMUNOTHERAPY; AZACITIDINE	NY-ESO-1 is a well-known cancer-testis antigen (CTA) with re-expression in numerous cancer types, but its expression is suppressed in myeloid leukemia cells. Patients with acute myeloid leukemia (AML) receiving decitabine (DAC) exhibit induced expression of NY-ESO-1 in blasts; thus, we investigated the effects of NY-ESO-1-specific TCR-engineered T (TCR-T) cells combined with DAC against AML. NY-ESO-1-specific TCR-T cells could efficiently eliminate AML cell lines (including U937, HL60, and Kasumi-1cells) and primary AML blasts in vitro by targeting the DAC-induced NY-ESO-1 expression. Moreover, the incubation of T cells with DAC during TCR transduction (designated as dTCR-T cells) could further enhance the anti-leukemia efficacy of TCR-T cells and increase the generation of memory-like phenotype. The combination of DAC with NY-ESO-1-specific dTCR-T cells showed a superior anti-tumor efficacy in vivo and prolonged the survival of an AML xenograft mouse model, with three out of five mice showing complete elimination of AML cells over 90 days. This outcome was correlated with enhanced expressions of IFN-gamma and TNF-alpha, and an increased proportion of central memory T cells (CD45RO(+)CD62L(+) and CD45RO(+)CCR7(+)). Taken together, these data provide preclinical evidence for the combined use of DAC and NY-ESO-1-specific dTCR-T cells for the treatment of AML.	[Kang, Synat; Wang, Lixin; Xu, Lu; Kang, Qingzheng; Gao, Xuefeng; Yu, Li] Shenzhen Univ, Clin Med Acad, Dept Hematol & Oncol,Int Canc Ctr,Hlth Sci Ctr, Gen Hosp,Shenzhen Key Lab Precis Med Hematol Mali, Shenzhen 518000, Guangdong, Peoples R China; [Wang, Ruiqi] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China; [Gao, Xuefeng] Shenzhen Univ, Cent Lab, Shenzhen Key Lab Precis Med Hematol Malignancies, Gen Hosp, Shenzhen 518000, Guangdong, Peoples R China	Shenzhen University; Nankai University; Shenzhen University	Gao, XF; Yu, L (corresponding author), Shenzhen Univ, Clin Med Acad, Dept Hematol & Oncol,Int Canc Ctr,Hlth Sci Ctr, Gen Hosp,Shenzhen Key Lab Precis Med Hematol Mali, Shenzhen 518000, Guangdong, Peoples R China.; Gao, XF (corresponding author), Shenzhen Univ, Cent Lab, Shenzhen Key Lab Precis Med Hematol Malignancies, Gen Hosp, Shenzhen 518000, Guangdong, Peoples R China.	xfgao@szu.edu.cn; yuli@szu.edu.cn	kang, synat/GRO-6634-2022	kang, synat/0000-0001-6898-5289; Gao, Xuefeng/0000-0002-1904-392X	Chinese National Major Project for New Drug Innovation [2019ZX09201002003]; National Natural Science Foundation of China [82030076, 82070161, 81970151, 81670162, 81870134, 81900474]; Shenzhen Science and Technology Foundation [JCYJ20190808163601776, JCYJ20200109113810154]; Shenzhen Key Laboratory Foundation [ZDSYS20200811143757022]; Sanming Project of Medicine in Shenzhen [SZSM202111004]; Stability support project in colleges and universities of Shenzhen Science and technology innovation Commission [20200830182623001]; Shenzhen Peacock Talent Programs Research Start-up Grant [827000644]; Natural Science Foundation of Shenzhen University General Hospital [SUGH2019QD012]	Chinese National Major Project for New Drug Innovation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science and Technology Foundation; Shenzhen Key Laboratory Foundation; Sanming Project of Medicine in Shenzhen; Stability support project in colleges and universities of Shenzhen Science and technology innovation Commission; Shenzhen Peacock Talent Programs Research Start-up Grant; Natural Science Foundation of Shenzhen University General Hospital	This work was supported by grants Chinese National Major Project for New Drug Innovation (2019ZX09201002003), National Natural Science Foundation of China (82030076, 82070161, 81970151, 81670162, 81870134 and 81900474), Shenzhen Science and Technology Foundation (JCYJ20190808163601776, JCYJ20200109113810154), Shenzhen Key Laboratory Foundation (ZDSYS20200811143757022), Sanming Project of Medicine in Shenzhen (SZSM202111004), Stability support project in colleges and universities of Shenzhen Science and technology innovation Commission (20200830182623001), Shenzhen Peacock Talent Programs Research Start-up Grant (827000644 to XG), and Natural Science Foundation of Shenzhen University General Hospital (SUGH2019QD012).	Acheampong DO, 2018, BIOMED PHARMACOTHER, V97, P225, DOI 10.1016/j.biopha.2017.10.100; Almstedt M, 2010, LEUKEMIA RES, V34, P899, DOI 10.1016/j.leukres.2010.02.004; Arai Y, 2015, BLOOD, V126, P415, DOI 10.1182/blood-2015-04-642652; Atanackovic D, 2011, AM J HEMATOL, V86, P918, DOI 10.1002/ajh.22141; Raneros AB, 2015, GENES IMMUN, V16, P71, DOI 10.1038/gene.2014.58; Bethune MT, 2018, P NATL ACAD SCI USA, V115, pE10702, DOI 10.1073/pnas.1810653115; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; Cany J, 2018, BLOOD, V131, P202, DOI 10.1182/blood-2017-06-790204; Cer?n-Maldonado R., 2015, REV MED HOSP GEN MEX, V78, P78; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Chou J, 2012, J IMMUNOTHER, V35, P131, DOI 10.1097/CJI.0b013e31824300c7; Dubovsky JA, 2007, PROSTATE, V67, P1781, DOI 10.1002/pros.20665; Elegheert J, 2018, NAT PROTOC, V13, P2991, DOI 10.1038/s41596-018-0075-9; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Griffiths EA, 2018, CLIN CANCER RES, V24, P1019, DOI 10.1158/1078-0432.CCR-17-1792; Jahn L, 2016, ONCOTARGET, V7, P77021, DOI 10.18632/oncotarget.12778; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Kang S, 2019, FRONT MED-PRC, V13, P69, DOI 10.1007/s11684-018-0677-1; Klar AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139221; Leonard SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087475; Lim SH, 1999, BRIT J CANCER, V81, P1162, DOI 10.1038/sj.bjc.6690824; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Mardiana S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00697; McCormack E, 2013, CANCER IMMUNOL IMMUN, V62, P773, DOI 10.1007/s00262-012-1384-4; Natsume A, 2008, INT J CANCER, V122, P2542, DOI 10.1002/ijc.23407; Negrotto S, 2012, LEUKEMIA, V26, P244, DOI 10.1038/leu.2011.207; Odunsi K, 2014, CANCER IMMUNOL RES, V2, P37, DOI 10.1158/2326-6066.CIR-13-0126; Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rohner A, 2007, LEUKEMIA RES, V31, P1393, DOI 10.1016/j.leukres.2007.02.020; Srivastava P., 2015, BLOOD, V126, P2873, DOI [10.1182/blood.V126.23.2873.2873, DOI 10.1182/BLOOD.V126.23.2873.2873]; Srivastava P, 2016, ONCOTARGET, V7, P12840, DOI 10.18632/oncotarget.7326; Srivastava P, 2015, EPIGENETICS-US, V10, P237, DOI 10.1080/15592294.2015.1017198; Stadtmauer EA, 2019, BLOOD ADV, V3, P2022, DOI 10.1182/bloodadvances.2019000194; Storb R, 2013, J CLIN ONCOL, V31, P1530, DOI 10.1200/JCO.2012.45.0247; Tawara I, 2017, BLOOD, V130, P1985, DOI 10.1182/blood-2017-06-791202; Topfer K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/918471; Toor AA, 2012, BRIT J HAEMATOL, V158, P700, DOI 10.1111/j.1365-2141.2012.09225.x; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Wakamatsu M, 2019, BLOOD ADV, V3, P105, DOI 10.1182/bloodadvances.2018025643; Walter RB, 2020, BLOOD REV, V44, DOI 10.1016/j.blre.2020.100679; Wang BH, 2021, HEMATOLOGY, V26, P371, DOI 10.1080/16078454.2021.1921434; Wang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20696-x; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Woloszynska-Read A, 2008, CLIN CANCER RES, V14, P3283, DOI 10.1158/1078-0432.CCR-07-5279; Xia Y, 2018, ONCOL LETT, V16, P6998, DOI 10.3892/ol.2018.9534; Xu Y, 2016, J CLIN INVEST, V126, P35, DOI 10.1172/JCI85631; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yao YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070522; You LS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01787; Zeiser R, 2019, BLOOD, V133, P1290, DOI 10.1182/blood-2018-10-846824; Zhang YK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-018-0720-y; Zhou JH, 2013, MOL MED REP, V8, P1549, DOI 10.3892/mmr.2013.1659	62	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4696	4708		10.1038/s41388-022-02455-y	http://dx.doi.org/10.1038/s41388-022-02455-y		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36097193	hybrid, Green Published			2022-12-17	WOS:000852927100001
J	Ahn, S; Saha, A; Clark, R; Kolonin, MG; DiGiovanni, J				Ahn, Songyeon; Saha, Achinto; Clark, Rachel; Kolonin, Mikhail G.; DiGiovanni, John			CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells	ONCOGENE			English	Article							ADIPOSE-TISSUE; CHEMOKINE RECEPTOR-4; FACTOR-I; GROWTH; METASTASIS; EXPRESSION; PATHWAYS; AXIS; DIFFERENTIATION; COMBINATION	Obesity is associated with increased prostate cancer (PCa) progression and higher mortality, however, the mechanism(s) remain still unclear. Here, we investigated signaling by the ASC-secreted chemokine CXCL12 in a mouse allograft model of PCa and in HiMyc mice in the context of diet-induced obesity. Treatment of mice with CXCR4 antagonist inhibited CXCL12-induced signaling pathways, tumor growth and EMT in HMVP2 allograft tumors. Similar results were obtained following prostate epithelium-specific deletion of CXCR4 in HiMyc mice. We also show that CXCR4 signaling regulates expression of JMJD2A histone demethylase and histone methylation which is modulated by AMD3100. Importantly, treatment with a CXCR7 antagonist also inhibited allograft tumor growth and EMT. The current results demonstrate that both CXCR4 and CXCR7 play an important role in cancer progression and establish CXCL12 signaling pathways, activated in obesity, as potential targets for PCa intervention. In addition, other factors secreted by ASCs, may also contribute to cancer aggressiveness in obesity.	[Ahn, Songyeon; Saha, Achinto; Clark, Rachel; DiGiovanni, John] Univ Texas Austin, Div Pharmacol & Toxicol, Austin, TX 78723 USA; [Ahn, Songyeon; Saha, Achinto; Clark, Rachel; DiGiovanni, John] Univ Texas Austin, Dell Pediat Res Inst, Austin, TX 78723 USA; [Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Ctr Mol Carcinogenesis & Toxicol, Austin, TX 78723 USA; [Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78723 USA; [Kolonin, Mikhail G.] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health Science Center Houston	DiGiovanni, J (corresponding author), Univ Texas Austin, Div Pharmacol & Toxicol, Austin, TX 78723 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Dell Pediat Res Inst, Austin, TX 78723 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Ctr Mol Carcinogenesis & Toxicol, Austin, TX 78723 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Dell Med Sch, Livestrong Canc Inst, Austin, TX 78723 USA.	john.digiovanni@austin.utexas.edu		Kolonin, Mikhail/0000-0002-3743-7869	NIH [R01 CA196259]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Steve Carbajal for his significant and extensive assistance to various aspects of this study. This study was supported by NIH grant R01 CA196259 (to JD and MGK).	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Balic A, 2014, MOL CANCER THER, V13, P1758, DOI 10.1158/1535-7163.MCT-13-0948; Bellows CF, 2011, CANCER EPIDEM BIOMAR, V20, P2461, DOI 10.1158/1055-9965.EPI-11-0556; Bhurosy Trishnee, 2014, ScientificWorldJournal, V2014, P964236, DOI 10.1155/2014/964236; Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Daquinag AC, 2015, CELL DEATH DIFFER, V22, P351, DOI 10.1038/cdd.2014.148; Daquinag AC, 2017, MOL THER-ONCOLYTICS, V6, P1, DOI 10.1016/j.omto.2017.05.003; Daquinag AC, 2011, CELL STEM CELL, V9, P74, DOI 10.1016/j.stem.2011.05.017; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; De Clercq Erik, 2019, Antiviral Chemistry & Chemotherapy, V27, p2040206619829382, DOI 10.1177/2040206619829382; Dickerman BA, 2019, CANCER-AM CANCER SOC, V125, P2877, DOI 10.1002/cncr.32167; Dubrovska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031226; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Fryar CD, 2018, NCHS HLTH E STATS; Gong ZH, 2007, CANCER-AM CANCER SOC, V109, P1192, DOI 10.1002/cncr.22534; Hales Craig M, 2020, NCHS Data Brief, P1; Hernandez L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3074; Himbert C, 2017, CANCER PREV RES, V10, P494, DOI 10.1158/1940-6207.CAPR-16-0322; Kim D, 2014, DIABETOLOGIA, V57, P1456, DOI 10.1007/s00125-014-3237-5; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; Kolonin MG, 2019, TRANSL ANDROL UROL, V8, pS348, DOI 10.21037/tau.2019.04.07; Kshattry S, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0088-z; Laurent V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10230; Lawrence M, 2016, TRENDS GENET, V32, P42, DOI 10.1016/j.tig.2015.10.007; Lengyel E, 2018, TRENDS CANCER, V4, P374, DOI 10.1016/j.trecan.2018.03.004; Li M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01177-z; Li Y, 2019, MOL MED REP, V19, P2489, DOI 10.3892/mmr.2019.9916; Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mimeault M, 2011, MOL MED, V17, P949, DOI 10.2119/molmed.2011.00115; Mochizuki H, 2004, BIOCHEM BIOPH RES CO, V320, P656, DOI 10.1016/j.bbrc.2004.06.013; Moore T, 2008, CANCER PREV RES, V1, P65, DOI 10.1158/1940-6207.CAPR-08-0022; Nunez NP, 2008, NUTR CANCER, V60, P534, DOI 10.1080/01635580801966195; Nunez NP, 2007, OBESITY, V15, P1980, DOI 10.1038/oby.2007.236; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Saglam K, 2003, J UROLOGY, V169, P1308, DOI 10.1097/01.ju.0000055903.18400.25; Saha A, 2017, CANCER RES, V77, P5158, DOI [10.1158/0008-5472.can-17-0284, 10.1158/0008-5472.CAN-17-0284]; Saha A, 2016, ONCOTARGET, V7, P25194, DOI 10.18632/oncotarget.7535; Saha A, 2015, CANCER PREV RES, V8, P597, DOI 10.1158/1940-6207.CAPR-15-0014; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shi Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.574667; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silva KR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174115; Singh AK, 2013, CYTOKINE GROWTH F R, V24, P41, DOI 10.1016/j.cytogfr.2012.08.007; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Song ZY, 2019, ONCOGENE, V38, P1560, DOI 10.1038/s41388-018-0519-2; Stillman B, 2018, CELL, V175, P6, DOI 10.1016/j.cell.2018.08.032; Su F, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00160-9; Su F, 2020, MOL THER-ONCOLYTICS, V18, P579, DOI 10.1016/j.omto.2020.08.012; Su F, 2019, ONCOGENE, V38, P1979, DOI 10.1038/s41388-018-0558-8; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Tian Y, 2017, ONCOL LETT, V13, P2253, DOI 10.3892/ol.2017.5694; Trautmann F, 2014, INT J RADIAT BIOL, V90, P687, DOI 10.3109/09553002.2014.906766; Wang FY, 2019, ONCOL REP, V42, P1431, DOI 10.3892/or.2019.7246; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wang XW, 2017, ONCOTARGET, V8, P36149, DOI 10.18632/oncotarget.15254; Wright ME, 2007, CANCER-AM CANCER SOC, V109, P675, DOI 10.1002/cncr.22443; Yang JH, 2018, MED SCI MONITOR, V24, P5185, DOI 10.12659/MSM.906180; Yang N, 2020, THERANOSTICS, V10, P5790, DOI 10.7150/thno.44789; Yasumoto K, 2006, CANCER RES, V66, P2181, DOI 10.1158/0008-5472.CAN-05-3393; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444; Zhao HL, 2015, ONCOTARGET, V6, P5022, DOI 10.18632/oncotarget.3217; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867	73	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4633	4644		10.1038/s41388-022-02466-9	http://dx.doi.org/10.1038/s41388-022-02466-9		SEP 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36088505				2022-12-17	WOS:000852343800002
J	Evan, T; Wang, VMY; Behrens, A				Evan, Theodore; Wang, Victoria Min-Yi; Behrens, Axel			The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; EMT-ACTIVATOR ZEB1; TUMOR-CELLS; METABOLISM; PLASTICITY; SUBTYPES; METASTASIS; MARKER; GROWTH	Intratumour heterogeneity (ITH) has become an important focus of cancer research in recent years. ITH describes the cellular variation that enables tumour evolution, including tumour progression, metastasis and resistance to treatment. The selection and expansion of genetically distinct treatment-resistant cancer cell clones provides one explanation for treatment failure. However, tumour cell variation need not be genetically encoded. In pancreatic ductal adenocarcinoma (PDAC) in particular, the complex tumour microenvironment as well as crosstalk between tumour and stromal cells result in exceptionally variable tumour cell phenotypes that are also highly adaptable. In this review we discuss four different types of phenotypic heterogeneity within PDAC, from morphological to metabolic heterogeneity. We suggest that these different types of ITH are not independent, but, rather, can inform one another. Lastly, we highlight recent findings that suggest how therapeutic efforts may halt PDAC progression by constraining cellular heterogeneity.	[Evan, Theodore; Behrens, Axel] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Canc Stem Cell Lab, London SW3 6JB, England; [Wang, Victoria Min-Yi] CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Behrens, Axel] Imperial Coll London, Dept Surg & Canc, London SW7 2AZ, England; [Behrens, Axel] Imperial Coll London, CRUK Convergence Sci Ctr, London SW7 2AZ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Beatson Institute; Imperial College London; Imperial College London	Behrens, A (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Canc Stem Cell Lab, London SW3 6JB, England.; Wang, VMY (corresponding author), CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland.; Behrens, A (corresponding author), Imperial Coll London, Dept Surg & Canc, London SW7 2AZ, England.; Behrens, A (corresponding author), Imperial Coll London, CRUK Convergence Sci Ctr, London SW7 2AZ, England.	vmy.wang@mail.utoronto.ca; axel.behrens@icr.ac.uk		Wang, Victoria/0000-0002-2657-6118	Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research [CTR-Q5-Y2]; CRUK Accelerator Award [C422/A23614]; Sir Henry Wellcome Postdoctoral Fellowship [221607/Z/20/Z]	Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research; CRUK Accelerator Award; Sir Henry Wellcome Postdoctoral Fellowship	We would like to thank Dr. Catherine Cremona for her editing of this review. This work was supported by the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research (CTR-Q5-Y2). TE was supported by a doctoral clinical fellowship from a CRUK Accelerator Award (C422/A23614). VW was supported by a Sir Henry Wellcome Postdoctoral Fellowship (221607/Z/20/Z).	Abrego J, 2017, CANCER LETT, V400, P37, DOI 10.1016/j.canlet.2017.04.029; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Aiello NM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12819; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Bailey JM, 2014, GASTROENTEROLOGY, V146, P245, DOI 10.1053/j.gastro.2013.09.050; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Ball CR, 2017, EMBO MOL MED, V9, P918, DOI 10.15252/emmm.201607354; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Biancur DE, 2018, BBA-REV CANCER, V1870, P67, DOI 10.1016/j.bbcan.2018.04.011; Biancur DE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15965; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bott AJ, 2019, CELL REP, V29, P1287, DOI 10.1016/j.celrep.2019.09.056; Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; Brunton H, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107625; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Carstens JL, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108990; Chan-Seng-Yue M, 2020, NAT GENET, V52, P231, DOI 10.1038/s41588-019-0566-9; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chiou SH, 2017, CANCER DISCOV, V7, P1184, DOI 10.1158/2159-8290.CD-17-0250; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Daemen A, 2015, P NATL ACAD SCI USA, V112, pE4410, DOI 10.1073/pnas.1501605112; Dawson MA, 2017, SCIENCE, V355, P1147, DOI 10.1126/science.aam7304; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Dosch JS, 2015, CANCER RES, V75, P4582, DOI 10.1158/0008-5472.CAN-14-2793; Dovmark TH, 2017, ONCOGENE, V36, P4538, DOI 10.1038/onc.2017.71; Encarnacion-Rosado J, 2021, NAT REV GASTRO HEPAT, V18, P482, DOI 10.1038/s41575-021-00431-7; Fox RG, 2016, NATURE, V534, P407, DOI 10.1038/nature17988; Galvan JA, 2015, BRIT J CANCER, V112, P1944, DOI 10.1038/bjc.2015.177; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; Grabocka E, 2016, CELL, V167, P1803, DOI 10.1016/j.cell.2016.11.035; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi A, 2020, NAT CANCER, V1, P59, DOI 10.1038/s43018-019-0010-1; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hermann PC, 2018, SEMIN CANCER BIOL, V53, P223, DOI 10.1016/j.semcancer.2018.08.007; Hosein AN, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129212; Huang JJ, 2021, GASTROENTEROLOGY, V160, P744, DOI 10.1053/j.gastro.2020.10.007; Juiz NA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00246; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Karasinska JM, 2020, CLIN CANCER RES, V26, P135, DOI 10.1158/1078-0432.CCR-19-1543; Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636; Komar G, 2009, CLIN CANCER RES, V15, P5511, DOI 10.1158/1078-0432.CCR-09-0414; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kumar S, 2019, CELL METAB, V30, P201, DOI 10.1016/j.cmet.2019.04.003; LaMonte G, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-23; Lan LX, 2022, NATURE, V607, P163, DOI 10.1038/s41586-022-04888-7; Laplane L, 2016, CANC STEM CELLS PHIL; Laplane L, 2019, ELIFE, V8, DOI 10.7554/eLife.46563; Lee SW, 2019, DEV CELL, V50, P381, DOI 10.1016/j.devcel.2019.05.043; Lehmann W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10498; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Lomberk G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04383-6; Lytle NK, 2019, CELL, V177, P572, DOI 10.1016/j.cell.2019.03.010; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Maruno T, 2021, ELIFE, V10, DOI 10.7554/eLife.55117; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Miyabayashi K, 2020, CANCER DISCOV, V10, P1566, DOI 10.1158/2159-8290.CD-20-0133; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459; Neesse A, 2019, GUT, V68, P159, DOI 10.1136/gutjnl-2018-316451; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Nicolle R, 2017, CELL REP, V21, P2458, DOI 10.1016/j.celrep.2017.11.003; Nollmann FI, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080281; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ozturk H, 2022, DEV CELL, V57, P1331, DOI 10.1016/j.devcel.2022.04.014; Parker SJ, 2020, CANCER DISCOV, V10, P1018, DOI 10.1158/2159-8290.CD-19-0959; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Patnaik S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00588; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Pourshams A, 2019, LANCET GASTROENTEROL, V4, P934, DOI 10.1016/S2468-1253(19)30347-4; Quinton RJ, 2021, NATURE, V590, P492, DOI 10.1038/s41586-020-03133-3; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Reichert M, 2018, DEV CELL, V45, P696, DOI 10.1016/j.devcel.2018.05.025; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rice AJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.54; Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007; Roerink SF, 2018, NATURE, V556, P457, DOI 10.1038/s41586-018-0024-3; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Seino T, 2018, CELL STEM CELL, V22, P454, DOI 10.1016/j.stem.2017.12.009; Seth S, 2019, CELL REP, V26, P1518, DOI 10.1016/j.celrep.2019.01.048; Sharick JT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00553; Shi JJ, 2019, CANCER LETT, V453, P158, DOI 10.1016/j.canlet.2019.03.051; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simeonov KP, 2021, CANCER CELL, V39, P1150, DOI 10.1016/j.ccell.2021.05.005; Singh SK, 2003, CANCER RES, V63, P5821; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Still ER, 2017, BRIT J CANCER, V116, P1375, DOI 10.1038/bjc.2017.113; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Viale A, 2015, CANCER RES, V75, P3687, DOI 10.1158/0008-5472.CAN-15-0491; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Walsh AJ, 2016, PANCREAS, V45, P863, DOI 10.1097/MPA.0000000000000543; Walsh AJ, 2014, CANCER RES, V74, P5184, DOI 10.1158/0008-5472.CAN-14-0663; Wang VMY, 2019, NAT CELL BIOL, V21, P1425, DOI 10.1038/s41556-019-0407-1; Wang WJ, 2019, GUT, V68, P1245, DOI 10.1136/gutjnl-2017-315541; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546; Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3; Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yoo HC, 2020, CELL METAB, V31, P267, DOI 10.1016/j.cmet.2019.11.020; Zhao XH, 2019, WORLD J GASTROENTERO, V25, P138, DOI 10.3748/wjg.v25.i1.138; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	132	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4686	4695		10.1038/s41388-022-02448-x	http://dx.doi.org/10.1038/s41388-022-02448-x		SEP 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36088504	Green Published, hybrid			2022-12-17	WOS:000852353400001
J	Li, YH; Deng, YR; Zhao, YN; Zhang, W; Zhang, S; Zhang, L; Wang, BY; Xu, YY; Chen, S				Li, Yaohua; Deng, Yiran; Zhao, Yannan; Zhang, Wei; Zhang, Si; Zhang, Li; Wang, Biyun; Xu, Yingying; Chen, She			Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK	ONCOGENE			English	Article							FOCAL-ADHESION KINASE; GENE-EXPRESSION; TUMOR-SUPPRESSOR; MUTANT P53; MUTATIONS; STATISTICS; SURVIVAL; MOLECULES; PROTEINS; GROWTH	Metastasis of breast cancer represents the major reason for its poor prognosis, leading to high mortality. In breast cancer, a tumor suppressor gene TP53 is commonly mutated. TP53 mutation leads to an altered expression of various genes, an event that is associated with aggressive tumor and is a strong independent marker for survival. In this study, we identified a novel p53 target gene, immunoglobulin superfamily 9 (IGSF9). IGSF9 is generally down-regulated in breast cancer tissues. Loss of IGSF9 is associated with frequent metastasis and poor prognosis of breast cancer patients. Wild-type p53, but not R175H mutant, trans-activates the transcription of IGSF9 via binding to its promoter (-137 to -131 bp), inhibits epithelial-mesenchymal transition (EMT), consequently the inhibition of breast cancer cells migration and invasion. IGSF9 interacts with focal adhesion kinase (FAK) and inhibits FAK/AKT signaling activity. PND1186, FAK inhibitor, inhibits breast cancer metastasis induced by IGSF9 knockdown in vitro and in vivo. Taken together, IGSF9 is trans-activated by p53 and inhibits breast cancer metastasis by modulating FAK/AKT signaling pathway. IGSF9 could serve as a prognostic marker and potential therapeutic target for breast cancer.	[Li, Yaohua; Deng, Yiran; Zhao, Yannan; Zhang, Wei; Zhang, Si; Zhang, Li; Xu, Yingying; Chen, She] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, NHC Key Lab Glycoconjugate Res, 130 Dongan Rd, Shanghai 200032, Peoples R China; [Li, Yaohua; Zhao, Yannan; Wang, Biyun] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Med Oncol, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Li, Yaohua] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Lab Med, Sch Med, Shanghai 200080, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University	Xu, YY; Chen, S (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, NHC Key Lab Glycoconjugate Res, 130 Dongan Rd, Shanghai 200032, Peoples R China.	yingyingxu@fudan.edu.cn; shechen@fudan.edu.cn		zhang, Si/0000-0002-5682-4995	National Natural Science Foundation of China (NSFC) [81772615, 81972294, 81772968]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	We thank Dr. Wenjiao Zeng from the Department of Pathology, School of Basic Medical Sciences, Fudan University, for technical assistance. This work was supported by the National Natural Science Foundation of China (NSFC) (81772615, 81972294, 81772968).	Bowden NA, 2007, HERED CANCER CLIN PR, V5, P79, DOI 10.1186/1897-4287-5-2-79; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Chang JW, 2018, ONCOGENE, V37, P4137, DOI 10.1038/s41388-018-0253-9; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Dong PP, 2020, J HEPATOL, V73, P1446, DOI 10.1016/j.jhep.2020.06.027; Doudney K, 2002, GENOMICS, V79, P663, DOI 10.1006/geno.2002.6757; Duffy MJ, 2018, BREAST CANCER RES TR, V170, P213, DOI 10.1007/s10549-018-4753-7; Golubovskaya VM, 2007, INT REV CYTOL, V263, P103, DOI 10.1016/S0074-7696(07)63003-4; Hansen M, 2013, NEUROCHEM RES, V38, P1236, DOI 10.1007/s11064-013-0999-y; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kelkar MG, 2017, BREAST CANCER RES TR, V164, P603, DOI 10.1007/s10549-017-4297-2; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kim JH, 2008, TUMOR BIOL, V29, P41, DOI 10.1159/000132570; Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001; Lee G, 2012, CANCER IMMUNOL IMMUN, V61, P89, DOI 10.1007/s00262-011-1088-1; Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Perrone C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228422; Press DJ, 2017, CLIN EXP METASTAS, V34, P457, DOI 10.1007/s10585-017-9871-9; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schneider Christoph, 2003, Archives of Gynecology and Obstetrics, V269, P9, DOI 10.1007/s00404-002-0445-x; Shapira I, 2013, CRIT REV ONCOL HEMAT, V88, P284, DOI 10.1016/j.critrevonc.2013.05.003; Shi ZG, 2018, J ONCOL, V2018, DOI 10.1155/2018/2439527; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Sigal A, 2000, CANCER RES, V60, P6788; Silwal-Pandit L, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026252; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walsh C, 2010, CANCER BIOL THER, V9, P778, DOI 10.4161/cbt.9.10.11433; Wang XX, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100730; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wu HJ, 2020, ONCOGENE, V39, P2539, DOI 10.1038/s41388-020-1162-2; Ye M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01273-0; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478	49	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4658	4672		10.1038/s41388-022-02459-8	http://dx.doi.org/10.1038/s41388-022-02459-8		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36088502	hybrid, Green Published			2022-12-17	WOS:000852343800001
J	Wang, C; Li, WC; Hu, Q; Feng, NH; Liu, CH; Shi, NP; Chen, SQ; Chen, M; Guan, H; You, ZH; Xu, B				Wang, Can; Li, Wenchao; Hu, Qiang; Feng, Ninghan; Liu, Chunhui; Shi, Naipeng; Chen, Shuqiu; Chen, Ming; Guan, Han; You, Zonghao; Xu, Bin			Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppression	ONCOGENE			English	Article							STEM-LIKE CELLS; GENE-EXPRESSION; IN-VITRO; MICRORNA; METASTASIS; TRANSITION; RESISTANCE; TARGETS	Although miR-7 suppresses the initiation and progression in cancers, little is known about its role in prostate cancer, especially in transgenic mouse models. In present study, we found that expression of miR-7, regulated by p53, was lower in prostate cancer tissues, and miR-7 overexpression significantly mitigated prostate cancer cells growth both in vitro, in organoids and in vivo regardless of p53 status. After we generated miR-7 overexpression transgenic mice and miR-7(+)/TRAMP mice, we found that transgenic overexpression of miR-7 in mice is safe and miR-7(+)/TRAMP mice have a preferred overall survival. Moreover, in vivo treatment of miR-7 inhibited subcutaneous tumour growth in mice and prolonged the survival of mice harboring prostate cancer lung metastasis when co-injection with PD-1 antibody. In addition, miR-7 downregulated glycolysis of prostate cancer cells by inhibiting several key pathways including HIF-1 alpha, and subsequently remodeled acidic tumour microenvironment, PanKLa level and T cell infiltration. In summary, our findings highlighted a promising target for development of miRNA-based therapeutics for prostate cancer patients regardless of p53 status.	[Wang, Can; Li, Wenchao; Hu, Qiang; Liu, Chunhui; Shi, Naipeng; Chen, Shuqiu; Chen, Ming; You, Zonghao; Xu, Bin] Southeast Univ, Dept Urol, Affiliated Zhongda Hosp, Nanjing 210009, Peoples R China; [Wang, Can; Li, Wenchao; Hu, Qiang; Liu, Chunhui; Shi, Naipeng; Chen, Shuqiu; Chen, Ming; You, Zonghao; Xu, Bin] Southeast Univ, Surg Res Ctr, Inst Urol, Med Sch, Nanjing 210009, Peoples R China; [Feng, Ninghan] Nanjing Med Univ, Wuxi 2 Hosp, Dept Urol, Wuxi 214002, Jiangsu, Peoples R China; [Guan, Han] Bengbu Med Coll, Dept Urol, Affiliated Hosp 1, Bengbu 233004, Peoples R China; [Xu, Bin] Southeast Univ, Affiliated Zhongda Hosp, Inst Med Phen Res, Nanjing 210009, Peoples R China	Southeast University - China; Southeast University - China; Nanjing Medical University; Bengbu Medical College; Southeast University - China	Chen, M; You, ZH; Xu, B (corresponding author), Southeast Univ, Dept Urol, Affiliated Zhongda Hosp, Nanjing 210009, Peoples R China.; Chen, M; You, ZH; Xu, B (corresponding author), Southeast Univ, Surg Res Ctr, Inst Urol, Med Sch, Nanjing 210009, Peoples R China.; Guan, H (corresponding author), Bengbu Med Coll, Dept Urol, Affiliated Hosp 1, Bengbu 233004, Peoples R China.; Xu, B (corresponding author), Southeast Univ, Affiliated Zhongda Hosp, Inst Med Phen Res, Nanjing 210009, Peoples R China.	mingchen0712@seu.edu.cn; gh668689@126.com; 101012899@seu.edu.cn; njxbseu@seu.edu.cn		Guan, Han/0000-0002-7043-6307; , Zonghao/0000-0003-4807-9750	National Natural Science Foundation of China [81872089, 81672551, 82102799]; Natural Science Foundation of Jiangsu Province [BK20210230]; Key Research and Development Program of Jiangsu Province [BE2019751]; Jiangsu Provincial Medical Talent [ZDRCA2016080]; Jiangsu Provincial Medical Innovation Team [CXTDA2017025]; Doctor of Entrepreneurship and Innovation in Jiangsu Province [JSSCBS20210138, JSSCBS20210088]; General Project of Medical Research of Jiangsu Health and Wellness Committee [M2020049]; Key R&D (Social Development) Projects of Jiangsu Province [BE2018629]; Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project, First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars [2019BYYFYYQ09]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Key Research and Development Program of Jiangsu Province; Jiangsu Provincial Medical Talent; Jiangsu Provincial Medical Innovation Team; Doctor of Entrepreneurship and Innovation in Jiangsu Province; General Project of Medical Research of Jiangsu Health and Wellness Committee; Key R&D (Social Development) Projects of Jiangsu Province; Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project, First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (grant numbers 81872089, 81672551 and 82102799), Natural Science Foundation of Jiangsu Province (grant number BK20210230), Key Research and Development Program of Jiangsu Province (grant number BE2019751), Jiangsu Provincial Medical Talent (grant number ZDRCA2016080), The Jiangsu Provincial Medical Innovation Team (grant number CXTDA2017025), Doctor of Entrepreneurship and Innovation in Jiangsu Province (grant number JSSCBS20210138, JSSCBS20210088), The General Project of Medical Research of Jiangsu Health and Wellness Committee (grant number M2020049), Key R&D (Social Development) Projects of Jiangsu Province (BE2018629) Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project, First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars (No. 2019BYYFYYQ09).	Bayraktar R, 2018, CLIN CANCER RES, V24, P4225, DOI 10.1158/1078-0432.CCR-17-1959; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cardozo V, 2021, NEUROCHEM INT, V147, DOI 10.1016/j.neuint.2021.105064; Chang YL, 2015, ONCOTARGET, V6, P24017, DOI 10.18632/oncotarget.4447; Cheteh EH, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0272-5; Culp MB, 2020, EUR UROL, V77, P38, DOI 10.1016/j.eururo.2019.08.005; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576; Gao YS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01421-6; George AL, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-80; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hu JH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01169-0; Irizarry-Caro RA, 2020, P NATL ACAD SCI USA, V117, P30628, DOI 10.1073/pnas.2009778117; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Lee KS, 2008, AM J RESP CRIT CARE, V178, P787, DOI 10.1164/rccm.200801-008OC; Lequeux A, 2021, ONCOGENE, V40, P4725, DOI 10.1038/s41388-021-01846-x; Li M, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01264-z; Li ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16306-5; Lin CL, 2020, MOL THER-NUCL ACIDS, V20, P699, DOI 10.1016/j.omtn.2020.04.009; Lin RW, 2018, CELL CYCLE, V17, P2175, DOI 10.1080/15384101.2018.1520565; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Ottosen S, 2015, ANTIMICROB AGENTS CH, V59, P599, DOI 10.1128/AAC.04220-14; Pan CM, 2020, CANCER LETT, V493, P133, DOI 10.1016/j.canlet.2020.08.024; Qi Z., 2022, NAT COMMUN, V13, DOI 10.1038/s41467-021-27833-0; Reid MA, 2017, NAT CELL BIOL, V19, P1298, DOI 10.1038/ncb3629; Ren RY, 2020, J CELL PHYSIOL, V235, P6204, DOI 10.1002/jcp.29549; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Riganti C, 2009, BRIT J PHARMACOL, V156, P1054, DOI 10.1111/j.1476-5381.2009.00117.x; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sahraei M, 2019, J CLIN INVEST, V129, P5518, DOI 10.1172/JCI127125; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun YF, 2016, AM J CANCER RES, V6, P114; Thapa D, 2014, CANCER RES, V74, P5644, DOI 10.1158/0008-5472.CAN-14-0562; van Zandwijk N, 2017, LANCET ONCOL, V18, P1386, DOI 10.1016/S1470-2045(17)30621-6; Wang CQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16966-3; Wang J, 2016, J CELL PHYSIOL, V231, P25, DOI 10.1002/jcp.25056; Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004; Westra J, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-61; Wu ZC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.517637; Xiong Le, 2021, Nanotheranostics, V5, P143, DOI 10.7150/ntno.53844; Yang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08759-0; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1; Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080544; Zhu HT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1159-2	47	0	0	21	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4645	4657		10.1038/s41388-022-02461-0	http://dx.doi.org/10.1038/s41388-022-02461-0		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36088503	Green Submitted			2022-12-17	WOS:000852343800003
J	Li, M; Xu, H; Qi, YH; Pan, ZW; Li, BY; Gao, ZJ; Zhao, RR; Xue, H; Li, G				Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang			Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression	ONCOGENE			English	Article							IMMUNITY; BRAIN; CELLS	Exosomes can selectively secrete harmful metabolic substances from cells to maintain cellular homeostasis, and complex crosstalk occurs between exosomes and tumor-associated macrophages (TAMs) in the glioma immune microenvironment. However, the precise mechanisms by which these exosome-encapsulated cargos create an immunosuppressive microenvironment remain unclear. Herein, we investigated the effect of glioma-derived exosomes (GDEs) on macrophage polarization and glioma progression. We performed sequencing analysis of cerebrospinal fluid (CSF) and tumor tissues from glioma patients to identify functional microRNAs (miRNAs). High levels of miR-3591-3p were found in CSF and GDEs but not in normal brain tissue or glial cells. Functionally, GDEs and miR-3591-3p significantly induced M2 macrophage polarization and increased the secretion of IL10 and TGF beta 1, which in turn promoted glioma invasion and migration. Moreover, miR-3591-3p overexpression in glioma cell lines resulted in G2/M arrest and markedly increased apoptosis. Mechanistically, miR-3591-3p can directly target CBLB and MAPK1 in macrophages and glioma cells, respectively, and further activate the JAK2/PI3K/AKT/mTOR, JAK2/STAT3, and MAPK signaling pathways. In vivo experiments confirmed that macrophages lentivirally transduced with miR-3591-3p can significantly promote glioma progression. Thus, our study demonstrates that tumor-suppressive miR-3591-3p in glioma cells can be secreted via exosomes and target TAMs to induce the formation of an immunosuppressive microenvironment. Collectively, these findings provide new insights into the role of glioma exosomal miRNAs in mediating the establishment of an immunosuppressive tumor microenvironment and show that miR-3591-3p may be a valuable biomarker and that blocking the encapsulation of miR-3591-3p into exosomes may become a novel immunotherapeutic strategy for glioma.	[Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China; [Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Inst Brain & Braininspired Sci, Jinan 250012, Shandong, Peoples R China; [Li, Ming; Xu, Hao; Qi, Yanhua; Pan, Ziwen; Li, Boyan; Gao, Zijie; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China; [Li, Ming] Qingdao Univ, Affiliated Taian City Cent Hosp, Dept Neurosurg, Tai An 271000, Shandong, Peoples R China; [Xu, Hao] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai 264000, Shandong, Peoples R China	Shandong University; Shandong University; Qingdao University; Qingdao University	Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Inst Brain & Braininspired Sci, Jinan 250012, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan 250012, Shandong, Peoples R China.	xuehao@sdu.edu.cn; dr.ligang@sdu.edu.cn			National Natural Science Foundation of China [82273195, 81874083, 82072776, 82273286, 82072775, 82203419]; Natural Science Foundation of Shandong Province of China [ZR2019BH057, ZR2020QH174, ZR2021LSW025]; Jinan Science and Technology Bureau of Shandong Province [2021GXRC029]; Key clinical Research project of Clinical Research Center of Shandong University [2020SDUCRCA011]; Taishan Pandeng Scholar Program of Shandong Province [tspd20210322]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province); Jinan Science and Technology Bureau of Shandong Province; Key clinical Research project of Clinical Research Center of Shandong University; Taishan Pandeng Scholar Program of Shandong Province	We are grateful to the surgeons, physicians, and patients who participated in our studies. We thank the Novogene Co. Ltd and Tianjin Novogene Bioinformatics Technology Co., Ltd for miRNA and mRNA Sequencing technical development and support. This work was supported by grants from the National Natural Science Foundation of China (Nos. 82273195; 81874083; 82072776; 82273286; 82072775; 82203419), Natural Science Foundation of Shandong Province of China (Nos. ZR2019BH057; ZR2020QH174; ZR2021LSW025), the Jinan Science and Technology Bureau of Shandong Province (2021GXRC029), Key clinical Research project of Clinical Research Center of Shandong University (2020SDUCRCA011) and Taishan Pandeng Scholar Program of Shandong Province (No. tspd20210322).	Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5; Anderson NR, 2021, CANCER RES, V81, P1201, DOI 10.1158/0008-5472.CAN-20-2990; Antunes ARP, 2021, NAT NEUROSCI, V24, P595, DOI 10.1038/s41593-020-00789-y; Barthel L, 2022, CANCER METAST REV, V41, P53, DOI 10.1007/s10555-021-09997-9; Chen CY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01511-1; Chen DG, 2021, THERANOSTICS, V11, P1016, DOI 10.7150/thno.51777; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; Dapash M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092257; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Guo X, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001975; He GP, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01440-5; Hoshino A, 2020, CELL, V182, P1044, DOI 10.1016/j.cell.2020.07.009; Hosseini R, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01492-7; Iguchi Y, 2016, BRAIN, V139, P3187, DOI 10.1093/brain/aww237; Janjua TI, 2021, ADV DRUG DELIVER REV, V171, P108, DOI 10.1016/j.addr.2021.01.012; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kang M, 2021, ADV MATER, V33, DOI 10.1002/adma.202103258; Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7; Li X, 2020, J EXP MED, V217, DOI 10.1084/jem.20191537; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Liu TQ, 2022, ONCOIMMUNOLOGY, V11, DOI 10.1080/2162402X.2022.2031499; Lv KS, 2017, GENE DEV, V31, P1007, DOI 10.1101/gad.297135.117; Ma FY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003217; Miller KD, 2021, CA-CANCER J CLIN, V71, P381, DOI 10.3322/caac.21693; Morrissey SM, 2021, CELL METAB, V33, P2040, DOI 10.1016/j.cmet.2021.09.002; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nguyen TTT, 2021, J EXP MED, V218, DOI 10.1084/jem.20202477; O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580-020-0251-y; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pan ZW, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01485-6; Qiu W, 2021, MOL THER, V29, P3449, DOI 10.1016/j.ymthe.2021.06.023; TAKAHASHI A, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15287, DOI 10.1038/NCOMMS15287]; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Tzetzo SL, 2021, CANCER CELL, V39, P734, DOI 10.1016/j.ccell.2021.03.002; Vignard V, 2020, CANCER IMMUNOL RES, V8, P255, DOI 10.1158/2326-6066.CIR-19-0522; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Wang YJ, 2021, CANCER CELL, V39, P1375, DOI 10.1016/j.ccell.2021.07.023; Wang Z, 2020, J CELL PHYSIOL, V235, P2825, DOI 10.1002/jcp.29188; Xia YQ, 2020, ADV MATER, V32, DOI 10.1002/adma.202002054; Xu JY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03664-1; Yan SJ, 2021, FEBS J, V288, P6174, DOI 10.1111/febs.15726; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang ZP, 2020, CANCER IMMUNOL RES, V8, P966, DOI 10.1158/2326-6066.CIR-19-0759; Zhou HH, 2021, MOL THER, V29, P3465, DOI 10.1016/j.ymthe.2021.06.019	46	0	0	15	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4618	4632		10.1038/s41388-022-02457-w	http://dx.doi.org/10.1038/s41388-022-02457-w		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36085418	Green Published, hybrid			2022-12-17	WOS:000852095400001
J	Chand, V; Liao, XB; Guzman, G; Benevolenskaya, E; Raychaudhuri, P				Chand, Vaibhav; Liao, Xiubei; Guzman, Grace; Benevolenskaya, Elizaveta; Raychaudhuri, Pradip			Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1-FOXO1 axis (vol 41, pg 3778, 2022)	ONCOGENE			English	Correction												pradip@uic.edu		raychaudhuri, pradip/0000-0003-2968-4701; Benevolenskaya, Elizaveta/0000-0003-3573-1754				Chand V, 2022, ONCOGENE, V41, P3778, DOI 10.1038/s41388-022-02394-8	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5315	5316		10.1038/s41388-022-02436-1	http://dx.doi.org/10.1038/s41388-022-02436-1		SEP 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36071276	Bronze			2022-12-17	WOS:000850752600002
J	Liu, W; Shen, DX; Ju, LA; Zhang, RJ; Du, WZ; Jin, W; Xiong, KP; Wang, G; Qian, KY; Zhang, Y; Xiao, Y; Wang, XH				Liu, Wei; Shen, Dexin; Ju, Lingao; Zhang, Renjie; Du, Wenzhi; Jin, Wan; Xiong, Kangping; Wang, Gang; Qian, Kaiyu; Zhang, Yi; Xiao, Yu; Wang, Xinghuan			MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3	ONCOGENE			English	Article							CELL-CYCLE; B-MYB; TARGET; FOXM1	The transcription factor MYB proto-oncogene like 2 (MYBL2) is critical in regulating gene expression and tumorigenesis. However, the biological function of MYBL2 in bladder cancer (BLCA) remains to be elucidated. Here, we first revealed that MYBL2 was elevated in BLCA tissues and significantly correlated with clinicopathological parameters and cancer-specific survival in BLCA patients. Phenotypic assays showed that MYBL2 deficiency suppressed the proliferation and migration of BLCA cells in vitro and in vivo, whereas MYBL2 overexpression contributed to the opposite phenotype. Mechanistically, MYBL2 could bind to the promoter of its downstream target gene cell division cycle-associated protein 3 (CDCA3) and transactivate it, which in turn promoted the malignant phenotype of BLCA cells. Further investigations revealed that MYBL2 interacted with forkhead box M1 (FOXM1) to co-regulate the transcription of CDCA3. In addition, MYBL2/FOXM1 and CDCA3 might activate Wnt/beta-catenin signaling, thereby promoting the malignant phenotype of BLCA cells. In conclusion, the current study identifies MYBL2 as an oncogene in BLCA. MYBL2 can accelerate the proliferation and metastasis of BLCA through the transactivation of CDCA3.	[Liu, Wei; Shen, Dexin; Zhang, Renjie; Du, Wenzhi; Xiong, Kangping; Qian, Kaiyu; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China; [Ju, Lingao; Jin, Wan; Wang, Gang; Qian, Kaiyu; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Peoples R China; [Jin, Wan; Zhang, Yi] Euler Technol, ZGC Life Sci Pk, Beijing, Peoples R China; [Zhang, Yi] Peking Univ, Ctr Quantitat Biol, Sch Life Sci, Beijing, Peoples R China; [Wang, Xinghuan] Chinese Acad Med Sci, Wuhan Res Ctr Infect Dis & Canc, Wuhan, Peoples R China	Wuhan University; Wuhan University; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College	Xiao, Y; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.; Xiao, Y; Wang, XH (corresponding author), Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Peoples R China.; Zhang, Y (corresponding author), Euler Technol, ZGC Life Sci Pk, Beijing, Peoples R China.; Zhang, Y (corresponding author), Peking Univ, Ctr Quantitat Biol, Sch Life Sci, Beijing, Peoples R China.; Wang, XH (corresponding author), Chinese Acad Med Sci, Wuhan Res Ctr Infect Dis & Canc, Wuhan, Peoples R China.	zy@eulertechnology.com; yu.xiao@whu.edu.cn; wangxinghuan@whu.edu.cn		Liu, Wei/0000-0002-7908-8476; Qian, Kaiyu/0000-0003-4153-1265; Zhang, Yi/0000-0001-5388-1276	National Natural Science Foundation of China [82172985, 81772730]; Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease (Tumor) from National Health Commission of China [ZLYNXM202006]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2020-PT320-004]; Research Fund of Zhongnan Hospital of Wuhan University [ZNJC201915, SWYBK00-03, 413100049, PTXM2020024]; Science and Technology Department of Hubei Province Key Project [2022EJD001, YYXKNL2022001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease (Tumor) from National Health Commission of China; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; Research Fund of Zhongnan Hospital of Wuhan University; Science and Technology Department of Hubei Province Key Project	The excellent technical assistance of Ms. Yayun Fang and Ms. Danni Shan are gratefully acknowledged. Part of the analysis was performed on the High Performance Computing Platform of the Center for Life Science (Peking University). The study was funded by National Natural Science Foundation of China (82172985 and 81772730), Improvement Project for Theranostic Ability on Difficulty Miscellaneous Disease (Tumor) from National Health Commission of China (ZLYNXM202006), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-PT320-004), Research Fund of Zhongnan Hospital of Wuhan University (ZNJC201915, SWYBK00-03, 413100049, and PTXM2020024), Science and Technology Department of Hubei Province Key Project (2022EJD001 and YYXKNL2022001).	[Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bayley R, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188407; Bian J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092125; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao R, 2018, CANCER LETT, V414, P278, DOI 10.1016/j.canlet.2017.11.015; Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994; Choi BR, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107540; Ciciro Y, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00309-y; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; Guiley KZ, 2018, P NATL ACAD SCI USA, V115, P10016, DOI 10.1073/pnas.1808136115; Han J, 2021, TRANSL CANCER RES, V10, P4076, DOI 10.21037/tcr-21-175; He S, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110851; Heinrichs S, 2013, ELIFE, V2, DOI 10.7554/eLife.00825; Hou XY, 2020, EXPERT REV ANTICANC, V20, P1107, DOI 10.1080/14737140.2020.1838280; Iness AN, 2019, ONCOGENE, V38, P1080, DOI 10.1038/s41388-018-0490-y; Li MS, 2019, AGING-US, V11, P10626, DOI 10.18632/aging.102481; Li QJ, 2021, THERANOSTICS, V11, P5794, DOI 10.7150/thno.56604; Liu Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03969-1; Okumura F, 2016, MOL CELL BIOL, V36, P1803, DOI 10.1128/MCB.00067-16; Pan CW, 2016, ONCOTARGET, V7, P35119, DOI 10.18632/oncotarget.9046; Ramirez JG, 2021, CANCERS, V13, DOI 10.3390/cancers13194980; Rimar KJ, 2017, CANCER-AM CANCER SOC, V123, P1912, DOI 10.1002/cncr.30631; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014; Shen DX, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01969-x; Sheng Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14590-9; Wang ZW, 2010, CANCER TREAT REV, V36, P151, DOI 10.1016/j.ctrv.2009.11.006; Xie HY, 2021, J CELL MOL MED, V25, P1958, DOI 10.1111/jcmm.15948; Xiong YC, 2020, MOL CELL BIOCHEM, V468, P185, DOI 10.1007/s11010-020-03721-x; Xue YJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-200; Xueling GE, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-33; Yu RJ, 2017, PATHOL RES PRACT, V213, P964, DOI 10.1016/j.prp.2017.04.024; Zhang X, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0573-6	36	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4606	4617		10.1038/s41388-022-02456-x	http://dx.doi.org/10.1038/s41388-022-02456-x		SEP 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36071275				2022-12-17	WOS:000850752600001
J	Boisteau, E; Posseme, C; Di Modugno, F; Edeline, J; Coulouarn, C; Hrstka, R; Martisova, A; Delom, F; Treton, X; Eriksson, LA; Chevet, E; Lievre, A; Ogier-Denis, E				Boisteau, Emeric; Posseme, Celine; Di Modugno, Federico; Edeline, Julien; Coulouarn, Cedric; Hrstka, Roman; Martisova, Andrea; Delom, Frederic; Treton, Xavier; Eriksson, Leif A.; Chevet, Eric; Lievre, Astrid; Ogier-Denis, Eric			Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology	ONCOGENE			English	Review							ADENOCARCINOMA-ASSOCIATED GENE; DISULFIDE-ISOMERASE; COLORECTAL-CANCER; PANCREATIC-CANCER; DIFFERENTIAL EXPRESSION; THIOREDOXIN SUPERFAMILY; PROGNOSTIC-FACTOR; GASTRIC-CANCER; PDI FAMILY; AGR2 GENE	Most of the organs of the digestive tract comprise secretory epithelia that require specialized molecular machines to achieve their functions. As such anterior gradient (AGR) proteins, which comprise AGR1, AGR2, and AGR3, belong to the protein disulfide isomerase family, and are involved in secretory and transmembrane protein biogenesis in the endoplasmic reticulum. They are generally expressed in epithelial cells with high levels in most of the digestive tract epithelia. To date, the vast majority of the reports concern AGR2, which has been shown to exhibit various subcellular localizations and exert pro-oncogenic functions. AGR2 overexpression has recently been associated with a poor prognosis in digestive cancers. AGR2 is also involved in epithelial homeostasis. Its deletion in mice results in severe diffuse gut inflammation, whereas in inflammatory bowel diseases, the secretion of AGR2 in the extracellular milieu participates in the reshaping of the cellular microenvironment. AGR2 thus plays a key role in inflammation and oncogenesis and may represent a therapeutic target of interest. In this review, we summarize the already known roles and mechanisms of action of the AGR family proteins in digestive diseases, their expression in the healthy digestive tract, and in digestive oncology. At last, we discuss the potential diagnostic and therapeutic implications underlying the biology of AGR proteins.	[Boisteau, Emeric; Posseme, Celine; Di Modugno, Federico; Edeline, Julien; Coulouarn, Cedric; Chevet, Eric; Lievre, Astrid; Ogier-Denis, Eric] Univ Rennes, INSERM U1242, Rennes, France; [Boisteau, Emeric; Lievre, Astrid] Univ Rennes, Univ Hosp Pontchaillou, Dept Gastroenterol, Rennes, France; [Posseme, Celine; Di Modugno, Federico; Edeline, Julien; Chevet, Eric; Ogier-Denis, Eric] Ctr Lutte Canc Eugene Marquis, Rennes, France; [Hrstka, Roman; Martisova, Andrea] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic; [Martisova, Andrea] Masaryk Univ, Fac Sci, Natl Ctr Biomol Res, Brno, Czech Republic; [Delom, Frederic] Univ Bordeaux, INSERM U1312, Bordeaux, France; [Treton, Xavier] Univ Paris, AP HP, Clichy, France; [Eriksson, Leif A.] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1; CHU Rennes; Universite de Rennes 1; UNICANCER; Centre Eugene Marquis; Masaryk Memorial Cancer Institute; Masaryk University Brno; UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Gothenburg	Chevet, E; Lievre, A; Ogier-Denis, E (corresponding author), Univ Rennes, INSERM U1242, Rennes, France.; Lievre, A (corresponding author), Univ Rennes, Univ Hosp Pontchaillou, Dept Gastroenterol, Rennes, France.; Chevet, E; Ogier-Denis, E (corresponding author), Ctr Lutte Canc Eugene Marquis, Rennes, France.	eric.chevet@inserm.fr; astrid.lievre@chu-rennes.fr; eric.ogier-denis@inserm.fr	; Edeline, Julien/F-6852-2013	Martisova, Andrea/0000-0002-0081-0498; Edeline, Julien/0000-0002-8289-7741; Di Modugno, Federico/0000-0001-8201-7997; Eriksson, Leif A./0000-0001-5654-3109	INCa [PRT-K20-136]; INCa (PLBIO); La Ligue Contre le Cancer Gironde; Site de recherche integree sur le cancer de Bordeaux (SIRIC Brio); Swedish research council [2019-3684]; Swedish Cancer Foundation [21-1447 Pj]; ministry of health	INCa(Institut National du Cancer (INCA) France); INCa (PLBIO); La Ligue Contre le Cancer Gironde; Site de recherche integree sur le cancer de Bordeaux (SIRIC Brio); Swedish research council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; ministry of health	We thank the Immuno-histopathology platform H2P2 for their expertise and work (https://histopathologie.univ-rennes1.fr/) and Raphael Pineau for his technical help. This work was funded by grants from INCa (PRT-K20-136) to CC and JE, INCa (PLBIO) to EC, La Ligue Contre le Cancer to EO-D and AL and from La Ligue Contre le Cancer Gironde and from the Site de recherche integree sur le cancer de Bordeaux (SIRIC Brio) to FD. LAE acknowledges funding from the Swedish research council (grant no 2019-3684) and the Swedish Cancer Foundation (grant no 21-1447 Pj). EB was funded by an "annee-recherche" grant from the ministry of health.	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Al-Shaibi AA, 2021, CELL MOL GASTROENTER, V12, P1809, DOI 10.1016/j.jcmgh.2021.07.001; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; [Anonymous], 2020, CBIOPORTAL CANC GEN; Arshavsky-Graham Sofia, 2021, ACS Meas Sci Au, V1, P82, DOI 10.1021/acsmeasuresciau.1c00019; Arumugam T, 2015, MOL CANCER THER, V14, P941, DOI 10.1158/1535-7163.MCT-14-0470; Bai ZG, 2011, INT J ONCOL, V38, P375, DOI 10.3892/ijo.2010.873; Barraclough DL, 2009, AM J PATHOL, V175, P1848, DOI 10.2353/ajpath.2009.090246; Bergstrom JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104186; Bialobrzeska W, 2021, BIOSENSORS-BASEL, V11, DOI 10.3390/bios11060184; Bonser LR, 2015, AM J RESP CELL MOL, V53, P536, DOI 10.1165/rcmb.2014-0318OC; Bouchalova P, 2022, MOL CELL PROTEOMICS, V21, DOI 10.1016/j.mcpro.2021.100188; Bradley L, 1996, DEVELOPMENT, V122, P2739; Brychtova V, 2014, EXP MOL PATHOL, V96, P375, DOI 10.1016/j.yexmp.2014.04.002; Brychtova V, 2014, PANCREAS, V43, P75, DOI 10.1097/MPA.0b013e3182a63bc3; cbioportal, CBIOPORTAL CANC GENO; Cernocka H, 2021, BIOELECTROCHEMISTRY, V140, DOI 10.1016/j.bioelechem.2021.107808; Chen SY, 2017, ONCOTARGET, V8, P41690, DOI 10.18632/oncotarget.16677; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Chi JY, 2020, CELL SIGNAL, V65, DOI 10.1016/j.cellsig.2019.109419; Clarke DJ, 2016, BBA-PROTEINS PROTEOM, V1864, P551, DOI 10.1016/j.bbapap.2016.02.011; Delom F, 2020, AM J PHYSIOL-CELL PH, V318, pC40, DOI 10.1152/ajpcell.00532.2018; depmap, DEPMAP DAT EXPL; DiMaio MA, 2012, HUM PATHOL, V43, P1799, DOI 10.1016/j.humpath.2012.03.019; Dong AW, 2011, J BIOL CHEM, V286, P18301, DOI 10.1074/jbc.M110.215707; Dumartin L, 2017, ONCOGENE, V36, P3094, DOI 10.1038/onc.2016.459; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Fessart D, 2021, BIORXIV, DOI [10.1101/2021.09.07.459258v1, DOI 10.1101/2021.09.07.459258V1]; Fessart D, 2022, OPEN BIOL, V12, DOI DOI 10.1098/RSOB.220068; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fomenko DE, 2002, PROTEIN SCI, V11, P2285, DOI 10.1110/ps.0218302; Camarillo GF, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/9238970; Gray TA, 2014, MOL BIOSYST, V10, P1409, DOI 10.1039/c4mb00113c; Gray TA, 2012, J IMMUNOL METHODS, V378, P20, DOI 10.1016/j.jim.2012.01.013; Guo H, 2017, ONCOGENE, V36, P5098, DOI 10.1038/onc.2017.132; Guo H, 2016, BIOCHEM BIOPH RES CO, V475, P57, DOI 10.1016/j.bbrc.2016.05.033; Gupta A, 2013, J BIOL CHEM, V288, P4321, DOI 10.1074/jbc.M112.433086; Gupta A, 2012, J BIOL CHEM, V287, P4773, DOI 10.1074/jbc.M111.301531; Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI [10.1089/ars.2009.2466, 10.1089/ARS.2009.2466]; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9; Hrstka R, 2016, MOL ONCOL, V10, P652, DOI 10.1016/j.molonc.2015.12.003; Ivanova AS, 2015, SCI REP-UK, V5, DOI 10.1038/srep08123; Ivanova AS, 2013, SCI REP-UK, V3, DOI 10.1038/srep01279; Jach D, 2021, AM J CANCER RES, V11, P5249; Jeon Y, 2022, HEPATOLOGY, DOI 10.1002/hep.32397; Jeong W, 2008, J BIOL CHEM, V283, P25557, DOI 10.1074/jbc.M803804200; Jess T, 2013, CLIN GASTROENTEROL H, V11, P43, DOI 10.1016/j.cgh.2012.09.026; Jessop CE, 2009, J CELL SCI, V122, P4287, DOI 10.1242/jcs.059154; Jia MQ, 2018, BBA-MOL BASIS DIS, V1864, P1622, DOI 10.1016/j.bbadis.2018.01.021; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kim HS, 2011, ONCOL REP, V25, P717, DOI 10.3892/or.2010.1126; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Kozlov G, 2010, FEBS J, V277, P3924, DOI 10.1111/j.1742-4658.2010.07793.x; Lamichane BD, 2019, BIOCHEM BIOPH RES CO, V515, P600, DOI 10.1016/j.bbrc.2019.05.154; Lee DH, 2011, MOL CELLS, V31, P563, DOI 10.1007/s10059-011-1053-z; Lee HJ, 2012, EXP MOL MED, V44, P60, DOI 10.3858/emm.2012.44.1.006; Lemaire SD, 2004, PHOTOSYNTH RES, V82, P203, DOI 10.1007/s11120-004-1091-x; Lepreux S, 2011, LIVER INT, V31, P322, DOI 10.1111/j.1478-3231.2010.02438.x; Li J, 2019, EXP CELL RES, V385, DOI 10.1016/j.yexcr.2019.111644; Liu ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103910; Ma SR, 2015, ONCOTARGET, V6, P8807, DOI 10.18632/oncotarget.3556; Maattanen P, 2010, SEMIN CELL DEV BIOL, V21, P500, DOI 10.1016/j.semcdb.2010.03.006; Makawita S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-404; Maslon MM, 2010, J MOL BIOL, V404, P418, DOI 10.1016/j.jmb.2010.09.035; Matsuo Y, 2022, ANTIOXID REDOX SIGN, V36, P984, DOI 10.1089/ars.2021.0187; Matsusaki M, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.04.003; Maurel M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810120; microvesicles, VESICLEPEDIA GENE SU; Mizuuchi Y, 2015, LAB INVEST, V95, P193, DOI 10.1038/labinvest.2014.138; Mohtar MA, 2018, MOL CELL PROTEOMICS, V17, P737, DOI 10.1074/mcp.RA118.000573; Moidu NA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05000; Nancarrow DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022513; ncbi, CALU CALUMENIN HOMO; ncbi, RCN1 RET 1; Negi H, 2019, CANCER LETT, V449, P125, DOI 10.1016/j.canlet.2019.01.025; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Norris AM, 2013, ONCOGENE, V32, P3867, DOI 10.1038/onc.2012.394; Obacz J, 2015, EUR J CELL BIOL, V94, P139, DOI 10.1016/j.ejcb.2015.01.002; Oka OBV, 2019, EMBO J, V38, DOI 10.15252/embj.2018100990; Oka OBV, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2122657119; Olen O, 2020, LANCET GASTROENTEROL, V5, P475, DOI 10.1016/S2468-1253(20)30005-4; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Patel P, 2013, J MOL BIOL, V425, P929, DOI 10.1016/j.jmb.2012.12.009; Pelaseyed T, 2014, IMMUNOL REV, V260, P8, DOI 10.1111/imr.12182; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Pizzi M, 2012, HUM PATHOL, V43, P1839, DOI 10.1016/j.humpath.2012.01.004; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; proteinatlas, AGR3 PROTEIN EXPRESS; proteinatlas, AGR2 PROT EXPR SUMM; proteinatlas, TXNDC12 PROTEIN EXPR; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Raykhel I, 2007, J CELL BIOL, V179, P1193, DOI 10.1083/jcb.200705180; Riener MO, 2014, EUR J CANCER, V50, P1722, DOI 10.1016/j.ejca.2014.04.012; Riener MO, 2009, HISTOL HISTOPATHOL, V24, P1121, DOI 10.14670/HH-24.1121; Schroeder BW, 2012, AM J RESP CELL MOL, V47, P178, DOI 10.1165/rcmb.2011-0421OC; Shih LJ, 2007, GENE EXPR PATTERNS, V7, P452, DOI 10.1016/j.modgep.2006.11.003; Sicari D, 2021, EMBO REP, V22, DOI 10.15252/embr.202051412; Simon EP, 2015, P NATL ACAD SCI USA, V112, pE5916, DOI 10.1073/pnas.1424894112; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Tian SB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15757-z; Tian SB, 2018, EXP CELL RES, V364, P198, DOI 10.1016/j.yexcr.2018.02.004; Tiemann K, 2019, ONCOGENE, V38, P3003, DOI 10.1038/s41388-018-0638-9; Tsuji T, 2015, CANCER RES, V75, P356, DOI 10.1158/0008-5472.CAN-14-1693; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Valladares-Ayerbes M, 2012, INT J MOL SCI, V13, P4367, DOI 10.3390/ijms13044367; Nguyen VD, 2018, ACTA CRYSTALLOGR F, V74, P425, DOI 10.1107/S2053230X18009093; Vanderlaag KE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2586; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vivekanandan P, 2009, HUM PATHOL, V40, P293, DOI 10.1016/j.humpath.2008.08.003; Worfolk JC, 2019, ANTIOXID REDOX SIGN, V31, P1117, DOI 10.1089/ars.2018.7647; Wu J, 2015, ONCOTARGET, V6, P11794, DOI 10.18632/oncotarget.3649; Ye XL, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6483860; Yosudjai J, 2018, BIOMED PHARMACOTHER, V107, P109, DOI 10.1016/j.biopha.2018.07.154; Yuan KF, 2020, CELL DEATH DIFFER, V27, P1355, DOI 10.1038/s41418-019-0421-7; Zhang J, 2016, ONCOL LETT, V11, P2075, DOI 10.3892/ol.2016.4160; Zhao F, 2010, DEV BIOL, V338, P268, DOI 10.1016/j.ydbio.2009.12.008; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263	120	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2022	41	42					4673	4685		10.1038/s41388-022-02452-1	http://dx.doi.org/10.1038/s41388-022-02452-1		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5I4GP	36068336				2022-12-17	WOS:000850425100001
J	Chen, J; Li, L; Liu, TY; Fu, HF; Lai, YH; Lei, X; Xu, JF; Yu, JS; Xia, YJ; Zhang, TH; Yang, DJ; He, YL				Chen, Jian; Li, Lu; Liu, Tian-Yu; Fu, Hua-Feng; Lai, Yuan-Hui; Lei, Xiong; Xu, Jun-Fa; Yu, Ji-Shang; Xia, Yu-Jian; Zhang, Tian-Hao; Yang, Dong-Jie; He, Yu-Long			CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies	ONCOGENE			English	Article							BINDING PROTEINS; GENE-THERAPY; GROWTH; GW182	Deciphering the crosstalk between RNA-binding proteins and corresponding RNAs will provide a better understanding of gastric cancer (GC) progression. The comprehensive bioinformatics study identified cytoplasmic polyadenylation element-binding protein 3 (CPEB3) might play a vital role in GC progression. Then we found CPEB3 was downregulated in GC and correlated with prognosis. In addition, CPEB3 suppressed GC cell proliferation, invasion and migration in vitro, as well as tumor growth and metastasis in vivo. Mechanistic study demonstrated CPEB3 interacted with 3 '-UTR of ADAR1 mRNA through binding to CPEC nucleotide element, and then inhibited its translation by localizing it to processing bodies (P bodies), eventually leading to the suppression of ADAR1-mediated RNA editing. Microscale thermophoresis assay further revealed that the direct interaction between CPEB3 and GW182, the P-body's major component, was through the 440-698AA region of CPEB3 binding to the 403-860AA region of GW182. Finally, AAV9-CPEB3 was developed and administrated in mouse models to assess its potential value in gene therapy. We found AAV9-CPEB3 inhibited GC growth and metastasis. Besides, AAV9-CPEB3 induced hydropic degeneration in mouse liver, but did not cause kidney damage. These findings concluded that CPEB3 suppresses GC progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies.	[Chen, Jian; Fu, Hua-Feng; Yu, Ji-Shang; Xia, Yu-Jian; Zhang, Tian-Hao; Yang, Dong-Jie; He, Yu-Long] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China; [Li, Lu] Guangdong Med Univ, Sch Med Technol, Guangdong Prov Key Lab Med Mol Diagnost, Inst Lab Med,Dept Clin Microbiol Lab, Dongguan, Guangdong, Peoples R China; [Liu, Tian-Yu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China; [Lai, Yuan-Hui] Sun Yat Sen Univ, Affiliated Hosp 1, Eastern Div, Dept Thyroid & Breast Surg, Guangzhou, Guangdong, Peoples R China; [Lei, Xiong] Nanchang Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Nanchang, Jiangxi, Peoples R China; [Xu, Jun-Fa] Guangdong Med Univ, Sch Med Technol, Guangdong Prov Key Lab Med Mol Diagnost, Dept Clin Immunol,Inst Lab Med, Dongguan, Guangdong, Peoples R China; [He, Yu-Long] Sun Yat Sen Univ, Affiliated Hosp 7, Digest Med Ctr, Shenzhen, Guangdong, Peoples R China	Sun Yat Sen University; Guangdong Medical University; Sun Yat Sen University; Sun Yat Sen University; Nanchang University; Guangdong Medical University; Sun Yat Sen University	Yang, DJ; He, YL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China.; He, YL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Digest Med Ctr, Shenzhen, Guangdong, Peoples R China.	ydongj@mail.sysu.edu.cn; heyulong@mail.sysu.edu.cn		Chen, Jian/0000-0002-8515-1179	National Natural Science Foundation of China [81802599, 81772579]; Center for Gastrointestinal Surgery; First Affiliated Hospital of Sun Yat-sen University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Center for Gastrointestinal Surgery; First Affiliated Hospital of Sun Yat-sen University	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81802599, 81772579). We thank Prof. Zun-Fu Ke (Department of Pathology, the First Affiliated Hospital of Sun Yat-sen University) and his colleagues for the help of pathological diagnoses and guidance. We appreciate Department of Laboratory Medicine, the First Affiliated Hospital of Sun Yat-sen University for the help of urine and serum detection. We appreciate all supports from Center for Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University.	Brannan KW, 2021, NAT METHODS, V18, P507, DOI 10.1038/s41592-021-01128-0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chan THM, 2016, GASTROENTEROLOGY, V151, P637, DOI 10.1053/j.gastro.2016.06.043; Chan THM, 2014, GUT, V63, P832, DOI 10.1136/gutjnl-2012-304037; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Chowdhury EA, 2021, ADV DRUG DELIVER REV, V170, P214, DOI 10.1016/j.addr.2021.01.017; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Ballesteros-Briones MC, 2019, MOL THER, V27, P1892, DOI 10.1016/j.ymthe.2019.09.016; D'Ambrogio A, 2013, NAT REV CANCER, V13, P283, DOI 10.1038/nrc3485; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Ford L, 2019, P NATL ACAD SCI USA, V116, P18078, DOI 10.1073/pnas.1815275116; Fritzell K, 2018, SEMIN CELL DEV BIOL, V79, P123, DOI 10.1016/j.semcdb.2017.11.018; Gebauer F, 2021, NAT REV GENET, V22, P185, DOI 10.1038/s41576-020-00302-y; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Han SW, 2014, J EXP MED, V211, P613, DOI 10.1084/jem.20132209; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Joshi Smita S, 2021, CA Cancer J Clin, V71, P264, DOI 10.3322/caac.21657; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Lee JE, 2020, SCIENCE, V367, P527, DOI 10.1126/science.aay7108; Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Luo NC, 2020, J BUON, V25, P2097; Mori Takuji, 2003, Gastric Cancer, V6 Suppl 1, P13, DOI 10.1007/s10120-003-0226-7; Okugawa Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1740-z; Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Qin YR, 2014, CANCER RES, V74, P840, DOI 10.1158/0008-5472.CAN-13-2545; Ramirez-Moya J, 2020, ONCOGENE, V39, P3738, DOI 10.1038/s41388-020-1248-x; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Richter JD, 2007, TRENDS BIOCHEM SCI, V32, P279, DOI 10.1016/j.tibs.2007.04.004; Shiromoto Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21921-x; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9; Wang E, 2019, CANCER CELL, V35, P369, DOI 10.1016/j.ccell.2019.01.010; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699; Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093; Wu XW, 2020, CELL DEATH DIFFER, V27, P55, DOI 10.1038/s41418-019-0339-0; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477; Yao F, 2015, CELL REP, V12, P272, DOI 10.1016/j.celrep.2015.06.020; Youn JY, 2019, MOL CELL, V76, P286, DOI 10.1016/j.molcel.2019.09.014; Zhang H, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02984-y; Zhang Y, 2008, LIFE SCI, V82, P1154, DOI 10.1016/j.lfs.2008.03.023; Zhao WC, 2019, CELL RES, V29, P895, DOI 10.1038/s41422-019-0229-5; Zhong Q, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01637-4; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	47	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4591	4605		10.1038/s41388-022-02454-z	http://dx.doi.org/10.1038/s41388-022-02454-z		SEP 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36068334				2022-12-17	WOS:000850425100002
J	Winkler, R; Magdefrau, AS; Piskor, EM; Kleemann, M; Beyer, M; Linke, K; Hansen, L; Schaffer, AM; Hoffmann, ME; Poepsel, S; Heyd, F; Beli, P; Moroy, T; Mahboobi, S; Kramer, OH; Kosan, C				Winkler, Rene; Magdefrau, Ann-Sophie; Piskor, Eva-Maria; Kleemann, Markus; Beyer, Mandy; Linke, Kevin; Hansen, Lisa; Schaffer, Anna-Maria; Hoffmann, Marina E.; Poepsel, Simon; Heyd, Florian; Beli, Petra; Moroy, Tarik; Mahboobi, Siavosh; Kramer, Oliver H.; Kosan, Christian			Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition	ONCOGENE			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; C-MYC; DOWN-REGULATION; HDAC6; CANCER; TUBULIN; ACETYLATION; EXPRESSION; LINES; NOXA	Overexpression of MYC is a genuine cancer driver in lymphomas and related to poor prognosis. However, therapeutic targeting of the transcription factor MYC remains challenging. Here, we show that inhibition of the histone deacetylase 6 (HDAC6) using the HDAC6 inhibitor Marbostat-100 (M-100) reduces oncogenic MYC levels and prevents lymphomagenesis in a mouse model of MYC-induced aggressive B-cell lymphoma. M-100 specifically alters protein-protein interactions by switching the acetylation state of HDAC6 substrates, such as tubulin. Tubulin facilitates nuclear import of MYC, and MYC-dependent B-cell lymphoma cells rely on continuous import of MYC due to its high turn-over. Acetylation of tubulin impairs this mechanism and enables proteasomal degradation of MYC. M-100 targets almost exclusively B-cell lymphoma cells with high levels of MYC whereas non-tumor cells are not affected. M-100 induces massive apoptosis in human and murine MYC-overexpressing B-cell lymphoma cells. We identified the heat-shock protein DNAJA3 as an interactor of tubulin in an acetylation-dependent manner and overexpression of DNAJA3 resulted in a pronounced degradation of MYC. We propose a mechanism by which DNAJA3 associates with hyperacetylated tubulin in the cytoplasm to control MYC turnover. Taken together, our data demonstrate a beneficial role of HDAC6 inhibition in MYC-dependent B-cell lymphoma.	[Winkler, Rene; Magdefrau, Ann-Sophie; Piskor, Eva-Maria; Kleemann, Markus; Linke, Kevin; Hansen, Lisa; Schaffer, Anna-Maria; Kosan, Christian] Friedrich Schiller Univ, Ctr Mol Biomed CMB, Dept Biochem, D-07745 Jena, Germany; [Beyer, Mandy; Kramer, Oliver H.] Univ Med Ctr Mainz, Inst Toxicol, D-55131 Mainz, Germany; [Hoffmann, Marina E.; Beli, Petra] Inst Mol Biol IMB, D-55128 Mainz, Germany; [Poepsel, Simon] Univ Cologne, Fac Med, Ctr Mol Med Cologne CMMC, D-50931 Cologne, Germany; [Poepsel, Simon] Univ Cologne, Univ Hosp, D-50931 Cologne, Germany; [Poepsel, Simon] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany; [Heyd, Florian] Free Univ Berlin, Inst Chem & Biochem, Lab RNA Biochem, D-14195 Berlin, Germany; [Moroy, Tarik] Inst Rech Clin Montreal IRCM, Montreal, PQ H2W 1R7, Canada; [Mahboobi, Siavosh] Univ Regensburg, Inst Pharm, Dept Pharmaceut Med Chem 1, D-93040 Regensburg, Germany; [Winkler, Rene] Josep Carreras Leukaemia Res Inst IJC, Campus ICO Germans Trias & Pujol, Badalona 08916, Spain	Friedrich Schiller University of Jena; Johannes Gutenberg University of Mainz; Institute of Molecular Biology (IMB); University of Cologne; University of Cologne; University of Cologne; Free University of Berlin; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Regensburg; Catalan Institute of Oncology; Institut de Recerca Contra la Leucemia Josep Carreras (IJC)	Kosan, C (corresponding author), Friedrich Schiller Univ, Ctr Mol Biomed CMB, Dept Biochem, D-07745 Jena, Germany.	christian.kosan@uni-jena.de	Winkler, René/ABB-4629-2020	Winkler, René/0000-0002-7570-0242	Carl Zeiss Foundation; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [GRK 1715]; Landesgraduiertenstipendium (Friedrich Schiller University Jena); DFG [393547839-SFB 1361, GRK 2291/9-1, 427404172]; Projekt DEAL	Carl Zeiss Foundation; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); Landesgraduiertenstipendium (Friedrich Schiller University Jena); DFG(German Research Foundation (DFG)); Projekt DEAL	RW was supported by a scholarship from the Carl Zeiss Foundation. CK received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), GRK 1715. E-MP was supported by a Landesgraduiertenstipendium (Friedrich Schiller University Jena). Work done in the group of OHK was done by MB and is funded by DFG, Project-ID 393547839-SFB 1361 and DFG, GRK 2291/9-1, project number 427404172. Open Access funding enabled and organized by Projekt DEAL.	ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Amengual JE, 2021, ONCOLOGIST, V26, DOI 10.1002/onco.13673; Amengual JE, 2017, CLIN CANCER RES, V23, P3084, DOI 10.1158/1078-0432.CCR-16-2022; Amengual JE, 2015, CLIN CANCER RES, V21, P4663, DOI 10.1158/1078-0432.CCR-14-3068; Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basso K, 2015, NAT REV IMMUNOL, V15, P172, DOI 10.1038/nri3814; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Beyer M, 2019, CANCERS, V11, DOI 10.3390/cancers11101436; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Croxford JL, 2013, BLOOD, V121, P2512, DOI 10.1182/blood-2012-08-449025; Deng WH, 2018, TRANSL ONCOL, V11, P1147, DOI 10.1016/j.tranon.2018.07.007; Depetter Y, 2019, INT J CANCER, V145, P735, DOI 10.1002/ijc.32169; Fernandez-Serrano M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010253; Gupta M, 2012, BLOOD, V120, P4400, DOI 10.1182/blood-2012-05-428466; Heidelberger JB, 2018, EMBO REP, V19, DOI 10.15252/embr.201744754; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113; Joshi G, 2020, CANCERS, V12, DOI 10.3390/cancers12103009; Karpova MB, 2005, LEUKEMIA, V19, P159, DOI 10.1038/sj.leu.2403534; Kleo K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5537-0; Koh CM, 2015, NATURE, V523, P96, DOI 10.1038/nature14351; Lechner S, 2022, NAT CHEM BIOL; Leonhardt M, 2018, EUR J MED CHEM, V152, P329, DOI 10.1016/j.ejmech.2018.04.046; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Lu B, 2006, J BIOL CHEM, V281, P13150, DOI 10.1074/jbc.M509179200; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Miyake Y, 2016, NAT CHEM BIOL, V12, P748, DOI 10.1038/nchembio.2140; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; Nebbioso A, 2017, CLIN CANCER RES, V23, P2542, DOI 10.1158/1078-0432.CCR-15-2388; New M, 2012, MOL ONCOL, V6, P637, DOI 10.1016/j.molonc.2012.09.003; Niklinski J, 2000, MOL CELL BIOL, V20, P5276, DOI 10.1128/MCB.20.14.5276-5284.2000; PHILIP I, 1984, J NATL CANCER I, V73, P835; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rempel RE, 2014, MOL CANCER THER, V13, P3219, DOI 10.1158/1535-7163.MCT-13-0044; Ross J, 2021, EUR J MED CHEM, V213, DOI 10.1016/j.ejmech.2020.113137; Ross J, 2019, CANCER RES, V79, P4184, DOI 10.1158/0008-5472.CAN-18-3038; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schafer C, 2017, CELL SIGNAL, V29, P218, DOI 10.1016/j.cellsig.2016.11.002; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schuster C, 2011, BLOOD, V118, P4635, DOI 10.1182/blood-2010-10-313098; Sellmer A, 2018, J MED CHEM, V61, P3454, DOI 10.1021/acs.jmedchem.7b01593; Shin DY, 2015, CANCER LETT, V364, P89, DOI 10.1016/j.canlet.2015.03.016; Sterrenberg JN, 2011, CANCER LETT, V312, P129, DOI 10.1016/j.canlet.2011.08.019; Stojanovic N, 2017, ONCOGENE, V36, P1804, DOI 10.1038/onc.2016.344; Stubbs MC, 2015, CLIN CANCER RES, V21, P2348, DOI 10.1158/1078-0432.CCR-14-1290; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Thompson JW, 2014, J BIOL CHEM, V289, P28942, DOI 10.1074/jbc.M114.573352; Trabucco SE, 2015, CLIN CANCER RES, V21, P113, DOI 10.1158/1078-0432.CCR-13-3346; Wachholz V, 2022, ARCH TOXICOL, V96, P177, DOI 10.1007/s00204-021-03174-1; Winkler R, 2017, METHODS MOL BIOL, V1510, P93, DOI 10.1007/978-1-4939-6527-4_7; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763	60	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4560	4572		10.1038/s41388-022-02450-3	http://dx.doi.org/10.1038/s41388-022-02450-3		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36068335	Green Submitted, hybrid, Green Published			2022-12-17	WOS:000850425100003
J	He, WT; Lin, SY; Guo, Y; Wu, YZ; Zhang, LL; Deng, QL; Du, ZM; Wei, MB; Zhu, WJ; Chen, WJ; Shao, JY; Xu, GL				He, Wenting; Lin, Shiyong; Guo, Yi; Wu, Yuanzhong; Zhang, Lu-Lu; Deng, Qiling; Du, Zi-Ming; Wei, Mingbiao; Zhu, Weijie; Chen, Wan-Juan; Shao, Jian-Yong; Xu, Guo-Liang			Targeted demethylation at ZNF154 promotor upregulates ZNF154 expression and inhibits the proliferation and migration of Esophageal Squamous Carcinoma cells	ONCOGENE			English	Article							TET PROTEINS; DNA METHYLATION; CANCER; GENES; 5-METHYLCYTOSINE; CONVERSION; DISEASE; LOCUS	Zinc finger protein 154 (ZNF154) is hypermethylated at the promoter in many epithelial-derived solid tumors. However, its methylation status and function in esophageal squamous carcinoma (ESCC) are poorly understood. We found that the ZNF154 promoter is hypermethylated in ESCC and portends poor prognosis. In addition, ZNF154 functions as a tumor suppressor gene (TSG) in ESCC, and is downregulated by promoter hypermethylation. We established a targeted demethylation strategy based on CRISPR/dCas9 technology and found that the hypermethylation of ZNF154 promoter repressed ZNF154 induction, which in turn promoted the proliferation and migration of ESCC cells in vitro and in vivo. Finally, high-throughput CUT&Tag analysis, GEPIA software and qPCR were used to revealed the role of ZNF154 as a transcription factor to upregulate the expression of ESCC-associated tumor suppressor genes. Taken together, hypermethylation of the ZNF154 promoter plays an important role in the development of ESCC, and epigenetic editing is a promising tool for inhibiting ESCC cells with aberrant DNA methylation.	[He, Wenting; Zhang, Lu-Lu; Deng, Qiling; Du, Zi-Ming; Wei, Mingbiao; Zhu, Weijie; Shao, Jian-Yong] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Lin, Shiyong; Xu, Guo-Liang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Endoscopy & Laser, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Guo, Yi] Shantou Univ, Dept Endoscopy, Canc Hosp, Shantou, Peoples R China; [Wu, Yuanzhong] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Chen, Wan-Juan] Anhui Targene Med Technol Co Ltd, Res & Dev Dept, Wuhu, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Shantou University; State Key Lab Oncology South China; Sun Yat Sen University	Shao, JY (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Xu, GL (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Endoscopy & Laser, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Chen, WJ (corresponding author), Anhui Targene Med Technol Co Ltd, Res & Dev Dept, Wuhu, Peoples R China.	chenwanjuan@targene.cn; shaojy@sysucc.org.cn; xugl@sysucc.org.cn	he, wenting/GYD-5727-2022	Wu, Yuanzhong/0000-0002-3577-7069	National Natural Science Foundation of China [82002220]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grant No. 82002220 from the National Natural Science Foundation of China. The sponsors or funding organizations had no role in the design or conduct of this research.	Aparicio Ana, 2002, Curr Opin Investig Drugs, V3, P627; Bender CM, 1998, CANCER RES, V58, P95; Chen FF, 2019, MOL MED REP, V20, P3649, DOI 10.3892/mmr.2019.10608; Chen NP, 2016, P NATL ACAD SCI USA, V113, P990, DOI 10.1073/pnas.1515605113; Cheng AW, 2013, CELL RES, V23, P1163, DOI 10.1038/cr.2013.122; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Falahi F, 2013, MOL CANCER RES, V11, P1029, DOI 10.1158/1541-7786.MCR-12-0567; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Hamilton JP, 2006, CLIN GASTROENTEROL H, V4, P701, DOI 10.1016/j.cgh.2006.03.007; Han SC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02859-2; He WW, 2018, J THORAC DIS, V10, P5714, DOI 10.21037/jtd.2018.09.55; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Heller EA, 2014, NAT NEUROSCI, V17, P1720, DOI 10.1038/nn.3871; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kaz AM, 2014, CANCER LETT, V342, P193, DOI 10.1016/j.canlet.2012.02.036; Lao-Sirieix P, 2012, NAT REV CLIN ONCOL, V9, P278, DOI 10.1038/nrclinonc.2012.35; Li JS, 2013, CHIN J CANCER, V32, P3, DOI 10.5732/cjc.011.10381; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Margolin G, 2016, J MOL DIAGN, V18, P283, DOI 10.1016/j.jmoldx.2015.11.004; Masoumi KC, 2017, MOL BIOL CELL, V28, P346, DOI 10.1091/mbc.E16-07-0547; Mehdipour P, 2020, PHARMACOL THERAPEUT, V205, DOI 10.1016/j.pharmthera.2019.107416; Mocciaro A, 2010, J CELL BIOL, V189, P631, DOI 10.1083/jcb.200910057; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pennathur A, 2009, ANN THORAC SURG, V87, P1048, DOI 10.1016/j.athoracsur.2008.12.060; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Sarbia M, 2007, BRIT J CANCER, V97, P1404, DOI 10.1038/sj.bjc.6604037; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; Verma N, 2018, NAT GENET, V50, P83, DOI 10.1038/s41588-017-0002-y; Xu XX, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.9; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3	42	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4537	4546		10.1038/s41388-022-02366-y	http://dx.doi.org/10.1038/s41388-022-02366-y		SEP 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36064578	Green Published, hybrid			2022-12-17	WOS:000849997400002
J	Hu, MN; Bao, RX; Lin, M; Han, XR; Ai, YJ; Gao, Y; Guan, KL; Xiong, Y; Yuan, HX				Hu, Mengnan; Bao, Ruoxuan; Lin, Miao; Han, Xiao-Ran; Ai, Ying-Jie; Gao, Yun; Guan, Kun-Liang; Xiong, Yue; Yuan, Hai-Xin			ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; 6-PHOSPHOFRUCTO-2-KINASE PFKFB3; TYROSINE KINASE; PROTEIN-KINASE; GROWTH-FACTOR; GLYCOLYSIS; IDENTIFICATION; INHIBITION; MECHANISMS; STRATEGY	Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase of the insulin receptor kinase subfamily, is activated in multiple cancer types through translocation or overexpression. Although several generations of ALK tyrosine kinase inhibitors (TKIs) have been developed for clinic use, drug resistance remains a major challenge. In this study, by quantitative proteomic approach, we identified the glycolytic regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), as a new target of ALK. Expression of PFKFB3 is highly dependent on ALK activity in ALK(+) anaplastic large cell lymphoma and non-small-cell lung cancer (NSCLC) cells. Notably, ALK and PFKFB3 expressions exhibit significant correlation in clinic ALK(+) NSCLC samples. We further demonstrated that ALK promotes PFKFB3 transcription through the downstream transcription factor STAT3. Upregulation of PFKFB3 by ALK is important for high glycolysis level as well as oncogenic activity of ALK(+) lymphoma cells. Finally, targeting PFKFB3 by its inhibitor can overcome drug resistance in cells bearing TKI-resistant mutants of ALK. Collectively, our studies reveal a novel ALK-STAT3-PFKFB3 axis to promote cell proliferation and tumorigenesis, providing an alternative strategy for the treatment of ALK-positive tumors.	[Hu, Mengnan; Bao, Ruoxuan; Gao, Yun; Yuan, Hai-Xin] Fudan Univ, Peoples Hosp Shanghai 5, Shanghai, Peoples R China; [Hu, Mengnan; Bao, Ruoxuan; Gao, Yun; Yuan, Hai-Xin] Fudan Univ, Mol & Cell Biol Lab, Inst Biomed Sci, Shanghai, Peoples R China; [Lin, Miao] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Lin, Miao] Fudan Univ, Zhongshan Hosp Xiamen, Dept Thorac Surg, Xiamen, Peoples R China; [Han, Xiao-Ran] Cullgen Shanghai Inc, Pu Dong New Area, 230 Chuan Hong Rd, Shanghai, Peoples R China; [Ai, Ying-Jie] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol & Hepatol, Shanghai, Peoples R China; [Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Yue] Cullgen Inc, 12671 High Bluff Dr, San Diego, CA 92130 USA; [Yuan, Hai-Xin] Chongqing Med Univ, Ctr Novel Target & Therapeut Intervent, Chongqing, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; Chongqing Medical University	Yuan, HX (corresponding author), Fudan Univ, Peoples Hosp Shanghai 5, Shanghai, Peoples R China.; Yuan, HX (corresponding author), Fudan Univ, Mol & Cell Biol Lab, Inst Biomed Sci, Shanghai, Peoples R China.; Yuan, HX (corresponding author), Chongqing Med Univ, Ctr Novel Target & Therapeut Intervent, Chongqing, Peoples R China.	yuanhaixin@fudan.edu.cn		Yuan, Hai-Xin/0000-0002-1624-3934	NSFC [82172595, 81773190]; National Key Research and Development Project of China [2018YFA0800304]; Supporting Program of Health Commission of Fujian Province for junior talents [2021GGB03]; Shanghai Pujiang Program [2020PJD009]; Innovative Research Team of High-level Local University in Shanghai	NSFC(National Natural Science Foundation of China (NSFC)); National Key Research and Development Project of China; Supporting Program of Health Commission of Fujian Province for junior talents; Shanghai Pujiang Program(Shanghai Pujiang Program); Innovative Research Team of High-level Local University in Shanghai	We thank Xian Chen and Ling Xie (UNC) for their aid with mass spectrometry analysis, and Jian Jin (Mount Sinai) and Jing Liu (Cullgen Inc.) for providing ALK degrader compound. We appreciate Hongbin Ji and Zhen Qin (SIBCB, CAS) for their help in the analysis of ALK mutant tumors. We also thank Kuirong Luo (Zhongshan Hospital, Fudan University) for the help with the interpretation of IHC results. This work was supported by the NSFC grants (No. 82172595 and 81773190 to H-XY), the National Key Research and Development Project of China (No. 2018YFA0800304 to H-XY), Supporting Program of Health Commission of Fujian Province for junior talents (2021GGB03 to ML) and Shanghai Pujiang Program (2020PJD009 to ML). H-XY is also supported by the Innovative Research Team of High-level Local University in Shanghai.	Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Chaft JE, 2012, MOL CANCER THER, V11, P485, DOI 10.1158/1535-7163.MCT-11-0692; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Fontana D, 2015, CANCER MED-US, V4, P953, DOI 10.1002/cam4.413; Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029; Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06287-x; Hallberg B, 2013, NAT REV CANCER, V13, P685, DOI 10.1038/nrc3580; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930; Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5; Lovly CM, 2014, NAT MED, V20, P1027, DOI 10.1038/nm.3667; Ma Y, 2016, ONCOGENE, V35, P6132, DOI 10.1038/onc.2016.150; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; McDonnell SRP, 2013, BLOOD, V122, P958, DOI 10.1182/blood-2013-01-482026; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Normant E, 2011, ONCOGENE, V30, P2581, DOI 10.1038/onc.2010.625; Olsen TK, 2015, NEURO-ONCOLOGY, V17, P1365, DOI 10.1093/neuonc/nov039; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Touriol Christian, 2000, Blood, V95, P3204; Tudzarova S, 2011, P NATL ACAD SCI USA, V108, P5278, DOI 10.1073/pnas.1102247108; US Food and Drug Administration, 2016, US; Wang YH, 2020, EUR J MED CHEM, V203, DOI 10.1016/j.ejmech.2020.112612; Wasik MA, 2009, SEMIN ONCOL, V36, pS27, DOI 10.1053/j.seminoncol.2009.02.007; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480; Zhang CW, 2018, EUR J MED CHEM, V151, P304, DOI 10.1016/j.ejmech.2018.03.071	44	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4547	4559		10.1038/s41388-022-02453-0	http://dx.doi.org/10.1038/s41388-022-02453-0		SEP 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36064579				2022-12-17	WOS:000849997400001
J	Lazaratos, AM; Annis, MG; Siegel, PM				Lazaratos, Anna-Maria; Annis, Matthew G.; Siegel, Peter M.			GPNMB: a potent inducer of immunosuppression in cancer	ONCOGENE			English	Review							ANTIBODY-DRUG CONJUGATE; MELANOMA PROTEIN-B; GLEMBATUMUMAB VEDOTIN; DC-HIL; THERAPEUTIC TARGET; NEGATIVE REGULATOR; DENDRITIC CELLS; PHASE I/II; TUMOR; GLYCOPROTEIN	The immune system is comprised of both innate and adaptive immune cells, which, in the context of cancer, collectively function to eliminate tumor cells. However, tumors can actively sculpt the immune landscape to favor the establishment of an immunosuppressive microenvironment, which promotes tumor growth and progression to metastatic disease. Glycoprotein-NMB (GPNMB) is a transmembrane glycoprotein that is overexpressed in a variety of cancers. It can promote primary tumor growth and metastasis, and GPNMB expression correlates with poor prognosis and shorter recurrence-free survival in patients. There is growing evidence supporting an immunosuppressive role for GPNMB in the context of malignancy. This review provides a description of the emerging roles of GPNMB as an inducer of immunosuppression, with a particular focus on its role in mediating cancer progression by restraining pro-inflammatory innate and adaptive immune responses.	[Lazaratos, Anna-Maria; Annis, Matthew G.; Siegel, Peter M.] McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada; [Annis, Matthew G.; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Siegel, Peter M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; [Siegel, Peter M.] McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Oncol, Montreal, PQ, Canada.	peter.siegel@mcgill.ca			Canadian Institutes of Health Research [CIHR PJT-153327]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. Work referenced from the author's laboratory was supported by a Project grant to PMS from the Canadian Institutes of Health Research (CIHR PJT-153327). PMS is a McGill University William Dawson Scholar. Figures created with BioRender.com.	Abe H, 2007, BIOCHEM BIOPH RES CO, V356, P610, DOI 10.1016/j.bbrc.2007.03.035; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Akiyoshi H, 2010, J IMMUNOL, V184, P3554, DOI 10.4049/jimmunol.0903250; Anderson MG, 2005, P NATL ACAD SCI USA, V102, P4566, DOI 10.1073/pnas.0407357102; Aponte PM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5619472; Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683; Biondini M, 2022, ONCOGENE, V41, P1701, DOI 10.1038/s41388-022-02206-z; Biswas KB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61931-1; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Burris HA, 2017, J CLIN ONCOL, V35, P2028, DOI 10.1200/JCO.2016.70.1508; Cao LY, 2016, J INVEST DERMATOL, V136, P1801, DOI 10.1016/j.jid.2016.02.816; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778; Chung JS, 2007, BLOOD, V109, P4320, DOI 10.1182/blood-2006-11-053769; Chung JS, 2020, CLIN CANCER RES, V26, P1449, DOI 10.1158/1078-0432.CCR-19-2360; Chung JS, 2014, J INVEST DERMATOL, V134, P2784, DOI 10.1038/jid.2014.254; Chung JS, 2014, J IMMUNOL, V192, P2576, DOI 10.4049/jimmunol.1301857; Chung JS, 2013, IMMUNOLOGY, V138, P173, DOI 10.1111/imm.12027; Chung JS, 2011, EUR J IMMUNOL, V41, P1794, DOI 10.1002/eji.201041233; Chung JS, 2009, EUR J IMMUNOL, V39, P965, DOI 10.1002/eji.200838990; Emerson DA, 2018, BIODRUGS, V32, P221, DOI 10.1007/s40259-018-0277-2; Feng X, 2020, ONCOL LETT, V20, P2356, DOI 10.3892/ol.2020.11787; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4; Gutknecht M, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0099-5; Hasanov M, 2020, CANCERS, V12, DOI 10.3390/cancers12082270; Hu XF, 2013, J CELL BIOCHEM, V114, P2729, DOI 10.1002/jcb.24621; Huang JJ, 2012, BRAIN BEHAV, V2, P85, DOI 10.1002/brb3.39; Kalbasi Anusha, 2020, Nat Rev Immunol, V20, P25, DOI 10.1038/s41577-019-0218-4; Katayama A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16920; Khan S, 2021, J THORAC ONCOL, V16, pS131, DOI 10.1016/j.jtocrr.2021.100166; Kitano S, 2014, CANCER IMMUNOL RES, V2, P812, DOI 10.1158/2326-6066.CIR-14-0013; Knodler A, 2009, LEUKEMIA, V23, P535, DOI 10.1038/leu.2008.301; Kobayashi M, 2019, CLIN CANCER RES, V25, P828, DOI 10.1158/1078-0432.CCR-18-0330; Kopp LM, 2019, EUR J CANCER, V121, P177, DOI 10.1016/j.ejca.2019.08.015; Kumagai K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143413; Lai YS, 2019, J CELL MOL MED, V23, P1257, DOI 10.1111/jcmm.14027; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10-154757; Li XF, 2019, P NATL ACAD SCI USA, V116, P3678, DOI 10.1073/pnas.1817652116; Liguori M, 2021, CELL MOL IMMUNOL, V18, P711, DOI 10.1038/s41423-020-0501-0; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Maric G, 2013, ONCOTARGETS THER, V6, P839, DOI 10.2147/OTT.S44906; Martin K, 2014, CANCER IMMUNOL IMMUN, V63, P925, DOI 10.1007/s00262-014-1565-4; Modi S, 2020, NEW ENGL J MED, V382, P610, DOI 10.1056/NEJMoa1914510; Muller P, 2014, CANCER IMMUNOL RES, V2, P741, DOI 10.1158/2326-6066.CIR-13-0198; Nakano Y, 2014, NEUROSCIENCE, V277, P123, DOI 10.1016/j.neuroscience.2014.06.065; Neal ML, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1100-1; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; O'Donnell JS, 2017, CANCER TREAT REV, V52, P71, DOI 10.1016/j.ctrv.2016.11.007; Okita Yukari, 2018, Oncotarget, V9, P37289, DOI 10.18632/oncotarget.26472; Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7; Ono Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23241; Ott PA, 2019, CANCER-AM CANCER SOC, V125, P1113, DOI 10.1002/cncr.31892; Ott PA, 2014, J CLIN ONCOL, V32, P3659, DOI 10.1200/JCO.2013.54.8115; Palisoc PJ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.814533; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Petroni G, 2022, NAT REV DRUG DISCOV, V21, P440, DOI 10.1038/s41573-022-00415-5; Pollack VA, 2007, CANCER CHEMOTH PHARM, V60, P423, DOI 10.1007/s00280-007-0490-z; Prabata A, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101232; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Ramani V, 2022, J INVEST DERMATOL, V142, P1372, DOI 10.1016/j.jid.2021.10.004; Ramani V, 2018, J INVEST DERMATOL, V138, P2443, DOI 10.1016/j.jid.2018.05.012; Ren FF, 2020, J CELL PHYSIOL, V235, P2738, DOI 10.1002/jcp.29177; Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2016, CLIN CANCER RES, V22, P6088, DOI 10.1158/1078-0432.CCR-16-1192; Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093; Saade M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.674739; Sasaki F, 2015, MOL MED REP, V12, P7503, DOI 10.3892/mmr.2015.4408; Schwarzbich MA, 2012, CANCER IMMUNOL IMMUN, V61, P193, DOI 10.1007/s00262-011-1096-1; Seligson JM, 2021, ANN PHARMACOTHER, V55, P921, DOI 10.1177/1060028020966548; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Song R, 2019, INFLAMMATION, V42, P1170, DOI 10.1007/s10753-019-00977-4; Sugimura K, 2015, J SURG ONCOL, V111, P752, DOI 10.1002/jso.23881; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Tanaka H, 2012, SCI REP-UK, V2, DOI 10.1038/srep00573; Tomihari M, 2010, CANCER RES, V70, P5778, DOI 10.1158/0008-5472.CAN-09-2538; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tsou PS, 2020, FASEB J, V34, P8810, DOI 10.1096/fj.202000651; Turaj AH, 2017, CANCER CELL, V32, P777, DOI 10.1016/j.ccell.2017.11.001; Turrentine J, 2014, J INVEST DERMATOL, V134, P2839, DOI 10.1038/jid.2014.248; Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; Xu XQ, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108199; Yamashita Y, 1999, J IMMUNOL, V162, P5940; Yardley DA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps1110; Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959; Yu B, 2018, J INVEST DERMATOL, V138, P219, DOI 10.1016/j.jid.2017.08.034; Yu B, 2016, J CELL BIOCHEM, V117, P1511, DOI 10.1002/jcb.25394; Zhang HF, 2022, TISSUE CELL, V74, DOI 10.1016/j.tice.2021.101683; Zhao SL, 2022, APPL BIONICS BIOMECH, V2022, DOI 10.1155/2022/1790104; Zhou LT, 2017, CELL IMMUNOL, V316, P53, DOI 10.1016/j.cellimm.2017.03.006; Zhou XH, 2005, J BIOL CHEM, V280, P31240, DOI 10.1074/jbc.M502641200; Zhuo H, 2016, PHARMAZIE, V71, P555, DOI 10.1691/ph.2016.6683	99	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2022	41	41					4573	4590		10.1038/s41388-022-02443-2	http://dx.doi.org/10.1038/s41388-022-02443-2		SEP 2022	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5D7BH	36050467				2022-12-17	WOS:000849283200001
J	Zhang, T; Li, JJ; Yang, MK; Ma, XL; Wang, ZY; Ma, XJ; Sun, MX; Sun, W; Xu, J; Hua, YQ; Cal, ZD				Zhang, Tao; Li, Jingjie; Yang, Mengkai; Ma, Xinglong; Wang, Zhuoying; Ma, Xiaojun; Sun, Mengxiong; Sun, Wei; Xu, Jing; Hua, Yingqi; Cal, Zhengdong			CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma	ONCOGENE			English	Article							CANCER GROWTH; ER CHAPERONE; CDK7; PROTEIN; GRP78; KINASE; TRANSCRIPTION; CHEMOTHERAPY; INDUCTION; PATHWAY	Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. Therapeutic targeting of osteosarcoma has been unsuccessful; therefore, identifying novel osteosarcoma pathogenesis could offer new therapeutic options. CDK7 is a subunit within the general transcription factor TFIIH. We aim to explore the new mechanism by which CDK7 regulates osteosarcoma and our studies may provide new theoretical support for the use of CDK7 inhibitors in the treatment of osteosarcoma. Here, we investigate the molecular mechanism underlying the association between CDK7 and GRP78 in osteosarcoma. Specifically, we find that an E3 ubiquitin ligase TRIM21 binds and targets GRP78 for ubiquitination and degradation, whereas CDK7 phosphorylates GRP78 at T69 to inhibit TRIM21 recruitment, leading to GRP78 stabilization. Notably, a CDK7-specific inhibitor, THZ1, blunts osteosarcoma growth and metastasis. Combination treatment with CDK7 and GRP78 inhibitors yield additive effects on osteosarcoma growth and progression inhibition. Thus, simultaneous suppression of CDK7 and GRP78 activity represents a potential new approach for the treatment of osteosarcoma. In conclusion, the discovery of this previously unknown CDK7/GRP78 signaling axis provides the molecular basis and the rationale to target human osteosarcoma.	[Zhang, Tao; Yang, Mengkai; Ma, Xinglong; Wang, Zhuoying; Ma, Xiaojun; Sun, Mengxiong; Sun, Wei; Xu, Jing; Hua, Yingqi; Cal, Zhengdong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai Bone Tumor Inst,Dept Orthoped, Shanghai 200080, Peoples R China; [Li, Jingjie] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Precis Res Ctr Refractory Dis, Sch Med, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, T; Hua, YQ; Cal, ZD (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai Bone Tumor Inst,Dept Orthoped, Shanghai 200080, Peoples R China.	zhangtaoabc@2008.sina.com; yhua@shsmu.edu.cn; caizhengdong@sjtu.edu.cn			NSFC [81874124]; Shanghai Science and Technology Committee Rising-Star Program [19QA1407200]	NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee Rising-Star Program	This work was supported by NSFC (81874124); Shanghai Science and Technology Committee Rising-Star Program (19QA1407200).	Bensimon A, 2011, FEBS LETT, V585, P1625, DOI 10.1016/j.febslet.2011.05.013; Cerezo M, 2016, CANCER CELL, V30, P183, DOI 10.1016/j.ccell.2016.06.007; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Cho YS, 2020, GENE DEV, V34, P53, DOI 10.1101/gad.333146.119; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226; Gonzalez-Gronow M, 2006, CANCER RES, V66, P11424, DOI 10.1158/0008-5472.CAN-06-1721; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hu SH, 2019, CANCER RES, V79, P3479, DOI 10.1158/0008-5472.CAN-19-0119; Itou J, 2018, J BIOL CHEM, V293, P6556, DOI 10.1074/jbc.RA117.000245; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Lee JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00906-9; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Lolli G, 2007, PROTEINS, V67, P1048, DOI 10.1002/prot.21370; Lolli G, 2009, NUCLEIC ACIDS RES, V37, P1260, DOI 10.1093/nar/gkn1061; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Pan JA, 2016, MOL CELL, V62, P149, DOI 10.1016/j.molcel.2016.03.015; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Rasool RU, 2019, CANCER DISCOV, V9, P1538, DOI 10.1158/2159-8290.CD-19-0189; Rosales JL, 2003, CELL PHYSIOL BIOCHEM, V13, P285, DOI 10.1159/000074543; Sava GP, 2020, CANCER METAST REV, V39, P805, DOI 10.1007/s10555-020-09885-8; Sava GP, 2020, ONCOGENE, V39, P651, DOI 10.1038/s41388-019-1008-y; Schachter MM, 2013, MOL CELL, V50, P250, DOI 10.1016/j.molcel.2013.04.003; Serra M, 2017, PHARMACOGENOMICS J, V17, P11, DOI 10.1038/tpj.2016.45; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Wang JQ, 2014, BREAST CANCER RES TR, V148, P279, DOI 10.1007/s10549-014-3165-6; Wang YC, 2013, J BIOL CHEM, V288, P9028, DOI 10.1074/jbc.M112.432005; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Wu ZC, 2016, SCI REP-UK, V6, DOI 10.1038/srep24611; Yang X, 2017, CANCER RES, V77, P1142, DOI 10.1158/0008-5472.CAN-16-1378; Yoo SA, 2012, J EXP MED, V209, P871, DOI 10.1084/jem.20111783; Yoshimi R, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/718237; Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143; Zhang HY, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3640; Zhang JJ, 2020, CLIN CANCER RES, V26, P2681, DOI 10.1158/1078-0432.CCR-19-1418; Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270; Zhang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06179-0; Zhang T, 2015, ELIFE, V4, DOI 10.7554/eLife.06734; Zhang Y, 2019, CLIN CANCER RES, V25, P6195, DOI 10.1158/1078-0432.CCR-18-3788	48	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4524	4536		10.1038/s41388-022-02446-z	http://dx.doi.org/10.1038/s41388-022-02446-z		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36042349				2022-12-17	WOS:000847653000001
J	Li, CH; Liu, JP; He, DH; Mao, FY; Rao, XJ; Zhao, Y; Lanman, NA; Kazemian, M; Farah, E; Liu, JH; Ngule, CM; Zhang, ZZ; Zhang, YQ; Kong, YF; Li, L; Wang, C; Liu, XQ				Li, Chaohao; Liu, Jinpeng; He, Daheng; Mao, Fengyi; Rao, Xiongjian; Zhao, Yue; Lanman, Nadia A.; Kazemian, Majid; Farah, Elia; Liu, Jinghui; Ngule, Chrispus M.; Zhang, Zhuangzhuang; Zhang, Yanquan; Kong, Yifan; Li, Lang; Wang, Chi; Liu, Xiaoqi			GSTM2 is a key molecular determinant of resistance to SG-ARIs	ONCOGENE			English	Article							PROSTATE-CANCER; OXIDATIVE STRESS; ENZALUTAMIDE; METASTASIS; SURVIVAL	Prostate cancer (PCa) continues to threaten men's health, and treatment targeting the androgen receptor (AR) pathway is the major therapy for PCa patients. Several second-generation androgen receptor inhibitors (SG-ARIs), including enzalutamide (ENZ), apalutamide (APA) and darolutamide (DARO), have been developed to better block the activity of AR. Unavoidably, emergence of resistance to these novel drugs still persists. Herein, we identified glutathione S-transferase Mu 2 (GSTM2) as an important determinant in the acquisition of resistance to SG-ARIs. Elevated GSTM2 was detected in enzalutamide-resistant (ENZ-R) PCa, and overexpression of GSTM2 in naive enzalutamide-sensitive (ENZ-S) cells effectively transformed them to ENZ-R PCa. Aryl hydrocarbon receptor (AhR), the upstream transcription factor, was implicated in the overexpression of GSTM2 in ENZ-R cells. Mechanistically, GSTM2 antagonized the effect of ENZ by rescuing cells from oxidative stress-associated damage and activation of p38 MAPK pathway. Surprisingly, high GSTM2 levels also associated with cross-resistance to APA and DARO. Taking together, these results provide new insight to ameliorate resistance to SG-ARIs and improve treatment outcome.	[Li, Chaohao; Mao, Fengyi; Rao, Xiongjian; Liu, Jinghui; Ngule, Chrispus M.; Zhang, Zhuangzhuang; Zhang, Yanquan; Kong, Yifan; Liu, Xiaoqi] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA; [Liu, Jinpeng; He, Daheng; Wang, Chi] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Liu, Jinpeng; He, Daheng; Wang, Chi; Liu, Xiaoqi] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; [Zhao, Yue; Li, Lang] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Lanman, Nadia A.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Lanman, Nadia A.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA; [Kazemian, Majid; Farah, Elia] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Kazemian, Majid] Purdue Univ, Dept Comp Sci, W Lafayette, IN 47907 USA	University of Kentucky; University of Kentucky; University of Kentucky; University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Liu, XQ (corresponding author), Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.; Liu, XQ (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.	xiaoqi.liu@uky.edu	Kazemian, Majid/C-7917-2018	Kazemian, Majid/0000-0001-7080-8820; Atallah, Nadia/0000-0002-1819-7070; Zhang, Zhuangzhuang/0000-0003-2578-7375	NIH [R01 CA157429, R01 CA196634, R01 CA264652, R01 CA256893]; University of Kentucky Markey Cancer Center [P30CA177558]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Kentucky Markey Cancer Center	The research is generously supported by NIH R01 CA157429 (XL), R01 CA196634 (XL), R01 CA264652 (XL), R01 CA256893 (XL). This research is also supported by the Biospecimen Procurement & Translational Pathology, Biostatistics and Bioinformatics, Redox Metabolism, and Flow Cytometry and Immune Monitoring Shared Resources of the University of Kentucky Markey Cancer Center (P30CA177558). We thanks Dr. Alumkal Joshi for the generous sharing of the RNA-seq raw data, and Eleanor Erikson for the critical reading and editing of the manuscript.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Allocati N, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0025-3; Alumkal JJ, 2020, P NATL ACAD SCI USA, V117, P12315, DOI 10.1073/pnas.1922207117; Andonova IE, 2010, BREAST CANCER RES TR, V121, P497, DOI 10.1007/s10549-009-0589-5; Bhattacharjee P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02704; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Canovas B, 2021, NAT REV MOL CELL BIO, V22, P346, DOI 10.1038/s41580-020-00322-w; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Coutinho I, 2016, ENDOCR-RELAT CANCER, V23, pT179, DOI 10.1530/ERC-16-0422; Davies A, 2021, NAT CELL BIOL, V23, P1023, DOI 10.1038/s41556-021-00743-5; de Vries R, 2019, DRUG METAB DISPOS, V47, P453, DOI 10.1124/dmd.118.084517; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gibbons JA, 2015, CLIN PHARMACOKINET, V54, P1043, DOI 10.1007/s40262-015-0271-5; Guo EN, 2020, BMC MED GENET, V21, DOI 10.1186/s12881-020-01066-2; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Han I, 2011, PROTEOMICS, V11, P352, DOI 10.1002/pmic.201000475; Hayer A, 2016, NAT CELL BIOL, V18, P1311, DOI 10.1038/ncb3438; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hayes JD, 2009, TOXICOL SCI, V111, P199, DOI 10.1093/toxsci/kfp168; He YD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21860-7; Higano C, 2019, NAT REV UROL, V16, P335, DOI 10.1038/s41585-019-0186-2; Ji CH, 2020, CHEM RES TOXICOL, V33, P211, DOI 10.1021/acs.chemrestox.9b00247; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Li CH, 2020, J BIOL CHEM, V295, P5470, DOI 10.1074/jbc.RA119.011385; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Moilanen AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12007; Neha K, 2019, EUR J MED CHEM, V178, P687, DOI 10.1016/j.ejmech.2019.06.010; Peng LS, 2021, PANCREATOLOGY, V21, P115, DOI 10.1016/j.pan.2020.12.008; Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200; Rothhammer V, 2019, NAT REV IMMUNOL, V19, P184, DOI 10.1038/s41577-019-0125-8; Sagar, 2016, DOES GLUTATHIONE TRA; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shiota M, 2010, ONCOGENE, V29, P237, DOI 10.1038/onc.2009.322; Shiota M, 2011, FREE RADICAL BIO MED, V51, P1320, DOI 10.1016/j.freeradbiomed.2011.07.011; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Tang SC, 2013, MOL CANCER RES, V11, P518, DOI 10.1158/1541-7786.MCR-12-0488; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teo MY, 2019, ANNU REV MED, V70, P479, DOI 10.1146/annurev-med-051517-011947; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zhao JG, 2020, MOL CANCER THER, V19, P1708, DOI 10.1158/1535-7163.MCT-20-0015; Zhao Liang, 2010, Front Biosci (Elite Ed), V2, P241, DOI 10.2741/e86; Zhao SG, 2020, NAT GENET, V52, P778, DOI 10.1038/s41588-020-0648-8; Zhou SG, 2008, MOL CELL BIOCHEM, V309, P99, DOI 10.1007/s11010-007-9647-7	49	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4498	4511		10.1038/s41388-022-02444-1	http://dx.doi.org/10.1038/s41388-022-02444-1		AUG 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36038661				2022-12-17	WOS:000847262000002
J	Zhan, Y; Qiao, W; Yi, BL; Yang, XY; Li, MM; Sun, L; Ji, L; Su, P; Wang, X; Zhang, FR; Zhang, R; Gao, MJ; Zhao, WJ; Song, YC				Zhan, Ying; Qiao, Wei; Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Sun, Lu; Ji, Lian; Su, Peng; Wang, Xin; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen			Dual role of pseudogene TMEM198B in promoting lipid metabolism and immune escape of glioma cells	ONCOGENE			English	Article							ATP CITRATE LYASE; TUMOR PROGRESSION; PROLIFERATION; DIFFERENTIATION; ACTIVATION; MIGRATION; INVASION	Dysregulation of pseudogenes, enhancement of fatty acid synthesis and formation of immunosuppressive microenvironment are important factors that promote the malignant progression of glioma. It is of great significance to search for the molecular mechanism of interaction between the three and then perform targeted interference for improving the treatment of glioma. In this study, we found that pseudogene transmembrane protein 198B (TMEM198B) was highly expressed in glioma tissues and cell lines, and it could promote malignant progression of glioma by regulating lipid metabolism reprogramming and remodeling immune microenvironment. Applying the experimental methods of gene interference, lipidomics and immunology, we further confirmed that TMEM198B promoted PLAG1 like zinc finger 2 (PLAGL2) expression by mediating tri-methylation of histone H3 on lysine 4 (H3K4me3) of PLAGL2 through binding to SET domain containing 1B (SETD1B). Increased PLAGL2 could transcriptional activate ATP citrate lyase (ACLY) and ELOVL fatty acid elongase 6 (ELOVL6) expression, and then influenced the biological behaviors of glioma cells via enhancing the de novo lipogenesis and fatty acid acyl chain elongation. At the same time, TMEM198B promoted macrophages lipid accumulation and intensification of fatty acid oxidation (FAO) through glioma-derived exosomes (GDEs), further induced macrophages to M2 polarization, which subsequently facilitated immune escape of glioma cells. In conclusion, our present study clarifies that the TMEM198B/PLAGL2/ACLY/ELOVL6 pathway conducts crucial regulatory effects on the malignant progression of glioma, which provides novel targets and new ideas for molecular targeted therapy and immunotherapy of glioma.	[Zhan, Ying; Qiao, Wei; Sun, Lu; Wang, Xin] China Med Univ, Dept Ultrasound, Shengjing Hosp, Shenyang 110004, Peoples R China; [Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen] China Med Univ, Dept Neurosurg, Shengjing Hosp, Shenyang 110004, Peoples R China; [Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen] Liaoning Clin Med Res Ctr Nervous Syst Dis, Shenyang 110004, Peoples R China; [Yi, Bolong; Yang, Xinyu; Li, Miaomiao; Zhang, Furong; Zhang, Rui; Gao, Mingjun; Zhao, Wujun; Song, Yichen] Key Lab Neurooncol Liaoning Prov, Shenyang 110004, Peoples R China; [Ji, Lian; Su, Peng] China Med Univ, Med Res Ctr, Liaoning Key Lab Res & Applicat Anim Models Envir, Shengjing Hosp, Shenyang 110004, Peoples R China	China Medical University; China Medical University; China Medical University	Song, YC (corresponding author), China Med Univ, Dept Neurosurg, Shengjing Hosp, Shenyang 110004, Peoples R China.; Song, YC (corresponding author), Liaoning Clin Med Res Ctr Nervous Syst Dis, Shenyang 110004, Peoples R China.; Song, YC (corresponding author), Key Lab Neurooncol Liaoning Prov, Shenyang 110004, Peoples R China.	songyc@sj-hospital.org			Natural Science Foundation of China [81571686, 81571868, 81372682]; Natural Science Foundation of Liaoning Province [2020-MS-170]; Outstanding Scientific Research Talent Plan of Shengjing hospital [2020M0322]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Liaoning Province(Natural Science Foundation of Liaoning Province); Outstanding Scientific Research Talent Plan of Shengjing hospital	This work is supported by grants from the Natural Science Foundation of China (81571686, 81571868 and 81372682), Natural Science Foundation of Liaoning Province (2020-MS-170) and Outstanding Scientific Research Talent Plan of Shengjing hospital (NO.2020M0322).	Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918; Broekman ML, 2018, NAT REV NEUROL, V14, P482, DOI 10.1038/s41582-018-0025-8; Chen X, 2020, THERANOSTICS, V10, P1479, DOI 10.7150/thno.40659; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; Chi KC, 2019, MOL NEUROBIOL, V56, P4589, DOI 10.1007/s12035-018-1392-2; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Dong WW, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.411; Geng F, 2016, CLIN CANCER RES, V22, P5337, DOI 10.1158/1078-0432.CCR-15-2973; Gimple RC, 2019, CANCER DISCOV, V9, P1248, DOI 10.1158/2159-8290.CD-19-0061; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Han W, 2018, ONCOGENE, V37, P710, DOI 10.1038/onc.2017.385; Hu WW, 2021, HEPATOLOGY, V73, P674, DOI 10.1002/hep.31293; Icard P, 2020, CANCER LETT, V471, P125, DOI 10.1016/j.canlet.2019.12.010; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Jiang L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02927; Koufaris C, 2016, ONCOGENE, V35, P2766, DOI 10.1038/onc.2015.333; Kumagai S, 2020, IMMUNITY, V53, P187, DOI 10.1016/j.immuni.2020.06.016; Kumari R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12194-6; Kwon M, 2020, NUCLEIC ACIDS RES, V48, P5442, DOI 10.1093/nar/gkaa317; Liao KM, 2020, CANCER LETT, V490, P111, DOI 10.1016/j.canlet.2020.07.012; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Lindner P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2340-4; Luo Q, 2020, CANCER SCI, V111, P4000, DOI 10.1111/cas.14616; Marien E, 2016, ONCOTARGET, V7, P12582, DOI 10.18632/oncotarget.7179; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Muir K, 2013, CANCER RES, V73, P4722, DOI 10.1158/0008-5472.CAN-12-3797; Muranaka H, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.51; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Redd PS, 2017, CANCER RES, V77, P2834, DOI 10.1158/0008-5472.CAN-16-2238; Shergalis A, 2018, PHARMACOL REV, V70, P412, DOI 10.1124/pr.117.014944; Song YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1200-5; Song YC, 2014, EXP CELL RES, V324, P54, DOI 10.1016/j.yexcr.2014.03.009; Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043; Su P, 2020, CANCER RES, V80, P1438, DOI 10.1158/0008-5472.CAN-19-2994; Sun M, 2017, MOL THER, V25, P739, DOI 10.1016/j.ymthe.2016.12.018; Wang M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03042-3; Wang SB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2345-z; Wu H, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910698; Wu L, 2021, THERANOSTICS, V11, P700, DOI 10.7150/thno.47800; Xi SY, 2021, ONCOGENE, V40, P4453, DOI 10.1038/s41388-021-01854-x; Yin XZ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108278; Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020; Zong ZQ, 2019, J CELL MOL MED, V23, P5048, DOI 10.1111/jcmm.14362	44	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4512	4523		10.1038/s41388-022-02445-0	http://dx.doi.org/10.1038/s41388-022-02445-0		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36038663				2022-12-17	WOS:000847262000001
J	Jia, XM; Liu, HJ; Ren, XN; Li, P; Song, RJ; Li, XR; Guo, YD; Li, XD				Jia, Xiaomeng; Liu, Huijiao; Ren, Xinmin; Li, Peng; Song, Runjie; Li, Xiru; Guo, Yangdong; Li, Xiangdong			Nucleolar protein NOC4L inhibits tumorigenesis and progression by attenuating SIRT1-mediated p53 deacetylation	ONCOGENE			English	Article							PROMOTES CELL-SURVIVAL; HEPATOCELLULAR-CARCINOMA; SIRT1 INTERACTS; POOR-PROGNOSIS; EXPRESSION; CANCER; TRANSCRIPTION; LOCALIZATION; COLON	SIRT1 is an NAD(+)-dependent deacetylase and plays an important role in the deacetylation of both histone and non-histone proteins. Many studies revealed that SIRT1 is upregulated in a variety of tumors and tightly associated with tumorigenesis and cancer progression, but the detailed underlying mechanism of the biological processes remains unclarified. In the present study, we found a nucleolar protein NOC4L, human ortholog of yeast Noc4p, which is essential for the nuclear export of the ribosomal 40S subunit and could bind to SIRT1 to inhibit SIRT1 mediated deacetylation of p53. NOC4L interacts with SIRT1 in variety of cells under nucleolar stress and directly interacts with SIRT1 in vitro. Furthermore, we determined the C-terminal of NOC4L and the catalytic domain of SIRT1 were required for their interaction. Overexpression of NOC4L did not change the protein levels of SIRT1 or p53, but increased the acetylation of p53 and promoted cell apoptosis. Additionally, NOC4L inhibited tumor cell proliferation in a p53-dependent manner and restrained tumor growth in a nude mice xenograft model. Clinically, colorectal cancer patients with the high expression of NOC4L had a better prognosis as TP53 was normally expressed, but no significant difference was observed in survival with mutant TP53. Taken together, our results identified a novel SIRT1 regulatory protein and broaden our understanding of the molecular mechanism of how nucleolar protein NOC4L regulates p53 under nucleolar stress. This research provides an insight into tumorigenesis and cell self-protection in the early stage of DNA damage.	[Jia, Xiaomeng; Liu, Huijiao; Ren, Xinmin; Li, Peng; Song, Runjie; Li, Xiangdong] China Agr Univ, Coll Biol Sci, State Key Lab Agro Biotechnol, Beijing 100193, Peoples R China; [Liu, Huijiao; Guo, Yangdong] China Agr Univ, Coll Hort Sci, Beijing 100193, Peoples R China; [Liu, Huijiao; Li, Xiangdong] China Agr Univ, Dept Nutr & Human Hlth, Beijing, Peoples R China; [Li, Xiru] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing, Peoples R China; [Li, Xiangdong] Med Univ Bialystok, Dept Reprod & Gynecol Endocrinol, Bialystok, Poland	China Agricultural University; China Agricultural University; China Agricultural University; Chinese People's Liberation Army General Hospital; Medical University of Bialystok	Li, XD (corresponding author), China Agr Univ, Coll Biol Sci, State Key Lab Agro Biotechnol, Beijing 100193, Peoples R China.; Li, XD (corresponding author), China Agr Univ, Dept Nutr & Human Hlth, Beijing, Peoples R China.; Li, XD (corresponding author), Med Univ Bialystok, Dept Reprod & Gynecol Endocrinol, Bialystok, Poland.	xiangdongli@cau.edu.cn		Li, Xiangdong/0000-0003-2261-2393	National Natural Science Foundation of China [82171854, 31970802]; Beijing Municipal Natural Science Foundation [7202099]; Open Project of the State Key Laboratory of Agrobiotechnology [2022SKLAB6-05]; Science & Technology Innovation Program for National Defense [19-163-15-ZD-009-001-03]; Ji Nan Science & Technology Bureau [2021GXRC060]; Medical University of Bialystok, Poland [SUB/1/DN/21/002/1104]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation); Open Project of the State Key Laboratory of Agrobiotechnology; Science & Technology Innovation Program for National Defense; Ji Nan Science & Technology Bureau; Medical University of Bialystok, Poland	This study was supported by grants from National Natural Science Foundation of China (31970802); National Natural Science Foundation of China (82171854); Beijing Municipal Natural Science Foundation (7202099); Open Project of the State Key Laboratory of Agrobiotechnology (2022SKLAB6-05); Science & Technology Innovation Program for National Defense (19-163-15-ZD-009-001-03); Ji Nan Science & Technology Bureau (2021GXRC060); Medical University of Bialystok, Poland (SUB/1/DN/21/002/1104). We are grateful to Prof. Xiaojuan Du and Prof. Jianyuan Luo for advising this research. We thank YunLiu for flow cytometry assistance. We thank Xin Ren for the revision of the manuscript language.	Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Byles V, 2010, INT J BIOL SCI, V6, P599; Cao WX, 2017, BIOCHEM BIOPH RES CO, V483, P638, DOI 10.1016/j.bbrc.2016.12.090; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; Chen HC, 2012, ANN SURG ONCOL, V19, P2011, DOI 10.1245/s10434-011-2159-4; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Feng AN, 2011, INT J SURG PATHOL, V19, P743, DOI 10.1177/1066896911412181; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451; Jang SH, 2012, J CLIN PATHOL, V65, P735, DOI 10.1136/jclinpath-2012-200685; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kerr LE, 2007, ONCOGENE, V26, P2554, DOI 10.1038/sj.onc.1210044; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lee S, 2012, CELL DEATH DIFFER, V19, P1613, DOI 10.1038/cdd.2012.40; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Liang XJ, 2008, MOL CANCER RES, V6, P1499, DOI 10.1158/1541-7786.MCR-07-2130; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Milkereit P, 2003, J BIOL CHEM, V278, P4072, DOI 10.1074/jbc.M208898200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Qin YL, 2017, PROTEIN CELL, V8, P230, DOI 10.1007/s13238-016-0335-9; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang HN, 2012, ONCOL REP, V28, P311, DOI 10.3892/or.2012.1788; Wang L, 2012, J BIOL CHEM, V287, P30157, DOI 10.1074/jbc.M112.376640; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Warda AS, 2016, HUM MOL GENET, V25, P5353, DOI 10.1093/hmg/ddw351; Wild T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000522; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Wu MQ, 2012, MED ONCOL, V29, P3240, DOI 10.1007/s12032-012-0260-6; Yang K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13599; Yao Z, 2010, ONCOGENE, V29, P1821, DOI 10.1038/onc.2009.473; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zhang R, 2010, J BIOL CHEM, V285, P7097, DOI 10.1074/jbc.M109.038604; Zhao J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1246-4; Zhu XP, 2019, CELL REP, V27, P1205, DOI 10.1016/j.celrep.2019.03.083	56	0	0	11	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4474	4484		10.1038/s41388-022-02447-y	http://dx.doi.org/10.1038/s41388-022-02447-y		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36030331				2022-12-17	WOS:000846097500001
J	Hamad, SH; Montgomery, SA; Simon, JM; Bowman, BM; Spainhower, KB; Murphy, RM; Knudsen, ES; Fenton, SE; Randell, SH; Holt, JR; Hayes, DN; Witkiewicz, AK; Oliver, TG; Ben Major, M; Weissman, BE				Hamad, Samera H.; Montgomery, Stephanie A.; Simon, Jeremy M.; Bowman, Brittany M.; Spainhower, Kyle B.; Murphy, Ryan M.; Knudsen, Erik S.; Fenton, Suzanne E.; Randell, Scott H.; Holt, Jeremiah R.; Hayes, D. Neil; Witkiewicz, Agnieszka K.; Oliver, Trudy G.; Ben Major, M.; Weissman, Bernard E.			TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice (vol 41, pg 3423, 2022)	ONCOGENE			English	Correction												bmajor@wustl.edu; weissman@med.unc.edu		Holt, Jeremiah/0000-0002-5201-5015				Hamad SH, 2022, ONCOGENE, V41, P3423, DOI 10.1038/s41388-022-02348-0	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4485	4485		10.1038/s41388-022-02442-3	http://dx.doi.org/10.1038/s41388-022-02442-3		AUG 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36002660	Bronze			2022-12-17	WOS:000844001000001
J	Kortum, B; Radhakrishnan, H; Zincke, F; Sachse, C; Burock, S; Keilholz, U; Dahlmann, M; Walther, W; Dittmar, G; Kobelt, D; Stein, U				Kortuem, Benedikt; Radhakrishnan, Harikrishnan; Zincke, Fabian; Sachse, Christoph; Burock, Susen; Keilholz, Ulrich; Dahlmann, Mathias; Walther, Wolfgang; Dittmar, Gunnar; Kobelt, Dennis; Stein, Ulrike			Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-beta-catenin-S100A4 axis of metastasis	ONCOGENE			English	Article							COLORECTAL-CANCER PATIENTS; BETA-CATENIN; COLON-CANCER; PROGNOSTIC VALUE; STEM-CELLS; S100A4; MACC1; PHOSPHORYLATION; TRANSCRIPTS; PROGRESSION	Colorectal cancer (CRC) is the second-most common malignant disease worldwide, and metastasis is the main culprit of CRC-related death. Metachronous metastases remain to be an unpredictable, unpreventable, and fatal complication, and tracing the molecular chain of events that lead to metastasis would provide mechanistically linked biomarkers for the maintenance of remission in CRC patients after curative treatment. We hypothesized, that Metastasis-associated in colorectal cancer-1 (MACC1) induces a secretory phenotype to enforce metastasis in a paracrine manner, and found, that the cell-free culture medium of MACC1-expressing CRC cells induces migration. Stable isotope labeling by amino acids in cell culture mass spectrometry (SILAC-MS) of the medium revealed, that S100A4 is significantly enriched in the MACC1-specific secretome. Remarkably, both biomarkers correlate in expression data of independent cohorts as well as within CRC tumor sections. Furthermore, combined elevated transcript levels of the metastasis genes MACC1 and S100A4 in primary tumors and in blood plasma robustly identifies CRC patients at high risk for poor metastasis-free (MFS) and overall survival (OS). Mechanistically, MACC1 strengthens the interaction of beta-catenin with TCF4, thus inducing S100A4 synthesis transcriptionally, resulting in elevated secretion to enforce cell motility and metastasis. In cell motility assays, S100A4 was indispensable for MACC1-induced migration, as shown via knock-out and pharmacological inhibition of S100A4. The direct transcriptional and functional relationship of MACC1 and S100A4 was probed by combined targeting with repositioned drugs. In fact, the MACC1-beta-catenin-S100A4 axis by statins (MACC1) and niclosamide (S100A4) synergized in inhibiting cancer cell motility in vitro and metastasis in vivo. The MACC1-beta-catenin-S100A4 signaling axis is causal for CRC metastasis. Selectively repositioned drugs synergize in restricting MACC1/S100A4-driven metastasis with cross-entity potential.	[Kortuem, Benedikt; Radhakrishnan, Harikrishnan; Zincke, Fabian; Dahlmann, Mathias; Walther, Wolfgang; Kobelt, Dennis; Stein, Ulrike] Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany; [Kortuem, Benedikt; Radhakrishnan, Harikrishnan; Zincke, Fabian; Dahlmann, Mathias; Walther, Wolfgang; Dittmar, Gunnar; Kobelt, Dennis; Stein, Ulrike] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany; [Zincke, Fabian; Dahlmann, Mathias; Kobelt, Dennis; Stein, Ulrike] German Canc Consortium DKTK, Heidelberg, Germany; [Sachse, Christoph] NMI TT Pharmaserv, Berlin, Germany; [Burock, Susen; Keilholz, Ulrich] Charite, Ctr Charite Comprehens Canc Ctr 10, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stein, U (corresponding author), Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany.; Stein, U (corresponding author), Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany.; Stein, U (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.	ustein@mdc-berlin.de	Radhakrishnan, Harikrishnan/GWZ-6616-2022	Radhakrishnan, Harikrishnan/0000-0002-5435-4520; Kortum, Benedikt/0000-0003-3734-6665	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Arlt F, 2009, INT J BIOCHEM CELL B, V41, P2356, DOI 10.1016/j.biocel.2009.08.001; Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573; Belot N, 2002, BBA-PROTEINS PROTEOM, V1600, P74, DOI 10.1016/S1570-9639(02)00447-8; Borgquist S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5263-z; Budczies J, 2020, SEMIN CANCER BIOL, V60, P365, DOI 10.1016/j.semcancer.2019.08.010; Burock S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4197-9; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Chowdhury MKH, 2016, BIOCHEM J, V473, P1247, DOI 10.1042/BCJ20160121; Dahlmann M, 2016, CANCERS, V8, DOI 10.3390/cancers8060059; Dahlmann M, 2015, METHODS MOL BIOL, V1317, P153, DOI 10.1007/978-1-4939-2727-2_10; Dahlmann M, 2014, ONCOTARGET, V5, P3220, DOI 10.18632/oncotarget.1908; Dammann K, 2015, CANCER PREV RES, V8, P1093, DOI 10.1158/1940-6207.CAPR-15-0205-T; Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008-5472.CAN-15-1519; Fei F, 2017, ONCOTARGET, V8, P73219, DOI 10.18632/oncotarget.18016; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Garrett SC, 2008, BIOCHEMISTRY-US, V47, P986, DOI 10.1021/bi7021624; Gohlke BO, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.726; Grum-Schwensen B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1034-2; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; IMBASTARI F, CELL MOL LIFE SCI, V2021; Jiang W, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02041-2; Juneja M, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000784; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kobelt D, 2021, ONCOGENE, V40, P5286, DOI 10.1038/s41388-021-01917-z; Kobelt D, 2021, METHODS MOL BIOL, V2294, P133, DOI 10.1007/978-1-0716-1350-4_9; Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980; Kopczynska EK, 2016, WSPOLCZESNA ONKOL, V20, P273, DOI 10.5114/wo.2016.61846; Koulis C, 2020, CANCERS, V12, DOI 10.3390/cancers12040812; Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037; Lemos C, 2016, CLIN CANCER RES, V22, P2812, DOI 10.1158/1078-0432.CCR-15-1425; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Link T, 2019, MOL ONCOL, V13, P1268, DOI 10.1002/1878-0261.12484; Malashkevich VN, 2010, P NATL ACAD SCI USA, V107, P8605, DOI 10.1073/pnas.0913660107; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735; Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004; Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626; Park MH, 2012, BIOCHEM BIOPH RES CO, V419, P543, DOI 10.1016/j.bbrc.2012.02.056; Pita-Fernandez S, 2015, ANN ONCOL, V26, P644, DOI 10.1093/annonc/mdu543; Radhakrishnan H, 2018, CANCER METAST REV, V37, P805, DOI 10.1007/s10555-018-9771-8; Rohr UP, 2017, ANN ONCOL, V28, P1869, DOI 10.1093/annonc/mdx207; Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190; Schubert-Fritschle G, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00234; Schutte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein U, 2006, GASTROENTEROLOGY, V131, P1486, DOI 10.1053/j.gastro.2006.08.041; Stein U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049249; Stein U, 2011, J MOL DIAGN, V13, P189, DOI 10.1016/j.jmoldx.2010.10.002; Stein U, 2010, J MOL MED, V88, P11, DOI 10.1007/s00109-009-0537-1; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Trochet D, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02045-y; Tsuji S, 2012, BRIT J CANCER, V106, P126, DOI 10.1038/bjc.2011.505; Tsukamoto S, 2011, CLIN CANCER RES, V17, P2444, DOI 10.1158/1078-0432.CCR-10-2884; Weidle UH, 2015, CLIN EXP METASTAS, V32, P623, DOI 10.1007/s10585-015-9732-3; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	62	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4446	4458		10.1038/s41388-022-02407-6	http://dx.doi.org/10.1038/s41388-022-02407-6		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36008464	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000844588600002
J	Niu, XD; Yang, Y; Ren, YM; Zhou, ST; Mao, Q; Wang, Y				Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Zhou, Shengtao; Mao, Qing; Wang, Yuan			Crosstalk between m(6)A regulators and mRNA during cancer progression	ONCOGENE			English	Review							METHYLTRANSFERASE METTL3 PROMOTES; STEM-LIKE CELLS; NUCLEAR-RNA; HEPATOCELLULAR-CARCINOMA; M6A MODIFICATION; GENE-EXPRESSION; BREAST-CANCER; SELF-RENEWAL; N-6-METHYLADENOSINE; N6-METHYLADENOSINE	m(6)A modification, the most abundant and widespread RNA modification, is present and involved in the occurrence and development of various cancers. To date, most studies have mainly focused on the roles of a single m(6)A regulator (writer/eraser/reader) in various cancers, but cumulative evidence shows that aberrant m(6)A regulators and m(6)A levels exert dual effects (promoting and/or inhibiting roles) in cancer progression. Recently, studies have investigated the direct interactions between different m(6)A regulators (writer/eraser and reader) and mRNAs in a variety of cancers. In this review, we summarize the functions of m(6)A regulators and their roles in various types of cancers. We further propose the possible crosstalk mechanisms (Writer-m(6)A-Reader-mRNA axis and Eraser-m(6)A-Reader-mRNA axis) between different m(6)A regulators and mRNAs during cancer progression. We also discuss the clinical potential of m(6)A regulator-targeting strategies.	[Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Mao, Qing; Wang, Yuan] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China; [Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Mao, Qing; Wang, Yuan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Niu, Xiaodong; Yang, Yuan; Ren, Yanming; Mao, Qing; Wang, Yuan] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China; [Zhou, Shengtao] Sichuan Univ, West China Hosp 2, State Key Lab Biotherapy, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University	Mao, Q; Wang, Y (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China.; Mao, Q; Wang, Y (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.; Mao, Q; Wang, Y (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China.	qingmao2000@163.com; wangyuan@scu.edu.cn		Niu, Xiaodong/0000-0003-4750-812X; Wang, Yuan/0000-0002-6324-6134; Zhou, Shengtao/0000-0001-8322-5536	National Natural Science Foundation of China [81902532, 82072773]; China Postdoctoral Science Foundation [2022M712255]; National Key Research and Development Program of China; Stem Cell and Translational Research [2017YFA0106500]; Distinguished Young Scientists Program of Sichuan Province [2019JDJQ0029]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYYC20019]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Key Research and Development Program of China; Stem Cell and Translational Research; Distinguished Young Scientists Program of Sichuan Province; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University	This work was supported by the National Natural Science Foundation of China (81902532 to YY and 82072773 to QM), the fellowship of China Postdoctoral Science Foundation (2022M712255 to XDN), the National Key Research and Development Program of China, Stem Cell and Translational Research (2017YFA0106500 to YW), the Distinguished Young Scientists Program of Sichuan Province (2019JDJQ0029 to YW), and the 1 center dot 3 center dot 5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYYC20019 to YW).	ADAMS JM, 1975, NATURE, V255, P28, DOI 10.1038/255028a0; Alarcon CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011; Baquero-Perez B, 2019, ELIFE, V8, DOI 10.7554/eLife.47261; BEEMON K, 1977, J MOL BIOL, V113, P165, DOI 10.1016/0022-2836(77)90047-X; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Brown JA, 2016, P NATL ACAD SCI USA, V113, P14013, DOI 10.1073/pnas.1614759113; Cai XL, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00703-w; Chai RC, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01124-z; Chen F, 2021, CANCER RES, V81, P2847, DOI 10.1158/0008-5472.CAN-20-3779; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen SJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28913-5; Chen WW, 2020, EUR REV MED PHARMACO, V24, P4263, DOI 10.26355/eurrev_202004_21006; Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01220-7; Chen YB, 2021, THERANOSTICS, V11, P7640, DOI 10.7150/thno.61178; Cheng C, 2021, MOL THER-NUCL ACIDS, V23, P487, DOI 10.1016/j.omtn.2020.12.001; Cheng MS, 2019, ONCOGENE, V38, P3667, DOI 10.1038/s41388-019-0683-z; Choe J, 2018, NATURE, V561, P556, DOI 10.1038/s41586-018-0538-8; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971; Dixit D, 2021, CANCER DISCOV, V11, P480, DOI 10.1158/2159-8290.CD-20-0331; Dominissini D, 2016, NATURE, V530, P441, DOI 10.1038/nature16998; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Dong SH, 2021, CANCER COMMUN, V41, P538, DOI 10.1002/cac2.12161; Fan ZY, 2021, J CELL MOL MED, V25, P10197, DOI 10.1111/jcmm.16957; Fan ZY, 2021, BIOCHEM BIOPH RES CO, V546, P169, DOI 10.1016/j.bbrc.2021.01.085; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Fukumoto T, 2019, CANCER RES, V79, P2812, DOI 10.1158/0008-5472.CAN-18-3592; Gkatza NA, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000297; Guimaraes-Teixeira C, 2021, J PERS MED, V11, DOI 10.3390/jpm11100996; Gutschner T, 2014, HEPATOLOGY, V59, P1900, DOI 10.1002/hep.26997; Han ST, 2021, THERANOSTICS, V11, P8464, DOI 10.7150/thno.60028; He HB, 2019, BIOCHEM BIOPH RES CO, V517, P581, DOI 10.1016/j.bbrc.2019.07.058; He J, 2021, MOL THER, V29, P1821, DOI 10.1016/j.ymthe.2021.01.019; Hsu PJ, 2017, CELL RES, V27, P1115, DOI 10.1038/cr.2017.99; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Huang Y, 2015, NUCLEIC ACIDS RES, V43, P373, DOI 10.1093/nar/gku1276; Huo FC, 2021, ONCOGENE, V40, P2968, DOI 10.1038/s41388-021-01753-1; Iaiza A, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01159-6; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jiang XL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00450-x; Jin D, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01161-1; Jin D, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0830-6; Jin H, 2019, EBIOMEDICINE, V47, P195, DOI 10.1016/j.ebiom.2019.07.068; Jin M, 2021, CANCER LETT, V518, P214, DOI 10.1016/j.canlet.2021.07.022; Kasowitz SD, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007412; Lee Y, 2020, TRENDS GENET, V36, P177, DOI 10.1016/j.tig.2019.12.007; Li EJ, 2022, ELIFE, V11, DOI 10.7554/eLife.75231; Li FX, 2019, CANCER RES, V79, P5785, DOI 10.1158/0008-5472.CAN-18-2868; Li H, 2021, MOL THER-NUCL ACIDS, V24, P25, DOI 10.1016/j.omtn.2021.02.001; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01267-6; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li XY, 2016, NAT CHEM BIOL, V12, P311, DOI [10.1038/nchembio.2040, 10.1038/NCHEMBIO.2040]; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu L, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.778; Liu X, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04950-2; Liu ZC, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01398-4; Lv DM, 2022, ONCOGENE, V41, P1727, DOI 10.1038/s41388-022-02214-z; Ma HG, 2021, AGING-US, V13, P22332, DOI 10.18632/aging.203541; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Tran NV, 2019, NUCLEIC ACIDS RES, V47, P7719, DOI 10.1093/nar/gkz619; Nombela P, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01263-w; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Qing Y, 2021, MOL CELL, V81, P922, DOI 10.1016/j.molcel.2020.12.026; Qiu XY, 2021, CANCER RES, V81, P4778, DOI 10.1158/0008-5472.CAN-21-0468; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Ruan DY, 2021, ONCOGENE, V40, P5168, DOI 10.1038/s41388-021-01916-0; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Singh B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159072; Song P, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00444-9; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tan Z, 2022, ONCOGENE, V41, P2860, DOI 10.1038/s41388-022-02306-w; Tang XD, 2019, ONCOL LETT, V17, P2473, DOI 10.3892/ol.2018.9873; Tassinari V, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02271-9; Tian JB, 2020, GUT, V69, P2180, DOI 10.1136/gutjnl-2019-320179; Tsuchiya K, 2022, CANCER GENE THER, DOI 10.1038/s41417-022-00451-8; Uddin MB, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01356-0; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wan WJ, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01447-y; Wang F, 2021, ONCOGENE, V40, P3885, DOI 10.1038/s41388-021-01820-7; Wang P, 2016, MOL CELL, V63, P306, DOI 10.1016/j.molcel.2016.05.041; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang SY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0847-4; Wang S, 2021, CANCER SCI, V112, P3243, DOI 10.1111/cas.15011; Wang W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23501-5; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01415-6; Wang X, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01871-4; Wei JC, 2020, J CELL MOL MED, V24, P11366, DOI 10.1111/jcmm.15738; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Wu GW, 2021, EMBO REP, V22, DOI 10.15252/embr.202051519; Wu HY, 2021, ACTA BIOCH BIOPH SIN, V53, P304, DOI 10.1093/abbs/gmaa170; Wu R, 2019, CELL RES, V29, P23, DOI 10.1038/s41422-018-0113-8; Xiang S, 2020, AM J TRANSL RES, V12, P1789; Xiao P, 2021, MOL CANCER RES, V19, P726, DOI 10.1158/1541-7786.MCR-20-0541; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xie F, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01359-x; Xie JP, 2021, J BUON, V26, P444; Xiong J, 2022, MOL CELL, V82, P1660, DOI 10.1016/j.molcel.2022.02.033; Xu AS, 2022, MOL THER, V30, P1104, DOI 10.1016/j.ymthe.2021.12.012; Xu HF, 2020, THERANOSTICS, V10, P5671, DOI 10.7150/thno.42539; Xu QC, 2022, ONCOGENE, V41, P1622, DOI 10.1038/s41388-022-02185-1; Xu YF, 2021, CANCER LETT, V522, P142, DOI 10.1016/j.canlet.2021.08.027; Yan F, 2018, CELL RES, V28, P1062, DOI 10.1038/s41422-018-0097-4; Yang F, 2019, ONCOGENE, V38, P4755, DOI 10.1038/s41388-019-0755-0; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1146-4; Yang XY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03739-z; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yang ZC, 2022, EBIOMEDICINE, V80, DOI 10.1016/j.ebiom.2022.104019; Yang Z, 2020, AGING-US, V12, P24967, DOI 10.18632/aging.103767; Yang Z, 2021, CANCER GENE THER, V28, P141, DOI 10.1038/s41417-020-0193-8; Yang ZZ, 2021, P NATL ACAD SCI USA, V118, DOI [10.1073/pnas.2025948118|1of8, 10.1073/pnas.2025948118]; Ye MF, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.12049; Yin HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21514-8; Yu XF, 2022, MINERVA MED, V113, P309, DOI 10.23736/S0026-4806.20.06653-7; Yuan Y, 2020, J CANCER, V11, P3588, DOI 10.7150/jca.42338; Yuan Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03315-x; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Zaccara S, 2020, CELL, V181, P1582, DOI 10.1016/j.cell.2020.05.012; Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0; Zhang DH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03793-7; Zhang LL, 2022, BRIT J CANCER, V127, P30, DOI 10.1038/s41416-022-01757-y; Zhang L, 2021, THERANOSTICS, V11, P1100, DOI 10.7150/thno.49345; Zhang RN, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0229-9; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1116-x; Zhao B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09060-w; Zhao W, 2020, MOL THER-NUCL ACIDS, V20, P1, DOI 10.1016/j.omtn.2020.01.033; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhou B, 2021, HEPATOLOGY, V73, P91, DOI 10.1002/hep.31220; Zhou D, 2021, MOL ONCOL, V15, P2172, DOI 10.1002/1878-0261.12898; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3; Zhu PP, 2021, ONCOGENE, V40, P1609, DOI 10.1038/s41388-020-01638-9; Zhu Y, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04817-6	149	0	0	14	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4407	4419		10.1038/s41388-022-02441-4	http://dx.doi.org/10.1038/s41388-022-02441-4		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36008465				2022-12-17	WOS:000844588600003
J	Vulin, M; Jehanno, C; Sethi, A; Correia, AL; Obradovic, MMS; Couto, JP; Coissieux, MM; Diepenbruck, M; Preca, BT; Volkmann, K; Maur, PAD; Schmidt, A; Munst, S; Sauteur, L; Kloc, M; Palafox, M; Britschgi, A; Unterreiner, V; Galuba, O; Claerr, I; Lopez-Romero, S; Galli, GG; Baeschlin, D; Okamoto, R; Soysal, SD; Mechera, R; Weber, WP; Radimerski, T; Bentires-Alj, M				Vulin, Milica; Jehanno, Charly; Sethi, Atul; Correia, Ana Luisa; Obradovic, Milan M. S.; Couto, Joana Pinto; Coissieux, Marie-May; Diepenbruck, Maren; Preca, Bogdan-Tiberius; Volkmann, Katrin; Maur, Priska Auf Der; Schmidt, Alexander; Munst, Simone; Sauteur, Loic; Kloc, Michal; Palafox, Marta; Britschgi, Adrian; Unterreiner, Vincent; Galuba, Olaf; Claerr, Isabelle; Lopez-Romero, Sandra; Galli, Giorgio G.; Baeschlin, Daniel; Okamoto, Ryoko; Soysal, Savas D.; Mechera, Robert; Weber, Walter P.; Radimerski, Thomas; Bentires-Alj, Mohamed			A high-throughput drug screen reveals means to differentiate triple-negative breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITOR; MAMMARY-GLAND DEVELOPMENT; STEM-CELL; GENE-EXPRESSION; ER; ACTIVATION; TRANSCRIPTION; MULTIPOTENCY; REACTIVATION	Plasticity delineates cancer subtypes with more or less favourable outcomes. In breast cancer, the subtype triple-negative lacks expression of major differentiation markers, e.g., estrogen receptor alpha (ER alpha), and its high cellular plasticity results in greater aggressiveness and poorer prognosis than other subtypes. Whether plasticity itself represents a potential vulnerability of cancer cells is not clear. However, we show here that cancer cell plasticity can be exploited to differentiate triple-negative breast cancer (TNBC). Using a high-throughput imaging-based reporter drug screen with 9 501 compounds, we have identified three polo-like kinase 1 (PLK1) inhibitors as major inducers of ER alpha protein expression and downstream activity in TNBC cells. PLK1 inhibition upregulates a cell differentiation program characterized by increased DNA damage, mitotic arrest, and ultimately cell death. Furthermore, cells surviving PLK1 inhibition have decreased tumorigenic potential, and targeting PLK1 in already established tumours reduces tumour growth both in cell line- and patient-derived xenograft models. In addition, the upregulation of genes upon PLK1 inhibition correlates with their expression in normal breast tissue and with better overall survival in breast cancer patients. Our results indicate that differentiation therapy based on PLK1 inhibition is a potential alternative strategy to treat TNBC.	[Vulin, Milica; Jehanno, Charly; Sethi, Atul; Correia, Ana Luisa; Obradovic, Milan M. S.; Couto, Joana Pinto; Coissieux, Marie-May; Diepenbruck, Maren; Preca, Bogdan-Tiberius; Volkmann, Katrin; Maur, Priska Auf Der; Sauteur, Loic; Kloc, Michal; Palafox, Marta; Okamoto, Ryoko; Bentires-Alj, Mohamed] Univ Basel, Univ Hosp Basel, Dept Biomed, Dept Surg, Basel, Switzerland; [Vulin, Milica; Sethi, Atul; Correia, Ana Luisa; Obradovic, Milan M. S.; Couto, Joana Pinto; Coissieux, Marie-May; Britschgi, Adrian; Okamoto, Ryoko; Bentires-Alj, Mohamed] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Sethi, Atul; Kloc, Michal] Swiss Inst Bioinformat, Basel, Switzerland; [Schmidt, Alexander] Univ Basel, Biozentrum, Prote Core Facil, Basel, Switzerland; [Munst, Simone] Univ Basel, Univ Hosp Basel, Inst Pathol & Med Genet, Basel, Switzerland; [Unterreiner, Vincent; Galuba, Olaf; Claerr, Isabelle; Lopez-Romero, Sandra; Galli, Giorgio G.; Baeschlin, Daniel; Radimerski, Thomas] Novartis Inst Biomed Res, Basel, Switzerland; [Soysal, Savas D.; Mechera, Robert; Weber, Walter P.] Univ Basel, Univ Hosp Basel, Dept Surg, Basel, Switzerland; [Soysal, Savas D.; Mechera, Robert; Weber, Walter P.] Univ Basel, Univ Hosp Basel, Breast Canc Ctr, Basel, Switzerland	University of Basel; Friedrich Miescher Institute for Biomedical Research; Swiss Institute of Bioinformatics; University of Basel; University of Basel; Novartis; University of Basel; University of Basel	Bentires-Alj, M (corresponding author), Univ Basel, Univ Hosp Basel, Dept Biomed, Dept Surg, Basel, Switzerland.; Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Basel, Switzerland.	m.bentires-alj@unibas.ch		Vulin, Milica/0000-0002-7686-5102; Coissieux, Marie-May/0000-0001-5017-5253; Correia, Ana Luisa/0000-0003-2414-0131	University of Basel	University of Basel	Open access funding provided by University of Basel.	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Ahrne E, 2016, J PROTEOME RES, V15, P2537, DOI 10.1021/acs.jproteome.6b00066; Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844; Arozarena I, 2019, NAT REV CANCER, V19, P377, DOI 10.1038/s41568-019-0154-4; Bahreini A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0851-4; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Berto M, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800055; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Canham SM, 2020, CELL CHEM BIOL, V27, P1124, DOI 10.1016/j.chembiol.2020.07.004; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; Chi D, 2019, P NATL ACAD SCI USA, V116, P11437, DOI 10.1073/pnas.1819155116; Clarke RB, 1997, CANCER RES, V57, P4987; Clevers H, 2018, ANNU REV BIOCHEM, V87, P1015, DOI 10.1146/annurev-biochem-062917-012341; Cottu P, 2012, BREAST CANCER RES TR, V133, P595, DOI 10.1007/s10549-011-1815-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943; Dekoninck S, 2019, NAT CELL BIOL, V21, P18, DOI 10.1038/s41556-018-0237-6; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Di Cosimo S, 2020, LANCET, V396, P1046, DOI 10.1016/S0140-6736(20)31962-0; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Ding Y, 2011, CANCER RES, V71, P5225, DOI 10.1158/0008-5472.CAN-11-0076; Du J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035957; Duss S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1734; Ershov D, 2022, NAT METHODS, V19, P829, DOI 10.1038/s41592-022-01507-1; Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x; Farcas AM, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqaa224; FERGUSON AT, 1995, CANCER RES, V55, P2279; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Hait NC, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.16; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Howlader N, 2018, CANCER EPIDEM BIOMAR, V27, P619, DOI 10.1158/1055-9965.EPI-17-0627; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ishay-Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002; Jehanno C., 2022, TRENDS CELL BIOL, VS0962-8924, P00079, DOI [10.1016/j.tcb.2022.03.007, DOI 10.1016/J.TCB.2022.03.007]; Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lapidus RG, 1998, CANCER RES, V58, P2515; Levin-Allerhand JA, 2003, CONTEMP TOP LAB ANIM, V42, P33; Li JY, 2020, CANCER RES, V80, P4037, DOI 10.1158/0008-5472.CAN-20-1420; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Molinuevo R, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001063; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Restall C, 2009, INT J CANCER, V125, P483, DOI 10.1002/ijc.24350; Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Sanz-Gomez N, 2020, CELL DEATH DIFFER, V27, P2451, DOI 10.1038/s41418-020-0515-2; Sappok A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-8; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmidt U, 2018, LECT NOTES COMPUT SC, V11071, P265, DOI 10.1007/978-3-030-00934-2_30; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Siersbaek R, 2018, GENE DEV, V32, P1141, DOI 10.1101/gad.316646.118; Slepicka PF, 2021, SEMIN CELL DEV BIOL, V114, P93, DOI 10.1016/j.semcdb.2020.09.014; Tanos T, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3166; Van Keymeulen A, 2015, NATURE, V525, P119, DOI 10.1038/nature14665; Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Wang JW, 2012, CELL, V148, P1001, DOI 10.1016/j.cell.2012.01.040; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549; Zhou Y, 2019, NAT COMMUN, V10, DOI [DOI 10.1038/S41467-019-09234-6, 10.1038/s41467-019-09234-6]; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	82	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4459	4473		10.1038/s41388-022-02429-0	http://dx.doi.org/10.1038/s41388-022-02429-0		AUG 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	36008466	Green Published, hybrid			2022-12-17	WOS:000844588600001
J	Ling, H; Cao, CH; Han, K; Lv, YR; Ma, XD; Cao, JH; Chen, JW; Li, S; Lin, JL; Fang, YJ; Pan, ZZ; Xie, D; Wang, FW				Ling, Han; Cao, Chen-Hui; Han, Kai; Lv, Yong-Rui; Ma, Xiao-Dan; Cao, Jing-Hua; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Fang, Yu-Jing; Pan, Zhi-Zhong; Xie, Dan; Wang, Feng-Wei			CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1	ONCOGENE			English	Article							MESSENGER-RNA; CHROMOSOME SEGREGATION; CENTROSOME; TRANSLATION; COMPLEX	Abnormal regulation of centrosome components can induce chromosome instability and tumorigenesis. Centrosomal protein 63 (CEP63) is a vital member for assembling centrosome. Yet, the involvement of CEP63 in cancer pathogenesis remains unclear. Here we identify CEP63 as an important mediator for RNA-binding proteins (RBPs) to facilitate regulation on their RNA targets in colorectal cancer (CRC). We demonstrate that CEP63 protein is upregulated in a large cohort of colorectal cancer tissues and predicts poor prognosis, and USP36 is identified for stabilizing CEP63 by enhancing its K48-dependent deubiquitination. CEP63 overexpression promotes the proliferation and tumor growth of CRC cells in vitro and in vivo. Furthermore, we find that CEP63 can promote cancer stem-like cell properties by enhancing YAP1 expression through binding with and inhibiting the K63-ubiquitylation degradation of RBP FXR1 in CRC cells. Importantly, we further verify that the KH domain of FXR1 is necessary for the interaction between CEP63 and FXR1. Moreover, microtube motor proteins can form a complex with CEP63 and FXR1 to mediate the regulation of FXR1 on RNA targets. Additionally, we also confirm that CEP63 can bind and regulate multiple RBPs. In conclusion, our findings unveil an unrecognized CEP63/RBPs/RNA axis that CEP63 may perform as an adapter facilitating the formation of RBPs complex to regulate RNA progression and discover the role of CEP63 involved in signal transduction and RNA regulation, providing potential therapeutic target for CRC patients.	[Ling, Han; Cao, Chen-Hui; Han, Kai; Lv, Yong-Rui; Ma, Xiao-Dan; Cao, Jing-Hua; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Fang, Yu-Jing; Pan, Zhi-Zhong; Xie, Dan; Wang, Feng-Wei] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Cao, Chen-Hui] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst,Integrat Canc Ctr, Chengdu 610041, Peoples R China; [Cao, Chen-Hui] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst,Canc Clin Res Ctr, Chengdu 610041, Peoples R China; [Han, Kai; Fang, Yu-Jing; Pan, Zhi-Zhong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou 510060, Peoples R China; [Chen, Jie-Wei; Xie, Dan] Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; Sun Yat Sen University; Sun Yat Sen University	Xie, D; Wang, FW (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Peoples R China.	xiedan@sysucc.org.cn; wangfengw@sysucc.org.cn			National Key R&D Program of China [2021YFA1300201]; National Natural Science Foundation of China [81972227, 81730072, 82072608, 81872001, 81903007, 82002467]; Guangzhou Science and Technology Plan Projects [201904020044]; China Postdoctoral Science Foundation [2020M672999]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Plan Projects; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Key R&D Program of China (grant number 2021YFA1300201); the National Natural Science Foundation of China (grant numbers 81972227, 81730072, 82072608, 81872001, 81903007 and 82002467); the Guangzhou Science and Technology Plan Projects (grant number 201904020044) and the China Postdoctoral Science Foundation (2020M672999).	Agote-Aran A, 2020, EMBO J, V39, DOI 10.15252/embj.2020104467; Auslander D, 2018, NAT METHODS, V15, P57, DOI [10.1038/nmeth.4505, 10.1038/NMETH.4505]; Boo SH, 2020, EXP MOL MED, V52, P400, DOI 10.1038/s12276-020-0407-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown NJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069986; Cai Z, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.674933; Conduit PT, 2015, NAT REV MOL CELL BIO, V16, P611, DOI 10.1038/nrm4062; De Simone A, 2016, CELL REP, V14, P2250, DOI 10.1016/j.celrep.2016.01.077; Denes LT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26383-9; Dockendorff TC, 2019, MOL NEUROBIOL, V56, P711, DOI 10.1007/s12035-018-1122-9; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Dumont J, 2012, TRENDS CELL BIOL, V22, P241, DOI 10.1016/j.tcb.2012.02.007; Eliscovich C, 2013, J BIOL CHEM, V288, P20361, DOI 10.1074/jbc.R113.452094; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fallmann J, 2016, NUCLEIC ACIDS RES, V44, pD90, DOI 10.1093/nar/gkv1238; Farina F, 2016, NAT CELL BIOL, V18, P65, DOI 10.1038/ncb3285; Frederick MI, 2021, BIOL CHEM, V402, P425, DOI 10.1515/hsz-2020-0325; Giampetruzzi A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11837-y; Gurkaslar HK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107630; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Herman AB, 2018, CELL REP, V24, P1176, DOI 10.1016/j.celrep.2018.07.002; Hirokawa N, 2006, J NEUROSCI, V26, P7139, DOI 10.1523/JNEUROSCI.1821-06.2006; Honda S, 2017, ONCOTARGET, V8, P14277, DOI 10.18632/oncotarget.15362; Hong AW, 2016, NAT REV GASTRO HEPAT, V13, P324, DOI 10.1038/nrgastro.2016.59; Jayaraman D, 2016, NEURON, V92, P813, DOI 10.1016/j.neuron.2016.09.056; Ke WL, 2022, BIOENGINEERED, V13, P5443, DOI 10.1080/21655979.2022.2030572; Kim TS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08838-2; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Liu Q, 2019, BIOCHEM BIOPH RES CO, V513, P502, DOI 10.1016/j.bbrc.2019.03.043; Loffler H, 2011, CANCER RES, V71, P2129, DOI 10.1158/0008-5472.CAN-10-2684; Lukinaviclus G, 2013, CURR BIOL, V23, P265, DOI 10.1016/j.cub.2012.12.030; Madiraju C, 2022, TRENDS IMMUNOL, V43, P148, DOI 10.1016/j.it.2021.12.005; Marjanovic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8676; Mondal T, 2018, CANCER CELL, V33, P417, DOI 10.1016/j.ccell.2018.01.020; Ohtake F, 2018, P NATL ACAD SCI USA, V115, pE1401, DOI 10.1073/pnas.1716673115; Peng F, 2021, CELL RES, V31, P345, DOI 10.1038/s41422-020-00397-2; Richards J, 2021, MOL MICROBIOL, V116, P361, DOI 10.1111/mmi.14723; Rowinsky EK, 2020, INVEST NEW DRUG, V38, P1448, DOI 10.1007/s10637-020-00915-4; SANTIAGO TC, 1987, NUCLEIC ACIDS RES, V15, P2417, DOI 10.1093/nar/15.6.2417; Say E, 2010, MOL CELL, V38, P236, DOI 10.1016/j.molcel.2010.04.004; Schaeffer C, 2003, BIOL CELL, V95, P221, DOI 10.1016/S0248-4900(03)00037-6; Sir JH, 2011, NAT GENET, V43, P1147, DOI 10.1038/ng.971; Turner-Bridger B, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200177; Uchida Y, 2019, J BIOCHEM, V166, P375, DOI 10.1093/jb/mvz067; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Vasudevan S, 2007, CELL, V128, P1105, DOI 10.1016/j.cell.2007.01.038; Watanabe Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13508; Wei Z, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00535-19; Xia WL, 2018, J CELL BIOL, V217, P3464, DOI 10.1083/jcb.201801143; Xu N, 2020, CIRC RES, V126, P907, DOI 10.1161/CIRCRESAHA.119.316444; Yan YL, 2020, NUCLEIC ACIDS RES, V48, P12711, DOI 10.1093/nar/gkaa1090; Zhang JY, 2019, CANCER LETT, V440, P106, DOI 10.1016/j.canlet.2018.10.010	53	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4433	4445		10.1038/s41388-022-02439-y	http://dx.doi.org/10.1038/s41388-022-02439-y		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	35989368				2022-12-17	WOS:000842428900001
J	Wang, J; Li, JJ; Yin, LJ; Pu, TJ; Wei, J; Karthikeyan, V; Lin, TP; Gao, AC; Wu, BJ				Wang, Jing; Li, Jingjing; Yin, Lijuan; Pu, Tianjie; Wei, Jing; Karthikeyan, Varsha; Lin, Tzu-Ping; Gao, Allen C.; Wu, Boyang Jason			Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-LINE; RECEPTOR; STAT3; DIFFERENTIATION; TYROSINE; PROTEIN; TRANSCRIPTION; ASSOCIATION; EXPRESSION	Neuroendocrine prostate cancer (NEPC), a lethal subset of prostate cancer, is characterized by loss of AR signaling and resulting resistance to AR-targeted therapy during neuroendocrine transdifferentiation, for which the molecular mechanisms remain unclear. Here, we report that neuropilin 2 (NRP2) is upregulated in both de novo and therapy-induced NEPC, which induces neuroendocrine markers, neuroendocrine cell morphology, and NEPC cell aggressive behavior. NRP2 silencing restricted NEPC tumor xenograft growth. Mechanistically, NRP2 engages in reciprocal crosstalk with AR, where NRP2 is transcriptionally inhibited by AR, and in turn suppresses AR signaling by downregulating the AR transcriptional program and confers resistance to enzalutamide. Moreover, NRP2 physically interacts with VEGFR2 through the intracellular SEA domain to activate STAT3 phosphorylation and subsequently SOX2, thus driving NEPC differentiation and growth. Collectively, these results characterize NRP2 as a driver of NEPC and suggest NRP2 as a potential therapeutic target in NEPC.	[Wang, Jing; Li, Jingjing; Pu, Tianjie; Wei, Jing; Wu, Boyang Jason] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA; [Yin, Lijuan] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Uro Oncol Res Program, Los Angeles, CA 90048 USA; [Karthikeyan, Varsha] Washington State Univ, Coll Pharm & Pharmaceut Sci, Summer Undergrad Res Fellowship Program, Spokane, WA 99202 USA; [Karthikeyan, Varsha] Oregon State Univ, Coll Sci, Sch Life Sci, Dept Integrat Biol, Corvallis, OR 97331 USA; [Lin, Tzu-Ping] Taipei Vet Gen Hosp, Dept Urol, Taipei 11217, Taiwan; [Lin, Tzu-Ping] Natl Yang Ming Chiao Tung Univ, Sch Med, Dept Urol, Taipei 11221, Taiwan; [Lin, Tzu-Ping] Natl Yang Ming Chiao Tung Univ, Shu Tien Urol Res Ctr, Taipei 11221, Taiwan; [Gao, Allen C.] Univ Calif Davis, Dept Urol Surg, Sacramento, CA 95817 USA; [Li, Jingjing] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, Shanghai 200240, Peoples R China; [Yin, Lijuan] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China	Washington State University; Cedars Sinai Medical Center; Washington State University; Oregon State University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; University of California System; University of California Davis; Shanghai Jiao Tong University; Sichuan University	Wu, BJ (corresponding author), Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA.	boyang.wu@wsu.edu		Karthikeyan, Varsha/0000-0003-3196-8850; Li, Jingjing/0000-0002-0661-5642	Department of Defense Prostate Cancer Research Program [W81XWH-19-1-0279]; NIH/NCI [R37CA233658]; WSU	Department of Defense Prostate Cancer Research Program(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WSU	This work was supported by the Department of Defense Prostate Cancer Research Program grant W81XWH-19-1-0279, NIH/NCI grant R37CA233658, and WSU startup funding to B.J.W. We thank Yidi Xu (Washington State University) for providing technical assistance, Mahul Amin (Cedars-Sinai Medical Center) for providing NEPC clinical samples, and Gary Mawyer for editorial assistance.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159-8290.CD-11-0259; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bland T, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101970; Borkowetz A, 2020, INT J CANCER, V146, P2619, DOI 10.1002/ijc.32679; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai HB, 1999, J NEUROSCI, V19, P6519; Chen SY, 2019, AM J CLIN EXP UROL, V7, P327; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Dutta S, 2022, ONCOGENE, V41, P3747, DOI 10.1038/s41388-022-02382-y; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gerhauser C, 2018, CANCER CELL, V34, P996, DOI 10.1016/j.ccell.2018.10.016; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gray MJ, 2008, J NATL CANCER I, V100, P109, DOI 10.1093/jnci/djm279; Gritsina G, 2019, ASIAN J ANDROL, V21, P215, DOI 10.4103/aja.aja_19_19; Hahn D, 2000, J UROLOGY, V164, P506, DOI 10.1016/S0022-5347(05)67414-9; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Jackson MW, 2002, CANCER RES, V62, P854; Kaushal V, 2005, CLIN CANCER RES, V11, P584; Khoury A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13753-7; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lajoie BR, 2015, METHODS, V72, P65, DOI 10.1016/j.ymeth.2014.10.031; Liu YZ, 2019, SCI TRANSL MED, V11, DOI [10.1126/scitranslmed.aax9364, 10.1126/scitranslmed.aaw4993]; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Polavaram NS, 2021, BONE RES, V9, DOI 10.1038/s41413-021-00136-2; Potiron VA, 2007, CANCER RES, V67, P8708, DOI 10.1158/0008-5472.CAN-06-3612; Prahst C, 2008, J BIOL CHEM, V283, P25110, DOI 10.1074/jbc.C800137200; Ren SC, 2018, EUR UROL, V73, P322, DOI 10.1016/j.eururo.2017.08.027; Ren XM, 2010, ACS MED CHEM LETT, V1, P454, DOI 10.1021/ml100146z; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Sulpice E, 2008, BLOOD, V111, P2036, DOI 10.1182/blood-2007-04-084269; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Taberlay PC, 2016, GENOME RES, V26, P719, DOI 10.1101/gr.201517.115; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Tam KJ, 2017, ONCOTARGET, V8, P9617, DOI 10.18632/oncotarget.14168; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tolomeo M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020603; Tsai HK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3729-z; Tse BWC, 2017, ONCOGENE, V36, P3417, DOI 10.1038/onc.2016.482; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Wang HT, 2014, J CLIN ONCOL, V32, P3383, DOI 10.1200/JCO.2013.54.3553; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu X, 2017, ASIAN J ANDROL, V19, P686, DOI 10.4103/1008-682X.191518; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhu H, 2018, THERANOSTICS, V8, P676, DOI 10.7150/thno.21463	58	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4307	4317		10.1038/s41388-022-02437-0	http://dx.doi.org/10.1038/s41388-022-02437-0		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35986103				2022-12-17	WOS:000843252700001
J	Yi, YM; Li, P; Huang, YF; Chen, DY; Fan, SW; Wang, J; Yang, MQ; Zeng, SS; Deng, J; Lv, XW; Luo, K; He, ZW; Liu, H				Yi, Yanmei; Li, Pan; Huang, Yuanfeng; Chen, Danyang; Fan, Siwen; Wang, Jun; Yang, Minqiang; Zeng, Shanshan; Deng, Jin; Lv, Xinwu; Luo, Kai; He, Zhiwei; Liu, Hao			P21-activated kinase 2-mediated beta-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; UP-REGULATION; OPEN-LABEL; INHIBITORS; MUTATION; TKI; CHEMOTHERAPY; CONTRIBUTES; ACTIVATION	Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used for treating patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-activating mutations or the resistant T790M mutation. However, acquired resistance to osimertinib is inevitable in EGFR-mutant NSCLC. By employing a global mass spectrometry-based phosphoproteomics approach, we identified that the activated p21-activated kinase 2 (PAK2)/beta-catenin axis acts as a driver of osimertinib resistance. We found that PAK2 directly phosphorylates beta-catenin and increases the nuclear localization of beta-catenin, leading to the increased expression and transcriptional activity of beta-catenin, which in turn enhances cancer stem-like properties and osimertinib resistance. Moreover, we revealed that HER3 as an upstream regulator of PAK2, drives the activation of PAK2/beta-catenin pathways in osimertinib-resistant cells. The clinical relevance of these findings was further confirmed by examining tissue specimens from patients with EGFR-mutant NSCLC. The results demonstrated that the levels of HER3, phospho-PAK2 (p-PAK2) and beta-catenin in the tissues from patients with EGFR-mutant NSCLC, that had relapsed after treatment with osimertinib, were elevated compared to those of the corresponding untreated tissues. Additionally, the high levels of HER3, p-PAK2 and beta-catenin correlated with shorter progression-free survival (PFS) in patients with EGFR-TKI-treated NSCLC. We additionally observed that the suppression of PAK2 via knockdown or pharmacological targeting with PAK inhibitors markedly restored the response of osimertinib-resistant NSCLC cells to osimertinib both in vitro and in vivo. In conclusion, these results indicated that the PAK2-mediated activation of beta-catenin is important for osimertinib resistance and targeting the HER3/PAK2/beta-catenin pathway has potential therapeutic value in NSCLCs with acquired resistance to osimertinib.	[Yi, Yanmei; Fan, Siwen; Lv, Xinwu; He, Zhiwei] Guangdong Med Univ, Sch Basic Med Sci, Zhanjiang, Guangdong, Peoples R China; [Li, Pan; Huang, Yuanfeng; Chen, Danyang; Wang, Jun; Yang, Minqiang; Zeng, Shanshan; Deng, Jin; Luo, Kai; Liu, Hao] Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China; [He, Zhiwei] Guangdong Med Univ, China Amer Canc Res Inst, Guangzhou, Guangdong, Peoples R China	Guangdong Medical University; Guangzhou Medical University; Guangdong Medical University	He, ZW (corresponding author), Guangdong Med Univ, Sch Basic Med Sci, Zhanjiang, Guangdong, Peoples R China.; Luo, K; Liu, H (corresponding author), Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China.; He, ZW (corresponding author), Guangdong Med Univ, China Amer Canc Res Inst, Guangzhou, Guangdong, Peoples R China.	luokainan@126.com; 467853605@qq.com; liuhao@gzhmu.edu.cn		Chen, Danyang/0000-0002-7894-9457	National Natural Science Foundation of China [81972194, 82172810, 81772825]; Guangdong Natural Science Funds [2019A1515010113]; Science and Technology Program of Guangzhou [202201010839]; Medical Scientific Research Foundation of Guangdong [B2020165]; Discipline construction project of Guangdong Medical University [4SG22005G]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds; Science and Technology Program of Guangzhou; Medical Scientific Research Foundation of Guangdong; Discipline construction project of Guangdong Medical University	This work was supported by the National Natural Science Foundation of China (81972194, 82172810, 81772825); Guangdong Natural Science Funds (2019A1515010113); The Science and Technology Program of Guangzhou (202201010839); Medical Scientific Research Foundation of Guangdong (B2020165); Discipline construction project of Guangdong Medical University (4SG22005G).	Araiza-Olivera D, 2018, ONCOGENE, V37, P944, DOI 10.1038/onc.2017.400; Arasada RR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05626-2; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Chiu CF, 2016, P NATL ACAD SCI USA, V113, pE2526, DOI 10.1073/pnas.1522612113; Coniglio SJ, 2008, MOL CELL BIOL, V28, P4162, DOI 10.1128/MCB.01532-07; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Del Re M, 2018, STEM CELLS, V36, P633, DOI 10.1002/stem.2787; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Eberlein CA, 2015, CANCER RES, V75, P2489, DOI 10.1158/0008-5472.CAN-14-3167; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gupta A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0887-0; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Huynh N, 2016, CANCER BIOL THER, V17, P813, DOI 10.1080/15384047.2016.1195045; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kuo MH, 2020, CANCER RES, V80, P4426, DOI 10.1158/0008-5472.CAN-19-3228; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Licciulli S, 2013, J BIOL CHEM, V288, P29105, DOI 10.1074/jbc.M113.510933; Lopez-Haber C, 2016, MOL CELL BIOL, V36, P2011, DOI 10.1128/MCB.00180-16; Lu HZ, 2017, NATURE, V550, P133, DOI 10.1038/nature24040; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mok Tony S, 2017, N Engl J Med, V376, P629, DOI 10.1056/NEJMoa1612674; Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184; Ortiz-Cuaran S, 2016, CLIN CANCER RES, V22, P4837, DOI 10.1158/1078-0432.CCR-15-1915; Papadimitrakopoulou VA, 2020, ANN ONCOL, V31, P1536, DOI 10.1016/j.annonc.2020.08.2100; Park K, 2016, LANCET ONCOL, V17, P577, DOI 10.1016/S1470-2045(16)30033-X; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rudolph J, 2016, J MED CHEM, V59, P5520, DOI 10.1021/acs.jmedchem.6b00638; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Sun J, 2009, ONCOGENE, V28, P3132, DOI 10.1038/onc.2009.167; Taniguchi H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08074-0; Togashi Y, 2015, J THORAC ONCOL, V10, P93, DOI 10.1097/JTO.0000000000000353; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang K, 2019, AM J TRANSL RES, V11, P3353; Yeo D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2057-z; Yonesaka K, 2022, CLIN CANCER RES, V28, P390, DOI 10.1158/1078-0432.CCR-21-3359; Yu HA, 2015, JAMA ONCOL, V1, P981, DOI 10.1001/jamaoncol.2015.1066; Zeng Y, 2022, CURR OPIN ONCOL, V34, P54, DOI 10.1097/CCO.0000000000000805; Zhang F, 2021, ONCOGENE, V40, P5854, DOI 10.1038/s41388-021-01986-0; Zhang X, 2021, CANCER RES, V81, P3051, DOI 10.1158/0008-5472.CAN-20-2435; Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	53	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4318	4329		10.1038/s41388-022-02438-z	http://dx.doi.org/10.1038/s41388-022-02438-z		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35986102				2022-12-17	WOS:000843252700002
J	Fukuoka, T; Moriwaki, K; Takamatsu, S; Kondo, J; Tanaka-Okamoto, M; Tomioka, A; Semba, M; Komazawa-Sakon, S; Kamada, Y; Kaji, H; Miyamoto, Y; Inoue, M; Bessho, K; Miyoshi, Y; Ozono, K; Nakano, H; Miyoshi, E				Fukuoka, Tomoya; Moriwaki, Kenta; Takamatsu, Shinji; Kondo, Jumpei; Tanaka-Okamoto, Miki; Tomioka, Azusa; Semba, Manami; Komazawa-Sakon, Sachiko; Kamada, Yoshihiro; Kaji, Hiroyuki; Miyamoto, Yasuhide; Inoue, Masahiro; Bessho, Kazuhiko; Miyoshi, Yoko; Ozono, Keiichi; Nakano, Hiroyasu; Miyoshi, Eiji			Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; LIPID RAFTS; RECEPTOR; NECROSIS; FUCOSYLATION; EXPRESSION; APOPTOSIS; ACTIVATION; COMPLEX; GLYCOSYLATION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death and contributes to tumor rejection by cytotoxic lymphocytes in cancer immunosurveillance and immunotherapy. TRAIL and TRAIL receptor agonists have garnered wide popularity as promising agents for cancer therapy. We previously demonstrated that the loss of fucosylation in cancer cells impairs TRAIL sensitivity; however, the precise structures of the fucosylated glycans that regulate TRAIL sensitivity and their carrier molecules remain elusive. Herein, we observed that Lewis glycans among various fucosylated glycans positively regulate TRAIL-induced cell death. Specifically, Lewis glycans on lacto/neolacto glycosphingolipids, but not glycoproteins including TRAIL receptors, enhanced TRAIL-induced formation of the cytosolic caspase 8 complex, without affecting the formation of the membranous receptor complex. Furthermore, type I Lewis glycan expression in colon cancer cell lines and patient-derived cancer organoids was positively correlated with TRAIL sensitivity. These findings provide novel insights into the regulatory mechanism of TRAIL-induced cell death and facilitate the identification of novel predictive biomarkers for TRAIL-related cancer therapies in future.	[Fukuoka, Tomoya; Takamatsu, Shinji; Kondo, Jumpei; Kamada, Yoshihiro; Miyoshi, Eiji] Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Suita, Osaka 5650871, Japan; [Fukuoka, Tomoya; Bessho, Kazuhiko; Miyoshi, Yoko; Ozono, Keiichi] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan; [Moriwaki, Kenta; Semba, Manami; Komazawa-Sakon, Sachiko; Nakano, Hiroyasu] Toho Univ, Sch Med, Dept Biochem, Ota Ku, Tokyo 1438540, Japan; [Kondo, Jumpei; Inoue, Masahiro] Kyoto Univ, Grad Sch Med, Dept Clin Bioresource Res & Dev, Sakyou Ku, Kyoto 6068501, Japan; [Tanaka-Okamoto, Miki; Miyamoto, Yasuhide] Osaka Int Canc Inst, Dept Mol Biol, Chuo Ku, Osaka 5418567, Japan; [Tomioka, Azusa; Kaji, Hiroyuki] Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst, Mol & Cellular Glycoprote Res Grp, Tsukuba, Ibaraki 3058565, Japan; [Semba, Manami] Tokyo Univ Sci, Fac Adv Engn, Dept Biol Sci & Technol, Katsushika Ku, Tokyo 1258585, Japan; [Kamada, Yoshihiro] Osaka Univ, Grad Sch Med, Dept Adv Metab Hepatol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo University of Science; Osaka University	Miyoshi, E (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Suita, Osaka 5650871, Japan.; Moriwaki, K (corresponding author), Toho Univ, Sch Med, Dept Biochem, Ota Ku, Tokyo 1438540, Japan.	kenta.moriwaki@med.toho-u.ac.jp; emiyoshi@sahs.med.osaka-u.ac.jp	; Kaji, Hiroyuki/L-7122-2018	Moriwaki, Kenta/0000-0002-8724-4715; TAKAMATSU, Shinji/0000-0003-1996-7740; Kaji, Hiroyuki/0000-0002-0910-9999	Japan Society for the Promotion of Science [16H06945, 19K07399]; Takeda Science Foundation; GSK Japan Research Grant; Japan Agency for Medical Research and Development [JP20ae0101042, JP20gm1210002]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); GSK Japan Research Grant; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This study was supported by the Japan Society for the Promotion of Science (KM: 16H06945 and 19K07399), the Takeda Science Foundation (KM), GSK Japan Research Grant 2020 (KM), and the Japan Agency for Medical Research and Development (JP20ae0101042 to KM and JP20gm1210002 to HN).	Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365, DOI 10.1053/j.gastro.2009.02.071; Deng D, 2020, TRENDS CANCER, V6, P989, DOI 10.1016/j.trecan.2020.06.006; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Dufour F, 2017, CELL DEATH DIFFER, V24, P500, DOI 10.1038/cdd.2016.150; Dufva O, 2020, BLOOD, V135, P597, DOI 10.1182/blood.2019002121; Fox JL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20806-9; Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022; Holdener BC, 2019, CURR OPIN STRUC BIOL, V56, P78, DOI 10.1016/j.sbi.2018.12.005; Jiang YL, 2020, FASEB J, V34, P11786, DOI 10.1096/fj.201900053RR; Jin ZY, 2006, MOL CELL BIOL, V26, P8136, DOI 10.1128/MCB.00257-06; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108; Lafont E, 2018, TRENDS BIOCHEM SCI, V43, P44, DOI 10.1016/j.tibs.2017.11.002; Lafont E, 2017, EMBO J, V36, P1147, DOI 10.15252/embj.201695699; Lavrik IN, 2008, J BIOL CHEM, V283, P26401, DOI 10.1074/jbc.M800823200; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Lemoine J, 2021, CLIN CANCER RES, V27, P6298, DOI 10.1158/1078-0432.CCR-21-1559; Linderoth E, 2013, J BIOL CHEM, V288, P32922, DOI 10.1074/jbc.M113.481507; Liu C, 2020, INT J ONCOL, V56, P900, DOI 10.3892/ijo.2020.4989; Ma B, 2006, GLYCOBIOLOGY, V16, p158R, DOI 10.1093/glycob/cwl040; Marconi M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.389; Miyoshi E, 2008, J BIOCHEM, V143, P725, DOI 10.1093/jb/mvn011; Moriwaki K, 2007, GLYCOBIOLOGY, V17, P1311, DOI 10.1093/glycob/cwm094; Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113; Moriwaki K, 2011, J BIOL CHEM, V286, P43123, DOI 10.1074/jbc.M111.262741; Moriwaki K, 2009, GASTROENTEROLOGY, V137, P188, DOI 10.1053/j.gastro.2009.04.002; Nakayama K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070298; Noda K, 2003, CANCER RES, V63, P6282; Ouyang W, 2013, INT J ONCOL, V42, P699, DOI 10.3892/ijo.2012.1748; Pan LQ, 2019, CELL, V176, P1477, DOI 10.1016/j.cell.2019.02.001; Seko A, 2008, J BIOL CHEM, V283, P33094, DOI 10.1074/jbc.M806933200; Singh N, 2020, CANCER DISCOV, V10, P552, DOI 10.1158/2159-8290.CD-19-0813; Song JJ, 2010, CELL SIGNAL, V22, P553, DOI 10.1016/j.cellsig.2009.11.012; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Togayachi A, 2010, P NATL ACAD SCI USA, V107, P11900, DOI 10.1073/pnas.0914298107; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; YAGO K, 1993, CANCER RES, V53, P5559; Zhang BJ, 2019, FEBS J, V286, P555, DOI 10.1111/febs.14742	40	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4385	4396		10.1038/s41388-022-02434-3	http://dx.doi.org/10.1038/s41388-022-02434-3		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35970887				2022-12-17	WOS:000840610900001
J	D'Agosto, S; Pezzini, F; Veghini, L; Delfino, P; Fiorini, C; Tane, GDT; Del Curatolo, A; Vicentini, C; Ferrari, G; Pasini, D; Andreani, S; Lupo, F; Fiorini, E; Lorenzon, G; Lawlor, RT; Rusev, B; Malinova, A; Luchini, C; Milella, M; Sereni, E; Pea, A; Bassi, C; Bailey, P; Scarpa, A; Bria, E; Corbo, V				D'Agosto, Sabrina; Pezzini, Francesco; Veghini, Lisa; Delfino, Pietro; Fiorini, Claudia; Tane, Gael D. Temgue; Del Curatolo, Anais; Vicentini, Caterina; Ferrari, Giorgia; Pasini, Davide; Andreani, Silvia; Lupo, Francesca; Fiorini, Elena; Lorenzon, Giulia; Lawlor, Rita T.; Rusev, Borislav; Malinova, Antonia; Luchini, Claudio; Milella, Michele; Sereni, Elisabetta; Pea, Antonio; Bassi, Claudio; Bailey, Peter; Scarpa, Aldo; Bria, Emilio; Corbo, Vincenzo			Loss of FGFR4 promotes the malignant phenotype of PDAC	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; PANCREATIC-CANCER; CELL IDENTITY; GROWTH; ACTIVATION; INHIBITOR; SUBTYPES	Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and FGFR4 in the definition of aggressive PDAC phenotypes. We found that the expression of FGFR4 is exclusively detected in epithelial cells, significantly elevated in the classical PDAC subtype, and associates with better outcomes. In highly aggressive basal-like/squamous PDAC, reduced FGFR4 expression aligns with hypermethylation of the gene and lower levels of histone marks associated with active transcription in its regulatory regions. Conversely, FGFR1 has more promiscuous expression in both normal and malignant pancreatic tissues and is strongly associated with the EMT phenotype but not with the basal-like cell lineage. Regardless of the genetic background, the increased proliferation of FGFR4-depleted PDAC cells correlates with hyperactivation of the mTORC1 pathway both in vitro and in vivo. Downregulation of FGFR4 in classical cell lines invariably leads to the enrichment of basal-like/squamous gene programs and is associated with either partial or full switch of phenotype. In sum, we show that endogenous levels of FGFR4 limit the malignant phenotype of PDAC cells. Finally, we propose FGFR4 as a valuable marker for the stratification of PDAC patients.	[D'Agosto, Sabrina; Pezzini, Francesco; Veghini, Lisa; Delfino, Pietro; Fiorini, Claudia; Tane, Gael D. Temgue; Ferrari, Giorgia; Pasini, Davide; Andreani, Silvia; Lupo, Francesca; Fiorini, Elena; Lorenzon, Giulia; Malinova, Antonia; Luchini, Claudio; Scarpa, Aldo; Corbo, Vincenzo] Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Verona, Italy; [Del Curatolo, Anais; Vicentini, Caterina; Lawlor, Rita T.; Rusev, Borislav; Scarpa, Aldo; Corbo, Vincenzo] Univ & Hosp Trust Verona, ARC Net Res Ctr, Verona, Italy; [Milella, Michele] Univ & Hosp Trust Verona, Dept Med, Sect Oncol, Verona, Italy; [Sereni, Elisabetta; Pea, Antonio; Bassi, Claudio] Univ & Hosp Trust Verona, Pancreas Inst, Dept Surg, Verona, Italy; [Bailey, Peter] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Bailey, Peter] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Bailey, Peter] Heidelberg Univ, Dept Gen Surg, Heidelberg, Germany; [Bria, Emilio] Fdn Policlin Univ Agostino Gemelli IRCCS, Comprehens Canc Ctr, Rome, Italy; [Bria, Emilio] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Sect Med Oncol, Rome, Italy; [D'Agosto, Sabrina] Human Technopole, Milan, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Glasgow; Beatson Institute; Ruprecht Karls University Heidelberg; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Human Technopole	Corbo, V (corresponding author), Univ & Hosp Trust Verona, Dept Diagnost & Publ Hlth, Verona, Italy.; Corbo, V (corresponding author), Univ & Hosp Trust Verona, ARC Net Res Ctr, Verona, Italy.	vincenzo.corbo@univr.it		Malinova, Antonia/0000-0003-0325-501X; Pasini, Davide/0000-0002-8270-7143	Associazione Italiana Ricerca sul Cancro (AIRC) [18178]; EU (MSCA project PRECODE) [861196]; National Cancer Institute (NCI) [HHSN26100008]; AIRC [IG20583, 24043, 19404, 20872, 25286]; Universita Cattolica del Sacro Cuore (UCSC); AIRC 5x1000 [12182]; Fondazione Nadia Valsecchi Onlus; Ontario Institute for Cancer Research through Government of Ontario	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); EU (MSCA project PRECODE); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIRC(Fondazione AIRC per la ricerca sul cancro); Universita Cattolica del Sacro Cuore (UCSC); AIRC 5x1000(Fondazione AIRC per la ricerca sul cancro); Fondazione Nadia Valsecchi Onlus; Ontario Institute for Cancer Research through Government of Ontario	We gratefully acknowledge the Centro Piattaforme Tecnologiche (CPT - University of Verona, Verona, Italy) for granting access to the genomic facility of University of Verona. In addition, we acknowledge the assistance provided by Serena Pedron, Valerio Crestani, Claudia Parolini, e Paola Perfetti for the execution of immunohistochemical staining. VC is supported by Associazione Italiana Ricerca sul Cancro (AIRC; Grant No. 18178). VC is also supported by the EU (MSCA project PRECODE, grant No: 861196) and the National Cancer Institute (NCI, HHSN26100008). EB is supported by the AIRC (Grant No. IG20583), and by Institutional funds of Universita Cattolica del Sacro Cuore (UCSC-project D1). AS is supported by AIRC 5x1000, grant n 12182. SDa is supported by AIRC (24043). CF was supported for by the Fondazione Umberto Veronesi. AdC was supported by AIRC (19404, 20872). PD is supported by Fondazione Nadia Valsecchi Onlus. EF is supported by AIRC (25286). This study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. The funding agencies had no role in the collection, analysis, and interpretation of data or in the writing of the paper.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Aguirre AJ, 2018, CANCER DISCOV, V8, P1096, DOI 10.1158/2159-8290.CD-18-0275; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Aung KL, 2018, CLIN CANCER RES, V24, P1344, DOI 10.1158/1078-0432.CCR-17-2994; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Bhushan A, 2001, DEVELOPMENT, V128, P5109; Brunton H, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107625; Chan-Seng-Yue M, 2020, NAT GENET, V52, P231, DOI 10.1038/s41588-019-0566-9; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Diaferia GR, 2016, EMBO J, V35, P595, DOI 10.15252/embj.201592404; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Dreyer SB, 2021, GASTROENTEROLOGY, V160, P362, DOI 10.1053/j.gastro.2020.09.043; Elghazi L, 2002, P NATL ACAD SCI USA, V99, P3884, DOI 10.1073/pnas.062321799; Frattini V, 2018, NATURE, V553, P222, DOI 10.1038/nature25171; Goncalves CA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23295-6; Grun D, 2016, CELL STEM CELL, V19, P266, DOI 10.1016/j.stem.2016.05.010; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Hayashi A, 2020, NAT CANCER, V1, P59, DOI 10.1038/s43018-019-0010-1; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Kalisz M, 2020, EMBO J, V39, DOI 10.15252/embj.2019102808; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kloesch B, 2022, GUT, V71, P766, DOI 10.1136/gutjnl-2020-321397; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lin W, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00776-9; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Meyers N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62106-8; Michl P, 2021, UNITED EUR GASTROENT, V9, P860, DOI 10.1002/ueg2.12123; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Motoda N, 2011, INT J ONCOL, V38, P133, DOI 10.3892/ijo_00000832; Muraro MJ, 2016, CELL SYST, V3, P385, DOI 10.1016/j.cels.2016.09.002; Neben CL, 2019, DEV BIOL, V447, P71, DOI 10.1016/j.ydbio.2017.10.017; Nicolle R, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102858; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Porter RL, 2019, P NATL ACAD SCI USA, V116, P26835, DOI 10.1073/pnas.1914915116; Rahib L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4708; Raoof S, 2019, ONCOGENE, V38, P6399, DOI 10.1038/s41388-019-0887-2; Sasaki N, 2020, CANCERS, V12, DOI 10.3390/cancers12102976; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Segerstolpe A, 2016, CELL METAB, V24, P593, DOI 10.1016/j.cmet.2016.08.020; Shah P, 2013, CELL, V153, P1589, DOI 10.1016/j.cell.2013.05.049; Somerville TDD, 2020, P NATL ACAD SCI USA, V117, P11471, DOI 10.1073/pnas.1921484117; Somerville TDD, 2020, ELIFE, V9, DOI 10.7554/eLife.53381; Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051; Steele NG, 2020, NAT CANCER, V1, P1097, DOI 10.1038/s43018-020-00121-4; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Ulaganathan VK, 2015, NATURE, V528, P570, DOI 10.1038/nature16449	53	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4371	4384		10.1038/s41388-022-02432-5	http://dx.doi.org/10.1038/s41388-022-02432-5		AUG 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35963908	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000840288700001
J	Mouillet-Richard, S; Martin-Lanneree, S; Le Corre, D; Hirsch, TZ; Ghazi, A; Sroussi, M; Pilati, C; de Reynies, A; Djouadi, F; Vodovar, N; Launay, JM; Laurent-Puig, P				Mouillet-Richard, Sophie; Martin-Lanneree, Severine; Le Corre, Delphine; Hirsch, Theo Z.; Ghazi, Alexandre; Sroussi, Marine; Pilati, Camilla; de Reynies, Aurelien; Djouadi, Fatima; Vodovar, Nicolas; Launay, Jean-Marie; Laurent-Puig, Pierre			A proof of concept for targeting the PrPC-Amyloid beta peptide interaction in basal prostate cancer and mesenchymal colon cancer	ONCOGENE			English	Article							CELLULAR PRION PROTEIN; CLEAVAGE	The cellular prion protein PrPC partners with caveolin-1 (CAV1) in neurodegenerative diseases but whether this interplay occurs in cancer has never been investigated. By leveraging patient and cell line datasets, we uncover a molecular link between PrPC and CAV1 across cancer. Using cell-based assays, we show that PrPC regulates the expression of and interacts with CAV1. PrPC additionally controls the expression of the amyloid precursor protein APP and of the A beta generating enzyme BACE1, and regulates the levels of A beta, whose accumulation is a central event in Alzheimer's disease. We further identify DKK1 and DKK3, involved in both Alzheimer's disease and cancer progression, as targets of the PrPC-dependent axis. Finally, we establish that antibody-mediated blocking of the A beta-PrPC interaction delays the growth of prostate cancer cell line-derived xenografts and prevents the development of metastases. Our data additionally support an enrichment of the A beta-PrPC-dependent pathway in the basal subtype of prostate cancer, associated with anti-hormonal therapy resistance, and in mesenchymal colon cancer, associated with poor prognosis. Thus, based on a parallel with neurodegenerative diseases, our results bring to light an A beta-PrPC axis and support the potential of targeting this pathway in patients with selected subtypes of prostate and colon cancer.	[Mouillet-Richard, Sophie; Martin-Lanneree, Severine; Le Corre, Delphine; Hirsch, Theo Z.; Ghazi, Alexandre; Sroussi, Marine; Pilati, Camilla; de Reynies, Aurelien; Djouadi, Fatima; Laurent-Puig, Pierre] Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, F-75006 Paris, France; [Sroussi, Marine] Ecole Super Phys & Chim Ind Ville Paris, Lab Biochim, F-75005 Paris, France; [Vodovar, Nicolas; Launay, Jean-Marie] Univ Paris Cite, Paris, France; [Vodovar, Nicolas; Launay, Jean-Marie] Inserm UMR S942 MASCOT, Paris, France; [Launay, Jean-Marie] F Hoffmann La Roche Ltd, Pharma Res Dept, CH-4070 Basel, Switzerland; [Laurent-Puig, Pierre] Hop Europeen Georges Pompidou, AP HP, Inst Canc Paris CARPEM, Dept Biol, F-75015 Paris, France; [Martin-Lanneree, Severine] IntegraGen SA, Genopole Campus 1,Rue Henri Desbrueres, F-91000 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Genopole	Mouillet-Richard, S (corresponding author), Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, F-75006 Paris, France.	sophie.mouillet-richard@parisdescartes.fr	Mouillet, Sophie/E-4960-2017; laurent-puig, pierre/B-2226-2013	Mouillet, Sophie/0000-0002-8950-1949; laurent-puig, pierre/0000-0001-8475-5459; Hirsch, Theo/0000-0003-4428-2997	Canceropole Ile de France [2016-1-EMERG-36-UP 5-1]; Association pour la Recherche sur le Cancer [PJA 20171206220]; SIRIC CARPEM (CAncer Research for PErsonalized Medicine) [INCaDGOS Inserm_12561]; Labex Immuno-oncology, SATT Ile de France [415]; INSERM; Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC); Fondation pour la Recherche Medicale [FDM202006011237]	Canceropole Ile de France(Region Ile-de-France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); SIRIC CARPEM (CAncer Research for PErsonalized Medicine); Labex Immuno-oncology, SATT Ile de France; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Grant support was provided by the following: Canceropole Ile de France (grant number 2016-1-EMERG-36-UP 5-1), Association pour la Recherche sur le Cancer (grant number PJA 20171206220), SIRIC CARPEM (CAncer Research for PErsonalized Medicine, INCaDGOS Inserm_12561), Labex Immuno-oncology, SATT Ile de France (grant number 415) as well as INSERM and Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC). M. Sroussi was supported by a fellowship from Fondation pour la Recherche Medicale (FRM grant FDM202006011237). The authors acknowledge N. Pierron and F. d'Agostini for expert methodological assistance.	Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bruggink KA, 2015, J NEUROCHEM, V134, P1152, DOI 10.1111/jnc.13216; D'Amico L, 2016, J EXP MED, V213, P827, DOI 10.1084/jem.20150950; Ferrari N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07987-0; Ghazi A, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1940674; Griffiths HH, 2011, J BIOL CHEM, V286, P33489, DOI 10.1074/jbc.M111.278556; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hampel H, 2021, BIOL PSYCHIAT, V89, P745, DOI 10.1016/j.biopsych.2020.02.001; Hirsch TZ, 2017, PROG MOL BIOL TRANSL, V150, P1, DOI 10.1016/bs.pmbts.2017.06.001; Kamoun A, 2018, ANN ONCOL, V29, P1814, DOI 10.1093/annonc/mdy224; Karran E, 2022, NAT REV DRUG DISCOV, V21, P306, DOI 10.1038/s41573-022-00391-w; Killick R, 2014, MOL PSYCHIATR, V19, P88, DOI 10.1038/mp.2012.163; Kleffman K, 2022, CANCER DISCOV, V12, P1314, DOI 10.1158/2159-8290.CD-21-1006; Kralovicova S, 2009, MOL CELL NEUROSCI, V41, P135, DOI 10.1016/j.mcn.2009.02.002; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; Le Corre D, 2019, EBIOMEDICINE, V46, P94, DOI 10.1016/j.ebiom.2019.07.036; Li J, 2017, CANCER CELL, V31, P225, DOI 10.1016/j.ccell.2017.01.005; Linsenmeier L, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abj1826; McHugh PC, 2012, NEUROCHEM INT, V61, P672, DOI 10.1016/j.neuint.2012.07.002; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Mouillet-Richard S, 2021, CANCERS, V13, DOI 10.3390/cancers13195032; Pankiewicz JE, 2019, MOL NEUROBIOL, V56, P2073, DOI 10.1007/s12035-018-1208-4; Parkin ET, 2007, P NATL ACAD SCI USA, V104, P11062, DOI 10.1073/pnas.0609621104; Qin KF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44317-w; Rajan P, 2014, EUR UROL, P66; Rajan P, 2014, EUR UROL, V66, P32, DOI 10.1016/j.eururo.2013.08.011; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Whitehouse IJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159119; Whitehouse IJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059554; Zhang DX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10798; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751	32	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4397	4404		10.1038/s41388-022-02430-7	http://dx.doi.org/10.1038/s41388-022-02430-7		AUG 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35962130	hybrid, Green Published			2022-12-17	WOS:000840000600002
J	Zhou, BJ; Zong, SM; Zhong, WL; Tian, YX; Wang, LM; Zhang, Q; Zhang, RY; Li, L; Wang, W; Zhao, JM; Chen, X; Feng, YJ; Zhai, BH; Sun, T; Liu, YR				Zhou, Bijiao; Zong, Shumin; Zhong, Weilong; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Zhang, Renya; Li, Lei; Wang, Wei; Zhao, Jianmin; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong			Interaction between laminin-5 gamma 2 and integrin beta 1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins (vol 39, pg 1527, 2020)	ONCOGENE			English	Correction; Early Access												sunrockmia@hotmail.com; liuyanrong1984@163.com						Zhou BJ, 2020, ONCOGENE, V39, P1527, DOI 10.1038/s41388-019-1082-1	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02422-7	http://dx.doi.org/10.1038/s41388-022-02422-7		AUG 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T0UV	35962131	Bronze			2022-12-17	WOS:000840000600001
J	Morales-Valencia, J; Lau, L; Marti-Nin, T; Ozerdem, U; David, G				Morales-Valencia, Jorge; Lau, Lena; Marti-Nin, Teresa; Ozerdem, Ugur; David, Gregory			Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELLULAR SENESCENCE; GROWTH; FIBROBLASTS; RESISTANCE; MECHANISMS; INVASION; IRON	The acquisition of novel detrimental cellular properties following exposure to cytotoxic drugs leads to aggressive and metastatic tumors that often translates into an incurable disease. While the bulk of the primary tumor is eliminated upon exposure to chemotherapeutic treatment, residual cancer cells and non-transformed cells within the host can engage a stable cell cycle exit program named senescence. Senescent cells secrete a distinct set of pro-inflammatory factors, collectively termed the senescence-associated secretory phenotype (SASP). Upon exposure to the SASP, cancer cells undergo cellular plasticity resulting in increased proliferation, migration and epithelial-to-mesenchymal transition. The molecular mechanisms by which the SASP regulates these pro-tumorigenic features are poorly understood. Here, we report that breast cancer cells exposed to the SASP strongly upregulate Lipocalin-2 (LCN2). Furthermore, we demonstrate that LCN2 is critical for SASP-induced increased migration in breast cancer cells, and its inactivation potentiates the response to chemotherapeutic treatment in mouse models of breast cancer. Finally, we show that neoadjuvant chemotherapy treatment leads to LCN2 upregulation in residual human breast tumors, and correlates with worse overall survival. These findings provide the foundation for targeting LCN2 as an adjuvant therapeutic approach to prevent the emergence of aggressive tumors following chemotherapy.	[Morales-Valencia, Jorge; Lau, Lena; Marti-Nin, Teresa; David, Gregory] NYU, Dept Biochem & Mol Pharmacol, Langone Med Ctr, New York, NY 10016 USA; [Morales-Valencia, Jorge; David, Gregory] NYU Langone Hlth, NYU Langone Perlmutter Canc Ctr, New York, NY 10016 USA; [Ozerdem, Ugur] NYU, NYU Langone Hlth, Dept Pathol, Sch Med, New York, NY 10016 USA; [David, Gregory] NYU, NYU Langone Hlth, Dept Urol, Sch Med, New York, NY 10016 USA	New York University; NYU Langone Medical Center; NYU Langone Medical Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	David, G (corresponding author), NYU, Dept Biochem & Mol Pharmacol, Langone Med Ctr, New York, NY 10016 USA.; David, G (corresponding author), NYU Langone Hlth, NYU Langone Perlmutter Canc Ctr, New York, NY 10016 USA.; David, G (corresponding author), NYU, NYU Langone Hlth, Dept Urol, Sch Med, New York, NY 10016 USA.	gregory.david@nyulangone.org		David, Gregory/0000-0002-1849-3232	NIH/NCI [CA246416]; NYS DoH [C36617GG]; NYSTEM Institutional Training Grant [C322560GG]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NYS DoH; NYSTEM Institutional Training Grant	The authors sincerely thank all members of the David lab for helpful discussions during the preparation of this manuscript. We wish to acknowledge the NYU Genome Technology Center for help with RNA sequencing (RNA-seq). We thank Dr. Richard Possemato (NYU School of Medicine), Dr. Eva Hernando (NYU School of Medicine), Dr. Thales Papagiannakopoulos (NYU School of Medicine), Dr. Benjamin Neel (NYU School of Medicine), and Dr. Judith Campisi (Buck Institute for Research on Aging) as well as members of their labs for the generous gift or reagents and plasmids and for helpful discussions. This work was funded by NIH/NCI (CA246416) [GD], NYS DoH (C36617GG) [GD] and the NYSTEM Institutional Training Grant (C322560GG) [JMV].	Asaoka M, 2020, BREAST CANCER-BASIC, V14, DOI 10.1177/1178223420980377; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chi Y, 2020, SCIENCE, V369, P276, DOI 10.1126/science.aaz2193; Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Duy C, 2021, CANCER DISCOV, V11, P1542, DOI 10.1158/2159-8290.CD-20-1375; Espinoza-Sanchez Nancy Adriana, 2018, Oncotarget, V9, P26679, DOI 10.18632/oncotarget.25465; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Hu CX, 2018, ONCOTARGETS THER, V11, P8099, DOI 10.2147/OTT.S181223; Jung M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020273; Karabicici M, 2021, MOL ONCOL, V15, P2185, DOI 10.1002/1878-0261.12916; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; La Manna G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089497; Laberge RM, 2012, CANCER MICROENVIRON, V5, P39, DOI 10.1007/s12307-011-0069-4; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lau L, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00586-18; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Moirangthem A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21903; Ortiz-Montero P, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0172-3; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Saxena M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.61; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Shi H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-83; Tong ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; Villodre ES, 2021, MOL ONCOL, V15, P2752, DOI 10.1002/1878-0261.13074; Xiao X, 2017, ANNU REV NUTR, V37, P103, DOI 10.1146/annurev-nutr-071816-064559; Xu HX, 2015, ONCOTARGETS THER, V8, P3783, DOI 10.2147/OTT.S95470; Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yedjou CG, 2019, ADV EXP MED BIOL, V1152, P31, DOI 10.1007/978-3-030-20301-6_3; Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22; Zhang N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020849; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	46	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4361	4370		10.1038/s41388-022-02433-4	http://dx.doi.org/10.1038/s41388-022-02433-4		AUG 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35953598	Green Submitted			2022-12-17	WOS:000839543400001
J	Diskin, B; Adam, S; Soto, GS; Liria, M; Aykut, B; Sundberg, B; Li, E; Leinwand, J; Chen, R; Kim, M; Salas, RD; Cassini, MF; Buttar, C; Wang, W; Farooq, MS; Shadaloey, SAA; Werba, G; Fnu, A; Yang, F; Hirsch, C; Glinski, J; Panjwani, A; Weitzner, Y; Cohen, D; Miller, G				Diskin, Brian; Adam, Salma; Soto, Gustavo Sanchez; Liria, Miguel; Aykut, Berk; Sundberg, Belen; Li, Eric; Leinwand, Joshua; Chen, Ruonan; Kim, Mirhee; Salas, Ruben D.; Cassini, Marcelo F.; Buttar, Chandan; Wang, Wei; Farooq, Mohammad Saad; Shadaloey, Sorin A. A.; Werba, Gregor; Fnu, Amreek; Yang, Fan; Hirsch, Carolina; Glinski, John; Panjwani, Angilee; Weitzner, Yael; Cohen, Deirdre; Miller, George			BTLA(+)CD200(+) B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer	ONCOGENE			English	Article							LIVER; ONCOGENESIS; RESPONSES; NICHE	Response to cancer immunotherapy in primary versus metastatic disease has not been well-studied. We found primary pancreatic ductal adenocarcinoma (PDA) is responsive to diverse immunotherapies whereas liver metastases are resistant. We discovered divergent immune landscapes in each compartment. Compared to primary tumor, liver metastases in both mice and humans are infiltrated by highly anergic T cells and MHCII(lo)IL10(+) macrophages that are unable to present tumor-antigen. Moreover, a distinctive population of CD24(+)CD44(-)CD40(-) B cells dominate liver metastases. These B cells are recruited to the metastatic milieu by Muc1(hi)IL18(hi) tumor cells, which are enriched >10-fold in liver metastases. Recruited B cells drive macrophage-mediated adaptive immune-tolerance via CD200 and BTLA. Depleting B cells or targeting CD200/BTLA enhanced macrophage and T-cell immunogenicity and enabled immunotherapeutic efficacy of liver metastases. Our data detail the mechanistic underpinnings for compartment-specific immunotherapy-responsiveness and suggest that primary PDA models are poor surrogates for evaluating immunity in advanced disease.	[Diskin, Brian; Adam, Salma; Soto, Gustavo Sanchez; Liria, Miguel; Aykut, Berk; Sundberg, Belen; Li, Eric; Leinwand, Joshua; Chen, Ruonan; Kim, Mirhee; Salas, Ruben D.; Cassini, Marcelo F.; Buttar, Chandan; Wang, Wei; Farooq, Mohammad Saad; Shadaloey, Sorin A. A.; Werba, Gregor; Fnu, Amreek; Yang, Fan; Hirsch, Carolina; Glinski, John; Panjwani, Angilee; Weitzner, Yael; Miller, George] NYU, Dept Surg, SA Localio Lab, Sch Med, New York, NY 10016 USA; [Cohen, Deirdre] NYU, Sch Med, Dept Med, New York, NY USA; [Miller, George] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Miller, George] Trinity Hlth New England, Waterbury, CT 06706 USA	New York University; New York University; New York University	Miller, G (corresponding author), NYU, Dept Surg, SA Localio Lab, Sch Med, New York, NY 10016 USA.; Miller, G (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.; Miller, G (corresponding author), Trinity Hlth New England, Waterbury, CT 06706 USA.	gedalyamil@gmail.com		Aykut, Berk/0000-0001-8343-4258; Salas Parra, Ruben Dario/0000-0002-8960-266X	American College of Surgeons Resident Research Fellowship; Deutsche Forschungsgemeinschaft [AY 126/1-1]; NIH [CA168611, CA203105, CA215471, CA19311, DK106025]	American College of Surgeons Resident Research Fellowship; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the American College of Surgeons Resident Research Fellowship (BD), Deutsche Forschungsgemeinschaft grant AY 126/1-1 (BA), and NIH grants CA168611 (DC, GM), CA203105 (GM), CA215471 (GM), CA19311 (GM), and DK106025 (GM).	Bodogai M, 2015, CANCER RES, V75, P3456, DOI 10.1158/0008-5472.CAN-14-3077; Canning C, 2006, IMMUNOL LETT, V107, P83, DOI 10.1016/j.imlet.2006.07.002; Chen J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/8282391; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Daley D, 2017, NAT MED, V23, P556, DOI 10.1038/nm.4314; Daley D, 2016, CELL, V166, P1485, DOI 10.1016/j.cell.2016.07.046; Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2; Enoksson SL, 2011, P NATL ACAD SCI USA, V108, pE1399, DOI 10.1073/pnas.1107830108; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Grunwald B, 2016, GASTROENTEROLOGY, V151, P1011, DOI 10.1053/j.gastro.2016.07.043; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Liu Y, 2016, J MOL MED, V94, P509, DOI 10.1007/s00109-015-1376-x; Mieli-Vergani G, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/nrdp.2018.17, 10.1038/nrdp.2018.18]; Moini M, 2015, WORLD J HEPATOL, V7, P1355, DOI 10.4254/wjh.v7.i10.1355; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Pylayeva-Gupta Y, 2016, CANCER DISCOV, V6, P247, DOI 10.1158/2159-8290.CD-15-0843; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang Wei, 2018, Cancer Cell, V34, P757, DOI 10.1016/j.ccell.2018.10.006; Wrenshall LE, 2001, TRANSPLANTATION, V71, P841, DOI 10.1097/00007890-200104150-00004; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Zhao Y., 2018, ONCOTARGET, V9, P14803, DOI [10.18632/oncotarget.22976, DOI 10.18632/ONCOTARGET.22976]; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014	28	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4349	4360		10.1038/s41388-022-02425-4	http://dx.doi.org/10.1038/s41388-022-02425-4		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35948648				2022-12-17	WOS:000838482900002
J	Tian, LS; Xie, XF; Das, U; Chen, YL; Sun, YL; Liu, F; Lu, HZ; Nan, P; Zhu, Y; Gu, XL; Deng, HT; Xie, JY; Zhao, XH				Tian, Lusong; Xie, Xiufeng; Das, Urmi; Chen, Yuling; Sun, Yulin; Liu, Fang; Lu, Haizhen; Nan, Peng; Zhu, Ying; Gu, Xinglu; Deng, Haiteng; Xie, Jiuyong; Zhao, Xiaohang			Forming cytoplasmic stress granules PUR alpha suppresses mRNA translation initiation of IGFBP3 to promote esophageal squamous cell carcinoma progression	ONCOGENE			English	Article							POSTNATAL BRAIN-DEVELOPMENT; FACTOR-BINDING-PROTEINS; SINGLE-STRANDED-DNA; GROWTH; CANCER; TRANSCRIPTION; ASSOCIATION; ACTIVATION; GENE; IDENTIFICATION	Esophageal squamous cell carcinoma (ESCC) is one of the most fatal malignancies worldwide. Recently, our group identified purine-rich element binding protein alpha (PUR alpha), a single-stranded DNA/RNA-binding protein, to be significantly associated with the progression of ESCC. Additional immunofluorescence staining demonstrated that PUR alpha forms cytoplasmic stress granules to suppress mRNA translation initiation. The expression level of cytoplasmic PUR alpha in ESCC tumor tissues was significantly higher than that in adjacent epithelia and correlated with a worse patient survival rate by immunohistochemistry. Functionally, PUR alpha strongly preferred to bind to UG-/U-rich motifs and mRNA 3 ' UTR by CLIP-seq analysis. Moreover, PUR alpha knockout significantly increased the protein level of insulin-like growth factor binding protein 3 (IGFBP3). In addition, it was further demonstrated that PUR alpha-interacting proteins are remarkably associated with translation initiation factors and ribosome-related proteins and that PUR alpha regulates protein expression by interacting with translation initiation factors, such as PABPC1, eIF3B and eIF3F, in an RNA-independent manner, while the interaction with ribosome-related proteins is significantly dependent on RNA. Specifically, PUR alpha was shown to interact with the mRNA 3 ' UTR of IGFBP3 and inhibit its expression by suppressing mRNA translation initiation. Together, this study identifies cytoplasmic PUR alpha as a modulator of IGFBP3, which could be a promising therapeutic target for ESCC treatment.	[Tian, Lusong; Xie, Xiufeng; Sun, Yulin; Liu, Fang; Nan, Peng; Zhu, Ying; Gu, Xinglu; Zhao, Xiaohang] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Das, Urmi; Xie, Jiuyong] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada; [Chen, Yuling; Deng, Haiteng] Tsinghua Univ, Ctr Synthet & Systemat Biol, Sch Life Sci, MOE Key Lab Bioinformat, Beijing, Peoples R China; [Lu, Haizhen] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Canc Hosp, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; University of Manitoba; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Zhao, XH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.; Xie, JY (corresponding author), Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada.; Deng, HT (corresponding author), Tsinghua Univ, Ctr Synthet & Systemat Biol, Sch Life Sci, MOE Key Lab Bioinformat, Beijing, Peoples R China.	dht@mail.tsinghua.edu.cn; xiej@umanitoba.ca; zhaoxh@cicams.ac.cn	Xie, Jiuyong/D-2899-2013	Xie, Jiuyong/0000-0003-2909-1033; Das, Urmi/0000-0001-7639-6521	National Natural Science Foundation of China [81872033, 81572365, 82073327]; National Key R&D Program of China [2018YFC1313101, 2016YFC0901403]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-001, 2019-I2M-1-003, 2021-I2M-1-066]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; CAMS Innovation Fund for Medical Sciences	This work was partly supported by the National Natural Science Foundation of China (81872033 and 81572365 to XZ; 82073327 to YS), the National Key R&D Program of China (2018YFC1313101 and 2016YFC0901403 to XZ) and the CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, 2019-I2M-1-003 and 2021-I2M-1-066 to XZ and YS) of China.	Asadi MR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.745394; Bassler J, 2019, ANNU REV BIOCHEM, V88, P281, DOI 10.1146/annurev-biochem-013118-110817; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; Bratkovic T, 2020, NUCLEIC ACIDS RES, V48, P1627, DOI 10.1093/nar/gkz1140; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai Q, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051261; Chen BB, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-1-r18; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Daigle JG, 2016, ACTA NEUROPATHOL, V131, P605, DOI 10.1007/s00401-015-1530-0; Daniel DC, 2018, GENE, V643, P133, DOI 10.1016/j.gene.2017.12.004; Darbinian N, 2004, ANTICANCER RES, V24, P2585; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Di Salvio M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.295; Gallia GL, 1999, P NATL ACAD SCI USA, V96, P11572, DOI 10.1073/pnas.96.20.11572; Gao JJ, 2021, CANCER LETT, V498, P98, DOI 10.1016/j.canlet.2020.10.030; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; Han JF, 2011, CANCER LETT, V307, P200, DOI 10.1016/j.canlet.2011.04.004; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hinnebusch AG, 2014, ANNU REV BIOCHEM, V83, P779, DOI 10.1146/annurev-biochem-060713-035802; Hirano H, 2019, JPN J CLIN ONCOL, V49, P412, DOI 10.1093/jjco/hyz034; Hokkanen S, 2012, HUM MOL GENET, V21, P473, DOI 10.1093/hmg/ddr476; Hunt D, 2014, J MED GENET, V51, P806, DOI 10.1136/jmedgenet-2014-102798; Ivanov P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032813; Jain S, 2016, CELL, V164, P487, DOI 10.1016/j.cell.2015.12.038; Johnson EM, 2006, J NEUROSCI RES, V83, P929, DOI 10.1002/jnr.20806; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Johnson MA, 2014, GROWTH HORM IGF RES, V24, P164, DOI 10.1016/j.ghir.2014.04.007; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim JH, 2011, BLOOD, V118, P2622, DOI 10.1182/blood-2010-08-299784; Lee HY, 2002, CANCER RES, V62, P3530; Lezon-Geyda K, 2001, LEUKEMIA, V15, P954, DOI 10.1038/sj.leu.2402108; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Merrick WC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a033092; Mitsumori K, 2017, MOL BIOL CELL, V28, P1412, DOI 10.1091/mbc.E16-07-0497; Natsuizaka M, 2014, AM J CANCER RES, V4, P29; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Ojha S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050783; Pandey PR, 2020, NUCLEIC ACIDS RES, V48, P3789, DOI 10.1093/nar/gkaa035; Protter DSW, 2016, TRENDS CELL BIOL, V26, P668, DOI 10.1016/j.tcb.2016.05.004; Rossi S, 2015, J CELL SCI, V128, P1787, DOI 10.1242/jcs.165332; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sariyer IK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156819; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Tanaka AJ, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000356; Trau SP, 2020, PEDIATR NEUROL, V104, P62, DOI 10.1016/j.pediatrneurol.2019.09.008; Turriziani Benedetta, 2014, Biology (Basel), V3, P320, DOI 10.3390/biology3020320; Van Nostrand EL, 2016, NAT METHODS, V13, P508, DOI [10.1038/NMETH.3810, 10.1038/nmeth.3810]; Wang LG, 2008, CANCER RES, V68, P2678, DOI 10.1158/0008-5472.CAN-07-6017; White MK, 2009, CELL CYCLE, V8, P414, DOI 10.4161/cc.8.3.7585; Wolozin B, 2019, NAT REV NEUROSCI, V20, P649, DOI 10.1038/s41583-019-0222-5; Xia H, 2017, BBA-GENE REGUL MECH, V1860, P911, DOI 10.1016/j.bbagrm.2017.07.004; Xu ZH, 2013, P NATL ACAD SCI USA, V110, P7778, DOI 10.1073/pnas.1219643110; Yang PG, 2020, CELL, V181, P325, DOI 10.1016/j.cell.2020.03.046; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x; Youn JY, 2019, MOL CELL, V76, P286, DOI 10.1016/j.molcel.2019.09.014	62	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4336	4348		10.1038/s41388-022-02426-3	http://dx.doi.org/10.1038/s41388-022-02426-3		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35945453	Green Published, hybrid			2022-12-17	WOS:000837926900001
J	Ipsen, MB; Sorensen, EMG; Thomsen, EA; Weiss, S; Haldrup, J; Dalby, A; Palmfeldt, J; Bross, P; Rasmussen, M; Fredsoe, J; Klingenberg, S; Jochumsen, MR; Bouchelouche, K; Ulhoi, BP; Borre, M; Mikkelsen, JG; Sorensen, KD				Ipsen, Malene Blond; Sorensen, Ea Marie Givskov; Thomsen, Emil Aagaard; Weiss, Simone; Haldrup, Jakob; Dalby, Anders; Palmfeldt, Johan; Bross, Peter; Rasmussen, Martin; Fredsoe, Jacob; Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten; Ulhoi, Benedicte Parm; Borre, Michael; Mikkelsen, Jacob Giehm; Sorensen, Karina Dalsgaard			A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer	ONCOGENE			English	Article							CELL-FREE DNA; POLY(ADP-RIBOSE); REPAIR; ACTIVATION; AUTOPHAGY; OLAPARIB	DNA repair gene mutations are frequent in castration-resistant prostate cancer (CRPC), suggesting eligibility for poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. However, therapy resistance is a major clinical challenge and genes contributing to PARPi resistance are poorly understood. Using a genome-wide CRISPR-Cas9 knockout screen, this study aimed at identifying genes involved in PARPi resistance in CRPC. Based on the screen, we identified PARP1, and six novel candidates associated with olaparib resistance upon knockout. For validation, we generated multiple knockout populations/clones per gene in C4 and/or LNCaP CRPC cells, which confirmed that loss of PARP1, ARH3, YWHAE, or UBR5 caused olaparib resistance. PARP1 or ARH3 knockout caused cross-resistance to other PARPis (veliparib and niraparib). Furthermore, PARP1 or ARH3 knockout led to reduced autophagy, while pharmacological induction of autophagy partially reverted their PARPi resistant phenotype. Tumor RNA sequencing of 126 prostate cancer patients identified low ARH3 expression as an independent predictor of recurrence. Our results advance the understanding of PARPi response by identifying four novel genes that contribute to PARPi sensitivity in CRPC and suggest a new model of PARPi resistance through decreased autophagy.	[Ipsen, Malene Blond; Sorensen, Ea Marie Givskov; Weiss, Simone; Haldrup, Jakob; Rasmussen, Martin; Fredsoe, Jacob; Klingenberg, Soren; Sorensen, Karina Dalsgaard] Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark; [Ipsen, Malene Blond; Sorensen, Ea Marie Givskov; Weiss, Simone; Haldrup, Jakob; Palmfeldt, Johan; Bross, Peter; Rasmussen, Martin; Fredsoe, Jacob; Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten; Borre, Michael; Sorensen, Karina Dalsgaard] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Thomsen, Emil Aagaard; Haldrup, Jakob; Mikkelsen, Jacob Giehm] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Dalby, Anders] Teitur Troph, Aarhus, Denmark; [Palmfeldt, Johan; Bross, Peter] Aarhus Univ Hosp, Res Unit Mol Med, Aarhus, Denmark; [Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark; [Klingenberg, Soren; Jochumsen, Mads R.; Bouchelouche, Kirsten] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark; [Ulhoi, Benedicte Parm] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark; [Borre, Michael] Aarhus Univ Hosp, Dept Urol, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Sorensen, KD (corresponding author), Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark.; Sorensen, KD (corresponding author), Aarhus Univ, Dept Clin Med, Aarhus, Denmark.	kdso@clin.au.dk	Rasmussen, Martin/GRY-5664-2022; Thomsen, Emil Aagaard/ABB-9850-2021; Bross, Peter/B-7219-2013	Rasmussen, Martin/0000-0001-9077-7857; Thomsen, Emil Aagaard/0000-0002-2685-7745; Jochumsen, Mads Ryo/0000-0002-7676-2322; Klingenberg, Soren/0000-0003-4308-2950; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Fredsoe, Jacob/0000-0002-7319-2467; Mikkelsen, Jacob Giehm/0000-0002-1322-3209; Palmfeldt, Johan/0000-0001-5585-639X; Bross, Peter/0000-0001-9526-8525	Novo Nordisk Foundation; Aase & Ejnar Danielsens Fond; Fabrikant Einar Willumsens Mindelegat; Tomrermester Jorgen Holm & Hustru Elisa F. Hansens Mindelegat; Direktor Emil C. Hertz og Hustru Inge Hertz Fond; Graduate School of Health (Aarhus University); Beckett Fonden (MBI); NEYE Fonden; Helge Peetz & Verner Peetz & Hustru Vilma Peetz Fond	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Aase & Ejnar Danielsens Fond; Fabrikant Einar Willumsens Mindelegat; Tomrermester Jorgen Holm & Hustru Elisa F. Hansens Mindelegat; Direktor Emil C. Hertz og Hustru Inge Hertz Fond; Graduate School of Health (Aarhus University); Beckett Fonden (MBI); NEYE Fonden; Helge Peetz & Verner Peetz & Hustru Vilma Peetz Fond	This work was supported by grants from The Novo Nordisk Foundation (KDS), Aase & Ejnar Danielsens Fond (MBI), Fabrikant Einar Willumsens Mindelegat (MBI), Tomrermester Jorgen Holm & Hustru Elisa F. Hansens Mindelegat (MBI), Direktor Emil C. Hertz og Hustru Inge Hertz Fond (MBI), Graduate School of Health (Aarhus University; MBI), Helge Peetz & Verner Peetz & Hustru Vilma Peetz Fond (MBI), Beckett Fonden (MBI), and NEYE Fonden (MBI). The Danish Cancer Biobank is acknowledged for providing patient samples and information on handling and storage.	Abida W, 2017, JCO PRECIS ONCOL, V2017, DOI [10.1200/po.17.00029, DOI 10.1200/PO.17.00029, 10.1200/PO.17.00029]; Arun B, 2015, INT J ONCOL, V47, P262, DOI 10.3892/ijo.2015.3003; Cahuzac M, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003-022-03210-5; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen X, 2019, BIOCHEM BIOPH RES CO, V508, P620, DOI 10.1016/j.bbrc.2018.11.062; Cornford P, 2021, EUR UROL, V79, P263, DOI 10.1016/j.eururo.2020.09.046; de Bono J, 2020, NEW ENGL J MED, V382, P2091, DOI 10.1056/NEJMoa1911440; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Eliopoulos AG, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00204; FDA, 2021, FDA APPR OL HRR GEN; Formentini L, 2009, J BIOL CHEM, V284, P17668, DOI 10.1074/jbc.M109.002931; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Gogola E, 2018, CANCER CELL, V33, P1078, DOI 10.1016/j.ccell.2018.05.008; Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261; Hazan I, 2019, CELL REP, V29, P560, DOI 10.1016/j.celrep.2019.09.001; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; Hopkins TA, 2015, MOL CANCER RES, V13, P1465, DOI 10.1158/1541-7786.MCR-15-0191-T; Hussain M, 2020, NEW ENGL J MED, V383, P2345, DOI 10.1056/NEJMoa2022485; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lee JS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092013; Li CYG, 2019, CELL REP, V26, P1333, DOI 10.1016/j.celrep.2019.01.013; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Niere M, 2008, MOL CELL BIOL, V28, P814, DOI 10.1128/MCB.01766-07; Pennington KL, 2018, ONCOGENE, V37, P5587, DOI 10.1038/s41388-018-0348-3; Pettitt SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03917-2; Quigley D, 2017, CANCER DISCOV, V7, P999, DOI 10.1158/2159-8290.CD-17-0146; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ryo Laura Barrett, 2019, Methods Mol Biol, V1961, P93, DOI 10.1007/978-1-4939-9170-9_7; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Steensel V, TIDE TRACKING INDELS; Tai S, 2012, MOL CANCER THER, V11, P1320, DOI 10.1158/1535-7163.MCT-11-0954; Tukachinsky H, 2021, CLIN CANCER RES, V27, P3094, DOI 10.1158/1078-0432.CCR-20-4805; Valabrega G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084203; Velimezi G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04649-z; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Zhang MQ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60849-y	45	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4271	4281		10.1038/s41388-022-02427-2	http://dx.doi.org/10.1038/s41388-022-02427-2		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35933519				2022-12-17	WOS:000836761200001
J	Meng, XQ; Peng, JX; Xie, XS; Yu, FH; Wang, WC; Pan, QH; Jin, HL; Huang, XL; Yu, HY; Li, SR; Feng, DY; Liu, QX; Fang, LK; Lee, MH				Meng, Xiangqi; Peng, Jingxuan; Xie, Xiaoshan; Yu, Fenghai; Wang, Wencong; Pan, Qihao; Jin, Huilin; Huang, Xiaoling; Yu, Hongyan; Li, Shengrong; Feng, Dianying; Liu, Qingxin; Fang, Lekun; Lee, Mong-Hong			Roles of lncRNA LVBU in regulating urea cycle/polyamine synthesis axis to promote colorectal carcinoma progression	ONCOGENE			English	Article							THERAPEUTIC TARGET; BCL6; HIF-1-ALPHA; IMMUNITY; HYPOXIA	Altered expression of Urea Cycle (UC) enzymes occurs in many tumors, resulting a metabolic hallmark termed as UC dysregulation. Polyamines are synthesized from ornithine, and polyamine synthetic genes are elevated in various tumors. However, the underlying deregulations of UC/ polyamine synthesis in cancer remain elusive. Here, we characterized a hypoxia-induced lncRNA LVBU (lncRNA regulation via BCL6/urea cycle) that is highly expressed in colorectal cancer (CRC) and correlates with poor cancer prognosis. Increased LVBU expression promoted CRC cells proliferation, foci formation and tumorigenesis. Further, LVBU regulates urea cycle and polyamine synthesis through BCL6, a negative regulator of p53. Mechanistically, overexpression of LVBU competitively bound miR-10a/miR-34c to protect BCL6 from miR-10a/34c-mediated degradation, which in turn allows BCL6 to block p53-mediated suppression of genes (arginase1 ARG1, ornithine transcarbamylase OTC, ornithine decarboxylase 1 ODC1) involved in UC/polyamine synthesis. Significantly, ODC1 inhibitor attenuated the growth of patient derived xenografts (PDX) that sustain high LVBU levels. Taken together, elevated LVBU can regulate BCL6-p53 signaling axis for systemic UC/polyamine synthesis reprogramming and confers a predilection toward CRC development. Our data demonstrates that further drug development and clinical evaluation of inhibiting UC/polyamine synthesis are warranted for CRC patients with high expression of LVBU.	[Meng, Xiangqi; Peng, Jingxuan; Xie, Xiaoshan; Yu, Fenghai; Wang, Wencong; Pan, Qihao; Jin, Huilin; Huang, Xiaoling; Feng, Dianying; Liu, Qingxin; Fang, Lekun; Lee, Mong-Hong] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Peoples R China; [Meng, Xiangqi; Peng, Jingxuan; Xie, Xiaoshan; Yu, Fenghai; Wang, Wencong; Pan, Qihao; Jin, Huilin; Huang, Xiaoling; Feng, Dianying; Liu, Qingxin; Fang, Lekun; Lee, Mong-Hong] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Res Inst Gastroenterol, Guangzhou 510655, Peoples R China; [Yu, Hongyan] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Dept Clin Biol Resource Bank, Guangzhou 510623, Peoples R China; [Li, Shengrong] Chengdu Univ Tradit Chinese Med, Pharm Coll, Chengdu 611137, Peoples R China; [Fang, Lekun] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510655, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Chengdu University of Traditional Chinese Medicine; Sun Yat Sen University	Meng, XQ; Fang, LK; Lee, MH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Peoples R China.; Meng, XQ; Fang, LK; Lee, MH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Res Inst Gastroenterol, Guangzhou 510655, Peoples R China.; Fang, LK (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510655, Peoples R China.	mengxq3@mail.sysu.edu.cn; fanglk3@mail.sysu.edu.cn; limh33@mail.sysu.edu.cn		Meng, Xiangqi/0000-0002-6407-6122	National Key R&D Program of China [2020YFA0803300]; National Natural Science Foundation of China [81630072, 81702533]; Natural Science Foundation of Guangdong Province [2019A1515010099, 2021A1515012081]; Shenzhen Municipal Government of China [KQTD20170810160226082]; Fundamental Research Funds for the Central Universities [19ykpy07]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Municipal Government of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	The authors would like to thank Xinhai Zhu for performing LC-MS/MS analysis, Xiangli Li, Junyan Feng and Manqi Meng for their technical help and Lishuo Shi for statistical analysis. This work was supported by the National Key R&D Program of China (2020YFA0803300), the National Natural Science Foundation of China (81630072 and 81702533), the Natural Science Foundation of Guangdong Province (2019A1515010099 and 2021A1515012081), Shenzhen Municipal Government of China (KQTD20170810160226082), and the Fundamental Research Funds for the Central Universities (19ykpy07).	Agostini M, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0247-6; Bachmann AS, 2018, J BIOL CHEM, V293, P18757, DOI 10.1074/jbc.TM118.003336; Bassiri H, 2015, TRANSL PEDIATR, V4, P226, DOI 10.3978/j.issn.2224-4336.2015.04.06; Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; Cardenas MG, 2017, CLIN CANCER RES, V23, P885, DOI 10.1158/1078-0432.CCR-16-2071; Cardenas MG, 2016, J CLIN INVEST, V126, P3351, DOI 10.1172/JCI85795; Casero RA, 2018, NAT REV CANCER, V18, P681, DOI 10.1038/s41568-018-0050-3; Choi HH, 2020, ADV SCI, V7, DOI 10.1002/advs.202000681; Colgan SP, 2020, ANNU REV IMMUNOL, V38, P341, DOI 10.1146/annurev-immunol-100819-121537; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Dragomir MP, 2020, GUT, V69, P748, DOI 10.1136/gutjnl-2019-318279; Fan Q, 2016, PROTEIN CELL, V7, P899, DOI 10.1007/s13238-016-0316-z; Gonzalez FJ, 2018, NAT REV ENDOCRINOL, V15, P21, DOI 10.1038/s41574-018-0096-z; He W, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0014-1; Hilton LK, 2019, BLOOD, V134, P1528, DOI 10.1182/blood.2019002600; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Kerres N, 2017, CELL REP, V20, P2860, DOI 10.1016/j.celrep.2017.08.081; Keshet R, 2018, NAT REV CANCER, V18, P634, DOI 10.1038/s41568-018-0054-z; Kocarnik JM, 2015, GASTROENTEROL REP, V3, P269, DOI 10.1093/gastro/gov046; Lee JS, 2018, CELL, V174, P1559, DOI 10.1016/j.cell.2018.07.019; Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y; Leeman-Neill RJ, 2018, EXPERT OPIN THER TAR, V22, P143, DOI 10.1080/14728222.2018.1420782; Li L, 2019, NATURE, V567, P253, DOI 10.1038/s41586-019-0996-7; Phan L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8530; Lucien F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15884; Matsumoto S, 2019, J HUM GENET, V64, P833, DOI 10.1038/s10038-019-0614-4; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Seiffert M, 2020, HAEMATOLOGICA, V105, P856, DOI 10.3324/haematol.2019.246330; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Slabicki M, 2020, NATURE, V588, P164, DOI 10.1038/s41586-020-2925-1; Sun NH, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00210-3; Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1; Taylor CT, 2017, NAT REV IMMUNOL, V17, P774, DOI 10.1038/nri.2017.103; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wang H, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0680-1; Welponer H, 2020, J CANCER, V11, P1446, DOI 10.7150/jca.33831; Willson JA, 2022, BLOOD, V139, P281, DOI 10.1182/blood.2021011010; Xiong SW, 2019, ONCOL REP, V42, P1635, DOI 10.3892/or.2019.7280; Xu L, 2017, P NATL ACAD SCI USA, V114, P3981, DOI 10.1073/pnas.1609758114; Zheng YL, 2019, THERANOSTICS, V9, P796, DOI 10.7150/thno.28992; Zou SM, 2018, GASTROENTEROL REP, V6, P1, DOI 10.1093/gastro/gox031	43	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4231	4243		10.1038/s41388-022-02413-8	http://dx.doi.org/10.1038/s41388-022-02413-8		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35906392	hybrid, Green Published			2022-12-17	WOS:000832824600001
J	Zheng, QW; Ni, QZ; Zhu, B; Liang, X; Ma, N; Wang, YK; Xu, S; Cao, HJ; Xia, J; Zhang, FK; Zhang, EB; Qiu, XS; Ding, XF; Qiu, L; Zhang, XL; Dong, ZH; Li, ZG; Zhang, XL; Xie, D; Li, JJ				Zheng, Qian-Wen; Ni, Qian-Zhi; Zhu, Bing; Liang, Xin; Ma, Ning; Wang, Yi-Kang; Xu, Sheng; Cao, Hui-Jun; Xia, Ji; Zhang, Feng-Kun; Zhang, Er-Bin; Qiu, Xiao-Song; Ding, Xu-Fen; Qiu, Lin; Zhang, Xi-Lin; Dong, Zhao-Hui; Li, Zhi-Gang; Zhang, Xue-Li; Xie, Dong; Li, Jing-Jing			PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3	ONCOGENE			English	Article							MUTATIONS; PHENOTYPE; RECEPTOR; BMPR2	Lung cancer is the most common malignancy and the leading cause of cancer death worldwide, and lung adenocarcinoma (LUAD) is the most prevalent subtype. Considering the emergence of resistance to therapies, it is urgent to develop more effective therapies to improve the prognosis. Here we reported that pancreatic progenitor cell differentiation and proliferation factor (PPDPF) deficiency inhibited LUAD development both in vitro and in vivo. Mechanistically, PPDPF induces hyperactive STAT3 by interfering STAT3-PTPN1 interaction. Activated STAT3 promoted BMPR2 transcription, which further inhibited apoptosis. Moreover, PPDPF reduced NK cell infiltration and activation to develop an immunosuppressive microenvironment, which was also mediated by STAT3. Furthermore, we identified that the expression of PPDPF was positively correlated with the malignant features of LUAD, as well as BMPR2 and p-STAT3 level in clinical samples. Therefore, our study suggests that PPDPF positively regulates BMPR2 expression and facilitates immune escape via regulating STAT3 activity, providing a potential therapy target for LUAD.	[Zheng, Qian-Wen; Ni, Qian-Zhi; Zhu, Bing; Liang, Xin; Wang, Yi-Kang; Xu, Sheng; Cao, Hui-Jun; Xia, Ji; Zhang, Feng-Kun; Zhang, Er-Bin; Qiu, Xiao-Song; Ding, Xu-Fen; Qiu, Lin; Xie, Dong; Li, Jing-Jing] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China; [Zheng, Qian-Wen; Qiu, Xiao-Song; Xie, Dong] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Ma, Ning; Li, Zhi-Gang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Sect Esophageal Surg, Shanghai 200030, Peoples R China; [Zhang, Xi-Lin] Huzhou Univ, Affiliated Hosp 1, Dept Cent Lab, Huzhou 313000, Zhejiang, Peoples R China; [Dong, Zhao-Hui] Huzhou Univ, Affiliated Hosp 1, Dept Crit Care Med, Huzhou 313000, Zhejiang, Peoples R China; [Zhang, Xue-Li] Shanghai Fengxian Cent Hosp, Dept Gen Surg, Shanghai 201499, Peoples R China; [Xie, Dong] China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; ShanghaiTech University; Shanghai Jiao Tong University; Huzhou University; Huzhou University	Xie, D; Li, JJ (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China.; Xie, D (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.; Zhang, XL (corresponding author), Shanghai Fengxian Cent Hosp, Dept Gen Surg, Shanghai 201499, Peoples R China.; Xie, D (corresponding author), China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China.	tide7@163.com; dxie@sibs.ac.cn; lejing_1996@163.com	Cao, Huijun/HDM-1523-2022	, Ning/0000-0003-1825-8854	National Natural Science Foundation of China [82172950, 81972757, 81730083, 82030084]; Youth Innovation Promotion Association of Chinese Academy of Sciences [2017324]; Sanofi-SIBS 2018 Young Faculty Award	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences; Sanofi-SIBS 2018 Young Faculty Award	This work was supported by the National Natural Science Foundation of China (82172950, 81972757), Youth Innovation Promotion Association of Chinese Academy of Sciences grant (2017324) and Sanofi-SIBS 2018 Young Faculty Award to J-JL; and the National Natural Science Foundation of China (81730083 and 82030084) to DX.	Aktas E, 2009, CELL IMMUNOL, V254, P149, DOI 10.1016/j.cellimm.2008.08.007; Augeri DJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0511-9; Bedel R, 2011, CANCER RES, V71, P1615, DOI 10.1158/0008-5472.CAN-09-4540; Beppu H, 2008, ONCOGENE, V27, P1063, DOI 10.1038/sj.onc.1210720; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bruno A, 2013, NEOPLASIA, V15, P133, DOI 10.1593/neo.121758; Cacalano NA, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00128; Degos C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00877; Galon J, 2020, IMMUNITY, V52, P55, DOI 10.1016/j.immuni.2019.12.018; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Jiang Z, 2008, PLOS BIOL, V6, P2450, DOI 10.1371/journal.pbio.0060293; Jiao G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.540; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Liu GH, 2019, BIOCHEM BIOPH RES CO, V513, P207, DOI 10.1016/j.bbrc.2019.03.213; Liu MY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05095; Liu ZP, 2009, BBA-MOL CELL RES, V1793, P1819, DOI 10.1016/j.bbamcr.2009.09.012; Lund IK, 2005, J MOL ENDOCRINOL, V34, P339, DOI 10.1677/jme.1.01694; Ma N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23285-8; Mao ZF, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014552; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nakamura T, 2010, MOL CELL, V39, P184, DOI 10.1016/j.molcel.2010.07.002; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Peng CW, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1060-2; Peters S, 2019, ANN ONCOL, V30, P884, DOI 10.1093/annonc/mdz109; Pickup MW, 2015, MOL ONCOL, V9, P179, DOI 10.1016/j.molonc.2014.08.004; Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Schuijs MJ, 2020, NAT IMMUNOL, V21, P998, DOI 10.1038/s41590-020-0745-y; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Soon E, 2015, AM J RESP CRIT CARE, V192, P859, DOI 10.1164/rccm.201408-1509OC; Sui QJ, 2014, J IMMUNOL, V193, P2016, DOI 10.4049/jimmunol.1302389; Sun XX, 2013, MOL CANCER THER, V12, P2885, DOI 10.1158/1535-7163.MCT-12-1087; Tkach M, 2012, J IMMUNOL, V189, P1162, DOI 10.4049/jimmunol.1102538; Tulotta C, 2019, CLIN CANCER RES, V25, P2769, DOI 10.1158/1078-0432.CCR-18-2202; Wang ZD, 2021, LEUKEMIA LYMPHOMA, V62, P937, DOI 10.1080/10428194.2020.1849680; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Xiao YJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.669603; Zeng FW, 2012, HYBRIDOMA, V31, P209, DOI 10.1089/hyb.2011.0115	41	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4244	4256		10.1038/s41388-022-02418-3	http://dx.doi.org/10.1038/s41388-022-02418-3		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35906391				2022-12-17	WOS:000832824600002
J	Bell, ES; Shah, P; Zuela-Sopilniak, N; Kim, D; Varlet, AA; Morival, JLP; McGregor, AL; Isermann, P; Davidson, PM; Elacqua, JJ; Lakins, JN; Vahdat, L; Weaver, VM; Smolka, MB; Span, PN; Lammerding, J				Bell, Emily S.; Shah, Pragya; Zuela-Sopilniak, Noam; Kim, Dongsung; Varlet, Alice-Anais; Morival, Julien L. P.; McGregor, Alexandra L.; Isermann, Philipp; Davidson, Patricia M.; Elacqua, Joshua J.; Lakins, Jonathan N.; Vahdat, Linda; Weaver, Valerie M.; Smolka, Marcus B.; Span, Paul N.; Lammerding, Jan			Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer	ONCOGENE			English	Article							A-TYPE LAMINS; NUCLEAR-ENVELOPE; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; CHROMATIN ORGANIZATION; MECHANICAL-PROPERTIES; AKT PHOSPHORYLATION; MESSENGER-RNA; TUMOR-CELLS; EXPRESSION	Aberrations in nuclear size and shape are commonly used to identify cancerous tissue. However, it remains unclear whether the disturbed nuclear structure directly contributes to the cancer pathology or is merely a consequence of other events occurring during tumorigenesis. Here, we show that highly invasive and proliferative breast cancer cells frequently exhibit Akt-driven lower expression of the nuclear envelope proteins lamin A/C, leading to increased nuclear deformability that permits enhanced cell migration through confined environments that mimic interstitial spaces encountered during metastasis. Importantly, increasing lamin A/C expression in highly invasive breast cancer cells reflected gene expression changes characteristic of human breast tumors with higher LMNA expression, and specifically affected pathways related to cell-ECM interactions, cell metabolism, and PI3K/Akt signaling. Further supporting an important role of lamins in breast cancer metastasis, analysis of lamin levels in human breast tumors revealed a significant association between lower lamin A levels, Akt signaling, and decreased disease-free survival. These findings suggest that downregulation of lamin A/C in breast cancer cells may influence both cellular physical properties and biochemical signaling to promote metastatic progression.	[Bell, Emily S.; Shah, Pragya; Zuela-Sopilniak, Noam; Kim, Dongsung; Varlet, Alice-Anais; Morival, Julien L. P.; McGregor, Alexandra L.; Isermann, Philipp; Davidson, Patricia M.; Elacqua, Joshua J.; Smolka, Marcus B.; Lammerding, Jan] Cornell Univ, Weill Inst Cell & Mol Biol, Ithaca, NY 14850 USA; [McGregor, Alexandra L.; Lammerding, Jan] Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14850 USA; [Lakins, Jonathan N.; Weaver, Valerie M.] Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, San Francisco, CA USA; [Vahdat, Linda] Weill Cornell Med, Dept Med, New York, NY USA; [Weaver, Valerie M.] Univ Calif San Francisco, Helen Diller Canc Ctr, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Weaver, Valerie M.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA; [Span, Paul N.] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol Radiotherapy & Oncolmmunol Lab, Nijmegen, Netherlands; [Bell, Emily S.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Cornell University; Cornell University; University of California System; University of California San Francisco; Cornell University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Radboud University Nijmegen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Lammerding, J (corresponding author), Cornell Univ, Weill Inst Cell & Mol Biol, Ithaca, NY 14850 USA.; Lammerding, J (corresponding author), Cornell Univ, Nancy E & Peter C Meinig Sch Biomed Engn, Ithaca, NY 14850 USA.	jan.lammerding@cornell.edu	Span, Paul/G-4710-2012	Span, Paul/0000-0002-1930-6638; Varlet, Alice-Anais/0000-0002-1670-4884; Morival, Julien/0000-0003-1252-025X	National Institutes of Health [R01 HL082792, R01 GM137605, U54 CA210184, U54 CA193461, R35 GM141159, R01 GM123018]; Department of Defense Breast Cancer Research Program [BC150580]; National Science Foundation [CBET-1254846, DGE-1144153, NNCI-2025233]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); National Science Foundation(National Science Foundation (NSF))	This work was supported by funding from the National Institutes of Health (R01 HL082792, R01 GM137605, U54 CA210184, and U54 CA193461 to JL, R35 GM141159 and R01 GM123018 to MBS), the Department of Defense Breast Cancer Research Program (Breakthrough Award BC150580 to JL), and the National Science Foundation (CAREER Award CBET-1254846 to JL and Graduate Research Fellowship DGE-1144153 to ALM). This work was performed in part at the Cornell NanoScale Science & Technology Facility (CNF), a member of the National Nanotechnology Coordinated Infrastructure NNCI), which is supported by the National Science Foundation (Grant NNCI-2025233).	Agrelo R, 2005, J CLIN ONCOL, V23, P3940, DOI 10.1200/JCO.2005.11.650; Alhudiri IM, 2019, BREAST CANCER RES TR, V174, P661, DOI 10.1007/s10549-018-05092-w; Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Aljada A, 2016, CELL ONCOL, V39, P161, DOI 10.1007/s13402-015-0265-1; Andres V, 2009, J CELL BIOL, V187, P945, DOI 10.1083/jcb.200904124; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barati MT, 2006, J PROTEOME RES, V5, P1636, DOI 10.1021/pr0502469; de Oliveira FMB, 2018, METHODS MOL BIOL, V1672, P645, DOI 10.1007/978-1-4939-7306-4_42; Batulan Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00285; Bell ES, 2016, EUR J CELL BIOL, V95, P449, DOI 10.1016/j.ejcb.2016.06.007; Belt EJT, 2011, EUR J CANCER, V47, P1837, DOI 10.1016/j.ejca.2011.04.025; Bertacchini J, 2013, FASEB J, V27, P2145, DOI 10.1096/fj.12-218214; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Bussolati G, 2014, ADV EXP MED BIOL, V773, P101, DOI 10.1007/978-1-4899-8032-8_5; Bustin M, 2016, SCIENCE, V352, DOI 10.1126/science.aad6933; Buxboim A, 2014, CURR BIOL, V24, P1909, DOI 10.1016/j.cub.2014.07.001; Caille N, 2002, J BIOMECH, V35, P177, DOI 10.1016/S0021-9290(01)00201-9; Capo-chichi Callinice D, 2011, Chin J Cancer, V30, P415; Cenni V, 2008, J PROTEOME RES, V7, P4727, DOI 10.1021/pr800262g; Cho S, 2019, DEV CELL, V49, P920, DOI 10.1016/j.devcel.2019.04.020; Cho S, 2017, J CELL BIOL, V216, P305, DOI 10.1083/jcb.201610042; Collas P, 1999, J CELL SCI, V112, P977; Concin N, 2003, BREAST CANCER RES TR, V79, P37, DOI 10.1023/A:1023351717408; Condor M, 2019, BIOPHYS J, V116, P1305, DOI 10.1016/j.bpj.2019.02.029; Coradeghini R, 2006, ONCOL REP, V15, P609; Davidson PM, 2019, LAB CHIP, V19, P3652, DOI 10.1039/c9lc00444k; Davidson PM, 2015, INTEGR BIOL-UK, V7, P1534, DOI 10.1039/c5ib00200a; Davidson PM, 2014, CELL MOL BIOENG, V7, P293, DOI 10.1007/s12195-014-0342-y; de las Heras JI, 2014, ADV EXP MED BIOL, V773, P5, DOI 10.1007/978-1-4899-8032-8_1; de Leeuw R, 2018, TRENDS CELL BIOL, V28, P34, DOI 10.1016/j.tcb.2017.08.004; de Oliveira FMB, 2015, MOL CELL, V57, P1124, DOI 10.1016/j.molcel.2015.01.043; Denais C, 2014, ADV EXP MED BIOL, V773, P435, DOI 10.1007/978-1-4899-8032-8_20; Denais CM, 2016, SCIENCE, V352, P353, DOI 10.1126/science.aad7297; DEXTER DL, 1978, CANCER RES, V38, P3174; DOERSCHUK CM, 1993, J APPL PHYSIOL, V74, P3040, DOI 10.1152/jappl.1993.74.6.3040; Dubik N, 2020, CANCERS, V12, DOI 10.3390/cancers12123688; Earle AJ, 2020, NAT MATER, V19, P464, DOI 10.1038/s41563-019-0563-5; Fong LG, 2006, J CLIN INVEST, V116, P743, DOI 10.1172/JCI27125; Frock RL, 2006, GENE DEV, V20, P486, DOI 10.1101/gad.1364906; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gong GH, 2015, PATHOL RES PRACT, V211, P175, DOI 10.1016/j.prp.2014.11.008; Gonzalez-Cruz RD, 2018, CELL MOL BIOENG, V11, P131, DOI 10.1007/s12195-018-0518-y; Gonzalo S, 2014, ADV EXP MED BIOL, V773, P377, DOI 10.1007/978-1-4899-8032-8_17; Gruenbaum Y, 2015, ANNU REV BIOCHEM, V84, P131, DOI 10.1146/annurev-biochem-060614-034115; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guz N, 2014, BIOPHYS J, V107, P564, DOI 10.1016/j.bpj.2014.06.033; Han EKH, 2007, ONCOGENE, V26, P5655, DOI 10.1038/sj.onc.1210343; Hanson PI, 2008, J CELL BIOL, V180, P389, DOI 10.1083/jcb.200707031; Harada T, 2014, J CELL BIOL, V204, P669, DOI 10.1083/jcb.201308029; Hetzer MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000539; Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568-019-0216-7; Irianto J, 2016, MOL BIOL CELL, V27, P4011, DOI 10.1091/mbc.E16-06-0428; Irianto J, 2016, CELL MOL BIOENG, V9, P258, DOI 10.1007/s12195-016-0437-8; Isermann P, 2013, CURR BIOL, V23, pR1113, DOI 10.1016/j.cub.2013.11.009; Ivorra' C, 2006, GENE DEV, V20, P307, DOI 10.1101/gad.349506; Johnson BR, 2004, P NATL ACAD SCI USA, V101, P9677, DOI 10.1073/pnas.0403250101; Kennedy BK, 2014, ADV EXP MED BIOL, V773, P127, DOI 10.1007/978-1-4899-8032-8_6; Kim D, 2018, NUCLEIC ACIDS RES, V46, P8311, DOI 10.1093/nar/gky625; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lammerding J, 2006, J BIOL CHEM, V281, P25768, DOI 10.1074/jbc.M513511200; Lautscham LA, 2015, BIOPHYS J, V109, P900, DOI 10.1016/j.bpj.2015.07.025; Lee H, 2015, EXP BIOL MED, V240, P1543, DOI 10.1177/1535370215583799; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Marmiroli S, 2009, J CELL PHYSIOL, V220, P553, DOI 10.1002/jcp.21807; Matsumoto A, 2015, CANCER MED-US, V4, P1547, DOI 10.1002/cam4.495; Maurer M, 2019, ANNU REV BIOMED ENG, V21, P443, DOI 10.1146/annurev-bioeng-060418-052139; Maynard S, 2019, NUCLEIC ACIDS RES, V47, P11709, DOI 10.1093/nar/gkz912; McGregor AL, 2016, CURR OPIN CELL BIOL, V40, P32, DOI 10.1016/j.ceb.2016.01.011; Mekhdjian AH, 2017, MOL BIOL CELL, V28, P1467, DOI 10.1091/mbc.E16-09-0654; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Mitchell MJ, 2015, AM J PHYSIOL-CELL PH, V309, pC736, DOI 10.1152/ajpcell.00050.2015; Mukherjee A, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008300; Mymrikov EV, 2011, PHYSIOL REV, V91, P1123, DOI 10.1152/physrev.00023.2010; Naeem AS, 2015, CELL DEATH DIFFER, V22, P2123, DOI 10.1038/cdd.2015.62; Nagelkerke A, 2011, RADIOTHER ONCOL, V101, P39, DOI 10.1016/j.radonc.2011.07.009; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Okumura K, 2004, BIOCHEM BIOPH RES CO, V320, P487, DOI 10.1016/j.bbrc.2004.05.191; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Ortega MA, 2020, J ONCOL, V2020, DOI 10.1155/2020/9258396; Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Pombo A, 2015, NAT REV MOL CELL BIO, V16, P245, DOI 10.1038/nrm3965; R Core Team, 2022, R LANG ENV STAT COMP; Raab M, 2016, SCIENCE, V352, P359, DOI 10.1126/science.aad7611; Reddy KL, 2013, SEMIN CANCER BIOL, V23, P109, DOI 10.1016/j.semcancer.2012.12.001; Redwood AB, 2011, CELL CYCLE, V10, P2549, DOI 10.4161/cc.10.15.16531; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Roncato F, 2021, CANCERS, V13, DOI 10.3390/cancers13102383; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Saleh T, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12030609; Schape J, 2009, BIOPHYS J, V96, P4319, DOI 10.1016/j.bpj.2009.02.048; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schreiber KH, 2013, CELL, V152, P1365, DOI 10.1016/j.cell.2013.02.015; Shah P, 2021, CURR BIOL, V31, P753, DOI 10.1016/j.cub.2020.11.037; Shimi T, 2008, GENE DEV, V22, P3409, DOI 10.1101/gad.1735208; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stephens AD, 2018, MOL BIOL CELL, V29, P220, DOI 10.1091/mbc.E17-06-0410; Stephens AD, 2017, MOL BIOL CELL, V28, P1984, DOI 10.1091/mbc.E16-09-0653; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; Stoitzner P, 2002, J INVEST DERMATOL, V118, P117, DOI 10.1046/j.0022-202x.2001.01631.x; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tseng Y, 2004, J CELL SCI, V117, P2159, DOI 10.1242/jcs.01073; Van Berlo JH, 2005, HUM MOL GENET, V14, P2839, DOI 10.1093/hmg/ddi316; Vargas JD, 2012, NUCLEUS-PHILA, V3, P88, DOI 10.4161/nucl.18954; Venables RS, 2001, BRIT J CANCER, V84, P512, DOI 10.1054/bjoc.2000.1632; Wang X, 2018, J CELL SCI, V131, DOI 10.1242/jcs.209627; Wazir U, 2013, CELL MOL BIOL LETT, V18, P595, DOI 10.2478/s11658-013-0109-9; Weigelin Bettina, 2012, Intravital, V1, P32, DOI 10.4161/intv.21223; Wennemers M, 2013, INT J BIOL MARKER, V28, P151, DOI [10.5301/JBM.5000008, 10.5301/jbm.5000008]; Willis ND, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002988; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wong XR, 2020, ANNU REV GENOM HUM G, V21, P263, DOI 10.1146/annurev-genom-121219-083616; Wu ZR, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-8; Zwerger M, 2013, HUM MOL GENET, V22, P2335, DOI 10.1093/hmg/ddt079	125	0	0	12	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4211	4230		10.1038/s41388-022-02420-9	http://dx.doi.org/10.1038/s41388-022-02420-9		JUL 2022	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35896617	Green Submitted			2022-12-17	WOS:000830954900001
J	Dou, CW; Zhou, ZY; Xu, QR; Liu, ZK; Zeng, YQ; Wang, YF; Li, Q; Wang, L; Yang, W; Liu, QG; Tu, KS				Dou, Changwei; Zhou, Zhenyu; Xu, Qiuran; Liu, Zhikui; Zeng, Yuqun; Wang, Yufeng; Li, Qing; Wang, Liang; Yang, Wei; Liu, Qingguang; Tu, Kangsheng			Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway (vol 38, pg 1239, 2019)	ONCOGENE			English	Correction												liuqingguang@vip.sina.com; tks0912@foxmail.com						Dou CW, 2019, ONCOGENE, V38, P1239, DOI 10.1038/s41388-018-0505-8	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4330	4332		10.1038/s41388-022-02421-8	http://dx.doi.org/10.1038/s41388-022-02421-8		JUL 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35902762	Bronze			2022-12-17	WOS:000832488900001
J	Dong, PP; Cai, ZQ; Li, BF; Zhu, YQ; Chan, AKY; Chiang, MWL; Au, CH; Sung, WK; Cheung, TT; Lo, CM; Man, K; Lee, NP				Dong, Pingping; Cai, Ziqing; Li, Bingfeng; Zhu, Yueqin; Chan, Alice K. Y.; Chiang, Michael W. L.; Au, Chun Hang; Sung, Wing Kin; Cheung, Tan To; Lo, Chung Mau; Man, Kwan; Lee, Nikki P.			HFE promotes mitotic cell division through recruitment of cytokinetic abscission machinery in hepatocellular carcinoma	ONCOGENE			English	Article								HFE (Hemochromatosis) is a conventional iron level regulator and its loss of function due to gene mutations increases the risk of cancers including hepatocellular carcinoma (HCC). Likewise, studies focusing on HFE overexpression in cancers are all limited to linking up these events as a consequence of iron level deregulation. No study has explored any iron unrelated role of HFE in cancers. Here, we first reported HFE as an oncogene in HCC and its undescribed function on promoting abscission in cytokinesis during mitotic cell division, independent of its iron-regulating ability. Clinical analyses revealed HFE upregulation in tumors linking to large tumor size and poor prognosis. Functionally and mechanistically, HFE promoted cytokinetic abscission via facilitating ESCRT abscission machinery recruitment to the abscission site through signaling a novel HFE/ALK3/Smads/LIF/Hippo/YAP/YY1/KIF13A axis. Pharmacological blockage of HFE signaling axis impeded tumor phenotypes in vitro and in vivo. Our data on HFE-driven HCC unveiled a new mechanism utilized by cancer cells to propel rapid cell division. This study also laid the groundwork for tumor intolerable therapeutics development given the high cytokinetic dependency of cancer cells and their vulnerability to cytokinetic blockage.	[Dong, Pingping; Cai, Ziqing; Li, Bingfeng; Zhu, Yueqin; Cheung, Tan To; Lo, Chung Mau; Man, Kwan; Lee, Nikki P.] Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Dong, Pingping] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiat Oncol, Hangzhou, Peoples R China; [Chan, Alice K. Y.; Chiang, Michael W. L.] City Univ Hong Kong, Dept Chem, Hong Kong, Peoples R China; [Chan, Alice K. Y.] Po Leung Kuk Tong Nai Kan Jr Secondary Coll, Hong Kong, Peoples R China; [Au, Chun Hang; Sung, Wing Kin] Hong Kong Genome Inst, Hong Kong, Peoples R China; [Sung, Wing Kin] Natl Univ Singapore, Sch Comp, Singapore, Singapore; [Sung, Wing Kin] Genome Inst Singapore, Computat & Syst Biol, Singapore, Singapore; [Lee, Nikki P.] Adv Biomed Instrumentat Ctr, Hong Kong Sci Pk, Hong Kong, Peoples R China	University of Hong Kong; Zhejiang University; City University of Hong Kong; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Man, K; Lee, NP (corresponding author), Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.; Lee, NP (corresponding author), Adv Biomed Instrumentat Ctr, Hong Kong Sci Pk, Hong Kong, Peoples R China.	kwanman@hku.hk; nikkilee@hku.hk		Sung, Wing-Kin/0000-0001-7806-7086; Chiang, Michael W. L./0000-0001-7661-5560	Theme-based Research Scheme of the Research Grants Council, Hong Kong [T42-103/16-N, T12-703/19-R]; Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government	Theme-based Research Scheme of the Research Grants Council, Hong Kong; Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government	This study was financially supported by Theme-based Research Scheme (T42-103/16-N and T12-703/19-R) of the Research Grants Council, Hong Kong and the Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government.	Barton JC, 2015, GENE, V574, P179, DOI 10.1016/j.gene.2015.10.009; Bui DA, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaa9227; D'Avino PP, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a015834; Dong FY, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108856; Donne R, 2020, NAT REV GASTRO HEPAT, V17, P391, DOI 10.1038/s41575-020-0284-x; Fan YH, 2021, INT J ONCOL, V58, DOI 10.3892/ijo.2021.5205; Fededa JP, 2012, NAT CELL BIOL, V14, P440, DOI 10.1038/ncb2482; Feder J N, 2003, J Hepatol, V38, P704; Henriques AC, 2019, CANCER LETT, V440, P64, DOI 10.1016/j.canlet.2018.10.005; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Hoxha S, 2020, CANCER RES, V80, P2512, DOI 10.1158/0008-5472.CAN-19-2415; Josson S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068366; Lenarduzzi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074075; Lens SMA, 2019, NAT REV CANCER, V19, P32, DOI 10.1038/s41568-018-0084-6; Liu XR, 2018, CANCER SCI, V109, P3450, DOI 10.1111/cas.13794; Lu MQ, 2018, IUBMB LIFE, V70, P328, DOI 10.1002/iub.1726; Maugeri-Sacca M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011; Muckenthaler MU, 2017, CELL, V168, P344, DOI 10.1016/j.cell.2016.12.034; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Poli M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00086; Reuben A, 2017, IMMUN INFLAMM DIS, V5, P218, DOI 10.1002/iid3.158; Sagona AP, 2010, NAT CELL BIOL, V12, P362, DOI 10.1038/ncb2036; Shen HY, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106222; Sun XT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1987-1; Tang H, 2019, DIGEST LIVER DIS, V51, P1314, DOI 10.1016/j.dld.2019.02.012; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; Verheul TCJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.592164; Wang MT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11044-9; Weston Cody, 2014, Transl Oncogenomics, V6, P1, DOI 10.4137/TOG.S19064; Xing TH, 2018, EXP THER MED, V15, P4932, DOI 10.3892/etm.2018.6075; Xu HD, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.23; Yang T, 2013, CANCER SCI, V104, P552, DOI 10.1111/cas.12128; Yang XM, 2018, GASTROENTEROLOGY, V155, P1233, DOI 10.1053/j.gastro.2018.07.010; Zhang SY, 2018, GASTROENTEROLOGY, V154, P1421, DOI 10.1053/j.gastro.2017.12.013	34	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4185	4199		10.1038/s41388-022-02419-2	http://dx.doi.org/10.1038/s41388-022-02419-2		JUL 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35882980				2022-12-17	WOS:000830346700002
J	Wan, HX; Gao, NN; Lu, W; Lu, C; Chen, J; Wang, YM; Dong, H				Wan, Hanxing; Gao, Nannan; Lu, Wei; Lu, Cheng; Chen, Jun; Wang, Yimin; Dong, Hui			NCX1 coupled with TRPC1 to promote gastric cancer via Ca2+/AKT/beta-catenin pathway	ONCOGENE			English	Article							CALCIUM-SENSING RECEPTOR; NA+/CA2+ EXCHANGER 1; EXPRESSION	Plasma membrane Na+/Ca2+ exchanger 1 (NCX1) is a bidirectional ion transporter to operate in Ca2+ entry or exit modes, and TRPC1 is Ca2+-permeable channel. Both NCX1 and TRPC1 play critical roles in maintaining cytosolic free Ca2+ ([Ca2+](cyt)) homeostasis in mammalian cells. Although either TRPC1 channel or Ca2+ entry mode of NCX1 is implicated in some tumorigenesis, it has not been explored if a coordination of NCX1 and TRPC1 involves in the pathogenesis of H. pylori-associated human gastric cancer (GC). Here we found the protein expression of NCX1 was significantly enhanced in human GC specimens, which correlated with tumor progression and poor survival in GC patients. TRPC1 and NCX1 were parallelly enhanced, co-localized and bound in human GC cells. By a functional coupling, TRPC1 drives NCX1 to the Ca2+ entry mode, raising [Ca2+](cyt) in GC cells. Moreover, CaCl2, H. pylori and their virulence factors all enhanced expressions and activities of NCX1 and TRPC1, and evoked aberrant Ca2+ entry to promote proliferation, migration, and invasion of GC cells through AKT/beta-catenin pathway. Tumor growth and metastasis also depended on the enhanced expression of NCX1 in subcutaneously xenografted GC mouse model. Overall, our findings indicate that TRPC1/NCX1 coupling may promote H. pylori-associated GC through the Ca2+/AKT/beta-catenin pathway. Since the Ca2+ exit mode and the Ca2+ entry mode of NCX1 play different roles under mostly physiological and pathological conditions respectively, targeting TRPC1/NCX1 coupling could be a novel strategy for selectively blocking Ca2+ entry mode to potentially treat digestive cancer with less side effect.	[Wan, Hanxing; Lu, Wei; Dong, Hui] Qingdao Univ, Sch Pharm, Dept Pharmacol, Med Coll, 1 Ningde Rd, Qingdao 266073, Peoples R China; [Wan, Hanxing; Gao, Nannan; Lu, Cheng; Chen, Jun] Army Med Univ, Xingiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China; [Wang, Yimin] First Hosp Qinhuangdao, Dept Gen Surg, Qinhuangdao, Hebei, Peoples R China; [Dong, Hui] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	Qingdao University; Army Medical University; University of California System; University of California San Diego	Dong, H (corresponding author), Qingdao Univ, Sch Pharm, Dept Pharmacol, Med Coll, 1 Ningde Rd, Qingdao 266073, Peoples R China.; Dong, H (corresponding author), Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.	h2dong@ucsd.edu		Gao, Nannan/0000-0003-1306-6749	National Natural Science Foundation of China [81972328, 81873544, 82103591]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	These studies were supported by research grants from the National Natural Science Foundation of China (No. 81972328 to HXW, No. 81873544 to HD, and No. 82103591 to NNG).	Berridge MJ, 2016, PHYSIOL REV, V96, P1261, DOI 10.1152/physrev.00006.2016; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai R, 2009, INT J CANCER, V125, P2281, DOI 10.1002/ijc.24551; Chen JL, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a035113; Chovancova B, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091257; Davis FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036923; Dong H, 2005, AM J PHYSIOL-GASTR L, V288, pG457, DOI 10.1152/ajpgi.00381.2004; DONG H, 2010, AM J PHYSIOL-CELL PH, V299; Dong H, 2019, ACTA PHYSIOL, V225, DOI 10.1111/apha.13223; du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI 10.1111/bph.15193; Elzamzamy OM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020388; Fujimoto Y, 2016, J PHARMACOL SCI, V132, P181, DOI 10.1016/j.jphs.2016.10.003; Gao NN, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01707-7; Ge PB, 2018, CELL BIOL INT, V42, P975, DOI 10.1002/cbin.10963; Ghanayem BI, 1987, GASTROENTEROLOGY, V92, P106, DOI 10.1016/0016-5085(87)90845-6; Harper AGS, 2016, ADV EXP MED BIOL, V898, P67, DOI 10.1007/978-3-319-26974-0_4; Hu HJ, 2019, BRIT J PHARMACOL, V176, P2691, DOI 10.1111/bph.14692; Iimuro M, 2013, ANTICANCER RES, V33, P3667; Joshi Smita S, 2021, CA Cancer J Clin, V71, P264, DOI 10.3322/caac.21657; Kemeny LV, 2013, AM J PHYSIOL-GASTR L, V305, pG552, DOI 10.1152/ajpgi.00394.2012; Li H, 2018, J CELL BIOCHEM, V119, P9997, DOI 10.1002/jcb.27329; LIU Z, 2022, INT J MOL SCI, V23; Long Y, 2013, ACTA PHARMACOL SIN, V34, P691, DOI 10.1038/aps.2013.4; Mahdi SHA, 2015, ARCH BIOCHEM BIOPHYS, V583, P18, DOI 10.1016/j.abb.2015.07.008; Marchi S, 2020, MOL CELL, V78, P1055, DOI 10.1016/j.molcel.2020.04.017; Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; Ottolia M, 2013, ADV EXP MED BIOL, V961, P49, DOI 10.1007/978-1-4614-4756-6_5; Patergnani S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218323; Rodrigues T, 2019, BIOCHEM PHARMACOL, V163, P357, DOI 10.1016/j.bcp.2019.02.032; Seo JH, 2011, GASTROENTEROLOGY, V141, P2064, DOI 10.1053/j.gastro.2011.08.048; Takenoue T, 2000, ANN ONCOL, V11, P273, DOI 10.1023/A:1008337913456; Tang B, 2019, ONCOGENE, V38, P3946, DOI 10.1038/s41388-019-0709-6; Tang B, 2016, CANCER LETT, V377, P44, DOI 10.1016/j.canlet.2016.04.027; TATSUTA M, 1990, CANCER RES, V50, P2095; Timmons JA, 2012, J GASTROINTEST SURG, V16, P1397, DOI 10.1007/s11605-012-1876-8; Wan HX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02562-x; Wang F, 2022, ONCOGENE, V41, P246, DOI 10.1038/s41388-021-02078-9; Wang HN, 2019, ONCOGENE, V38, P1489, DOI 10.1038/s41388-018-0532-5; Wen JX, 2016, ONCOTARGET, V7, P63816, DOI 10.18632/oncotarget.11695; Wessler S, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0171-4; Wong JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12648-1; Xie R, 2017, CANCER RES, V77, P6499, DOI 10.1158/0008-5472.CAN-17-0360; Xu JY, 2018, CANCER RES, V78, P2564, DOI 10.1158/0008-5472.CAN-17-2061; Xu JY, 2016, CARCINOGENESIS, V37, P290, DOI 10.1093/carcin/bgw004; Zhang FL, 2021, BRIT J PHARMACOL, V178, P346, DOI 10.1111/bph.15287; Zhang FL, 2019, BRIT J PHARMACOL, V176, P1700, DOI 10.1111/bph.14640; Zhang ZY, 2020, BIOCHEM BIOPH RES CO, V529, P85, DOI 10.1016/j.bbrc.2020.05.181; Zhao JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0629-4	50	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4169	4182		10.1038/s41388-022-02412-9	http://dx.doi.org/10.1038/s41388-022-02412-9		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35882979	hybrid, Green Submitted, Green Published			2022-12-17	WOS:000830346700001
J	Shen, ZJ; Gu, LK; Liu, YW; Wang, LF; Zhu, JW; Tang, SS; Wei, XY; Wang, JY; Zhang, SF; Wang, XY; Cheng, XD; Xie, X; Lu, WG				Shen, Zhangjin; Gu, Lingkai; Liu, Yuwan; Wang, Lingfang; Zhu, Jiawei; Tang, Sangsang; Wei, Xinyi; Wang, Jiaying; Zhang, Songfa; Wang, Xinyu; Cheng, Xiaodong; Xie, Xing; Lu, Weiguo			PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA	ONCOGENE			English	Article							ACTIVATING PROTEIN; CALCIUM; N6-METHYLADENOSINE; PROGRESSION; METABOLISM	Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA) is inactivated in some cancers, but its role in cancer metastasis remains unknown. Here, we found that PLAA was significantly downregulated in ovarian cancer highly metastatic cell lines and patients, and the low expression of PLAA was associated with poorer prognosis and high-risk clinicopathological features of patients. PLAA inhibited the migration and invasion of ovarian cancer cells and metastasis of transplanted tumor in the orthotopic xenograft mouse model. Meanwhile, PLAA inhibited metastasis of ovarian cancer by inhibiting transient receptor potential channel canonical 3 (TRPC3)-mediated the intracellular Ca2+ level. Mechanistically, PLAA inhibited methyltransferase-like 3 (METTL3) expression through the ubiquitin-mediated degradation, and METTL3 stabilized TRPC3 mRNA expression via N6-methyladenosine (m(6)A) modification. Our study verified the function and mechanism of the PLAA-METTL3-TRPC3 axis involved in ovarian cancer metastasis, with a view to providing a potential therapeutic approach for ovarian cancer.	[Shen, Zhangjin; Gu, Lingkai; Liu, Yuwan; Wang, Lingfang; Tang, Sangsang; Wei, Xinyi] Zhejiang Univ, Sch Med, Womens Hosp, Womens Reprod Hlth Lab Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China; [Zhu, Jiawei; Zhang, Songfa; Wang, Xinyu; Cheng, Xiaodong; Xie, Xing; Lu, Weiguo] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China; [Wang, Jiaying] Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Obstet & Gynecol, Beijing 100853, Peoples R China; [Wang, Xinyu; Cheng, Xiaodong; Lu, Weiguo] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China; [Wang, Xinyu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Hangzhou 310003, Zhejiang, Peoples R China; [Cheng, Xiaodong] Zhejiang Univ, Sch Med, Womens Hosp, Zhejiang Prov Key Lab Precis Diag & Therapy Major, Hangzhou 310006, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Chinese People's Liberation Army General Hospital; Zhejiang University; Zhejiang University; Zhejiang University	Lu, WG (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China.; Lu, WG (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China.	lbwg@zju.edu.cn	Lu, Wei/AAE-2921-2022	Lu, Wei/0000-0002-4150-8674	National Natural Science Foundation of China [82072856]; Key Research and Development Program of Zhejiang Province, China [2019C03010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Zhejiang Province, China	We thank our laboratory members and teachers for critical discussions. Thanks for the technical support by the core facilities, Zhejiang University School of Medicine. This work was supported by National Natural Science Foundation of China (Grant number: 82072856) and the Key Research and Development Program of Zhejiang Province, China (Grant number: 2019C03010).	Baljinnyam E, 2010, CANCER RES, V70, P5607, DOI 10.1158/0008-5472.CAN-10-0056; Beatty BG, 1999, GENOMICS, V62, P529, DOI 10.1006/geno.1999.5999; Bi XH, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00600-2; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Cortes-Guiral D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00326-6; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Goddard DH, 1998, DRUG NEWS PERSPECT, V11, P104, DOI 10.1358/dnp.1998.11.2.863682; Grasset EM, 2018, CANCER RES, V78, P5229, DOI 10.1158/0008-5472.CAN-18-0601; Han J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1036-9; Hsu KF, 2015, BRIT J CANCER, V113, P414, DOI 10.1038/bjc.2015.254; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jiang HN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067637; Jiang RB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3972534; Jiang XL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00450-x; Jin D, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01048-8; Kim JM, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.40; Koivisto AP, 2022, NAT REV DRUG DISCOV, V21, P41, DOI 10.1038/s41573-021-00268-4; Lee Y, 2020, TRENDS GENET, V36, P177, DOI 10.1016/j.tig.2019.12.007; Lin DC, 2021, CANCER LETT, V519, P211, DOI 10.1016/j.canlet.2021.07.038; Liu T, 2020, NUCLEIC ACIDS RES, V48, P3816, DOI 10.1093/nar/gkaa048; Moccia F, 2018, J CELL PHYSIOL, V233, P3901, DOI 10.1002/jcp.26152; Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18; Muller S, 2018, NUCLEIC ACIDS RES, V46, P6285, DOI 10.1093/nar/gky229; Mullally JE, 2006, MOL CELL BIOL, V26, P822, DOI 10.1128/MCB.26.3.822-830.2006; Numaga-Tomita T, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00056; Papadopoulos C, 2017, EMBO J, V36, P135, DOI 10.15252/embj.201695148; Pashkova N, 2010, MOL CELL, V40, P433, DOI 10.1016/j.molcel.2010.10.018; Peer E, 2017, CURR OPIN CHEM BIOL, V41, P93, DOI 10.1016/j.cbpa.2017.10.008; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Roberts JZ, 2022, CELL DEATH DIFFER, V29, P272, DOI 10.1038/s41418-021-00922-9; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Shen XM, 2021, J OVARIAN RES, V14, DOI 10.1186/s13048-021-00776-2; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sommerfeld L, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.633; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang HB, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107497; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zaccai TCF, 2017, BRAIN, V140, P370, DOI 10.1093/brain/aww295; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	44	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4145	4158		10.1038/s41388-022-02411-w	http://dx.doi.org/10.1038/s41388-022-02411-w		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35869392	Green Published, hybrid			2022-12-17	WOS:000828959400001
J	Balinth, S; Fisher, ML; Hwangbo, Y; Wu, CZ; Ballon, C; Sun, XQ; Mills, AA				Balinth, Seamus; Fisher, Matthew L.; Hwangbo, Yon; Wu, Caizhi; Ballon, Carlos; Sun, Xueqin; Mills, Alea A.			EZH2 regulates a SETDB1/Delta Np63 alpha axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma	ONCOGENE			English	Article							P53 HOMOLOG; EXPRESSION; P63; PROLIFERATION; MELANOMA; PROMOTER; ENHANCER; TARGETS; GENE; HEAD	Enhancer of zeste homolog 2 (EZH2) and SET domain bifurcated 1 (SETDB1, also known as ESET) are oncogenic methyltransferases implicated in a number of human cancers. These enzymes typically function as epigenetic repressors of target genes by methylating histone H3 K27 and H3-K9 residues, respectively. Here, we show that EZH2 and SETDB1 are essential to proliferation in 3 SCC cell lines, HSC-5, FaDu, and Cal33. Additionally, we find both of these proteins highly expressed in an aggressive stem-like SCC sub-population. Depletion of either EZH2 or SETDB1 disrupts these stem-like cells and their associated phenotypes of spheroid formation, invasion, and tumor growth. We show that SETDB1 regulates this SCC stem cell phenotype through cooperation with Delta Np63 alpha, an oncogenic isoform of the p53-related transcription factor p63. Furthermore, EZH2 is upstream of both SETDB1 and Delta Np63 alpha, activating these targets via repression of the tumor suppressor RUNX3. We show that targeting this pathway with inhibitors of EZH2 results in activation of RUNX3 and repression of both SETDB1 and Delta Np63 alpha, antagonizing the SCC cancer stem cell phenotype. This work highlights a novel pathway that drives an aggressive cancer stem cell phenotype and demonstrates a means of pharmacological intervention.	[Balinth, Seamus; Fisher, Matthew L.; Hwangbo, Yon; Wu, Caizhi; Ballon, Carlos; Sun, Xueqin; Mills, Alea A.] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA; [Balinth, Seamus] SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Mills, AA (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	mills@cshl.edu		Balinth, Seamus/0000-0003-2926-7051	Office of the Director, National Institutes of Health [5P30CA045508, CA247400, CA225134, R01CA190997, R21OD018332]; Cold Spring Harbor Laboratory; Northwell Health Affiliation	Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cold Spring Harbor Laboratory; Northwell Health Affiliation	This work was supported by the Office of the Director, National Institutes of Health through award numbers 5P30CA045508 (Cancer Center Support Grant), CA247400 (to SB), CA225134 (to MLF), as well as R01CA190997 and R21OD018332 (to AAM). This project was also supported through the Cold Spring Harbor Laboratory and Northwell Health Affiliation.	Antonini D, 2006, MOL CELL BIOL, V26, P3308, DOI 10.1128/MCB.26.8.3308-3318.2006; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bacciu A, 2004, CLIN OTOLARYNGOL, V29, P545, DOI 10.1111/j.1365-2273.2004.00851.x; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bailey TL, 2015, NUCLEIC ACIDS RES, V43, pW39, DOI 10.1093/nar/gkv416; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Date Y, 2020, MOL CELLS, V43, P176, DOI 10.14348/molcells.2019.0285; Deng HY, 2017, EUR J CARDIO-THORAC, V51, P421, DOI 10.1093/ejcts/ezw315; Dragu DL, 2015, WORLD J STEM CELLS, V7, P1185, DOI 10.4252/wjsc.v7.i9.1185; Fisher ML, 2021, CANCER RES, V81, P6246, DOI 10.1158/0008-5472.CAN-21-0707; Fisher ML, 2020, J CELL SCI, V133, DOI 10.1242/jcs.228015; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x; Jian Z, 2017, J INVEST DERMATOL, V137, P31, DOI 10.1016/j.jid.2016.07.033; Jiang LM, 2022, CANCERS, V14, DOI 10.3390/cancers14020415; Johnson N, 2001, J Dent Educ, V65, P328; Kaidar-Person O, 2018, DRUG RESIST UPDATE, V40, P13, DOI 10.1016/j.drup.2018.09.001; Kanumuri R, 2021, ONCOGENE, V40, P5327, DOI 10.1038/s41388-021-01927-x; Karanth AV, 2017, EXPERT OPIN THER TAR, V21, P319, DOI 10.1080/14728222.2017.1279604; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Kikuchi K, 2017, JPN DENT SCI REV, V53, P95, DOI 10.1016/j.jdsr.2017.01.002; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Kumar A, 2016, ONCOGENE, V35, P4857, DOI 10.1038/onc.2016.18; Lee SH, 2019, TUBERC RESPIR DIS, V82, P179, DOI 10.4046/trd.2018.0068; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Lin CW, 2015, ONCOTARGET, V6, P8434, DOI 10.18632/oncotarget.3020; Liu-Smith F, 2017, ADV EXP MED BIOL, V996, P27, DOI 10.1007/978-3-319-56017-5_3; Lu B, 2018, CANCER CELL, V34, P970, DOI 10.1016/j.ccell.2018.10.015; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Oshimori N, 2020, CANCER SCI, V111, P3985, DOI 10.1111/cas.14639; Otani S, 2022, ONCOGENE, V41, P683, DOI 10.1038/s41388-021-02120-w; Paver EC, 2020, PATHOLOGY, V52, P179, DOI 10.1016/j.pathol.2019.10.008; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Regina C, 2016, ONCOTARGET, V7, P28836, DOI 10.18632/oncotarget.7089; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Selvarajan V, 2017, LEUKEMIA, V31, P2219, DOI 10.1038/leu.2017.40; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Soares E, 2018, CELL MOL LIFE SCI, V75, P1179, DOI 10.1007/s00018-017-2701-z; Somerville TDD, 2018, CELL REP, V25, P1741, DOI 10.1016/j.celrep.2018.10.051; Su JL, 2016, CELL BIOCHEM FUNCT, V34, P597, DOI 10.1002/cbf.3233; Sugiura H, 2008, ONCOL REP, V19, P713; Tagliamento M, 2018, EXPERT OPIN PHARMACO, V19, P2055, DOI 10.1080/14656566.2018.1540591; Tsusaka T, 2019, EMBO REP, V20, DOI 10.15252/embr.201948297; Xiao ZH, 2020, ONCOL REP, V43, P1289, DOI 10.3892/or.2020.7508; Yan W, 2011, AM J CANCER RES, V1, P275; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhao MH, 2019, INT J ONCOL, V55, P1165, DOI 10.3892/ijo.2019.4880	55	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4130	4144		10.1038/s41388-022-02417-4	http://dx.doi.org/10.1038/s41388-022-02417-4		JUL 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35864175				2022-12-17	WOS:000828442600002
J	Gu, YY; Gao, HY; Zhang, H; John, A; Zhu, XJ; Shivaram, S; Yu, J; Weinshilboum, RM; Wang, LW				Gu, Yayun; Gao, Huanyao; Zhang, Huan; John, August; Zhu, Xiujuan; Shivaram, Suganti; Yu, Jia; Weinshilboum, Richard M.; Wang, Liewei			TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer	ONCOGENE			English	Article							UBIQUITIN LIGASE SMURF2; FACTOR RECEPTOR; ACTIVATION; MECHANISMS; PATHWAY	The HER2 receptor modulates downstream signaling by forming homodimers and heterodimers with other members of the HER family. For patients with HER2-positive breast cancer, Trastuzumab, an anti-HER2 monoclonal antibody as first-line therapy has shown significant survival benefits. However, the development of acquired resistance to Trastuzumab continues to be a significant obstacle. TNF receptor-associated factor 4 (TRAF4) upregulation was discovered to be associated with a worse clinical outcome. Here we identified TRAF4 overexpression as one of the putative mechanisms for HER2-positive breast cancer cells to maintain HER2 signaling during Trastuzumab treatment, while TRAF4 knockdown reduced HER2 stability and improved Trastuzumab sensitivity. Mechanistically, TRAF4 regulates HER2 level through its impact on SMAD specific E3 ubiquitin protein ligase protein 2 (SMURF2). The development of a membrane-associated protein complex containing HER2, TRAF4, and SMURF2 has been observed. SMURF2 bound to the HER2 cytoplasmic domain, and directly ubiquitinated it leading to HER2 degradation, whereas TRAF4 stabilized HER2 by degrading SMURF2 and inhibiting the binding of SMURF2 to HER2. Moreover, downregulation of TRAF4 has decreased the AKT/mTOR signaling. In conclusion, we discovered a new HER2 signaling regulation that involves the TRAF4-SMURF2 complex, a possible mechanism that might contribute to anti-HER2 resistance, making TRAF4 a viable target for treating HER2 + breast cancer.	[Gu, Yayun; Gao, Huanyao; Zhang, Huan; John, August; Zhu, Xiujuan; Shivaram, Suganti; Yu, Jia; Weinshilboum, Richard M.; Wang, Liewei] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA	Mayo Clinic	Wang, LW (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA.	Wang.Liewei@mayo.edu		John, August/0000-0003-4615-9474	Breast Cancer Research Foundation (BCRF); Eisenberg Foundation; Nan Sawyer Breast Cancer Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence [P50CA116201]	Breast Cancer Research Foundation (BCRF); Eisenberg Foundation; Nan Sawyer Breast Cancer Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence	This work was supported by the Breast Cancer Research Foundation (BCRF), The Eisenberg Foundation, The Nan Sawyer Breast Cancer Fund, P50CA116201(Mayo Clinic Breast Cancer Specialized Program of Research Excellence).	Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Ahmad A, 2019, ADV EXP MED BIOL, V1152, P217, DOI 10.1007/978-3-030-20301-6_10; Ahmad S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04483; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Boughey JC, 2021, CLIN CANCER RES, V27, P4696, DOI 10.1158/1078-0432.CCR-21-0641; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Cai G, 2018, P NATL ACAD SCI USA, V115, P11531, DOI 10.1073/pnas.1809599115; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Chandhoke AS, 2016, CELL DEATH DIFFER, V23, P876, DOI 10.1038/cdd.2015.152; Emanuelli A, 2019, CANCERS, V11, DOI 10.3390/cancers11040556; Exman P, 2021, CLIN ADV HEMATOL ONC, V19, P40; Fennell LM, 2018, FEBS J, V285, P2746, DOI 10.1111/febs.14478; Fu L, 2020, SEMIN CANCER BIOL, V67, P102, DOI 10.1016/j.semcancer.2019.12.023; Gijsen M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000563; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hendriks BS, 2005, J BIOL CHEM, V280, P6157, DOI 10.1074/jbc.M410491200; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Klupp F, 2019, CANCER MANAG RES, V11, P1795, DOI 10.2147/CMAR.S178111; Koganti P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00295; Kreutzfeldt J, 2020, AM J CANCER RES, V10, P1045; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Lazaro G, 2013, ENDOCR-RELAT CANCER, V20, P691, DOI 10.1530/ERC-13-0019; Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418-019-0328-3; Li S, 2010, MOL CELL BIOCHEM, V338, P11, DOI 10.1007/s11010-009-0315-y; Li YH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00603-7; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Moustakas A, 2013, MOL CELL, V51, P555, DOI 10.1016/j.molcel.2013.08.034; Nami B, 2018, CANCERS, V10, DOI 10.3390/cancers10100342; O'Brien NA, 2014, CLIN CANCER RES, V20, P3507, DOI 10.1158/1078-0432.CCR-13-2769; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Park HH, 2021, ARCH PHARM RES, V44, P475, DOI 10.1007/s12272-021-01330-w; Park J, 2020, ARCH PHARM RES, V43, P1144, DOI 10.1007/s12272-020-01281-8; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Ray D, 2011, NEOPLASIA, V13, P570, DOI 10.1593/neo.11632; Ray P, 2020, J BIOL CHEM, V295, P12661, DOI 10.1074/jbc.RA120.013519; Ren HY, 2020, BREAST CANCER RES TR, V183, P275, DOI 10.1007/s10549-020-05789-x; Ren YL, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00426-y; Roskoski R, 2019, PHARMACOL RES, V139, P395, DOI 10.1016/j.phrs.2018.11.014; Rousseau Adrien, 2011, Cancers (Basel), V3, P2734, DOI 10.3390/cancers3022734; Sajjad N, 2019, INT J BIOCHEM CELL B, V115, DOI 10.1016/j.biocel.2019.105589; Sawyers CL, 2019, CELL, V179, P8, DOI 10.1016/j.cell.2019.08.027; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Singh R, 2018, J CLIN INVEST, V128, P3129, DOI 10.1172/JCI96060; Swaidani S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01293; Wang XC, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.472704; Wilken JA, 2010, ANN NY ACAD SCI, V1210, P53, DOI 10.1111/j.1749-6632.2010.05782.x; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Zazo S, 2016, AM J CANCER RES, V6, P2661; Zepp JA, 2015, J IMMUNOL, V194, P2826, DOI 10.4049/jimmunol.1402647; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zhou J, 2020, ANTI-CANCER DRUG, V31, P558, DOI 10.1097/CAD.0000000000000943	52	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4119	4129		10.1038/s41388-022-02415-6	http://dx.doi.org/10.1038/s41388-022-02415-6		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35864174	hybrid, Green Published			2022-12-17	WOS:000828442600001
J	Liu, C; Wang, JL; Zheng, YJ; Zhu, Y; Zhou, ZH; Liu, ZY; Lin, CD; Wan, YY; Wen, YT; Liu, CY; Yuan, MY; Zeng, YARA; Yan, ZJ; Ge, GX; Chen, JF				Liu, Cui; Wang, JunLei; Zheng, YaJuan; Zhu, Yue; Zhou, ZhengHang; Liu, ZhaoYuan; Lin, ChangDong; Wan, YaoYing; Wen, YaTing; Liu, ChunYe; Yuan, MengYa; Zeng, Yi Arial; Yan, ZhanJun; Ge, GaoXiang; Chen, JianFeng			Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin alpha v beta 3	ONCOGENE			English	Article							ASPARAGINYL ENDOPEPTIDASE; ALPHA(V)BETA(3) INTEGRIN; THERAPEUTIC TARGETS; MAMMALIAN LEGUMAIN; BONE METASTASIS; OUTSIDE-IN; EXPRESSION; ACTIVATION; PROSTATE; PATHWAYS	Tumor metastasis is the leading cause of cancer-associated mortality. Unfortunately, the underlying mechanism of metastasis is poorly understood. Expression of legumain (LGMN), an endo-lysosomal cysteine protease, positively correlates with breast cancer metastatic progression and poor prognosis. Here, we report that LGMN is secreted in the zymogen form by motile breast cancer cells. Through binding to cell surface integrin alpha v beta 3 via an RGD motif, the autocrine pro-LGMN activates FAK-Src-RhoA signaling in cancer cells and promotes cancer cell migration and invasion independent of LGMN protease activity. Either silencing LGMN expression or mutationally abolishing pro-LGMN-alpha v beta 3 interaction significantly inhibits cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Finally, we developed a monoclonal antibody against LGMN RGD motif, which blocks pro-LGMN-alpha v beta 3 binding, and effectively suppresses cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Thus, disruption of pro-LGMN-integrin alpha v beta 3 interaction may be a potentially promising strategy for treating breast cancer metastasis.	[Liu, Cui; Wang, JunLei; Zheng, YaJuan; Zhu, Yue; Liu, ZhaoYuan; Wan, YaoYing; Wen, YaTing; Liu, ChunYe; Yuan, MengYa; Zeng, Yi Arial; Ge, GaoXiang; Chen, JianFeng] Chinese Acad Sci, State Key Lab Cell Biol, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci,Univ Chinese Acad Sci, Shanghai 200031, Peoples R China; [Zhou, ZhengHang; Zeng, Yi Arial; Ge, GaoXiang; Chen, JianFeng] Univ Chinese Acad Sci, Sch Life Sci, Hangzhou Inst Adv Study, Key Lab Syst Hlth Sci Zhejiang Prov, Hangzhou 310024, Peoples R China; [Lin, ChangDong] Tongji Univ, Sch Life Sci & Technol, Orthopaed Dept,Tongji Hosp, Minist Educ,Key Lab Spine & Spinal Cord Injury Re, Shanghai 200092, Peoples R China; [Yan, ZhanJun] Soochow Univ, Suzhou Peoples Hosp 9, Dept Orthoped, Suzhou 215000, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Tongji University; Soochow University - China	Ge, GX; Chen, JF (corresponding author), Chinese Acad Sci, State Key Lab Cell Biol, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci,Univ Chinese Acad Sci, Shanghai 200031, Peoples R China.; Ge, GX; Chen, JF (corresponding author), Univ Chinese Acad Sci, Sch Life Sci, Hangzhou Inst Adv Study, Key Lab Syst Hlth Sci Zhejiang Prov, Hangzhou 310024, Peoples R China.; Yan, ZJ (corresponding author), Soochow Univ, Suzhou Peoples Hosp 9, Dept Orthoped, Suzhou 215000, Peoples R China.	yanzhanjun2010@163.com; gxge@sibcb.ac.cn; jfchen@sibcb.ac.cn			National Key Research and Development Program of China [2020YFA0509102, 2020YFA0803203]; National Natural Science Foundation of China [31970702, 32030024, 31830112, 31525016, 32070789]; Program of Shanghai Academic Research Leader [19XD1404200]; National Ten Thousand Talents Program; SA-SIBS scholarship program	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Shanghai Academic Research Leader; National Ten Thousand Talents Program; SA-SIBS scholarship program	This work was supported by grants from National Key Research and Development Program of China (2020YFA0509102 to J.F.C., 2020YFA0803203 to G.X.G.), National Natural Science Foundation of China (31970702 to C.D.L., 32030024, 31830112, 31525016 to J.F.C., 32070789 to G.X.G.). Program of Shanghai Academic Research Leader (19XD1404200), National Ten Thousand Talents Program. The authors gratefully acknowledge the support of SA-SIBS scholarship program.	Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Braulke T, 2009, BBA-MOL CELL RES, V1793, P605, DOI 10.1016/j.bbamcr.2008.10.016; Briggs JJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-17; Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007; Dall E, 2016, BIOCHIMIE, V122, P126, DOI 10.1016/j.biochi.2015.09.022; Dall E, 2013, P NATL ACAD SCI USA, V110, P10940, DOI 10.1073/pnas.1300686110; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017; Gawenda J, 2007, BREAST CANCER RES TR, V102, P1, DOI 10.1007/s10549-006-9311-z; Gehler S, 2013, CRIT REV EUKAR GENE, V23, P139, DOI 10.1615/CritRevEukarGeneExpr.2013006647; Guo PT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073090; Haeger A, 2020, J EXP MED, V217, DOI 10.1084/jem.20181184; Haugen MH, 2015, EUR J CANCER, V51, P9, DOI 10.1016/j.ejca.2014.10.020; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Karagiannis GS, 2014, MOL ONCOL, V8, P178, DOI 10.1016/j.molonc.2013.10.008; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Liao D, 2011, NANOMED-NANOTECHNOL, V7, P665, DOI 10.1016/j.nano.2011.03.001; Lin YY, 2013, CANCER SCI, V104, P1217, DOI 10.1111/cas.12202; Liu Y, 2012, MOL PHARMACEUT, V9, P168, DOI 10.1021/mp200434n; Lu L, 2016, J BIOL CHEM, V291, P10363, DOI 10.1074/jbc.M116.717694; Maire V, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063712, 10.1371/journal.pone.0077372]; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Maubant S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122333; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; Meng F, 2015, ONCOL RES, V23, P7, DOI 10.3727/096504015X14410238486649; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Murthy RV, 2005, CLIN CANCER RES, V11, P2293, DOI 10.1158/1078-0432.CCR-04-1642; Nagalla S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r34; Nakashima Y, 2013, CANCER SCI, V104, P1718, DOI 10.1111/cas.12286; Natali PG, 1997, CANCER RES, V57, P1554; Ohno Y, 2013, WORLD J UROL, V31, P359, DOI 10.1007/s00345-012-0977-z; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qi Q, 2017, J MED CHEM, V60, P7244, DOI 10.1021/acs.jmedchem.7b00228; Richardson AM, 2018, CLIN CANCER RES, V24, P420, DOI 10.1158/1078-0432.CCR-17-1776; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sepulveda FE, 2009, IMMUNITY, V31, P737, DOI 10.1016/j.immuni.2009.09.013; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Upheber S, 2015, CELL SIGNAL, V27, P652, DOI 10.1016/j.cellsig.2014.11.028; van der Horst G, 2011, NEOPLASIA, V13, P516, DOI 10.1593/neo.11122; Mercedes SVA, 2021, NAT REV CANCER, V21, P592, DOI 10.1038/s41568-021-00376-8; Wang LN, 2012, J CELL BIOCHEM, V113, P2679, DOI 10.1002/jcb.24143; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Westcott JM, 2015, J CLIN INVEST, V125, P1927, DOI 10.1172/JCI77767; Wu WY, 2006, CANCER RES, V66, P970, DOI 10.1158/0008-5472.CAN-05-2591; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang CX, 2019, ONCOGENE, V38, P7113, DOI 10.1038/s41388-019-0899-y; Zeltz C, 2020, SEMIN CANCER BIOL, V62, P166, DOI 10.1016/j.semcancer.2019.08.004; Zhao LX, 2014, CELL RES, V24, P344, DOI 10.1038/cr.2014.4; Zhu JQ, 2007, BLOOD, V110, P2475, DOI 10.1182/blood-2007-03-080077	59	0	0	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4091	4103		10.1038/s41388-022-02409-4	http://dx.doi.org/10.1038/s41388-022-02409-4		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35854065				2022-12-17	WOS:000827369300001
J	Bellenghi, M; Talarico, G; Botti, L; Puglisi, R; Tabolacci, C; Portararo, P; Piva, A; Pontecorvi, G; Care, A; Colombo, MP; Mattia, G; Sangaletti, S				Bellenghi, Maria; Talarico, Giovanna; Botti, Laura; Puglisi, Rossella; Tabolacci, Claudio; Portararo, Paola; Piva, Annamaria; Pontecorvi, Giada; Care, Alessandra; Colombo, Mario P.; Mattia, Gianfranco; Sangaletti, Sabina			SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; SUPPRESSOR-CELLS; BREAST-CANCER; MESENCHYMAL TRANSITION; BONE-MARROW; REGULATORS; FIBROSIS	Dysregulated fatty acid metabolism interacts with oncogenic signals, thereby worsening tumor aggressiveness. The stearoyl-CoA desaturating enzymes, SCD1 and SCD5, convert of saturated fatty acids to monounsaturated fatty acids. While SCD1 is frequently overexpressed in tumor cells and has been widely studied, SCD5 has both limited expression and poor characterization. Here we evaluated, in vitro and in vivo, the effects of SCD5 overexpression in a metastatic clone of 4T1. The results showed SCD5-driven reprogramming of fatty acid metabolism, involving desaturation of stearic acid to oleic acid, which eventually blocked SPARC secretion. The latter event reduced the aggressiveness of the 4T1 subclone by decreasing the ECM deposition and reverting the Epithelial to Mesenchymal Transition (EMT) status. Variation of the fatty acid profile by SCD5-gene transduction or the direct administration oleic acid reduces the immune suppressive activity of myeloid cells and promoting granulocytic myeloid-derived suppressor cell maturation, eventually favoring T-cell activation. The less immunosuppressive microenvironment generated by SCD5 overexpression was enhanced in Sparc-KO mice, indicating that both extracellular and endogenous SPARC additively regulate myeloid cell-suppressive activities. Overall, our data sheds light on exploring the oleic acid-dependent inhibition of SPARC secretion as a possible mechanism to reduce breast cancer malignancy.	[Bellenghi, Maria; Puglisi, Rossella; Pontecorvi, Giada; Care, Alessandra; Mattia, Gianfranco] Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy; [Talarico, Giovanna; Botti, Laura; Portararo, Paola; Piva, Annamaria; Colombo, Mario P.; Sangaletti, Sabina] Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy; [Tabolacci, Claudio] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy	Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS)	Mattia, G (corresponding author), Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy.; Sangaletti, S (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Res, Mol Immunol Unit, Milan, Italy.	gianfranco.mattia@iss.it; sabina.sangaletti@istitutotumori.mi.it	Tabolacci, Claudio/U-4194-2017; Colombo, Mario P./V-7166-2017	Tabolacci, Claudio/0000-0001-5001-285X; Colombo, Mario P./0000-0003-0042-7955	AIRC IG [22204, 24363, 18815]; FIRC-AIRC fellowship "Fabrizio Ansuini" [22474]; FIRC-AIRC fellowship "Giorgio Boglio' [22460]; Fondazione Umberto Veronesi	AIRC IG(Fondazione AIRC per la ricerca sul cancro); FIRC-AIRC fellowship "Fabrizio Ansuini"; FIRC-AIRC fellowship "Giorgio Boglio'; Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	This work was supported by AIRC IG no. 22204 to SS, IG no. 24363 to MPC and IG no 18815 to AC. MB was partially supported by the FIRC-AIRC fellowship "Fabrizio Ansuini" n. 22474, GT was supported by the FIRC-AIRC fellowship "Giorgio Boglio' no. 22460, and CT by Fondazione Umberto Veronesi, which we gratefully acknowledge.	Al-Khami AA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1344804; Al-Khami AA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1200771; Angelucci Cristiana, 2018, Oncotarget, V9, P24364, DOI 10.18632/oncotarget.25273; Bellenghi M, 2015, J PATHOL, V236, P315, DOI 10.1002/path.4535; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chiodoni C, 2017, J LEUKOCYTE BIOL, V102, P287, DOI 10.1189/jlb.3MR1016-447R; Clark AM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.676135; Craven KE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83913-7; Donati K, 2017, CANCER GROWTH METAST, V10, DOI 10.1177/1179064417738513; Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Harusato A, 2019, CANCER IMMUNOL RES, V7, P544, DOI 10.1158/2326-6066.CIR-18-0444; Hawila E, 2017, CELL REP, V21, P2212, DOI 10.1016/j.celrep.2017.10.104; He MW, 2015, SCI REP-UK, V5, DOI 10.1038/srep11298; Holder AM, 2013, BREAST CANCER RES TR, V137, P319, DOI 10.1007/s10549-012-2354-4; Hossain F, 2015, CANCER IMMUNOL RES, V3, P1236, DOI 10.1158/2326-6066.CIR-15-0036; Li HC, 2020, THERANOSTICS, V10, P7053, DOI 10.7150/thno.41388; Lope V, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103132; Martinek N, 2008, J CELL SCI, V121, P1671, DOI 10.1242/jcs.021931; Masjedi A, 2018, BIOMED PHARMACOTHER, V108, P1415, DOI 10.1016/j.biopha.2018.09.177; Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008-5472.CAN-07-1882; Ojala PJ, 2007, J LEUKOCYTE BIOL, V82, P1501, DOI 10.1189/jlb.0507292; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Pelekanou V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00301; Poltavets V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00431; Puglisi Rossella, 2018, Oncotarget, V9, P7567, DOI 10.18632/oncotarget.24085; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202; Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008-5472.CAN-08-1327; Sangaletti S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01369; Sangaletti S, 2016, CELL REP, V17, P233, DOI 10.1016/j.celrep.2016.08.075; Sangaletti S, 2011, AM J PATHOL, V179, P3000, DOI 10.1016/j.ajpath.2011.08.027; Strauss L, 2015, CANCER CELL, V28, P253, DOI 10.1016/j.ccell.2015.07.006; Tzanakakis G, 2018, DEV DYNAM, V247, P368, DOI 10.1002/dvdy.24557; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Wong SLI, 2017, BRIT J PHARMACOL, V174, P3, DOI 10.1111/bph.13653; Zhu AJ, 2016, ONCOTARGET, V7, P76628, DOI 10.18632/oncotarget.10532	40	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4055	4065		10.1038/s41388-022-02401-y	http://dx.doi.org/10.1038/s41388-022-02401-y		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35851846				2022-12-17	WOS:000826844200002
J	Wang, WH; Meng, YY; Chen, YX; Yu, YH; Wang, H; Yang, S; Sun, W				Wang, Wenhao; Meng, Yingying; Chen, Yaxin; Yu, Yanhong; Wang, Hang; Yang, Shuang; Sun, Wei			A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation	ONCOGENE			English	Article							GENE-THERAPY; BREAST-CANCER; CELL LEUKEMIA; EXPRESSION; PROTEIN; BINDING; LEUKEMOGENESIS; TRANSLOCATIONS; IDENTIFICATION; ONCOGENE	LMO2 is a well-known leukemic proto-oncogene, its ectopic expression in T-lineage specifically initiates malignant transformation of immature T cells and ultimately causes the onset of acute T-lymphocytic leukemia (T-ALL) in both mouse models and human patients. In this study, we systematically explored the LMO2 performance on the profiles of transcriptome, DNA-binding and protein interactions during T-lineage development in the pre-leukemic stage. Our data indicated that large-scale transcriptional dysregulation caused by LMO2 primarily occurred in DN3 thymocytes, characterized by enriched upregulation of the target genes of typical LMO2 complex, RUNX, ETS and STATs, and ectopic LMO2 primarily targeted to RUNX motifs along with intensive interaction with RUNX1 and H3K4 methyltransferase component ASH2L in this stage. However, binding of LMO2 on specific motifs was largely reduced in the following DP and SP stages, along with gradually disappeared LMO2-RUNX1 and LMO2-ASH2L interactions and less alteration of certain transcriptional factor profiles. Moreover, LMO2 showed relatively less influence on cellular behavior of DN3 thymocyte whereas displayed more prominent effects in DP and SP stages, including promoting Notch signaling and cell cycles. These findings provide a high-resolution landscape of the pathogenic role of LMO2 during T-lineage development in molecular level, and may benefit further clinical investigations for LMO2-associated T-lineage malignancies.	[Wang, Wenhao; Meng, Yingying; Chen, Yaxin; Yu, Yanhong; Wang, Hang; Yang, Shuang; Sun, Wei] Nankai Univ, Sch Med, Tianjin, Peoples R China	Nankai University	Sun, W (corresponding author), Nankai Univ, Sch Med, Tianjin, Peoples R China.	sunweibio@nankai.edu.cn	Yu, Yan/GYV-4514-2022	Wang, Wenhao/0000-0001-9777-2143	National Natural Science Foundation of China General Programs [81772976]	National Natural Science Foundation of China General Programs(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China General Programs (No. 81772976).	BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Chambers J, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150062; Cubedo E, 2012, BLOOD, V119, P5478, DOI 10.1182/blood-2012-01-403154; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fujimoto T, 2007, EMBO J, V26, P2361, DOI 10.1038/sj.emboj.7601675; Gao P, 2020, GENE DEV, V34, P950, DOI 10.1101/gad.338202.120; Gao TS, 2016, BIOINFORMATICS, V32, P3543, DOI 10.1093/bioinformatics/btw495; Goode DK, 2016, DEV CELL, V36, P572, DOI 10.1016/j.devcel.2016.01.024; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Hosokawa H, 2018, IMMUNITY, V48, P1119, DOI 10.1016/j.immuni.2018.04.024; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; LARSON RC, 1994, ONCOGENE, V9, P3675; Liu Y, 2017, ONCOTARGET, V8, P9513, DOI 10.18632/oncotarget.13434; Liu Y, 2017, MED SCI MONITOR, V23, P695, DOI 10.12659/MSM.903261; Liu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep36050; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Malumbres R, 2011, HAEMATOL-HEMATOL J, V96, P980, DOI 10.3324/haematol.2011.040568; Mao SF, 1999, MOL CELL BIOL, V19, P3635; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; Natkunam Y, 2008, J CLIN ONCOL, V26, P447, DOI 10.1200/JCO.2007.13.0690; Natkunam Y, 2007, BLOOD, V109, P1636, DOI 10.1182/blood-2006-08-039024; Palii CG, 2011, EMBO J, V30, P494, DOI 10.1038/emboj.2010.342; Parvin S, 2019, CANCER CELL, V36, P237, DOI 10.1016/j.ccell.2019.07.007; Pike-Overzet K, 2007, LEUKEMIA, V21, P754, DOI 10.1038/sj.leu.2404563; Rothenberg EV, 2007, IMMUNITY, V26, P690, DOI 10.1016/j.immuni.2007.06.005; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Shin B, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019655118; Smith S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085883; Sun W, 2010, EUR J HAEMATOL, V85, P508, DOI 10.1111/j.1600-0609.2010.01519.x; Sun W, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-22; Wang WH, 2020, MED SCI MONIT BASIC, V26, DOI 10.12659/MSMBR.924421; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wu C, 2018, BBA-MOL BASIS DIS, V1864, P2511, DOI 10.1016/j.bbadis.2018.05.013; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	38	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4079	4090		10.1038/s41388-022-02414-7	http://dx.doi.org/10.1038/s41388-022-02414-7		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35851847				2022-12-17	WOS:000826844200001
J	Bian, TF; Wang, YZ; Botello, JF; Hu, Q; Jiang, YH; Zingone, A; Ding, HC; Wu, YG; Aly, FZ; Salloum, RG; Warren, G; Huo, ZG; Ryan, BM; Jin, LT; Xing, CG				Bian, Tengfei; Wang, Yuzhi; Botello, Jordy F.; Hu, Qi; Jiang, Yunhan; Zingone, Adriana; Ding, Haocheng; Wu, Yougen; Aly, F. Zahra; Salloum, Ramzi G.; Warren, Graham; Huo, Zhiguang; Ryan, Brid M.; Jin, Lingtao; Xing, Chengguo			LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner	ONCOGENE			English	Article							PROTEIN-KINASE; SMOKING STATUS; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; NITROSAMINE; BIOMARKER; MOUSE; GENE; PHARMACOKINETICS; GLUCURONIDATION; ADENOCARCINOMA	LKB1 loss of function is one key oncogenic event in lung cancer. Clinical data suggest that LKB1 loss of function is associated with patients' smoking status. The responsible ingredients and molecular mechanisms in tobacco for LKB1 loss of function, however, are not defined. In this study, we reported that NNAL, a major metabolite of a tobacco-specific carcinogen NNK, induces LKB1 phosphorylation and its loss of function via the beta-AR/PKA signaling pathway in an isomer-dependent manner in human lung cancer cells. NNAL exposure also resulted in enhanced lung cancer cell migration and chemoresistance in an LKB1-dependent manner. A 120-day NNAL exposure in lung cancer cells, mimicking its chronic exposure among smokers, resulted in more prominent LKB1 phosphorylation, cell migration, and chemoresistance even in the absence of NNAL, indicating the long-lasting LKB1 loss of function although such an effect eventually disappeared after NNAL was removed for two months. These observations were confirmed in a lung cancer xenograft model. More importantly, human lung cancer tissues revealed elevated LKB1 phosphorylation in comparison to the paired normal lung tissues. These results suggest that LKB1 loss of function in human lung cancer could be extended to its phosphorylation, which may be mediated by NNAL from tobacco smoke in an isomer-dependent manner via the beta-AR/PKA signaling pathway.	[Bian, Tengfei; Wang, Yuzhi; Botello, Jordy F.; Hu, Qi; Wu, Yougen; Xing, Chengguo] Univ Florida, Dept Med Chem, Ctr Nat Prod Drug Discovery & Dev CNPD3, Gainesville, FL 32610 USA; [Jiang, Yunhan; Jin, Lingtao] UT Hlth San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Zingone, Adriana; Ryan, Brid M.] NCI, Lab Human Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Ding, Haocheng; Huo, Zhiguang] Univ Florida, Coll Publ Hlth & Hlth Profess, Coll Med, Dept Biostat, Gainesville, FL 32610 USA; [Wu, Yougen] Hainan Univ, Coll Trop Agr & Forestry, 58 Renmin Ave, Haikou 570228, Hainan, Peoples R China; [Aly, F. Zahra] Univ Florida, Dept Pathol Immunol & Lab Med, 1345 Ctr Dr, Gainesville, FL 32610 USA; [Salloum, Ramzi G.] Univ Florida, Coll Med, Dept Hlth Outcome & Biomed Informat, Gainesville, FL 32610 USA; [Warren, Graham] Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA	State University System of Florida; University of Florida; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; Hainan University; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Medical University of South Carolina	Xing, CG (corresponding author), Univ Florida, Dept Med Chem, Ctr Nat Prod Drug Discovery & Dev CNPD3, Gainesville, FL 32610 USA.	chengguoxing@cop.ufl.edu			National Institute of Health [R01CA193286]; Harry T. Mangurian Jr.; College of Pharmacy Frank Duckworth Endowment; University of Florida Health Cancer Center Startup fund; University of Florida Medicinal Chemistry Mass Spectrometry Support; National Science Foundation of China	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harry T. Mangurian Jr.; College of Pharmacy Frank Duckworth Endowment; University of Florida Health Cancer Center Startup fund; University of Florida Medicinal Chemistry Mass Spectrometry Support; National Science Foundation of China(National Natural Science Foundation of China (NSFC))	The work was partly supported by grants from the National Institute of Health (R01CA193286) to CX, the Harry T. Mangurian Jr. Foundation to CX, College of Pharmacy Frank Duckworth Endowment to CX, University of Florida Health Cancer Center Startup fund to CX, and University of Florida Medicinal Chemistry Mass Spectrometry Support to CX. Y Wu was supported by a scholarship from the National Science Foundation of China. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication. We also acknowledge the National Cancer Institute for providing PLCO information used in this manuscript. We would like to thank Sreekanth C. Narayanapillai, Santanu Hati, and Pedro Corral for the assistance with sample collection and characterization. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.	ADAMS JD, 1985, CARCINOGENESIS, V6, P509, DOI 10.1093/carcin/6.4.509; Amin RMS, 2008, PATHOL INT, V58, P84, DOI 10.1111/j.1440-1827.2007.02194.x; Baser S, 2006, CHEST, V130, P1784, DOI 10.1016/S0012-3692(15)50902-1; Borzi C, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110385; Calles A, 2015, CLIN CANCER RES, V21, P2851, DOI 10.1158/1078-0432.CCR-14-3112; Carmella SG, 2005, CANCER EPIDEM BIOMAR, V14, P2669, DOI 10.1158/1055-9965.EPI-05-0129; Carmella SG, 1999, CANCER RES, V59, P3602; Carmella SG, 2006, CANCER EPIDEM BIOMAR, V15, P1490, DOI 10.1158/1055-9965.EPI-06-0199; Chen G, 2016, CANCER EPIDEM BIOMAR, V25, P1175, DOI 10.1158/1055-9965.EPI-15-1245; Church TR, 2009, CANCER EPIDEM BIOMAR, V18, P260, DOI 10.1158/1055-9965.EPI-08-0718; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Erickson P, 2018, CANCER EPIDEM BIOMAR, V27, P1518, DOI [10.1158/1055-9965.epi-18-0366, 10.1158/1055-9965.EPI-18-0366]; Ferketich AK, 2013, CANCER-AM CANCER SOC, V119, P847, DOI 10.1002/cncr.27824; Gemine RE, 2019, LUNG CANCER, V129, P1, DOI 10.1016/j.lungcan.2018.12.028; Gill RK, 2011, ONCOGENE, V30, P3784, DOI 10.1038/onc.2011.98; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Hasegawa T, 2020, IN VIVO, V34, P2997, DOI 10.21873/invivo.12131; HECHT SS, 1993, CARCINOGENESIS, V14, P229, DOI 10.1093/carcin/14.2.229; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 1999, CANCER RES, V59, P590; HHS, 2014, HLTH CONS SMOK 50 YE; Jalas JR, 2003, CHEM RES TOXICOL, V16, P782, DOI 10.1021/tx034021t; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jin LT, 2018, CANCER CELL, V34, P315, DOI 10.1016/j.ccell.2018.06.012; Jin LT, 2018, MOL CELL, V69, P87, DOI 10.1016/j.molcel.2017.11.025; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kozlovich S, 2015, CHEM RES TOXICOL, V28, P2112, DOI 10.1021/acs.chemrestox.5b00278; Lee SJ, 2014, THORAC CANCER, V5, P43, DOI 10.1111/1759-7714.12051; Lin CX, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027841; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Meaney CL, 2019, J THORAC ONCOL, V14, P1192, DOI 10.1016/j.jtho.2019.03.014; Mitchell KG, 2020, ANN THORAC SURG, V110, P1131, DOI 10.1016/j.athoracsur.2020.03.114; Modesto JL, 2015, MOL CARCINOGEN, V54, pE94, DOI 10.1002/mc.22187; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Murphy SE, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0057-y; Narayanapillai SC, 2016, DRUG METAB DISPOS, V44, P422, DOI 10.1124/dmd.115.068387; Nia PS, 2005, LUNG CANCER-J IASLC, V47, P351, DOI 10.1016/j.lungcan.2004.08.011; PLCO Datasets, 2020, US; Pore N, 2021, CANCER DISCOV, V11, P2828, DOI 10.1158/2159-8290.CD-20-1543; Richter E, 2009, CHEM RES TOXICOL, V22, P1008, DOI 10.1021/tx800461d; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Schuller HM, 1999, CANCER RES, V59, P4510; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shen J, 2012, CANCER LETT, V318, P106, DOI 10.1016/j.canlet.2011.12.008; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Siegel RL, 2018, CA-CANCER J CLIN, V68, P329, DOI 10.3322/caac.21460; Smoking Cessation, 2020, REP SURG GEN; Stepanov I, 2008, CANCER EPIDEM BIOMAR, V17, P1764, DOI 10.1158/1055-9965.EPI-07-2844; Upadhyaya P, 1999, CARCINOGENESIS, V20, P1577, DOI 10.1093/carcin/20.8.1577; Wang Y, 2020, CANCER PREV RES, V13, P483, DOI 10.1158/1940-6207.CAPR-19-0501; Wang Y, 2019, TOXICOL LETT, V311, P11, DOI 10.1016/j.toxlet.2019.04.020; Wang Y, 2018, CHEM RES TOXICOL, V31, P836, DOI 10.1021/acs.chemrestox.8b00155; Wei BN, 2016, J EXPO SCI ENV EPID, V26, P249, DOI 10.1038/jes.2014.88; Xia Y, 2011, BIOMARKERS, V16, P112, DOI 10.3109/1354750X.2010.533288; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yang CC, 2019, J NURS RES, V27, DOI 10.1097/jnr.0000000000000293	56	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4042	4054		10.1038/s41388-022-02410-x	http://dx.doi.org/10.1038/s41388-022-02410-x		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35835853				2022-12-17	WOS:000825171000001
J	Yang, R; Li, XX; Wu, YA; Zhang, GH; Liu, XR; Li, YP; Bao, YH; Yang, WC; Cui, HJ				Yang, Rui; Li, Xiuxiu; Wu, Yanan; Zhang, Guanghui; Liu, Xiaoran; Li, Yanping; Bao, Yonghua; Yang, Wancai; Cui, Hongjuan			EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma (vol 39, pg 2975, 2020)	ONCOGENE			English	Correction												simply_yang@126.com; hcui@swu.edu.cn		Yang, Wancai/0000-0001-7437-9197				Yang R, 2020, ONCOGENE, V39, P2975, DOI 10.1038/s41388-020-1199-2	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4257	4258		10.1038/s41388-022-02392-w	http://dx.doi.org/10.1038/s41388-022-02392-w		JUL 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35831581	Bronze			2022-12-17	WOS:000824241300001
J	Chen, PW; Dey, P				Chen, Peiwen; Dey, Prasenjit			Co-dependencies in the tumor immune microenvironment	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; BETA-CATENIN; LUNG ADENOCARCINOMA; T-CELLS; PD-L1 EXPRESSION; DENDRITIC CELLS; CANCER; PTEN; PROMOTES; IMMUNOTHERAPY	Activated oncogenes and disrupted tumor suppressor genes (TSGs) not only endow aspiring cancer cells with new biological capabilities but also influence the composition and function of host cells in the tumor microenvironment (TME). These non-cancer host cells can in turn provide cancer cells with growth support and protection from the anti-tumor immune response. In this ecosystem, geospatially heterogenous "subTME" adds to the complexity of the "global" TME which bestows tumors with increased tumorigenic ability and resistance to therapy. This review highlights how specific genetic alterations in cancer cells establish various symbiotic co-dependencies with surrounding host cells and details the cooperative role of the host cells in tumor biology. These essential interactions expand the repertoire of targets for the development of precision cancer treatments.	[Chen, Peiwen] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA; [Dey, Prasenjit] Roswell Park Comprehens Canc Ctr, Dept Immunol, Buffalo, NY 14263 USA	Northwestern University; Feinberg School of Medicine	Dey, P (corresponding author), Roswell Park Comprehens Canc Ctr, Dept Immunol, Buffalo, NY 14263 USA.	prasenjit.dey@roswellpark.org		dey, prasenjit/0000-0001-6678-503X	Roswell Park Alliance Foundation [62-2839-01]; NCI Cancer Center Support Grant [P30CA016056]; NIH [R00 CA240896]; DoD Career Development Award [W81XWH-21-1-0380]; Cancer Research Foundation Young Investigator Award; Lynn Sage Scholar Award; American Cancer Society Institutional Research Grant [IRG-21-144-27]; Bill Bass Foundation;  [5R00CA218891-04];  [1R01CA262822-01]	Roswell Park Alliance Foundation; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD Career Development Award; Cancer Research Foundation Young Investigator Award; Lynn Sage Scholar Award; American Cancer Society Institutional Research Grant(American Cancer Society); Bill Bass Foundation; ; 	This study was supported in part by 5R00CA218891-04 (PD); 1R01CA262822-01 (PD), The Roswell Park Alliance Foundation-62-2839-01 (PD); NCI Cancer Center Support Grant P30CA016056 (PD); NIH R00 CA240896 (PC), DoD Career Development Award W81XWH-21-1-0380 (PC), Cancer Research Foundation Young Investigator Award (PC), Lynn Sage Scholar Award (PC), American Cancer Society Institutional Research Grant IRG-21-144-27 (PC), philanthropic donation from Mindy Jacobson and the Bill Bass Foundation (PC). Figures created with BioRender.com.	AbdulJabbar K, 2020, NAT MED, V26, P1054, DOI 10.1038/s41591-020-0900-x; Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Ahn MJ, 2017, EXPERT OPIN DRUG SAF, V16, P465, DOI 10.1080/14740338.2017.1300656; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Alam A, 2022, CANCER CELL, V40, P153, DOI 10.1016/j.ccell.2022.01.003; An ZY, 2018, CANCER RES, V78, P6785, DOI 10.1158/0008-5472.CAN-17-3551; Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Armstrong CWD, 2016, ONCOTARGET, V7, P7885, DOI 10.18632/oncotarget.6955; Atkins D, 2004, INT J CANCER, V109, P265, DOI 10.1002/ijc.11681; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Bassanelli M, 2018, ANTICANCER RES, V38, P3789, DOI 10.21873/anticanres.12662; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Bezzi M, 2018, NAT MED, V24, P165, DOI 10.1038/nm.4463; Bister K, 2015, P NATL ACAD SCI USA, V112, P15259, DOI 10.1073/pnas.1521145112; Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Brandetti E, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1316439; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Burnet F M, 1971, Transplant Rev, V7, P3; Busch SE, 2016, J IMMUNOL, V197, P4493, DOI 10.4049/jimmunol.1600576; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Cheng Y, 2019, BBA-REV CANCER, V1871, P289, DOI 10.1016/j.bbcan.2019.01.005; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi M, 2017, ANN ONCOL, V28, P83, DOI 10.1093/annonc/mdw437; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Coley W B, 1910, Proc R Soc Med, V3, P1; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Dart Anna, 2016, Nat Rev Cancer, V16, P411, DOI 10.1038/nrc.2016.67; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Dey P, 2020, CANCER DISCOV, V10, P608, DOI 10.1158/2159-8290.CD-19-0297; Di Mitri D, 2019, CELL REP, V28, P2156, DOI 10.1016/j.celrep.2019.07.068; DUESBERG PH, 1970, P NATL ACAD SCI USA, V67, P1673, DOI 10.1073/pnas.67.4.1673; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Ehrlich P., 1960, COLLECTED PAPERS P E; Eng CHL, 2019, NATURE, V568, P235, DOI 10.1038/s41586-019-1049-y; Faget J, 2017, CELL REP, V21, P3190, DOI 10.1016/j.celrep.2017.11.052; Falk AT, 2018, LUNG CANCER, V121, P70, DOI 10.1016/j.lungcan.2018.05.009; Fu CM, 2015, P NATL ACAD SCI USA, V112, P2823, DOI 10.1073/pnas.1414167112; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Garcia AJ, 2014, MOL CELL BIOL, V34, P2017, DOI 10.1128/MCB.00090-14; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001; Grunwald BT, 2021, CELL, V184, P5577, DOI 10.1016/j.cell.2021.09.022; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Ham SW, 2019, CELL DEATH DIFFER, V26, P409, DOI 10.1038/s41418-018-0126-3; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hlaing AM, 2018, BIOCHEM BIOPH RES CO, V503, P2764, DOI 10.1016/j.bbrc.2018.08.037; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377; Horton BL, 2019, TRENDS CANCER, V5, P593, DOI 10.1016/j.trecan.2019.07.006; Hurwitz H, 2018, INVEST NEW DRUG, V36, P683, DOI 10.1007/s10637-018-0580-2; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jaspers JE, 2017, PHARMACOL THERAPEUT, V178, P83, DOI 10.1016/j.pharmthera.2017.03.012; Kadara H, 2017, ANN ONCOL, V28, P75, DOI 10.1093/annonc/mdw436; Kargl J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130850; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerr KM, 2019, LUNG CANCER, V131, P95, DOI 10.1016/j.lungcan.2019.03.012; Kim SH, 2017, J INVEST DERMATOL, V137, P1740, DOI 10.1016/j.jid.2017.03.033; Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689; Knox T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42237-3; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Layer JP, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1320626; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee R, 2022, CANCER DISCOV, V12, P1702, DOI 10.1158/2159-8290.CD-21-0680; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li YJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0428; Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008; Ligorio M, 2019, CELL, V178, P160, DOI 10.1016/j.cell.2019.05.012; Liu CM, 2020, CANCER LETT, V470, P95, DOI 10.1016/j.canlet.2019.10.027; Liu HS, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00534-2; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Lubeck E, 2014, NAT METHODS, V11, P360, DOI 10.1038/nmeth.2892; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942; Maddalena M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025631118; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Nakamura K, 2020, CELL MOL IMMUNOL, V17, P1, DOI 10.1038/s41423-019-0306-1; Neubert NJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3311; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Pang L, 2022, TRENDS CANCER; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Pathria P, 2019, TRENDS IMMUNOL, V40, P310, DOI 10.1016/j.it.2019.02.003; Pena CG, 2015, J CLIN INVEST, V125, P4063, DOI 10.1172/JCI82152; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Raedler Lisa A, 2015, Am Health Drug Benefits, V8, P75; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Salgia R, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2020.100186; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Siolas D, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109578; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2016, P NATL ACAD SCI USA, V113, pE7759, DOI 10.1073/pnas.1609376113; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Stromnes IM, 2014, GUT, V63, P1769, DOI 10.1136/gutjnl-2013-306271; Sugiyama E, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3937; Sumimoto H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166626; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Torphy RJ, 2018, ANN GASTROENT SURG, V2, P274, DOI 10.1002/ags3.12176; Umansky V, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040036; Wang DH, 2017, CLIN CANCER RES, V23, P778, DOI 10.1158/1078-0432.CCR-15-2597; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6; Werb Z, 2015, CANCER J, V21, P250, DOI 10.1097/PPO.0000000000000127; White MC, 2014, AM J PREV MED, V46, pS7, DOI 10.1016/j.amepre.2013.10.029; Wormann SM, 2016, GASTROENTEROLOGY, V151, P180, DOI 10.1053/j.gastro.2016.03.010; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yetil A, 2015, ONCOTARGET, V6, P3563, DOI 10.18632/oncotarget.2969; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; Zdanov S, 2016, CANCER IMMUNOL RES, V4, P354, DOI 10.1158/2326-6066.CIR-15-0241; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhao D, 2020, CANCER DISCOV, V10, P1374, DOI 10.1158/2159-8290.CD-19-1352; Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357; Zhao J, 2019, NAT MED, V25, P462, DOI 10.1038/s41591-019-0349-y; Zhao Y, 2020, PHARMACOL THERAPEUT, V212, DOI 10.1016/j.pharmthera.2020.107556; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723; Zucman D, 2018, NEW ENGL J MED, V378, P2144, DOI 10.1056/NEJMc1804812	144	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3821	3829		10.1038/s41388-022-02406-7	http://dx.doi.org/10.1038/s41388-022-02406-7		JUL 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35817840				2022-12-17	WOS:000825078900001
J	Gao, M; Qi, ZJ; Deng, M; Huang, HY; Xu, ZJ; Guo, GJ; Jing, JJ; Huang, XF; Xu, M; Kloeber, JA; Liu, SJ; Huang, JZ; Lou, ZK; Han, JX				Gao, Ming; Qi, Zijuan; Deng, Min; Huang, Hongyang; Xu, Zhijie; Guo, Guijie; Jing, Jiajun; Huang, Xiaofeng; Xu, Ming; Kloeber, Jake A.; Liu, Sijin; Huang, Jinzhou; Lou, Zhenkun; Han, Jinxiang			The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1	ONCOGENE			English	Article							HEME OXYGENASE-1; ARSENIC TOXICITY; UBIQUITINATION; USP7/HAUSP; ACTIVATION; MECHANISMS; CANCER; NRF2; P53	Heme oxygenase-1 (HO-1) is an inducible heme degradation enzyme that plays a cytoprotective role against various oxidative and inflammatory stresses. However, it has also been shown to exert an important role in cancer progression through a variety of mechanisms. Although transcription factors such as Nrf2 are involved in HO-1 regulation, the posttranslational modifications of HO-1 after oxidative insults and the underlying mechanisms remain unexplored. Here, we screened and identified that the deubiquitinase USP7 plays a key role in the control of redox homeostasis through promoting HO-1 deubiquitination and stabilization in hepatocytes. We used low-dose arsenic as a stress model which does not affect the transcriptional level of HO-1, and found that the interaction between USP7 and HO-1 is increased after arsenic exposure, leading to enhanced HO-1 expression and attenuated oxidative damages. Furthermore, HO-1 protein is ubiquitinated at K243 and subjected to degradation under resting conditions; whereas when after arsenic exposure, USP7 itself can be ubiquitinated at K476, thereafter promoting the binding between USP7 and HO-1, finally leading to enhanced HO-1 deubiquitination and protein accumulation. Moreover, depletion of USP7 and HO-1 inhibit liver tumor growth in vivo, and USP7 positively correlates with HO-1 protein level in clinical human hepatocellular carcinoma (HCC) specimens. In summary, our findings reveal a critical role of USP7 as a HO-1 deubiquitinating enzyme in the regulation of oxidative stresses, and suggest that USP7 inhibitor might be a potential therapeutic agent for treating HO-1 overexpressed liver cancers.	[Gao, Ming; Jing, Jiajun; Huang, Xiaofeng; Xu, Ming; Liu, Sijin] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, Beijing 100085, Peoples R China; [Gao, Ming; Jing, Jiajun; Huang, Xiaofeng; Xu, Ming; Liu, Sijin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China; [Qi, Zijuan; Han, Jinxiang] Shandong First Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Jinan 250014, Shandong, Peoples R China; [Deng, Min] Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Deng, Min] Chinese Acad Med Sci, Dept Radiat Oncol, Beijing 100021, Peoples R China; [Huang, Hongyang] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong 999077, Peoples R China; [Xu, Zhijie] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Guo, Guijie; Kloeber, Jake A.; Huang, Jinzhou; Lou, Zhenkun] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Kloeber, Jake A.] Mayo Clin, Mayo Clin Med Scientist Training Program, Rochester, MN 55905 USA	Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shandong First Medical University & Shandong Academy of Medical Sciences; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; University of Hong Kong; Central South University; Mayo Clinic; Mayo Clinic	Han, JX (corresponding author), Shandong First Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Jinan 250014, Shandong, Peoples R China.; Huang, JZ; Lou, ZK (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.	huang.jinzhou@mayo.edu; lou.zhenkun@mayo.edu; jxhan9888@aliyun.com		Kloeber, Jake/0000-0002-6646-564X; Huang, Hongyang/0000-0002-5138-7781	National Natural Science Foundation of China [22076212]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDPB2004]; Science Fund for Creative Research Groups of the National Natural Science Foundation of China [22021003]; Youth Innovation Promotion Association of CAS [2021040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Science Fund for Creative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of CAS	This research was supported by National Natural Science Foundation of China (Grant no. 22076212), Strategic Priority Research Program of the Chinese Academy of Sciences (XDPB2004), Science Fund for Creative Research Groups of the National Natural Science Foundation of China (22021003) and Youth Innovation Promotion Association of CAS (2021040).	Abiko Y, 2010, J TOXICOL SCI, V35, P419, DOI 10.2131/jts.35.419; Alam J, 2007, AM J RESP CELL MOL, V36, P166, DOI 10.1165/rcmb.2006-0340TR; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Fernandez-Montalvan A, 2007, FEBS J, V274, P4256, DOI 10.1111/j.1742-4658.2007.05952.x; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326; Gao M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19202-0; Han JJW, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100732; Hsu FF, 2017, ONCOGENE, V36, P6805, DOI 10.1038/onc.2017.294; Hubaux R, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-20; Hughes MF, 2002, TOXICOL LETT, V133, P1, DOI 10.1016/S0378-4274(02)00084-X; Jomova K, 2011, J APPL TOXICOL, V31, P95, DOI 10.1002/jat.1649; Kashiwaba S, 2015, CELL REP, V13, P2072, DOI 10.1016/j.celrep.2015.11.014; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Khoronenkova SV, 2011, NUCLEIC ACIDS RES, V39, P2604, DOI 10.1093/nar/gkq1210; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kumagai Y, 2007, ANNU REV PHARMACOL, V47, P243, DOI 10.1146/annurev.pharmtox.47.120505.105144; Lee G, 2016, BIOCHEM BIOPH RES CO, V470, P181, DOI 10.1016/j.bbrc.2016.01.021; Lee JG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2532; Li CY, 2020, J HAZARD MATER, V395, DOI 10.1016/j.jhazmat.2020.122588; Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0; Hoang KNL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658315; Morotti A, 2014, LEUKEMIA, V28, P1326, DOI 10.1038/leu.2013.370; Nininahazwe L, 2021, DRUG DISCOV TODAY, V26, P490, DOI 10.1016/j.drudis.2020.10.028; Nitti M, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020029; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Pozhidaeva A, 2019, DNA REPAIR, V76, P30, DOI 10.1016/j.dnarep.2019.02.005; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Song J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1007-9; Soza-Ried C, 2019, CRIT REV ONCOL HEMAT, V139, P128, DOI 10.1016/j.critrevonc.2019.01.012; Srisook K, 2005, ANTIOXID REDOX SIGN, V7, P1674, DOI 10.1089/ars.2005.7.1674; Sun TS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01262-x; Tan JQ, 2020, BIOTECHNOL LETT, V42, P2453, DOI 10.1007/s10529-020-02982-2; Toro A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010035; Waalkes MP, 2004, TOXICOL APPL PHARM, V198, P377, DOI 10.1016/j.taap.2003.10.028; Wang ZR, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00427; Was H, 2010, CURR DRUG TARGETS, V11, P1551, DOI 10.2174/1389450111009011551; Yi GF, 2020, FOOD FUNCT, V11, P2725, DOI 10.1039/c9fo01466g; Zhou J, 2018, MED CHEM, V14, P3, DOI 10.2174/1573406413666171020115539; Zhou Y, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.67; Zhu CP, 2014, SCI REP-UK, V4, DOI 10.1038/srep05029; Zou CX, 2016, ONCOL REP, V36, P2715, DOI 10.3892/or.2016.5056	42	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4018	4027		10.1038/s41388-022-02403-w	http://dx.doi.org/10.1038/s41388-022-02403-w		JUL 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35821281				2022-12-17	WOS:000823350200001
J	Chen, ZZ; Gao, YF; Yao, LT; Liu, YT; Huang, L; Yan, ZY; Zhao, WS; Zhu, PP; Weng, HB				Chen, Zhenzhen; Gao, Yanfeng; Yao, Lintong; Liu, Yating; Huang, Lan; Yan, Zhongyi; Zhao, Wenshan; Zhu, Pingping; Weng, Haibo			LncFZD6 initiates Wnt/beta-catenin and liver TIC self-renewal through BRG1-mediated FZD6 transcriptional activation (vol 37, 3098, 2018)	ONCOGENE			English	Correction												chenzz2015@zzu.edu.cn; pingpingchustc@hotmail.com; whb@zzu.edu.cn						Chen ZZ, 2018, ONCOGENE, V37, P3098, DOI 10.1038/s41388-018-0203-6	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4115	4118	s41388-022-02381-z	10.1038/s41388-022-02381-z	http://dx.doi.org/10.1038/s41388-022-02381-z		JUL 2022	4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35798879	Green Published, Bronze			2022-12-17	WOS:000821721300002
J	Dieter, SM; Lovecchio, D; Pataskar, A; Zowada, MK; Korner, PR; Khalizieva, A; van Tellingen, O; Jager, D; Glimm, H; Agami, R				Dieter, Sebastian M.; Lovecchio, Domenica; Pataskar, Abhijeet; Zowada, Martina K.; Korner, Pierre-Rene; Khalizieva, Anna; van Tellingen, Olaf; Jaeger, Dirk; Glimm, Hanno; Agami, Reuven			Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors	ONCOGENE			English	Article							BRAF(V600E) INHIBITION; MOLECULAR-CLONING; CANCER-CELLS; COLON-CANCER; KAPPA-B; GROWTH; RESISTANCE; HIPPO; YAP; YAP/TAZ	Accumulating evidence identifies non-genetic mechanisms substantially contributing to drug resistance in cancer patients. Preclinical and clinical data implicate the transcriptional co-activators YAP1 and its paralog TAZ in resistance to multiple targeted therapies, highlighting the strong need for therapeutic strategies overcoming YAP1/TAZ-mediated resistance across tumor entities. Here, we show particularly high YAP1/TAZ activity in MITFlow/AXL(high) melanomas characterized by resistance to MAPK pathway inhibition and broad receptor tyrosine kinase activity. To uncover genetic dependencies of melanoma cells with high YAP1/TAZ activity, we used a genome-wide CRISPR/Cas9 functional screen and identified SLC35B2, the 3 '-phosphoadenosine-5 '-phosphosulfate transporter of the Golgi apparatus, as an essential gene for YAP1/TAZ-driven drug resistance. SLC35B2 expression correlates with tumor progression, and its loss decreases heparan sulfate expression, reduces receptor tyrosine kinase activity, and sensitizes resistant melanoma cells to BRAF inhibition in vitro and in vivo. Thus, targeting heparan sulfation via SLC35B2 represents a novel approach for breaking receptor tyrosine kinase-mediated resistance to MAPK pathway inhibitors.	[Dieter, Sebastian M.; Lovecchio, Domenica; Pataskar, Abhijeet; Korner, Pierre-Rene; Khalizieva, Anna; Agami, Reuven] Netherlands Canc Inst, Oncode Inst, Div Oncogen, Amsterdam, Netherlands; [Dieter, Sebastian M.; Zowada, Martina K.] Natl Ctr Tumor Dis NCT, Translat Funct Canc Genom, Heidelberg & German Canc Res Ctr DKFZ, Heidelberg, Germany; [Dieter, Sebastian M.; Glimm, Hanno] Heidelberg Univ Hosp, Dept Med Oncol, Dept Med Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Dieter, Sebastian M.; Jaeger, Dirk; Glimm, Hanno] Dresden & German Canc Res Ctr DKFZ, Dept Translat Med Oncol, Natl Ctr Tumor Dis NCT, Dresden, Germany; [van Tellingen, Olaf] Netherlands Canc Inst, Div Pharmacol, Amsterdam, Netherlands; [Jaeger, Dirk; Glimm, Hanno] German Canc Consortium DKTK, Heidelberg, Germany; [Glimm, Hanno] Tech Univ Dresden, Natl Ctr Tumor Dis NCT, Ctr Personalized Oncol, Dresden & Univ Hosp Carl Gustav Carus Dresden, Dresden, Germany; [Glimm, Hanno] German Canc Consortium DKTK, Dresden, Germany; [Agami, Reuven] Rotterdam Univ, Erasmus MC, Rotterdam, Netherlands	Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Helmholtz Association; German Cancer Research Center (DKFZ); Erasmus University Rotterdam; Erasmus MC	Dieter, SM; Agami, R (corresponding author), Netherlands Canc Inst, Oncode Inst, Div Oncogen, Amsterdam, Netherlands.; Dieter, SM (corresponding author), Natl Ctr Tumor Dis NCT, Translat Funct Canc Genom, Heidelberg & German Canc Res Ctr DKFZ, Heidelberg, Germany.; Dieter, SM (corresponding author), Heidelberg Univ Hosp, Dept Med Oncol, Dept Med Oncol, Natl Ctr Tumor Dis NCT, Heidelberg, Germany.; Dieter, SM (corresponding author), Dresden & German Canc Res Ctr DKFZ, Dept Translat Med Oncol, Natl Ctr Tumor Dis NCT, Dresden, Germany.; Agami, R (corresponding author), Rotterdam Univ, Erasmus MC, Rotterdam, Netherlands.	s.dieter@nki.nl; r.agami@nki.nl	agami, reuven/GOG-8289-2022	Dieter, Sebastian/0000-0003-1324-7638; Agami, Reuven/0000-0002-2848-2473; Zowada, Martina/0000-0002-4231-1021				Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akervall J, 2014, EUR J CANCER, V50, P570, DOI 10.1016/j.ejca.2013.11.007; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biehs B, 2018, NATURE, V562, P429, DOI 10.1038/s41586-018-0596-y; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Cecchi F, 2012, CANCER CELL, V22, P250, DOI 10.1016/j.ccr.2012.06.029; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; D'Arienzo A, 2019, ORTHOP RES REV, V11, P199, DOI 10.2147/ORR.S183979; Dieter SM, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109394; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Gao HX, 2019, VIROLOGY, V529, P91, DOI 10.1016/j.virol.2019.01.019; Germain N, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9120474; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297; Hinata K, 2003, ONCOGENE, V22, P1955, DOI 10.1038/sj.onc.1206198; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Janostiak R, 2019, ISCIENCE, V16, P453, DOI 10.1016/j.isci.2019.06.001; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; Kamiyama S, 2006, J BIOL CHEM, V281, P10945, DOI 10.1074/jbc.M508991200; Kamiyama S, 2003, J BIOL CHEM, V278, P25958, DOI 10.1074/jbc.M302439200; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim MH, 2016, EMBO J, V35, P462, DOI 10.15252/embj.201592081; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Korkmaz G, 2016, NAT BIOTECHNOL, V34, P192, DOI 10.1038/nbt.3450; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li L, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02272-8; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin L, 2015, NAT REV DRUG DISCOV, V14, P543, DOI 10.1038/nrd4626; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Nguyen CDK, 2019, TRENDS CANCER, V5, P283, DOI 10.1016/j.trecan.2019.02.010; Ohkawa Y, 2021, MOL CANCER RES, V19, P150, DOI 10.1158/1541-7786.MCR-20-0420; Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741; Pham TH, 2021, CANCER DISCOV, V11, P778, DOI 10.1158/2159-8290.CD-20-0706; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Reijmers RM, 2010, BLOOD, V115, P601, DOI 10.1182/blood-2009-02-204396; Salgia R, 2018, TRENDS CANCER, V4, P110, DOI 10.1016/j.trecan.2018.01.001; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Thamamongood T, 2020, J VIROL, V94, DOI 10.1128/JVI.00752-20; TheUniProtConsortium, 2017, Nucleic Acids Res, V45, pD158, DOI 10.1093/nar/gkw1099; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang JY, 2017, INT J ONCOL, V50, P345, DOI 10.3892/ijo.2016.3811; Wang Tim, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot090803; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Weiss RJ, 2017, ORG BIOMOL CHEM, V15, P5656, DOI 10.1039/c7ob01058c; Winter J, 2016, BIOINFORMATICS, V32, P632, DOI 10.1093/bioinformatics/btv617; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Yang YS, 2015, MOLECULES, V20, P2138, DOI 10.3390/molecules20022138; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang XM, 2020, ONCOGENE, V39, P5267, DOI 10.1038/s41388-020-1362-9; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	76	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3953	3968		10.1038/s41388-022-02400-z	http://dx.doi.org/10.1038/s41388-022-02400-z		JUL 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798875	Green Published, hybrid			2022-12-17	WOS:000821721300006
J	Liu, F; Zhang, H; Xie, F; Tao, D; Xiao, XY; Huang, C; Wang, M; Gu, CH; Zhang, XP; Jiang, GS				Liu, Feng; Zhang, Hui; Xie, Fei; Tao, Dan; Xiao, Xingyuan; Huang, Chao; Wang, Miao; Gu, Chaohui; Zhang, Xiaoping; Jiang, Guosong			Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis (vol 39, 1696, 2020)	ONCOGENE			English	Correction												xzhang@hust.edu.cn; jiangguosongdoc@hotmail.com						Liu F, 2020, ONCOGENE, V39, P1696, DOI 10.1038/s41388-019-1092-z	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4183	4183	s41388-022-02358-y	10.1038/s41388-022-02358-y	http://dx.doi.org/10.1038/s41388-022-02358-y		JUL 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35798880	Bronze			2022-12-17	WOS:000821721300004
J	Oh, KS; Nam, AR; Bang, JH; Seo, HR; Kim, JM; Yoon, J; Kim, TY; Oh, D				Oh, Kyoung-Seok; Nam, Ah-Rong; Bang, Ju-Hee; Seo, Hye-Rim; Kim, Jae-Min; Yoon, Jeesun; Kim, Tae-Yong; Oh, Do-Youn			A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; ADP-RIBOSYLATION; MECHANISM; PATHWAY; REPAIR; CELLS	Despite its clinical efficacy in HER2-positive cancers, resistance to trastuzumab inevitably occurs. The DNA damage response (DDR) pathway is essential for maintaining genomic stability and cell survival. However, the role of the DDR pathway in HER2-positive tumors and trastuzumab resistance remains elusive. In this study, we verified that increased PARP1 expression in trastuzumab-resistant (TR) cells, owing to its augmented stability by escape from proteasomal degradation, confers tolerability to trastuzumab-induced DNA damage. Interruption of PARP1 in TR cells restrains its cellular growth, while simultaneously activating ATM to retain its genome stability. Dual inhibition of PARP and ATM induces synthetic lethality in TR cells by favoring the toxic NHEJ pathway instead of the HRR pathway. Our results highlight the potential of clinical development of DDR-targeting strategies for trastuzumab-resistant HER2-positive cancer patients.	[Oh, Kyoung-Seok; Nam, Ah-Rong; Bang, Ju-Hee; Seo, Hye-Rim; Kim, Jae-Min; Kim, Tae-Yong; Oh, Do-Youn] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul 03080, South Korea; [Seo, Hye-Rim; Kim, Jae-Min; Oh, Do-Youn] Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul 03080, South Korea; [Yoon, Jeesun; Kim, Tae-Yong; Oh, Do-Youn] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Oh, D (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul 03080, South Korea.; Oh, D (corresponding author), Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul 03080, South Korea.; Oh, D (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea.	ohdoyoun@snu.ac.kr			SNUH research fund [03-2019-0220]; National Research Foundation of Korea (NRF) - Korea government (MSIT) [2021R1A2C2007430]; 3rd AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program [06-2016-2920]; Institute of Smart Healthcare Innovative Medical Sciences, a Brain Korea 21 four program, Seoul National University	SNUH research fund; National Research Foundation of Korea (NRF) - Korea government (MSIT)(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); 3rd AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program; Institute of Smart Healthcare Innovative Medical Sciences, a Brain Korea 21 four program, Seoul National University	This research was supported by the SNUH research fund (Grant No. 03-2019-0220) and the Institute of Smart Healthcare Innovative Medical Sciences, a Brain Korea 21 four program, Seoul National University, and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (Grant No. 2021R1A2C2007430). This research was also supported by 3rd AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program (Grant No. 06-2016-2920).	Balmus G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07729-2; Boone JJM, 2009, MOL CANCER THER, V8, P3015, DOI 10.1158/1535-7163.MCT-09-0219; Britton S, 2020, NUCLEIC ACIDS RES, V48, P9710, DOI 10.1093/nar/gkaa723; Caron MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10741-9; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Ekman S, 2019, ANN ONCOL, V30, P353, DOI 10.1093/annonc/mdz043; Gatti M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107985; Gibbs-Seymour I, 2016, MOL CELL, V62, P432, DOI 10.1016/j.molcel.2016.03.008; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Haince JF, 2007, J BIOL CHEM, V282, P16441, DOI 10.1074/jbc.M608406200; Hu YD, 2014, CANCER DISCOV, V4, P1430, DOI 10.1158/2159-8290.CD-13-0891; Jin MH, 2017, MOL CANCER THER, V16, P1145, DOI 10.1158/1535-7163.MCT-16-0669; Jin MH, 2021, GASTRIC CANCER, V24, P1003, DOI 10.1007/s10120-021-01176-7; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Lae M, 2010, ANN ONCOL, V21, P815, DOI 10.1093/annonc/mdp488; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Li M, 2013, GENE DEV, V27, P1752, DOI 10.1101/gad.226357.113; Lubennikova E, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e12562; Mak JPY, 2020, MOL CANCER THER, V19, P123, DOI 10.1158/1535-7163.MCT-19-0474; Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5; Nam AR, 2016, ONCOTARGET, V7, P58007, DOI 10.18632/oncotarget.11157; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Pilie PG, 2019, CLIN CANCER RES, V25, P3759, DOI 10.1158/1078-0432.CCR-18-0968; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Qian H, 2020, J CELL MOL MED, V24, P4600, DOI 10.1111/jcmm.15121; Riches LC, 2020, MOL CANCER THER, V19, P13, DOI 10.1158/1535-7163.MCT-18-1394; Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100; Smeenk G, 2013, J CELL SCI, V126, P889, DOI 10.1242/jcs.109413; Suskiewicz MJ, 2020, NATURE, V579, P598, DOI 10.1038/s41586-020-2013-6; Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475; Wielgos ME, 2018, MOL CANCER THER, V17, P921, DOI 10.1158/1535-7163.MCT-17-0302; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yarlagadda B, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0091-4; Yazinski SA, 2017, GENE DEV, V31, P318, DOI 10.1101/gad.290957.116	38	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3939	3952		10.1038/s41388-022-02384-w	http://dx.doi.org/10.1038/s41388-022-02384-w		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798878				2022-12-17	WOS:000821721300007
J	Xu, H; Jin, J; Chen, Y; Wu, GQ; Zhu, H; Wang, Q; Wang, J; Li, SG; Grigore, FN; Ma, J; Chen, CC; Lan, Q; Li, M				Xu, Hui; Jin, Jing; Chen, Ying; Wu, Guoqing; Zhu, Hua; Wang, Qing; Wang, Ji; Li, Shenggang; Grigore, Florina-Nicoleta; Ma, Jun; Chen, Clark C.; Lan, Qing; Li, Ming			GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; BREAST-CANCER; STING PATHWAY; NRF2; INFLAMMATION; ACTIVATION; PROTEINS; ADAPTER; HEALTH; GLIOMA	Glioblastoma is the most common malignant brain cancer with dismal survival and prognosis. Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but the emergence of drug resistance limits its anti-tumor activity. We previously discovered that the interferon inducible guanylate binding protein 3 (GBP3) is highly elevated and promotes tumorigenicity of glioblastoma. Here, we show that TMZ treatment significantly upregulates the expression of GBP3 and stimulator of interferon genes (STING), both of which increase TMZ-induced DNA damage repair and reduce cell apoptosis of glioblastoma cells. Mechanistically, relying on its N-terminal GTPase domain, GBP3 physically interacts with STING to stabilize STING protein levels, which in turn induces expression of p62 (Sequestosome 1), nuclear factor erythroid 2 like 2 (NFE2L2, NRF2), and O6-methlyguanine-DNA-methyltransferase (MGMT), leading to the resistance to TMZ treatment. Reducing GBP3 levels by RNA interference in glioblastoma cells markedly increases the sensitivity to TMZ treatment in vitro and in murine glioblastoma models. Clinically, GBP3 expression is high and positively correlated with STING, NRF2, p62, and MGMT expression in human glioblastoma tumors, and is associated with poor outcomes. These findings provide novel insight into TMZ resistance and suggest that GBP3 may represent a novel potential target for the treatment of glioblastoma.	[Xu, Hui; Jin, Jing; Chen, Ying; Wu, Guoqing; Wang, Qing; Wang, Ji; Li, Shenggang; Lan, Qing] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou 215004, Jiangsu, Peoples R China; [Xu, Hui; Lan, Qing] Soochow Univ, Inst Neurosci, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215004, Jiangsu, Peoples R China; [Zhu, Hua] China Med Univ, Hosp 1, Dept Pediat, Shenyang 110122, Liaoning, Peoples R China; [Grigore, Florina-Nicoleta; Ma, Jun; Chen, Clark C.; Li, Ming] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA	Soochow University - China; Soochow University - China; China Medical University; University of Minnesota System; University of Minnesota Twin Cities	Lan, Q (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou 215004, Jiangsu, Peoples R China.; Lan, Q (corresponding author), Soochow Univ, Inst Neurosci, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215004, Jiangsu, Peoples R China.; Li, M (corresponding author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.	szlq006@163.com; m2li@umn.edu	Ma, Jun/ADU-1664-2022	Ma, Jun/0000-0003-0427-8205	National Natural Science Foundation of China [81572480]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Key Laboratory of Minimally Invasive Neurosurgery of Suzhou [SZ2021262]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions; Key Laboratory of Minimally Invasive Neurosurgery of Suzhou	This work was supported by grants from the National Natural Science Foundation of China (81572480), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Key Laboratory of Minimally Invasive Neurosurgery of Suzhou (SZ2021262).	Cheng LF, 2020, INT J ONCOL, V57, P858, DOI 10.3892/ijo.2020.5086; Cheng ZL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0198-7; Cong ZX, 2014, J NEURO-ONCOL, V116, P41, DOI 10.1007/s11060-013-1260-x; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Deng DN, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1004-x; Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3; Dunphy G, 2018, MOL CELL, V71, P745, DOI 10.1016/j.molcel.2018.07.034; Fukumoto M, 2014, CANCER SCI, V105, P1351, DOI 10.1111/cas.12489; Godoy P, 2014, BREAST CANCER-TOKYO, V21, P491, DOI 10.1007/s12282-012-0404-8; Guimaraes DP, 2009, INT J CANCER, V124, P272, DOI 10.1002/ijc.23944; Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017; Kitange GJ, 2009, NEURO-ONCOLOGY, V11, P281, DOI 10.1215/15228517-2008-090; Kwon J, 2020, CANCER DISCOV, V10, P26, DOI 10.1158/2159-8290.CD-19-0761; Li M, 2017, ONCOTARGET, V8, P55319, DOI 10.18632/oncotarget.19429; Li M, 2011, J EXP MED, V208, P2657, DOI 10.1084/jem.20111102; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Liu JH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01641-8; Liu YX, 2007, P NATL ACAD SCI USA, V104, P5205, DOI 10.1073/pnas.0700898104; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Ma LN, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0517-y; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Nordmann A, 2012, FASEB J, V26, P1290, DOI 10.1096/fj.11-189886; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Paranjpe A, 2016, J BIOMED RES, V30, P393, DOI 10.7555/JBR.30.20160040; Pilla-Moffett D, 2016, J MOL BIOL, V428, P3495, DOI 10.1016/j.jmb.2016.04.032; Polonen P, 2019, ONCOGENE, V38, P7473, DOI 10.1038/s41388-019-0956-6; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Quintero M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3726-2; Rocha CRR, 2016, ONCOTARGET, V7, P48081, DOI 10.18632/oncotarget.10129; Reislander T, 2020, MOL CELL, V80, P21, DOI 10.1016/j.molcel.2020.07.026; Ryoo IG, 2018, REDOX BIOL, V17, P246, DOI 10.1016/j.redox.2018.04.015; Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651; Storozynsky Q, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228877; Tretina K, 2019, J EXP MED, V216, P482, DOI 10.1084/jem.20182031; Vashi N, 2021, TRENDS BIOCHEM SCI, V46, P446, DOI 10.1016/j.tibs.2020.12.010; Wang J, 2020, J CELL BIOCHEM, V121, P1250, DOI 10.1002/jcb.29358; Wu JF, 2019, BIOCHEM BIOPH RES CO, V518, P698, DOI 10.1016/j.bbrc.2019.08.113; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Xu H, 2018, BIOCHEM BIOPH RES CO, V495, P446, DOI 10.1016/j.bbrc.2017.11.050; Yu SY, 2020, ONCOGENE, V39, P5042, DOI 10.1038/s41388-020-1348-7; Yu XT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03492-3; Zhang Q, 2019, CELL DEATH DIFFER, V26, P2300, DOI 10.1038/s41418-019-0303-z; Zhao J, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01494; Zheng JY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01250-1	44	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3876	3885		10.1038/s41388-022-02397-5	http://dx.doi.org/10.1038/s41388-022-02397-5		JUL 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780181				2022-12-17	WOS:000819907600003
J	Ying, C; Jin, CM; Zeng, SY; Chao, M; Hu, X				Ying, Chang; Jin, Chengmeng; Zeng, Siying; Chao, Ming; Hu, Xun			Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function	ONCOGENE			English	Article							PERMEABILITY TRANSITION PORE; ACTIVATED PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; INHIBITION; AMPK; MODULATION; MACHINERY; APOPTOSIS; EFFICACY	We previously found that lactic acidosis in the tumor environment was permissive to cancer cell surviving under glucose deprivation and demonstrated that neutralizing lactic acidosis restored cancer cell susceptibility to glucose deprivation. We then reported that alternate infusion of bicarbonate and anticancer agent into tumors via tumor feeding artery markedly enhanced the efficacy of transarterial chemoembolization (TACE) in the local control of hepatocellular carcinoma (HCC). Here we sought to further investigate the mechanism by which bicarbonate enhances the anticancer activity of TACE. We propose that interfering cellular pH by bicarbonate could induce a cascade of molecular events leading to cancer cell death. Alkalizing cellular pH by bicarbonate decreased pH gradient (Delta pH), membrane potential (Delta psi(m)), and proton motive force (Delta p) across the inner membrane of mitochondria; disruption of oxidative phosphorylation (OXPHOS) due to collapsed Delta p led to a significant increase in adenosine monophosphate (AMP), which activated the classical AMPK-mediated autophagy. Meanwhile, the autophagic flux was ultimately blocked by increased cellular pH, reduced OXPHOS, and inhibition of lysosomal proton pump in alkalized lysosome. Bicarbonate also induced persistent mitochondrial permeability (MPT) and damaged mitochondria. Collectively, this study reveals that interfering cellular pH may provide a valuable approach to treat cancer.	[Ying, Chang; Jin, Chengmeng; Zeng, Siying; Hu, Xun] Zhejiang Univ, Affiliated Hosp 2, Canc Inst,Key Lab Canc Intervent & Prevent, Sch Med,China Natl Minist Educ,Zhejiang Prov Key, Hangzhou, Peoples R China; [Chao, Ming] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Intervent Radiol,Dept Radiol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Hu, X (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Canc Inst,Key Lab Canc Intervent & Prevent, Sch Med,China Natl Minist Educ,Zhejiang Prov Key, Hangzhou, Peoples R China.; Chao, M (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Intervent Radiol,Dept Radiol, Hangzhou, Peoples R China.	chaoming@zju.edu.cn; huxun@zju.edu.cn	Zeng, Siying/HDO-3064-2022		China Natural Sciences Foundation [82073038, 81772947]; Zhejiang Provincial Department of Sciences and Technologies [2018C03009]; Fundamental Research Funds for the Central Universities [2017XZZX001-01, 2019FZJD009]; National Ministry of Education, China	China Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Department of Sciences and Technologies; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Ministry of Education, China(Ministry of Education, China)	This work has been supported in part by China Natural Sciences Foundation projects (82073038, 81772947 to XH), a key project (2018C03009) funded by Zhejiang Provincial Department of Sciences and Technologies (to XH & MC), and the Fundamental Research Funds for the Central Universities (2017XZZX001-01, 2019FZJD009, to XH), National Ministry of Education, China. We thank Dr. Guo-Hua Fong (University of Connecticut School of Medicine, USA) for critical readings of our manuscript and constructive comments, Dr. Wei Liu (Zhejiang University) for the kind gift of plasmids GFP-LC3, Cherry-GFP-LC3, and Dr. Shanrong Cai for the statistical assistance (Zhejiang University).	Ahmad F, 2019, J LIPID RES, V60, P98, DOI 10.1194/jlr.M088245; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bartel K, 2019, J BIOL CHEM, V294, P17239, DOI 10.1074/jbc.RA119.010243; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Caricato R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00319; Chao M, 2016, ELIFE, V5, DOI [10.7754/eLife.15691, 10.7554/eLife.15691]; Chen JC, 2019, J BIOL CHEM, V294, P11994, DOI 10.1074/jbc.RA118.007161; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Vasconcelos NM, 2019, CELL DEATH DIFFER, V26, P146, DOI 10.1038/s41418-018-0106-7; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; Gong YN, 2017, CELL, V169, P286, DOI 10.1016/j.cell.2017.03.020; Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018; Gowans GJ, 2013, CELL METAB, V18, P556, DOI 10.1016/j.cmet.2013.08.019; Hawley SA, 2016, DIABETES, V65, P2784, DOI 10.2337/db16-0058; Hu X, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.47; Ibrahim-Hashim A, 2012, J UROLOGY, V188, P624, DOI 10.1016/j.juro.2012.03.113; Jansen MC, 2005, EJSO-EUR J SURG ONC, V31, P331, DOI 10.1016/j.ejso.2004.10.011; Jin CM, 2020, J BIOL CHEM, V295, P6425, DOI 10.1074/jbc.RA119.012312; Ju JS, 2010, AUTOPHAGY, V6, P929, DOI 10.4161/auto.6.7.12785; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kloditz K, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0146-x; Lencioni R, 2016, HEPATOLOGY, V64, P106, DOI 10.1002/hep.28453; Liu B, 2014, AUTOPHAGY, V10, P416, DOI 10.4161/auto.27286; Liu J, 2020, CELL CHEM BIOL, V27, P420, DOI 10.1016/j.chembiol.2020.02.005; Liu YE, 2020, MEDCOMM, V1, P129, DOI 10.1002/mco2.16; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Malhi H, 2006, HEPATOLOGY, V43, pS31, DOI 10.1002/hep.21062; Martin NK, 2012, BRIT J CANCER, V106, P1280, DOI 10.1038/bjc.2012.58; Martin NK, 2011, MATH BIOSCI, V230, P1, DOI 10.1016/j.mbs.2010.12.002; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Pasquier A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11170-4; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610; Piscaglia F, 2018, LIVER CANCER, V7, P104, DOI 10.1159/000485471; Piscaglia F, 2010, DIGEST LIVER DIS, V42, pS258, DOI 10.1016/S1590-8658(10)60514-2; Poburko D, 2011, J BIOL CHEM, V286, P11672, DOI 10.1074/jbc.M110.159962; Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007; Shlomovitz I, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0437-0; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Wu H, 2012, J PATHOL, V227, P189, DOI 10.1002/path.3978; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Xie JS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04927; Yang KX, 2016, NANOMEDICINE-UK, V11, DOI 10.2217/nnm-2016-0289; Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865; Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997; Zargarian S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002711; Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667	58	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3886	3897		10.1038/s41388-022-02396-6	http://dx.doi.org/10.1038/s41388-022-02396-6		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780182				2022-12-17	WOS:000819907600001
J	Zeng, YJ; Yin, L; Zhou, JL; Zeng, RY; Xiao, Y; Black, AR; Hu, T; Singh, PK; Yin, F; Batra, SK; Yu, F; Chen, YH; Dong, JX				Zeng, Yongji; Yin, Ling; Zhou, Jiuli; Zeng, Renya; Xiao, Yi; Black, Adrian R.; Hu, Tuo; Singh, Pankaj K.; Yin, Feng; Batra, Surinder K.; Yu, Fang; Chen, Yuanhong; Dong, Jixin			MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; HIPPO PATHWAY; MITOTIC PHOSPHORYLATION; NAB-PACLITAXEL; SIZE-CONTROL; MITOSIS; KINASE; GROWTH; GEMCITABINE; HOMEOSTASIS	Despite paclitaxel's wide use in cancer treatment, patient response rate is still low and drug resistance is a major clinical obstacle. Through a Phos-tag-based kinome-wide screen, we identified MARK2 as a critical regulator for paclitaxel chemosensitivity in PDAC. We show that MARK2 is phosphorylated by CDK1 in response to antitubulin chemotherapeutics and in unperturbed mitosis. Phosphorylation is essential for MARK2 in regulating mitotic progression and paclitaxel cytotoxicity in PDAC cells. Mechanistically, our findings also suggest that MARK2 controls paclitaxel chemosensitivity by regulating class IIa HDACs. MARK2 directly phosphorylates HDAC4 specifically during antitubulin treatment. Phosphorylated HDAC4 promotes YAP activation and controls expression of YAP target genes induced by paclitaxel. Importantly, combination of HDAC inhibition and paclitaxel overcomes chemoresistance in organoid culture and preclinical PDAC animal models. The expression levels of MARK2, HDACs, and YAP are upregulated and positively correlated in PDAC patients. Inhibition of MARK2 or class IIa HDACs potentiates paclitaxel cytotoxicity by inducing mitotic abnormalities in PDAC cells. Together, our findings identify the MARK2-HDAC axis as a druggable target for overcoming chemoresistance in PDAC.	[Zeng, Yongji; Yin, Ling; Zhou, Jiuli; Zeng, Renya; Xiao, Yi; Black, Adrian R.; Hu, Tuo; Singh, Pankaj K.; Chen, Yuanhong; Dong, Jixin] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Yin, Feng] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Yu, Fang] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA; [Zhou, Jiuli] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Tongji University	Dong, JX (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	dongj@unmc.edu	Hu, Tuo/HDM-3005-2022; Yin, Ling/AAD-8990-2022	Hu, Tuo/0000-0001-7069-1466; Yin, Ling/0000-0003-1606-2620; Zeng, Yongji/0000-0002-1184-1900; Singh, Pankaj/0000-0001-8903-0131; Batra, Surinder K./0000-0001-9470-9317	Fred & Pamela Buffett Cancer Center Support Grant [P30 CA036727]; National Institutes of Health (NIH) [R01 GM109066]	Fred & Pamela Buffett Cancer Center Support Grant; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Xiao-long Yang (Queens University) for the TetO-shCDK1 HeLa cell line. All fluorescence images were acquired by a Zeiss LSM 800 microscope and processed with accompanying software at the Advanced Microscopy Core at the University of Nebraska Medical Center. Research in the Dong laboratory is supported by Fred & Pamela Buffett Cancer Center Support Grant (P30 CA036727) and R01 GM109066 from the the National Institutes of Health (NIH). We are very grateful to Dr. Joyce Solheim for critical reading and comments on the paper.	Adamska Aleksandra, 2018, Advances in Biological Regulation, V68, P77, DOI 10.1016/j.jbior.2017.11.007; Ahrari S, 2017, ARCH BIOCHEM BIOPHYS, V630, P66, DOI 10.1016/j.abb.2017.07.002; Arash EH, 2017, EMBO REP, V18, P420, DOI 10.15252/embr.201642455; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Chen XC, 2016, CELL SIGNAL, V28, P1826, DOI 10.1016/j.cellsig.2016.08.013; Chen XC, 2016, J BIOL CHEM, V291, P14761, DOI 10.1074/jbc.M116.722751; Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775; Dequiedt F, 2006, MOL CELL BIOL, V26, P7086, DOI 10.1128/MCB.00231-06; Dietrich CS, 2010, GYNECOL ONCOL, V116, P126, DOI 10.1016/j.ygyno.2009.09.039; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dowdy SC, 2006, MOL CANCER THER, V5, P2767, DOI 10.1158/1535-7163.MCT-06-0209; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Duong-Ly Krisna C, 2013, Curr Protoc Pharmacol, VChapter 2, DOI 10.1002/0471141755.ph0209s60; Fu V, 2017, CURR OPIN CELL BIOL, V49, P99, DOI 10.1016/j.ceb.2017.12.012; Goodwin JM, 2014, MOL CELL, V55, P436, DOI 10.1016/j.molcel.2014.06.021; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henriques AC, 2019, CANCER LETT, V440, P64, DOI 10.1016/j.canlet.2018.10.005; Hessmann E, 2017, GUT, V66, P168, DOI 10.1136/gutjnl-2016-312539; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huang HL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001620; Hubaux R, 2015, INT J CANCER, V137, P2072, DOI 10.1002/ijc.29577; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Jenardhanan P, 2014, MOL BIOSYST, V10, P1845, DOI 10.1039/c3mb70591a; Kato T, 2001, NEOPLASIA, V3, P4, DOI 10.1038/sj.neo.7900132; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; Koutsounas I, 2013, WORLD J GASTROENTERO, V19, P1173, DOI 10.3748/wjg.v19.i8.1173; Kwan J, 2016, GENE DEV, V30, P2696, DOI 10.1101/gad.284539.116; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Ma A, 2001, MOL BIOL CELL, V12, P1; Ma WW, 2013, CLIN CANCER RES, V19, P5572, DOI 10.1158/1078-0432.CCR-13-1356; Magnani I, 2011, ANAL CELL PATHOL, V34, P319, DOI [10.1155/2011/206756, 10.3233/ACP-2011-0031]; Maugeri-Sacca M, 2018, PHARMACOL THERAPEUT, V186, P60, DOI 10.1016/j.pharmthera.2017.12.011; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723; Natalia MA., 2018, CELLS MICRORNA, V7, P54, DOI [10.2174/2211536606666171024160244, DOI 10.2174/2211536606666171024160244]; Ni X, 2015, ONCOL LETT, V9, P515, DOI 10.3892/ol.2014.2714; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Pardo OE, 2016, EMBO REP, V17, P570, DOI 10.15252/embr.201540970; Qiu Wanglong, 2013, Methods Mol Biol, V980, P215, DOI 10.1007/978-1-62703-287-2_11; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Roche J, 2016, EUR J MED CHEM, V121, P451, DOI 10.1016/j.ejmech.2016.05.047; Sarantis P, 2020, WORLD J GASTRO ONCOL, V12, DOI 10.4251/wjgo.v12.i2.173; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sild M, 2019, MOL PSYCHIATR, V24, P1425, DOI 10.1038/s41380-019-0366-8; Sinn M, 2017, J CLIN ONCOL, V35, P3330, DOI 10.1200/JCO.2017.72.6463; Stauffer S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236000; Stauffer S, 2017, CELL SIGNAL, V39, P74, DOI 10.1016/j.cellsig.2017.08.001; Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092; Tang EI, 2013, J ENDOCRINOL, V217, pR13, DOI 10.1530/JOE-12-0586; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Tsai HC, 2014, BBA-MOL CELL RES, V1843, P846, DOI 10.1016/j.bbamcr.2014.01.007; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742; Wanek J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103128; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.328; Wang Z, 2018, CELL SIGNAL, V52, P137, DOI 10.1016/j.cellsig.2018.09.007; Wang ZK, 2014, EPIGENOMICS-UK, V6, P139, DOI 10.2217/epi.13.73; Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14-04-0916; Woodring PJ, 2005, J BIOL CHEM, V280, P10318, DOI 10.1074/jbc.M410658200; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yang CPH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081733; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhang L, 2012, J BIOL CHEM, V287, P34069, DOI 10.1074/jbc.M112.385518; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao YL, 2015, ONCOTARGET, V6, P21906, DOI 10.18632/oncotarget.4259; Zhou JL, 2018, P NATL ACAD SCI USA, V115, pE6760, DOI 10.1073/pnas.1800621115	79	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3859	3875		10.1038/s41388-022-02399-3	http://dx.doi.org/10.1038/s41388-022-02399-3		JUL 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780183	Green Submitted			2022-12-17	WOS:000819907600002
J	Wenta, T; Schmidt, A; Zhang, Q; Devarajan, R; Singh, P; Yang, XY; Ahtikoski, A; Vaarala, M; Wei, GH; Manninen, A				Wenta, Tomasz; Schmidt, Anette; Zhang, Qin; Devarajan, Raman; Singh, Prateek; Yang, Xiayun; Ahtikoski, Anne; Vaarala, Markku; Wei, Gong-Hong; Manninen, Aki			Disassembly of alpha 6 beta 4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions	ONCOGENE			English	Article							EXPRESSION; INTEGRIN; INHIBITION; LANDSCAPE; CARCINOMA; EVOLUTION; HALLMARKS; INVASION; TUMORS; CELLS	Loss of alpha 6 beta 4-dependent hemidesmosomal adhesions has been observed during prostate cancer progression. However, the significance and underlying mechanisms by which aberrant hemidesmosome assembly may modulate tumorigenesis remain elusive. Using an extensive CRISPR/Cas9-mediated genetic engineering approaches in different prostate cancer cell lines combined with in vivo tumorigenesis studies in mice, bone marrow-on-chip assays and bioinformatics, as well as histological analysis of prostate cancer patient cohorts, we demonstrated that simultaneous loss of PTEN and hemidesmosomal adhesions induced several tumorigenic properties including proliferation, migration, resistance to anoikis, apoptosis, and drug treatment in vitro, and increased metastatic capacity in vivo. These effects were plectin-depended and plectin was associated with actin-rich adhesions upon hemidesmosome disruption in PTEN-negative prostate cancer cells leading to activation of EGFR/PI3K/Akt- and FAK/Src-pathways. These results suggest that analysis of PTEN and hemidesmosomal proteins may have diagnostic value helping to stratify prostate cancer patients with high risk for development of aggressive disease and highlight actin-associated plectin as a potential therapeutic target specifically in PTEN/hemidesmosome dual-negative prostate cancer.	[Wenta, Tomasz; Schmidt, Anette; Zhang, Qin; Devarajan, Raman; Yang, Xiayun; Wei, Gong-Hong; Manninen, Aki] Univ Oulu, Fac Biochem & Mol Med, Dis Networks Res Unit, Oulu, Finland; [Singh, Prateek] Finnadvance, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Dept Urol, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Dept Pathol, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Dept Radiol, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Oulu Univ Hosp, Med Res Ctr, Oulu, Finland; [Ahtikoski, Anne; Vaarala, Markku] Univ Oulu, Oulu, Finland; [Wei, Gong-Hong] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Wei, Gong-Hong] Fudan Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Shanghai, Peoples R China; [Wei, Gong-Hong] Fudan Univ, Key Lab Metab & Mol Med, Minist Educ, Sch Basic Med Sci, Shanghai, Peoples R China	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; Fudan University; Fudan University; Fudan University	Manninen, A (corresponding author), Univ Oulu, Fac Biochem & Mol Med, Dis Networks Res Unit, Oulu, Finland.	aki.manninen@oulu.fi	Devarajan, Raman/GOH-0098-2022; Manninen, Aki/AAC-8067-2019; Ahtikoski, Anne/GQH-8901-2022; Vaarala, Markku/B-4116-2013	Manninen, Aki/0000-0002-6263-8101; Ahtikoski, Anne/0000-0003-4100-5900; Vaarala, Markku/0000-0003-4735-815X; Wenta, Tomasz/0000-0002-1927-9959	University of Oulu including Oulu University Hospital	University of Oulu including Oulu University Hospital	Open Access funding provided by University of Oulu including Oulu University Hospital.	Alix-Panabieres C, 2021, CANCER DISCOV, V11, P858, DOI 10.1158/2159-8290.CD-20-1311; Allen MV, 1998, HUM PATHOL, V29, P311, DOI 10.1016/S0046-8177(98)90109-5; Andrews S., 2010, FASTQC QUALITY CONTR; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Bausch D, 2011, CLIN CANCER RES, V17, P302, DOI 10.1158/1078-0432.CCR-10-0999; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Buckup M, 2021, ONCOGENE, V40, P663, DOI 10.1038/s41388-020-01557-9; Burch TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065005; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaudhari PR, 2017, EXP CELL RES, V360, P125, DOI 10.1016/j.yexcr.2017.08.034; Cooperberg MR, 2009, JNCI-J NATL CANCER I, V101, P878, DOI 10.1093/jnci/djp122; COX DR, 1972, J R STAT SOC B, V34, P187; Dasari A, 2020, NAT REV CLIN ONCOL, V17, P757, DOI 10.1038/s41571-020-0392-0; Davis TL, 2001, PROSTATE, V46, P240; Demetriou MC, 2004, J CELL BIOCHEM, V91, P26, DOI 10.1002/jcb.10675; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; Gerhauser C, 2018, CANCER CELL, V34, P996, DOI 10.1016/j.ccell.2018.10.016; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kang HM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180251; Kassambara A., 2020, RSTATIX PIPE FRIENDL; Katada K, 2012, J PROTEOMICS, V75, P1803, DOI 10.1016/j.jprot.2011.12.018; KNOX JD, 1994, AM J PATHOL, V145, P167; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Latonen L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03573-6; Litjens SHM, 2006, TRENDS CELL BIOL, V16, P376, DOI 10.1016/j.tcb.2006.05.004; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martini V, 2019, CANCERS, V11, DOI 10.3390/cancers11111659; Myllymaki S-M, 2019, MATTERS, DOI [10.19185/matters.201902000007, DOI 10.19185/MATTERS.201902000007]; Myllymaki SM, 2019, MOL CELL PROTEOMICS, V18, P277, DOI 10.1074/mcp.RA118.001095; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Dalton GN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1535-z; Okubo K, 2017, EJSO-EUR J SURG ONC, V43, P1050, DOI 10.1016/j.ejso.2017.01.241; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; R Core Team, 2022, R LANG ENV STAT COMP; R Studio Team, 2019, R STUDIO INTEGRATED; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sandhofer N, 2015, LEUKEMIA, V29, P828, DOI 10.1038/leu.2014.305; Sartor AO, 2008, UROLOGY, V72, P12, DOI 10.1016/j.urology.2008.10.004; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Sinha A, 2019, CANCER CELL, V35, P414, DOI 10.1016/j.ccell.2019.02.005; Song BG, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.616440; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Therneau T., **DATA OBJECT**; TM Therneau., 2000, MODELING SURVIVAL DA, DOI DOI 10.1007/978; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Turnham DJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112342; van den Dries K, 2013, MOL BIOL CELL, V24, P2112, DOI 10.1091/mbc.E12-12-0856; van den Dries K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2402; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Walko G, 2015, CELL TISSUE RES, V360, P529, DOI 10.1007/s00441-015-2216-6; Wang W, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201904137; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Whitington T, 2016, NAT GENET, V48, P387, DOI 10.1038/ng.3523; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang K, 2017, ONCOGENE, V36, P5681, DOI 10.1038/onc.2017.177	72	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3804	3820		10.1038/s41388-022-02389-5	http://dx.doi.org/10.1038/s41388-022-02389-5		JUL 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35773413	Green Published, hybrid			2022-12-17	WOS:000819316400001
J	Pan, D; Yang, WW; Zeng, Y; Qin, HK; Xu, YT; Gui, YP; Fan, XS; Tian, G; Wu, YJ; Sun, HP; Ye, YT; Yang, SH; Zhou, JY; Guo, QL; Zhao, L				Pan, Di; Yang, Wanwan; Zeng, Yao; Qin, Hongkun; Xu, Yuting; Gui, Yanping; Fan, Xiangshan; Tian, Geng; Wu, Yujia; Sun, Haopeng; Ye, Yuting; Yang, Shihe; Zhou, Jieying; Guo, Qinglong; Zhao, Li			AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma	ONCOGENE			English	Article							KETO REDUCTASE 1C3	Aldo-keto reductase family 1 member C3 (AKR1C3) serves as a contributor to numerous kinds of tumors, and its expression is elevated in patients with hepatocellular carcinoma (HCC). However, the biological function of AKR1C3 in HCC remains unclear. Here we investigated the role of AKR1C3 in liver carcinogenesis using in vitro and in vivo models. We determined that AKR1C3 is frequently increased in HCC tissues with poor prognosis. Genetically manipulated cells with AKR1C3 construction were examined to highlight the pro-tumoral growth of both wild-type AKR1C3 and mutant in vitro and in vivo. We observed promising treatment effects of AKR1C3 shRNA by intratumoral injection in mice. Mechanically, we demonstrated that the transcription factor heterodimer NRF2/MAFG was able to bind directly to AKR1C3 promoter to activate its transcription. Further, AKR1C3 stabilized PARP1 by decreasing its ubiquitination, which resulted in HCC cell proliferation and low sensitivity of Cisplatin. Moreover, we discovered that the tumorigenic role of AKR1C3 was non-catalytic dependent and the NRF2/MAFG-AKR1C3-PARP1 axis might be one of the important proliferation pathways in HCC. In conclusion, blockage of AKR1C3 expression provides potential therapeutic benefits against HCC.	[Pan, Di; Yang, Wanwan; Zeng, Yao; Qin, Hongkun; Xu, Yuting; Gui, Yanping; Tian, Geng; Wu, Yujia; Ye, Yuting; Yang, Shihe; Guo, Qinglong; Zhao, Li] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Physiol, Nanjing 211198, Jiangsu, Peoples R China; [Pan, Di] Guizhou Med Univ, Sch Pharmaceut Sci, Key Lab Optimal Utilizat Nat Med Resources, Guiyang 550025, Guizhou, Peoples R China; [Fan, Xiangshan] Nanjing Univ, Sch Med, Dept Pathol, Nanjing Drum Tower Hosp, Nanjing 210000, Jiangsu, Peoples R China; [Sun, Haopeng] China Pharmaceut Univ, Dept Pharm, Nanjing 211198, Jiangsu, Peoples R China; [Zhou, Jieying] Florida Int Univ, Dept Chem & Biochem, Miami, FL 33199 USA; [Guo, Qinglong] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Jiangsu, Peoples R China	China Pharmaceutical University; Guizhou Medical University; Nanjing University; China Pharmaceutical University; State University System of Florida; Florida International University; China Pharmaceutical University	Guo, QL; Zhao, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Physiol, Nanjing 211198, Jiangsu, Peoples R China.; Guo, QL (corresponding author), China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Jiangsu, Peoples R China.	anticancer_drug@163.com; zhaoli@cpu.edu.cn	yang, wanwan/GZM-4650-2022	wu, wu yu jia/0000-0001-9542-273X; Tian, Geng/0000-0001-6320-6346; fan, xiangshan/0000-0003-4552-5858	Key Program of the National Science Foundation of China [81830105]; National Science Foundation of China [81773774]	Key Program of the National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Key Program of the National Science Foundation of China (81830105); the program of the National Science Foundation of China (81773774).	Bortolozzi R, 2018, BRIT J CANCER, V118, P985, DOI 10.1038/s41416-018-0014-0; Cao CG, 2020, J MED CHEM, V63, P11012, DOI 10.1021/acs.jmedchem.0c00821; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Curtin NJ, 2020, NAT REV DRUG DISCOV, V19, P711, DOI 10.1038/s41573-020-0076-6; Dong QZ, 2019, CANCER RES, V79, P819, DOI 10.1158/0008-5472.CAN-18-1273; Feng M, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.100032; Gatti M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107985; Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827; Hu ZH, 2021, ONCOGENE, V40, P647, DOI 10.1038/s41388-020-01551-1; Jackson VJ, 2012, ACTA CRYSTALLOGR F, V68, P409, DOI 10.1107/S1744309112009049; Katsuoka F, 2016, GENE, V586, P197, DOI 10.1016/j.gene.2016.03.058; Kim SY, 2021, ONCOGENE, V40, P4652, DOI 10.1038/s41388-021-01875-6; Ko HL, 2011, HEPATOLOGY, V54, P1190, DOI 10.1002/hep.24502; Rizner TL, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104446; Liu Y, 2020, J MED CHEM, V63, P11305, DOI 10.1021/acs.jmedchem.9b02138; Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3; Mantel A, 2012, J INVEST DERMATOL, V132, P1103, DOI 10.1038/jid.2011.412; Matsunaga T, 2020, CHEM-BIOL INTERACT, V332, DOI 10.1016/j.cbi.2020.109295; Noordermeer SM, 2019, TRENDS CELL BIOL, V29, P820, DOI 10.1016/j.tcb.2019.07.008; Penning TM, 2019, ENDOCR REV, V40, P447, DOI 10.1210/er.2018-00089; Penning TM, 2019, MOL CELL ENDOCRINOL, V489, P82, DOI 10.1016/j.mce.2018.07.002; Penning TM, 2017, EXPERT OPIN THER PAT, V27, P1329, DOI 10.1080/13543776.2017.1379503; Penning TM, 2015, CHEM-BIOL INTERACT, V234, P236, DOI 10.1016/j.cbi.2014.09.024; Powell K, 2015, CLIN CANCER RES, V21, P2569, DOI 10.1158/1078-0432.CCR-14-2352; Rheinbay E, 2020, NATURE, V578, P102, DOI 10.1038/s41586-020-1965-x; Ricciotti E, 2021, CANCER RES, V81, P3751, DOI 10.1158/0008-5472.CAN-21-0758; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Vallim TQD, 2015, CELL METAB, V21, P298, DOI 10.1016/j.cmet.2015.01.007; Velica P, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-121; Vera-Puente O, 2018, TRANSL RES, V200, P1, DOI 10.1016/j.trsl.2018.06.005; Wu T, 2014, FREE RADICAL BIO MED, V67, P69, DOI 10.1016/j.freeradbiomed.2013.10.806; Xie L, 2013, CANCER GENE THER, V20, P260, DOI 10.1038/cgt.2013.15; Zeng CM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00119; Zhang L, 2019, NUCLEIC ACIDS RES, V47, P8502, DOI 10.1093/nar/gkz545; Zhao QY, 2019, CHEM COMMUN, V55, P369, DOI 10.1039/c8cc07813k; Zhao SF, 2019, ONCOL LETT, V18, P4515, DOI 10.3892/ol.2019.10802; Zhou QQ, 2021, CANCER RES, V81, P1361, DOI 10.1158/0008-5472.CAN-20-2480	37	0	0	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3846	3858		10.1038/s41388-022-02379-7	http://dx.doi.org/10.1038/s41388-022-02379-7		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35773412				2022-12-17	WOS:000819316500001
J	Tarantino, D; Walker, C; Weekes, D; Pemberton, H; Davidson, K; Torga, G; Frankum, J; Mendes-Pereira, AM; Prince, C; Ferro, R; Brough, R; Pettitt, SJ; Lord, CJ; Grigoriadis, A; Tutt, ANJ				Tarantino, Dalia; Walker, Callum; Weekes, Daniel; Pemberton, Helen; Davidson, Kathryn; Torga, Gonzalo; Frankum, Jessica; Mendes-Pereira, Ana M.; Prince, Cynthia; Ferro, Riccardo; Brough, Rachel; Pettitt, Stephen J.; Lord, Christopher J.; Grigoriadis, Anita; Tutt, Andrew N. J.			Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance	ONCOGENE			English	Article							DNA-POLYMERASES; BREAST-CANCER; EXPRESSION; INHIBITOR; MUTATIONS; BRCANESS; TUMORS	HORMAD1 expression is usually restricted to germline cells, but it becomes mis-expressed in epithelial cells in similar to 60% of triple-negative breast cancers (TNBCs), where it is associated with elevated genomic instability (1). HORMAD1 expression in TNBC is bimodal with HORMAD1-positive TNBC representing a biologically distinct disease group. Identification of HORMAD1-driven genetic dependencies may uncover novel therapies for this disease group. To study HORMAD1-driven genetic dependencies, we generated a SUM159 cell line model with doxycycline-inducible HORMAD1 that replicated genomic instability phenotypes seen in HORMAD1-positive TNBC (1). Using small interfering RNA screens, we identified candidate genes whose depletion selectively inhibited the cellular growth of HORMAD1-expressing cells. We validated five genes (ATR, BRIP1, POLH, TDP1 and XRCC1), depletion of which led to reduced cellular growth or clonogenic survival in cells expressing HORMAD1. In addition to the translesion synthesis (TLS) polymerase POLH, we identified a HORMAD1-driven dependency upon additional TLS polymerases, namely POLK, REV1, REV3L and REV7. Our data confirms that out-of-context somatic expression of HORMAD1 can lead to genomic instability and reveals that HORMAD1 expression induces dependencies upon replication stress tolerance pathways, such as translesion synthesis. Our data also suggest that HORMAD1 expression could be a patient selection biomarker for agents targeting replication stress.	[Tarantino, Dalia; Weekes, Daniel; Mendes-Pereira, Ana M.; Prince, Cynthia; Ferro, Riccardo; Grigoriadis, Anita; Tutt, Andrew N. J.] Kings Coll London, Breast Canc Now Res Unit, London, England; [Tarantino, Dalia; Weekes, Daniel; Mendes-Pereira, Ana M.; Prince, Cynthia; Ferro, Riccardo; Grigoriadis, Anita; Tutt, Andrew N. J.] Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, Kings Hlth Partners AHSC, London, England; [Walker, Callum; Weekes, Daniel; Pemberton, Helen; Davidson, Kathryn; Torga, Gonzalo; Frankum, Jessica; Brough, Rachel; Pettitt, Stephen J.; Lord, Christopher J.; Tutt, Andrew N. J.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England; [Pemberton, Helen; Frankum, Jessica; Brough, Rachel; Pettitt, Stephen J.; Lord, Christopher J.] Inst Canc Res, CRUK Gene Funct Lab, London, England	University of London; King's College London; King's Health Partners; University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Tutt, ANJ (corresponding author), Kings Coll London, Breast Canc Now Res Unit, London, England.; Tutt, ANJ (corresponding author), Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, Kings Hlth Partners AHSC, London, England.; Tutt, ANJ (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England.	Andrew.Tutt@icr.ac.uk		Torga, Gonzalo/0000-0002-6401-5127; Tutt, Andrew/0000-0001-8715-2901; Grigoriadis, Anita/0000-0003-3434-201X	Programme Grants from Breast Cancer Now; Cancer Research UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; NIHR Royal Marsden Hospital Biomedical Research Centre	Programme Grants from Breast Cancer Now; Cancer Research UK(Cancer Research UK); National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; NIHR Royal Marsden Hospital Biomedical Research Centre	This work was funded by Programme Grants from Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre and by funding from Cancer Research UK, the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and the NIHR Royal Marsden Hospital Biomedical Research Centre to Prof. Andrew Tutt. We thank King's College London Genomic Core Facility for supporting the RT-qPCR data acquisition and analysis. We thank the Nikon Imaging Centre (KCL) for access to and assistance with the microscope facilities. We thank Sorapun Utting, Melanie Ferrao and Caroline Carey for technical and administrative assistance. We thank Dr. Rebecca Marlow for providing training in immunofluorescence image processing. We thank Dr. Tencho Tenev for providing assistance with the design and optimisation of the CRISPR-Cas9 based gene editing experiments. We thank Dr. Olivia Rossanese and the Cancer Therapeutics Unit (ICR) for kindly providing laboratory space for conducting part of the experimental work.	Bradbury A, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107450; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Campbell J, 2016, CELL REP, V14, P2490, DOI 10.1016/j.celrep.2016.02.023; Campeau PM, 2008, HUM GENET, V124, P31, DOI 10.1007/s00439-008-0529-1; Chen B, 2019, CANCER MANAG RES, V11, P179, DOI 10.2147/CMAR.S187151; Daniel K, 2011, NAT CELL BIOL, V13, P599, DOI 10.1038/ncb2213; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gao YZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33601-w; Il'ina IV, 2020, MOLECULES, V25, DOI 10.3390/molecules25153496; Jones SE, 2017, CANCER RES, V77, P7014, DOI 10.1158/0008-5472.CAN-17-2056; Ketkar A, 2019, ACS CHEM BIOL, V14, P1337, DOI 10.1021/acschembio.9b00304; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liu K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2736-1; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lord CJ, 2008, DNA REPAIR, V7, P2010, DOI 10.1016/j.dnarep.2008.08.014; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Menolfi D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07798-3; Nichols BA, 2018, CANCER RES, V78, P6196, DOI 10.1158/0008-5472.CAN-18-1377; Pommier Y, 2014, DNA REPAIR, V19, P114, DOI 10.1016/j.dnarep.2014.03.020; Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Ryan CJ, 2018, TRENDS CANCER, V4, P671, DOI 10.1016/j.trecan.2018.08.003; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sale JE, 2012, NAT REV MOL CELL BIO, V13, P141, DOI 10.1038/nrm3289; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Temprine K, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aau1453; Tonzi P, 2018, ELIFE, V7, DOI 10.7554/eLife.41426; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt ANJ, 2021, NEW ENGL J MED, V384, P2394, DOI 10.1056/NEJMoa2105215; Wang Xian, 2018, Oncotarget, V9, P30115, DOI 10.18632/oncotarget.25728; Watkins J, 2015, CANCER DISCOV, V5, P488, DOI 10.1158/2159-8290.CD-14-1092; Wojtaszek JL, 2019, CELL, V178, P152, DOI 10.1016/j.cell.2019.05.028; Yamanaka K, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006842; Yang W, 2018, ANNU REV BIOCHEM, V87, P239, DOI 10.1146/annurev-biochem-062917-012405; Zafar MK, 2018, BIOCHEMISTRY-US, V57, P1262, DOI 10.1021/acs.biochem.7b01176; Zhang J, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080051	40	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3969	3977		10.1038/s41388-022-02369-9	http://dx.doi.org/10.1038/s41388-022-02369-9		JUN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35768547	hybrid, Green Published			2022-12-17	WOS:000818607200001
J	Liu, YQ; Luo, M; Shi, Y; Guo, Y; Zhang, H; Yang, KD; Li, TR; Yang, LQ; Liu, TT; Huang, B; Liu, Q; He, ZC; Zhang, XN; Wang, WY; Wang, S; Zeng, H; Niu, Q; Zhang, X; Cui, YH; Zhang, ZR; Bian, XW; Ping, YF				Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Ting-Ting; Huang, Bo; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Zhang, Zhi-Ren; Bian, Xiu-Wu; Ping, Yi-Fang			Dicer deficiency impairs proliferation but potentiates anti-tumoral effect of macrophages in glioblastoma	ONCOGENE			English	Article							MICRORNA; GLIOMA; INVASIVENESS; POLARIZATION	Glioblastoma is a lethal primary brain tumor with abundant immune-suppressive glioblastoma-associated macrophage (GAM) infiltration. Skewing immune suppressive GAMs towards an immune-activating phenotype represents a promising immunotherapeutic strategy against glioblastoma. Herein, we reported that genetic deletion of miRNA-processing enzyme Dicer in macrophages inhibited the growth of GL261 murine glioblastoma xenografts and prolonged survival of tumor-bearing mice. Single cell RNA sequencing (scRNA-seq) of the tumor-infiltrating immune cells revealed that Dicer deletion in macrophages reduced the proportion of cell-cycling GAM cluster and reprogramed the remaining GAMs towards a proinflammatory activation state (enhanced phagocytotic and IFN-producing signature). Dicer-deficient GAMs showed reduced level of cyclin-dependent kinases (CDK1 and CDK2) and increased expression of CDK inhibitor p27 Kip1, thus manifesting impaired proliferation. Dicer knockout enhanced phagocytotic activity of GAMs to eliminate GL261 tumor cells. Increased proinflammatory GAM clusters in macrophage Dicer-deficient mice actively interacted with tumor-infiltrating T cells and NK cells through TNF paracrine signaling to create a pro-inflammatory immune microenvironment for tumor cell elimination. Our work identifies the role of Dicer deletion in macrophages in generating an immune-activating microenvironment, which could be further developed as a potential immunotherapeutic strategy against glioblastoma.	[Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Bian, Xiu-Wu; Ping, Yi-Fang] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China; [Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Bian, Xiu-Wu; Ping, Yi-Fang] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [Liu, Yu-Qi; Luo, Min; Shi, Yu; Guo, Ying; Zhang, Hua; Yang, Kai-Di; Li, Tian-Ran; Yang, Liu-Qing; Liu, Qing; He, Zhi-Cheng; Zhang, Xiao-Ning; Wang, Wen-Ying; Wang, Shuai; Zeng, Hui; Niu, Qin; Zhang, Xia; Cui, You-Hong; Bian, Xiu-Wu; Ping, Yi-Fang] Minist Educ China, Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China; [Liu, Yu-Qi] Third Mil Med Univ, Army Med Univ, Xingiao Hosp, Army Hosp 953,Shigatse Branch, Shigatse 857000, Peoples R China; [Liu, Ting-Ting; Huang, Bo; Zhang, Zhi-Ren] Third Mil Med Univ, Army Med Univ, Inst Immunol, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University; Ministry of Education, China; Army Medical University; Army Medical University	Bian, XW; Ping, YF (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.; Bian, XW; Ping, YF (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.; Bian, XW; Ping, YF (corresponding author), Minist Educ China, Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China.; Zhang, ZR (corresponding author), Third Mil Med Univ, Army Med Univ, Inst Immunol, Chongqing 400038, Peoples R China.	zhangzhiren@tmmu.edu.cn; bianxiuwu@263.net; pingyifang@126.com	liu, ting/GZM-3326-2022; Zhang, Xia/B-8152-2008	Zhang, Xia/0000-0002-9040-1486; Liu, Yuqi/0000-0002-5247-2152; liuqing, yang/0000-0002-9727-8580	National Natural Science Foundation of China [81821003, 81702940, 81922056]; National Key Research and Development Program of China [2016YFA0502201]; Science and Technology Innovation Project of Chongqing Science and Technology Commission, China [cstc2021yszx-jcyj0003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Science and Technology Innovation Project of Chongqing Science and Technology Commission, China	This research was supported by the National Natural Science Foundation of China under Grants [Nos. 81821003, 81702940 and 81922056], the National Key Research and Development Program of China (2016YFA0502201), and Science and Technology Innovation Project of Chongqing Science and Technology Commission, China (No. cstc2021yszx-jcyj0003).	Antonios JP, 2017, NEURO-ONCOLOGY, V19, P796, DOI 10.1093/neuonc/now287; Antunes ARP, 2021, NAT NEUROSCI, V24, P595, DOI 10.1038/s41593-020-00789-y; Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Canfran-Duque A, 2017, EMBO MOL MED, V9, P1244, DOI 10.15252/emmm.201607492; Chen ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01004; Cho YK, 2019, MOL METAB, V29, P86, DOI 10.1016/j.molmet.2019.08.015; Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Dupont G, 2019, CLIN ANAT, V32, P117, DOI 10.1002/ca.23308; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Frederico SC, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.672508; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Grabowski MM, 2021, J NEURO-ONCOL, V151, P3, DOI 10.1007/s11060-020-03483-y; Gross TJ, 2014, J BIOL CHEM, V289, P12823, DOI 10.1074/jbc.M114.565473; Gutmann DH, 2019, NEURON, V104, P442, DOI 10.1016/j.neuron.2019.08.028; Horwitz SM, 2018, BLOOD, V131, P888, DOI 10.1182/blood-2017-08-802470; Jackson CM, 2019, NAT IMMUNOL, V20, P1100, DOI 10.1038/s41590-019-0433-y; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Ma PF, 2017, J HEPATOL, V67, P770, DOI 10.1016/j.jhep.2017.05.022; Mathsyaraja H, 2015, ONCOGENE, V34, P3651, DOI 10.1038/onc.2014.294; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ostrom QT, 2018, JAMA ONCOL, V4, P1254, DOI 10.1001/jamaoncol.2018.1789; Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977; Piao Y, 2016, NEURO-ONCOLOGY, V18, P1230, DOI 10.1093/neuonc/now030; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Romani M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00464; Ruckerl D, 2012, BLOOD, V120, P2307, DOI 10.1182/blood-2012-02-408252; Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5; Shen C, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006259; Shi Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah6816; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Spigel DR, 2021, ANN ONCOL, V32, P631, DOI 10.1016/j.annonc.2021.01.071; Szulzewsky F, 2018, NEURO-ONCOLOGY, V20, P355, DOI 10.1093/neuonc/nox165; von Roemeling CA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15129-8; Wang X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1085-3; Wei YY, 2018, CIRCULATION, V138, P2007, DOI 10.1161/CIRCULATIONAHA.117.031589; Weiss T, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb2311; Wu KY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01731; Xie F, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0892-z; Xun QJ, 2020, CURR MED CHEM, V27, P3944, DOI 10.2174/1573394715666190618121649; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289	42	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3791	3803		10.1038/s41388-022-02393-9	http://dx.doi.org/10.1038/s41388-022-02393-9		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35764885				2022-12-17	WOS:000817826700001
J	Li, YJ; Yang, Q; Chen, H; Yang, XT; Han, JR; Yao, XJ; Wei, XJ; Si, JY; Yao, HL; Liu, HL; Wan, LX; Yang, HS; Wang, YM; Bao, DK				Li, Yujia; Yang, Qi; Chen, Hui; Yang, Xiaotian; Han, Jingru; Yao, Xiaojuan; Wei, Xiajie; Si, Jiaoyang; Yao, Huanling; Liu, Hongliang; Wan, Lixin; Yang, Hushan; Wang, Yanming; Bao, Dengke			TFAM downregulation promotes autophagy and ESCC survival through mtDNA stress-mediated STING pathway	ONCOGENE			English	Article								The dynamics of mitochondrial biogenesis regulation is critical in maintaining cellular homeostasis for immune regulation and tumor prevention. Here, we report that mitochondrial biogenesis disruption through TFAM reduction significantly impairs mitochondrial function, induces autophagy, and promotes esophageal squamous cell carcinoma (ESCC) growth. We found that TFAM protein reduction promotes mitochondrial DNA (mtDNA) release into the cytosol, induces cytosolic mtDNA stress, subsequently activates the cGAS-STING signaling pathway, thereby stimulating autophagy and ESCC growth. STING depletion or mtDNA degradation by DNase I abrogates mtDNA stress response, attenuates autophagy, and decreases the growth of TFAM depleted cells. In addition, autophagy inhibitor also ameliorates mitochondrial dysfunction-induced activation of the cGAS-STING signaling pathway and ESCC growth. In conclusion, our results indicate that mtDNA stress induced by mitochondria biogenesis perturbation activates the cGAS-STING pathway and autophagy to promote ESCC growth, revealing an underappreciated therapeutic strategy for ESCC. [GRAPHICS] .	[Li, Yujia; Yang, Qi; Chen, Hui; Yang, Xiaotian; Han, Jingru; Yao, Xiaojuan; Wei, Xiajie; Si, Jiaoyang; Liu, Hongliang; Bao, Dengke] Henan Univ, Sch Pharm, Lab Canc Biomarkers & Liquid Biopsy, Kaifeng 475004, Henan, Peoples R China; [Li, Yujia; Yang, Qi; Yao, Huanling; Wang, Yanming] Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China; [Wan, Lixin; Bao, Dengke] Henan Univ, Nanyang Cent Hosp, Nanyang 473000, Henan, Peoples R China; [Yang, Hushan] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA	Henan University; Henan University; Henan University; Jefferson University	Bao, DK (corresponding author), Henan Univ, Sch Pharm, Lab Canc Biomarkers & Liquid Biopsy, Kaifeng 475004, Henan, Peoples R China.; Wang, YM (corresponding author), Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China.; Bao, DK (corresponding author), Henan Univ, Nanyang Cent Hosp, Nanyang 473000, Henan, Peoples R China.; Yang, HS (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Med Oncol, Philadelphia, PA 19107 USA.	hushan.yang@jefferson.edu; yanmingwang@henu.edu.cn; bdkmydy12004@126.com	wan, li/GRY-7634-2022		China Postdoctoral Science Foundation [2020M682286, 2021T140180]; Young Core Instructor of Henan [2021GGJS027]; Henan University	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Young Core Instructor of Henan; Henan University	Project funded by China Postdoctoral Science Foundation (NO. 2020M682286, 2021T140180) to DB, the Young Core Instructor of Henan (NO. 2021GGJS027) to DB. Thanks for startup fund from Henan University to YW and DB.		0	0	0	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3735	3746		10.1038/s41388-022-02365-z	http://dx.doi.org/10.1038/s41388-022-02365-z		JUN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35750756				2022-12-17	WOS:000815475400001
J	Wang, YY; Zhang, Y; Mi, JQ; Jiang, CC; Wang, Q; Li, XW; Zhao, ML; Geng, ZJ; Song, X; Li, J; Zuo, LG; Ge, ST; Zhang, ZN; Wen, HX; Wang, ZS; Su, F				Wang, Yanyan; Zhang, Yue; Mi, Jiaqi; Jiang, Chenchen; Wang, Qiang; Li, Xinwei; Zhao, Menglin; Geng, Zhijun; Song, Xue; Li, Jing; Zuo, Lugen; Ge, Sitang; Zhang, Zining; Wen, Hexin; Wang, Zishu; Su, Fang			ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma	ONCOGENE			English	Article							ANKYRIN REPEAT; CANCER; PATHWAYS; GENE; ARCHITECTURE; ACTIVATION; THERAPY; KINASES	Ankyrin repeat and fibronectin type III domain containing 1 (ANKFN1) is reported to be involved in human height and developmental abnormalities, but the expression profile and molecular function of ANKFN1 in hepatocellular carcinoma (HCC) remain unknown. This study aimed to evaluate the clinical significance and biological function of ANKFN1 in HCC and investigate whether ANKFN1 can be used for differential diagnosis in HCC. Here, we showed that ANKFN1 was upregulated in 126 tumor tissues compared with adjacent nontumorous tissues in HCC patients. The upregulation of ANKFN1 in HCC was associated with cirrhosis, alpha-fetoprotein (AFP) levels and poor prognosis. Moreover, silencing ANKFN1 expression suppressed HCC cell proliferation, migration, invasion, and metastasis in vitro and subcutaneous tumorigenesis in vivo. However, ANKFN1 overexpression promoted HCC proliferation and metastasis in an orthotopic liver transplantation model and attenuated the above biological effects in HCC cells. ANKFN1 significantly affected HCC cell proliferation by inducing G1/S transition and cell apoptosis. Mechanistically, we demonstrated that ANKFN1 promoted cell proliferation, migration, and invasion via activation of the cyclin D1/Cdk4/Cdk6 pathway by stimulating the MEK1/2-ERK1/2 pathway. Moreover, ANKFN1-induced cell proliferation, migration, and invasion were partially reversed by ERK1/2 inhibitors. Taken together, our results indicate that ANKFN1 promotes HCC cell proliferation and metastasis by activating the MEK1/2-ERK1/2 signaling pathway. Our work also suggests that ANKFN1 is a potential therapeutic target for HCC.	[Wang, Yanyan; Zhang, Yue; Mi, Jiaqi; Li, Xinwei; Zhao, Menglin; Geng, Zhijun; Song, Xue; Li, Jing; Zuo, Lugen; Ge, Sitang; Zhang, Zining; Wen, Hexin; Wang, Zishu; Su, Fang] Bengbu Med Coll, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China; [Jiang, Chenchen] Univ Newcastle, Canc Neurobiol Grp, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Jiang, Chenchen] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Wang, Qiang] Bengbu Med Coll, Bengbu 233004, Anhui, Peoples R China	Bengbu Medical College; University of Newcastle; University of Newcastle; Bengbu Medical College	Wang, ZS; Su, F (corresponding author), Bengbu Med Coll, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China.	wzshahbb@163.com; sufang2899@163.com	Wen, He/GZL-8825-2022		College Student Innovation Training Program of Bengbu Medical College [Byycx20045]; Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province [gxyq2018038]; 512 Talent Cultivation Plan of Bengbu Medical College [51201319, 51201107]; Science and Technology Development Fund Project of Bengbu Medical College [BYKF1846]; Research and Innovation Team of Bengbu Medical College [BYKC201908, BYKC201909]	College Student Innovation Training Program of Bengbu Medical College; Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province; 512 Talent Cultivation Plan of Bengbu Medical College; Science and Technology Development Fund Project of Bengbu Medical College; Research and Innovation Team of Bengbu Medical College	The present study was supported by the 2019 College Student Innovation Training Program of Bengbu Medical College (grant no. Byycx20045), Support Program for Outstanding Young Talents in Colleges and Universities of Anhui Province (grant no. gxyq2018038), 512 Talent Cultivation Plan of Bengbu Medical College (grant numbers by51201319, by 51201107), Science and Technology Development Fund Project of Bengbu Medical College (grant no. BYKF1846) and Research and Innovation Team of Bengbu Medical College (grant no. BYKC201908, grant no. BYKC201909).	Agrawal A, 2011, ADDICT BIOL, V16, P514, DOI 10.1111/j.1369-1600.2010.00255.x; Alvarez-Fernandez M, 2020, CANCER CELL, V37, P514, DOI 10.1016/j.ccell.2020.03.010; Asl ER, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119499; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Braicu C, 2019, CANCERS, V11, DOI 10.3390/cancers11101618; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Chandler PG, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030610; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Drosten M, 2020, CANCER CELL, V37, P543, DOI 10.1016/j.ccell.2020.03.013; Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008; Gao XL, 2020, ADV CANCER RES, V148, P147, DOI 10.1016/bs.acr.2020.02.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Ingham M, 2017, J CLIN ONCOL, V35, P2949, DOI 10.1200/JCO.2016.69.0032; Iyer M, 2021, EUR J PHARMACOL, V894, DOI 10.1016/j.ejphar.2020.173815; Kane EI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020609; Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065; Kwon JH, 2021, J GASTROINTEST SURG, V25, P941, DOI 10.1007/s11605-020-04555-0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7; LITTLE E, 1994, J MOL EVOL, V39, P631, DOI 10.1007/BF00160409; Lu WZ, 2021, METAB BRAIN DIS, V36, P1101, DOI 10.1007/s11011-021-00709-4; Martinez-Fernandez ML, 2015, AM J MED GENET A, V167, P2034, DOI 10.1002/ajmg.a.37117; Mishra S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.601929; Moon H, 2021, CANCERS, V13, DOI 10.3390/cancers13123026; Mosaddeghzadeh N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071831; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Muhammad RN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71531-8; Petrick JL, 2020, INT J CANCER, V147, P317, DOI 10.1002/ijc.32723; Petroni G, 2020, NAT REV IMMUNOL, V20, P669, DOI 10.1038/s41577-020-0300-y; Qi YQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1415-5; Ren M, 2019, ARTIF CELL NANOMED B, V47, P1014, DOI 10.1080/21691401.2019.1584566; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Semenov MV, 2007, CELL, V131, DOI 10.1016/j.cell.2007.12.011; Serper M, 2017, GASTROENTEROLOGY, V152, P1954, DOI 10.1053/j.gastro.2017.02.040; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sucandy I, 2016, HPB, V18, P756, DOI 10.1016/j.hpb.2016.06.010; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6; Syed AS, 2010, NUCLEIC ACIDS RES, V38, pD670, DOI 10.1093/nar/gkp957; Tarhouni-Jabberi S, 2017, MAR DRUGS, V15, DOI 10.3390/md15070221; Tian T, 2020, INT J CANCER, V147, P3075, DOI 10.1002/ijc.33130; Unal EB, 2017, FEBS LETT, V591, P2607, DOI 10.1002/1873-3468.12740; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wang YY, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0397-9; Wood AR, 2014, NAT GENET, V46, P1173, DOI 10.1038/ng.3097; Wu QH, 2020, J ENZYM INHIB MED CH, V35, P574, DOI 10.1080/14756366.2020.1720013; Ye LB, 2017, DRUG DISCOV TODAY, V22, P1092, DOI 10.1016/j.drudis.2017.04.011; Ye ZD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3803; Zhou X, 2013, J BIOL CHEM, V288, P36179, DOI 10.1074/jbc.R113.515486	52	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3680	3693		10.1038/s41388-022-02380-0	http://dx.doi.org/10.1038/s41388-022-02380-0		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35725908	hybrid, Green Published			2022-12-17	WOS:000813707500001
J	Boice, AG; Lopez, KE; Pandita, RK; Parsons, MJ; Charendoff, CI; Charaka, V; Carisey, AF; Pandita, TK; Bouchier-Hayes, L				Boice, Ashley G.; Lopez, Karla E.; Pandita, Raj K.; Parsons, Melissa J.; Charendoff, Chloe I.; Charaka, Vijay; Carisey, Alexandre F.; Pandita, Tej K.; Bouchier-Hayes, Lisa			Caspase-2 regulates S-phase cell cycle events to protect from DNA damage accumulation independent of apoptosis (vol 41, pg 204, 2022)	ONCOGENE			English	Correction												bouchier@bcm.edu	Carisey, Alexandre F/A-5026-2015	Carisey, Alexandre F/0000-0003-1326-2205; Bouchier-Hayes, Lisa/0000-0003-3886-5977				ASHLEY G, 2022, ONCOGENE, V41, P204, DOI DOI 10.1038/S41388-021-02085-W	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3732	3734		10.1038/s41388-022-02373-z	http://dx.doi.org/10.1038/s41388-022-02373-z		JUN 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35705736	Bronze			2022-12-17	WOS:000811468900002
J	Rong, ZX; Zhang, L; Li, Z; Xiao, Z; Duan, YM; Ren, XX; Zi, YY; Gao, J; Mu, Y; Guan, YD; Cao, Z; Wang, XT; Pei, Q; Zeng, Y; Fan, Q; Zeng, ZM; Ou, DM; He, J; Nie, YJ; Tan, R; Weng, L; Li, YH; Xiang, R; Deng, YZ; Sun, LQ				Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Xiao, Zhi; Duan, Yumei; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Nie, Yingjie; Tan, Rong; Weng, Liang; Li, Yuhao; Xiang, Rong; Deng, Yuezhen; Sun, Lunquan			SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling (vol 41, 2390, 2022)	ONCOGENE			English	Correction												yuezhendeng@csu.edu.cn; lunquansun@csu.edu.cn						Rong ZX, 2022, ONCOGENE, V41, P2390, DOI 10.1038/s41388-022-02259-0	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3585	3585		10.1038/s41388-022-02374-y	http://dx.doi.org/10.1038/s41388-022-02374-y		JUN 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35701535	Bronze			2022-12-17	WOS:000810849500001
J	Li, YY; Yang, J; Zhang, QQ; Xu, SQ; Sun, W; Ge, SF; Xu, XW; Jager, MJ; Jia, RB; Zhang, JM; Fan, XQ				Li, Yongyun; Yang, Jie; Zhang, Qianqian; Xu, Shiqiong; Sun, Wei; Ge, Shengfang; Xu, Xiaowei; Jager, Martine J.; Jia, Renbing; Zhang, Jianming; Fan, Xianqun			Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma	ONCOGENE			English	Article							BREAST-CANCER METASTASIS; REPRESSES E-CADHERIN; OXIDATIVE STRESS; OCULAR MELANOMA; DRUG ELESCLOMOL; PHASE-I; INHIBITION; SLUG; ESTABLISHMENT; EXPRESSION	Unlike cutaneous melanoma, uveal melanoma (UM) is characterized by mutations in GNAQ and GNA11 and remains a fatal disease because there is essentially no effective targeted therapy or immunotherapy available. We report the discovery of the copper ionophore elesclomol as a GNAQ/11-specific UM inhibitor. Elesclomol was identified in a differential cytotoxicity screen of an in-house tool compound library, and its in vivo pharmacological efficacy was further confirmed in zebrafish and mouse UM models. Mechanistically, elesclomol transports copper to mitochondria and produces a large amount of reactive oxygen species (ROS) as Cu(II) is reduced to Cu(I) in GNAQ/11-mutant UM cells, which selectively activates LATS1 kinase in the Hippo signaling pathway and consequently promotes YAP phosphorylation and inhibits its nuclear accumulation. The inactivation of YAP downregulates the expression of SNAI2, which in turn suppresses the migration of UM cells. These findings were cross validated by our clinical observation that YAP activation was found specifically in UM samples with a GNAQ/11 mutation. Furthermore, addition of binimetinib, a MEK inhibitor, to elesclomol increased its synthetic lethality to GNAQ/11-mutant UM cells, thereby overriding drug resistance. This effect was confirmed in an orthotopic xenograft model and in a patient-derived xenograft model of UM. These studies reveal a novel mechanistic basis for repurposing elesclomol by showing that copper homeostasis is a GNAQ/11-specific vulnerability in UM. Elesclomol may provide a new therapeutic path for selectively targeting malignant GNAQ/11-mutant UM.	[Li, Yongyun; Yang, Jie; Xu, Shiqiong; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China; [Li, Yongyun; Yang, Jie; Xu, Shiqiong; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China; [Zhang, Qianqian; Sun, Wei; Zhang, Jianming] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China; [Xu, Xiaowei] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Jager, Martine J.] Leiden Univ, Dept Ophthalmol, Med Ctr, Leiden, Netherlands	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; University of Pennsylvania; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jia, RB; Fan, XQ (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.; Jia, RB; Fan, XQ (corresponding author), Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China.; Zhang, JM (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China.	renbingjia@sjtu.edu.cn; jzuc@shsmu.edu.cn; fanxq@sjtu.edu.cn	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; Zhang, Jianming/0000-0001-6326-3906	National Natural Science Foundation of China [82073889]; Science and Technology Commission of Shanghai [20DZ2270800]; Shanghai Municipal Science and Technology Major Project [19JC1410200]; National Facility for Translational Medicine (Shanghai) [TMSZ2020-206]; Innovative Research Team of High-level Local Universities in Shanghai [SHSMU-ZDCX20210900]; State Key Laboratory of Medical Genomics	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Science and Technology Major Project; National Facility for Translational Medicine (Shanghai); Innovative Research Team of High-level Local Universities in Shanghai; State Key Laboratory of Medical Genomics	This research was supported by the National Natural Science Foundation of China (grant 82073889), the Science and Technology Commission of Shanghai (20DZ2270800), the Shanghai Municipal Science and Technology Major Project (19JC1410200), the National Facility for Translational Medicine (Shanghai) (TMSZ2020-206), the Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20210900), and startup funding of State Key Laboratory of Medical Genomics to JZ. We thank Drs. David E. Fisher and Xu Wu (Massachusetts General Hospital), Yantao Chen, and Yunqi Li (Shanghai Jiao Tong University) for review of this work and discussions on various topics relating to this project.	Albayrak G, 2019, J CELL BIOCHEM, V120, P10564, DOI 10.1002/jcb.28342; Ambrosini G, 2013, MOL CANCER THER, V12, P768, DOI 10.1158/1535-7163.MCT-12-1020; Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Asnaghi L, 2015, MOL VIS, V21, P919; Aubert L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17549-y; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Berkenblit A, 2007, CLIN CANCER RES, V13, P584, DOI 10.1158/1078-0432.CCR-06-0964; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brady DC, 2014, NATURE, V509, P492, DOI 10.1038/nature13180; Brouwer NJ, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.3; Campbell AP, 2018, NAT REV DRUG DISCOV, V17, P789, DOI 10.1038/nrd.2018.135; Carlson BA, 1996, CANCER RES, V56, P2973; Chen PW, 1997, CLIN EXP METASTAS, V15, P509, DOI 10.1023/A:1018479011340; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208; Fan HJ, 2020, GENE DEV, V34, P1359, DOI 10.1101/gad.339796.120; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Gunst JD, 2019, J VIRUS ERAD, V5, P133; Hajra KM, 2002, CANCER RES, V62, P1613; Harrington BS, 2020, CANCERS, V12, DOI 10.3390/cancers12061645; Harris IS, 2020, TRENDS CELL BIOL, V30, P440, DOI 10.1016/j.tcb.2020.03.002; Hasinoff BB, 2015, BIOCHEM PHARMACOL, V93, P266, DOI 10.1016/j.bcp.2014.12.008; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Hedley D, 2016, LEUKEMIA LYMPHOMA, V57, P2437, DOI 10.3109/10428194.2016.1138293; Khoja L, 2019, ANN ONCOL, V30, P1370, DOI 10.1093/annonc/mdz176; Kirshner JR, 2008, MOL CANCER THER, V7, P2319, DOI 10.1158/1535-7163.MCT-08-0298; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; KSANDER BR, 1991, INVEST OPHTH VIS SCI, V32, P3198; Li WY, 2020, GENE DEV, V34, P1310, DOI 10.1101/gad.339804.120; Li YY, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920965852; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luyten GPM, 1996, INT J CANCER, V66, P380, DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Monk BJ, 2018, GYNECOL ONCOL, V151, P422, DOI 10.1016/j.ygyno.2018.10.001; Nagai M, 2012, FREE RADICAL BIO MED, V52, P2142, DOI 10.1016/j.freeradbiomed.2012.03.017; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; O'Day S, 2009, J CLIN ONCOL, V27, P5452, DOI 10.1200/JCO.2008.17.1579; O'Day SJ, 2013, J CLIN ONCOL, V31, P1211, DOI 10.1200/JCO.2012.44.5585; Onken MD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6852; Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324; Populoa H, 2010, MELANOMA RES, V20, P107, DOI 10.1097/CMR.0b013e32832ccd09; Qu Y, 2010, BREAST CANCER RES TR, V121, P311, DOI 10.1007/s10549-009-0470-6; Schrage R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10156; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Shanbhag V, 2019, P NATL ACAD SCI USA, V116, P6836, DOI 10.1073/pnas.1817473116; Shields CL, 2009, CLIN DERMATOL, V27, P122, DOI 10.1016/j.clindermatol.2008.09.010; Shimada K, 2018, CELL CHEM BIOL, V25, P585, DOI 10.1016/j.chembiol.2018.02.010; Shoushtari AN, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9511; Singh AD, 2003, OPHTHALMOLOGY, V110, P956, DOI 10.1016/S0161-6420(03)00078-2; Smit KN, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100800; Steeb T, 2018, EUR J CANCER, V103, P41, DOI 10.1016/j.ejca.2018.08.005; Tardito S, 2011, J AM CHEM SOC, V133, P6235, DOI 10.1021/ja109413c; Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200; Tsvetkov P, 2019, NAT CHEM BIOL, V15, P681, DOI 10.1038/s41589-019-0291-9; van der Ent W, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15202; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wang W, 2019, FASEB J, V33, P7180, DOI 10.1096/fj.201801635R; White SM, 2019, DEV CELL, V49, P425, DOI 10.1016/j.devcel.2019.04.014; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zhang ZH, 2020, LEUKEMIA, V34, P380, DOI 10.1038/s41375-019-0566-x	63	0	0	15	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3539	3553		10.1038/s41388-022-02364-0	http://dx.doi.org/10.1038/s41388-022-02364-0		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35697803				2022-12-17	WOS:000810359900002
J	Ma, XL; Zhu, KY; Chen, YD; Tang, WG; Xie, SH; Zheng, H; Tong, Y; Wang, YC; Ren, N; Guo, L; Lu, RQ				Ma, Xiao-Lu; Zhu, Ke-Yu; Chen, Yue-Da; Tang, Wei-Guo; Xie, Su-Hong; Zheng, Hui; Tong, Ying; Wang, Yan-Chun; Ren, Ning; Guo, Lin; Lu, Ren-Quan			Identification of a novel Calpain-2-SRC feed-back loop as necessity for beta-Catenin accumulation and signaling activation in hepatocellular carcinoma	ONCOGENE			English	Article							PROTEINS; PATHWAY; BINDING; CAPN2; SRC	Rapid progression is the major cause of the poor prognosis of hepatocellular carcinoma (HCC); however, the underlying mechanism remained unclear. Here, we found Calpain-2 (CAPN2), a well-established protease that accelerates tumor progression in several malignancies, is overexpressed in HCC and acts as an independent predictor for poor outcomes. Furthermore, CAPN2 promoted the proliferation and invasion of HCC, and showed a positive correlation with the levels of invasion-related markers. Mechanistically, a novel CAPN2-SRC positive regulatory loop was identified upstream of beta-catenin to prevent its ubiquitination and degradation, and subsequently promoted HCC progression: CAPN2 could proteolyze PTP1B to form a truncation of approximately 42 kDa with increased phosphatase activity, resulting in reduced SRC Y530 phosphorylation and increased SRC kinase activity; meanwhile, CAPN2 itself was a bone fide substrate of SRC that was primarily phosphorylated at Y625 by SRC and exhibited increased proteolysis activity upon phosphorylation. Interestingly, the CAPN2-SRC loop could not only restrain most of cytoplasmic beta-catenin degradation by inhibiting GSK3 beta pathway, but also prevented TRIM33-induced nuclear beta-catenin degradation even in beta-catenin-mutant cells. Present study identified a CAPN2-SRC positive loop responsible for intracellular beta-catenin accumulation and signaling activation, and targeting CAPN2 protease activity might be a promising approach for preventing HCC progression.	[Ma, Xiao-Lu; Zhu, Ke-Yu; Xie, Su-Hong; Zheng, Hui; Tong, Ying; Wang, Yan-Chun; Guo, Lin; Lu, Ren-Quan] Fudan Univ, Shanghai Canc Ctr, Dept Clin Lab, Shanghai 200032, Peoples R China; [Ma, Xiao-Lu; Zhu, Ke-Yu; Xie, Su-Hong; Zheng, Hui; Tong, Ying; Wang, Yan-Chun; Guo, Lin; Lu, Ren-Quan] Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China; [Chen, Yue-Da] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Xiamen Branch, Shanghai 200032, Peoples R China; [Tang, Wei-Guo; Ren, Ning] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai 200032, Peoples R China; [Tang, Wei-Guo; Ren, Ning] Fudan Univ, Minhang Hosp, Dept Hepatobiliary & Pancreat Surg, Shanghai 201100, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Guo, L; Lu, RQ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Clin Lab, Shanghai 200032, Peoples R China.; Guo, L; Lu, RQ (corresponding author), Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai 200032, Peoples R China.; Ren, N (corresponding author), Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai 200032, Peoples R China.; Ren, N (corresponding author), Fudan Univ, Minhang Hosp, Dept Hepatobiliary & Pancreat Surg, Shanghai 201100, Peoples R China.	ren.ning@zs-hospital.sh.cn; guolin500@hotmail.com; renquanlu@fudan.edu.cn	Wang, Yin/HCI-9352-2022; wang, yixuan/GXW-2866-2022; wang, yi/GVT-8516-2022; Wang, Yu/GZL-9655-2022; Wang, Yixuan/GZK-6559-2022; Wang, Yijun/GXW-1763-2022	chen, yueda/0000-0002-0642-5312	National Natural Science Foundation of China [81772774, 82072876, 81772808, 81472672, 82002618, 81800190]; Program of scientific and technological innovation action plan, Shanghai Municipal Commission of science and technology [20XD1434200, 20Y11903500]; Shanghai International Science and Technology Collaboration Program [18410721900]; Shanghai Sailing Program [20YF1407900]; Shanghai Natural Science Foundation; Shanghai Municipal Commission of science and technology [19ZR1410300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of scientific and technological innovation action plan, Shanghai Municipal Commission of science and technology; Shanghai International Science and Technology Collaboration Program; Shanghai Sailing Program; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Shanghai Municipal Commission of science and technology	LR-Q was sponsored by National Natural Science Foundation of China (81772774, 82072876); Program of scientific and technological innovation action plan, Shanghai Municipal Commission of science and technology (20XD1434200, 20Y11903500). GL was sponsored by National Natural Science Foundation of China (81772808). RN was sponsored by the Shanghai International Science and Technology Collaboration Program (18410721900), and the National Natural Science Foundation of China (81472672). MX-L was sponsored by Shanghai Sailing Program (20YF1407900); National Natural Science Foundation of China (82002618). WY-C was sponsored by National Natural Science Foundation of China (81800190). ZH was sponsored by Shanghai Natural Science Foundation, Shanghai Municipal Commission of science and technology (19ZR1410300).	Ahn JC, 2021, HEPATOLOGY, V73, P422, DOI 10.1002/hep.31165; Baudry M, 2016, TRENDS NEUROSCI, V39, P235, DOI 10.1016/j.tins.2016.01.007; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Caruso S, 2019, GASTROENTEROLOGY, V157, P760, DOI 10.1053/j.gastro.2019.05.001; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Cortesio CL, 2008, J CELL BIOL, V180, P957, DOI 10.1083/jcb.200708048; Dong ZR, 2020, HEPATOLOGY, V72, P923, DOI 10.1002/hep.31076; Finn RS, 2021, HEPATOLOGY, V73, P150, DOI 10.1002/hep.31306; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Hu B, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.233; Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8; Kong FH, 2021, THERANOSTICS, V11, P5464, DOI 10.7150/thno.54822; Lee TKW, 2021, NAT REV GASTRO HEPAT, DOI 10.1038/s41575-021-00508-3; Lee WJ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03575-1; Leung HW, 2021, CANCER RES, V81, P3229, DOI 10.1158/0008-5472.CAN-21-0184; Lin JT, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118659; Liu L, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12588; Liu QH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01021-x; Liu Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0595-0; Lyle CL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050498; Moro L, 2020, NAT CELL BIOL, V22, P1130, DOI 10.1038/s41556-020-0560-6; Ngan E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15059; Perugorria MJ, 2019, NAT REV GASTRO HEPAT, V16, P121, DOI 10.1038/s41575-018-0075-9; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Shao HS, 2006, MOL CELL BIOL, V26, P5481, DOI 10.1128/MCB.02243-05; Shen CP, 2012, PROTEOMICS, V12, P1917, DOI 10.1002/pmic.201200027; Song YZ, 2020, SEMIN CANCER BIOL, V67, P43, DOI 10.1016/j.semcancer.2020.02.001; Storr SJ, 2012, ANN ONCOL, V23, P2289, DOI 10.1093/annonc/mds176; Sun YF, 2013, HEPATOLOGY, V57, P1458, DOI 10.1002/hep.26151; Tai WT, 2016, HEPATOLOGY, V63, P1528, DOI 10.1002/hep.28478; Wang CW, 2020, GENOM PROTEOM BIOINF, V18, P72, DOI 10.1016/j.gpb.2020.01.001; Xie XQ, 2020, MOL THER-ONCOLYTICS, V17, P320, DOI 10.1016/j.omto.2020.04.003; Xu FK, 2019, INT J BIOL SCI, V15, P127, DOI 10.7150/ijbs.28834; Xue JF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7156; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zhang YX, 2020, J CELL MOL MED, V24, P9125, DOI 10.1111/jcmm.15549; Zhu XD, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0794-6	38	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3554	3569		10.1038/s41388-022-02367-x	http://dx.doi.org/10.1038/s41388-022-02367-x		JUN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35697802				2022-12-17	WOS:000810359900001
J	Gallardo, A; Molina, A; Asenjo, HG; Lopez-Onieva, L; Martorell-Marugan, J; Espinosa-Martinez, M; Grinan-Lison, C; Alvarez-Perez, JC; Cara, FE; Navarro-Marchal, SA; Carmona-Saez, P; Medina, PP; Marchal, JA; Granados-Principal, S; Sanchez-Pozo, A; Landeira, D				Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Lopez-Onieva, Lourdes; Martorell-Marugan, Jordi; Espinosa-Martinez, Mencia; Grinan-Lison, Carmen; Carlos Alvarez-Perez, Juan; Cara, Francisca E.; Navarro-Marchal, Saul A.; Carmona-Saez, Pedro; Medina, Pedro P.; Antonio Marchal, Juan; Granados-Principal, Sergio; Sanchez-Pozo, Antonio; Landeira, David			EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization	ONCOGENE			English	Article							E-CADHERIN; POLYCOMB; TRANSCRIPTION; INHIBITION; EXPRESSION; REPRESSION; GENES; MUTATIONS; SUZ12	Reversible transition between the epithelial and mesenchymal states are key aspects of carcinoma cell dissemination and the metastatic disease, and thus, characterizing the molecular basis of the epithelial to mesenchymal transition (EMT) is crucial to find druggable targets and more effective therapeutic approaches in cancer. Emerging studies suggest that epigenetic regulators might endorse cancer cells with the cell plasticity required to conduct dynamic changes in cell state during EMT. However, epigenetic mechanisms involved remain mostly unknown. Polycomb Repressive Complexes (PRCs) proteins are well-established epigenetic regulators of development and stem cell differentiation, but their role in different cancer systems is inconsistent and sometimes paradoxical. In this study, we have analysed the role of the PRC2 protein EZH2 in lung carcinoma cells. We found that besides its described role in CDKN2A-dependent cell proliferation, EZH2 upholds the epithelial state of cancer cells by repressing the transcription of hundreds of mesenchymal genes. Chemical inhibition or genetic removal of EZH2 promotes the residence of cancer cells in the mesenchymal state during reversible epithelial-mesenchymal transition. In fitting, analysis of human patient samples and tumour xenograft models indicate that EZH2 is required to efficiently repress mesenchymal genes and facilitate tumour colonization in vivo. Overall, this study discloses a novel role of PRC2 as a master regulator of EMT in carcinoma cells. This finding has important implications for the design of therapies based on EZH2 inhibitors in human cancer patients.	[Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Lopez-Onieva, Lourdes; Martorell-Marugan, Jordi; Espinosa-Martinez, Mencia; Grinan-Lison, Carmen; Carlos Alvarez-Perez, Juan; Cara, Francisca E.; Carmona-Saez, Pedro; Medina, Pedro P.; Granados-Principal, Sergio; Sanchez-Pozo, Antonio; Landeira, David] Ctr Genom & Oncol Res GENYO, Ave Ilustrac 114, Granada 18016, Spain; [Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Espinosa-Martinez, Mencia; Granados-Principal, Sergio; Sanchez-Pozo, Antonio; Landeira, David] Univ Granada, Fac Pharm, Dept Biochem & Mol Biol 2, Granada, Spain; [Gallardo, Amador; Molina, Aldara; Asenjo, Helena G.; Lopez-Onieva, Lourdes; Espinosa-Martinez, Mencia; Grinan-Lison, Carmen; Carlos Alvarez-Perez, Juan; Navarro-Marchal, Saul A.; Medina, Pedro P.; Antonio Marchal, Juan; Granados-Principal, Sergio; Landeira, David] Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain; [Lopez-Onieva, Lourdes; Carlos Alvarez-Perez, Juan; Medina, Pedro P.] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, Granada, Spain; [Martorell-Marugan, Jordi; Carmona-Saez, Pedro] Univ Granada, Fac Sci, Dept Stat, Granada, Spain; [Martorell-Marugan, Jordi] Fdn Bruno Kessler, Data Sci Hlth Res Unit, Trento, Italy; [Grinan-Lison, Carmen] Complejo Hosp Jaen, UGC Oncol Med, Jaen 23007, Spain; [Navarro-Marchal, Saul A.] Univ Granada, Fac Sci, Dept Appl Phys, Granada 18071, Spain; [Navarro-Marchal, Saul A.; Antonio Marchal, Juan] Univ Granada, Ctr Biomed Res CIBM, Biopathol & Regenerat Med Inst IBIMER, Granada 18016, Spain; [Navarro-Marchal, Saul A.; Antonio Marchal, Juan] Univ Granada, Excellence Res Unit Modelling Nat MNat, Granada 18016, Spain; [Navarro-Marchal, Saul A.] Univ Edinburgh, Inst Genet & Canc, Canc Res UK Edinburgh Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; [Antonio Marchal, Juan] Univ Granada, Sch Med, Dept Human Anat & Embryol, Granada, Spain	University of Granada; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; University of Granada; Fondazione Bruno Kessler; Complejo Hospitalario de Jaen; University of Granada; University of Granada; University of Granada; University of Edinburgh; University of Granada	Landeira, D (corresponding author), Ctr Genom & Oncol Res GENYO, Ave Ilustrac 114, Granada 18016, Spain.; Landeira, D (corresponding author), Univ Granada, Fac Pharm, Dept Biochem & Mol Biol 2, Granada, Spain.; Landeira, D (corresponding author), Inst Invest Biosanitaria Ibs GRANADA, Granada, Spain.	davidlandeira@ugr.es	Landeira, David/ADY-5662-2022; Granados-Principal, Sergio/B-4987-2014; Martorell-Marugan, Jordi/M-5996-2019; Landeira, David/F-5001-2018; Navarro, Saul Abenhamar/B-7425-2016; medina, pedro p./D-1688-2013; Lopez Onieva, Lourdes/A-6475-2019	Granados-Principal, Sergio/0000-0001-8773-9489; Martorell-Marugan, Jordi/0000-0002-5186-0735; Landeira, David/0000-0002-3267-454X; Navarro, Saul Abenhamar/0000-0003-3508-6396; medina, pedro p./0000-0002-7834-7093; Lopez Onieva, Lourdes/0000-0001-5509-3804	Consejeria de Salud y Familias, Junta de Andalucia [RH-0139-2020]; Instituto de Salud Carlos III [CP19/00029, PI15/00336, PI19/01533]; MCIN/AEI/FEDER "Una manera de hacer Europa" [RTI2018.101309B-C22]; Chair "Doctors Galera-Requena in cancer stem cell research"; Ministerio de Ciencia e Innovacion [PID2020-119032RB-I00]; FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades [P20_00335, B-CTS-40-UGR20]; Spanish ministry of science and innovation [PID2019-108108-100, EUR2021-122005]; Andalusian regional government [PC-0246-2017, PIER-0211-2019, PY20_00681]; University of Granada [A-BIO-6-UGR20]	Consejeria de Salud y Familias, Junta de Andalucia(Junta de Andalucia); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); MCIN/AEI/FEDER "Una manera de hacer Europa"; Chair "Doctors Galera-Requena in cancer stem cell research"; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades; Spanish ministry of science and innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Andalusian regional government; University of Granada	CGL was funded by the Consejeria de Salud y Familias, Junta de Andalucia (RH-0139-2020) and SG-P is funded by Instituto de Salud Carlos III (CP19/00029, PI15/00336, PI19/01533). JAM is supported by RTI2018.101309B-C22 funded by MCIN/AEI/10.13039/501100011033/FEDER "Una manera de hacer Europa" and by the Chair "Doctors Galera-Requena in cancer stem cell research". PCS is funded by Ministerio de Ciencia e Innovacion (grant PID2020-119032RB-I00) and FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades (grants P20_00335 and B-CTS-40-UGR20). The Landeira lab is supported by the Spanish ministry of science and innovation (PID2019-108108-100, EUR2021-122005), the Andalusian regional government (PC-0246-2017, PIER-0211-2019, PY20_00681) and the University of Granada (A-BIO-6-UGR20) grants.	[Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Asenjo HG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay4768; Awla D, 2012, J LEUKOCYTE BIOL, V91, P711, DOI 10.1189/jlb.0811443; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Fursova NA, 2019, MOL CELL, V74, P1020, DOI 10.1016/j.molcel.2019.03.024; Gallardo A, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900535; Gonzalez-Gonzalez A, 2018, CLIN CANCER RES, V24, P5697, DOI 10.1158/1078-0432.CCR-17-3125; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hardavella G, 2016, TRANSL LUNG CANCER R, V5, P272, DOI 10.21037/tlcr.2016.02.01; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Horibata S, 2015, JOVE-J VIS EXP, DOI 10.3791/52727; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Landeira D, 2015, CELL REP, V12, P573, DOI 10.1016/j.celrep.2015.06.060; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Marasca F, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201700137; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007; Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680; Piunti A, 2021, NAT REV MOL CELL BIO, V22, P326, DOI 10.1038/s41580-021-00341-1; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Schuettengruber B, 2017, CELL, V171, P34, DOI 10.1016/j.cell.2017.08.002; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Serresi M, 2018, J EXP MED, V215, P3115, DOI 10.1084/jem.20180801; Serresi M, 2016, CANCER CELL, V29, P17, DOI 10.1016/j.ccell.2015.12.006; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tarazona S, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv711; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	57	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3611	3624		10.1038/s41388-022-02375-x	http://dx.doi.org/10.1038/s41388-022-02375-x		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35680984				2022-12-17	WOS:000808419000002
J	Motohara, T; Masuda, K; Morotti, M; Zheng, YY; El-Sahhar, S; Chong, KY; Wietek, N; Alsaadi, A; Carrami, EM; Hu, ZY; Artibani, M; Gonzalez, LS; Katabuchi, H; Saya, H; Ahmed, AA				Motohara, Takeshi; Masuda, Kenta; Morotti, Matteo; Zheng, Yiyan; El-Sahhar, Salma; Chong, Kay Yi; Wietek, Nina; Alsaadi, Abdulkhaliq; Carrami, Eli M.; Hu, Zhiyuan; Artibani, Mara; Gonzalez, Laura Santana; Katabuchi, Hidetaka; Saya, Hideyuki; Ahmed, Ahmed Ashour			An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment (Dec, 10.1038/s41388-018-0637-x, 2018)	ONCOGENE			English	Correction												ahmed.ahmed@wrh.ox.ac.uk						Motohara T, 2019, ONCOGENE, V38, P2885, DOI 10.1038/s41388-018-0637-x	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3584	3584		10.1038/s41388-022-02356-0	http://dx.doi.org/10.1038/s41388-022-02356-0		JUN 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35662285	Green Published, hybrid			2022-12-17	WOS:000806108500001
J	Wang, XH; Zhang, LH; Chan, FKL; Ji, JF; Yu, J; Liang, JQ				Wang, Xiaohong; Zhang, Lianhai; Chan, Francis K. L.; Ji, Jiafu; Yu, Jun; Liang, Jessie Qiaoyi			Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagy	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; EPIGENETIC ALTERATIONS; AUTOPHAGY; GROWTH	We identified gamma-glutamyltransferase 7 (GGT7) to be frequently downregulated in gastric cancer, but its role remains unknown. Here we elucidated the clinical significance, functional roles, and molecular mechanism of GGT7 in gastric cancer. GGT7 was downregulated by promoter methylation and restored by demethylation treatment in gastric cancer cells. GGT7 methylation inversely correlated with mRNA expression in gastric tumors (n = 221; r = -0.686, P < 0.0001). High-expression of GGT7 in adjacent non-tumor tissues was significantly associated with favorable survival in gastric cancer patients (n = 138; P = 0.009), and was an independent prognostic factor by multivariate Cox regression (HR = 0.381, P < 0.05). GGT7 significantly inhibited gastric cancer cell growth, G1-S transition, and migration and invasion abilities. GGT7 also significantly attenuated the growth of subcutaneous xenograft tumors and reduced metastasis to the lung in nude mice. The mitophagy regulator RAB7 was identified as a direct downstream co-player of GGT7 by co-immunoprecipitation followed by mass spectrometry. Growth suppression effect of GGT7 was at least partly dependent on RAB7 by rescue experiments. GGT7 induced autophagy as shown by electron microscopy and confirmed by the increased LC3B and decreased p62. GGT7 recruited RAB7 by direct binding and drove RAB7 to translocate from nucleus to cytoplasm, subsequently mediating mitophagy by increasing mitophagy mediators/inducers. GGT7 inhibited intracellular ROS, which was associated with increased mitophagy, and subsequently suppressed MAPK signaling. Collectively, GGT7 plays a pivotal tumor-suppressing role in gastric cancer by directly binding with RAB7 to induce mitophagy and inhibit ROS and MAPK cascades. GGT7 is an independent prognostic factor for gastric cancer patients.	[Wang, Xiaohong; Chan, Francis K. L.; Yu, Jun; Liang, Jessie Qiaoyi] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China; [Wang, Xiaohong; Chan, Francis K. L.; Yu, Jun; Liang, Jessie Qiaoyi] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Dept Med & Therapeut State, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Peoples R China; [Wang, Xiaohong; Zhang, Lianhai; Ji, Jiafu] Peking Univ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Yu, J; Liang, JQ (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J; Liang, JQ (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Dept Med & Therapeut State, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Hong Kong, Peoples R China.; Ji, JF (corresponding author), Peking Univ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst, Beijing, Peoples R China.	jijiafu@hsc.pku.edu.cn; junyu@cuhk.edu.hk; JessieQY@cuhk.edu.hk	Liang, Qiaoyi Jessie/G-9612-2019; Chan, Francis K. L./F-4851-2010; Jun, Yu/D-8569-2015	Liang, Qiaoyi Jessie/0000-0001-8496-3442; Chan, Francis K. L./0000-0001-7388-2436; JI, JIAFU/0000-0001-6878-5543; Jun, Yu/0000-0001-5008-2153	RGC-GRF Hong Kong [C7065-18GF]; National Nature and Science Foundation of China [81773000]	RGC-GRF Hong Kong(Hong Kong Research Grants Council); National Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC))	The project was supported by the RGC-GRF Hong Kong (14116418), National Nature and Science Foundation of China (81773000), RGC-GRF Hong Kong (C7065-18GF), and Vice-Chancellor's Discretionary Fund CUHK.	Alonso-Curbelo D, 2015, ONCOTARGET, V6, P11848, DOI 10.18632/oncotarget.4055; Alonso-Curbelo D, 2014, CANCER CELL, V26, P61, DOI 10.1016/j.ccr.2014.04.030; Bloemberg D, 2019, AM J PHYSIOL-CELL PH, V317, pC111, DOI 10.1152/ajpcell.00261.2018; Bui TT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1232-y; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Carroll B, 2013, DEV CELL, V25, P15, DOI 10.1016/j.devcel.2013.03.005; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Guerra F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030034; Heisterkamp N, 2008, HUM GENET, V123, P321, DOI 10.1007/s00439-008-0487-7; Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775; Jimenez-Orgaz A, 2018, EMBO J, V37, P235, DOI 10.15252/embj.201797128; Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171; Li X, 2016, ONCOGENE, V35, P2453, DOI 10.1038/onc.2015.300; Liang QY, 2014, GASTROENTEROLOGY, V147, P1350, DOI 10.1053/j.gastro.2014.08.036; Lim JS, 2004, FREE RADICAL BIO MED, V37, P1018, DOI 10.1016/j.freeradbiomed.2004.06.032; Magnelli L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082893; Otani K, 2013, EXPERT REV MOL DIAGN, V13, P445, DOI [10.1586/erm.13.32, 10.1586/ERM.13.32]; Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Wang KN, 2016, GUT, V65, P1619, DOI 10.1136/gutjnl-2015-309276; Yamano K, 2014, ELIFE, V3, DOI 10.7554/eLife.01612; Yang XZ, 2016, ONCOGENE, V35, P5699, DOI 10.1038/onc.2016.81; Yu J, 2017, ONCOGENE, V36, P182, DOI 10.1038/onc.2016.187; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang M, 2009, BIOSCIENCE REP, V29, P193, DOI 10.1042/BSR20090032; Zhao T, 2017, J BIOL CHEM, V292, P19198, DOI 10.1074/jbc.M116.773093	28	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3485	3497		10.1038/s41388-022-02339-1	http://dx.doi.org/10.1038/s41388-022-02339-1		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35662282				2022-12-17	WOS:000805724700001
J	Georgiou, M; Ntavelou, P; Stokes, W; Roy, R; Maher, GJ; Stoilova, T; Choo, JAMY; Rakhit, CP; Martins, M; Ajuh, P; Horowitz, N; Berkowitz, RS; Elias, K; Seckl, MJ; Pardo, OE				Georgiou, Marina; Ntavelou, Panagiota; Stokes, William; Roy, Rajat; Maher, Geoffrey J.; Stoilova, Tsvetana; Choo, Josephine A. M. Y.; Rakhit, Callum P.; Martins, Miguel; Ajuh, Paul; Horowitz, Neil; Berkowitz, Ross S.; Elias, Kevin; Seckl, Michael J.; Pardo, Olivier E.			ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma (vol 4, pg 2540, 2022)	ONCOGENE			English	Correction												m.seckl@imperial.ac.uk; o.pardo@imperial.ac.uk	Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435				Georgiou M, 2022, ONCOGENE, V41, P2540, DOI 10.1038/s41388-022-02251-8	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3510	3510		10.1038/s41388-022-02354-2	http://dx.doi.org/10.1038/s41388-022-02354-2		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35637251	hybrid, Green Published			2022-12-17	WOS:000802880500001
J	Jiang, Y; Zhao, JS; Xu, JK; Zhang, HY; Zhou, JP; Li, H; Zhang, GQ; Xu, K; Jing, ZT				Jiang, Yang; Zhao, Junshuang; Xu, Jinkun; Zhang, Haiying; Zhou, Jinpeng; Li, Hao; Zhang, Guoqing; Xu, Kai; Jing, Zhitao			Glioblastoma-associated microglia-derived exosomal circKIF18A promotes angiogenesis by targeting FOXC2	ONCOGENE			English	Article							ENDOTHELIAL-CELLS; GLIOMAS; EXPRESSION; INDUCTION; RNA	Glioblastoma multiforme (GBM) is the most lethal primary tumor with active neovascularization in the central nervous system. Studying the novel molecular mechanisms of GBM angiogenesis is very important. The glioblastoma-associated microglia (GAM) M2 polarization was constructed, and microglia-derived exosomes (MDEs) were isolated to co-culture with human brain microvessel endothelial cells (hBMECs). CircRNA sequence and molecular biological experiments were used to detect the expression levels and regulation functions among circKIF18A, FOXC2, ITGB3, CXCR4, DLL4 and the PI3K/AKT signaling. The functional effects of silencing or overexpression of these molecules were evaluated in hBMECs viability, invasion, and tube formation in vitro and tumorigenicity in vivo. M2 microglia polarization is positively correlated with microvessels' density in GBM patients. M2 GAM can promote the angiogenesis of GBM via transporting exosomal circKIF18A into hBMECs. Mechanistically, circKIF18A can bind to, maintain the stability and nuclear translocation of FOXC2 in hBMECs. Furtherly, as a transcription factor, FOXC2 can directly bind to the promoter of ITGB3, CXCR4, and DLL4 and upregulate their expressions. Besides, FOXC2 can also activate the PI3K/AKT signaling and promote the angiogenesis of GBM. Our study identified a novel molecular mechanism for M2 GAM-derived exosomal circKIF18A participating in GBM angiogenesis via targeting FOXC2. This may provide a novel treatment target to improve the outcomes for anti-angiogenic therapies in GBM.	[Jiang, Yang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai 200072, Peoples R China; [Zhao, Junshuang; Xu, Jinkun; Zhou, Jinpeng; Li, Hao; Zhang, Guoqing; Xu, Kai; Jing, Zhitao] China Med Univ, Hosp 1, Dept Neurosurg, 155 North Nanjing St, Shenyang 110001, Peoples R China; [Zhang, Haiying] Liaoning Univ Tradit Chinese Med, Int Educ Coll, 79 Chongshan East Rd, Shenyang 110042, Peoples R China	Tongji University; China Medical University; Liaoning University of Traditional Chinese Medicine	Jing, ZT (corresponding author), China Med Univ, Hosp 1, Dept Neurosurg, 155 North Nanjing St, Shenyang 110001, Peoples R China.	jingzhitao@hotmail.com			National Natural Science Foundation of China [82072794, 82004423]; Major Disease Prevention and Control Technology Action Plan of China [2018ZX-07S-006]; Natural Science Foundation of Liaoning province [2021-MS-207]; Social Development Program from Shenyang Science and Technology Bureau, China [20-205-4-075]; Shanghai Sailing Program [21YF1449900]; Shanghai Post-doctoral Excellence Program [2021336]; China Postdoctoral Science Foundation [267285]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Disease Prevention and Control Technology Action Plan of China; Natural Science Foundation of Liaoning province(Natural Science Foundation of Liaoning Province); Social Development Program from Shenyang Science and Technology Bureau, China; Shanghai Sailing Program; Shanghai Post-doctoral Excellence Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (Nos. 82072794, 82004423), the Major Disease Prevention and Control Technology Action Plan of China (2018ZX-07S-006), the Natural Science Foundation of Liaoning province (2021-MS-207), the Social Development Program from Shenyang Science and Technology Bureau, China (20-205-4-075), Shanghai Sailing Program (No. 21YF1449900), Shanghai Post-doctoral Excellence Program (No. 2021336) and China Postdoctoral Science Foundation (No. 267285).	Bydoun M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32433-y; Cheng N, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114354; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Ding CY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01942-6; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Han YG, 2021, AGING-US, V13, P13287, DOI 10.18632/aging.203013; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Hayashi H, 2008, BIOCHEM BIOPH RES CO, V367, P584, DOI 10.1016/j.bbrc.2007.12.183; Hayashi H, 2009, CELL ADHES MIGR, V3, P24, DOI 10.4161/cam.3.1.7252; He ZW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1065-7; Huang XY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1529-9; Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8; Jiang Y, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01691-y; Jiang Y, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102651; Jiang Y, 2019, EBIOMEDICINE, V48, P36, DOI 10.1016/j.ebiom.2019.09.037; Jiang Y, 2018, EBIOMEDICINE, V37, P78, DOI 10.1016/j.ebiom.2018.10.053; Li WH, 2013, ONCOL RES, V21, P111, DOI 10.3727/096504013X13814233062171; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1371-0; Liu XB, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01625-8; Ma X, 2017, AM J TRANSL RES, V9, P5012; Nie JH, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5020036; Peterson TE, 2016, P NATL ACAD SCI USA, V113, P4470, DOI 10.1073/pnas.1525349113; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Sahebjam S, 2020, NEURO-ONCOLOGY; Sorensen MD, 2018, NEUROPATH APPL NEURO, V44, P185, DOI 10.1111/nan.12428; Sun SF, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01779-5; Tu JJ, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12929; Wang M, 2020, MOL THER-NUCL ACIDS, V21, P367, DOI 10.1016/j.omtn.2020.06.008; Wang T, 2018, CLIN CHIM ACTA, V479, P84, DOI 10.1016/j.cca.2018.01.019; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wang ZF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1181-4; Yang YH, 2021, MOL THER, V29, P1226, DOI 10.1016/j.ymthe.2020.11.024; Yin JL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16789-2; You WL, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-199; Zhang Y, 2018, NAT COMMUN, V9, DOI [10.1038/s41467-017-02251-3, 10.1038/s41467-018-06269-z]	36	0	0	8	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3461	3473		10.1038/s41388-022-02360-4	http://dx.doi.org/10.1038/s41388-022-02360-4		MAY 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35637250				2022-12-17	WOS:000802880500002
J	Ratze, MAK; Koorman, T; Sijnesael, T; Bassey-Archibong, B; van de Ven, R; Enserink, L; Visser, D; Jaksani, S; Viciano, I; Bakker, ERM; Richard, F; Tutt, A; O'Leary, L; Fitzpatrick, A; Roca-Cusachs, P; van Diest, PJ; Desmedt, C; Daniel, JM; Isacke, CM; Derksen, PWB				Ratze, Max A. K.; Koorman, Thijs; Sijnesael, Thijmen; Bassey-Archibong, Blessing; van de Ven, Robert; Enserink, Lotte; Visser, Daan; Jaksani, Sridevi; Viciano, Ignacio; Bakker, Elvira R. M.; Richard, Francois; Tutt, Andrew; O'Leary, Lynda; Fitzpatrick, Amanda; Roca-Cusachs, Pere; van Diest, Paul J.; Desmedt, Christine; Daniel, Juliet M.; Isacke, Clare M.; Derksen, Patrick W. B.			Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer (vol 41, pg 2932, 2022)	ONCOGENE			English	Correction												p.w.b.derksen@umcutrecht.nl	; Desmedt, Christine/P-7438-2017	Isacke, Clare/0000-0002-9222-3345; Sijnesael, Thijmen/0000-0003-2248-9786; Desmedt, Christine/0000-0002-5223-5579; Koorman, Thijs/0000-0002-6064-3353; Tutt, Andrew/0000-0001-8715-2901				Ratze MAK, 2022, ONCOGENE, V41, P2932, DOI 10.1038/s41388-022-02314-w	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3507	3509		10.1038/s41388-022-02355-1	http://dx.doi.org/10.1038/s41388-022-02355-1		MAY 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35610485	hybrid, Green Published			2022-12-17	WOS:000801080700001
J	Chen, YQ; Zhou, S; Wan, KR; Yu, L; Zhao, CC; Deng, HT; Ou, QJ; Qin, JY; Hu, JB; Hou, ZL				Chen, Yaqi; Zhou, Sha; Wan, Kairui; Yu, Long; Zhao, Chongchong; Deng, Haiteng; Ou, Qingjian; Qin, Jiayi; Hu, Junbo; Hou, Zhenlin			RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2	ONCOGENE			English	Article							ENDORIBONUCLEASE G3BP; MDM2; RADIOTHERAPY; BIOGENESIS; RESISTANCE; PROMOTES; KINASES; CELLS	RIO Kinase 1 (RIOK1) is involved in various pathologies, including cancer. However, the role of RIOK1 in radioresistance of colorectal cancer (CRC) remains largely unknown. In this study, we reported that RIOK1 was overexpressed in rectal cancer tissue with weaker tumor regression after neoadjuvant chemoradiotherapy (neoCRT). Moreover, higher RIOK1 expression predicted a poor prognosis in patients with rectal cancer. Blockade of RIOK1 using Toyocamycin, a pharmacological inhibitor of RIOK1, or by knocking down its expression, decreased the resistance of CRC cells to radiotherapy in vitro and in vivo. A mechanistic study revealed that RIOK1 regulates radioresistance by suppressing the p53 signaling pathway. Furthermore, we found that RIOK1 and Ras-GAP SH3 domain binding protein 2 (G3BP2) interact with each other. RIOK1 phosphorylates G3BP2 at Thr226, which increases the activity of G3BP2. RIOK1-mediated phosphorylation of G3BP2 facilitated ubiquitination of p53 by murine double minute 2 protein (MDM2). Altogether, our study revealed the clinical significance of RIOK1 in CRC, and therapies targeting RIOK1 might alleviate the CRC tumor burden in patients.	[Chen, Yaqi; Wan, Kairui; Hu, Junbo] Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Wuhan 430030, Peoples R China; [Zhou, Sha] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Peoples R China; [Yu, Long; Ou, Qingjian; Qin, Jiayi; Hou, Zhenlin] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Colorectal Surg, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Peoples R China; [Zhao, Chongchong; Deng, Haiteng] Tsinghua Univ, Prot Chem & Prote Facil, Technol Ctr Prot Res, Beijing 100084, Peoples R China	Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Tsinghua University	Hou, ZL (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Colorectal Surg, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Peoples R China.	houzl@sysucc.org.cn		Yu, Long/0000-0003-1045-5407; Deng, Haiteng/0000-0001-9496-1280; Wan, Kairui/0000-0001-5991-5334	China Postdoctoral Science Foundation [2019M663289]; Natural Science Foundation of Guangdong Province [2019A1515110144, 2021A1515111014]; National Natural Science Foundation of China [81572725]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by China Postdoctoral Science Foundation (No. 2019M663289), Natural Science Foundation of Guangdong Province (Nos. 2019A1515110144 and 2021A1515111014) and National Natural Science Foundation of China (No. 81572725).	Angermayr M, 2002, FEBS LETT, V524, P31, DOI 10.1016/S0014-5793(02)02993-9; Angermayr M, 2002, MOL MICROBIOL, V44, P309, DOI 10.1046/j.1365-2958.2002.02881.x; Baker B, 2012, SURG ONCOL, V21, pE103, DOI 10.1016/j.suronc.2012.03.004; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; Ferreira-Cerca S, 2014, NUCLEIC ACIDS RES, V42, P8635, DOI 10.1093/nar/gku542; Gal J, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00052-19; Gu XY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0308-x; Guderian G, 2011, J BIOL CHEM, V286, P1976, DOI 10.1074/jbc.M110.148486; Hinata N, 2003, UROL RES, V31, P387, DOI 10.1007/s00240-003-0355-9; Hong HQ, 2018, ACTA PHARMACOL SIN, V39, P184, DOI 10.1038/aps.2017.58; Hong XH, 2018, ELIFE, V7, DOI 10.7554/eLife.29511; Hu S, 2015, AM J CANCER RES, V5, P651; Huang QH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.586025; Huang QH, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01214; Iacovella MG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7643; Kim BM, 2015, INT J MOL SCI, V16, P26880, DOI 10.3390/ijms161125991; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Kong XH, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12922; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; LaRonde-LeBlanc N, 2005, J BIOL CHEM, V280, P37297, DOI 10.1074/jbc.R500013200; LaRonde-LeBlanc N, 2005, BBA-PROTEINS PROTEOM, V1754, P14, DOI 10.1016/j.bbapap.2005.07.037; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Li JQ, 2015, J CELL PHYSIOL, V230, P2318, DOI 10.1002/jcp.24994; Line A, 2002, CANCER IMMUNOL IMMUN, V51, P574, DOI 10.1007/s00262-002-0322-2; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Prentzell MT, 2021, CELL, V184, P655, DOI 10.1016/j.cell.2020.12.024; Read RD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003253; Singleton DC, 2015, ONCOGENE, V34, P4713, DOI 10.1038/onc.2014.396; Sun Y, 2019, ONCOGENE, V38, P4856, DOI 10.1038/s41388-019-0762-1; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tsai WC, 2017, J BIOL CHEM, V292, P18886, DOI 10.1074/jbc.M117.800706; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Weinberg F, 2017, EBIOMEDICINE, V20, P79, DOI 10.1016/j.ebiom.2017.04.015; Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070; Williams E, 2007, EXTREMOPHILES, V11, P19, DOI 10.1007/s00792-006-0002-9; Xie J, 2018, THERANOSTICS, V8, P650, DOI 10.7150/thno.21963; Yang PX, 2017, J GASTROEN HEPATOL, V32, P837, DOI 10.1111/jgh.13606	43	0	0	6	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3433	3444		10.1038/s41388-022-02352-4	http://dx.doi.org/10.1038/s41388-022-02352-4		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35589951				2022-12-17	WOS:000799459800002
J	Constantin, TA; Greenland, KK; Varela-Carver, A; Bevan, CL				Constantin, Theodora A.; Greenland, Kyle K.; Varela-Carver, Anabel; Bevan, Charlotte L.			Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer	ONCOGENE			English	Review							NUCLEOTIDE EXCISION-REPAIR; INHIBITOR BAY 1251152; P-TEFB; ANDROGEN RECEPTOR; PRECLINICAL MODELS; SERINE PHOSPHORYLATION; PREINITIATION COMPLEX; SELECTIVE INHIBITOR; COVALENT INHIBITOR; ANTITUMOR-ACTIVITY	Transcriptional deregulation has emerged as a hallmark of several cancer types. In metastatic castration-resistant prostate cancer, a stage in which systemic androgen deprivation therapies fail to show clinical benefit, transcriptional addiction to the androgen receptor is maintained in most patients. This has led to increased efforts to find novel therapies that prevent oncogenic transactivation of the androgen receptor. In this context, a group of druggable protein kinases, known as transcription associated cyclin-dependent kinases (tCDKs), show great potential as therapeutic targets. Despite initial reservations about targeting tCDKs due to their ubiquitous and prerequisite nature, preclinical studies showed that selectively inhibiting such kinases could provide sufficient therapeutic window to exert antitumour effects in the absence of systemic toxicity. As a result, several highly specific inhibitors are currently being trialled in solid tumours, including prostate cancer. This article summarises the roles of tCDKs in regulating gene transcription and highlights rationales for their targeting in prostate cancer. It provides an overview of the most recent developments in this therapeutic area, including the most recent clinical advances, and discusses the utility of tCDK inhibitors in combination with established cancer agents.	[Constantin, Theodora A.; Greenland, Kyle K.; Varela-Carver, Anabel; Bevan, Charlotte L.] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London, England	Imperial College London	Bevan, CL (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London, England.	charlotte.bevan@imperial.ac.uk	; Bevan, Charlotte/K-2276-2012	Greenland, Kyle/0000-0003-3887-4160; Bevan, Charlotte/0000-0002-7533-0552; Constantin, Theodora Alexandra/0000-0003-2132-5165	Medical Research Council Doctoral Training Partnership [MR/N014103/1]; Imperial President's PhD Scholarship	Medical Research Council Doctoral Training Partnership(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Imperial President's PhD Scholarship	This work was supported by the Medical Research Council Doctoral Training Partnership (TAC and KKG) (grant number MR/N014103/1) and the Imperial President's PhD Scholarship (TAC).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Araujo SJ, 2000, GENE DEV, V14, P349; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Barlaam B, 2020, J MED CHEM, V63, P15564, DOI 10.1021/acs.jmedchem.0c01754; Bose P, 2013, EXPERT OPIN INV DRUG, V22, P723, DOI 10.1517/13543784.2013.789859; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Byrne M, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117257; Chen MQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111413; Chen XR, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-00137-0; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Cidado J, 2020, CLIN CANCER RES, V26, P922, DOI 10.1158/1078-0432.CCR-19-1853; Clarke PA, 2016, ELIFE, V5, DOI 10.7554/eLife.20722; Coin F, 2008, MOL CELL, V31, P9, DOI 10.1016/j.molcel.2008.04.024; Daniels D., 2013, J PROTEOM BIOINFORM, V2, P004, DOI DOI 10.4172/JPB.S2-004; Diamond JR, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2507; Dubbury SJ, 2018, NATURE, V564, P141, DOI 10.1038/s41586-018-0758-y; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Ebmeier CC, 2017, CELL REP, V20, P1173, DOI 10.1016/j.celrep.2017.07.021; Egloff S, 2018, TRANSCR-AUSTIN, V9, P95, DOI 10.1080/21541264.2017.1344346; Egloff S, 2012, RNA BIOL, V9, P1033, DOI 10.4161/rna.21166; Eick D, 2013, CHEM REV, V113, P8456, DOI 10.1021/cr400071f; Fisher RP, 2019, TRANSCR-AUSTIN, V10, P47, DOI 10.1080/21541264.2018.1553483; Gajduskova P, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0406-8; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Greber BJ, 2019, ELIFE, V8, DOI 10.7554/eLife.44771; Greenleaf AL, 2019, TRANSCR-AUSTIN, V10, P91, DOI 10.1080/21541264.2018.1535211; Guarducci C, 2019, P 2018 SAN ANTONIO B, pPD712; Guen VJ, 2013, P NATL ACAD SCI USA, V110, P19525, DOI 10.1073/pnas.1306814110; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henry SH, 2021, ANN ONCOL, V32, pS364, DOI 10.1016/j.annonc.2021.08.291; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Hsin JP, 2011, SCIENCE, V334, P683, DOI 10.1126/science.1206034; Hu SH, 2019, CANCER RES, V79, P3479, DOI 10.1158/0008-5472.CAN-19-0119; Jaeger MG, 2020, NAT GENET, V52, P719, DOI 10.1038/s41588-020-0635-0; Jiang BS, 2021, EUR J MED CHEM, V221, DOI 10.1016/j.ejmech.2021.113481; Jiang BS, 2021, NAT CHEM BIOL, V17, P675, DOI 10.1038/s41589-021-00765-y; Johannessen LH, 2019, P AACR NCI EORTC INT, pC091; Kalan S, 2017, CELL REP, V21, P467, DOI 10.1016/j.celrep.2017.09.056; Kasten M, 2001, ONCOGENE, V20, P1832, DOI 10.1038/sj.onc.1204295; Kokic G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10745-5; Krajewska M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09703-y; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Laitem C, 2015, NAT STRUCT MOL BIOL, V22, P396, DOI 10.1038/nsmb.3000; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lei HQ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04027-6; Li YC, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd4484; Liang K, 2015, MOL CELL BIOL, V35, P928, DOI 10.1128/MCB.01426-14; Liu XM, 2017, NUCLEIC ACIDS RES, V45, P3738, DOI 10.1093/nar/gkw1291; Loyer P, 2008, J BIOL CHEM, V283, P7721, DOI 10.1074/jbc.M708188200; Lucking U, 2017, CHEMMEDCHEM, V12, P1776, DOI 10.1002/cmdc.201700447; Luedtke DA, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0112-3; Luse DS, 2013, BBA-GENE REGUL MECH, V1829, P63, DOI 10.1016/j.bbagrm.2012.08.010; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Marineau JJ, 2022, J MED CHEM, V65, P1458, DOI 10.1021/acs.jmedchem.1c01171; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Mbonye U, 2018, J BIOL CHEM, V293, P10009, DOI 10.1074/jbc.RA117.001347; McCalmont H, 2020, BLOOD ADV, V4, P296, DOI 10.1182/bloodadvances.2019000586; McDermott MSJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030638; McLaughlin RP, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1161-9; Minzel W, 2018, CELL, V175, P171, DOI 10.1016/j.cell.2018.07.045; Moreno V, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.7538; Nagaraja S, 2017, CANCER CELL, V31, P635, DOI 10.1016/j.ccell.2017.03.011; Nakamura Akito, 2018, Oncotarget, V9, P13474, DOI 10.18632/oncotarget.24414; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Narita T, 2017, BLOOD, V130, P1114, DOI 10.1182/blood-2016-09-741983; Nilson KA, 2015, MOL CELL, V59, P576, DOI 10.1016/j.molcel.2015.06.032; Olson CM, 2019, CELL CHEM BIOL, V26, P792, DOI 10.1016/j.chembiol.2019.02.012; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Perales R, 2009, MOL CELL, V36, P178, DOI 10.1016/j.molcel.2009.09.018; Phillips DC, 2020, LEUKEMIA, V34, P1646, DOI 10.1038/s41375-019-0652-0; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200; Poss ZC, 2016, CELL REP, V15, P436, DOI 10.1016/j.celrep.2016.03.030; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Rasool RU, 2019, CANCER DISCOV, V9, P1538, DOI 10.1158/2159-8290.CD-19-0189; Richters A, 2021, CELL CHEM BIOL, V28, P134, DOI 10.1016/j.chembiol.2020.10.001; Rimel JK, 2020, GENE DEV, V34, P1452, DOI 10.1101/gad.341545.120; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Rzymski T, 2017, ONCOTARGET, V8, P33779, DOI 10.18632/oncotarget.16810; Sanso M, 2016, GENE DEV, V30, P117, DOI 10.1101/gad.269589.115; Sanso M, 2013, TRANSCR-AUSTIN, V4, P146, DOI 10.4161/trns.25146; Satyam LK, 2020, EUR J CANCER, V138, pS47; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Soutourina J, 2018, NAT REV MOL CELL BIO, V19, P262, DOI 10.1038/nrm.2017.115; Sun BW, 2020, ONCOGENE, V39, P50, DOI 10.1038/s41388-019-0953-9; Tien JF, 2017, NUCLEIC ACIDS RES, V45, P6698, DOI 10.1093/nar/gkx187; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Vos SM, 2018, NATURE, V560, P601, DOI 10.1038/s41586-018-0442-2; Wei Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01301-7; West TA, 2014, EUR J CANCER, V50, P1916, DOI 10.1016/j.ejca.2014.04.004; Wong KH, 2014, MOL CELL, V54, P601, DOI 10.1016/j.molcel.2014.03.024; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhang HH, 2018, CELL, V175, P1244, DOI 10.1016/j.cell.2018.09.051; Zhang H, 2020, CANCER CELL, V37, P37, DOI 10.1016/j.ccell.2019.11.003; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	104	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3303	3315		10.1038/s41388-022-02347-1	http://dx.doi.org/10.1038/s41388-022-02347-1		MAY 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35568739	Green Published, hybrid			2022-12-17	WOS:000795517600002
J	Zhang, YX; Wu, JZ; Fu, Y; Yu, RR; Su, HC; Zheng, QS; Wu, H; Zhou, SQ; Wang, K; Zhao, J; Shen, SS; Xu, GF; Wang, L; Yan, C; Zou, XP; Lv, Y; Zhang, S				Zhang, Yixuan; Wu, Jianzhuang; Fu, Yao; Yu, Ranran; Su, Haochen; Zheng, Qisi; Wu, Hao; Zhou, Siqi; Wang, Kun; Zhao, Jing; Shen, Shanshan; Xu, Guifang; Wang, Lei; Yan, Chao; Zou, Xiaoping; Lv, Ying; Zhang, Shu			Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; MODIFIED-FOLFIRINOX; INDUCED APOPTOSIS; INCREASING ROS; ER STRESS; MITOCHONDRIA; AUTOPHAGY; INHIBITION; METABOLISM	Pancreatic cancer (PC) is a fatal disease with poor survival and limited therapeutic strategies. In this study, we identified Hesperadin as a potent anti-cancer compound against PC, from a high-throughput screening of a commercial chemical library associated with cell death. Hesperadin induced potent growth inhibition in PC cell lines and patient-derived tumor organoids in a dose- and time-dependent manner, with IC50 values in the nanomolar range. Cellular studies showed that Hesperadin caused mitochondria damage in PC cells, resulting in reactive oxygen species production, ER stress and apoptotic cell death. Transcriptomic analysis using RNA-sequencing data identified GADD45A as a potential target of Hesperadin. Mechanistic studies showed that Hesperadin could increase GADD45A expression in PC cells via ATF4, leading to apoptosis. Moreover, immunohistochemical staining of 92 PC patient samples demonstrated the correlation between ATF4 and GADD45A expression. PC xenograft studies demonstrated that Hesperadin could effectively inhibit the growth of PC cells in vivo. Together, these findings suggest that Hesperadin is a novel drug candidate for PC.	[Zhang, Yixuan; Wu, Hao; Zhao, Jing; Shen, Shanshan; Xu, Guifang; Wang, Lei; Zou, Xiaoping; Lv, Ying; Zhang, Shu] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Gastroenterol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China; [Zhang, Yixuan; Wu, Jianzhuang; Su, Haochen; Wu, Hao; Zhou, Siqi; Wang, Kun; Zhao, Jing; Shen, Shanshan; Xu, Guifang; Wang, Lei; Yan, Chao; Zou, Xiaoping; Lv, Ying; Zhang, Shu] Nanjing Univ, Inst Pancreatol, Nanjing, Peoples R China; [Wu, Jianzhuang; Yu, Ranran; Yan, Chao] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China; [Fu, Yao] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Pathol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China; [Su, Haochen] Nanjing Med Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Gastroenterol, Nanjing, Peoples R China; [Zheng, Qisi] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Clin Lab, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China; [Zhou, Siqi] Jiangsu Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Dept Gastroenterol, Nanjing, Peoples R China; [Wang, Kun] Xuzhou Med Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Dept Gastroenterol, Nanjing, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University; Nanjing Medical University; Nanjing University; Nanjing University; Jiangsu University; Nanjing University; Nanjing University; Xuzhou Medical University	Zou, XP; Lv, Y; Zhang, S (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Gastroenterol, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Zou, XP; Lv, Y; Zhang, S (corresponding author), Nanjing Univ, Inst Pancreatol, Nanjing, Peoples R China.	zouxp@nju.edu.cn; lvying@njglyy.com; zhangsgastro@nju.edu.cn		Fu, Yao/0000-0001-9864-1030	National Natural Science Foundation of China [81802396, 82072652]; Natural Science Foundation of Jiangsu Province [SBK2019022491, BK20180117]; General Project of Nanjing Medical Science and Technology Development Project [YKK17077]; Nanjing Science and Technology Development Plan Project [201715023]; Nanjing Medical Science and Technology Development Key Project [ZKX18022]; Nanjing Science and technology project [201911038]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); General Project of Nanjing Medical Science and Technology Development Project; Nanjing Science and Technology Development Plan Project; Nanjing Medical Science and Technology Development Key Project; Nanjing Science and technology project	This work was supported by the National Natural Science Foundation of China (81802396 and 82072652), Natural Science Foundation of Jiangsu Province (SBK2019022491 and BK20180117), General Project of Nanjing Medical Science and Technology Development Project (YKK17077), Nanjing Science and Technology Development Plan Project (201715023), Nanjing Medical Science and Technology Development Key Project (ZKX18022), and Nanjing Science and technology project (201911038).	Aggarwal V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110735; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen WQ, 2016, REDOX BIOL, V10, P78, DOI 10.1016/j.redox.2016.09.006; Chen X, 2021, NAT REV CANCER, V21, P71, DOI 10.1038/s41568-020-00312-2; Chen X, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.019; Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046; Chiu HY, 2020, ANTIOXID REDOX SIGN, V32, P309, DOI 10.1089/ars.2019.7898; Chuang KC, 2020, J DERMATOL SCI, V98, P152, DOI 10.1016/j.jdermsci.2020.03.009; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; DU J, 2021, CELL DEATH DIS, V12; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guo XY, 2020, NATURE, V579, P427, DOI 10.1038/s41586-020-2078-2; Harris IS, 2020, TRENDS CELL BIOL, V30, P440, DOI 10.1016/j.tcb.2020.03.002; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hu YL, 2019, ONCOGENE, V38, P731, DOI 10.1038/s41388-018-0478-7; Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Li W, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0805-4; Li X, 2017, CANCER LETT, V406, P22, DOI 10.1016/j.canlet.2017.07.012; Li X, 2018, INT J BIOL SCI, V14, P1291, DOI 10.7150/ijbs.26776; Lin YN, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109249; Liu CY, 2020, ENVIRON TOXICOL, V35, P1100, DOI 10.1002/tox.22946; Liu S, 2017, REDOX BIOL, V13, P528, DOI 10.1016/j.redox.2017.06.007; Missiroli S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102943; Moore Alexandra, 2019, JAMA, V322, P1426, DOI 10.1001/jama.2019.14699; Nano M, 2019, CURR BIOL, V29, P3937, DOI 10.1016/j.cub.2019.09.041; Neoptolemos JP, 2018, NAT REV GASTRO HEPAT, V15, P332, DOI 10.1038/s41575-018-0005-x; Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276-020-0384-2; Rodic S, 2018, INT J CANCER, V142, P440, DOI 10.1002/ijc.31069; Sasaki K, 2020, BIOSCIENCE REP, V40; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silva JM, 2009, NEUROBIOL DIS, V34, P357, DOI 10.1016/j.nbd.2009.02.005; Su MQ, 2018, INT J ONCOL, V53, P750, DOI 10.3892/ijo.2018.4402; Tempero MA, 2019, J NATL COMPR CANC NE, V17, P603, DOI 10.6004/jnccn.2019.5007; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Verfaillie T, 2012, CELL DEATH DIFFER, V19, P1880, DOI 10.1038/cdd.2012.74; Verfaillie T, 2013, CANCER LETT, V332, P249, DOI 10.1016/j.canlet.2010.07.016; Wang ZQ, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0367-7; Westrate LM, 2015, ANNU REV BIOCHEM, V84, P791, DOI 10.1146/annurev-biochem-072711-163501; Xiong WP, 2016, MOL CANCER THER, V15, P412, DOI 10.1158/1535-7163.MCT-15-0703; Yang LX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02807-0; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151; Zhou SQ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0218-z; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	47	0	0	8	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3394	3408		10.1038/s41388-022-02328-4	http://dx.doi.org/10.1038/s41388-022-02328-4		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35551503				2022-12-17	WOS:000794082100002
J	Zheng, J; Zhang, H; Ma, RR; Liu, HT; Gao, P				Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng			Long non-coding RNA KRT19P3 suppresses proliferation and metastasis through COPS7A-mediated NF-kappa B pathway in gastric cancer (vol 38, pg 7073, 2019)	ONCOGENE			English	Correction												gaopeng@sdu.edu.cn						Zheng J, 2019, ONCOGENE, V38, P7073, DOI 10.1038/s41388-019-0934-z	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3454	3454		10.1038/s41388-022-02346-2	http://dx.doi.org/10.1038/s41388-022-02346-2		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35551504	Bronze			2022-12-17	WOS:000794082100001
J	Garzon, R; Pichiorri, F; Palumbo, T; Visentini, M; Aqeilan, R; Cimmino, A; Wang, H; Sun, H; Volinia, S; Alder, H; Calin, GA; Liu, CG; Andreeff, M; Croce, CM				Garzon, R.; Pichiorri, F.; Palumbo, T.; Visentini, M.; Aqeilan, R.; Cimmino, A.; Wang, H.; Sun, H.; Volinia, S.; Alder, H.; Calin, G. A.; Liu, C. -G; Andreeff, M.; Croce, C. M.			MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia (vol 26, pg 4148, 2007)	ONCOGENE			English	Correction												Carlo.Croce@osumc.edu						Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3452	3453		10.1038/s41388-022-02351-5	http://dx.doi.org/10.1038/s41388-022-02351-5		MAY 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35546352	Bronze			2022-12-17	WOS:000793636100002
J	Ueshima, S; Fang, J				Ueshima, Shuhei; Fang, Jia			Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis	ONCOGENE			English	Article							DNA METHYLATION; MESENCHYMAL TRANSITION; LUNG-CANCER; E-CADHERIN; FOXA2; PROGRESSION; EXPRESSION; ESET; TRANSCRIPTION; SUPPRESSOR	Non-small cell lung cancer (NSCLC) is one of leading causes of cancer-related mortality worldwide, which harbors various accumulated genetic and epigenetic abnormalities. Histone methyltransferase SETDB1 is a pivotal epigenetic regulator whose focal amplification and upregulation are commonly detected in NSCLC. However, molecular mechanisms underlying the pro-oncogenic function of SETDB1 remain poorly characterized. Here, we demonstrate that SETDB1 augments the migration and invasion capabilities of NSCLC cells by reinforcing invadopodia formation and mediated ECM degradation. At the molecular level, SETDB1 suppresses the expression of FOXA2, a crucial tumor and metastasis suppressor via coordinated epigenetic mechanisms - SETDB1 not only catalyzes histone H3K9 methylation on FOXA2 genomic locus, but also recruits DNMT3A to regulate DNA methylation on CpG island. Consequently, depletion of Setdb1 in murine lung adenocarcinoma cells completely abolished their full and spontaneous metastatic capabilities in mouse xenograft models. These findings together establish the pro-metastasis activity of SETDB1 in NSCLC and elucidate the underlying cellular and molecular mechanisms.	[Ueshima, Shuhei; Fang, Jia] Roswell Park Comprehens Canc Ctr, Dept Pharmacol Therapeut, Buffalo, NY 14263 USA		Fang, J (corresponding author), Roswell Park Comprehens Canc Ctr, Dept Pharmacol Therapeut, Buffalo, NY 14263 USA.	Jia.Fang@RoswellPark.org		Fang, Jia/0000-0001-8583-1652	NIH [CA172774]; Roswell Park Alliance Foundation; RPCCC; NCI center grant [P30CA016056]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roswell Park Alliance Foundation; RPCCC; NCI center grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Tyler Jacks for murine lung adenocarcinoma cell lines, Dr. Shengyu Yang for technical assistance with invadopodia assays, Dr. David Goodrich for constructive discussion and suggestions and support from Roswell Park Comprehensive Cancer Center (RPCCC) Shared Resources, including BIOINFO, GSR, TISR, and LASR. This project was supported, in part, by grants from the NIH (CA172774) and Roswell Park Alliance Foundation (all to JF), and by RPCCC and NCI center grant P30CA016056.	Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Basseres DS, 2012, LUNG CANCER, V77, P31, DOI 10.1016/j.lungcan.2012.01.011; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Bowden ET, 2001, METHOD CELL BIOL, V63, P613; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Cruz-Tapias P, 2019, CANCERS, V11, DOI 10.3390/cancers11081134; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Duruisseaux M, 2018, SEMIN CANCER BIOL, V51, P116, DOI 10.1016/j.semcancer.2017.09.005; Eckert MA, 2017, J CELL SCI, V130, P2036, DOI 10.1242/jcs.198200; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Fei Q, 2015, GENOME RES, V25, P1325, DOI 10.1101/gr.177576.114; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fukuda K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060596; Gauchier M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3673; Griffin GK, 2021, NATURE, V595, P309, DOI 10.1038/s41586-021-03520-4; Guler GD, 2017, CANCER CELL, V32, P221, DOI 10.1016/j.ccell.2017.07.002; Halmos B, 2004, CANCER RES, V64, P4137, DOI 10.1158/0008-5472.CAN-03-4052; Halpern KB, 2014, J BIOL CHEM, V289, P23882, DOI 10.1074/jbc.M114.573469; Hawkins AG, 2019, NEOPLASIA, V21, P1063, DOI 10.1016/j.neo.2019.08.007; Holemon H, 2007, BIOTECHNIQUES, V43, P683, DOI 10.2144/000112597; Juznic L, 2021, GUT, V70, P485, DOI 10.1136/gutjnl-2020-321339; Kang YK, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.573515; Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239; Lafuente-Sanchis A, 2016, CLIN TRANSL ONCOL, V18, P798, DOI 10.1007/s12094-015-1440-6; Lee T, 2016, J PATHOL TRANSL MED, V50, P197, DOI 10.4132/jptm.2016.03.09; Leung D, 2014, P NATL ACAD SCI USA, V111, P6690, DOI 10.1073/pnas.1322273111; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Li CMC, 2013, GENE DEV, V27, P1557, DOI 10.1101/gad.222745.113; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Liu JH, 2018, CANCER MANAG RES, V10, P391, DOI 10.2147/CMAR.S150552; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Mozzetta C, 2015, NAT REV MOL CELL BIO, V16, P499, DOI 10.1038/nrm4029; Naciri I, 2019, NUCLEIC ACIDS RES, V47, P3407, DOI 10.1093/nar/gkz080; Nyren-Erickson EK, 2013, BBA-GEN SUBJECTS, V1830, P4445, DOI 10.1016/j.bbagen.2013.05.011; Pelaez R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181579; Rodriguez-Paredes M, 2014, ONCOGENE, V33, P2807, DOI 10.1038/onc.2013.239; Saini P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.203661; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807; Strepkos D, 2021, CANCER RES, V81, P525, DOI 10.1158/0008-5472.CAN-20-2906; Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1; Takikita S, 2016, J IMMUNOL, V197, P2269, DOI 10.4049/jimmunol.1502486; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wang BL, 2018, EXP THER MED, V16, P133, DOI 10.3892/etm.2018.6157; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wu PC, 2014, CANCER RES, V74, P7333, DOI 10.1158/0008-5472.CAN-13-3572; Yuan P, 2009, GENE DEV, V23, P2507, DOI 10.1101/gad.1831909; Zhang SM, 2021, NATURE, V598, P682, DOI 10.1038/s41586-021-03994-2; Zhang Z, 2015, CANCER LETT, V361, P240, DOI 10.1016/j.canlet.2015.03.008	51	0	0	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3370	3380		10.1038/s41388-022-02345-3	http://dx.doi.org/10.1038/s41388-022-02345-3		MAY 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35546351				2022-12-17	WOS:000793636100001
J	Simond, AM; Bui, T; Zuo, DM; Sanguin-Gendreau, V; Rao, T; Phillips, WA; Cardiff, RD; Muller, WJ				Simond, Alexandra M.; Bui, Tung; Zuo, Dongmei; Sanguin-Gendreau, Virginie; Rao, Trisha; Phillips, Wayne A.; Cardiff, Robert D.; Muller, William J.			Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PIK3CA MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; TUMORIGENESIS; AMPLIFICATION; ONCOGENE; PROTEIN; IMPACT; ROLES; GENE	p110 alpha is a catalytic subunit of phosphoinositide 3-kinase (PI3K), a major downstream effector of receptor tyrosine kinase ErbB2, that is amplified and overexpressed in 20-30% of breast cancers, 40% of which have an activating mutation in p110 alpha. Despite the high frequency of PIK3CA gain-of-function mutations, their prognostic value is controversial. Here, we employ a knock-in transgenic strategy to restrict the expression of an activated form of ErbB2 and p110 alpha kinase domain mutation (p110 alpha(HR)) in the mammary epithelium. Physiological levels of transgene expression under the control of their endogenous promoters did not result in a major synergistic effect. However, tumors arising in ErbB2/p110 alpha(HR) bi-genic strain metastasized to the lung with significantly reduced capacity compared to tumors expressing ErbB2 alone. The reduced metastasis was further associated with retention of the myoepithelial layer reminiscent of ductal carcinoma in situ (DCIS), a non-invasive stage of human breast cancer. Molecular and biochemical analyses revealed that these poorly metastatic tumors exhibited a significant decrease in phospho-myosin light chain 2 (MLC2) associated with cellular contractility and migration. Examination of human samples for MLC2 activity revealed a progressive increase in cellular contractility between non-invasive DCIS and invasive ductal carcinoma. Collectively, these data argue that p110 alpha(HR) mutation attenuates metastatic behavior in the context of ErbB2-driven breast cancer.	[Simond, Alexandra M.; Bui, Tung; Zuo, Dongmei; Sanguin-Gendreau, Virginie; Rao, Trisha; Muller, William J.] McGill Univ, Rosalind & Morris Goodman Canc Res Inst, Montreal, PQ, Canada; [Simond, Alexandra M.; Bui, Tung; Muller, William J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Phillips, Wayne A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Phillips, Wayne A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Cardiff, Robert D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Muller, William J.] McGill Univ, Fac Med, Montreal, PQ, Canada	McGill University; McGill University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of California System; University of California Davis; McGill University	Muller, WJ (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Inst, Montreal, PQ, Canada.; Muller, WJ (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.; Muller, WJ (corresponding author), McGill Univ, Fac Med, Montreal, PQ, Canada.	william.muller@mcgill.ca	Phillips, Wayne/H-8070-2013	Phillips, Wayne/0000-0002-7961-638X	Canada Research Councils Chair in Molecular Oncology [950-2310-33]; Canadian Institutes of Health Research [CIHR-FDN-148373]	Canada Research Councils Chair in Molecular Oncology; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a Canada Research Councils Chair in Molecular Oncology (950-2310-33), and a Foundation award from the Canadian Institutes of Health Research (CIHR-FDN-148373) (all to W.J.M.).	Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Barbareschi M, 2007, CLIN CANCER RES, V13, P6064, DOI 10.1158/1078-0432.CCR-07-0266; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cizkova M, 2013, BRIT J CANCER, V108, P1807, DOI 10.1038/bjc.2013.164; Cizkova M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3113; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DAVIES BR, 1993, ONCOGENE, V8, P999; Dumont AG, 2012, CHIN J CANCER, V31, P327, DOI 10.5732/cjc.012.10032; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; Koren S, 2013, FEBS J, V280, P2758, DOI 10.1111/febs.12175; Li YR, 2016, ONCOTARGET, V7, P46785, DOI 10.18632/oncotarget.8800; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Pandey PR, 2010, FRONT BIOSCI-LANDMRK, V15, P226, DOI 10.2741/3617; Shimoi T, 2018, CANCER SCI, V109, P2558, DOI 10.1111/cas.13696; Simond AM, 2020, ADV CANCER RES, V147, P189, DOI 10.1016/bs.acr.2020.04.004; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244	31	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3445	3451		10.1038/s41388-022-02323-9	http://dx.doi.org/10.1038/s41388-022-02323-9		MAY 2022	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35538223				2022-12-17	WOS:000793037400001
J	Lorenzo-Martin, LF; Menacho-Marquez, M; Fernandez-Parejo, N; Rodriguez-Fdez, S; Pascual, G; Abad, A; Crespo, P; Dosil, M; Benitah, SA; Bustelo, XR				Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Fernandez-Parejo, Natalia; Rodriguez-Fdez, Sonia; Pascual, Gloria; Abad, Antonio; Crespo, Piero; Dosil, Mercedes; Benitah, Salvador A.; Bustelo, Xose R.			The Rho guanosine nucleotide exchange factors Vav2 and Vav3 modulate epidermal stem cell function	ONCOGENE			English	Article							HAIR FOLLICLE; ENRICHMENT ANALYSIS; IN-VIVO; RAC1; DIFFERENTIATION; TRANSCRIPTION; PROTEINS; DELETION; TURNOVER; PROGRAM	It is known that Rho GTPases control different aspects of the biology of skin stem cells (SSCs). However, little information is available on the role of their upstream regulators under normal and tumorigenic conditions in this process. To address this issue, we have used here mouse models in which the activity of guanosine nucleotide exchange factors of the Vav subfamily has been manipulated using both gain- and loss-of-function strategies. These experiments indicate that Vav2 and Vav3 regulate the number, functional status, and responsiveness of hair follicle bulge stem cells. This is linked to gene expression programs related to the reinforcement of the identity and the quiescent state of normal SSCs. By contrast, in the case of cancer stem cells, they promote transcriptomal programs associated with the identity, activation state, and cytoskeletal remodeling. These results underscore the role of these Rho exchange factors in the regulation of normal and tumor epidermal stem cells.	[Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Fernandez-Parejo, Natalia; Rodriguez-Fdez, Sonia; Abad, Antonio; Dosil, Mercedes; Bustelo, Xose R.] Univ Salamanca, Ctr Invest Canc, CSIC, Mol Mech Canc Program, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Fernandez-Parejo, Natalia; Rodriguez-Fdez, Sonia; Abad, Antonio; Dosil, Mercedes; Bustelo, Xose R.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Abad, Antonio; Crespo, Piero; Dosil, Mercedes; Bustelo, Xose R.] Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain; [Pascual, Gloria; Benitah, Salvador A.] Inst Reserca Biomed, Barcelona 08028, Spain; [Crespo, Piero] Univ Cantabria, Inst Biomed & Biotecnol Cantabria, CSIC, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC)	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, Mol Mech Canc Program, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain.	xbustelo@usal.es	; Bustelo, Xose R./A-9526-2010; Dosil, Mercedes/A-9536-2016; Aznar Benitah, Salvador/F-4761-2016; Crespo, Piero/M-3273-2014	Rodriguez-Fdez, Sonia/0000-0001-5369-2969; Lorenzo-Martin, L. Francisco/0000-0003-4717-9338; Bustelo, Xose R./0000-0001-9398-6072; Abad de Blas, Antonio Luis/0000-0001-8019-2775; Dosil, Mercedes/0000-0001-8119-8263; Aznar Benitah, Salvador/0000-0002-9059-5049; Crespo, Piero/0000-0003-2825-7783	Worldwide Cancer Research [14-1248, RTI2018-096481-B-100, MCIN/AEI/10.13039/501100011033]; European Research Development Fund "A way of making Europe" of the European Union; Spanish Association against Cancer [GC16173472GARC]; Castilla-Leon autonomous government [CSI252P18, CSI145P20, CLC-2017-01]; "la Caixa" Banking Foundation [HR20-00164]; Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government [CLC-2017-01]; Spanish Ministry of Education, Culture and Sports [MCIN/AEI/10.13039/501100011033, CLC-2017-01, FPU13/02923, BES-2013-063573]; European Social Fund "Investing in your future" of the European Union; European Regional Development Fund	Worldwide Cancer Research; European Research Development Fund "A way of making Europe" of the European Union; Spanish Association against Cancer; Castilla-Leon autonomous government; "la Caixa" Banking Foundation(La Caixa Foundation); Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government; Spanish Ministry of Education, Culture and Sports(Spanish Government); European Social Fund "Investing in your future" of the European Union; European Regional Development Fund(European Commission)	We thank M. Blazquez and the personnel of the CIC Flow Cytometry, Microscopy, Pathology and Genomics Units for expert technical work. The X.R.B.'s project leading to these results has received funding from Worldwide Cancer Research (14-1248), the RTI2018-096481-B-100 grant cofunded by MCIN/AEI/10.13039/501100011033 and the European Research Development Fund "A way of making Europe" of the European Union, the Spanish Association against Cancer (GC16173472GARC), the Castilla-Leon autonomous government (CSI252P18, CSI145P20, CLC-2017-01), and "la Caixa" Banking Foundation (HR20-00164). X.R.B.'s institution is supported by the Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government (CLC-2017-01) L.F.L.-M. contract has been mostly supported by funding from the Spanish Ministry of Education, Culture and Sports (FPU13/02923) and, subsequently, by the CLC-2017-01 grant. S.R.-F. contracts was supported by the grant BES-2013-063573 funded by both the MCIN/AEI/10.13039/501100011033 and the European Social Fund "Investing in your future" of the European Union. The funding from the Castilla-Leon governments has been also partially supported by the European Regional Development Fund.	Artegiani B, 2015, EMBO J, V34, P896, DOI 10.15252/embj.201490061; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Borrelli S, 2010, CELL DEATH DIFFER, V17, P1896, DOI 10.1038/cdd.2010.59; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo Xose R, 2014, Small GTPases, V5, P9, DOI 10.4161/21541248.2014.973757; Cangkrama M, 2013, INT J MOL SCI, V14, P13670, DOI 10.3390/ijms140713670; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; Chai LL, 2010, INT J MOL MED, V25, P723, DOI 10.3892/ijmm_00000397; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Doles J, 2012, GENE DEV, V26, P2144, DOI 10.1101/gad.192294.112; Doody GM, 2000, EMBO J, V19, P6173, DOI 10.1093/emboj/19.22.6173; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Eckert RL, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/537028; Eigentler TK, 2017, J INVEST DERMATOL, V137, P2309, DOI 10.1016/j.jid.2017.06.025; Fabbiano S, 2014, MOL CELL BIOL, V34, P4404, DOI 10.1128/MCB.01066-14; Lorenzo-Martin LF, 2020, ONCOGENE, V39, P5098, DOI 10.1038/s41388-020-1353-x; Lorenzo-Martin LF, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010165; Lorenzo-Martin LF, 2020, CANCERS, V12, DOI 10.3390/cancers12092498; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; HALPRIN KM, 1972, BRIT J DERMATOL, V86, P14, DOI 10.1111/j.1365-2133.1972.tb01886.x; Heath J, 2009, J INVEST DERMATOL, V129, P2358, DOI 10.1038/jid.2009.102; Hsu YC, 2014, CELL, V157, P935, DOI 10.1016/j.cell.2014.02.057; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ito M, 2008, J INVEST DERMATOL, V128, P1059, DOI 10.1038/jid.2008.86; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Langton AK, 2008, J INVEST DERMATOL, V128, P1311, DOI 10.1038/sj.jid.5701178; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Leishman E, 2013, DEVELOPMENT, V140, P3809, DOI 10.1242/dev.097477; Lien WH, 2011, CELL STEM CELL, V9, P219, DOI 10.1016/j.stem.2011.07.015; Lorenzo-Martin LF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18524-3; Mair B, 2019, CELL REP, V27, P599, DOI 10.1016/j.celrep.2019.02.041; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Mignone JL, 2007, CELL CYCLE, V6, P2161, DOI 10.4161/cc.6.17.4593; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodriguez-Fdez S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10090857; Rodriguez-Fdez S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19489-z; Rodriguez-Fdez S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050465; Salgado G, 2017, DIFFERENTIATION, V98, P14, DOI 10.1016/j.diff.2017.09.004; Sauzeau V, 2006, NAT MED, V12, P841, DOI 10.1038/nm1426; Sauzeau V, 2007, MOL BIOL CELL, V18, P943, DOI 10.1091/mbc.E06-09-0877; Sauzeau V, 2010, J CLIN INVEST, V120, P315, DOI 10.1172/JCI38356; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426; Vanheer L, 2019, J CELL SCI, V132, DOI 10.1242/jcs.232223; Wang F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172613; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Zhan RX, 2016, SCI REP-UK, V6, DOI 10.1038/srep30687; Zhao SL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/986048	63	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3341	3354		10.1038/s41388-022-02341-7	http://dx.doi.org/10.1038/s41388-022-02341-7		MAY 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35534539	Green Published, hybrid			2022-12-17	WOS:000792558400001
J	Odeniyide, P; Yohe, ME; Pollard, K; Vaseva, AV; Calizo, A; Zhang, L; Rodriguez, FJ; Gross, JM; Allen, AN; Wan, XL; Somwar, R; Schreck, KC; Kessler, L; Wang, JW; Pratilas, CA				Odeniyide, Patience; Yohe, Marielle E.; Pollard, Kai; Vaseva, Angelina V.; Calizo, Ana; Zhang, Lindy; Rodriguez, Fausto J.; Gross, John M.; Allen, Amy N.; Wan, Xiaolin; Somwar, Romel; Schreck, Karisa C.; Kessler, Linda; Wang, Jiawan; Pratilas, Christine A.			Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Apr, 10.1038/s41388-02202305-x, 2022)	ONCOGENE			English	Correction												cpratil1@jhmi.edu		Odeniyide, Patience/0000-0002-9783-1657; Rodriguez, Fausto/0000-0001-8662-1219				Odeniyide P, 2022, ONCOGENE, V41, P2973, DOI 10.1038/s41388-022-02305-x	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3037	3037		10.1038/s41388-022-02342-6	http://dx.doi.org/10.1038/s41388-022-02342-6		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35534540	Green Published, hybrid			2022-12-17	WOS:000792558400002
J	Chen, S; Cheng, JH; Zhong, YH; Liu, RM; Lu, ZX; Luo, XY				Chen, Shuai; Cheng, Jianghong; Zhong, Yanhong; Liu, Ruimin; Lu, Zhongxian; Luo, Xianyang			Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells (Apr, 10.1038/s41388-022-02298-7, 2022)	ONCOGENE			English	Correction												zhongxian@xmu.edu.cn; luoxianyang126@126.com		Lu, zhongxian/0000-0002-1682-7147	 [8210115473];  [82103189]	; 	In the "Financial Support" section, one of the grant numbers was incorrectly listed as 8210115473 but should be 82103189.	Chen S, 2022, ONCOGENE, V41, P3316, DOI 10.1038/s41388-022-02298-7	1	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3381	3381		10.1038/s41388-022-02337-3	http://dx.doi.org/10.1038/s41388-022-02337-3		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35523947	Bronze			2022-12-17	WOS:000791643000003
J	Huang, D; Wang, XS; Huang, ZH; Liu, YZ; Liu, XD; Gin, T; Wong, SH; Yu, J; Zhang, L; Chan, MTV; Chen, HR; Wu, WKK				Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Gin, Tony; Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei			3 ' untranslated regions of tumor suppressor genes evolved specific features to favor cancer resistance	ONCOGENE			English	Article							POSTTRANSCRIPTIONAL REGULATION; RNA METHYLATION; 3' UTRS; EXPRESSION; SELECTION; PROTEINS; IMPACT	Cancer-related genes have evolved specific genetic and genomic features to favor tumor suppression. Previously we reported that tumor suppressor genes (TSGs) acquired high promoter CpG dinucleotide frequencies during evolution to maintain high expression in normal tissues and resist cancer-specific downregulation. In this study, we investigated whether 3 ' untranslated regions (3 ' UTRs) of TSGs have evolved specific features to carry out similar functions. We found that 3 ' UTRs of TSGs, especially those involved in multiple histological types and pediatric cancers, are longer than those of non-cancer genes. 3 ' UTRs of TSGs also exhibit higher density of binding sites for RNA-binding proteins (RBPs), particularly those having high affinities to C-rich motifs. Both longer 3 ' UTR length and RBP binding sites enrichment are correlated with higher gene expression in normal tissues across tissue types. Moreover, both features together with the correlated N-6-methyladenosine modification and the extent of protein-protein interactions are positively associated with the ability of TSGs to resist cancer-specific downregulation. These results were successfully validated with independent datasets. Collectively, these findings indicate that TSGs have evolved longer 3 ' UTR with increased propensity to RBP binding, N-6-methyladenosine modification and protein-protein interactions for optimizing their tumor-suppressing functions.	[Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Gin, Tony; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China; [Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Gin, Tony; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, Peter Hung Pain Res Inst, Hong Kong, Peoples R China; [Huang, Dan; Wang, Xiansong; Huang, Ziheng; Liu, Yingzhi; Liu, Xiaodong; Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] CUHK Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China; [Wong, Sunny Hei; Yu, Jun; Zhang, Lin] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China; [Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chan, Matthew Tak Vai; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Wong, Sunny Hei; Yu, Jun; Zhang, Lin; Chen, Huarong; Wu, William Ka Kei] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Wong, Sunny Hei] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Chan, MTV; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China.; Chan, MTV; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, Peter Hung Pain Res Inst, Hong Kong, Peoples R China.; Chan, MTV; Chen, HR; Wu, WKK (corresponding author), CUHK Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China.; Chan, MTV; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.; Chen, HR; Wu, WKK (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China.	mtvchan@cuhk.edu.hk; hchen2@cuhk.edu.hk; wukakei@cuhk.edu.hk	GIN, Tony/J-2521-2013; chen, huarong/ABH-8561-2020; Wu, William K.K./A-3277-2009; Jun, Yu/D-8569-2015; Chan, Matthew/J-2884-2013	GIN, Tony/0000-0001-7283-6761; chen, huarong/0000-0003-2192-1864; Wu, William K.K./0000-0002-5662-5240; Jun, Yu/0000-0001-5008-2153; Wang, Xiansong/0000-0001-7308-0978; dan, huang/0000-0003-3022-5772; Chan, Matthew/0000-0002-3574-7855	Shenzhen Science and Technology Programme [JCYJ20180508161604382]; Shenzhen Science and Technology Innovation Commission; National Natural Science Foundation of China (NSFC) [82103245]	Shenzhen Science and Technology Programme; Shenzhen Science and Technology Innovation Commission; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the Shenzhen Science and Technology Programme (JCYJ20180508161604382 awarded to WKKW), Shenzhen Science and Technology Innovation Commission, and National Natural Science Foundation of China (NSFC; 82103245).	Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Alba MM, 2005, MOL BIOL EVOL, V22, P598, DOI 10.1093/molbev/msi045; Alkan SA, 2006, BIOCHEM J, V393, P361, DOI 10.1042/BJ20050538; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brouwer-Visser J, 2018, CANCER EPIDEM BIOMAR, V27, P103, DOI 10.1158/1055-9965.EPI-17-0461; Chen CL, 2010, GENOME RES, V20, P447, DOI 10.1101/gr.098947.109; Dolnik A, 2012, BLOOD, V120, pE83, DOI 10.1182/blood-2011-12-401471; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Gealy C, 2005, J VIROL, V79, P472, DOI 10.1128/JVI.79.1.472-485.2005; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Guo MZ, 2017, EMBO MOL MED, V9, P462, DOI 10.15252/emmm.201606711; Gupta S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r24; Huang D, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab040; Huang HL, 2020, ANNU REV CANC BIOL, V4, P221, DOI 10.1146/annurev-cancerbio-030419-033357; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lever J, 2019, NAT METHODS, V16, P505, DOI 10.1038/s41592-019-0422-y; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Linker K, 2005, NUCLEIC ACIDS RES, V33, P4813, DOI 10.1093/nar/gki797; Liu S, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02012-4; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Mayr C, 2017, ANNU REV GENET, V51, P171, DOI 10.1146/annurev-genet-120116-024704; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Ren GX, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01276; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Smit AFA, 2013, REPEATMASKER OPEN 4; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Thomas MA, 2003, MOL BIOL EVOL, V20, P964, DOI 10.1093/molbev/msg110; Vishnoi A, 2010, GENOME RES, V20, P1574, DOI 10.1101/gr.109595.110; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Wang X, 2018, ANN ONCOL, V29, P2254, DOI 10.1093/annonc/mdy397; Warnefors M, 2011, GENOME BIOL EVOL, V3, P667, DOI 10.1093/gbe/evr019; Wu L, 2006, MICRORNAS DIRECT RAP, V103, P40349; Wu WKK, 2017, MOL BIOL EVOL, V34, P903, DOI 10.1093/molbev/msw295; Xiao S, 2019, NAT CELL BIOL, V21, P651, DOI 10.1038/s41556-019-0315-4; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yabe-Wada T, 2020, FEBS OPEN BIO, V10, P407, DOI 10.1002/2211-5463.12794; Yin HY, 2019, BRIEF BIOINFORM, V20, P2141, DOI 10.1093/bib/bby074; Yin HY, 2016, GENOME BIOL EVOL, V8, P3083, DOI 10.1093/gbe/evw216; Yu H, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky1294; Zhang CY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00922; Zhang Z, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax0250; Zhao M, 2016, NUCLEIC ACIDS RES, V44, pD1023, DOI 10.1093/nar/gkv1268; Zhao YC, 2021, THERANOSTICS, V11, P4549, DOI 10.7150/thno.54967; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006	52	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3278	3288		10.1038/s41388-022-02343-5	http://dx.doi.org/10.1038/s41388-022-02343-5		MAY 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35523946				2022-12-17	WOS:000791643000002
J	Srinivas, US; Tay, NSC; Jaynes, P; Anbuselvan, A; Ramachandran, GK; Wardyn, JD; Hoppe, MM; Hoang, PM; Peng, YF; Lim, S; Lee, MY; Peethala, PC; An, O; Shendre, A; Tan, BWQ; Jemimah, S; Lakshmanan, M; Hu, LY; Jakhar, R; Sachaphibulkij, K; Lim, LHK; Pervaiz, S; Crasta, K; Yang, H; Tan, P; Liang, C; Ho, L; Khanchandani, V; Kappei, D; Yong, WP; Tan, DSP; Bordi, M; Campello, S; Tam, WL; Frezza, C; Jeyasekharan, AD				Srinivas, Upadhyayula S.; Tay, Norbert S. C.; Jaynes, Patrick; Anbuselvan, Akshaya; Ramachandran, Gokula K.; Wardyn, Joanna D.; Hoppe, Michal M.; Hoang, Phuong Mai; Peng, Yanfen; Lim, Sherlly; Lee, May Yin; Peethala, Praveen C.; An, Omer; Shendre, Akshay; Tan, Bryce W. Q.; Jemimah, Sherlyn; Lakshmanan, Manikandan; Hu, Longyu; Jakhar, Rekha; Sachaphibulkij, Karishma; Lim, Lina H. K.; Pervaiz, Shazib; Crasta, Karen; Yang, Henry; Tan, Patrick; Liang, Chao; Ho, Lena; Khanchandani, Vartika; Kappei, Dennis; Yong, Wei Peng; Tan, David S. P.; Bordi, Matteo; Campello, Silvia; Tam, Wai Leong; Frezza, Christian; Jeyasekharan, Anand D.			PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production (vol 41, pg 1986, 2022)	ONCOGENE			English	Correction												csiadj@nus.edu.sg	Lee, May Yin/AAB-3450-2021	Lee, May Yin/0000-0003-2366-9463; Hoppe, Michal Marek/0000-0002-0364-6080; Peng, Yanfen/0000-0003-1753-8547; Tay, Norbert/0000-0002-4960-9250	Singapore Ministry of Education under its Singapore Ministry of Education Academic Research Fund Tier 2 [MOE2018-T2-2-179]	Singapore Ministry of Education under its Singapore Ministry of Education Academic Research Fund Tier 2(Ministry of Education, Singapore)	The following statement was missing in Funding section: "This research was also funded by the Singapore Ministry of Education under its Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2018-T2-2-179) to Karen Crasta".	Srinivas US, 2022, ONCOGENE, V41, P1986, DOI 10.1038/s41388-022-02219-8	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3382	3382		10.1038/s41388-022-02338-2	http://dx.doi.org/10.1038/s41388-022-02338-2		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35523948	Bronze			2022-12-17	WOS:000791643000001
J	Ji, DL; Shang, GL; Wei, EW; Jia, YJ; Wang, CY; Zhang, Q; Zeng, L				Ji, Donglei; Shang, Guanglei; Wei, Enwei; Jia, Yanjie; Wang, Chunyu; Zhang, Qiang; Zeng, Lei			Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; ANDROGEN DEPRIVATION THERAPY; BET BROMODOMAIN PROTEINS; CUB-DOMAIN; PROGNOSTIC MARKER; MECHANISMS; IDENTIFICATION; INHIBITION; SURVIVAL; GROWTH	CUB domain-containing protein 1 (CDCP1), a transmembrane protein with tumor pro-metastatic activity, is highly expressed in late-stage and castrate-resistant prostate cancer (CRPC). However, the molecular mechanism driving CDCP1 overexpression in CRPC progress remains elusive. Here we report that transcription cofactors BRD4 and CBP/p300 co-regulate transcriptional expression of CDCP1 in CRPC tumorigenesis. In contrast to androgen receptor (AR) in CRPC, increased expression of BRD4 and CBP/p300 is strongly correlated with CDCP1 gene amplification. Combined knockdown or dual-inhibition of BRD4 and CBP/p300 down-regulated CDCP1 transcription and downstream PI3K/AKT and/or SRC/MAPK signaling pathways in CRPC cells much more so than single-protein perturbation. Our biochemical and structural analyses further showed that NEO2734, a dual-inhibitor targeting BRD4 and p300 bromodomains exhibits greater efficacy than single inhibitors for BRD4 or CBP/p300 in suppressing CDCP1 transcriptional expression and its downstream signaling pathways in CRPC cell proliferation and metastasis. Our study illustrates that targeting CDCP1 through dual-inhibition of BRD4 and CBP/p300 represents a synergistic therapeutic strategy for new treatment of CRPC.	[Ji, Donglei; Shang, Guanglei; Wei, Enwei; Jia, Yanjie; Zhang, Qiang; Zeng, Lei] Jilin Univ, Hosp 1, Bethune Inst Epigenet Med, Changchun 130021, Jilin, Peoples R China; [Ji, Donglei; Shang, Guanglei; Wei, Enwei; Zeng, Lei] Jilin Univ, Int Ctr Future Sci, Changchun 130012, Peoples R China; [Wang, Chunyu] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Jilin, Peoples R China	Jilin University; Jilin University; Jilin University	Zeng, L (corresponding author), Jilin Univ, Hosp 1, Bethune Inst Epigenet Med, Changchun 130021, Jilin, Peoples R China.; Zeng, L (corresponding author), Jilin Univ, Int Ctr Future Sci, Changchun 130012, Peoples R China.	leizeng@jlu.edu.cn		Zeng, Lei/0000-0002-4236-6735	First Hospital of Jilin University (Changchun, China); Open Project of State Key Laboratory for Supramolecular Structure and Materials, JLU [SKLSSM201602]; JLU Science and Technology Innovative Research Team (JLUSTIRT) [2017TD-25]; International Center of Future Science, JLU; National Natural Science Foundation of China [31770780]	First Hospital of Jilin University (Changchun, China); Open Project of State Key Laboratory for Supramolecular Structure and Materials, JLU; JLU Science and Technology Innovative Research Team (JLUSTIRT); International Center of Future Science, JLU; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported in part by the research fund from the First Hospital of Jilin University (Changchun, China), the Open Project of State Key Laboratory for Supramolecular Structure and Materials, JLU (SKLSSM201602), JLU Science and Technology Innovative Research Team (JLUSTIRT, 2017TD-25), International Center of Future Science, JLU, and National Natural Science Foundation of China (31770780; L.Z.).	Alajati A, 2020, J CLIN INVEST, V130, P2435, DOI 10.1172/JCI131133; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai L, 2018, MOL CELL, V72, P341, DOI 10.1016/j.molcel.2018.08.029; Cao MQ, 2016, TUMOR BIOL, V37, P1651, DOI 10.1007/s13277-015-3527-7; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Devaiah BN, 2020, P NATL ACAD SCI USA, V117, P13457, DOI 10.1073/pnas.1919507117; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garcia-Carpizo V, 2019, MOL CANCER RES, V17, P720, DOI 10.1158/1541-7786.MCR-18-0719; Gioia R, 2011, BLOOD, V118, P2211, DOI 10.1182/blood-2010-10-313692; Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396; Hammitzsch A, 2015, P NATL ACAD SCI USA, V112, P10768, DOI 10.1073/pnas.1501956112; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Hay DA, 2014, J AM CHEM SOC, V136, P9308, DOI 10.1021/ja412434f; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Heitmann JS, 2020, ANN HEMATOL, V99, P477, DOI 10.1007/s00277-020-03907-9; Holmes L, 2007, PROSTATE CANCER P D, V10, P388, DOI 10.1038/sj.pcan.4500973; Huang YQ, 2018, ONCOL LETT, V15, P6063, DOI 10.3892/ol.2018.8123; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jin LY, 2017, CANCER RES, V77, P5564, DOI 10.1158/0008-5472.CAN-17-0314; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Khan T, 2021, CANCER RES, V81, P2259, DOI 10.1158/0008-5472.CAN-20-2978; Kryza T, 2020, THERANOSTICS, V10, P4116, DOI 10.7150/thno.43589; Leroy C, 2015, ONCOGENE, V34, P5593, DOI 10.1038/onc.2015.19; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Ren CY, 2018, P NATL ACAD SCI USA, V115, P7949, DOI 10.1073/pnas.1720000115; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Shorstova T, 2021, BRIT J CANCER, V124, P1478, DOI 10.1038/s41416-021-01321-0; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Spriano F, 2020, BLOOD ADV, V4, P4124, DOI 10.1182/bloodadvances.2020001879; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Welti J, 2021, CANCER DISCOV, V11, P1118, DOI 10.1158/2159-8290.CD-20-0751; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Wu D, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108744; Wyce A, 2013, ONCOTARGET, V4, P2419, DOI 10.18632/oncotarget.1572; Yang CH, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-21; Zaware N, 2019, NAT STRUCT MOL BIOL, V26, P870, DOI 10.1038/s41594-019-0309-8; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang JW, 2017, APOPTOSIS, V22, P877, DOI 10.1007/s10495-017-1368-0; Zucconi BE, 2019, BIOCHEMISTRY-US, V58, P2133, DOI 10.1021/acs.biochem.9b00160	50	0	0	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3251	3262		10.1038/s41388-022-02327-5	http://dx.doi.org/10.1038/s41388-022-02327-5		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35513563				2022-12-17	WOS:000791081400002
J	Mancuso, P; Tricarico, R; Bhattacharjee, V; Cosentino, L; Kadariya, Y; Jelinek, J; Nicolas, E; Einarson, M; Beeharry, N; Devarajan, K; Katz, RA; Dorjsuren, DG; Sun, H; Simeonov, A; Giordano, A; Testa, JR; Davidson, G; Davidson, I; Larue, L; Sobol, RW; Yen, TJ; Bellacosa, A				Mancuso, Pietro; Tricarico, Rossella; Bhattacharjee, Vikram; Cosentino, Laura; Kadariya, Yuwaraj; Jelinek, Jaroslav; Nicolas, Emmanuelle; Einarson, Margret; Beeharry, Neil; Devarajan, Karthik; Katz, Richard A.; Dorjsuren, Dorjbal G.; Sun, Hongmao; Simeonov, Anton; Giordano, Antonio; Testa, Joseph R.; Davidson, Guillaume; Davidson, Irwin; Larue, Lionel; Sobol, Robert W.; Yen, Timothy J.; Bellacosa, Alfonso			Thymine DNA glycosylase as a novel target for melanoma (vol 38, pg 3710, 2019)	ONCOGENE			English	Correction												Alfonso.Bellacosa@fccc.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Mancuso P, 2019, ONCOGENE, V38, P3710, DOI 10.1038/s41388-018-0640-2	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3300	3301		10.1038/s41388-022-02335-5	http://dx.doi.org/10.1038/s41388-022-02335-5		MAY 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35505094	Bronze			2022-12-17	WOS:000790289600001
J	Chen, SY; Chen, KL; Ding, LY; Yu, CH; Wu, HY; Chou, YY; Chang, CJ; Chang, CH; Wu, YN; Wu, SR; Hou, YC; Lee, CT; Chen, PC; Shan, YS; Huang, PH				Chen, Szu-Ying; Chen, Kuan-Lin; Ding, Li-Yun; Yu, Chien-Hung; Wu, Hsin-Yi; Chou, Ya-Yi; Chang, Chia-Jung; Chang, Chih-Han; Wu, Ya-Na; Wu, Shang-Rung; Hou, Ya-Chin; Lee, Chung-Ta; Chen, Peng-Chieh; Shan, Yan-Shen; Huang, Po-Hsien			RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer	ONCOGENE			English	Article							NSUN2; 5-METHYLCYTOSINE; METHYLATION; PROGRESSION; METHYLTRANSFERASE; TRANSCRIPTOME; EXPRESSION; GROWTH; DNMT2; M(5)C	Posttranscriptional modifications in RNA have been considered to contribute to disease pathogenesis and tumor progression. NOL1/NOP2/Sun domain family member 2 (NSUN2) is an RNA methyltransferase that promotes tumor progression in several cancers. Pancreatic cancer relapse inevitably occurs even in cases where primary tumors have been successfully treated. Associations of cancer progression due to reprogramming of the cancer methyl-metabolome and the cancer genome have been noted, but the effect of base modifications, namely 5-methylcytosine (m(5)C), in the transcriptome remains unclear. Aberrant regulation of 5-methylcytosine turnover in cancer may affect posttranscriptional modifications in coding and noncoding RNAs in disease pathogenesis. Mutations in NSUN2 have been reported as drivers of neurodevelopmental disorders in mice, and upregulated expression of NSUN2 in tumors of the breast, bladder, and pancreas has been reported. In this study, we conducted mRNA whole transcriptomic bisulfite sequencing to categorize NSUN2 target sites in the mRNA of human pancreatic cancer cells. We identified a total of 2829 frequent m(5)C sites in mRNA from pancreatic cancer cells. A total of 90.9% (2572/2829) of these m(5)C sites were mapped to annotated genes in autosomes and sex chromosomes X and Y. Immunohistochemistry staining confirmed that the NSUN2 expression was significantly upregulated in cancer lesions in the LSL-Kras(G12D/+);Trp53(fl/fl);Pdx1-Cre (KPC) spontaneous pancreatic cancer mouse model induced by Pdx1-driven Cre/lox system expressing mutant Kras(G12D) and p53 deletion. The in vitro phenotypic analysis of NSUN2 knockdown showed mild effects on pancreatic cancer cell 2D/3D growth, morphology and gemcitabine sensitivity in the early phase of tumorigenesis, but cumulative changes after multiple cell doubling passages over time were required for these mutations to accumulate. Syngeneic transplantation of NSUN2-knockdown KPC cells via subcutaneous injection showed decreased stromal fibrosis and restored differentiation of ductal epithelium in vivo. Significance Transcriptome-wide mRNA bisulfite sequencing identified candidate m5C sites of mRNAs in human pancreatic cancer cells. NSUN2-mediated m5C mRNA metabolism was observed in a mouse model of pancreatic cancer. NSUN2 regulates cancer progression and epithelial differentiation via mRNA methylation.	[Chen, Szu-Ying; Chen, Kuan-Lin; Yu, Chien-Hung; Chou, Ya-Yi; Huang, Po-Hsien] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan; [Chen, Szu-Ying; Ding, Li-Yun; Yu, Chien-Hung; Huang, Po-Hsien] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Wu, Hsin-Yi] Natl Taiwan Univ, Coll Sci, Instrumentat Ctr, Tainan, Taiwan; [Chang, Chia-Jung; Chang, Chih-Han] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan; [Chang, Chih-Han] Natl Cheng Kung Univ, Med Device Innovat Ctr, Tainan, Taiwan; [Chang, Chih-Han] Natl Cheng Kung Univ, Ctr Corp Relat & Technol Transfer, Tainan, Taiwan; [Wu, Ya-Na; Wu, Shang-Rung] Int Inst Macromol Anal & Nanomed Innovat, Tainan, Taiwan; [Wu, Shang-Rung] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan; [Hou, Ya-Chin; Chen, Peng-Chieh; Shan, Yan-Shen] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Hou, Ya-Chin; Shan, Yan-Shen] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Div Gen Surg, Tainan, Taiwan; [Lee, Chung-Ta] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Huang, PH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan.; Huang, PH (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.; Shan, YS (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan.; Shan, YS (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Div Gen Surg, Tainan, Taiwan.	ysshan@mail.ncku.edu.tw; phhuang@mail.ncku.edu.tw		CHANG, CHIA-JUNG/0000-0003-0977-8743; Chen, Kuan-Lin/0000-0003-1387-1596; Chen, SzuYing/0000-0002-3998-5922; Chen, Peng-Chieh ( Jessica )/0000-0002-2060-1765	Ministry of Science and Technology, Taiwan; MOST [110-2320-B-006-038-, 110-2314-B-006-107-]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); MOST	The authors acknowledge technical services from core facilities: Research Center of Clinical Medicine, Center of Cell Therapy, and the Human Biobank and the Cancer Data Bank of National Cheng Kung University Hospital. The authors thank the Core Research Laboratory and the Laboratory Animal Center, College of Medicine, National Cheng Kung University; and Taiwan Animal Consortium. We thank the technical services provided by the following National Core Facilities: Bioimaging Core Facility; and the International Institute for Macromolecular Analysis and Nanomedicine Innovations, National Core Facility for Biopharmaceuticals, Ministry of Science and Technology, Taiwan. Sequencing run, computational analyses and data mining were performed using the system provided by the Center for Bioinformatics and Digital Health at the National Cheng Kung University, supported by Ministry of Science and Technology, Taiwan. The authors acknowledge the mass spectrometry technical research services from NTU Consortia of Key Technologies and NTU Instrumentation Center. We thank the National RNAi Core Facility at Academia Sinica in Taiwan for providing shRNA reagents and related services. This work is supported by grant support from the MOST (110-2320-B-006-038-and 110-2314-B-006-107-) to PHH.	Aldaz P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57047-w; Amort T, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1139-1; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Chen X, 2019, NAT CELL BIOL, V21, P978, DOI 10.1038/s41556-019-0361-y; Courtney DG, 2019, CELL HOST MICROBE, V26, P217, DOI 10.1016/j.chom.2019.07.005; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Ding LY, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00878-6; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Gao Y, 2019, CANCER SCI, V110, P3510, DOI 10.1111/cas.14190; Gigova A, 2014, RNA, V20, P1632, DOI 10.1261/rna.043398.113; Huang T, 2019, NAT STRUCT MOL BIOL, V26, P380, DOI 10.1038/s41594-019-0218-x; Kang M, 2008, J ATHL TRAINING, V43, P215, DOI 10.4085/1062-6050-43.2.215; Kapil S, 2017, ONCOTARGET, V8, P26515, DOI 10.18632/oncotarget.15713; Legrand C, 2017, GENOME RES, V27, P1589, DOI 10.1101/gr.210666.116; Li Q, 2017, J CELL BIOCHEM, V118, P2587, DOI 10.1002/jcb.25957; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Martinez NM, 2018, QUANT BIOL, V6, P210, DOI 10.1007/s40484-018-0147-4; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Motorin Y, 2010, NUCLEIC ACIDS RES, V38, P1415, DOI 10.1093/nar/gkp1117; Okamoto M, 2012, DNA CELL BIOL, V31, P660, DOI 10.1089/dna.2011.1446; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Rieder D, 2016, BIOINFORMATICS, V32, P782, DOI 10.1093/bioinformatics/btv647; SALDITTGEORGIEFF M, 1976, CELL, V7, P227, DOI 10.1016/0092-8674(76)90022-2; Schaefer M, 2010, GENE DEV, V24, P1590, DOI 10.1101/gad.586710; Schaefer M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn954; Schosserer M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7158; Schumann U, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00769-5; Selmi T, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1193; Squires JE, 2012, NUCLEIC ACIDS RES, V40, P5023, DOI 10.1093/nar/gks144; Sun Z, 2019, EPIGENOMICS-UK, V11, P439, DOI 10.2217/epi-2018-0169; Tang H, 2015, AGING-US, V7, P1143, DOI 10.18632/aging.100860; Taoka M, 2018, NUCLEIC ACIDS RES, V46, P9289, DOI 10.1093/nar/gky811; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Tuorto F, 2012, NAT STRUCT MOL BIOL, V19, P900, DOI 10.1038/nsmb.2357; Xing JY, 2015, MOL CELL BIOL, V35, P4043, DOI 10.1128/MCB.00742-15; Yang X, 2017, CELL RES, V27, P606, DOI 10.1038/cr.2017.55; Yang Y, 2019, MOL CELL, V75, P1188, DOI 10.1016/j.molcel.2019.06.033; Yi J, 2017, ONCOTARGET, V8, P20751, DOI 10.18632/oncotarget.10612; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151	42	0	0	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3162	3176		10.1038/s41388-022-02325-7	http://dx.doi.org/10.1038/s41388-022-02325-7		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35501460				2022-12-17	WOS:000789736500003
J	Zhang, Y; Xu, ZF; Wen, W; Liu, ZC; Zhang, C; Li, M; Hu, FP; Wei, S; Bae, SH; Zhou, JB; Liu, RH; Wang, LZ				Zhang, Yue; Xu, Zhifang; Wen, Wen; Liu, Zhichao; Zhang, Chao; Li, Ming; Hu, Fengping; Wei, Shi; Bae, Sejong; Zhou, Jiangbing; Liu, Runhua; Wang, Lizhong			The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; FOXP3; EXPRESSION; REPRESSION; APOPTOSIS; SITES; MYC; P53	For human prostate cancer, the chromosome 8p21 locus, which contains NKX3.1 and the microRNA (miR)-3622 family (miR-3622a/b), is a frequently deleted region. Thus, miR-3622 is proposed as a suppressor for prostate cancer, but its role remains debatable. In the present study, we found that expression of miR-3622a was lower, whereas expression of miR-3622b-3p was higher in human prostate cancer tissues than in normal prostate tissues. miR-3622a-3p inhibited cell migration and invasion of human prostate cancer cells, whereas miR-3622b-3p facilitated cell proliferation, migration, and invasion. To address the opposing roles of miR-3622 family members in various human prostate cancer cell lines, we knocked out (KO) endogenous miR-3622, including both miR-3622a/b. Our results showed that miR-3622 KO reduced cell proliferation, migration, and invasion in vitro and tumor growth and metastasis in vivo. Functional analyses revealed that miR-3622 regulated the p53-downstream gene network, including AIFM2, c-MYC, and p21, to control apoptosis and the cell cycle. Furthermore, using CRISPR interference, miRNA/mRNA immunoprecipitation assays, and dual-luciferase assays, we established that AIFM2, a direct target of miR-3622b-3p, is responsible for miR-3622 KO-induced apoptosis. We identified an miR-3622-AIFM2 axis that contributes to oncogenic function during tumor progression. In addition, miR-3622 KO inhibited the epithelial-mesenchymal transition involved in prostate cancer metastasis via upregulation of vimentin. The results show that miR-3622b-3p is upregulated in human prostate cancers and has an oncogenic function in tumor progression and metastasis via repression of p53 signaling, especially through an miR-3622-AIFM2 axis. In contrast, for human prostate cancer, deletion of the miR-3622 locus at 8p21 reduced the oncogenic effects on tumor progression and metastasis.	[Zhang, Yue; Xu, Zhifang; Wen, Wen; Liu, Zhichao; Zhang, Chao; Li, Ming; Hu, Fengping; Liu, Runhua; Wang, Lizhong] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; [Wei, Shi; Bae, Sejong; Liu, Runhua; Wang, Lizhong] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Wei, Shi] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Wei, Shi] Univ Kansas, Dept Pathol & Lab Med, Sch Med, Kansas City, KS USA; [Bae, Sejong] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA; [Zhou, Jiangbing] Yale Univ, Dept Neurosurg, New Haven, CT USA; [Zhou, Jiangbing] Yale Univ, Dept Biomed Engn, New Haven, CT USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Kansas; University of Kansas Medical Center; University of Alabama System; University of Alabama Birmingham; Yale University; Yale University	Liu, RH; Wang, LZ (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.; Liu, RH; Wang, LZ (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.	runhua@uab.edu; lwang12@uab.edu		Zhang, Yue/0000-0003-3817-8253; bae, sejong/0000-0001-9982-3223	National Cancer Institute [CA118948]; Department of Defense [W81XWH-21-1-0100, W81XWH-15-1-0323, W81XWH-20-1-0426]; Mike Slive Foundation for Prostate Cancer Research	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Mike Slive Foundation for Prostate Cancer Research	We thank Dr. Donald Hill for editorial assistance in preparing this paper. This work was supported by grants from the National Cancer Institute (CA118948 for LW), the Department of Defense (W81XWH-21-1-0100 for LW and W81XWH-15-1-0323 and W81XWH-20-1-0426 for RL) and the Mike Slive Foundation for Prostate Cancer Research (RL). Results are based, in part, upon data generated by TargetScan (http://www.targetscan.org/), the UALCAN portal (http://ualcan.path.uab.edu/), and the cBioPortal (http://www.cbioportal.org).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2; Bhagirath D, 2019, CARCINOGENESIS, V40, P633, DOI 10.1093/carcin/bgz058; Bucay N, 2017, CELL DEATH DIFFER, V24, P1263, DOI 10.1038/cdd.2017.69; Bucay N, 2016, ONCOTARGET, V7, P70388, DOI 10.18632/oncotarget.11865; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chang SC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02789-z; Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fabris L, 2016, EUR UROL, V70, P312, DOI 10.1016/j.eururo.2015.12.054; Fu S, 2019, GENE, V701, P23, DOI 10.1016/j.gene.2019.02.083; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; KAGAN J, 1995, ONCOGENE, V11, P2121; Liu RH, 2015, CANCER RES, V75, P1714, DOI 10.1158/0008-5472.CAN-14-2109; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Lu J, 2016, TOXICOL LETT, V258, P227, DOI 10.1016/j.toxlet.2016.07.002; Lu MJ, 2017, ONCOTARGET, V8, P23008, DOI 10.18632/oncotarget.14968; Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016; Rebello RJ, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00243-0; Schoenborn JR, 2013, CLIN CANCER RES, V19, P4058, DOI 10.1158/1078-0432.CCR-12-3606; Shenoy A, 2014, NAT REV MOL CELL BIO, V15, P565, DOI 10.1038/nrm3854; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Tao YF, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-014-0118-1; Theodore S, 2010, INT J ONCOL, V37, P1477, DOI 10.3892/ijo_00000800; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Vernon M, 2020, MOL CANCER THER, V19, P1506, DOI 10.1158/1535-7163.MCT-19-0510; Wallis Christopher J D, 2015, EJIFCC, V26, P79; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wang M, 2020, MOL CANCER RES, V18, P943, DOI 10.1158/1541-7786.MCR-19-1033; Wang YC, 2019, ONCOGENE, V38, P4820, DOI 10.1038/s41388-019-0760-3; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Zhang W, 2016, CLIN CANCER RES, V22, P2545, DOI 10.1158/1078-0432.CCR-15-1927	37	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3186	3196		10.1038/s41388-022-02289-8	http://dx.doi.org/10.1038/s41388-022-02289-8		MAY 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501464	Green Accepted			2022-12-17	WOS:000789736500001
J	Li, K; Niu, Y; Yuan, YC; Qiu, JL; Shi, YX; Zhong, CR; Qiu, ZY; Li, KR; Lin, Z; Huang, ZK; Zhang, C; Zuo, DL; He, W; Yuan, YF; Li, BK				Li, Kai; Niu, Yi; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; Zhang, Chao; Zuo, Dinglan; He, Wei; Yuan, Yunfei; Li, Binkui			Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-beta signaling	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; RADIOFREQUENCY ABLATION; CANCER STATISTICS; PROLIFERATION; MECHANISMS; RECEPTOR; BINDING; PROTEIN; WEB	Thermal ablation is a main curative therapy for early-stage hepatocellular carcinoma (HCC). However, insufficient ablation has been shown to promote HCC progression. E3 ligases have been approved to play important roles in malignant tumors. Whether E3 ligases are involved in HCC progression caused by insufficient ablation remains unclear. Herein, using RNA-sequencing coupled with an in vitro loss-of-function screen, we found that the E3 ligase Neuronal Precursor cell-expressed Developmentally Downregulated 4 (Nedd4) was upregulated in HCC insufficient ablation tissues and promoted HCC cells migration. The upregulation of Nedd4 was induced by METTL14-mediated N-6-methyladenosine modification after sublethal heat treatment. Knockdown of Nedd4 inhibited HCC metastasis and growth in vitro and in vivo. Mechanistically, Nedd4 enhanced TGF-beta signal transduction mediated tumor progression by directly binding to TGF-beta type I receptor (TGFBR1) and forming K27-linked ubiquitin at Lysine 391. Additionally, the adverse effect on HCC of sublethal heat treatment was mediated by Nedd4. Clinically, high Nedd4 expression was positively correlated with aggressive tumor phenotypes and poor prognosis in HCC patients. Patient-derived xenograft (PDX) model confirmed this conclusion. Collectively, this study demonstrated that Nedd4 induced by insufficient ablation plays a crucial role in promoting HCC progression and provides a novel therapeutic target for HCC.	[Li, Kai; Niu, Yi; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; Zhang, Chao; Zuo, Dinglan; He, Wei; Yuan, Yunfei; Li, Binkui] Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Li, Kai; Niu, Yi; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; Zhang, Chao; Zuo, Dinglan; He, Wei; Yuan, Yunfei; Li, Binkui] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China; [Li, Kai; Yuan, Yichuan; Qiu, Jiliang; Shi, Yunxing; Zhong, Chengrui; Qiu, Zhiyu; Li, Keren; Lin, Zhu; Huang, Zhenkun; He, Wei; Yuan, Yunfei; Li, Binkui] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China; [Zhang, Chao] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Yuan, YF; Li, BK (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.; Yuan, YF; Li, BK (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China.; Yuan, YF; Li, BK (corresponding author), Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China.	yuanyf@mail.sysu.edu.cn; libk@sysucc.org.cn		Yuan, Yunfei/0000-0003-2467-3683; Li, Binkui/0000-0003-3201-2914	National Natural Science Foundation of China [81772625, 81972301, 81802421]; Guangzhou Science and Technology Program of China [201804020093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Program of China	National Natural Science Foundation of China (No. 81772625, No. 81972301 and No. 81802421). Guangzhou Science and Technology Program of China (No. 201804020093).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen Y, 2021, CANCER LETT, V518, P23, DOI 10.1016/j.canlet.2021.06.001; Chesarino NM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005095; Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672; Damgaard RB, 2021, CELL DEATH DIFFER, V28, P423, DOI 10.1038/s41418-020-00703-w; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Gatti M, 2015, CELL REP, V10, P226, DOI 10.1016/j.celrep.2014.12.021; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Han ZY, 2014, J VIROL, V88, P7294, DOI 10.1128/JVI.00591-14; Hang XF, 2016, CELL PHYSIOL BIOCHEM, V39, P768, DOI 10.1159/000445667; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56; Huang ZJ, 2017, ONCOL LETT, V14, P2649, DOI 10.3892/ol.2017.6532; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lee DH, 2014, RADIOLOGY, V270, P900, DOI 10.1148/radiol.13130940; Li JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38550; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Li YY, 2015, CELL PROLIFERAT, V48, P338, DOI 10.1111/cpr.12184; Lian QY, 2018, GENOM PROTEOM BIOINF, V16, P269, DOI 10.1016/j.gpb.2018.07.003; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu WW, 2018, ALIMENT PHARM THER, V48, P671, DOI 10.1111/apt.14929; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Narita T, 2019, NAT REV MOL CELL BIO, V20, P156, DOI 10.1038/s41580-018-0081-3; Niu Y, 2021, HEPATOLOGY, V74, P1461, DOI 10.1002/hep.31846; Ohtake F, 2016, MOL CELL, V64, P251, DOI 10.1016/j.molcel.2016.09.014; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Rape M, 2018, NAT REV MOL CELL BIO, V19, P59, DOI 10.1038/nrm.2017.83; Shao GB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0784-2; Shi LR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13204-3; Su TH, 2021, HEPATOLOGY, V74, P1339, DOI 10.1002/hep.31766; Su TH, 2018, ONCOGENE, V37, P3514, DOI 10.1038/s41388-018-0169-4; Sun AQ, 2017, AUTOPHAGY, V13, P522, DOI 10.1080/15548627.2016.1268301; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Wan T, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.625169; Wang L, 2017, ONCOL REP, V37, P2565, DOI 10.3892/or.2017.5572; Wang Z, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11224-7; Xu C, 2015, ONCOGENE, V34, P342, DOI 10.1038/onc.2013.557; Xu JJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01281-8; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yang YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14324-x; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zhang ZK, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02029-7; Zhao ZZ, 2018, CANCER LETT, V421, P73, DOI 10.1016/j.canlet.2018.02.024; Zhou WH, 2014, ONCOTARGET, V5, P6746, DOI 10.18632/oncotarget.2246	50	0	0	5	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3197	3209		10.1038/s41388-022-02334-6	http://dx.doi.org/10.1038/s41388-022-02334-6		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501461				2022-12-17	WOS:000789736600001
J	Chen, ZY; Zhang, XG; Xing, Z; Lv, SJ; Huang, LX; Liu, JP; Ye, SBA; Li, XY; Chen, MQ; Zuo, SW; Tao, YX; He, YM				Chen, Ziyang; Zhang, Xiaogang; Xing, Zhe; Lv, Shuaijun; Huang, Linxuan; Liu, Jingping; Ye, Shubiao; Li, Xinyao; Chen, Meiqi; Zuo, Shaowen; Tao, Yingxu; He, Yumei			OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment	ONCOGENE			English	Article							SUPPRESSOR-CELLS; INNATE IMMUNITY; COLON-CANCER; OLFACTOMEDIN-4; IMMUNOTHERAPY; INFLAMMATION; EFFICACY; MARKER; STEM	Chronic inflammatory bowel disease (IBD) is strongly associated with the development of colitis-associated tumorigenesis (CAT). Despite recent advances in the understanding of polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) responses in cancer, the mechanisms of these cells during this process remain largely uncharacterized. Here, we discovered a glycoprotein, olfactomedin-4 (OLFM4), was highly expressed in PMN-MDSCs from colitis to colorectal cancer (CRC), and its expression level and PMN-MDSC population positively correlated with the progression of IBD to CRC. Moreover, mice lacking OLFM4 in myeloid cells showed poor recruitment of PMN-MDSCs, impaired intestinal homeostasis, and delayed development from IBD to CRC, and increased response to anti-PD1 therapy. The main mechanism of OLFM4-mediated PMN-MDSC activity involved the NF-kappa B/PTGS2 pathway, through the binding of LGALS3, a galactoside-binding protein expressed on PMN-MDSCs. Our results showed that the OLFM4/NF-kappa B/PTGS2 pathway promoted PMN-MDSC recruitment, which played an essential role in the maintenance of intestinal homeostasis, but showed resistance to anti-PD1 therapy in CRC.	[Chen, Ziyang; He, Yumei] Southern Med Univ, Dongguan Peoples Hosp, Dept Neurosurg, Affiliated Dongguan Hosp, Dongguan, Peoples R China; [Chen, Ziyang; Zhang, Xiaogang; Xing, Zhe; Lv, Shuaijun; Li, Xinyao; Chen, Meiqi; Zuo, Shaowen; Tao, Yingxu; He, Yumei] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China; [Huang, Linxuan] Southern Med Univ, Affiliated Dongguan Hosp, Dongguan Inst Clin Canc Res, Dept Med Oncol,Dongguan Peoples Hosp, Dongguan, Peoples R China; [Liu, Jingping; He, Yumei] Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China; [Ye, Shubiao] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gastroenterol, Guangzhou, Peoples R China; [He, Yumei] Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Sun Yat Sen University; Southern Medical University - China	He, YM (corresponding author), Southern Med Univ, Dongguan Peoples Hosp, Dept Neurosurg, Affiliated Dongguan Hosp, Dongguan, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Peoples R China.; He, YM (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou, Peoples R China.	hym0909@smu.edu.cn	ye, shubiao/GZM-4506-2022	Huang, Linxuan/0000-0001-6035-495X; Li, Xinyao/0000-0003-1407-8450	Department of Immunology at the School of Basic Medical Sciences; Southern Medical University; High level Talent Start-up Funding of Southern Medical University; National Natural Science Foundation of China [82171706, 81971420, 81991511]; Guangdong Special Support Program for Youth Science and Technology Innovation Talents [2019TQ05Y585]; National Natural Science Foundation of Guangdong [2019A1515011435]; College Students' Innovative Entrepreneurial Training Plan Program [S202012121102]; post-doctoral research project start-up funding of Affiliated Dongguan Hospital [294526]; Dongguan Science and Technology of Social Development Program [2019507163147]	Department of Immunology at the School of Basic Medical Sciences; Southern Medical University; High level Talent Start-up Funding of Southern Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Special Support Program for Youth Science and Technology Innovation Talents; National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); College Students' Innovative Entrepreneurial Training Plan Program; post-doctoral research project start-up funding of Affiliated Dongguan Hospital; Dongguan Science and Technology of Social Development Program	We thank XL and YZ from Southern Medical University for their technical assistance. We thank ZXL from South China University of Technology, ZPZ and LZ from Southern Medical University for their mice resource support. We thank XD. Wu from Tianjin Medical University for providing murine myeloid cell line 32D. We also thank YXZ and LD from Yangzhou University for providing the BiFC vector. Flow cytometry used in this work was supported by the Department of Immunology at the School of Basic Medical Sciences, the Southern Medical University, and Department of Developmental Biology at the School of Basic Medical Sciences, the Southern Medical University. This work was supported by the following grants to YMH: the High level Talent Start-up Funding of Southern Medical University, the National Natural Science Foundation of China (grants 82171706, 81971420, and 81991511), the Guangdong Special Support Program for Youth Science and Technology Innovation Talents (grant 2019TQ05Y585), the National Natural Science Foundation of Guangdong (grant 2019A1515011435), the College Students' Innovative Entrepreneurial Training Plan Program (grant S202012121102), and the post-doctoral research project start-up funding of Affiliated Dongguan Hospital (grant 294526 to ZYC). It was also supported by the Dongguan Science and Technology of Social Development Program (grant 2019507163147 to LXH).	Alder MN, 2019, INNATE IMMUN-LONDON, V25, P22, DOI 10.1177/1753425918817611; Alder MN, 2017, CRIT CARE MED, V45, pE426, DOI 10.1097/CCM.0000000000002102; Amirbeagi F, 2015, J LEUKOCYTE BIOL, V97, P181, DOI 10.1189/jlb.5A0614-311R; Angell HK, 2020, CLIN CANCER RES, V26, P332, DOI 10.1158/1078-0432.CCR-18-1851; Benson AB, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021; Berg KCG, 2019, ONCOGENE, V38, P6109, DOI 10.1038/s41388-019-0868-5; Block AS, 2011, PROSTATE, V71, P711, DOI 10.1002/pros.21287; Cao L, 2020, J MOL CELL BIOL, V12, P688, DOI 10.1093/jmcb/mjaa011; Chen BQ, 2020, GASTROENTEROLOGY, V159, P2146, DOI 10.1053/j.gastro.2020.08.018; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen L, 2021, ONCOGENE, V40, P5925, DOI 10.1038/s41388-021-01965-5; Chen ZY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641874; Clemmensen SN, 2015, J CELL MOL MED, V19, P2865, DOI 10.1111/jcmm.12679; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; d'Aldebert E, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00363; Davis RJ, 2017, CANCER RES, V77, P2607, DOI 10.1158/0008-5472.CAN-16-2534; Ding L, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02057-8; Dong X, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1590; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Gao XZ, 2019, J CELL PHYSIOL, V234, P15035, DOI 10.1002/jcp.28144; Gersemann M, 2012, J CROHNS COLITIS, V6, P425, DOI 10.1016/j.crohns.2011.09.013; Glassner KL, 2020, J ALLERGY CLIN IMMUN, V145, P16, DOI 10.1016/j.jaci.2019.11.003; He YM, 2018, NAT MED, V24, P224, DOI 10.1038/nm.4467; He YM, 2017, NUCLEIC ACIDS RES, V45, P106, DOI 10.1093/nar/gkw818; Hirata N, 2018, ONCOGENE, V37, P5367, DOI 10.1038/s41388-018-0330-0; Kajino-Sakamoto R, 2021, ONCOGENE, V40, P408, DOI 10.1038/s41388-020-01541-3; Kan GY, 2021, ADV SCI, V8, DOI 10.1002/advs.202004344; Keenan TE, 2020, J NATL COMPR CANC NE, V18, P479, DOI 10.6004/jnccn.2020.7554; Kim HJ, 2020, TRENDS IMMUNOL, V41, P948, DOI 10.1016/j.it.2020.08.010; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Krishnamoorthy M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051170; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li T, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0061-3; Li ZW, 2019, GASTROENTEROLOGY, V156, P2297, DOI 10.1053/j.gastro.2019.02.040; Liang J, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104417; Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008; Liu W, 2016, ONCOGENE, V35, P5237, DOI 10.1038/onc.2016.58; Liu WL, 2022, ONCOGENE, V41, P72, DOI 10.1038/s41388-021-02072-1; Liu WL, 2016, CANCER METAST REV, V35, P201, DOI 10.1007/s10555-016-9624-2; Liu WL, 2010, P NATL ACAD SCI USA, V107, P11056, DOI 10.1073/pnas.1001269107; Liu YF, 2019, J CLIN INVEST, V129, P4261, DOI 10.1172/JCI128164; Lv J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1638-6; Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014; Nan G, 2022, ONCOGENE, V41, P983, DOI 10.1038/s41388-021-02143-3; Nan J, 2018, IMMUNOLOGY, V154, P144, DOI 10.1111/imm.12876; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Pilzecker B, 2017, P NATL ACAD SCI USA, V114, pE6875, DOI 10.1073/pnas.1706508114; Piovani D, 2019, GASTROENTEROLOGY, V157, P647, DOI 10.1053/j.gastro.2019.04.016; Proietti M, 2014, IMMUNITY, V41, P789, DOI 10.1016/j.immuni.2014.10.010; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Schuijers J, 2014, STEM CELL REP, V3, P234, DOI 10.1016/j.stemcr.2014.05.018; Segal AW, 2019, J INTERN MED, V286, P373, DOI 10.1111/joim.12945; Seko N, 2010, EXP THER MED, V1, P73, DOI 10.3892/etm_00000013; Sharma D, 2018, GASTROENTEROLOGY, V154, P948, DOI 10.1053/j.gastro.2017.11.276; Shi MY, 2021, CELL MOL IMMUNOL, V18, P1692, DOI 10.1038/s41423-021-00704-w; Tao Y, 2018, ONCOGENE, V37, P5887, DOI 10.1038/s41388-018-0363-4; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592; Wang LL, 2020, EMBO J, V39, DOI 10.15252/embj.2020104514; Wang Shi, 2016, Int J Biol Sci, V12, P746, DOI 10.7150/ijbs.13988; Wang SJ, 2019, ACS APPL MATER INTER, V11, P41829, DOI 10.1021/acsami.9b09560; Wang XY, 2018, WORLD J GASTROENTERO, V24, P1881, DOI 10.3748/wjg.v24.i17.1881; Wang YG, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000609; Wang YG, 2019, ADV SCI, V6, DOI 10.1002/advs.201901278; Yan GF, 2018, CANCER RES, V78, P5586, DOI 10.1158/0008-5472.CAN-17-3962; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Yassin M, 2019, IMMUNOLOGY, V158, P35, DOI 10.1111/imm.13093; Ye LT, 2020, CLIN TRANSL GASTROEN, V11, DOI 10.14309/ctg.0000000000000124; Yip PK, 2017, SCI REP-UK, V7, DOI 10.1038/srep41689; Zhang JN, 2021, ONCOGENE, V40, P5829, DOI 10.1038/s41388-021-01877-4; Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270; Zhao S, 2017, P NATL ACAD SCI USA, V114, pE7245, DOI 10.1073/pnas.1704155114	75	0	0	7	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3131	3150		10.1038/s41388-022-02324-8	http://dx.doi.org/10.1038/s41388-022-02324-8		APR 2022	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35487976				2022-12-17	WOS:000788990000001
J	Cao, L; Wang, SY; Zhang, YQ; Wong, KC; Nakatsu, G; Wang, XH; Wong, S; Ji, JF; Yu, J				Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Wong, Ka-Chun; Nakatsu, Geicho; Wang, Xiaohong; Wong, Sunny; Ji, Jiafu; Yu, Jun			Zinc-finger protein 471 suppresses gastric cancer through transcriptionally repressing downstream oncogenic PLS3 and TFAP2A (vol 37, pg 3601, 2018)	ONCOGENE			English	Correction												junyu@cuhk.edu.hk						Cao L, 2018, ONCOGENE, V37, P3601, DOI 10.1038/s41388-018-0220-5	1	0	0	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3298	3299		10.1038/s41388-022-02216-x	http://dx.doi.org/10.1038/s41388-022-02216-x		APR 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35484334	Bronze			2022-12-17	WOS:000788432600001
J	Muller, GA; Asthana, A; Rubin, SM				Mueller, Gerd A.; Asthana, Anushweta; Rubin, Seth M.			Structure and function of MuvB complexes	ONCOGENE			English	Review							CELL-CYCLE PROGRESSION; B-MYB; DREAM COMPLEX; TRANSCRIPTION FACTOR; GENE-EXPRESSION; HISTONE METHYLATION; POCKET PROTEINS; TERMINAL DOMAIN; DROSOPHILA MYB; G2/M GENES	Proper progression through the cell-division cycle is critical to normal development and homeostasis and is necessarily misregulated in cancer. The key to cell-cycle regulation is the control of two waves of transcription that occur at the onset of DNA replication (S phase) and mitosis (M phase). MuvB complexes play a central role in the regulation of these genes. When cells are not actively dividing, the MuvB complex DREAM represses G1/S and G2/M genes. Remarkably, MuvB also forms activator complexes together with the oncogenic transcription factors B-MYB and FOXM1 that are required for the expression of the mitotic genes in G2/M. Despite this essential role in the control of cell division and the relationship to cancer, it has been unclear how MuvB complexes inhibit and stimulate gene expression. Here we review recent discoveries of MuvB structure and molecular interactions, including with nucleosomes and other chromatin-binding proteins, which have led to the first mechanistic models for the biochemical function of MuvB complexes.	[Mueller, Gerd A.; Asthana, Anushweta; Rubin, Seth M.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Muller, GA; Rubin, SM (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	gemuelle@ucsc.edu; srubin@ucsc.edu	Müller, Gerd Armin/AAO-6714-2021; Müller, Gerd Armin/GYU-9447-2022	Müller, Gerd Armin/0000-0002-4967-2487; Müller, Gerd Armin/0000-0002-4967-2487; Rubin, Seth/0000-0002-1670-4147; Asthana, Anushweta/0000-0001-6112-6668	National Institutes of Health [R01GM124148, R01GM127707, R01CA228413]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Research in the authors' laboratory is funded by grants from the National Institutes of Health (R01GM124148, R01GM127707, and R01CA228413 to S.M.R.). Figures 1 and 3 were created with BioRender.com.	Adams MK, 2020, MOL CELL PROTEOMICS, V19, DOI 10.1074/mcp.RA120.002078; Andrejka L, 2011, P NATL ACAD SCI USA, V108, P17438, DOI 10.1073/pnas.1111855108; Asthana A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28094-1; Bainor AJ, 2018, CELL REP, V25, P2797, DOI 10.1016/j.celrep.2018.11.024; Barger CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11020251; Beall EL, 2007, GENE DEV, V21, P904, DOI 10.1101/gad.1516607; Beall EL, 2004, GENE DEV, V18, P1667, DOI 10.1101/gad.1206604; Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Blanchard DP, 2014, P NATL ACAD SCI USA, V111, pE4234, DOI 10.1073/pnas.1416321111; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Branigan TB, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108808; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Chen BR, 2021, ELIFE, V10, DOI 10.7554/eLife.68466; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Cheng MH, 2017, BIOL OPEN, V6, P967, DOI 10.1242/bio.025825; Ciciro Y, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00309-y; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Colino-Sanguino Y, 2022, TRENDS GENET, V38, P273, DOI 10.1016/j.tig.2021.10.003; DeBruhl H, 2013, MOL CELL BIOL, V33, P1809, DOI 10.1128/MCB.01401-12; Dick FA, 2018, NAT REV CANCER, V18, P442, DOI 10.1038/s41568-018-0008-5; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Duan L., 2022, SCI REP-UK, V12; Duffy MJ, 2022, SEMIN CANCER BIOL, V79, P58, DOI 10.1016/j.semcancer.2020.07.005; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Enrico TP, 2021, ELIFE, V10, DOI [10.7554/eLife.70691, 10.7554/eLife.70691.sa0, 10.7554/eLife.70691.sa1, 10.7554/eLife.70691.sa2]; Esterlechner J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062882; Fera D, 2012, CHEM BIOL, V19, P518, DOI 10.1016/j.chembiol.2012.03.007; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02831-9; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Forristal C, 2014, MOL CELL BIOL, V34, P2221, DOI 10.1128/MCB.01523-13; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gartel AL, 2017, CANCER RES, V77, P3135, DOI 10.1158/0008-5472.CAN-16-3566; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Goetsch PD, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007088; Grant GD, 2013, MOL BIOL CELL, V24, P3634, DOI 10.1091/mbc.E13-05-0264; Grundl M, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008818; Guiley KZ, 2018, P NATL ACAD SCI USA, V115, P10016, DOI 10.1073/pnas.1808136115; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrison MM, 2006, P NATL ACAD SCI USA, V103, P16782, DOI 10.1073/pnas.0608461103; Hsu J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10901-x; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iltzsche F, 2017, ONCOGENE, V36, P110, DOI 10.1038/onc.2016.181; Iness AN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.637193; Iness AN, 2019, ONCOGENE, V38, P1080, DOI 10.1038/s41388-018-0490-y; Jiang JQ, 2007, DEVELOPMENT, V134, P1549, DOI 10.1242/dev.000521; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Kim MJ, 2021, MOL CELL, V81, P1698, DOI 10.1016/j.molcel.2021.02.001; Knight AS, 2009, ONCOGENE, V28, P1737, DOI 10.1038/onc.2009.22; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Korenjak M, 2014, NUCLEIC ACIDS RES, V42, P8939, DOI 10.1093/nar/gku609; Kurimchak A, 2012, GENE, V499, P1, DOI 10.1016/j.gene.2012.02.015; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Latorre I, 2015, GENE DEV, V29, P495, DOI 10.1101/gad.255810.114; Lewis PW, 2012, MOL CELL BIOL, V32, P3218, DOI 10.1128/MCB.00432-12; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Liban TJ, 2016, J MOL BIOL, V428, P3960, DOI 10.1016/j.jmb.2016.08.017; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Lu R, 2013, TRENDS BIOCHEM SCI, V38, P546, DOI 10.1016/j.tibs.2013.08.002; MacDonald J, 2017, MOL CANCER RES, V15, P371, DOI 10.1158/1541-7786.MCR-16-0323-T; Mages CFS, 2017, ELIFE, V6, DOI 10.7554/eLife.26876; Marceau AH, 2019, ELIFE, V8, DOI 10.7554/eLife.46131; Marceau AH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12301; Matsuo T, 2012, CELL CYCLE, V11, P3227, DOI 10.4161/cc.21569; Morgan DO, 2007, CELL CYCLE PRINCIPLE; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Muller GA, 2014, NUCLEIC ACIDS RES, V42, P10331, DOI 10.1093/nar/gku696; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Nilsson MB, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz4589; Oji A, 2020, BIOL REPROD, V102, P975, DOI 10.1093/biolre/ioaa002; Oka O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052906; Okumura F, 2016, MOL CELL BIOL, V36, P1803, DOI 10.1128/MCB.00067-16; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Patel AJ, 2019, P NATL ACAD SCI USA, V116, P21715, DOI 10.1073/pnas.1912858116; Pattschull G, 2019, CELL REP, V27, P3533, DOI 10.1016/j.celrep.2019.05.071; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Rashid NN, 2011, J GEN VIROL, V92, P2620, DOI 10.1099/vir.0.035352-0; Reichert N, 2010, MOL CELL BIOL, V30, P2896, DOI 10.1128/MCB.00028-10; Roberts MS, 2020, CANCER RES, V80, P1693, DOI 10.1158/0008-5472.CAN-19-3466; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sahni JM, 2017, CANCER RES, V77, P5395, DOI 10.1158/0008-5472.CAN-17-1571; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sanders DA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0696-z; Schade AE, 2019, NUCLEIC ACIDS RES, V47, P11197, DOI 10.1093/nar/gkz961; Schade AE, 2019, ONCOGENE, V38, P4962, DOI 10.1038/s41388-019-0767-9; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schmit F, 2009, FEBS J, V276, P5703, DOI 10.1111/j.1742-4658.2009.07261.x; Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2000, CANCER RES, V60, P3689; Song JJ, 2008, GENE DEV, V22, P1313, DOI 10.1101/gad.1653308; Tabuchi TM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002074; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Uxa S, 2019, NUCLEIC ACIDS RES, V47, P9087, DOI 10.1093/nar/gkz635; van Oevelen C, 2008, MOL CELL, V32, P359, DOI 10.1016/j.molcel.2008.10.015; Vorster PJ, 2020, BIOL OPEN, V9, DOI 10.1242/bio.051508; Wang C, 2022, J BIOL CHEM, V298; Wang XX, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00609-16; Wei T, 2019, ONCOGENE, V38, P5541, DOI 10.1038/s41388-019-0801-y; Wen H, 2008, GENE DEV, V22, P601, DOI 10.1101/gad.1626308; Werwein E, 2019, NUCLEIC ACIDS RES, V47, P103, DOI 10.1093/nar/gky935; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Wiseman EF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0339-8; Wolter P, 2017, ONCOTARGET, V8, P11160, DOI 10.18632/oncotarget.14466; Xu C, 2011, PROTEIN CELL, V2, P202, DOI 10.1007/s13238-011-1018-1; Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	120	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2909	2919		10.1038/s41388-022-02321-x	http://dx.doi.org/10.1038/s41388-022-02321-x		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35468940	Green Accepted			2022-12-17	WOS:000787133300001
J	Liu, Y; Luo, YW; Yan, SM; Lian, YF; Wu, SY; Xu, M; Feng, L; Zhang, X; Li, R; Zhang, XT; Feng, QS; Zeng, YX; Zhang, H				Liu, Yang; Luo, Yuewen; Yan, Shumei; Lian, Yi-Fan; Wu, Shiyu; Xu, Miao; Feng, Lin; Zhang, Xu; Li, Rong; Zhang, Xiantao; Feng, Qi-Sheng; Zeng, Yi-Xin; Zhang, Hui			CRL2(KLHDC3) mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression	ONCOGENE			English	Article							UBIQUITIN LIGASE; CANCER; MUTATIONS; RESISTANCE; PROTEIN; DICHLOROACETATE; EXPRESSION; GEFITINIB; MDM2	Kelch superfamily involves a variety of proteins containing multiple kelch motif and is well characterized as substrate adaptors for CUL3 E3 ligases, which play critical roles in carcinogenesis. However, the role of kelch proteins in lung cancer remains largely unknown. In this study, the non-small cell lung cancer (NSCLC) patients with higher expression of a kelch protein, kelch domain containing 3 (KLHDC3), showed worse overall survival. KLHDC3 deficiency affected NSCLC cell lines proliferation in vitro and in vivo. Further study indicated that KLHDC3 mediated CUL2 E3 ligase and tumor suppressor p14ARF interaction, facilitating the N-terminal ubiquitylation and subsequent degradation of p14ARF. Interestingly, Gefitinib-resistant NSCLC cell lines displayed higher KLHDC3 protein levels. Gefitinib and Osimertinib medications were capable of upregulating KLHDC3 expression to promote p14ARF degradation in the NSCLC cell lines. KLHDC3 shortage significantly increased the sensitivity of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs, providing an alternative explanation for the development of Gefitinib and Osimertinib resistance in NSCLC therapy. Our works suggest that CRL2(KLHDC3) could be a valuable target to regulate the abundance of p14ARF and postpone the occurrence of EGFR-targeted drugs resistance.	[Liu, Yang; Xu, Miao; Feng, Lin; Feng, Qi-Sheng; Zeng, Yi-Xin] Sun Yat Sen Univ Canc Ctr, Dept Expt Res, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Luo, Yuewen; Wu, Shiyu; Zhang, Xu; Li, Rong; Zhang, Xiantao; Zhang, Hui] Sun Yat Sen Univ, Guangdong Engn Res Ctr Antimicrobial Agent & Immu, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist, Guangzhou, Guangdong, Peoples R China; [Luo, Yuewen] Sun Yat Sen Univ, Sch Med, Guangzhou 510080, Peoples R China; [Yan, Shumei] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Lian, Yi-Fan] Sun Yat Sen Univ, Guangdong Prov Key Lab Liver Dis Res, Affiliated Hosp 3, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Zeng, YX (corresponding author), Sun Yat Sen Univ Canc Ctr, Dept Expt Res, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Zhang, H (corresponding author), Sun Yat Sen Univ, Guangdong Engn Res Ctr Antimicrobial Agent & Immu, Zhongshan Sch Med, Inst Human Virol,Key Lab Trop Dis Control,Minist, Guangzhou, Guangdong, Peoples R China.	zengyx@sysucc.org.cn; zhangh92@mail.sysu.edu.cn			Special Reserach Program of Sun Yat-sen University Cancer Center; National Special Research Program of China for Important Infectious Diseases [2018ZX10302103, 2017ZX10202102]; Important Key Program of NSFC [81730060]; Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou [201803040002]; Natural Science Foundation of Guangdong, China (Excellent Youth Foundation); Fundamental Research Funds for the Central Universities	Special Reserach Program of Sun Yat-sen University Cancer Center; National Special Research Program of China for Important Infectious Diseases; Important Key Program of NSFC; Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou; Natural Science Foundation of Guangdong, China (Excellent Youth Foundation); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Dr Li Zhang for kindly providing lung cancer cell lines. This work was supported by the Special Reserach Program of Sun Yat-sen University Cancer Center to Y-XZ; the National Special Research Program of China for Important Infectious Diseases (2018ZX10302103 and 2017ZX10202102), the Important Key Program of NSFC (81730060), and the Joint-Innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou (201803040002) to HZ; the Natural Science Foundation of Guangdong, China (Excellent Youth Foundation) and the Fundamental Research Funds for the Central Universities to MX.	Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Chen J, 2018, NATURE, V557, P585, DOI 10.1038/s41586-018-0128-9; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Dhanoa BS, 2013, HUM GENOMICS, V7, DOI 10.1186/1479-7364-7-13; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Garon EB, 2014, J CANCER RES CLIN, V140, P443, DOI 10.1007/s00432-014-1583-9; Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; Juan O, 2017, THER ADV MED ONCOL, V9, P201, DOI 10.1177/1758834016687262; Kamijo T, 1999, CANCER RES, V59, P2217; Khazaei Z, 2019, ADV HUM BIOL, V9, P245, DOI 10.4103/2321-8568.262891; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kwon YT, 2017, TRENDS BIOCHEM SCI, V42, P873, DOI 10.1016/j.tibs.2017.09.002; Lian YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152820; Luo YW, 2019, J IMMUNOL, V203, P269, DOI 10.4049/jimmunol.1900125; Mahrour N, 2008, J BIOL CHEM, V283, P8005, DOI 10.1074/jbc.M706987200; Maione P, 2015, THER ADV MED ONCOL, V7, P263, DOI 10.1177/1758834015595048; Nacak TG, 2007, CIRC RES, V100, P1155, DOI 10.1161/01.RES.0000265844.56493.ac; Ohinata Y, 2003, FEBS LETT, V537, P1, DOI 10.1016/S0014-5793(03)00036-X; Olszewski U, 2010, CLIN PHARMACOL-ADV A, V2, P177, DOI 10.2147/CPAA.S11795; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Schwaederle M, 2015, CANCER RES, V75, P1187, DOI 10.1158/0008-5472.CAN-14-2305; Senga SS, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.200358; Shibata S, 2013, P NATL ACAD SCI USA, V110, P7838, DOI 10.1073/pnas.1304592110; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Strutt H, 2013, DEVELOPMENT, V140, P1693, DOI 10.1242/dev.089656; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Wang D, 2017, CANCER METAST REV, V36, P683, DOI 10.1007/s10555-017-9703-z; Wang XW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2533; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yan SM, 2016, J CANCER, V7, P618, DOI 10.7150/jca.14030; Yu WS, 2008, MOL CELLS, V26, P443; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhong WZ, 2018, ANN ONCOL, V29, P738	50	0	0	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3104	3117		10.1038/s41388-022-02318-6	http://dx.doi.org/10.1038/s41388-022-02318-6		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35468939				2022-12-17	WOS:000787133900002
J	Zhu, S; Zhang, CL; Cao, DY; Bai, J; Yu, SN; Chen, J; Wang, J; Ren, T; Yang, JX; Yu, M; Xiao, X; Gong, YH; Guan, YF; Li, PL; Yue, Y; Yin, RT; Wang, YJ; An, RF; Lou, G; Yuan, JL; Zhang, GN; Xia, XF; Yang, L; Xiang, Y				Zhu, Shan; Zhang, Chunliu; Cao, Dongyan; Bai, Jing; Yu, Shuangni; Chen, Jie; Wang, Jing; Ren, Tong; Yang, Jiaxin; Yu, Mei; Xiao, Xiao; Gong, Yuhua; Guan, Yanfang; Li, Peiling; Yue, Ying; Yin, Rutie; Wang, Yongjun; An, Ruifang; Lou, Ge; Yuan, Jianlin; Zhang, Guonan; Xia, Xuefeng; Yang, Ling; Xiang, Yang			Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes	ONCOGENE			English	Article							MICROSATELLITE INSTABILITY; ANTITUMOR-ACTIVITY; DNA-REPAIR; CHEMOTHERAPY; MUTATIONS; RESISTANT; BLOCKADE; SAFETY; CELLS	Epithelial ovarian cancer (EOC) is classified into five major histotypes: high-grade serous (HGSOC), low-grade serous (LGSOC), clear cell (CCOC), endometrioid (ENOC), and mucinous (MOC). However, the landscape of molecular and immunological alterations in these histotypes, especially LGSOC, CCOC, ENOC, and MOC, is largely uncharacterized. We collected 101 treatment-naive EOC patients. The resected tumor tissues and paired preoperative peripheral blood samples were collected and subjected to target sequencing of 1021 cancer-associated genes and T cell repertoire sequencing. Distinct characteristics of mutations were identified among the five histotypes. Furthermore, tumor mutation burden (TMB) was found to be higher in CCOC and ENOC, but lower in LGSOC and HGSOC. Alterations associated with DNA damage repair (DDR) pathways and homologous recombination deficiencies (HRD) were prevalent in five histotypes. CCOC demonstrated increased level of T cell clonality compared with HSGOC. Interestingly, the proportion of the 100 most common T cell clones was associated with TMB and tumor neoantigen burden in CCOC, highlighting more sensitive anti-tumor responses in this histotype, which was also evidenced by the enhanced convergent recombination of T cell clones. These findings shed light on the molecular traits of genomic alteration and T cell repertoire in the five major EOC histotypes and may help optimize clinical management of EOC with different histotypes.	[Zhu, Shan; Cao, Dongyan; Ren, Tong; Yang, Jiaxin; Yu, Mei; Xiang, Yang] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol,State Key Lab Complex Sever, Beijing, Peoples R China; [Zhang, Chunliu; Bai, Jing; Gong, Yuhua; Guan, Yanfang; Xia, Xuefeng; Yang, Ling] Geneplus Inst, Beijing, Peoples R China; [Yu, Shuangni; Chen, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China; [Wang, Jing] Cent South Univ, Hunan Canc Hosp, Dept Gynecol Oncol, Changsha, Peoples R China; [Wang, Jing] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China; [Xiao, Xiao] Geneplus Shenzhen, Shenzhen, Peoples R China; [Li, Peiling] Harbin Med Univ, Dept Obstet & Gynecolgoy, Affiliated Hosp 2, Harbin, Peoples R China; [Yue, Ying] First Hosp Jilin Univ, Dept Gynecol Oncol, Changchun, Peoples R China; [Yin, Rutie] Sichuan Univ, Dept Obstet & Gynecol, West China Hosp 2, Chengdu, Peoples R China; [Wang, Yongjun] Peking Univ Int Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China; [An, Ruifang] Xi An Jiao Tong Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Lou, Ge] Harbin Med Univ Canc Hosp, Dept Gynecol Oncol, Harbin, Peoples R China; [Yuan, Jianlin] Xinjiang Med Univ, Dept Gynecol, Affiliated Tumor Hosp, Urumqi, Peoples R China; [Zhang, Guonan] Sichuan Canc Hosp, Dept Gynecol Oncol, Chengdu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Central South University; Central South University; Harbin Medical University; Jilin University; Sichuan University; Peking University; Xi'an Jiaotong University; Xinjiang Medical University	Xiang, Y (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol,State Key Lab Complex Sever, Beijing, Peoples R China.; Yang, L (corresponding author), Geneplus Inst, Beijing, Peoples R China.	yangl@geneplus.org.cn; xiangy@pumch.cn			National Natural Science Foundation of China [81772783, 81971475]; Chinese Academy of Medical Sciences Initiative for Innovative Medicine [CAMS-2017-I2M-1-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Medical Sciences Initiative for Innovative Medicine	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81772783 and 81971475) and the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (Nos. CAMS-2017-I2M-1-002).	Abbosh C, 2018, NAT REV CLIN ONCOL, V15, P577, DOI 10.1038/s41571-018-0058-3; Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Alexandros Karatzoglou AS, 2004, J STAT SOFTW, V011, pI09; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Assasi N, 2016, DNA MISMATCH REPAIR; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Banerjee S, 2021, LANCET ONCOL, V22, P1721, DOI 10.1016/S1470-2045(21)00531-3; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheasley D, 2021, J PATHOL, V253, P41, DOI 10.1002/path.5545; Chui MH, 2019, CANCER RES, V79, P5536, DOI 10.1158/0008-5472.CAN-18-3029; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Csardi G., 2006, INTERJOURNAL COMPLEX; Dash P, 2017, NATURE, V547, P89, DOI 10.1038/nature22383; Dejima H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22890-x; Disis ML, 2019, JAMA ONCOL, V5, P393, DOI 10.1001/jamaoncol.2018.6258; Elsherif SB, 2021, ABDOM RADIOL, V46, P2264, DOI 10.1007/s00261-021-03081-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Gorringe KL, 2020, GYNECOL ONCOL, V156, P552, DOI 10.1016/j.ygyno.2019.12.015; GRIFFITHS CT, 1978, SURG CLIN N AM, V58, P131, DOI 10.1016/s0039-6109(16)41440-4; Gulhan DC, 2019, NAT GENET, V51, P912, DOI 10.1038/s41588-019-0390-2; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Han C, 2018, GYNECOL ONCOL REP, V25, P41, DOI 10.1016/j.gore.2018.05.011; Han JF, 2020, CANCER IMMUNOL RES, V8, P146, DOI 10.1158/2326-6066.CIR-19-0398; Hess V, 2004, J CLIN ONCOL, V22, P1040, DOI 10.1200/JCO.2004.08.078; Hoffmann K, 2020, EMBO J, V39, DOI 10.15252/embj.2019104013; Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136; Hollis RL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18819-5; Jessen E, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-00898-y; Jia QZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07767-w; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Lan AH, 2019, FUTURE ONCOL, V15, P2029, DOI 10.2217/fon-2018-0886; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146; Mabuchi S, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e31; Macintyre G, 2018, NAT GENET, V50, P1262, DOI 10.1038/s41588-018-0179-8; Matulonis UA, 2019, ANN ONCOL, V30, P1080, DOI 10.1093/annonc/mdz135; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mendivil AA, 2018, GYNECOL ONCOL REP, V26, P41, DOI 10.1016/j.gore.2018.09.002; Moioli M, 2019, EXPERT OPIN INV DRUG, V28, P1025, DOI 10.1080/13543784.2019.1693999; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; O'Donnell T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3825-0; Oliveira DVNP, 2021, CANCERS, V13, DOI 10.3390/cancers13205242; Pisano C, 2005, ANTICANCER RES, V25, P3501; Prat J, 2012, VIRCHOWS ARCH, V460, P237, DOI 10.1007/s00428-012-1203-5; Previs RA, 2016, EXPERT REV MOL DIAGN, V16, P1337, DOI 10.1080/14737159.2016.1259069; Pujade-Lauraine E, 2017, ANN ONCOL, V28, P57, DOI 10.1093/annonc/mdx442; Radovich M, 2020, JAMA ONCOL, V6, P1410, DOI 10.1001/jamaoncol.2020.2295; Reuben A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14273-0; Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Sato N, 2012, ONCOL REP, V27, P1336, DOI 10.3892/or.2012.1626; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Sun YX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00430; Takekuma Munetaka, 2016, Gynecol Oncol Res Pract, V3, P5, DOI 10.1186/s40661-016-0026-5; Tarazona N, 2019, ANN ONCOL, V30, P1804, DOI 10.1093/annonc/mdz390; Tholander B, 2020, UPSALA J MED SCI, V125, P325, DOI 10.1080/03009734.2020.1826612; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wang ZJ, 2018, CANCER RES, V78, P6486, DOI 10.1158/0008-5472.CAN-18-1814; Xu W, 2016, CRIT REV ONCOL HEMAT, V102, P26, DOI 10.1016/j.critrevonc.2016.03.015; Yamamoto H, 2015, ARCH TOXICOL, V89, P899, DOI 10.1007/s00204-015-1474-0; Zamarin D, 2020, J CLIN ONCOL, V38, P1814, DOI 10.1200/JCO.19.02059; Zhang AW, 2018, CELL, V173, P1755, DOI 10.1016/j.cell.2018.03.073; Zhang L, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1544-9	76	0	0	6	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3093	3103		10.1038/s41388-022-02277-y	http://dx.doi.org/10.1038/s41388-022-02277-y		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35468938				2022-12-17	WOS:000787133900001
J	Jiao, DY; Chen, YJ; Wang, YL; Sun, HR; Shi, Q; Zhang, L; Zhao, XY; Liu, YJ; He, HY; Lv, ZH; Liu, C; Zhang, PZ; Gao, K; Huang, Y; Li, Y; Li, L; Wang, CJ				Jiao, Dongyue; Chen, Yingji; Wang, Yalan; Sun, Huiru; Shi, Qing; Zhang, Liang; Zhao, Xiaying; Liu, Yajuan; He, Huiying; Lv, Zeheng; Liu, Chuan; Zhang, Pingzhao; Gao, Kun; Huang, Yan; Li, Yao; Li, Liang; Wang, Chenji			DCAF12 promotes apoptosis and inhibits NF-kappa B activation by acting as an endogenous antagonist of IAPs	ONCOGENE			English	Article							STRUCTURAL BASIS; CASPASE INHIBITORS; SERINE-PROTEASE; CELL-DEATH; XIAP; IDENTIFICATION; FAMILY; REAPER; GROWTH; GENE	Members of the Inhibitor of Apoptosis Protein (IAP) family are essential for cell survival and appear to neutralize the cell death machinery by binding pro-apoptotic caspases. dcaf12 was recently identified as an apoptosis regulator in Drosophila. However, the underlying molecular mechanisms are unknown. Here we revealed that human DCAF12 homolog binds multiple IAPs, including XIAP, cIAP1, cIAP2, and BRUCE, through recognition of BIR domains in IAPs. The pro-apoptotic function of DCAF12 is dependent on its capacity to bind IAPs. In response to apoptotic stimuli, DCAF12 translocates from the nucleus to the cytoplasm, where it blocks the interaction between XIAP and pro-apoptotic caspases to facilitate caspase activation and apoptosis execution. Similarly, DCAF12 suppresses NF-kappa B activation in an IAP binding-dependent manner. Moreover, DCAF12 acts as a tumor suppressor to restrict the malignant phenotypes of cancer cells. Together, our results suggest that DCAF12 is an evolutionarily conserved IAP antagonist.	[Jiao, Dongyue; Chen, Yingji; Wang, Yalan; Sun, Huiru; Shi, Qing; Zhang, Liang; Zhao, Xiaying; Liu, Yajuan; He, Huiying; Huang, Yan; Li, Yao; Wang, Chenji] Fudan Univ, Shanghai Stomatol Hosp, Shanghai 200438, Peoples R China; [Jiao, Dongyue; Chen, Yingji; Wang, Yalan; Sun, Huiru; Shi, Qing; Zhang, Liang; Zhao, Xiaying; Liu, Yajuan; He, Huiying; Huang, Yan; Li, Yao; Wang, Chenji] Fudan Univ, MOE Engn Res Ctr Gene Technol, Shanghai Engn Res Ctr Ind Microorg, Sch Stomatol,Sch Life Sci,State Key Lab Genet Eng, Shanghai 200438, Peoples R China; [Lv, Zeheng; Gao, Kun] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Clin Lab, Shanghai 200092, Peoples R China; [Liu, Chuan; Li, Liang] Zibo Cent Hosp, Dept Thyroid & Breast Surg, Zibo 255036, Peoples R China; [Zhang, Pingzhao] Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Zhang, Pingzhao] Fudan Univ, Dept Pathol, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Tongji University; Fudan University; Fudan University	Wang, CJ (corresponding author), Fudan Univ, Shanghai Stomatol Hosp, Shanghai 200438, Peoples R China.; Wang, CJ (corresponding author), Fudan Univ, MOE Engn Res Ctr Gene Technol, Shanghai Engn Res Ctr Ind Microorg, Sch Stomatol,Sch Life Sci,State Key Lab Genet Eng, Shanghai 200438, Peoples R China.; Li, L (corresponding author), Zibo Cent Hosp, Dept Thyroid & Breast Surg, Zibo 255036, Peoples R China.	liliangzb@sina.com; chenjiwang@fudan.edu.cn			National Natural Science Foundation of China [91957125, 81972396, 81672558, 91954106, 81872109, 81872260, 81572768]; Natural Science Foundation of Shanghai [22ZR1449200, 22ZR1406600]; Natural Science Foundation of Shandong Province [ZR2021MH212]; Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University [SKLGE-2111]; Science and Technology Research Program of Shanghai [9DZ2282100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University; Science and Technology Research Program of Shanghai	We thank Dr. Mikihiko Naito for providing BRUCE cDNAs. This work was in part supported by the National Natural Science Foundation of China (No. 91957125, 81972396, 81672558 to CW; No. 91954106, 81872109 to KG.; No. 81872260, 81572768 to PZ) the Natural Science Foundation of Shanghai (No. 22ZR1449200 to KG; 22ZR1406600 to CW), the Natural Science Foundation of Shandong Province (No. ZR2021MH212 to LL), the Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University (No. SKLGE-2111 to KG), the Science and Technology Research Program of Shanghai (No. 9DZ2282100).	BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cho YS, 2020, GENE DEV, V34, P53, DOI 10.1101/gad.333146.119; Damgaard RB, 2013, EMBO MOL MED, V5, P1278, DOI 10.1002/emmm.201303090; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036, DOI 10.4161/cc.7.8.5783; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Gao K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0561-6; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hu XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1200-y; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; Hwangbo DS, 2016, DEV BIOL, V413, P50, DOI 10.1016/j.ydbio.2016.03.003; Jackson S, 2009, TRENDS BIOCHEM SCI, V34, P562, DOI 10.1016/j.tibs.2009.07.002; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kalkavan H, 2018, CELL DEATH DIFFER, V25, P46, DOI 10.1038/cdd.2017.179; Kim K, 2013, MOL CELL, V52, P459, DOI 10.1016/j.molcel.2013.09.017; Koren I, 2018, CELL, V173, P1622, DOI 10.1016/j.cell.2018.04.028; Kumar S, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107610; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Patron LA, 2019, J CELL BIOL, V218, P993, DOI 10.1083/jcb.201805099; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Ravichandran R, 2019, EMBO REP, V20, DOI 10.15252/embr.201847352; Richter B W, 2000, Sci STKE, V2000, ppe1, DOI 10.1126/stke.2000.44.pe1; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2001, GENOME BIOL, V2; Wajant H, 2011, FEBS J, V278, P862, DOI 10.1111/j.1742-4658.2011.08015.x; Wang XX, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00609-16; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zheng C, 2010, MOL CELL, V38, P101, DOI 10.1016/j.molcel.2010.03.009	45	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3000	3010		10.1038/s41388-022-02319-5	http://dx.doi.org/10.1038/s41388-022-02319-5		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459779				2022-12-17	WOS:000787474100002
J	Wu, JQ; Shen, S; Liu, TQ; Ren, XF; Zhu, C; Liang, QY; Cui, X; Chen, L; Cheng, P; Cheng, W; Wu, AH				Wu, Jianqi; Shen, Shuai; Liu, Tianqi; Ren, Xiufang; Zhu, Chen; Liang, Qingyu; Cui, Xiao; Chen, Ling; Cheng, Peng; Cheng, Wen; Wu, Anhua			Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner	ONCOGENE			English	Article							KAPPA-B; MICROARRAY DATA; RECEPTOR CCRL2; RNA-SEQ; CANCER; CELLS; EXPRESSION; GPR1; MACROPHAGES; PROGRESSION	Glioblastoma multiforme (GBM) with mesenchymal features exhibits enhanced chemotherapeutic resistance and results in reduced overall survival. Recent studies have suggested that there is a positive correlation between the GBM mesenchymal status and immune cell infiltration. However, the mechanisms by which GBM acquires its mesenchymal features in a tumor immune microenvironment-dependent manner remains unknown. Here, we uncovered a chemerin-mediated autocrine and paracrine network by which the mesenchymal phenotype of GBM cells is strengthened. We identified chemerin as a prognostic secretory protein mediating the mesenchymal phenotype-promoting network between tumor-associated macrophages (TAMs) and tumor cells in GBM. Mechanistically, chemerin promoted the mesenchymal features of GBM by suppressing the ubiquitin-proteasomal degradation of CMKLR1, a chemerin receptor predominantly expressed on TAMs and partially expressed on GBM cells, thereby enhancing NF-kappa B pathway activation. Moreover, chemerin was found to be involved in the recruitment of TAMs in the GBM tumor microenvironment. We revealed that chemerin also enhances the mesenchymal phenotype-promoting ability of TAMs and promotes their M2 polarization via a CMKLR1/NF-kappa B axis, which further exacerbates the mesenchymal features of GBM. Blocking the chemerin/CMKLR1 axis with 2-(alpha-naphthoyl) ethyltrimethylammonium iodide disrupted the mesenchymal network and suppressed tumor growth in GBM. These results suggest the therapeutic potential of targeting the chemerin/CMKLR1 axis to block the mesenchymal network in GBM.	[Wu, Jianqi; Shen, Shuai; Liu, Tianqi; Zhu, Chen; Liang, Qingyu; Cui, Xiao; Cheng, Peng; Cheng, Wen; Wu, Anhua] China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China; [Ren, Xiufang] China Med Univ, Hosp 1, Dept Pathol, Shenyang, Peoples R China; [Chen, Ling] Chinese Peoples Liberat Army China PLA, Gen Hosp, Inst Neurosurg Chinese PLA, Med Sch Chinese PLA,Dept Neurosurg, Beijing, Peoples R China	China Medical University; China Medical University	Cheng, W; Wu, AH (corresponding author), China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China.	cmu071207@163.com; ahwu@cmu.edu.cn						Achyut BR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14079-4; Al Delbany D, 2021, CANCERS, V13, DOI 10.3390/cancers13195000; Baj T, 2018, RECENT PATENTS INFLA, V12, P69, DOI [10.2174/1872213X12666180703163824, 10.2174/1872213x12666180703163824]; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Barberi T, 2018, CANCER IMMUNOL IMMUN, V67, P1491, DOI 10.1007/s00262-018-2184-2; Baumert BG, 2016, LANCET ONCOL, V17, P1521, DOI 10.1016/S1470-2045(16)30313-8; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Cahill KE, 2016, NEURO-ONCOLOGY, V18, P329, DOI 10.1093/neuonc/nov265; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Cheng W, 2017, J NEUROSURG, V126, P249, DOI 10.3171/2015.11.JNS15432; Cheng W, 2016, NEUROLOGY, V86, P2226, DOI 10.1212/WNL.0000000000002770; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Del Prete A, 2017, BLOOD, V130, P1223, DOI 10.1182/blood-2017-04-777680; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Dimitriadis Georgios K, 2018, Oncotarget, V9, P16678, DOI 10.18632/oncotarget.24659; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Dubois-Vedrenne Ingrid, 2021, Oncotarget, V12, P1903, DOI 10.18632/oncotarget.28056; El-Sagheer G, 2018, BREAST CANCER-TARGET, V10, P169, DOI 10.2147/BCTT.S178181; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Fedele M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112746; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; Goralski KB, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194778; Graham KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112925; Guo Deliang, 2013, CNS Oncol, V2, P289; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hoffmann M, 2018, TOXICOL LETT, V291, P61, DOI 10.1016/j.toxlet.2018.04.004; Huang C, 2020, MOL THER-ONCOLYTICS, V18, P602, DOI 10.1016/j.omto.2020.08.013; Huang JF, 2010, BMB REP, V43, P491, DOI 10.5483/BMBRep.2010.43.7.491; Jacenik D, 2020, CLIN CHIM ACTA, V504, P146, DOI 10.1016/j.cca.2020.02.008; Ji ZS, 2022, CELL BIOL TOXICOL, V38, P611, DOI 10.1007/s10565-021-09636-7; Jia QZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07767-w; Kiczmer P, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104377; Kumar JD, 2016, BRIT J CANCER, V114, P1152, DOI 10.1038/bjc.2016.93; Kumar JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104877; Kumar V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43428-8; Kusne Y, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005196; Li JJ, 2018, BRIT J CANCER, V118, P1337, DOI 10.1038/s41416-018-0077-y; Li M, 2021, ARCH PHARM RES, V44, P194, DOI 10.1007/s12272-021-01311-z; Liang QY, 2021, THERANOSTICS, V11, P9884, DOI 10.7150/thno.63202; Lin Y, 2017, ONCOGENE, V36, P3599, DOI 10.1038/onc.2016.516; Long PM, 2015, J CELL PHYSIOL, V230, P1929, DOI 10.1002/jcp.24927; Lu YB, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820948053; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Pachynski RK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00983; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pozniak PD, 2014, J NEUROIMMUNE PHARM, V9, P133, DOI 10.1007/s11481-013-9517-x; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Regan-Komito D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01621; Rennier K, 2020, CLIN CANCER RES, V26, P5019, DOI 10.1158/1078-0432.CCR-19-4245; Rourke JL, 2015, MOL CELL ENDOCRINOL, V417, P36, DOI 10.1016/j.mce.2015.09.002; Rourke JL, 2014, J ENDOCRINOL, V222, P201, DOI 10.1530/JOE-14-0069; Schioppa T, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.615031; Schmitt MJ, 2021, CANCER DISCOV, V11, P754, DOI 10.1158/2159-8290.CD-20-0219; Segerman A, 2016, CELL REP, V17, P2994, DOI 10.1016/j.celrep.2016.11.056; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Su X, 2021, CLIN CHIM ACTA, V517, P41, DOI 10.1016/j.cca.2021.02.010; Tong N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.706286; Treeck O, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153750; Tummler C, 2017, ONCOTARGET, V8, P95135, DOI 10.18632/oncotarget.19619; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang CH, 2014, PEPTIDES, V51, P131, DOI 10.1016/j.peptides.2013.10.009; Wang GY, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.798837; Wang QH, 2018, CANCER CELL, V33, P152, DOI 10.1016/j.ccell.2017.12.012; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wang Y, 2019, J CELL BIOCHEM, V120, P6459, DOI 10.1002/jcb.27936; Wei J, 2020, NEURO-ONCOLOGY, V22, P180, DOI 10.1093/neuonc/noz212; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Woroniecka KI, 2018, CLIN CANCER RES, V24, P3792, DOI 10.1158/1078-0432.CCR-18-0047; Xu CH, 2017, ONCOTARGET, V8, P22483, DOI 10.18632/oncotarget.14956; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yamini B, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090125; Yang YL, 2018, REPROD BIOL ENDOCRIN, V16, P1, DOI 10.1186/s12958-018-0363-9; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ye YS, 2021, J PERIODONTOL, V92, P1470, DOI 10.1002/JPER.20-0675; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zhang CB, 2017, CLIN CANCER RES, V23, P6279, DOI 10.1158/1078-0432.CCR-16-2598; Zhang RL, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151416; Zhang ZP, 2020, CANCER IMMUNOL RES, V8, P966, DOI 10.1158/2326-6066.CIR-19-0759; Zhu L, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119530	87	0	0	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3024	3036		10.1038/s41388-022-02295-w	http://dx.doi.org/10.1038/s41388-022-02295-w		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459783	hybrid, Green Published			2022-12-17	WOS:000787474100001
J	Yu, HG; Bijian, K; da Silva, SD; Su, J; Morand, G; Spatz, A; Alaoui-Jamali, MA				Yu, Henry G.; Bijian, Krikor; da Silva, Sabrina D.; Su, Jie; Morand, Gregoire; Spatz, Alan; Alaoui-Jamali, Moulay A.			NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation	ONCOGENE			English	Article							PROGNOSTIC IMPLICATIONS; METASTASIS; CELLS; ACTIVATION; CARCINOMA; EVOLUTION; HETEROGENEITY; AMPLIFICATION; ASSOCIATION; MECHANISMS	Stemness and chromosomal instability (CIN) are two common contributors to intratumor heterogeneity and therapy relapse in advanced cancer, but their interplays are poorly defined. Here, in anaplastic thyroid cancer (ATC), we show that ALDH+ stem-like cancer cells possess increased CIN-tolerance owing to transcriptional upregulation of the scaffolding protein NEDD9. Thyroid patient tissues and transcriptomic data reveals NEDD9/ALDH1A3 to be co-expressed and co-upregulated in ATC. Compared to bulk ALDH- cells, ALDH+ cells were highly efficient at propagating CIN due to their intrinsic tolerance of both centrosome amplification and micronuclei. ALDH+ cells mitigated the fitness-impairing effects of centrosome amplification by partially inactivating supernumerary centrosomes. Meanwhile, ALDH+ cells also mitigated cell death caused by micronuclei-mediated type 1 interferon secretion by suppressing the expression of the DNA-sensor protein STING. Both mechanisms of CIN-tolerance were lost upon RNAi-mediated NEDD9 silencing. Both in vitro and in vivo, NEDD9-depletion attenuated stemness, CIN, cell/tumor growth, while enhancing paclitaxel effectiveness. Collectively, these findings reveal that ATC progression can involve an ALDH1A3/NEDD9-regulated program linking their stemness to CIN-tolerance that could be leveraged for ATC treatment.	[Yu, Henry G.; Bijian, Krikor; da Silva, Sabrina D.; Su, Jie; Morand, Gregoire; Spatz, Alan; Alaoui-Jamali, Moulay A.] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ, Canada; [Yu, Henry G.; Bijian, Krikor; da Silva, Sabrina D.; Su, Jie; Morand, Gregoire; Spatz, Alan; Alaoui-Jamali, Moulay A.] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada; [da Silva, Sabrina D.; Morand, Gregoire] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Otolaryngol Head & Neck Surg, Montreal, PQ, Canada; [Spatz, Alan] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ, Canada.; Alaoui-Jamali, MA (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ, Canada.	moulay.alaoui-jamali@mcgill.ca		Spatz, Alan/0000-0003-3020-1420; Morand, Gregoire/0000-0002-6150-6772	Canadian Institutes of Health Research [178116]; McGill Interdisciplinary Initiative in Infection and Immunity (MI4); Swiss Cancer League [BIL KFS-3002-082012]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); McGill Interdisciplinary Initiative in Infection and Immunity (MI4); Swiss Cancer League	This study was supported by the Canadian Institutes of Health Research (Grant#178116) and in part by McGill Interdisciplinary Initiative in Infection and Immunity (MI4); GB Morand was supported by the Swiss Cancer League (BIL KFS-3002-082012).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ahn J, 2012, J CELL SCI, V125, P1814, DOI 10.1242/jcs.101444; Bajar BT, 2016, NAT METHODS, V13, P993, DOI [10.1038/NMETH.4045, 10.1038/nmeth.4045]; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Bible KC, 2021, THYROID, V31, P337, DOI 10.1089/thy.2020.0944; Binder JX, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau012; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen H, 2016, MOL BIOL EVOL, V33, P4, DOI 10.1093/molbev/msv212; Cosenza MR, 2017, CELL REP, V20, P1906, DOI 10.1016/j.celrep.2017.08.005; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Gabbasov R, 2018, ONCOGENE, V37, P4854, DOI 10.1038/s41388-018-0296-y; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Ganly I, 2014, THYROID, V24, P662, DOI 10.1089/thy.2013.0503; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gentili M, 2019, CELL REP, V26, P2377, DOI 10.1016/j.celrep.2019.01.105; Hatch EM, 2013, CELL, V154, P47, DOI 10.1016/j.cell.2013.06.007; Heiden KB, 2014, J CLIN ENDOCR METAB, V99, pE2178, DOI 10.1210/jc.2014-1844; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Hopfner KP, 2020, NAT REV MOL CELL BIO, V21, P501, DOI 10.1038/s41580-020-0244-x; Isham CR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004358; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Knutson DC, 2008, ARCH BIOCHEM BIOPHYS, V477, P163, DOI 10.1016/j.abb.2008.06.005; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Li W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065095; Lin RY, 2011, NAT REV ENDOCRINOL, V7, P609, DOI 10.1038/nrendo.2011.127; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lohard S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13689-y; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Mariappan A, 2019, EMBO J, V38, DOI 10.15252/embj.201899876; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Miao YX, 2019, CELL, V177, P1172, DOI 10.1016/j.cell.2019.03.025; Milunovic-Jevtic A, 2016, CURR OPIN BIOTECH, V40, P113, DOI 10.1016/j.copbio.2016.03.011; Miranda A, 2019, P NATL ACAD SCI USA, V116, P9020, DOI 10.1073/pnas.1818210116; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Morel AP, 2017, NAT MED, V23, P568, DOI 10.1038/nm.4323; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Nagayama Y, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00020; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Pillai S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10072; Prabakaran T, 2018, EMBO J, V37, DOI 10.15252/embj.201797858; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Ranjan R, 2019, CELL STEM CELL, V25, P666, DOI 10.1016/j.stem.2019.08.014; Reeb N., 2015, J THYROID DISORD THE, V4, P2, DOI [10.4172/2167-7948.1000e179, DOI 10.4172/2167-7948.1000E179]; Shagisultanova E, 2015, GENE, V567, P1, DOI 10.1016/j.gene.2015.04.086; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shimamura M, 2014, ENDOCR J, V61, P481, DOI 10.1507/endocrj.EJ13-0526; Shiraiwa K, 2019, THYROID, V29, P674, DOI 10.1089/thy.2018.0212; Singh MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI 10.1007/s12013-007-0036-3; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Visciano C, 2015, ONCOGENE, V34, P5175, DOI 10.1038/onc.2014.441; Wang ZP, 2017, ONCOTARGET, V8, P1714, DOI 10.18632/oncotarget.13852; Wilkens L, 2004, P NATL ACAD SCI USA, V101, P1309, DOI 10.1073/pnas.0305817101; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yamashita YM, 2008, J CELL BIOL, V180, P261, DOI 10.1083/jcb.200707083; Yamashita YM, 2007, SCIENCE, V315, P518, DOI 10.1126/science.1134910; Zhou W, 2014, LEUKEMIA, V28, P1155, DOI 10.1038/leu.2013.383; Zhu XG, 2019, ENDOCR-RELAT CANCER, V26, P739, DOI 10.1530/ERC-19-0107; Zierhut C, 2019, CELL, V178, P302, DOI 10.1016/j.cell.2019.05.035	74	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2984	2999		10.1038/s41388-022-02317-7	http://dx.doi.org/10.1038/s41388-022-02317-7		APR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35449243				2022-12-17	WOS:000784606800001
J	He, RS; Xhabija, B; Gopi, LK; Kurup, JT; Xu, ZS; Liu, Z; Kidder, BL				He, Runsheng; Xhabija, Besa; Gopi, Lijin K.; Kurup, Jiji T.; Xu, Zhishan; Liu, Zhe; Kidder, Benjamin L.			H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity	ONCOGENE			English	Article							GENE-EXPRESSION; STEM-CELLS; DRUG-RESISTANCE; MESSENGER-RNA; BREAST-CANCER; SELF-RENEWAL; JARID1B; METHYLATION; PATTERNS; PROLIFERATION	The H3K4 demethylase KDM5B is overexpressed in multiple cancer types, and elevated expression levels of KDM5B is associated with decreased survival. However, the underlying mechanistic contribution of dysregulated expression of KDM5B and H3K4 demethylation in cancer is poorly understood. Our results show that loss of KDM5B in multiple types of cancer cells leads to increased proliferation and elevated expression of cancer stem cell markers. In addition, we observed enhanced tumor formation following KDM5B depletion in a subset of representative cancer cell lines. Our findings also support a role for KDM5B in regulating epigenetic plasticity, where loss of KDM5B in cancer cells with elevated KDM5B expression leads to alterations in activity of chromatin states, which facilitate activation or repression of alternative transcriptional programs. In addition, we define KDM5B-centric epigenetic and transcriptional patterns that support cancer cell plasticity, where KDM5B depleted cancer cells exhibit altered epigenetic and transcriptional profiles resembling a more primitive cellular state. This study also provides a resource for evaluating associations between alterations in epigenetic patterning upon depletion of KDM5B and gene expression in a diverse set of cancer cells.	[He, Runsheng; Xhabija, Besa; Gopi, Lijin K.; Kurup, Jiji T.; Xu, Zhishan; Kidder, Benjamin L.] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48202 USA; [He, Runsheng; Xhabija, Besa; Gopi, Lijin K.; Kurup, Jiji T.; Xu, Zhishan; Kidder, Benjamin L.] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48202 USA; [Xu, Zhishan] Xinxiang Med Univ, Inst Precis Med, Xinxiang 453000, Henan, Peoples R China; [Xu, Zhishan] Shandong Normal Univ, Coll Chem Chem Engn & Mat Sci, Jinan 250014, Shandong, Peoples R China; [Liu, Zhe] Qufu Normal Univ, Dept Chem & Chem Engn, Qufu 273165, Shandong, Peoples R China; [Xhabija, Besa] Univ Michigan, Dept Chem & Biochem, Flint, MI 48503 USA; [Kurup, Jiji T.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Xinxiang Medical University; Shandong Normal University; Qufu Normal University; University of Michigan System; University of Michigan; University of Michigan Flint; Columbia University	Kidder, BL (corresponding author), Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI 48202 USA.; Kidder, BL (corresponding author), Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48202 USA.	benjamin.kidder@wayne.edu	LIU, zhe/HGD-6875-2022; Xhabija, Besa/GOP-2447-2022	Xhabija, Besa/0000-0002-4784-2454	Wayne State University, Karmanos Cancer Institute; Elsa U. Pardee Foundation	Wayne State University, Karmanos Cancer Institute; Elsa U. Pardee Foundation	This work was supported by Wayne State University, Karmanos Cancer Institute, and a grant from the Elsa U. Pardee Foundation awarded to BLK.	Abaan OD, 2013, CANCER RES, V73, P4372, DOI 10.1158/0008-5472.CAN-12-3342; Albert M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003461; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Benayoun BA, 2014, CELL, V158, P673, DOI 10.1016/j.cell.2014.06.027; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen KF, 2015, NAT GENET, V47, P1149, DOI 10.1038/ng.3385; Cheng CJ, 2009, CANCER RES, V69, P3634, DOI 10.1158/0008-5472.CAN-08-3615; Cutcliffe C, 2005, CLIN CANCER RES, V11, P7986, DOI 10.1158/1078-0432.CCR-05-1354; Dai B, 2014, BIOCHEM BIOPH RES CO, V454, P221, DOI 10.1016/j.bbrc.2014.10.078; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dey BK, 2008, MOL CELL BIOL, V28, P5312, DOI 10.1128/MCB.00128-08; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010; Evertts AG, 2013, MOL BIOL CELL, V24, P3025, DOI 10.1091/mbc.E12-07-0529; Facompre ND, 2016, CANCER RES, V76, P5538, DOI 10.1158/0008-5472.CAN-15-3377; Frankenberg S, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-8; Gopi LK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21707-1; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59; He RS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29074-6; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hinohara K, 2018, CANCER CELL, V34, P939, DOI 10.1016/j.ccell.2018.10.014; Hu GQ, 2014, METHODS MOL BIOL, V1150, P175, DOI 10.1007/978-1-4939-0512-6_11; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Khan A, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1708-7; Kidder BL, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0115-7; Kidder BL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r32; Kidder BL, 2013, MOL CELL BIOL, V33, P4793, DOI 10.1128/MCB.00692-13; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Li X, 2013, INT J MOL SCI, V14, P7866, DOI 10.3390/ijms14047866; Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Min MW, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000178; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Muntean AG, 2009, AM J PATHOL, V175, P1353, DOI 10.2353/ajpath.2009.081142; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Ohta K, 2013, INT J ONCOL, V42, P1212, DOI 10.3892/ijo.2013.1799; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Reinhold WC, 2019, CANCER RES, V79, P3514, DOI 10.1158/0008-5472.CAN-18-2047; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roesch A, 2006, J INVEST DERMATOL, V126, P1850, DOI 10.1038/sj.jid.5700324; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shigekawa Yoshinobu, 2018, Oncotarget, V9, P34320, DOI 10.18632/oncotarget.26144; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Taylor-Papadimitriou J, 2017, EXPERT OPIN THER TAR, V21, P5, DOI 10.1080/14728222.2017.1263616; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Vinogradova M, 2016, NAT CHEM BIOL, V12, P531, DOI 10.1038/nchembio.2085; Wang LS, 2015, TUMOR BIOL, V36, P2465, DOI 10.1007/s13277-014-2859-z; Wang ZR, 2015, AM J CANCER RES, V5, P87; Xhabija B, 2019, SEMIN CANCER BIOL, V57, P79, DOI 10.1016/j.semcancer.2018.11.001; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91; Xu J, 2018, BIOL OPEN, V7, DOI 10.1242/bio.031245; Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024; Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340	84	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2958	2972		10.1038/s41388-022-02311-z	http://dx.doi.org/10.1038/s41388-022-02311-z		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35440714	Green Accepted			2022-12-17	WOS:000784875000001
J	Lim, JS; Lee, KW; Ko, KP; Jeong, SI; Ryu, BK; Lee, MG; Chi, SG				Lim, Ji-Sun; Lee, Kyung-Woo; Ko, Kyung-Phil; Jeong, Seong-In; Ryu, Byung-Kyu; Lee, Min-Goo; Chi, Sung-Gil			XAF1 destabilizes estrogen receptor alpha through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis	ONCOGENE			English	Article							XIAP-ASSOCIATED FACTOR-1; ESTRADIOL-INDUCED APOPTOSIS; BREAST-CANCER; LIGASE ACTIVITY; EXPRESSION; BRCA1; IDENTIFICATION; GENE; GROWTH; SWITCH	X-linked inhibitor of apoptosis-associated factor 1 (XAF1) is a pro-apoptotic tumor suppressor that is frequently inactivated in multiple human cancers. However, its candidacy as a suppressor in the pathogenesis of breast cancer remains undefined. Here, we report that XAF1 acts as a molecular switch in estrogen (E2)-mediated cell-fate decisions favoring apoptosis over cell proliferation. XAF1 promoter hypermethylation is observed predominantly in estrogen receptor alpha (ER alpha)-positive versus ER alpha-negative tumor cells and associated with attenuated apoptotic response to E2. XAF1 is activated by E2 through a G protein-coupled estrogen receptor-mediated non-genomic pathway and induces ER alpha degradation and apoptosis while it is repressed by ER alpha for E2 stimulation of cell proliferation. The XAF1-ER alpha mutual antagonism dictates the outcomes of E2 signaling and its alteration is linked to the development of E2-resistant tumors. Mechanistically, XAF1 destabilizes ER alpha through the assembly of breast cancer-associated gene 1 (BRCA1)-mediated destruction complex. XAF1 interacts with ER alpha and BRCA1 via the zinc finger (ZF) domains 5/6 and 4, respectively, and the mutants lacking either of these domains fail to drive ER alpha ubiquitination and apoptosis. E2-induced regression of XAF1(+/+) tumors is abolished by XAF1 depletion while XAF1(-/-) tumors recover E2 response by XAF1 restoration. XAF1 and ER alpha expression show an inverse correlation in primary breast tumors, and XAF1 expression is associated with the overall survival of patients with ER alpha-positive but not ER alpha-negative cancer. Together, this study uncovers an important role for the XAF1-ER alpha antagonism as a linchpin to govern E2-mediated cell-fate decisions, illuminating the mechanistic consequence of XAF1 alteration in breast tumorigenesis.	[Lim, Ji-Sun; Lee, Kyung-Woo; Ko, Kyung-Phil; Jeong, Seong-In; Ryu, Byung-Kyu; Lee, Min-Goo; Chi, Sung-Gil] Korea Univ, Coll Life Sci & Technol, Dept Life Sci, Seoul 02841, South Korea; [Ryu, Byung-Kyu] Korea Univ, Sch Med, Dept Neurosurg, Seoul 02841, South Korea	Korea University; Korea University; Korea University Medicine (KU Medicine)	Chi, SG (corresponding author), Korea Univ, Coll Life Sci & Technol, Dept Life Sci, Seoul 02841, South Korea.	chi6302@korea.ac.kr			National Cancer Center [HA17C0034]; National Research Foundation of Korea [NRF-2021R1A2B03002487]; Korea University Grant, Republic of Korea [K2006781]	National Cancer Center; National Research Foundation of Korea(National Research Foundation of Korea); Korea University Grant, Republic of Korea	This work was supported in part by the National Cancer Center (HA17C0034, SGC), the National Research Foundation of Korea (NRF-2021R1A2B03002487, SGC), and Korea University Grant (K2006781, SGC), Republic of Korea.	Acconcia F, 2017, MOL CELL ENDOCRINOL, V457, P3, DOI 10.1016/j.mce.2016.10.033; Altiok N, 2007, BREAST CANCER RES TR, V105, P247, DOI 10.1007/s10549-006-9451-1; Altiok N, 2011, ONCOL LETT, V2, P1281, DOI 10.3892/ol.2011.385; Bennink HJTC, 2017, MATURITAS, V95, P11, DOI 10.1016/j.maturitas.2016.10.010; Burns KA, 2012, ARCH TOXICOL, V86, P1491, DOI 10.1007/s00204-012-0868-5; Byun DS, 2003, CANCER RES, V63, P7068; Carmeci C, 1997, GENOMICS, V45, P607, DOI 10.1006/geno.1997.4972; Carroll JS, 2016, EUR J ENDOCRINOL, V175, pR41, DOI 10.1530/EJE-16-0124; Chi D, 2019, P NATL ACAD SCI USA, V116, P11437, DOI 10.1073/pnas.1819155116; Chung SK, 2007, GASTROENTEROLOGY, V132, P2459, DOI 10.1053/j.gastro.2007.04.024; Deng Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57819-9; Dizin E, 2010, INT J BIOCHEM CELL B, V42, P693, DOI 10.1016/j.biocel.2009.12.025; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Fan SJ, 2002, CANCER RES, V62, P141; Fang XL, 2006, INT J CANCER, V118, P2485, DOI 10.1002/ijc.21636; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Han J, 2013, CELL DEATH DIFFER, V20, P1055, DOI 10.1038/cdd.2013.33; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Jeong SI, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0867-4; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kota K, 2017, CUREUS, V9, DOI 10.7759/cureus.1434; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leclercq G, 2006, CURR CANCER DRUG TAR, V6, P39, DOI 10.2174/156800906775471716; Lee MG, 2006, ONCOGENE, V25, P5807, DOI 10.1038/sj.onc.1209867; Lee MG, 2014, P NATL ACAD SCI USA, V111, P15532, DOI 10.1073/pnas.1411746111; Lewis JS, 2005, JNCI-J NATL CANCER I, V97, P1746, DOI 10.1093/jnci/dji400; Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Micali OC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-52; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Osborne CK, 2001, CLIN CANCER RES, V7, p4338S; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Rahman Syed Azizur, 2019, Asian Pac J Cancer Prev, V20, P1901, DOI 10.31557/APJCP.2019.20.6.1901; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Seval Y, 2006, J CLIN ENDOCR METAB, V91, P2349, DOI 10.1210/jc.2005-2132; Shin CH, 2017, P NATL ACAD SCI USA, V114, P5683, DOI 10.1073/pnas.1700861114; Sun M, 2012, MOL ENDOCRINOL, V26, P736, DOI 10.1210/me.2011-1158; Sun PH, 2011, CANCER LETT, V310, P170, DOI 10.1016/j.canlet.2011.06.037; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tu SP, 2010, CANCER-AM CANCER SOC, V116, P1252, DOI 10.1002/cncr.24814; Wang J, 2009, CARCINOGENESIS, V30, P1507, DOI 10.1093/carcin/bgp155; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xia Y, 2006, MOL CELL BIOCHEM, V286, P67, DOI 10.1007/s11010-005-9094-2; Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622; Zhu LM, 2014, ONCOTARGET, V5, P5403, DOI 10.18632/oncotarget.2114	51	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2897	2908		10.1038/s41388-022-02315-9	http://dx.doi.org/10.1038/s41388-022-02315-9		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35430604				2022-12-17	WOS:000782888200002
J	Koppenhafer, SL; Goss, KL; Voigt, E; Croushore, E; Terry, WW; Ostergaard, J; Gordon, PM; Gordon, DJ				Koppenhafer, Stacia L.; Goss, Kelli L.; Voigt, Ellen; Croushore, Emma; Terry, William W.; Ostergaard, Jason; Gordon, Peter M.; Gordon, David J.			Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma	ONCOGENE			English	Article							LOOP-HELIX PROTEIN; MYELOID-LEUKEMIA; FUSION PROTEINS; UP-REGULATION; STEM-CELLS; DIFFERENTIATION; TARGET; INITIATION; FAMILY; OVEREXPRESSION	Sarcomas are difficult to treat and the therapy, even when effective, is associated with long-term and life-threatening side effects. In addition, the treatment regimens for many sarcomas, including Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, are relatively unchanged over the past two decades, indicating a critical lack of progress. Although differentiation-based therapies are used for the treatment of some cancers, the application of this approach to sarcomas has proven challenging. Here, using a CRISPR-mediated gene knockout approach, we show that Inhibitor of DNA Binding 2 (ID2) is a critical regulator of developmental-related genes and tumor growth in vitro and in vivo in Ewing sarcoma tumors. We also identified that homoharringtonine, which is an inhibitor of protein translation and FDA-approved for the treatment of leukemia, decreases the level of the ID2 protein and significantly reduces tumor growth and prolongs mouse survival in an Ewing sarcoma xenograft model. Furthermore, in addition to targeting ID2, homoharringtonine also reduces the protein levels of ID1 and ID3, which are additional members of the ID family of proteins with well-described roles in tumorigenesis, in multiple types of cancer. Overall, these results provide insight into developmental regulation in Ewing sarcoma tumors and identify a novel, therapeutic approach to target the ID family of proteins using an FDA-approved drug.	[Koppenhafer, Stacia L.; Goss, Kelli L.; Croushore, Emma; Terry, William W.; Gordon, David J.] Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, Iowa City, IA 52242 USA; [Voigt, Ellen] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA; [Ostergaard, Jason; Gordon, Peter M.] Univ Minnesota, Div Pediat Hematol Oncol, Dept Pediat, Minneapolis, MN 55455 USA	University of Iowa; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities	Gordon, DJ (corresponding author), Univ Iowa, Div Pediat Hematol Oncol, Dept Pediat, Iowa City, IA 52242 USA.	david-j-gordon@uiowa.edu		Gordon, David/0000-0003-1830-4371; Croushore, Emma/0000-0002-8029-9289	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; Aiming for a Cure; NIH [R37-CA217910]; NCI [P30CA086862]; University of Iowa Carver College of Medicine; Holden Comprehensive Cancer Center (NCI) [P30CA086862]	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; Aiming for a Cure; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Iowa Carver College of Medicine; Holden Comprehensive Cancer Center (NCI)	We would like to acknowledge Henry Keen for assistance with the analysis of the RNAseq data. DJG is supported by a University of Iowa Dance Marathon Award, a Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant, Sammy's Superheroes, The Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation, Aiming for a Cure, and NIH Grant R37-CA217910. This work was also supported by a grant (P30CA086862) from the NCI, administered through the Holden Comprehensive Cancer Center at The University of Iowa. The authors would like to acknowledge use of the University of Iowa Flow Cytometry Facility and the DNA sequencing facility (Genomics Division of the Iowa Institute of Human Genetics) which are supported, in part, by the University of Iowa Carver College of Medicine and the Holden Comprehensive Cancer Center (NCI P30CA086862).	Bae WJ, 2017, BRIT J CANCER, V117, P1810, DOI 10.1038/bjc.2017.373; Bajikar SS, 2017, DEV CELL, V43, P418, DOI 10.1016/j.devcel.2017.10.027; Balamuth NJ, 2010, LANCET ONCOL, V11, P184, DOI 10.1016/S1470-2045(09)70286-4; Behjati S, 2021, CANCER DISCOV, V11, P542, DOI 10.1158/2159-8290.CD-20-0926; Bell BA, 2001, MED PEDIATR ONCOL, V37, P103, DOI 10.1002/mpo.1177; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x; Benezra R, 2001, BBA-REV CANCER, V1551, pF39, DOI 10.1016/S0304-419X(01)00028-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Chen XX, 2019, FRONT MED-PRC, V13, P378, DOI 10.1007/s11684-018-0658-4; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ehrlich M, 2017, P NATL ACAD SCI USA, V114, pE2243, DOI 10.1073/pnas.1614412114; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gordon DJ, 2016, ONCOGENE, V35, P3092, DOI 10.1038/onc.2015.368; Goss KL, 2021, ONCOGENE, V40, P564, DOI 10.1038/s41388-020-01552-0; Goss KL, 2017, ONCOTARGET, V8, P87016, DOI 10.18632/oncotarget.18776; Goss KL, 2016, ONCOTARGET, V7, P63003, DOI 10.18632/oncotarget.11416; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hao L, 2016, BIOCHEM BIOPH RES CO, V470, P643, DOI 10.1016/j.bbrc.2016.01.090; Howard TP, 2020, CLIN CANCER RES, V26, P4995, DOI 10.1158/1078-0432.CCR-19-2717; Huang YH, 2020, CANCER DISCOV, V10, P142, DOI 10.1158/2159-8290.CD-19-0529; Hwang DH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-117; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Islam MS, 2009, NEUROCHEM INT, V54, P192, DOI 10.1016/j.neuint.2008.10.011; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jin J, 2013, LANCET ONCOL, V14, P599, DOI 10.1016/S1470-2045(13)70152-9; Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446; Khoury JD, 2005, ADV ANAT PATHOL, V12, P212, DOI 10.1097/01.pap.0000175114.55541.52; Koppenhafer SL, 2018, MOL CANCER THER, V17, P2676, DOI 10.1158/1535-7163.MCT-18-0260; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lachmann A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03751-6; Lam SSY, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf3735; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Leacock SW, 2012, DIS MODEL MECH, V5, P95, DOI 10.1242/dmm.007401; Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood-2005-07-2798; Lessnick SL, 2012, ANNU REV PATHOL-MECH, V7, P145, DOI 10.1146/annurev-pathol-011110-130237; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Maire CL, 2010, STEM CELLS, V28, P1611, DOI 10.1002/stem.480; Maire CL, 2009, J NEUROSCI RES, V87, P3438, DOI 10.1002/jnr.22194; Meng J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2327-1; Merritt N, 2021, ELIFE, V10, DOI 10.7554/eLife.62857; Mistry H, 2013, MOL CANCER THER, V12, P2651, DOI 10.1158/1535-7163.MCT-13-0103-T; Nair R, 2014, MOL THER, V22, P1407, DOI 10.1038/mt.2014.83; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ohmura S, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01393-9; Park HR, 2006, TUMORI, V92, P236, DOI 10.1177/030089160609200309; Patel AV, 2016, EBIOMEDICINE, V9, P110, DOI 10.1016/j.ebiom.2016.06.007; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Potikyan G, 2008, LAB INVEST, V88, P1291, DOI 10.1038/labinvest.2008.99; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Riggi N, 2009, EXPERT REV ANTICANC, V9, P1025, DOI 10.1586/ERA.09.81; Roschger C, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-016-0161-y; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sachdeva R, 2019, CANCER RES, V79, P4057, DOI 10.1158/0008-5472.CAN-18-1357; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schwentner R, 2017, ONCOTARGET, V8, P10980, DOI 10.18632/oncotarget.14091; Sole A, 2021, CANCER RES, V81, P4994, DOI 10.1158/0008-5472.CAN-20-3837; Svoboda LK, 2014, EPIGENETICS-US, V9, P1613, DOI 10.4161/15592294.2014.988048; Szu J, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.659601; Tam WF, 2008, BLOOD, V112, P1981, DOI 10.1182/blood-2007-07-103010; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Torchia EC, 2003, CANCER RES, V63, P3464; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Veerasamy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051842; Venneti S, 2011, AM J SURG PATHOL, V35, P1463, DOI 10.1097/PAS.0b013e318224d2cd; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wang L, 2015, BLOOD, V126, P640, DOI 10.1182/blood-2015-03-635532; Waters T, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07668-6; Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040; Winer ES, 2018, ONCOL THER, V6, P9, DOI 10.1007/s40487-018-0058-6; Wojnarowicz PM, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/s41523-021-00266-0; Wojnarowicz PM, 2019, CELL REP, V29, P62, DOI 10.1016/j.celrep.2019.08.073; Zhang CX, 2020, CANCER-AM CANCER SOC, V126, P344, DOI 10.1002/cncr.32534; Zhao GS, 2019, AM J TRANSL RES, V11, P2117; Zhao ZX, 2020, INT J MED SCI, V17, P995, DOI 10.7150/ijms.42805; Zhao ZY, 2015, TUMOR BIOL, V36, P4189, DOI 10.1007/s13277-015-3055-5; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	93	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2873	2884		10.1038/s41388-022-02310-0	http://dx.doi.org/10.1038/s41388-022-02310-0		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35422476	Green Accepted			2022-12-17	WOS:000782543300002
J	Berger, AH; Imielinski, M; Duke, F; Wala, J; Kaplan, N; Shi, GX; Andres, DA; Meyerson, M				Berger, A. H.; Imielinski, M.; Duke, F.; Wala, J.; Kaplan, N.; Shi, G. -X; Andres, D. A.; Meyerson, M.			Oncogenic RIT1 mutations in lung adenocarcinoma (vol 33, pg 4418, 2014)	ONCOGENE			English	Correction												matthew_meyerson@dfci.harvard.edu						Berger AH, 2014, ONCOGENE, V33, P4418, DOI 10.1038/onc.2013.581	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2788	2788		10.1038/s41388-022-02300-2	http://dx.doi.org/10.1038/s41388-022-02300-2		APR 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35418694	Bronze			2022-12-17	WOS:000783468200004
J	Copello, VA; Burnstein, KL				Copello, Valeria A.; Burnstein, Kerry L.			The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor	ONCOGENE			English	Article							PROTEOMIC ANALYSIS; VARIANT	Prostate cancer that recurs following androgen-deprivation therapy is termed castration-resistant, which is incurable and is marked by reactivation of androgen receptor (AR) signaling. KIF20A, a kinesin with unique structural features, is overexpressed in human castration-resistant prostate cancer (CRPC) compared to androgen-dependent PC and benign tissue. KIF20A has well-described roles in mitotic processes, but it has a less characterized function in vesicle fission and trafficking within Golgi-driven secretory pathways. Stable expression of KIF20A in androgen-dependent PC cells promoted progression to CRPC through the activation of AR signaling in vitro and in vivo. KIF20A expression resulted in the secretion of autocrine factors in the conditioned media that activated AR and caused castration-resistant proliferation of naive androgen-dependent cells. Pharmacologic disruption of vesicle biogenesis blocked KIF20A-driven castration-resistant proliferation of androgen-dependent PC. KIF20A depletion or treatment with the KIF20A-specific inhibitor, paprotrain, reduced CRPC. These data are the first to establish KIF20A as a driver of CRPC progression through AR activation and as a promising therapeutic target against CRPC.	[Copello, Valeria A.] Sheila & David Fuente Grad Program Canc Biol, Miami, FL USA; [Copello, Valeria A.; Burnstein, Kerry L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Copello, Valeria A.; Burnstein, Kerry L.] Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami	Burnstein, KL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.; Burnstein, KL (corresponding author), Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	kburnstein@med.miami.edu		Copello, Valeria/0000-0002-7035-4467	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) [P30-CA240139]; VA Merit Review [1I01BX002773]; Mike Slive Foundation; Sylvester Comprehensive Cancer Center	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG); VA Merit Review(US Department of Veterans Affairs); Mike Slive Foundation; Sylvester Comprehensive Cancer Center	We thank Dr. Deukwoo Kwon (University of Miami) for assistance with statistical analyses, and the Cancer Modeling Shared Resource (Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine), which is supported by the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) P30-CA240139, for the immunohistochemistry assistance. We thank Drs. M. Julia Martinez and Nahuel Peinetti for helpful comments on the manuscript. This work was supported by VA Merit Review 1I01BX002773 (to KLB), the Mike Slive Foundation (to KLB), and Developmental Funds from the Sylvester Comprehensive Cancer Center (to KLB).	Adriaans IE, 2020, CURR BIOL, V30, P2628, DOI 10.1016/j.cub.2020.04.081; Archer M, 2020, CANCERS, V12, DOI 10.3390/cancers12102984; Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211; Atherton J, 2017, ELIFE, V6, DOI 10.7554/eLife.27793; Auchus RJ, 2020, ANNU REV MED, V71, P33, DOI 10.1146/annurev-med-051418-060357; Catalano M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1703244; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Crowe AR, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3465; Dalela Deepansh, 2016, Rev Urol, V18, P1; Desai K, 2021, ENDOCR REV, V42, P354, DOI 10.1210/endrev/bnab002; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Einstein DJ, 2019, CURR OPIN ONCOL, V31, P175, DOI 10.1097/CCO.0000000000000520; Fernandes RC, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108585; Gaglani S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810131; Galligan JT, 2015, J PROTEOME RES, V14, P953, DOI 10.1021/pr501005v; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gregory CW, 2001, CANCER RES, V61, P2892; Hizir MS, 2014, ACS APPL MATER INTER, V6, P14772, DOI 10.1021/am504190a; Hu LL, 2021, ONCOGENE, V40, P6479, DOI 10.1038/s41388-021-02026-7; Imai K, 2011, BRIT J CANCER, V104, P300, DOI 10.1038/sj.bjc.6606052; Kaur SP, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88519-7; Labriere C, 2016, BIOORGAN MED CHEM, V24, P721, DOI 10.1016/j.bmc.2015.12.042; Landini G, 2021, BIOINFORMATICS, V37, P1485, DOI 10.1093/bioinformatics/btaa847; Li YW, 2020, EXP CELL RES, V395, DOI 10.1016/j.yexcr.2020.112212; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Ma TF, 2021, CANCER LETT, V504, P37, DOI 10.1016/j.canlet.2020.12.037; Magani F, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188202; Magani F, 2017, MOL CANCER RES, V15, P1469, DOI 10.1158/1541-7786.MCR-17-0280; Miserey-Lenkei S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01266-0; Nakamura M, 2020, INT J ONCOL, V57, P277, DOI 10.3892/ijo.2020.5060; Rayford W, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02140-y; Ren XH, 2020, AGING-US, V12, P25878, DOI 10.18632/aging.202153; Ridge SM, 2018, INT J CANCER, V142, P2056, DOI 10.1002/ijc.31226; Roggero CM, 2021, ONCOGENE, V40, P1106, DOI 10.1038/s41388-020-01585-5; Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017; Saito K, 2017, J NEURO-ONCOL, V132, P63, DOI 10.1007/s11060-016-2360-1; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tcherniuk S, 2010, ANGEW CHEM INT EDIT, V49, P8228, DOI 10.1002/anie.201003254; Terada Y, 2003, J CELL BIOL, V162, P757, DOI 10.1083/jcb.200305048; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang YA, 2020, ONCOGENE, V39, P7225, DOI 10.1038/s41388-020-01496-5; Wu JR, 2010, PHARM STAT, V9, P46, DOI 10.1002/pst.369; Zhang Z, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/4782730	46	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2824	2832		10.1038/s41388-022-02307-9	http://dx.doi.org/10.1038/s41388-022-02307-9		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418689	Green Accepted			2022-12-17	WOS:000783468200001
J	Hochnadel, I; Hoenicke, L; Petriv, N; Neubert, L; Reinhard, E; Hirsch, T; Alfonso, JCL; Suo, HZ; Longerich, T; Geffers, R; Lichtinghagen, R; Guzman, CA; Wedemeyer, H; Lenzen, H; Manns, MP; Bruder, D; Yevsa, T				Hochnadel, Inga; Hoenicke, Lisa; Petriv, Nataliia; Neubert, Lavinia; Reinhard, Elena; Hirsch, Tatjana; Alfonso, Juan Carlos Lopez; Suo, Huizhen; Longerich, Thomas; Geffers, Robert; Lichtinghagen, Ralf; Guzman, Carlos Alberto; Wedemeyer, Heiner; Lenzen, Henrike; Manns, Michael Peter; Bruder, Dunja; Yevsa, Tetyana			Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers (vol 41, pg 2039, 2022)	ONCOGENE			English	Correction												Yevsa.Tetyana@mh-hannover.de		Hoenicke, Lisa/0000-0003-0613-8337				Hochnadel I, 2022, ONCOGENE, V41, P2039, DOI 10.1038/s41388-022-02222-z	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2787	2787		10.1038/s41388-022-02261-6	http://dx.doi.org/10.1038/s41388-022-02261-6		APR 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35418693	Green Published, hybrid			2022-12-17	WOS:000783468200002
J	Lin, HY; Ko, CJ; Lo, TY; Wu, SR; Lan, SW; Huang, CA; Lin, YC; Lin, HH; Tu, HF; Lee, CF; Hsiao, PW; Huang, HP; Chen, MJ; Chang, KH; Lee, MS				Lin, Hsin-Ying; Ko, Chun-Jung; Lo, Tzu-Yu; Wu, Shang-Ru; Lan, Shao-Wei; Huang, Chen-An; Lin, Yi-Chin; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Hsiao, Pei-Wen; Huang, Hsiang-Po; Chen, Mei-Jou; Chang, Kai-Hsiung; Lee, Ming-Shyue			Matriptase-2/NR4A3 axis switches TGF-beta action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis	ONCOGENE			English	Article							SERINE-PROTEASE MATRIPTASE-2; UROKINASE PLASMINOGEN-ACTIVATOR; ORPHAN NUCLEAR RECEPTORS; BREAST-CANCER; IN-VITRO; IRON; TMPRSS6; SMAD2; EXPRESSION; PROGNOSIS	Dysregulation of pericellular proteolysis is strongly implicated in cancer metastasis through alteration of cell invasion and the microenvironment. Matriptase-2 (MT-2) is a membrane-anchored serine protease which can suppress prostate cancer (PCa) cell invasion. In this study, we showed that MT-2 was down-regulated in PCa and could suppress PCa cell motility, tumor growth, and metastasis. Using microarray and biochemical analysis, we found that MT-2 shifted TGF-beta action towards its tumor suppressor function by repressing epithelial-to-mesenchymal transition (EMT) and promoting Smad2 phosphorylation and nuclear accumulation to upregulate two TGF-beta 1 downstream effectors (p21 and PAI-1), culminating in hindrance of PCa cell motility and malignant growth. Mechanistically, MT-2 could dramatically up-regulate the expression of nuclear receptor NR4A3 via iron metabolism in PCa cells. MT-2-induced NR4A3 further coactivated Smad2 to activate p21 and PAI-1 expression. In addition, NR4A3 functioned as a suppressor of PCa and mediated MT-2 signaling to inhibit PCa tumorigenesis and metastasis. These results together indicate that NR4A3 sustains MT-2 signaling to suppress PCa cell invasion, tumor growth, and metastasis, and serves as a contextual factor for the TGF-beta/Smad2 signaling pathway in favor of tumor suppression via promoting p21 and PAI-1 expression.	[Lin, Hsin-Ying; Ko, Chun-Jung; Lo, Tzu-Yu; Wu, Shang-Ru; Lan, Shao-Wei; Huang, Chen-An; Lin, Yi-Chin; Lin, Hsin-Hsien; Tu, Hsin-Fang; Lee, Cheng-Fan; Lee, Ming-Shyue] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan; [Hsiao, Pei-Wen] Acad Sinica, Agr Biotechnol Res Ctr, Taipei, Taiwan; [Huang, Hsiang-Po] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei, Taiwan; [Chen, Mei-Jou] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; [Chang, Kai-Hsiung] Natl Hlth Res Inst, Inst Cellular & Syst Med, Miaoli, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan	Lee, MS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei, Taiwan.	mslee2006@ntu.edu.tw	Tu, Hsin-Fang/HGA-9284-2022	CHEN, MEI-JOU/0000-0002-2305-1105; Ko, Chun-Jung/0000-0001-6565-7060	National Health Research Institutes grants [NHRI-EX106-10401BI, NHRI-EX109-10725BI]; Ministry of Science and Technology grants [MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3, MOST 108-2320-B-002-024-MY3, MOST 110-2320-B-002-067-MY3]; National Taiwan University grants [NTU105R89612, NTU107L890504, NTU110L893503]; NTUH Grant [UN110-029]	National Health Research Institutes grants; Ministry of Science and Technology grants; National Taiwan University grants; NTUH Grant	We appreciate the service of the First Core Laboratory of National Taiwan University College of Medicine. We thank the Laboratory Animal Core Facility (ABRC, Academia Sinica) for their services and Ms. Miranda Loney (Editor, ABRC) for critical suggestions for editing this article. This study was supported by National Health Research Institutes grants NHRI-EX106-10401BI and NHRI-EX109-10725BI, Ministry of Science and Technology grants MOST 104-2320-B-002-044-MY3, MOST 105-2911-I-002-521, MOST 106-2320-B-002-046-MY3 and MOST 108-2320-B-002-024-MY3, MOST 110-2320-B-002-067-MY3, National Taiwan University grants NTU105R89612, NTU107L890504 and NTU110L893503 to M.S. Lee, and NTUH Grant UN110-029 to M.J. Chen and M.S. Lee.	Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Bohm L, 2013, J CANCER RES CLIN, V139, P1221, DOI 10.1007/s00432-013-1428-y; Buck A, 2006, MOL CANCER RES, V4, P861, DOI 10.1158/1541-7786.MCR-06-0081; Cheng MF, 2017, APPL IMMUNOHISTO M M, V25, P481, DOI 10.1097/PAI.0000000000000324; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Deutsch AJA, 2017, CANCER RES, V77, P2375, DOI 10.1158/0008-5472.CAN-16-2320; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; Duffy MJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0428-4; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Fedorova O, 2019, ONCOGENE, V38, P2108, DOI 10.1038/s41388-018-0566-8; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Folgueras AR, 2008, BLOOD, V112, P2539, DOI 10.1182/blood-2008-04-149773; Graham CH, 1997, PLACENTA, V18, P137, DOI 10.1016/S0143-4004(97)90085-0; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053; Huynh LK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110743; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kwaan HC, 2013, SEMIN THROMB HEMOST, V39, P382, DOI 10.1055/s-0033-1338127; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Palumbo-Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777; Parr C, 2007, CLIN CANCER RES, V13, P3568, DOI 10.1158/1078-0432.CCR-06-2357; Perttu MC, 2006, PROSTATE CANCER P D, V9, P185, DOI 10.1038/sj.pcan.4500871; Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426; Ramsay AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P569, DOI 10.2741/2702; Ranhotra HS, 2015, J RECEPT SIG TRANSD, V35, P184, DOI 10.3109/10799893.2014.948555; Riggins GJ, 1997, CANCER RES, V57, P2578; Rodriguez-Calvo R, 2017, EXPERT OPIN THER TAR, V21, P291, DOI 10.1080/14728222.2017.1279146; Safe S, 2014, MOL ENDOCRINOL, V28, P157, DOI 10.1210/me.2013-1291; Sanchez M, 2011, BLOOD, V118, pE168, DOI 10.1182/blood-2011-04-343541; Sanders AJ, 2008, J CELL PHYSIOL, V216, P780, DOI 10.1002/jcp.21460; Santibanez JF, 2006, FEBS LETT, V580, P5385, DOI 10.1016/j.febslet.2006.09.003; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; Silvestri L, 2008, CELL METAB, V8, P502, DOI 10.1016/j.cmet.2008.09.012; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Tu WH, 2003, NEOPLASIA, V5, P267, DOI 10.1016/S1476-5586(03)80058-1; Tuhkanen H, 2013, INT J CANCER, V133, P2334, DOI 10.1002/ijc.28254; Vela D, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.273; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Webb SL, 2012, ONCOL REP, V28, P1491, DOI 10.3892/or.2012.1945; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yeh CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep31690; Yeh HW, 2019, CANCER RES, V79, P3797, DOI 10.1158/0008-5472.CAN-18-2019; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Ying Z, 2017, J CLIN INVEST, V127, P1725, DOI 10.1172/JCI90439; Zhao XG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1705-z	51	0	0	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2833	2845		10.1038/s41388-022-02303-z	http://dx.doi.org/10.1038/s41388-022-02303-z		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418692				2022-12-17	WOS:000783468200003
J	Hiwatari, M; Seki, M; Matsuno, R; Yoshida, K; Nagasawa, T; Sato-Otsubo, A; Yamamoto, S; Kato, M; Watanabe, K; Sekiguchi, M; Miyano, S; Ogawa, S; Takita, J				Hiwatari, Mitsuteru; Seki, Masafumi; Matsuno, Ryosuke; Yoshida, Kenichi; Nagasawa, Takeshi; Sato-Otsubo, Aiko; Yamamoto, Shohei; Kato, Motohiro; Watanabe, Kentaro; Sekiguchi, Masahiro; Miyano, Satoru; Ogawa, Seishi; Takita, Junko			Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma	ONCOGENE			English	Article							ANAPLASTIC LYMPHOMA KINASE; YOUNG-ADULTS; EML4-ALK; PROTEIN; GENE; MUTATIONS; INHIBITOR; FAMILY; NPM; TRANSLOCATIONS	The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3-ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-Prkdc(scid)Il2rg(tm1Sug)/ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5 ' partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.	[Hiwatari, Mitsuteru; Seki, Masafumi; Nagasawa, Takeshi; Sato-Otsubo, Aiko; Kato, Motohiro; Watanabe, Kentaro; Sekiguchi, Masahiro] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Hiwatari, Mitsuteru] Univ Tokyo Hosp, Dept Cell Therapy & Transplantat Med, Tokyo, Japan; [Hiwatari, Mitsuteru] Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Matsuno, Ryosuke] Kansai Med Univ, Dept Pediat, Osaka, Japan; [Yoshida, Kenichi; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Yoshidakonoecho, Kyoto, Japan; [Yamamoto, Shohei] Tokai Univ, Dept Pediat, Sch Med, Isehara, Kanagawa, Japan; [Miyano, Satoru] Tokyo Med & Dent Univ, Med & Dent Data Sci Ctr, Tokyo, Japan; [Ogawa, Seishi] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Sakyo Ku, Yoshidakonoecho, Kyoto, Japan; [Ogawa, Seishi] Karolinska Inst, Dept Med, Ctr Hematol & Regenerat Med, Stockholm, Sweden; [Takita, Junko] Kyoto Univ, Dept Pediat, Sakyo Ku, Yoshidakonoecho, Kyoto, Japan	University of Tokyo; University of Tokyo; Teikyo University; Kansai Medical University; Kyoto University; Tokai University; Tokyo Medical & Dental University (TMDU); Kyoto University; Karolinska Institutet; Kyoto University	Hiwatari, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan.; Hiwatari, M (corresponding author), Univ Tokyo Hosp, Dept Cell Therapy & Transplantat Med, Tokyo, Japan.; Hiwatari, M (corresponding author), Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan.	mhiwatari-tky@umin.ac.jp	HIWATARI, Mitsuteru/HDM-0869-2022; Seki, Masafumi/AAN-1025-2021	Seki, Masafumi/0000-0003-4671-7026; Matsuno, Ryosuke/0000-0003-3231-4760; Yoshida, Kenichi/0000-0003-4612-2778; Sekiguchi, Masahiro/0000-0002-7941-9319; Nagasawa, Takeshi/0000-0002-1552-3619; Yamamoto, Shohei/0000-0003-1582-7062	JSPS KAKENHI [JP19J11112, JP17H04224, JP18K19467, JP20H00528]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) [JP19cm0106509h9904]; Japan Agency for Medical Research and Development (AMED) [JP19ck0106468h001]; Princess Takamatsu Cancer Research Fund; RIKEN Advanced Institute for Computational Science through the HPCI System Research project [hp140230, hp160219, hp150232]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project for Cancer Research and Therapeutic Evolution (P-CREATE); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Princess Takamatsu Cancer Research Fund; RIKEN Advanced Institute for Computational Science through the HPCI System Research project	The authors would like to thank M. Matsumura, K. Yin, and F. Saito for their excellent technical assistance, Dr. T. Kitamura (Division of Cellular Therapy/Division of Stem Cell Signaling, The Institute of Medical Sciences, The University of Tokyo, Japan) for the kind gift of expression vector pMYs-IRES-Neo. The authors also wish to express their appreciation to K. Chiba and H. Tanaka (The University of Tokyo) for the supercomputer. This work was supported by JSPS KAKENHI Grant Numbers JP19J11112, JP17H04224, JP18K19467, and JP20H00528; Project for Cancer Research and Therapeutic Evolution (P-CREATE; grant no. JP19cm0106509h9904), and Practical Research for Innovative Cancer Control (grant no. JP19ck0106468h001) from the Japan Agency for Medical Research and Development (AMED); Princess Takamatsu Cancer Research Fund. This research also used the computational resources of the K computer provided by the RIKEN Advanced Institute for Computational Science through the HPCI System Research project (hp140230, hp160219, and hp150232) (SM and SO).	Amano Y, 2015, BIOCHEM BIOPH RES CO, V457, P457, DOI 10.1016/j.bbrc.2015.01.014; Arregui CO, 2000, NEUROCHEM RES, V25, P95, DOI 10.1023/A:1007595617447; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Camidge DR, 2018, NEW ENGL J MED, V379, P2027, DOI 10.1056/NEJMoa1810171; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Cazes A, 2013, CANCER RES, V73, P195, DOI 10.1158/0008-5472.CAN-12-1242; Ceccon M, 2016, ONCOGENE, V35, P3854, DOI 10.1038/onc.2015.456; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Choi YL, 2014, J THORAC ONCOL, V9, P563, DOI 10.1097/JTO.0000000000000093; Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365; Della Corte CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0776-2; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Feng K, 2002, J BIOL CHEM, V277, P26128, DOI 10.1074/jbc.M203722200; Fransson S, 2015, GENE CHROMOSOME CANC, V54, P99, DOI 10.1002/gcc.22223; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Grande E, 2011, MOL CANCER THER, V10, P569, DOI 10.1158/1535-7163.MCT-10-0615; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Infarinato NR, 2016, CANCER DISCOV, V6, P96, DOI 10.1158/2159-8290.CD-15-1056; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Johnson TW, 2014, J MED CHEM, V57, P4720, DOI 10.1021/jm500261q; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Li ZB, 2014, AM J CLIN PATHOL, V141, P420, DOI 10.1309/AJCPHF51LSPCAXTA; Mano H, 2008, CANCER SCI, V99, P2349, DOI 10.1111/j.1349-7006.2008.00972.x; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Martelli MP, 2009, AM J PATHOL, V174, P661, DOI 10.2353/ajpath.2009.080755; Mason DY, 1998, CANCER RES, V58, P1057; Matsuno R, 2020, PEDIATR INT, V62, P507, DOI 10.1111/ped.14117; Mazzocco K, 2015, PEDIATR BLOOD CANCER, V62, P1725, DOI 10.1002/pbc.25552; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2014, PEDIATR BLOOD CANCER, V61, P627, DOI 10.1002/pbc.24777; Okubo J, 2012, ONCOGENE, V31, P4667, DOI 10.1038/onc.2011.616; Oohashi T, 1999, J CELL BIOL, V145, P563, DOI 10.1083/jcb.145.3.563; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Richards MW, 2015, BIOCHEM J, V467, P529, DOI 10.1042/BJ20150039; Richards MW, 2014, P NATL ACAD SCI USA, V111, P5195, DOI 10.1073/pnas.1322892111; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Roskoski R, 2013, PHARMACOL RES, V68, P68, DOI 10.1016/j.phrs.2012.11.007; Seki M, 2017, NAT GENET, V49, P1274, DOI 10.1038/ng.3900; Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557; SHIOTA M, 1994, ONCOGENE, V9, P1567; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stein H, 2000, BLOOD, V96, P3681; Tabbo F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00041; Takeuchi K, 2008, CLIN CANCER RES, V14, P6618, DOI 10.1158/1078-0432.CCR-08-1018; Takita J, 2017, CANCER SCI, V108, P1913, DOI 10.1111/cas.13333; Tang ZY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163939; Young TR, 2009, INT J BIOCHEM CELL B, V41, P990, DOI 10.1016/j.biocel.2008.06.014; Ziegler A, 2012, CANCER LETT, V326, P1, DOI 10.1016/j.canlet.2012.07.021	55	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2789	2797		10.1038/s41388-022-02301-1	http://dx.doi.org/10.1038/s41388-022-02301-1		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35411036				2022-12-17	WOS:000780668900003
J	Lane, R; Cilibrasi, C; Chen, JN; Shah, KL; Messuti, E; Mazarakis, NK; Stebbing, J; Critchley, G; Song, ER; Simon, T; Giamas, G				Lane, Rosemary; Cilibrasi, Chiara; Chen, Jianing; Shah, Kalpit; Messuti, Eleonora; Mazarakis, Nektarios K.; Stebbing, Justin; Critchley, Giles; Song, Erwei; Simon, Thomas; Giamas, Georgios			PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38(MAPK) signalling	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR RECEPTOR; TUMOR-CELLS; ANTITUMOR-ACTIVITY; STEM-CELL; KINASE; PHOSPHORYLATION; THERAPY; CLASSIFICATION; IDENTIFICATION	Glioblastoma (GBM) is the most common and fatal primary brain tumour in adults. Considering that resistance to current therapies leads to limited response in patients, new therapeutic options are urgently needed. In recent years, differentiation therapy has been proposed as an alternative for GBM treatment, with the aim of bringing cancer cells into a post-mitotic/differentiated state, ultimately limiting tumour growth. As an integral component of cancer development and regulation of differentiation processes, kinases are potential targets of differentiation therapies. The present study describes how the screening of a panel of kinase inhibitors (KIs) identified PDGF-R alpha/beta inhibitor CP-673451 as a potential differentiation agent in GBM. We show that targeting PDGF-R alpha/beta with CP-673451 in vitro triggers outgrowth of neurite-like processes in GBM cell lines and GBM stem cells (GSCs), suggesting differentiation into neural-like cells, while reducing proliferation and invasion in 3D hyaluronic acid hydrogels. In addition, we report that treatment with CP-673451 improves the anti-tumour effects of temozolomide in vivo using a subcutaneous xenograft mouse model. RNA sequencing and follow-up proteomic analysis revealed that upregulation of phosphatase DUSP1 and consecutive downregulation of phosphorylated-p38(MAPK) can underlie the pro-differentiation effect of CP-673451 on GBM cells. Overall, the present study identifies a potential novel therapeutic option that could benefit GBM patients in the future, through differentiation of residual GSCs post-surgery, with the aim to limit recurrence and improve quality of life.	[Lane, Rosemary; Cilibrasi, Chiara; Messuti, Eleonora; Simon, Thomas; Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Chen, Jianing; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Peoples R China; [Shah, Kalpit] Genentech Inc, San Francisco, CA 94080 USA; [Mazarakis, Nektarios K.] Royal Coll Surgeons Ireland, Dublin D02 YN77, Ireland; [Mazarakis, Nektarios K.] Beaumont Hosp, Dept Neurosurg, Dublin D09 V2N0, Ireland; [Stebbing, Justin] Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London, England; [Critchley, Giles] Univ Hosp Sussex, Dept Neurosurg, Brighton BN2 5BE, E Sussex, England; [Simon, Thomas] Univ Southern Calif, Keck Sch Med, Dept Translat Genom, Los Angeles, CA 90033 USA	University of Sussex; Sun Yat Sen University; Roche Holding; Genentech; Royal College of Surgeons - Ireland; Imperial College London; University of Southern California	Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	g.giamas@sussex.ac.uk		Simon, Thomas/0000-0002-3280-2716; Stebbing, Justin/0000-0002-1117-6947; Messuti, Eleonora/0000-0002-5613-4337; Lane, Rosemary/0000-0002-9463-8034	Action Against Cancer [ID6758/G1867]	Action Against Cancer	This research was funded by Action Against Cancer, grant number ID6758/G1867.	Albini A, 2015, CONNECT TISSUE RES, V56, P414, DOI 10.3109/03008207.2015.1066780; Ardito F, 2017, INT J MOL MED, V40, P271, DOI 10.3892/ijmm.2017.3036; Arrizabalaga O, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0003-9; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bates A, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2924; Bonnin DAA, 2017, MOL CANCER THER, V16, P705, DOI 10.1158/1535-7163.MCT-16-0616; Chao CC, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.414; Cohen MH, 2005, CLIN CANCER RES, V11, P6767, DOI 10.1158/1078-0432.CCR-05-0722; Collins LM, 2013, NEUROMOL MED, V15, P435, DOI 10.1007/s12017-013-8230-5; Corona SP, 2018, DRUG DES DEV THER, V12, P321, DOI 10.2147/DDDT.S137783; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Dolma S, 2016, CANCER CELL, V29, P859, DOI 10.1016/j.ccell.2016.05.002; Erlichman C, 2006, J CLIN ONCOL, V24, P2252, DOI 10.1200/JCO.2005.01.8960; Floryk D, 2004, CANCER RES, V64, P9049, DOI 10.1158/0008-5472.CAN-04-1553; Garcia-Romero N, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01610-0; Ghosh D, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0211-8; Giamas G, 2007, BIOCHEM J, V406, P389, DOI 10.1042/BJ20070091; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Gupta A, 2017, J NEUROSCI RURAL PRA, V8, P629, DOI 10.4103/jnrp.jnrp_168_17; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hart S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.43; Hoppstadter J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01446; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ishay-Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002; Jeanneteau F, 2010, NAT NEUROSCI, V13, P1373, DOI 10.1038/nn.2655; Kong Ling-Ling, 2017, Chronic Dis Transl Med, V3, P221, DOI 10.1016/j.cdtm.2017.11.001; Lane R, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0560-x; Laser-Azogui A, 2015, CURR OPIN CELL BIOL, V32, P92, DOI 10.1016/j.ceb.2015.01.003; Lehman NL, 2012, CELL CYCLE, V11, P489, DOI 10.4161/cc.11.3.18996; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mei X, 2017, NEURO-ONCOLOGY, V19, P1109, DOI 10.1093/neuonc/nox016; Mikitsh JL, 2014, PERSPECT MED CHEM, V6, P11, DOI 10.4137/PMC.S13384; Nunes M, 2004, MOL CANCER THER, V3, P21; Peinado-Ramon P, 1998, MOL BRAIN RES, V56, P256, DOI 10.1016/S0169-328X(98)00047-3; Perez-Sen R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081999; Raub TJ, 2015, DRUG METAB DISPOS, V43, P1360, DOI 10.1124/dmd.114.062745; Roberts WG, 2005, CANCER RES, V65, P957; Sestito S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00874; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Simon T, 2017, TRENDS MOL MED, V23, P282, DOI 10.1016/j.molmed.2017.01.002; Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8; Singh SK, 2003, CANCER RES, V63, P5821; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Song K, 2018, AM J CANCER RES, V8, P792; Stebbing J, 2018, ONCOGENE, V37, P3113, DOI 10.1038/s41388-018-0197-0; Taylor OG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00963; Van Brocklyn JR, 2014, CANCER RES, V74, P5364, DOI 10.1158/0008-5472.CAN-14-0386; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; William AD, 2011, J MED CHEM, V54, P4638, DOI 10.1021/jm200326p; Xing F, 2017, CELL REP, V18, P468, DOI 10.1016/j.celrep.2016.12.037; Xu WP, 2014, J DIGEST DIS, V15, P159, DOI 10.1111/1751-2980.12122; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	56	0	0	4	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2749	2763		10.1038/s41388-022-02294-x	http://dx.doi.org/10.1038/s41388-022-02294-x		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393545	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000779227700001
J	Shi, CX; Tao, SS; Ren, GW; Yang, EJ; Shu, XD; Mou, PK; Liu, YF; Dang, YJ; Xu, XL; Shim, JS				Shi, Changxiang; Tao, Shishi; Ren, Guowen; Yang, Eun Ju; Shu, Xiaodong; Mou, Pui Kei; Liu, Yifan; Dang, Yongjun; Xu, Xiaoling; Shim, Joong Sup			Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation	ONCOGENE			English	Article							TGF-BETA; CHROMOSOMAL INSTABILITY; A KINASE; CENP-E; SMAD4; PHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION; SEGREGATION; EXPRESSION	SMAD4 loss-of-function mutations have been frequently observed in colorectal cancer (CRC) and are recognized as a drug target for therapeutic exploitation. In this study, we performed a synthetic lethal drug screening with SMAD4-isogenic CRC cells and found that aurora kinase A (AURKA) inhibition is synthetic lethal with SMAD4 loss. Inhibition of AURKA selectively inhibited the growth of SMAD4(-/-) CRC in vitro and in vivo. Mechanistically, SMAD4 negatively regulated AURKA level, resulting in the significant elevation of AURKA in SMAD4(-/-) CRC cells. Inhibition of AURKA induced G(2)/M cell cycle delay in SMAD4(+/+) CRC cells, but induced apoptosis in SMAD4(-/-) CRC cells. We further observed that a high level of AURKA in SMAD4(-/-) CRC cells led to abnormal mitotic spindles, leading to cellular aneuploidy. Moreover, SMAD4(-/-) CRC cells expressed high levels of spindle assembly checkpoint (SAC) proteins, suggesting the hyperactivation of SAC. The silencing of key SAC proteins significantly rescued the AURKA inhibition-induced cell death in SMAD4(-/-) cells, suggesting that SMAD4(-/-) CRC cells are hyper-dependent on AURKA activity for mitotic exit and survival during SAC hyperactivation. This study presents a unique synthetic lethal interaction between SMAD4 and AURKA and suggests that AURKA could be a potential drug target in SMAD4-deficient CRC.	[Shi, Changxiang; Tao, Shishi; Ren, Guowen; Yang, Eun Ju; Shu, Xiaodong; Mou, Pui Kei; Liu, Yifan; Xu, Xiaoling; Shim, Joong Sup] Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China; [Shi, Changxiang; Tao, Shishi; Ren, Guowen; Yang, Eun Ju; Shu, Xiaodong; Mou, Pui Kei; Liu, Yifan; Xu, Xiaoling; Shim, Joong Sup] Univ Macau, MOE Frontiers Sci Ctr Precis Oncol, Taipa, Macau, Peoples R China; [Shi, Changxiang] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Womens Hosp, Nanjing Matern & Child Hlth Care Inst, Nanjing, Peoples R China; [Dang, Yongjun] Chongqing Med Univ, Inst Life Sci, Ctr Novel Target & Therapeut Intervent, Chongqing, Peoples R China	University of Macau; University of Macau; Nanjing Medical University; Chongqing Medical University	Shim, JS (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China.; Shim, JS (corresponding author), Univ Macau, MOE Frontiers Sci Ctr Precis Oncol, Taipa, Macau, Peoples R China.	jsshim@um.edu.mo	Shim, Joong Sup/G-8383-2011	Shim, Joong Sup/0000-0003-0167-7307	Science and Technology Development Fund, Macau SAR [FDCT/0107/2020/A, FDCT/0030/2020/A]; Multi-Year Research Grant, University of Macau [MYRG2019-00116-FHS, MYRG2020-00229-FHS]	Science and Technology Development Fund, Macau SAR; Multi-Year Research Grant, University of Macau	This study was supported by Science and Technology Development Fund, Macau SAR (FDCT/0107/2020/A and FDCT/0030/2020/A to JSS), and the Multi-Year Research Grant, University of Macau (MYRG2019-00116-FHS and MYRG2020-00229-FHS to JSS).	Alfieri C, 2016, NATURE, V536, P431, DOI 10.1038/nature19083; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Boult JKR, 2012, BRIT J CANCER, V106, P1960, DOI 10.1038/bjc.2012.208; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheerambathur DK, 2013, SCIENCE, V342, P1239, DOI 10.1126/science.1246232; Davies RJ, 2005, NAT REV CANCER, V5, P199, DOI 10.1038/nrc1569; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jia L, 2014, MOL CANCER RES, V12, P1779, DOI 10.1158/1541-7786.MCR-14-0191; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kawaguchi Y, 2019, CLIN CANCER RES, V25, P5843, DOI 10.1158/1078-0432.CCR-19-0863; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lara-Gonzalez P, 2012, CURR BIOL, V22, pR966, DOI 10.1016/j.cub.2012.10.006; Lee JW, 2019, CLIN CANCER RES, V25, P3430, DOI 10.1158/1078-0432.CCR-18-0440; Lee S, 2011, CANCER RES, V71, P3225, DOI 10.1158/0008-5472.CAN-10-2167; Lheureux S, 2018, CLIN CANCER RES, V24, P6168, DOI 10.1158/1078-0432.CCR-18-1244; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Lyu J., 2020, NAT COMMUN, V11; Maia ARR, 2014, NAT CELL BIOL, V16, P739, DOI 10.1038/ncb3018; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Montal R, 2020, J HEPATOL, V73, P315, DOI 10.1016/j.jhep.2020.03.008; Mou PK, 2021, EXP MOL MED, V53, P835, DOI 10.1038/s12276-021-00635-6; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Musacchio A, 2015, CURR BIOL, V25, pR1002, DOI 10.1016/j.cub.2015.08.051; O'Connor OA, 2019, J CLIN ONCOL, V37, P613, DOI 10.1200/JCO.18.00899; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Shi CX, 2021, ONCOGENE, V40, P937, DOI 10.1038/s41388-020-01580-w; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tagal V, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14098; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wang H, 2006, CANCER RES, V66, P9722, DOI 10.1158/0008-5472.CAN-05-4602; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wu CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05694-4; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhang C, 2010, ACTA BIOCH BIOPH SIN, V42, P834, DOI 10.1093/abbs/gmq088; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu JW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58051-1; 2014, BRIT J CANCER, V110, P946	63	0	0	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2734	2748		10.1038/s41388-022-02293-y	http://dx.doi.org/10.1038/s41388-022-02293-y		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393542				2022-12-17	WOS:000779227700002
J	Sala, M; Allain, N; Moreau, M; Jabouille, A; Henriet, E; Abou-Hammoud, A; Uguen, A; Di-Tommaso, S; Dourthe, C; Raymond, AA; Dupuy, JW; Gerard, E; Dugot-Senant, N; Rousseau, B; Merlio, JP; Pham-Ledart, A; Vergier, B; Tartare-Deckert, S; Moreau, V; Saltel, F				Sala, Margaux; Allain, Nathalie; Moreau, Melanie; Jabouille, Arnaud; Henriet, Elodie; Abou-Hammoud, Aya; Uguen, Arnaud; Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Dupuy, Jean-William; Gerard, Emilie; Dugot-Senant, Nathalie; Rousseau, Benoit; Merlio, Jean-Phillipe; Pham-Ledart, Anne; Vergier, Beatrice; Tartare-Deckert, Sophie; Moreau, Violaine; Saltel, Frederic			Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation	ONCOGENE			English	Article							DOWN-REGULATION; DDR1; INHIBITION; METASTASIS; ACTIVATION; MUTATIONS; DISCOVERY; FAMILY; CANCER; GENE	Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.	[Sala, Margaux; Allain, Nathalie; Moreau, Melanie; Jabouille, Arnaud; Henriet, Elodie; Abou-Hammoud, Aya; Uguen, Arnaud; Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Moreau, Violaine; Saltel, Frederic] BoRdeaux Inst OnCol, BRIC, UMR1312, INSERM, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Sala, Margaux; Allain, Nathalie; Moreau, Melanie; Jabouille, Arnaud; Henriet, Elodie; Abou-Hammoud, Aya; Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Moreau, Violaine; Saltel, Frederic] Bordeaux Univ, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Uguen, Arnaud] Brest Univ Hosp Ctr, Dept Pathol, F-29200 Brest, France; [Di-Tommaso, Sylvaine; Dourthe, Cyril; Raymond, Anne-Aurelie; Saltel, Frederic] UMS 005, Oncoprot, F-33076 Bordeaux, France; [Dupuy, Jean-William] Bordeaux Univ, Plateforme Proteome, F-33000 Bordeaux, France; [Gerard, Emilie] Bordeaux Univ Hosp, Dermatol Dept, 1 Ave Jean Burguet, F-33000 Bordeaux, France; [Dugot-Senant, Nathalie] Histol Plateforme, UMS 005, F-33076 Bordeaux, France; [Rousseau, Benoit] Bordeaux Univ, Common Anim Housing Serv, F-33076 Bordeaux, France; [Merlio, Jean-Phillipe; Pham-Ledart, Anne; Vergier, Beatrice] Bordeaux Res Translat Oncol, Cutaneous Lymphoma Oncogenesis, BaRITOn, INSERM,UMR1053,Team 3, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Merlio, Jean-Phillipe; Pham-Ledart, Anne; Vergier, Beatrice] Bordeaux Univ Hosp, Tumor Bank & Tumor Biol Lab, Ave Magellan, F-33604 Pessac, France; [Tartare-Deckert, Sophie] Univ Cote dAzur, C3M, INSERM, F-06204 Nice, France; [Henriet, Elodie] Johns Hopkins Univ, Sch Med, Ewalds Lab, Dept Cell Biol, Baltimore, MD USA; [Abou-Hammoud, Aya] Bordeaux Univ, MFP, UMR 5234, 146 Rue Leo Saignat, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Brest; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Johns Hopkins University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Saltel, F (corresponding author), BoRdeaux Inst OnCol, BRIC, UMR1312, INSERM, 146 Rue Leo Saignat, F-33076 Bordeaux, France.; Saltel, F (corresponding author), Bordeaux Univ, 146 Rue Leo Saignat, F-33076 Bordeaux, France.; Saltel, F (corresponding author), UMS 005, Oncoprot, F-33076 Bordeaux, France.	frederic.saltel@inserm.fr	JABOUILLE, Arnaud/ABC-5823-2020; TARTARE-DECKERT, Sophie/P-6057-2015; Dupuy, Jean-William JWD/F-5335-2012	JABOUILLE, Arnaud/0000-0002-2281-430X; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Dupuy, Jean-William JWD/0000-0002-2448-4797; Moreau, Violaine/0000-0002-4513-7022; Sala, Margaux/0000-0003-3483-361X; saltel, frederic/0000-0002-0724-9680	Inca (PLBIO Inca) [PLBIO15-135]; SIRIC BRIO 2; Fondation de France; FRM, equipe labellisee [DEQ20180839586]; French ministere superieur de l'enseignement et de la recherche	Inca (PLBIO Inca); SIRIC BRIO 2; Fondation de France(Fondation de France); FRM, equipe labellisee; French ministere superieur de l'enseignement et de la recherche	This work is supported by Inca (PLBIO Inca, PLBIO15-135), SIRIC BRIO 2, Fondation de France, FRM, equipe labellisee (grant number DEQ20180839586). Margaux Sala is financed by a PhD grant from the French ministere superieur de l'enseignement et de la recherche.	Ambrogio C, 2016, NAT MED, V22, P270, DOI 10.1038/nm.4041; Arozarena I, 2019, NAT REV CANCER, V19, P377, DOI 10.1038/s41568-019-0154-4; Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Badiola I, 2011, ONCOL REP, V26, P971, DOI 10.3892/or.2011.1356; Basile KJ, 2014, PIGM CELL MELANOMA R, V27, P479, DOI 10.1111/pcmr.12218; Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008-5472.CAN-06-1215; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Day E, 2008, EUR J PHARMACOL, V599, P44, DOI 10.1016/j.ejphar.2008.10.014; de Moura CR, 2019, PIGM CELL MELANOMA R, V32, P697, DOI 10.1111/pcmr.12809; Deutsch EW, 2020, NUCLEIC ACIDS RES, V48, pD1145, DOI 10.1093/nar/gkz984; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; El Azreq MA, 2016, ONCOTARGET, V7, P44975, DOI 10.18632/oncotarget.10455; Gao MS, 2013, J MED CHEM, V56, P3281, DOI 10.1021/jm301824k; Girard CA, 2020, CANCER RES, V80, P1927, DOI 10.1158/0008-5472.CAN-19-2914; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Grither WR, 2018, P NATL ACAD SCI USA, V115, pE7786, DOI 10.1073/pnas.1805020115; Grither WR, 2018, ONCOGENE, V37, P1714, DOI 10.1038/s41388-017-0043-9; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Hartman ML, 2015, CELL MOL LIFE SCI, V72, P1249, DOI 10.1007/s00018-014-1791-0; Hedberg ML, 2016, J CLIN INVEST, V126, P169, DOI 10.1172/JCI82066; Henriet E, 2018, CELL ADHES MIGR, V12, P363, DOI 10.1080/19336918.2018.1465156; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Juin A, 2014, J CELL BIOL, V207, P517, DOI 10.1083/jcb.201404079; Juin A, 2012, MOL BIOL CELL, V23, P297, DOI 10.1091/mbc.E11-07-0594; Keating GM, 2017, DRUGS, V77, P85, DOI 10.1007/s40265-016-0677-x; Kim HG, 2013, ACS CHEM BIOL, V8, P2145, DOI 10.1021/cb400430t; Korshunov VA, 2012, CLIN SCI, V122, P361, DOI 10.1042/CS20110411; Kurashige J, 2016, SCI REP-UK, V6, DOI 10.1038/srep22371; Larkin JMG, 2015, J CLIN ONCOL, V33; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Misek SA, 2020, ONCOGENE, V39, P1466, DOI 10.1038/s41388-019-1074-1; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Park JW, 2015, J CANCER RES CLIN, V141, P1973, DOI 10.1007/s00432-015-1967-5; Rammal H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00055; Ren TT, 2014, J PATHOL, V234, P526, DOI 10.1002/path.4415; Ren TT, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0397-3; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Sullivan RJ, 2013, EUR J CANCER, V49, P1297, DOI 10.1016/j.ejca.2012.11.019; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Valiathan RR, 2012, CANCER METAST REV, V31, P295, DOI 10.1007/s10555-012-9346-z; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wagenaar TR, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12171; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Wang YG, 2016, DIGEST DIS SCI, V61, P2272, DOI 10.1007/s10620-016-4116-3; Xie BH, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0218-6	52	0	0	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2571	2586		10.1038/s41388-022-02266-1	http://dx.doi.org/10.1038/s41388-022-02266-1		MAR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35322197				2022-12-17	WOS:000772273600002
J	Zhang, H; Ma, RR; Wang, XJ; Su, ZX; Chen, X; Shi, DB; Guo, XY; Liu, HT; Gao, P				Zhang, H.; Ma, R-R; Wang, X-J; Su, Z-X; Chen, X.; Shi, D-B; Guo, X-Y; Liu, H-T; Gao, P.			KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer (vol 36, 5609, 2017)	ONCOGENE			English	Correction												gaopeng@sdu.edu.cn						Zhang H, 2017, ONCOGENE, V36, P5609, DOI 10.1038/onc.2017.163	1	0	0	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2528	2528		10.1038/s41388-022-02268-z	http://dx.doi.org/10.1038/s41388-022-02268-z		MAR 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35322198	Bronze			2022-12-17	WOS:000772273600001
J	Humbert, PO; Pryjda, TZ; Pranjic, B; Farrell, A; Fujikura, K; Simoes, RD; Karim, R; Kozieradzki, I; Cronin, SJF; Neely, GG; Meyer, TF; Hagelkruys, A; Richardson, HE; Penninger, JM				Humbert, Patrick O.; Pryjda, Tamara Zoranovic; Pranjic, Blanka; Farrell, Andrew; Fujikura, Kohei; de Matos Simoes, Ricardo; Karim, Rezaul; Kozieradzki, Ivona; Cronin, Shane J. F.; Neely, G. Gregory; Meyer, Thomas F.; Hagelkruys, Astrid; Richardson, Helena E.; Penninger, Josef M.			TSPAN6 is a suppressor of Ras-driven cancer (Feb, 10.1038/s41388-022-02223-y, 2022)	ONCOGENE			English	Correction												P.Humbert@latrobe.edu.au; H.Richardson@latrobe.edu.au; josef.penninger@ubc.ca	Humbert, Patrick/L-4264-2016	Humbert, Patrick/0000-0002-1366-6691; zoranovic, tamara/0000-0002-5369-6385				Humbert PO, 2022, ONCOGENE, V41, P2095, DOI 10.1038/s41388-022-02223-y	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2138	2138		10.1038/s41388-022-02265-2	http://dx.doi.org/10.1038/s41388-022-02265-2		MAR 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35292775	hybrid, Green Published			2022-12-17	WOS:000769296900002
J	Yu, S; Liu, CA; Hou, YT; Li, J; Guo, ZM; Chen, XW; Zhang, LY; Peng, S; Hong, SB; Xu, LX; Li, XX; Liu, RY; Chen, SW; Li, B; Weng, ZP; Li, YB; Lv, WM; Yu, J; Xiao, HP				Yu, Shuang; Liu, Changan; Hou, Yingtong; Li, Jie; Guo, Zhuming; Chen, Xinwen; Zhang, Luyao; Peng, Sui; Hong, Shubin; Xu, Lixia; Li, Xiaoxing; Liu, Rengyun; Chen, Shuwei; Li, Bin; Weng, Zongpeng; Li, Yanbing; Lv, Weiming; Yu, Jun; Xiao, Haipeng			Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer	ONCOGENE			English	Article							NEEDLE-ASPIRATION-CYTOLOGY; INCREASING INCIDENCE; LARGE-SCALE; SERUM; MICROCARCINOMA; ASSOCIATION; LIMITATIONS; ULTRASOUND; BIOMARKERS; BLOOD	Discrimination of malignancy from thyroid nodules poses challenges in clinical practice. We aimed to identify the plasma metabolomic biomarkers in discriminating papillary thyroid cancer (PTC) from benign thyroid nodule (BTN). Metabolomics profiling of plasma was performed in two independent cohorts of 651 subjects of PTC (n = 215), BTN (n = 230), and healthy controls (n = 206). In addition, 132 patients with thyroid micronodules (<1 cm) and 44 patients with BTN suspected malignancy by ultrasound were used for biomarker validation. Recursive feature elimination algorithm was used for metabolic biomarkers selecting. Significant differential metabolites were demonstrated in patients with thyroid nodules (PTC and BTN) from healthy controls (P = 0.0001). A metabolic biomarker panel (17 differential metabolites) was identified to discriminate PTC from BTN with an AUC of 97.03% (95% CI: 95.28-98.79%), 91.89% sensitivity, and 92.63% specificity in discovery cohort. The panel had an AUC of 92.72% (95% CI: 87.46-97.99%), 86.57% sensitivity, and 92.50% specificity in validation cohort. The metabolic biomarker signature could correctly identify 84.09% patients whose nodules were suspected malignant by ultrasonography but finally histological benign. Moreover, high accuracy of 87.88% for diagnosis of papillary thyroid microcarcinoma was displayed by this panel and showed significant improvement in accuracy, AUC and specificity when compared with ultrasound. We identified a novel metabolic biomarker signature to discriminate PTC from BTN. The clinical use of this biomarker panel would have improved diagnosis stratification of thyroid microcarcinoma in comparison to ultrasound.	[Yu, Shuang; Hou, Yingtong; Chen, Xinwen; Zhang, Luyao; Hong, Shubin; Li, Yanbing; Xiao, Haipeng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China; [Liu, Changan; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Liu, Changan; Yu, Jun] Chinese Univ Hong Kong, State Key Lab Digest Dis, Dept Med & Therapeut, Hong Kong, Peoples R China; [Li, Jie; Lv, Weiming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Guangzhou, Peoples R China; [Guo, Zhuming; Chen, Shuwei] Sun Yat Sen Univ, Canc Ctr, Dept Head & Neck Surg, Guangzhou, Peoples R China; [Peng, Sui; Li, Bin; Weng, Zongpeng] Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Peoples R China; [Peng, Sui; Xu, Lixia; Li, Xiaoxing; Liu, Rengyun] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China; [Xu, Lixia] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China	Sun Yat Sen University; Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xiao, HP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Dept Med & Therapeut, Hong Kong, Peoples R China.; Lv, WM (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Guangzhou, Peoples R China.	lvwm@mail.sysu.edu.cn; junyu@cuhk.edu.hk; xiaohp@mail.sysu.edu.cn	Li, Xiao-xing/B-9114-2008; Liu, Rengyun/O-4039-2018; li, yan/GTI-4638-2022	Li, Xiao-xing/0000-0001-8791-7505; Liu, Rengyun/0000-0002-1408-2372; Li, Jie/0000-0003-1232-3248				Abooshahab R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00385; Abraham A, 2019, CRIT REV FOOD SCI, V59, P2831, DOI 10.1080/10408398.2018.1474169; Banales JM, 2019, HEPATOLOGY, V70, P547, DOI 10.1002/hep.30319; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brito JP, 2014, J CLIN ENDOCR METAB, V99, P1253, DOI 10.1210/jc.2013-2928; Burman KD, 2015, NEW ENGL J MED, V373, P2347, DOI 10.1056/NEJMcp1415786; Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6; Cao ST, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-4544; Chen J, 2019, ENDOCR-RELAT CANCER, V26, P829, DOI 10.1530/ERC-19-0344; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng YR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20877-8; Chong Jasmine, 2019, Curr Protoc Bioinformatics, V68, pe86, DOI 10.1002/cpbi.86; Chong J, 2019, METABOLITES, V9, DOI 10.3390/metabo9030057; Cibas ES, 2013, ANN INTERN MED, V159, P325, DOI 10.7326/0003-4819-159-5-201309030-00006; Cradic KW, 2009, J CLIN ENDOCR METAB, V94, P5001, DOI 10.1210/jc.2009-1349; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Davies L, 2015, ENDOCR PRACT, V21, P686, DOI 10.4158/EP14466.DSCR; de Meer SGA, 2012, DIAGN CYTOPATHOL, V40, pE21, DOI 10.1002/dc.21521; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Fussey JM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00132; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hofland J, 2018, NAT REV ENDOCRINOL, V14, P656, DOI 10.1038/s41574-018-0082-5; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Hu SY, 2006, J CLIN ENDOCR METAB, V91, P98, DOI 10.1210/jc.2005-1810; Huang FQ, 2019, INT J CANCER, V144, P868, DOI 10.1002/ijc.31925; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Klubo-Gwiezdzinska J, 2018, J CLIN ENDOCR METAB, V103, P3507, DOI 10.1210/jc.2018-01081; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Lamartina L, 2020, LANCET DIABETES ENDO, V8, P81, DOI 10.1016/S2213-8587(19)30324-9; Leboulleux S, 2016, LANCET DIABETES ENDO, V4, P933, DOI 10.1016/S2213-8587(16)30180-2; Lee JC, 2013, CANCER-AM CANCER SOC, V119, P4358, DOI 10.1002/cncr.28254; Li JK, 2019, GASTROENTEROLOGY, V157, P257, DOI 10.1053/j.gastro.2019.03.020; Luo P, 2018, HEPATOLOGY, V67, P662, DOI 10.1002/hep.29561; Ma HJ, 2017, ACTA RADIOL, V58, P1303, DOI 10.1177/0284185117692167; Manning AM, 2017, OTOLARYNG HEAD NECK, V156, P611, DOI 10.1177/0194599816688190; Mayerle J, 2018, GUT, V67, P128, DOI 10.1136/gutjnl-2016-312432; Mazeh H, 2011, NAT REV ENDOCRINOL, V7, P581, DOI 10.1038/nrendo.2011.140; Nikiforova MN, 2018, CANCER-AM CANCER SOC, V124, P1682, DOI 10.1002/cncr.31245; Nishino M, 2018, ARCH PATHOL LAB MED, V142, P446, DOI 10.5858/arpa.2017-0174-RA; Nixon AM, 2017, CLIN ENDOCRINOL, V87, P117, DOI 10.1111/cen.13369; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Stevens VL, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1393-1; Steward DL, 2019, JAMA ONCOL, V5, P204, DOI 10.1001/jamaoncol.2018.4616; Tessler FN, 2017, J AM COLL RADIOL, V14, P587, DOI 10.1016/j.jacr.2017.01.046; Valvo V, 2021, THYROID, V31, P1335, DOI 10.1089/thy.2020.0311; Wada N, 2003, ANN SURG, V237, P399, DOI 10.1097/00000658-200303000-00015; Wagner K, 2005, J CLIN ENDOCR METAB, V90, P1921, DOI 10.1210/jc.2004-1793; Xu SL, 2020, CLIN ENDOCRINOL, V93, P489, DOI 10.1111/cen.14217; Yang RN, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.598225; Yekta RF, 2018, IRAN J BASIC MED SCI, V21, P1140, DOI 10.22038/IJBMS.2018.30375.7323; Yu XM, 2011, ANN SURG, V254, P653, DOI 10.1097/SLA.0b013e318230036d	55	0	0	11	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2422	2430		10.1038/s41388-022-02254-5	http://dx.doi.org/10.1038/s41388-022-02254-5		MAR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35279704				2022-12-17	WOS:000767909000001
J	Komatsu, M; Nakamura, K; Takeda, T; Chiwaki, F; Banno, K; Aoki, D; Takeshita, F; Sasaki, H				Komatsu, Masayuki; Nakamura, Kanako; Takeda, Takashi; Chiwaki, Fumiko; Banno, Kouji; Aoki, Daisuke; Takeshita, Fumitaka; Sasaki, Hiroki			Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; TYROSINE KINASE; LUNG-CANCER; INHIBITOR; THERAPY; HEAD; NECK; OVEREXPRESSION	Oncogenic signalling confers tumour-progression advantages; thus, its pharmacological blockade is the best strategy for cancer chemotherapy. However, drug resistance and heterogeneous dependency of tumour hamper their therapeutic potential, suggesting the necessity for a new ubiquitous modality based on evading drug resistance. Here, we proposed a denovoaddiction to oncogenic signalling (Dead-On) concept, wherein specific blockade of target molecules forces cancer cells to develop dependency on an oncogenic signalling. In cervical squamous cell carcinoma cells, Aurora A/B dual blockade elicited rapid addiction to EGFR-Erk signalling, and its pharmacological/genetic inhibition synergistically enhanced anti-cancer activities in vitro, in vivo, and in a patient-derived organoid model. The signal activation was independent of EGFR genetic status, it was triggered by receptor accumulation on the plasma membrane via Rab11-mediated endocytic recycling machinery. These findings support our novel Dead-On concept which may lead to drug discovery as well as expand the adaptation of approved targeted drugs.	[Komatsu, Masayuki; Chiwaki, Fumiko; Takeshita, Fumitaka; Sasaki, Hiroki] Natl Canc Ctr, Dept Translat Oncol, Tokyo, Japan; [Nakamura, Kanako; Takeda, Takashi; Banno, Kouji; Aoki, Daisuke] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan	National Cancer Center - Japan; Keio University	Komatsu, M; Sasaki, H (corresponding author), Natl Canc Ctr, Dept Translat Oncol, Tokyo, Japan.	makomats@ncc.go.jp; hksasaki@ncc.go.jp	Takeda, Takashi/AAB-1391-2019	Takeda, Takashi/0000-0001-6686-5742; Chiwaki, Fumiko/0000-0002-0914-9157; Komatsu, Masayuki/0000-0003-1180-1746; BANNO, KOUJI/0000-0003-2610-2833	Pfizer [WO195177]; National Cancer Center Research and Development Fund [28-A-11, 29-A-2]	Pfizer(Pfizer); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	This work was supported by Pfizer Investigator-Initiated Research (WO195177) Program and by the National Cancer Center Research and Development Fund (28-A-11, 29-A-2). We would like to thank Editage (www.editage.com) for English language editing.	Arjonen A, 2012, TRAFFIC, V13, P610, DOI 10.1111/j.1600-0854.2012.01327.x; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Barsouk A., 2019, MED SCI, V7, P1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carlton JG, 2012, SCIENCE, V336, P220, DOI 10.1126/science.1217180; Carvajal RD, 2006, CLIN CANCER RES, V12, P6869, DOI 10.1158/1078-0432.CCR-06-1405; Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-84; Cortot AB, 2013, CANCER RES, V73, P834, DOI 10.1158/0008-5472.CAN-12-2066; Crafton SM, 2016, CLIN THER, V38, P449, DOI 10.1016/j.clinthera.2016.02.007; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010; Flaherty KT, 2020, JNCI-J NATL CANCER I, V112, DOI 10.1093/jnci/djz245; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Fukuoka S, 2017, ONCOTARGET, V8, P11020, DOI 10.18632/oncotarget.14209; Gabrielli B, 2015, MOL CANCER THER, V14, P2753, DOI 10.1158/1535-7163.MCT-15-0506; Gao ML, 2012, EMBO MOL MED, V4, P776, DOI 10.1002/emmm.201100944; Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Gonzalez-Loyola A, 2015, MOL CELL BIOL, V35, P3566, DOI 10.1128/MCB.01286-14; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hehnly H, 2014, DEV CELL, V28, P497, DOI 10.1016/j.devcel.2014.01.014; Hochegger H, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120185; Huang XF, 2008, BLOOD, V111, P2854, DOI 10.1182/blood-2007-07-099325; Jani JP, 2010, MOL CANCER THER, V9, P883, DOI 10.1158/1535-7163.MCT-09-0915; Jonker CTH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.231225; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li LK, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam7479; Lim SM, 2018, CANCER TREAT REV, V65, P1, DOI 10.1016/j.ctrv.2018.02.006; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lin G, 2015, ONCOL LETT, V10, P901, DOI 10.3892/ol.2015.3277; Lin L, 2019, CANCERS, V11, DOI 10.3390/cancers11081156; Lou K, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9450; Lowenberg B, 2011, BLOOD, V118, P6030, DOI 10.1182/blood-2011-07-366930; Madshus IH, 2009, J CELL SCI, V122, P3433, DOI 10.1242/jcs.050260; McLornan DP, 2014, NEW ENGL J MED, V371, P1725, DOI 10.1056/NEJMra1407390; Mehra Ranee, 2008, Clin Adv Hematol Oncol, V6, P742; Melichar B, 2015, LANCET ONCOL, V16, P395, DOI 10.1016/S1470-2045(15)70051-3; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schilder RJ, 2009, INT J GYNECOL CANCER, V19, P929, DOI 10.1111/IGC.0b013e3181a83467; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Song HN, 2016, J THORAC ONCOL, V11, pE45, DOI 10.1016/j.jtho.2015.12.093; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Thalappilly S, 2010, ONCOGENE, V29, P2528, DOI 10.1038/onc.2010.1; Thomas R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00800; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Twu NF, 2009, EUR J OBSTET GYN R B, V142, P57, DOI 10.1016/j.ejogrb.2008.09.012; Vojnic M, 2019, J THORAC ONCOL, V14, P802, DOI 10.1016/j.jtho.2018.12.038; Vora C, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000462; Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176; Wang SH, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0268-z; Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x; Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044	65	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2326	2339		10.1038/s41388-022-02256-3	http://dx.doi.org/10.1038/s41388-022-02256-3		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35250028				2022-12-17	WOS:000765203000001
J	Sun, R; Lei, C; Chen, L; He, LQ; Guo, HX; Zhang, X; Feng, WK; Yan, J; McClain, CJ; Deng, ZB				Sun, Rui; Lei, Chao; Chen, Liang; He, Liqing; Guo, Haixun; Zhang, Xiang; Feng, Wenke; Yan, Jun; McClain, Craig J.; Deng, Zhongbin			Alcohol-driven metabolic reprogramming promotes development of ROR gamma t-deficient thymic lymphoma	ONCOGENE			English	Article							C-MYC; GLUTAMINE-METABOLISM; MTOR; INHIBITION; EXPRESSION; PROTEIN; DIFFERENTIATION; REQUIREMENT; ADAPTATION; GLYCOLYSIS	ROR gamma t is a master regulator of Th17 cells. Despite evidence linking ROR gamma t deficiency/inhibition with metastatic thymic T cell lymphomas, the role of ROR gamma t in lymphoma metabolism is unknown. Chronic alcohol consumption plays a causal role in many human cancers. The risk of T cell lymphoma remains unclear in humans with alcohol use disorders (AUD) after chronic ROR gamma t inhibition. Here we demonstrated that alcohol consumption accelerates ROR gamma t deficiency-induced lymphomagenesis. Loss of ROR gamma t signaling in the thymus promotes aerobic glycolysis and glutaminolysis and increases allocation of glutamine carbon into lipids. Importantly, alcohol consumption results in a shift from aerobic glycolysis to glutaminolysis. Both ROR gamma t deficiency- and alcohol-induced metabolic alterations are mediated by c-Myc, as silencing of c-Myc decreases the effects of alcohol consumption and ROR gamma t deficiency on glutaminolysis, biosynthesis, and tumor growth in vivo. The ethanol-mediated c-Myc activation coupled with increased glutaminolysis underscore the critical role of ROR gamma t-Myc signaling and translation in lymphoma.	[Sun, Rui; Lei, Chao; Chen, Liang; Yan, Jun; Deng, Zhongbin] Univ Louisville, Dept Surg, Div Immunotherapy, Louisville, KY 40292 USA; [Sun, Rui] Huazhong Univ Sci & Technol, Wuhan Hosp 4, Puai Hosp, Tongji Med Coll,Dept Oncol, Wuhan 430033, Peoples R China; [Sun, Rui; Lei, Chao; Chen, Liang; Yan, Jun; Deng, Zhongbin] Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA; [He, Liqing; Zhang, Xiang] Univ Louisville, Dept Chem, Louisville, KY 40292 USA; [Guo, Haixun] Univ Louisville, Dept Radiol, Louisville, KY 40292 USA; [Zhang, Xiang; Feng, Wenke; McClain, Craig J.; Deng, Zhongbin] Univ Louisville, Alcohol Res Ctr, Louisville, KY 40292 USA; [Zhang, Xiang; Feng, Wenke; McClain, Craig J.; Deng, Zhongbin] Univ Louisville, Hepatobiol & Toxicol Ctr, Louisville, KY 40292 USA; [Feng, Wenke; McClain, Craig J.] Univ Louisville, Dept Med, Louisville, KY 40292 USA; [McClain, Craig J.] Robley Rex VA Med Ctr, Louisville, KY USA	University of Louisville; Huazhong University of Science & Technology; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville	Deng, ZB (corresponding author), Univ Louisville, Dept Surg, Div Immunotherapy, Louisville, KY 40292 USA.; Deng, ZB (corresponding author), Univ Louisville, Brown Canc Ctr, Louisville, KY 40292 USA.; Deng, ZB (corresponding author), Univ Louisville, Alcohol Res Ctr, Louisville, KY 40292 USA.; Deng, ZB (corresponding author), Univ Louisville, Hepatobiol & Toxicol Ctr, Louisville, KY 40292 USA.	z0deng01@louisville.edu	Yan, Jun/A-8988-2008; Guo, Haixun/GYR-1920-2022; Lei, Chao/AFK-3169-2022	Guo, Haixun/0000-0002-9702-5444; Lei, Chao/0000-0002-5220-086X	NIH [R21AA025724, R21AI128206, R21AI159194, R01 DK115406, P50AA024337, P20GM113226]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the NIH R21AA025724, R21AI128206, R21AI159194 and R01 DK115406 (ZD), and NIH P50AA024337, P20GM113226, (CJM). We thank Dr. J. Ainsworth for editorial assistance.	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Choi WM, 2019, CELL METAB, V30, P877, DOI 10.1016/j.cmet.2019.08.001; Chu SH, 2021, HEPATOLOGY, V73, P952, DOI 10.1002/hep.31321; Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Evangelisti C, 2011, LEUKEMIA, V25, P781, DOI 10.1038/leu.2011.20; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao YH, 2019, GUT, V68, P1311, DOI 10.1136/gutjnl-2018-316221; Gu Y, 2017, CANCER CELL, V32, P115, DOI 10.1016/j.ccell.2017.06.001; Guntermann C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91127; Guo YX, 2016, CELL REP, V17, P3206, DOI 10.1016/j.celrep.2016.11.073; He YW, 2000, J IMMUNOL, V164, P5668, DOI 10.4049/jimmunol.164.11.5668; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jun S, 2021, CELL METAB, V33, P1777, DOI 10.1016/j.cmet.2021.07.016; Kalaitzidis D, 2012, CELL STEM CELL, V11, P429, DOI 10.1016/j.stem.2012.06.009; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kishton RJ, 2016, CELL METAB, V23, P649, DOI 10.1016/j.cmet.2016.03.008; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Liljevald M, 2016, AUTOIMMUN REV, V15, P1062, DOI 10.1016/j.autrev.2016.07.036; Ma HY, 2020, J HEPATOL, V72, P946, DOI 10.1016/j.jhep.2019.12.016; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mak TW, 2017, IMMUNITY, V46, P675, DOI 10.1016/j.immuni.2017.03.019; Nevzorova YA, 2016, J HEPATOL, V64, P628, DOI 10.1016/j.jhep.2015.11.005; Odera JO, 2020, BIOCHEM J, V477, P3075, DOI 10.1042/BCJ20200452; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pollizzi KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121710; Ramstead AG, 2020, CELL REP, V30, P2889, DOI 10.1016/j.celrep.2020.02.042; Scheepstra M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9833; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shao T, 2018, J HEPATOL, V69, P886, DOI 10.1016/j.jhep.2018.05.021; Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Ueda E, 2002, CANCER RES, V62, P901; Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xiao S, 2014, IMMUNITY, V40, P477, DOI 10.1016/j.immuni.2014.04.004; Yang K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9818; Zakhari S, 2007, HEPATOLOGY, V46, P2032, DOI 10.1002/hep.22010	46	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2287	2302		10.1038/s41388-022-02257-2	http://dx.doi.org/10.1038/s41388-022-02257-2		MAR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35246617	Green Accepted			2022-12-17	WOS:000764592500001
J	Liu, R; Yang, GX; Bao, M; Zhou, ZM; Mao, XY; Liu, WJ; Jiang, XY; Zhu, D; Ren, XL; Huang, J; Chen, CS				Liu, Rong; Yang, Guangxi; Bao, Min; Zhou, Zhongmei; Mao, Xiaoyun; Liu, Wenjing; Jiang, Xiaoyan; Zhu, Di; Ren, Xinle; Huang, Jian; Chen, Ceshi			STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression	ONCOGENE			English	Article							PROTEIN-KINASE PHOSPHATASE-1; TUMORIGENESIS; ERK	Dual-specificity mitogen-activated protein kinase phosphatase-1 (MKP-1/DUSP1/CL-100) has been documented to promote breast cancer cell survival and chemoresistance. MKP-1 is an unstable protein that is ubiquitinated and degraded via the ubiquitin-proteasome system. However, it is not clear how MKP-1 protein stability is regulated in breast cancer. In this study, we performed a genome-wide siRNA library screen of deubiquitinases (DUBs) and identified STAMBPL1 as an MKP-1 DUB in breast cancer cells. STAMBPL1 interacts with MKP-1 and stabilizes MKP-1 via deubiquitination. Both STAMBPL1 and MKP-1 depletion sensitize breast cancer cells to cisplatin in vitro and in vivo, and ectopic overexpression of MKP-1 partially rescues STAMBPL1 depletion-induced cisplatin sensitivity. Furthermore, STAMBPL1 and MKP-1 depletion increased breast cancer sensitivity to cisplatin by increasing the phosphorylation and activation of c-Jun N-terminal protein kinase (JNK). Collectively, our findings not only identify STAMBPL1 as an MKP-1 DUB but also reveal a critical mechanism that regulates MKP-1 expression in breast cancer. Our findings indicate that the STAMBPL1/MKP-1 axis represents a potential therapeutic target in breast cancer.	[Liu, Rong; Yang, Guangxi; Bao, Min; Zhou, Zhongmei; Liu, Wenjing; Jiang, Xiaoyan; Chen, Ceshi] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; [Liu, Rong] Peking Univ First Hosp, Translat Canc Res Ctr, Beijing 100034, Peoples R China; [Bao, Min] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215000, Peoples R China; [Mao, Xiaoyun] China Med Univ, Dept Breast Surg, Affiliated Hosp 1, Shenyang 110000, Peoples R China; [Zhu, Di; Ren, Xinle; Huang, Jian] Guangdong Med Univ, Affiliated Hosp, Ctr Pathol Diag & Res, Dept Pathol, Zhanjiang 524000, Peoples R China; [Chen, Ceshi] Chinese Acad Sci, Kunming Inst Zool, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Kunming 650223, Yunnan, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Soochow University - China; China Medical University; Guangdong Medical University; Chinese Academy of Sciences; Kunming Institute of Zoology	Liu, R; Chen, CS (corresponding author), Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China.; Liu, R (corresponding author), Peking Univ First Hosp, Translat Canc Res Ctr, Beijing 100034, Peoples R China.; Huang, J (corresponding author), Guangdong Med Univ, Affiliated Hosp, Ctr Pathol Diag & Res, Dept Pathol, Zhanjiang 524000, Peoples R China.; Chen, CS (corresponding author), Chinese Acad Sci, Kunming Inst Zool, KIZ CUHK Joint Lab Bioresources & Mol Res Common, Kunming 650223, Yunnan, Peoples R China.	liurong@pkufh.com; 18665763598@163.com; chenc@mail.kiz.ac.cn		Chen, Ceshi/0000-0001-6398-3516; Liu, Rong/0000-0001-6123-9152	National Key Research and Development Program of China [2020YFA0112300, 2018YFC2000400]; National Natural Science Foundation of China [81772847, 82073270, U1502222, 81572610, 81830087, U2102203]; Shortage of Talent of Project in Guangdong Province, China [4YF16002G]; Project of Innovative Research Team of Yunnan Province [2019HC005]; Yunnan Fundamental Research Projects [202001AW070018, 202101AS070050]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shortage of Talent of Project in Guangdong Province, China; Project of Innovative Research Team of Yunnan Province; Yunnan Fundamental Research Projects	This work was supported by the National Key Research and Development Program of China [2020YFA0112300 and 2018YFC2000400 to CC], National Natural Science Foundation of China [81772847, 82073270 and U1502222 to RL; 81572610 to JH; 81830087 and U2102203 to CC], a Shortage of Talent of Project in Guangdong Province, China [4YF16002G], Project of Innovative Research Team of Yunnan Province [2019HC005] and Yunnan Fundamental Research Projects (202001AW070018 and 202101AS070050).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen X, 2019, CANCER LETT, V456, P49, DOI 10.1016/j.canlet.2019.04.020; D'Arcy P, 2015, PHARMACOL THERAPEUT, V147, P32, DOI 10.1016/j.pharmthera.2014.11.002; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Eckstein N, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-91; Fang J, 2018, ONCOL LETT, V16, P1869, DOI 10.3892/ol.2018.8822; Guo F, 2020, CELL DEATH DIFFER, V27, P1938, DOI 10.1038/s41418-019-0473-8; Hill DP, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6278-9; Jamdade VS, 2015, BRIT J PHARMACOL, V172, P4228, DOI 10.1111/bph.13211; Kang YS, 2016, BIOCHEM BIOPH RES CO, V478, P403, DOI 10.1016/j.bbrc.2016.07.035; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lavorgna A, 2012, J VIROL, V86, P3357, DOI 10.1128/JVI.06456-11; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Liu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084982; Liu R, 2020, INT J BIOL SCI, V16, P611, DOI 10.7150/ijbs.39491; Liu R, 2016, THERANOSTICS, V6, P533, DOI 10.7150/thno.14315; Liu R, 2009, J BIOL CHEM, V284, P16791, DOI 10.1074/jbc.M808919200; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lornejad-Schafer MR, 2005, CELL PHYSIOL BIOCHEM, V16, P193, DOI 10.1159/000089845; Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61; Petrelli F, 2016, BREAST CANCER RES TR, V160, P425, DOI 10.1007/s10549-016-4025-3; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Rincon R, 2016, MOL CANCER THER, V15, P2780, DOI 10.1158/1535-7163.MCT-15-0920; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Sato Y, 2008, NATURE, V455, P358, DOI 10.1038/nature07254; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Shahriyar SA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103280; Shen JL, 2016, CANCER MED-US, V5, P2061, DOI 10.1002/cam4.772; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Wang ZQ, 2006, CANCER RES, V66, P8870, DOI 10.1158/0008-5472.CAN-06-1280; Woo SM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120838; Yu DJ, 2019, ONCOL LETT, V18, P4421, DOI 10.3892/ol.2019.10789; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	42	0	0	9	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2265	2274		10.1038/s41388-022-02252-7	http://dx.doi.org/10.1038/s41388-022-02252-7		MAR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35236965				2022-12-17	WOS:000763262700003
J	Lv, B; Pan, YD; Hou, DS; Chen, P; Zhang, J; Chu, YW; Li, MQ; Zeng, Y; Yang, DQ; Liu, J				Lv, Bin; Pan, Yida; Hou, Daisen; Chen, Ping; Zhang, Jun; Chu, Yiwei; Li, Mingqi; Zeng, Yan; Yang, Dongqin; Liu, Jie			RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; OXIDATIVE STRESS; HEPATITIS-B; AUTOPHAGY; CANCER; SUMO; PROTEIN; P62/SQSTM1; REPAIR; ANGIOGENESIS	Hepatocellular carcinoma (HCC) is one of the largest causes of cancer-related deaths worldwide owing to the limitation of effective treatment options. The ubiquitin-proteasome system has been rapidly recognized as a frequent target of deregulation leading to cancers. Enhanced DNA damage response (DDR) promotes HCC growth and prevents chemosensitivity, and ubiquitin E3 ligases are key modulators in DDR. Therefore, a better understanding of how E3 ligases regulate cell growth and DNA damage may provide novel insights in understanding the oncogenic mechanism and improving the efficacy of DNA damage therapeutic agents. Here, we performed a high-content RNAi screening targeting 52 DDR-related E3 ligases in HCC and found that ring finger protein 4 (RNF4) was essential for HCC growth. RNF4 was highly expressed in HCC tissues, and the expression levels of RNF4 were associated with poor outcomes. RNF4 silencing significantly suppressed the cell growth, and subsequently induced G2/M arrest and apoptosis of HCC cells in vitro; RNF4 silencing also demonstrated the tumor-suppressive efficacy on HCC in vivo. Moreover, RNF4 silencing increased DNA damage, and rendered HCC cells more sensitive to DNA damage drugs and radiation. We found RNF4 functionally interacts with p62, and mechanistic analyses indicated that RNF4 silencing triggered the nuclear enrichment of p62. Moreover, the p62 nuclear targeting was required for increased DNA damage and growth suppression mediated by RNF4 silencing. Thus, our findings suggest RNF4 is essential for HCC proliferation via preventing nuclear translocation of p62. RNF4 silencing promotes DNA damage and may serve as a novel strategy to suppress cell growth and increase the sensitivity of DNA damage therapeutic agents in HCC.	[Lv, Bin; Pan, Yida; Zhang, Jun; Yang, Dongqin; Liu, Jie] Fudan Univ, Huashan Hosp, Dept Digest Dis, 12 Middle Wulumuqi Rd, Shanghai, Peoples R China; [Hou, Daisen; Chen, Ping; Liu, Jie] Fudan Univ, Sch Basic Med Sci, Inst Biomed Sci, 130 Dongan Rd, Shanghai, Peoples R China; [Hou, Daisen; Chen, Ping; Chu, Yiwei; Liu, Jie] Fudan Univ, Sch Basic Med Sci, Dept Immunol, 130 Dongan Rd, Shanghai, Peoples R China; [Li, Mingqi] Univ Tennessee, Ctr Canc Res, Hlth Sci Ctr, Memphis, TN 38163 USA; [Zeng, Yan] Jilin Agr Univ, Coll Vet Med, 2888 Xincheng St, Changchun, Peoples R China	Fudan University; Fudan University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center; Jilin Agricultural University	Yang, DQ; Liu, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Digest Dis, 12 Middle Wulumuqi Rd, Shanghai, Peoples R China.; Liu, J (corresponding author), Fudan Univ, Sch Basic Med Sci, Inst Biomed Sci, 130 Dongan Rd, Shanghai, Peoples R China.; Liu, J (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Immunol, 130 Dongan Rd, Shanghai, Peoples R China.	kobesakura@fudan.edu.cn; jieliu@fudan.edu.cn			National Natural Science Foundation Grant of China [81770579, 81830080, 81861168038, 81970506, 81800477]	National Natural Science Foundation Grant of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation Grant of China [81770579, 81830080, 81861168038, 81970506, 81800477]. The authors thank Ying Zhao for p62 WT, p62 Delta UBA, p62 Delta PB1, p62 Delta NES and p62 Delta NLS plasmids. The authors thank Dr. Zhaohui Wu and Dr. Mingfang Lv for revising our manuscript. The authors thank Mengxiao Ge for replenishing our experimental data.	Al-Hakim AK, 2008, BIOCHEM J, V411, P249, DOI 10.1042/BJ20080067; Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI 10.2147/JHC.S61146; Bartolini D, 2018, TRANSL RES, V193, P54, DOI 10.1016/j.trsl.2017.11.007; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Brinkmann K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00098; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226; Collins GA, 2017, CELL, V169, P792, DOI 10.1016/j.cell.2017.04.023; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Denk H, 2019, EXPERT OPIN THER TAR, V23, P393, DOI 10.1080/14728222.2019.1601703; Erpapazoglou Zoi, 2014, Cells, V3, P1027, DOI 10.3390/cells3041027; Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577; Feng YC, 2017, AUTOPHAGY, V13, P995, DOI 10.1080/15548627.2017.1317427; Fryrear KA, 2012, BLOOD, V119, P1173, DOI 10.1182/blood-2011-06-358564; Gartner A, 2014, MOL CELL, V55, P1, DOI 10.1016/j.molcel.2014.06.022; Galanty Y, 2012, GENE DEV, V26, P1179, DOI 10.1101/gad.188284.112; Goto Y, 2017, MUTAT RES-FUND MOL M, V803, P76, DOI 10.1016/j.mrfmmm.2017.07.007; Groocock LM, 2014, EMBO REP, V15, P601, DOI 10.1002/embr.201338369; Hao ZL, 2015, FRONT BIOSCI-LANDMRK, V20, P474, DOI 10.2741/4320; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Jung YS, 2012, FEBS LETT, V586, P1397, DOI 10.1016/j.febslet.2012.03.052; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Lin XL, 2013, DNA CELL BIOL, V32, P220, DOI 10.1089/dna.2012.1915; Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925; Saito T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12030; Sanchez-Martin P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.222836; Sang YZ, 2015, ONCOTARGET, V6, P42590, DOI 10.18632/oncotarget.6052; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Sriramachandran AM, 2014, BBA-MOL CELL RES, V1843, P75, DOI 10.1016/j.bbamcr.2013.08.022; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Su YT, 2013, MOL CELL BIOL, V33, P1546, DOI 10.1128/MCB.01146-12; Sun L, 2008, J INT MED RES, V36, P1015, DOI 10.1177/147323000803600519; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Taniguchi K, 2016, FEBS LETT, V590, P2375, DOI 10.1002/1873-3468.12301; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Uckelmann M, 2017, DNA REPAIR, V56, P92, DOI 10.1016/j.dnarep.2017.06.011; Vyas R, 2013, CELL DEATH DIFFER, V20, P490, DOI 10.1038/cdd.2012.145; Wang GC, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00005; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Xiang X, 2017, CANCER MED-US, V6, P2357, DOI 10.1002/cam4.1176; Yang D, 2013, CELL DEATH DIFFER, V20, P235, DOI 10.1038/cdd.2012.113; Yang DQ, 2019, EBIOMEDICINE, V47, P114, DOI 10.1016/j.ebiom.2019.08.068; Yang DQ, 2012, AUTOPHAGY, V8, P1856, DOI 10.4161/auto.22024; Yi T, 2008, CANCER RES, V68, P1843, DOI 10.1158/0008-5472.CAN-07-5944; Zhao XM, 2018, RADIAT RES, V190, P385, DOI 10.1667/RR14981.1	47	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2275	2286		10.1038/s41388-022-02247-4	http://dx.doi.org/10.1038/s41388-022-02247-4		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35236966				2022-12-17	WOS:000763262700002
J	Aschtgen, MS; Fragkoulis, K; Sanz, G; Normark, S; Selivanova, G; Henriques-Normark, B; Peuget, S				Aschtgen, Marie-Stephanie; Fragkoulis, Konstantinos; Sanz, Gema; Normark, Staffan; Selivanova, Galina; Henriques-Normark, Birgitta; Peuget, Sylvain			Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization	ONCOGENE			English	Article							PYOGENIC LIVER-ABSCESS; HELICOBACTER-PYLORI; COLORECTAL-CANCER; GENE; ACTIVATION; PROMOTES; TARGETS; MICROBIOTA; MODEL; RAS	Increasing evidence highlights the role of bacteria in the physiopathology of cancer. However, the underlying molecular mechanisms remains poorly understood. Several cancer-associated bacteria have been shown to produce toxins which interfere with the host defense against tumorigenesis. Here, we show that lipopolysaccharides from Klebsiella pneumoniae and other Enterobacteria strongly inhibit the host tumor suppressor p53 pathway through a novel mechanism of p53 regulation. We found that lipopolysaccharides destabilize TP53 mRNA through a TLR4-NF-kappa B-mediated inhibition of the RNA-binding factor Wig-1. Importantly, we show that K. pneumoniae disables two major tumor barriers, oncogene-induced DNA damage signaling and senescence, by impairing p53 transcriptional activity upon DNA damage and oncogenic stress. Furthermore, we found an inverse correlation between the levels of TLR4 and p53 mutation in colorectal tumors. Hence, our data suggest that the repression of p53 by Enterobacteria via TLR4 alleviates the selection pressure for p53 oncogenic mutations and shapes the genomic evolution of cancer.	[Aschtgen, Marie-Stephanie; Fragkoulis, Konstantinos; Sanz, Gema; Normark, Staffan; Selivanova, Galina; Henriques-Normark, Birgitta; Peuget, Sylvain] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden; [Normark, Staffan; Henriques-Normark, Birgitta] Karolinska Univ Hosp, Clin Microbiol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Aschtgen, MS; Peuget, S (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden.	marie-stephanie.aschtgen@ki.se; sylvain.peuget@ki.se	Peuget, Sylvain/AAB-4730-2022	Peuget, Sylvain/0000-0002-3315-1935; aschtgen, marie-stephanie/0000-0003-2413-8226	Swedish Research Council; Swedish Cancer Society; Knut and Alice Wallenberg Foundation; Swedish foundation for Strategic Research; Karolinska Institute; EMBO	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish foundation for Strategic Research(Swedish Foundation for Strategic Research); Karolinska Institute(Karolinska Institutet); EMBO(European Molecular Biology Organization (EMBO))	We thank all our colleagues for sharing precious reagents and material with us, especially Dr. Yunn-Hwen Gan (National University of Singapore), Dr. Gary Huffnagle (University of Michigan) and Mr. Alexandros Petropoulos (Karolinska Institute) for bacteria strains, and Prof. Klas Wiman (Karolinska Institute) for Wig-1 antibody. We thank Ms. Aleksandra Boikova and Mr. Riccardo Bevilacqua for technical support. This study was supported by the Swedish Research Council, the Swedish Cancer Society, Knut and Alice Wallenberg Foundation, the Swedish foundation for Strategic Research and the Karolinska Institute. MSA was supported by a short-term fellowship from EMBO.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115; Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Berezow AB, 2009, MICROB PATHOGENESIS, V47, P68, DOI 10.1016/j.micpath.2009.04.015; Bergounioux J, 2012, CELL HOST MICROBE, V11, P240, DOI 10.1016/j.chom.2012.01.013; Bersani C, 2014, ONCOGENE, V33, P4407, DOI 10.1038/onc.2013.594; Bersani C, 2016, ONCOTARGET, V7, P1895, DOI 10.18632/oncotarget.6557; Bieging-Rolett KT, 2020, MOL CELL, V80, P452, DOI 10.1016/j.molcel.2020.10.022; Brennan CA, 2019, NAT REV MICROBIOL, V17, P156, DOI 10.1038/s41579-018-0129-6; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; Buti L, 2011, P NATL ACAD SCI USA, V108, P9238, DOI 10.1073/pnas.1106200108; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan W, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm163; Chen J, 2010, GENE DEV, V24, P2146, DOI 10.1101/gad.1968910; Costa L, 2020, GUT, V69, P1582, DOI 10.1136/gutjnl-2019-318640; Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Waal GM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65324-2; Diaz-Munoz MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00454-2; Ewels PA, 2020, NAT BIOTECHNOL, V38, P276, DOI 10.1038/s41587-020-0439-x; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ge ZM, 2007, CELL MICROBIOL, V9, P2070, DOI 10.1111/j.1462-5822.2007.00939.x; Gonzalez E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6201; Greathouse KL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1501-6; Gudkov AV, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026161; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Haronikova L, 2019, NUCLEIC ACIDS RES, V47, P3257, DOI 10.1093/nar/gkz124; He XY, 2015, CELL REP, V13, P888, DOI 10.1016/j.celrep.2015.09.045; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; HORNICK DB, 1995, INFECT IMMUN, V63, P2026, DOI 10.1128/IAI.63.5.2026-2032.1995; Horvat A, 2018, ONCOGENE, V37, P5054, DOI 10.1038/s41388-018-0343-8; Huang Tzu-Wen, 2014, BMC Res Notes, V7, P13, DOI 10.1186/1756-0500-7-13; Huang WK, 2012, COLORECTAL DIS, V14, pe794, DOI 10.1111/j.1463-1318.2012.03174.x; Janic A, 2018, NAT MED, V24, P947, DOI 10.1038/s41591-018-0043-5; Jeong SW, 2012, J GASTROEN HEPATOL, V27, P248, DOI 10.1111/j.1440-1746.2011.06851.x; Jimenez N, 2009, J BACTERIOL, V191, P2228, DOI 10.1128/JB.01395-08; Joruiz SM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026039; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Lam MMC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05114-7; Lan Y, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22838; Lee IR, 2016, SCI REP-UK, V6, DOI 10.1038/srep29316; Lee YK, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00587-18; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Liu G, 2009, J IMMUNOL, V182, P5063, DOI 10.4049/jimmunol.0803526; Madenspacher JH, 2013, J EXP MED, V210, P891, DOI 10.1084/jem.20121674; Mei QX, 2018, PANCREATOLOGY, V18, P438, DOI 10.1016/j.pan.2018.03.005; Menendez D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001360; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Nguyen HCB, 2020, NATURE, V584, P286, DOI 10.1038/s41586-020-2576-2; Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005; Pai AA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006338; Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199; Rivas C, 2010, VIRUSES-BASEL, V2, P298, DOI 10.3390/v2010298; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Siegl C, 2015, NAT REV MICROBIOL, V13, P741, DOI 10.1038/nrmicro3537; Tornesello ML, 2018, CANCERS, V10, DOI 10.3390/cancers10070213; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wang TT, 2012, ISME J, V6, P320, DOI 10.1038/ismej.2011.109; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Wei JX, 2010, GASTROENTEROLOGY, V139, P1333, DOI 10.1053/j.gastro.2010.06.018; Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6; Wu N, 2013, MICROB ECOL, V66, P462, DOI 10.1007/s00248-013-0245-9; Zella D, 2018, P NATL ACAD SCI USA, V115, pE12005, DOI 10.1073/pnas.1815660115; Zhang MQZ, 2018, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00323	76	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2173	2186		10.1038/s41388-022-02238-5	http://dx.doi.org/10.1038/s41388-022-02238-5		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35197571	Green Published, hybrid			2022-12-17	WOS:000760099800002
J	Liu, YL; Ma, L; Hua, FL; Min, ZH; Zhan, YX; Zhang, W; Yao, JX				Liu, Yonglei; Ma, Li; Hua, Fanli; Min, Zhihui; Zhan, Yanxia; Zhang, Wei; Yao, Junxia			Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer (Jan, 10.1038/s41388-021-02061-4, 2022)	ONCOGENE			English	Correction									[Zhan, Yanxia] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China; [Yao, Junxia] Fudan Univ, Zhongshan Hosp, Qingpu Branch, Dept Pathol, Shanghai, Peoples R China	Fudan University; Fudan University	Zhan, YX (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China.	yongleiliu@yeah.net						Liu YL, 2022, ONCOGENE, V41, P2012, DOI 10.1038/s41388-021-02061-4	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2137	2137		10.1038/s41388-022-02217-w	http://dx.doi.org/10.1038/s41388-022-02217-w		FEB 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35194153	Bronze			2022-12-17	WOS:000759404700001
J	Aponte, E; Lafitte, M; Sirvent, A; Simon, V; Barbery, M; Fourgous, E; Boublik, Y; Maffei, M; Armand, F; Hamelin, R; Pannequin, J; Fort, P; Pons, M; Roche, S				Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Boublik, Yvan; Maffei, Mariano; Armand, Florence; Hamelin, Romain; Pannequin, Julie; Fort, Philippe; Pons, Miquel; Roche, Serge			Regulation of Src tumor activity by its N-terminal intrinsically disordered region (vol 41, pg 960, 2022)	ONCOGENE			English	Correction												mpons@ub.edu; serge.roche@crbm.cnrs.fr	pons, miquel/C-8657-2011; Maffei, Mariano/AAD-3508-2021	pons, miquel/0000-0002-0586-8322; roche, serge/0000-0003-3413-3859				Aponte E, 2022, ONCOGENE, V41, P960, DOI 10.1038/s41388-021-02092-x	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2786	2786		10.1038/s41388-022-02231-y	http://dx.doi.org/10.1038/s41388-022-02231-y		FEB 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35190643	hybrid, Green Published			2022-12-17	WOS:000758960300002
J	Teoh, PJ; An, O; Chung, TH; Vaiyapuri, T; Raju, A; Hoppe, MM; Toh, SHM; Wang, W; Chan, MC; Fullwood, MJ; Jeyasekharan, AD; Tergaonkar, V; Chen, LL; Yang, H; Chng, WJ				Teoh, Phaik Ju; An, Omer; Chung, Tae-Hoon; Vaiyapuri, Thamil; Raju, Anandhkumar; Hoppe, Michal M.; Toh, Sabrina H. M.; Wang, Wilson; Chan, Ming Chun; Fullwood, Melissa J.; Jeyasekharan, Anand D.; Tergaonkar, Vinay; Chen, Leilei; Yang, Henry; Chng, Wee Joo			p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain)	ONCOGENE			English	Article							CHECKPOINT KINASE INHIBITOR; DNA-REPAIR; PLASMA-CELLS; DEXAMETHASONE; AZD7762; CANCER; DAMAGE; LENALIDOMIDE; CARFILZOMIB; MECHANISMS	Recurrent cytogenetic abnormalities are the main hallmark of multiple myeloma (MM) and patients having 2 or more high-risk prognostic events are associated with extremely poor outcome. 17p13(del) and 1q21(gain) are critical and independent high-risk cytogenetic markers, however, the biological significance underlying the poor outcome in MM patients having co-occurrence of both these chromosomal aberrations has never been interrogated. Herein, we identified that patients harbouring concomitant 17p13(del) with 1q21(gain) demonstrated the worst prognosis as compared to patients with single- (either 17p13(del) or 1q21(gain)) and with no chromosomal events (WT for both chromosomal loci); and they are highly enriched for genomic instability (GI) signature. We discovered that the GI feature in the patients with concomitant 17p13(del)-1q21(gain) was recapitulating the biological properties of myeloma cells with co-existing p53-deficiency and NEIL1 mRNA-hyper-editing (associated with chromosome 17p and 1q, respectively) that have inherent DNA damage response (DDR) and persistent activation of Chk1 pathway. Importantly, this became a vulnerable point for therapeutic targeting whereby the cells with this co-abnormalities demonstrated hyper-sensitivity to siRNA- and pharmacological-mediated-Chk1 inhibition, as observed at both the in vitro and in vivo levels. Mechanistically, this was attributable to the synthetic lethal relationship between p53-NEIL1-Chk1 abnormalities. The Chk1 inhibitor (AZD7762) tested showed good synergism with standard-of-care myeloma drugs, velcade and melphalan, thus further reinforcing the translational potential of this therapeutic approach. In summary, combination of NEIL1-p53 abnormalities with an ensuing Chk1 activation could serve as an Achilles heel and predispose MM cells with co-existing 1q21(gain) and 17p13(del) to therapeutic vulnerability for Chk1 inhibition.	[Teoh, Phaik Ju; Jeyasekharan, Anand D.; Chng, Wee Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Teoh, Phaik Ju; An, Omer; Chung, Tae-Hoon; Hoppe, Michal M.; Toh, Sabrina H. M.; Fullwood, Melissa J.; Jeyasekharan, Anand D.; Chen, Leilei; Yang, Henry; Chng, Wee Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Vaiyapuri, Thamil; Raju, Anandhkumar; Tergaonkar, Vinay] ASTAR, Inst Mol & Cell Biol IMCB, Singapore, Singapore; [Wang, Wilson; Chan, Ming Chun] Natl Univ Singapore Hosp, Dept Orthopaed Surg, Singapore, Singapore; [Wang, Wilson; Chan, Ming Chun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Orthopaed Surg, Singapore, Singapore; [Jeyasekharan, Anand D.; Chng, Wee Joo] Natl Univ Canc Inst, Singapore, Singapore; [Jeyasekharan, Anand D.; Chng, Wee Joo] Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst Singapore, Singapore, Singapore	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore	Teoh, PJ (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.; Teoh, PJ (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.	mdctpju@nus.edu.sg	wang, wilson/GYD-5657-2022	Hoppe, Michal Marek/0000-0002-0364-6080; Teoh, Phaik Ju/0000-0001-8350-1641	Ministry of Education of Singapore [MOE2019-T2-1-083]; NMRC OF-YIRG grant [NMRC/OFYIRG/032/201700]	Ministry of Education of Singapore(Ministry of Education, Singapore); NMRC OF-YIRG grant	This study was funded by Tier 2 grant provided by the Ministry of Education of Singapore (MOE2019-T2-1-083) and NMRC OF-YIRG grant (NMRC/OFYIRG/032/201700). We would like to thank Pamela Chng for helping out with tissue culture and functional assays, Y.F. Goh, J.Q. Thng and W.N. Fam for helping with the processing and isolation of normal CD138 + plasma cells from healthy volunteers' samples and M.Y. Koh for assisting in lentivirus work.	Agnelli L, 2013, EXPERT OPIN BIOL TH, V13, pS55, DOI 10.1517/14712598.2013.793305; Avet-Loiseau H, 2010, J CLIN ONCOL, V28, P4630, DOI 10.1200/JCO.2010.28.3945; Herrero AB, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00098; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bolli N, 2018, LEUKEMIA, V32, P2604, DOI 10.1038/s41375-018-0037-9; Boyd KD, 2012, LEUKEMIA, V26, P349, DOI 10.1038/leu.2011.204; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chang H, 2011, LEUKEMIA RES, V35, P95, DOI 10.1016/j.leukres.2010.05.002; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Chng WJ, 2011, LEUKEMIA, V25, P1026, DOI 10.1038/leu.2011.53; Chung TH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066361; Cottini F, 2015, CANCER DISCOV, V5, P972, DOI 10.1158/2159-8290.CD-14-0943; Dimopoulos MA, 2010, LEUKEMIA, V24, P1769, DOI 10.1038/leu.2010.175; Eischen CM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026096; Fonseca R, 2009, LEUKEMIA, V23, P2210, DOI 10.1038/leu.2009.174; Gkotzamanidou M, 2016, BLOOD, V128, P1214, DOI 10.1182/blood-2016-01-691618; Gourzones-Dmitriev C, 2013, CELL CYCLE, V12, P2760, DOI 10.4161/cc.25951; Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01380-0; Hao SY, 2021, MODERN PATHOL, V34, P327, DOI 10.1038/s41379-020-00669-7; Hayden PJ, 2007, HUM MOL GENET, V16, P3117, DOI 10.1093/hmg/ddm273; Herrero AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122003; Herrero AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121581; Jakubowiak AJ, 2013, LEUKEMIA, V27, P2351, DOI 10.1038/leu.2013.152; Janz S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00424; Kawasumi M, 2014, CANCER RES, V74, P7534, DOI 10.1158/0008-5472.CAN-14-2650; Kumar SK, 2019, CANCER J, V25, P59, DOI 10.1097/PPO.0000000000000353; Landau HJ, 2012, MOL CANCER THER, V11, P1781, DOI 10.1158/1535-7163.MCT-11-0949; Lazzari E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01890-w; Ma ZK, 2012, MOL MED REP, V6, P897, DOI 10.3892/mmr.2012.999; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Neri P, 2013, EXPERT OPIN BIOL TH, V13, pS69, DOI 10.1517/14712598.2013.814637; Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood-2011-06-363911; Qiu ZJ, 2018, RADIOTHER ONCOL, V126, P450, DOI 10.1016/j.radonc.2017.09.043; Ray A, 2016, BRIT J HAEMATOL, V174, P397, DOI 10.1111/bjh.14065; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Schmidt TM, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00474-8; Shah V, 2018, LEUKEMIA, V32, P102, DOI 10.1038/leu.2017.179; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Sonneveld P, 2016, HAEMATOLOGICA, V101, P396, DOI 10.3324/haematol.2015.129189; Sousa MML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055493; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321; Tembhare P, 2012, LEUKEMIA LYMPHOMA, V53, P721, DOI 10.3109/10428194.2011.623257; Teoh PJ, 2021, LEUKEMIA, V35, P346, DOI 10.1038/s41375-020-01076-2; Teoh PJ, 2020, HAEMATOLOGICA, V105, P1391, DOI 10.3324/haematol.2019.221176; Teoh PJ, 2018, BLOOD, V132, P1304, DOI 10.1182/blood-2018-02-832576; Walker BA, 2019, LEUKEMIA, V33, P159, DOI 10.1038/s41375-018-0196-8; Yan, 2014, LEUKEMIA, V14, P102; Yang CG, 2009, CHEMBIOCHEM, V10, P417, DOI 10.1002/cbic.200800580; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492	51	0	0	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2106	2121		10.1038/s41388-022-02227-8	http://dx.doi.org/10.1038/s41388-022-02227-8		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35190641				2022-12-17	WOS:000758960300001
J	de Wet, L; Williams, A; Gillard, M; Kregel, S; Lamperis, S; Gutgesell, LC; Vellky, JE; Brown, R; Conger, K; Paner, GP; Wang, H; Platz, EA; De Marzo, AM; Mu, P; Coloff, JL; Szmulewitz, RZ; Vander Griend, DJ				de Wet, Larischa; Williams, Anthony; Gillard, Marc; Kregel, Steven; Lamperis, Sophia; Gutgesell, Lisa C.; Vellky, Jordan E.; Brown, Ryan; Conger, Kelly; Paner, Gladell P.; Wang, Heng; Platz, Elizabeth A.; De Marzo, Angelo M.; Mu, Ping; Coloff, Jonathan L.; Szmulewitz, Russell Z.; Vander Griend, Donald J.			SOX2 mediates metabolic reprogramming of prostate cancer cells (vol 41, pg 1190, 2022)	ONCOGENE			English	Correction												dvanderg@uic.edu						de Wet L, 2022, ONCOGENE, V41, P1190, DOI 10.1038/s41388-021-02157-x	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1234	1234		10.1038/s41388-022-02228-7	http://dx.doi.org/10.1038/s41388-022-02228-7		FEB 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35145235	Bronze			2022-12-17	WOS:000754012300001
J	Mota, A; Oltra, SS; Selenica, P; Moiola, CP; Casas-Arozamena, C; Lopez-Gil, C; Diaz, E; Gatius, S; Ruiz-Miro, M; Calvo, A; Rojo-Sebastian, A; Hurtado, P; Pineiro, R; Colas, E; Gil-Moreno, A; Reis-Filho, JS; Muinelo-Romay, L; Abal, M; Matias-Guiu, X; Weigelt, B; Moreno-Bueno, G				Mota, Alba; Oltra, Sara S.; Selenica, Pier; Moiola, Cristian P.; Casas-Arozamena, Carlos; Lopez-Gil, Carlos; Diaz, Eva; Gatius, Sonia; Ruiz-Miro, Maria; Calvo, Ana; Rojo-Sebastian, Alejandro; Hurtado, Pablo; Pineiro, Roberto; Colas, Eva; Gil-Moreno, Antonio; Reis-Filho, Jorge S.; Muinelo-Romay, Laura; Abal, Miguel; Matias-Guiu, Xavier; Weigelt, Britta; Moreno-Bueno, Gema			Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression	ONCOGENE			English	Article							SYNCHRONOUS PRIMARY CANCERS; GENOMIC CHARACTERIZATION; INTERNATIONAL SOCIETY; MUTATIONAL PROCESSES; TUMOR HETEROGENEITY; OVARIAN CANCERS; CELL CARCINOMAS; BREAST; RECOMMENDATIONS; CHEMOTHERAPY	Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). In this study, we sought to characterize the spatial and temporal heterogeneity of 9 different ECs using whole-exome sequencing, and by performing targeted sequencing validation of the 42 primary tumor regions and 30 metastatic samples analyzed. In addition, copy number alterations of serous carcinomas were assessed by comparative genomic hybridization arrays. From the somatic mutations, identified by whole-exome sequencing, 532 were validated by targeted sequencing. Based on these data, the phylogenetic tree reconstructed for each case allowed us to establish the tumors' evolution and correlate this to tumor progression, prognosis, and the presence of recurrent disease. Moreover, we studied the genetic landscape of an ambiguous EC and the molecular profile obtained was used to guide the selection of a potential personalized therapy for this patient, which was subsequently validated by preclinical testing in patient-derived xenograft models. Overall, our study reveals the impact of analyzing different tumor regions to decipher the ITGH in ECs, which could help make the best treatment decision.	[Mota, Alba; Oltra, Sara S.; Diaz, Eva; Moreno-Bueno, Gema] MD Anderson Int Fdn, Madrid 28033, Spain; [Mota, Alba; Oltra, Sara S.; Moreno-Bueno, Gema] Univ Autonoma Madrid UAM, Inst Invest Biomed Alberto Sols CSIC UAM, Biochem Dept, IdiPaz, Madrid 28029, Spain; [Oltra, Sara S.; Moiola, Cristian P.; Rojo-Sebastian, Alejandro; Colas, Eva; Gil-Moreno, Antonio; Muinelo-Romay, Laura; Abal, Miguel; Matias-Guiu, Xavier; Moreno-Bueno, Gema] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain; [Selenica, Pier; Reis-Filho, Jorge S.; Weigelt, Britta] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Moiola, Cristian P.; Lopez-Gil, Carlos; Rojo-Sebastian, Alejandro; Colas, Eva; Gil-Moreno, Antonio] Univ Autonoma Barcelona, Vall Hebron Inst Res, Biomed Res Grp Gynecol, Barcelona 08035, Spain; [Casas-Arozamena, Carlos; Muinelo-Romay, Laura; Abal, Miguel] Univ Hosp Santiago de Compostela SERGAS, Hlth Res Inst Santiago de Compostela IDIS, Translat Med Oncol Grp Oncomet, Trav Choupana S-N, Santiago De Compostela 15706, Spain; [Gatius, Sonia; Matias-Guiu, Xavier] Univ Lleida, Hosp U Arnau de Vilanova, Dept Pathol, Lleida, Spain; [Ruiz-Miro, Maria] IRBLLEIDA, Biobank, Lleida, Spain; [Calvo, Ana] Hosp U Arnau de Vilanova, Dept Gynecol, IRBLLEIDA, Lleida, Spain; [Rojo-Sebastian, Alejandro] MD Anderson Canc Ctr, Madrid, Spain; [Hurtado, Pablo; Pineiro, Roberto] Hlth Res Inst Santiago de Compostela IDIS, Roche Chus Joint Unit, Translat Med Oncol Grp Oncomet, Travesia Da Choupana S-N, Santiago De Compostela 15706, Spain; [Gil-Moreno, Antonio] Vall Hebron Univ Hosp, Gynaecol Dept, Barcelona 08035, Spain; [Matias-Guiu, Xavier] Univ Lleida, Hosp U Bellvitge, Dept Pathol, Lleida, Spain; [Matias-Guiu, Xavier] Univ Barcelona, Hosp U Bellvitge, Dept Pathol, Barcelona, Spain; [Matias-Guiu, Xavier] IDIBELL Lleida & Barcelona, Barcelona, Spain	University of Texas System; UTMD Anderson Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Memorial Sloan Kettering Cancer Center; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Complexo Hospitalario Universitario de Santiago de Compostela; Universitat de Lleida; University of Texas System; UTMD Anderson Cancer Center; Complexo Hospitalario Universitario de Santiago de Compostela; Hospital Universitari Vall d'Hebron; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Universitat de Lleida; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Moreno-Bueno, G (corresponding author), MD Anderson Int Fdn, Madrid 28033, Spain.; Moreno-Bueno, G (corresponding author), Univ Autonoma Madrid UAM, Inst Invest Biomed Alberto Sols CSIC UAM, Biochem Dept, IdiPaz, Madrid 28029, Spain.; Moreno-Bueno, G (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.	gmoreno@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Piñeiro, Roberto/AAN-5561-2020; Oltra, Sara/Y-4002-2019; Selenica, Pier/GQY-8678-2022	Moreno-Bueno, Gema/0000-0002-5030-6687; Piñeiro, Roberto/0000-0001-9479-139X; Casas-Arozamena, Carlos/0000-0002-3279-2482	MD Anderson Foundation Biobank [B.0000745]; "Plataforma de Biobancos" ISCIII [PT13/0010/0014, B.000609]; Spanish Ministry of Economy and Innovation [PID2019-104644RB-I00]; Instituto de Salud Carlos III (ISCIII, CIBERONC) [FEDER funds] [CB16/12/00295 - GMB, CB16/12/00328 -EC, CB16/12/00231 -XMG]; AECC Scientific Foundation [FC_AECC PROYE19036MOR -GMB]; AECC; Breast Cancer Research Foundation; NIH/NCI [P50 CA247749 01, P30CA008748]	MD Anderson Foundation Biobank; "Plataforma de Biobancos" ISCIII; Spanish Ministry of Economy and Innovation(Spanish Government); Instituto de Salud Carlos III (ISCIII, CIBERONC) [FEDER funds]; AECC Scientific Foundation; AECC; Breast Cancer Research Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all those at the Translational Research Laboratory of the MD Anderson Cancer Center Madrid for their invaluable help with this study. Tissue samples were obtained with the support of the MD Anderson Foundation Biobank (record number B.0000745, ISCIII National Biobank Record), the "Xarxa Catalana de Bancs de Tumors" and "Plataforma de Biobancos" ISCIII (PT13/0010/0014, B.000609). This study has been supported by the Spanish Ministry of Economy and Innovation (PID2019-104644RB-I00 (GMB), the Instituto de Salud Carlos III (ISCIII, CIBERONC, CB16/12/00295 - GMB-, CB16/12/00328 -EC, AGM- and CB16/12/00231 -XMG- [all partly supported by FEDER funds]) and by the AECC Scientific Foundation (FC_AECC PROYE19036MOR -GMB- and Coordinated groups 2018 -XMG, AGM, GMB-). SO is funded by an AECC-postdoctoral grant (2020). JSR-F and BW are funded in part by the Breast Cancer Research Foundation and in part by the NIH/NCI P50 CA247749 01 grant. Research reported in this publication was supported in part by a Cancer Center Support Grant of the NIH/NCI (Grant No. P30CA008748; MSK). We thank the Eurofins Megalab laboratory for helping us to perform the analysis of DNA HPV detection.	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428; Ashley CW, 2019, GYNECOL ONCOL, V152, P11, DOI 10.1016/j.ygyno.2018.10.032; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Beck-Engeser GB, 2015, EUR J IMMUNOL, V45, P695, DOI 10.1002/eji.201445218; Belhadj H, 2014, INT J GYNECOL OBSTET, V125, P97, DOI 10.1016/j.ijgo.2014.02.003; Bell DW, 2019, ANNU REV PATHOL-MECH, V14, P339, DOI 10.1146/annurev-pathol-020117-043609; Bestvina CM, 2016, ONCOLOGIST, V21, P1250, DOI 10.1634/theoncologist.2016-0062; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Budczies J, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1526613; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannataro VL, 2019, ONCOGENE, V38, P3475, DOI 10.1038/s41388-018-0657-6; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Casas-Arozamena C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020585; Chao A, 2016, GYNECOL ONCOL, V143, P60, DOI 10.1016/j.ygyno.2016.07.114; Chiang YC, 2008, INT J GYNECOL CANCER, V18, P159, DOI 10.1111/j.1525-1438.2007.00975.x; Choi M, 2016, MOL CANCER THER, V15, P1781, DOI 10.1158/1535-7163.MCT-15-0945; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Connell PP, 1999, GYNECOL ONCOL, V74, P74, DOI 10.1006/gyno.1999.5415; Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Demeulemeester J, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1109-7; Dessources K, 2020, JCO PRECIS ONCOL, V4, P1217, DOI 10.1200/PO.20.00044; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Eritja N, 2017, ADV EXP MED BIOL, V943, P149, DOI 10.1007/978-3-319-43139-0_6; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; Evans T, 2016, J NATL COMPR CANC NE, V14, P1165, DOI 10.6004/jnccn.2016.0123; GALL JG, 1986, SCIENCE, V233, P1367, DOI 10.1126/science.233.4771.1367-e; Garg K, 2010, MODERN PATHOL, V23, P80, DOI 10.1038/modpathol.2009.153; Gatius S, 2018, PATHOBIOLOGY, V85, P35, DOI 10.1159/000475529; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gibson WJ, 2016, NAT GENET, V48, P848, DOI 10.1038/ng.3602; Grondin CJ, 2016, ENVIRON HEALTH PERSP, V124, P1592, DOI 10.1289/EHP174; Guerini-Rocco E, 2015, J PATHOL, V237, P166, DOI 10.1002/path.4566; Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347; Heitz F, 2014, INT J GYNECOL CANCER, V24, P54, DOI 10.1097/IGC.0000000000000019; HEPPNER GH, 1984, CANCER RES, V44, P2259; Hiley C, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0453-8; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jette NR, 2020, CANCERS, V12, DOI 10.3390/cancers12030687; Jiang TT, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-876; Kiess AP, 2012, GYNECOL ONCOL, V127, P321, DOI 10.1016/j.ygyno.2012.07.112; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kommoss S, 2018, ANN ONCOL, V29, P1180, DOI 10.1093/annonc/mdy058; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kurman RJ, 2014, WORLD HLTH ORG CLASS, V4th; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Lax S F, 1997, Verh Dtsch Ges Pathol, V81, P228; Le Gallo M, 2014, CLIN CHEM, V60, P98, DOI 10.1373/clinchem.2013.205740; Lee JY, 2019, CLIN CANCER RES, V25, P674, DOI 10.1158/1078-0432.CCR-18-1103; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Marquard AM, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0130-0; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Mota A, 2017, MODERN PATHOL, V30, P134, DOI 10.1038/modpathol.2016.143; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; NIKZAINAL S, 2012, CELL, V149; Norman JM, 2011, NAT IMMUNOL, V12, P975, DOI 10.1038/ni.2087; Peterson LE, 2019, MOLECULES, V24, DOI 10.3390/molecules24030645; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Rabban JT, 2019, INT J GYNECOL PATHOL, V38, pS25, DOI 10.1097/PGP.0000000000000512; Reijnen C, 2020, INT J CANCER, V147, P478, DOI 10.1002/ijc.32907; Reiter JG, 2019, NAT REV CANCER, V19, P639, DOI 10.1038/s41568-019-0185-x; Roberts NJ, 2016, CANCER DISCOV, V6, P166, DOI 10.1158/2159-8290.CD-15-0402; Robertson AG, 2018, CELL, V174, P1033, DOI 10.1016/j.cell.2018.07.036; Rosa-Rosa JM, 2016, MODERN PATHOL, V29, P1594, DOI 10.1038/modpathol.2016.184; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Rye IH, 2018, MOL ONCOL, V12, P1838, DOI 10.1002/1878-0261.12375; Ryu D, 2016, HUM GENET, V135, P635, DOI 10.1007/s00439-016-1670-x; Saber A, 2017, CARCINOGENESIS, V38, P144, DOI 10.1093/carcin/bgw128; Santacana M, 2014, HUM PATHOL, V45, P2394, DOI 10.1016/j.humpath.2014.06.031; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schliep KP, 2011, BIOINFORMATICS, V27, P592, DOI 10.1093/bioinformatics/btq706; Schmitt A, 2017, CANCER RES, V77, P3040, DOI 10.1158/0008-5472.CAN-16-3398; Schultheis AM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv427; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shi WW, 2018, CELL REP, V25, P1446, DOI 10.1016/j.celrep.2018.10.046; Siegel RL., 2020, CA-CANCER J CLIN, V70; Soliman PT, 2004, GYNECOL ONCOL, V94, P456, DOI 10.1016/j.ygyno.2004.05.006; Soslow RA, 2019, INT J GYNECOL PATHOL, V38, pS64, DOI 10.1097/PGP.0000000000000518; Soslow RA, 2010, SEMIN DIAGN PATHOL, V27, P261, DOI 10.1053/j.semdp.2010.09.003; Talhouk A, 2017, CANCER-AM CANCER SOC, V123, P802, DOI 10.1002/cncr.30496; Tang Wan, 2015, Shanghai Arch Psychiatry, V27, P62, DOI 10.11919/j.issn.1002-0829.215010; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Uchi R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005778; Vermij L, 2020, HISTOPATHOLOGY, V76, P52, DOI 10.1111/his.14015; Weigelt B, 2018, JNCI-J NATL CANCER I, V110, P1030, DOI 10.1093/jnci/djy028; Weinreb I, 2014, NAT GENET, V46, P1166, DOI 10.1038/ng.3096; Wilkerson MD, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku489; Wu H, 2017, ONCOGENE, V36, P2857, DOI 10.1038/onc.2016.438; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yi K, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0112-3; Zapatka M, 2020, NAT GENET, V52, P320, DOI 10.1038/s41588-019-0558-9; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhang W, 2020, ONCOLOGIST, V25, P375, DOI 10.1634/theoncologist.2019-0498	104	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1835	1850		10.1038/s41388-022-02221-0	http://dx.doi.org/10.1038/s41388-022-02221-0		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35145232	hybrid, Green Published			2022-12-17	WOS:000754012300003
J	Gu, X; Zhuang, A; Yu, J; Chai, PW; Jia, RB; Ruan, J				Gu, Xiang; Zhuang, Ai; Yu, Jie; Chai, Peiwei; Jia, Renbing; Ruan, Jing			Phase separation drives tumor pathogenesis and evolution: all roads lead to Rome	ONCOGENE			English	Review							RNA-POLYMERASE-II; SUPER-ENHANCERS; CELL IDENTITY; CANCER; TRANSCRIPTION; PML; GRANULES; COMPLEX; BINDING; FUS	Cells coordinate numerous biochemical reactions in space and time, depending on the subdivision of the intracellular space into functional compartments. Compelling evidence has demonstrated that phase separation induces the formation of membrane-less compartments to partition intracellular substances in a strictly regulated manner and participates in various biological processes. Based on the strong association of cancer with the dysregulation of intracellular physiological processes and the occurrence of phase separation in cancer-associated condensates, phase separation undoubtedly plays a significant role in tumorigenesis. In this review, we summarize the drivers and functions of phase separation, elaborate on the roles of phase separation in tumor pathogenesis and evolution, and propose substantial research and therapeutic prospects for phase separation in cancer.	[Gu, Xiang; Zhuang, Ai; Yu, Jie; Chai, Peiwei; Jia, Renbing; Ruan, Jing] Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai 20025, Peoples R China; [Gu, Xiang; Zhuang, Ai; Yu, Jie; Chai, Peiwei; Jia, Renbing; Ruan, Jing] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai 20025, Peoples R China	Shanghai Jiao Tong University	Chai, PW; Jia, RB; Ruan, J (corresponding author), Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai 20025, Peoples R China.; Chai, PW; Jia, RB; Ruan, J (corresponding author), Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai 20025, Peoples R China.	chaipeiwei123@sjtu.edu.cn; renbingjia@sjtu.edu.cn; drjruan@163.com	Ruan, Jing/GON-6485-2022	Ruan, Jing/0000-0001-8728-4568	National Key Research and Development Plan [2017YFE0196300]; National Natural Science Foundation of China [81772875, 81972530, 82073889, U1932135]; Science and Technology Commission of Shanghai Municipality [SHDC2020CR1009A, 20DZ2270800, 19JC1410200]; Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine [JYYQ001]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine	This work was supported by the National Key Research and Development Plan (2017YFE0196300), the National Natural Science Foundation of China (81772875, 81972530, 82073889 and U1932135), Science and Technology Commission of Shanghai Municipality (SHDC2020CR1009A, 20DZ2270800 and 19JC1410200), Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (JYYQ001).	Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Abu Ahmad Y, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092374; Adjei AA, 2005, J CLIN ONCOL, V23, P5386, DOI 10.1200/JCO.2005.23.648; Altmeyer M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9088; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bergeron-Sandoval LP, 2016, CELL, V165, P1067, DOI 10.1016/j.cell.2016.05.026; Bienz M, 2020, CELL, V182, P799, DOI 10.1016/j.cell.2020.07.037; Boeynaems S, 2018, TRENDS CELL BIOL, V28, P420, DOI 10.1016/j.tcb.2018.02.004; Boija A, 2021, CANCER CELL, V39, P174, DOI 10.1016/j.ccell.2020.12.003; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Bouchard JJ, 2018, MOL CELL, V72, P19, DOI 10.1016/j.molcel.2018.08.027; Boulay G, 2017, CELL, V171, P163, DOI 10.1016/j.cell.2017.07.036; Boysen G, 2015, ELIFE, V4, DOI 10.7554/eLife.09207; Brangwynne CP, 2009, SCIENCE, V324, P1729, DOI 10.1126/science.1172046; Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024; Burke KA, 2015, MOL CELL, V60, P231, DOI 10.1016/j.molcel.2015.09.006; Cai DF, 2019, NAT CELL BIOL, V21, P1578, DOI 10.1038/s41556-019-0433-z; Carabet LA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010120; Case LB, 2019, SCIENCE, V363, P1093, DOI 10.1126/science.aau6313; Caslini C, 2019, ONCOGENE, V38, P6599, DOI 10.1038/s41388-019-0897-0; Chang HR, 2018, MUTAT RES-FUND MOL M, V809, P99, DOI 10.1016/j.mrfmmm.2017.05.002; Chen D, 2020, DEV CELL, V55, P588, DOI 10.1016/j.devcel.2020.10.010; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; De Vitis M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020606; di Masi A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.115; Du MJ, 2018, SCIENCE, V361, P704, DOI 10.1126/science.aat1022; Feric M, 2013, NAT CELL BIOL, V15, P1253, DOI 10.1038/ncb2830; Frottin F, 2019, SCIENCE, V365, P342, DOI 10.1126/science.aaw9157; Fu Y, 2020, NAT CHEM BIOL, V16, P955, DOI 10.1038/s41589-020-0524-y; Fujioka Y, 2020, NATURE, V578, P301, DOI 10.1038/s41586-020-1977-6; Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026; Gao P, 2013, CELL, V153, P1094, DOI 10.1016/j.cell.2013.04.046; Gao YF, 2019, CELL RES, V29, P767, DOI 10.1038/s41422-019-0210-3; Gibson BA, 2019, CELL, V179, P470, DOI 10.1016/j.cell.2019.08.037; Guo YE, 2019, NATURE, V572, P543, DOI 10.1038/s41586-019-1464-0; Gupta R, 2020, ONCOGENE, V39, P7093, DOI 10.1038/s41388-020-01490-x; Harlen KM, 2017, NAT REV MOL CELL BIO, V18, P263, DOI 10.1038/nrm.2017.10; Henninger JE, 2021, CELL, V184, P207, DOI 10.1016/j.cell.2020.11.030; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hofweber M, 2018, CELL, V173, P706, DOI 10.1016/j.cell.2018.03.004; Hu J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13347; Hyman AA, 2014, ANNU REV CELL DEV BI, V30, P39, DOI 10.1146/annurev-cellbio-100913-013325; Hyman AA, 2012, SCIENCE, V337, P1047, DOI 10.1126/science.1223728; Iconaru LI, 2015, SCI REP-UK, V5, DOI 10.1038/srep15686; Jeggo PA, 2016, NAT REV CANCER, V16, P35, DOI 10.1038/nrc.2015.4; Jia WL, 2020, NUCLEIC ACIDS RES, V48, pW415, DOI 10.1093/nar/gkaa371; Jiang H, 2013, NAT STRUCT MOL BIOL, V20, P1156, DOI 10.1038/nsmb.2656; Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6; Kedersha N, 2013, TRENDS BIOCHEM SCI, V38, P494, DOI 10.1016/j.tibs.2013.07.004; Kilic S, 2019, EMBO J, V38, DOI 10.15252/embj.2018101379; Kim TH, 2019, SCIENCE, V365, P825, DOI 10.1126/science.aax4240; Klein IA, 2020, SCIENCE, V368, P1386, DOI 10.1126/science.aaz4427; Kwon I, 2013, CELL, V155, P1049, DOI 10.1016/j.cell.2013.10.033; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Li W, 2020, NAT CELL BIOL, V22, P960, DOI 10.1038/s41556-020-0550-8; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Lu Y, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0485-0; Mastrocola AS, 2013, J BIOL CHEM, V288, P24731, DOI 10.1074/jbc.M113.497974; Mateju D, 2020, CELL, V183, P1801, DOI 10.1016/j.cell.2020.11.010; Mirza-Aghazadeh-Attari M, 2019, DNA REPAIR, V73, P110, DOI 10.1016/j.dnarep.2018.11.008; Mitrea DM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03255-3; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Oshidari R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14546-z; Pak CW, 2016, MOL CELL, V63, P72, DOI 10.1016/j.molcel.2016.05.042; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Plys AJ, 2019, GENE DEV, V33, P799, DOI 10.1101/gad.326488.119; Potts PR, 2007, NAT STRUCT MOL BIOL, V14, P581, DOI 10.1038/nsmb1259; Ries RJ, 2019, NATURE, V571, P424, DOI 10.1038/s41586-019-1374-1; Ryan JJ, 2019, J BIOL CHEM, V294, P11286, DOI 10.1074/jbc.RA119.009494; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Saito M, 2019, NAT CHEM BIOL, V15, P51, DOI 10.1038/s41589-018-0180-7; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sanulli S, 2019, NATURE, V575, P390, DOI 10.1038/s41586-019-1669-2; Seton-Rogers Sarah, 2018, Nat Rev Cancer, V18, P667, DOI 10.1038/s41568-018-0066-8; Shima Y, 2008, MOL CELL BIOL, V28, P7126, DOI 10.1128/MCB.00897-08; Shin Y, 2017, SCIENCE, V357, DOI 10.1126/science.aaf4382; Shrinivas K, 2019, MOL CELL, V75, P549, DOI 10.1016/j.molcel.2019.07.009; Somasekharan SP, 2015, J CELL BIOL, V208, P913, DOI 10.1083/jcb.201411047; Song YZ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1124-x; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Su XL, 2016, SCIENCE, V352, P595, DOI 10.1126/science.aad9964; Sun DX, 2018, CELL RES, V28, P405, DOI 10.1038/s41422-018-0017-7; Tatavosian R, 2019, J BIOL CHEM, V294, P1451, DOI 10.1074/jbc.RA118.006620; Tsai WC, 2016, J BIOL CHEM, V291, P22671, DOI 10.1074/jbc.M116.739573; Tsang B, 2019, P NATL ACAD SCI USA, V116, P4218, DOI 10.1073/pnas.1814385116; Varadi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139731; Vernon RM, 2018, ELIFE, V7, DOI 10.7554/eLife.31486; Wang JH, 2020, PROTEIN CELL, V11, P304, DOI 10.1007/s13238-019-00660-2; Wang L, 2019, MOL CELL, V76, P646, DOI 10.1016/j.molcel.2019.08.019; Wang RJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5708; Wangeline MA, 2017, ANNU REV CELL DEV BI, V33, P467, DOI 10.1146/annurev-cellbio-111315-125036; Weber SC, 2015, CURR BIOL, V25, P641, DOI 10.1016/j.cub.2015.01.012; Wheeler RJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0193; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu H, 2016, CELL, V165, P1055, DOI 10.1016/j.cell.2016.05.004; Xia SY, 2021, PROTEIN CELL, V12, P680, DOI 10.1007/s13238-021-00839-6; Xie W, 2013, SCIENCE, V341, P245, DOI 10.1126/science.1236254; Yamasaki A, 2020, MOL CELL, V77, P1163, DOI 10.1016/j.molcel.2019.12.026; Yamazaki T, 2018, MOL CELL, V70, P1038, DOI 10.1016/j.molcel.2018.05.019; Yasuda S, 2020, NATURE, V578, P296, DOI 10.1038/s41586-020-1982-9; Yu M, 2021, MOL CELL, V81, P1216, DOI 10.1016/j.molcel.2021.01.010; Zaborowska J, 2016, NAT STRUCT MOL BIOL, V23, P771, DOI 10.1038/nsmb.3285; Zamaraev AV, 2017, TRENDS CELL BIOL, V27, P322, DOI 10.1016/j.tcb.2017.01.003; Zhang GM, 2018, CELL, V174, P1492, DOI 10.1016/j.cell.2018.08.006; Zhang H, 2020, SCI CHINA LIFE SCI, V63, P953, DOI 10.1007/s11427-020-1702-x; Zhang HY, 2020, MOL BIOL CELL, V31, P2048, DOI 10.1091/mbc.E19-10-0589; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhou W, 2021, MOL CELL, V81, P739, DOI 10.1016/j.molcel.2021.01.024; Zhu GY, 2021, CELL RES, V31, P1028, DOI 10.1038/s41422-021-00504-x; Zhu GY, 2020, CELL, V183, P490, DOI 10.1016/j.cell.2020.09.002	116	0	0	8	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1527	1535		10.1038/s41388-022-02195-z	http://dx.doi.org/10.1038/s41388-022-02195-z		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35132182				2022-12-17	WOS:000752287800001
J	Yuan, SK; Zhang, PT; Wen, LQ; Jia, SK; Wu, YF; Zhang, ZL; Guan, LZ; Yu, ZQ; Zhao, L				Yuan, Shukai; Zhang, Peitao; Wen, Liqi; Jia, Shikai; Wu, Yufan; Zhang, Zhenlei; Guan, Lizhao; Yu, Zhengquan; Zhao, Li			miR-22 promotes stem cell traits via activating Wnt/beta-catenin signaling in cutaneous squamous cell carcinoma (vol 40, pg 5799, 2021)	ONCOGENE			English	Correction												shzhaoli@tmu.edu.cn						Yuan SK, 2021, ONCOGENE, V40, P5799, DOI 10.1038/s41388-021-01973-5	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1674	1676		10.1038/s41388-022-02188-y	http://dx.doi.org/10.1038/s41388-022-02188-y		FEB 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35121828	hybrid, Green Published			2022-12-17	WOS:000751251500004
J	Ma, AH; Tang, M; Zhang, L; Wang, BS; Yang, ZJ; Liu, Y; Xu, GQ; Wu, L; Jing, TT; Xu, XL; Yang, SL; Liu, YZ				Ma, Aihui; Tang, Ming; Zhang, Li; Wang, Boshi; Yang, Zhaojuan; Liu, Yun; Xu, Guiqin; Wu, Lin; Jing, Tiantian; Xu, Xiaoli; Yang, Shengli; Liu, Yongzhong			USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis (vol 38, pg 2405, 2019)	ONCOGENE			English	Correction												liuyzg@shsci.org						Ma AH, 2019, ONCOGENE, V38, P2405, DOI 10.1038/s41388-018-0590-8	1	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1673	1673		10.1038/s41388-022-02215-y	http://dx.doi.org/10.1038/s41388-022-02215-y		FEB 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35115639	Bronze			2022-12-17	WOS:000750678200001
J	Bharathy, N; Cleary, MM; Kim, JA; Nagamori, K; Crawford, KA; Wang, E; Saha, D; Settelmeyer, TP; Purohit, R; Skopelitis, D; Chang, K; Doran, JA; Kirschbaum, CW; Bharathy, S; Crews, DW; Randolph, ME; Karnezis, AN; Hudson-Price, L; Dhawan, J; Michalek, JE; Ciulli, A; Vakoc, CR; Keller, C				Bharathy, Narendra; Cleary, Megan M.; Kim, Jin-Ah; Nagamori, Kiyo; Crawford, Kenneth A.; Wang, Eric; Saha, Debarya; Settelmeyer, Teagan P.; Purohit, Reshma; Skopelitis, Damianos; Chang, Kenneth; Doran, Jessica A.; Kirschbaum, C. Ward; Bharathy, Suriya; Crews, Davis W.; Randolph, Matthew E.; Karnezis, Anthony N.; Hudson-Price, Lisa; Dhawan, Jyotsna; Michalek, Joel E.; Ciulli, Alessio; Vakoc, Christopher R.; Keller, Charles			SMARCA4 biology in alveolar rhabdomyosarcoma	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; METASTATIC RHABDOMYOSARCOMA; SWI/SNF COMPLEXES; GENETIC LANDSCAPE; MUTATIONS; OVARY; BROMODOMAIN; CHILDREN; OUTCOMES; SARCOMA	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and phenocopies a muscle precursor that fails to undergo terminal differentiation. The alveolar subtype (ARMS) has the poorest prognosis and represents the greatest unmet medical need for RMS. Emerging evidence supports the role of epigenetic dysregulation in RMS. Here we show that SMARCA4/BRG1, an ATP-dependent chromatin remodeling enzyme of the SWI/SNF complex, is prominently expressed in primary tumors from ARMS patients and cell cultures. Our validation studies for a CRISPR screen of 400 epigenetic targets identified SMARCA4 as a unique factor for long-term (but not short-term) tumor cell survival in ARMS. A SMARCA4/SMARCA2 protein degrader (ACBI-1) demonstrated similar long-term tumor cell dependence in vitro and in vivo. These results credential SMARCA4 as a tumor cell dependency factor and a therapeutic target in ARMS.	[Bharathy, Narendra; Cleary, Megan M.; Kim, Jin-Ah; Nagamori, Kiyo; Crawford, Kenneth A.; Saha, Debarya; Settelmeyer, Teagan P.; Purohit, Reshma; Doran, Jessica A.; Kirschbaum, C. Ward; Bharathy, Suriya; Crews, Davis W.; Randolph, Matthew E.; Hudson-Price, Lisa; Keller, Charles] Childrens Canc Therapy Dev Inst, Beaverton, OR 97005 USA; [Wang, Eric; Skopelitis, Damianos; Chang, Kenneth; Vakoc, Christopher R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Saha, Debarya; Dhawan, Jyotsna] CSIR CCMB, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India; [Karnezis, Anthony N.] Univ Calif C Davis Med Ctr, Sacramento, CA 95817 USA; [Karnezis, Anthony N.] British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; [Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Ciulli, Alessio] Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland; [Bharathy, Narendra] Univ Penn, Perelman Sch Med, Gene Therapy Program, Philadelphia, PA 19104 USA	Cold Spring Harbor Laboratory; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); British Columbia Cancer Agency; University of Texas System; University of Texas Health San Antonio; University of Dundee; University of Pennsylvania; Pennsylvania Medicine	Keller, C (corresponding author), Childrens Canc Therapy Dev Inst, Beaverton, OR 97005 USA.; Ciulli, A (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland.	a.ciulli@dundee.ac.uk; charles@cc-tdi.org		Nagamori, Kiyo/0000-0002-7891-3534; Keller, Charles/0000-0003-2505-7487	Braver Stronger Smarter Foundation; Maddie's Promise Foundation; NIH [R01CA189299, R01CA258720]; Boehringer Ingelheim; Pershing Square Sohn Cancer Research Alliance, Northwell Health Translational Research Award; Christina Renna Foundation; Clark Gillies Foundation; Friends of T.J. Foundation; Michelle Paternoster Foundation; National Cancer Institute [CA2455859]; Department of Biotechnology (DBT), Govt. of India; Indo-U.S. Science and Technology Forum (IUSSTF)	Braver Stronger Smarter Foundation; Maddie's Promise Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boehringer Ingelheim(Boehringer Ingelheim); Pershing Square Sohn Cancer Research Alliance, Northwell Health Translational Research Award(Pershing Square Sohn Cancer Research Alliance); Christina Renna Foundation; Clark Gillies Foundation; Friends of T.J. Foundation; Michelle Paternoster Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Biotechnology (DBT), Govt. of India(Department of Biotechnology (DBT) India); Indo-U.S. Science and Technology Forum (IUSSTF)	We thank Dr. Manfred Kogl for generously providing vectors LMH-SMARCA2 and LMH-PBRM1. This study was funded by Braver Stronger Smarter Foundation, Maddie's Promise Foundation and by NIH grants R01CA189299 & R01CA258720. The ACBI-1 PROTAC degrader was developed with funding support to the Ciulli Laboratory by Boehringer Ingelheim. CRV was supported by the Pershing Square Sohn Cancer Research Alliance, Northwell Health Translational Research Award, The Christina Renna Foundation, The Clark Gillies Foundation, The Friends of T.J. Foundation, The Michelle Paternoster Foundation, and a grant from National Cancer Institute (CA2455859). DS was supported by the Indo-U.S. GETin program from Department of Biotechnology (DBT), Govt. of India and Indo-U.S. Science and Technology Forum (IUSSTF).	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Albini S, 2010, EXP CELL RES, V316, P3073, DOI 10.1016/j.yexcr.2010.05.023; Bell EH, 2016, CLIN CANCER RES, V22, P2396, DOI 10.1158/1078-0432.CCR-15-1468; Bharathy N, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau7632; Bharathy N, 2016, J PATHOL, V240, P269, DOI 10.1002/path.4773; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Chan-Penebre E, 2017, MOL CANCER THER, V16, P850, DOI 10.1158/1535-7163.MCT-16-0678; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Dagher R, 1999, Oncologist, V4, P34; Farnaby W, 2019, NAT CHEM BIOL, V15, P672, DOI 10.1038/s41589-019-0294-6; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Karnezis AN, 2016, J PATHOL, V238, P389, DOI 10.1002/path.4633; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Malempati S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.10556; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; McBride MJ, 2018, J PATHOL, V244, P638, DOI 10.1002/path.5042; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Ohkawa Y, 2006, EMBO J, V25, P490, DOI 10.1038/sj.emboj.7600943; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Rudzinski ER, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26645; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Shi J, 2013, GENE DEV, V27, P2648, DOI 10.1101/gad.232710.113; Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798; Wexler LH, 1997, J PEDIATR-US, V131, P508; Williams BA, 2004, J PEDIAT HEMATOL ONC, V26, P243, DOI 10.1097/00043426-200404000-00006; Willis MS, 2012, CIRC RES, V111, pE111, DOI 10.1161/CIRCRESAHA.112.265587; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931	36	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1647	1656		10.1038/s41388-022-02205-0	http://dx.doi.org/10.1038/s41388-022-02205-0		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094009	Green Submitted			2022-12-17	WOS:000750486500002
J	Melnyk, JE; Steri, V; Nguyen, HG; Hwang, YC; Gordan, JD; Hann, B; Feng, FY; Shokat, KM				Melnyk, James E.; Steri, Veronica; Nguyen, Hao G.; Hwang, Y. Christina; Gordan, John D.; Hann, Byron; Feng, Felix Y.; Shokat, Kevan M.			Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC beta 1	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; ENZALUTAMIDE RESISTANCE; DOWN-REGULATION; VARIANTS; ENZASTAURIN; EXPRESSION; DOMAIN; PHOSPHORYLATION; OLIGONUCLEOTIDE; ANTIANDROGEN	The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling leads to resistance. Alternative splicing of AR mRNA yields the AR-V7 splice variant, which is currently an undruggable mechanism of ARSi resistance: AR-V7 lacks a ligand binding domain, where hormones and anti-androgen antagonists act, but still activates AR signaling. We reveal PKC beta as a druggable regulator of transcription and splicing at the AR genomic locus. We identify a clinical PKC beta inhibitor in combination with an FDA-approved anti-androgen as an approach for repressing AR genomic locus expression, including expression of AR-V7, while antagonizing full-length AR. PKC beta inhibition reduces total AR gene expression, thus reducing AR-V7 protein levels and sensitizing prostate cancer cells to current anti-androgen therapies. We demonstrate that this combination may be a viable therapeutic strategy for AR-V7-positive prostate cancer.	[Melnyk, James E.; Shokat, Kevan M.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Steri, Veronica; Nguyen, Hao G.; Hwang, Y. Christina; Gordan, John D.; Hann, Byron; Feng, Felix Y.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA; [Steri, Veronica; Hann, Byron] Univ Calif San Francisco, Preclin Therapeut Core, San Francisco, CA 94158 USA; [Nguyen, Hao G.; Feng, Felix Y.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA; [Hwang, Y. Christina; Gordan, John D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; [Hwang, Y. Christina; Gordan, John D.] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94158 USA; [Feng, Felix Y.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; [Feng, Felix Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Shokat, Kevan M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Shokat, KM (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA.; Shokat, KM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	Kevan.shokat@ucsf.edu		Melnyk, James/0000-0003-1915-8089	NIH [1F32CA236347-01, R01 CA227025, 1R01CA221969-01, 1R01CA244550]; PCF YI; Burroughs Wellcome Fund Career Award; Benioff Initiative for Prostate Cancer Research; Howard Hughes Medical Institute; Samuel Waxman Cancer Research Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PCF YI; Burroughs Wellcome Fund Career Award(Burroughs Wellcome Fund); Benioff Initiative for Prostate Cancer Research; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Samuel Waxman Cancer Research Foundation	We thank Davide Ruggero, the UCSF Preclinical Therapeutics Core and the UCSF/Gladstone Institutes Thermo Fisher Scientific Proteomics Facility for research assistance and discussion. We thank Amy Crossan, Shizong A. Dai, Douglas Wassarman, and Jack Stevenson for critical reading of this paper. Portions of Fig. 1A and Fig. 6A were created with BioRender.com. This work is supported by NIH grant 1F32CA236347-01 (to J.E.M.); PCF YI and Challenge grants (to H.G.N.); Burroughs Wellcome Fund Career Award (to J.D. G.); NIH R01 CA227025 and the Benioff Initiative for Prostate Cancer Research (to F.Y.F.), the Howard Hughes Medical Institute, Samuel Waxman Cancer Research Foundation, NIH 1R01CA221969-01 and NIH 1R01CA244550 (to K.M.S.).	An SA, 2018, EBIOMEDICINE, V36, P553, DOI 10.1016/j.ebiom.2018.09.005; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Armstrong CM, 2019, ASIAN J UROL, V6, P42, DOI 10.1016/j.ajur.2018.07.003; Bain DL, 2007, ANNU REV PHYSIOL, V69, P201, DOI 10.1146/annurev.physiol.69.031905.160308; Beretta GL, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00369; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Bianchini D, 2013, BRIT J CANCER, V109, P2579, DOI 10.1038/bjc.2013.619; Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Carabet LA, 2019, MOLECULES, V24, DOI 10.3390/molecules24040763; Choi M, 2014, BIOINFORMATICS, V30, P2524, DOI 10.1093/bioinformatics/btu305; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; De Mol E, 2016, ACS CHEM BIOL, V11, P2499, DOI 10.1021/acschembio.6b00182; De Velasco MA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122688; Dreicer R, 2013, INVEST NEW DRUG, V31, P1044, DOI 10.1007/s10637-013-9940-0; Dreicer R, 2011, INVEST NEW DRUG, V29, P1441, DOI 10.1007/s10637-010-9428-0; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Han D, 2019, CANCER RES, V79, P5260, DOI 10.1158/0008-5472.CAN-19-0815; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; HUANG FL, 1989, J BIOL CHEM, V264, P4238; Hwang DJ, 2019, J MED CHEM, V62, P491, DOI 10.1021/acs.jmedchem.8b00973; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Khurana N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010068; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Kwegyir-Afful AK, 2015, ONCOTARGET, V6, P27440, DOI 10.18632/oncotarget.4578; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Li HF, 2014, J MED CHEM, V57, P6458, DOI 10.1021/jm500802j; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Loberg RD, 2006, UROL ONCOL-SEMIN ORI, V24, P161, DOI 10.1016/j.urolonc.2005.11.005; Makkonen H, 2011, MOL CELL ENDOCRINOL, V331, P57, DOI 10.1016/j.mce.2010.08.008; Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057; Melnyk JE, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115712; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398; Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009; Podar K, 2007, BLOOD, V109, P1669, DOI 10.1182/blood-2006-08-042747; Ponnusamy S, 2019, CLIN CANCER RES, V25, P6764, DOI 10.1158/1078-0432.CCR-19-1458; Prekovic S, 2016, MOL CANCER THER, V15, P1702, DOI 10.1158/1535-7163.MCT-15-0892; Putney James W, 2012, Adv Biol Regul, V52, P152; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Saha SK, 2016, CANCER DISCOV, V6, P727, DOI 10.1158/2159-8290.CD-15-1442; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Scher Howard I, 2016, JAMA Oncol, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Schilling B, 2012, MOL CELL PROTEOMICS, V11, P202, DOI 10.1074/mcp.M112.017707; Shiota M, 2014, CLIN CANCER RES, V20, P951, DOI 10.1158/1078-0432.CCR-13-1809; Thorne CA, 2015, NAT CHEM BIOL, V11, P58, DOI 10.1038/nchembio.1690; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Velez MVL, 2019, ONCOGENE, V38, P3696, DOI 10.1038/s41388-019-0696-7; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xiao LB, 2018, CANCER RES, V78, P5731, DOI 10.1158/0008-5472.CAN-18-0941; Yadav B, 2015, COMPUT STRUCT BIOTEC, V13, P504, DOI 10.1016/j.csbj.2015.09.001; Yang ZY, 2020, MOL CANCER THER, V19, P75, DOI 10.1158/1535-7163.MCT-19-0489; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang XW, 2017, MOL THER, V25, P79, DOI 10.1016/j.ymthe.2016.10.017	68	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1536	1549		10.1038/s41388-022-02179-z	http://dx.doi.org/10.1038/s41388-022-02179-z		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35087237	Green Published, hybrid			2022-12-17	WOS:000749068200001
J	Zhang, YF; Li, Q; Huang, PQ; Su, T; Jiang, SH; Hu, LP; Zhang, XL; Sun, Y; Pan, H; Yang, XM; Li, J; Gai, YZ; Zhu, L; Yao, LL; Li, DX; Sun, YW; Zhang, ZG; Liu, DJ; Zhang, YL; Nie, HZ				Zhang, Yi-Fan; Li, Qing; Huang, Pei-Qi; Su, Tong; Jiang, Shu-Heng; Hu, Li-Peng; Zhang, Xue-Li; Sun, Yue; Pan, Hong; Yang, Xiao-Mei; Li, Jun; Gai, Yan-Zhi; Zhu, Lei; Yao, Lin-Li; Li, Dong-Xue; Sun, Yong-Wei; Zhang, Zhi-Gang; Liu, De-Jun; Zhang, Yan-Li; Nie, Hui-Zhen			A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							PROTEIN; TUMOR; INHIBITOR	Pancreatic ductal adenocarcinoma (PDAC), cancer with a high mortality rate and the highest rate of KRAS mutation, reportedly internalizes proteins via macropinocytosis to adapt to low amino acid levels in the tumor microenvironment. Here, we aimed to identify a key regulator of macropinocytosis for the survival of tumor cells in a low amino acid environment in PDAC. FYVE, RhoGEF, and PH domain-containing protein 6 (FGD6) were identified as key regulators of macropinocytosis. FGD6 promoted PDAC cell proliferation, macropinocytosis, and tumor growth both in vitro and in vivo. The macropinocytosis level was decreased with FGD6 knockdown in PDAC cell lines. Moreover, FGD6 promoted macropinocytosis by participating in the trans-Golgi network and enhancing the membrane localization of growth factor receptors, especially the TGF-beta receptor. TGF-beta enhanced macropinocytosis in PDAC cells. Additionally, YAP nuclear translocation induced by a low amino acid tumor environment initiated FGD6 expression by coactivation with YY1. Clinical data analysis based on TCGA and GEO datasets showed that FGD6 expression was upregulated in PDAC tissue, and high FGD6 expression was correlated with poor prognosis in patients with PDAC. In tumor tissue from Kras(G12D/+)/Trp53(R172H/-)/Pdx1-Cre (KPC) mice, FGD6 expression escalated during PDAC development. Our results uncover a previously unappreciated mechanism of macropinocytosis in PDAC. Strategies to target FGD6 and growth factors membrane localization might be developed for the treatment of PDAC.	[Zhang, Yi-Fan; Li, Qing; Huang, Pei-Qi; Jiang, Shu-Heng; Hu, Li-Peng; Zhang, Xue-Li; Sun, Yue; Pan, Hong; Yang, Xiao-Mei; Li, Jun; Gai, Yan-Zhi; Zhu, Lei; Yao, Lin-Li; Li, Dong-Xue; Zhang, Zhi-Gang; Zhang, Yan-Li; Nie, Hui-Zhen] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai 200240, Peoples R China; [Su, Tong] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai Key Lab Gynecol & Oncol,Dept Gynecol & O, Shanghai 200127, Peoples R China; [Sun, Yong-Wei; Liu, De-Jun] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, YL; Nie, HZ (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai 200240, Peoples R China.; Liu, DJ (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China.	Liudejun@renji.com; ylzhang@shsci.org; hznie@shsci.org		Hu, Lipeng/0000-0002-5941-3825; Zhang, Xueli/0000-0001-8306-0639	National Natural Science Foundation of China [81672837, 81872242, 82002485]; Natural Science Foundation of Shanghai [21ZR1461400, 19ZR1452500]; Shanghai Municipal Health Commission [202040104]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Shanghai Municipal Health Commission	This study was supported by the National Natural Science Foundation of China (81672837, to H.-Z. Nie; 81872242, to Y.-L. Zhang; 82002485, to Q.Li), the Natural Science Foundation of Shanghai (21ZR1461400, to H.-Z. Nie; 19ZR1452500 to X.-M. Yang), Shanghai Municipal Health Commission (202040104, to Y.-L. Zhang).	Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Boncompain G, 2012, NAT METHODS, V9, P493, DOI [10.1038/NMETH.1928, 10.1038/nmeth.1928]; Commisso C, 2014, NAT PROTOC, V9, P182, DOI 10.1038/nprot.2014.004; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Davidson SM, 2017, NAT MED, V23, P235, DOI 10.1038/nm.4256; Donaldson JG, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0148; Edwards DN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4667; Egorov MV, 2009, MOL BIOL CELL, V20, P2413, DOI 10.1091/mbc.E08-11-1136; Eitzen G, 2019, BIOCHEM CELL BIOL, V97, P257, DOI 10.1139/bcb-2018-0185; Ferreira APA, 2018, TRENDS CELL BIOL, V28, P188, DOI 10.1016/j.tcb.2017.11.004; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Hassan Z, 2018, BRIT J CANCER, V118, P366, DOI 10.1038/bjc.2017.421; Hong L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02818-x; Hong L, 2013, J BIOL CHEM, V288, P8531, DOI 10.1074/jbc.M112.435941; Hoxha S, 2020, CANCER RES, V80, P2512, DOI 10.1158/0008-5472.CAN-19-2415; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; King B, 2020, GENE DEV, V34, P1345, DOI 10.1101/gad.340661.120; Koo JH, 2018, CELL METAB, V28, P196, DOI 10.1016/j.cmet.2018.07.010; Lee SW, 2019, DEV CELL, V50, P381, DOI 10.1016/j.devcel.2019.05.043; Lee SW, 2019, METHODS MOL BIOL, V1882, P171, DOI 10.1007/978-1-4939-8879-2_16; Lim JP, 2011, IMMUNOL CELL BIOL, V89, P836, DOI 10.1038/icb.2011.20; Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137; Marques PE, 2017, CELL, V169, P766, DOI 10.1016/j.cell.2017.04.031; Moffitt RA, 2015, NAT GENET, V47, P1168, DOI 10.1038/ng.3398; Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8; Nakazawa MS, 2016, NAT REV CANCER, V16, P663, DOI 10.1038/nrc.2016.84; Nofal M, 2017, MOL CELL, V67, P936, DOI 10.1016/j.molcel.2017.08.011; Palm W, 2017, P NATL ACAD SCI USA, V114, pE8628, DOI 10.1073/pnas.1712726114; Palm W, 2017, NATURE, V546, P234, DOI 10.1038/nature22379; Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rashidian J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005735; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Steenblock C, 2014, J BIOL CHEM, V289, P18347, DOI 10.1074/jbc.M113.504894; Swanson JA, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0157; Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496; Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190; Yang CS, 2018, EMBO REP, V19, DOI 10.15252/embr.201643577; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017; Zhang Y-F, 2019, TARGETING TUMOR MICR, V8, P4; Zhang YL, 2018, CANCER RES, V78, P2305, DOI 10.1158/0008-5472.CAN-17-2867	45	0	0	9	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1203	1215		10.1038/s41388-021-02159-9	http://dx.doi.org/10.1038/s41388-021-02159-9		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35082383				2022-12-17	WOS:000749084700001
J	Steiner, S; Seleznik, GM; Reding, T; Stopic, M; Lenggenhager, D; ten Buren, E; Eshmuminov, D; Endhardt, K; Hagedorn, C; Heidenblut, AM; Bratus-Neuenschwander, A; Grossmann, J; Trachsel, C; Jabbar, KS; Hahn, SA; vom Berg, J; Graf, R; Gupta, A				Steiner, Sabrina; Seleznik, Gitta M.; Reding, Theresia; Stopic, Matea; Lenggenhager, Daniela; ten Buren, Emiel; Eshmuminov, Dilmurodjon; Endhardt, Katharina; Hagedorn, Catherine; Heidenblut, Anna M.; Bratus-Neuenschwander, Anna; Grossmann, Jonas; Trachsel, Christian; Jabbar, Karolina S.; Hahn, Stephan A.; vom Berg, Johannes; Graf, Rolf; Gupta, Anurag			De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer	ONCOGENE			English	Article							1 INDUCES SENESCENCE; TUMOR-SUPPRESSOR; BIOLOGY; INHIBITION; ACTIVATION; HEDGEHOG; MARKERS	Molecular events occurring in stepwise progression from pre-malignant lesions (pancreatic intraepithelial neoplasia; PanIN) to the development of pancreatic ductal adenocarcinoma (PDAC) are poorly understood. Thus, characterization of early PanIN lesions may reveal markers that can help in diagnosing PDAC at an early stage and allow understanding the pathology of the disease. We performed the molecular and histological assessment of patient-derived PanINs, tumor tissues and pancreas from mouse models with PDAC (KC mice that harbor K-RAS mutation in pancreatic tissue), where we noted marked upregulation of gastrokine (GKN) proteins. To further understand the role of gastrokine proteins in PDAC development, GKN-deficient KC mice were developed by intercrossing gastrokine-deficient mice with KC mice. Panc-02 (pancreatic cancer cells of mouse origin) were genetically modified to express GKN1 for further in vitro and in vivo analysis. Our results show that gastrokine proteins were absent in healthy pancreas and invasive cancer, while its expression was prominent in low-grade PanINs. We could detect these proteins in pancreatic juice and serum of KC mice. Furthermore, accelerated PanIN and tumor development were noted in gastrokine deficient KC mice. Loss of gastrokine 1 protein delayed apoptosis during carcinogenesis leading to the development of desmoplastic stroma while loss of gastrokine 2 increased the proliferation rate in precursor lesions. In summary, we identified gastrokine proteins in early pancreatic precursor lesions, where gastrokine proteins delay pancreatic carcinogenesis.	[Steiner, Sabrina; Seleznik, Gitta M.; Reding, Theresia; Stopic, Matea; Eshmuminov, Dilmurodjon; Hagedorn, Catherine; Graf, Rolf; Gupta, Anurag] Univ Hosp Zurich, Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland; [Lenggenhager, Daniela; Endhardt, Katharina] Univ Hosp Zurich, Dept Pathol & Mol Pathol, CH-8091 Zurich, Switzerland; [Lenggenhager, Daniela; Endhardt, Katharina] Univ Zurich, CH-8091 Zurich, Switzerland; [ten Buren, Emiel; vom Berg, Johannes] Univ Zurich, Inst Lab Anim Sci, CH-8952 Schlieren, Switzerland; [Heidenblut, Anna M.; Hahn, Stephan A.] Ruhr Univ Bochum, Fac Med, Dept Mol GI Oncol, D-44780 Bochum, Germany; [Bratus-Neuenschwander, Anna; Grossmann, Jonas; Trachsel, Christian] Univ Zurich, ETH, Funct Genom Ctr Zurich, CH-8093 Zurich, Switzerland; [Jabbar, Karolina S.] Univ Gothenburg, Dept Med Biochem, S-40530 Gothenburg, Sweden	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; Ruhr University Bochum; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Gothenburg	Graf, R; Gupta, A (corresponding author), Univ Hosp Zurich, Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland.	Rolf.graf@usz.ch; Anurag.Gupta@usz.ch	Hahn, Stephan/E-3880-2010	Hahn, Stephan/0000-0003-0855-9741; vom Berg, Johannes/0000-0002-4086-1564; Gupta, Anurag/0000-0001-6850-3489; Lenggenhager, Daniela/0000-0002-5382-9854; Steiner, Sabrina/0000-0002-1562-2430	Vontobel Stiftung Zurich; Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung; Swiss National Science Foundation (SNF) [310030_166645]	Vontobel Stiftung Zurich; Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung; Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF))	For the excellent support with microarray and proteomics analysis, we would like to acknowledge Lennart Opitz and Nathalie Selevsek from the Functional Genomics Centre Zurich (FGCZ). For the technical support with histology samples, we would like to thank Dr. Ursula Suss, Pia Fuchs, Andrea Garcete, and Ines Kleiber. For the outstanding service, we would like to acknowledge the animal care taker team of the University Hospital Zurich (BZL) and University of Zurich (LASC). We also thank Ms. Noelle Bayyoud for proofreading/English editing of the manuscript. This work was supported by grants from Vontobel Stiftung Zurich (R.G.) and Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung (A.G.) and by a grant by the Swiss National Science Foundation (SNF GRANT number: 310030_166645).	Algul H, 2007, INT J CANCER, V121, P1410, DOI 10.1002/ijc.22779; Bernadotte A, 2016, AGING-US, V8, P3, DOI 10.18632/aging.100871; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cicenas J, 2017, CANCERS, V9, DOI 10.3390/cancers9050042; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collisson EA, 2019, NAT REV GASTRO HEPAT, V16, P207, DOI 10.1038/s41575-019-0109-y; Distler M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474905; Fahlbusch FB, 2013, PLACENTA, V34, P1027, DOI 10.1016/j.placenta.2013.08.005; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hutchings D, 2018, AM J SURG PATHOL, V42, P1556, DOI 10.1097/PAS.0000000000001148; Jabbar KS, 2018, J CLIN ONCOL, V36, P367, DOI 10.1200/JCO.2017.73.7288; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; MATSUZAWA K, 1992, HUM PATHOL, V23, P925, DOI 10.1016/0046-8177(92)90407-T; Menheniott TR, 2016, J CLIN INVEST, V126, P1383, DOI 10.1172/JCI82655; Menheniott TR, 2013, AM J PHYSIOL-GASTR L, V304, pG109, DOI 10.1152/ajpgi.00374.2012; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Nollmann FI, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080281; Notta F, 2017, GUT, V66, P2170, DOI 10.1136/gutjnl-2016-313317; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Ray K, 2017, NAT REV GASTRO HEPAT, V14, P504, DOI 10.1038/nrgastro.2017.111; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sah RP, 2013, GASTROENTEROLOGY, V144, P1076, DOI 10.1053/j.gastro.2013.01.041; Seleznik GM, 2012, GASTROENTEROLOGY, V143, P1361, DOI 10.1053/j.gastro.2012.07.112; SESSA F, 1990, GASTROENTEROLOGY, V98, P1655, DOI 10.1016/0016-5085(90)91104-E; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Toback FG, 2003, AM J PHYSIOL-GASTR L, V285, pG344, DOI 10.1152/ajpgi.00455.2002; Xing R, 2012, GUT, V61, P43, DOI 10.1136/gut.2010.230623; Xu ZH, 2010, AM J PATHOL, V177, P2585, DOI 10.2353/ajpath.2010.090899; Yan GR, 2011, PROTEOMICS, V11, P3657, DOI 10.1002/pmic.201100215; Yoon JH, 2017, GASTRIC CANCER, V20, P274, DOI 10.1007/s10120-016-0617-1; Yoon JH, 2014, ONCOTARGET, V5, P11695, DOI 10.18632/oncotarget.2586; Yoon JH, 2011, J CANCER RES CLIN, V137, P1697, DOI 10.1007/s00432-011-1051-8	36	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1507	1517		10.1038/s41388-022-02182-4	http://dx.doi.org/10.1038/s41388-022-02182-4		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35082384	Green Published, hybrid			2022-12-17	WOS:000749084600001
J	Okpechi, SC; Yousefi, H; Nguyen, K; Cheng, T; Alahari, NV; Collins-Burow, B; Burow, ME; Alahari, SK				Okpechi, Samuel C.; Yousefi, Hassan; Nguyen, Khoa; Cheng, Thomas; Alahari, Nikhilesh, V; Collins-Burow, Bridgette; Burow, Matthew E.; Alahari, Suresh K.			Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer	ONCOGENE			English	Review							BINDING PROTEIN NISCHARIN; IMIDAZOLINE RECEPTOR; DOWN-REGULATION; EXPRESSION; KINASE; IRAS; INHIBITION; MODULATION; ACTIVATION; SECRETION	Nischarin has been demonstrated to have tumor suppressor functions. In this review, we comprehensively discuss up to date information about Nischarin. In addition, this paper aims to report the prognostic value, clinical relevance, and biological significance of the Nischarin gene (NISCH) in breast cancer (BCa) patients using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) datasets. We evaluated NISCH gene expression and its correlation to patient survival, baseline expression, and expression variation based on age groups, tumor stage, tumor size, tumor grade, and lymph node status in different subtypes of BCa. Since NISCH has been extensively reported to inhibit EMT and cancer cell migration, we also checked for the correlation between NISCH and EMT genes in addition to the correlation between NISCH and cell migration genes. Our results indicate that NISCH is a tumor suppressor that plays a critical role in BCa initiation, progression, and tumor development. We find that there is a higher level of NISCH expression in normal breast tissues compared to breast cancer tissues. Also, aggressive subtypes of breast cancers, such as the triple negative/basal category, have decreased levels of NISCH as the disease progresses. Finally, we report that NISCH is inversely correlated with many EMT and cancer cell migration genes in BCa. Interestingly, we identified a significant negative correlation between NISCH expression and its methylation in breast cancer patients. Overall, the goal of this report is to establish a strong clinical basis for further investigation into the cellular, molecular, and physiological roles of NISCH in BCa. Ultimately, NISCH gene expression might be clinically harnessed as a biomarker or predictor of invasiveness and metastasis in BCa.	[Okpechi, Samuel C.; Yousefi, Hassan; Alahari, Suresh K.] Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Okpechi, Samuel C.; Yousefi, Hassan; Alahari, Suresh K.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA; [Okpechi, Samuel C.; Yousefi, Hassan; Alahari, Suresh K.] Louisiana State Univ, Sch Med, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; [Nguyen, Khoa; Cheng, Thomas; Collins-Burow, Bridgette; Burow, Matthew E.] Tulane Univ, Sch Med, Sect Hematol & Med Oncol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Alahari, Nikhilesh, V] Louisiana State Univ Biol Sci, Baton Rouge, LA USA	Louisiana State University System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Tulane University; Louisiana State University System; Louisiana State University	Alahari, SK (corresponding author), Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.; Alahari, SK (corresponding author), Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA.; Alahari, SK (corresponding author), Louisiana State Univ, Sch Med, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu			Fred G. Brazda Foundation; Department of Biochemistry and Molecular Biology, Louisiana State University School of Medicine and Health Sciences Center, New Orleans	Fred G. Brazda Foundation; Department of Biochemistry and Molecular Biology, Louisiana State University School of Medicine and Health Sciences Center, New Orleans	We wish to thank the Fred G. Brazda Foundation and the Department of Biochemistry and Molecular Biology, Louisiana State University School of Medicine and Health Sciences Center, New Orleans, for their financial support.	Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Amisten S, 2018, J DIABETES COMPLICAT, V32, P813, DOI 10.1016/j.jdiacomp.2018.06.010; Baranwal S, 2011, J NATL CANCER I, V103, P1513, DOI 10.1093/jnci/djr350; Cai YJ, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12154; Chang C, 2017, BIOCHEM BIOPH RES CO, V484, P536, DOI 10.1016/j.bbrc.2017.01.109; Chen J, 2015, MOL MED REP, V12, P77, DOI 10.3892/mmr.2015.3373; Chen MJ, 2003, ANN NY ACAD SCI, V1009, P427, DOI 10.1196/annals.1304.057; Crompton M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006969; Ding YM, 2017, NEURAL REGEN RES, V12, P1687, DOI 10.4103/1673-5374.217348; Ding YM, 2008, MOL CELL BIOL, V28, P3742, DOI 10.1128/MCB.01832-07; Ding YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144948; Ding YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054563; Dong SL, 2020, INT J CANCER, V146, P2576, DOI 10.1002/ijc.32690; Dong SL, 2019, INT J OBESITY, V43, P1046, DOI 10.1038/s41366-018-0241-8; Dong SL, 2017, J BIOL CHEM, V292, P16833, DOI 10.1074/jbc.M117.784256; Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945; Geng RS, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01395; Guo ZP, 2020, NEUROREPORT, V31, P1199, DOI 10.1097/WNR.0000000000001536; Guo ZP, 2019, EXP THER MED, V17, P663, DOI 10.3892/etm.2018.7017; Heid IM, 2010, NAT GENET, V42, P949, DOI 10.1038/ng.685; Hotta K, 2013, J ATHEROSCLER THROMB, V20, P336, DOI 10.5551/jat.14589; Jain P, 2013, J BIOL CHEM, V288, P15495, DOI 10.1074/jbc.M112.418103; Jemal A., 2021, J CLIN, V71, P33, DOI [10.3322/caac.21654, DOI 10.3322/CAAC.21654]; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Keller B, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00258; Keller B, 2017, NEUROCHEM INT, V108, P169, DOI 10.1016/j.neuint.2017.03.012; Keller B, 2017, J AFFECT DISORDERS, V208, P646, DOI 10.1016/j.jad.2016.10.007; Kuijl C, 2013, EMBO J, V32, P713, DOI 10.1038/emboj.2013.10; Li F, 2006, J CELL BIOCHEM, V98, P1615, DOI 10.1002/jcb.20806; Li F, 2016, MOL NEUROBIOL, V53, P4918, DOI 10.1007/s12035-015-9417-6; Li F, 2012, ADDICT BIOL, V17, P392, DOI 10.1111/j.1369-1600.2011.00373.x; Li J, 2015, MOL CANCER THER, V14, P1202, DOI 10.1158/1535-7163.MCT-14-0911; Li S, 2019, BIOCHEM BIOPH RES CO, V512, P460, DOI 10.1016/j.bbrc.2019.03.055; Lim KP, 2004, J BIOL CHEM, V279, P54770, DOI 10.1074/jbc.M411315200; Lin MH, 2017, CLIN EXP PHARMACOL P, V44, P1254, DOI 10.1111/1440-1681.12815; Maziveyi M, 2019, CANCER RES, V79, P2152, DOI 10.1158/0008-5472.CAN-18-0842; Maziveyi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0764-6; Maziveyi M, 2015, CANCER RES, V75, P4252, DOI 10.1158/0008-5472.CAN-15-1395; McAndrews KM, 2019, CANCER RES, V79, P2099, DOI 10.1158/0008-5472.CAN-19-0387; McGuire A, 2015, CANCERS, V7, P908, DOI 10.3390/cancers7020815; Nagakura Y, 2021, NEUROSCI LETT, V761, DOI 10.1016/j.neulet.2021.136113; Nagini S, 2017, ANTI-CANCER AGENT ME, V17, P152, DOI 10.2174/1871520616666160502122724; Ostrow KL, 2010, CLIN CANCER RES, V16, P3463, DOI 10.1158/1078-0432.CCR-09-3304; Piletz JE, 1999, ANN NY ACAD SCI, V881, P1, DOI 10.1111/j.1749-6632.1999.tb09335.x; Rathnam C, 2017, ARTIF INTELL MED, V75, P1, DOI 10.1016/j.artmed.2016.10.003; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tsang JYS, 2020, ADV ANAT PATHOL, V27, P27, DOI 10.1097/PAP.0000000000000232; Uren C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174738; Wiatrak B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040958; Wu N, 2006, EUR J PHARMACOL, V548, P21, DOI 10.1016/j.ejphar.2006.07.013; Wu XH, 2013, INFLAMM RES, V62, P929, DOI 10.1007/s00011-013-0631-2; Zhang J, 2008, J PHARMACOL EXP THER, V324, P72, DOI 10.1124/jpet.107.129049; Zhang L, 2013, CNS NEUROSCI THER, V19, P978, DOI 10.1111/cns.12192; Zhao Y, 2018, NEUROSCI BIOBEHAV R, V95, P347, DOI 10.1016/j.neubiorev.2018.10.005	54	0	0	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1079	1086		10.1038/s41388-021-02150-4	http://dx.doi.org/10.1038/s41388-021-02150-4		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35064214				2022-12-17	WOS:000745402900002
J	Rugolo, F; Bazan, NG; Calandria, J; Jun, B; Raschella, G; Melino, G; Agostini, M				Rugolo, Francesco; Bazan, Nicolas G.; Calandria, Jorgelina; Jun, Bokkyoo; Raschella, Giuseppe; Melino, Gerry; Agostini, Massimiliano			The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome (vol 40, pg 5741, 2021)	ONCOGENE			English	Correction												melino@uniroma2.it; m.agostini@med.uniroma2.it	; Agostini, Massimiliano/G-9579-2014	Bazan, Nicolas/0000-0002-9243-5444; Agostini, Massimiliano/0000-0003-3124-2072; MELINO, GERRY/0000-0001-9428-5972; Rugolo, Francesco/0000-0002-3174-100X				Rugolo F, 2021, ONCOGENE, V40, P5741, DOI 10.1038/s41388-021-01959-3	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1386	1387		10.1038/s41388-021-02164-y	http://dx.doi.org/10.1038/s41388-021-02164-y		JAN 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35058598	Bronze			2022-12-17	WOS:000744835300001
J	Du, SC; Yang, Z; Lu, XF; Yousuf, S; Zhao, M; Li, WX; Miao, J; Wang, XZ; Yu, H; Zhu, XY; Chen, H; Shi, LS; Xu, E; Xia, XF; Guan, WX				Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Yousuf, Suhail; Zhao, Min; Li, Wenxi; Miao, Ji; Wang, Xingzhou; Yu, Heng; Zhu, Xinya; Chen, Hong; Shi, Linseng; Xu, En; Xia, Xuefeng; Guan, Wenxian			Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBP beta-mediated PDGFB autocrine and paracrine signaling (vol 40, pg 5764, 2021)	ONCOGENE			English	Correction												657416504@qq.com; danielxuefeng@hotmail.com; 15850502391@163.com						Du SC, 2021, ONCOGENE, V40, P5764, DOI 10.1038/s41388-021-01988-y	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1384	1385		10.1038/s41388-021-02096-7	http://dx.doi.org/10.1038/s41388-021-02096-7		JAN 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35046535	Bronze			2022-12-17	WOS:000744391700001
J	Liu, Y; Nelson, MV; Bailey, C; Zhang, P; Zheng, P; Dome, JS; Liu, Y; Wang, Y				Liu, Yan; Nelson, Marie V.; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Dome, Jeffrey S.; Liu, Yang; Wang, Yin			Targeting the HIF-1 alpha-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor (vol 40, pg 4809, 2021)	ONCOGENE			English	Correction												yanliu@ihv.umaryland.edu; yangl@oncoc4.com; ywang@ihv.umaryland.edu		Wang, Yin/0000-0002-4749-3768				Liu Y, 2021, ONCOGENE, V40, P4809, DOI 10.1038/s41388-021-01907-1	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1383	1383		10.1038/s41388-021-02042-7	http://dx.doi.org/10.1038/s41388-021-02042-7		JAN 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35046533	Bronze			2022-12-17	WOS:000744391700002
J	Mao, LF; Yuan, WJ; Cai, KM; Lai, C; Huang, CH; Xu, Y; Zhong, SW; Yang, C; Wang, R; Zeng, PW; Huang, HY; Chen, ZK; Chen, ZH				Mao, Linfeng; Yuan, Weijie; Cai, Kaimei; Lai, Chen; Huang, Changhao; Xu, Yi; Zhong, Shangwei; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua			EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis (vol 40, pg 3610, 2021)	ONCOGENE			English	Correction												zihuachenxy@126.com		Mao, Lin-feng/0000-0001-8113-1253				Mao LF, 2021, ONCOGENE, V40, P3610, DOI 10.1038/s41388-021-01786-6	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1228	1230		10.1038/s41388-021-02163-z	http://dx.doi.org/10.1038/s41388-021-02163-z		JAN 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35046536	hybrid, Green Published			2022-12-17	WOS:000744389100002
J	Zhou, CF; Ma, J; Huang, L; Yi, HY; Zhang, YM; Wu, XG; Yan, RM; Liang, L; Zhong, M; Yu, YH; Wu, S; Wang, W				Zhou, Chen-Fei; Ma, Jing; Huang, Lei; Yi, Hong-Yan; Zhang, Yan-Mei; Wu, Xiang-Guang; Yan, Rui-Ming; Liang, Li; Zhong, Mei; Yu, Yan-Hong; Wu, Sha; Wang, Wei			Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1 (vol 38, pg 1256, 2019)	ONCOGENE			English	Correction												shawu99@outlook.com; smugowwang@126.com	Yu, Yan/GYV-4514-2022					Zhou CF, 2019, ONCOGENE, V38, P1256, DOI 10.1038/s41388-018-0511-x	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1231	1233		10.1038/s41388-021-02165-x	http://dx.doi.org/10.1038/s41388-021-02165-x		JAN 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35046534	hybrid, Green Published			2022-12-17	WOS:000744389100001
J	Wang, ZB; Liu, YQ; Peng, L; Till, B; Liao, YW; Yuan, SM; Yan, X; Chen, L; Fu, Q; Qin, ZH				Wang, Zibing; Liu, Yuqing; Peng, Ling; Till, Brian; Liao, Yuwei; Yuan, Shumin; Yan, Xiang; Chen, Lin; Fu, Qiang; Qin, Zhihai			Role of fibrosarcoma-induced CD11b(+) myeloid cells and tumor necrosis factor-alpha in B cell responses	ONCOGENE			English	Article							TRANS-RETINOIC ACID; SUPPRESSOR-CELLS; T-CELLS; DIFFERENTIATION; IMMUNOTHERAPY; LYMPHOCYTES; POPULATION; ACTIVATION; LINEAGE	The role of B cells in the anti-tumor immune response remains controversial. An increase in the number of B cells in the peripheral blood of some tumor patients has been associated with poor immunotherapy efficacy. However, the mechanism leading to the generation of these cells is not well-described. Using a fibrosarcoma model, we show that intraperitoneal administration of a xenogeneic antigen in tumor-bearing mice evokes large increases in antigen-specific serum immunoglobulin formation compared to tumor-naive mice. An inability of tumor-bearing mice to induce enhanced antibody production after myeloid cell depletion suggests the antibody responses are CD11b(+) myeloid cell-dependent. In vitro, CD11b(+) myeloid cells promoted B cell proliferation, activation, and survival. High levels of tumor necrosis factor (TNF)-alpha were produced by CD11b(+) cells, and TNF-alpha blockade inhibited B cell responses. CD11b(+) cells appear to be important promoters of B cell responses and targeting B cells may increase the efficacy of immunotherapy in tumor-bearing hosts.	[Wang, Zibing; Yuan, Shumin] Zhengzhou Univ, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Wang, Zibing; Yuan, Shumin; Fu, Qiang] Henan Canc Hosp, Zhengzhou, Peoples R China; [Liu, Yuqing] Xinxiang Med Coll, Dept Oncol, Affiliated Hosp 3, Xinxiang, Henan, Peoples R China; [Peng, Ling] Zhejiang Prov Peoples Hosp, Dept Resp Dis, Hangzhou, Peoples R China; [Till, Brian] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA; [Liao, Yuwei] Yangjiang Peoples Hosp, Yangjiang Key Lab Resp Dis, Yangjiang, Peoples R China; [Yan, Xiang] Chinese Peoples Liberat Army Gen Hosp, Med Oncol Dept, Beijing, Peoples R China; [Chen, Lin] Guangzhou Med Univ, GZMU GIBH Sch Life Sci, Guangzhou, Peoples R China; [Fu, Qiang] Zhengzhou Univ, Dept Gen Surg, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Qin, Zhihai] Chinese Acad Sci, Inst Biophys, Key Lab Prot & Peptide Pharmaceut, Beijing, Peoples R China	Zhengzhou University; Zhengzhou University; Xinxiang Medical University; Zhejiang Provincial People's Hospital; Fred Hutchinson Cancer Center; Chinese People's Liberation Army General Hospital; Guangzhou Medical University; Zhengzhou University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, ZB (corresponding author), Zhengzhou Univ, Dept Immunotherapy, Affiliated Canc Hosp, Zhengzhou, Peoples R China.; Wang, ZB (corresponding author), Henan Canc Hosp, Zhengzhou, Peoples R China.	zlyywzb2118@zzu.edu.cn	yan, Xiang/ABI-1846-2020	yan, Xiang/0000-0002-3683-474X	National Natural Science Foundation of China [81972690, 81000914]; Medical Science and Technology Research Project of Health Commission of Henan Province [2018010033]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science and Technology Research Project of Health Commission of Henan Province	This work was supported by the National Natural Science Foundation of China (Grant No. 81972690 and 81000914) and Medical Science and Technology Research Project of Health Commission of Henan Province (2018010033). The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bauer R, 2018, CANCER RES, V78, P3220, DOI 10.1158/0008-5472.CAN-17-3415; Bodogai M, 2015, CANCER RES, V75, P3456, DOI 10.1158/0008-5472.CAN-14-3077; BURDIN N, 1995, J IMMUNOL, V154, P2533; Cani PD, 2018, NAT REV GASTRO HEPAT, V15, P671, DOI 10.1038/s41575-018-0025-6; Cook MB, 2019, GUT, V68, P960, DOI 10.1136/gutjnl-2018-316678; Dawson HD, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-27; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Forster M, 2017, J LEUKOCYTE BIOL, V101, P643, DOI 10.1189/jlb.1AB0415-177RR; Fridman WH, 2021, J EXP MED, V218, DOI 10.1084/jem.20200851; Grover A, 2021, CANCER DISCOV, V11, P2693, DOI 10.1158/2159-8290.CD-21-0764; Gu Y, 2019, NAT MED, V25, P312, DOI 10.1038/s41591-018-0309-y; Holmgaard RB, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1151595; Hutchins AP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09100; Iwata M, 2003, INT IMMUNOL, V15, P1017, DOI 10.1093/intimm/dxg101; Jaufmann J, 2020, EUR J IMMUNOL, V50, P33, DOI 10.1002/eji.201948240; Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926; Knier B, 2018, NAT IMMUNOL, V19, P1341, DOI 10.1038/s41590-018-0237-5; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Lamichhane P, 2017, CANCER RES, V77, P6667, DOI 10.1158/0008-5472.CAN-17-0740; Lechner A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1535293; Lee-Chang C, 2019, CANCER IMMUNOL RES, V7, P1928, DOI 10.1158/2326-6066.CIR-19-0240; Long AH, 2016, CANCER IMMUNOL RES, V4, P869, DOI 10.1158/2326-6066.CIR-15-0230; Lv ZW, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1747688; Ma YF, 2013, J IMMUNOL, V190, P5588, DOI 10.4049/jimmunol.1203216; Medoff BD, 2009, J IMMUNOL, V182, P623, DOI 10.4049/jimmunol.182.1.623; Minguet S, 2008, EUR J IMMUNOL, V38, P2475, DOI 10.1002/eji.200738094; Montes CL, 2006, EUR J IMMUNOL, V36, P1474, DOI 10.1002/eji.200535537; Montinaro A, 2018, IMMUNITY, V48, P481, DOI 10.1016/j.immuni.2018.03.011; Morikawa K, 2005, INT IMMUNOPHARMACOL, V5, P1830, DOI 10.1016/j.intimp.2005.06.002; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Qin ZH, 1998, NAT MED, V4, P627, DOI 10.1038/nm0598-627; Rastad Jessica L, 2018, Immunohorizons, V2, P87, DOI 10.4049/immunohorizons.1700066; Schmid T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01471; Shen M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1413520; Somasundaram R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00452-4; Spiotto MT, 2003, P NATL ACAD SCI USA, V100, P5425, DOI 10.1073/pnas.0930140100; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tang A, 2016, INT J CANCER, V139, P1358, DOI 10.1002/ijc.30169; Tang CHA, 2018, CANCER IMMUNOL RES, V6, P696, DOI 10.1158/2326-6066.CIR-17-0582; Tobin RP, 2018, INT IMMUNOPHARMACOL, V63, P282, DOI 10.1016/j.intimp.2018.08.007; Tokunaga R, 2019, CANCER TREAT REV, V73, P10, DOI 10.1016/j.ctrv.2018.12.001; Vasilevsky S, 2008, J IMMUNOL, V181, P1787, DOI 10.4049/jimmunol.181.3.1787; Waffarn EE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9991; Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x; Wang ZB, 2016, ONCOTARGET, V7, P4760, DOI 10.18632/oncotarget.6734; Wang ZB, 2010, J IMMUNOTHER, V33, P167, DOI 10.1097/CJI.0b013e3181bed2ba; Wu WC, 2019, CANCER IMMUNOL RES, V7, P1605, DOI 10.1158/2326-6066.CIR-18-0902; Xu X, 2017, CELL MOL IMMUNOL, V14, P597, DOI 10.1038/cmi.2015.103; Yuan SM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563622; Yuan SM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.563653; Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115	55	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1434	1444		10.1038/s41388-022-02187-z	http://dx.doi.org/10.1038/s41388-022-02187-z		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35034094				2022-12-17	WOS:000742809900001
J	Roetman, JJ; Apostolova, MKI; Philip, M				Roetman, Jessica J.; Apostolova, Minna K., I; Philip, Mary			Viral and cellular oncogenes promote immune evasion	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; MHC CLASS-I; TUMOR-SUPPRESSOR GENES; HEPATITIS-B-VIRUS; ANTIGEN PRESENTATION; ACQUIRED-RESISTANCE; HODGKIN LYMPHOMA; CANCER-CELLS; EXPRESSION; PROTEIN	Thirteen percent of cancers worldwide are associated with viral infections. While many human oncogenic viruses are widely endemic, very few infected individuals develop cancer. This raises the question why oncogenic viruses encode viral oncogenes if they can replicate and spread between human hosts without causing cancer. Interestingly, viral infection triggers innate immune signaling pathways that in turn activate tumor suppressors such as p53, suggesting that tumor suppressors may have evolved not primarily to prevent cancer, but to thwart viral infection. Here, we summarize and compare several major immune evasion strategies used by viral and non-viral cancers, with a focus on oncogenes that play dual roles in promoting tumorigenicity and immune evasion. By highlighting important and illustrative examples of how oncogenic viruses evade the immune system, we aim to shed light on how non-viral cancers avoid immune detection. Further study and understanding of how viral and non-viral oncogenes impact immune function could lead to improved strategies to combine molecular therapies targeting oncoproteins in combination with immunomodulators.	[Roetman, Jessica J.; Philip, Mary] Vanderbilt Univ, Program Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Apostolova, Minna K., I] Vanderbilt Univ, Dept Biochem & Chem Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Philip, Mary] Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Philip, M (corresponding author), Vanderbilt Univ, Program Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.; Philip, M (corresponding author), Vanderbilt Univ, Med Ctr, Div Hematol & Oncol, Dept Med, Nashville, TN 37235 USA.	mary.philip@vumc.org			V Foundation [P30DK058404, 50CA098131]; Serodino Adventure Allee Fund	V Foundation; Serodino Adventure Allee Fund	This work was supported by funding from the V Foundation, P30DK058404, 50CA098131, and the Serodino Adventure Allee Fund.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Alcocer-Gonzalez JM, 2006, VIRAL IMMUNOL, V19, P481, DOI 10.1089/vim.2006.19.481; Anastasiadou E, 2019, LEUKEMIA, V33, P132, DOI 10.1038/s41375-018-0178-x; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Bermudez-Morales VH, 2011, MOL MED REP, V4, P369, DOI 10.3892/mmr.2011.429; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bradley SD, 2015, CANCER IMMUNOL RES, V3, P602, DOI 10.1158/2326-6066.CIR-15-0030; Brea EJ, 2016, CANCER IMMUNOL RES, V4, P936, DOI 10.1158/2326-6066.CIR-16-0177; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang HC, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-015-0242-3; Chang Y, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0264; Chin EN, 2020, SCIENCE, V369, P993, DOI 10.1126/science.abb4255; Clark DN, 2015, FUTURE VIROL, V10, P283, DOI 10.2217/FVL.14.113; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Cornel AM, 2020, CANCERS, V12, DOI 10.3390/cancers12071760; Corrales L, 2017, CELL RES, V27, P96, DOI 10.1038/cr.2016.149; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; Croft NP, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000490; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; de Queiroz NMGP, 2019, MOL CANCER RES, V17, P974, DOI 10.1158/1541-7786.MCR-18-0504; del Campo AB, 2014, INT J CANCER, V134, P102, DOI 10.1002/ijc.28338; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Forloni M, 2010, CANCER RES, V70, P916, DOI 10.1158/0008-5472.CAN-09-2582; Gaglia MM, 2018, CURR OPIN VIROL, V32, P48, DOI 10.1016/j.coviro.2018.09.003; Galluzzi L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000337; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Griguolo G, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0548-6; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannesdottir L, 2013, EUR J IMMUNOL, V43, P2718, DOI 10.1002/eji.201242505; Hansen TH, 2009, NAT REV IMMUNOL, V9, P503, DOI 10.1038/nri2575; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Hasim A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044952; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hislop AD, 2007, J EXP MED, V204, P1863, DOI 10.1084/jem.20070256; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Inoue M, 2012, ONCOIMMUNOLOGY, V1, P1104, DOI 10.4161/onci.21056; Jiao L, 2020, J GENE MED, V22, DOI 10.1002/jgm.3148; Kansara M, 2013, J CLIN INVEST, V123, P5351, DOI 10.1172/JCI70559; Khan G, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037505; Kontomanolis EN, 2020, ANTICANCER RES, V40, P6009, DOI 10.21873/anticanres.14622; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Krump NA, 2018, NAT REV MICROBIOL, V16, P684, DOI 10.1038/s41579-018-0064-6; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lau L, 2015, SCIENCE, V350, P568, DOI 10.1126/science.aab3291; Le Naour J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1777624; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Li P, 2019, J IMMUNOL, V202, P3065, DOI 10.4049/jimmunol.1801199; Liu YH, 2015, J VIROL, V89, P2287, DOI 10.1128/JVI.02760-14; Lu WJ, 2006, CELL DEATH DIFFER, V13, P909, DOI 10.1038/sj.cdd.4401922; Ma Z, 2016, CELL HOST MICROBE, V19, P150, DOI 10.1016/j.chom.2016.01.010; Mandai M, 2016, CLIN CANCER RES, V22, P2329, DOI 10.1158/1078-0432.CCR-16-0224; Marcus A, 2018, IMMUNITY, V49, P754, DOI 10.1016/j.immuni.2018.09.016; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; Menendez D, 2013, CURR OPIN ONCOL, V25, P85, DOI 10.1097/CCO.0b013e32835b6386; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mogensen TH, 2001, MICROBIOL MOL BIOL R, V65, P131, DOI 10.1128/MMBR.65.1.131-150.2001; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moore PS, 2010, NAT REV CANCER, V10, P878, DOI 10.1038/nrc2961; Muhr LSA, 2017, INT J CANCER, V141, P2498, DOI 10.1002/ijc.31017; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Nakayama A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211358; Ng KW, 2018, TRENDS IMMUNOL, V39, P44, DOI 10.1016/j.it.2017.07.013; Pan BS, 2020, SCIENCE, V369, P935, DOI 10.1126/science.aba6098; Pandey Nitesh Vinodbhai, 2020, VirusDisease, V31, P1, DOI 10.1007/s13337-019-00563-0; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Pedersen MH, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1305531; Petrazzuolo A, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03997-x; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Philip M, 2022, NAT REV IMMUNOL, V22, P209, DOI 10.1038/s41577-021-00574-3; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Rivas C, 2010, VIRUSES-BASEL, V2, P298, DOI 10.3390/v2010298; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sapkota B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22890; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Schneider JW, 2017, AM J CLIN DERMATOL, V18, P529, DOI 10.1007/s40257-017-0270-4; Schoenfeld AJ, 2020, CANCER CELL, V37, P443, DOI 10.1016/j.ccell.2020.03.017; Shaikh MH, 2019, MICROB PATHOGENESIS, V132, P162, DOI 10.1016/j.micpath.2019.05.004; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stanley M, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0268; Strong MJ, 2015, J VIROL, V89, P10110, DOI 10.1128/JVI.01110-15; Sugiyama E, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3937; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Taura M, 2012, MOL CELL BIOL, V32, P1581, DOI 10.1128/MCB.06454-11; Toso A, 2014, CELL REP, V9, P75, DOI 10.1016/j.celrep.2014.08.044; Tsurumi T, 2005, REV MED VIROL, V15, P3, DOI 10.1002/rmv.441; Uzhachenko RV, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108944; Wang X, 2015, CELL SIGNAL, V27, P443, DOI 10.1016/j.cellsig.2014.12.003; Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003; Wang ZL, 2015, CANCER IMMUNOL IMMUN, V64, P1057, DOI 10.1007/s00262-015-1713-5; Wienand K, 2019, BLOOD ADV, V3, P4065, DOI 10.1182/bloodadvances.2019001012; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Wu SY, 2019, NAT CELL BIOL, V21, P1027, DOI 10.1038/s41556-019-0352-z; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Yang CA, 2017, ONCOLOGY-BASEL, V92, P115, DOI 10.1159/000452281; Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92; Yum S, 2020, CELL RES, V30, P639, DOI 10.1038/s41422-020-0346-1; Zhou QJ, 2015, J BIOL CHEM, V290, P14729, DOI 10.1074/jbc.M114.633065; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315; Zuo JM, 2011, J VIROL, V85, P1604, DOI 10.1128/JVI.01608-10; Zuo JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000255; zur Hausen H, 2009, VIROLOGY, V392, P1, DOI 10.1016/j.virol.2009.06.001	112	0	0	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					921	929		10.1038/s41388-021-02145-1	http://dx.doi.org/10.1038/s41388-021-02145-1		JAN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	35022539	Green Accepted			2022-12-17	WOS:000741853200001
J	DiNatale, A; Kaur, R; Qian, C; Zhang, JY; Marchioli, M; Ipe, D; Castelli, M; McNair, CM; Kumar, G; Meucci, O; Fatatis, A				DiNatale, Anthony; Kaur, Ramanpreet; Qian, Chen; Zhang, Jieyi; Marchioli, Michael; Ipe, Darin; Castelli, Maria; McNair, Chris M.; Kumar, Gaurav; Meucci, Olimpia; Fatatis, Alessandro			Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to chemotherapy	ONCOGENE			English	Article							FRACTALKINE RECEPTOR CX(3)CR1; STEM-CELLS; CHEMOKINE CX3CL1; TUMOR-CELLS; ADHESION; BONE; PLASTICITY; MIGRATION; SALL4; PLURIPOTENCY	Metastasis-initiating cells (MICs) display stem cell-like features, cause metastatic recurrences and defy chemotherapy, which leads to patients' demise. Here we show that prostate and breast cancer patients harbor contingents of tumor cells with high expression of CX3CR1, OCT4a (POU5F1), and NANOG. Impairing CX3CR1 expression or signaling hampered the formation of tumor spheroids by cell lines from which we isolated small subsets co-expressing CX3CR1 and stemness-related markers, similarly to patients' tumors. These rare CX3CR1(High) cells show transcriptomic profiles enriched in pathways that regulate pluripotency and endowed with metastasis-initiating behavior in murine models. Cancer cells lacking these features (CX3CR1(Low)) were capable of re-acquiring CX3CR1-associated features over time, implying that MICs can continuously emerge from non-stem cancer cells. CX3CR1 expression also conferred resistance to docetaxel, and prolonged treatment with docetaxel selected CX3CR1(High) phenotypes with de-enriched transcriptomic profiles for apoptotic pathways. These findings nominate CX3CR1 as a novel marker of stem-like tumor cells and provide conceptual ground for future development of approaches targeting CX3CR1 signaling and (re)expression as therapeutic means to prevent or contain metastasis initiation.	[DiNatale, Anthony; Kaur, Ramanpreet; Qian, Chen; Zhang, Jieyi; Marchioli, Michael; Ipe, Darin; Castelli, Maria; Meucci, Olimpia; Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Pharmacol & Physiol, Philadelphia, PA 19102 USA; [McNair, Chris M.; Kumar, Gaurav] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [McNair, Chris M.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Canc Informat, Philadelphia, PA 19107 USA; [Meucci, Olimpia] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Immune Cell Regulat & Targeting, Philadelphia, PA 19107 USA; [Fatatis, Alessandro] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Translat & Cellular Oncol, Philadelphia, PA 19107 USA; [Kaur, Ramanpreet] Champ Oncol, 1330 Piccard Dr, Rockville, MD 20850 USA; [Qian, Chen] Cedars Sinai, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA; [Castelli, Maria] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Drexel University; Jefferson University; Jefferson University; Jefferson University; Jefferson University; Cedars Sinai Medical Center; University of Pennsylvania; Pennsylvania Medicine	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Pharmacol & Physiol, Philadelphia, PA 19102 USA.; Fatatis, A (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Program Translat & Cellular Oncol, Philadelphia, PA 19107 USA.	af39@drexel.edu	Qian, Chen/GWV-0990-2022	Meucci, Olimpia/0000-0001-8333-4804; DiNatale, Anthony/0000-0003-3221-7506	NCI [R01-CA202929]; DoD [BC150659]; Wallace H. Coulter Foundation; Pennsylvania Breast Cancer Coalition; Breast Cancer Alliance; Sidney Kimmel Cancer Center (SKCC) Support Grant [5P30CA056036-21]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); Wallace H. Coulter Foundation; Pennsylvania Breast Cancer Coalition; Breast Cancer Alliance; Sidney Kimmel Cancer Center (SKCC) Support Grant	This work was supported by NCI grant R01-CA202929 (AF and OM), DoD grant BC150659 (AF), Wallace H. Coulter Foundation (AF and OM), Pennsylvania Breast Cancer Coalition (AF), Exceptional Project Grant from Breast Cancer Alliance (AF), and the Sidney Kimmel Cancer Center (SKCC) Support Grant 5P30CA056036-21 (AF). We would like to thank: Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA) and Dr. Edward Hartsough (Pharmacology and Physiology, Drexel University College of Medicine) for providing the WM793 and 1205Lu human melanoma cell lines; Dr. Edward Hartsough (Pharmacology and Physiology, Drexel University College of Medicine) and Dr. Josep Domingo-Domenech (Cancer Biology, SKCC at Thomas Jefferson University) for helpful discussions; Dr. Paolo Fortina, Professor of Cancer Biology and Director of the Cancer Genomics and Translational Research/Pathology core services at SKCC for consultation and advice with RNA Sequencing; Ms. Shannon Cremin (Translational Research Project Manager), Ms. Danielle Wentworth (Biorepository Manager) and the SKCC Biorepository of Thomas Jefferson University for providing the human specimens used in this study. The authors are also grateful to Dr. Bradley Nash (Director, Office of Scientific Communications, Department of Pharmacology and Physiology, Drexel University College of Medicine) for critically reading and editing the manuscript.	Agarwal N, 2014, ANN ONCOL, V25, P1700, DOI 10.1093/annonc/mdu038; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Annett S, 2018, PHARMACOL THERAPEUT, V187, P13, DOI 10.1016/j.pharmthera.2018.02.001; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bendas Gerd, 2012, Int J Cell Biol, V2012, P676731, DOI 10.1155/2012/676731; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Celia-Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556-018-0145-9; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chandrakesan P, 2016, J Carcinog Mutagen, V7; Chen W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1740936; Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591; Chimento A, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00807; Do DV, 2013, GENE DEV, V27, P1378, DOI 10.1101/gad.221176.113; Das PK, 2020, STEM CELL REV REP, V16, P397, DOI 10.1007/s12015-019-09942-y; Dillekas H, 2019, CANCER MED-US, V8, P5574, DOI 10.1002/cam4.2474; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8; Erreni M, 2010, EUR J CANCER, V46, P3383, DOI 10.1016/j.ejca.2010.07.022; Esposito M, 2014, PHARMACOL THERAPEUT, V141, P222, DOI 10.1016/j.pharmthera.2013.10.006; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Francescone R, 2021, CANCER DISCOV, V11, P446, DOI 10.1158/2159-8290.CD-20-0775; Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4; Gassenmaier M, 2013, STEM CELLS, V31, P1467, DOI 10.1002/stem.1407; Geng Y, 2012, ANN BIOMED ENG, V40, P790, DOI 10.1007/s10439-011-0463-6; Gravina GL, 2015, PROSTATE, V75, P1227, DOI 10.1002/pros.23007; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huang LY, 2017, BIOCHEM BIOPH RES CO, V493, P1510, DOI 10.1016/j.bbrc.2017.10.006; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Igntiadis M, 2008, EUR J CANCER, V44, P2726, DOI 10.1016/j.ejca.2008.09.033; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jamieson WL, 2008, CANCER RES, V68, P1715, DOI 10.1158/0008-5472.CAN-07-1315; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; JavanMoghadam-Kamrani S, 2008, CELL CYCLE, V7, P2434, DOI 10.4161/cc.6364; Jiao XM, 2019, CANCER RES, V79, P4801, DOI 10.1158/0008-5472.CAN-19-1167; Kakinuma T, 2006, J LEUKOCYTE BIOL, V79, P639, DOI 10.1189/jlb.1105633; Karatas OF, 2016, PROSTATE, V76, P434, DOI 10.1002/pros.23137; Kato H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046576; Kim J, 2016, ONCOGENE, V35, P1334, DOI 10.1038/onc.2015.205; Kim M, 2012, MOL CANCER RES, V10, P11, DOI 10.1158/1541-7786.MCR-11-0256; Kim SY, 2013, CELL SIGNAL, V25, P961, DOI 10.1016/j.cellsig.2013.01.007; King KM, 2009, CURR ONCOL, V16, P149; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; LaFave LM, 2012, TRENDS PHARMACOL SCI, V33, P574, DOI 10.1016/j.tips.2012.08.005; Lee SJ, 2006, AM J PHYSIOL-HEART C, V291, pH2836, DOI 10.1152/ajpheart.00113.2006; Li WZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14364-2; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu AF, 2013, CHIN J CANCER, V32, P483, DOI 10.5732/cjc.012.10282; Liu Y, 2021, CLIN TRANSL ONCOL, V23, P378, DOI 10.1007/s12094-020-02431-6; Locatelli M, 2010, EUR CYTOKINE NETW, V21, P27, DOI 10.1684/ecn.2009.0184; Lombardo Y, 2015, JOVE-J VIS EXP, DOI 10.3791/52671; Main HG, 2017, ONCOGENE, V36, P3025, DOI 10.1038/onc.2016.456; Mandegar MA, 2016, CELL STEM CELL, V18, P541, DOI 10.1016/j.stem.2016.01.022; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Micalizzi DS, 2017, GENE DEV, V31, P1827, DOI 10.1101/gad.305805.117; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Morein D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00952; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Palmeri Laura, 2008, Ther Clin Risk Manag, V4, P1047; Pasello M, 2020, SEMIN CANCER BIOL, V60, P57, DOI 10.1016/j.semcancer.2019.10.004; Pein M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15188-x; Putzer BM, 2017, ADV DRUG DELIVER REV, V120, P89, DOI 10.1016/j.addr.2017.07.013; Qian C, 2018, MOL CANCER RES, V16, P1844, DOI 10.1158/1541-7786.MCR-18-0302; Quayle LA, 2018, CLIN EXP METASTAS, V35, P831, DOI 10.1007/s10585-018-9946-2; Qureshi-Baig K, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0602-2; Ramsey DM, 2013, BIOORG MED CHEM LETT, V23, P20, DOI 10.1016/j.bmcl.2012.10.138; Rao S, 2010, BIOL BLOOD MARROW TR, V16, pS187, DOI 10.1016/j.bbmt.2009.12.111; Riethdorf S, 2008, INT J CANCER, V123, P1991, DOI 10.1002/ijc.23825; Riihimaki M, 2018, CANCER MED-US, V7, P5534, DOI 10.1002/cam4.1697; Shahriari K, 2017, ONCOGENE, V36, P2846, DOI 10.1038/onc.2016.436; Shen F, 2016, MOL CANCER RES, V14, P518, DOI 10.1158/1541-7786.MCR-16-0013; Shen Y, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw023; Shi GL, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt39; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Singh SK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19643-0; Stojic L, 2018, NUCLEIC ACIDS RES, V46, P5950, DOI 10.1093/nar/gky437; Tatetsu H, 2016, GENE, V584, P111, DOI 10.1016/j.gene.2016.02.019; Thankamony AP, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00079; Tsubooka N, 2009, GENES CELLS, V14, P683, DOI 10.1111/j.1365-2443.2009.01301.x; Wada A, 2015, ONCOL REP, V33, P2935, DOI 10.3892/or.2015.3941; Walcher L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01280; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Wang YJ, 2015, AM J PHYSIOL-CELL PH, V309, pC709, DOI 10.1152/ajpcell.00212.2015; Weber MR, 2016, THROMB RES, V140, pS27, DOI 10.1016/S0049-3848(16)30095-0; Worrede A, 2019, PHARMACOL THERAPEUT, V199, P117, DOI 10.1016/j.pharmthera.2019.03.007; Yang JC, 2018, BIOMARK RES, V6, DOI 10.1186/s40364-017-0115-6; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766; Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105; Yang XP, 2007, CIRC RES, V101, P1001, DOI 10.1161/CIRCRESAHA.107.160812; Yao X, 2014, UROL ONCOL-SEMIN ORI, V32, P162, DOI 10.1016/j.urolonc.2012.12.006; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011; Zhao Wenxiu, 2017, Cancer Transl Med, V3, P87, DOI 10.4103/ctm.ctm_69_16; Zhao Y, 2018, SEMIN CANCER BIOL, V53, P139, DOI 10.1016/j.semcancer.2018.08.002; Zheng DQ, 1999, CANCER RES, V59, P1655	114	0	0	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1337	1351		10.1038/s41388-021-02174-w	http://dx.doi.org/10.1038/s41388-021-02174-w		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34999735	Green Accepted			2022-12-17	WOS:000740423700003
J	Zheng, DD; Cao, M; Zuo, SY; Xia, X; Zhi, CC; Lin, YB; Deng, ST; Yuan, XQ				Zheng, Dandan; Cao, Meng; Zuo, Siyu; Xia, Xin; Zhi, Chunchun; Lin, Yanbing; Deng, Sitong; Yuan, Xiaoqin			RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP (Oct, 10.1038/s41388-021-02036-5, 2021)	ONCOGENE			English	Correction												yuanxq@njmu.edu.cn						Zheng DD, 2022, ONCOGENE, V41, P930, DOI 10.1038/s41388-021-02036-5	1	0	0	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1070	1070		10.1038/s41388-021-02152-2	http://dx.doi.org/10.1038/s41388-021-02152-2		JAN 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34983930	Bronze			2022-12-17	WOS:000738430400001
J	Guo, F; Cheng, X; Jing, BP; Wu, HS; Jin, X				Guo, Feng; Cheng, Xiang; Jing, Boping; Wu, Heshui; Jin, Xin			FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression	ONCOGENE			English	Article							FACTOR-KAPPA-B; HEAT-SHOCK FACTORS; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; R PACKAGE; GENE; GEMCITABINE; GROWTH; CELLS	Pancreatic cancer is regarded as the most lethal solid tumor worldwide. Deregulated and constitutively activated NF-kappa B signaling is one of the major characteristics of pancreatic cancer. The total expression level and subcellular localization of RelA/p65 have been shown to determine the activation of canonical NF-kappa B signaling in pancreatic cancer. FGD3, which is involved in regulating the actin cytoskeleton and cell shape, has been reported to inhibit cancer cell migration and predict a favorable prognosis in multiple types of cancer. However, the specific role of FGD3 in pancreatic cancer is still unknown. In this study, we conducted a systematic investigation of the cancer-related role of FGD3 in pancreatic cancer. We demonstrated that FGD3 was abnormally downregulated in pancreatic cancer tissues and that low expression of FGD3 was associated with unfavorable prognosis in patients with pancreatic cancer. Then, we showed that FGD3 inhibited pancreatic cancer cell proliferation, invasion and metastasis in vivo and in vitro. Moreover, we revealed that FGD3 silencing activated the NF-kappa B signaling pathway by promoting HSF4 nuclear translocation and increasing p65 expression in pancreatic cancer cells. Therefore, our results identified a novel and targetable FGD3/HSF4/p65 signaling axis in pancreatic cancer cells.	[Guo, Feng; Wu, Heshui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pancreat Surg, Wuhan 430022, Peoples R China; [Guo, Feng; Wu, Heshui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Sino German Lab Personalized Med Pancreat Canc, Wuhan 430022, Peoples R China; [Cheng, Xiang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China; [Jing, Boping] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ultrasound, Wuhan 430022, Hubei, Peoples R China; [Jin, Xin] Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China; [Jin, Xin] Cent South Univ, Urooncol Inst, Changsha 410011, Hunan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Central South University; Central South University	Wu, HS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pancreat Surg, Wuhan 430022, Peoples R China.; Wu, HS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Sino German Lab Personalized Med Pancreat Canc, Wuhan 430022, Peoples R China.; Jin, X (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China.; Jin, X (corresponding author), Cent South Univ, Urooncol Inst, Changsha 410011, Hunan, Peoples R China.	Heshuiwu@hust.edu.cn; jinxinxy2@csu.edu.cn		Jin, Xin/0000-0001-6461-6005; jing, boping/0000-0001-8664-201X; Guo, Feng/0000-0003-0882-5296	National Natural Science Foundation of China [82073178, 82073321]; Science Foundation of Ministry of Education of China [2172019kfyRCPY069]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Ministry of Education of China(Ministry of Education, China)	This work was supported by grants from the National Natural Science Foundation of China (Grant No. 82073178 (H.W.), Grant No. 82073321 (X.J.)) and Science Foundation of Ministry of Education of China (Grant No. 2172019kfyRCPY069 (X.J.)).	Abane R, 2010, FEBS J, V277, P4150, DOI 10.1111/j.1742-4658.2010.07830.x; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Azoitei N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0490-2; Cable J, 2021, ANN NY ACAD SCI, V1489, P30, DOI 10.1111/nyas.14526; Chen R, 2011, ONCOGENE, V30, P2570, DOI 10.1038/onc.2010.623; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Cui XK, 2012, BBA-MOL BASIS DIS, V1822, P1308, DOI 10.1016/j.bbadis.2012.05.005; Dougan SK, 2017, CANCER J, V23, P321, DOI 10.1097/PPO.0000000000000288; Fan P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1044-z; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Hanson JL, 2004, CANCER RES, V64, P7248, DOI 10.1158/0008-5472.CAN-03-3898; Jin X, 2019, MOL CELL, V73, P22, DOI 10.1016/j.molcel.2018.10.034; Jin XJ, 2012, MOL CANCER RES, V10, P523, DOI 10.1158/1541-7786.MCR-11-0530; Jing BP, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-020-00746-8; Kabacaoglu D, 2019, CANCERS, V11, DOI 10.3390/cancers11070937; Khalaf N, 2021, CLIN GASTROENTEROL H, V19, P876, DOI 10.1016/j.cgh.2020.02.054; Kong R, 2010, CANCER LETT, V291, P90, DOI 10.1016/j.canlet.2009.10.001; Liao SJ, 2018, GENE, V655, P30, DOI 10.1016/j.gene.2018.02.033; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Ma C, 2019, BIOMARK MED, V13, P1399, DOI 10.2217/bmm-2019-0273; Ma P, 2020, LIVER INT, V40, P1211, DOI 10.1111/liv.14410; Makieva S, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.009; Matsuo Y, 2004, PANCREAS, V28, P344, DOI 10.1097/00006676-200404000-00025; Meng QC, 2020, THERANOSTICS, V10, P3967, DOI 10.7150/thno.40566; Nakanishi H, 2008, J CELL MOL MED, V12, P1169, DOI 10.1111/j.1582-4934.2008.00345.x; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Oshima T, 2010, BIOL PHARM BULL, V33, P35, DOI 10.1248/bpb.33.35; Pan X, 2008, CLIN CANCER RES, V14, P8143, DOI 10.1158/1078-0432.CCR-08-1539; Pasteris NG, 2000, GENE, V242, P237, DOI 10.1016/S0378-1119(99)00518-1; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Renda I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51766-w; Shi XH, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-10; Susini T, 2020, ANTICANCER RES, V40, P3645, DOI 10.21873/anticanres.14353; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang L, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0627-6; Wang LL, 2017, CANCER LETT, V398, P24, DOI 10.1016/j.canlet.2017.04.001; Wang WX, 1999, CLIN CANCER RES, V5, P119; Willis S, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00009; Wu J, 2021, DIGEST DIS SCI, V66, P359, DOI 10.1007/s10620-020-06183-9; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Wu W, 2020, THERANOSTICS, V10, P2859, DOI 10.7150/thno.41279; Yan J, 2013, CELL, V154, P801, DOI 10.1016/j.cell.2013.07.034; Yang YC, 2017, IUBMB LIFE, V69, P956, DOI 10.1002/iub.1692; Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	46	0	0	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					838	851		10.1038/s41388-021-02140-6	http://dx.doi.org/10.1038/s41388-021-02140-6		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34975151				2022-12-17	WOS:000737109100002
J	Mirzakhani, K; Kallenbach, J; Rasa, SMM; Ribaudo, F; Ungelenk, M; Ehsani, M; Gong, WR; Gassler, N; Leeder, M; Grimm, MO; Neri, F; Baniahmad, A				Mirzakhani, Kimia; Kallenbach, Julia; Rasa, Seyed Mohammad Mahdi; Ribaudo, Federico; Ungelenk, Martin; Ehsani, Marzieh; Gong, Wenrong; Gassler, Nikolaus; Leeder, Mirjam; Grimm, Marc-Oliver; Neri, Francesco; Baniahmad, Aria			The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells (Oct, 10.1038/s41388-021-02060-5, 2021)	ONCOGENE			English	Correction												aria.baniahmad@med.uni-jena.de	Neri, Francesco/A-3321-2014	Neri, Francesco/0000-0003-3903-1974				Mirzakhani K, 2022, ONCOGENE, V41, P943, DOI 10.1038/s41388-021-02060-5	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1071	1077		10.1038/s41388-021-02125-5	http://dx.doi.org/10.1038/s41388-021-02125-5		DEC 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34930998	Green Published, hybrid			2022-12-17	WOS:000731822800002
J	Zhang, SY; Guo, XM; Liu, XF; Zhong, ZX; Yang, SL; Wang, HH				Zhang, Shaoyang; Guo, Xuemin; Liu, Xiufeng; Zhong, Zhixiong; Yang, Shulan; Wang, Haihe			Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation (40, pg g5677, 2021)	ONCOGENE			English	Correction												yangshl3@mail.sysu.edu.cn; wanghaih@mail.sysu.edu.cn		Zhong, Zhixiong/0000-0002-3200-3105; Yang, Shu-Lan/0000-0002-6864-2195; , Haihe/0000-0002-9302-2334; Guo, Xuemin/0000-0003-2929-7461				Zhang SY, 2021, ONCOGENE, V40, P5677, DOI 10.1038/s41388-021-01970-8	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1227	1227		10.1038/s41388-021-02129-1	http://dx.doi.org/10.1038/s41388-021-02129-1		DEC 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	34930999	Bronze			2022-12-17	WOS:000731822800001
J	Cao, X; Geradts, J; Dewhirst, MW; Lo, HW				Cao, X.; Geradts, J.; Dewhirst, M. W.; Lo, H. -W.			Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells (vol 31, pg 104, 2021)	ONCOGENE			English	Correction												hlo@wakehealth.edu						Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1225	1226		10.1038/s41388-021-02043-6	http://dx.doi.org/10.1038/s41388-021-02043-6		DEC 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	34887555	Bronze			2022-12-17	WOS:000728477000001
J	Zhang, YJ; Zhang, YX; Ai, B; Gong, JJ; Li, YC; Yu, SY; Cai, XY; Zhang, L				Zhang, Yujie; Zhang, Yuxin; Ai, Bo; Gong, Juejun; Li, Yichen; Yu, Shiying; Cai, Xiuyu; Zhang, Li			GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis	ONCOGENE			English	Article							TRANSCRIPTION; EXPRESSION; TFIIE; MUTATIONS; MICRORNAS; COMPLEX	Esophageal squamous cell carcinoma (ESCC) is one of the most lethal gastrointestinal malignancies with high mortality. Recurrence develops within only a few years after curative resection and perioperative adjuvant therapy in 30-50% of these patients. Therefore, it is essential to identify postoperative recurrence biomarkers to facilitate selecting the following surveillance and therapeutic strategies. The general transcription factor IIE subunit beta (GTF2E2) is crucial for physiological and pathological functions, but its roles in the aggression and recurrence of ESCC remain ambiguous. In this study, we found that GTF2E2 was highly expressed in ESCC samples, and elevated GTF2E2 expression predicted early recurrence after surgery for ESCC patients. High expression of GTF2E2 associated with more aggressive clinic features and poor prognosis. GTF2E2 promoted the proliferation and mobility of ESCC cells in vitro and in vivo. We further revealed that miR-139-5p repressed GTF2E2 expression by downregulating its mRNA through binding with Argonaute 2 (Ago2). Rescue assays suggested that miR-139-5p affected GTF2E2-mediated ESCC progression. Moreover, GTF2E2 positively interacted with FUS promoter and regulated FUS expression, and the phenotype changes caused by GTF2E2 manipulation were recovered by rescuing FUS expression in ESCC cells. Additionally, we demonstrated that GTF2E2 promotes ESCC cells progression via activation of the AKT/ERK/mTOR pathway. In conclusion, GTF2E2 may serve as a novel biomarker for recurrence after surgery and a potential therapeutic target for ESCC patients, and it promotes ESCC progression via miR-139-5p/GTF2E2/FUS axis.	[Zhang, Yujie; Gong, Juejun; Li, Yichen; Yu, Shiying; Zhang, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Zhang, Yuxin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Ai, Bo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Thorac Surg Ctr, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Cai, Xiuyu] Sun Yet Sen Univ, Collaborat Innovat Ctr Canc Med, Dept VIP Inpatient, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University	Yu, SY; Zhang, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.; Cai, XY (corresponding author), Sun Yet Sen Univ, Collaborat Innovat Ctr Canc Med, Dept VIP Inpatient, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	syyu_qh@163.com; caixy_84@outlook.com; luzigang@163.com	yuxin, Zhang/GNH-2283-2022	Cai, Xiuyu/0000-0002-5251-9272; zhang, yujie/0000-0002-9109-3171	National Science Foundation of China [81572934, 82172825]; Chinese Society of Clinical Oncology Foundation [Y-BMS2019070]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Society of Clinical Oncology Foundation	This work was supported by the National Science Foundation of China (No. 81572934, 82172825) and Chinese Society of Clinical Oncology Foundation (No. Y-BMS2019070).	Baiu Ioana, 2020, JAMA, V324, P1580, DOI 10.1001/jama.2020.2101; Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bi GS, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01878-z; Borggreve AS, 2018, ANN NY ACAD SCI, V1434, P192, DOI 10.1111/nyas.13677; Compe E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10131-1; Davies AR, 2014, J SURG ONCOL, V109, P459, DOI 10.1002/jso.23511; Dhar SK, 2014, ANTIOXID REDOX SIGN, V20, P1550, DOI 10.1089/ars.2012.4984; Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273; Du F, 2020, THERANOSTICS, V10, P7335, DOI 10.7150/thno.45971; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Dziuba N, 2012, AIDS RES HUM RETROV, V28, P1329, DOI 10.1089/aid.2011.0358; Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017; Feng Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2028-9; Gao L, 2019, CELL DEATH DIS, V10, DOI [10.1038/s41419-019-1971, 10.1038/s41419-019-1971-9]; Hamai Y, 2018, WORLD J SURG, V42, P2190, DOI 10.1007/s00268-017-4430-8; Hua SN, 2018, ONCOGENE, V37, P1624, DOI 10.1038/s41388-017-0057-3; Jiao WP, 2019, DIGEST LIVER DIS, V51, P149, DOI 10.1016/j.dld.2018.07.017; Kakeji Y, 2021, ESOPHAGUS-TOKYO, V18, P25, DOI 10.1007/s10388-020-00782-1; Kuschal C, 2016, AM J HUM GENET, V98, P627, DOI 10.1016/j.ajhg.2016.02.008; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Liu R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077068; Liu SX, 2021, J CELL PHYSIOL, V236, P79, DOI 10.1002/jcp.29481; LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018; Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034; Mariette C, 2003, CANCER-AM CANCER SOC, V97, P1616, DOI 10.1002/cncr.11228; Miwa K, 2016, J MOL BIOL, V428, P4258, DOI 10.1016/j.jmb.2016.09.008; Montero-Conde C, 2020, INT J CANCER, V146, P521, DOI 10.1002/ijc.32622; Ni WJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6622-0; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Roskoski R, 2019, PHARMACOL RES, V142, P151, DOI 10.1016/j.phrs.2019.01.039; Schirle NT, 2014, SCIENCE, V346, P608, DOI 10.1126/science.1258040; Tang S, 2021, CANCER IMAGING, V21, DOI 10.1186/s40644-021-00407-5; Thei AF, 2019, AM J HUM GENET, V105, P434, DOI 10.1016/j.ajhg.2019.06.017; Theil AF, 2017, HUM MOL GENET, V26, P4689, DOI 10.1093/hmg/ddx351; Wang ZJ, 2020, J ONCOL, V2020, DOI 10.1155/2020/8813800; Wei WQ, 2020, LANCET ONCOL, V21, pE342, DOI 10.1016/S1470-2045(20)30073-5; Wen J, 2021, ANN SURG, V273, P523, DOI 10.1097/SLA.0000000000003369; Wu Q, 2020, CANCER BIOL THER, V21, P17, DOI 10.1080/15384047.2019.1647050; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Yang LW, 2020, WORLD NEUROSURG, V138, pE492, DOI 10.1016/j.wneu.2020.02.159; Yang M, 2013, ONCOL REP, V29, P169, DOI 10.3892/or.2012.2105; Yang S, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00981-4; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3; Zhu ZJ, 2011, ANN THORAC SURG, V91, P1502, DOI 10.1016/j.athoracsur.2011.01.007	46	0	0	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					782	796		10.1038/s41388-021-02122-8	http://dx.doi.org/10.1038/s41388-021-02122-8		DEC 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34853466	hybrid, Green Published			2022-12-17	WOS:000724661100001
J	Mazzu, YZ; Liao, YR; Nandakumar, S; Jehane, LE; Koche, RP; Rajanala, SH; Li, RF; Zhao, HY; Gerke, TA; Chakraborty, G; Lee, GSM; Nanjangud, GJ; Gopalan, A; Chen, Y; Kantoff, PW				Mazzu, Ying Z.; Liao, Yu-Rou; Nandakumar, Subhiksha; Jehane, Lina E.; Koche, Richard P.; Rajanala, Sai Harisha; Li, Ruifang; Zhao, HuiYong; Gerke, Travis A.; Chakraborty, Goutam; Lee, Gwo-Shu Mary; Nanjangud, Gouri J.; Gopalan, Anuradha; Chen, Yu; Kantoff, Philip W.			Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer	ONCOGENE			English	Article							ANDROGEN DEPRIVATION; RECEPTOR; TRANSCRIPTION; EXPRESSION; RESISTANCE; JAB1/CSN5; REVEALS; PATHWAY; JAB1	Chromosome 8q gain is associated with poor clinical outcomes in prostate cancer, but the underlying biological mechanisms remain to be clarified. CSN5, a putative androgen receptor (AR) partner that is located on chromosome 8q, is the key subunit of the COP9 signalosome, which deactivates ubiquitin ligases. Deregulation of CSN5 could affect diverse cellular functions that contribute to tumor development, but there has been no comprehensive study of its function in prostate cancer. The clinical significance of CSN5 amplification/overexpression was evaluated in 16 prostate cancer clinical cohorts. Its oncogenic activity was assessed by genetic and pharmacologic perturbations of CSN5 activity in prostate cancer cell lines. The molecular mechanisms of CSN5 function were assessed, as was the efficacy of the CSN5 inhibitor CSN5i-3 in vitro and in vivo. Finally, the transcription cofactor activity of CSN5 in prostate cancer cells was determined. The prognostic significance of CSN5 amplification and overexpression in prostate cancer was independent of MYC amplification. Inhibition of CSN5 inhibited its oncogenic function by targeting AR signaling, DNA repair, multiple oncogenic pathways, and spliceosome regulation. Furthermore, inhibition of CSN5 repressed metabolic pathways, including oxidative phosphorylation and glycolysis in AR-negative prostate cancer cells. Targeting CSN5 with CSN5i-3 showed potent antitumor activity in vitro and in vivo. Importantly, CSN5i-3 synergizes with PARP inhibitors to inhibit prostate cancer cell growth. CSN5 functions as a transcription cofactor to cooperate with multiple transcription factors in prostate cancer. Inhibiting CSN5 strongly attenuates prostate cancer progression and could enhance PARP inhibition efficacy in the treatment of prostate cancer.	[Mazzu, Ying Z.; Liao, Yu-Rou; Jehane, Lina E.; Rajanala, Sai Harisha; Chakraborty, Goutam; Chen, Yu; Kantoff, Philip W.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Nandakumar, Subhiksha] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA; [Koche, Richard P.; Li, Ruifang] Mem Sloan Kettering Canc Ctr, Epigenet Innovat Lab, Ctr Epigenet Res, New York, NY 10065 USA; [Zhao, HuiYong] Mem Sloan Kettering Canc Ctr, Antitumor Assessment Core Facil, 1275 York Ave, New York, NY 10021 USA; [Gerke, Travis A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Lee, Gwo-Shu Mary] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Nanjangud, Gouri J.] Mem Sloan Kettering Canc Ctr, Mol Cytogenet Core Facil, 1275 York Ave, New York, NY 10021 USA; [Gopalan, Anuradha] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Chen, Yu] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; H Lee Moffitt Cancer Center & Research Institute; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Mazzu, YZ; Kantoff, PW (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	yingzmazzu@gmail.com; kantoffp@outlook.com		Mazzu, Ying/0000-0003-0265-6970	Department of Defense Prostate Cancer Research Program Translational Science Award [W81XWH-20-1-0114]; NIH/NCI Cancer Center Support Grant [P30 CA008748]	Department of Defense Prostate Cancer Research Program Translational Science Award(United States Department of Defense); NIH/NCI Cancer Center Support Grant	This research was funded by a Department of Defense Prostate Cancer Research Program Translational Science Award (W81XWH-20-1-0114 to P.W. Kantoff) and in part through the NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748). We acknowledge that Eva Altmann from Novartis Institutes for BioMedical Research (Switzerland) kindly provided CSN5i-3 for the study; Lorelei A. Mucci from the Department of Epidemiology, Harvard T.H. Chan School of Public Health (Boston, Massachusetts) kindly provided information on the PHS/HPFS cohorts. We thank Margaret McPartland for editing and members of the Kantoff laboratory for help and discussion. This research was funded by a Department of Defense Prostate Cancer Research Program Translational Science Award (W81XWH-20-1-0114 to P.W. Kantoff) and in part through the NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748).	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Adler AS, 2008, CANCER RES, V68, P506, DOI 10.1158/0008-5472.CAN-07-3060; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Altomare DA, 2012, CURR MED CHEM, V19, P3748; Armenia J, 2019, NAT GENET, V51, P1194, DOI 10.1038/s41588-019-0451-6; Azad AA, 2015, EUR UROL, V67, P23, DOI 10.1016/j.eururo.2014.06.045; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Caggiano C, 2019, NUCLEIC ACIDS RES, V47, P6160, DOI 10.1093/nar/gkz344; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Civenni G, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00385; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Danielpour D, 2019, BIOCHEM BIOPH RES CO, V518, P374, DOI 10.1016/j.bbrc.2019.08.066; Devlies W, 2021, CANCERS, V13, DOI 10.3390/cancers13040915; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo Z, 2019, GENE, V687, P219, DOI 10.1016/j.gene.2018.11.061; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hwang JH, 2019, CELL REP, V29, P2355, DOI 10.1016/j.celrep.2019.10.068; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Liu GH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00135; Loriot Y, 2013, ANN ONCOL, V24, P1807, DOI 10.1093/annonc/mdt136; Lu RQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12044; Macoska JA, 2000, UROLOGY, V55, P776, DOI 10.1016/S0090-4295(00)00468-4; Mazzu YZ, 2019, CLIN CANCER RES, V25, P4480, DOI 10.1158/1078-0432.CCR-18-4046; Mullard A, 2020, NAT REV DRUG DISCOV, V19, P435, DOI 10.1038/d41573-020-00107-y; Nielsen T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-177; Nishimoto A, 2020, BIOCHEM BIOPH RES CO, V533, P548, DOI 10.1016/j.bbrc.2020.09.007; Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Phillips JW, 2020, P NATL ACAD SCI USA, V117, P5269, DOI 10.1073/pnas.1915975117; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sankpal UT, 2011, MED CHEM, V7, P518; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Q, 2009, MOL ENDOCRINOL, V23, P2038, DOI 10.1210/me.2009-0092; Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zhang D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16649-z; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751; Zhou XC, 2020, NEOPLASIA, V22, P192, DOI 10.1016/j.neo.2020.02.002	50	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					671	682		10.1038/s41388-021-02118-4	http://dx.doi.org/10.1038/s41388-021-02118-4		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34802033	Green Accepted			2022-12-17	WOS:000720700200001
J	Yin, L; Zeng, YJ; Zeng, RY; Chen, YH; Wang, TL; Rodabaugh, KJ; Yu, F; Natarajan, A; Karpf, AR; Dong, JX				Yin, Ling; Zeng, Yongji; Zeng, Renya; Chen, Yuanhong; Wang, Tian-Li; Rodabaugh, Kerry J.; Yu, Fang; Natarajan, Amarnath; Karpf, Adam R.; Dong, Jixin			Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR FUNCTION; PHOSPHATASE-ACTIVITY; PKR; PHOSPHORYLATION; EXPRESSION; INHIBITOR; APOPTOSIS; STRESS; MOTILITY; MITOSIS	Anti-tubulin agents, such as paclitaxel, have been used extensively for treatment of several types of cancer, including ovarian, lung, breast, and pancreatic cancers. Despite their wide use in cancer treatment, however, patient response is highly variable and drug resistance remains a major clinical issue. Protein kinase RNA-activated (PKR) plays a critical role in immune response to viral infection. We identified PKR as a phospho-protein in response to anti-tubulin agents and this phosphorylation occurs independent of its own kinase activity. PKR is phosphorylated by cyclin-dependent kinase 1 (CDK1) during anti-tubulin treatment and unperturbed mitosis and that PKR regulates mitotic progression in a phosphorylation-dependent manner. Furthermore, inactivation of PKR confers resistance to paclitaxel in ovarian and breast cancer cells in vitro and in vivo. PKR expression levels and activity are decreased in chemotherapeutic recurrent ovarian cancer patients. Mechanistically, our findings suggest that PKR controls paclitaxel chemosensitivity through repressing Bcl2 expression. Pharmacological inhibition of Bcl2 with FDA-approved agent venetoclax overcomes paclitaxel resistance in preclinical animal models of ovarian cancer. Our results suggest that PKR is a critical determinant of paclitaxel cytotoxicity and that PKR-Bcl2 axis as a potential therapeutic target for the treatment of recurrent drug-resistant ovarian tumors.	[Yin, Ling; Zeng, Yongji; Zeng, Renya; Chen, Yuanhong; Natarajan, Amarnath; Karpf, Adam R.; Dong, Jixin] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Wang, Tian-Li] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Wang, Tian-Li] Johns Hopkins Med Inst, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Rodabaugh, Kerry J.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Dept Gynecol Oncol, Omaha, NE 68198 USA; [Yu, Fang] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Yin, Ling] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; State Key Lab Oncology South China; Sun Yat Sen University	Dong, JX (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	dongj@unmc.edu	Yin, Ling/AAD-8990-2022	Yin, Ling/0000-0003-1606-2620; Natarajan, Amarnath/0000-0001-5067-0203; Karpf, Adam/0000-0002-0866-0666	National Institutes of Health (NIH) [P30 GM106397]; Fred & Pamela Buffett Cancer Center Support [P30 CA036727]; NIH [P30 GM106397, R01 GM109066]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fred & Pamela Buffett Cancer Center Support; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are very grateful to Dr. Michael Seiden for the SKOV3/SKOV3-Taxol resistant cell lines [43]. All fluorescence images were acquired by Zeiss LSM 710 or LSM 800 confocal microscopes at the Advanced Microscopy Core at the University of Nebraska Medical Center. The core is supported in part by grant P30 GM106397 from the National Institutes of Health (NIH). Research in the Dong laboratory is supported by Fred & Pamela Buffett Cancer Center Support Grant (P30 CA036727), grants P30 GM106397 and R01 GM109066 from the NIH. We also thank Dr. Joyce Solheim for critical reading and comments on the manuscript.	Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887; Barage S, 2017, J MOL GRAPH MODEL, V75, P322, DOI 10.1016/j.jmgm.2017.06.009; Barille-Nion S, 2012, ANTICANCER RES, V32, P4225; Basu S, 1997, CANCER RES, V57, P943; Beretta L, 1996, ONCOGENE, V12, P1593; Blalock WL, 2009, J CELL PHYSIOL, V221, P232, DOI 10.1002/jcp.21848; Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0224-3; Carvalho BM, 2013, OBESITY, V21, P2452, DOI 10.1002/oby.20410; Chen XC, 2016, J BIOL CHEM, V291, P14761, DOI 10.1074/jbc.M116.722751; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Darini C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10138-8; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Dzananovic E, 2018, BIOTECHNOL GENET ENG, V34, P33, DOI 10.1080/02648725.2018.1467151; Eichhorn JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.360; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Garcia-Ortega MB, 2017, EXPERT REV MOL MED, V19, DOI 10.1017/erm.2017.11; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; He Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024855; Henriques AC, 2019, CANCER LETT, V440, P64, DOI 10.1016/j.canlet.2018.10.005; Hu CW, 2015, ONCOL RES, V22, P159, DOI 10.3727/096504015X14298122915628; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kim Y, 2014, GENE DEV, V28, P1310, DOI 10.1101/gad.242644.114; Lamendola DE, 2003, CANCER RES, V63, P2200; Lee ES, 2007, FEBS LETT, V581, P4325, DOI 10.1016/j.febslet.2007.08.001; Lee YS, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1558; Li XL, 2017, ELIFE, V6, DOI 10.7554/eLife.27301; Marchal JA, 2014, FASEB J, V28, P1965, DOI 10.1096/fj.13-248294; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Natarajan A, 2004, J MED CHEM, V47, P1882, DOI 10.1021/jm0499716; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76; Pyo CW, 2008, BIOCHEM BIOPH RES CO, V377, P1001, DOI 10.1016/j.bbrc.2008.10.103; Roh MS, 2005, PATHOL INT, V55, P688, DOI 10.1111/j.1440-1827.2005.01892.x; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ruvolo VR, 2008, J BIOL CHEM, V283, P35474, DOI 10.1074/jbc.M800951200; Schmidt S, 2019, NAT CELL BIOL, V21, P1413, DOI 10.1038/s41556-019-0408-0; Shimada A, 1998, CANCER RES, V58, P4434; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Stauffer S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236000; Stauffer S, 2017, CELL SIGNAL, V39, P74, DOI 10.1016/j.cellsig.2017.08.001; Tang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11526-0; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Tronel C, 2014, NEUROCHEM INT, V64, P73, DOI 10.1016/j.neuint.2013.10.012; Wang YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19598; Wang Z, 2018, CELL SIGNAL, V52, P137, DOI 10.1016/j.cellsig.2018.09.007; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Xiao JL, 2016, MED SCI MONITOR, V22, P5074, DOI 10.12659/MSM.898139; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yang SP, 2013, CANCER RES, V73, P6722, DOI 10.1158/0008-5472.CAN-13-2049; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Yu Y, 2015, CANCER CELL, V28, P82, DOI 10.1016/j.ccell.2015.05.009; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhang L, 2012, J BIOL CHEM, V287, P34069, DOI 10.1074/jbc.M112.385518; Zhou JL, 2018, P NATL ACAD SCI USA, V115, pE6760, DOI 10.1073/pnas.1800621115	61	0	0	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6772	6785		10.1038/s41388-021-02117-5	http://dx.doi.org/10.1038/s41388-021-02117-5		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34799660	Green Accepted			2022-12-17	WOS:000720611600001
J	Jiang, CC; Marsland, M; Wang, YF; Dowdell, A; Eden, E; Gao, FF; Faulkner, S; Jobling, P; Li, X; Liu, LH; He, ZY; Hondermarck, H				Jiang, Chen Chen; Marsland, Mark; Wang, Yufang; Dowdell, Amiee; Eden, Edward; Gao, Fangfang; Faulkner, Sam; Jobling, Phillip; Li, Xiang; Liu, Lihua; He, Zhangyu; Hondermarck, Hubert			Tumor innervation is triggered by endoplasmic reticulum stress	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; GENE; CANCER; MICROENVIRONMENT; EXPRESSION; SURVIVAL	Nerve infiltration in the tumor microenvironment is emerging as a promoter of cancer progression that could be targeted in therapies, but the mechanisms initiating tumor innervation remain to be elucidated. Here we report that endoplasmic reticulum (ER) stress in cancer cells is transmitted to neuronal cells, resulting in neurite outgrowth and tumor innervation. In vitro, the induction of ER stress in various human cancer cells resulted in the synthesis and release of the precursor for brain-derived neurotrophic factor (proBDNF) through a mechanism dependent on the transcription factor X-box binding protein 1 (XBP1). Cancer cell-released proBDNF was found to mediate the transmission of ER stress to neurons, resulting in the stimulation of neurite outgrowth. Next-generation sequencing indicated the increased expression of the Egl-9 family hypoxia inducible factor 3 (EGLN3) that was mediated by c-MYC and necessary to neurite outgrowth induced by proBDNF. In orthotopic tumor xenograft, ER stress stimulated XBP1 and proBDNF expression as well as tumor innervation. Anti-proBDNF antibody inhibited both tumor innervation and cancer progression induced by ER stress. Interestingly, the chemotherapeutic drug 5-Fluorouracil (5-FU) was found to induce ER stress and tumor innervation, and this effect was inhibited by anti-proBDNF antibody. Finally, in human tumors, cancer tissues with nerve infiltration expressed high XBP1 and proBDNF while EGLN3 was upregulated in infiltrated nerves. This study reveals that ER stress participates in tumor innervation through the release of proBDNF and that targeting this pathway could be used in future therapies.	[Jiang, Chen Chen; Marsland, Mark; Dowdell, Amiee; Eden, Edward; Gao, Fangfang; Faulkner, Sam; Jobling, Phillip; Li, Xiang; Hondermarck, Hubert] Univ Newcastle, Sch Biomed Sci & Pharm, Canc Neurobiol Grp, Callaghan, NSW 2308, Australia; [Jiang, Chen Chen; Marsland, Mark; Dowdell, Amiee; Eden, Edward; Gao, Fangfang; Faulkner, Sam; Jobling, Phillip; Li, Xiang; Hondermarck, Hubert] Hunter Med Res Inst, New Lambton, NSW 2305, Australia; [Jiang, Chen Chen] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Wang, Yufang; Liu, Lihua; He, Zhangyu] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China; [Gao, Fangfang] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiotherapy, Zhengzhou 450000, Henan, Peoples R China	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Sichuan University; Zhengzhou University	Hondermarck, H (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Canc Neurobiol Grp, Callaghan, NSW 2308, Australia.; Hondermarck, H (corresponding author), Hunter Med Res Inst, New Lambton, NSW 2305, Australia.	hubert.hondermarck@newcastle.edu.au		Faulkner, Sam/0000-0002-4732-8252; Li, Xiang/0000-0003-1199-7152	University of Newcastle (Australia); Hunter Cancer Research Alliance; Hunter Medical Research Institute; Maitland Cancer Appeal Committee (NSW Australia)	University of Newcastle (Australia); Hunter Cancer Research Alliance; Hunter Medical Research Institute; Maitland Cancer Appeal Committee (NSW Australia)	Y This work was supported by the University of Newcastle (Australia), the Hunter Cancer Research Alliance, the Hunter Medical Research Institute, and the Maitland Cancer Appeal Committee (NSW Australia). We thank Kristen McEwan for excellent technical contribution. We also thank Kathryn Leaney from Cancer Voice NSW for her excellent consumer contribution.	Allen JK, 2018, CANCER RES, V78, P3233, DOI 10.1158/0008-5472.CAN-16-1701; Bai YY, 2016, NEUROPSYCHOPHARMACOL, V41, P2882, DOI 10.1038/npp.2016.100; Cao ZY, 2014, ONCOL LETT, V7, P1260, DOI 10.3892/ol.2014.1856; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Demir IE, 2020, CANCER CELL, V38, P11, DOI 10.1016/j.ccell.2020.05.023; Evans JP, 2019, LAB ANIM-UK, V53, P598, DOI 10.1177/0023677219826165; Faulkner S, 2019, CANCER DISCOV, V9, P702, DOI 10.1158/2159-8290.CD-18-1398; Griffin N, 2020, AM J PATHOL, V190, P1921, DOI 10.1016/j.ajpath.2020.05.012; Guo ST, 2016, ONCOGENE, V35, P3049, DOI 10.1038/onc.2015.361; Haberberger RV, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00184; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Hayashi A, 2007, J BIOL CHEM, V282, P34525, DOI 10.1074/jbc.M704300200; Henze AT, 2010, CANCER RES, V70, P357, DOI 10.1158/0008-5472.CAN-09-1876; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; Kim JK, 2016, ENVIRON TOXICOL PHAR, V44, P128, DOI 10.1016/j.etap.2016.05.005; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; LUNDBERG LM, 1988, HISTOCHEMISTRY, V90, P9, DOI 10.1007/BF00495700; Maclean KN, 2012, J BIOL CHEM, V287, P31994, DOI 10.1074/jbc.M112.355172; Maertens GN, 2006, J CELL SCI, V119, P2563, DOI 10.1242/jcs.02995; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Monje M, 2020, CELL, V181, P219, DOI 10.1016/j.cell.2020.03.034; Murao N, 2017, J BIOCHEM, V162, P155, DOI 10.1093/jb/mvx047; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Peterson SC, 2015, CELL STEM CELL, V16, P400, DOI 10.1016/j.stem.2015.02.006; Pundavela J, 2015, MOL ONCOL, V9, P1626, DOI 10.1016/j.molonc.2015.05.001; Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Saloman JL, 2016, P NATL ACAD SCI USA, V113, P3078, DOI 10.1073/pnas.1512603113; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; Valdes P, 2014, P NATL ACAD SCI USA, V111, P6804, DOI 10.1073/pnas.1321845111; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wiatrak B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040958; Xie H, 2018, J CLIN INVEST, V128, P1300, DOI 10.1172/JCI95864; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569	44	0	0	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					586	599		10.1038/s41388-021-02108-6	http://dx.doi.org/10.1038/s41388-021-02108-6		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785777				2022-12-17	WOS:000719277200001
J	Dewaele, S; Delhaye, L; De Paepe, B; de Bony, EJ; De Wilde, J; Vanderheyden, K; Anckaert, J; Yigit, N; Nuytens, J; Vanden Eynde, E; Smet, J; Verschoore, M; Nemati, F; Decaudin, D; Rodrigues, M; Zhao, PH; Jochemsen, A; Leucci, E; Vandesompele, J; Van Dorpe, J; Marine, JC; Van Coster, R; Eyckerman, S; Mestdagh, P				Dewaele, Shanna; Delhaye, Louis; De Paepe, Boel; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Smet, Joel; Verschoore, Maxime; Nemati, Fariba; Decaudin, Didier; Rodrigues, Manuel; Zhao, Peihua; Jochemsen, Aart; Leucci, Eleonora; Vandesompele, Jo; Van Dorpe, Jo; Marine, Jean-Christophe; Van Coster, Rudy; Eyckerman, Sven; Mestdagh, Pieter			The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival (Sept, 10.1038/s41388-021-02006-x, 2021)	ONCOGENE			English	Correction									[Marine, Jean-Christophe] VIB, Ctr Canc Biol, Lab Mol Canc Biol, Leuven, Belgium; [Marine, Jean-Christophe] Katholieke Univ Leuven, Dept Oncol, Lab Mol Canc Biol, Leuven, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven		pieter.mestdagh@ugent.be	Rodrigues, Manuel/C-8506-2018; Leucci, Eleonora/G-4938-2011; Marine, Jean-Christophe/K-3292-2016; De Paepe, Boel/B-7548-2013	Rodrigues, Manuel/0000-0002-5443-0802; Leucci, Eleonora/0000-0002-2898-748X; Delhaye, Louis/0000-0001-8876-7385; Marine, Jean-Christophe/0000-0003-2433-9837; Dewaele, Shanna/0000-0002-2219-8930; De Paepe, Boel/0000-0001-9403-4401; Vanden Eynde, Eveline/0000-0003-0454-4171; Nuytens, Justine/0000-0002-4878-1200; de Bony, Eric James/0000-0002-1289-7199; Yigit, Nurten/0000-0003-1183-8688; ANCKAERT, JASPER/0000-0001-8144-4639				Dewaele S, 2022, ONCOGENE, V41, P15, DOI 10.1038/s41388-021-02006-x	1	0	0	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					146	146		10.1038/s41388-021-02051-6	http://dx.doi.org/10.1038/s41388-021-02051-6		NOV 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34782722	Green Published, hybrid			2022-12-17	WOS:000718778400001
J	Gu, GW; Tian, L; Herzog, SK; Rechoum, Y; Gelsomino, L; Gao, M; Du, LL; Kim, JA; Dustin, D; Lo, HC; Beyer, AR; Edwards, DG; Gonzalez, T; Tsimelzon, A; Huang, HLJ; Fernandez, NM; Grimm, SL; Hilsenbeck, SG; Liu, D; Xu, J; Alaniz, A; Li, SQ; Mills, GB; Janku, F; Kittler, R; Zhang, XHF; Coarfa, C; Foulds, CE; Symmans, WF; Ando, S; Fuqua, SAW				Gu, Guowei; Tian, Lin; Herzog, Sarah K.; Rechoum, Yassine; Gelsomino, Luca; Gao, Meng; Du, Lili; Kim, Jin-Ah; Dustin, Derek; Lo, Hin Ching; Beyer, Amanda R.; Edwards, David G.; Gonzalez, Thomas; Tsimelzon, Anna; Huang, Helen J.; Fernandez, Natalie M.; Grimm, Sandra L.; Hilsenbeck, Susan G.; Liu, Dan; Xu, Jun; Alaniz, Alyssa; Li, Shunqiang; Mills, Gordon B.; Janku, Filip; Kittler, Ralf; Zhang, Xiang H. -F.; Coarfa, Cristian; Foulds, Charles E.; Symmans, W. Fraser; Ando, Sebastiano; Fuqua, Suzanne A. W.			Hormonal modulation of ESR1 mutant metastasis (vol 40, pg 997, 2021)	ONCOGENE			English	Correction												sfuqua@bcm.edu	; Kittler, Ralf/I-4662-2013	Tian, Lin/0000-0003-3661-4453; Kittler, Ralf/0000-0002-0098-6792				GUOWEI G, 2021, ONCOGENE, V40, P997, DOI DOI 10.1038/S41388-020-01563-X	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					460	460		10.1038/s41388-021-02104-w	http://dx.doi.org/10.1038/s41388-021-02104-w		NOV 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34782721	Bronze			2022-12-17	WOS:000718778400003
J	Wu, XN; Seraia, E; Hatch, SB; Wan, X; Ebner, DV; Aroldi, F; Jiang, YY; Ryan, AJ; Bogenrieder, T; Weyer-Czernilofsky, U; Rieunier, G; Macaulay, VM				Wu, Xiaoning; Seraia, Elena; Hatch, Stephanie B.; Wan, Xiao; Ebner, Daniel V.; Aroldi, Francesca; Jiang, Yanyan; Ryan, Anderson J.; Bogenrieder, Thomas; Weyer-Czernilofsky, Ulrike; Rieunier, Guillaume; Macaulay, Valentine M.			CHK1 inhibition exacerbates replication stress induced by IGF blockade	ONCOGENE			English	Article							DNA-DAMAGING AGENTS; BREAST-CANCER; H2AX PHOSPHORYLATION; CELLS; CHECKPOINT; EFFICACY; MK-8776; REPAIR; ATR; RADIOSENSITIVITY	We recently reported that genetic or pharmacological inhibition of insulin-like growth factor receptor (IGF-1R) slows DNA replication and induces replication stress by downregulating the regulatory subunit RRM2 of ribonucleotide reductase, perturbing deoxynucleotide triphosphate (dNTP) supply. Aiming to exploit this effect in therapy we performed a compound screen in five breast cancer cell lines with IGF neutralising antibody xentuzumab. Inhibitor of checkpoint kinase CHK1 was identified as a top screen hit. Co-inhibition of IGF and CHK1 caused synergistic suppression of cell viability, cell survival and tumour growth in 2D cell culture, 3D spheroid cultures and in vivo. Investigating the mechanism of synthetic lethality, we reveal that CHK1 inhibition in IGF-1R depleted or inhibited cells further downregulated RRM2, reduced dNTP supply and profoundly delayed replication fork progression. These effects resulted in significant accumulation of unreplicated single-stranded DNA and increased cell death, indicative of replication catastrophe. Similar phenotypes were induced by IGF:WEE1 co-inhibition, also via exacerbation of RRM2 downregulation. Exogenous RRM2 expression rescued hallmarks of replication stress induced by co-inhibiting IGF with CHK1 or WEE1, identifying RRM2 as a critical target of the functional IGF:CHK1 and IGF:WEE1 interactions. These data identify novel therapeutic vulnerabilities and may inform future trials of IGF inhibitory drugs.	[Wu, Xiaoning; Aroldi, Francesca] Univ Oxford, Dept Oncol, Oxford, England; [Seraia, Elena; Hatch, Stephanie B.; Wan, Xiao; Ebner, Daniel V.] Univ Oxford, Target Discovery Inst, Oxford, England; [Jiang, Yanyan; Ryan, Anderson J.] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England; [Bogenrieder, Thomas; Weyer-Czernilofsky, Ulrike] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; [Bogenrieder, Thomas] CO Fdn Recherches Med, AMAL Therapeut, CH-1205 Geneva, Switzerland; [Bogenrieder, Thomas] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Urol, Munich, Germany; [Macaulay, Valentine M.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England; [Rieunier, Guillaume] Immunocore Ltd, Abingdon, Oxon, England	University of Oxford; University of Oxford; University of Oxford; Boehringer Ingelheim; University of Munich; University of Oxford	Macaulay, VM (corresponding author), Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.; Rieunier, G (corresponding author), Immunocore Ltd, Abingdon, Oxon, England.	guillaume.rieunier@immunocore.com; valentine.macaulay@nds.ox.ac.uk	RYAN, Anderson/ACG-0319-2022	RYAN, Anderson/0000-0001-6241-7969; Hatch, Stephanie/0000-0002-7401-9279; Jiang, Yanyan/0000-0001-6014-811X; Wu, Xiaoning/0000-0002-8279-1517; Ebner, Daniel/0000-0002-6495-7026	Breast Cancer Now [2014NovPR364]; Cancer Research UK [C476/A27060]; Oxfordshire Health Services Research Committee [1326]; NIHR Oxford Biomedical Research Centre; Harrington Discovery Institute	Breast Cancer Now; Cancer Research UK(Cancer Research UK); Oxfordshire Health Services Research Committee; NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Harrington Discovery Institute	We acknowledge the assistance and expertise provided by Rhodri Wilson and Graham Brown from the Microscopy core facility, Department of Oncology, University of Oxford. We thank Dr Anthony Kong for MCF7, ZR-75-1, T47D, and HCC1143 breast cancer cell lines, Prof. Adrian Harris for HeLa cells and Michael Sanderson (ex-Boehringer Ingelheim, now Merck) for the generous supply of BI885578. This study was supported by Breast Cancer Now (grant 2014NovPR364 to VMM), Cancer Research UK (grant C476/A27060 to VMM and GR), Oxfordshire Health Services Research Committee (grant 1326 to FA) and support to VMM from the NIHR Oxford Biomedical Research Centre and the Harrington Discovery Institute. We are grateful to Andrew Blackford, Tim Humphrey and Ian Mills for comments on the paper.	Amin O, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1803-y; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Booth L, 2018, CANCER BIOL THER, V19, P786, DOI 10.1080/15384047.2018.1472189; Borowiec AS, 2011, BBA-MOL CELL RES, V1813, P723, DOI 10.1016/j.bbamcr.2011.01.025; Brideau C, 2003, J BIOMOL SCREEN, V8, P634, DOI 10.1177/1087057103258285; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Chitnis MM, 2014, ONCOGENE, V33, P5262, DOI 10.1038/onc.2013.460; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Conti C, 2007, MOL BIOL CELL, V18, P3059, DOI 10.1091/mbc.E06-08-0689; Cosaceanu D, 2007, ONCOGENE, V26, P2423, DOI 10.1038/sj.onc.1210037; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Dai Y, 2013, MOL CANCER THER, V12, P878, DOI 10.1158/1535-7163.MCT-12-0902; de Bono J, 2020, BRIT J CANCER, V122, P1324, DOI 10.1038/s41416-020-0774-1; ELLWART JW, 1990, CYTOMETRY, V11, P239, DOI 10.1002/cyto.990110204; Ferte C, 2013, MOL CANCER THER, V12, P1213, DOI 10.1158/1535-7163.MCT-12-1067; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Gonzalez Besteiro MA, 2019, EMBO J, V38, DOI 10.15252/embj.2018101284; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Hill SJ, 2014, MOL CELL BIOL, V34, P3828, DOI 10.1128/MCB.01646-13; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Koppenhafer SL, 2020, MOL CANCER RES, V18, P91, DOI 10.1158/1541-7786.MCR-19-0585; Lodhia KA, 2015, INT J CANCER, V136, P2961, DOI 10.1002/ijc.29327; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Ma XB, 2019, BREAST CANCER RES TR, V176, P109, DOI 10.1007/s10549-019-05189-w; Mathews CK, 2015, NAT REV CANCER, V15, P528, DOI 10.1038/nrc3981; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Mladenova V, 2008, Z NATURFORSCH C, V63, P289; Moeglin E, 2019, CANCERS, V11, DOI 10.3390/cancers11030355; Moiseeva T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01401-x; Montano R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-604; Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013; O'Flanagan CH, 2016, ONCOTARGET, V7, P56826, DOI 10.18632/oncotarget.10862; Parsels LA, 2018, CELL CYCLE, V17, P1076, DOI 10.1080/15384101.2018.1475827; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Rafiei S, 2020, CANCER RES, V80, P2094, DOI 10.1158/0008-5472.CAN-19-3126; Riesterer O, 2011, INT J RADIAT ONCOL, V79, P1179, DOI 10.1016/j.ijrobp.2010.10.003; Rieunier G, 2021, CANCER RES, V81, P2128, DOI 10.1158/0008-5472.CAN-20-2860; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanderson MP, 2015, MOL CANCER THER, V14, P2762, DOI 10.1158/1535-7163.MCT-15-0539; Sanjiv K, 2016, CELL REP, V17, P3407, DOI 10.1016/j.celrep.2016.12.031; Sant Shilpa, 2017, Drug Discov Today Technol, V23, P27, DOI 10.1016/j.ddtec.2017.03.002; Schmid P, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-020-01382-8; Sen T, 2019, J THORAC ONCOL, V14, P2152, DOI 10.1016/j.jtho.2019.08.009; Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08; Speroni J, 2012, P NATL ACAD SCI USA, V109, P7344, DOI 10.1073/pnas.1116345109; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Suomalainen A, 2018, BIOL METHODS PROTOC, V3; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Turney BW, 2012, RADIOTHER ONCOL, V103, P402, DOI 10.1016/j.radonc.2012.03.009; Vesela E, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7010019; Wang C, 2017, TRANSL ONCOL, V10, P190, DOI 10.1016/j.tranon.2017.01.007; Webster JA, 2017, LEUKEMIA RES, V61, P108, DOI 10.1016/j.leukres.2017.09.005; Yamaguchi R, 2015, FEBS LETT, V589, P4097, DOI 10.1016/j.febslet.2015.11.009; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zhou ZR, 2017, ACTA PHARMACOL SIN, V38, P513, DOI 10.1038/aps.2016.136	66	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					476	488		10.1038/s41388-021-02080-1	http://dx.doi.org/10.1038/s41388-021-02080-1		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34773074	Green Submitted, hybrid, Green Published			2022-12-17	WOS:000717915200003
J	He, F; Song, Z; Chen, HC; Chen, ZP; Yang, P; Li, WL; Yang, Z; Zhang, T; Wang, F; Wei, JC; Wei, F; Wang, Q; Cao, J				He, Feng; Song, Zhi; Chen, Huacui; Chen, Zhuanpeng; Yang, Ping; Li, Wanglin; Yang, Zhi; Zhang, Tong; Wang, Fei; Wei, Jianchang; Wei, Fang; Wang, Qiang; Cao, Jie			Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128 (vol 38, pg 164, 2019)	ONCOGENE			English	Correction												czhongt@126.com						He F, 2019, ONCOGENE, V38, P164, DOI 10.1038/s41388-018-0432-8	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					459	459		10.1038/s41388-021-02093-w	http://dx.doi.org/10.1038/s41388-021-02093-w		NOV 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34754081	Bronze			2022-12-17	WOS:000716255200002
J	He, SW; Xu, C; Li, YQ; Li, YQ; Zhao, Y; Zhang, PP; Lei, Y; Liang, YL; Li, JY; Li, Q; Chen, Y; Huang, SY; Ma, J; Liu, N				He, Shi-Wei; Xu, Cheng; Li, Ying-Qing; Li, Ying-Qin; Zhao, Yin; Zhang, Pan-Pan; Lei, Yuan; Liang, Ye-Lin; Li, Jun-Yan; Li, Qian; Chen, Yang; Huang, Sheng-Yan; Ma, Jun; Liu, Na			AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma (vol 39, pg 5616, 2020)	ONCOGENE			English	Correction												liun1@sysucc.org.cn		Ma, Jun/0000-0002-1137-9349				He SW, 2020, ONCOGENE, V39, P5616, DOI 10.1038/s41388-020-01388-8	1	0	0	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6703	6704		10.1038/s41388-021-02050-7	http://dx.doi.org/10.1038/s41388-021-02050-7		OCT 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34635801	Green Published, hybrid			2022-12-17	WOS:000706082100003
J	Leonard, MK; Puts, GS; Pamidimukkala, N; Adhikary, G; Xu, YL; Kwok, E; Jin, YX; Snyder, D; Matsangos, N; Novak, M; Mahurkar, A; Shetty, AC; Slominski, RM; De Fabo, EC; Noonan, FP; Day, CP; Rigi, M; Slominski, AT; Webb, MG; Craig, DW; Merlino, G; Eckert, RL; Carpten, JD; Manojlovic, Z; Kaetzel, DM				Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Xu, Yili; Kwok, Eric; Jin, Yuxin; Snyder, Devin; Matsangos, Nicolette; Novak, Marian; Mahurkar, Anup; Shetty, Amol C.; Slominski, Radomir M.; De Fabo, Edward C.; Noonan, Frances P.; Day, Chi-Ping; Rigi, Mohammed; Slominski, Andrzej T.; Webb, Michelle G.; Craig, David W.; Merlino, Glenn; Eckert, Richard L.; Carpten, John D.; Manojlovic, Zarko; Kaetzel, David M.			Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients (October, 10.1038/s41388-021-02045-4, 2021)	ONCOGENE			English	Correction												DKaetzel@som.umaryland.edu		LEONARD, M. Kathryn/0000-0002-8432-6803; Matsangos, Nicolette/0000-0002-3542-2612; Xu, Yili/0000-0001-8508-4706; Snyder, Devin/0000-0001-8528-7538				LEONARD MK, 2021, COMPREHENSIVE MOLECU, DOI DOI 10.1038/S41388-021-02045-4	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6394	6394		10.1038/s41388-021-02045-4	http://dx.doi.org/10.1038/s41388-021-02045-4		OCT 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34635800	Bronze			2022-12-17	WOS:000706082100002
J	Berditchevski, F; Fennell, E; Murray, PG				Berditchevski, Fedor; Fennell, Eanna; Murray, Paul G.			Calcium-dependent signalling in B-cell lymphomas	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; BRUTONS TYROSINE KINASE; PKC-BETA; DOWN-REGULATION; BURKITT-LYMPHOMA; C-BETA; EXPRESSION; SURVIVAL	Induced waves of calcium fluxes initiate multiple signalling pathways that play an important role in the differentiation and maturation of B-cells. Finely tuned transient Ca+2 fluxes from the endoplasmic reticulum in response to B-cell receptor (BCR) or chemokine receptor activation are followed by more sustained calcium influxes from the extracellular environment and contribute to the mechanisms responsible for the proliferation of B-cells, their migration within lymphoid organs and their differentiation. Dysregulation of these well-balanced mechanisms in B-cell lymphomas results in uncontrolled cell proliferation and resistance to apoptosis. Consequently, several cytotoxic drugs (and anti-proliferative compounds) used in standard chemotherapy regimens for the treatment of people with lymphoma target calcium-dependent pathways. Furthermore, similar to 10% of lymphoma associated mutations are found in genes with functions in calcium-dependent signalling, including those affecting B-cell receptor signalling pathways. In this review, we provide an overview of the Ca2+-dependent signalling network and outline the contribution of its key components to B cell lymphomagenesis. We also consider how the oncogenic Epstein-Barr virus, which is causally linked to the pathogenesis of a number of B-cell lymphomas, can modify Ca2+-dependent signalling.	[Berditchevski, Fedor] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England; [Fennell, Eanna; Murray, Paul G.] Univ Limerick, Hlth Res Inst, Limerick V94 T9PX, Ireland; [Murray, Paul G.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Limerick; University of Birmingham	Berditchevski, F (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.; Murray, PG (corresponding author), Univ Limerick, Hlth Res Inst, Limerick V94 T9PX, Ireland.; Murray, PG (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England.	f.berditchevski@bham.ac.uk; P.G.Murray@bham.ac.uk		Berditchevski, Fedor/0000-0003-0911-834X; Fennell, Eanna/0000-0002-1280-3439	Wellcome Trust [202708/Z/16/A]; European Regional Development Fund Project [ENOCH: CZ.02.1.01/0.0/0.0/16_019/0000868]	Wellcome Trust(Wellcome TrustEuropean Commission); European Regional Development Fund Project	The work was funded by the Seeding Discovery award from the Wellcome Trust [202708/Z/16/A] and a European Regional Development Fund Project (ENOCH: CZ.02.1.01/0.0/0.0/16_019/0000868). Figures were created with BioRender.com.	Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Azar AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70191-y; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Ben Dhiab M, 2015, CELL ONCOL, V38, P453, DOI 10.1007/s13402-015-0242-8; Blair D, 2012, BIOCHEM J, V448, P165, DOI 10.1042/BJ20121225; Borgstrom A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020229; Chen J, 2004, NAT IMMUNOL, V5, P651, DOI 10.1038/ni1072; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Chen WP, 1999, J IMMUNOL, V163, P2483; Chen YQ, 2021, IMMUNOL RES, V69, P8, DOI 10.1007/s12026-021-09177-5; Cheng CY, 2018, CANCER MED-US, V7, P380, DOI 10.1002/cam4.1276; Chuang SS, 2007, AM J CLIN PATHOL, V128, P558, DOI 10.1309/EQJR3D3V0CCQGP04; Conacci-Sorrell M, 2014, GENE DEV, V28, P689, DOI 10.1101/gad.231894.113; Conacci-Sorrell M, 2011, CELL CYCLE, V10, P604, DOI 10.4161/cc.10.4.14794; Creamer TP, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00636-4; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Porto AP, 2019, MOL MED, V25, DOI 10.1186/s10020-018-0069-7; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; Dellis O, 2011, J BIOL CHEM, V286, P18583, DOI 10.1074/jbc.M111.222257; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Dong XQ, 2019, CELL SIGNAL, V53, P68, DOI 10.1016/j.cellsig.2018.09.012; Engelke M, 2007, IMMUNOL REV, V218, P235, DOI 10.1111/j.1600-065X.2007.00539.x; Espinosa I, 2006, ANN HEMATOL, V85, P597, DOI 10.1007/s00277-006-0144-y; Fish K, 2020, P NATL ACAD SCI USA, V117, P26318, DOI 10.1073/pnas.2007946117; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Frazzi R, 2017, LEUKEMIA RES, V57, P89, DOI 10.1016/j.leukres.2017.02.012; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Gauchy AC, 2020, HEMATOL ONCOL, V38, P326, DOI 10.1002/hon.2735; Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892; Giachelia M, 2014, J MOL DIAGN, V16, P467, DOI 10.1016/j.jmoldx.2014.03.003; Hans CP, 2005, MODERN PATHOL, V18, P1377, DOI 10.1038/modpathol.3800434; Havranek O, 2017, BLOOD, V130, P995, DOI 10.1182/blood-2016-10-747303; He XF, 2020, EXP HEMATOL, V86, P21, DOI 10.1016/j.exphem.2020.05.001; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hobeika E, 2015, J MOL MED, V93, P143, DOI 10.1007/s00109-015-1252-8; Jones RJ, 2007, INT J CANCER, V121, P1274, DOI 10.1002/ijc.22839; Jung HJ, 2012, BLOOD, V119, P2568, DOI 10.1182/blood-2011-09-377598; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kapoor I, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2158-0; Khadra N, 2011, P NATL ACAD SCI USA, V108, P19072, DOI 10.1073/pnas.1116946108; Kim CW, 2021, LIFE SCI, V277, DOI 10.1016/j.lfs.2021.119607; Kim JE, 2014, MOL CELL BIOL, V34, P325, DOI 10.1128/MCB.00912-13; Kim J, 2012, J IMMUNOL, V188, P182, DOI 10.4049/jimmunol.1102297; Kondo E, 2003, EUR J IMMUNOL, V33, P1, DOI 10.1002/immu.200390000; Kosowicz JG, 2017, J VIROL, V91, DOI 10.1128/JVI.00747-17; Kristensen LS, 2014, ONCOTARGET, V5, P9798, DOI 10.18632/oncotarget.2394; Krysiak K, 2017, BLOOD, V129, P473, DOI 10.1182/blood-2016-07-729954; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Latour S, 2019, CANCERS, V11, DOI 10.3390/cancers11030291; Latour S, 2018, CANCERS, V10, DOI 10.3390/cancers10110402; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li SY, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-8; Linley A, 2015, BLOOD, V126, P1902, DOI 10.1182/blood-2015-04-640805; Loo SK, 2017, HISTOPATHOLOGY, V71, P98, DOI 10.1111/his.13204; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Mahtani T, 2019, IMMUNOL REV, V291, P104, DOI 10.1111/imr.12770; Mao J, 2020, CLIN CHIM ACTA, V510, P741, DOI 10.1016/j.cca.2020.09.011; Marafiot T, 2005, BRIT J HAEMATOL, V128, P333, DOI 10.1111/j.1365-2141.2004.05313.x; Marshall MJE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01245; Maxwell SA, 2011, LEUKEMIA LYMPHOMA, V52, P849, DOI 10.3109/10428194.2010.551793; Medyouf H, 2008, CELL CYCLE, V7, P297, DOI 10.4161/cc.7.3.5357; Merchant M, 2001, VIROLOGY, V291, P46, DOI 10.1006/viro.2001.1187; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Montresor Alessio, 2018, Oncotarget, V9, P35123, DOI 10.18632/oncotarget.26212; Mukhopadhyay S, 2001, FEBS LETT, V505, P37, DOI 10.1016/S0014-5793(01)02765-X; MURRAY PG, 1992, J PATHOL, V166, P1, DOI 10.1002/path.1711660102; Nakashima M, 2018, BIOL CELL, V110, P109, DOI 10.1111/boc.201800002; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Numaga T, 2010, J CELL SCI, V123, P927, DOI 10.1242/jcs.061051; Oellerich T, 2011, EMBO J, V30, P3620, DOI 10.1038/emboj.2011.251; Ok CY, 2013, BLOOD, V122, P328, DOI 10.1182/blood-2013-03-489708; Ondrisova L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.591577; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Pfeifhofer C, 2006, J IMMUNOL, V176, P6004, DOI 10.4049/jimmunol.176.10.6004; Polouliakh N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004189; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Portis T, 2003, BLOOD, V102, P4166, DOI 10.1182/blood-2003-04-1018; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Romero-Masters JC, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008365; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Saijo K, 2003, ANN NY ACAD SCI, V987, P125, DOI 10.1111/j.1749-6632.2003.tb06040.x; SATO S, 1995, P NATL ACAD SCI USA, V92, P11558, DOI 10.1073/pnas.92.25.11558; Schaadt E, 2005, J GEN VIROL, V86, P551, DOI 10.1099/vir.0.80440-0; Schain F, 2008, INT J CANCER, V123, P2285, DOI 10.1002/ijc.23781; Schain F, 2008, CLIN LYMPHOMA MYELOM, V8, P340, DOI 10.3816/CLM.2008.n.049; Scott DW, 2014, NAT REV CANCER, V14, P517, DOI 10.1038/nrc3774; Seifert M, 2019, METHODS MOL BIOL, V1956, P1, DOI 10.1007/978-1-4939-9151-8_1; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Shirakawa AK, 2010, CELL MOL IMMUNOL, V7, P428, DOI 10.1038/cmi.2010.46; Sicari D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111347; Singh K, 2016, MUTAT RES-REV MUTAT, V769, P1, DOI [10.1016/j.mrrev.2016.06.001, 10.1016/j.md.2017.03.001]; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; Tao L, 2013, ELIFE, V2, DOI 10.7554/eLife.00518; Taylor CW, 2017, CELL CALCIUM, V63, P48, DOI 10.1016/j.ceca.2016.10.005; Taylor J, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1734326; ten Hacken E, 2017, CANCER CELL, V32, P716, DOI 10.1016/j.ccell.2017.10.015; Vacher P, 2015, J IMMUNOL, V195, P2207, DOI 10.4049/jimmunol.1402942; Vallet N, 2020, ANN HEMATOL, V99, P229, DOI 10.1007/s00277-019-03890-w; Varela-Lopez A, 2019, FOOD CHEM TOXICOL, V134, DOI 10.1016/j.fct.2019.110834; Varghese E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123017; Venkataraman C, 2006, IMMUNOL LETT, V105, P83, DOI 10.1016/j.imlet.2006.01.006; Vockerodt M, 2008, J PATHOL, V216, P83, DOI 10.1002/path.2384; Vockerodt M, 2013, J PATHOL, V230, P399, DOI 10.1002/path.4198; Wang L, 2021, CHINESE MED J-PEKING, V134, P253, DOI 10.1097/CM9.0000000000001294; Wang L, 2013, ONCOL REP, V30, P2427, DOI 10.3892/or.2013.2729; Weniger MA, 2021, LEUKEMIA, V35, P968, DOI 10.1038/s41375-021-01204-6; Wist M, 2020, J BIOL CHEM, V295, P5717, DOI 10.1074/jbc.RA119.011946; Xue C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01518-y; Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92; Young RM, 2015, P NATL ACAD SCI USA, V112, P13447, DOI 10.1073/pnas.1514944112; Zhang JY, 2019, CLIN CANCER RES, V25, P4168, DOI 10.1158/1078-0432.CCR-18-2146; Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007; Zhu DM, 2000, CLIN CANCER RES, V6, P2456	119	0	0	6	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6321	6328		10.1038/s41388-021-02025-8	http://dx.doi.org/10.1038/s41388-021-02025-8		OCT 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34625709	Green Published, hybrid			2022-12-17	WOS:000705760400002
J	Zhang, JW; Zhai, JN; Wong, CC; Chen, HR; Wang, XH; Ji, JF; Yu, J				Zhang, Jingwan; Zhai, Jianning; Wong, Chi Chun; Chen, Huarong; Wang, Xiaohong; Ji, Jiafu; Yu, Jun			A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML)	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CADHERIN EXPRESSION; CELL; ONCOGENE; CLEAVAGE; PATHWAY; DAMAGE	Using whole genome sequencing, PCI Domain Containing 2 (PCID2) was identified to be amplified in colorectal cancer (CRC). In this study, we investigated the expression, biological function, molecular mechanism, and clinical implication of PCID2 in CRC. PCID2 mRNA and protein expression were higher in CRC cells and tumor tissues compared to healthy colonic tissues. The copy number of PCID2 was positively correlated with its mRNA expression. Multivariate analysis revealed that PCID2 is an independent prognostic factor for CRC recurrence. Functional studies showed that PCID2 promoted cell growth, cell cycle progression, and cell migration/invasion, while apoptosis was suppressed. Moreover, PCID2 promoted xenograft growth and lung metastasis in nude mice. Using co-immunoprecipitation and mass spectroscopy, we showed that PCID2 binds to promyelocytic leukemia (PML), a tumor suppressor involved in non-canonical beta-catenin signaling. PCID2 promoted the degradation of PML via poly-ubiquitination, which in turn, induced Wnt/beta-catenin signaling while simultaneously repressing ARF-p53 pathway. Thus, these results demonstrated that PCID2 functions as an oncogene in CRC by enhancing canonical Wnt/beta-catenin signaling and inhibition of CTNNB1-ARF-p53 axis. PCID2 promoted canonical Wnt/beta-catenin signaling in CRC via degradation of PML. PCID2 may serve as an independent prediction marker for CRC recurrence.	[Zhang, Jingwan; Zhai, Jianning; Wong, Chi Chun; Chen, Huarong; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China; [Zhang, Jingwan; Zhai, Jianning; Wong, Chi Chun; Chen, Huarong; Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,Shenzhen Res Inst, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Chen, Huarong/ABZ-5810-2022; zhai, jianning/GSD-4306-2022; ZHANG, Jingwan/AIC-2560-2022; chen, huarong/ABH-8561-2020; Jun, Yu/D-8569-2015	zhai, jianning/0000-0002-8780-492X; chen, huarong/0000-0003-2192-1864; ZHANG, Jingwan/0000-0002-0344-3398; JI, JIAFU/0000-0001-6878-5543; Jun, Yu/0000-0001-5008-2153; Wong, Chi Chun/0000-0003-1362-3541	National Natural Science Foundation of China [81972576]; RGC-CRF Hong Kong [C4039-19GF, C7065-18GF]; RGC-GRF Hong Kong [14163817, 14110819]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council)	This project was supported by National Natural Science Foundation of China (81972576), RGC-CRF Hong Kong (C4039-19GF, C7065-18GF), RGC-GRF Hong Kong (14163817, 14110819), Vice-Chancellor's Discretionary Fund CUHK.	ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Calcagno DQ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-141; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Erdem JS, 2016, J CANCER, V7, P512, DOI 10.7150/jca.13651; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Harada K, 2000, ORAL ONCOL, V36, P3, DOI 10.1016/S1368-8375(99)00049-4; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Loser T, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110157; Melchor L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2456; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Norton N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153411; Salari K, 2012, P NATL ACAD SCI USA, V109, pE3196, DOI 10.1073/pnas.1206004109; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Sasaki H, 2011, J THORAC ONCOL, V6, P15, DOI 10.1097/JTO.0b013e31820594f0; Schmidt H, 2005, MODERN PATHOL, V18, P638, DOI 10.1038/modpathol.3800326; Shtutman Michael, 2002, Cancer Research, V62, P5947; Stella A, 2007, CLIN GENET, V71, P130, DOI 10.1111/j.1399-0004.2007.00745.x; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wang YT, 2017, J CLIN INVEST, V127, P2982, DOI 10.1172/JCI89957; Xie T, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042001, 10.1371/journal.pone.0047577]; Yang YM, 2015, ONCOGENE, V34, P2910, DOI 10.1038/onc.2014.218; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	29	0	0	5	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6641	6652		10.1038/s41388-021-01941-z	http://dx.doi.org/10.1038/s41388-021-01941-z		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34625711	hybrid, Green Published			2022-12-17	WOS:000705760400003
J	Lee, SO; Lou, W; Hou, M; Onate, SA; Gao, AC				Lee, Soo Ok; Lou, Wei; Hou, Min; Onate, Sergio A.; Gao, Allen C.			Editorial Expression of Concern: Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway	ONCOGENE			English	Editorial Material							GROWTH					allen.gao@roswellpark.org						DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Lee SO, 2003, CLIN CANCER RES, V9, P370; Lee SO, 2003, ONCOGENE, V22, P7981, DOI 10.1038/sj.onc.1206735	3	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6547	6547		10.1038/s41388-021-02034-7	http://dx.doi.org/10.1038/s41388-021-02034-7		OCT 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34599276	Bronze			2022-12-17	WOS:000702648500001
J	Qi, M; Jiao, M; Li, X; Hu, J; Wang, L; Zou, Y; Zhao, M; Zhang, R; Liu, H; Mi, J; Zhang, L; Liu, L; Gong, Y; Han, B				Qi, M.; Jiao, M.; Li, X.; Hu, J.; Wang, L.; Zou, Y.; Zhao, M.; Zhang, R.; Liu, H.; Mi, J.; Zhang, L.; Liu, L.; Gong, Y.; Han, B.			CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2 (vol 37, pg 1075, 2018)	ONCOGENE			English	Correction												boh@sdu.edu.cn						Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6140	6141		10.1038/s41388-021-01995-z	http://dx.doi.org/10.1038/s41388-021-01995-z		SEP 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34584220	Bronze			2022-12-17	WOS:000701638300003
J	Xia, X; Wang, SC; Ni, B; Xing, SP; Cao, H; Zhang, ZZ; Yu, FR; Zhao, EH; Zhao, G				Xia, Xiang; Wang, Shuchang; Ni, Bo; Xing, Shunpeng; Cao, Hui; Zhang, Zizhen; Yu, Fengrong; Zhao, Enhao; Zhao, Gang			Hypoxic gastric cancer-derived exosomes promote progression and metastasis via MiR-301a-3p/PHD3/HIF-1 alpha positive feedback loop (vol 39, pg 6231, 2020)	ONCOGENE			English	Correction												yufengrongrj@163.com; zhaoenhao@renji.com; zhaogangrj@163.com						Xia X, 2020, ONCOGENE, V39, P6231, DOI 10.1038/s41388-020-01425-6	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6058	6058		10.1038/s41388-021-01989-x	http://dx.doi.org/10.1038/s41388-021-01989-x		SEP 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34493811	Bronze			2022-12-17	WOS:000693481700001
J	Ray, A; Song, Y; Du, T; Chauhan, D; Anderson, KC				Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.			Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma (vol 39, pg 2786, 2020)	ONCOGENE			English	Correction												Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu						Ray A, 2020, ONCOGENE, V39, P2786, DOI 10.1038/s41388-020-1172-0	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6057	6057		10.1038/s41388-021-01996-y	http://dx.doi.org/10.1038/s41388-021-01996-y		SEP 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34489552	Bronze			2022-12-17	WOS:000692963500001
J	Qiu, PX; Hou, WL; Wang, HT; Lei, KKW; Wang, SW; Chen, WP; Pardeshi, LA; Prothro, K; Shukla, Y; Su, SSM; Schrump, DS; Chen, Q; Deng, CX; Xu, XL; Wang, RH				Qiu, Pengxiang; Hou, Weilong; Wang, Haitao; Lei, Kimmy Ka Wing; Wang, Shaowei; Chen, Weiping; Pardeshi, Lakhansing Arun; Prothro, Katherine; Shukla, Yashvita; Su, Samson Sek Man; Schrump, David S.; Chen, Qiang; Deng, Chu-Xia; Xu, Xiaoling; Wang, Ruihong			Sirt1 deficiency upregulates glutathione metabolism to prevent hepatocellular carcinoma initiation in mice	ONCOGENE			English	Article							OXIDATIVE DNA-DAMAGE; CELL-SURVIVAL; HEPATOCYTE DEATH; NRF2; LIVER; TRANSCRIPTION; MODULATION; GROWTH; PROLIFERATION; DEACETYLATION	Sirtuin-1 (SIRT1) is involved in various metabolic pathways, including fatty acid synthesis and gluconeogenesis in the liver. However, its role in initiation and progression of liver cancer remains unclear. Studying Sirt1 liver-specific knockout (LKO) mice in combination with diethylnitrosamine (DEN) treatment, we demonstrated that loss of Sirt1 rendered mice resistant to DEN-induced hepatocellular carcinoma (HCC) development. RNA-seq revealed that livers from LKO mice exhibited an enrichment in glutathione metabolism eight months after DEN challenge. Sirt1 deficiency elevated the expression of glutathione-s-transferase family genes by increasing the level of Nrf2, a key regulator of glutathione metabolism. Hence, LKO livers displayed a reductive environment with an increased ratio of GSH to GSSG and an elevated GSH level. Furthermore, using CRISPR knockout techniques, we confirmed that the impairment of HCC formation in LKO mice is mainly dependent on NRF2 signaling. Meanwhile, HCC induced by DEN could be blocked by the administration of N-acetyl cysteine (NAC) when administered one month after DEN challenge. However, NAC treatment starting five months after DEN injection was not able to prevent tumor development. In conclusion, our findings indicate that a reductive environment orchestrated by glutathione metabolism at an early stage can prevent the initiation of HCC.	[Qiu, Pengxiang; Hou, Weilong; Wang, Haitao; Lei, Kimmy Ka Wing; Wang, Shaowei; Pardeshi, Lakhansing Arun; Su, Samson Sek Man; Chen, Qiang; Deng, Chu-Xia; Xu, Xiaoling; Wang, Ruihong] Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China; [Qiu, Pengxiang; Su, Samson Sek Man; Chen, Qiang; Deng, Chu-Xia; Xu, Xiaoling] Univ Macau, Fac Hlth Sci, Ctr Precis Med Res & Training, Macau, Peoples R China; [Chen, Weiping] Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA; [Prothro, Katherine; Shukla, Yashvita; Schrump, David S.; Wang, Ruihong] NCI, Thorac Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Macau; University of Macau; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX; Xu, XL; Wang, RH (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China.; Deng, CX; Xu, XL (corresponding author), Univ Macau, Fac Hlth Sci, Ctr Precis Med Res & Training, Macau, Peoples R China.; Wang, RH (corresponding author), NCI, Thorac Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	cxdeng@um.edu.mo; xiaolingx@um.edu.mo; ruihongw@nih.gov	Chen, Wei/GZK-7348-2022	Qiu, Pengxiang/0000-0003-1766-3727; Wang, Haitao/0000-0001-6910-974X; Pardeshi, Lakhansing/0000-0003-0702-5465	University of Macau [SRG2015-00008-FHS, MYRG2016-00054-FHS, MYRG2017-00096-FHS, MYRG2019-0064-FHS, CPG202000004-FHS]	University of Macau	This project was supported by grants SRG2015-00008-FHS, MYRG2016-00054-FHS and MYRG2017-00096-FHS to RHW; MYRG2019-0064-FHS to XLX; and CPG202000004-FHS to CXD from the University of Macau.	Agarwal A, 2004, AM J PATHOL, V164, P1683, DOI 10.1016/S0002-9440(10)63727-3; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alves-Fernandes DK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133153; Amini A, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0092-7; Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7; Atkuri KR, 2009, P NATL ACAD SCI USA, V106, P3941, DOI 10.1073/pnas.0813409106; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cabello CM, 2007, CURR OPIN INVEST DR, V8, P1022; Circu ML, 2012, BBA-MOL CELL RES, V1823, P1767, DOI 10.1016/j.bbamcr.2012.06.019; Cuadrado A, 2003, J BIOL CHEM, V278, P241, DOI 10.1074/jbc.M201010200; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Deng J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1016-8; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; Higgs MR, 2014, J GEN VIROL, V95, P991, DOI 10.1099/vir.0.059485-0; Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Jayakumar S, 2015, MUTAT RES-FUND MOL M, V779, P33, DOI 10.1016/j.mrfmmm.2015.06.007; Jeong Jaemin, 2007, Exp Mol Med, V39, P8; Jungst C, 2004, HEPATOLOGY, V39, P1663, DOI 10.1002/hep.20241; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Kim SB, 2012, P NATL ACAD SCI USA, V109, pE2949, DOI 10.1073/pnas.1207718109; Kolaja KL, 1997, TOXICOL APPL PHARM, V143, P380, DOI 10.1006/taap.1996.8089; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Malhi H, 2010, PHYSIOL REV, V90, P1165, DOI 10.1152/physrev.00061.2009; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Mao B, 2014, ONCOGENE, V33, P1468, DOI 10.1038/onc.2013.88; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Portmann S, 2013, MOL CANCER THER, V12, P499, DOI 10.1158/1535-7163.MCT-12-0700; Satoh H, 2016, CANCER RES, V76, P3088, DOI 10.1158/0008-5472.CAN-15-1584; Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Tanaka H, 2008, BRIT J CANCER, V98, P580, DOI 10.1038/sj.bjc.6604204; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wai Ling Khoo TS., 2019, TYROSINE KINASE INHI; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang RH, 2011, J CLIN INVEST, V121, P4477, DOI 10.1172/JCI46243; Wang RH, 2010, INT J BIOL SCI, V6, P682; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	50	0	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6023	6033		10.1038/s41388-021-01993-1	http://dx.doi.org/10.1038/s41388-021-01993-1		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34433910				2022-12-17	WOS:000688395700001
J	Li, XD; Zhang, JX; Jiang, LJ; Wang, FW; Liu, LL; Liao, YJ; Jin, XH; Chen, WH; Chen, X; Guo, SJ; Zhou, FJ; Zeng, YX; Guan, XY; Liu, ZW; Xie, D				Li, Xiang-Dong; Zhang, Jia-Xing; Jiang, Li-Juan; Wang, Feng-Wei; Liu, Lu-Lu; Liao, Yi-Ji; Jin, Xiao-Han; Chen, Wen-Hui; Chen, Xin; Guo, Shen-Jie; Zhou, Fang-Jian; Zeng, Yi-Xin; Guan, Xin-Yuan; Liu, Zhuo-Wei; Xie, Dan			Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically down-regulating MTSS1 through DNMT3B (vol 35, pg 6281, 2016)	ONCOGENE			English	Correction												liuzhw@sysucc.org.cn						Li XD, 2016, ONCOGENE, V35, P6281, DOI 10.1038/onc.2016.165	1	0	0	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5970	5971		10.1038/s41388-021-01935-x	http://dx.doi.org/10.1038/s41388-021-01935-x		AUG 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT					2022-12-17	WOS:000685396300003
J	Kundu, A; Kowarz, E; Marschalek, R				Kundu, Arpita; Kowarz, Eric; Marschalek, Rolf			The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(6;11)	ONCOGENE			English	Article							METHYLTRANSFERASE ACTIVITY; ADHERENS JUNCTIONS; CELL-ADHESION; PHD FINGERS; CPG DNA; DOMAIN; BINDING; PROTEIN; MENIN; AF6	Leukemia patients bearing t(6;11)(q27;q23) translocations can be divided in two subgroups: those with breakpoints in the major breakpoint cluster region of MLL (introns 9-10; associated mainly with AML M1/4/5), and others with breakpoints in the minor breakpoint cluster region (introns 21-23), associated with T-ALL. We cloned all four of the resulting fusion genes (MLL-AF6, AF6-MLL, exMLL-AF6, AF6-shMLL) and subsequently transfected them to generate stable cell culture models. Their molecular function was tested by inducing gene expression for 48 h in a Doxycycline-dependent fashion. Here, we present our results upon differential gene expression (DGE) that were obtained by the "Massive Analyses of cDNA Ends" (MACE-Seq) technology, an established 3 '-end based RNA-Seq method. Our results indicate that the PHD/BD domain, present in the AF6-MLL and the exMLL-AF6 fusion protein, is responsible for chromatin activation in a genome-wide fashion. This led to strong deregulation of transcriptional processes involving protein-coding genes, pseudogenes, non-annotated genes, and RNA genes, e.g., LincRNAs and microRNAs, respectively. While cooperation between the MLL-AF6 and AF6-MLL fusion proteins appears to be required for the above-mentioned effects, exMLL-AF6 is able to cause similar effects on its own. The exMLL-AF6/AF6-shMLL co-expressing cell line displayed the induction of a myeloid-specific and a T-cell specific gene signature, which may explain the T-ALL disease phenotype observed in patients with such breakpoints. This again demonstrated that MLL fusion proteins are instructive and allow to study their pathomolecular mechanisms.	[Kundu, Arpita; Kowarz, Eric; Marschalek, Rolf] Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol DCAL, Max von Laue Str 9, D-60438 Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol DCAL, Max von Laue Str 9, D-60438 Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de		Marschalek, Rolf/0000-0003-4870-3445	DFG [Ma 1876/12-1, Ma 1876/13-1]; Wilhelm Sander foundation [2018.070.1, 2018.070.2]; Projekt DEAL	DFG(German Research Foundation (DFG)); Wilhelm Sander foundation; Projekt DEAL	This work is funded by DFG grants Ma 1876/12-1 and Ma 1876/13-1, and grants 2018.070.1 and 2018.070.2 from the Wilhelm Sander foundation. Open Access funding enabled and organized by Projekt DEAL.	Ali M, 2014, BBA-MOL CELL RES, V1843, P366, DOI 10.1016/j.bbamcr.2013.11.016; Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340; Andriano N, 2019, BRIT J HAEMATOL, V185, P563, DOI 10.1111/bjh.15534; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Bach C, 2009, ONCOGENE, V28, P815, DOI 10.1038/onc.2008.443; Balgobind BV, 2009, BLOOD, V114, P2489, DOI 10.1182/blood-2009-04-215152; Begay-Muller V, 2002, FEBS LETT, V521, P36, DOI 10.1016/S0014-5793(02)02814-4; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Cao F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014102; Chang PY, 2010, J MOL BIOL, V400, P137, DOI 10.1016/j.jmb.2010.05.005; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Hom RA, 2010, J MOL BIOL, V400, P145, DOI 10.1016/j.jmb.2010.04.067; Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Liedtke M, 2010, BLOOD, V116, P63, DOI 10.1182/blood-2009-09-243386; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manara E, 2014, BLOOD, V124, P263, DOI 10.1182/blood-2013-09-525741; Marschalek R, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2020.194547; Marschalek R, 2019, HAEMATOLOGICA, V104, P1098, DOI 10.3324/haematol.2018.213397; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Nakanishi H, 2004, BIOL CHEM, V385, P885, DOI 10.1515/BC.2004.116; Okumura N, 2018, CORNEA, V37, P633, DOI 10.1097/ICO.0000000000001526; Pannekoek WJ, 2009, BBA-BIOMEMBRANES, V1788, P790, DOI 10.1016/j.bbamem.2008.12.010; Park S, 2010, BIOCHEMISTRY-US, V49, P6576, DOI 10.1021/bi1009387; Risner LE, 2013, J BIOL CHEM, V288, P29901, DOI 10.1074/jbc.M113.474858; Rivard N, 2009, FRONT BIOSCI-LANDMRK, V14, P510, DOI 10.2741/3259; Rossler T, 2013, PHARMAZIE, V68, P601, DOI 10.1691/ph.2013.6514; Sharaf-Eldein M, 2018, CLIN LAB, V64, P1429, DOI 10.7754/Clin.Lab.2018.180308; Smith MJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01326-5; Southall SM, 2009, MOL CELL, V33, P181, DOI 10.1016/j.molcel.2008.12.029; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Wachter K, 2014, CANCER LETT, V352, P196, DOI 10.1016/j.canlet.2014.06.016; Wang AY, 2021, CANCER GENOM PROTEOM, V18, P43, DOI 10.21873/cgp.20240; Wang JY, 2012, BLOOD, V119, P1151, DOI 10.1182/blood-2011-06-362079; Wang ZX, 2010, CELL, V141, P1183, DOI 10.1016/j.cell.2010.05.016; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2008, CANCER CELL, V14, P36, DOI 10.1016/j.ccr.2008.05.003	48	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5902	5912		10.1038/s41388-021-01983-3	http://dx.doi.org/10.1038/s41388-021-01983-3		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34354240	hybrid, Green Published			2022-12-17	WOS:000681543500001
J	Cabot, D; Brun, S; Paco, N; Ginesta, MM; Gendrau-Sanclemente, N; Abuasaker, B; Ruiz-Farina, T; Barcelo, C; Cuatrecasas, M; Bosch, M; Rentero, C; Pons, G; Estanyol, JM; Capella, G; Jaumot, M; Agell, N				Cabot, Debora; Brun, Sonia; Paco, Noelia; Ginesta, Mireia M.; Gendrau-Sanclemente, Nuria; Abuasaker, Baraa; Ruiz-Farina, Triana; Barcelo, Carles; Cuatrecasas, Miriam; Bosch, Marta; Rentero, Carles; Pons, Gabriel; Estanyol, Josep M.; Capella, Gabriel; Jaumot, Montserrat; Agell, Neus			KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer	ONCOGENE			English	Article							K-RAS; ONCOGENIC KRAS; ALPHA-CATENIN; CALMODULIN; EXPRESSION; PROTEINS; IDENTIFICATION; ASSOCIATION; PROMOTES; MODELS	Oncogenic mutations of KRAS are found in the most aggressive human tumors, including colorectal cancer. It has been suggested that oncogenic KRAS phosphorylation at Ser181 modulates its activity and favors cell transformation. Using nonphosphorylatable (S181A), phosphomimetic (S181D), and phospho-/dephosphorylatable (S181) oncogenic KRAS mutants, we analyzed the role of this phosphorylation to the maintenance of tumorigenic properties of colorectal cancer cells. Our data show that the presence of phospho-/dephosphorylatable oncogenic KRAS is required for preserving the epithelial organization of colorectal cancer cells in 3D cultures, and for supporting subcutaneous tumor growth in mice. Interestingly, gene expression differed according to the phosphorylation status of KRAS. In DLD-1 cells, CTNNA1 was only expressed in phospho-/dephosphorylatable oncogenic KRAS-expressing cells, correlating with cell polarization. Moreover, lack of oncogenic KRAS phosphorylation leads to changes in expression of genes related to cell invasion, such as SERPINE1, PRSS1,2,3, and NEO1, and expression of phosphomimetic oncogenic KRAS resulted in diminished expression of genes involved in enterocyte differentiation, such as HNF4G. Finally, the analysis, in a public data set of human colorectal cancer, of the gene expression signatures associated with phosphomimetic and nonphosphorylatable oncogenic KRAS suggests that this post-translational modification regulates tumor progression in patients.	[Cabot, Debora; Brun, Sonia; Paco, Noelia; Gendrau-Sanclemente, Nuria; Abuasaker, Baraa; Ruiz-Farina, Triana; Barcelo, Carles; Bosch, Marta; Rentero, Carles; Estanyol, Josep M.; Jaumot, Montserrat; Agell, Neus] Univ Barcelona, Fac Med & Ciencies Salut, Dept Biomed, Barcelona, Spain; [Cabot, Debora; Brun, Sonia; Paco, Noelia; Abuasaker, Baraa; Barcelo, Carles; Cuatrecasas, Miriam; Bosch, Marta; Rentero, Carles; Jaumot, Montserrat; Agell, Neus] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Ginesta, Mireia M.; Capella, Gabriel] Catalan Inst Oncol, Hosp Llobregat, Hereditary Canc Program, ICO IDIBELL,Translat Res Lab, Barcelona, Spain; [Ginesta, Mireia M.; Capella, Gabriel] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Cuatrecasas, Miriam] Univ Barcelona, Dept Fonaments Clin, Fac Med & Ciencies Salut, Barcelona, Spain; [Cuatrecasas, Miriam] Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain; [Cuatrecasas, Miriam] Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain; [Cuatrecasas, Miriam] Hosp Clin Barcelona, Tumor Bank Biobank, Barcelona, Spain; [Pons, Gabriel] Univ Barcelona, Fac Med & Ciencies Salut, Dept Ciencies Fisiol, Barcelona, Spain; [Pons, Gabriel] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain; [Estanyol, Josep M.] Univ Barcelona, Prote Unit, CCiT UB, Barcelona, Spain; [Gendrau-Sanclemente, Nuria] Hosp Duran & Reynals, Catalan Inst Oncol, Inst Invest Biomed Bellvitge IDIBELL, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain; [Barcelo, Carles] Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Institut Investigacio Sanitaria Illes Balears (IdISBa)	Jaumot, M; Agell, N (corresponding author), Univ Barcelona, Fac Med & Ciencies Salut, Dept Biomed, Barcelona, Spain.; Jaumot, M; Agell, N (corresponding author), Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.	mjaumot@ub.edu; neusagell@ub.edu	Rentero Alfonso, Carles/L-4430-2017; BARCELO, PhD, CARLES/K-4299-2014	Rentero Alfonso, Carles/0000-0003-4684-0278; Morell Ginesta, Mireia/0000-0002-1708-0110; Estanyol Ullate, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; BARCELO, PhD, CARLES/0000-0003-2551-2136; Jaumot, Montserrat/0000-0003-2864-357X; Brun, Sonia/0000-0002-2056-3180; Gendrau, Nuria/0000-0002-7761-3695; Bosch, Marta/0000-0003-3934-6781	Ministerio de Economia y Competitividad; FEDER funds-a way to build Europe [SAF2016-76239-R, PID2019-105483RB-I00, SAF2015-68016-R]; CIBERONC; Government of Catalonia [2017SGR1282, SLT002/16/0037]; Instituto de Salud Carlos III [PI17/01304]; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Generalitat de Catalunya; University of Barcelona; Serra Hunter Program (Generalitat de Catalunya)	Ministerio de Economia y Competitividad(Spanish Government); FEDER funds-a way to build Europe; CIBERONC; Government of Catalonia(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Generalitat de Catalunya(Generalitat de Catalunya); University of Barcelona; Serra Hunter Program (Generalitat de Catalunya)(Generalitat de Catalunya)	We thank the personnel of the Advanced Microscopy Unit of CCiT-UB (Campus Clinic) for help in setting up image acquisition and analysis. This work was supported by grants from the Ministerio de Economia y Competitividad and co funded by FEDER funds-a way to build Europe- (SAF2016-76239-R and PID2019-105483RB-I00 to NA, SAF2015-68016-R to GC), CIBERONC and the Government of Catalonia (grants 2017SGR1282 and PERIS SLT002/16/0037), and from Instituto de Salud Carlos III (grant PI17/01304 to MC); a FPU fellowship from Ministerio de Educacion, Cultura y Deporte for DC, a FI fellowship from Generalitat de Catalunya for NP, and a Predoc-UB from University of Barcelona to BA; CR is supported by the Serra Hunter Program (Generalitat de Catalunya).	Alvarez-Moya B, 2010, ONCOGENE, V29, P5911, DOI 10.1038/onc.2010.298; Barcelo C, 2014, GASTROENTEROLOGY, V147, P882, DOI 10.1053/j.gastro.2014.06.041; Barcelo C, 2014, CANCER RES, V74, P1190, DOI 10.1158/0008-5472.CAN-13-1750; Barcelo C, 2013, J CELL SCI, V126, P4553, DOI 10.1242/jcs.123737; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brookes MJ, 2006, GUT, V55, P1449, DOI 10.1136/gut.2006.094060; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Chaturvedi V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40886-y; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; Cortazar AR, 2018, CANCER RES, V78, P6320, DOI 10.1158/0008-5472.CAN-18-1669; Elia AEH, 2015, MOL CELL, V60, P280, DOI 10.1016/j.molcel.2015.09.011; Garrido E, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006552; Gogarten SM, 2012, BIOINFORMATICS, V28, P3329, DOI 10.1093/bioinformatics/bts610; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hou ZL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0922-x; Hu DG, 2016, DRUG METAB REV, V48, P47, DOI 10.3109/03602532.2015.1131292; Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836; Inder KL, 2009, J BIOL CHEM, V284, P28410, DOI 10.1074/jbc.M109.001537; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee SK, 2018, EMBO REP, V19, DOI 10.15252/embr.201846060; Li SJ, 2018, BIOMED PHARMACOTHER, V105, P83, DOI 10.1016/j.biopha.2018.05.119; Lindeboom RGH, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188227; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Alcala C, 2008, J BIOL CHEM, V283, P10621, DOI 10.1074/jbc.M706238200; Maher DM, 2011, MOL CANCER RES, V9, P531, DOI 10.1158/1541-7786.MCR-10-0443; Maiden SL, 2011, J CELL BIOL, V195, P543, DOI 10.1083/jcb.201103106; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Roman-Fernandez A, 2016, TRAFFIC, V17, P1244, DOI 10.1111/tra.12417; Santiago L, 2017, AM J CANCER RES, V7, P1389; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Shalom-Feuerstein R, 2008, CANCER RES, V68, P6608, DOI 10.1158/0008-5472.CAN-08-1117; Shibata H, 2007, P NATL ACAD SCI USA, V104, P18199, DOI 10.1073/pnas.0705730104; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Short SP, 2017, J CLIN INVEST, V127, P4462, DOI 10.1172/JCI77217; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Villalonga P, 2002, J BIOL CHEM, V277, P37929, DOI 10.1074/jbc.M202245200; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Wang Jingyu, 2018, Oncotarget, V9, P18018, DOI 10.18632/oncotarget.22933; Wang MT, 2015, CELL, V163, P1237, DOI 10.1016/j.cell.2015.10.041; Yamamoto H, 2003, J PATHOL, V199, P176, DOI 10.1002/path.1277; Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109; Yin N, 2019, CANCER CELL, V36, P156, DOI 10.1016/j.ccell.2019.07.002	50	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5730	5740		10.1038/s41388-021-01967-3	http://dx.doi.org/10.1038/s41388-021-01967-3		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34333552	Green Accepted			2022-12-17	WOS:000679771600002
J	Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV				Yin, Xiao-ying; Landay, Melanie F.; Han, Weiping; Levitan, Edwin S.; Watkins, Simon C.; Levenson, Richard M.; Farkas, Daniel L.; Prochownik, Edward V.			Editorial Expression of Concern: Dynamic in vivo interactions among Myc network members	ONCOGENE			English	Editorial Material												edward_prochownik@poplar.chp.edu						Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6308	6308		10.1038/s41388-021-01953-9	http://dx.doi.org/10.1038/s41388-021-01953-9		JUL 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34326468	Bronze			2022-12-17	WOS:000679262900001
J	Wang, L; Du, L; Xiong, X; Lin, YS; Zhu, JL; Yao, ZM; Wang, SH; Guo, Y; Chen, YP; Geary, K; Pan, YL; Zhou, FY; Gao, SG; Zhang, DZ; Yeung, SCJ; Zhang, H				Wang, Lu; Du, Liang; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Guo, Yi; Chen, Yuping; Geary, Kyla; Pan, Yunlong; Zhou, Fuyou; Gao, Shegan; Zhang, Dianzheng; Yeung, Sai-Ching Jim; Zhang, Hao			Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling (Feb, 10.1038/s41388-021-01682-z, 2021)	ONCOGENE			English	Correction												haolabcancercenter@163.com		Lin, Yusheng/0000-0002-3693-3377				Wang L, 2021, ONCOGENE, V40, P1974, DOI 10.1038/s41388-021-01682-z	1	0	0	6	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5356	5356		10.1038/s41388-021-01936-w	http://dx.doi.org/10.1038/s41388-021-01936-w		JUL 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34302119	hybrid, Green Published			2022-12-17	WOS:000676064800001
J	Mei, L; Qv, MY; Bao, HY; He, QQ; Xu, YN; Zhang, Q; Shi, W; Ren, QL; Yan, ZY; Xu, CY; Tang, C; Hussain, M; Zeng, LH; Wu, XM				Mei, Liu; Qv, Meiyu; Bao, Hangyang; He, Qiangqiang; Xu, Yana; Zhang, Qin; Shi, Wei; Ren, Qianlei; Yan, Ziyi; Xu, Chengyun; Tang, Chao; Hussain, Musaddique; Zeng, Ling-Hui; Wu, Ximei			SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling	ONCOGENE			English	Article							CELL-PROLIFERATION; SUMO E3-LIGASES; KINASE-ACTIVITY; HUMAN HOMOLOG; SIZE-CONTROL; ORGAN SIZE; PATHWAY; YAP; DROSOPHILA; PHOSPHORYLATION	Large tumour suppressor (LATS) 1/2, the core kinases of Hippo signalling, are critical for maintaining tissue homeostasis. Here, we investigate the role of SUMOylation in the regulation of LATS activation. High cell density induces the expression of components of the SUMOylation machinery and enhances the SUMOylation and activation of Lats1 but not Lats2, whereas genetic deletion of the SUMOylation E2 ligase, Ubc9, abolishes this Lats1 activation. Moreover, SUMOylation occurs at the K830 (mouse K829) residue to activate LATS1 and depends on the PIAS1/2 E3 ligase. Whereas the K830 deSUMOylation mutation of LATS1 found in the human metastatic prostate cancers eliminates the kinase activity by attenuating the formation of the phospho-MOB1/phospho-LATS1 complex. As a result, the LATS1(K830R) transgene phenocopies Yap transgene to cause the oversized livers in mice, whereas Lats1(K829R) knock-in phenocopies the deletion of Lats1 in causing the reproductive and endocrine defects and ovary tumours in mice. Thus, SUMOylation-mediated LATS1 activation is an integral component of Hippo signalling in the regulation of tissues homeostasis.	[Mei, Liu; Qv, Meiyu; He, Qiangqiang; Xu, Yana; Zhang, Qin; Shi, Wei; Yan, Ziyi; Xu, Chengyun; Tang, Chao; Hussain, Musaddique; Wu, Ximei] Zhejiang Univ, Dept Pharmacol, Sch Med, Hangzhou, Peoples R China; [Mei, Liu] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA; [Qv, Meiyu; Xu, Yana; Tang, Chao; Hussain, Musaddique; Wu, Ximei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou, Peoples R China; [Bao, Hangyang] Zhejiang Chinese Med Univ, Dept Physiol, Coll Basic Med Sci, Hangzhou, Peoples R China; [Shi, Wei] Univ N Carolina, Dept Biol & Genet, Chapel Hill, NC 27515 USA; [Ren, Qianlei; Zeng, Ling-Hui] Zhejiang Univ City Coll, Dept Pharmacol, Hangzhou, Peoples R China	Zhejiang University; University of North Carolina; University of North Carolina Chapel Hill; Zhejiang University; Zhejiang Chinese Medical University; University of North Carolina; University of North Carolina Chapel Hill; Zhejiang University City College	Wu, XM (corresponding author), Zhejiang Univ, Dept Pharmacol, Sch Med, Hangzhou, Peoples R China.; Wu, XM (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou, Peoples R China.; Zeng, LH (corresponding author), Zhejiang Univ City Coll, Dept Pharmacol, Hangzhou, Peoples R China.	zenglh@zucc.edu.cn; xiwu@zju.edu.cn		Wu, Ximei/0000-0002-3316-893X; Hussain, Musaddique/0000-0001-8766-6339	973 Programme [2018YFC1004404]; National Natural Science Foundation of China [31871395, 31801207, 81741043, 31571493]	973 Programme(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by 973 Programme (No. 2018YFC1004404) and National Natural Science Foundation of China (Nos. 31871395, 31801207, 81741043, 31571493). We thank Dr. Bin Zhao from Zhejiang University Life Science Institute for constructs and Dr. Congyi Wang from Tongji Hospital of Huazhong University of Science and Technology for Ubc9<SUP>flox/flox</SUP> founder mice.	Aukrust I, 2013, J BIOL CHEM, V288, P5951, DOI 10.1074/jbc.M112.393769; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eifler K, 2015, TRENDS BIOCHEM SCI, V40, P779, DOI 10.1016/j.tibs.2015.09.006; Eswar Narayanan, 2008, V426, P145, DOI 10.1007/978-1-60327-058-8_8; Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15, 10.1002/cpps.20]; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; He XY, 2018, DIABETOLOGIA, V61, P881, DOI 10.1007/s00125-017-4523-9; Kim MJ, 2016, EMBO REP, V17, P64, DOI 10.15252/embr.201540809; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Liao X, 2013, INT J MOL MED, V32, P1110, DOI 10.3892/ijmm.2013.1480; Liu NH, 2016, CANCER LETT, V378, P38, DOI 10.1016/j.canlet.2016.05.010; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Mei L, 2017, CANCER LETT, V386, P1, DOI 10.1016/j.canlet.2016.11.009; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035; Rabellino A, 2017, CANCER RES, V77, P1542, DOI 10.1158/0008-5472.CAN-16-2958; Ritho J, 2015, CELL REP, V12, P734, DOI 10.1016/j.celrep.2015.07.002; Rubio T, 2013, MOL BIOL CELL, V24, P1801, DOI 10.1091/mbc.E12-11-0806; Schimmel J, 2014, MOL CELL, V53, P1053, DOI 10.1016/j.molcel.2014.02.001; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; Severgnini M, 2012, CYTOTECHNOLOGY, V64, P187, DOI 10.1007/s10616-011-9407-0; Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tang FY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13591-7; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wang XD, 2015, NAT IMMUNOL, V16, P1195, DOI 10.1038/ni.3259; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yagil Z, 2010, TRENDS IMMUNOL, V31, P199, DOI 10.1016/j.it.2010.01.005; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yang Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8961; Yi J, 2016, HEPATOLOGY, V64, P1757, DOI 10.1002/hep.28768; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang H, 2016, NAT GENET, V48, P537, DOI 10.1038/ng.3536; Zhang Q, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118655	45	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5357	5366		10.1038/s41388-021-01937-9	http://dx.doi.org/10.1038/s41388-021-01937-9		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34267330				2022-12-17	WOS:000673880800001
J	Guo, M; Goudarzi, KM; Abedi, S; Pieber, M; Sjoberg, E; Behnan, J; Zhang, XM; Harris, RA; Bartek, J; Lindstrom, MS; Nister, M; Hagerstrand, D				Guo, Min; Goudarzi, Kaveh M.; Abedi, Shiva; Pieber, Melanie; Sjoberg, Elin; Behnan, Jinan; Zhang, Xing-Mei; Harris, Robert A.; Bartek, Jiri; Lindstrom, Mikael S.; Nister, Monica; Hagerstrand, Daniel			SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma (May, 10.1038/s41388-021-01825-2, 2021)	ONCOGENE			English	Correction												min.guo@ki.se; daniel.hagerstrand@ki.se	Sjöberg, Elin/AFQ-2245-2022; Lindström, Mikael S/AAA-1451-2019	Lindström, Mikael S/0000-0003-1148-8497; Behnan, Jinan/0000-0001-5780-0971				Guo M, 2021, ONCOGENE, V40, P5066, DOI 10.1038/s41388-021-01825-2	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5153	5153		10.1038/s41388-021-01929-9	http://dx.doi.org/10.1038/s41388-021-01929-9		JUL 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34257430	hybrid, Green Published			2022-12-17	WOS:000672997300001
J	Schwalbe, EC; Lalchungnunga, H; Lafta, F; Barrow, TM; Strathdee, G				Schwalbe, Edward C.; Lalchungnunga, H.; Lafta, Fadhel; Barrow, Timothy M.; Strathdee, Gordon			Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets	ONCOGENE			English	Article							DNA METHYLATION; OUTCOME PREDICTION; MEDULLOBLASTOMA; CLASSIFICATION; LEUKEMIA; CANCER; IGF2BP1	The identification of cancer-specific vulnerability genes is one of the most promising approaches for developing more effective and less toxic cancer treatments. Cancer genomes exhibit thousands of changes in DNA methylation and gene expression, with the vast majority likely to be passenger changes. We hypothesised that, through integration of genome-wide DNA methylation/expression data, we could exploit this inherent variability to identify cancer subtype-specific vulnerability genes that would represent novel therapeutic targets that could allow cancer-specific cell killing. We developed a bioinformatics pipeline integrating genome-wide DNA methylation/gene expression data to identify candidate subtype-specific vulnerability partner genes for the genetic drivers of individual genetic/molecular subtypes. Using acute lymphoblastic leukaemia as an initial model, 21 candidate subtype-specific vulnerability genes were identified across the five common genetic subtypes, with at least one per subtype. To confirm the approach was applicable across cancer types, we also assessed medulloblastoma, identifying 15 candidate subtype-specific vulnerability genes across three of four established subtypes. Almost all identified genes had not previously been implicated in these diseases. Functional analysis of seven candidate subtype-specific vulnerability genes across the two tumour types confirmed that siRNA-mediated knockdown induced significant inhibition of proliferation/induction of apoptosis, which was specific to the cancer subtype in which the gene was predicted to be specifically lethal. Thus, we present a novel approach that integrates genome-wide DNA methylation/expression data to identify cancer subtype-specific vulnerability genes as novel therapeutic targets. We demonstrate this approach is applicable to multiple cancer types and identifies true functional subtype-specific vulnerability genes with high efficiency.	[Schwalbe, Edward C.; Lalchungnunga, H.; Lafta, Fadhel; Barrow, Timothy M.; Strathdee, Gordon] Newcastle Univ, Biosci Inst, Ctr Canc, Newcastle Upon Tyne, Tyne & Wear, England; [Schwalbe, Edward C.] Northumbria Univ, Dept Appl Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Lafta, Fadhel] Univ Baghdad, Coll Sci, Dept Biol, Baghdad, Iraq; [Barrow, Timothy M.] Univ Sunderland, Fac Hlth Sci & Wellbeing, Sunderland, England	Newcastle University - UK; Northumbria University; University of Baghdad; University of Sunderland	Strathdee, G (corresponding author), Newcastle Univ, Biosci Inst, Ctr Canc, Newcastle Upon Tyne, Tyne & Wear, England.	Gordon.Strathdee@ncl.ac.uk		, Lalchungnunga/0000-0003-2718-6223; Barrow, Timothy/0000-0003-4551-3857; Schwalbe, Ed/0000-0002-1190-9469; Strathdee, Gordon/0000-0001-9681-8429	KidsCan; Bloodwise [14024]	KidsCan; Bloodwise	The authors wish to thank Prof James Allan, Prof Steven Clifford, Dr Daniel Williamson and Dr Lisa Russell for the critical reading of the manuscript. This work was supported by project grants from KidsCan (Grant number N/A) and Bloodwise (Grant number 14024).	Bo XC., 2020, SYNTHETIC LETHAL INT; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Flora A, 2009, SCIENCE, V326, P1424, DOI 10.1126/science.1181453; Gabriel AS, 2015, EPIGENETICS-US, V10, P717, DOI 10.1080/15592294.2015.1061174; Gao SS, 2018, FUTURE MED CHEM, V10, P2129, DOI 10.4155/fmc-2018-0227; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo J, 2016, NUCLEIC ACIDS RES, V44, pD1011, DOI 10.1093/nar/gkv1108; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrison CJ, 2011, CLIN LAB MED, V31, P631, DOI 10.1016/j.cll.2011.08.016; Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009; Kondo Y, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001559; Kulis M, 2015, NAT GENET, V47, P746, DOI 10.1038/ng.3291; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/B978-0-12-380866-0.60002-2, 10.1016/S0065-2660(10)70002-X]; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Liu C, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007701; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Moorman AV, 2010, LANCET ONCOL, V11, P429, DOI 10.1016/S1470-2045(10)70066-8; Nordlund J, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r105; Northcott PA, 2012, ACTA NEUROPATHOL, V123, P615, DOI 10.1007/s00401-011-0899-7; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Oakes CC, 2016, NAT GENET, V48, P253, DOI 10.1038/ng.3488; Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Ryan CJ, 2014, CANCER CELL, V26, P306, DOI 10.1016/j.ccr.2014.08.008; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; Schwalbe EC, 2013, ACTA NEUROPATHOL, V125, P359, DOI 10.1007/s00401-012-1077-2; Sharma T, 2019, ACTA NEUROPATHOL, V138, P309, DOI 10.1007/s00401-019-02020-0; Stoskus M, 2016, LEUKEMIA RES, V47, P16, DOI 10.1016/j.leukres.2016.05.009; Stoskus M, 2016, BLOOD CELL MOL DIS, V57, P30, DOI 10.1016/j.bcmd.2015.11.006; Thompson Jordan M., 2015, Yale Journal of Biology and Medicine, V88, P145; Tirado-Magallanes R, 2017, ONCOTARGET, V8, P5629, DOI 10.18632/oncotarget.13562	34	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5213	5223		10.1038/s41388-021-01923-1	http://dx.doi.org/10.1038/s41388-021-01923-1		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34230614	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000670148000002
J	Sun, L; Patai, AV; Hogenson, TL; Fernandez-Zapico, ME; Qin, B; Sinicrope, FA				Sun, Lei; Patai, Arpad V.; Hogenson, Tara L.; Fernandez-Zapico, Martin E.; Qin, Bo; Sinicrope, Frank A.			Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; BCL2 FAMILY; RNA EXOSOME; ACTIVATION; PHOSPHORYLATION; APOPTOSIS; BIM; KINASE; CELLS; BAX	Colorectal cancer (CRC) cells have low or absent tumor cell PD-L1 expression that we previously demonstrated can confer chemotherapy resistance. Here, we demonstrate that PD-L1 depletion enhances JNK activity resulting in increased Bim(Thr116) phosphorylation and its sequestration by MCL-1 and BCL-2. Activated JNK signaling in PD-L1-depeted cells was due to reduced mRNA stability of the CYLD deubiquitinase. PD-L1 was found to compete with the ribonuclease EXOSC10 for binding to CYLD mRNA. Thus, loss of PD-L1 promoted binding and degradation of CYLD mRNA by EXOSC10 which enhanced JNK activity. An irreversible JNK inhibitor (JNK-IN-8) reduced Bim(Thr116) phosphorylation and unsequestered Bim from MCL-1 and BCL-2 to promote apoptosis. In cells lacking PD-L1, treatment with JNK-IN-8, an MCL-1 antagonist (AZD5991), or their combination promoted apoptosis and reduced long-term clonogenic survival by anticancer drugs. Similar effects of the JNK inhibitor on cell viability were observed in CRC organoids with suppression of PD-L1. These data indicate that JNK inhibition may represent a promising strategy to overcome drug resistance in CRC cells with low or absent PD-L1 expression.	[Sun, Lei; Patai, Arpad V.; Qin, Bo; Sinicrope, Frank A.] Mayo Clin, Gastrointestinal Res Unit, Rochester, MN 55905 USA; [Sun, Lei] Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Guangzhou, Peoples R China; [Hogenson, Tara L.; Fernandez-Zapico, Martin E.] Mayo Clin, Div Oncol Res, Dept Oncol, Schulze Ctr Novel Therapeut, Rochester, MN USA; [Sinicrope, Frank A.] Mayo Clin, Dept Med, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Guangzhou Medical University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Qin, B; Sinicrope, FA (corresponding author), Mayo Clin, Gastrointestinal Res Unit, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Clin, Dept Med, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA.	Qin.Bo@mayo.edu; Sinicrope.Frank@mayo.edu		Sinicrope, Frank/0000-0002-2907-1000	NCI [R01 CA210509-01A1]; Mayo Clinic Center for Biomedical Discovery Pilot Grant Program; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Rosztoczy Foundation Hungarian Scholarship Program	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mayo Clinic Center for Biomedical Discovery Pilot Grant Program; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Rosztoczy Foundation Hungarian Scholarship Program	This study was supported, by NCI R01 CA210509-01A1 and Mayo Clinic Center for Biomedical Discovery Pilot Grant Program (both to FAS). LS is supported by the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. AP is supported by the Rosztoczy Foundation Hungarian Scholarship Program.	Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delmas A, 2015, ONCOTARGET, V6, P15250, DOI 10.18632/oncotarget.3888; Dong HD, 1999, NAT MED, V5, P1365; Ebelt ND, 2017, ONCOTARGET, V8, P104894, DOI 10.18632/oncotarget.20581; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Feng DF, 2019, ONCOGENE, V38, P6752, DOI 10.1038/s41388-019-0919-y; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Haeusgen W, 2011, EUR J CELL BIOL, V90, P536, DOI 10.1016/j.ejcb.2010.11.008; Hamanishi J, 2016, INT J CLIN ONCOL, V21, P462, DOI 10.1007/s10147-016-0959-z; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kulangara K, 2019, ARCH PATHOL LAB MED, V143, P330, DOI 10.5858/arpa.2018-0043-OA; Laine Aaron, 2005, Sci STKE, V2005, pre5, DOI 10.1126/stke.2812005re5; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lipner MB, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.129905; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Pefanis E, 2015, CELL, V161, P774, DOI 10.1016/j.cell.2015.04.034; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Qiu XY, 2018, BBA-MOL BASIS DIS, V1864, P1754, DOI 10.1016/j.bbadis.2018.03.002; Ramkissoon A, 2019, CLIN CANCER RES, V25, P4117, DOI 10.1158/1078-0432.CCR-18-3224; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Sheng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20090; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Soderquist RS, 2016, MOL CANCER THER, V15, P2011, DOI 10.1158/1535-7163.MCT-16-0031; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tron AE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07551-w; Tu XY, 2019, MOL CELL, V74, P1215, DOI 10.1016/j.molcel.2019.04.005; Vasilevskaya I, 2003, DRUG RESIST UPDATE, V6, P147, DOI 10.1016/S1368-7646(03)00043-8; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wyss J, 2019, CLIN COLORECTAL CANC, V18, pE20, DOI 10.1016/j.clcc.2018.09.007; Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010; Zinder JC, 2017, GENE DEV, V31, P88, DOI 10.1101/gad.294769.116	48	0	0	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5105	5115		10.1038/s41388-021-01910-6	http://dx.doi.org/10.1038/s41388-021-01910-6		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34193942				2022-12-17	WOS:000668403200002
J	Zhang, JX; Chen, ZH; Chen, DL; Tian, XP; Wang, CY; Zhou, ZW; Gao, Y; Xu, Y; Chen, C; Zheng, ZS; Weng, HW; Ye, S; Xie, D; Peng, S				Zhang, J. X.; Chen, Z. H.; Chen, D. L.; Tian, X. P.; Wang, C. Y.; Zhou, Z. W.; Gao, Y.; Xu, Y.; Chen, C.; Zheng, Z. S.; Weng, H. W.; Ye, S.; Xie, D.; Peng, S.			LINC01410-miR-532-NCF2- NF-kB feedback loop promotes gastric cancer angiogenesis and metastasis (vol 37, pg 2660, 2018)	ONCOGENE			English	Correction												xiedan@sysucc.org.cn; pengsui@vip.163.com						Zhang JX, 2018, ONCOGENE, V37, P2660, DOI 10.1038/s41388-018-0162-y	1	0	0	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5247	5252		10.1038/s41388-021-01796-4	http://dx.doi.org/10.1038/s41388-021-01796-4		JUN 2021	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34183773	hybrid, Green Published			2022-12-17	WOS:000667587200002
J	Chen, J; Dang, YZ; Feng, WB; Qiao, CY; Liu, DF; Zhang, TY; Wang, YJ; Tian, D; Fan, DM; Nie, YZ; Wu, KC; Xia, LM				Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Tian, Dean; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin			SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7 (vol 39, pg 5536, 2020)	ONCOGENE			English	Correction												xialimin@tjh.tjmu.edu.cn	wang, yi/GVT-8516-2022; wang, yixuan/GXW-2866-2022; Wang, Yijun/GXW-1763-2022; Wang, Yixuan/GZK-6559-2022; Wang, Yu/GZL-9655-2022; Wang, Yin/HCI-9352-2022					Chen J, 2020, ONCOGENE, V39, P5536, DOI 10.1038/s41388-020-1378-1	1	0	0	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4242	4243		10.1038/s41388-021-01828-z	http://dx.doi.org/10.1038/s41388-021-01828-z		MAY 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34021260	Bronze			2022-12-17	WOS:000652945900001
J	Lee, HC; Ou, CH; Huang, YC; Hou, PC; Creighton, CJ; Lin, YS; Hu, CY; Lin, SC				Lee, Hsiu-Chi; Ou, Chien-Hui; Huang, Yun-Chen; Hou, Pei-Chi; Creighton, Chad J.; Lin, Yi-Syuan; Hu, Che-Yuan; Lin, Shih-Chieh			YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer (vol 40, pg 2407, 2021)	ONCOGENE			English	Correction									[Lee, Hsiu-Chi; Hou, Pei-Chi; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan; [Ou, Chien-Hui; Hu, Che-Yuan] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Urol, Tainan, Taiwan; [Huang, Yun-Chen; Lin, Shih-Chieh] Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan, Taiwan; [Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, Houston, TX 77030 USA; [Lin, Yi-Syuan; Lin, Shih-Chieh] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan; [Hu, Che-Yuan] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; Baylor College of Medicine; National Cheng Kung University; National Cheng Kung University	Lin, SC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan.; Lin, SC (corresponding author), Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan, Taiwan.; Lin, SC (corresponding author), Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan.	Jaylin@mail.ncku.edu.tw						Lee HC, 2021, ONCOGENE, V40, P2407, DOI 10.1038/s41388-021-01718-4	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4060	4060		10.1038/s41388-021-01836-z	http://dx.doi.org/10.1038/s41388-021-01836-z		MAY 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34012099	Bronze, Green Published			2022-12-17	WOS:000652080600002
J	Li, W; Hu, M; Wang, C; Lu, H; Chen, F; Xu, J; Shang, Y; Wang, F; Qin, J; Yan, Q; Krueger, BJ; Renne, R; Gao, SJ; Lu, C				Li, W.; Hu, M.; Wang, C.; Lu, H.; Chen, F.; Xu, J.; Shang, Y.; Wang, F.; Qin, J.; Yan, Q.; Krueger, B. J.; Renne, R.; Gao, S. -J.; Lu, C.			A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling (vol 36, pg 5407, 2017)	ONCOGENE			English	Correction												clu@njmu.edu.cn						Li W, 2017, ONCOGENE, V36, P5407, DOI 10.1038/onc.2017.139	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3771	3771		10.1038/s41388-021-01823-4	http://dx.doi.org/10.1038/s41388-021-01823-4		MAY 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33958728	Bronze			2022-12-17	WOS:000648041500003
J	Shapira, S; Finkelshtein, E; Kazanov, D; Naftali, E; Stepansky, I; Loyter, A; Elbirt, D; Hay-Levy, M; Brazowski, E; Bedny, F; Dekel, R; Hershkovitz, D; Blachar, A; Wolf, I; Arber, N				Shapira, Shiran; Finkelshtein, Eynat; Kazanov, Dina; Naftali, Esmira; Stepansky, Irena; Loyter, Abraham; Elbirt, Daniel; Hay-Levy, Mori; Brazowski, Eli; Bedny, Faina; Dekel, Roy; Hershkovitz, Dov; Blachar, Arye; Wolf, Ido; Arber, Nadir			Integrase-derived peptides together with CD24-targeted lentiviral particles inhibit the growth of CD24 expressing cancer cells	ONCOGENE			English	Article							HIV-1 INTEGRASE; REV; GENE; CARCINOGENESIS; REPLICATION; MARKER	The integration of viral DNA into the host genome is mediated by viral integrase, resulting in the accumulation of double-strand breaks. Integrase-derived peptides (INS and INR) increase the number of integration events, leading to escalated genomic instability that induces apoptosis. CD24 is a surface protein expressed mostly in cancer cells and is very rarely found in normal cells. Here, we propose a novel targeted cancer therapeutic platform based on the lentiviral integrase, stimulated by integrase-derived peptides, that are specifically delivered to cancerous cells via CD24 antigen-antibody targeting. INS and INR were synthesized and humanized and anti-CD24 antibodies were fused to the lentivirus envelope. The activity, permeability, stability, solubility, and toxicity of these components were analyzed. Cell death was measured by fluorescent microscopy and enzymatic assays and potency were tested in vitro and in vivo. Lentivirus particles, containing non-functional DNA led to massive cell death (40-70%). Raltegravir, an antiretroviral drug, inhibited the induction of apoptosis. In vivo, single and repeated administrations of INS/INR were well tolerated without any adverse effects. Tumor development in nude mice was significantly inhibited (by 50%) as compared to the vehicle arm. In summary, a novel and generic therapeutic platform for selective cancer cell eradication with excellent efficacy and safety are presented.	[Shapira, Shiran; Kazanov, Dina; Hay-Levy, Mori; Dekel, Roy; Arber, Nadir] Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel; [Shapira, Shiran; Kazanov, Dina; Hay-Levy, Mori; Dekel, Roy; Arber, Nadir] Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel; [Shapira, Shiran; Arber, Nadir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Finkelshtein, Eynat; Naftali, Esmira] Zion Med BV, De Bilt, Netherlands; [Stepansky, Irena; Wolf, Ido] Tel Aviv Med Ctr & Sch Med, Oncol Div, Tel Aviv, Israel; [Loyter, Abraham] Hebrew Univ Jerusalem, Alexander Inst Life Sci, Dept Biol Chem, Jerusalem, Israel; [Elbirt, Daniel] Hadassah Hebrew Univ, Clin Immunol Allergy & AIDS Ctr Kaplan Med Ctr, Med Sch Jerusalem, Rehovot, Israel; [Brazowski, Eli; Bedny, Faina; Hershkovitz, Dov] Tel Aviv Sourasky Med Ctr, Pathol Inst, Tel Aviv, Israel; [Blachar, Arye] Tel Aviv Sourasky Med Ctr, Dept Radiol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Arber, N (corresponding author), Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	nadir@tlvmc.gov.il						Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cooper A, 2013, NATURE, V498, P376, DOI 10.1038/nature12274; Craigie R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006890; Fogel M, 1999, CANCER LETT, V143, P87, DOI 10.1016/S0304-3835(99)00195-0; Gelderblom HC, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-60; Grewe B, 2010, J GEN VIROL, V91, P1893, DOI 10.1099/vir.0.022509-0; Gromova I, 1999, ELECTROPHORESIS, V20, P241, DOI 10.1002/(SICI)1522-2683(19990201)20:2<241::AID-ELPS241>3.3.CO;2-1; HUANG LR, 1995, CANCER RES, V55, P4717; Kammerer R, 2004, J PATHOL, V204, P258, DOI 10.1002/path.1657; Lesbats P, 2016, CHEM REV, V116, P12730, DOI 10.1021/acs.chemrev.6b00125; Levin A, 2010, NUCLEUS-PHILA, V1, P190, DOI 10.4161/nucl.1.2.11300; Levin A, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-31; Levin A, 2010, BIOPOLYMERS, V93, P740, DOI 10.1002/bip.21469; Levin A, 2009, PROTEIN ENG DES SEL, V22, P753, DOI 10.1093/protein/gzp060; Levin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004155; Redston M, 2001, MODERN PATHOL, V14, P236, DOI 10.1038/modpathol.3880292; Rosenbluh J, 2007, J BIOL CHEM, V282, P15743, DOI 10.1074/jbc.M609864200; Rutsaert S, 2019, J ANTIMICROB CHEMOTH, V74, P3030, DOI 10.1093/jac/dkz269; Rutsaert S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35403-6; Rutsaert S, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0399-0; Sagiv E, 2006, BIOMED PHARMACOTHER, V60, P280, DOI 10.1016/j.biopha.2006.06.006; Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Senner V, 1999, J NEUROPATH EXP NEUR, V58, P795, DOI 10.1097/00005072-199908000-00002; Shapira S, 2011, GASTROENTEROLOGY, V140, P935, DOI 10.1053/j.gastro.2010.12.004; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000	27	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3815	3825		10.1038/s41388-021-01779-5	http://dx.doi.org/10.1038/s41388-021-01779-5		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958722	Green Published, hybrid			2022-12-17	WOS:000648041500002
J	Williams, CB; Phelps-Polirer, K; Dingle, IP; Williams, CJ; Rhett, MJ; Eblen, ST; Armeson, K; Hill, EG; Yeh, ES				Williams, Carly B.; Phelps-Polirer, Kendall; Dingle, Ivan P.; Williams, Christina J.; Rhett, Matthew J.; Eblen, Scott T.; Armeson, Kent; Hill, Elizabeth G.; Yeh, Elizabeth S.			HUNK phosphorylates EGFR to regulate breast cancer metastasis (vol 39, pg 1112, 2020)	ONCOGENE			English	Correction												esyeh@iu.edu						Williams CB, 2020, ONCOGENE, V39, P1112, DOI 10.1038/s41388-019-1046-5	1	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3635	3636		10.1038/s41388-021-01797-3	http://dx.doi.org/10.1038/s41388-021-01797-3		MAY 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33958726	hybrid, Green Published			2022-12-17	WOS:000648041500009
J	Zeng, KX; Chen, XX; Hu, XX; Liu, XX; Xu, T; Sun, HL; Pan, YQ; He, BS; Wang, SK				Zeng, Kaixuan; Chen, Xiaoxiang; Hu, Xiuxiu; Liu, Xiangxiang; Xu, Tao; Sun, Huiling; Pan, Yuqin; He, Bangshun; Wang, Shukui			LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation (vol 37, pg 5534, 2018)	ONCOGENE			English	Correction												sk_wang@njmu.edu.cn						Zeng KX, 2018, ONCOGENE, V37, P5534, DOI 10.1038/s41388-018-0352-7	1	0	0	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3772	3773		10.1038/s41388-021-01795-5	http://dx.doi.org/10.1038/s41388-021-01795-5		MAY 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33958725	Bronze			2022-12-17	WOS:000648041500008
J	Zhu, YZ; Dalrymple, SL; Coleman, I; Zheng, SL; Xu, JF; Hooper, JE; Antonarakis, ES; De Marzo, AM; Meeker, AK; Nelson, PS; Isaacs, WB; Denmeade, SR; Luo, J; Brennen, WN; Isaacs, JT				Zhu, Yezi; Dalrymple, Susan L.; Coleman, Ilsa; Zheng, S. Lilly; Xu, Jianfeng; Hooper, Jody E.; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Nelson, Peter S.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.			Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (vol 39, pg 6935, 2020)	ONCOGENE			English	Correction												isaacjo@jhmi.edu		, Jody/0000-0002-8209-3559				Zhu YZ, 2020, ONCOGENE, V39, P6935, DOI 10.1038/s41388-020-01479-6	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3914	3916		10.1038/s41388-021-01805-6	http://dx.doi.org/10.1038/s41388-021-01805-6		MAY 2021	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958727	Bronze			2022-12-17	WOS:000648041500005
J	Ozenne, P; Dayde, D; Brambilla, E; Eymin, B; Gazzeri, S				Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.			p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway (vol 32, pg 1050, 2013)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01653-4				Sylvie.Gazzeri@ujf-grenoble.f						Ozenne P, 2013, ONCOGENE, V32, P1050, DOI 10.1038/onc.2012.107	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3633	3634		10.1038/s41388-021-01653-4	http://dx.doi.org/10.1038/s41388-021-01653-4		MAY 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33947964	Bronze			2022-12-17	WOS:000647084500003
J	Stebbing, J; Zhang, H; Xu, Y; Lit, LC; Green, AR; Grothey, A; Lombardo, Y; Periyasamy, M; Blighe, K; Zhang, W; Shaw, JA; Ellis, IO; Lenz, HJ; Giamas, G				Stebbing, J.; Zhang, H.; Xu, Y.; Lit, L. C.; Green, A. R.; Grothey, A.; Lombardo, Y.; Periyasamy, M.; Blighe, K.; Zhang, W.; Shaw, J. A.; Ellis, I. O.; Lenz, H. J.; Giamas, G.			KSR1 regulates BRCA1 degradation and inhibits breast cancer growth (vol 34, pg 2103, 2015)	ONCOGENE			English	Correction; Early Access												g.giamas@imperial.ac.uk	Lit, Lei Cheng/AAS-9778-2021	Lit, Lei Cheng/0000-0002-3210-4491				Stebbing J, 2015, ONCOGENE, V34, P2103, DOI 10.1038/onc.2014.129	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-021-01794-6	http://dx.doi.org/10.1038/s41388-021-01794-6		MAY 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX2VW	33947963	Bronze			2022-12-17	WOS:000647084500002
J	Stebbing, J; Zhang, H; Xu, Y; Lit, LC; Green, AR; Grothey, A; Lombardo, Y; Periyasamy, M; Blighe, K; Zhang, W; Shaw, JA; Ellis, IO; Lenz, HJ; Giamas, G				Stebbing, J.; Zhang, H.; Xu, Y.; Lit, L. C.; Green, A. R.; Grothey, A.; Lombardo, Y.; Periyasamy, M.; Blighe, K.; Zhang, W.; Shaw, J. A.; Ellis, I. O.; Lenz, H. J.; Giamas, G.			KSR1 regulates BRCA1 degradation and inhibits breast cancer growth (vol 31, pg 2103, 2015)	ONCOGENE			English	Correction												g.giamas@imperial.ac.uk	Lit, Lei Cheng/AAS-9778-2021; Giamas, Georgios/AAP-3487-2021	Lit, Lei Cheng/0000-0002-3210-4491; Stebbing, Justin/0000-0002-1117-6947				Stebbing J, 2015, ONCOGENE, V34, P2103, DOI 10.1038/onc.2014.129	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3473	3473		10.1038/s41388-021-01759-9	http://dx.doi.org/10.1038/s41388-021-01759-9		APR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33888869	Bronze			2022-12-17	WOS:000642379300002
J	Wei, YY; Lu, W; Yu, YH; Zhai, YM; Guo, HZ; Yang, SX; Zhao, C; Zhang, YJ; Liu, JL; Liu, YH; Fei, J; Shi, J				Wei, Yanyu; Lu, Wei; Yu, Yehua; Zhai, Yuanmei; Guo, Hezhou; Yang, Shaoxin; Zhao, Chong; Zhang, Yanjie; Liu, Jiali; Liu, Yuhui; Fei, Jian; Shi, Jun			miR-29c&b2 encourage extramedullary infiltration resulting in the poor prognosis of acute myeloid leukemia	ONCOGENE			English	Article							MICRORNA-29 FAMILY; EXPRESSION; GROWTH; AML; PROMOTES; CANCER; IDENTIFICATION; ABNORMALITIES; DIAGNOSIS; INVASION	Extramedullary infiltration (EMI), as a concomitant symptom of acute myeloid leukemia (AML), is associated with low complete remission and poor prognosis in AML. However, the mechanism of EMI remains indistinct. Clinical trials showed that increased miR-29s were associated with a poor overall survival in AML [14]. Nevertheless, they were proved to work as tumor suppressor genes by encouraging apoptosis and inhibiting proliferation in vitro. These contradictory results led us to the hypothesis that miR-29s may play a notable role in the prognosis of AML rather than leukemogenesis. Thus, we explored the specimens of AML patients and addressed this issue into miR-29c&b2 knockout mice. As a result, a poor overall survival and invasive blast cells were observed in high miR-29c&b2-expression patients, and the wildtype mice presented a shorter survival with heavier leukemia infiltration in extramedullary organs. Subsequently, we found that the miR-29c&b2 inside leukemia cells promoted EMI, but not the one in the microenvironment. The analysis of signal pathway revealed that miR-29c&b2 could target HMG-box transcription factor 1 (Hbp1) directly, then reduced Hbp1 bound to the promoter of non-muscle myosin IIB (Myh10) as a transcript inhibitor. Thus, increased Myh10 encouraged the migration of leukemia cells. Accordingly, AML patients with EMI were confirmed to have high miR- 29c&b2 and MYH10 with low HBP1. Therefore, we identify that miR-29c&b2 contribute to the poor prognosis of AML patients by promoting EMI, and related genes analyses are prospectively feasible in assessment of AML outcome.	[Wei, Yanyu; Lu, Wei; Yu, Yehua; Guo, Hezhou; Yang, Shaoxin; Zhao, Chong; Zhang, Yanjie; Liu, Jiali; Shi, Jun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China; [Zhai, Yuanmei] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept Hematol, Shanghai, Peoples R China; [Liu, Yuhui; Fei, Jian] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China; [Fei, Jian] SMOC, Shanghai Engn Res Ctr Model Organisms, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University	Shi, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China.; Fei, J (corresponding author), Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.; Fei, J (corresponding author), SMOC, Shanghai Engn Res Ctr Model Organisms, Shanghai, Peoples R China.	jfei@tongji.edu.cn; junshi@sjtu.edu.cn		Liu, Yuhui/0000-0002-5952-8948	National Natural Science Foundation of China [81870132, 81261120568]; Science and Technology Commission of Shanghai Municipality [18DZ2290700,18DZ2293500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This study was supported by the National Natural Science Foundation of China (No. 81870132, 81261120568) and the Science and Technology Commission of Shanghai Municipality (18DZ2290700,18DZ2293500).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bollaert E, 2019, CELL MOL LIFE SCI, V76, P1529, DOI 10.1007/s00018-019-03012-9; Butrym A, 2016, ONCOTARGET, V7, P30250, DOI 10.18632/oncotarget.7172; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Chang H, 2004, LEUKEMIA RES, V28, P1007, DOI 10.1016/j.leukres.2004.01.006; Chen W, 1996, J VIROL, V70, P7773, DOI 10.1128/JVI.70.11.7773-7782.1996; Chen X, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160576; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V355, P15, DOI 10.1016/j.mce.2011.12.020; DAWSON PJ, 1963, CANCER RES, V23, P349; DEHARVEN E, 1960, J BIOPHYS BIOCHEM CY, V7, P747, DOI 10.1083/jcb.7.4.747; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Estey EH, 2018, AM J HEMATOL, V93, P1267, DOI 10.1002/ajh.25214; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gutzman JH, 2015, DEV BIOL, V397, P103, DOI 10.1016/j.ydbio.2014.10.017; Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831; Hu GH, 2020, CL LYMPH MYELOM LEUK, V20, pE813, DOI 10.1016/j.clml.2020.06.009; Hugo HJ, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0880-z; Junge A, 2018, HEMATOL ONCOL, V36, P576, DOI 10.1002/hon.2516; Kiani FA, 2014, P NATL ACAD SCI USA, V111, pE2947, DOI 10.1073/pnas.1401862111; Kobayashi R, 2007, PEDIATR BLOOD CANCER, V48, P393, DOI 10.1002/pbc.20824; Kwon JJ, 2019, MOL THER-ONCOLYTICS, V12, P173, DOI 10.1016/j.omto.2018.12.011; Lackie, 1986, CRAWLING MOVEMENT CE, P145; Le Goff C, 2011, HUM MOL GENET, V20, pR163, DOI 10.1093/hmg/ddr361; Li Y, 2017, CANCER LETT, V397, P111, DOI 10.1016/j.canlet.2017.03.032; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Patel SS, 2018, BLOOD, V131, P2816, DOI 10.1182/blood-2018-01-828467; Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567; Qu XQ, 2018, ONCOL LETT, V16, P853, DOI 10.3892/ol.2018.8735; Ridge LA, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007068; Robaina MC, 2015, EXP MOL PATHOL, V98, P200, DOI 10.1016/j.yexmp.2015.03.006; Robert-Paganin J, 2020, CHEM REV, V120, P5, DOI 10.1021/acs.chemrev.9b00264; Rostas JW, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-200; Su CY, 2018, CANCER MED-US, V7, P2485, DOI 10.1002/cam4.1294; Sun R, 2018, CANCER RES, V78, P5274, DOI 10.1158/0008-5472.CAN-17-3647; Sun XJ, 2015, CELL PHYSIOL BIOCHEM, V37, P707, DOI 10.1159/000430389; Sun XH, 2015, MOL CELL BIOCHEM, V403, P139, DOI 10.1007/s11010-015-2344-z; THIELE J, 1985, PATHOL RES PRACT, V179, P328, DOI 10.1016/S0344-0338(85)80142-4; VIADANA E, 1978, ONCOLOGY, V35, P87, DOI 10.1159/000225262; Wang Y, 2018, MED SCI MONITOR, V24, P9110, DOI 10.12659/MSM.911523; Wu H, 2016, GUT, V65, P1850, DOI 10.1136/gutjnl-2014-308430; Xu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0337-3; XU W, 2017, NAT COMMUN, V8; Yan ZY, 2014, FEBS LETT, V588, P3038, DOI 10.1016/j.febslet.2014.06.017; Yang ZR, 2013, BIOCHEM BIOPH RES CO, V434, P143, DOI 10.1016/j.bbrc.2013.03.054; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zhou T, 2020, PEDIATR HEMAT ONCOL, V37, P76, DOI 10.1080/08880018.2019.1683107; Zhu CL, 2013, CLIN BIOCHEM, V46, P49, DOI 10.1016/j.clinbiochem.2012.09.002; Zhu JQ, 2015, CANCER RES, V75, P1580, DOI 10.1158/0008-5472.CAN-14-1027; Zhu LH, 2015, GENET MOL RES, V14, P6028, DOI 10.4238/2015.June.1.20; 刘景华, 2014, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V34, P1112	54	0	0	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3434	3448		10.1038/s41388-021-01775-9	http://dx.doi.org/10.1038/s41388-021-01775-9		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33888868				2022-12-17	WOS:000642379300001
J	Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S				Eymin, Beatrice; Leduc, Camille; Coll, Jean-Luc; Brambilla, Elisabeth; Gazzeri, Sylvie			p14(ARF) induces G(2) arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice (vol 22, pg 1822, 2003)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01648-1				Sylvie.Gazzeri@ujf-grenoble.fr	Coll, Jean-Luc/G-2520-2013	Coll, Jean-Luc/0000-0002-2453-3552				Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303	1	0	0	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3470	3470		10.1038/s41388-021-01648-1	http://dx.doi.org/10.1038/s41388-021-01648-1		APR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875788	Bronze			2022-12-17	WOS:000641218600001
J	Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L				Katuri, V.; Tang, Y.; Li, C.; Jogunoori, W.; Deng, C. -X.; Rashid, A.; Sidawy, A. N.; Evans, S.; Reddy, E. P.; Mishra, B.; Mishra, L.			critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression (vol 25, pg 1871, 2006)	ONCOGENE			English	Correction												bm72@georgetown.edu; lopamishra@yahoo.com						Katuri V, 2006, ONCOGENE, V25, P1871, DOI 10.1038/sj.onc.1209211	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3348	3349		10.1038/s41388-020-01632-1	http://dx.doi.org/10.1038/s41388-020-01632-1		APR 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33875789	Bronze			2022-12-17	WOS:000641218600002
J	Jin, C; Rajabi, H; Rodrigo, CM; Porco, JA; Kufe, D				Jin, C.; Rajabi, H.; Rodrigo, C. M.; Porco, J. A., Jr.; Kufe, D.			Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein (vol 32, pg 2179, 2013)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01727-3				donald_kufe@dfci.harvard.edu						Jin C, 2013, ONCOGENE, V32, P2179, DOI 10.1038/onc.2012.236	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3347	3347		10.1038/s41388-021-01727-3	http://dx.doi.org/10.1038/s41388-021-01727-3		APR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33850266	Bronze			2022-12-17	WOS:000639730800002
J	Su, Y; Wang, XY; Guo, Z; Wang, J				Su, Yao; Wang, Xueying; Guo, Zhen; Wang, Jun			Aberrant JmjC domain-containing protein 8 (JMJD8) expression promotes activation of AKT and tumor epithelial-mesenchymal transition (vol 39, pg 6451, 2020)	ONCOGENE			English	Correction												zhenguo@ustc.edu.cn; wangjun0457@ipp.ac.cn						Su Y, 2020, ONCOGENE, V39, P6451, DOI 10.1038/s41388-020-01446-1	1	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3180	3186		10.1038/s41388-021-01643-6	http://dx.doi.org/10.1038/s41388-021-01643-6		MAR 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33772145	Bronze			2022-12-17	WOS:000633273900001
J	Chen, WH; Cai, MY; Zhang, JX; Wang, FW; Tang, LQ; Liao, YJ; Jin, XH; Wang, CY; Guo, L; Jiang, YG; Ren, CP; Mai, HQ; Zeng, MS; Kung, HF; Qian, CN; Xie, D				Chen, Wen-Hui; Cai, Mu-Yan; Zhang, Jia-Xing; Wang, Feng-Wei; Tang, Lin-Quan; Liao, Yi-Ji; Jin, Xiao-Han; Wang, Chen-Yuan; Guo, Ling; Jiang, Yi-Guo; Ren, Cai-Ping; Mai, Hai-Qiang; Zeng, Mu-Sheng; Kung, Hsiang-Fu; Qian, Chao-Nan; Xie, Dan			FMNL1 mediates nasopharyngeal carcinoma cell aggressiveness by epigenetically upregulating MTA1 (vol 37, pg 6243, 2018)	ONCOGENE			English	Correction												xiedan@sysucc.org.cn						Chen WH, 2018, ONCOGENE, V37, P6243, DOI 10.1038/s41388-018-0351-8	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2998	3000		10.1038/s41388-021-01751-3	http://dx.doi.org/10.1038/s41388-021-01751-3		MAR 2021	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33767442	Bronze			2022-12-17	WOS:000632820300003
J	Liang, YR; Song, XJ; Li, YM; Su, P; Han, DW; Ma, TT; Guo, RB; Chen, B; Zhao, WJ; Sang, YT; Zhang, N; Li, XY; Zhang, HW; Liu, Y; Duan, Y; Wang, LJ; Yang, QF				Liang, Yiran; Song, Xiaojin; Li, Yaming; Su, Peng; Han, Dianwen; Ma, Tingting; Guo, Renbo; Chen, Bing; Zhao, Wenjing; Sang, Yuting; Zhang, Ning; Li, Xiaoyan; Zhang, Hanwen; Liu, Ying; Duan, Yi; Wang, Lijuan; Yang, Qifeng			circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer (vol 38, pg 6850, 2019)	ONCOGENE			English	Correction												qifengy_sdu@163.com	yang, qiang/GYJ-0971-2022; Zhang, Hanwen/CAG-1998-2022	Yang, Qifeng/0000-0003-0576-8513				Liang YR, 2019, ONCOGENE, V38, P6850, DOI 10.1038/s41388-019-0926-z	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2816	2816		10.1038/s41388-021-01750-4	http://dx.doi.org/10.1038/s41388-021-01750-4		MAR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33767441	Bronze			2022-12-17	WOS:000632820300002
J	Wang, YH; Chan, YT; Hung, TH; Hung, JT; Kuo, MW; Wang, SH; Huang, YL; Lin, YJ; Chen, SC; Yu, JC; Wu, JC; Yu, J; Yu, AL				Wang, Ya-Hui; Chan, Yu-Tzu; Hung, Tsai-Hsien; Hung, Jung-Tung; Kuo, Ming-Wei; Wang, Sheng-Hung; Huang, Yenlin; Lin, Yu-Ju; Chen, Shin-Cheh; Yu, Jyh-Cherng; Wu, Jen-Chine; Yu, John; Yu, Alice L.			Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation	ONCOGENE			English	Article								Cancer stem cells (CSC) play a pivotal role in cancer metastasis and resistance to therapy. Previously, we compared the phosphoproteomes of breast cancer stem cells (BCSCs) enriched subpopulation and non-BCSCs sorted from breast cancer patient-derived xenograft (PDX), and identified a function unknown protein, transmembrane and coiled-coil domain family 3 (TMCC3) to be a potential enrichment marker for BCSCs. We demonstrated greater expression of TMCC3 in BCSCs than non-BCSCs and higher expression of TMCC3 in metastatic lymph nodes and lungs than in primary tumor of breast cancer PDXs. TMCC3 silencing suppressed mammosphere formation, ALDH activity and cell migration in vitro, along with reduced tumorigenicity and metastasis in vivo. Mechanistically, we found that AKT activation was reduced by TMCC3 silencing, but enhanced by TMCC3 overexpression. We further demonstrated that TMCC3 interacted directly with AKT through its 1-153 a.a. domain by cell-free biochemical assay in vitro and co-immunoprecipitation and interaction domain mapping assays in vivo. Based on domain truncation studies, we showed that the AKT-interacting domain of TMCC3 was essential for TMCC3-induced AKT activation, self-renewal, and metastasis. Clinically, TMCC3 mRNA expression in 202 breast cancer specimens as determined by qRT-PCR assay showed that higher TMCC3 expression correlated with poorer clinical outcome of breast cancer, including early-stage breast cancer. Multivariable analysis identified TMCC3 expression as an independent risk factor for survival. These findings suggest that TMCC3 is crucial for maintenance of BCSCs features through AKT regulation, and TMCC3 expression has independent prognostic significance in breast cancer. Thus, TMCC3 may serve as a new target for therapy directed against CSCs.	[Wang, Ya-Hui; Chan, Yu-Tzu; Hung, Tsai-Hsien; Hung, Jung-Tung; Kuo, Ming-Wei; Wang, Sheng-Hung; Lin, Yu-Ju; Wu, Jen-Chine; Yu, John; Yu, Alice L.] Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan; [Huang, Yenlin] Chang Gung Mem Hosp Linkou, Dept Anat Pathol, Taoyuan, Taiwan; [Huang, Yenlin; Yu, John; Yu, Alice L.] Chang Gung Univ, Taoyuan, Taiwan; [Chen, Shin-Cheh] Chang Gung Mem Hosp Linkou, Gen Surg Dept, Taoyuan, Taiwan; [Yu, Jyh-Cherng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Yu, Alice L.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; National Defense Medical Center; Tri-Service General Hospital; University of California System; University of California San Diego	Yu, J; Yu, AL (corresponding author), Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan.; Yu, J; Yu, AL (corresponding author), Chang Gung Univ, Taoyuan, Taiwan.; Yu, AL (corresponding author), Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.	johnyu@gate.sinica.edu.tw; alyu@ucsd.edu		Hung, Jung-Tung/0000-0001-7161-1915; Yu, John/0000-0002-3237-4272; yu, alice/0000-0003-2444-0505	Ministry of Science and Technology in Taiwan [MOST106-3114-B-182A-001, MOST106-2811-B-182A-017, MOST107-2321-B-182A-005, MOST107-2811-B182A-504, MOST108-2321-B-182A-004, MOST 108-2811-B-182A-505, MOST109-2321-B-182A-005, MOST109-2811-B-182A-501]; Taiwan Biosignature for Breast Cancer [BP004]; Chang Gung Medical Foundation [OMRPG3C0011-16, CMRPG3F0973, CMRPG3G1531-1533]; Chang Gung Postdoctoral Fellowship	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Biosignature for Breast Cancer; Chang Gung Medical Foundation; Chang Gung Postdoctoral Fellowship	This study was supported by grants to ALY from the Ministry of Science and Technology in Taiwan (MOST106-3114-B-182A-001, MOST106-2811-B-182A-017, MOST107-2321-B-182A-005, MOST107-2811-B182A-504, MOST108-2321-B-182A-004, MOST 108-2811-B-182A-505, MOST109-2321-B-182A-005, MOST109-2811-B-182A-501), Taiwan Biosignature for Breast Cancer (BP004), and Chang Gung Medical Foundation (OMRPG3C0011-16). Grant from Chang Gung Medical Foundation (CMRPG3F0973 to JY; CMRPG3G1531-1533 to JTH) and Chang Gung Postdoctoral Fellowship Award to YHW.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Bozorgi A, 2015, J BREAST CANCER, V18, P303, DOI 10.4048/jbc.2015.18.4.303; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Chan YT, 2020, INT J CANCER, V146, P1674, DOI 10.1002/ijc.32588; Chang WW, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3423; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Clark DW, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.82; Cochrane CR, 2015, CANCERS, V7, P1554, DOI 10.3390/cancers7030851; Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x; Desai A, 2019, STEM CELL TRANSL MED, V8, P75, DOI 10.1002/sctm.18-0123; DESOUSA E, 2016, CANCERS, V8, P60, DOI DOI 10.3390/cancers8070060; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hopkins PCR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055810; Hopkins PCR, 2011, J ALZHEIMERS DIS, V26, P239, DOI 10.3233/JAD-2011-102115; Hoyer MJ, 2018, CELL, V175, P254, DOI 10.1016/j.cell.2018.08.030; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jain MV, 2015, CELL CYCLE, V14, P2109, DOI 10.1080/15384101.2015.1041692; Johnston HE, 2018, MOL CELL PROTEOMICS, V17, P776, DOI 10.1074/mcp.RA117.000539; Kahn M, 2018, PROG MOL BIOL TRANSL, V153, P209, DOI 10.1016/bs.pmbts.2017.11.007; Kaltschmidt C, 2019, CANCERS, V11, DOI 10.3390/cancers11050655; Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Kume H, 2014, MOL CELL PROTEOMICS, V13, P1471, DOI 10.1074/mcp.M113.037093; Kuo MW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004980; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49; Liao Y, 2010, AM J TRANSL RES, V2, P19; Lombardo Y, 2015, JOVE-J VIS EXP, DOI 10.3791/52671; Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065; Matsui WH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004765; Petersen OW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003160; Prossomariti A, 2020, CELL MOL GASTROENTER, V10, P491, DOI 10.1016/j.jcmgh.2020.04.007; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Saadin K, 2013, EXPERT REV MOL DIAGN, V13, P49, DOI [10.1586/ERM.12.117, 10.1586/erm.12.117]; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507; Sohn WJ, 2016, BMB REP, V49, P629, DOI 10.5483/BMBRep.2016.49.11.151; Swiatkowski P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01826-w; Vieira AF, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00248; Wang T, 2016, CANCER BIOL THER, V17, P698, DOI 10.1080/15384047.2016.1190488; Wang W, 2019, J CLIN INVEST, V129, P1015, DOI 10.1172/JCI97712; Wang YK, 2010, CARCINOGENESIS, V31, P1376, DOI 10.1093/carcin/bgq120; Wisesa S, 2019, BIOCHEM J, V476, P3241, DOI 10.1042/BCJ20190359; Yap TA, 2015, CURR OPIN PHARMACOL, V23, P98, DOI 10.1016/j.coph.2015.05.016; Yeo HL, 2019, INT J CANCER, V144, P1996, DOI 10.1002/ijc.31891; Yin H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024080; Yudushkin I, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9020067; Zhang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085206	53	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2858	2871		10.1038/s41388-021-01729-1	http://dx.doi.org/10.1038/s41388-021-01729-1		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742122	hybrid, Green Published			2022-12-17	WOS:000630675000002
J	Kerr, C; Szmacinski, H; Fisher, ML; Nance, B; Lakowicz, JR; Akbar, A; Keillor, JW; Wong, TL; Godoy-Ruiz, R; Toth, EA; Weber, DJ; Eckert, RL				Kerr, C.; Szmacinski, H.; Fisher, M. L.; Nance, B.; Lakowicz, J. R.; Akbar, A.; Keillor, J. W.; Wong, T. Lok; Godoy-Ruiz, R.; Toth, E. A.; Weber, D. J.; Eckert, R. L.			Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival (vol 36, pg 2981, 2017)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01709-5				reckert@umaryland.edu	Weber, David J/B-5349-2011; Godoy Ruiz, Raquel/GOH-1617-2022	Weber, David J/0000-0002-8824-1110; GODOY-RUIZ, RAQUEL/0000-0003-4569-0781				Kerr C, 2017, ONCOGENE, V36, P2981, DOI 10.1038/onc.2016.452	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2479	2481		10.1038/s41388-021-01709-5	http://dx.doi.org/10.1038/s41388-021-01709-5		MAR 2021	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33658629	Bronze			2022-12-17	WOS:000625039900002
J	Sullivan, RJ; Flaherty, K				Sullivan, R. J.; Flaherty, K.			MAP kinase signaling and inhibition in melanoma (vol 32, pg 2373, 2013)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01716-6				kflaherty@partners.org						Sullivan RJ, 2013, ONCOGENE, V32, P2373, DOI 10.1038/onc.2012.345; Sullivan RJ, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/423239	2	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2482	2482		10.1038/s41388-021-01716-6	http://dx.doi.org/10.1038/s41388-021-01716-6		MAR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33658630	Bronze			2022-12-17	WOS:000625039900001
J	Sirkisoon, SR; Carpenter, RL; Rimkus, T; Doheny, D; Zhu, D; Aguayo, NR; Xing, F; Chan, M; Ruiz, J; Metheny-Barlow, LJ; Strowd, R; Lin, J; Regua, AT; Arrigo, A; Anguelov, M; Pasche, B; Debinski, W; Watabe, K; Lo, HW				Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Doheny, Daniel; Zhu, Dongqin; Aguayo, Noah R.; Xing, Fei; Chan, Michael; Ruiz, Jimmy; Metheny-Barlow, Linda J.; Strowd, Roy; Lin, Jiayuh; Regua, Angelina T.; Arrigo, Austin; Anguelov, Marlyn; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen			TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment (vol 39, pg 64, 2019)	ONCOGENE			English	Correction																		Sirkisoon SR, 2020, ONCOGENE, V39, P64, DOI 10.1038/s41388-019-0959-3	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2338	2338		10.1038/s41388-020-01620-5	http://dx.doi.org/10.1038/s41388-020-01620-5		MAR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654200	Bronze			2022-12-17	WOS:000624398900001
J	Bao, YH; Guo, YC; Yang, YQ; Wei, XN; Zhang, SS; Zhang, YM; Li, K; Yuan, M; Guo, DL; Macias, V; Zhu, XD; Zhang, W; Yang, WC				Bao, Yonghua; Guo, Yongchen; Yang, Yiqiong; Wei, Xiaonan; Zhang, Shanshan; Zhang, Yongmeng; Li, Kai; Yuan, Ming; Guo, Dongli; Macias, Virgilia; Zhu, Xiangdong; Zhang, Wei; Yang, Wancai			PRSS8 suppresses colorectal carcinogenesis and metastasis (vol 38, pg 497, 2019)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01646-3				wyang06@uic.edu						Bao YH, 2019, ONCOGENE, V38, P497, DOI 10.1038/s41388-018-0453-3	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1922	1924		10.1038/s41388-021-01646-3	http://dx.doi.org/10.1038/s41388-021-01646-3		FEB 2021	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33619325	Bronze			2022-12-17	WOS:000620414400004
J	Peng, KS; Zhuo, MH; Li, M; Chen, Q; Mo, P; Yu, CD				Peng, Kesong; Zhuo, Minghui; Li, Ming; Chen, Qiang; Mo, Pingli; Yu, Chundong			Histone demethylase JMJD2D activates HIF1 signaling pathway via multiple mechanisms to promote colorectal cancer glycolysis and progression (vol 39, pg 7076, 2020)	ONCOGENE			English	Correction																		Peng KS, 2020, ONCOGENE, V39, P7076, DOI 10.1038/s41388-020-01483-w	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2336	2337		10.1038/s41388-021-01678-9	http://dx.doi.org/10.1038/s41388-021-01678-9		FEB 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33619324	Bronze			2022-12-17	WOS:000620414400003
J	Zhang, X; Huang, ZN; Guo, YY; Xiao, T; Tang, L; Zhao, S; Wu, LS; Su, J; Zeng, WQ; Huang, HB; Li, Z; Tao, J; Zhou, JD; Chen, X; Peng, C				Zhang, Xu; Huang, Zunnan; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Huang, Hongbin; Li, Zheng; Tao, Juan; Zhou, Jianda; Chen, Xiang; Peng, Cong			The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis (vol 39, pg 4183, 2020)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01641-8				chenxiangck@126.com; pengcongxy@csu.edu.cn	wu, Xianrui/AAM-6540-2021; Wu, Lisha/ABG-2923-2021	wu, Xianrui/0000-0003-4803-5934; Wu, Lisha/0000-0003-2847-1982; Huang, Zunnan/0000-0002-5821-703X				Zhang X, 2020, ONCOGENE, V39, P4183, DOI 10.1038/s41388-020-1287-3	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1925	1925		10.1038/s41388-021-01641-8	http://dx.doi.org/10.1038/s41388-021-01641-8		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33619323	Bronze			2022-12-17	WOS:000620414400002
J	Kwon, OS; Lee, H; Kong, HJ; Kwon, EJ; Park, JE; Lee, W; Kang, S; Kim, M; Kim, W; Cha, HJ				Kwon, Ok-Seon; Lee, Haeseung; Kong, Hyeon-Joon; Kwon, Eun-Ji; Park, Ji Eun; Lee, Wooin; Kang, Seungmin; Kim, Mirang; Kim, Wankyu; Cha, Hyuk-Jin			Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer (vol 39, pg 4567, 2020)	ONCOGENE			English	Correction												wkim@ewha.ac.kr; hjcha93@snu.ac.kr	; Lee, Wooin/K-7789-2012	Lee, Haeseung/0000-0002-9947-4032; Cha, Hyuk-Jin/0000-0001-9277-2662; Lee, Wooin/0000-0001-7805-869X	National Research Foundation of Korea [NRF-2017M3C9A5028691, NRF-2019R1C1C1008710, NRF-2017M3C9A5028690]	National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by a grant from the National Research Foundation of Korea (NRF-2017M3C9A5028691 from H-JC, NRF-2019R1C1C1008710 from O-SK and NRF-2017M3C9A5028690 from WK).	Kwon OS, 2020, ONCOGENE, V39, P4567, DOI 10.1038/s41388-020-1316-2	1	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1921	1921		10.1038/s41388-021-01642-7	http://dx.doi.org/10.1038/s41388-021-01642-7		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33574481	Bronze			2022-12-17	WOS:000617088400001
J	Wang, GW; Wang, J; Chang, A; Cheng, DM; Huang, S; Wu, D; Sirkisoon, S; Yang, S; Lin, HK; Lo, HW; Xiang, R; Sun, PQ				Wang, Guanwen; Wang, Juan; Chang, Antao; Cheng, Dongmei; Huang, Shan; Wu, Dan; Sirkisoon, Sherona; Yang, Shuang; Lin, Hui-Kuan; Lo, Hui-Wen; Xiang, Rong; Sun, Peiqing			Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2 (vol 39, pg 7034, 2020)	ONCOGENE			English	Correction														Lo, Hui-Wen/0000-0002-0681-7914; Lin, Hui-Kuan/0000-0002-3501-2410				Wang GW, 2020, ONCOGENE, V39, P7034, DOI 10.1038/s41388-020-01481-y	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2335	2335		10.1038/s41388-021-01652-5	http://dx.doi.org/10.1038/s41388-021-01652-5		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33568787	Bronze			2022-12-17	WOS:000616940500001
J	Kung, CP; Cottrell, KA; Ryu, S; Bramel, ER; Kladney, RD; Bao, EA; Freeman, EC; Sabloak, T; Maggi, L; Weber, JD				Kung, Che-Pei; Cottrell, Kyle A.; Ryu, Sua; Bramel, Emily R.; Kladney, Raleigh D.; Bao, Emily A.; Freeman, Eric C.; Sabloak, Thwisha; Maggi, Leonard, Jr.; Weber, Jason D.			Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer (vol 40, pg 189, 2021)	ONCOGENE			English	Correction													Kung, Che-Pei/I-6276-2019	Kung, Che-Pei/0000-0002-1150-4998; Weber, Jason/0000-0002-1069-6983; Maggi, Leonard/0000-0003-0138-0984				Kung CP, 2021, ONCOGENE, V40, P189, DOI 10.1038/s41388-020-01515-5	1	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2147	2147		10.1038/s41388-021-01669-w	http://dx.doi.org/10.1038/s41388-021-01669-w		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33564075	Bronze			2022-12-17	WOS:000616489100002
J	Xu, H; Liu, L; Li, WL; Zou, DW; Yu, J; Wang, LF; Wong, CC				Xu, Hui; Liu, Lei; Li, Weilin; Zou, Duowu; Yu, Jun; Wang, Lifu; Wong, Chi Chun			Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications (Dec, 10.1038/s41388-020-01587-3, 2020)	ONCOGENE			English	Correction													; Jun, Yu/D-8569-2015	Wong, Chi Chun/0000-0003-1362-3541; Jun, Yu/0000-0001-5008-2153				Xu H, 2021, ONCOGENE, V40, P1555, DOI 10.1038/s41388-020-01587-3	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1756	1756		10.1038/s41388-021-01651-6	http://dx.doi.org/10.1038/s41388-021-01651-6		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33564076	Bronze			2022-12-17	WOS:000616489100009
J	Zhu, YZ; Dalrymple, SL; Coleman, I; Zheng, SL; Xu, JF; Hooper, JE; Antonarakis, ES; De Marzo, AM; Meeker, AK; Nelson, PS; Isaacs, WB; Denmeade, SR; Luo, J; Brennen, WN; Isaacs, JT				Zhu, Yezi; Dalrymple, Susan L.; Coleman, Ilsa; Zheng, S. Lilly; Xu, Jianfeng; Hooper, Jody E.; Antonarakis, Emmanuel S.; De Marzo, Angelo M.; Meeker, Alan K.; Nelson, Peter S.; Isaacs, William B.; Denmeade, Samuel R.; Luo, Jun; Brennen, W. Nathaniel; Isaacs, John T.			Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (vol 39, pg 6935, 2020)	ONCOGENE			English	Correction														, Jody/0000-0002-8209-3559				Zhu YZ, 2020, ONCOGENE, V39, P6935, DOI 10.1038/s41388-020-01479-6	1	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2148	2148		10.1038/s41388-021-01640-9	http://dx.doi.org/10.1038/s41388-021-01640-9		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33564077	Bronze			2022-12-17	WOS:000616489100008
J	Kim, JY; Kim, HJ; Jung, CW; Choi, BI; Lee, DH; Park, MJ				Kim, Jeong-Yub; Kim, Hee-Jin; Jung, Chan-Woong; Choi, Byung-Il; Lee, Dae-Hee; Park, Myung-Jin			PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III (vol 40, pg 508, 2021)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01644-5				neogene@gwnu.ac.kr; mjpark@kirams.re.kr						Kim JY, 2021, ONCOGENE, V40, P508, DOI 10.1038/s41388-020-01543-1	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2146	2146		10.1038/s41388-021-01644-5	http://dx.doi.org/10.1038/s41388-021-01644-5		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33558667	Bronze			2022-12-17	WOS:000616018800001
J	Liang, ER; Lu, YS; Shi, YQ; Zhou, Q; Zhi, FC				Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao			MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity (vol 39, pg 6437, 2020)	ONCOGENE			English	Correction									[Liang, Erbo; Lu, Yishi; Shi, Yanqiang; Zhou, Qian; Zhi, Fachao] Southern Med Univ, Nanfang Hosp, Inst Gastroenterol Guangdong Prov, Guangdong Prov Key Lab Gastroenterol,Dept Gastroe, Guangzhou 510515, Peoples R China	Southern Medical University - China	Zhi, FC (corresponding author), Southern Med Univ, Nanfang Hosp, Inst Gastroenterol Guangdong Prov, Guangdong Prov Key Lab Gastroenterol,Dept Gastroe, Guangzhou 510515, Peoples R China.	zhifc41532@163.com		Zhi, Fachao/0000-0001-8674-4737				Liang ER, 2020, ONCOGENE, V39, P6437, DOI 10.1038/s41388-020-01443-4	1	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1755	1755		10.1038/s41388-021-01650-7	http://dx.doi.org/10.1038/s41388-021-01650-7		FEB 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33536580	Bronze			2022-12-17	WOS:000614320700002
J	Cheng, L; Zhou, Z; Flesken-Nikitin, A; Toshkov, IA; Wang, W; Camps, J; Ried, T; Nikitin, AY				Cheng, L.; Zhou, Z.; Flesken-Nikitin, A.; Toshkov, I. A.; Wang, W.; Camps, J.; Ried, T.; Nikitin, A. Y.			Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency (vol 29, pg 5700, 2010)	ONCOGENE			English	Correction																		Cheng L, 2010, ONCOGENE, V29, P5700, DOI 10.1038/onc.2010.300	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1754	1754		10.1038/s41388-021-01647-2	http://dx.doi.org/10.1038/s41388-021-01647-2		JAN 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33510357	Bronze			2022-12-17	WOS:000612563100004
J	Han, A; Purwin, TJ; Bechtel, N; Liao, C; Chua, V; Seifert, E; Sato, T; Schug, ZT; Speicher, DW; Harbour, JW; Aplin, AE				Han, Anna; Purwin, Timothy J.; Bechtel, Nelisa; Liao, Connie; Chua, Vivian; Seifert, Erin; Sato, Takami; Schug, Zachary T.; Speicher, David W.; Harbour, J. William; Aplin, Andrew E.			BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors (vol 40, pg 618, 2021)	ONCOGENE			English	Correction														Purwin, Timothy/0000-0002-7053-8039	NCI NIH HHS [R01 CA253977, R01 CA196278] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Han AN, 2021, ONCOGENE, V40, P618, DOI 10.1038/s41388-020-01554-y	1	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1753	1753		10.1038/s41388-021-01645-4	http://dx.doi.org/10.1038/s41388-021-01645-4		JAN 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33510355	Bronze			2022-12-17	WOS:000612563100002
J	Tabassum, N; Constantin, TA; Cereser, B; Stebbing, J				Tabassum, Neha; Constantin, Theodora A.; Cereser, Biancastella; Stebbing, Justin			A cell-cycle signature classifier for pan-cancer analysis (vol 39, pg 6041, 2020)	ONCOGENE			English	Correction														Stebbing, Justin/0000-0002-1117-6947; Tabassum, Neha/0000-0002-0812-3692; Cereser, Biancastella/0000-0003-1243-1767				Tabassum N, 2020, ONCOGENE, V39, P6041, DOI 10.1038/s41388-020-01426-5	1	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1752	1752		10.1038/s41388-021-01649-0	http://dx.doi.org/10.1038/s41388-021-01649-0		JAN 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33510356	Bronze			2022-12-17	WOS:000612563100001
J	Plowman, PN; Plowman, CE				Plowman, P. N.; Plowman, C. E.			Onco-ontogeny recapitulates phylogeny - a consideration	ONCOGENE			English	Article							CONSENSUS MOLECULAR SUBTYPES; BRAIN-STEM GLIOMAS; COLORECTAL-CANCER; PATTERNS; MODIFIER; FUMARATE; CELLS	Cancers necessarily rely on the (embryologic) fundamental growth patterning genes to serve their uncontrolled growth. Studying a cancer's behavior, depending on which side of an embryological divide it derives, together with its transcriptome and its relationship to immigrant cells with stem cell potential, intercellular signaling and transducer cascades to transcription factors-all help our understanding of the cancer phenotype. To these can be added the acquired methylome and possibly a "knock-on" metabolome. These aspects are reviewed in the context of Haeckel's law.	[Plowman, P. N.] St Bartholomews Hosp, Dept Clin Oncol, London, England; [Plowman, C. E.] UCL, London, England	University of London; Queen Mary University London; University of London; University College London	Plowman, PN (corresponding author), St Bartholomews Hosp, Dept Clin Oncol, London, England.	nick.plowman1@nhs.net						Aiello NM, 2016, DIS MODEL MECH, V9, P105, DOI 10.1242/dmm.023184; Al-Olabi L, 2018, J CLIN INVEST, V128, P1496, DOI 10.1172/JCI98589; Ashrafian H, 2010, CANCER RES, V70, P9153, DOI 10.1158/0008-5472.CAN-10-1949; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Daoud EV, 2018, J NEUROPATH EXP NEUR, V77, P302, DOI 10.1093/jnen/nly006; Fessler E, 2016, ONCOGENE, V35, P6026, DOI 10.1038/onc.2016.134; Fontana E, 2019, ANN ONCOL, V30, P520, DOI 10.1093/annonc/mdz052; Fromme Julia Elisabeth, 2018, Oncotarget, V9, P32204, DOI 10.18632/oncotarget.25941; Gomez DR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.19.00201; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Irving C, 2000, DEVELOPMENT, V127, P177; Jiao XM, 2019, CANCER RES, V79, P4801, DOI 10.1158/0008-5472.CAN-19-1167; Kinsler VA, 2020, HARPERS TXB PEDIAT D, P1283; Li HJ, 2012, DEV BIOL, V371, P156, DOI 10.1016/j.ydbio.2012.08.023; Liu J, 2019, J PATHOL, V247, P481, DOI 10.1002/path.5207; Maffeis V, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01255; Makabe T, 2019, CARCINOGENESIS, V40, P611, DOI 10.1093/carcin/bgz046; May CL, 2010, MOL CELL ENDOCRINOL, V323, P70, DOI 10.1016/j.mce.2009.12.009; Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009; Mo J, 2020, CANCER RES TREAT, V52, P74, DOI 10.4143/crt.2019.062; Nishikawa G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1508-2; Oberheim-Bush NA, 2020, P AM SOC CLIN ONCOL; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Palma DA, 2019, LANCET, V393, P2051, DOI 10.1016/S0140-6736(18)32487-5; Perrone-Capano C, 2000, INT J DEV BIOL, V44, P679; Pinheiro M, 2015, BRIT J CANCER, V113, P686, DOI 10.1038/bjc.2015.281; Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z; Plowman PN, 2004, BRIT J NEUROSURG, V18, P500, DOI 10.1080/02688690400012400; Schreck KC, 2019, J NEURO-ONCOL, V143, P87, DOI 10.1007/s11060-019-03134-x; Sciacovelli M, 2016, NATURE, V540, DOI 10.1038/nature20144; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166; Sulkowski PL, 2018, NAT GENET, V50, P1086, DOI 10.1038/s41588-018-0170-4; Summerbell ER, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6197; Tapial S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47014-w; Theeler BJ, 2015, J NEUROL SCI, V353, P92, DOI 10.1016/j.jns.2015.04.014; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Wallace AS, 2011, WORLD J GASTROENTERO, V17, P4937, DOI 10.3748/wjg.v17.i45.4937; Whitehall VLJ, 2014, EPIGENETICS-US, V9, P1454, DOI 10.4161/15592294.2014.971624; Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486	42	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1542	1550		10.1038/s41388-020-01624-1	http://dx.doi.org/10.1038/s41388-020-01624-1		JAN 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452457				2022-12-17	WOS:000607998600004
J	Burgess, M; Chen, YCE; Mapp, S; Blumenthal, A; Mollee, P; Gill, D; Saunders, NA				Burgess, M.; Chen, Y. C. E.; Mapp, S.; Blumenthal, A.; Mollee, P.; Gill, D.; Saunders, N. A.			HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (vol 39, pg 5756, 2020)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-020-01619-y.				nsaunders@uq.edu.au	; saunders, nicholas/E-1544-2014	Chen, Yu Chen Enya/0000-0003-4223-5054; saunders, nicholas/0000-0002-2478-3420				Burgess M, 2020, ONCOGENE, V39, P5756, DOI 10.1038/s41388-020-01394-w	1	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1203	1203		10.1038/s41388-020-01619-y	http://dx.doi.org/10.1038/s41388-020-01619-y		DEC 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33353962	Bronze			2022-12-17	WOS:000601140800001
J	Jessen, C; Kress, JKC; Baluapuri, A; Hufnagel, A; Schmitz, W; Kneitz, S; Roth, S; Marquardt, A; Appenzeller, S; Ade, CP; Glutsch, V; Wobser, M; Friedmann-Angeli, JP; Mosteo, L; Goding, CR; Schilling, B; Geissinger, E; Wolf, E; Meierjohann, S				Jessen, Christina; Kress, Julia K. C.; Baluapuri, Apoorva; Hufnagel, Anita; Schmitz, Werner; Kneitz, Susanne; Roth, Sabine; Marquardt, Andre; Appenzeller, Silke; Ade, Carsten P.; Glutsch, Valerie; Wobser, Marion; Friedmann-Angeli, Jose Pedro; Mosteo, Laura; Goding, Colin R.; Schilling, Bastian; Geissinger, Eva; Wolf, Elmar; Meierjohann, Svenja			The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression (vol 39, pg 6841, 2020)	ONCOGENE			English	Correction												svenja.meierjohann@uni-wuerzburg.de	Marquardt, André/AAY-8844-2021; Schilling, Bastian/AAY-8646-2020; Baluapuri, Apoorva/AAF-4624-2020	Schilling, Bastian/0000-0001-8859-4103; Ade, Carsten/0000-0001-7226-1179; Baluapuri, Apoorva/0000-0002-3723-7891; Appenzeller, Silke/0000-0002-5472-8692; Schmitz, Werner/0000-0003-0485-7303; Marquardt, Andre/0000-0002-2425-7033	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Jessen C, 2020, ONCOGENE, V39, P6841, DOI 10.1038/s41388-020-01477-8	1	0	0	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1391	1391		10.1038/s41388-020-01535-1	http://dx.doi.org/10.1038/s41388-020-01535-1		DEC 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33262465	Bronze, Green Published			2022-12-17	WOS:000595928700007
J	Rose, M; Maurer, A; Wirtz, J; Bleilevens, A; Waldmann, T; Wenz, M; Eyll, M; Geelvink, M; Gereitzig, M; Ruchel, N; Denecke, B; Eltze, E; Herrmann, E; Toma, M; Horst, D; Grimm, T; Denzinger, S; Ecke, T; Vogeli, TA; Knuechel, R; Maurer, J; Gaisa, NT				Rose, Michael; Maurer, Angela; Wirtz, Julia; Bleilevens, Andreas; Waldmann, Tanja; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruchel, Nadine; Denecke, Bernd; Eltze, Elke; Herrmann, Edwin; Toma, Marieta; Horst, David; Grimm, Tobias; Denzinger, Stefan; Ecke, Thorsten; Vogeli, Thomas Alexander; Knuechel, Ruth; Maurer, Jochen; Gaisa, Nadine T.			EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer (vol 39, pg 6856, 2020)	ONCOGENE			English	Correction												ngaisa@ukaachen.de	Toma, Marieta/AAI-8022-2021	Wirtz, Julia/0000-0003-0220-6312	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Rose M, 2020, ONCOGENE, V39, P6856, DOI 10.1038/s41388-020-01465-y	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1390	1390		10.1038/s41388-020-01534-2	http://dx.doi.org/10.1038/s41388-020-01534-2		DEC 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33262466	Bronze, Green Published			2022-12-17	WOS:000595928700002
J	Ahuja, A; Journo, G; Eitan, R; Rubin, E; Shamay, M				Ahuja, Anuj; Journo, Guy; Eitan, Ron; Rubin, Eitan; Shamay, Meir			High levels of LINE-1 transposable elements expressed in Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma	ONCOGENE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ENDOGENOUS RETROVIRUS HERV-K18; ENCODED REVERSE-TRANSCRIPTASE; GENE-EXPRESSION; CELL-PROLIFERATION; DNA; RETROTRANSPOSITION; DIFFERENTIATION; HYPOMETHYLATION; IDENTIFICATION	Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8) is a gamma herpesvirus associated with several human malignancies. Transposable elements (TEs) are ubiquitous in eukaryotic genomes, occupying about 45% of the human genome. TEs have been linked with a variety of disorders and malignancies, though the precise nature of their contribution to many of them has yet to be elucidated. Global transcriptome analysis for differentially expressed TEs in KSHV-associated primary effusion lymphoma (PEL) cells (BCBL1 and BC3) revealed large number of differentially expressed TEs. These differentially expressed TEs include LTR transposons, long interspersed nuclear elements (LINEs), and short interspersed nuclear elements (SINEs). Further analysis of LINE-1 (L1) elements revealed expression upregulation, hypo-methylation, and transition into open chromatin in PEL. In agreement with high L1 expression, PEL cells express ORF1 protein and possess high reverse transcriptase (RT)-activity. Interestingly, inhibition of this RT-activity suppressed PEL cell growth. Collectively, we identified high expression of TEs, and specifically of L1 as a critical component in the proliferation of PEL cells. This observation is relevant for the treatment of KSHV-associated malignancies since they often develop in AIDS patients that are treated with RT inhibitors with potent inhibition for both HIV and L1 RT activity.	[Ahuja, Anuj; Journo, Guy; Eitan, Ron; Shamay, Meir] Bar Ilan Univ, Azrieli Fac Med, Daniella Lee Casper Lab Viral Oncol, Safed, Israel; [Rubin, Eitan] Ben Gurion Univ Negev, Shraga Segal Dept Microbiol & Immunol, Fac Hlth Sci, IL-84105 Beer Sheva, Israel	Bar Ilan University; Ben Gurion University	Shamay, M (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Daniella Lee Casper Lab Viral Oncol, Safed, Israel.	meir.shamay@biu.ac.il	Ahuja, Anuj/ABA-2550-2021; Rubin, Eitan/E-5256-2011	Ahuja, Anuj/0000-0002-0558-1356; Rubin, Eitan/0000-0002-7807-4005	Israel Science Foundation [1134/16]; Israel Cancer Association - Walter Bela foundation [20150095, 20161143]; Research Career Development Award from the Israel Cancer Research Fund [01282]; Elias, Genevieve, and Georgianna Atol Charitable Trust	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association - Walter Bela foundation; Research Career Development Award from the Israel Cancer Research Fund; Elias, Genevieve, and Georgianna Atol Charitable Trust	We would like to thank S. Diane hayward, Richard F. Ambinder, Jeffrey Vieira, Shou-Jiang (SJ) Gao, Milana Frenkel-Morgenstern, and Ronit Sarid for cell lines. This work was supported by grants from the Israel Science Foundation (https://www.isf.org.il) (1134/16), the Israel Cancer Association (20150095, 20161143) funded by the Walter Bela foundation, and a Research Career Development Award from the Israel Cancer Research Fund (https://www.icrfonline.org/) (01282) to MS. We are grateful for the support of the Elias, Genevieve, and Georgianna Atol Charitable Trust to the Daniella Lee Casper Laboratory in Viral Oncology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Alisch RS, 2006, GENE DEV, V20, P210, DOI 10.1101/gad.1380406; Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; Ardeljan D, 2019, MOBILE DNA-UK, V11, DOI 10.1186/s13100-019-0191-2; Aschacher T, 2016, ONCOGENE, V35, P94, DOI 10.1038/onc.2015.65; Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Burger D, 2006, BRIT J CLIN PHARMACO, V61, P148, DOI 10.1111/j.1365-2125.2005.02536.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Crauwels H, 2013, AIDS REV, V15, P87; Criscione SW, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2800-5; Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18; Dai L, 2018, ONCOGENE, V37, P4534, DOI 10.1038/s41388-018-0282-4; de Koning APJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002384; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erichsen L, 2018, SAUDI J BIOL SCI, V25, P1220, DOI 10.1016/j.sjbs.2018.02.005; Goering W, 2011, CARCINOGENESIS, V32, P1484, DOI 10.1093/carcin/bgr181; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Henke-Gendo C, 2004, CURR OPIN INFECT DIS, V17, P53, DOI 10.1097/00001432-200402000-00011; Johnson WE, 2015, ANNU REV VIROL, V2, P135, DOI 10.1146/annurev-virology-100114-054945; Jones RB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001547; Jonsson ME, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11150-8; Journo G, 2018, J VIROL, V92, DOI 10.1128/JVI.00008-18; Karijolich J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005260; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Klein U, 2003, BLOOD, V101, P4115, DOI 10.1182/blood-2002-10-3090; Kopylova E, 2012, BIOINFORMATICS, V28, P3211, DOI 10.1093/bioinformatics/bts611; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Lee J, 2007, GENE, V390, P18, DOI 10.1016/j.gene.2006.08.029; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12; Nakayama R, 2019, ONCOGENE, V38, P4340, DOI 10.1038/s41388-019-0726-5; Oakes CC, 2016, NAT GENET, V48, P253, DOI 10.1038/ng.3488; Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214; Patnala R, 2014, BREAST CANCER RES TR, V143, P239, DOI 10.1007/s10549-013-2812-7; Pizzato M, 2009, J VIROL METHODS, V156, P1, DOI 10.1016/j.jviromet.2008.10.012; Poole LJ, 2002, J VIROL, V76, P3395, DOI 10.1128/JVI.76.7.3395-3420.2002; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Sciamanna I, 2013, ONCOTARGET, V4, P2271, DOI 10.18632/oncotarget.1403; Shamay M, 2010, J BIOL CHEM, V285, P36377, DOI 10.1074/jbc.M110.155721; Sharma M, 2013, J ANTIMICROB CHEMOTH, V68, P250, DOI 10.1093/jac/dks404; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Sutkowski N, 2001, IMMUNITY, V15, P579, DOI 10.1016/S1074-7613(01)00210-2; Sutkowski N, 2004, J VIROL, V78, P7852, DOI 10.1128/JVI.78.14.7852-7860.2004; Tangkijvanich P, 2007, CLIN CHIM ACTA, V379, P127, DOI 10.1016/j.cca.2006.12.029; Tinari A, 2008, INT J IMMUNOPATH PH, V21, P999, DOI 10.1177/039463200802100425; Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242; Vermeire J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050859; Vieira J, 2004, VIROLOGY, V325, P225, DOI 10.1016/j.virol.2004.03.049; Viollet C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006143; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384; Xie Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1076; Zheng YN, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0733-y	61	0	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					536	550		10.1038/s41388-020-01549-9	http://dx.doi.org/10.1038/s41388-020-01549-9		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33188297				2022-12-17	WOS:000589573800001
J	Abd-Elrahman, I; Nassar, T; Khairi, N; Perlman, R; Benita, S; Ben Yehuda, D				Abd-Elrahman, Ihab; Nassar, Taher; Khairi, Noha; Perlman, Riki; Benita, Simon; Ben Yehuda, Dina			Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma	ONCOGENE			English	Article							GAUSSIA LUCIFERASE; PROTEIN LIVIN; CD40 ANTIGEN; CANCER; APOPTOSIS; DELIVERY; RESISTANCE; INHIBITOR; THERAPY; SYSTEM	We previously showed that Livin, an inhibitor of apoptosis protein, is specifically cleaved to produce a truncated protein, tLivin, and demonstrated its paradoxical proapoptotic activity. We further demonstrated that mini-tLivin (MTV), a 70 amino acids derivative of tLivin, is a proapoptotic protein as potent as tLivin. Based on these findings, in this study we aimed to develop a venue to target MTV for the treatment of diffuse large B-cell lymphoma (DLBCL). MTV was conjugated to poly (lactide-co-glycolic acid) surface-activated nanoparticles (NPs). In order to target MTV-NPs we also conjugated CD40 ligand (CD40L) to the surface of the NPs and evaluated the efficacy of the bifunctional CD40L-MTV-NPs. In vitro, CD40L-MTV-NPs elicited significant apoptosis of DLBCL cells. In a disseminated mouse model of DLBCL, 37.5% of MTV-NPs treated mice survived at the end of the experiment. Targeting MTV-NPs using CD40L greatly improved survival and 71.4% of these mice survived. CD40L-MTV-NPs also greatly reduced CNS involvement of DLBCL. Only 20% of these mice presented infiltration of lymphoma to the brain in comparison to 77% of the MTV-NPs treated mice. In a subcutaneous mouse model, CD40L-MTV-NPs significantly reduced tumor volume in correlation with significant increased caspase-3 activity. Thus, targeted MTV-NPs suggest a novel approach to overcome apoptosis resistance in cancer.	[Abd-Elrahman, Ihab; Khairi, Noha; Perlman, Riki; Ben Yehuda, Dina] Hadassah Med Org, Dept Hematol, Jerusalem, Israel; [Nassar, Taher; Benita, Simon] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel; [Ben Yehuda, Dina] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Ben Yehuda, D (corresponding author), Hadassah Med Org, Dept Hematol, Jerusalem, Israel.; Ben Yehuda, D (corresponding author), Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel.	Dbyehuda@hadassah.org.il		abd-elrahman, ihab/0000-0003-2012-2024	Kamin Incentive Program, Israel Innovation Authority; Dorot foundation; Eleanor Fox; Aleen and David M. Epstein Fund for Hematology/oncology research	Kamin Incentive Program, Israel Innovation Authority; Dorot foundation; Eleanor Fox; Aleen and David M. Epstein Fund for Hematology/oncology research	We thank Galina Skarzinski for immunohistochemistry. This work was supported by Kamin Incentive Program, Israel Innovation Authority (DBY and SB), Dorot foundation (DBY), Eleanor Fox (DBY), and Aleen and David M. Epstein Fund for Hematology/oncology research (DBY).	Abd-Elrahman I, 2009, CANCER RES, V69, P5475, DOI 10.1158/0008-5472.CAN-09-0424; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Bartok E, 2013, NAT METHODS, V10, P147, DOI [10.1038/nmeth.2327, 10.1038/NMETH.2327]; Bicho A, 2010, INT J PHARMACEUT, V399, P80, DOI 10.1016/j.ijpharm.2010.08.005; Bierman P, 2005, HEMATOL ONCOL CLIN N, V19, P597, DOI 10.1016/j.hoc.2005.05.003; Bovenberg MSS, 2012, ANAL CHEM, V84, P1189, DOI 10.1021/ac202833r; Bugajska U, 2002, J NATL CANCER I, V94, P1381; Calimeri T., 2019, ANN LYMPHOMA, V3, P7, DOI DOI 10.21037/AOL.2019.06.01; Carreno BM, 2009, CLIN CANCER RES, V15, P3277, DOI 10.1158/1078-0432.CCR-08-2502; Carvalho C, 2009, CURR MED CHEM, V16, P3267, DOI 10.2174/092986709788803312; Chavez JC, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719841581; Chen WC, 2010, BLOOD, V115, P4778, DOI 10.1182/blood-2009-12-257386; Choi J, 2007, BLOOD, V109, P471, DOI 10.1182/blood-2006-07-032557; Chung E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008316; Dong XW, 2009, CANCER RES, V69, P3918, DOI 10.1158/0008-5472.CAN-08-2747; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0; Foo J, 2014, J THEOR BIOL, V355, P10, DOI 10.1016/j.jtbi.2014.02.025; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Georgopoulos NT, 2007, INT J CANCER, V121, P1373, DOI 10.1002/ijc.22846; Ghose A, 2015, CL LYMPH MYELOM LEUK, V15, P451, DOI 10.1016/j.clml.2015.02.026; Girotti MR, 2013, CANCER DISCOV, V3, P487, DOI 10.1158/2159-8290.CD-13-0131; Goldstein D, 2007, BIOMED PHARMACOTHER, V61, P97, DOI 10.1016/j.biopha.2006.08.005; Harush-Frenkel O, 2010, TOXICOL APPL PHARM, V246, P83, DOI 10.1016/j.taap.2010.04.011; Hostager BS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00376; Huang LF, 2020, BIOMATER SCI-UK, V8, P2376, DOI 10.1039/d0bm00129e; Inoue Y, 2011, MOL IMAGING, V10, P377, DOI 10.2310/7290.2010.00057; Jia J, 2015, MOL MED REP, V11, P1623, DOI 10.3892/mmr.2014.2953; Jin Y, 2010, MOL PHARMACEUT, V7, P196, DOI 10.1021/mp900205r; Karra N, 2013, SMALL, V9, P4221, DOI 10.1002/smll.201301417; Kojima C, 2013, NANOMED-NANOTECHNOL, V9, P767, DOI 10.1016/j.nano.2013.01.004; Lazar I, 2012, ONCOLOGY-BASEL, V82, P197, DOI 10.1159/000334234; Liang XJ, 2010, METHODS MOL BIOL, V596, P467, DOI 10.1007/978-1-60761-416-6_21; Lu Y, 2004, ADV DRUG DELIVER REV, V56, P1621, DOI 10.1016/j.addr.2004.05.002; Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3; Milane L, 2011, MOL PHARMACEUT, V8, P185, DOI 10.1021/mp1002653; Muhamad N, 2018, INT J NANOMED, V13, P3921, DOI 10.2147/IJN.S165210; Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002; Nachmias B, 2003, CANCER RES, V63, P6340; Nachmias B, 2007, APOPTOSIS; Nagamitsu A, 2009, JPN J CLIN ONCOL, V39, P756, DOI 10.1093/jjco/hyp074; Niers JM, 2011, MOL THER, V19, P1090, DOI 10.1038/mt.2011.17; Phongpradist R, 2010, CURR PHARM DESIGN, V16, P2321, DOI 10.2174/138161210791920450; Rubenstein JL, 2003, BLOOD, V101, P466, DOI 10.1182/blood-2002-06-1636; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schultze J, 1999, LANCET, V354, P1225, DOI 10.1016/S0140-6736(99)90130-7; SCHULTZE JL, 1995, P NATL ACAD SCI USA, V92, P8200, DOI 10.1073/pnas.92.18.8200; Shi JQ, 2012, MOL CANCER THER, V11, P2045, DOI 10.1158/1535-7163.MCT-11-1036; Shiloach T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101075; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; Stiff PJ, 2013, NEW ENGL J MED, V369, P1681, DOI 10.1056/NEJMoa1301077; Szocinski JL, 2002, BLOOD, V100, P217, DOI 10.1182/blood.V100.1.217; T Georgopoulos N, 2006, CELL DEATH DIFFER, V13, P1789, DOI 10.1038/sj.cdd.4401859; UCKUN FM, 1990, BLOOD, V76, P2449; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Wang SN, 2010, BIOSENS BIOELECTRON, V26, P778, DOI 10.1016/j.bios.2010.06.025; Wennhold K, 2017, ONCOTARGET, V8, P27740, DOI 10.18632/oncotarget.7720; Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1	61	0	0	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					334	344		10.1038/s41388-020-01529-z	http://dx.doi.org/10.1038/s41388-020-01529-z		OCT 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33128043				2022-12-17	WOS:000585769600001
J	Karra, L; Romero-Moya, D; Ksionda, O; Krush, M; Gu, ZH; Mues, M; Depeille, P; Mullighan, C; Roose, JP				Karra, Laila; Romero-Moya, Damia; Ksionda, Olga; Krush, Milana; Gu, Zhaohui; Mues, Marsilius; Depeille, Philippe; Mullighan, Charles; Roose, Jeroen P.			Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis	ONCOGENE			English	Article							DEVELOPMENTAL DISORDERS; CONDITIONAL EXPRESSION; NOTCH1 MUTATIONS; RAS ACTIVATION; ONCOGENIC NRAS; SELF-RENEWAL; LEUKEMIA; DISTINCT; CANCER; MTOR	Oncogenic mutations inRASgenes, likeKRAS(G12D)orNRAS(G12D), trap Ras in the active state and cause myeloproliferative disorder and T cell leukemia (T-ALL) when induced in the bone marrow viaMx1CRE. The RAS exchange factor RASGRP1 is frequently overexpressed in T-ALL patients. In T-ALL cell lines overexpression of RASGRP1 increases flux through the RASGTP/RasGDP cycle. Here we expandedRASGRP1expression surveys in pediatric T-ALL and generated aRoLoRiGmouse model crossed toMx1CREto determine the consequences of induced RASGRP1 overexpression in primary hematopoietic cells. RASGRP1-overexpressing, GFP-positive cells outcompeted wild type cells and dominated the peripheral blood compartment over time. RASGRP1 overexpression bestows gain-of-function colony formation properties to bone marrow progenitors in medium containing limited growth factors. RASGRP1 overexpression enhances baseline mTOR-S6 signaling in the bone marrow, but not in vitro cytokine-induced signals. In agreement with these mechanistic findings, hRASGRP1-ires-EGFP enhances fitness of stem- and progenitor- cells, but only in the context of native hematopoiesis. RASGRP1 overexpression is distinct fromKRAS(G12D)orNRAS(G12D), does not cause acute leukemia on its own, and leukemia virus insertion frequencies predict that RASGRP1 overexpression can effectively cooperate with lesions in many other genes to cause acute T-ALL.	[Karra, Laila; Romero-Moya, Damia; Ksionda, Olga; Krush, Milana; Mues, Marsilius; Depeille, Philippe; Roose, Jeroen P.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Gu, Zhaohui; Mullighan, Charles] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gu, Zhaohui; Mullighan, Charles] St Jude Childrens Res Hosp, Hematol Malignancies Program, 332 N Lauderdale St, Memphis, TN 38105 USA; [Ksionda, Olga] Univ Auckland, Liggins Inst, Auckland, New Zealand; [Mues, Marsilius] Miltenyi Biotec GmbH, Friedrich Ebert Str 68, D-51429 Bergisch Gladbach, Germany	University of California System; University of California San Francisco; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Auckland; Miltenyi Biotec	Roose, JP (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	jeroen.roose@ucsf.edu	Mullighan, Charles/H-3253-2011	Mullighan, Charles/0000-0002-1871-1850; Krush, Milana/0000-0003-4833-8564; Karra, Laila/0000-0001-5503-2809; Roose, Jeroen/0000-0003-4746-2811; Romero-Moya, Damia/0000-0001-9947-3577	Alex' Lemonade Stand Foundation Innovator Award; NIH/NCI [R01 - CA187318]; NIH/NHLBI [R01 - HL120724]; Leukemia & Lymphoma Society; Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering; Mark Foundation for Cancer Research; NCI [CA021765]; NCI R35 Outstanding Investigator Award [R35 CA197695]; St. Baldrick's Foundation Robert J. Arceci Innovation award; DRC Center Grant [NIH P30 DK063720]	Alex' Lemonade Stand Foundation Innovator Award; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering; Mark Foundation for Cancer Research; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI R35 Outstanding Investigator Award; St. Baldrick's Foundation Robert J. Arceci Innovation award; DRC Center Grant	This work was supported by an Alex' Lemonade Stand Foundation Innovator Award, the NIH/NCI (R01 - CA187318), and the NIH/NHLBI (R01 - HL120724) (all to JPR). Further support came from a Leukemia & Lymphoma Society grant (to MM) and the Rothschild Fellowship for postdoctoral fellows in the Natural, Exact or Life Sciences and Engineering (to LK), and PD is a Mark Foundation Momentum Fellow supported by a fellowship from the Mark Foundation for Cancer Research; and by NCI grants CA021765 (St Jude Comprehensive Cancer Center Support Grant), an NCI R35 Outstanding Investigator Award (R35 CA197695) and a St. Baldrick's Foundation Robert J. Arceci Innovation award. We thank the members of the Roose lab and the Heme-Onc community at UCSF for useful suggestions and comments. We thank UCSF flow cytometry facility and DRC Center Grant NIH P30 DK063720. We thank Emmanuelle Passague and her lab for kindly providing us Mx1-CRE mice.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Beck-Engeser GB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-4; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Downward J, 2006, NATURE, V439, P274, DOI 10.1038/439274a; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hartzell C, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003848; Herault A, 2017, NATURE, V544, P53, DOI 10.1038/nature21693; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jun JE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00239; Kalaitzidis D, 2012, CELL STEM CELL, V11, P429, DOI 10.1016/j.stem.2012.06.009; Kentsis A, 2012, CELL STEM CELL, V11, P281, DOI 10.1016/j.stem.2012.08.007; Kindler T, 2008, BLOOD, V112, P3373, DOI 10.1182/blood-2008-03-147587; Klinger MB, 2005, ONCOGENE, V24, P2695, DOI 10.1038/sj.onc.1208334; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kortum RL, 2012, MOL CELL BIOL, V32, P2748, DOI 10.1128/MCB.00317-12; Ksionda O, 2016, ONCOGENE, V35, P3658, DOI 10.1038/onc.2015.431; Ksionda O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193849; Ksionda Olga, 2013, Front Biol (Beijing), V8, P508; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Li Q, 2013, NATURE, V504, P143, DOI 10.1038/nature12830; Li Q, 2011, BLOOD, V117, P2022, DOI 10.1182/blood-2010-04-280750; Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Magee JA, 2012, CELL STEM CELL, V11, P415, DOI 10.1016/j.stem.2012.05.026; Montes R, 2014, LEUKEMIA, V28, P666, DOI 10.1038/leu.2013.346; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Mues Marsilius, 2017, Small GTPases, V8, P20, DOI 10.1080/21541248.2016.1187323; Myers DR, 2019, IMMUNOL REV, V291, P134, DOI 10.1111/imr.12796; Myers DR, 2019, CELL REP, V27, P1858, DOI 10.1016/j.celrep.2019.04.037; Norment AM, 2003, J IMMUNOL, V170, P1141, DOI 10.4049/jimmunol.170.3.1141; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Oki T, 2012, LEUKEMIA, V26, P1038, DOI 10.1038/leu.2011.328; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Pietras EM, 2015, CELL STEM CELL, V17, P35, DOI 10.1016/j.stem.2015.05.003; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Romero-Moya D, 2013, HAEMATOLOGICA, V98, P1022, DOI 10.3324/haematol.2012.079244; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sabnis AJ, 2009, PLOS BIOL, V7, P537, DOI 10.1371/journal.pbio.1000059; Sanjuan-Pla A, 2016, STEM CELLS DEV, V25, P259, DOI 10.1089/scd.2015.0309; Sanjuan-Pla A, 2015, BLOOD, V126, P2676, DOI 10.1182/blood-2015-09-667378; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schubbert S, 2007, CURR OPIN GENET DEV, V17, P15, DOI 10.1016/j.gde.2006.12.004; Seita J, 2010, WIRES SYST BIOL MED, V2, P640, DOI 10.1002/wsbm.86; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stine RR, 2013, TRENDS CELL BIOL, V23, P357, DOI 10.1016/j.tcb.2013.03.001; Sun CC, 2017, ONCOTARGET, V8, P35445, DOI 10.18632/oncotarget.16367; Sun JL, 2014, NATURE, V514, P322, DOI 10.1038/nature13824; Terwilliger T, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.53; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; von Lintig FC, 2000, CLIN CANCER RES, V6, P1804; Wang JY, 2013, BLOOD, V121, P5203, DOI 10.1182/blood-2012-12-475863; Wang JY, 2010, BLOOD, V116, P5991, DOI 10.1182/blood-2010-04-281527; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Winter SS, 2018, J CLIN ONCOL, V36, P2926, DOI 10.1200/JCO.2018.77.7250; Xu ZF, 2009, LEUKEMIA RES, V33, P891, DOI 10.1016/j.leukres.2009.01.041; Zhang CC, 2008, CURR OPIN HEMATOL, V15, P307, DOI 10.1097/MOH.0b013e3283007db5; Zhang YF, 2018, TRENDS CELL BIOL, V28, P976, DOI 10.1016/j.tcb.2018.06.001	59	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6920	6934		10.1038/s41388-020-01469-8	http://dx.doi.org/10.1038/s41388-020-01469-8		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32989257	Green Submitted, Green Accepted			2022-12-17	WOS:000573446900003
J	Rayter, S; Elliott, R; Travers, J; Rowlands, MG; Richardson, TB; Boxall, K; Jones, K; Linardopoulos, S; Workman, P; Aherne, W; Lord, CJ; Ashworth, A				Rayter, S.; Elliott, R.; Travers, J.; Rowlands, M. G.; Richardson, T. B.; Boxall, K.; Jones, K.; Linardopoulos, S.; Workman, P.; Aherne, W.; Lord, C. J.; Ashworth, A.			A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D (vol 27, pg 1036, 2008)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.				Alan.Ashworth@icr.ac.uk						Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4780	4780		10.1038/s41388-020-1309-1	http://dx.doi.org/10.1038/s41388-020-1309-1		MAY 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32427987	Bronze			2022-12-17	WOS:000534203100001
J	Yang, G; Rosen, DG; Colacino, JA; Mercado-Uribe, I; Liu, J				Yang, G.; Rosen, D. G.; Colacino, J. A.; Mercado-Uribe, I.; Liu, J.			Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells (vol 26, pg 1492, 2007)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.				jliu@mdanderson.org						Yang G, 2007, ONCOGENE, V26, P1492, DOI 10.1038/sj.onc.1209905	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4475	4475		10.1038/s41388-020-1294-4	http://dx.doi.org/10.1038/s41388-020-1294-4			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32303688	Bronze			2022-12-17	WOS:000536009500012
J	Gray, MJ; Dallas, NA; Van Buren, G; Xia, L; Yang, AD; Somcio, RJ; Gaur, P; Mangala, LS; Vivas-Mejia, PE; Fan, F; Sanguino, AM; Gallick, GE; Lopez-Berestein, G; Sood, AK; Ellis, LM				Gray, M. J.; Dallas, N. A.; Van Buren, G.; Xia, L.; Yang, A. D.; Somcio, R. J.; Gaur, P.; Mangala, L. S.; Vivas-Mejia, P. E.; Fan, F.; Sanguino, A. M.; Gallick, G. E.; Lopez-Berestein, G.; Sood, A. K.; Ellis, L. M.			Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver (vol 27, pg 7192, 2020)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.				mgray@osip.com; lellis@mdanderson.org	Sood, Anoop Kumar/A-7344-2013; Khaitan, Puja/AAQ-6413-2020	Sood, Anoop Kumar/0000-0001-5702-4108; Khaitan, Puja/0000-0001-8654-062X				Gray MJ, 2008, ONCOGENE, V27, P7192, DOI 10.1038/onc.2008.356	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4619	4619		10.1038/s41388-020-1310-8	http://dx.doi.org/10.1038/s41388-020-1310-8		APR 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366906	Bronze			2022-12-17	WOS:000530270700001
J	Loveridge, CJ; Slater, S; Campbell, KJ; Nam, NA; Knight, J; Ahmad, I; Hedley, A; Lilla, S; Repiscak, P; Patel, R; Salji, M; Fleming, J; Mitchell, L; Nixon, C; Strathdee, D; Neilson, M; Ntala, C; Bryson, S; Zanivan, S; Edwards, J; Robson, CN; Goodyear, CS; Blyth, K; Leung, HY				Loveridge, Carolyn J.; Slater, Sarah; Campbell, Kirsteen J.; Nam, Noor A.; Knight, John; Ahmad, Imran; Hedley, Ann; Lilla, Sergio; Repiscak, Peter; Patel, Rachana; Salji, Mark; Fleming, Janis; Mitchell, Louise; Nixon, Colin; Strathdee, Douglas; Neilson, Matthew; Ntala, Chara; Bryson, Sheila; Zanivan, Sara; Edwards, Joanne; Robson, Craig N.; Goodyear, Carl S.; Blyth, Karen; Leung, Hing Y.			BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration (vol 39, pg 4797, 2020)	ONCOGENE			English	Correction												h.leung@beatson.gla.ac.uk	Edwards, Joanne/J-1903-2015; Nam, Noor Akmar/AAG-2571-2019; Zanivan, Sara/GOV-5505-2022	Edwards, Joanne/0000-0002-7192-6906; Nam, Noor Akmar/0000-0002-7703-2049; Ahmad, Imran/0000-0002-4404-1926; Loveridge, Carolyn/0000-0002-6237-8661				Loveridge CJ, 2020, ONCOGENE, V39, P1797, DOI 10.1038/s41388-019-1106-x	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2450	2450		10.1038/s41388-019-1149-z	http://dx.doi.org/10.1038/s41388-019-1149-z			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31857667	Bronze, Green Published			2022-12-17	WOS:000519440400015
J	Semba, S; Trapasso, F; Fabbri, M; McCorkell, KA; Volinia, S; Druck, T; Iliopoulos, D; Pekarsky, Y; Ishii, H; Garrison, PN; Barnes, LD; Croce, CM; Huebner, K				Semba, S.; Trapasso, F.; Fabbri, M.; McCorkell, K. A.; Volinia, S.; Druck, T.; Iliopoulos, D.; Pekarsky, Y.; Ishii, H.; Garrison, P. N.; Barnes, L. D.; Croce, C. M.; Huebner, K.			Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential (vol 25, pg 2860, 2006)	ONCOGENE			English	Correction								After publication of this Article the authors noticed errors in several figures. In Fig. 2b the Gapdh panels are incorrect. The lysates are identical to those used in Fig. 1b, therefore the Gapdh panels should be the same in both figures. In Fig. 3b the Gapdh panels for Ad-Fhit-wt and Ad-Fhit-Y114F are incorrect and have been replaced with scans from original films. In Fig. 4A the Gapdh panels are incorrect. The lysates are identical to those used in Fig. 3b, therefore the Gapdh panels should be the same in both figures. In Fig. 4Bb the Gapdh panels for Fhit siRNA were incorrect and have been replaced with scans from original films. All resupplied figures are provided below. In Fig. 5C several panels are incorrect. The Authors were unable to locate the original films for all of these panels so Fig. 5c has been deleted. The scientific conclusions of this paper have not been affected.				kay.huebner@osumc.edu						Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323	1	0	0	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2224	2226		10.1038/s41388-019-1130-x	http://dx.doi.org/10.1038/s41388-019-1130-x			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819168	Bronze			2022-12-17	WOS:000518584000015
J	Zhang, C; Stockwell, SR; Elbanna, M; Ketteler, R; Freeman, J; Al-Lazikani, B; Eccles, S; Brandon, AD; Raynaud, F; Hayes, A; Clarke, PA; Workman, P; Mittnacht, S				Zhang, Chi; Stockwell, Simon R.; Elbanna, May; Ketteler, Robin; Freeman, Jamie; Al-Lazikani, Bissan; Eccles, Suzanne; De Haven Brandon, Alexis; Raynaud, Florence; Hayes, Angela; Clarke, Paul A.; Workman, Paul; Mittnacht, Sibylle			Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases (vol 38, pg 5905, 2020)	ONCOGENE			English	Correction												paul.workman@icr.ac.uk; s.mittnacht@cancer.ucl.ac.uk	Al-Lazikani, Bissan/AAG-4723-2022; Al-Lazikani, Bissan/AFK-6457-2022; Elbanna, May/ABC-3736-2021	Elbanna, May/0000-0002-9745-9066; Raynaud, Florence/0000-0003-0957-6279; Al-Lazikani, Bissan/0000-0003-3367-2519; Clarke, Paul/0000-0001-9342-1290	Medical Research Council [MC_EX_G0800785] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Zhang C, 2019, ONCOGENE, V38, P5905, DOI 10.1038/s41388-019-0850-2	1	0	0	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3411	3412		10.1038/s41388-020-1221-8	http://dx.doi.org/10.1038/s41388-020-1221-8		FEB 2020	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32094403	Green Published, hybrid			2022-12-17	WOS:000515475800002
J	Nitta, RT; Bolin, S; Luo, E; Solow-Cordero, DE; Samghabadi, P; Purzner, T; Aujla, PS; Nwagbo, G; Cho, YJ; Li, GD				Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Solow-Cordero, David E.; Samghabadi, Peyman; Purzner, Teresa; Aujla, Parvir S.; Nwagbo, Ginikachi; Cho, Yoon-Jae; Li, Gordon			Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide (vol 68, pg 6867, 2019)	ONCOGENE			English	Correction								The original version of this Article contained an error in the spelling of the author David Solow-Cordero, which was incorrectly given as David Solow-Codero. This has now been corrected in both the PDF and HTML versions of the Article.	[Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Aujla, Parvir S.; Nwagbo, Ginikachi; Li, Gordon] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Solow-Cordero, David E.] Stanford Univ, High Throughput Biosci Ctr, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Samghabadi, Peyman] Stanford Univ, Dept Neuropathol, Stanford, CA 94305 USA; [Purzner, Teresa] Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; [Purzner, Teresa] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Cho, Yoon-Jae] Oregon Hlth & Sci Univ, Knight Canc Inst, Pape Family Pediat Res Inst, Dept Pediat, Portland, OR 97201 USA	Stanford University; Stanford University; Stanford University; Stanford University; University of Toronto; Oregon Health & Science University	Nitta, RT (corresponding author), Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.	rnitta@stanford.edu		Bolin, Sara/0000-0003-2835-1518; Li, Gordon/0000-0001-8372-0676; Solow-Cordero, David/0000-0002-9886-5058	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS085333] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Nitta RT, 2019, ONCOGENE, V38, P6867, DOI 10.1038/s41388-019-0927-y	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2029	2029		10.1038/s41388-019-1077-y	http://dx.doi.org/10.1038/s41388-019-1077-y			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31659253	hybrid, Green Published			2022-12-17	WOS:000516579800018
J	Green, AL; DeSisto, J; Flannery, P; Lemma, R; Knox, A; Lemieux, M; Sanford, B; O'Rourke, R; Ramkissoon, S; Jones, K; Perry, J; Hui, X; Moroze, E; Balakrishnan, I; O'Neill, AF; Dunn, K; DeRyckere, D; Danis, E; Safadi, A; Gilani, A; Hubbell-Engler, B; Nuss, Z; Levy, JMM; Serkova, N; Venkataraman, S; Graham, DK; Foreman, N; Ligon, K; Jones, K; Kung, AL; Vibhakar, R				Green, Adam L.; DeSisto, John; Flannery, Patrick; Lemma, Rakeb; Knox, Aaron; Lemieux, Madeleine; Sanford, Bridget; O'Rourke, Rebecca; Ramkissoon, Shakti; Jones, Kristen; Perry, Jennifer; Hui, Xu; Moroze, Erin; Balakrishnan, Ilango; O'Neill, Allison F.; Dunn, Katherine; DeRyckere, Deborah; Danis, Etienne; Safadi, Aaron; Gilani, Ahmed; Hubbell-Engler, Benjamin; Nuss, Zachary; Levy, Jean M. Mulcahy; Serkova, Natalie; Venkataraman, Sujatha; Graham, Douglas K.; Foreman, Nicholas; Ligon, Keith; Jones, Ken; Kung, Andrew L.; Vibhakar, Rajeev			BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway (vol 56, pg 148, 2019)	ONCOGENE			English	Correction								The original version of this Article omitted the following from the Acknowledgements: This work was supported by the Luke's Army Pediatric Cancer Research Fund St. Baldrick's Scholar Award. This has now been corrected in both the PDF and HTML versions of the Article.				adam.green@cuanschutz.edu	Gilani, Ahmed/GYJ-5201-2022; Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Kung, Andrew L/0000-0002-9091-488X; Lemieux, Madeleine/0000-0001-6355-8691; Knox, Aaron/0000-0002-2179-9961	Luke's Army Pediatric Cancer Research Fund St. Baldrick's Scholar Award	Luke's Army Pediatric Cancer Research Fund St. Baldrick's Scholar Award	The original version of this Article omitted the following from the Acknowledgements:; This work was supported by the Luke's Army Pediatric Cancer Research Fund St. Baldrick's Scholar Award.	Green AL, 2020, ONCOGENE, V39, P2305, DOI 10.1038/s41388-019-1125-7	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2641	2641		10.1038/s41388-020-1155-1	http://dx.doi.org/10.1038/s41388-020-1155-1		JAN 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31969682	Bronze			2022-12-17	WOS:000508795500001
J	Kim, SJ; Garcia-Recio, S; Creighton, CJ; Perou, CM; Rosen, JM				Kim, S. J.; Garcia-Recio, S.; Creighton, C. J.; Perou, C. M.; Rosen, J. M.			Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression (vol 39, pg 950, 2019)	ONCOGENE			English	Correction								The original version of this Article incorrectly matched the supplementary files with their titles. This has been corrected. The following information has also been added to the Methods section.	[Kim, S. J.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Garcia-Recio, S.; Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Garcia-Recio, S.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	jrosen@bcm.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247; Rosen, Jeffrey/0000-0002-6637-844X				Kim SJ, 2019, ONCOGENE, V38, P5942, DOI 10.1038/s41388-019-0852-0	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					950	950		10.1038/s41388-019-1017-x	http://dx.doi.org/10.1038/s41388-019-1017-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31558798	Bronze			2022-12-17	WOS:000509197200016
J	Shin, SB; Jang, HR; Xu, R; Won, JY; Yim, H				Shin, Sol-Bi; Jang, Hay-Ran; Xu, Rong; Won, Jae-Yeon; Yim, Hyungshin			Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer (vol 38, pg 5942, 2019)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.	[Shin, Sol-Bi; Jang, Hay-Ran; Xu, Rong; Won, Jae-Yeon; Yim, Hyungshin] Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan, Gyeonggi Do, South Korea	Hanyang University	Yim, H (corresponding author), Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan, Gyeonggi Do, South Korea.	hsyim@hanyang.ac.kr						Shin SB, 2020, ONCOGENE, V39, P767, DOI 10.1038/s41388-019-1023-z	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					951	951		10.1038/s41388-019-1049-2	http://dx.doi.org/10.1038/s41388-019-1049-2			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31595031	hybrid, Green Published			2022-12-17	WOS:000509197200017
J	Salama, MF; Liu, ML; Clarke, CJ; Espaillat, MP; Haley, JD; Jin, T; Wang, DF; Obeid, LM; Hannun, YA				Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Haley, John D.; Jin, Ting; Wang, Daifeng; Obeid, Lina M.; Hannun, Yusuf A.			PKC alpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation (vol 38, pg 7311, 2019)	ONCOGENE			English	Correction									[Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Obeid, Lina M.; Hannun, Yusuf A.] Stony Brook Univ Hosp, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Salama, Mohamed F.] Mansoura Univ, Dept Biochem, Fac Vet Med, Mansoura, Egypt; [Liu, Mengling] HD Biosci Inc, Dept Immunooncol, San Diego, CA 92121 USA; [Haley, John D.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; [Haley, John D.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Jin, Ting; Wang, Daifeng] SUNY Stony Brook, Dept Biomed Informat, Stony Brook, NY 11794 USA; [Wang, Daifeng] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Wang, Daifeng] Univ Wisconsin, Waisman Ctr, Madison, WI 53792 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Egyptian Knowledge Bank (EKB); Mansoura University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hannun, YA (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), Stony Brook Univ Hosp, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	yusuf.hannun@stonybrookmedicine.edu	Salama, Mohamed/S-3493-2019	Salama, Mohamed/0000-0002-0002-9108				Salama MF, 2019, ONCOGENE, V38, P7311, DOI 10.1038/s41388-019-0950-z	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7366	7366		10.1038/s41388-019-1019-8	http://dx.doi.org/10.1038/s41388-019-1019-8			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31576014	Bronze			2022-12-17	WOS:000499631000007
J	Zhao, LJ; Wang, W; Xu, L; Yi, T; Zhao, X; Wei, YQ; Vermeulen, L; Goel, A; Zhou, ST; Wang, X				Zhao, Linjie; Wang, Wei; Xu, Lian; Yi, Tao; Zhao, Xia; Wei, Yuquan; Vermeulen, Louis; Goel, Ajay; Zhou, Shengtao; Wang, Xin			Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer (vol 38, pg 2305, 2019)	ONCOGENE			English	Correction									[Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao; Wang, Xin] Sichuan Univ, West China Univ Hosp 2, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China; [Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao; Wang, Xin] Sichuan Univ, West China Univ Hosp 2, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao; Wang, Xin] Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China; [Wang, Wei; Wang, Xin] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China	Sichuan University; Sichuan University; City University of Hong Kong	Zhou, ST; Wang, X (corresponding author), Sichuan Univ, West China Univ Hosp 2, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China.; Zhou, ST; Wang, X (corresponding author), Sichuan Univ, West China Univ Hosp 2, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.; Zhou, ST; Wang, X (corresponding author), Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China.; Wang, X (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China.	taotaovip2005@163.com; xin.wang@cityu.edu.hk	Wang, Xin/A-1130-2012	Wang, Xin/0000-0002-5122-2418				Zhao LJ, 2019, ONCOGENE, V38, P2305, DOI 10.1038/s41388-018-0577-5	1	0	1	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7279	7280		10.1038/s41388-019-0896-1	http://dx.doi.org/10.1038/s41388-019-0896-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31481747	Bronze, Green Published			2022-12-17	WOS:000497989400008
J	Agelaki, S				Agelaki, Sofia			Circulating tumor cells and circulating micro ribonucleic acids (miRNA) in breast cancer	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Agelaki, Sofia] Univ Crete, Iraklion, Greece	University of Crete					Hellenic Society of Medical Oncology (HESMO); Anticancer Research Support Association (ARSA)	Hellenic Society of Medical Oncology (HESMO); Anticancer Research Support Association (ARSA)	This work was partly supported by the Hellenic Society of Medical Oncology (HESMO) and the Anticancer Research Support Association (ARSA).	Agelaki S, 2017, ONCOTARGET, V8, P5309, DOI 10.18632/oncotarget.14144; Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5; Papadaki C, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1001-3; Papadaki MA, 2019, MOL CANCER THER, V18, P437, DOI 10.1158/1535-7163.MCT-18-0584; Spiliotaki M, 2018, MOL ONCOL, V12, P21, DOI 10.1002/1878-0261.12114	5	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-09	7	8						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200011
J	Anders, R				Anders, Robert			The role of pathology in the development of immunotherapy clinical trials	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ			BLOCKADE; TUMORS		[Anders, Robert] Johns Hopkins Univ, Baltimore, MD USA	Johns Hopkins University								Giraldo NA, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0404-0; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Taube JM, 2018, MODERN PATHOL, V31, P214, DOI 10.1038/modpathol.2017.156; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690	7	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-02	2	3						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200004
J	Berenguer, J				Berenguer, Jordi			Cancer diagnosis by machine learning-powered RNA-sequencing of tumor-educated platelets	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Berenguer, Jordi] Quiron Dexeus Univ Hosp, Pangaea Oncol, Barcelona, Spain				Berenguer, Jordi/AAK-5540-2020		European Union [712949]; Agency for Business Competitiveness of the Government of Catalonia	European Union(European Commission); Agency for Business Competitiveness of the Government of Catalonia	This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 712949 (TECNIOspring PLUS) and from the Agency for Business Competitiveness of the Government of Catalonia.	Best MG, 2015, CANCER CELL, V28, P666, DOI 10.1016/j.ccell.2015.09.018; Nilsson RJA, 2016, ONCOTARGET, V7, P1066, DOI 10.18632/oncotarget.6279; Bracht JWP, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0720-z	3	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-10	8	8						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200012
J	Chatzipantsiou, C; Roe, OD				Chatzipantsiou, Christina; Roe, Oluf Dimitri			Metabolomics signatures in serum years before thoracic cancer: the Nord-Trondelag Health Study/Helseundersokelsen i Nord-Trondelag (HUNT)	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Chatzipantsiou, Christina] Univ Crete, Iraklion, Greece; [Roe, Oluf Dimitri] Levanger Hosp, Levanger, Norway; [Roe, Oluf Dimitri] Norwegian Univ Sci & Technol, Trondheim, Norway; [Roe, Oluf Dimitri] Aalborg Univ Hosp, Aalborg, Denmark	University of Crete; Norwegian University of Science & Technology (NTNU); Aalborg University; Aalborg University Hospital								Krokstad S, 2013, INT J EPIDEMIOL, V42, P968, DOI 10.1093/ije/dys095	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-05	4	5						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200007
J	Hirsch, FR				Hirsch, Fred R.			Lung cancer-from best supportive care to immunotherapy. The biomarkers tale	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Hirsch, Fred R.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA; [Hirsch, Fred R.] Mt Sinai Hlth Syst, New York, NY USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Icahn School of Medicine at Mount Sinai								Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56	4	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-01	1	2						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200003
J	Hveem, K				Hveem, Kristian			HUNT Biobank-a unique resource for biomarker discovery and validation	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Hveem, Kristian] Norwegian Univ Sci & Technol, Trondheim, Norway	Norwegian University of Science & Technology (NTNU)			Hveem, Kristian/AFV-4683-2022						0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-16	12	12						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200018
J	Max, K				Max, Klaas			Extracellular small RNAs in human plasma and serum: clinical utility	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Max, Klaas] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA	Rockefeller University								Li K, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98942; Max KEA, 2018, P NATL ACAD SCI USA, V115, pE5334, DOI 10.1073/pnas.1714397115	2	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-07	6	6						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200009
J	Milosevic, V; Riganti, C				Milosevic, Vladan; Riganti, Chiara			Interleukin 1 beta (IL1 beta) and Interleukin 8 (IL8) as biomarkers and mediators of chemo-resistance in malignant pleural mesothelioma	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Milosevic, Vladan; Riganti, Chiara] Univ Turin, Turin, Italy	University of Turin									0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-11	9	9						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200013
J	Nost, T				Nost, Therese			DNA methylation and associated gene expression prior to lung cancer diagnosis: A study of pre-diagnostic blood samples from the Norwegian Women and Cancer Cohort	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Nost, Therese] Arctic Univ Norway, Tromso, Norway	UiT The Arctic University of Tromso			Nøst, Therese Haugdahl/AGZ-1100-2022	Nøst, Therese Haugdahl/0000-0001-6805-3094				Joehanes R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506; Pelosof L, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw295; Sandanger TM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34334-6	3	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-04	4	4						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200006
J	Robles, AI; Borset, M; Sundan, A; Sponaas, AM; Roe, OD				Robles, Ana I.; Borset, Magne; Sundan, Anders; Sponaas, Anne-Marit; Roe, Oluf Dimitri			Current and Future Clinical Biomarkers of Cancer: From diagnosis to immunotherapy-why is precision medicine so difficult?	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ									Borset, Magne/AAY-1713-2021		Norwegian University of Science and Technology (Norges Teknisk-Naturvitenskapelige Universitet, NTNU); HUNT (Helse-undersokelsen i Nord-Trondelag) research center; Norwegian Research Council; Immunological Society of Norway; Norwegian Society of Biochemistry; Norwegian Cancer Society; AstraZeneca; BMS; MSD; Amgen; Celgene; Pfizer; Roche; EISAI; Norwegian University of Science and Technology (NTNU)	Norwegian University of Science and Technology (Norges Teknisk-Naturvitenskapelige Universitet, NTNU); HUNT (Helse-undersokelsen i Nord-Trondelag) research center; Norwegian Research Council(Research Council of NorwayEuropean Commission); Immunological Society of Norway; Norwegian Society of Biochemistry; Norwegian Cancer Society(Norwegian Cancer Society); AstraZeneca(AstraZeneca); BMS(Bristol-Myers Squibb); MSD; Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Pfizer(Pfizer); Roche(Roche Holding); EISAI(Eisai Co Ltd); Norwegian University of Science and Technology (NTNU)	The symposium was sponsored by the Norwegian University of Science and Technology (Norges Teknisk-Naturvitenskapelige Universitet, NTNU), HUNT (Helse-undersokelsen i Nord-Trondelag) research center, the Norwegian Research Council and Immunological Society of Norway, Norwegian Society of Biochemistry, Norwegian Cancer Society and AstraZeneca, BMS, MSD, Amgen, Celgene, Pfizer, Roche and EISAI. All content was reviewed and approved by the authors and organizers, which held full responsibility for the abstract selections. Publication of the supplement was sponsored by Norwegian University of Science and Technology (NTNU).		0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S			1	1						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200002
J	Robles, AI				Robles, Ana I.			Lung cancer biomarkers: Beyond Genomics	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ			METHYLATION		[Robles, Ana I.] NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Greathouse KL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1501-6; Lissa D, 2018, LUNG CANCER, V122, P151, DOI 10.1016/j.lungcan.2018.05.021; Robles AI, 2017, LUNG CANCER, V107, P50, DOI 10.1016/j.lungcan.2016.06.003; Robles AI, 2015, J THORAC ONCOL, V10, P1037, DOI 10.1097/JTO.0000000000000560	4	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-12	9	10						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200014
J	Robles, AI				Robles, Ana I.			Why is precision medicine so difficult? Conclusions and thoughts	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Robles, Ana I.] NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Blum A, 2018, CELL, V173, P530, DOI 10.1016/j.cell.2018.03.059; Krokstad S, 2013, INT J EPIDEMIOL, V42, P968, DOI 10.1093/ije/dys095	2	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-17	12	12						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200019
J	Sulheim, E				Sulheim, Einar			Blood vessel function as a biomarker for susceptibility to nanomedicines	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Sulheim, Einar] Norwegian Univ Sci & Technol, Trondheim, Norway	Norwegian University of Science & Technology (NTNU)								Sulheim E, 2018, J CONTROL RELEASE, V279, P292, DOI 10.1016/j.jconrel.2018.04.026	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-14	10	11						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200016
J	Tessem, MB				Tessem, May-Britt			How to identify aggressive from indolent prostate cancer?	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Tessem, May-Britt] Norwegian Univ Sci & Technol, Trondheim, Norway	Norwegian University of Science & Technology (NTNU)					NATIONAL CANCER INSTITUTE [F31CA213627] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen MK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32549-1; Braadland PR, 2017, BRIT J CANCER, V117, P1656, DOI 10.1038/bjc.2017.346; Euceda LR, 2018, METHODS MOL BIOL, V1786, P237, DOI 10.1007/978-1-4939-7845-8_14	3	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-13	10	10						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200015
J	Tondell, A; Haug, M				Tondell, Anders; Haug, Markus			Expression and co-expression of checkpoint signaling receptors cluster of differentiation 39 (CD39) and programmed death 1 (PD-1) are highly elevated in intratumoral immune cells in non-small cell lung cancer	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Tondell, Anders; Haug, Markus] Norwegian Univ Sci & Technol, Trondheim, Norway; [Tondell, Anders; Haug, Markus] St Olavs Univ Hosp, Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)								Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-03	3	4						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200005
J	Tsimberidou, AM				Tsimberidou, Apostolia-Maria			Precision medicine: prognostic and predictive biomarkers Implementation of precision oncology: strategies to overcome challenges	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Tsimberidou, Apostolia-Maria] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [F31CA213627] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Fountzilas E, 2018, EXPERT REV CLIN PHAR, V11, P797, DOI 10.1080/17512433.2018.1504677; Tsimberidou Apostolia-Maria, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00002; Tsimberidou AM, 2017, CURR PROB CANCER, V41, P176, DOI 10.1016/j.currproblcancer.2017.02.002	3	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-08	6	7						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200010
J	Zenklusen, JC				Zenklusen, Jean Claude			Open access to human gene, proteomics and metabolomics data (TCGA); Escalating biomarker research or not?	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ					[Zenklusen, Jean Claude] NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [F31CA213627] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blum A, 2018, CELL, V173, P530, DOI 10.1016/j.cell.2018.03.059; Hutter C, 2018, CELL, V173, P283, DOI 10.1016/j.cell.2018.03.042	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-15	11	12						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200017
J	Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH				Saleem, Ahamed; Dutta, Jayeeta; Malegaonkar, Diptee; Rasheed, Farheena; Rasheed, Zeshaan; Rajendra, Rajeev; Marshall, Henderson; Luo, Minjie; Li, Honghua; Rubin, Eric H.			The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor (vol 23, pg 5293, 2004)	ONCOGENE			English	Correction									[Saleem, Ahamed; Dutta, Jayeeta; Malegaonkar, Diptee; Rasheed, Farheena; Rasheed, Zeshaan; Rajendra, Rajeev; Marshall, Henderson; Rubin, Eric H.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; [Luo, Minjie; Li, Honghua] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Canc Inst New Jersey, New Brunswick, NJ USA; [Rubin, Eric H.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08903 USA.; Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, New Brunswick, NJ 08903 USA.	ehrubin@umdnj.edu						Saleem A, 2004, ONCOGENE, V23, P5293, DOI 10.1038/sj.onc.1207700	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6322	6322		10.1038/s41388-019-0874-7	http://dx.doi.org/10.1038/s41388-019-0874-7			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31296957	Bronze			2022-12-17	WOS:000483919400007
J	Wagner, S; Vlachogiannis, G; Brandon, AD; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR				Wagner, Steve; Vlachogiannis, Georgios; Brandon, Alexis De Haven; Valenti, Melanie; Box, Gary; Jenkins, Liam; Mancusi, Caterina; Self, Annette; Manodoro, Floriana; Assiotis, Ioannis; Robinson, Penny; Chauhan, Ritika; Rust, Alistair G.; Matthews, Nik; Eason, Kate; Khan, Khurum; Starling, Naureen; Cunningham, David; Sadanandam, Anguraj; Isacke, Clare M.; Kirkin, Vladimir; Valeri, Nicola; Whittaker, Steven R.			Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer (vol 38, pg 1717, 2019)	ONCOGENE			English	Correction									[Wagner, Steve; Brandon, Alexis De Haven; Valenti, Melanie; Box, Gary; Mancusi, Caterina; Self, Annette; Kirkin, Vladimir; Whittaker, Steven R.] Inst Canc Res, Div Canc Therapeut, London, England; [Vlachogiannis, Georgios; Eason, Kate; Sadanandam, Anguraj; Valeri, Nicola] Inst Canc Res, Div Mol Pathol, London, England; [Jenkins, Liam; Isacke, Clare M.] Inst Canc Res, Breast Canc Now Res Ctr, London, England; [Manodoro, Floriana; Assiotis, Ioannis; Robinson, Penny; Chauhan, Ritika; Rust, Alistair G.; Matthews, Nik] Inst Canc Res, Tumour Profiling Unit, London, England; [Khan, Khurum; Starling, Naureen; Cunningham, David; Valeri, Nicola] Royal Marsden NHS Fdn Trust, Dept Med, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Whittaker, SR (corresponding author), Inst Canc Res, Div Canc Therapeut, London, England.	steven.whittaker@icr.ac.uk		Starling, Naureen/0000-0002-1496-6792; Isacke, Clare/0000-0002-9222-3345; Kirkin, Vladimir/0000-0002-8049-3663; Cunningham, David/0000-0001-5158-1069				Wagner S, 2019, ONCOGENE, V38, P1717, DOI 10.1038/s41388-018-0554-z	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5746	5746		10.1038/s41388-019-0835-1	http://dx.doi.org/10.1038/s41388-019-0835-1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31147600	hybrid, Green Published			2022-12-17	WOS:000474845100017
J	Karadedou, CT; Gomes, AR; Chen, J; Petkovic, M; Ho, KK; Zwolinska, AK; Feltes, A; Wong, SY; Chan, KYK; Cheung, YN; Tsang, JWH; Brosens, JJ; Khoo, US; Lam, EWF				Karadedou, C. T.; Gomes, A. R.; Chen, J.; Petkovic, M.; Ho, K. -K.; Zwolinska, A. K.; Feltes, A.; Wong, S. Y.; Chan, K. Y. K.; Cheung, Y. -N.; Tsang, J. W. H.; Brosens, J. J.; Khoo, U. -S.; Lam, E. W. -F.			FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer (vol 31, pg 1845, 2011)	ONCOGENE			English	Correction									[Karadedou, C. T.; Gomes, A. R.; Chen, J.; Petkovic, M.; Ho, K. -K.; Zwolinska, A. K.; Feltes, A.; Brosens, J. J.; Lam, E. W. -F.] Imperial Coll London, Canc Res UK Labs, Dept Surg & Canc, Hammersmith Hosp Campus, London, England; [Chen, J.; Wong, S. Y.; Chan, K. Y. K.; Cheung, Y. -N.; Khoo, U. -S.] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; [Tsang, J. W. H.] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China	Cancer Research UK; Imperial College London; University of Hong Kong; University of Hong Kong	Lam, EWF (corresponding author), Imperial Coll London, Canc Res UK Labs, Dept Surg & Canc, Hammersmith Hosp Campus, London, England.	eric.lam@imperial.ac.uk	Chan, Kelvin/HGA-3097-2022; Khoo, Ui Soon/C-4293-2009; Khoo, Ui Soon/C-1345-2014; Lam, Eric W-F/AAW-8566-2020	Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576				Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368	1	0	0	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5111	5112		10.1038/s41388-019-0770-1	http://dx.doi.org/10.1038/s41388-019-0770-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30867566	Bronze, Green Published			2022-12-17	WOS:000472145900018
J	Hernandez-Perez, S; Cabrera, E; Salido, E; Lim, M; Reid, L; Lakhani, SR; Khanna, KK; Saunus, JM; Freire, R				Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Lim, M.; Reid, L.; Lakhani, S. R.; Khanna, K. K.; Saunus, J. M.; Freire, R.			DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer (vol 36, pg 4802, 2017)	ONCOGENE			English	Correction									[Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, San Cristobal la Laguna, Spain; [Lim, M.; Reid, L.; Lakhani, S. R.; Saunus, J. M.] Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia; [Lim, M.; Reid, L.; Saunus, J. M.] QIMR Berghofer Med Res Inst, Herston, Qld, Australia; [Lakhani, S. R.] Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia; [Lakhani, S. R.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Khanna, K. K.] QIMR Berghofer Inst Med Res, Signal Transduct Lab, Brisbane, Qld, Australia	Universidad de la Laguna; University of Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; QIMR Berghofer Medical Research Institute	Freire, R (corresponding author), Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, San Cristobal la Laguna, Spain.; Saunus, JM (corresponding author), Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia.; Saunus, JM (corresponding author), QIMR Berghofer Med Res Inst, Herston, Qld, Australia.	j.saunus@uq.edu.au; rfreire@ull.edu.es	Cabrera, Elisa/GPX-3455-2022; Freire, Raimundo/Q-7660-2019; Salido, Eduardo/I-2232-2015	Freire, Raimundo/0000-0003-4473-8894; Salido, Eduardo/0000-0001-9599-9854	Instituto de Salud Carlos III [BA15/00092]; Spanish Ministry of Economy and Competitiveness/EU-ERDF [SAF2016-80626-R, SAF2013-49149-R, BFU2014-51672-REDC]; Fundacion CajaCanarias [AP2015/008]; Australian National Health and Medical Research (NHMRC program grant) [APP1017028]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Ministry of Economy and Competitiveness/EU-ERDF; Fundacion CajaCanarias; Australian National Health and Medical Research (NHMRC program grant)(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by grants from Instituto de Salud Carlos III (BA15/00092), Spanish Ministry of Economy and Competitiveness/EU-ERDF (SAF2016-80626-R, SAF2013-49149-R, BFU2014-51672-REDC), Fundacion CajaCanarias (AP2015/008) to RF, and the Australian National Health and Medical Research (NHMRC program grant to SRL and KKK (APP1017028).	Cabrera E, 2017, ONCOGENE, V36, P678, DOI 10.1038/onc.2016.239	1	0	0	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4886	4886		10.1038/s41388-019-0753-2	http://dx.doi.org/10.1038/s41388-019-0753-2			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	31068665	Bronze			2022-12-17	WOS:000471160500017
J	Zhu, SM; Tian, H; Niu, XD; Wang, J; Li, X; Jiang, N; Wen, SM; Chen, XR; Ren, SC; Xu, CL; Chang, CS; Flores-Morales, A; Shang, ZQ; Sun, YH; Niu, YJ				Zhu, Shimiao; Tian, Hao; Niu, Xiaodan; Wang, Jiang; Li, Xing; Jiang, Ning; Wen, Simeng; Chen, Xuanrong; Ren, Shancheng; Xu, Chuanliang; Chang, Chawnshang; Flores-Morales, Amilcar; Shang, Zhiqun; Sun, Yinghao; Niu, Yuanjie			Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer (vol 38, pg 4875, 2019)	ONCOGENE			English	Correction									[Zhu, Shimiao; Tian, Hao; Wang, Jiang; Li, Xing; Jiang, Ning; Wen, Simeng; Chen, Xuanrong; Shang, Zhiqun; Niu, Yuanjie] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China; [Niu, Xiaodan] Univ Minnesota, Minneapolis, MN 55455 USA; [Ren, Shancheng; Xu, Chuanliang; Sun, Yinghao] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China; [Chang, Chawnshang] Univ Rochester, Dept Pathol, Rochester, NY 14620 USA; [Flores-Morales, Amilcar] Univ Copenhagen, Dept Hlth Sci, Fac Hlth & Med Sci, DK-2200 Copenhagen, Denmark	Tianjin Medical University; University of Minnesota System; University of Minnesota Twin Cities; Naval Medical University; University of Rochester; University of Copenhagen	Shang, ZQ; Niu, YJ (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China.; Sun, YH (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.	zhiqun_shang@tmu.edu.cn; sunyh@medmail.com.cn; niuyuanjie9317@163.com		Wen, Simeng/0000-0001-7989-7700				Zhu SM, 2019, ONCOGENE, V38, P4875, DOI 10.1038/s41388-019-0750-5	1	0	0	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4885	4885		10.1038/s41388-019-0827-1	http://dx.doi.org/10.1038/s41388-019-0827-1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	31048775	Green Published, hybrid			2022-12-17	WOS:000471160500016
J	Zhang, T; Li, J; Yin, F; Lin, B; Wang, Z; Xu, J; Wang, H; Zuo, D; Wang, G; Hua, Y; Cai, Z				Zhang, T.; Li, J.; Yin, F.; Lin, B.; Wang, Z.; Xu, J.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.			Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3 (vol 36, pg 6627, 2017)	ONCOGENE			English	Correction									[Zhang, T.; Yin, F.; Wang, Z.; Hua, Y.; Cai, Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai, Peoples R China; [Zhang, T.; Yin, F.; Lin, B.; Wang, Z.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.] Shanghai Bone Tumor Inst, Shanghai, Peoples R China; [Li, J.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Inst Translat Med, Shanghai, Peoples R China; [Xu, J.] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, T; Hua, Y; Cai, Z (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai, Peoples R China.; Zhang, T; Hua, Y; Cai, Z (corresponding author), Shanghai Bone Tumor Inst, Shanghai, Peoples R China.	zhangtaoabc@2008.sina.com; hua_yingqi@163.com; czd856@vip.163.com						Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270	1	0	0	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4655	4656		10.1038/s41388-019-0738-1	http://dx.doi.org/10.1038/s41388-019-0738-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30770898	Bronze, Green Published			2022-12-17	WOS:000470240300015
J	Khan, I; Spencer-Smith, R; O'Bryan, JP				Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.			Targeting the alpha 4-alpha 5 dimerization interface of K-RAS inhibits tumor formation in vivo (vol 38, pg 2984, 2019)	ONCOGENE			English	Correction									[Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.] Univ Illinois, Canc Ctr, Dept Pharmacol, Chicago, IL 60612 USA; [Khan, Imran; Spencer-Smith, Russell; O'Bryan, John P.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA; [Khan, Imran; O'Bryan, John P.] Med Univ South Carolina, Hollings Canc Ctr, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Khan, Imran; O'Bryan, John P.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	O'Bryan, JP (corresponding author), Univ Illinois, Canc Ctr, Dept Pharmacol, Chicago, IL 60612 USA.; O'Bryan, JP (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.; O'Bryan, JP (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.; O'Bryan, JP (corresponding author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.	obryanjo@musc.edu		O'Bryan, John/0000-0001-5386-1080; Spencer-Smith, Russell/0000-0002-8865-0520				Khan I, 2019, ONCOGENE, V38, P2984, DOI 10.1038/s41388-018-0636-y	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4426	4426		10.1038/s41388-019-0720-y	http://dx.doi.org/10.1038/s41388-019-0720-y			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30710144	Bronze			2022-12-17	WOS:000469339100017
J	Yang, CY; Chang, PW; Hsu, WH; Chang, HC; Chen, CL; Lai, CC; Chiu, WT; Chen, HC				Yang, Cheng-Yi; Chang, Po-Wei; Hsu, Wen-Hsin; Chang, Hsuan-Chia; Chen, Chien-Lin; Lai, Chien-Chen; Chiu, Wen-Tai; Chen, Hong-Chen			Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration (vol 38, pg 4075, 2019)	ONCOGENE			English	Correction									[Yang, Cheng-Yi; Chang, Po-Wei; Chen, Chien-Lin] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Hsu, Wen-Hsin; Chen, Hong-Chen] Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan; [Chang, Hsuan-Chia; Chen, Hong-Chen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [Lai, Chien-Chen] Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan; [Chiu, Wen-Tai] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan	National Chung Hsing University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Chung Hsing University; National Cheng Kung University	Chen, HC (corresponding author), Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan.; Chen, HC (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan.; Lai, CC (corresponding author), Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan.; Chiu, WT (corresponding author), Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan.	lailai@dragon.nchu.edu.tw; wtchiu@mail.ncku.edu.tw; hcchen1029@ym.edu.tw	/AGZ-4617-2022	/0000-0002-7133-8266; Chiu, Wen-Tai/0000-0003-0310-0675				Yang CY, 2019, ONCOGENE, V38, P4075, DOI 10.1038/s41388-019-0705-x	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4197	4198		10.1038/s41388-019-0742-5	http://dx.doi.org/10.1038/s41388-019-0742-5			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30814683	Bronze, Green Published			2022-12-17	WOS:000468740200016
J	Hwang, MH; Cho, KH; Jeong, KJ; Park, YY; Kim, JM; Yu, SL; Park, CG; Mills, GB; Lee, HY				Hwang, M. H.; Cho, K. H.; Jeong, K. J.; Park, Y-Y; Kim, J. M.; Yu, S-L; Park, C. G.; Mills, G. B.; Lee, H. Y.			RCP induces Slug expression and cancer cell invasion by stabilizing beta 1 integrin (vol 36, pg 1102, 2017)	ONCOGENE			English	Correction									[Hwang, M. H.; Cho, K. H.; Yu, S-L; Park, C. G.; Lee, H. Y.] Konyang Univ, Dept Pharmacol, Coll Med, Daejeon, South Korea; [Hwang, M. H.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Jeong, K. J.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Park, Y-Y] Univ Ulsan, Dept Med, Coll Med, Asan Inst Life Sci,Asan Med Ctr, Seoul, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Reg Canc Ctr, Canc Res Inst, Daejeon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Daejeon, South Korea	Konyang University; Konyang University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Ulsan; Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Dept Pharmacol, Coll Med, Daejeon, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022	Mills, Gordon/0000-0002-0144-9614; KIM, JIN MAN/0000-0003-0905-9730				Hwang MH, 2017, ONCOGENE, V36, P1102, DOI 10.1038/onc.2016.277	1	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3970	3971		10.1038/s41388-019-0678-9	http://dx.doi.org/10.1038/s41388-019-0678-9			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30679788	Bronze			2022-12-17	WOS:000468035600015
J	Johnson, CE; Dunlop, EA; Seifan, S; McCann, HD; Hay, T; Parfitt, GJ; Jones, AT; Giles, PJ; Shen, MH; Sampson, JR; Errington, RJ; Davies, DM; Tee, AR				Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Hay, Trevor; Parfitt, Geraint J.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.			Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death (vol 37, pg 5913, 2019)	ONCOGENE			English	Correction									[Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.] Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales; [Hay, Trevor; Parfitt, Geraint J.] Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Davies, D. Mark] Singleton Hosp, Dept Oncol, South West Wales Canc Ctr, Swansea SA2 8QA, W Glam, Wales	Cardiff University; Cardiff University; Singleton Hospital	Tee, AR (corresponding author), Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk						Johnson CE, 2018, ONCOGENE, V37, P5913, DOI 10.1038/s41388-018-0381-2	1	0	0	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3102	3102		10.1038/s41388-018-0598-0	http://dx.doi.org/10.1038/s41388-018-0598-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30622341	Green Published, hybrid			2022-12-17	WOS:000465167600016
J	Karni-Schmidt, O; Friedler, A; Zupnick, A; McKinney, K; Mattia, M; Beckerman, R; Bouvet, P; Sheetz, M; Fersht, A; Prives, C				Karni-Schmidt, O.; Friedler, A.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Bouvet, P.; Sheetz, M.; Fersht, A.; Prives, C.			Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus (vol 26, pg 3878, 2007)	ONCOGENE			English	Correction									[Karni-Schmidt, O.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Sheetz, M.; Prives, C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Friedler, A.; Fersht, A.] MRC, Dept MRC CPE, Ctr Prot Engn, Cambridge, England; [Friedler, A.] Hebrew Univ Jerusalem, Dept Organ Chem, Jerusalem, Israel; [Bouvet, P.] Ecole Normale Super Lyon, Lab Biol Mol Cellule UMR 5161, 46 Allee Italie, F-69364 Lyon, France	Columbia University; University of Cambridge; Hebrew University of Jerusalem; Ecole Normale Superieure de Lyon (ENS de LYON)	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu	Fersht, Alan R/B-2189-2008; , Bouvet/AAC-8779-2020		Medical Research Council [MC_EX_G0901534] Funding Source: Medline; MRC [MC_EX_G0901534] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4901	4902		10.1038/s41388-018-0321-1	http://dx.doi.org/10.1038/s41388-018-0321-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	30068941	Bronze			2022-12-17	WOS:000443146000010
J	Cheng, Y; Ren, X; Yuan, Y; Shan, Y; Li, L; Chen, X; Zhang, L; Takahashi, Y; Yang, JW; Han, B; Liao, J; Li, Y; Harvey, H; Ryazanov, A; Robertson, GP; Wan, G; Liu, D; Chen, AF; Tao, Y; Yang, JM				Cheng, Y.; Ren, X.; Yuan, Y.; Shan, Y.; Li, L.; Chen, X.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Ryazanov, A.; Robertson, G. P.; Wan, G.; Liu, D.; Chen, A. F.; Tao, Y.; Yang, J-M			eEF-2 kinase is a critical regulator of Warbrug effect through controlling PP2A-A synthesis (vol 35, pg 6293, 2016)	ONCOGENE			English	Correction									[Cheng, Y.; Li, L.; Chen, X.] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Li, Y.; Robertson, G. P.; Wan, G.; Yang, J-M] Penn State Univ, Coll Med, Dept Pharmacol, Penn State Hershey Canc Inst, Hershey, PA 17033 USA; [Cheng, Y.; Ren, X.; Shan, Y.; Zhang, L.; Takahashi, Y.; Yang, J. W.; Han, B.; Liao, J.; Li, Y.; Harvey, H.; Robertson, G. P.; Wan, G.; Yang, J-M] Milton S Hershey Med Ctr, Hershey, PA 17033 USA; [Yuan, Y.; Liu, D.] Washington State Univ, Dept Pharmaceut Sci, Coll Pharm, Spokane, WA USA; [Han, B.] Penn State Univ, Coll Med, Dept Pathol, Penn State Hershey Canc Inst, Hershey, PA USA; [Liao, J.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Div Biostat & Bioinformat, Hershey, PA USA; [Harvey, H.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Med, Hershey, PA USA; [Ryazanov, A.] Rutgers State Univ, Dept Pharmacol, Robert wood Jonson Med Sch, Piscataway, NJ USA; [Chen, A. F.] Cent S Univ, Xiangya Hosp 3, Coll Pharm, Ctr Vasc & Translat Med, Changsha, Hunan, Peoples R China; [Tao, Y.] Cent S Univ, Canc Res Inst, Sch Basic Med, Changsha, Hunan, Peoples R China; [Tao, Y.] Cent S Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China	Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Washington State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Rutgers State University New Brunswick; Rutgers State University Medical Center; Central South University; Central South University; Central South University	Cheng, Y (corresponding author), Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China.; Cheng, Y (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Penn State Hershey Canc Inst, Hershey, PA 17033 USA.; Cheng, Y (corresponding author), Milton S Hershey Med Ctr, Hershey, PA 17033 USA.	chengyan0677@163.com; juy16@psu.edu						Cheng Y, 2016, ONCOGENE, V35, P6293, DOI 10.1038/onc.2016.166	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4633	4634		10.1038/s41388-018-0322-0	http://dx.doi.org/10.1038/s41388-018-0322-0			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29973686	Bronze			2022-12-17	WOS:000441736700011
J	Miller, G; Stebbing, J				Miller, G.; Stebbing, J.			Thirty years of Oncogene	ONCOGENE			English	Editorial Material							COLORECTAL-CANCER; EXPRESSION		[Miller, G.] NYU, Dept Surg, Sch Med, New York, NY 10016 USA; [Miller, G.] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; [Stebbing, J.] Imperial Coll, Dept Surg & Canc, London, England	New York University; New York University; Imperial College London	Miller, G (corresponding author), NYU, Dept Surg, Sch Med, New York, NY 10016 USA.; Miller, G (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.	George.Miller@nyumc.org		Stebbing, Justin/0000-0002-1117-6947	Department of Health [NIHR-RP-011-053] Funding Source: Medline	Department of Health		Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; FURTH ME, 1987, ONCOGENE, V1, P47; KAMATA T, 1987, ONCOGENE, V1, P37; MIYASHITA T, 1994, ONCOGENE, V9, P1799; RANDO RF, 1987, ONCOGENE, V1, P13; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; VANDEWOUDE GF, 1990, ONCOGENE, V5, P3; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397	9	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					553	554		10.1038/onc.2017.388	http://dx.doi.org/10.1038/onc.2017.388			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	29059165	Green Submitted, Bronze			2022-12-17	WOS:000423812200001
J	Chen, X; Bosques, L; Sung, P; Kupfer, GM				Chen, X.; Bosques, L.; Sung, P.; Kupfer, G. M.			A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage (vol 35, pg 22, 2016)	ONCOGENE			English	Correction															 [R01CA168635]		This work was supported by R01CA168635 (PS and GMK).	Chen X, 2016, ONCOGENE, V35, P22, DOI 10.1038/onc.2015.68	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5220	5220		10.1038/onc.2017.238	http://dx.doi.org/10.1038/onc.2017.238			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28671668	Bronze			2022-12-17	WOS:000409371100014
J	Jen, J; Lin, LL; Lo, FY; Chen, HT; Liao, SY; Tang, YA; Su, WC; Salgia, R; Hsu, CL; Huang, HC; Juan, HF; Wang, YC				Jen, J.; Lin, L-L; Lo, F-Y; Chen, H-T; Liao, S-Y; Tang, Y-A; Su, W-C; Salgia, R.; Hsu, C-L; Huang, H-C; Juan, H-F; Wang, Y-C			Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer (vol 35, pg 2357, 2016)	ONCOGENE			English	Correction													; Huang, Hsuan-Cheng/C-7266-2011	Jen, Jayu/0000-0002-0926-9984; Huang, Hsuan-Cheng/0000-0002-3386-0934				Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4526	4526		10.1038/onc.2017.77	http://dx.doi.org/10.1038/onc.2017.77			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368404	Green Published, hybrid			2022-12-17	WOS:000406806000015
J	Zhang, Q; Wei, T; Shim, K; Wright, K; Xu, K; Palka-Hamblin, HL; Jurkevich, A; Khare, S				Zhang, Q.; Wei, T.; Shim, K.; Wright, K.; Xu, K.; Palka-Hamblin, H. L.; Jurkevich, A.; Khare, S.			Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial-mesenchymal transition (vol 35, pg 3151, 2016)	ONCOGENE			English	Correction																		Zhang Q, 2016, ONCOGENE, V35, P3151, DOI 10.1038/onc.2015.365	1	0	0	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4088	4088		10.1038/onc.2017.56	http://dx.doi.org/10.1038/onc.2017.56			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288131	Green Published, hybrid			2022-12-17	WOS:000405379900015
J	Natsume, A; Kato, T; Kinjo, S; Enomoto, A; Toda, H; Shimato, S; Ohka, F; Motomura, K; Kondo, Y; Miyata, T; Takahashi, M; Wakabayashi, T				Natsume, A.; Kato, T.; Kinjo, S.; Enomoto, A.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Kondo, Y.; Miyata, T.; Takahashi, M.; Wakabayashi, T.			Girdin maintains the stemness of glioblastoma stem cells (vol 31, pg 2715, 2012)	ONCOGENE			English	Correction													Motomura, Kazuya/AAF-8776-2021; Ohka, Fumiharu/A-3420-2016; Enomoto, Atsushi/I-7272-2014; Natsume, Atsushi/I-7364-2014	Motomura, Kazuya/0000-0002-4376-1104; Enomoto, Atsushi/0000-0002-9206-6116; Natsume, Atsushi/0000-0002-9113-0470; Ohka, Fumiharu/0000-0002-5569-5626				Natsume A, 2012, ONCOGENE, V31, P2715, DOI 10.1038/onc.2011.466	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3796	3796		10.1038/onc.2017.17	http://dx.doi.org/10.1038/onc.2017.17			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28218901	Bronze			2022-12-17	WOS:000404349700015
J	Shen, J; Vakifahmetoglu, H; Stridh, H; Zhivotovsky, B; Wiman, KG				Shen, J.; Vakifahmetoglu, H.; Stridh, H.; Zhivotovsky, B.; Wiman, K. G.			RETRACTION: PRIMA-1(MET) induces mitochondrial apoptosis through activation of caspase-2 (Retraction of Vol 27, Pg 6571, 2008)	ONCOGENE			English	Retraction													Wiman, Klas/AAB-8399-2021; Zhivotovsky, Boris/A-4346-2014	Wiman, Klas/0000-0002-7113-524X; Zhivotovsky, Boris/0000-0002-2238-3482				Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249	1	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3650	3650		10.1038/onc.2017.9	http://dx.doi.org/10.1038/onc.2017.9			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28192401	Bronze			2022-12-17	WOS:000403878600015
J	D'Brot, A; Kurtz, P; Regan, E; Jakubowski, B; Abrams, JM				D'Brot, A.; Kurtz, P.; Regan, E.; Jakubowski, B.; Abrams, J. M.			A platform for interrogating cancer-associated p53 alleles (vol 36, pg 286, 2017)	ONCOGENE			English	Correction																		D'Brot A, 2017, ONCOGENE, V36, P286, DOI 10.1038/onc.2016.48	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					292	292		10.1038/onc.2016.190	http://dx.doi.org/10.1038/onc.2016.190			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27991923	Bronze			2022-12-17	WOS:000393938100014
J	Jiang, CC; Croft, A; Tseng, HY; Guo, ST; Jin, L; Hersey, P; Zhang, XD				Jiang, C. C.; Croft, A.; Tseng, H-Y; Guo, S. T.; Jin, L.; Hersey, P.; Zhang, X. D.			Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma (vol 33, pg 2577, 2013)	ONCOGENE			English	Correction													Tseng, Cindy Hsin-Yi/AAB-8958-2022	Tseng, Cindy Hsin-Yi/0000-0002-7499-7515				Jiang CC, 2014, ONCOGENE, V33, P2577, DOI 10.1038/onc.2013.237	1	0	0	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6044	6044		10.1038/onc.2016.144	http://dx.doi.org/10.1038/onc.2016.144			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27345411	Bronze			2022-12-17	WOS:000388509400012
J	Hoyos, JM; Ferraro, A; Sacchetti, S; Keller, S; De Martino, I; Borbone, E; Pallante, P; Fedele, M; Montanaro, D; Esposito, F; Cserjesi, P; Chiariotti, L; Troncone, G; Fusco, A				Hoyos, J. M.; Ferraro, A.; Sacchetti, S.; Keller, S.; De Martino, I.; Borbone, E.; Pallante, P.; Fedele, M.; Montanaro, D.; Esposito, F.; Cserjesi, P.; Chiariotti, L.; Troncone, G.; Fusco, A.			HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas (vol 28, pg 876, 2009)	ONCOGENE			English	Correction													Pallante, Pierlorenzo/AAX-8758-2020; Chiariotti, Lorenzo/AAC-5262-2022					Hoyos JM, 2009, ONCOGENE, V28, P876, DOI 10.1038/onc.2008.438	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5930	5930		10.1038/onc.2016.137	http://dx.doi.org/10.1038/onc.2016.137			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27345408	Bronze			2022-12-17	WOS:000387560800012
J	Oweida, A; Abdulkarim, B				Oweida, A.; Abdulkarim, B.			Ablative versus fractionated radiation therapy: a controversial role in cancer invasion and metastasis	ONCOGENE			English	Letter							LUNG-CANCER; CELLS; INVASIVENESS; EXPRESSION; SINGLE		[Oweida, A.; Abdulkarim, B.] McGill Univ, Div Radiat Oncol, Montreal, PQ, Canada	McGill University	Abdulkarim, B (corresponding author), McGill Univ, Div Radiat Oncol, Montreal, PQ, Canada.	bassam.abdulkarim@mcgill.ca	Oweida, Ayman/AAA-1029-2019	Oweida, Ayman/0000-0003-1256-4893				Chou CH, 2012, ONCOGENE, V31, P458, DOI 10.1038/onc.2011.240; Cui YH, 2015, ONCOGENE, V34, P5372, DOI 10.1038/onc.2014.466; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Horsman MR, 2006, ACTA ONCOL, V45, P876, DOI 10.1080/02841860600900068; Kang Y, 2006, CANCER SCI, V97, P996, DOI 10.1111/j.1349-7006.2006.00276.x; Oweida A, 2015, J THORAC ONCOL, V10, pS722; Oweida AJ, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-A66; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Yates B, 2007, EXP CELL RES, V313, P3718, DOI 10.1016/j.yexcr.2007.07.026	9	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5928	5929		10.1038/onc.2016.130	http://dx.doi.org/10.1038/onc.2016.130			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109097	Bronze			2022-12-17	WOS:000387560800011
J	Le Pera, I; Iuliano, R; Florio, T; Susini, C; Trapasso, F; Santoro, M; Chiariotti, L; Schettini, G; Viglietto, G; Fusco, A				Le Pera, I.; Iuliano, R.; Florio, T.; Susini, C.; Trapasso, F.; Santoro, M.; Chiariotti, L.; Schettini, G.; Viglietto, G.; Fusco, A.			The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (vol 25, pg 3187, 2016)	ONCOGENE			English	Correction													Chiariotti, Lorenzo/AAC-5262-2022; Viglietto, Giuseppe/AAC-2852-2019	Viglietto, Giuseppe/0000-0003-2327-7515				Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5456	5456		10.1038/onc.2016.138	http://dx.doi.org/10.1038/onc.2016.138			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27425594	Bronze			2022-12-17	WOS:000386677800011
J	Joly, AL; Deepti, A; Seignez, A; Goloudina, A; Hebrard, S; Schmitt, E; Richaud, S; Fourmaux, E; Hammann, A; Collura, A; Svrcek, M; Jego, G; Robinet, E; Solary, E; Demidov, O; Kohli, E; Garrido, C				Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Collura, A.; Svrcek, M.; Jego, G.; Robinet, E.; Solary, E.; Demidov, O.; Kohli, E.; Garrido, C.			The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development (vol 35, pg 2842, 2016)	ONCOGENE			English	Correction									[Joly, A-L] INSERM, UMR 866, Equipe Labellisee, Ligue Natl Canc, Dijon, France; [Joly, A-L] Lab Excellence LipSTIC, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Joly, AL (corresponding author), INSERM, UMR 866, Equipe Labellisee, Ligue Natl Canc, Dijon, France.; Joly, AL (corresponding author), Lab Excellence LipSTIC, Dijon, France.		Garrido, Carolina/GWM-5557-2022; Demidov, Oleg/AAC-4462-2021; Garrido, carmen/G-1633-2018; jego, gaetan/N-7226-2018	Demidov, Oleg/0000-0003-4323-7174; Garrido, carmen/0000-0003-1368-1493; jego, gaetan/0000-0003-0376-9299				Joly AL, 2016, ONCOGENE, V35, P2842, DOI 10.1038/onc.2015.242	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22												1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT					2022-12-17	WOS:000377473700016
J	Marchesini, M; Matocci, R; Tasselli, L; Cambiaghi, V; Orleth, A; Furia, L; Marinelli, C; Lombardi, S; Sammarelli, G; Aversa, F; Minucci, S; Faretta, M; Pelicci, PG; Grignani, F				Marchesini, M.; Matocci, R.; Tasselli, L.; Cambiaghi, V.; Orleth, A.; Furia, L.; Marinelli, C.; Lombardi, S.; Sammarelli, G.; Aversa, F.; Minucci, S.; Faretta, M.; Pelicci, P. G.; Grignani, F.			PML is required for telomere stability in non-neoplastic human cells (vol 35, pg 1811, 2016)	ONCOGENE			English	Correction													Faretta, Mario/H-8946-2012; Grignani, Francesco/AAC-2565-2022; Tasselli, Luisa/AAM-6781-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Marchesini, Matteo/AAC-4629-2022	Faretta, Mario/0000-0003-1678-5781; Tasselli, Luisa/0000-0003-3349-1371; 				Marchesini M, 2016, ONCOGENE, V35, P1811, DOI 10.1038/onc.2015.246	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1876	1876		10.1038/onc.2015.312	http://dx.doi.org/10.1038/onc.2015.312			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	27052595	Green Published, Bronze			2022-12-17	WOS:000373610400013
J	Gelles, JD; Elkholi, R; Serasinghe, MN; Luna-Vargas, MPA; Chipuk, JE				Gelles, J. D.; Elkholi, R.; Serasinghe, M. N.; Luna-Vargas, M. P. A.; Chipuk, J. E.			From zero to sixty: cell death signaling in the city that never sleeps	ONCOGENE			English	Article									[Gelles, J. D.; Elkholi, R.; Serasinghe, M. N.; Luna-Vargas, M. P. A.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Gelles, J. D.; Elkholi, R.; Serasinghe, M. N.; Luna-Vargas, M. P. A.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Gelles, J. D.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA; [Gelles, J. D.; Elkholi, R.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA; [Serasinghe, M. N.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.; Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, New York, NY 10029 USA.; Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.; Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA.	jerry.chipuk@mssm.edu		Chipuk, Jerry Edward/0000-0002-1337-842X	Oncogene; Cell Death & Differentiation; FEBS Journal; 3i-Intelligent Imaging Innovations; Faculty of 1000; Nature Publishing Group; Icahn School of Medicine at Mount Sinai; Tisch Cancer Institute of Mount Sinai; St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE [R01CA206005, R01CA157740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F31AA024681] Funding Source: NIH RePORTER	Oncogene; Cell Death & Differentiation; FEBS Journal; 3i-Intelligent Imaging Innovations; Faculty of 1000; Nature Publishing Group; Icahn School of Medicine at Mount Sinai; Tisch Cancer Institute of Mount Sinai; St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We would like to thank the generous sponsors of the conference: Oncogene, Cell Death & Differentiation, FEBS Journal, 3i-Intelligent Imaging Innovations, Faculty of 1000 and the Nature Publishing Group; research institutions including The Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute of Mount Sinai and St Jude Children's Research Hospital. In addition, this conference would not have been possible without the support of Drs Steven Burakoff and Ramon Parsons; the administrative team of Diana Cintron, Donna Chiodi and Evelina Berman in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, New York, NY, USA; Rona and Maggie Green; Usman Hameedi, Lauren Zhao and the organizing committee: Drs Lisa Bouchier-Hayes (Baylor College of Medicine, Houston, TX, USA), Jennifer Martinez (NIH/NIEHS, Bethesda, MD, USA), Gavin McStay (New York Institute of Technology, New York, NY, USA), Andrew Oberst (University of Washington, Seattle, WA, USA), and Stephen Tait (University of Glasgow/The Beatson Institute for Cancer Research, Glasgow, UK).		0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1457	1460		10.1038/onc.2015.194	http://dx.doi.org/10.1038/onc.2015.194			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26148239	Green Accepted			2022-12-17	WOS:000372196400011
J	Vetter, G; Saumet, A; Moes, M; Vallar, L; Le Bechec, A; Laurini, C; Sabbah, M; Arar, K; Theillet, C; Lecellier, CH; Friederich, E				Vetter, G.; Saumet, A.; Moes, M.; Vallar, L.; Le Bechec, A.; Laurini, C.; Sabbah, M.; Arar, K.; Theillet, C.; Lecellier, C-H; Friederich, E.			RETRACTION: miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers (Retraction of vol 29, pg 4436, 2010)	ONCOGENE			English	Retraction													Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Vallar, Laurent/0000-0002-4404-1010				Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181	1	0	0	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					670	670		10.1038/onc.2015.265	http://dx.doi.org/10.1038/onc.2015.265			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	32667144	Green Published, Bronze			2022-12-17	WOS:000369548800014
J	Pardo, OE				Pardo, O. E.			Meningioma dissemination and growth: a role for microRNAs	ONCOGENE			English	Editorial Material							MYOSIN; PROLIFERATION; MIGRATION		Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England	Imperial College London	Pardo, OE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England.	o.pardo@imperial.ac.uk	Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435				Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Gupta V, 2013, RARE TUMORS, V5, P192, DOI 10.4081/rt.2013.e59; Kerber ML, 2011, J CELL SCI, V124, P3733, DOI 10.1242/jcs.023549; Kliese N, 2013, ONCOGENE, V32, P4712, DOI 10.1038/onc.2012.468; Lanfranchi M, 2013, CLIN NUCL MED, V38, P668, DOI 10.1097/RLU.0b013e31829962ac; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Shi L, 2012, J NEURO-ONCOL, V110, P155, DOI 10.1007/s11060-012-0951-z; Zhi F, 2013, INT J CANCER, V132, P128, DOI 10.1002/ijc.27658	9	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1743	1744		10.1038/onc.2014.263	http://dx.doi.org/10.1038/onc.2014.263			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	25838054	Bronze			2022-12-17	WOS:000352158000001
J	Pardo, OE; Arcaro, A; Salerno, G; Tetley, TD; Valovka, T; Gout, I; Seckl, MJ				Pardo, O. E.; Arcaro, A.; Salerno, G.; Tetley, T. D.; Valovka, T.; Gout, I.; Seckl, M. J.			Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells (vol 20, pg 7658, 2014)	ONCOGENE			English	Correction													Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435				Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5740	5740		10.1038/onc.2014.369	http://dx.doi.org/10.1038/onc.2014.369			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB		Bronze			2022-12-17	WOS:000346089300009
J	Lu, D; Han, C; Wu, T				Lu, D.; Han, C.; Wu, T.			15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE(2)/PPAR gamma-mediated activation of p21(WAF1/Cip1) (vol 33, pg 1101, 2014)	ONCOGENE			English	Correction																		Lu D, 2014, ONCOGENE, V33, P1101, DOI 10.1038/onc.2013.69	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4966	4966		10.1038/onc.2014.288	http://dx.doi.org/10.1038/onc.2014.288			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA		Bronze			2022-12-17	WOS:000343767900010
J	Shimazu, T; Komatsu, Y; Nakayama, KI; Fukazawa, H; Horinouchi, S; Yoshida, M				Shimazu, T.; Komatsu, Y.; Nakayama, K. I.; Fukazawa, H.; Horinouchi, S.; Yoshida, M.			Regulation of SV40 large T-antigen stability by reversible acetylation (vol 25, pg 7391, 2006)	ONCOGENE			English	Correction													SHIMAZU, Tadahiro/ABC-3950-2020					Shimazu T, 2006, ONCOGENE, V25, P7391, DOI 10.1038/sj.onc.1209731	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3886	3886		10.1038/onc.2014.176	http://dx.doi.org/10.1038/onc.2014.176			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU		Bronze			2022-12-17	WOS:000339394100015
J	Maekawa, T; Sano, Y; Shinagawa, T; Rahman, Z; Sakuma, T; Nomura, S; Licht, JD; Ishii, S				Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Sakuma, T.; Nomura, S.; Licht, J. D.; Ishii, S.			ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors (vol 27, pg 1045, 2008)	ONCOGENE			English	Correction													Licht, Jonathan/AAL-9184-2020	Licht, Jonathan/0000-0002-3942-1369				Maekawa T, 2008, ONCOGENE, V27, P1045, DOI 10.1038/sj.onc.1210727	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3618	3618		10.1038/onc.2014.140	http://dx.doi.org/10.1038/onc.2014.140			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK		Bronze			2022-12-17	WOS:000338941100014
J	Suzuki, M; Toyooka, S; Shivapurkar, N; Shigematsu, H; Miyajima, K; Takahashi, T; Stastny, V; Zern, AL; Fujisawa, T; Pass, HI; Carbone, M; Gazdar, AF				Suzuki, M.; Toyooka, S.; Shivapurkar, N.; Shigematsu, H.; Miyajima, K.; Takahashi, T.; Stastny, V.; Zern, A. L.; Fujisawa, T.; Pass, H. I.; Carbone, M.; Gazdar, A. F.			Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection Retraction of (vol 24, pg 1302, 2005)	ONCOGENE			English	Correction																		Suzuki M, 2005, ONCOGENE, V24, P1302, DOI 10.1038/sj.onc.1208263	1	0	0	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2814	2814		10.1038/onc.2014.100	http://dx.doi.org/10.1038/onc.2014.100			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH		Bronze			2022-12-17	WOS:000337231700015
J	Terrinoni, A; Pagani, IS; Zucchi, I; Chiaravalli, AM; Serra, V; Rovera, F; Sirchia, S; Dionigi, G; Miozzo, M; Frattini, A; Ferrari, A; Capella, C; Pasquali, F; Lo Curto, F; Albertini, A; Melino, G; Porta, G				Terrinoni, A.; Pagani, I. S.; Zucchi, I.; Chiaravalli, A. M.; Serra, V.; Rovera, F.; Sirchia, S.; Dionigi, G.; Miozzo, M.; Frattini, A.; Ferrari, A.; Capella, C.; Pasquali, F.; Lo Curto, F.; Albertini, A.; Melino, G.; Porta, G.			OTX1 expression in breast cancer is regulated by p53 (vol 30, 3096, 2011)	ONCOGENE			English	Correction													Dionigi, Gianlorenzo/R-4381-2017; CHIARAVALLI, Anna Maria/AAC-2679-2022; Chiaravalli, Anna Maria/AAC-4135-2022; Sirchia, Silvia/AAB-2620-2019; Miozzo, Monica Rosa/AAC-6401-2022; TERRINONI, Alessandro/J-1533-2012	Dionigi, Gianlorenzo/0000-0003-0864-6087; CHIARAVALLI, Anna Maria/0000-0002-3924-2117; Miozzo, Monica Rosa/0000-0002-6523-4575; TERRINONI, Alessandro/0000-0002-7442-2252				Terrinoni A, 2011, ONCOGENE, V30, P3096, DOI 10.1038/onc.2011.31	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1340	1340		10.1038/onc.2013.572	http://dx.doi.org/10.1038/onc.2013.572			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI		Bronze			2022-12-17	WOS:000332631100015
J	Wada, O; Oishi, H; Takada, I; Yanagisawa, J; Yano, T; Kato, S				Wada, O.; Oishi, H.; Takada, I.; Yanagisawa, J.; Yano, T.; Kato, S.			BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220 (Retraction of vol 23, pg 6000, 2014)	ONCOGENE			English	Correction													Oishi, Hajime/GRX-5428-2022					Wada O, 2004, ONCOGENE, V23, P6000, DOI 10.1038/sj.onc.1207786	1	0	0	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					804	804		10.1038/onc.2013.526	http://dx.doi.org/10.1038/onc.2013.526			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL		Bronze			2022-12-17	WOS:000331129200014
J	Hromas, R; Williamson, EA; Fnu, S; Lee, YJ; Park, SJ; Beck, BD; You, JS; Leitao, A; Nickoloff, JA; Lee, SH				Hromas, R.; Williamson, E. A.; Fnu, S.; Lee, Y-J; Park, S-J; Beck, B. D.; You, J-S; Leitao, A.; Nickoloff, J. A.; Lee, S-H			Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart (vol 31, pg 4245, 2012)	ONCOGENE			English	Correction													Leitao, Andrei/B-7942-2012	Leitao, Andrei/0000-0002-6601-6609				Hromas R, 2012, ONCOGENE, V31, P4245, DOI 10.1038/onc.2011.586	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					536	536		10.1038/onc.2013.510	http://dx.doi.org/10.1038/onc.2013.510			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX		Bronze			2022-12-17	WOS:000330214600015
J	Shaw, JA; Graham, TA; Stebbing, J				Shaw, J. A.; Graham, T. A.; Stebbing, J.			Genomic instability in pre-neoplastic colonic lesions	ONCOGENE			English	Editorial Material							NONPOLYPOSIS COLORECTAL-CANCER; GENETIC INSTABILITY; HMLH1 PROMOTER; HYPERMETHYLATION; PROGRESSION; HISTORY	Genomic instability is a characteristic of most cancers and it is argued that genomic instability is a driving force for tumorigenesis. Data herein demonstrate that genomic instability, as evidenced by microsatellite instability (MSI) and promoter methylation of DNA mismatch repair genes, is common in individual glands of pre-malignant colorectal lesions and raises interesting questions about the role of MSI in the development of colorectal carcinoma.	[Shaw, J. A.] Leicester Royal Infirm, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Graham, T. A.] Univ Calif San Francisco, Dept Surg, Helen Diller Family Comprehens Canc Ctr, Ctr Evolut & Canc, San Francisco, CA USA; [Stebbing, J.] Imperial Coll Sch Med, Div Canc, London W12 0NN, England	University of Leicester; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Imperial College London	Stebbing, J (corresponding author), Imperial Coll Sch Med, Div Canc, Hammersmith Hosp Campus, London W12 0NN, England.	j.stebbing@imperial.ac.uk		Stebbing, Justin/0000-0002-1117-6947; Shaw, Jacqui/0000-0003-4227-503X	Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Cancer Research UK [13462] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); Department of Health		Beggs AD, 2013, ONCOGENE, V32, P5333, DOI 10.1038/onc.2012.584; Bodmer W, 2008, CANCER RES, V68, P3558, DOI 10.1158/0008-5472.CAN-07-6544; Cunningham JM, 1998, CANCER RES, V58, P3455; Datta RS, 2013, EVOL APPL, V6, P20, DOI 10.1111/eva.12024; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; KIM HG, 1994, AM J PATHOL, V145, P148; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lynch HT, 1999, J MED GENET, V36, P801; Maley CC, 2004, CANCER RES, V64, P7629, DOI 10.1158/0008-5472.CAN-04-1738; Nakagawa H, 2001, CANCER RES, V61, P6991; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193	14	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5331	5332		10.1038/onc.2013.21	http://dx.doi.org/10.1038/onc.2013.21			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23396367	Green Published			2022-12-17	WOS:000326922400002
J	Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F				Agirre, X.; Roman-Gomez, J.; Jimenez-Velasco, A.; Garate, L.; Montiel-Duarte, C.; Navarro, G.; Vazquez, I.; Zalacain, M.; Calasanz, M. J.; Heiniger, A.; Torres, A.; Minna, J. D.; Prosper, F.			ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia (vol 25, pg 1862, 2006)	ONCOGENE			English	Correction													Calasanz, MJ/R-5813-2016; Montiel-Duarte, Cristina/AAB-3758-2019; Agirre, Xabier/ABE-4110-2020; Prosper, Felipe/H-6859-2017	Calasanz, MJ/0000-0002-0374-3008; Montiel-Duarte, Cristina/0000-0002-9144-8809; Prosper, Felipe/0000-0001-6115-8790				Agirre X, 2006, ONCOGENE, V25, P1862, DOI 10.1038/sj.onc.1209236	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					803	803		10.1038/onc.2012.593	http://dx.doi.org/10.1038/onc.2012.593			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF		Bronze			2022-12-17	WOS:000315746700014
J	Roman-Gomez, J; Jimenez-Velasco, A; Agirre, X; Cervantes, F; Sanchez, J; Garate, L; Barrios, M; Castillejo, JA; Navarro, G; Colomer, D; Prosper, F; Heiniger, A; Torres, A				Roman-Gomez, J.; Jimenez-Velasco, A.; Agirre, X.; Cervantes, F.; Sanchez, J.; Garate, L.; Barrios, M.; Castillejo, J. A.; Navarro, G.; Colomer, D.; Prosper, F.; Heiniger, A.; Torres, A.			Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (Retraction of vol 24, pg 7213, 2005)	ONCOGENE			English	Correction													COLOMER, DOLORS/ABG-6894-2020; Prosper, Felipe/H-6859-2017; Agirre, Xabier/ABE-4110-2020	Prosper, Felipe/0000-0001-6115-8790; COLOMER, DOLORS/0000-0001-7486-8484				Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866	1	0	0	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					804	804		10.1038/onc.2012.592	http://dx.doi.org/10.1038/onc.2012.592			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF		Bronze			2022-12-17	WOS:000315746700015
J	Massard, C; Zermati, Y; Pauleau, AL; Larochette, N; Metivier, D; Sabatier, L; Kroemer, G; Soria, JC				Massard, C.; Zermati, Y.; Pauleau, A-L; Larochette, N.; Metivier, D.; Sabatier, L.; Kroemer, G.; Soria, J-C			hTERT: a novel endogenous inhibitor of the mitochonthial cell death pathway (vol 25, pg 4505, 2006)	ONCOGENE			English	Correction													LAROCHETTE, Nathanael/R-4298-2017; Soria, Jean-Charles/F-3619-2014; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405				Massard C, 2006, ONCOGENE, V25, P4505, DOI 10.1038/sj.onc.1209487	1	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					536	536		10.1038/onc.2012.568	http://dx.doi.org/10.1038/onc.2012.568			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR					2022-12-17	WOS:000315551300014
J	Green, D				Green, D.			Oncogenesis-our little sister	ONCOGENE			English	Editorial Material									St Jude Childrens Hosp, Memphis, TN USA	St Jude Children's Research Hospital	Green, D (corresponding author), St Jude Childrens Hosp, MS 351, Memphis, TN USA.	douglas.green@stjude.org							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1341	1341		10.1038/onc.2012.35	http://dx.doi.org/10.1038/onc.2012.35			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL		Bronze			2022-12-17	WOS:000301780000001
J	Keith, WN; Lafferty-Whyte, K; Cairney, CJ; Zaffaroni, N; Bilsland, A				Keith, W. N.; Lafferty-Whyte, K.; Cairney, C. J.; Zaffaroni, N.; Bilsland, A.			Response to 'Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms'	ONCOGENE			English	Letter							REVEALS		[Keith, W. N.; Lafferty-Whyte, K.; Cairney, C. J.; Bilsland, A.] Univ Glasgow, Inst Canc Sci, Canc Res UK Beatson Labs, Glasgow, Lanark, Scotland; [Zaffaroni, N.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Milan, Italy	Beatson Institute; University of Glasgow; Fondazione IRCCS Istituto Nazionale Tumori Milan	Keith, WN (corresponding author), Univ Glasgow, Inst Canc Sci, Canc Res UK Beatson Labs, Glasgow, Lanark, Scotland.	nicol.keith@glasgow.ac.uk	Zaffaroni, Nadia/J-8178-2016; Keith, Nicol/D-3325-2009	Zaffaroni, Nadia/0000-0002-4669-0890; Keith, Nicol/0000-0001-7862-3580				Costa A, 2006, CANCER RES, V66, P8918, DOI 10.1158/0008-5472.CAN-06-0273; Johnson JE, 2007, CANCER RES, V67, P9221, DOI 10.1158/0008-5472.CAN-07-1133; Johnson JE, 2005, CLIN CANCER RES, V11, P5347, DOI 10.1158/1078-0432.CCR-05-0684; Lafferty-Whyte K, 2009, ONCOGENE, V28, P3765, DOI 10.1038/onc.2009.238; Lafferty-Whyte K, 2010, NEOPLASIA, V12, P405, DOI 10.1593/neo.10180	5	0	0	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	2					267	268		10.1038/onc.2011.374	http://dx.doi.org/10.1038/onc.2011.374			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN					2022-12-17	WOS:000299307400012
J	Zhang, B; Chambers, KJ; Leprince, D; Faller, DV; Wang, S				Zhang, B.; Chambers, K. J.; Leprince, D.; Faller, D. V.; Wang, S.			Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control (Retraction of vol 28, pg 651, 2009)	ONCOGENE			English	Correction																		ZHANG B, 2009, ONCOGENE, V30, P4374, DOI DOI 10.1038/0NC.2008.419	1	0	0	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4374	4374		10.1038/onc.2011.388	http://dx.doi.org/10.1038/onc.2011.388			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP		Bronze, Green Accepted			2022-12-17	WOS:000296356400009
J	Nakahata, S; Yamazaki, S; Nakauchi, H; Morishita, K				Nakahata, S.; Yamazaki, S.; Nakauchi, H.; Morishita, K.			Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta 1-mediated growth suppression in adult T-cell leukemia/lymphoma (vol 29, pg 4157, 2011)	ONCOGENE			English	Correction																		Nakahata S, 2010, ONCOGENE, V29, P4157, DOI 10.1038/onc.2010.172	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2900	2900		10.1038/onc.2011.158	http://dx.doi.org/10.1038/onc.2011.158			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV		Bronze			2022-12-17	WOS:000291977800009
J	Qiuping, Z; Jie, X; Youxin, J; Qun, W; Wei, J; Chun, L; Jin, W; Yan, L; Chunsong, H; Mingzhen, Y; Qingping, G; Qun, L; Kejian, Z; Zhimin, S; Junyan, L; Jinquan, T				Qiuping, Z.; Jie, X.; Youxin, J.; Qun, W.; Wei, J.; Chun, L.; Jin, W.; Yan, L.; Chunsong, H.; Mingzhen, Y.; Qingping, G.; Qun, L.; Kejian, Z.; Zhimin, S.; Junyan, L.; Jinquan, T.			Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+) CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia (Retraction of vol 24, pg 573, 2005)	ONCOGENE			English	Correction																		Qiuping Zhang, 2005, Oncogene, V24, P573, DOI 10.1038/sj.onc.1208184	1	0	0	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2798	2798		10.1038/onc.2011.67	http://dx.doi.org/10.1038/onc.2011.67			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB		Bronze			2022-12-17	WOS:000291678500011
J	Bender, TP; Gonda, TJ; Frampton, J; Ness, SA; Ramsay, RG				Bender, T. P.; Gonda, T. J.; Frampton, J.; Ness, S. A.; Ramsay, R. G.			Professor Alan M Gewirtz (1949-2010) OBITUARY	ONCOGENE			English	Biographical-Item									[Bender, T. P.] Univ Virginia, Sch Med, Dept Microbiol, Ctr Canc, Charlottesville, VA 22908 USA; [Bender, T. P.] Univ Virginia, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; [Gonda, T. J.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia; [Frampton, J.] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Ness, S. A.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA; [Ness, S. A.] Dept Mol Genet & Microbiol, Albuquerque, NM USA; [Ramsay, R. G.] Univ Melbourne, Dept Pathol, Peter MacCallum Canc Ctr, Parkville, Vic 3052, Australia	University of Virginia; University of Virginia; University of Queensland; University of Birmingham; University of New Mexico; Peter Maccallum Cancer Center; University of Melbourne	Bender, TP (corresponding author), Univ Virginia, Sch Med, Dept Microbiol, Ctr Canc, Charlottesville, VA 22908 USA.	tpb3e@Virginia.edu; rob.ramsay@petermac.org	Ramsay, Robert G/C-3291-2015; Ness, Scott/AAV-4009-2020	Ramsay, Robert G/0000-0001-5003-0433; Ness, Scott/0000-0001-6965-8909					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2187	2187		10.1038/onc.2011.78	http://dx.doi.org/10.1038/onc.2011.78			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD		Bronze			2022-12-17	WOS:000290514600001
J	Hassan, M; Alaoui, A; Feyen, O; Mirmohammadsadegh, A; Essmann, F; Tannapfel, A; Gulbins, E; Schulze-Osthoff, K; Hengge, UR				Hassan, M.; Alaoui, A.; Feyen, O.; Mirmohammadsadegh, A.; Essmann, F.; Tannapfel, A.; Gulbins, E.; Schulze-Osthoff, K.; Hengge, U. R.			The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways (vol 27, pg 4557, 2008)	ONCOGENE			English	Correction													Gulbins, Erich/L-6989-2014; Essmann, Frank/ABG-7409-2020	Gulbins, Erich/0000-0002-3117-1342; Essmann, Frank/0000-0003-4369-8456				Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	17					2086	2086		10.1038/onc.2011.64	http://dx.doi.org/10.1038/onc.2011.64			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL		Bronze			2022-12-17	WOS:000289977400012
J	Mishra, PJ; Ha, L; Rieker, J; Sviderskaya, EV; Bennett, DC; Oberst, MD; Kelly, K; Merlino, G				Mishra, P. J.; Ha, L.; Rieker, J.; Sviderskaya, E. V.; Bennett, D. C.; Oberst, M. D.; Kelly, K.; Merlino, G.			Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation (vol 29, pg 2449, 2010)	ONCOGENE			English	Correction																		Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1850	1850		10.1038/onc.2011.65	http://dx.doi.org/10.1038/onc.2011.65			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM		Bronze			2022-12-17	WOS:000289512200012
J	Cao, XX; Liu, XP				Cao, X-X; Liu, X-P			Response to 'Evidence for a pro-apoptotic function of RACK1 in human breast cancer'	ONCOGENE			English	Letter							CARCINOMA; PREDICTOR		[Cao, X-X; Liu, X-P] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200433, Peoples R China	Fudan University	Cao, XX (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200433, Peoples R China.	xpliu1228@fudan.edu.cn	Cao, Xixi/L-6794-2014					Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120; Cao XX, 2011, BREAST CANCER RES TR, V126, P555, DOI 10.1007/s10549-010-0955-3; CAO XX, 2009, BREAST CANC RES TREA, DOI DOI 10.1007/S10549-1009-0657-X; Wang Z, 2008, MOL CELL PROTEOMICS, V7, P1639, DOI 10.1074/mcp.M700520-MCP200; Wang Z, 2009, EUR J CANCER, V45, P490, DOI 10.1016/j.ejca.2008.11.012	5	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5652	5652		10.1038/onc.2010.293	http://dx.doi.org/10.1038/onc.2010.293			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX					2022-12-17	WOS:000282946900012
J	Yamagata, H; Shimizu, S; Nishida, Y; Watanabe, Y; Craigen, WJ; Tsujimoto, Y				Yamagata, H.; Shimizu, S.; Nishida, Y.; Watanabe, Y.; Craigen, W. J.; Tsujimoto, Y.			Requirement of voltage-dependent anion channel 2 for pro-apoptotic activity of Bax (vol 28, pg 3563, 2009)	ONCOGENE			English	Correction																		Yamagata H, 2009, ONCOGENE, V28, P3563, DOI 10.1038/onc.2009.213	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2892	2892		10.1038/onc.2010.98	http://dx.doi.org/10.1038/onc.2010.98			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW		Bronze			2022-12-17	WOS:000277591900014
J	Hall, B				Hall, B.			Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells Response to Sehgal	ONCOGENE			English	Letter							CARCINOMA CELLS; GROWTH-FACTOR; METASTASIS; TRANSITION; SEPARATION; EXPRESSION; MIGRATION; PHENOTYPE; MANNER; RATES		Janssen Pharmaceut, Oncol Biomarkers, B-2340 Beerse, Belgium	Johnson & Johnson; Janssen Pharmaceuticals	Hall, B (corresponding author), Janssen Pharmaceut, Oncol Biomarkers, B-2340 Beerse, Belgium.	bhall3@its.jnj.com						Badache A, 2001, CANCER RES, V61, P383; GREENBURG G, 1986, DEV BIOL, V115, P363, DOI 10.1016/0012-1606(86)90256-3; GREENBURG G, 1988, DEVELOPMENT, V102, P605; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com; Sasser AK, 2007, CANCER LETT, V254, P255, DOI 10.1016/j.canlet.2007.03.012; SEHGAL PB, 1991, EXP SUPPL, V59, P178; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; TAMM I, 1991, CYTOKINE, V3, P212, DOI 10.1016/1043-4666(91)90019-A; TAMM I, 1994, P NATL ACAD SCI USA, V91, P3329, DOI 10.1073/pnas.91.8.3329; TAMM I, 1994, P NATL ACAD SCI USA, V91, P4338, DOI 10.1073/pnas.91.10.4338; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TAMM I, 1998, MOL ASPECTS CANC ITS, P89; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	19	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2601	2603		10.1038/onc.2010.45	http://dx.doi.org/10.1038/onc.2010.45			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB					2022-12-17	WOS:000277169400017
J	Li, R				Li, R.			Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells Response to Sehgal	ONCOGENE			English	Letter									Univ Texas San Antonio, Inst Biotechnol, San Antonio, TX USA	University of Texas System; University of Texas at San Antonio (UTSA)	Li, R (corresponding author), Univ Texas San Antonio, Inst Biotechnol, San Antonio, TX USA.	lir3@uthscsa.edu						Sehgal PB, 2010, ONCOGENE, V29, P2599, DOI 10.1038/onc.2010.4; SEHGAL PB, 1991, EXP SUPPL, V59, P178	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2601	2601		10.1038/onc.2010.44	http://dx.doi.org/10.1038/onc.2010.44			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB					2022-12-17	WOS:000277169400016
J	Wicovsky, A; Henkler, F; Salzmann, S; Scheurich, P; Kneitz, C; Wajant, H				Wicovsky, A.; Henkler, F.; Salzmann, S.; Scheurich, P.; Kneitz, C.; Wajant, H.			Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation (vol 28, pg 1769, 2009)	ONCOGENE			English	Correction													Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Wicovsky A, 2009, ONCOGENE, V28, P1769, DOI 10.1038/onc.2009.29	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	2009	28	33					3008	3008		10.1038/onc.2009.219	http://dx.doi.org/10.1038/onc.2009.219			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA		Bronze			2022-12-17	WOS:000269142800010
J	Li, Y; Lau, YFC				Li, Y.; Lau, Y-F Chris			TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities (vol 27, pg 6141, 2008)	ONCOGENE			English	Correction													Lau, Yun-Fai C/E-4465-2014	Lau, Yun-Fai C/0000-0002-9119-7050				Li Y, 2008, ONCOGENE, V27, P6141, DOI 10.1038/onc.2008.206	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	2009	28	16					1879	1879		10.1038/onc.2009.64	http://dx.doi.org/10.1038/onc.2009.64			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW		Bronze			2022-12-17	WOS:000265640500007
J	Greem, DR				Greem, D. R.			April Fish	ONCOGENE			English	Editorial Material													Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2009	28	13					1569	1569		10.1038/onc.2009.28	http://dx.doi.org/10.1038/onc.2009.28			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19339979	Bronze			2022-12-17	WOS:000264780500001
J	Embry, MR; Billiard, SM; Di Giulio, RT				Embry, M. Rau; Billiard, S. M.; Di Giulio, R. T.			Lack of p53 induction in fish cells by model chemotherapeutics (vol 25, pg 2004, 2006)	ONCOGENE			English	Correction																		Embry MR, 2006, ONCOGENE, V25, P2004, DOI 10.1038/sj.onc.1209238	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2009	28	10					1400	1400		10.1038/onc.2009.8	http://dx.doi.org/10.1038/onc.2009.8			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC		Bronze			2022-12-17	WOS:000264116000013
J	Schwab, R; Bussolari, R; Corvetta, D; Chayka, O; Santilli, G; Kwok, JMM; Ferrari-Amorotti, G; Tonini, GP; Iacoviello, L; Bertorelle, R; Menin, C; Hubank, M; Calabretta, B; Sala, A				Schwab, R.; Bussolari, R.; Corvetta, D.; Chayka, O.; Santilli, G.; Kwok, J. M-M; Ferrari-Amorotti, G.; Tonini, G. P.; Iacoviello, L.; Bertorelle, R.; Menin, C.; Hubank, M.; Calabretta, B.; Sala, A.			Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk (vol 27,pg 2929,2008)	ONCOGENE			English	Correction													Iacoviello, Licia/K-4676-2016; sala, arturo/C-4959-2008; Menin, Chiara/L-5770-2016; Iacoviello, Licia/AGX-7071-2022	Iacoviello, Licia/0000-0003-0514-5885; Menin, Chiara/0000-0002-8907-772X; Iacoviello, Licia/0000-0003-0514-5885; Sala, Arturo/0000-0002-2841-7866				Schwab R, 2008, ONCOGENE, V27, P2929, DOI 10.1038/sj.onc.1210947	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3360	3360		10.1038/onc.2008.135	http://dx.doi.org/10.1038/onc.2008.135			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ		Bronze			2022-12-17	WOS:000256111400014
J	Cheng, Z; Ke, Y; Ding, X; Wang, F; Wang, H; Wang, W; Ahmed, K; Liu, Z; Xu, Y; Aikhionbare, F; Yan, H; Liu, J; Xue, Y; Yu, J; Powell, M; Liang, S; Wu, Q; Reddy, SE; Hu, R; Huang, H; Jin, C; Yao, X				Cheng, Z.; Ke, Y.; Ding, X.; Wang, F.; Wang, H.; Wang, W.; Ahmed, K.; Liu, Z.; Xu, Y.; Aikhionbare, F.; Yan, H.; Liu, J.; Xue, Y.; Yu, J.; Powell, M.; Liang, S.; Wu, Q.; Reddy, S. E.; Hu, R.; Huang, H.; Jin, C.; Yao, X.			Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response (vol 27, pg 931, 2008)	ONCOGENE			English	Correction									[Cheng, Z.; Ke, Y.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Yan, H.; Liu, J.; Xue, Y.; Wu, Q.; Jin, C.; Yao, X.] Hefei Natl Lab, Lab Cellular Dynam, Hefei, Peoples R China; [Cheng, Z.; Ke, Y.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Yan, H.; Liu, J.; Xue, Y.; Wu, Q.; Jin, C.; Yao, X.] Univ Sci & Technol China, Hefei 230026, Peoples R China; [Ding, X.; Wang, F.; Aikhionbare, F.; Powell, M.; Reddy, S. E.; Yao, X.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA USA; [Ding, X.; Wang, W.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Xu, Y.; Yu, J.; Huang, H.] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310027, Peoples R China; [Liang, S.] Hunan Normal Univ, MOE Key Lab Protein Chem, Changsha, Peoples R China; [Hu, R.] Fudan Univ, Sch Med, Dept Endocrinol & Metab, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; Beijing University of Chinese Medicine; Zhejiang University; Hunan Normal University; Fudan University	Cheng, Z (corresponding author), Hefei Natl Lab, Lab Cellular Dynam, Hefei, Peoples R China.							Cheng Z, 2008, ONCOGENE, V27, P931, DOI 10.1038/sj.onc.1210710	1	0	0	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1812	1812		10.1038/onc.2008.11	http://dx.doi.org/10.1038/onc.2008.11			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF		Bronze			2022-12-17	WOS:000253962100019
J	Ueki, N; Zhang, L; Hayman, MJ				Ueki, N.; Zhang, L.; Hayman, M. J.			Ski can negatively regulates macrophage differentiation through its interaction with PU.1 (vol 27, pg 300, 2008)	ONCOGENE			English	Correction																		Ueki N, 2008, ONCOGENE, V27, P300, DOI 10.1038/sj.onc.1210654	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1344	1344		10.1038/sj.onc.1211002	http://dx.doi.org/10.1038/sj.onc.1211002			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT		Bronze			2022-12-17	WOS:000253407000022
J	Wang, X; Hu, B; Weiss, RS; Wang, Y				Wang, X.; Hu, B.; Weiss, R. S.; Wang, Y.			The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining (vol 25, pg 1980, 2006)	ONCOGENE			English	Correction																		Wang X, 2006, ONCOGENE, V25, P1980, DOI 10.1038/sj.onc.1209212	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1343	1343		10.1038/onc.2008.1	http://dx.doi.org/10.1038/onc.2008.1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT		Bronze			2022-12-17	WOS:000253407000020
J	Wang, Z; Rong, YP; Malone, MH; Davis, MC; Zhong, F; Distelhorst, CW				Wang, Z.; Rong, Y. P.; Malone, M. H.; Davis, M. C.; Zhong, F.; Distelhorst, C. W.			Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis (vol 25, pg 1903, 2006)	ONCOGENE			English	Correction													Davis, Michael C/L-8920-2013	Davis, Michael C/0000-0003-2293-5694				Wang Z, 2006, ONCOGENE, V25, P1903, DOI 10.1038/sj.onc.1209218	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1342	1342		10.1038/sj.onc.1211001	http://dx.doi.org/10.1038/sj.onc.1211001			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT		Bronze			2022-12-17	WOS:000253407000019
J	Natarajan, M; Stewart, JE; Golemis, EA; Pugacheva, EN; Alexandropoulos, K; Cox, BD; Wang, W; Grammer, JR; Gladson, CL				Natarajan, M.; Stewart, J. E., Jr.; Golemis, E. A.; Pugacheva, E. N.; Alexandropoulos, K.; Cox, B. D.; Wang, W.; Grammer, J. R.; Gladson, C. L.			HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells (vol 25, pg 1721, 2006)	ONCOGENE			English	Correction														McFarland, Braden C./0000-0002-7517-9688; Golemis, Erica/0000-0003-3618-3673				NATARAJAN, 2006, HEF1 IS A NECESSARY, V25, P1721	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7282	7282		10.1038/sj.onc.1210837	http://dx.doi.org/10.1038/sj.onc.1210837			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO		Bronze			2022-12-17	WOS:000250955600012
J	Petrovics, G; Liu, A; Shaheduzzaman, S; Furusato, B; Sun, C; Chen, Y; Nau, M; Ravindranath, L; Chen, Y; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S				Petrovics, G.; Liu, A.; Shaheduzzaman, S.; Furusato, B.; Sun, C.; Chen, Y.; Nau, M.; Ravindranath, L.; Chen, Y.; Dobi, A.; Srikantan, V.; Sesterhenn, I. A.; McLeod, D. G.; Vahey, M.; Moul, J. W.; Srivastava, S.			Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (Vol 24, pg 3847, 2005)	ONCOGENE			English	Correction														Furusato, Bungo/0000-0003-4614-9882				Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6684	6684		10.1038/sj.onc.1210745	http://dx.doi.org/10.1038/sj.onc.1210745			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT		Bronze			2022-12-17	WOS:000250081500010
J	Friedman, AD				Friedman, A. D.			Normal and malignant hematopoiesis - Introduction	ONCOGENE			English	Editorial Material									Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21218 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21218 USA.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	47					6686	6686		10.1038/sj.onc.1210753	http://dx.doi.org/10.1038/sj.onc.1210753			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934477				2022-12-17	WOS:000250147000001
J	Karagiannis, TC; Harikrishnan, KN; El-Osta, A				Karagiannis, T. C.; Harikrishnan, K. N.; El-Osta, A.			Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments (vol 26, pg 3963, 2007)	ONCOGENE			English	Correction														Karagiannis, Tom/0000-0002-9967-1546; El-Osta, Assam/0000-0003-2969-9137				KARAGIANNIS, 2007, CORRIGENDUM, V26, P3963	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5028	5028		10.1038/sj.onc.1210554	http://dx.doi.org/10.1038/sj.onc.1210554			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV		Bronze			2022-12-17	WOS:000248322500016
J	Labib, K				Labib, K.			Highlights of the 23rd Genes and Cancer meeting University of Warwick 11-13 December 2006	ONCOGENE			English	Editorial Material									Univ Manchester, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England	Cancer Research UK; Paterson Institute for Cancer Research; University of Manchester	Labib, K (corresponding author), Univ Manchester, Paterson Inst Canc Res, Canc Res UK, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Klabib@picr.man.ac.uk							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2675	2677		10.1038/sj.onc.1210437	http://dx.doi.org/10.1038/sj.onc.1210437			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17460715				2022-12-17	WOS:000246210600001
J	Hahn, MA; Marsh, DJ				Hahn, M. A.; Marsh, D. J.			Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin (vol 24, pg 6241, 2005)	ONCOGENE			English	Correction													Marsh, Deborah/I-1491-2014	Marsh, Deborah/0000-0001-5899-4931				Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					788	788		10.1038/sj.onc.1210177	http://dx.doi.org/10.1038/sj.onc.1210177			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM		Bronze			2022-12-17	WOS:000243902200017
J	Huang, Y; Zhao, Q; Zhou, CX; Gu, ZM; Li, D; Xu, HZ; Wiedmer, T; Sims, PJ; Zhao, KW; Chen, GQ				Huang, Y.; Zhao, Q.; Zhou, C-X; Gu, Z-M; Li, D.; Xu, H-Z; Wiedmer, T.; Sims, P. J.; Zhao, K-W; Chen, G-Q			Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells (vol 25, pg 6618, 2006)	ONCOGENE			English	Correction																		Huang Y, 2006, ONCOGENE, V25, P6618, DOI 10.1038/sj.onc.1209677	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7224	7224		10.1038/sj.onc.1210082	http://dx.doi.org/10.1038/sj.onc.1210082			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH		Bronze			2022-12-17	WOS:000242046900012
J	Ren, Y; Chan, HM; Xie, Y; Chen, YX; Li, W; Jiang, GP; Liu, Q; Meinhardt, A; Tam, PKH				Ren, Y.; Chan, H. M.; Xie, Y.; Chen, Y. X.; Li, W.; Jiang, G. P.; Liu, Q.; Meinhardt, A.; Tam, P. K. H.			Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastomas (vol 25, pg 3501, 2006)	ONCOGENE			English	Correction													Tam, Paul Kwong Hang/C-4405-2009					Ren Y, 2006, ONCOGENE, V25, P3501, DOI 10.1038/sj.onc.1209395	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7224	7224		10.1038/sj.onc.1210005	http://dx.doi.org/10.1038/sj.onc.1210005			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH		Bronze			2022-12-17	WOS:000242046900011
J	Hutvagner, G				Hutvagner, G.			Biography of Dr Gyorgy Hutvagner	ONCOGENE			English	Biographical-Item									Univ Dundee, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Hutvagner, G (corresponding author), Univ Dundee, Div Gene Regulat & Express, MSI WTB Complex, Dundee DD1 5EH, Scotland.			Hutvagner, Gyorgy/0000-0002-7231-9446					0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2006	25	46					6153	6153		10.1038/sj.onc.1209916	http://dx.doi.org/10.1038/sj.onc.1209916			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL		Bronze			2022-12-17	WOS:000241158900001
J	Ashworth, A; Rahman, N				Ashworth, A.; Rahman, N.			Introduction	ONCOGENE			English	Editorial Material									Inst Canc Res, Breakthrough Breast Canc Res Ctr, London, England; Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, London, England.		Rahman, Nazneen/B-8890-2012						0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2006	25	43					5824	5824		10.1038/sj.onc.1209869	http://dx.doi.org/10.1038/sj.onc.1209869			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS					2022-12-17	WOS:000240765900001
J	Mishra, L; Marshall, J; Sporn, M				Mishra, L.; Marshall, J.; Sporn, M.			Obituary - Dr Anita B Roberts 1942-2006	ONCOGENE			English	Biographical-Item									Georgetown Univ, Washington, DC USA; Dartmouth Coll Sch Med, Hanover, NH USA	Georgetown University; Dartmouth College	Mishra, L (corresponding author), Georgetown Univ, Washington, DC USA.	lopamishra@yahoo.com							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2006	25	42					5707	5707		10.1038/sj.onc.1209900	http://dx.doi.org/10.1038/sj.onc.1209900			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR		Bronze			2022-12-17	WOS:000240765800001
J	Giordano, A; Lee, WH				Giordano, A.; Lee, W-H			Preface	ONCOGENE			English	Editorial Material									Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA	University of California System; University of California Irvine	Giordano, A (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92717 USA.	whlee@uci.edu							0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5189	5189		10.1038/sj.onc.1209721	http://dx.doi.org/10.1038/sj.onc.1209721			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD		Bronze			2022-12-17	WOS:000240064100001
J	Zheng, Z; Cantor, A; Bepler, G				Zheng, Z.; Cantor, A.; Bepler, G.			A global genome damage score predictive of lung cancer patients outcome	ONCOGENE			English	Article						lung cancer; chromosome aberrations; prognosis; survival	PROGNOSTIC-SIGNIFICANCE; DNA; HETEROZYGOSITY; CARCINOMAS; MECHANISMS; NEOPLASIA; REGIONS; GENE; 18Q	Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected loci that are thought to harbor genes important in cancer biology. We adapted a global, high-resolution genotyping method for determination of global and unbiased allelic loss. We generated a score, termed global genome damage score (GGDS), that is a continuous variable from zero to one and a measure of the extent of damaged DNA in individual tumors. In 71 patients with completely resected non-small-cell lung cancer, the GGDS ranged from 0.0006 to 0.5530 with a median value of 0.0401 indicating that between 0.06 and 55.3% of the genome has allelic loss. Patients with high scores (> 0.04) had a significantly worse outcome than those with low scores (median overall survival time 35.5 vs > 120.0 months, P = 0.006 log-rank test; median disease free survival 28.3 vs > 120.0 months, P = 0.003 log-rank test). This suggests that the clinical behavior of lung tumors with low GGDS is relatively benign whereas tumors with high GGDS are aggressive resulting in early death of patients.	H Lee Moffit Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA		Bepler, G (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Thorac Oncol Program, MRC-4W,12902 Magnolia Dr, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [U01CA101222, R01CA102726] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102726, U01 CA101222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; AUER G, 1984, CANCER RES, V44, P394; BARLOGIE B, 1982, CANCER GENET CYTOGEN, V6, P17, DOI 10.1016/0165-4608(82)90017-6; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FONG KM, 1995, CANCER RES, V55, P220; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Mandrekar J, 2003, SUGI, V28, P261; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOLM M, 1985, CANCER-AM CANCER SOC, V56, P1396, DOI 10.1002/1097-0142(19850915)56:6<1396::AID-CNCR2820560630>3.0.CO;2-L; WOLLEY RC, 1982, J NATL CANCER I, V69, P15; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	22	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4491	4494		10.1038/sj.onc.1209476	http://dx.doi.org/10.1038/sj.onc.1209476			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16518406				2022-12-17	WOS:000239326000012
J	Brechot, C				Brechot, C.			Overview	ONCOGENE			English	Editorial Material									INSERM, Direct Gen, F-75654 Paris 13, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Brechot, C (corresponding author), INSERM, Direct Gen, 101 Rue Tolbiac, F-75654 Paris 13, France.	Christian.brechot@tolbiac.inserm.fr							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	27					3755	3755		10.1038/sj.onc.1209546	http://dx.doi.org/10.1038/sj.onc.1209546			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY		Bronze			2022-12-17	WOS:000238559600002
J	[Anonymous]				[Anonymous]			Christian B Brechot	ONCOGENE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3753	3754						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY					2022-12-17	WOS:000238559600001
J	Khalili, P; Arakelian, A; Chen, G; Singh, G; Rabbani, SA				Khalili, P; Arakelian, A; Chen, G; Singh, G; Rabbani, SA			Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer (vol 24, pg 6657, 2005)	ONCOGENE			English	Correction																		Khalili P, 2005, ONCOGENE, V24, P6657, DOI 10.1038/sj.onc.1208790	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					492	492		10.1038/sj.onc.1209316	http://dx.doi.org/10.1038/sj.onc.1209316			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY		Bronze			2022-12-17	WOS:000234714100018
J	Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y				Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y			Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer (vol 23, pg 9289, 2004)	ONCOGENE			English	Correction																		Takahashi M, 2004, ONCOGENE, V23, P9289, DOI 10.1038/sj.onc.1208100	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4320	4320		10.1038/sj.onc.1208763	http://dx.doi.org/10.1038/sj.onc.1208763			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY		Bronze			2022-12-17	WOS:000229815300018
J	Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Thomssen, C; Dittmer, JR				Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Thomssen, C; Dittmer, JR			Ets1 is an effector of protein kinase Ca in cancer cells (vol 24, pg 650, 2005)	ONCOGENE			English	Correction													Manns, J/AAA-4986-2020					Vetter M, 2005, ONCOGENE, V24, P650, DOI 10.1038/sj.onc.1208234	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4319	4319		10.1038/sj.onc.1208764	http://dx.doi.org/10.1038/sj.onc.1208764			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY		Bronze			2022-12-17	WOS:000229815300016
J	Elias, B; Laine, A; Ronai, Z				Elias, B; Laine, A; Ronai, Z			Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2 (vol 24, pg 2574, 2005)	ONCOGENE			English	Correction														RONAI, ZEEV/0000-0002-3859-0400				Elias B, 2005, ONCOGENE, V24, P2574, DOI 10.1038/sj.onc.1208488	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 9	2005	24	25					4164	4164		10.1038/sj.onc.1208768	http://dx.doi.org/10.1038/sj.onc.1208768			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA		Bronze			2022-12-17	WOS:000229680300018
J	Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE				Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE			Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms (vol 24, pg 790, 2005)	ONCOGENE			English	Correction																		Huh JI, 2005, ONCOGENE, V24, P790, DOI 10.1038/sj.onc.1208221	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 9	2005	24	25					4164	4164		10.1038/sj.onc.1208767	http://dx.doi.org/10.1038/sj.onc.1208767			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA		Bronze			2022-12-17	WOS:000229680300017
J	Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE				Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE			Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death (vol 23, pg 7458, 2004)	ONCOGENE			English	Correction																		Miron MJ, 2004, ONCOGENE, V23, P7458, DOI 10.1038/sj.onc.1207919	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 9	2005	24	25					4162	4162		10.1038/sj.onc.1208769	http://dx.doi.org/10.1038/sj.onc.1208769			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA		Bronze			2022-12-17	WOS:000229680300015
J	Joerges, C; Kuntze, I; Herzinge, T				Joerges, C; Kuntze, I; Herzinge, T			Induction of a caffeine-sensitive S-phase cell cycle checkpoint by psoralen plus ultraviolet A radiation (vol 22, pg 6119, 2003)	ONCOGENE			English	Correction																		Joerges C, 2003, ONCOGENE, V22, P6119, DOI 10.1038/sj.onc.1206613	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2005	24	6					1128	1128		10.1038/sj.onc.1208364	http://dx.doi.org/10.1038/sj.onc.1208364			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS		Bronze			2022-12-17	WOS:000226749200021
J	Lachat, Y; Diserens, AC; Nozaki, M; Kobayashi, H; Hamou, MF; Godard, S; de Tribolet, N; Hegi, ME				Lachat, Y; Diserens, AC; Nozaki, M; Kobayashi, H; Hamou, MF; Godard, S; de Tribolet, N; Hegi, ME			INK4a/Arf is required for suppression of EGFR/Delta EGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma (vol 23, pg 6854, 2004)	ONCOGENE			English	Correction																		Lachat Y, 2004, ONCOGENE, V23, P6854, DOI 10.1038/sj.onc.1207872	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2005	24	6					1128	1128		10.1038/sj.onc.1208366	http://dx.doi.org/10.1038/sj.onc.1208366			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS		Bronze			2022-12-17	WOS:000226749200022
J	Gudkov, A				Gudkov, A			In memory of a scientist and friend - Alexander G Tatosyan, 1952-2004 - Obituary	ONCOGENE			English	Biographical-Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2005	24	3					313	313		10.1038/sj.onc.1208253	http://dx.doi.org/10.1038/sj.onc.1208253			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH		Bronze			2022-12-17	WOS:000226279700001
J	Chiba, S; Ishikawa, F; Miyazono, K				Chiba, S; Ishikawa, F; Miyazono, K			Obituary of Dr Hisamaru Hirai (vol 23, pg 4196, 2004)	ONCOGENE			English	Correction																		Chiba S, 2004, ONCOGENE, V23, P4196, DOI 10.1038/sj.onc.1207626	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9447	9447		10.1038/sj.onc.1208321	http://dx.doi.org/10.1038/sj.onc.1208321			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100018
J	Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY				Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY			TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin (vol 23, pg 4690, 2004)	ONCOGENE			English	Correction									Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; GlaxoSmithKline, King Of Prussia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; GlaxoSmithKline	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Carr, Steven A./AAH-8366-2019; Tsygankov, Alexander Y/K-6205-2017	Teckchandani, Anjali/0000-0002-2237-9598				Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627	1	0	0	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9449	9449		10.1038/sj.onc.1208320	http://dx.doi.org/10.1038/sj.onc.1208320			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100021
J	Leong, CTC; Ng, CY; Ong, CK; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H				Leong, CTC; Ng, CY; Ong, CK; Ng, CP; Ma, ZS; Nguyen, TH; Tay, SK; Huynh, H			Molecular cloning, characterization and isolation of novel spliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein, UO-44 (vol 23, pg 5707, 2004)	ONCOGENE			English	Correction																		Leong CTC, 2004, ONCOGENE, V23, P5707, DOI 10.1038/sj.onc.1207754	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	2004	23	54					8857	8857		10.1038/sj.onc.1208155	http://dx.doi.org/10.1038/sj.onc.1208155			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ		Bronze			2022-12-17	WOS:000225165100016
J	Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC				Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC			Upregulation of IKK alpha/IKK beta by integrin-linked kinase is required for HER2/neu-induced NF-kappa B antiapoptotic pathway (vol 23, pg 3883, 2004)	ONCOGENE			English	Correction													Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Makino K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	2004	23	54					8857	8857		10.1038/sj.onc.1207868	http://dx.doi.org/10.1038/sj.onc.1207868			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ		Bronze			2022-12-17	WOS:000225165100017
J	Adriaenssens, E; Mougel, A; Goormachtigh, G; Loing, E; Fafeur, V; Auriault, C; Coll, J				Adriaenssens, E; Mougel, A; Goormachtigh, G; Loing, E; Fafeur, V; Auriault, C; Coll, J			A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways (vol 23, pg 2681, 2004)	ONCOGENE			English	Correction													Fafeur, Veronique/L-9072-2018					Adriaenssens E, 2004, ONCOGENE, V23, P2681, DOI 10.1038/sj.onc.1207432	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	2004	23	49					8184	8184		10.1038/sj.onc.1207866	http://dx.doi.org/10.1038/sj.onc.1207866			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE		Green Published, Bronze			2022-12-17	WOS:000224692500016
J	[Anonymous]				[Anonymous]			Cancer epidemiology	ONCOGENE			English	Editorial Material																		DOLL R, 1978, CANCER RES, V38, P3573; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256	2	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6328	6328		10.1038/sj.onc.1207876	http://dx.doi.org/10.1038/sj.onc.1207876			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ					2022-12-17	WOS:000223468800001
J	Kadaja, L; Laos, S; Maimets, T				Kadaja, L; Laos, S; Maimets, T			Overexpression of leukocyte marker CD43 causes activation of the tumor- suppressor proteins p53 and ARF (vol 23, pg 2523, 2004)	ONCOGENE			English	Correction													Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				Kadaja L, 2004, ONCOGENE, V23, P2523, DOI 10.1038/sj.onc.1207359	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6326	6326		10.1038/sj.onc.1207745	http://dx.doi.org/10.1038/sj.onc.1207745			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC		Bronze			2022-12-17	WOS:000223399000020
J	Mishra, S; Reichert, A; Cunnick, J; Senadheera, D; Hemmeryckx, B; Heisterkamp, N; Groffen, J				Mishra, S; Reichert, A; Cunnick, J; Senadheera, D; Hemmeryckx, B; Heisterkamp, N; Groffen, J			Protein kinase CKIIa interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells (vol 22, pg 8255, 2003)	ONCOGENE			English	Correction													Hemmeryckx, Bianca/AAR-2360-2021					Mishra S, 2003, ONCOGENE, V22, P8255, DOI 10.1038/sj.onc.1207156	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6325	6325		10.1038/sj.onc.1207743	http://dx.doi.org/10.1038/sj.onc.1207743			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC		Bronze			2022-12-17	WOS:000223399000017
J	O'Nions, J; Allday, MJ				O'Nions, J; Allday, MJ			Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2 (vol 22, pg 7181, 2003)	ONCOGENE			English	Correction																		O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6326	6326		10.1038/sj.onc.1207742	http://dx.doi.org/10.1038/sj.onc.1207742			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC		Bronze			2022-12-17	WOS:000223399000019
J	Brummer, T; Stehelin, D; Misawa, Y; Reth, M				Brummer, T; Stehelin, D; Misawa, Y; Reth, M			A revised and complete map of the chicken c-mil/raf-1 locus	ONCOGENE			English	Article						chicken; c-mil; DT40; genomics; protooncogene; Raf-1; serine/threonine kinase	ONCOGENE V-MIL; AVIAN CARCINOMA VIRUS-MH2; MURINE SARCOMA VIRUS-3611; C-MIL; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RETROVIRUS MH2; GENE; RAF; PROTEIN	The chicken c-mil/raf-1 gene (formerly also known as c-mht) was originally identified in the search for the cellular counterpart to the v-mil oncogene of the Mill Hill 2 retrovirus and was among the first cellular proto-oncogenes discovered. Although the c-mil/raf-1 promotor, as well as the exons transduced into v-mil, were characterized in detail, an entire map of this locus has never been published. Here, we now report the location of five previously unmapped exons. In addition, we have noticed inconsistent numbering of the c-mil/raf-1 exons in the literature and the GenBank database. Thus, we provide here a complete map of the c-mil/raf-1 gene and a revision of the exon numbers. Comparison of the chicken c-mil/raf-1 gene with those of other vertebrates suggests that the numbers and lengths of the translated exons of the raf-1 locus were established early in the vertebrate lineage and have been conserved during the divergent evolution of teleosts and tetrapods.	Univ Freiburg, Inst Biol 3, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunbiol, D-79108 Freiburg, Germany; Univ Lille 2, Inst Pasteur Lille, Inst Biol Lille, Dept 3,Lab Oncol Mol, F-59021 Lille, France	University of Freiburg; Max Planck Society; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Reth, M (corresponding author), Univ Freiburg, Inst Biol 3, Dept Mol Immunol, Stubeweg 51, D-79108 Freiburg, Germany.	reth@immunbio.mpg.de	Brummer, Tilman/AAA-9428-2020; Brummer, Tilman/B-6218-2016	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; DOZIER C, 1991, ONCOGENE, V6, P1307; EYCHENE A, 1990, J VIROL, V64, P231; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KAN NC, 1984, SCIENCE, V223, P813, DOI 10.1126/science.6320371; KOENEN M, 1988, ONCOGENE, V2, P179; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SYMONDS G, 1986, J VIROL, V59, P172, DOI 10.1128/JVI.59.1.172-175.1986; VOGT PK, 1979, ONCOGENIC VIRUSES HO	22	0	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3128	3131		10.1038/sj.onc.1207434	http://dx.doi.org/10.1038/sj.onc.1207434			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14968114				2022-12-17	WOS:000220845200018
J	Fukuhara, H; Masuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y				Fukuhara, H; Masuda, M; Yageta, M; Fukami, T; Kuramochi, M; Maruyama, T; Kitamura, T; Murakami, Y			Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg (vol 22, pg 6160, 2003)	ONCOGENE			English	Correction																		Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					629	629		10.1038/sj.onc.1207365	http://dx.doi.org/10.1038/sj.onc.1207365			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH		Bronze			2022-12-17	WOS:000188098300036
J	Reed, JC				Reed, JC			Apoptosis - Part 1 - Foreword	ONCOGENE			English	Editorial Material									Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, La Jolla, CA 92037 USA.								0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2003	22	53					8541	8542		10.1038/sj.onc.1207208	http://dx.doi.org/10.1038/sj.onc.1207208			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX					2022-12-17	WOS:000186720000001
J	Giordano, A; Maio, M				Giordano, A; Maio, M			Biomolecular strategies for therapeutic intervention in cancer	ONCOGENE			English	Editorial Material													Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Maio, Michele/0000-0002-0323-6321; coral, sandra/0000-0002-1308-3082					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 29	2003	22	42					6469	6469		10.1038/sj.onc.1207030	http://dx.doi.org/10.1038/sj.onc.1207030			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV		Bronze			2022-12-17	WOS:000185700700001
J	[Anonymous]				[Anonymous]			Guest Editor Rupert K Schmidt-Ulrich	ONCOGENE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5729	5729		10.1038/sj.onc.1206661	http://dx.doi.org/10.1038/sj.onc.1206661			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV					2022-12-17	WOS:000185086100001
J	Arlinghaus, R				Arlinghaus, R			CML: Molecular mechanisms & therapeutic strategies - Guest editor	ONCOGENE			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.								0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8535	8535		10.1038/sj.onc.1206079	http://dx.doi.org/10.1038/sj.onc.1206079			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF		Bronze			2022-12-17	WOS:000179734300001
J	Bianco, NR; Montano, MM				Bianco, NR; Montano, MM			Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth (vol 21, pg 5233, 2002)	ONCOGENE			English	Correction																		Bianco NR, 2002, ONCOGENE, V21, P5233, DOI 10.1038/sj.onc.1205645	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8221	8221		10.1038/sj.onc.1205995	http://dx.doi.org/10.1038/sj.onc.1205995			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW		Bronze			2022-12-17	WOS:000179231400018
J	Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS				Benvenuti, S; Cramer, R; Bruce, J; Waterfield, MD; Jat, PS			Identification of novel candidates for replicative senescence by functional proteomics (vol 21, pg 4403, 2002)	ONCOGENE			English	Correction														Cramer, Rainer/0000-0002-8037-2511				Benvenuti S, 2002, ONCOGENE, V21, P4403, DOI 10.1038/sj.onc.1205525	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7609	7609		10.1038/sj.onc.1205982	http://dx.doi.org/10.1038/sj.onc.1205982			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX		Bronze			2022-12-17	WOS:000178618200018
J	Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T				Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T			A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes (vol 21, pg 3804, 2002)	ONCOGENE			English	Correction														Miyamoto, Yuji/0000-0003-3948-5044				Shiraishi M, 2002, ONCOGENE, V21, P3804, DOI 10.1038/sj.onc.1205454	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6866	6866		10.1038/sj.onc.1205797	http://dx.doi.org/10.1038/sj.onc.1205797			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD		Bronze			2022-12-17	WOS:000178315800018
J	Jones, PA				Jones, PA			DNA methylation and cancer	ONCOGENE			English	Biographical-Item																			0	0	0	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5357	5357		10.1038/sj.onc.1205769	http://dx.doi.org/10.1038/sj.onc.1205769			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC		Bronze			2022-12-17	WOS:000177197700001
J	Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y				Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y			HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas (vol 21, pg 3659, 2002)	ONCOGENE			English	Correction														Miyamoto, Yuji/0000-0003-3948-5044				Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5356	5356		10.1038/sj.onc.1205717	http://dx.doi.org/10.1038/sj.onc.1205717			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL		Bronze			2022-12-17	WOS:000177193900016
J	Hoffman, B; Leibermann, DA				Hoffman, B; Leibermann, DA			Hematopoiesis - Preface	ONCOGENE			English	Editorial Material						hematopolesis; leukemogenesis; differentiation; apoptosis			Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	hoffman@unix.temple.edu							0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3260	3261		10.1038/sj.onc.1205401	http://dx.doi.org/10.1038/sj.onc.1205401			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL		Bronze			2022-12-17	WOS:000175633300001
J	Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B				Sayed, M; Pelech, S; Wong, C; Marotta, A; Salh, B			Protein kinase CK2 is involved in G2 arrest and apoptosis following spindle damage in epithelial cells (vol 20, pg 6994, 2001)	ONCOGENE			English	Correction														Pelech, Steven/0000-0003-1112-903X				Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2446	2446		10.1038/sj.onc.1205097	http://dx.doi.org/10.1038/sj.onc.1205097			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY		Bronze			2022-12-17	WOS:000174635600019
J	Sepehr, A; Taniere, P; Martel-Planche, G; Zia'ee, AA; Rastgar-Jazii, F; Yazdanbod, M; Etemad-Moghadam, G; Kamangar, F; Saidi, F; Hainaut, P				Sepehr, A; Taniere, P; Martel-Planche, G; Zia'ee, AA; Rastgar-Jazii, F; Yazdanbod, M; Etemad-Moghadam, G; Kamangar, F; Saidi, F; Hainaut, P			Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran (vol 20, pg 7368, 2002)	ONCOGENE			English	Correction								Extremely high rates of squamous cell carcinoma of the esophagus (SCCE) are observed in Iran, reflecting unknown, genetic and/or epidemiological risk factors. Among genetic alterations in SCCE, TP53 mutations are the most frequent, vary among populations, and may provide clues on etiological mechanisms. We have analysed mutations in TP53 (exons 5-8) in 98 SCCE from Iran by temporal temperature gel electrophoresis and direct sequencing. We found 58 mutations in 49 patients (50%), with a high prevalence of C to T transitions at CpG dinucleotides (29.3%). The TP53 mutation pattern in Iran was significantly different from that observed in SCCEs from high incidence areas of China and Western Europe (P=0.007). Moreover, the prevalence of mutations at A:T base pairs (transitions and transversions) was higher in men than in women (38.7% vs 11.1%, P=0.033). COX-2 overexpression was detected in 69% of the cases evaluated (24/35), without significant association with TP53 mutation. Accumulation of nitrotyrosine, a marker of protein damage by excess levels of nitric oxide, was observed in tumor cells in six of 18 cases analysed. These results are consistent with the hypothesis that several factors are involved in TP53 mutagenesis in Iran. These factors include a baseline of chronic inflammatory stress, which may have a multiplicative impact on the sensitivity of esophageal cells to exogenous factors of risk.										Sepehr A, 2001, ONCOGENE, V20, P7368, DOI 10.1038/sj.onc.1204912	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1632	1632		10.1038/sj.onc.1205284	http://dx.doi.org/10.1038/sj.onc.1205284			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA		Bronze			2022-12-17	WOS:000173956800020
J	Alema, S; Cossu, G; Schneider, C; Tocchini-Valentini, G				Alema, S; Cossu, G; Schneider, C; Tocchini-Valentini, G			Prof Franco Tato 1949-2001 - Obituary	ONCOGENE			English	Biographical-Item									CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; H San Raffaele, Dibit, Milan, Italy; LNCIB, Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR)	Alema, S (corresponding author), CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy.								0	0	0	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6809	6810		10.1038/sj.onc.1204906	http://dx.doi.org/10.1038/sj.onc.1204906			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK		Bronze			2022-12-17	WOS:000171641000001
J	Nestle, FO				Nestle, FO			Dendritic cell vaccination for cancer therapy (vol 19, pg 6673, 2000)	ONCOGENE			English	Correction																		Nestle FO, 2000, ONCOGENE, V19, P6673, DOI 10.1038/sj.onc.1204095	1	0	0	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6970	6970		10.1038/sj.onc.1204930	http://dx.doi.org/10.1038/sj.onc.1204930			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK		Bronze			2022-12-17	WOS:000171641000020
J	Wang, PL; Sait, F; Winter, G				Wang, PL; Sait, F; Winter, G			The 'wildtype' conformation of p53: epitope mapping using hybrid proteins (vol 20, pg 2318, 2001)	ONCOGENE			English	Correction																		Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; WANG PL, 2000, ONCOGENE, V16, P3	2	0	0	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6971	6971		10.1038/sj.onc.1204934	http://dx.doi.org/10.1038/sj.onc.1204934			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK		Bronze			2022-12-17	WOS:000171641000021
J	Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DV				Ma, XR; Karra, S; Lindner, DJ; Hu, JB; Reddy, SPM; Kimchi, A; Yodoi, J; Kalvakolanu, DV			Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination (vol 20, pg 3703, 2001)	ONCOGENE			English	Correction													Lindner, Daniel/ABB-5440-2020					Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477	1	0	0	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6651	6651		10.1038/sj.onc.1204822	http://dx.doi.org/10.1038/sj.onc.1204822			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU		Bronze			2022-12-17	WOS:000171404200020
J	Archer, T; Baylin, S; Hansen, J; Hayes, J; Pelicci, PG; Robertson, K; Stunnenberg, H; Urnov, F; Wade, P				Archer, T; Baylin, S; Hansen, J; Hayes, J; Pelicci, PG; Robertson, K; Stunnenberg, H; Urnov, F; Wade, P			Dr Alan P Wolffe 1959-2000 - Obituary	ONCOGENE			English	Biographical-Item									NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Rochester, Rochester, NY USA; European Inst Oncol, Milan, Italy; Catholic Univ Nijmegen, Nijmegen, Netherlands; Emory Univ, Atlanta, GA 30322 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; University of Rochester; IRCCS European Institute of Oncology (IEO); Radboud University Nijmegen; Emory University	Archer, T (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.		Stunnenberg, Hendrik G./D-6875-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Stunnenberg, Hendrik G./0000-0002-0066-1576; 				WOLFFE AP, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4439	4439		10.1038/sj.onc.1204716	http://dx.doi.org/10.1038/sj.onc.1204716			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK		Bronze, Green Published			2022-12-17	WOS:000169912600021
J	Bowers, G; Reardon, D; Hewitt, T; Dent, P; Mikkelsen, RB; Valerie, K; Lammering, G; Amir, C; Schmidt-Ullrich, RK				Bowers, G; Reardon, D; Hewitt, T; Dent, P; Mikkelsen, RB; Valerie, K; Lammering, G; Amir, C; Schmidt-Ullrich, RK			The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells (vol 20, pg 1388, 2001)	ONCOGENE			English	Correction													Valerie, Kristoffer/AAL-8299-2021					Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255	1	0	0	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3927	3927		10.1038/sj.onc.1204643	http://dx.doi.org/10.1038/sj.onc.1204643			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE		Bronze			2022-12-17	WOS:000169494700019
J	Greene, MI				Greene, MI			Breast cancer genes - Foreword	ONCOGENE			English	Editorial Material									Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.								0	0	0	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6092	6092		10.1038/sj.onc.1203998	http://dx.doi.org/10.1038/sj.onc.1203998			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH					2022-12-17	WOS:000166121400001
J	O'Hagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA				O'Hagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA			The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades (vol 13, pg 1323, 1996)	ONCOGENE			English	Correction																		OHagan RC, 1996, ONCOGENE, V13, P1323	1	0	0	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5039	5039		10.1038/sj.onc.1203866	http://dx.doi.org/10.1038/sj.onc.1203866			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF		Bronze			2022-12-17	WOS:000089834300013
J	Borriello, A				Borriello, A			p27(Kip1) accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation (vol 19, pg 51, 2000)	ONCOGENE			English	Correction									Natl Inst Canc Res, Lab Populat Genet, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST			Borriello, Adriana/K-3464-2018					Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231	1	0	0	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3960	3960						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ					2022-12-17	WOS:000088614300016
J	Masutani, H; Magnaghi-Jaulin, L; Ait-Si-Ali, S; Groisman, R; Robin, P; Harel-Bellan, A				Masutani, H; Magnaghi-Jaulin, L; Ait-Si-Ali, S; Groisman, R; Robin, P; Harel-Bellan, A			Activation of the c-fos SRE through SAP-1a (vol 15, pg 1661, 1997)	ONCOGENE			English	Correction													Masutani, Hiroshi/B-5114-2014; Harel-Bellan, Annick/M-9795-2015					Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328	1	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5246	5246						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE					2022-12-17	WOS:000082555700015
J	Martincic, D				Martincic, D			Detection of mutations by automated fluorescence/RNA-based dideoxy fingerprinting (ARddf) (vol 18, pg 617, 1999)	ONCOGENE			English	Correction																		Martincic D, 1999, ONCOGENE, V18, P617, DOI 10.1038/sj.onc.1202295	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3186	3186						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB					2022-12-17	WOS:000080388000016
J	White, GRM; Varley, JM; Heighway, J				White, GRM; Varley, JM; Heighway, J			Isolation and characterization of a human homologue of the latrophilin gene from a region of 1p31.1 implicated in breast cancer (vol 17, pg 3513, 1998)	ONCOGENE			English	Correction																		White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2167	2167		10.1038/sj.onc.1202724	http://dx.doi.org/10.1038/sj.onc.1202724			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX		Bronze			2022-12-17	WOS:000079346200016
J	Battista, S; Mega, T				Battista, S; Mega, T			Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo (vol 17, pg 377, 1998)	ONCOGENE			English	Correction																		Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953	1	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1649	1649						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX					2022-12-17	WOS:000078770700017
J	Froeschle				Froeschle			Retinoic acid receptors and muscle b-HLH proteins: partners in retinoid-induced myogenesis (vol 16, pg 3369, 1998)	ONCOGENE			English	Correction																		Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					3071	3071						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL					2022-12-17	WOS:000077427800015
J	Hallberg				Hallberg			Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase (vol 17, pg 691, 1998)	ONCOGENE			English	Correction																		Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2677	2677						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN					2022-12-17	WOS:000077058900016
J	Yuille, MAR				Yuille, MAR			ATM is usually rearranged in T-cell prolymphocytic leukaemia (vol 16, pg 789, 1998)	ONCOGENE			English	Correction																		Yuille MAR, 1998, ONCOGENE, V16, P789, DOI 10.1038/sj.onc.1201603	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2955	2955						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544					2022-12-17	WOS:000073988200015
J	Frederick, A				Frederick, A			The human UNP locus at 3p21.31 encodes two tissue-selective, cytoplasmic isoforms with deubiquitinating activity that have reduced expression in small cell lung carcinoma cell lines (vol 16, pg 153, 1998)	ONCOGENE			English	Correction																		Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2293	2293						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226					2022-12-17	WOS:000073298000015
J	Della Valle, V				Della Valle, V			The human protein p19(ARF) is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16(INK4a)/MTS1 gene (vol 15, pg 2475, 1997)	ONCOGENE			English	Correction																		DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1095	1095						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169					2022-12-17	WOS:000072335900016
J	Fitzer-Attas, CJ; Do, MS; Feigelson, S				Fitzer-Attas, CJ; Do, MS; Feigelson, S			Modification of PDGF alpha receptor expression or function alters the metastatic phenotype of 3LL cells (vol 15, pg 1545, 1997)	ONCOGENE			English	Correction																		FitzerAttas CJ, 1997, ONCOGENE, V15, P1545, DOI 10.1038/sj.onc.1201321	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					561	561						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644					2022-12-17	WOS:000071739400016
J	Das				Das			Identification of a novel Bcl2-related gene, BRAG-1, in human glioma (vol 12, pg 947, 1996)	ONCOGENE			English	Correction																		Das R, 1996, ONCOGENE, V12, P947	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					429	429						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262					2022-12-17	WOS:000071582100016
J	Thomas, RS				Thomas, RS			ETS1, NF kappa-B and AP1 synergistically transactivate the human GM-CSF promoter (vol 14, pg 2845, 1997)	ONCOGENE			English	Correction, Addition																		Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2255	2255						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019					2022-12-17	WOS:A1997YD01900015
J	Ide, H				Ide, H			Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs (vol 14, pg 1377, 1997)	ONCOGENE			English	Correction, Addition																		Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1121	1121						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161					2022-12-17	WOS:A1997XT16100015
J	Casola, S				Casola, S			Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma (vol 14, pg 1503, 1997)	ONCOGENE			English	Correction, Addition																		Casola S, 1997, ONCOGENE, V14, P1503, DOI 10.1038/sj.onc.1200956	1	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					875	875						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117					2022-12-17	WOS:A1997XQ11700015
J	Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronova, V				Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronova, V			Isolation from a multigene family of the active human gene of the metastasis-associated multifunctional protein 37 LRP/p40 at chromosome 3p21.3 (vol 13, pg 495, 1996)	ONCOGENE			English	Correction, Addition													sozzi, gabriella/G-8259-2011	sozzi, gabriella/0000-0001-9360-6914				Jackers P, 1996, ONCOGENE, V13, P495	1	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					627	627						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524					2022-12-17	WOS:A1997WF52400016
J	Gangopadhyay, SB; Peacock, JW; Benchimol, S				Gangopadhyay, SB; Peacock, JW; Benchimol, S			A transcript exhibiting homology to endogenous rat retroviral-like elements is regulated by p53	ONCOGENE			English	Article						p53; differential display; RAL retroviral-like elements	WILD-TYPE P53; PROTEIN; GENE; EXPRESSION; GROWTH; CELLS; CHECKPOINT; SEQUENCES; APOPTOSIS; BINDING	Rat embryo fibroblasts transformed with HPV-16 E7 and the Ha-ras oncogene (ER clones) fall into two distinct groups based on their endogenous p53 status, wild-type or mutant, We have taken advantage of such clones in order to study the p53 target genes by the differential display method of RNA fingerprinting, We have identified a cDNA clone, clone 16, that recognises a large transcript on Northern blots. The clone 16 transcript is overexpressed in ER cell lines that express wild-type p53 compared with ER cell lines that express mutant p53. Similar to the waf1/p21 gene, which is transcriptionally activated in cells treated with ionizing radiation in a p53-dependent manner, the clone transcript was also induced in response to irradiation, The sequence of clone 16 exhibits a high homology to two members of RAL retroviral-like elements.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				BRISTOW RG, 1994, ONCOGENE, V9, P1527; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P318, DOI 10.1016/S0006-291X(05)80147-0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; HARPER JW, 1993, CELL, V75, P805; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamuta M, 1989, Virus Genes, V3, P69, DOI 10.1007/BF00301988; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUZUKI N, 1986, NUCLEIC ACIDS RES, V14, P9271, DOI 10.1093/nar/14.23.9271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	28	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2731	2735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000148				2022-12-17	WOS:A1996VZ65400024
J	Akagi				Akagi			Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells (vol 13, pg 399, 1996)	ONCOGENE			English	Correction, Addition																		AKAGI, 1996, ONCOGENE, V13, P399	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2505	2505						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108					2022-12-17	WOS:A1996VX10800027
J	Kanazawa, S				Kanazawa, S			Impaired development of CD4(+) CD8(+) thymocytes by csk-'knock-in into fyn locus (vol 13, pg 199, 1996)	ONCOGENE			English	Correction, Addition																		Kanazawa S, 1996, ONCOGENE, V13, P199	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2295	2295						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145					2022-12-17	WOS:A1996VV14500028
J	Sunitha, I; Avigan, MI				Sunitha, I; Avigan, MI			The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn-related tyrosine kinase (vol 13, pg 547, 1996)	ONCOGENE			English	Correction, Addition																		Sunitha I, 1996, ONCOGENE, V13, P547	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2045	2045						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795					2022-12-17	WOS:A1996VR79500027
J	Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B				Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B			Blocking c-myc and max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells (vol 11, pg 2439, 1995)	ONCOGENE			English	Correction, Addition																		Nguyen HQ, 1995, ONCOGENE, V11, P2439	1	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2481	2481						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220					2022-12-17	WOS:A1996UQ22000029
J	Veyrune, JL; Carilo, S; Vie, A; Blanchard, JM				Veyrune, JL; Carilo, S; Vie, A; Blanchard, JM			c-fos mRNA instability determinants present within both the coding and the 3' non coding region link the degradation of this mRNA to its translation (vol 11, pg 2127, 1995)	ONCOGENE			English	Correction, Addition																		VEYRUNE JL, 1995, ONCOGENE, V11, P2127	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2479	2479						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220					2022-12-17	WOS:A1996UQ22000028
J	Myers, A; Weinhouse, S; Nowell, PC; Liebermann, DA; Fornace, AJ; Kastan, MB; White, E; Tlstys, TD; Ihle, JN; Waxman, S; Reddy, P				Myers, A; Weinhouse, S; Nowell, PC; Liebermann, DA; Fornace, AJ; Kastan, MB; White, E; Tlstys, TD; Ihle, JN; Waxman, S; Reddy, P			Molecular biology of normal development, malignancy and its suppression	ONCOGENE			English	Editorial Material											Myers, A (corresponding author), TEMPLE UNIV,DEPT BIOCHEM,SCH MED,INST CANC RES & MOL BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.								0	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2247	2250						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668352				2022-12-17	WOS:A1996UP28300025
J	Garrido, C; Leprince, D; Plaza, S; Aumercier, M; Stehelin, D; Saule, S				Garrido, C; Leprince, D; Plaza, S; Aumercier, M; Stehelin, D; Saule, S			Back-mutation of the v-Ets to the c-Ets carboxy-terminal amino acids in the P135(gag-myb-ets) results in chicken neuroretina cells transformation and loss of basic fibroblast growth factor responsiveness	ONCOGENE			English	Article						neuroretina; bFGF; ets; myb	AVIAN-MYELOBLASTOSIS VIRUS; LEUKEMIA-VIRUS; MYB ONCOGENE; DNA-BINDING; NUCLEOTIDE-SEQUENCE; ERYTHROID-CELLS; C-ETS-1 LOCUS; MYELOID CELLS; GENE FAMILY; E26 VIRUS	The v-Myb, v-Ets containing E26 retrovirus (called in this work E26ABC) induces the proliferation of chicken neuroretina (CNR) cells in minimal medium, strongly stimulated by basic Fibroblast Growth Factor (bFGF) which confers on them the ability to form colonies in soft agar. V-Ets differs from its cellular counterpart c-Ets-l by two point mutations and by the replacement of the 13 last C-terminal amino acids by 16 unrelated residues as a consequence of DNA segment inversion in the viral sequence. It has been documented that this different C-terminal sequence influences DNA binding activity and specificity. Replacement in E26ABC virus of the sequence encoding the 16 v-Ets last C-terminal amino acids by the sequence encoding the 13 c-Ets-l derived C-terminus (virus E26ABO), results in the production of a P135(gag-myb-ets) with modified biological properties on CNR cells. E26ABO infected CNR cells proliferate in minimal medium more efficiently than E26ABC, are unresponsive to bFGF and able to grow in soft agar. In contrast, CNR cells infected by viruses encoding Myb and Ets proteins either in the E26ABO or in the E26ABC configuration are bFGF responsive. Since Myb alone is sufficient to induce bFGF responsiveness on CNR cells, these results suggest that the c-Ets-l C-terminus interferes with the Myb activity of the E26ABO P135(gag-myb-ets) protein in CNR cells.	INST PASTEUR,CNRS EP56,F-59019 LILLE,FRANCE; INST PASTEUR,CNRS UA 1160,F-59019 LILLE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			plaza, serge/F-5290-2015; Garrido, Carolina/GWM-5557-2022	Aumercier, Marc/0000-0002-0370-3452				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMBES PC, 1977, CELL TISSUE RES, V185, P159; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frykberg L, 1988, Oncogene Res, V3, P313; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GARRIDO C, 1992, ONCOGENE, V8, P2713; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LI RP, 1989, ONCOGENE RES, V5, P137; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; QUEVA C, 1993, ONCOGENE, V8, P2511; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	49	0	0	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1449	1456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622861				2022-12-17	WOS:A1996UF07600009
J	Ohta, M; Nagai, H; Nyunoya, H; Shimotohno, K				Ohta, M; Nagai, H; Nyunoya, H; Shimotohno, K			Src-homology domain 2 is responsible for transcriptional suppression induced by expression of Lck	ONCOGENE			English	Article						Lck; Src; SH2; transcriptional suppression; tyrosine kinase	TYROSINE-PROTEIN-KINASE; RETROVIRUS PROMOTER INSERTION; SIGNAL TRANSDUCTION; CD4 RECEPTOR; SH3 DOMAINS; P56LCK; ACTIVATION; IDENTIFICATION; CELLS; GENE	Overexpression of Lck was shown, by our previous study, to suppress gene transcription from various viral and cellular promoters. The suppression of transcription from human T-cell leukemia virus promoter by Lck was independent of the presence of the enhancer core sequences within the long terminal repeat. The suppression of transcription was observed with Lck mutants that had either diminished or enhanced tyrosine-kinase activity. A mutant lacking the myristylation site also suppressed transcription. From the analysis with various deletion mutants of Lck, it was suggested that Src-homology domain 2 (SH2) is both necessary and sufficient for the suppression of transcription. A similar effect was also observed with the SH2 domain of the v-src gene. Thus, overexpression of Lck could suppress gene expression through a unique function of the SH2 domain.	NATL CANC CTR, RES INST, DIV VIROL, TOKYO 104, JAPAN	National Cancer Center - Japan			Nyunoya, Hiroshi/C-9705-2013	Nyunoya, Hiroshi/0000-0002-3237-9639				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; KAMPS MP, 1988, ONCOGENE, V2, P305; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NYUNOYA H, 1990, AIDS RES HUM RETROV, V6, P1311, DOI 10.1089/aid.1990.6.1311; OHTA M, 1990, JPN J CANCER RES, V81, P440, DOI 10.1111/j.1349-7006.1990.tb02588.x; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					989	997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649816				2022-12-17	WOS:A1996UA88400006
J	Amler				Amler			A reciprocal translocation (1;15) (36.2;q24) in a neuroblastoma cell line is accompanied by DNA duplication and may signal the site of a putative tumor suppressor-gene (vol 10, pg 1095, 1995)	ONCOGENE			English	Correction, Addition						D1S160/D1S244; pediatric cancer; yeast artificial chromosome (YAC); fluorescence in situ hybridization (FISH)												AMLER, 1995, ONCOGENE, V10, P1095	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2453	2453						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702					2022-12-17	WOS:A1995TK70200032
J	Baldari				Baldari			Inhibition of CD4/p561ck signaling by a dominant negative mutant of the Shc adaptor protein (vol 10, pg 1141, 1995)	ONCOGENE			English	Correction, Addition																		BALDARI, 1995, ONCOGENE, V10, P1141	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2451	2451						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702					2022-12-17	WOS:A1995TK70200031
J	Thomson, JAF				Thomson, JAF			The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells (vol 11, pg 691, 1995)	ONCOGENE			English	Correction																		ANGUS J, 1995, ONCOGENE, V11, P691	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2457	2457						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702					2022-12-17	WOS:A1995TK70200034
J	SHOU, CC; WURMSER, A; SUEN, KL; BARBACID, M; FEIG, LA				SHOU, CC; WURMSER, A; SUEN, KL; BARBACID, M; FEIG, LA			DIFFERENTIAL RESPONSE OF THE RAS EXCHANGE FACTOR, RAS-GRF TO TYROSINE KINASE AND G-PROTEIN MEDIATED SIGNALS (VOL 10, PG 1887, 1995)	ONCOGENE			English	Correction, Addition									BRISTOL MYERS SQUIBB,DEPT BIOL MOLEC,PRINCETON,NJ 08543	Bristol-Myers Squibb	SHOU, CC (corresponding author), TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111, USA.							SHOU CC, 1995, ONCOGENE, V10, P1887	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1929	1929						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094					2022-12-17	WOS:A1995TD09400031
J	PODHIPLEUX, N; WILLMAN, CL				PODHIPLEUX, N; WILLMAN, CL			ISOLATION AND CHARACTERIZATION OF THE MURINE C-FGR GENOMIC LOCUS - EXONS IB-XII	ONCOGENE			English	Note						FGR; GENOMIC ORGANIZATION; SRC FAMILY MEMBER; PROTOONCOGENE	PROTEIN-TYROSINE KINASE; ONCOGENE; EXPRESSION; CELLS; SRC; IDENTIFICATION; PROTOONCOGENE; LYMPHOCYTES; ACTIVATION; GENE	The c-fgr proto-oncogene is a member of the src family of intracellular protein tyrosine kinases. C-fgr is selectively expressed in hematopoietic cells, particularly in monocytes, neutrophils and natural killer cells. Although c-fgr is presumed to play a role in signal transduction, its normal function has not been completely elucidated. In contrast to all other members of the src family, the presumed murine and human c-fgr homologues have a low degree of homology in their amino terminal domains which likely mediate the association of c-fgr proteins with signalling complexes and other targets; murine and human c-fgr proteins exhibit other functional differences as well. In contrast to human C-FGR, the murine C-FGR genomic locus has not been characterized. We have now isolated and mapped three overlapping phage clones spanning 33 kb of the murine C-FGR genomic locus. Contained within these clones are 18 kb of DNA containing the C-FGR coding exons (exons IT-XII), one 5' untranslated region exon (exon Tb) located 1.7 kb upstream of exon II, 6.5 kb of DNA upstream of exon Ib, and 6.7 kb of DNA downstream of the polyadenylation site in exon XII. From exons Ib-XII, the exon-intron organization, exon-intron junctions and intron lengths of the murine and human C-FGR genomic loci are quite similar; with the exception of exon II, the exon lengths are also quite similar. Although these studies suggest that the murine and human C-FGR genes are in fact homologues, the organization of these genes upstream of exon Ib is quite divergent.	UNIV NEW MEXICO,SCH MED,CTR CANC,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT CELL BIOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043042] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK/CA-43042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HATAKEYAMA S, 1994, P NATL ACAD SCI USA, V91, P3458, DOI 10.1073/pnas.91.8.3458; INOUE K, 1990, MOL CELL BIOL, V11, P6279; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KING FJ, 1990, ONCOGENE, V5, P338; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LINK DC, 1992, ONCOGENE, V7, P877; LINK DC, 1995, BLOOD, V85, P472; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; PATEL M, 1990, ONCOGENE, V5, P201; POTTER JW, 1994, UNPUB; POTTER JW, 1994, J CELL BIOL B, V18, P287; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, 1991, BLOOD, V77, P6; WILLMAN CL, 1992, J CELL BIOCHEM, V16, P219; YI TL, 1989, ONCOGENE, V4, P1081	23	0	0	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					781	784						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651742				2022-12-17	WOS:A1995RQ46900021
J	SHAY				SHAY			HELATG CELLS HAVE MITOCHONDRIAL-DNA INSERTED INTO THE C-MYC ONCOGENE (VOL 6, PG 1869, 1991)	ONCOGENE			English	Correction, Addition																		HADLER HI, 1991, J ANTIBIOT, V24, P405; SHAY JW, 1991, ONCOGENE, V6, P1869	2	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1689	1689						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681					2022-12-17	WOS:A1995QU68100029
J	ANDRES				ANDRES			EXPRESSION OF 2 NOVEL EPH-RELATED RECEPTOR PROTEIN-TYROSINE KINASES IN MAMMARY-GLAND DEVELOPMENT AND CARCINOGENESIS (VOL 9, PG 1461, 1994)	ONCOGENE			English	Correction, Addition																		ANDRES, 1994, ONCOGENE, V9, P1461	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2431	2431						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629					2022-12-17	WOS:A1994NX62900039
J	STACEY				STACEY			SCANNING THE STRUCTURE AND ANTIGENICITY OF HPV-16 E6 AND E7 ONCOPROTEINS USING ANTIPEPTIDE ANTIBODIES (VOL 9, PG 635, 1994)	ONCOGENE			English	Correction, Addition																		STACEY, 1994, ONCOGENE, V9, P635	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1515	1515						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401					2022-12-17	WOS:A1994NH40100027
J	ZHANG				ZHANG			THE HOX-11 (TCL-3) HOMEOBOX PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN THAT UNDERGOES CELL CYCLE-DEPENDENT REGULATION (VOL 8, PG 3265, 1993)	ONCOGENE			English	Correction, Addition																		ZHANG, 1993, ONCOGENE, V8, P3265	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1305	1305						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048					2022-12-17	WOS:A1994NC04800038
J	TORNALETTI				TORNALETTI			THE DISTRIBUTION OF UV PHOTOPRODUCTS ALONG THE HUMAN P53 GENE AND ITS RELATION TO MUTATIONS IN SKIN-CANCER (VOL 8, PG 2051, 1993)	ONCOGENE			English	Correction, Addition																		TORNALETTI, 1993, ONCOGENE, V8, P2051	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3469	3469						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782					2022-12-17	WOS:A1993MG78200035
J	ESCOT				ESCOT			POTENTIAL VALUE OF INCREASED MYC BUT NOT ERBB2 RNA LEVELS AS A MARKER OF HIGH-RISK MASTOPATHIES (VOL 8, PG 969, 1993)	ONCOGENE			English	Correction, Addition																		ESCOT, 1993, ONCOGENE, V8, P969	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2023	2023						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682					2022-12-17	WOS:A1993LG68200037
J	LIU				LIU			BCR-ABL TYROSINE KINASE IS AUTOPHOSPHORYLATED OR TRANSPHOSPHORYLATES P160 BCR ON TYROSINE PREDOMINANTLY WITHIN THE 1ST BCR EXON (VOL 8, PG 101, 1993)	ONCOGENE			English	Correction, Addition																		LIU, 1993, ONCOGENE, V8, P101	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2021	2021						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682					2022-12-17	WOS:A1993LG68200036
J	OREN, M				OREN, M			ALONI,YOSEF - (1936-1993) - OBITUARY	ONCOGENE			English	Item About an Individual											OREN, M (corresponding author), WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL.								0	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1405	1405						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064					2022-12-17	WOS:A1993LE06400001
J	VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP				VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP			ALTERNATIVE MESSENGER-RNA FORMS AND OPEN READING FRAMES OF THE MAX GENE (VOL 8, PG 503, 1993)	ONCOGENE			English	Correction, Addition													makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044				VASTRIK I, 1993, ONCOGENE, V8, P503	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1711	1711						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064					2022-12-17	WOS:A1993LE06400039
J	BONHAM				BONHAM			BOTH MYELOPROLIFERATIVE DISEASE AND LEUKEMIA ARE INDUCED BY TRANSPLANTATION OF BONE-MARROW CELLS EXPRESSING V-MYC (VOL 7, PG 2219, 1992)	ONCOGENE			English	Correction, Addition																		BONHAM, 1992, ONCOGENE, V7, P2219	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1403	1403						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328					2022-12-17	WOS:A1993KY32800036
J	LANDESMAN				LANDESMAN			MODIFICATIONS OF CELL-CYCLE CONTROLLING NUCLEAR PROTEINS BY TRANSFORMING GROWTH FACTOR-(BETA) IN THE HACAT KERATINOCYTE CELL-LINE (ONCOGENE, VOL 7, PG 1661, 1992)	ONCOGENE			English	Correction, Addition																		LANDESMAN, 1992, ONCOGENE, V7, P1661	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					229	229						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005					2022-12-17	WOS:A1993KN00500030
J	MICHALSKI				MICHALSKI			CORRECTION	ONCOGENE			English	Correction, Addition																		MICHALSKI, 1992, ONCOGENE, V7, P1595	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2575	2575						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856					2022-12-17	WOS:A1992KA85600026
J	GIVOL				GIVOL			CORRECTION	ONCOGENE			English	Correction, Addition																		GIVOL, 1992, ONCOGENE, V7, P141	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1457	1457						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971					2022-12-17	WOS:A1992HZ97100028
J	GREEN				GREEN			CORRECTION	ONCOGENE			English	Correction, Addition																		GREEN, 1992, ONCOGENE, V4, P653	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1459	1459						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971					2022-12-17	WOS:A1992HZ97100029
J	PEREGO				PEREGO			CORRECTION	ONCOGENE			English	Correction, Addition																		PEREGO, 1991, ONCOGENE, V6, P1899	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					607	607						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005					2022-12-17	WOS:A1992HK00500031
J	PROSSER, J				PROSSER, J			CORRECTION	ONCOGENE			English	Correction, Addition																		PROSSER J, 1990, ONCOGENE, V5, P1573	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2161	2161						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119					2022-12-17	WOS:A1991GX11900030
J	BOYD, JM; SIMMONS, DT				BOYD, JM; SIMMONS, DT			EVIDENCE THAT SV40 SURFACE TUMOR-ANTIGEN ORIGINATES FROM THE NUCLEUS AND CYTOPLASM	ONCOGENE			English	Article							LARGE-T-ANTIGEN; TRANSPORT-DEFECTIVE MUTANT; SIMIAN VIRUS-40; PLASMA-MEMBRANE; CELL-SURFACE; HYBRID VIRUSES; WILD-TYPE; ASSOCIATION; BINDING; PHOSPHORYLATION	Simian virus 40 large T antigen exposed at the cell surface is oligomerized and phosphorylated in a mature fashion. NP40-soluble surface T antigen, prepared from infected cells, sediments mainly as a tetramer and has a nuclear phosphorylation pattern. Since these are modifications that occur over several hours, surface T appears to be a population of older molecules. This is in apparent contradiction to kinetic studies showing that T antigen arrives at the surface in 20 min. We present a model to account for this apparent discrepancy. It postulates that both newly-synthesized and older, mature molecules are transported to the surface. The newly-synthesized molecules are highly unstable and lost rapidly from the surface whereas the mature molecules are stable and accumulate over time. This stability may be due to oligomerization and/or phosphorylation or to an interaction with other surface molecules that act as anchors. Our model further proposes that most of the T antigen in transit to the surface is newly-synthesized protein from the cytoplasm, while the majority of the T antigen at the surface is mature protein from the nucleus.			BOYD, JM (corresponding author), UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716, USA.				NATIONAL CANCER INSTITUTE [R01CA036118] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; DEPPERT W, 1982, VIROLOGY, V122, P56, DOI 10.1016/0042-6822(82)90377-4; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HENNING R, 1983, NATURE, V305, P736, DOI 10.1038/305736a0; JARVIS DL, 1984, VIROLOGY, V134, P168, DOI 10.1016/0042-6822(84)90282-4; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLOCKMANN U, 1985, J VIROL, V56, P541, DOI 10.1128/JVI.56.2.541-548.1985; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; KLOCKMANN U, 1983, VIROLOGY, V126, P717, DOI 10.1016/S0042-6822(83)80029-4; LANFORD RE, 1980, VIROLOGY, V105, P314, DOI 10.1016/0042-6822(80)90033-1; LANFORD RE, 1980, VIROLOGY, V105, P303, DOI 10.1016/0042-6822(80)90032-X; LANFORD RE, 1982, VIROLOGY, V119, P169, DOI 10.1016/0042-6822(82)90074-5; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVITSKY K, 1983, INT J CANCER, V32, P597, DOI 10.1002/ijc.2910320513; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; RINKE Y, 1989, VIROLOGY, V170, P424, DOI 10.1016/0042-6822(89)90433-9; SANTOS M, 1984, J VIROL, V51, P376, DOI 10.1128/JVI.51.2.376-383.1984; SANTOS M, 1984, J VIROL, V49, P50, DOI 10.1128/JVI.49.1.50-56.1984; SANTOS M, 1982, VIROLOGY, V120, P1, DOI 10.1016/0042-6822(82)90002-2; SCHEIDTMANN KH, 1986, VIROLOGY, V150, P85, DOI 10.1016/0042-6822(86)90268-0; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SIMMONS D, 1980, VIROLOGY, V34, P650; SIMMONS DT, 1984, J BIOL CHEM, V259, P8633; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; SIMMONS DT, 1977, J VIROL, V24, P319, DOI 10.1128/JVI.24.1.319-325.1977; SOULE HR, 1982, INT J CANCER, V29, P337, DOI 10.1002/ijc.2910290318; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989; WALSER A, 1989, ONCOGENE, V4, P249	36	0	0	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					379	387						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011395				2022-12-17	WOS:A1991FT34400005
J	RAY, D				RAY, D			CORRECTION	ONCOGENE			English	Correction, Addition																		KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; MOREAUGACHELIN, 1990, ONCOGENE, V5, P941; MOREAUGACHELIN, 1990, ONCOGENE, V4, P1449; RAY D, 1990, ONCOGENE, V5, P663	4	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1611	1612						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502					2022-12-17	WOS:A1990EK50200025
J	HERZOG, NK				HERZOG, NK			CORRECTION	ONCOGENE			English	Correction, Addition																		HERZOG NK, 1989, ONCOGENE, V4, P1307	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					623	623						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853					2022-12-17	WOS:A1990DB85300026
J	VARLEY, JM				VARLEY, JM			CORRECTION	ONCOGENE			English	Correction, Addition																		VARLEY JM, 1989, ONCOGENE, V4, P725	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					245	245						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029					2022-12-17	WOS:A1990CU02900014
J	GELINAS, C				GELINAS, C			CORRECTION	ONCOGENE			English	Correction, Addition																		GELINAS C, 1988, ONCOGENE, V3, P349	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					525	525						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677					2022-12-17	WOS:A1989U567700020
J	RAO, VN				RAO, VN			CORRECTION	ONCOGENE			English	Correction, Addition																		RAO VN, 1988, ONCOGENE, V3, P497	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					525	525						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677					2022-12-17	WOS:A1989U567700021
J	YUAN, CC				YUAN, CC			CORRECTION	ONCOGENE			English	Correction, Addition																		YUAN CC, 1988, ONCOGENE, V2, P99	1	0	0	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					235	235						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534					2022-12-17	WOS:A1988Q053400017
J	[Anonymous]				[Anonymous]			GENOMIC P53 GENE IMMORTALIZES	ONCOGENE			English	Editorial Material																		BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986	22	0	0	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					419	420						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348					2022-12-17	WOS:A1988N434800001
J	DONIGER, J				DONIGER, J			ALTERNATIVE SPLICING RESULTS IN A TRUNCATED N-RAS PROTEIN	ONCOGENE			English	Article											DONIGER, J (corresponding author), NCI,DIV CANC ETIOL,BIOL LAB,BLDG 37,RM 2A19,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Doniger J, 1985, Carcinog Compr Surv, V9, P51; DONIGER J, 1987, ONCOGENE, V1, P331; DONIGER J, 1987, J BIOL CHEM, V262, P3813; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SUKUMAR S, 1984, SCIENCE, V223, P1197, DOI 10.1126/science.6322298; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	13	0	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					293	294						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281097				2022-12-17	WOS:A1988M593100014
